Comparison	O
of	O
the	O
backbone	O
dynamics	O
of	O
the	O
apo	O
-	O
and	O
holo	O
-	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
biotin	B-Protein
carboxyl	I-Protein
carrier	I-Protein
subunit	I-Protein
of	O
Escherichia	O
coli	O
acetyl	O
-	O
CoA	O
carboxylase	O
.	O
<EOS>	B-X
The	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
(	B-X
BCCP	B-X
)	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
a	B-X
biotin-dependent	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
of	B-X
fatty	B-X
acid	B-X
biosynthesis	B-X
.	B-X
Apo-BCCP	B-X
interacts	B-X
specifically	B-X
with	B-X
the	B-X
biotin	B-X
holoenzyme	B-X
synthetase	B-X
,	B-X
BirA	B-X
,	B-X
which	B-X
results	B-X
in	B-X
the	B-X
post-translational	B-X
attachment	B-X
of	B-X
biotin	B-X
to	B-X
a	B-X
single	B-X
lysine	B-X
residue	B-X
on	B-X
BCCP	B-X
.	B-X
Holo-BCCP	B-X
then	B-X
interacts	B-X
with	B-X
the	B-X
biotin	B-X
carboxylase	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
carboxylate	B-X
group	B-X
of	B-X
bicarbonate	B-X
to	B-X
biotin	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
carboxy-biotinylated	B-X
form	B-X
of	B-X
BCCP	B-X
interacts	B-X
with	B-X
transcarboxylase	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
carboxylate	B-X
to	B-X
acetyl-CoA	B-X
to	B-X
form	B-X
malonyl-CoA	B-X
.	B-X
The	B-X
NMR	B-X
solution	B-X
structure	B-X
of	B-X
the	B-X
unbiotinylated	B-X
form	B-X
of	B-X
an	B-X
87	B-X
residue	B-X
C-terminal	B-X
domain	B-X
fragment	B-X
(	B-X
residue	B-X
70-156	B-X
)	B-X
of	B-X
BCCP	B-X
(	B-X
holoBCCP87	B-X
)	B-X
and	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
biotinylated	B-X
form	B-X
of	B-X
a	B-X
C-terminal	B-X
fragment	B-X
(	B-X
residue	B-X
77-156	B-X
)	B-X
of	B-X
BCCP	B-X
from	B-X
Escherichia	B-X
coli	B-X
acetyl-CoA	B-X
carboxylase	B-X
have	B-X
previously	B-X
been	B-X
determined	B-X
.	B-X
Comparative	B-X
analysis	B-X
of	B-X
these	B-X
structures	B-X
provided	B-X
evidence	B-X
for	B-X
small	B-X
,	B-X
localized	B-X
conformational	B-X
changes	B-X
in	B-X
the	B-X
biotin-binding	B-X
region	B-X
upon	B-X
biotinylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Since	B-X
the	B-X
dynamic	B-X
properties	B-X
of	B-X
proteins	B-X
are	B-X
correlated	B-X
with	B-X
local	B-X
structural	B-X
environments	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
relaxation	B-X
parameters	B-X
of	B-X
the	B-X
backbone	B-X
15N	B-X
nuclear	B-X
spins	B-X
of	B-X
holoBCCP87	B-X
,	B-X
and	B-X
compared	B-X
these	B-X
with	B-X
the	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
apo	B-X
protein	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
upon	B-X
biotinylation	B-X
,	B-X
the	B-X
inherent	B-X
mobility	B-X
of	B-X
the	B-X
biotin-binding	B-X
region	B-X
and	B-X
the	B-X
protruding	B-X
thumb	B-X
,	B-X
with	B-X
which	B-X
the	B-X
biotin	B-X
group	B-X
interacts	B-X
in	B-X
the	B-X
holo	B-X
protein	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
.	B-X

The	O
biotin	B-Protein
carboxyl	I-Protein
carrier	I-Protein
protein	I-Protein
(	O
BCCP	B-Protein
)	O
is	O
a	O
subunit	O
of	O
acetyl	O
-	O
CoA	O
carboxylase	O
,	O
a	O
biotin	O
-	O
dependent	O
enzyme	O
that	O
catalyzes	O
the	O
first	O
committed	O
step	O
of	O
fatty	O
acid	O
biosynthesis	O
.	O
<EOS>	B-X
Acetyl-CoA	B-X
carboxylase	B-X
(	B-X
ACCase	B-X
)	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
in	B-X
the	B-X
The	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
(	B-X
BCCP	B-X
)	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
a	B-X
biotin-dependent	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
of	B-X
fatty	B-X
acid	B-X
biosynthesis	B-X
.	B-X
In	B-X
its	B-X
functional	B-X
cycle	B-X
,	B-X
this	B-X
protein	B-X
engages	B-X
in	B-X
heterologous	B-X
protein-protein	B-X
interactions	B-X
with	B-X
three	B-X
distinct	B-X
partners	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
state	B-X
of	B-X
post-translational	B-X
modification	B-X
.	B-X
Apo-BCCP	B-X
interacts	B-X
specifically	B-X
with	B-X
the	B-X
biotin	B-X
holoenzyme	B-X
synthetase	B-X
,	B-X
BirA	B-X
,	B-X
which	B-X
results	B-X
in	B-X
the	B-X
post-translational	B-X
attachment	B-X
of	B-X
biotin	B-X
to	B-X
a	B-X
single	B-X
lysine	B-X
residue	B-X
on	B-X
BCCP	B-X
.	B-X
Holo-BCCP	B-X
then	B-X
interacts	B-X
with	B-X
the	B-X
biotin	B-X
carboxylase	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
carboxylate	B-X
group	B-X
of	B-X
bicarbonate	B-X
to	B-X
biotin	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
carboxy-biotinylated	B-X
form	B-X
of	B-X
BCCP	B-X
interacts	B-X
with	B-X
transcarboxylase	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
carboxylate	B-X
to	B-X
acetyl-CoA	B-X
to	B-X
form	B-X
malonyl-CoA	B-X
.	B-X
The	B-X
determinants	B-X
of	B-X
protein-protein	B-X
interaction	B-X
specificity	B-X
in	B-X
this	B-X
system	B-X
are	B-X
unknown	B-X
.	B-X
The	B-X
NMR	B-X
solution	B-X
structure	B-X
of	B-X
the	B-X
unbiotinylated	B-X
form	B-X
of	B-X
an	B-X
87	B-X
residue	B-X
C-terminal	B-X
domain	B-X
fragment	B-X
(	B-X
residue	B-X
70-156	B-X
)	B-X
of	B-X
BCCP	B-X
(	B-X
holoBCCP87	B-X
)	B-X
and	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
biotinylated	B-X
form	B-X
of	B-X
a	B-X
C-terminal	B-X
fragment	B-X
(	B-X
residue	B-X
77-156	B-X
)	B-X
of	B-X
BCCP	B-X
from	B-X
Escherichia	B-X
coli	B-X
acetyl-CoA	B-X
carboxylase	B-X
have	B-X
previously	B-X
been	B-X
determined	B-X
.	B-X
Comparative	B-X
analysis	B-X
of	B-X
these	B-X
structures	B-X
provided	B-X
evidence	B-X
for	B-X
small	B-X
,	B-X
localized	B-X
conformational	B-X
changes	B-X
in	B-X
the	B-X
biotin-binding	B-X
region	B-X
upon	B-X
biotinylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
These	B-X
structural	B-X
changes	B-X
may	B-X
be	B-X
important	B-X
for	B-X
regulating	B-X
specific	B-X
protein-protein	B-X
interactions	B-X
.	B-X
Since	B-X
the	B-X
dynamic	B-X
properties	B-X
of	B-X
proteins	B-X
are	B-X
correlated	B-X
with	B-X
local	B-X
structural	B-X
environments	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
relaxation	B-X
parameters	B-X
of	B-X
the	B-X
backbone	B-X
15N	B-X
nuclear	B-X
spins	B-X
of	B-X
holoBCCP87	B-X
,	B-X
and	B-X
compared	B-X
these	B-X
with	B-X
the	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
apo	B-X
protein	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
upon	B-X
biotinylation	B-X
,	B-X
the	B-X
inherent	B-X
mobility	B-X
of	B-X
the	B-X
biotin-binding	B-X
region	B-X
and	B-X
the	B-X
protruding	B-X
thumb	B-X
,	B-X
with	B-X
which	B-X
the	B-X
biotin	B-X
group	B-X
interacts	B-X
in	B-X
the	B-X
holo	B-X
protein	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
.	B-X

In	O
its	O
functional	O
cycle	O
,	O
this	O
protein	O
engages	O
in	O
heterologous	O
protein	O
-	O
protein	O
interactions	O
with	O
three	O
distinct	O
partners	O
,	O
depending	O
on	O
its	O
state	O
of	O
post	O
-	O
translational	O
modification	O
.	O
<EOS>	B-X
The	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
(	B-X
BCCP	B-X
)	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
a	B-X
biotin-dependent	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
of	B-X
fatty	B-X
acid	B-X
biosynthesis	B-X
.	B-X
In	B-X
its	B-X
functional	B-X
cycle	B-X
,	B-X
this	B-X
protein	B-X
engages	B-X
in	B-X
heterologous	B-X
protein-protein	B-X
interactions	B-X
with	B-X
three	B-X
distinct	B-X
partners	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
state	B-X
of	B-X
post-translational	B-X
modification	B-X
.	B-X
Apo-BCCP	B-X
interacts	B-X
specifically	B-X
with	B-X
the	B-X
biotin	B-X
holoenzyme	B-X
synthetase	B-X
,	B-X
BirA	B-X
,	B-X
which	B-X
results	B-X
in	B-X
the	B-X
post-translational	B-X
attachment	B-X
of	B-X
biotin	B-X
to	B-X
a	B-X
single	B-X
lysine	B-X
residue	B-X
on	B-X
BCCP	B-X
.	B-X
The	B-X
determinants	B-X
of	B-X
protein-protein	B-X
interaction	B-X
specificity	B-X
in	B-X
this	B-X
system	B-X
are	B-X
unknown	B-X
.	B-X
Comparative	B-X
analysis	B-X
of	B-X
these	B-X
structures	B-X
provided	B-X
evidence	B-X
for	B-X
small	B-X
,	B-X
localized	B-X
conformational	B-X
changes	B-X
in	B-X
the	B-X
biotin-binding	B-X
region	B-X
upon	B-X
biotinylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
These	B-X
structural	B-X
changes	B-X
may	B-X
be	B-X
important	B-X
for	B-X
regulating	B-X
specific	B-X
protein-protein	B-X
interactions	B-X
.	B-X
Since	B-X
the	B-X
dynamic	B-X
properties	B-X
of	B-X
proteins	B-X
are	B-X
correlated	B-X
with	B-X
local	B-X
structural	B-X
environments	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
relaxation	B-X
parameters	B-X
of	B-X
the	B-X
backbone	B-X
15N	B-X
nuclear	B-X
spins	B-X
of	B-X
holoBCCP87	B-X
,	B-X
and	B-X
compared	B-X
these	B-X
with	B-X
the	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
apo	B-X
protein	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
upon	B-X
biotinylation	B-X
,	B-X
the	B-X
inherent	B-X
mobility	B-X
of	B-X
the	B-X
biotin-binding	B-X
region	B-X
and	B-X
the	B-X
protruding	B-X
thumb	B-X
,	B-X
with	B-X
which	B-X
the	B-X
biotin	B-X
group	B-X
interacts	B-X
in	B-X
the	B-X
holo	B-X
protein	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
.	B-X

Apo	O
-	O
BCCP	B-Protein
interacts	O
specifically	O
with	O
the	O
biotin	O
holoenzyme	O
synthetase	O
,	O
BirA	B-Protein
,	O
which	O
results	O
in	O
the	O
post	O
-	O
translational	O
attachment	O
of	O
biotin	O
to	O
a	O
single	O
lysine	O
residue	O
on	O
BCCP	B-Protein
.	O
<EOS>	B-X
The	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
(	B-X
BCCP	B-X
)	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
a	B-X
biotin-dependent	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
of	B-X
fatty	B-X
acid	B-X
biosynthesis	B-X
.	B-X
In	B-X
its	B-X
functional	B-X
cycle	B-X
,	B-X
this	B-X
protein	B-X
engages	B-X
in	B-X
heterologous	B-X
protein-protein	B-X
interactions	B-X
with	B-X
three	B-X
distinct	B-X
partners	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
state	B-X
of	B-X
post-translational	B-X
modification	B-X
.	B-X
Apo-BCCP	B-X
interacts	B-X
specifically	B-X
with	B-X
the	B-X
biotin	B-X
holoenzyme	B-X
synthetase	B-X
,	B-X
BirA	B-X
,	B-X
which	B-X
results	B-X
in	B-X
the	B-X
post-translational	B-X
attachment	B-X
of	B-X
biotin	B-X
to	B-X
a	B-X
single	B-X
lysine	B-X
residue	B-X
on	B-X
BCCP	B-X
.	B-X
Holo-BCCP	B-X
then	B-X
interacts	B-X
with	B-X
the	B-X
biotin	B-X
carboxylase	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
carboxylate	B-X
group	B-X
of	B-X
bicarbonate	B-X
to	B-X
biotin	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
carboxy-biotinylated	B-X
form	B-X
of	B-X
BCCP	B-X
interacts	B-X
with	B-X
transcarboxylase	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
carboxylate	B-X
to	B-X
acetyl-CoA	B-X
to	B-X
form	B-X
malonyl-CoA	B-X
.	B-X
The	B-X
NMR	B-X
solution	B-X
structure	B-X
of	B-X
the	B-X
unbiotinylated	B-X
form	B-X
of	B-X
an	B-X
87	B-X
residue	B-X
C-terminal	B-X
domain	B-X
fragment	B-X
(	B-X
residue	B-X
70-156	B-X
)	B-X
of	B-X
BCCP	B-X
(	B-X
holoBCCP87	B-X
)	B-X
and	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
biotinylated	B-X
form	B-X
of	B-X
a	B-X
C-terminal	B-X
fragment	B-X
(	B-X
residue	B-X
77-156	B-X
)	B-X
of	B-X
BCCP	B-X
from	B-X
Escherichia	B-X
coli	B-X
acetyl-CoA	B-X
carboxylase	B-X
have	B-X
previously	B-X
been	B-X
determined	B-X
.	B-X
Comparative	B-X
analysis	B-X
of	B-X
these	B-X
structures	B-X
provided	B-X
evidence	B-X
for	B-X
small	B-X
,	B-X
localized	B-X
conformational	B-X
changes	B-X
in	B-X
the	B-X
biotin-binding	B-X
region	B-X
upon	B-X
biotinylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Since	B-X
the	B-X
dynamic	B-X
properties	B-X
of	B-X
proteins	B-X
are	B-X
correlated	B-X
with	B-X
local	B-X
structural	B-X
environments	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
relaxation	B-X
parameters	B-X
of	B-X
the	B-X
backbone	B-X
15N	B-X
nuclear	B-X
spins	B-X
of	B-X
holoBCCP87	B-X
,	B-X
and	B-X
compared	B-X
these	B-X
with	B-X
the	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
apo	B-X
protein	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
upon	B-X
biotinylation	B-X
,	B-X
the	B-X
inherent	B-X
mobility	B-X
of	B-X
the	B-X
biotin-binding	B-X
region	B-X
and	B-X
the	B-X
protruding	B-X
thumb	B-X
,	B-X
with	B-X
which	B-X
the	B-X
biotin	B-X
group	B-X
interacts	B-X
in	B-X
the	B-X
holo	B-X
protein	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
.	B-X

Holo	O
-	O
BCCP	B-Protein
then	O
interacts	O
with	O
the	O
biotin	B-Protein
carboxylase	I-Protein
subunit	I-Protein
of	I-Protein
acetyl	I-Protein
-	I-Protein
CoA	I-Protein
carboxylase	I-Protein
,	O
which	O
leads	O
to	O
the	O
addition	O
of	O
the	O
carboxylate	O
group	O
of	O
bicarbonate	O
to	O
biotin	O
.	O

Finally	O
,	O
the	O
carboxy	O
-	O
biotinylated	O
form	O
of	O
BCCP	B-Protein
interacts	O
with	O
transcarboxylase	B-Protein
in	O
the	O
transfer	O
of	O
the	O
carboxylate	O
to	O
acetyl	O
-	O
CoA	O
to	O
form	O
malonyl	O
-	O
CoA	O
.	O
<EOS>	B-X
The	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
(	B-X
BCCP	B-X
)	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
a	B-X
biotin-dependent	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
of	B-X
fatty	B-X
acid	B-X
biosynthesis	B-X
.	B-X
Apo-BCCP	B-X
interacts	B-X
specifically	B-X
with	B-X
the	B-X
biotin	B-X
holoenzyme	B-X
synthetase	B-X
,	B-X
BirA	B-X
,	B-X
which	B-X
results	B-X
in	B-X
the	B-X
post-translational	B-X
attachment	B-X
of	B-X
biotin	B-X
to	B-X
a	B-X
single	B-X
lysine	B-X
residue	B-X
on	B-X
BCCP	B-X
.	B-X
Holo-BCCP	B-X
then	B-X
interacts	B-X
with	B-X
the	B-X
biotin	B-X
carboxylase	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
carboxylate	B-X
group	B-X
of	B-X
bicarbonate	B-X
to	B-X
biotin	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
carboxy-biotinylated	B-X
form	B-X
of	B-X
BCCP	B-X
interacts	B-X
with	B-X
transcarboxylase	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
carboxylate	B-X
to	B-X
acetyl-CoA	B-X
to	B-X
form	B-X
malonyl-CoA	B-X
.	B-X
The	B-X
NMR	B-X
solution	B-X
structure	B-X
of	B-X
the	B-X
unbiotinylated	B-X
form	B-X
of	B-X
an	B-X
87	B-X
residue	B-X
C-terminal	B-X
domain	B-X
fragment	B-X
(	B-X
residue	B-X
70-156	B-X
)	B-X
of	B-X
BCCP	B-X
(	B-X
holoBCCP87	B-X
)	B-X
and	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
biotinylated	B-X
form	B-X
of	B-X
a	B-X
C-terminal	B-X
fragment	B-X
(	B-X
residue	B-X
77-156	B-X
)	B-X
of	B-X
BCCP	B-X
from	B-X
Escherichia	B-X
coli	B-X
acetyl-CoA	B-X
carboxylase	B-X
have	B-X
previously	B-X
been	B-X
determined	B-X
.	B-X
Comparative	B-X
analysis	B-X
of	B-X
these	B-X
structures	B-X
provided	B-X
evidence	B-X
for	B-X
small	B-X
,	B-X
localized	B-X
conformational	B-X
changes	B-X
in	B-X
the	B-X
biotin-binding	B-X
region	B-X
upon	B-X
biotinylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Since	B-X
the	B-X
dynamic	B-X
properties	B-X
of	B-X
proteins	B-X
are	B-X
correlated	B-X
with	B-X
local	B-X
structural	B-X
environments	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
relaxation	B-X
parameters	B-X
of	B-X
the	B-X
backbone	B-X
15N	B-X
nuclear	B-X
spins	B-X
of	B-X
holoBCCP87	B-X
,	B-X
and	B-X
compared	B-X
these	B-X
with	B-X
the	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
apo	B-X
protein	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
upon	B-X
biotinylation	B-X
,	B-X
the	B-X
inherent	B-X
mobility	B-X
of	B-X
the	B-X
biotin-binding	B-X
region	B-X
and	B-X
the	B-X
protruding	B-X
thumb	B-X
,	B-X
with	B-X
which	B-X
the	B-X
biotin	B-X
group	B-X
interacts	B-X
in	B-X
the	B-X
holo	B-X
protein	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
.	B-X

The	O
determinants	O
of	O
protein	O
-	O
protein	O
interaction	O
specificity	O
in	O
this	O
system	O
are	O
unknown	O
.	O
<EOS>	B-X
A	B-X
fluid	B-X
mosaic	B-X
model	B-X
is	B-X
presented	B-X
for	B-X
the	B-X
gross	B-X
organization	B-X
and	B-X
structure	B-X
of	B-X
the	B-X
proteins	B-X
and	B-X
lipids	B-X
of	B-X
biological	B-X
membranes	B-X
.	B-X
In	B-X
this	B-X
model	B-X
,	B-X
the	B-X
proteins	B-X
that	B-X
are	B-X
integral	B-X
to	B-X
the	B-X
membrane	B-X
are	B-X
a	B-X
heterogeneous	B-X
set	B-X
of	B-X
globular	B-X
molecules	B-X
,	B-X
each	B-X
arranged	B-X
in	B-X
an	B-X
amphipathic	B-X
structure	B-X
,	B-X
that	B-X
is	B-X
,	B-X
with	B-X
the	B-X
ionic	B-X
and	B-X
highly	B-X
polar	B-X
groups	B-X
protruding	B-X
from	B-X
the	B-X
membrane	B-X
into	B-X
the	B-X
aqueous	B-X
phase	B-X
,	B-X
and	B-X
the	B-X
nonpolar	B-X
groups	B-X
largely	B-X
buried	B-X
in	B-X
the	B-X
hydrophobic	B-X
interior	B-X
of	B-X
the	B-X
membrane	B-X
.	B-X
The	B-X
bulk	B-X
of	B-X
the	B-X
phospholipid	B-X
is	B-X
organized	B-X
as	B-X
a	B-X
discontinuous	B-X
,	B-X
fluid	B-X
bilayer	B-X
,	B-X
although	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
the	B-X
lipid	B-X
may	B-X
interact	B-X
specifically	B-X
with	B-X
the	B-X
membrane	B-X
proteins	B-X
.	B-X
The	B-X
fluid	B-X
mosaic	B-X
structure	B-X
is	B-X
therefore	B-X
formally	B-X
analogous	B-X
to	B-X
a	B-X
two-dimensional	B-X
oriented	B-X
solution	B-X
of	B-X
integral	B-X
proteins	B-X
(	B-X
or	B-X
lipoproteins	B-X
)	B-X
in	B-X
the	B-X
viscous	B-X
phospholipid	B-X
bilayer	B-X
solvent	B-X
.	B-X
Recent	B-X
experiments	B-X
with	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
techniqes	B-X
and	B-X
several	B-X
different	B-X
membrane	B-X
systems	B-X
are	B-X
described	B-X
,	B-X
all	B-X
of	B-X
which	B-X
abet	B-X
consistent	B-X
with	B-X
,	B-X
and	B-X
add	B-X
much	B-X
detail	B-X
to	B-X
,	B-X
the	B-X
fluid	B-X
mosaic	B-X
model	B-X
.	B-X
As	B-X
examples	B-X
,	B-X
experimentally	B-X
testable	B-X
mechanisms	B-X
are	B-X
suggested	B-X
for	B-X
cell	B-X
surface	B-X
changes	B-X
in	B-X
malignant	B-X
transformation	B-X
,	B-X
and	B-X
for	B-X
cooperative	B-X
effects	B-X
exhibited	B-X
in	B-X
the	B-X
interactions	B-X
of	B-X
membranes	B-X
with	B-X
some	B-X
specific	B-X
ligands	B-X
.	B-X
This	B-X
aggregation	B-X
then	B-X
appears	B-X
to	B-X
trigger	B-X
off	B-X
the	B-X
pinocytosis	B-X
of	B-X
the	B-X
membrane	B-X
components	B-X
by	B-X
some	B-X
unknown	B-X
mechanism	B-X
.	B-X

The	O
NMR	O
solution	O
structure	O
of	O
the	O
unbiotinylated	O
form	O
of	O
an	O
87	O
residue	O
C	O
-	O
terminal	O
domain	O
fragment	O
(	O
residue	O
70	O
-	O
156	O
)	O
of	O
BCCP	B-Protein
(	O
holoBCCP87	B-Protein
)	O
and	O
the	O
crystal	O
structure	O
of	O
the	O
biotinylated	O
form	O
of	O
a	O
C	O
-	O
terminal	O
fragment	O
(	O
residue	O
77	O
-	O
156	O
)	O
of	O
BCCP	B-Protein
from	O
Escherichia	O
coli	O
acetyl	O
-	O
CoA	O
carboxylase	O
have	O
previously	O
been	O
determined	O
.	O

Comparative	O
analysis	O
of	O
these	O
structures	O
provided	O
evidence	O
for	O
small	O
,	O
localized	O
conformational	O
changes	O
in	O
the	O
biotin	O
-	O
binding	O
region	O
upon	O
biotinylation	O
of	O
the	O
protein	O
.	O
<EOS>	B-X
The	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
(	B-X
BCCP	B-X
)	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
a	B-X
biotin-dependent	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
of	B-X
fatty	B-X
acid	B-X
biosynthesis	B-X
.	B-X
In	B-X
its	B-X
functional	B-X
cycle	B-X
,	B-X
this	B-X
protein	B-X
engages	B-X
in	B-X
heterologous	B-X
protein-protein	B-X
interactions	B-X
with	B-X
three	B-X
distinct	B-X
partners	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
state	B-X
of	B-X
post-translational	B-X
modification	B-X
.	B-X
Apo-BCCP	B-X
interacts	B-X
specifically	B-X
with	B-X
the	B-X
biotin	B-X
holoenzyme	B-X
synthetase	B-X
,	B-X
BirA	B-X
,	B-X
which	B-X
results	B-X
in	B-X
the	B-X
post-translational	B-X
attachment	B-X
of	B-X
biotin	B-X
to	B-X
a	B-X
single	B-X
lysine	B-X
residue	B-X
on	B-X
BCCP	B-X
.	B-X
Holo-BCCP	B-X
then	B-X
interacts	B-X
with	B-X
the	B-X
biotin	B-X
carboxylase	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
carboxylate	B-X
group	B-X
of	B-X
bicarbonate	B-X
to	B-X
biotin	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
carboxy-biotinylated	B-X
form	B-X
of	B-X
BCCP	B-X
interacts	B-X
with	B-X
transcarboxylase	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
carboxylate	B-X
to	B-X
acetyl-CoA	B-X
to	B-X
form	B-X
malonyl-CoA	B-X
.	B-X
The	B-X
determinants	B-X
of	B-X
protein-protein	B-X
interaction	B-X
specificity	B-X
in	B-X
this	B-X
system	B-X
are	B-X
unknown	B-X
.	B-X
The	B-X
NMR	B-X
solution	B-X
structure	B-X
of	B-X
the	B-X
unbiotinylated	B-X
form	B-X
of	B-X
an	B-X
87	B-X
residue	B-X
C-terminal	B-X
domain	B-X
fragment	B-X
(	B-X
residue	B-X
70-156	B-X
)	B-X
of	B-X
BCCP	B-X
(	B-X
holoBCCP87	B-X
)	B-X
and	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
biotinylated	B-X
form	B-X
of	B-X
a	B-X
C-terminal	B-X
fragment	B-X
(	B-X
residue	B-X
77-156	B-X
)	B-X
of	B-X
BCCP	B-X
from	B-X
Escherichia	B-X
coli	B-X
acetyl-CoA	B-X
carboxylase	B-X
have	B-X
previously	B-X
been	B-X
determined	B-X
.	B-X
Comparative	B-X
analysis	B-X
of	B-X
these	B-X
structures	B-X
provided	B-X
evidence	B-X
for	B-X
small	B-X
,	B-X
localized	B-X
conformational	B-X
changes	B-X
in	B-X
the	B-X
biotin-binding	B-X
region	B-X
upon	B-X
biotinylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
These	B-X
structural	B-X
changes	B-X
may	B-X
be	B-X
important	B-X
for	B-X
regulating	B-X
specific	B-X
protein-protein	B-X
interactions	B-X
.	B-X
Since	B-X
the	B-X
dynamic	B-X
properties	B-X
of	B-X
proteins	B-X
are	B-X
correlated	B-X
with	B-X
local	B-X
structural	B-X
environments	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
relaxation	B-X
parameters	B-X
of	B-X
the	B-X
backbone	B-X
15N	B-X
nuclear	B-X
spins	B-X
of	B-X
holoBCCP87	B-X
,	B-X
and	B-X
compared	B-X
these	B-X
with	B-X
the	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
apo	B-X
protein	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
upon	B-X
biotinylation	B-X
,	B-X
the	B-X
inherent	B-X
mobility	B-X
of	B-X
the	B-X
biotin-binding	B-X
region	B-X
and	B-X
the	B-X
protruding	B-X
thumb	B-X
,	B-X
with	B-X
which	B-X
the	B-X
biotin	B-X
group	B-X
interacts	B-X
in	B-X
the	B-X
holo	B-X
protein	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
.	B-X

These	O
structural	O
changes	O
may	O
be	O
important	O
for	O
regulating	O
specific	O
protein	O
-	O
protein	O
interactions	O
.	O
<EOS>	B-X
Using	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
,	B-X
live-cell	B-X
microscopy	B-X
,	B-X
and	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
revealed	B-X
the	B-X
structural	B-X
basis	B-X
for	B-X
these	B-X
interactions	B-X
and	B-X
found	B-X
that	B-X
TND-TIM	B-X
sequences	B-X
were	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
induce	B-X
strong	B-X
and	B-X
specific	B-X
colocalization	B-X
in	B-X
the	B-X
crowded	B-X
nuclear	B-X
environment	B-X
.	B-X
Disruption	B-X
of	B-X
a	B-X
single	B-X
TIM	B-X
in	B-X
IWS1	B-X
induced	B-X
robust	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
and	B-X
RNAP2	B-X
elongation	B-X
dynamics	B-X
,	B-X
which	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
TND-TIM	B-X
surfaces	B-X
for	B-X
transcription	B-X
elongation	B-X
.	B-X
Phosphodiesterase	B-X
5	B-X
(	B-X
PDE5	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
well-studied	B-X
phosphodiesterases	B-X
(	B-X
PDEs	B-X
)	B-X
that	B-X
specifically	B-X
targets	B-X
cGMP	B-X
typically	B-X
generated	B-X
by	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
-mediated	B-X
activation	B-X
of	B-X
the	B-X
soluble	B-X
guanylyl	B-X
cyclase	B-X
.	B-X
While	B-X
they	B-X
are	B-X
designed	B-X
to	B-X
inhibit	B-X
PDE5	B-X
,	B-X
the	B-X
inhibitors	B-X
show	B-X
different	B-X
affinities	B-X
and	B-X
specificities	B-X
against	B-X
all	B-X
PDE	B-X
subtypes	B-X
.	B-X
Additionally	B-X
,	B-X
they	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
allosteric	B-X
structural	B-X
changes	B-X
in	B-X
the	B-X
protein	B-X
.	B-X
These	B-X
are	B-X
mostly	B-X
attributed	B-X
to	B-X
their	B-X
chemical	B-X
structure	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
binding	B-X
interactions	B-X
with	B-X
PDE	B-X
catalytic	B-X
domains	B-X
.	B-X
Therefore	B-X
,	B-X
understanding	B-X
how	B-X
these	B-X
inhibitors	B-X
interact	B-X
with	B-X
PDE5	B-X
and	B-X
the	B-X
structural	B-X
basis	B-X
of	B-X
their	B-X
selectivity	B-X
is	B-X
critically	B-X
important	B-X
for	B-X
the	B-X
design	B-X
of	B-X
novel	B-X
,	B-X
highly	B-X
selective	B-X
PDE5	B-X
inhibitors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
structure	B-X
of	B-X
PDE5	B-X
,	B-X
how	B-X
its	B-X
function	B-X
is	B-X
regulated	B-X
,	B-X
and	B-X
discuss	B-X
the	B-X
clinically	B-X
available	B-X
inhibitors	B-X
that	B-X
target	B-X
phosphodiesterase	B-X
5	B-X
,	B-X
aiming	B-X
to	B-X
better	B-X
understand	B-X
the	B-X
structural	B-X
bases	B-X
of	B-X
their	B-X
affinity	B-X
and	B-X
specificity	B-X
.	B-X

Since	O
the	O
dynamic	O
properties	O
of	O
proteins	O
are	O
correlated	O
with	O
local	O
structural	O
environments	O
,	O
we	O
have	O
determined	O
the	O
relaxation	O
parameters	O
of	O
the	O
backbone	O
15N	O
nuclear	O
spins	O
of	O
holoBCCP87	B-Protein
,	O
and	O
compared	O
these	O
with	O
the	O
data	O
obtained	O
for	O
the	O
apo	O
protein	O
.	O
<EOS>	B-X
The	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
(	B-X
BCCP	B-X
)	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
a	B-X
biotin-dependent	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
of	B-X
fatty	B-X
acid	B-X
biosynthesis	B-X
.	B-X
In	B-X
its	B-X
functional	B-X
cycle	B-X
,	B-X
this	B-X
protein	B-X
engages	B-X
in	B-X
heterologous	B-X
protein-protein	B-X
interactions	B-X
with	B-X
three	B-X
distinct	B-X
partners	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
state	B-X
of	B-X
post-translational	B-X
modification	B-X
.	B-X
The	B-X
determinants	B-X
of	B-X
protein-protein	B-X
interaction	B-X
specificity	B-X
in	B-X
this	B-X
system	B-X
are	B-X
unknown	B-X
.	B-X
The	B-X
NMR	B-X
solution	B-X
structure	B-X
of	B-X
the	B-X
unbiotinylated	B-X
form	B-X
of	B-X
an	B-X
87	B-X
residue	B-X
C-terminal	B-X
domain	B-X
fragment	B-X
(	B-X
residue	B-X
70-156	B-X
)	B-X
of	B-X
BCCP	B-X
(	B-X
holoBCCP87	B-X
)	B-X
and	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
biotinylated	B-X
form	B-X
of	B-X
a	B-X
C-terminal	B-X
fragment	B-X
(	B-X
residue	B-X
77-156	B-X
)	B-X
of	B-X
BCCP	B-X
from	B-X
Escherichia	B-X
coli	B-X
acetyl-CoA	B-X
carboxylase	B-X
have	B-X
previously	B-X
been	B-X
determined	B-X
.	B-X
Comparative	B-X
analysis	B-X
of	B-X
these	B-X
structures	B-X
provided	B-X
evidence	B-X
for	B-X
small	B-X
,	B-X
localized	B-X
conformational	B-X
changes	B-X
in	B-X
the	B-X
biotin-binding	B-X
region	B-X
upon	B-X
biotinylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
These	B-X
structural	B-X
changes	B-X
may	B-X
be	B-X
important	B-X
for	B-X
regulating	B-X
specific	B-X
protein-protein	B-X
interactions	B-X
.	B-X
Since	B-X
the	B-X
dynamic	B-X
properties	B-X
of	B-X
proteins	B-X
are	B-X
correlated	B-X
with	B-X
local	B-X
structural	B-X
environments	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
relaxation	B-X
parameters	B-X
of	B-X
the	B-X
backbone	B-X
15N	B-X
nuclear	B-X
spins	B-X
of	B-X
holoBCCP87	B-X
,	B-X
and	B-X
compared	B-X
these	B-X
with	B-X
the	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
apo	B-X
protein	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
upon	B-X
biotinylation	B-X
,	B-X
the	B-X
inherent	B-X
mobility	B-X
of	B-X
the	B-X
biotin-binding	B-X
region	B-X
and	B-X
the	B-X
protruding	B-X
thumb	B-X
,	B-X
with	B-X
which	B-X
the	B-X
biotin	B-X
group	B-X
interacts	B-X
in	B-X
the	B-X
holo	B-X
protein	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
.	B-X

The	O
results	O
indicate	O
that	O
upon	O
biotinylation	O
,	O
the	O
inherent	O
mobility	O
of	O
the	O
biotin	O
-	O
binding	O
region	O
and	O
the	O
protruding	O
thumb	O
,	O
with	O
which	O
the	O
biotin	O
group	O
interacts	O
in	O
the	O
holo	O
protein	O
,	O
are	O
significantly	O
reduced	O
.	O
<EOS>	B-X
The	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
(	B-X
BCCP	B-X
)	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
a	B-X
biotin-dependent	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
the	B-X
first	B-X
committed	B-X
step	B-X
of	B-X
fatty	B-X
acid	B-X
biosynthesis	B-X
.	B-X
In	B-X
its	B-X
functional	B-X
cycle	B-X
,	B-X
this	B-X
protein	B-X
engages	B-X
in	B-X
heterologous	B-X
protein-protein	B-X
interactions	B-X
with	B-X
three	B-X
distinct	B-X
partners	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
state	B-X
of	B-X
post-translational	B-X
modification	B-X
.	B-X
Apo-BCCP	B-X
interacts	B-X
specifically	B-X
with	B-X
the	B-X
biotin	B-X
holoenzyme	B-X
synthetase	B-X
,	B-X
BirA	B-X
,	B-X
which	B-X
results	B-X
in	B-X
the	B-X
post-translational	B-X
attachment	B-X
of	B-X
biotin	B-X
to	B-X
a	B-X
single	B-X
lysine	B-X
residue	B-X
on	B-X
BCCP	B-X
.	B-X
Holo-BCCP	B-X
then	B-X
interacts	B-X
with	B-X
the	B-X
biotin	B-X
carboxylase	B-X
subunit	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
carboxylate	B-X
group	B-X
of	B-X
bicarbonate	B-X
to	B-X
biotin	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
carboxy-biotinylated	B-X
form	B-X
of	B-X
BCCP	B-X
interacts	B-X
with	B-X
transcarboxylase	B-X
in	B-X
the	B-X
transfer	B-X
of	B-X
the	B-X
carboxylate	B-X
to	B-X
acetyl-CoA	B-X
to	B-X
form	B-X
malonyl-CoA	B-X
.	B-X
The	B-X
determinants	B-X
of	B-X
protein-protein	B-X
interaction	B-X
specificity	B-X
in	B-X
this	B-X
system	B-X
are	B-X
unknown	B-X
.	B-X
The	B-X
NMR	B-X
solution	B-X
structure	B-X
of	B-X
the	B-X
unbiotinylated	B-X
form	B-X
of	B-X
an	B-X
87	B-X
residue	B-X
C-terminal	B-X
domain	B-X
fragment	B-X
(	B-X
residue	B-X
70-156	B-X
)	B-X
of	B-X
BCCP	B-X
(	B-X
holoBCCP87	B-X
)	B-X
and	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
biotinylated	B-X
form	B-X
of	B-X
a	B-X
C-terminal	B-X
fragment	B-X
(	B-X
residue	B-X
77-156	B-X
)	B-X
of	B-X
BCCP	B-X
from	B-X
Escherichia	B-X
coli	B-X
acetyl-CoA	B-X
carboxylase	B-X
have	B-X
previously	B-X
been	B-X
determined	B-X
.	B-X
Comparative	B-X
analysis	B-X
of	B-X
these	B-X
structures	B-X
provided	B-X
evidence	B-X
for	B-X
small	B-X
,	B-X
localized	B-X
conformational	B-X
changes	B-X
in	B-X
the	B-X
biotin-binding	B-X
region	B-X
upon	B-X
biotinylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
These	B-X
structural	B-X
changes	B-X
may	B-X
be	B-X
important	B-X
for	B-X
regulating	B-X
specific	B-X
protein-protein	B-X
interactions	B-X
.	B-X
Since	B-X
the	B-X
dynamic	B-X
properties	B-X
of	B-X
proteins	B-X
are	B-X
correlated	B-X
with	B-X
local	B-X
structural	B-X
environments	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
relaxation	B-X
parameters	B-X
of	B-X
the	B-X
backbone	B-X
15N	B-X
nuclear	B-X
spins	B-X
of	B-X
holoBCCP87	B-X
,	B-X
and	B-X
compared	B-X
these	B-X
with	B-X
the	B-X
data	B-X
obtained	B-X
for	B-X
the	B-X
apo	B-X
protein	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
upon	B-X
biotinylation	B-X
,	B-X
the	B-X
inherent	B-X
mobility	B-X
of	B-X
the	B-X
biotin-binding	B-X
region	B-X
and	B-X
the	B-X
protruding	B-X
thumb	B-X
,	B-X
with	B-X
which	B-X
the	B-X
biotin	B-X
group	B-X
interacts	B-X
in	B-X
the	B-X
holo	B-X
protein	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
.	B-X

Correlation	O
of	O
activity	O
regulation	O
and	O
substrate	O
recognition	O
of	O
the	O
ADP	O
-	O
ribosyltransferase	O
that	O
regulates	O
nitrogenase	O
activity	O
in	O
Rhodospirillum	O
rubrum	O
.	O
<EOS>	B-X
In	B-X
Rhodospirillum	B-X
rubrum	B-X
,	B-X
nitrogenase	B-X
activity	B-X
is	B-X
regulated	B-X
posttranslationally	B-X
through	B-X
the	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
by	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DRAT	B-X
)	B-X
.	B-X
Several	B-X
DRAT	B-X
variants	B-X
that	B-X
are	B-X
altered	B-X
both	B-X
in	B-X
the	B-X
posttranslational	B-X
regulation	B-X
of	B-X
DRAT	B-X
activity	B-X
and	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
recognize	B-X
variants	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
have	B-X
been	B-X
found	B-X
.	B-X

In	O
Rhodospirillum	O
rubrum	O
,	O
nitrogenase	O
activity	O
is	O
regulated	O
posttranslationally	O
through	O
the	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
by	O
dinitrogenase	B-Protein
reductase	I-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
(	O
DRAT	B-Protein
)	O
.	O
<EOS>	B-X
In	B-X
a	B-X
number	B-X
of	B-X
nitrogen-fixing	B-X
bacteria	B-X
,	B-X
nitrogenase	B-X
is	B-X
posttranslationally	B-X
regulated	B-X
by	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
from	B-X
Azotobacter	B-X
vinelandii	B-X
is	B-X
known	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
mutant	B-X
forms	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
from	B-X
A.	B-X
vinelandii	B-X
that	B-X
are	B-X
affected	B-X
in	B-X
various	B-X
protein	B-X
activities	B-X
were	B-X
tested	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
be	B-X
ADP-ribosylated	B-X
or	B-X
to	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DRAT	B-X
)	B-X
from	B-X
Rhodospirillum	B-X
rubrum	B-X
.	B-X
R140Q	B-X
dinitrogenase	B-X
reductase	B-X
could	B-X
not	B-X
be	B-X
ADP-ribosylated	B-X
by	B-X
DRAT	B-X
,	B-X
although	B-X
it	B-X
still	B-X
formed	B-X
a	B-X
cross-linkable	B-X
complex	B-X
with	B-X
DRAT	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
Arg	B-X
140	B-X
residue	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
ADP-ribosylation	B-X
reaction	B-X
.	B-X
Conformational	B-X
changes	B-X
in	B-X
dinitrogenase	B-X
reductase	B-X
induced	B-X
by	B-X
an	B-X
F135Y	B-X
substitution	B-X
or	B-X
by	B-X
removal	B-X
of	B-X
the	B-X
Fe	B-X
(	B-X
4	B-X
)	B-X
S	B-X
(	B-X
4	B-X
)	B-X
cluster	B-X
resulted	B-X
in	B-X
dinitrogenase	B-X
reductase	B-X
not	B-X
being	B-X
a	B-X
substrate	B-X
for	B-X
ADP-ribosylation	B-X
.	B-X
Through	B-X
cross-linking	B-X
studies	B-X
it	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
these	B-X
changes	B-X
decreased	B-X
the	B-X
ability	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
to	B-X
form	B-X
a	B-X
cross-linkable	B-X
complex	B-X
with	B-X
DRAT	B-X
.	B-X
Substitution	B-X
of	B-X
D129E	B-X
or	B-X
deletion	B-X
of	B-X
Leu	B-X
127	B-X
,	B-X
which	B-X
result	B-X
in	B-X
altered	B-X
nucleotide	B-X
binding	B-X
regions	B-X
of	B-X
these	B-X
dinitrogenase	B-X
reductases	B-X
,	B-X
did	B-X
not	B-X
significantly	B-X
change	B-X
the	B-X
interaction	B-X
between	B-X
dinitrogenase	B-X
reductase	B-X
and	B-X
DRAT	B-X
.	B-X
Previous	B-X
results	B-X
showed	B-X
that	B-X
changing	B-X
Lys	B-X
143	B-X
to	B-X
Gln	B-X
decreased	B-X
the	B-X
binding	B-X
between	B-X
dinitrogenase	B-X
reductase	B-X
and	B-X
dinitrogenase	B-X
(	B-X
L.	B-X
C.	B-X
Seefeldt	B-X
,	B-X
Protein	B-X
Sci	B-X
.	B-X
3:2073-2081	B-X
,	B-X
1994	B-X
)	B-X
;	B-X
however	B-X
,	B-X
this	B-X
change	B-X
did	B-X
not	B-X
have	B-X
a	B-X
substantial	B-X
effect	B-X
on	B-X
the	B-X
interaction	B-X
between	B-X
dinitrogenase	B-X
reductase	B-X
and	B-X
DRAT	B-X
.	B-X

Several	O
DRAT	B-Protein
variants	O
that	O
are	O
altered	O
both	O
in	O
the	O
posttranslational	O
regulation	O
of	O
DRAT	B-Protein
activity	O
and	O
in	O
the	O
ability	O
to	O
recognize	O
variants	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
have	O
been	O
found	O
.	O
<EOS>	B-X
In	B-X
Rhodospirillum	B-X
rubrum	B-X
,	B-X
nitrogenase	B-X
activity	B-X
is	B-X
regulated	B-X
posttranslationally	B-X
through	B-X
the	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
by	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DRAT	B-X
)	B-X
.	B-X
Several	B-X
DRAT	B-X
variants	B-X
that	B-X
are	B-X
altered	B-X
both	B-X
in	B-X
the	B-X
posttranslational	B-X
regulation	B-X
of	B-X
DRAT	B-X
activity	B-X
and	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
recognize	B-X
variants	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
have	B-X
been	B-X
found	B-X
.	B-X

This	O
correlation	O
suggests	O
that	O
these	O
two	O
properties	O
are	O
biochemically	O
connected	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
this	B-X
phenomenon	B-X
by	B-X
comparing	B-X
the	B-X
metabolic	B-X
networks	B-X
of	B-X
134	B-X
bacterial	B-X
species	B-X
with	B-X
known	B-X
phylogenetic	B-X
relationships	B-X
,	B-X
and	B-X
by	B-X
studying	B-X
a	B-X
neutral	B-X
model	B-X
of	B-X
metabolic	B-X
network	B-X
evolution	B-X
.	B-X
Constraint-based	B-X
reconstruction	B-X
and	B-X
analysis	B-X
(	B-X
COBRA	B-X
)	B-X
is	B-X
used	B-X
for	B-X
modeling	B-X
genome-scale	B-X
metabolic	B-X
networks	B-X
(	B-X
MNs	B-X
)	B-X
.	B-X
ExPa	B-X
analysis	B-X
has	B-X
been	B-X
successfully	B-X
applied	B-X
to	B-X
MNs	B-X
to	B-X
reveal	B-X
their	B-X
phenotypic	B-X
capabilities	B-X
and	B-X
properties	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
COBRA	B-X
framework	B-X
has	B-X
been	B-X
extended	B-X
to	B-X
transcriptional	B-X
regulatory	B-X
networks	B-X
(	B-X
TRNs	B-X
)	B-X
and	B-X
transcriptional	B-X
and	B-X
translational	B-X
networks	B-X
(	B-X
TTNs	B-X
)	B-X
,	B-X
so	B-X
efforts	B-X
are	B-X
needed	B-X
to	B-X
determine	B-X
whether	B-X
ExPa	B-X
analysis	B-X
is	B-X
also	B-X
effective	B-X
on	B-X
these	B-X
two	B-X
types	B-X
of	B-X
networks	B-X
.	B-X

Mass	O
spectral	O
study	O
of	O
polymorphism	O
of	O
the	O
apolipoproteins	O
of	O
very	O
low	O
density	O
lipoprotein	O
.	O
<EOS>	B-X
New	B-X
isoforms	B-X
of	B-X
apolipoprotein	B-X
(	B-X
apo	B-X
)	B-X
C-I	B-X
and	B-X
apoC-III	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
delipidated	B-X
fractions	B-X
from	B-X
very	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
VLDL	B-X
)	B-X
using	B-X
matrix-assisted	B-X
laser	B-X
desorption	B-X
(	B-X
MALDI	B-X
)	B-X
and	B-X
electrospray	B-X
ionization	B-X
(	B-X
ESI	B-X
)	B-X
mass	B-X
spectrometry	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
VLDL	B-X
fractions	B-X
were	B-X
isolated	B-X
by	B-X
fixed-angle	B-X
single-spin	B-X
ultracentrifugation	B-X
using	B-X
a	B-X
self-generating	B-X
sucrose	B-X
density	B-X
gradient	B-X
and	B-X
delipidated	B-X
using	B-X
a	B-X
newly	B-X
developed	B-X
C18	B-X
solid	B-X
phase	B-X
extraction	B-X
protocol	B-X
.	B-X

New	O
isoforms	O
of	O
apolipoprotein	B-Protein
(	I-Protein
apo	I-Protein
)	I-Protein
C	I-Protein
-	I-Protein
I	I-Protein
and	O
apoC	B-Protein
-	I-Protein
III	I-Protein
have	O
been	O
detected	O
in	O
delipidated	O
fractions	O
from	O
very	O
low	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
(	O
MALDI	O
)	O
and	O
electrospray	O
ionization	O
(	O
ESI	O
)	O
mass	O
spectrometry	O
(	O
MS	O
)	O
.	O

The	O
cleavage	O
sites	O
of	O
truncated	O
apoC	B-Protein
-	I-Protein
III	I-Protein
isoforms	O
have	O
also	O
been	O
identified	O
.	O
<EOS>	B-X
New	B-X
isoforms	B-X
of	B-X
apolipoprotein	B-X
(	B-X
apo	B-X
)	B-X
C-I	B-X
and	B-X
apoC-III	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
delipidated	B-X
fractions	B-X
from	B-X
very	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
VLDL	B-X
)	B-X
using	B-X
matrix-assisted	B-X
laser	B-X
desorption	B-X
(	B-X
MALDI	B-X
)	B-X
and	B-X
electrospray	B-X
ionization	B-X
(	B-X
ESI	B-X
)	B-X
mass	B-X
spectrometry	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
cleavage	B-X
sites	B-X
of	B-X
truncated	B-X
apoC-III	B-X
isoforms	B-X
have	B-X
also	B-X
been	B-X
identified	B-X
.	B-X
Fifteen	B-X
apoC	B-X
isoforms	B-X
and	B-X
apoE	B-X
were	B-X
identified	B-X
in	B-X
the	B-X
MALDI	B-X
spectra	B-X
and	B-X
the	B-X
existence	B-X
of	B-X
the	B-X
more	B-X
abundant	B-X
species	B-X
was	B-X
verified	B-X
by	B-X
ESI-MS	B-X
.	B-X
The	B-X
relative	B-X
intensities	B-X
of	B-X
the	B-X
apoCs	B-X
are	B-X
closely	B-X
correlated	B-X
in	B-X
three	B-X
normolipidemic	B-X
subjects	B-X
.	B-X
A	B-X
fourth	B-X
subject	B-X
with	B-X
type	B-X
V	B-X
hyperlipidemia	B-X
exhibited	B-X
an	B-X
elevated	B-X
apoC-III	B-X
level	B-X
and	B-X
a	B-X
suppressed	B-X
level	B-X
of	B-X
the	B-X
newly	B-X
discovered	B-X
truncated	B-X
apoC-I	B-X
isoform	B-X
.	B-X
The	B-X
dynamic	B-X
range	B-X
and	B-X
specificity	B-X
of	B-X
the	B-X
MALDI	B-X
assay	B-X
shows	B-X
that	B-X
the	B-X
complete	B-X
apoC	B-X
isoform	B-X
profile	B-X
and	B-X
apoE	B-X
phenotype	B-X
can	B-X
be	B-X
obtained	B-X
in	B-X
a	B-X
single	B-X
measurement	B-X
from	B-X
the	B-X
delipidated	B-X
VLDL	B-X
fraction	B-X
.	B-X

The	O
VLDL	O
fractions	O
were	O
isolated	O
by	O
fixed	O
-	O
angle	O
single	O
-	O
spin	O
ultracentrifugation	O
using	O
a	O
self	O
-	O
generating	O
sucrose	O
density	O
gradient	O
and	O
delipidated	O
using	O
a	O
newly	O
developed	O
C18	O
solid	O
phase	O
extraction	O
protocol	O
.	O
<EOS>	B-X
New	B-X
isoforms	B-X
of	B-X
apolipoprotein	B-X
(	B-X
apo	B-X
)	B-X
C-I	B-X
and	B-X
apoC-III	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
delipidated	B-X
fractions	B-X
from	B-X
very	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
VLDL	B-X
)	B-X
using	B-X
matrix-assisted	B-X
laser	B-X
desorption	B-X
(	B-X
MALDI	B-X
)	B-X
and	B-X
electrospray	B-X
ionization	B-X
(	B-X
ESI	B-X
)	B-X
mass	B-X
spectrometry	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
VLDL	B-X
fractions	B-X
were	B-X
isolated	B-X
by	B-X
fixed-angle	B-X
single-spin	B-X
ultracentrifugation	B-X
using	B-X
a	B-X
self-generating	B-X
sucrose	B-X
density	B-X
gradient	B-X
and	B-X
delipidated	B-X
using	B-X
a	B-X
newly	B-X
developed	B-X
C18	B-X
solid	B-X
phase	B-X
extraction	B-X
protocol	B-X
.	B-X
A	B-X
fourth	B-X
subject	B-X
with	B-X
type	B-X
V	B-X
hyperlipidemia	B-X
exhibited	B-X
an	B-X
elevated	B-X
apoC-III	B-X
level	B-X
and	B-X
a	B-X
suppressed	B-X
level	B-X
of	B-X
the	B-X
newly	B-X
discovered	B-X
truncated	B-X
apoC-I	B-X
isoform	B-X
.	B-X
The	B-X
dynamic	B-X
range	B-X
and	B-X
specificity	B-X
of	B-X
the	B-X
MALDI	B-X
assay	B-X
shows	B-X
that	B-X
the	B-X
complete	B-X
apoC	B-X
isoform	B-X
profile	B-X
and	B-X
apoE	B-X
phenotype	B-X
can	B-X
be	B-X
obtained	B-X
in	B-X
a	B-X
single	B-X
measurement	B-X
from	B-X
the	B-X
delipidated	B-X
VLDL	B-X
fraction	B-X
.	B-X

Fifteen	O
apoC	O
isoforms	O
and	O
apoE	B-Protein
were	O
identified	O
in	O
the	O
MALDI	O
spectra	O
and	O
the	O
existence	O
of	O
the	O
more	O
abundant	O
species	O
was	O
verified	O
by	O
ESI	O
-	O
MS	O
.	O
<EOS>	B-X
New	B-X
isoforms	B-X
of	B-X
apolipoprotein	B-X
(	B-X
apo	B-X
)	B-X
C-I	B-X
and	B-X
apoC-III	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
delipidated	B-X
fractions	B-X
from	B-X
very	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
VLDL	B-X
)	B-X
using	B-X
matrix-assisted	B-X
laser	B-X
desorption	B-X
(	B-X
MALDI	B-X
)	B-X
and	B-X
electrospray	B-X
ionization	B-X
(	B-X
ESI	B-X
)	B-X
mass	B-X
spectrometry	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
cleavage	B-X
sites	B-X
of	B-X
truncated	B-X
apoC-III	B-X
isoforms	B-X
have	B-X
also	B-X
been	B-X
identified	B-X
.	B-X
Fifteen	B-X
apoC	B-X
isoforms	B-X
and	B-X
apoE	B-X
were	B-X
identified	B-X
in	B-X
the	B-X
MALDI	B-X
spectra	B-X
and	B-X
the	B-X
existence	B-X
of	B-X
the	B-X
more	B-X
abundant	B-X
species	B-X
was	B-X
verified	B-X
by	B-X
ESI-MS	B-X
.	B-X
The	B-X
relative	B-X
intensities	B-X
of	B-X
the	B-X
apoCs	B-X
are	B-X
closely	B-X
correlated	B-X
in	B-X
three	B-X
normolipidemic	B-X
subjects	B-X
.	B-X
A	B-X
fourth	B-X
subject	B-X
with	B-X
type	B-X
V	B-X
hyperlipidemia	B-X
exhibited	B-X
an	B-X
elevated	B-X
apoC-III	B-X
level	B-X
and	B-X
a	B-X
suppressed	B-X
level	B-X
of	B-X
the	B-X
newly	B-X
discovered	B-X
truncated	B-X
apoC-I	B-X
isoform	B-X
.	B-X
The	B-X
dynamic	B-X
range	B-X
and	B-X
specificity	B-X
of	B-X
the	B-X
MALDI	B-X
assay	B-X
shows	B-X
that	B-X
the	B-X
complete	B-X
apoC	B-X
isoform	B-X
profile	B-X
and	B-X
apoE	B-X
phenotype	B-X
can	B-X
be	B-X
obtained	B-X
in	B-X
a	B-X
single	B-X
measurement	B-X
from	B-X
the	B-X
delipidated	B-X
VLDL	B-X
fraction	B-X
.	B-X

The	O
relative	O
intensities	O
of	O
the	O
apoCs	O
are	O
closely	O
correlated	O
in	O
three	O
normolipidemic	O
subjects	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
intensities	B-X
of	B-X
the	B-X
apoCs	B-X
are	B-X
closely	B-X
correlated	B-X
in	B-X
three	B-X
normolipidemic	B-X
subjects	B-X
.	B-X

A	O
fourth	O
subject	O
with	O
type	O
V	O
hyperlipidemia	O
exhibited	O
an	O
elevated	O
apoC	B-Protein
-	I-Protein
III	I-Protein
level	O
and	O
a	O
suppressed	O
level	O
of	O
the	O
newly	O
discovered	O
truncated	O
apoC	B-Protein
-	I-Protein
I	I-Protein
isoform	O
.	O

ApoC	B-Protein
-	I-Protein
II	I-Protein
was	O
found	O
to	O
be	O
particularly	O
sensitive	O
to	O
in	O
vitro	O
oxidation	O
.	O
<EOS>	B-X
New	B-X
isoforms	B-X
of	B-X
apolipoprotein	B-X
(	B-X
apo	B-X
)	B-X
C-I	B-X
and	B-X
apoC-III	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
delipidated	B-X
fractions	B-X
from	B-X
very	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
VLDL	B-X
)	B-X
using	B-X
matrix-assisted	B-X
laser	B-X
desorption	B-X
(	B-X
MALDI	B-X
)	B-X
and	B-X
electrospray	B-X
ionization	B-X
(	B-X
ESI	B-X
)	B-X
mass	B-X
spectrometry	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
cleavage	B-X
sites	B-X
of	B-X
truncated	B-X
apoC-III	B-X
isoforms	B-X
have	B-X
also	B-X
been	B-X
identified	B-X
.	B-X
A	B-X
fourth	B-X
subject	B-X
with	B-X
type	B-X
V	B-X
hyperlipidemia	B-X
exhibited	B-X
an	B-X
elevated	B-X
apoC-III	B-X
level	B-X
and	B-X
a	B-X
suppressed	B-X
level	B-X
of	B-X
the	B-X
newly	B-X
discovered	B-X
truncated	B-X
apoC-I	B-X
isoform	B-X
.	B-X
ApoC-II	B-X
was	B-X
found	B-X
to	B-X
be	B-X
particularly	B-X
sensitive	B-X
to	B-X
in	B-X
vitro	B-X
oxidation	B-X
.	B-X

The	O
dynamic	O
range	O
and	O
specificity	O
of	O
the	O
MALDI	O
assay	O
shows	O
that	O
the	O
complete	O
apoC	O
isoform	O
profile	O
and	O
apoE	B-Protein
phenotype	O
can	O
be	O
obtained	O
in	O
a	O
single	O
measurement	O
from	O
the	O
delipidated	O
VLDL	O
fraction	O
.	O

Evidence	O
that	O
halogenated	O
furanones	O
from	O
Delisea	O
pulchra	O
inhibit	O
acylated	O
homoserine	O
lactone	O
(	O
AHL	O
)	O
-	O
mediated	O
gene	O
expression	O
by	O
displacing	O
the	O
AHL	O
signal	O
from	O
its	O
receptor	O
protein	O
.	O
<EOS>	B-X
Acylated	B-X
homoserine	B-X
lactone	B-X
(	B-X
AHL	B-X
)	B-X
-mediated	B-X
gene	B-X
expression	B-X
controls	B-X
phenotypes	B-X
involved	B-X
in	B-X
colonization	B-X
,	B-X
often	B-X
specifically	B-X
of	B-X
higher	B-X
organisms	B-X
,	B-X
in	B-X
both	B-X
marine	B-X
and	B-X
terrestrial	B-X
environments	B-X
.	B-X
The	B-X
marine	B-X
red	B-X
alga	B-X
Delisea	B-X
pulchra	B-X
produces	B-X
halogenated	B-X
furanones	B-X
which	B-X
resemble	B-X
AHLs	B-X
structurally	B-X
and	B-X
show	B-X
inhibitory	B-X
activity	B-X
at	B-X
ecologically	B-X
realistic	B-X
concentrations	B-X
in	B-X
AHL	B-X
bioassays	B-X
.	B-X
Evidence	B-X
is	B-X
presented	B-X
that	B-X
halogenated	B-X
furanones	B-X
displace	B-X
tritiated	B-X
OHHL	B-X
[	B-X
N-3-	B-X
(	B-X
oxohexanoyl	B-X
)	B-X
-L-homoserine	B-X
lactone	B-X
]	B-X
from	B-X
Escherichia	B-X
coli	B-X
cells	B-X
overproducing	B-X
LuxR	B-X
with	B-X
potencies	B-X
corresponding	B-X
to	B-X
their	B-X
respective	B-X
inhibitory	B-X
activities	B-X
in	B-X
an	B-X
AHL-regulated	B-X
bioluminescence	B-X
assay	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
is	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
furanones	B-X
inhibit	B-X
AHL-dependent	B-X
phenotypes	B-X
.	B-X
General	B-X
metabolic	B-X
disruption	B-X
was	B-X
assessed	B-X
with	B-X
two-dimensional	B-X
PAGE	B-X
,	B-X
revealing	B-X
limited	B-X
non-AHL-related	B-X
effects	B-X
.	B-X
A	B-X
direct	B-X
chemical	B-X
interaction	B-X
between	B-X
the	B-X
algal	B-X
compounds	B-X
and	B-X
AHLs	B-X
,	B-X
as	B-X
monitored	B-X
by	B-X
1H	B-X
NMR	B-X
spectroscopy	B-X
,	B-X
was	B-X
shown	B-X
not	B-X
to	B-X
occur	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
contention	B-X
that	B-X
furanones	B-X
,	B-X
at	B-X
the	B-X
concentrations	B-X
produced	B-X
by	B-X
the	B-X
alga	B-X
,	B-X
can	B-X
control	B-X
bacterial	B-X
colonization	B-X
of	B-X
surfaces	B-X
by	B-X
specifically	B-X
interfering	B-X
with	B-X
AHL-mediated	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
the	B-X
LuxR	B-X
protein	B-X
.	B-X

Acylated	O
homoserine	O
lactone	O
(	O
AHL	O
)	O
-	O
mediated	O
gene	O
expression	O
controls	O
phenotypes	O
involved	O
in	O
colonization	O
,	O
often	O
specifically	O
of	O
higher	O
organisms	O
,	O
in	O
both	O
marine	O
and	O
terrestrial	O
environments	O
.	O
<EOS>	B-X
Acylated	B-X
homoserine	B-X
lactone	B-X
(	B-X
AHL	B-X
)	B-X
-mediated	B-X
gene	B-X
expression	B-X
controls	B-X
phenotypes	B-X
involved	B-X
in	B-X
colonization	B-X
,	B-X
often	B-X
specifically	B-X
of	B-X
higher	B-X
organisms	B-X
,	B-X
in	B-X
both	B-X
marine	B-X
and	B-X
terrestrial	B-X
environments	B-X
.	B-X
The	B-X
marine	B-X
red	B-X
alga	B-X
Delisea	B-X
pulchra	B-X
produces	B-X
halogenated	B-X
furanones	B-X
which	B-X
resemble	B-X
AHLs	B-X
structurally	B-X
and	B-X
show	B-X
inhibitory	B-X
activity	B-X
at	B-X
ecologically	B-X
realistic	B-X
concentrations	B-X
in	B-X
AHL	B-X
bioassays	B-X
.	B-X
Evidence	B-X
is	B-X
presented	B-X
that	B-X
halogenated	B-X
furanones	B-X
displace	B-X
tritiated	B-X
OHHL	B-X
[	B-X
N-3-	B-X
(	B-X
oxohexanoyl	B-X
)	B-X
-L-homoserine	B-X
lactone	B-X
]	B-X
from	B-X
Escherichia	B-X
coli	B-X
cells	B-X
overproducing	B-X
LuxR	B-X
with	B-X
potencies	B-X
corresponding	B-X
to	B-X
their	B-X
respective	B-X
inhibitory	B-X
activities	B-X
in	B-X
an	B-X
AHL-regulated	B-X
bioluminescence	B-X
assay	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
is	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
furanones	B-X
inhibit	B-X
AHL-dependent	B-X
phenotypes	B-X
.	B-X
General	B-X
metabolic	B-X
disruption	B-X
was	B-X
assessed	B-X
with	B-X
two-dimensional	B-X
PAGE	B-X
,	B-X
revealing	B-X
limited	B-X
non-AHL-related	B-X
effects	B-X
.	B-X
A	B-X
direct	B-X
chemical	B-X
interaction	B-X
between	B-X
the	B-X
algal	B-X
compounds	B-X
and	B-X
AHLs	B-X
,	B-X
as	B-X
monitored	B-X
by	B-X
1H	B-X
NMR	B-X
spectroscopy	B-X
,	B-X
was	B-X
shown	B-X
not	B-X
to	B-X
occur	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
contention	B-X
that	B-X
furanones	B-X
,	B-X
at	B-X
the	B-X
concentrations	B-X
produced	B-X
by	B-X
the	B-X
alga	B-X
,	B-X
can	B-X
control	B-X
bacterial	B-X
colonization	B-X
of	B-X
surfaces	B-X
by	B-X
specifically	B-X
interfering	B-X
with	B-X
AHL-mediated	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
the	B-X
LuxR	B-X
protein	B-X
.	B-X

The	O
marine	O
red	O
alga	O
Delisea	O
pulchra	O
produces	O
halogenated	O
furanones	O
which	O
resemble	O
AHLs	O
structurally	O
and	O
show	O
inhibitory	O
activity	O
at	O
ecologically	O
realistic	O
concentrations	O
in	O
AHL	O
bioassays	O
.	O
<EOS>	B-X
Acylated	B-X
homoserine	B-X
lactone	B-X
(	B-X
AHL	B-X
)	B-X
-mediated	B-X
gene	B-X
expression	B-X
controls	B-X
phenotypes	B-X
involved	B-X
in	B-X
colonization	B-X
,	B-X
often	B-X
specifically	B-X
of	B-X
higher	B-X
organisms	B-X
,	B-X
in	B-X
both	B-X
marine	B-X
and	B-X
terrestrial	B-X
environments	B-X
.	B-X
The	B-X
marine	B-X
red	B-X
alga	B-X
Delisea	B-X
pulchra	B-X
produces	B-X
halogenated	B-X
furanones	B-X
which	B-X
resemble	B-X
AHLs	B-X
structurally	B-X
and	B-X
show	B-X
inhibitory	B-X
activity	B-X
at	B-X
ecologically	B-X
realistic	B-X
concentrations	B-X
in	B-X
AHL	B-X
bioassays	B-X
.	B-X
Evidence	B-X
is	B-X
presented	B-X
that	B-X
halogenated	B-X
furanones	B-X
displace	B-X
tritiated	B-X
OHHL	B-X
[	B-X
N-3-	B-X
(	B-X
oxohexanoyl	B-X
)	B-X
-L-homoserine	B-X
lactone	B-X
]	B-X
from	B-X
Escherichia	B-X
coli	B-X
cells	B-X
overproducing	B-X
LuxR	B-X
with	B-X
potencies	B-X
corresponding	B-X
to	B-X
their	B-X
respective	B-X
inhibitory	B-X
activities	B-X
in	B-X
an	B-X
AHL-regulated	B-X
bioluminescence	B-X
assay	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
is	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
furanones	B-X
inhibit	B-X
AHL-dependent	B-X
phenotypes	B-X
.	B-X
General	B-X
metabolic	B-X
disruption	B-X
was	B-X
assessed	B-X
with	B-X
two-dimensional	B-X
PAGE	B-X
,	B-X
revealing	B-X
limited	B-X
non-AHL-related	B-X
effects	B-X
.	B-X
A	B-X
direct	B-X
chemical	B-X
interaction	B-X
between	B-X
the	B-X
algal	B-X
compounds	B-X
and	B-X
AHLs	B-X
,	B-X
as	B-X
monitored	B-X
by	B-X
1H	B-X
NMR	B-X
spectroscopy	B-X
,	B-X
was	B-X
shown	B-X
not	B-X
to	B-X
occur	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
contention	B-X
that	B-X
furanones	B-X
,	B-X
at	B-X
the	B-X
concentrations	B-X
produced	B-X
by	B-X
the	B-X
alga	B-X
,	B-X
can	B-X
control	B-X
bacterial	B-X
colonization	B-X
of	B-X
surfaces	B-X
by	B-X
specifically	B-X
interfering	B-X
with	B-X
AHL-mediated	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
the	B-X
LuxR	B-X
protein	B-X
.	B-X

Evidence	O
is	O
presented	O
that	O
halogenated	O
furanones	O
displace	O
tritiated	O
OHHL	O
[	O
N	O
-	O
3	O
-	O
(	O
oxohexanoyl	O
)	O
-	O
L	O
-	O
homoserine	O
lactone	O
]	O
from	O
Escherichia	O
coli	O
cells	O
overproducing	O
LuxR	B-Protein
with	O
potencies	O
corresponding	O
to	O
their	O
respective	O
inhibitory	O
activities	O
in	O
an	O
AHL	O
-	O
regulated	O
bioluminescence	O
assay	O
,	O
indicating	O
that	O
this	O
is	O
the	O
mechanism	O
by	O
which	O
furanones	O
inhibit	O
AHL	O
-	O
dependent	O
phenotypes	O
.	O

Alternative	O
mechanisms	O
for	O
this	O
phenomenon	O
are	O
also	O
addressed	O
.	O
<EOS>	B-X
Preventive	B-X
analgesia	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
an	B-X
approach	B-X
to	B-X
mitigate	B-X
the	B-X
phenomenon	B-X
of	B-X
central	B-X
sensitization	B-X
,	B-X
which	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
chronic	B-X
pain	B-X
after	B-X
surgery	B-X
.	B-X
Multiple	B-X
classes	B-X
of	B-X
systemic	B-X
analgesic	B-X
medications	B-X
have	B-X
been	B-X
used	B-X
to	B-X
accomplish	B-X
these	B-X
tasks	B-X
,	B-X
and	B-X
the	B-X
aim	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
outline	B-X
these	B-X
medications	B-X
,	B-X
their	B-X
mechanisms	B-X
of	B-X
action	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
evidence	B-X
behind	B-X
their	B-X
individual	B-X
roles	B-X
in	B-X
multimodal	B-X
analgesia	B-X
.	B-X
Regional	B-X
anesthesia	B-X
has	B-X
also	B-X
been	B-X
embraced	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
multimodal	B-X
analgesia	B-X
in	B-X
orthopedic	B-X
surgery	B-X
;	B-X
however	B-X
,	B-X
over	B-X
the	B-X
past	B-X
several	B-X
years	B-X
,	B-X
local	B-X
infiltration	B-X
analgesia	B-X
(	B-X
LIA	B-X
)	B-X
emerged	B-X
as	B-X
a	B-X
viable	B-X
alternative	B-X
,	B-X
particularly	B-X
in	B-X
total	B-X
knee	B-X
arthroplasty	B-X
.	B-X
This	B-X
phenomenon	B-X
mirrors	B-X
the	B-X
worldwide	B-X
increase	B-X
in	B-X
antimicrobial	B-X
resistance	B-X
and	B-X
the	B-X
emergence	B-X
of	B-X
other	B-X
MDR	B-X
pathogens	B-X
,	B-X
such	B-X
as	B-X
malaria	B-X
,	B-X
HIV	B-X
,	B-X
and	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
The	B-X
traditional	B-X
view	B-X
that	B-X
acquired	B-X
resistance	B-X
to	B-X
antituberculous	B-X
drugs	B-X
is	B-X
driven	B-X
by	B-X
poor	B-X
compliance	B-X
and	B-X
programmatic	B-X
failure	B-X
is	B-X
now	B-X
being	B-X
questioned	B-X
,	B-X
and	B-X
several	B-X
lines	B-X
of	B-X
evidence	B-X
suggest	B-X
that	B-X
alternative	B-X
mechanisms-including	B-X
pharmacokinetic	B-X
variability	B-X
,	B-X
induction	B-X
of	B-X
efflux	B-X
pumps	B-X
that	B-X
transport	B-X
the	B-X
drug	B-X
out	B-X
of	B-X
cells	B-X
,	B-X
and	B-X
suboptimal	B-X
drug	B-X
penetration	B-X
into	B-X
tuberculosis	B-X
lesions-are	B-X
likely	B-X
crucial	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
drug-resistant	B-X
tuberculosis	B-X
.	B-X
These	B-X
factors	B-X
have	B-X
implications	B-X
for	B-X
the	B-X
design	B-X
of	B-X
new	B-X
interventions	B-X
,	B-X
drug	B-X
delivery	B-X
and	B-X
dosing	B-X
mechanisms	B-X
,	B-X
and	B-X
public	B-X
health	B-X
policy	B-X
.	B-X

General	O
metabolic	O
disruption	O
was	O
assessed	O
with	O
two	O
-	O
dimensional	O
PAGE	O
,	O
revealing	O
limited	O
non	O
-	O
AHL	O
-	O
related	O
effects	O
.	O
<EOS>	B-X
Acylated	B-X
homoserine	B-X
lactone	B-X
(	B-X
AHL	B-X
)	B-X
-mediated	B-X
gene	B-X
expression	B-X
controls	B-X
phenotypes	B-X
involved	B-X
in	B-X
colonization	B-X
,	B-X
often	B-X
specifically	B-X
of	B-X
higher	B-X
organisms	B-X
,	B-X
in	B-X
both	B-X
marine	B-X
and	B-X
terrestrial	B-X
environments	B-X
.	B-X
The	B-X
marine	B-X
red	B-X
alga	B-X
Delisea	B-X
pulchra	B-X
produces	B-X
halogenated	B-X
furanones	B-X
which	B-X
resemble	B-X
AHLs	B-X
structurally	B-X
and	B-X
show	B-X
inhibitory	B-X
activity	B-X
at	B-X
ecologically	B-X
realistic	B-X
concentrations	B-X
in	B-X
AHL	B-X
bioassays	B-X
.	B-X
Evidence	B-X
is	B-X
presented	B-X
that	B-X
halogenated	B-X
furanones	B-X
displace	B-X
tritiated	B-X
OHHL	B-X
[	B-X
N-3-	B-X
(	B-X
oxohexanoyl	B-X
)	B-X
-L-homoserine	B-X
lactone	B-X
]	B-X
from	B-X
Escherichia	B-X
coli	B-X
cells	B-X
overproducing	B-X
LuxR	B-X
with	B-X
potencies	B-X
corresponding	B-X
to	B-X
their	B-X
respective	B-X
inhibitory	B-X
activities	B-X
in	B-X
an	B-X
AHL-regulated	B-X
bioluminescence	B-X
assay	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
is	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
furanones	B-X
inhibit	B-X
AHL-dependent	B-X
phenotypes	B-X
.	B-X
Alternative	B-X
mechanisms	B-X
for	B-X
this	B-X
phenomenon	B-X
are	B-X
also	B-X
addressed	B-X
.	B-X
General	B-X
metabolic	B-X
disruption	B-X
was	B-X
assessed	B-X
with	B-X
two-dimensional	B-X
PAGE	B-X
,	B-X
revealing	B-X
limited	B-X
non-AHL-related	B-X
effects	B-X
.	B-X
A	B-X
direct	B-X
chemical	B-X
interaction	B-X
between	B-X
the	B-X
algal	B-X
compounds	B-X
and	B-X
AHLs	B-X
,	B-X
as	B-X
monitored	B-X
by	B-X
1H	B-X
NMR	B-X
spectroscopy	B-X
,	B-X
was	B-X
shown	B-X
not	B-X
to	B-X
occur	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
contention	B-X
that	B-X
furanones	B-X
,	B-X
at	B-X
the	B-X
concentrations	B-X
produced	B-X
by	B-X
the	B-X
alga	B-X
,	B-X
can	B-X
control	B-X
bacterial	B-X
colonization	B-X
of	B-X
surfaces	B-X
by	B-X
specifically	B-X
interfering	B-X
with	B-X
AHL-mediated	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
the	B-X
LuxR	B-X
protein	B-X
.	B-X

A	O
direct	O
chemical	O
interaction	O
between	O
the	O
algal	O
compounds	O
and	O
AHLs	O
,	O
as	O
monitored	O
by	O
1H	O
NMR	O
spectroscopy	O
,	O
was	O
shown	O
not	O
to	O
occur	O
in	O
vitro	O
.	O

These	O
results	O
support	O
the	O
contention	O
that	O
furanones	O
,	O
at	O
the	O
concentrations	O
produced	O
by	O
the	O
alga	O
,	O
can	O
control	O
bacterial	O
colonization	O
of	O
surfaces	O
by	O
specifically	O
interfering	O
with	O
AHL	O
-	O
mediated	O
gene	O
expression	O
at	O
the	O
level	O
of	O
the	O
LuxR	B-Protein
protein	O
.	O
<EOS>	B-X
Acylated	B-X
homoserine	B-X
lactone	B-X
(	B-X
AHL	B-X
)	B-X
-mediated	B-X
gene	B-X
expression	B-X
controls	B-X
phenotypes	B-X
involved	B-X
in	B-X
colonization	B-X
,	B-X
often	B-X
specifically	B-X
of	B-X
higher	B-X
organisms	B-X
,	B-X
in	B-X
both	B-X
marine	B-X
and	B-X
terrestrial	B-X
environments	B-X
.	B-X
The	B-X
marine	B-X
red	B-X
alga	B-X
Delisea	B-X
pulchra	B-X
produces	B-X
halogenated	B-X
furanones	B-X
which	B-X
resemble	B-X
AHLs	B-X
structurally	B-X
and	B-X
show	B-X
inhibitory	B-X
activity	B-X
at	B-X
ecologically	B-X
realistic	B-X
concentrations	B-X
in	B-X
AHL	B-X
bioassays	B-X
.	B-X
Evidence	B-X
is	B-X
presented	B-X
that	B-X
halogenated	B-X
furanones	B-X
displace	B-X
tritiated	B-X
OHHL	B-X
[	B-X
N-3-	B-X
(	B-X
oxohexanoyl	B-X
)	B-X
-L-homoserine	B-X
lactone	B-X
]	B-X
from	B-X
Escherichia	B-X
coli	B-X
cells	B-X
overproducing	B-X
LuxR	B-X
with	B-X
potencies	B-X
corresponding	B-X
to	B-X
their	B-X
respective	B-X
inhibitory	B-X
activities	B-X
in	B-X
an	B-X
AHL-regulated	B-X
bioluminescence	B-X
assay	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
is	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
furanones	B-X
inhibit	B-X
AHL-dependent	B-X
phenotypes	B-X
.	B-X
General	B-X
metabolic	B-X
disruption	B-X
was	B-X
assessed	B-X
with	B-X
two-dimensional	B-X
PAGE	B-X
,	B-X
revealing	B-X
limited	B-X
non-AHL-related	B-X
effects	B-X
.	B-X
A	B-X
direct	B-X
chemical	B-X
interaction	B-X
between	B-X
the	B-X
algal	B-X
compounds	B-X
and	B-X
AHLs	B-X
,	B-X
as	B-X
monitored	B-X
by	B-X
1H	B-X
NMR	B-X
spectroscopy	B-X
,	B-X
was	B-X
shown	B-X
not	B-X
to	B-X
occur	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
contention	B-X
that	B-X
furanones	B-X
,	B-X
at	B-X
the	B-X
concentrations	B-X
produced	B-X
by	B-X
the	B-X
alga	B-X
,	B-X
can	B-X
control	B-X
bacterial	B-X
colonization	B-X
of	B-X
surfaces	B-X
by	B-X
specifically	B-X
interfering	B-X
with	B-X
AHL-mediated	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
the	B-X
LuxR	B-X
protein	B-X
.	B-X

Activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
by	O
oxidized	O
LDL	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
:	O
mediation	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
and	O
association	O
with	O
oxidized	O
LDL	O
-	O
induced	O
cytotoxicity	O
.	O
<EOS>	B-X
Oxidized	B-X
low-density	B-X
lipoproteins	B-X
(	B-X
oxLDL	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
understood	B-X
.	B-X
The	B-X
present	B-X
study	B-X
showed	B-X
that	B-X
oxLDL	B-X
strongly	B-X
evoked	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
in	B-X
rat	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manners	B-X
,	B-X
reaching	B-X
the	B-X
maximal	B-X
activation	B-X
at	B-X
100	B-X
microg/mL	B-X
within	B-X
5	B-X
minutes	B-X
.	B-X
The	B-X
results	B-X
from	B-X
immunofluorescence	B-X
staining	B-X
also	B-X
revealed	B-X
that	B-X
p38	B-X
MAPK	B-X
was	B-X
activated	B-X
by	B-X
oxLDL	B-X
in	B-X
5	B-X
minutes	B-X
,	B-X
and	B-X
the	B-X
activated	B-X
p38	B-X
MAPK	B-X
was	B-X
translocated	B-X
from	B-X
cytoplasm	B-X
to	B-X
nucleus	B-X
of	B-X
VSMCs	B-X
in	B-X
15	B-X
minutes	B-X
.	B-X
Activation	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
oxLDL	B-X
was	B-X
apparently	B-X
not	B-X
mediated	B-X
by	B-X
their	B-X
classical	B-X
scavenger	B-X
receptors	B-X
and	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X
However	B-X
,	B-X
activation	B-X
of	B-X
p38	B-X
MAPK	B-X
was	B-X
effectively	B-X
blocked	B-X
by	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
and	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
phospholipase	B-X
C	B-X
inhibitor	B-X
U-73122	B-X
.	B-X
OxLDL	B-X
also	B-X
inhibited	B-X
forskolin-stimulated	B-X
cAMP	B-X
accumulation	B-X
and	B-X
increased	B-X
inositol	B-X
phosphate	B-X
formation	B-X
.	B-X
More	B-X
interestingly	B-X
,	B-X
inhibition	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
its	B-X
specific	B-X
inhibitor	B-X
SB203580	B-X
significantly	B-X
blocked	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
(	B-X
increased	B-X
leakage	B-X
of	B-X
cytoplasmic	B-X
lactate	B-X
dehydrogenase	B-X
to	B-X
the	B-X
culture	B-X
medium	B-X
,	B-X
reduced	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
,	B-X
and	B-X
attenuated	B-X
mitochondrial	B-X
metabolism	B-X
of	B-X
tetrazolium	B-X
salt	B-X
,	B-X
(	B-X
3-	B-X
(	B-X
4	B-X
,	B-X
5-dimethylthiazol-2-yl	B-X
)	B-X
-5-	B-X
(	B-X
3-carboxymethoxyphenyl	B-X
)	B-X
-2-	B-X
(	B-X
4-s	B-X
ulfophenyl	B-X
)	B-X
-	B-X
2H-tetrazolium	B-X
)	B-X
,	B-X
MTS	B-X
)	B-X
in	B-X
VSMCs	B-X
,	B-X
and	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
also	B-X
inhibited	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
clearly	B-X
demonstrated	B-X
that	B-X
oxLDL	B-X
effectively	B-X
activated	B-X
p38	B-X
MAPK	B-X
in	B-X
VSMCs	B-X
,	B-X
which	B-X
was	B-X
likely	B-X
mediated	B-X
via	B-X
pertussis	B-X
toxin-sensitive	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
the	B-X
p38	B-X
activation	B-X
was	B-X
functionally	B-X
associated	B-X
with	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
in	B-X
VSMCs	B-X
.	B-X

Oxidized	O
low	O
-	O
density	O
lipoproteins	O
(	O
oxLDL	O
)	O
have	O
been	O
shown	O
to	O
play	O
a	O
crucial	O
role	O
in	O
atherosclerosis	O
,	O
but	O
the	O
underlying	O
molecular	O
mechanisms	O
have	O
not	O
been	O
fully	O
understood	O
.	O
<EOS>	B-X
Aberrant	B-X
activation	B-X
of	B-X
inflammation	B-X
and	B-X
excess	B-X
accumulation	B-X
of	B-X
lipids	B-X
play	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
occurrence	B-X
and	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
(	B-X
AS	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
of	B-X
OCT	B-X
in	B-X
AS	B-X
are	B-X
not	B-X
completely	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
stimulated	B-X
murine	B-X
RAW264.7	B-X
cells	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
oxidized	B-X
low-density	B-X
lipoproteins	B-X
(	B-X
ox-LDL	B-X
)	B-X
to	B-X
mimic	B-X
the	B-X
development	B-X
of	B-X
AS	B-X
.	B-X

The	O
present	O
study	O
showed	O
that	O
oxLDL	O
strongly	O
evoked	O
phosphorylation	O
and	O
activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
in	O
rat	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
in	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manners	O
,	O
reaching	O
the	O
maximal	O
activation	O
at	O
100	O
microg	O
/	O
mL	O
within	O
5	O
minutes	O
.	O
<EOS>	B-X
Oxidized	B-X
low-density	B-X
lipoproteins	B-X
(	B-X
oxLDL	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
understood	B-X
.	B-X
The	B-X
present	B-X
study	B-X
showed	B-X
that	B-X
oxLDL	B-X
strongly	B-X
evoked	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
in	B-X
rat	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manners	B-X
,	B-X
reaching	B-X
the	B-X
maximal	B-X
activation	B-X
at	B-X
100	B-X
microg/mL	B-X
within	B-X
5	B-X
minutes	B-X
.	B-X
The	B-X
results	B-X
from	B-X
immunofluorescence	B-X
staining	B-X
also	B-X
revealed	B-X
that	B-X
p38	B-X
MAPK	B-X
was	B-X
activated	B-X
by	B-X
oxLDL	B-X
in	B-X
5	B-X
minutes	B-X
,	B-X
and	B-X
the	B-X
activated	B-X
p38	B-X
MAPK	B-X
was	B-X
translocated	B-X
from	B-X
cytoplasm	B-X
to	B-X
nucleus	B-X
of	B-X
VSMCs	B-X
in	B-X
15	B-X
minutes	B-X
.	B-X
Activation	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
oxLDL	B-X
was	B-X
apparently	B-X
not	B-X
mediated	B-X
by	B-X
their	B-X
classical	B-X
scavenger	B-X
receptors	B-X
and	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X
However	B-X
,	B-X
activation	B-X
of	B-X
p38	B-X
MAPK	B-X
was	B-X
effectively	B-X
blocked	B-X
by	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
and	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
phospholipase	B-X
C	B-X
inhibitor	B-X
U-73122	B-X
.	B-X
More	B-X
interestingly	B-X
,	B-X
inhibition	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
its	B-X
specific	B-X
inhibitor	B-X
SB203580	B-X
significantly	B-X
blocked	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
(	B-X
increased	B-X
leakage	B-X
of	B-X
cytoplasmic	B-X
lactate	B-X
dehydrogenase	B-X
to	B-X
the	B-X
culture	B-X
medium	B-X
,	B-X
reduced	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
,	B-X
and	B-X
attenuated	B-X
mitochondrial	B-X
metabolism	B-X
of	B-X
tetrazolium	B-X
salt	B-X
,	B-X
(	B-X
3-	B-X
(	B-X
4	B-X
,	B-X
5-dimethylthiazol-2-yl	B-X
)	B-X
-5-	B-X
(	B-X
3-carboxymethoxyphenyl	B-X
)	B-X
-2-	B-X
(	B-X
4-s	B-X
ulfophenyl	B-X
)	B-X
-	B-X
2H-tetrazolium	B-X
)	B-X
,	B-X
MTS	B-X
)	B-X
in	B-X
VSMCs	B-X
,	B-X
and	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
also	B-X
inhibited	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
clearly	B-X
demonstrated	B-X
that	B-X
oxLDL	B-X
effectively	B-X
activated	B-X
p38	B-X
MAPK	B-X
in	B-X
VSMCs	B-X
,	B-X
which	B-X
was	B-X
likely	B-X
mediated	B-X
via	B-X
pertussis	B-X
toxin-sensitive	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
the	B-X
p38	B-X
activation	B-X
was	B-X
functionally	B-X
associated	B-X
with	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
in	B-X
VSMCs	B-X
.	B-X

The	O
results	O
from	O
immunofluorescence	O
staining	O
also	O
revealed	O
that	O
p38	O
MAPK	O
was	O
activated	O
by	O
oxLDL	O
in	O
5	O
minutes	O
,	O
and	O
the	O
activated	O
p38	O
MAPK	O
was	O
translocated	O
from	O
cytoplasm	O
to	O
nucleus	O
of	O
VSMCs	O
in	O
15	O
minutes	O
.	O
<EOS>	B-X
Oxidized	B-X
low-density	B-X
lipoproteins	B-X
(	B-X
oxLDL	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
understood	B-X
.	B-X
The	B-X
present	B-X
study	B-X
showed	B-X
that	B-X
oxLDL	B-X
strongly	B-X
evoked	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
in	B-X
rat	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manners	B-X
,	B-X
reaching	B-X
the	B-X
maximal	B-X
activation	B-X
at	B-X
100	B-X
microg/mL	B-X
within	B-X
5	B-X
minutes	B-X
.	B-X
The	B-X
results	B-X
from	B-X
immunofluorescence	B-X
staining	B-X
also	B-X
revealed	B-X
that	B-X
p38	B-X
MAPK	B-X
was	B-X
activated	B-X
by	B-X
oxLDL	B-X
in	B-X
5	B-X
minutes	B-X
,	B-X
and	B-X
the	B-X
activated	B-X
p38	B-X
MAPK	B-X
was	B-X
translocated	B-X
from	B-X
cytoplasm	B-X
to	B-X
nucleus	B-X
of	B-X
VSMCs	B-X
in	B-X
15	B-X
minutes	B-X
.	B-X
Activation	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
oxLDL	B-X
was	B-X
apparently	B-X
not	B-X
mediated	B-X
by	B-X
their	B-X
classical	B-X
scavenger	B-X
receptors	B-X
and	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X
However	B-X
,	B-X
activation	B-X
of	B-X
p38	B-X
MAPK	B-X
was	B-X
effectively	B-X
blocked	B-X
by	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
and	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
phospholipase	B-X
C	B-X
inhibitor	B-X
U-73122	B-X
.	B-X
OxLDL	B-X
also	B-X
inhibited	B-X
forskolin-stimulated	B-X
cAMP	B-X
accumulation	B-X
and	B-X
increased	B-X
inositol	B-X
phosphate	B-X
formation	B-X
.	B-X
More	B-X
interestingly	B-X
,	B-X
inhibition	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
its	B-X
specific	B-X
inhibitor	B-X
SB203580	B-X
significantly	B-X
blocked	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
(	B-X
increased	B-X
leakage	B-X
of	B-X
cytoplasmic	B-X
lactate	B-X
dehydrogenase	B-X
to	B-X
the	B-X
culture	B-X
medium	B-X
,	B-X
reduced	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
,	B-X
and	B-X
attenuated	B-X
mitochondrial	B-X
metabolism	B-X
of	B-X
tetrazolium	B-X
salt	B-X
,	B-X
(	B-X
3-	B-X
(	B-X
4	B-X
,	B-X
5-dimethylthiazol-2-yl	B-X
)	B-X
-5-	B-X
(	B-X
3-carboxymethoxyphenyl	B-X
)	B-X
-2-	B-X
(	B-X
4-s	B-X
ulfophenyl	B-X
)	B-X
-	B-X
2H-tetrazolium	B-X
)	B-X
,	B-X
MTS	B-X
)	B-X
in	B-X
VSMCs	B-X
,	B-X
and	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
also	B-X
inhibited	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
clearly	B-X
demonstrated	B-X
that	B-X
oxLDL	B-X
effectively	B-X
activated	B-X
p38	B-X
MAPK	B-X
in	B-X
VSMCs	B-X
,	B-X
which	B-X
was	B-X
likely	B-X
mediated	B-X
via	B-X
pertussis	B-X
toxin-sensitive	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
the	B-X
p38	B-X
activation	B-X
was	B-X
functionally	B-X
associated	B-X
with	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
in	B-X
VSMCs	B-X
.	B-X

Activation	O
of	O
p38	O
MAPK	O
by	O
oxLDL	O
was	O
apparently	O
not	O
mediated	O
by	O
their	O
classical	O
scavenger	O
receptors	O
and	O
was	O
not	O
affected	O
by	O
tyrosine	O
kinase	O
inhibitors	O
.	O
<EOS>	B-X
Lectin-like	B-X
oxidized	B-X
low-density	B-X
lipoprotein	B-X
(	B-X
oxLDL	B-X
)	B-X
receptor-1	B-X
(	B-X
LOX-1	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
to	B-X
regulate	B-X
cardiac	B-X
remodeling	B-X
and	B-X
oxidative	B-X
stress	B-X
after	B-X
ischemia-reperfusion	B-X
.	B-X
Echocardiography	B-X
and	B-X
catheter-based	B-X
hemodynamic	B-X
assessment	B-X
apparently	B-X
revealed	B-X
preserved	B-X
left	B-X
ventricular	B-X
(	B-X
LV	B-X
)	B-X
fractional	B-X
shortening	B-X
(	B-X
FS	B-X
)	B-X
and	B-X
cavity	B-X
size	B-X
of	B-X
LOX-1	B-X
KO	B-X
mice	B-X
compared	B-X
with	B-X
those	B-X
of	B-X
WT	B-X
mice	B-X
after	B-X
DOX	B-X
administration	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
also	B-X
showed	B-X
lower	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
κB	B-X
(	B-X
NF-κB	B-X
)	B-X
and	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
in	B-X
LOX-1	B-X
KO	B-X
mice	B-X
treated	B-X
with	B-X
DOX	B-X
than	B-X
WT	B-X
mice	B-X
treated	B-X
with	B-X
DOX	B-X
.	B-X
Meanwhile	B-X
,	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
MAPK	B-X
(	B-X
ERK	B-X
)	B-X
inactivation	B-X
and	B-X
decreased	B-X
expression	B-X
of	B-X
sarcomeric	B-X
proteins	B-X
and	B-X
related	B-X
transcription	B-X
factor	B-X
GATA-4	B-X
in	B-X
WT	B-X
mice	B-X
treated	B-X
with	B-X
DOX	B-X
administration	B-X
were	B-X
not	B-X
seen	B-X
in	B-X
LOX-1	B-X
KO	B-X
mice	B-X
treated	B-X
with	B-X
DOX	B-X
administration	B-X
and	B-X
WT	B-X
and	B-X
LOX-1	B-X
KO	B-X
mice	B-X
treated	B-X
with	B-X
vehicle	B-X
.	B-X

However	O
,	O
activation	O
of	O
p38	O
MAPK	O
was	O
effectively	O
blocked	O
by	O
pretreatment	O
with	O
pertussis	O
toxin	O
and	O
was	O
significantly	O
reduced	O
by	O
phospholipase	O
C	O
inhibitor	O
U	O
-	O
73122	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
showed	B-X
that	B-X
oxLDL	B-X
strongly	B-X
evoked	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
in	B-X
rat	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manners	B-X
,	B-X
reaching	B-X
the	B-X
maximal	B-X
activation	B-X
at	B-X
100	B-X
microg/mL	B-X
within	B-X
5	B-X
minutes	B-X
.	B-X
The	B-X
results	B-X
from	B-X
immunofluorescence	B-X
staining	B-X
also	B-X
revealed	B-X
that	B-X
p38	B-X
MAPK	B-X
was	B-X
activated	B-X
by	B-X
oxLDL	B-X
in	B-X
5	B-X
minutes	B-X
,	B-X
and	B-X
the	B-X
activated	B-X
p38	B-X
MAPK	B-X
was	B-X
translocated	B-X
from	B-X
cytoplasm	B-X
to	B-X
nucleus	B-X
of	B-X
VSMCs	B-X
in	B-X
15	B-X
minutes	B-X
.	B-X
Activation	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
oxLDL	B-X
was	B-X
apparently	B-X
not	B-X
mediated	B-X
by	B-X
their	B-X
classical	B-X
scavenger	B-X
receptors	B-X
and	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X
However	B-X
,	B-X
activation	B-X
of	B-X
p38	B-X
MAPK	B-X
was	B-X
effectively	B-X
blocked	B-X
by	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
and	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
phospholipase	B-X
C	B-X
inhibitor	B-X
U-73122	B-X
.	B-X
More	B-X
interestingly	B-X
,	B-X
inhibition	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
its	B-X
specific	B-X
inhibitor	B-X
SB203580	B-X
significantly	B-X
blocked	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
(	B-X
increased	B-X
leakage	B-X
of	B-X
cytoplasmic	B-X
lactate	B-X
dehydrogenase	B-X
to	B-X
the	B-X
culture	B-X
medium	B-X
,	B-X
reduced	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
,	B-X
and	B-X
attenuated	B-X
mitochondrial	B-X
metabolism	B-X
of	B-X
tetrazolium	B-X
salt	B-X
,	B-X
(	B-X
3-	B-X
(	B-X
4	B-X
,	B-X
5-dimethylthiazol-2-yl	B-X
)	B-X
-5-	B-X
(	B-X
3-carboxymethoxyphenyl	B-X
)	B-X
-2-	B-X
(	B-X
4-s	B-X
ulfophenyl	B-X
)	B-X
-	B-X
2H-tetrazolium	B-X
)	B-X
,	B-X
MTS	B-X
)	B-X
in	B-X
VSMCs	B-X
,	B-X
and	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
also	B-X
inhibited	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
clearly	B-X
demonstrated	B-X
that	B-X
oxLDL	B-X
effectively	B-X
activated	B-X
p38	B-X
MAPK	B-X
in	B-X
VSMCs	B-X
,	B-X
which	B-X
was	B-X
likely	B-X
mediated	B-X
via	B-X
pertussis	B-X
toxin-sensitive	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
the	B-X
p38	B-X
activation	B-X
was	B-X
functionally	B-X
associated	B-X
with	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
in	B-X
VSMCs	B-X
.	B-X

OxLDL	O
also	O
inhibited	O
forskolin	O
-	O
stimulated	O
cAMP	O
accumulation	O
and	O
increased	O
inositol	O
phosphate	O
formation	O
.	O
<EOS>	B-X
The	B-X
results	B-X
from	B-X
immunofluorescence	B-X
staining	B-X
also	B-X
revealed	B-X
that	B-X
p38	B-X
MAPK	B-X
was	B-X
activated	B-X
by	B-X
oxLDL	B-X
in	B-X
5	B-X
minutes	B-X
,	B-X
and	B-X
the	B-X
activated	B-X
p38	B-X
MAPK	B-X
was	B-X
translocated	B-X
from	B-X
cytoplasm	B-X
to	B-X
nucleus	B-X
of	B-X
VSMCs	B-X
in	B-X
15	B-X
minutes	B-X
.	B-X
OxLDL	B-X
also	B-X
inhibited	B-X
forskolin-stimulated	B-X
cAMP	B-X
accumulation	B-X
and	B-X
increased	B-X
inositol	B-X
phosphate	B-X
formation	B-X
.	B-X
More	B-X
interestingly	B-X
,	B-X
inhibition	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
its	B-X
specific	B-X
inhibitor	B-X
SB203580	B-X
significantly	B-X
blocked	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
(	B-X
increased	B-X
leakage	B-X
of	B-X
cytoplasmic	B-X
lactate	B-X
dehydrogenase	B-X
to	B-X
the	B-X
culture	B-X
medium	B-X
,	B-X
reduced	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
,	B-X
and	B-X
attenuated	B-X
mitochondrial	B-X
metabolism	B-X
of	B-X
tetrazolium	B-X
salt	B-X
,	B-X
(	B-X
3-	B-X
(	B-X
4	B-X
,	B-X
5-dimethylthiazol-2-yl	B-X
)	B-X
-5-	B-X
(	B-X
3-carboxymethoxyphenyl	B-X
)	B-X
-2-	B-X
(	B-X
4-s	B-X
ulfophenyl	B-X
)	B-X
-	B-X
2H-tetrazolium	B-X
)	B-X
,	B-X
MTS	B-X
)	B-X
in	B-X
VSMCs	B-X
,	B-X
and	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
also	B-X
inhibited	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
.	B-X

More	O
interestingly	O
,	O
inhibition	O
of	O
p38	O
MAPK	O
by	O
its	O
specific	O
inhibitor	O
SB203580	O
significantly	O
blocked	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
(	O
increased	O
leakage	O
of	O
cytoplasmic	O
lactate	O
dehydrogenase	O
to	O
the	O
culture	O
medium	O
,	O
reduced	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
and	O
attenuated	O
mitochondrial	O
metabolism	O
of	O
tetrazolium	O
salt	O
,	O
(	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
5	O
-	O
(	O
3	O
-	O
carboxymethoxyphenyl	O
)	O
-	O
2	O
-	O
(	O
4	O
-	O
s	O
ulfophenyl	O
)	O
-	O
2H	O
-	O
tetrazolium	O
)	O
,	O
MTS	O
)	O
in	O
VSMCs	O
,	O
and	O
pretreatment	O
with	O
pertussis	O
toxin	O
also	O
inhibited	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
.	O

Taken	O
together	O
,	O
our	O
data	O
clearly	O
demonstrated	O
that	O
oxLDL	O
effectively	O
activated	O
p38	O
MAPK	O
in	O
VSMCs	O
,	O
which	O
was	O
likely	O
mediated	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
,	O
and	O
the	O
p38	O
activation	O
was	O
functionally	O
associated	O
with	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
in	O
VSMCs	O
.	O
<EOS>	B-X
Oxidized	B-X
low-density	B-X
lipoproteins	B-X
(	B-X
oxLDL	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
understood	B-X
.	B-X
The	B-X
present	B-X
study	B-X
showed	B-X
that	B-X
oxLDL	B-X
strongly	B-X
evoked	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
in	B-X
rat	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manners	B-X
,	B-X
reaching	B-X
the	B-X
maximal	B-X
activation	B-X
at	B-X
100	B-X
microg/mL	B-X
within	B-X
5	B-X
minutes	B-X
.	B-X
The	B-X
results	B-X
from	B-X
immunofluorescence	B-X
staining	B-X
also	B-X
revealed	B-X
that	B-X
p38	B-X
MAPK	B-X
was	B-X
activated	B-X
by	B-X
oxLDL	B-X
in	B-X
5	B-X
minutes	B-X
,	B-X
and	B-X
the	B-X
activated	B-X
p38	B-X
MAPK	B-X
was	B-X
translocated	B-X
from	B-X
cytoplasm	B-X
to	B-X
nucleus	B-X
of	B-X
VSMCs	B-X
in	B-X
15	B-X
minutes	B-X
.	B-X
Activation	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
oxLDL	B-X
was	B-X
apparently	B-X
not	B-X
mediated	B-X
by	B-X
their	B-X
classical	B-X
scavenger	B-X
receptors	B-X
and	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X
However	B-X
,	B-X
activation	B-X
of	B-X
p38	B-X
MAPK	B-X
was	B-X
effectively	B-X
blocked	B-X
by	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
and	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
phospholipase	B-X
C	B-X
inhibitor	B-X
U-73122	B-X
.	B-X
More	B-X
interestingly	B-X
,	B-X
inhibition	B-X
of	B-X
p38	B-X
MAPK	B-X
by	B-X
its	B-X
specific	B-X
inhibitor	B-X
SB203580	B-X
significantly	B-X
blocked	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
(	B-X
increased	B-X
leakage	B-X
of	B-X
cytoplasmic	B-X
lactate	B-X
dehydrogenase	B-X
to	B-X
the	B-X
culture	B-X
medium	B-X
,	B-X
reduced	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
,	B-X
and	B-X
attenuated	B-X
mitochondrial	B-X
metabolism	B-X
of	B-X
tetrazolium	B-X
salt	B-X
,	B-X
(	B-X
3-	B-X
(	B-X
4	B-X
,	B-X
5-dimethylthiazol-2-yl	B-X
)	B-X
-5-	B-X
(	B-X
3-carboxymethoxyphenyl	B-X
)	B-X
-2-	B-X
(	B-X
4-s	B-X
ulfophenyl	B-X
)	B-X
-	B-X
2H-tetrazolium	B-X
)	B-X
,	B-X
MTS	B-X
)	B-X
in	B-X
VSMCs	B-X
,	B-X
and	B-X
pretreatment	B-X
with	B-X
pertussis	B-X
toxin	B-X
also	B-X
inhibited	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
clearly	B-X
demonstrated	B-X
that	B-X
oxLDL	B-X
effectively	B-X
activated	B-X
p38	B-X
MAPK	B-X
in	B-X
VSMCs	B-X
,	B-X
which	B-X
was	B-X
likely	B-X
mediated	B-X
via	B-X
pertussis	B-X
toxin-sensitive	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
the	B-X
p38	B-X
activation	B-X
was	B-X
functionally	B-X
associated	B-X
with	B-X
oxLDL-induced	B-X
cytotoxicity	B-X
in	B-X
VSMCs	B-X
.	B-X

Characterization	O
of	O
residues	O
in	O
human	O
IgE	O
and	O
IgG	O
binding	O
site	O
by	O
chemical	O
modification	O
of	O
ovomucoid	O
third	O
domain	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
ovomucoid	B-X
third	B-X
domain	B-X
(	B-X
DIII	B-X
)	B-X
has	B-X
been	B-X
conducted	B-X
to	B-X
characterize	B-X
the	B-X
binding	B-X
site	B-X
residues	B-X
that	B-X
determine	B-X
antigenecity	B-X
and	B-X
allergenecity	B-X
of	B-X
DIII	B-X
.	B-X
Nitration	B-X
of	B-X
Tyr	B-X
,	B-X
ethoxyformylation	B-X
of	B-X
His	B-X
and	B-X
succinylation	B-X
of	B-X
Lys	B-X
residues	B-X
led	B-X
to	B-X
a	B-X
decrease	B-X
of	B-X
alpha-helix	B-X
content	B-X
of	B-X
DIII	B-X
.	B-X
Modification	B-X
of	B-X
His	B-X
,	B-X
Tyr	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
and	B-X
Lys	B-X
residues	B-X
on	B-X
DIII	B-X
resulted	B-X
in	B-X
a	B-X
reduction	B-X
of	B-X
human	B-X
IgG	B-X
binding	B-X
activity	B-X
,	B-X
but	B-X
little	B-X
effect	B-X
on	B-X
IgE	B-X
binding	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
hydrophilic	B-X
residues	B-X
appear	B-X
to	B-X
be	B-X
more	B-X
critical	B-X
for	B-X
human	B-X
IgG	B-X
binding	B-X
site	B-X
,	B-X
whereas	B-X
hydrophobic	B-X
residues	B-X
may	B-X
be	B-X
more	B-X
important	B-X
for	B-X
IgG	B-X
binding	B-X
site	B-X
.	B-X

Chemical	O
modification	O
of	O
ovomucoid	O
third	O
domain	O
(	O
DIII	O
)	O
has	O
been	O
conducted	O
to	O
characterize	O
the	O
binding	O
site	O
residues	O
that	O
determine	O
antigenecity	O
and	O
allergenecity	O
of	O
DIII	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
ovomucoid	B-X
third	B-X
domain	B-X
(	B-X
DIII	B-X
)	B-X
has	B-X
been	B-X
conducted	B-X
to	B-X
characterize	B-X
the	B-X
binding	B-X
site	B-X
residues	B-X
that	B-X
determine	B-X
antigenecity	B-X
and	B-X
allergenecity	B-X
of	B-X
DIII	B-X
.	B-X
Nitration	B-X
of	B-X
Tyr	B-X
,	B-X
ethoxyformylation	B-X
of	B-X
His	B-X
and	B-X
succinylation	B-X
of	B-X
Lys	B-X
residues	B-X
led	B-X
to	B-X
a	B-X
decrease	B-X
of	B-X
alpha-helix	B-X
content	B-X
of	B-X
DIII	B-X
.	B-X
Modification	B-X
of	B-X
His	B-X
,	B-X
Tyr	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
and	B-X
Lys	B-X
residues	B-X
on	B-X
DIII	B-X
resulted	B-X
in	B-X
a	B-X
reduction	B-X
of	B-X
human	B-X
IgG	B-X
binding	B-X
activity	B-X
,	B-X
but	B-X
little	B-X
effect	B-X
on	B-X
IgE	B-X
binding	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
hydrophilic	B-X
residues	B-X
appear	B-X
to	B-X
be	B-X
more	B-X
critical	B-X
for	B-X
human	B-X
IgG	B-X
binding	B-X
site	B-X
,	B-X
whereas	B-X
hydrophobic	B-X
residues	B-X
may	B-X
be	B-X
more	B-X
important	B-X
for	B-X
IgG	B-X
binding	B-X
site	B-X
.	B-X

Nitration	O
of	O
Tyr	O
,	O
ethoxyformylation	O
of	O
His	O
and	O
succinylation	O
of	O
Lys	O
residues	O
led	O
to	O
a	O
decrease	O
of	O
alpha	O
-	O
helix	O
content	O
of	O
DIII	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
ovomucoid	B-X
third	B-X
domain	B-X
(	B-X
DIII	B-X
)	B-X
has	B-X
been	B-X
conducted	B-X
to	B-X
characterize	B-X
the	B-X
binding	B-X
site	B-X
residues	B-X
that	B-X
determine	B-X
antigenecity	B-X
and	B-X
allergenecity	B-X
of	B-X
DIII	B-X
.	B-X
Nitration	B-X
of	B-X
Tyr	B-X
,	B-X
ethoxyformylation	B-X
of	B-X
His	B-X
and	B-X
succinylation	B-X
of	B-X
Lys	B-X
residues	B-X
led	B-X
to	B-X
a	B-X
decrease	B-X
of	B-X
alpha-helix	B-X
content	B-X
of	B-X
DIII	B-X
.	B-X
Modification	B-X
of	B-X
His	B-X
,	B-X
Tyr	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
and	B-X
Lys	B-X
residues	B-X
on	B-X
DIII	B-X
resulted	B-X
in	B-X
a	B-X
reduction	B-X
of	B-X
human	B-X
IgG	B-X
binding	B-X
activity	B-X
,	B-X
but	B-X
little	B-X
effect	B-X
on	B-X
IgE	B-X
binding	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
hydrophilic	B-X
residues	B-X
appear	B-X
to	B-X
be	B-X
more	B-X
critical	B-X
for	B-X
human	B-X
IgG	B-X
binding	B-X
site	B-X
,	B-X
whereas	B-X
hydrophobic	B-X
residues	B-X
may	B-X
be	B-X
more	B-X
important	B-X
for	B-X
IgG	B-X
binding	B-X
site	B-X
.	B-X

Modification	O
of	O
His	O
,	O
Tyr	O
,	O
Glu	O
,	O
Asp	O
and	O
Lys	O
residues	O
on	O
DIII	O
resulted	O
in	O
a	O
reduction	O
of	O
human	O
IgG	O
binding	O
activity	O
,	O
but	O
little	O
effect	O
on	O
IgE	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
hydrophilic	O
residues	O
appear	O
to	O
be	O
more	O
critical	O
for	O
human	O
IgG	O
binding	O
site	O
,	O
whereas	O
hydrophobic	O
residues	O
may	O
be	O
more	O
important	O
for	O
IgG	O
binding	O
site	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
ovomucoid	B-X
third	B-X
domain	B-X
(	B-X
DIII	B-X
)	B-X
has	B-X
been	B-X
conducted	B-X
to	B-X
characterize	B-X
the	B-X
binding	B-X
site	B-X
residues	B-X
that	B-X
determine	B-X
antigenecity	B-X
and	B-X
allergenecity	B-X
of	B-X
DIII	B-X
.	B-X
Nitration	B-X
of	B-X
Tyr	B-X
,	B-X
ethoxyformylation	B-X
of	B-X
His	B-X
and	B-X
succinylation	B-X
of	B-X
Lys	B-X
residues	B-X
led	B-X
to	B-X
a	B-X
decrease	B-X
of	B-X
alpha-helix	B-X
content	B-X
of	B-X
DIII	B-X
.	B-X
Modification	B-X
of	B-X
His	B-X
,	B-X
Tyr	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
and	B-X
Lys	B-X
residues	B-X
on	B-X
DIII	B-X
resulted	B-X
in	B-X
a	B-X
reduction	B-X
of	B-X
human	B-X
IgG	B-X
binding	B-X
activity	B-X
,	B-X
but	B-X
little	B-X
effect	B-X
on	B-X
IgE	B-X
binding	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
hydrophilic	B-X
residues	B-X
appear	B-X
to	B-X
be	B-X
more	B-X
critical	B-X
for	B-X
human	B-X
IgG	B-X
binding	B-X
site	B-X
,	B-X
whereas	B-X
hydrophobic	B-X
residues	B-X
may	B-X
be	B-X
more	B-X
important	B-X
for	B-X
IgG	B-X
binding	B-X
site	B-X
.	B-X

A	O
new	O
30	O
-	O
kDa	O
ubiquitin	B-Protein
-	O
related	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
from	O
bovine	O
brain	O
.	O
<EOS>	B-X
SUMO-1	B-X
is	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
functioning	B-X
as	B-X
an	B-X
important	B-X
reversible	B-X
protein	B-X
modifier	B-X
.	B-X
To	B-X
date	B-X
there	B-X
is	B-X
no	B-X
report	B-X
on	B-X
a	B-X
SUMO-1	B-X
hydrolase/isopeptidase	B-X
catalyzing	B-X
the	B-X
release	B-X
of	B-X
SUMO-1	B-X
from	B-X
its	B-X
precursor	B-X
or	B-X
SUMO-1-ligated	B-X
proteins	B-X
in	B-X
mammalian	B-X
tissues	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
multiple	B-X
activities	B-X
that	B-X
cleave	B-X
the	B-X
SUMO-1	B-X
moiety	B-X
from	B-X
two	B-X
model	B-X
substrates	B-X
,	B-X
(	B-X
125	B-X
)	B-X
I-SUMO-1-alphaNH-HSTVGSMHISPPEPESEEEEEHYC	B-X
and/or	B-X
GST-SUMO-1-	B-X
(	B-X
35	B-X
)	B-X
S-RanGAP1	B-X
conjugate	B-X
,	B-X
in	B-X
bovine	B-X
brain	B-X
extracts	B-X
.	B-X
Of	B-X
them	B-X
,	B-X
a	B-X
major	B-X
SUMO-1	B-X
C-terminal	B-X
hydrolase	B-X
had	B-X
been	B-X
partially	B-X
purified	B-X
by	B-X
successive	B-X
chromatographic	B-X
operations	B-X
.	B-X
The	B-X
enzyme	B-X
had	B-X
the	B-X
ability	B-X
to	B-X
cleave	B-X
SUMO-1	B-X
not	B-X
only	B-X
from	B-X
its	B-X
precursor	B-X
but	B-X
also	B-X
from	B-X
a	B-X
SUMO-1-ligated	B-X
RanGAP1	B-X
but	B-X
did	B-X
not	B-X
exhibit	B-X
any	B-X
significant	B-X
cleavage	B-X
of	B-X
the	B-X
ubiquitin-	B-X
and	B-X
NEDD8-precursor	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
SUMO-1	B-X
hydrolase	B-X
was	B-X
almost	B-X
completely	B-X
inhibited	B-X
by	B-X
N-ethylmaleimide	B-X
,	B-X
but	B-X
not	B-X
by	B-X
phenylmethanesulfonyl	B-X
fluoride	B-X
,	B-X
EDTA	B-X
,	B-X
and	B-X
ubiquitin-aldehyde	B-X
known	B-X
as	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
deubiquitinylating	B-X
enzymes	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
the	B-X
isolated	B-X
SUMO-1	B-X
hydrolase	B-X
was	B-X
approximately	B-X
30	B-X
kDa	B-X
,	B-X
which	B-X
is	B-X
significantly	B-X
smaller	B-X
than	B-X
the	B-X
recently	B-X
identified	B-X
yeast	B-X
Smt3/SUMO-1	B-X
specific	B-X
protease	B-X
Ulp1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
there	B-X
are	B-X
multiple	B-X
SUMO-1	B-X
hydrolase/isopeptidases	B-X
in	B-X
mammalian	B-X
cells	B-X
and	B-X
that	B-X
the	B-X
30-kDa	B-X
small	B-X
SUMO-1	B-X
hydrolase	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
processing	B-X
of	B-X
the	B-X
SUMO-1-precursor	B-X
.	B-X

SUMO	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
ubiquitin	B-Protein
-	O
like	O
protein	O
functioning	O
as	O
an	O
important	O
reversible	O
protein	O
modifier	O
.	O
<EOS>	B-X
In	B-X
eukaryotic	B-X
cells	B-X
,	B-X
the	B-X
reversible	B-X
attachment	B-X
of	B-X
small	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
protein	B-X
is	B-X
a	B-X
post-translational	B-X
modification	B-X
that	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
various	B-X
cellular	B-X
processes	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
found	B-X
that	B-X
SUMO	B-X
as	B-X
an	B-X
N-terminal	B-X
fusion	B-X
partner	B-X
enhances	B-X
functional	B-X
protein	B-X
production	B-X
in	B-X
prokaryotic	B-X
and	B-X
eukaryotic	B-X
expression	B-X
systems	B-X
,	B-X
based	B-X
upon	B-X
significantly	B-X
improved	B-X
protein	B-X
stability	B-X
and	B-X
solubility	B-X
.	B-X
Following	B-X
the	B-X
expression	B-X
and	B-X
purification	B-X
of	B-X
the	B-X
fusion	B-X
protein	B-X
,	B-X
the	B-X
SUMO-tag	B-X
can	B-X
be	B-X
cleaved	B-X
by	B-X
specific	B-X
(	B-X
SUMO	B-X
)	B-X
proteases	B-X
via	B-X
their	B-X
endopeptidase	B-X
activity	B-X
in	B-X
vitro	B-X
to	B-X
generate	B-X
the	B-X
desired	B-X
N-terminus	B-X
of	B-X
the	B-X
released	B-X
protein	B-X
partner	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
physiological	B-X
relevance	B-X
in	B-X
eukaryotes	B-X
,	B-X
SUMO	B-X
can	B-X
,	B-X
thus	B-X
,	B-X
be	B-X
used	B-X
as	B-X
a	B-X
powerful	B-X
biotechnological	B-X
tool	B-X
for	B-X
protein	B-X
expression	B-X
in	B-X
prokaryotic	B-X
and	B-X
eukaryotic	B-X
cell	B-X
systems.In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
will	B-X
describe	B-X
the	B-X
construction	B-X
of	B-X
a	B-X
fusion	B-X
protein	B-X
with	B-X
the	B-X
SUMO-tag	B-X
,	B-X
its	B-X
expression	B-X
in	B-X
Escherichia	B-X
coli	B-X
,	B-X
and	B-X
its	B-X
purification	B-X
followed	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
SUMO-tag	B-X
by	B-X
a	B-X
SUMO-specific	B-X
protease	B-X
in	B-X
vitro	B-X
.	B-X

To	O
date	O
there	O
is	O
no	O
report	O
on	O
a	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
/	O
isopeptidase	O
catalyzing	O
the	O
release	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
from	O
its	O
precursor	O
or	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
ligated	O
proteins	O
in	O
mammalian	O
tissues	O
.	O
<EOS>	B-X
SUMO-1	B-X
is	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
functioning	B-X
as	B-X
an	B-X
important	B-X
reversible	B-X
protein	B-X
modifier	B-X
.	B-X
To	B-X
date	B-X
there	B-X
is	B-X
no	B-X
report	B-X
on	B-X
a	B-X
SUMO-1	B-X
hydrolase/isopeptidase	B-X
catalyzing	B-X
the	B-X
release	B-X
of	B-X
SUMO-1	B-X
from	B-X
its	B-X
precursor	B-X
or	B-X
SUMO-1-ligated	B-X
proteins	B-X
in	B-X
mammalian	B-X
tissues	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
multiple	B-X
activities	B-X
that	B-X
cleave	B-X
the	B-X
SUMO-1	B-X
moiety	B-X
from	B-X
two	B-X
model	B-X
substrates	B-X
,	B-X
(	B-X
125	B-X
)	B-X
I-SUMO-1-alphaNH-HSTVGSMHISPPEPESEEEEEHYC	B-X
and/or	B-X
GST-SUMO-1-	B-X
(	B-X
35	B-X
)	B-X
S-RanGAP1	B-X
conjugate	B-X
,	B-X
in	B-X
bovine	B-X
brain	B-X
extracts	B-X
.	B-X
Of	B-X
them	B-X
,	B-X
a	B-X
major	B-X
SUMO-1	B-X
C-terminal	B-X
hydrolase	B-X
had	B-X
been	B-X
partially	B-X
purified	B-X
by	B-X
successive	B-X
chromatographic	B-X
operations	B-X
.	B-X
The	B-X
enzyme	B-X
had	B-X
the	B-X
ability	B-X
to	B-X
cleave	B-X
SUMO-1	B-X
not	B-X
only	B-X
from	B-X
its	B-X
precursor	B-X
but	B-X
also	B-X
from	B-X
a	B-X
SUMO-1-ligated	B-X
RanGAP1	B-X
but	B-X
did	B-X
not	B-X
exhibit	B-X
any	B-X
significant	B-X
cleavage	B-X
of	B-X
the	B-X
ubiquitin-	B-X
and	B-X
NEDD8-precursor	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
SUMO-1	B-X
hydrolase	B-X
was	B-X
almost	B-X
completely	B-X
inhibited	B-X
by	B-X
N-ethylmaleimide	B-X
,	B-X
but	B-X
not	B-X
by	B-X
phenylmethanesulfonyl	B-X
fluoride	B-X
,	B-X
EDTA	B-X
,	B-X
and	B-X
ubiquitin-aldehyde	B-X
known	B-X
as	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
deubiquitinylating	B-X
enzymes	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
the	B-X
isolated	B-X
SUMO-1	B-X
hydrolase	B-X
was	B-X
approximately	B-X
30	B-X
kDa	B-X
,	B-X
which	B-X
is	B-X
significantly	B-X
smaller	B-X
than	B-X
the	B-X
recently	B-X
identified	B-X
yeast	B-X
Smt3/SUMO-1	B-X
specific	B-X
protease	B-X
Ulp1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
there	B-X
are	B-X
multiple	B-X
SUMO-1	B-X
hydrolase/isopeptidases	B-X
in	B-X
mammalian	B-X
cells	B-X
and	B-X
that	B-X
the	B-X
30-kDa	B-X
small	B-X
SUMO-1	B-X
hydrolase	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
processing	B-X
of	B-X
the	B-X
SUMO-1-precursor	B-X
.	B-X

Here	O
we	O
found	O
multiple	O
activities	O
that	O
cleave	O
the	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
moiety	O
from	O
two	O
model	O
substrates	O
,	O
(	O
125	O
)	O
I	O
-	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
alphaNH	O
-	O
HSTVGSMHISPPEPESEEEEEHYC	O
and	O
/	O
or	O
GST	B-Protein
-	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
(	O
35	O
)	O
S	O
-	O
RanGAP1	B-Protein
conjugate	O
,	O
in	O
bovine	O
brain	O
extracts	O
.	O

Of	O
them	O
,	O
a	O
major	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
C	O
-	O
terminal	O
hydrolase	O
had	O
been	O
partially	O
purified	O
by	O
successive	O
chromatographic	O
operations	O
.	O

The	O
enzyme	O
had	O
the	O
ability	O
to	O
cleave	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
not	O
only	O
from	O
its	O
precursor	O
but	O
also	O
from	O
a	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
ligated	O
RanGAP1	B-Protein
but	O
did	O
not	O
exhibit	O
any	O
significant	O
cleavage	O
of	O
the	O
ubiquitin	B-Protein
-	O
and	O
NEDD8	B-Protein
-	O
precursor	O
.	O
<EOS>	B-X
YopJ	B-X
is	B-X
a	B-X
cysteine	B-X
protease	B-X
that	B-X
cleaves	B-X
a	B-X
reversible	B-X
post-translational	B-X
modification	B-X
in	B-X
the	B-X
form	B-X
of	B-X
ubiquitin	B-X
or	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
YopJ	B-X
to	B-X
block	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
,	B-X
its	B-X
activity	B-X
as	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
protease	B-X
and	B-X
its	B-X
activity	B-X
with	B-X
respect	B-X
to	B-X
mammalian	B-X
signalling	B-X
pathways	B-X
are	B-X
discussed	B-X
in	B-X
this	B-X
review	B-X
.	B-X
OTUB	B-X
(	B-X
otubain	B-X
)	B-X
1	B-X
is	B-X
a	B-X
human	B-X
deubiquitinating	B-X
enzyme	B-X
that	B-X
is	B-X
implicated	B-X
in	B-X
mediating	B-X
lymphocyte	B-X
antigen	B-X
responsiveness	B-X
,	B-X
but	B-X
whose	B-X
molecular	B-X
function	B-X
is	B-X
generally	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
A	B-X
structural	B-X
analysis	B-X
of	B-X
OTUB1	B-X
shows	B-X
differences	B-X
in	B-X
accessibility	B-X
to	B-X
the	B-X
active	B-X
site	B-X
and	B-X
in	B-X
surface	B-X
properties	B-X
of	B-X
the	B-X
substrate-binding	B-X
regions	B-X
when	B-X
compared	B-X
with	B-X
its	B-X
close	B-X
homologue	B-X
,	B-X
OTUB2	B-X
,	B-X
suggesting	B-X
variations	B-X
in	B-X
regulatory	B-X
mechanisms	B-X
and	B-X
substrate	B-X
specificity	B-X
.	B-X
Biochemical	B-X
analysis	B-X
reveals	B-X
that	B-X
OTUB1	B-X
has	B-X
a	B-X
preference	B-X
for	B-X
cleaving	B-X
Lys	B-X
(	B-X
48	B-X
)	B-X
-linked	B-X
polyubiquitin	B-X
chains	B-X
over	B-X
Lys	B-X
(	B-X
63	B-X
)	B-X
-linked	B-X
polyubiquitin	B-X
chains	B-X
,	B-X
and	B-X
it	B-X
is	B-X
capable	B-X
of	B-X
cleaving	B-X
NEDD8	B-X
(	B-X
neural-precursor-cell-expressed	B-X
developmentally	B-X
down-regulated	B-X
8	B-X
)	B-X
,	B-X
but	B-X
not	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
1/2/3	B-X
and	B-X
ISG15	B-X
(	B-X
interferon-stimulated	B-X
gene	B-X
15	B-X
)	B-X
conjugates	B-X
.	B-X
A	B-X
functional	B-X
comparison	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
indicated	B-X
a	B-X
differential	B-X
reactivity	B-X
towards	B-X
ubiquitin-based	B-X
active-site	B-X
probes	B-X
carrying	B-X
a	B-X
vinyl	B-X
methyl	B-X
ester	B-X
,	B-X
a	B-X
2-chloroethyl	B-X
or	B-X
a	B-X
2-bromoethyl	B-X
group	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
Mutational	B-X
analysis	B-X
suggested	B-X
that	B-X
a	B-X
narrow	B-X
P1	B-X
'	B-X
site	B-X
,	B-X
as	B-X
observed	B-X
in	B-X
OTUB1	B-X
,	B-X
correlates	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
preferentially	B-X
cleave	B-X
Lys	B-X
(	B-X
48	B-X
)	B-X
-linked	B-X
ubiquitin	B-X
chains	B-X
.	B-X
Analysis	B-X
of	B-X
cellular	B-X
interaction	B-X
partners	B-X
of	B-X
OTUB1	B-X
by	B-X
co-immunoprecipitation	B-X
and	B-X
MS/MS	B-X
(	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
)	B-X
experiments	B-X
demonstrated	B-X
that	B-X
FUS	B-X
[	B-X
fusion	B-X
involved	B-X
in	B-X
t	B-X
(	B-X
12	B-X
;	B-X
6	B-X
)	B-X
in	B-X
malignant	B-X
liposarcoma	B-X
;	B-X
also	B-X
known	B-X
as	B-X
TLS	B-X
(	B-X
translocation	B-X
in	B-X
liposarcoma	B-X
)	B-X
or	B-X
CHOP	B-X
(	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
homologous	B-X
protein	B-X
)	B-X
]	B-X
and	B-X
RACK1	B-X
[	B-X
receptor	B-X
for	B-X
activated	B-X
kinase	B-X
1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
GNB2L1	B-X
(	B-X
guanine-nucleotide-binding	B-X
protein	B-X
beta	B-X
polypeptide	B-X
2-like	B-X
1	B-X
)	B-X
]	B-X
are	B-X
part	B-X
of	B-X
OTUB1-containing	B-X
complexes	B-X
,	B-X
pointing	B-X
towards	B-X
a	B-X
molecular	B-X
function	B-X
of	B-X
this	B-X
deubiquitinating	B-X
enzyme	B-X
in	B-X
RNA	B-X
processing	B-X
and	B-X
cell	B-X
adhesion/morphology	B-X
.	B-X

The	O
activity	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
was	O
almost	O
completely	O
inhibited	O
by	O
N	O
-	O
ethylmaleimide	O
,	O
but	O
not	O
by	O
phenylmethanesulfonyl	O
fluoride	O
,	O
EDTA	O
,	O
and	O
ubiquitin	B-Protein
-	O
aldehyde	O
known	O
as	O
a	O
potent	O
inhibitor	O
of	O
deubiquitinylating	O
enzymes	O
.	O

Intriguingly	O
,	O
the	O
apparent	O
molecular	O
mass	O
of	O
the	O
isolated	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
was	O
approximately	O
30	O
kDa	O
,	O
which	O
is	O
significantly	O
smaller	O
than	O
the	O
recently	O
identified	O
yeast	O
Smt3	B-Protein
/	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
specific	O
protease	O
Ulp1	B-Protein
.	O

These	O
results	O
indicate	O
that	O
there	O
are	O
multiple	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
/	O
isopeptidases	O
in	O
mammalian	O
cells	O
and	O
that	O
the	O
30	O
-	O
kDa	O
small	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
plays	O
a	O
central	O
role	O
in	O
processing	O
of	O
the	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
precursor	O
.	O

Cell	O
cycle	O
-	O
regulated	O
attachment	O
of	O
the	O
ubiquitin	B-Protein
-	O
related	O
protein	O
SUMO	O
to	O
the	O
yeast	O
septins	O
.	O

SUMO	O
is	O
a	O
ubiquitin	B-Protein
-	O
related	O
protein	O
that	O
functions	O
as	O
a	O
posttranslational	O
modification	O
on	O
other	O
proteins	O
.	O
<EOS>	B-X
Sentrin/small	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
is	B-X
protein	B-X
modification	B-X
pathway	B-X
that	B-X
regulates	B-X
multiple	B-X
biological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
division	B-X
,	B-X
DNA	B-X
replication/repair	B-X
,	B-X
signal	B-X
transduction	B-X
,	B-X
and	B-X
cellular	B-X
metabolism	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
mechanisms	B-X
of	B-X
disease	B-X
pathogenesis	B-X
,	B-X
such	B-X
as	B-X
cancer	B-X
,	B-X
diabetes	B-X
,	B-X
seizure	B-X
,	B-X
and	B-X
heart	B-X
failure	B-X
,	B-X
which	B-X
have	B-X
been	B-X
linked	B-X
to	B-X
the	B-X
SUMO	B-X
pathway	B-X
.	B-X
SUMO	B-X
is	B-X
conjugated	B-X
to	B-X
lysine	B-X
residues	B-X
in	B-X
target	B-X
proteins	B-X
through	B-X
an	B-X
isopeptide	B-X
linkage	B-X
catalyzed	B-X
by	B-X
SUMO-specific	B-X
activating	B-X
(	B-X
E1	B-X
)	B-X
,	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
,	B-X
and	B-X
ligating	B-X
(	B-X
E3	B-X
)	B-X
enzymes	B-X
.	B-X
In	B-X
steady	B-X
state	B-X
,	B-X
the	B-X
quantity	B-X
of	B-X
SUMO-modified	B-X
substrates	B-X
is	B-X
usually	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
unmodified	B-X
substrates	B-X
due	B-X
to	B-X
the	B-X
deconjugation	B-X
activity	B-X
of	B-X
the	B-X
family	B-X
Sentrin/SUMO-specific	B-X
proteases	B-X
(	B-X
SENPs	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
ubiquitination/deubiquitination	B-X
machinery	B-X
,	B-X
the	B-X
biochemistry	B-X
of	B-X
SUMOylation	B-X
and	B-X
de-SUMOylation	B-X
is	B-X
relatively	B-X
modest	B-X
.	B-X
Specificity	B-X
of	B-X
the	B-X
SUMO	B-X
pathway	B-X
is	B-X
achieved	B-X
through	B-X
redox	B-X
regulation	B-X
,	B-X
acetylation	B-X
,	B-X
phosphorylation	B-X
,	B-X
or	B-X
other	B-X
posttranslational	B-X
protein	B-X
modification	B-X
of	B-X
the	B-X
SUMOylation	B-X
and	B-X
de-SUMOylation	B-X
enzymes	B-X
.	B-X
There	B-X
are	B-X
three	B-X
major	B-X
SUMOs	B-X
.	B-X
SUMO-1	B-X
usually	B-X
modifies	B-X
a	B-X
substrate	B-X
as	B-X
a	B-X
monomer	B-X
;	B-X
however	B-X
,	B-X
SUMO-2/3	B-X
can	B-X
form	B-X
poly-SUMO	B-X
chains	B-X
.	B-X
The	B-X
monomeric	B-X
SUMO-1	B-X
or	B-X
poly-SUMO	B-X
chains	B-X
can	B-X
interact	B-X
with	B-X
other	B-X
proteins	B-X
through	B-X
SUMO-interactive	B-X
motif	B-X
(	B-X
SIM	B-X
)	B-X
.	B-X
Thus	B-X
SUMO	B-X
modification	B-X
provides	B-X
a	B-X
platform	B-X
to	B-X
enhance	B-X
protein-protein	B-X
interaction	B-X
.	B-X
The	B-X
consequence	B-X
of	B-X
SUMOylation	B-X
includes	B-X
changes	B-X
in	B-X
cellular	B-X
localization	B-X
,	B-X
protein	B-X
activity	B-X
,	B-X
or	B-X
protein	B-X
stability	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO	B-X
may	B-X
join	B-X
force	B-X
with	B-X
ubiquitin	B-X
to	B-X
degrade	B-X
proteins	B-X
through	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
STUbL	B-X
)	B-X
.	B-X
After	B-X
20	B-X
yr	B-X
of	B-X
research	B-X
,	B-X
SUMO	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
biological	B-X
pathways	B-X
.	B-X
Thus	B-X
the	B-X
SUMO	B-X
enzymes	B-X
could	B-X
be	B-X
targets	B-X
for	B-X
drug	B-X
development	B-X
to	B-X
treat	B-X
human	B-X
diseases	B-X
.	B-X

SUMO	O
conjugation	O
is	O
essential	O
for	O
viability	O
in	O
Saccharomyces	O
cerevisiae	O
and	O
is	O
required	O
for	O
entry	O
into	O
mitosis	O
.	O
<EOS>	B-X
SUMO	B-X
is	B-X
a	B-X
ubiquitin-related	B-X
protein	B-X
that	B-X
functions	B-X
as	B-X
a	B-X
posttranslational	B-X
modification	B-X
on	B-X
other	B-X
proteins	B-X
.	B-X
SUMO	B-X
conjugation	B-X
is	B-X
essential	B-X
for	B-X
viability	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
and	B-X
is	B-X
required	B-X
for	B-X
entry	B-X
into	B-X
mitosis	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
SUMO	B-X
is	B-X
attached	B-X
to	B-X
the	B-X
septins	B-X
Cdc3	B-X
,	B-X
Cdc11	B-X
,	B-X
and	B-X
Shs1/Sep7	B-X
specifically	B-X
during	B-X
mitosis	B-X
,	B-X
with	B-X
conjugates	B-X
appearing	B-X
shortly	B-X
before	B-X
anaphase	B-X
onset	B-X
and	B-X
disappearing	B-X
abruptly	B-X
at	B-X
cytokinesis	B-X
.	B-X
We	B-X
have	B-X
identified	B-X
four	B-X
major	B-X
SUMO	B-X
attachment-site	B-X
lysine	B-X
residues	B-X
in	B-X
Cdc3	B-X
,	B-X
one	B-X
in	B-X
Cdc11	B-X
,	B-X
and	B-X
two	B-X
in	B-X
Shs1	B-X
,	B-X
all	B-X
within	B-X
the	B-X
consensus	B-X
sequence	B-X
(	B-X
IVL	B-X
)	B-X
KX	B-X
(	B-X
ED	B-X
)	B-X
.	B-X
Mutating	B-X
these	B-X
sites	B-X
eliminated	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
bud	B-X
neck-associated	B-X
SUMO	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
bulk	B-X
of	B-X
total	B-X
SUMO	B-X
conjugates	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M-arrested	B-X
cells	B-X
,	B-X
indicating	B-X
that	B-X
sumoylated	B-X
septins	B-X
are	B-X
the	B-X
most	B-X
abundant	B-X
SUMO	B-X
conjugates	B-X
at	B-X
this	B-X
point	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X
Thus	B-X
,	B-X
SUMO	B-X
conjugation	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
septin	B-X
ring	B-X
dynamics	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

We	O
have	O
found	O
that	O
SUMO	O
is	O
attached	O
to	O
the	O
septins	B-Protein
Cdc3	I-Protein
,	O
Cdc11	B-Protein
,	O
and	O
Shs1	B-Protein
/	O
Sep7	B-Protein
specifically	O
during	O
mitosis	O
,	O
with	O
conjugates	O
appearing	O
shortly	O
before	O
anaphase	O
onset	O
and	O
disappearing	O
abruptly	O
at	O
cytokinesis	O
.	O

Septins	O
are	O
components	O
of	O
a	O
belt	O
of	O
10	O
-	O
nm	O
filaments	O
encircling	O
the	O
yeast	O
bud	O
neck	O
.	O
<EOS>	B-X
Septins	B-X
are	B-X
components	B-X
of	B-X
a	B-X
belt	B-X
of	B-X
10-nm	B-X
filaments	B-X
encircling	B-X
the	B-X
yeast	B-X
bud	B-X
neck	B-X
.	B-X
Intriguingly	B-X
,	B-X
only	B-X
septins	B-X
on	B-X
the	B-X
mother	B-X
cell	B-X
side	B-X
of	B-X
the	B-X
bud	B-X
neck	B-X
are	B-X
sumoylated	B-X
.	B-X
Mutating	B-X
these	B-X
sites	B-X
eliminated	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
bud	B-X
neck-associated	B-X
SUMO	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
bulk	B-X
of	B-X
total	B-X
SUMO	B-X
conjugates	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M-arrested	B-X
cells	B-X
,	B-X
indicating	B-X
that	B-X
sumoylated	B-X
septins	B-X
are	B-X
the	B-X
most	B-X
abundant	B-X
SUMO	B-X
conjugates	B-X
at	B-X
this	B-X
point	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

Intriguingly	O
,	O
only	O
septins	O
on	O
the	O
mother	O
cell	O
side	O
of	O
the	O
bud	O
neck	O
are	O
sumoylated	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
SUMO	B-X
is	B-X
attached	B-X
to	B-X
the	B-X
septins	B-X
Cdc3	B-X
,	B-X
Cdc11	B-X
,	B-X
and	B-X
Shs1/Sep7	B-X
specifically	B-X
during	B-X
mitosis	B-X
,	B-X
with	B-X
conjugates	B-X
appearing	B-X
shortly	B-X
before	B-X
anaphase	B-X
onset	B-X
and	B-X
disappearing	B-X
abruptly	B-X
at	B-X
cytokinesis	B-X
.	B-X
Septins	B-X
are	B-X
components	B-X
of	B-X
a	B-X
belt	B-X
of	B-X
10-nm	B-X
filaments	B-X
encircling	B-X
the	B-X
yeast	B-X
bud	B-X
neck	B-X
.	B-X
Intriguingly	B-X
,	B-X
only	B-X
septins	B-X
on	B-X
the	B-X
mother	B-X
cell	B-X
side	B-X
of	B-X
the	B-X
bud	B-X
neck	B-X
are	B-X
sumoylated	B-X
.	B-X
Mutating	B-X
these	B-X
sites	B-X
eliminated	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
bud	B-X
neck-associated	B-X
SUMO	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
bulk	B-X
of	B-X
total	B-X
SUMO	B-X
conjugates	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M-arrested	B-X
cells	B-X
,	B-X
indicating	B-X
that	B-X
sumoylated	B-X
septins	B-X
are	B-X
the	B-X
most	B-X
abundant	B-X
SUMO	B-X
conjugates	B-X
at	B-X
this	B-X
point	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X
Thus	B-X
,	B-X
SUMO	B-X
conjugation	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
septin	B-X
ring	B-X
dynamics	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

We	O
have	O
identified	O
four	O
major	O
SUMO	O
attachment	O
-	O
site	O
lysine	O
residues	O
in	O
Cdc3	B-Protein
,	O
one	O
in	O
Cdc11	B-Protein
,	O
and	O
two	O
in	O
Shs1	B-Protein
,	O
all	O
within	O
the	O
consensus	O
sequence	O
(	O
IVL	O
)	O
KX	O
(	O
ED	O
)	O
.	O
<EOS>	B-X
SUMO	B-X
is	B-X
a	B-X
ubiquitin-related	B-X
protein	B-X
that	B-X
functions	B-X
as	B-X
a	B-X
posttranslational	B-X
modification	B-X
on	B-X
other	B-X
proteins	B-X
.	B-X
SUMO	B-X
conjugation	B-X
is	B-X
essential	B-X
for	B-X
viability	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
and	B-X
is	B-X
required	B-X
for	B-X
entry	B-X
into	B-X
mitosis	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
SUMO	B-X
is	B-X
attached	B-X
to	B-X
the	B-X
septins	B-X
Cdc3	B-X
,	B-X
Cdc11	B-X
,	B-X
and	B-X
Shs1/Sep7	B-X
specifically	B-X
during	B-X
mitosis	B-X
,	B-X
with	B-X
conjugates	B-X
appearing	B-X
shortly	B-X
before	B-X
anaphase	B-X
onset	B-X
and	B-X
disappearing	B-X
abruptly	B-X
at	B-X
cytokinesis	B-X
.	B-X
Septins	B-X
are	B-X
components	B-X
of	B-X
a	B-X
belt	B-X
of	B-X
10-nm	B-X
filaments	B-X
encircling	B-X
the	B-X
yeast	B-X
bud	B-X
neck	B-X
.	B-X
We	B-X
have	B-X
identified	B-X
four	B-X
major	B-X
SUMO	B-X
attachment-site	B-X
lysine	B-X
residues	B-X
in	B-X
Cdc3	B-X
,	B-X
one	B-X
in	B-X
Cdc11	B-X
,	B-X
and	B-X
two	B-X
in	B-X
Shs1	B-X
,	B-X
all	B-X
within	B-X
the	B-X
consensus	B-X
sequence	B-X
(	B-X
IVL	B-X
)	B-X
KX	B-X
(	B-X
ED	B-X
)	B-X
.	B-X
Mutating	B-X
these	B-X
sites	B-X
eliminated	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
bud	B-X
neck-associated	B-X
SUMO	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
bulk	B-X
of	B-X
total	B-X
SUMO	B-X
conjugates	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M-arrested	B-X
cells	B-X
,	B-X
indicating	B-X
that	B-X
sumoylated	B-X
septins	B-X
are	B-X
the	B-X
most	B-X
abundant	B-X
SUMO	B-X
conjugates	B-X
at	B-X
this	B-X
point	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X
This	B-X
mutant	B-X
has	B-X
a	B-X
striking	B-X
defect	B-X
in	B-X
disassembly	B-X
of	B-X
septin	B-X
rings	B-X
,	B-X
resulting	B-X
in	B-X
accumulation	B-X
of	B-X
septin	B-X
rings	B-X
marking	B-X
previous	B-X
division	B-X
sites	B-X
.	B-X
Thus	B-X
,	B-X
SUMO	B-X
conjugation	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
septin	B-X
ring	B-X
dynamics	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

Mutating	O
these	O
sites	O
eliminated	O
the	O
vast	O
majority	O
of	O
bud	O
neck	O
-	O
associated	O
SUMO	O
,	O
as	O
well	O
as	O
the	O
bulk	O
of	O
total	O
SUMO	O
conjugates	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
-	O
arrested	O
cells	O
,	O
indicating	O
that	O
sumoylated	O
septins	O
are	O
the	O
most	O
abundant	O
SUMO	O
conjugates	O
at	O
this	O
point	O
in	O
the	O
cell	O
cycle	O
.	O

This	O
mutant	O
has	O
a	O
striking	O
defect	O
in	O
disassembly	O
of	O
septin	O
rings	O
,	O
resulting	O
in	O
accumulation	O
of	O
septin	O
rings	O
marking	O
previous	O
division	O
sites	O
.	O

Thus	O
,	O
SUMO	O
conjugation	O
plays	O
a	O
role	O
in	O
regulating	O
septin	O
ring	O
dynamics	O
during	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
a	O
prenylation	O
-	O
deficient	O
Rab4	B-Protein
interferes	O
with	O
propagation	O
of	O
insulin	B-Protein
signaling	O
through	O
insulin	B-Protein
receptor	I-Protein
substrate	I-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
Rab4	B-X
isoform	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
insulin	B-X
action	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
overexpression	B-X
of	B-X
a	B-X
prenylation-deficient	B-X
form	B-X
of	B-X
Rab4	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
insulin-dependent	B-X
GLUT4	B-X
translocation	B-X
.	B-X
Other	B-X
steps	B-X
affected	B-X
by	B-X
Rab4	B-X
in	B-X
the	B-X
cascade	B-X
of	B-X
events	B-X
resulting	B-X
from	B-X
insulin	B-X
receptor	B-X
activation	B-X
have	B-X
not	B-X
been	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
we	B-X
measured	B-X
effects	B-X
on	B-X
insulin-signaling	B-X
proteins	B-X
in	B-X
3T3-L1	B-X
adipocytes	B-X
transiently	B-X
expressing	B-X
cytoplasmic	B-X
forms	B-X
of	B-X
Rab4	B-X
and	B-X
Rab5	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
mutant	B-X
Rab4	B-X
lacking	B-X
a	B-X
prenylation	B-X
site	B-X
resulted	B-X
in	B-X
reduced	B-X
insulin-dependent	B-X
phosphorylation	B-X
ofcytoplasmic	B-X
and	B-X
internal	B-X
membrane-associated	B-X
insulin	B-X
receptor	B-X
substrate-1	B-X
,	B-X
leading	B-X
to	B-X
decreased	B-X
insulin	B-X
receptor	B-X
substrate-1-associated	B-X
phosphatidylinositol	B-X
3'-OH	B-X
kinase	B-X
activation	B-X
and	B-X
decreased	B-X
Akt	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Rab4	B-X
or	B-X
a	B-X
Rab4-associated	B-X
protein	B-X
is	B-X
involved	B-X
at	B-X
one	B-X
or	B-X
more	B-X
steps	B-X
in	B-X
propagating	B-X
the	B-X
insulin	B-X
signal	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
any	B-X
role	B-X
it	B-X
may	B-X
play	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
GLUT4	B-X
vesicle	B-X
translocation	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
models	B-X
of	B-X
insulin	B-X
signaling	B-X
in	B-X
which	B-X
regulation	B-X
of	B-X
internal	B-X
membrane	B-X
trafficking	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
transduction	B-X
of	B-X
the	B-X
insulin	B-X
signal	B-X
.	B-X

Rab	O
proteins	O
are	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
the	O
Ras	O
superfamily	O
that	O
function	O
in	O
the	O
regulation	O
of	O
vesicle	O
transport	O
processes	O
.	O
<EOS>	B-X
Autophagy	B-X
(	B-X
macroautophagy	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
intracellular	B-X
and	B-X
lysosome-dependent	B-X
degradation	B-X
process	B-X
in	B-X
which	B-X
autophagic	B-X
substrates	B-X
are	B-X
enclosed	B-X
and	B-X
degraded	B-X
by	B-X
a	B-X
double-membrane	B-X
vesicular	B-X
structure	B-X
in	B-X
a	B-X
continuous	B-X
and	B-X
dynamic	B-X
vesicle	B-X
transport	B-X
process	B-X
.	B-X
The	B-X
Rab	B-X
protein	B-X
is	B-X
a	B-X
small	B-X
GTPase	B-X
that	B-X
belongs	B-X
to	B-X
the	B-X
Ras-like	B-X
GTPase	B-X
superfamily	B-X
and	B-X
regulates	B-X
the	B-X
vesicle	B-X
traffic	B-X
process	B-X
.	B-X
Numerous	B-X
Rab	B-X
proteins	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
various	B-X
stages	B-X
of	B-X
autophagy	B-X
.	B-X
Rab1	B-X
,	B-X
Rab5	B-X
,	B-X
Rab7	B-X
,	B-X
Rab9A	B-X
,	B-X
Rab11	B-X
,	B-X
Rab23	B-X
,	B-X
Rab32	B-X
,	B-X
and	B-X
Rab33B	B-X
participate	B-X
in	B-X
autophagosome	B-X
formation	B-X
,	B-X
whereas	B-X
Rab9	B-X
is	B-X
required	B-X
in	B-X
non-canonical	B-X
autophagy	B-X
.	B-X
Rab7	B-X
,	B-X
Rab8B	B-X
,	B-X
and	B-X
Rab24	B-X
have	B-X
a	B-X
key	B-X
role	B-X
in	B-X
autophagosome	B-X
maturation	B-X
.	B-X
Rab8A	B-X
and	B-X
Rab25	B-X
are	B-X
also	B-X
involved	B-X
in	B-X
autophagy	B-X
,	B-X
but	B-X
their	B-X
role	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
new	B-X
findings	B-X
regarding	B-X
the	B-X
involvement	B-X
of	B-X
Rabs	B-X
in	B-X
autophagy	B-X
and	B-X
provide	B-X
insights	B-X
regarding	B-X
future	B-X
research	B-X
on	B-X
the	B-X
mechanisms	B-X
of	B-X
autophagy	B-X
regulation	B-X
.	B-X

The	O
Rab4	B-Protein
isoform	O
has	O
been	O
implicated	O
in	O
insulin	B-Protein
action	O
.	O
<EOS>	B-X
The	B-X
Rab4	B-X
isoform	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
insulin	B-X
action	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
overexpression	B-X
of	B-X
a	B-X
prenylation-deficient	B-X
form	B-X
of	B-X
Rab4	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
insulin-dependent	B-X
GLUT4	B-X
translocation	B-X
.	B-X
Other	B-X
steps	B-X
affected	B-X
by	B-X
Rab4	B-X
in	B-X
the	B-X
cascade	B-X
of	B-X
events	B-X
resulting	B-X
from	B-X
insulin	B-X
receptor	B-X
activation	B-X
have	B-X
not	B-X
been	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
we	B-X
measured	B-X
effects	B-X
on	B-X
insulin-signaling	B-X
proteins	B-X
in	B-X
3T3-L1	B-X
adipocytes	B-X
transiently	B-X
expressing	B-X
cytoplasmic	B-X
forms	B-X
of	B-X
Rab4	B-X
and	B-X
Rab5	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
mutant	B-X
Rab4	B-X
lacking	B-X
a	B-X
prenylation	B-X
site	B-X
resulted	B-X
in	B-X
reduced	B-X
insulin-dependent	B-X
phosphorylation	B-X
ofcytoplasmic	B-X
and	B-X
internal	B-X
membrane-associated	B-X
insulin	B-X
receptor	B-X
substrate-1	B-X
,	B-X
leading	B-X
to	B-X
decreased	B-X
insulin	B-X
receptor	B-X
substrate-1-associated	B-X
phosphatidylinositol	B-X
3'-OH	B-X
kinase	B-X
activation	B-X
and	B-X
decreased	B-X
Akt	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Rab4	B-X
or	B-X
a	B-X
Rab4-associated	B-X
protein	B-X
is	B-X
involved	B-X
at	B-X
one	B-X
or	B-X
more	B-X
steps	B-X
in	B-X
propagating	B-X
the	B-X
insulin	B-X
signal	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
any	B-X
role	B-X
it	B-X
may	B-X
play	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
GLUT4	B-X
vesicle	B-X
translocation	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
models	B-X
of	B-X
insulin	B-X
signaling	B-X
in	B-X
which	B-X
regulation	B-X
of	B-X
internal	B-X
membrane	B-X
trafficking	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
transduction	B-X
of	B-X
the	B-X
insulin	B-X
signal	B-X
.	B-X

For	O
instance	O
,	O
overexpression	O
of	O
a	O
prenylation	O
-	O
deficient	O
form	O
of	O
Rab4	B-Protein
has	O
been	O
shown	O
to	O
inhibit	O
insulin	B-Protein
-	O
dependent	O
GLUT4	B-Protein
translocation	O
.	O
<EOS>	B-X
The	B-X
Rab4	B-X
isoform	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
insulin	B-X
action	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
overexpression	B-X
of	B-X
a	B-X
prenylation-deficient	B-X
form	B-X
of	B-X
Rab4	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
insulin-dependent	B-X
GLUT4	B-X
translocation	B-X
.	B-X
Other	B-X
steps	B-X
affected	B-X
by	B-X
Rab4	B-X
in	B-X
the	B-X
cascade	B-X
of	B-X
events	B-X
resulting	B-X
from	B-X
insulin	B-X
receptor	B-X
activation	B-X
have	B-X
not	B-X
been	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
we	B-X
measured	B-X
effects	B-X
on	B-X
insulin-signaling	B-X
proteins	B-X
in	B-X
3T3-L1	B-X
adipocytes	B-X
transiently	B-X
expressing	B-X
cytoplasmic	B-X
forms	B-X
of	B-X
Rab4	B-X
and	B-X
Rab5	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
mutant	B-X
Rab4	B-X
lacking	B-X
a	B-X
prenylation	B-X
site	B-X
resulted	B-X
in	B-X
reduced	B-X
insulin-dependent	B-X
phosphorylation	B-X
ofcytoplasmic	B-X
and	B-X
internal	B-X
membrane-associated	B-X
insulin	B-X
receptor	B-X
substrate-1	B-X
,	B-X
leading	B-X
to	B-X
decreased	B-X
insulin	B-X
receptor	B-X
substrate-1-associated	B-X
phosphatidylinositol	B-X
3'-OH	B-X
kinase	B-X
activation	B-X
and	B-X
decreased	B-X
Akt	B-X
activation	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
not	B-X
observed	B-X
upon	B-X
introduction	B-X
of	B-X
a	B-X
similar	B-X
mutant	B-X
form	B-X
of	B-X
Rab5	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Rab4	B-X
or	B-X
a	B-X
Rab4-associated	B-X
protein	B-X
is	B-X
involved	B-X
at	B-X
one	B-X
or	B-X
more	B-X
steps	B-X
in	B-X
propagating	B-X
the	B-X
insulin	B-X
signal	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
any	B-X
role	B-X
it	B-X
may	B-X
play	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
GLUT4	B-X
vesicle	B-X
translocation	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
models	B-X
of	B-X
insulin	B-X
signaling	B-X
in	B-X
which	B-X
regulation	B-X
of	B-X
internal	B-X
membrane	B-X
trafficking	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
transduction	B-X
of	B-X
the	B-X
insulin	B-X
signal	B-X
.	B-X

Other	O
steps	O
affected	O
by	O
Rab4	B-Protein
in	O
the	O
cascade	O
of	O
events	O
resulting	O
from	O
insulin	B-Protein
receptor	I-Protein
activation	O
have	O
not	O
been	O
elucidated	O
.	O

In	O
the	O
present	O
studies	O
,	O
we	O
measured	O
effects	O
on	O
insulin	B-Protein
-	O
signaling	O
proteins	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
transiently	O
expressing	O
cytoplasmic	O
forms	O
of	O
Rab4	B-Protein
and	O
Rab5	B-Protein
.	O
<EOS>	B-X
Rab	B-X
proteins	B-X
are	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
that	B-X
function	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
vesicle	B-X
transport	B-X
processes	B-X
.	B-X
The	B-X
Rab4	B-X
isoform	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
insulin	B-X
action	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
overexpression	B-X
of	B-X
a	B-X
prenylation-deficient	B-X
form	B-X
of	B-X
Rab4	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
insulin-dependent	B-X
GLUT4	B-X
translocation	B-X
.	B-X
Other	B-X
steps	B-X
affected	B-X
by	B-X
Rab4	B-X
in	B-X
the	B-X
cascade	B-X
of	B-X
events	B-X
resulting	B-X
from	B-X
insulin	B-X
receptor	B-X
activation	B-X
have	B-X
not	B-X
been	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
we	B-X
measured	B-X
effects	B-X
on	B-X
insulin-signaling	B-X
proteins	B-X
in	B-X
3T3-L1	B-X
adipocytes	B-X
transiently	B-X
expressing	B-X
cytoplasmic	B-X
forms	B-X
of	B-X
Rab4	B-X
and	B-X
Rab5	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
mutant	B-X
Rab4	B-X
lacking	B-X
a	B-X
prenylation	B-X
site	B-X
resulted	B-X
in	B-X
reduced	B-X
insulin-dependent	B-X
phosphorylation	B-X
ofcytoplasmic	B-X
and	B-X
internal	B-X
membrane-associated	B-X
insulin	B-X
receptor	B-X
substrate-1	B-X
,	B-X
leading	B-X
to	B-X
decreased	B-X
insulin	B-X
receptor	B-X
substrate-1-associated	B-X
phosphatidylinositol	B-X
3'-OH	B-X
kinase	B-X
activation	B-X
and	B-X
decreased	B-X
Akt	B-X
activation	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
not	B-X
observed	B-X
upon	B-X
introduction	B-X
of	B-X
a	B-X
similar	B-X
mutant	B-X
form	B-X
of	B-X
Rab5	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Rab4	B-X
or	B-X
a	B-X
Rab4-associated	B-X
protein	B-X
is	B-X
involved	B-X
at	B-X
one	B-X
or	B-X
more	B-X
steps	B-X
in	B-X
propagating	B-X
the	B-X
insulin	B-X
signal	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
any	B-X
role	B-X
it	B-X
may	B-X
play	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
GLUT4	B-X
vesicle	B-X
translocation	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
models	B-X
of	B-X
insulin	B-X
signaling	B-X
in	B-X
which	B-X
regulation	B-X
of	B-X
internal	B-X
membrane	B-X
trafficking	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
transduction	B-X
of	B-X
the	B-X
insulin	B-X
signal	B-X
.	B-X

Expression	O
of	O
a	O
mutant	O
Rab4	B-Protein
lacking	O
a	O
prenylation	O
site	O
resulted	O
in	O
reduced	O
insulin	B-Protein
-	O
dependent	O
phosphorylation	O
ofcytoplasmic	O
and	O
internal	O
membrane	O
-	O
associated	O
insulin	B-Protein
receptor	I-Protein
substrate	I-Protein
-	I-Protein
1	I-Protein
,	O
leading	O
to	O
decreased	O
insulin	B-Protein
receptor	I-Protein
substrate	I-Protein
-	I-Protein
1	I-Protein
-	O
associated	O
phosphatidylinositol	O
3	O
'	O
-	O
OH	O
kinase	O
activation	O
and	O
decreased	O
Akt	O
activation	O
.	O
<EOS>	B-X
The	B-X
Rab4	B-X
isoform	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
insulin	B-X
action	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
overexpression	B-X
of	B-X
a	B-X
prenylation-deficient	B-X
form	B-X
of	B-X
Rab4	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
insulin-dependent	B-X
GLUT4	B-X
translocation	B-X
.	B-X
Other	B-X
steps	B-X
affected	B-X
by	B-X
Rab4	B-X
in	B-X
the	B-X
cascade	B-X
of	B-X
events	B-X
resulting	B-X
from	B-X
insulin	B-X
receptor	B-X
activation	B-X
have	B-X
not	B-X
been	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
we	B-X
measured	B-X
effects	B-X
on	B-X
insulin-signaling	B-X
proteins	B-X
in	B-X
3T3-L1	B-X
adipocytes	B-X
transiently	B-X
expressing	B-X
cytoplasmic	B-X
forms	B-X
of	B-X
Rab4	B-X
and	B-X
Rab5	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
mutant	B-X
Rab4	B-X
lacking	B-X
a	B-X
prenylation	B-X
site	B-X
resulted	B-X
in	B-X
reduced	B-X
insulin-dependent	B-X
phosphorylation	B-X
ofcytoplasmic	B-X
and	B-X
internal	B-X
membrane-associated	B-X
insulin	B-X
receptor	B-X
substrate-1	B-X
,	B-X
leading	B-X
to	B-X
decreased	B-X
insulin	B-X
receptor	B-X
substrate-1-associated	B-X
phosphatidylinositol	B-X
3'-OH	B-X
kinase	B-X
activation	B-X
and	B-X
decreased	B-X
Akt	B-X
activation	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
not	B-X
observed	B-X
upon	B-X
introduction	B-X
of	B-X
a	B-X
similar	B-X
mutant	B-X
form	B-X
of	B-X
Rab5	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Rab4	B-X
or	B-X
a	B-X
Rab4-associated	B-X
protein	B-X
is	B-X
involved	B-X
at	B-X
one	B-X
or	B-X
more	B-X
steps	B-X
in	B-X
propagating	B-X
the	B-X
insulin	B-X
signal	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
any	B-X
role	B-X
it	B-X
may	B-X
play	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
GLUT4	B-X
vesicle	B-X
translocation	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
models	B-X
of	B-X
insulin	B-X
signaling	B-X
in	B-X
which	B-X
regulation	B-X
of	B-X
internal	B-X
membrane	B-X
trafficking	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
transduction	B-X
of	B-X
the	B-X
insulin	B-X
signal	B-X
.	B-X

These	O
effects	O
were	O
not	O
observed	O
upon	O
introduction	O
of	O
a	O
similar	O
mutant	O
form	O
of	O
Rab5	B-Protein
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
ACBT	B-X
on	B-X
COPD	B-X
patients	B-X
have	B-X
shown	B-X
mixed	B-X
results	B-X
.	B-X
Additional	B-X
research	B-X
is	B-X
warranted	B-X
to	B-X
determine	B-X
comparative	B-X
effectiveness	B-X
and	B-X
long-term	B-X
effects	B-X
of	B-X
mindfulness	B-X
training	B-X
.	B-X
How	B-X
Can	B-X
Synergism	B-X
of	B-X
Traditional	B-X
Medicines	B-X
Benefit	B-X
from	B-X
Network	B-X
Pharmacology	B-X
?	B-X
Self-Rated	B-X
Effectiveness	B-X
of	B-X
Microdosing	B-X
With	B-X
Psychedelics	B-X
for	B-X
Mental	B-X
and	B-X
Physical	B-X
Health	B-X
Problems	B-X
Among	B-X
Microdosers	B-X
.	B-X

These	O
data	O
indicate	O
that	O
Rab4	B-Protein
or	O
a	O
Rab4	B-Protein
-	O
associated	O
protein	O
is	O
involved	O
at	O
one	O
or	O
more	O
steps	O
in	O
propagating	O
the	O
insulin	B-Protein
signal	O
,	O
in	O
addition	O
to	O
any	O
role	O
it	O
may	O
play	O
in	O
the	O
regulation	O
of	O
GLUT4	B-Protein
vesicle	O
translocation	O
.	O
<EOS>	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
outer	B-X
membrane	B-X
of	B-X
the	B-X
Gram-negative	B-X
bacteria	B-X
,	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
myocardial	B-X
anomalies	B-X
in	B-X
sepsis	B-X
.	B-X
Recent	B-X
evidence	B-X
depicted	B-X
an	B-X
essential	B-X
role	B-X
for	B-X
mitochondrial	B-X
aldehyde	B-X
dehydrogenase	B-X
(	B-X
ALDH2	B-X
)	B-X
in	B-X
cardiac	B-X
homeostasis	B-X
.	B-X
HRES-1/Rab4	B-X
is	B-X
a	B-X
small	B-X
GTPase	B-X
that	B-X
regulates	B-X
endocytic	B-X
recycling	B-X
.	B-X
Since	B-X
the	B-X
autophagosomal	B-X
membrane	B-X
component	B-X
microtubule-associated	B-X
protein	B-X
light	B-X
chain	B-X
3	B-X
(	B-X
LC3	B-X
)	B-X
is	B-X
derived	B-X
from	B-X
mitochondria	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
impact	B-X
of	B-X
HRES-1/Rab4	B-X
on	B-X
the	B-X
formation	B-X
of	B-X
LC3	B-X
(	B-X
+	B-X
)	B-X
autophagosomes	B-X
,	B-X
their	B-X
colocalization	B-X
with	B-X
HRES-1/Rab4	B-X
and	B-X
mitochondria	B-X
,	B-X
and	B-X
the	B-X
retention	B-X
of	B-X
mitochondria	B-X
during	B-X
autophagy	B-X
induced	B-X
by	B-X
starvation	B-X
and	B-X
rapamycin	B-X
.	B-X
HRES-1/Rab4	B-X
exhibited	B-X
minimal	B-X
baseline	B-X
colocalization	B-X
with	B-X
LC3	B-X
,	B-X
which	B-X
was	B-X
enhanced	B-X
22-fold	B-X
upon	B-X
starvation	B-X
or	B-X
6-fold	B-X
upon	B-X
rapamycin	B-X
treatment	B-X
.	B-X
Colocalization	B-X
of	B-X
HRES-1/Rab4	B-X
with	B-X
mitochondria	B-X
was	B-X
increased	B-X
>	B-X
2-fold	B-X
by	B-X
starvation	B-X
or	B-X
rapamycin	B-X
.	B-X
HRES-1/Rab4	B-X
overexpression	B-X
promoted	B-X
the	B-X
colocalization	B-X
of	B-X
mitochondria	B-X
with	B-X
LC3	B-X
upon	B-X
starvation	B-X
or	B-X
rapamycin	B-X
treatment	B-X
.	B-X
A	B-X
dominant-negative	B-X
mutant	B-X
,	B-X
HRES-1/Rab4	B-X
(	B-X
S27N	B-X
)	B-X
had	B-X
reduced	B-X
colocalization	B-X
with	B-X
LC3	B-X
and	B-X
mitochondria	B-X
upon	B-X
starvation	B-X
but	B-X
not	B-X
rapamycin	B-X
treatment	B-X
.	B-X
A	B-X
constitutively	B-X
active	B-X
mutant	B-X
,	B-X
HRES-1/Rab4	B-X
(	B-X
Q72L	B-X
)	B-X
showed	B-X
diminished	B-X
colocalization	B-X
with	B-X
LC3	B-X
but	B-X
promoted	B-X
the	B-X
partitioning	B-X
of	B-X
mitochondria	B-X
with	B-X
LC3	B-X
upon	B-X
starvation	B-X
or	B-X
rapamycin	B-X
treatment	B-X
.	B-X
Phosphorylation-resistant	B-X
mutant	B-X
HRES-1/Rab4	B-X
(	B-X
S204Q	B-X
)	B-X
showed	B-X
diminished	B-X
colocalization	B-X
with	B-X
LC3	B-X
but	B-X
increased	B-X
partitioning	B-X
to	B-X
mitochondria	B-X
.	B-X
A	B-X
newly	B-X
discovered	B-X
C-terminally	B-X
truncated	B-X
native	B-X
isoform	B-X
,	B-X
HRES-1/Rab4	B-X
(	B-X
1-121	B-X
)	B-X
,	B-X
showed	B-X
enhanced	B-X
localization	B-X
to	B-X
LC3	B-X
and	B-X
mitochondria	B-X
without	B-X
starvation	B-X
or	B-X
rapamycin	B-X
treatment	B-X
.	B-X
HRES-1/Rab4	B-X
(	B-X
1-121	B-X
)	B-X
increased	B-X
the	B-X
formation	B-X
of	B-X
LC3	B-X
(	B-X
+	B-X
)	B-X
autophagosomes	B-X
in	B-X
resting	B-X
cells	B-X
,	B-X
while	B-X
other	B-X
isoforms	B-X
promoted	B-X
autophagosome	B-X
formation	B-X
upon	B-X
starvation	B-X
.	B-X
HRES-1/Rab4	B-X
,	B-X
HRES-1/Rab4	B-X
(	B-X
1-121	B-X
)	B-X
,	B-X
HRES-1/Rab4	B-X
(	B-X
Q72L	B-X
)	B-X
and	B-X
HRES-1/Rab4	B-X
(	B-X
S204Q	B-X
)	B-X
promoted	B-X
the	B-X
accumulation	B-X
of	B-X
mitochondria	B-X
during	B-X
starvation	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
HRES-1/Rab4-mediated	B-X
mitochondrial	B-X
accumulation	B-X
is	B-X
indicated	B-X
by	B-X
its	B-X
abrogation	B-X
by	B-X
dominant-negative	B-X
HRES-1/Rab4	B-X
(	B-X
S27N	B-X
)	B-X
mutation	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
interconnected	B-X
mitochondrial	B-X
tubular	B-X
networks	B-X
was	B-X
markedly	B-X
enhanced	B-X
by	B-X
HRES-1/Rab4	B-X
(	B-X
Q72L	B-X
)	B-X
upon	B-X
starvation	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
retention	B-X
of	B-X
mitochondria	B-X
during	B-X
autophagy	B-X
.	B-X
The	B-X
present	B-X
study	B-X
thus	B-X
indicates	B-X
that	B-X
HRES-1/Rab4	B-X
regulates	B-X
autophagy	B-X
through	B-X
promoting	B-X
the	B-X
formation	B-X
of	B-X
LC3	B-X
(	B-X
+	B-X
)	B-X
autophagosomes	B-X
and	B-X
the	B-X
preservation	B-X
of	B-X
mitochondria	B-X
.	B-X

Our	O
results	O
support	O
models	O
of	O
insulin	B-Protein
signaling	O
in	O
which	O
regulation	O
of	O
internal	O
membrane	O
trafficking	O
plays	O
a	O
role	O
in	O
transduction	O
of	O
the	O
insulin	B-Protein
signal	O
.	O

Structural	O
determinants	O
of	O
post	O
-	O
translational	O
modification	O
and	O
catalytic	O
specificity	O
for	O
the	O
lipoyl	O
domains	O
of	O
the	O
pyruvate	O
dehydrogenase	O
multienzyme	O
complex	O
of	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acyltransferase	B-X
(	B-X
E2p	B-X
,	B-X
E2o	B-X
)	B-X
components	B-X
of	B-X
the	B-X
pyruvate	B-X
and	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
are	B-X
specifically	B-X
recognised	B-X
by	B-X
their	B-X
cognate	B-X
2-oxo	B-X
acid	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
,	B-X
E1o	B-X
)	B-X
.	B-X
A	B-X
prominent	B-X
surface	B-X
loop	B-X
links	B-X
the	B-X
first	B-X
and	B-X
second	B-X
beta-strands	B-X
in	B-X
all	B-X
lipoyl	B-X
domains	B-X
,	B-X
close	B-X
in	B-X
space	B-X
to	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
.	B-X
This	B-X
loop	B-X
was	B-X
subjected	B-X
to	B-X
various	B-X
modifications	B-X
by	B-X
directed	B-X
mutagenesis	B-X
of	B-X
a	B-X
sub-gene	B-X
encoding	B-X
a	B-X
lipoyl	B-X
domain	B-X
of	B-X
Escherichia	B-X
coli	B-X
E2p	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
loop	B-X
(	B-X
four	B-X
residues	B-X
)	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
acetylation	B-X
by	B-X
E.	B-X
coli	B-X
E1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
pyruvate	B-X
,	B-X
but	B-X
insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
(	B-X
six	B-X
residues	B-X
)	B-X
corresponding	B-X
to	B-X
that	B-X
in	B-X
the	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
partly	B-X
restored	B-X
this	B-X
ability	B-X
,	B-X
albeit	B-X
with	B-X
a	B-X
much	B-X
lower	B-X
rate	B-X
.	B-X
Exchanging	B-X
the	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
in	B-X
the	B-X
E2p	B-X
and	B-X
E2o	B-X
domains	B-X
(	B-X
G39T	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
E2p	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
but	B-X
did	B-X
confer	B-X
a	B-X
slight	B-X
increase	B-X
in	B-X
susceptibility	B-X
to	B-X
reductive	B-X
succinylation	B-X
.	B-X
All	B-X
mutant	B-X
E2p	B-X
domains	B-X
,	B-X
apart	B-X
from	B-X
that	B-X
with	B-X
the	B-X
loop	B-X
deletion	B-X
(	B-X
LD	B-X
)	B-X
,	B-X
were	B-X
readily	B-X
lipoylated	B-X
in	B-X
vitro	B-X
by	B-X
E.	B-X
coli	B-X
lipoate	B-X
protein	B-X
ligase	B-X
A	B-X
;	B-X
the	B-X
E2p	B-X
LD	B-X
mutant	B-X
could	B-X
be	B-X
lipoylated	B-X
only	B-X
at	B-X
a	B-X
significantly	B-X
lower	B-X
rate	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
evidently	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
domain	B-X
and	B-X
may	B-X
help	B-X
to	B-X
stabilize	B-X
the	B-X
thioester	B-X
bond	B-X
linking	B-X
the	B-X
acyl	B-X
group	B-X
to	B-X
the	B-X
reduced	B-X
lipoyl-lysine	B-X
swinging	B-X
arm	B-X
as	B-X
part	B-X
of	B-X
the	B-X
catalytic	B-X
mechanism	B-X
.	B-X
Recognition	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
by	B-X
its	B-X
partner	B-X
E1	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
complex	B-X
process	B-X
and	B-X
not	B-X
attributable	B-X
to	B-X
any	B-X
single	B-X
determinant	B-X
on	B-X
the	B-X
domain	B-X
.	B-X

The	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	O
acyltransferase	O
(	O
E2p	B-Protein
,	O
E2o	B-Protein
)	O
components	O
of	O
the	O
pyruvate	O
and	O
2	O
-	O
oxoglutarate	O
dehydrogenase	O
multienzyme	O
complexes	O
are	O
specifically	O
recognised	O
by	O
their	O
cognate	O
2	O
-	O
oxo	O
acid	O
decarboxylase	O
(	O
E1p	B-Protein
,	O
E1o	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acyltransferase	B-X
(	B-X
E2p	B-X
,	B-X
E2o	B-X
)	B-X
components	B-X
of	B-X
the	B-X
pyruvate	B-X
and	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
are	B-X
specifically	B-X
recognised	B-X
by	B-X
their	B-X
cognate	B-X
2-oxo	B-X
acid	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
,	B-X
E1o	B-X
)	B-X
.	B-X
A	B-X
prominent	B-X
surface	B-X
loop	B-X
links	B-X
the	B-X
first	B-X
and	B-X
second	B-X
beta-strands	B-X
in	B-X
all	B-X
lipoyl	B-X
domains	B-X
,	B-X
close	B-X
in	B-X
space	B-X
to	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
.	B-X
This	B-X
loop	B-X
was	B-X
subjected	B-X
to	B-X
various	B-X
modifications	B-X
by	B-X
directed	B-X
mutagenesis	B-X
of	B-X
a	B-X
sub-gene	B-X
encoding	B-X
a	B-X
lipoyl	B-X
domain	B-X
of	B-X
Escherichia	B-X
coli	B-X
E2p	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
loop	B-X
(	B-X
four	B-X
residues	B-X
)	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
acetylation	B-X
by	B-X
E.	B-X
coli	B-X
E1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
pyruvate	B-X
,	B-X
but	B-X
insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
(	B-X
six	B-X
residues	B-X
)	B-X
corresponding	B-X
to	B-X
that	B-X
in	B-X
the	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
partly	B-X
restored	B-X
this	B-X
ability	B-X
,	B-X
albeit	B-X
with	B-X
a	B-X
much	B-X
lower	B-X
rate	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modified	B-X
domain	B-X
remained	B-X
unable	B-X
to	B-X
undergo	B-X
reductive	B-X
succinylation	B-X
by	B-X
E1o	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
2-oxoglutarate	B-X
.	B-X
Exchanging	B-X
the	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
in	B-X
the	B-X
E2p	B-X
and	B-X
E2o	B-X
domains	B-X
(	B-X
G39T	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
E2p	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
but	B-X
did	B-X
confer	B-X
a	B-X
slight	B-X
increase	B-X
in	B-X
susceptibility	B-X
to	B-X
reductive	B-X
succinylation	B-X
.	B-X
All	B-X
mutant	B-X
E2p	B-X
domains	B-X
,	B-X
apart	B-X
from	B-X
that	B-X
with	B-X
the	B-X
loop	B-X
deletion	B-X
(	B-X
LD	B-X
)	B-X
,	B-X
were	B-X
readily	B-X
lipoylated	B-X
in	B-X
vitro	B-X
by	B-X
E.	B-X
coli	B-X
lipoate	B-X
protein	B-X
ligase	B-X
A	B-X
;	B-X
the	B-X
E2p	B-X
LD	B-X
mutant	B-X
could	B-X
be	B-X
lipoylated	B-X
only	B-X
at	B-X
a	B-X
significantly	B-X
lower	B-X
rate	B-X
.	B-X
Likewise	B-X
,	B-X
this	B-X
domain	B-X
exhibited	B-X
1D	B-X
and	B-X
2D	B-X
NMR	B-X
spectra	B-X
characteristic	B-X
of	B-X
a	B-X
partially	B-X
folded	B-X
protein	B-X
,	B-X
whereas	B-X
the	B-X
spectra	B-X
of	B-X
mutants	B-X
with	B-X
modified	B-X
loops	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
evidently	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
domain	B-X
and	B-X
may	B-X
help	B-X
to	B-X
stabilize	B-X
the	B-X
thioester	B-X
bond	B-X
linking	B-X
the	B-X
acyl	B-X
group	B-X
to	B-X
the	B-X
reduced	B-X
lipoyl-lysine	B-X
swinging	B-X
arm	B-X
as	B-X
part	B-X
of	B-X
the	B-X
catalytic	B-X
mechanism	B-X
.	B-X
Recognition	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
by	B-X
its	B-X
partner	B-X
E1	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
complex	B-X
process	B-X
and	B-X
not	B-X
attributable	B-X
to	B-X
any	B-X
single	B-X
determinant	B-X
on	B-X
the	B-X
domain	B-X
.	B-X

A	O
prominent	O
surface	O
loop	O
links	O
the	O
first	O
and	O
second	O
beta	O
-	O
strands	O
in	O
all	O
lipoyl	O
domains	O
,	O
close	O
in	O
space	O
to	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
.	O

This	O
loop	O
was	O
subjected	O
to	O
various	O
modifications	O
by	O
directed	O
mutagenesis	O
of	O
a	O
sub	O
-	O
gene	O
encoding	O
a	O
lipoyl	O
domain	O
of	O
Escherichia	O
coli	O
E2p	B-Protein
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acyltransferase	B-X
(	B-X
E2p	B-X
,	B-X
E2o	B-X
)	B-X
components	B-X
of	B-X
the	B-X
pyruvate	B-X
and	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
are	B-X
specifically	B-X
recognised	B-X
by	B-X
their	B-X
cognate	B-X
2-oxo	B-X
acid	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
,	B-X
E1o	B-X
)	B-X
.	B-X
A	B-X
prominent	B-X
surface	B-X
loop	B-X
links	B-X
the	B-X
first	B-X
and	B-X
second	B-X
beta-strands	B-X
in	B-X
all	B-X
lipoyl	B-X
domains	B-X
,	B-X
close	B-X
in	B-X
space	B-X
to	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
.	B-X
This	B-X
loop	B-X
was	B-X
subjected	B-X
to	B-X
various	B-X
modifications	B-X
by	B-X
directed	B-X
mutagenesis	B-X
of	B-X
a	B-X
sub-gene	B-X
encoding	B-X
a	B-X
lipoyl	B-X
domain	B-X
of	B-X
Escherichia	B-X
coli	B-X
E2p	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
loop	B-X
(	B-X
four	B-X
residues	B-X
)	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
acetylation	B-X
by	B-X
E.	B-X
coli	B-X
E1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
pyruvate	B-X
,	B-X
but	B-X
insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
(	B-X
six	B-X
residues	B-X
)	B-X
corresponding	B-X
to	B-X
that	B-X
in	B-X
the	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
partly	B-X
restored	B-X
this	B-X
ability	B-X
,	B-X
albeit	B-X
with	B-X
a	B-X
much	B-X
lower	B-X
rate	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modified	B-X
domain	B-X
remained	B-X
unable	B-X
to	B-X
undergo	B-X
reductive	B-X
succinylation	B-X
by	B-X
E1o	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
2-oxoglutarate	B-X
.	B-X
Additional	B-X
exchange	B-X
of	B-X
the	B-X
two	B-X
residues	B-X
on	B-X
the	B-X
C-terminal	B-X
side	B-X
of	B-X
the	B-X
loop	B-X
(	B-X
V14A	B-X
,	B-X
E15T	B-X
)	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
Insertion	B-X
of	B-X
a	B-X
different	B-X
four-residue	B-X
loop	B-X
also	B-X
restored	B-X
a	B-X
limited	B-X
ability	B-X
to	B-X
undergo	B-X
reductive	B-X
acetylation	B-X
,	B-X
but	B-X
still	B-X
significantly	B-X
less	B-X
than	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
Exchanging	B-X
the	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
in	B-X
the	B-X
E2p	B-X
and	B-X
E2o	B-X
domains	B-X
(	B-X
G39T	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
E2p	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
but	B-X
did	B-X
confer	B-X
a	B-X
slight	B-X
increase	B-X
in	B-X
susceptibility	B-X
to	B-X
reductive	B-X
succinylation	B-X
.	B-X
All	B-X
mutant	B-X
E2p	B-X
domains	B-X
,	B-X
apart	B-X
from	B-X
that	B-X
with	B-X
the	B-X
loop	B-X
deletion	B-X
(	B-X
LD	B-X
)	B-X
,	B-X
were	B-X
readily	B-X
lipoylated	B-X
in	B-X
vitro	B-X
by	B-X
E.	B-X
coli	B-X
lipoate	B-X
protein	B-X
ligase	B-X
A	B-X
;	B-X
the	B-X
E2p	B-X
LD	B-X
mutant	B-X
could	B-X
be	B-X
lipoylated	B-X
only	B-X
at	B-X
a	B-X
significantly	B-X
lower	B-X
rate	B-X
.	B-X
Likewise	B-X
,	B-X
this	B-X
domain	B-X
exhibited	B-X
1D	B-X
and	B-X
2D	B-X
NMR	B-X
spectra	B-X
characteristic	B-X
of	B-X
a	B-X
partially	B-X
folded	B-X
protein	B-X
,	B-X
whereas	B-X
the	B-X
spectra	B-X
of	B-X
mutants	B-X
with	B-X
modified	B-X
loops	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
evidently	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
domain	B-X
and	B-X
may	B-X
help	B-X
to	B-X
stabilize	B-X
the	B-X
thioester	B-X
bond	B-X
linking	B-X
the	B-X
acyl	B-X
group	B-X
to	B-X
the	B-X
reduced	B-X
lipoyl-lysine	B-X
swinging	B-X
arm	B-X
as	B-X
part	B-X
of	B-X
the	B-X
catalytic	B-X
mechanism	B-X
.	B-X
Recognition	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
by	B-X
its	B-X
partner	B-X
E1	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
complex	B-X
process	B-X
and	B-X
not	B-X
attributable	B-X
to	B-X
any	B-X
single	B-X
determinant	B-X
on	B-X
the	B-X
domain	B-X
.	B-X

Deletion	O
of	O
the	O
loop	O
(	O
four	O
residues	O
)	O
rendered	O
the	O
domain	O
incapable	O
of	O
reductive	O
acetylation	O
by	O
E	O
.	O
coli	O
E1p	B-Protein
in	O
the	O
presence	O
of	O
pyruvate	O
,	O
but	O
insertion	O
of	O
a	O
new	O
loop	O
(	O
six	O
residues	O
)	O
corresponding	O
to	O
that	O
in	O
the	O
E2o	B-Protein
lipoyl	O
domain	O
partly	O
restored	O
this	O
ability	O
,	O
albeit	O
with	O
a	O
much	O
lower	O
rate	O
.	O

However	O
,	O
the	O
modified	O
domain	O
remained	O
unable	O
to	O
undergo	O
reductive	O
succinylation	O
by	O
E1o	B-Protein
in	O
the	O
presence	O
of	O
2	O
-	O
oxoglutarate	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acyltransferase	B-X
(	B-X
E2p	B-X
,	B-X
E2o	B-X
)	B-X
components	B-X
of	B-X
the	B-X
pyruvate	B-X
and	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
are	B-X
specifically	B-X
recognised	B-X
by	B-X
their	B-X
cognate	B-X
2-oxo	B-X
acid	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
,	B-X
E1o	B-X
)	B-X
.	B-X
A	B-X
prominent	B-X
surface	B-X
loop	B-X
links	B-X
the	B-X
first	B-X
and	B-X
second	B-X
beta-strands	B-X
in	B-X
all	B-X
lipoyl	B-X
domains	B-X
,	B-X
close	B-X
in	B-X
space	B-X
to	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
.	B-X
This	B-X
loop	B-X
was	B-X
subjected	B-X
to	B-X
various	B-X
modifications	B-X
by	B-X
directed	B-X
mutagenesis	B-X
of	B-X
a	B-X
sub-gene	B-X
encoding	B-X
a	B-X
lipoyl	B-X
domain	B-X
of	B-X
Escherichia	B-X
coli	B-X
E2p	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
loop	B-X
(	B-X
four	B-X
residues	B-X
)	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
acetylation	B-X
by	B-X
E.	B-X
coli	B-X
E1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
pyruvate	B-X
,	B-X
but	B-X
insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
(	B-X
six	B-X
residues	B-X
)	B-X
corresponding	B-X
to	B-X
that	B-X
in	B-X
the	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
partly	B-X
restored	B-X
this	B-X
ability	B-X
,	B-X
albeit	B-X
with	B-X
a	B-X
much	B-X
lower	B-X
rate	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modified	B-X
domain	B-X
remained	B-X
unable	B-X
to	B-X
undergo	B-X
reductive	B-X
succinylation	B-X
by	B-X
E1o	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
2-oxoglutarate	B-X
.	B-X
Insertion	B-X
of	B-X
a	B-X
different	B-X
four-residue	B-X
loop	B-X
also	B-X
restored	B-X
a	B-X
limited	B-X
ability	B-X
to	B-X
undergo	B-X
reductive	B-X
acetylation	B-X
,	B-X
but	B-X
still	B-X
significantly	B-X
less	B-X
than	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
Exchanging	B-X
the	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
in	B-X
the	B-X
E2p	B-X
and	B-X
E2o	B-X
domains	B-X
(	B-X
G39T	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
E2p	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
but	B-X
did	B-X
confer	B-X
a	B-X
slight	B-X
increase	B-X
in	B-X
susceptibility	B-X
to	B-X
reductive	B-X
succinylation	B-X
.	B-X
All	B-X
mutant	B-X
E2p	B-X
domains	B-X
,	B-X
apart	B-X
from	B-X
that	B-X
with	B-X
the	B-X
loop	B-X
deletion	B-X
(	B-X
LD	B-X
)	B-X
,	B-X
were	B-X
readily	B-X
lipoylated	B-X
in	B-X
vitro	B-X
by	B-X
E.	B-X
coli	B-X
lipoate	B-X
protein	B-X
ligase	B-X
A	B-X
;	B-X
the	B-X
E2p	B-X
LD	B-X
mutant	B-X
could	B-X
be	B-X
lipoylated	B-X
only	B-X
at	B-X
a	B-X
significantly	B-X
lower	B-X
rate	B-X
.	B-X
Likewise	B-X
,	B-X
this	B-X
domain	B-X
exhibited	B-X
1D	B-X
and	B-X
2D	B-X
NMR	B-X
spectra	B-X
characteristic	B-X
of	B-X
a	B-X
partially	B-X
folded	B-X
protein	B-X
,	B-X
whereas	B-X
the	B-X
spectra	B-X
of	B-X
mutants	B-X
with	B-X
modified	B-X
loops	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
evidently	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
domain	B-X
and	B-X
may	B-X
help	B-X
to	B-X
stabilize	B-X
the	B-X
thioester	B-X
bond	B-X
linking	B-X
the	B-X
acyl	B-X
group	B-X
to	B-X
the	B-X
reduced	B-X
lipoyl-lysine	B-X
swinging	B-X
arm	B-X
as	B-X
part	B-X
of	B-X
the	B-X
catalytic	B-X
mechanism	B-X
.	B-X
Recognition	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
by	B-X
its	B-X
partner	B-X
E1	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
complex	B-X
process	B-X
and	B-X
not	B-X
attributable	B-X
to	B-X
any	B-X
single	B-X
determinant	B-X
on	B-X
the	B-X
domain	B-X
.	B-X

Additional	O
exchange	O
of	O
the	O
two	O
residues	O
on	O
the	O
C	O
-	O
terminal	O
side	O
of	O
the	O
loop	O
(	O
V14A	O
,	O
E15T	O
)	O
had	O
no	O
effect	O
.	O

Insertion	O
of	O
a	O
different	O
four	O
-	O
residue	O
loop	O
also	O
restored	O
a	O
limited	O
ability	O
to	O
undergo	O
reductive	O
acetylation	O
,	O
but	O
still	O
significantly	O
less	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
domain	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acyltransferase	B-X
(	B-X
E2p	B-X
,	B-X
E2o	B-X
)	B-X
components	B-X
of	B-X
the	B-X
pyruvate	B-X
and	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
are	B-X
specifically	B-X
recognised	B-X
by	B-X
their	B-X
cognate	B-X
2-oxo	B-X
acid	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
,	B-X
E1o	B-X
)	B-X
.	B-X
A	B-X
prominent	B-X
surface	B-X
loop	B-X
links	B-X
the	B-X
first	B-X
and	B-X
second	B-X
beta-strands	B-X
in	B-X
all	B-X
lipoyl	B-X
domains	B-X
,	B-X
close	B-X
in	B-X
space	B-X
to	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
.	B-X
This	B-X
loop	B-X
was	B-X
subjected	B-X
to	B-X
various	B-X
modifications	B-X
by	B-X
directed	B-X
mutagenesis	B-X
of	B-X
a	B-X
sub-gene	B-X
encoding	B-X
a	B-X
lipoyl	B-X
domain	B-X
of	B-X
Escherichia	B-X
coli	B-X
E2p	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
loop	B-X
(	B-X
four	B-X
residues	B-X
)	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
acetylation	B-X
by	B-X
E.	B-X
coli	B-X
E1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
pyruvate	B-X
,	B-X
but	B-X
insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
(	B-X
six	B-X
residues	B-X
)	B-X
corresponding	B-X
to	B-X
that	B-X
in	B-X
the	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
partly	B-X
restored	B-X
this	B-X
ability	B-X
,	B-X
albeit	B-X
with	B-X
a	B-X
much	B-X
lower	B-X
rate	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modified	B-X
domain	B-X
remained	B-X
unable	B-X
to	B-X
undergo	B-X
reductive	B-X
succinylation	B-X
by	B-X
E1o	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
2-oxoglutarate	B-X
.	B-X
Additional	B-X
exchange	B-X
of	B-X
the	B-X
two	B-X
residues	B-X
on	B-X
the	B-X
C-terminal	B-X
side	B-X
of	B-X
the	B-X
loop	B-X
(	B-X
V14A	B-X
,	B-X
E15T	B-X
)	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
Insertion	B-X
of	B-X
a	B-X
different	B-X
four-residue	B-X
loop	B-X
also	B-X
restored	B-X
a	B-X
limited	B-X
ability	B-X
to	B-X
undergo	B-X
reductive	B-X
acetylation	B-X
,	B-X
but	B-X
still	B-X
significantly	B-X
less	B-X
than	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
Exchanging	B-X
the	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
in	B-X
the	B-X
E2p	B-X
and	B-X
E2o	B-X
domains	B-X
(	B-X
G39T	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
E2p	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
but	B-X
did	B-X
confer	B-X
a	B-X
slight	B-X
increase	B-X
in	B-X
susceptibility	B-X
to	B-X
reductive	B-X
succinylation	B-X
.	B-X
All	B-X
mutant	B-X
E2p	B-X
domains	B-X
,	B-X
apart	B-X
from	B-X
that	B-X
with	B-X
the	B-X
loop	B-X
deletion	B-X
(	B-X
LD	B-X
)	B-X
,	B-X
were	B-X
readily	B-X
lipoylated	B-X
in	B-X
vitro	B-X
by	B-X
E.	B-X
coli	B-X
lipoate	B-X
protein	B-X
ligase	B-X
A	B-X
;	B-X
the	B-X
E2p	B-X
LD	B-X
mutant	B-X
could	B-X
be	B-X
lipoylated	B-X
only	B-X
at	B-X
a	B-X
significantly	B-X
lower	B-X
rate	B-X
.	B-X
Likewise	B-X
,	B-X
this	B-X
domain	B-X
exhibited	B-X
1D	B-X
and	B-X
2D	B-X
NMR	B-X
spectra	B-X
characteristic	B-X
of	B-X
a	B-X
partially	B-X
folded	B-X
protein	B-X
,	B-X
whereas	B-X
the	B-X
spectra	B-X
of	B-X
mutants	B-X
with	B-X
modified	B-X
loops	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
evidently	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
domain	B-X
and	B-X
may	B-X
help	B-X
to	B-X
stabilize	B-X
the	B-X
thioester	B-X
bond	B-X
linking	B-X
the	B-X
acyl	B-X
group	B-X
to	B-X
the	B-X
reduced	B-X
lipoyl-lysine	B-X
swinging	B-X
arm	B-X
as	B-X
part	B-X
of	B-X
the	B-X
catalytic	B-X
mechanism	B-X
.	B-X
Recognition	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
by	B-X
its	B-X
partner	B-X
E1	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
complex	B-X
process	B-X
and	B-X
not	B-X
attributable	B-X
to	B-X
any	B-X
single	B-X
determinant	B-X
on	B-X
the	B-X
domain	B-X
.	B-X

Exchanging	O
the	O
residue	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
in	O
the	O
E2p	B-Protein
and	O
E2o	B-Protein
domains	O
(	O
G39T	O
)	O
,	O
both	O
singly	O
and	O
in	O
conjunction	O
with	O
the	O
loop	O
exchange	O
,	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
the	O
E2p	B-Protein
domain	O
to	O
be	O
reductively	O
acetylated	O
but	O
did	O
confer	O
a	O
slight	O
increase	O
in	O
susceptibility	O
to	O
reductive	O
succinylation	O
.	O

All	O
mutant	O
E2p	B-Protein
domains	O
,	O
apart	O
from	O
that	O
with	O
the	O
loop	O
deletion	O
(	O
LD	O
)	O
,	O
were	O
readily	O
lipoylated	O
in	O
vitro	O
by	O
E	O
.	O
coli	O
lipoate	B-Protein
protein	I-Protein
ligase	I-Protein
A	I-Protein
;	O
the	O
E2p	B-Protein
LD	O
mutant	O
could	O
be	O
lipoylated	O
only	O
at	O
a	O
significantly	O
lower	O
rate	O
.	O

Likewise	O
,	O
this	O
domain	O
exhibited	O
1D	O
and	O
2D	O
NMR	O
spectra	O
characteristic	O
of	O
a	O
partially	O
folded	O
protein	O
,	O
whereas	O
the	O
spectra	O
of	O
mutants	O
with	O
modified	O
loops	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
domain	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acyltransferase	B-X
(	B-X
E2p	B-X
,	B-X
E2o	B-X
)	B-X
components	B-X
of	B-X
the	B-X
pyruvate	B-X
and	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
are	B-X
specifically	B-X
recognised	B-X
by	B-X
their	B-X
cognate	B-X
2-oxo	B-X
acid	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
,	B-X
E1o	B-X
)	B-X
.	B-X
A	B-X
prominent	B-X
surface	B-X
loop	B-X
links	B-X
the	B-X
first	B-X
and	B-X
second	B-X
beta-strands	B-X
in	B-X
all	B-X
lipoyl	B-X
domains	B-X
,	B-X
close	B-X
in	B-X
space	B-X
to	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
.	B-X
This	B-X
loop	B-X
was	B-X
subjected	B-X
to	B-X
various	B-X
modifications	B-X
by	B-X
directed	B-X
mutagenesis	B-X
of	B-X
a	B-X
sub-gene	B-X
encoding	B-X
a	B-X
lipoyl	B-X
domain	B-X
of	B-X
Escherichia	B-X
coli	B-X
E2p	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
loop	B-X
(	B-X
four	B-X
residues	B-X
)	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
acetylation	B-X
by	B-X
E.	B-X
coli	B-X
E1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
pyruvate	B-X
,	B-X
but	B-X
insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
(	B-X
six	B-X
residues	B-X
)	B-X
corresponding	B-X
to	B-X
that	B-X
in	B-X
the	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
partly	B-X
restored	B-X
this	B-X
ability	B-X
,	B-X
albeit	B-X
with	B-X
a	B-X
much	B-X
lower	B-X
rate	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modified	B-X
domain	B-X
remained	B-X
unable	B-X
to	B-X
undergo	B-X
reductive	B-X
succinylation	B-X
by	B-X
E1o	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
2-oxoglutarate	B-X
.	B-X
Insertion	B-X
of	B-X
a	B-X
different	B-X
four-residue	B-X
loop	B-X
also	B-X
restored	B-X
a	B-X
limited	B-X
ability	B-X
to	B-X
undergo	B-X
reductive	B-X
acetylation	B-X
,	B-X
but	B-X
still	B-X
significantly	B-X
less	B-X
than	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
Exchanging	B-X
the	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
in	B-X
the	B-X
E2p	B-X
and	B-X
E2o	B-X
domains	B-X
(	B-X
G39T	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
E2p	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
but	B-X
did	B-X
confer	B-X
a	B-X
slight	B-X
increase	B-X
in	B-X
susceptibility	B-X
to	B-X
reductive	B-X
succinylation	B-X
.	B-X
All	B-X
mutant	B-X
E2p	B-X
domains	B-X
,	B-X
apart	B-X
from	B-X
that	B-X
with	B-X
the	B-X
loop	B-X
deletion	B-X
(	B-X
LD	B-X
)	B-X
,	B-X
were	B-X
readily	B-X
lipoylated	B-X
in	B-X
vitro	B-X
by	B-X
E.	B-X
coli	B-X
lipoate	B-X
protein	B-X
ligase	B-X
A	B-X
;	B-X
the	B-X
E2p	B-X
LD	B-X
mutant	B-X
could	B-X
be	B-X
lipoylated	B-X
only	B-X
at	B-X
a	B-X
significantly	B-X
lower	B-X
rate	B-X
.	B-X
Likewise	B-X
,	B-X
this	B-X
domain	B-X
exhibited	B-X
1D	B-X
and	B-X
2D	B-X
NMR	B-X
spectra	B-X
characteristic	B-X
of	B-X
a	B-X
partially	B-X
folded	B-X
protein	B-X
,	B-X
whereas	B-X
the	B-X
spectra	B-X
of	B-X
mutants	B-X
with	B-X
modified	B-X
loops	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
domain	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
evidently	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
domain	B-X
and	B-X
may	B-X
help	B-X
to	B-X
stabilize	B-X
the	B-X
thioester	B-X
bond	B-X
linking	B-X
the	B-X
acyl	B-X
group	B-X
to	B-X
the	B-X
reduced	B-X
lipoyl-lysine	B-X
swinging	B-X
arm	B-X
as	B-X
part	B-X
of	B-X
the	B-X
catalytic	B-X
mechanism	B-X
.	B-X
Recognition	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
by	B-X
its	B-X
partner	B-X
E1	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
complex	B-X
process	B-X
and	B-X
not	B-X
attributable	B-X
to	B-X
any	B-X
single	B-X
determinant	B-X
on	B-X
the	B-X
domain	B-X
.	B-X

The	O
surface	O
loop	O
is	O
evidently	O
important	O
to	O
the	O
structural	O
integrity	O
of	O
the	O
domain	O
and	O
may	O
help	O
to	O
stabilize	O
the	O
thioester	O
bond	O
linking	O
the	O
acyl	O
group	O
to	O
the	O
reduced	O
lipoyl	O
-	O
lysine	O
swinging	O
arm	O
as	O
part	O
of	O
the	O
catalytic	O
mechanism	O
.	O

Recognition	O
of	O
the	O
lipoyl	O
domain	O
by	O
its	O
partner	O
E1	O
appears	O
to	O
be	O
a	O
complex	O
process	O
and	O
not	O
attributable	O
to	O
any	O
single	O
determinant	O
on	O
the	O
domain	O
.	O

Identification	O
of	O
a	O
novel	O
isopeptidase	O
with	O
dual	O
specificity	O
for	O
ubiquitin	B-Protein
-	O
and	O
NEDD8	B-Protein
-	O
conjugated	O
proteins	O
.	O
<EOS>	B-X
Covalent	B-X
conjugation	B-X
of	B-X
proteins	B-X
by	B-X
ubiquitin	B-X
or	B-X
ubiquitin-like	B-X
molecules	B-X
is	B-X
an	B-X
important	B-X
form	B-X
of	B-X
post-translational	B-X
modification	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
many	B-X
cellular	B-X
processes	B-X
.	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
cloned	B-X
cDNA	B-X
contains	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
1,143	B-X
base	B-X
pairs	B-X
encoding	B-X
a	B-X
novel	B-X
protease	B-X
,	B-X
USP21	B-X
,	B-X
which	B-X
is	B-X
composed	B-X
of	B-X
381	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
43	B-X
kDa	B-X
.	B-X
The	B-X
human	B-X
USP21	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
1q21	B-X
and	B-X
encodes	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
family	B-X
with	B-X
highly	B-X
conserved	B-X
Cys	B-X
and	B-X
His	B-X
domains	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
specificity	B-X
of	B-X
USP21	B-X
were	B-X
determined	B-X
by	B-X
using	B-X
a	B-X
COS	B-X
cell	B-X
expression	B-X
system	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
ubiquitin	B-X
from	B-X
ubiquitinated	B-X
proteins	B-X
as	B-X
expected	B-X
.	B-X
Furthermore	B-X
,	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
NEDD8	B-X
from	B-X
NEDD8	B-X
conjugates	B-X
but	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
Sentrin-1	B-X
conjugates	B-X
.	B-X
Thus	B-X
,	B-X
USP21	B-X
is	B-X
the	B-X
first	B-X
ubiquitin-specific	B-X
protease	B-X
shown	B-X
to	B-X
have	B-X
dual	B-X
specificity	B-X
for	B-X
both	B-X
ubiquitin	B-X
and	B-X
NEDD8	B-X
and	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X

Covalent	O
conjugation	O
of	O
proteins	O
by	O
ubiquitin	B-Protein
or	O
ubiquitin	B-Protein
-	O
like	O
molecules	O
is	O
an	O
important	O
form	O
of	O
post	O
-	O
translational	O
modification	O
and	O
plays	O
a	O
critical	O
role	O
in	O
many	O
cellular	O
processes	O
.	O
<EOS>	B-X
Ubiquitination	B-X
regulates	B-X
many	B-X
essential	B-X
cellular	B-X
processes	B-X
in	B-X
eukaryotes	B-X
.	B-X
This	B-X
post-translational	B-X
modification	B-X
(	B-X
PTM	B-X
)	B-X
is	B-X
typically	B-X
achieved	B-X
by	B-X
E1	B-X
,	B-X
E2	B-X
,	B-X
and	B-X
E3	B-X
enzymes	B-X
that	B-X
sequentially	B-X
catalyze	B-X
activation	B-X
,	B-X
conjugation	B-X
,	B-X
and	B-X
ligation	B-X
reactions	B-X
,	B-X
respectively	B-X
,	B-X
leading	B-X
to	B-X
covalent	B-X
attachment	B-X
of	B-X
ubiquitin	B-X
,	B-X
usually	B-X
to	B-X
lysine	B-X
residues	B-X
of	B-X
substrate	B-X
proteins	B-X
.	B-X
Ubiquitin	B-X
can	B-X
also	B-X
be	B-X
successively	B-X
linked	B-X
to	B-X
one	B-X
of	B-X
the	B-X
seven	B-X
lysine	B-X
residues	B-X
on	B-X
ubiquitin	B-X
to	B-X
form	B-X
distinctive	B-X
forms	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
,	B-X
which	B-X
,	B-X
depending	B-X
upon	B-X
the	B-X
lysine	B-X
used	B-X
and	B-X
the	B-X
length	B-X
of	B-X
the	B-X
chains	B-X
,	B-X
dictate	B-X
the	B-X
fate	B-X
of	B-X
substrate	B-X
proteins	B-X
.	B-X
Recent	B-X
discoveries	B-X
revealed	B-X
that	B-X
this	B-X
ubiquitin	B-X
code	B-X
is	B-X
further	B-X
expanded	B-X
by	B-X
PTMs	B-X
such	B-X
as	B-X
phosphorylation	B-X
,	B-X
acetylation	B-X
,	B-X
deamidation	B-X
,	B-X
and	B-X
ADP-ribosylation	B-X
,	B-X
on	B-X
ubiquitin	B-X
,	B-X
components	B-X
of	B-X
the	B-X
ubiquitination	B-X
machinery	B-X
,	B-X
or	B-X
both	B-X
.	B-X
These	B-X
PTMs	B-X
provide	B-X
additional	B-X
regulatory	B-X
nodes	B-X
to	B-X
integrate	B-X
development	B-X
or	B-X
insulting	B-X
signals	B-X
with	B-X
cellular	B-X
homeostasis	B-X
.	B-X
Understanding	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
these	B-X
PTMs	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
ubiquitin	B-X
signaling	B-X
will	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanisms	B-X
and	B-X
treatment	B-X
of	B-X
various	B-X
human	B-X
diseases	B-X
linked	B-X
to	B-X
ubiquitination	B-X
,	B-X
including	B-X
neurodegenerative	B-X
diseases	B-X
,	B-X
cancer	B-X
,	B-X
infection	B-X
,	B-X
and	B-X
immune	B-X
disorders	B-X
.	B-X

Similar	O
to	O
the	O
concept	O
of	O
phosphorylation	O
and	O
dephosphorylation	O
,	O
these	O
conjugates	O
are	O
regulated	O
by	O
a	O
large	O
number	O
of	O
deconjugating	O
enzymes	O
.	O

Here	O
,	O
we	O
report	O
the	O
cloning	O
of	O
a	O
2	O
,	O
141	O
-	O
base	O
pair	O
DNA	O
fragment	O
from	O
human	O
placenta	O
cDNA	O
library	O
by	O
a	O
strategy	O
that	O
involves	O
expressed	O
sequence	O
tag	O
data	O
base	O
searching	O
,	O
polymerase	O
chain	O
reaction	O
,	O
and	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
cloning	B-X
of	B-X
a	B-X
2,141-base	B-X
pair	B-X
DNA	B-X
fragment	B-X
from	B-X
human	B-X
placenta	B-X
cDNA	B-X
library	B-X
by	B-X
a	B-X
strategy	B-X
that	B-X
involves	B-X
expressed	B-X
sequence	B-X
tag	B-X
data	B-X
base	B-X
searching	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
and	B-X
rapid	B-X
amplification	B-X
of	B-X
cDNA	B-X
ends	B-X
.	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
cloned	B-X
cDNA	B-X
contains	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
1,143	B-X
base	B-X
pairs	B-X
encoding	B-X
a	B-X
novel	B-X
protease	B-X
,	B-X
USP21	B-X
,	B-X
which	B-X
is	B-X
composed	B-X
of	B-X
381	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
43	B-X
kDa	B-X
.	B-X
The	B-X
human	B-X
USP21	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
1q21	B-X
and	B-X
encodes	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
family	B-X
with	B-X
highly	B-X
conserved	B-X
Cys	B-X
and	B-X
His	B-X
domains	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
specificity	B-X
of	B-X
USP21	B-X
were	B-X
determined	B-X
by	B-X
using	B-X
a	B-X
COS	B-X
cell	B-X
expression	B-X
system	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
ubiquitin	B-X
from	B-X
ubiquitinated	B-X
proteins	B-X
as	B-X
expected	B-X
.	B-X
Furthermore	B-X
,	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
NEDD8	B-X
from	B-X
NEDD8	B-X
conjugates	B-X
but	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
Sentrin-1	B-X
conjugates	B-X
.	B-X
As	B-X
expected	B-X
from	B-X
its	B-X
biochemical	B-X
activity	B-X
,	B-X
overexpression	B-X
of	B-X
USP21	B-X
has	B-X
a	B-X
profound	B-X
growth	B-X
inhibitory	B-X
effect	B-X
on	B-X
U2OS	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
USP21	B-X
is	B-X
the	B-X
first	B-X
ubiquitin-specific	B-X
protease	B-X
shown	B-X
to	B-X
have	B-X
dual	B-X
specificity	B-X
for	B-X
both	B-X
ubiquitin	B-X
and	B-X
NEDD8	B-X
and	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X

Nucleotide	O
sequence	O
analysis	O
revealed	O
that	O
the	O
cloned	O
cDNA	O
contains	O
an	O
open	O
reading	O
frame	O
of	O
1	O
,	O
143	O
base	O
pairs	O
encoding	O
a	O
novel	O
protease	O
,	O
USP21	B-Protein
,	O
which	O
is	O
composed	O
of	O
381	O
residues	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
43	O
kDa	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
cloning	B-X
of	B-X
a	B-X
2,141-base	B-X
pair	B-X
DNA	B-X
fragment	B-X
from	B-X
human	B-X
placenta	B-X
cDNA	B-X
library	B-X
by	B-X
a	B-X
strategy	B-X
that	B-X
involves	B-X
expressed	B-X
sequence	B-X
tag	B-X
data	B-X
base	B-X
searching	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
and	B-X
rapid	B-X
amplification	B-X
of	B-X
cDNA	B-X
ends	B-X
.	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
cloned	B-X
cDNA	B-X
contains	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
1,143	B-X
base	B-X
pairs	B-X
encoding	B-X
a	B-X
novel	B-X
protease	B-X
,	B-X
USP21	B-X
,	B-X
which	B-X
is	B-X
composed	B-X
of	B-X
381	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
43	B-X
kDa	B-X
.	B-X
The	B-X
human	B-X
USP21	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
1q21	B-X
and	B-X
encodes	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
family	B-X
with	B-X
highly	B-X
conserved	B-X
Cys	B-X
and	B-X
His	B-X
domains	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
specificity	B-X
of	B-X
USP21	B-X
were	B-X
determined	B-X
by	B-X
using	B-X
a	B-X
COS	B-X
cell	B-X
expression	B-X
system	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
ubiquitin	B-X
from	B-X
ubiquitinated	B-X
proteins	B-X
as	B-X
expected	B-X
.	B-X
Furthermore	B-X
,	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
NEDD8	B-X
from	B-X
NEDD8	B-X
conjugates	B-X
but	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
Sentrin-1	B-X
conjugates	B-X
.	B-X
As	B-X
expected	B-X
from	B-X
its	B-X
biochemical	B-X
activity	B-X
,	B-X
overexpression	B-X
of	B-X
USP21	B-X
has	B-X
a	B-X
profound	B-X
growth	B-X
inhibitory	B-X
effect	B-X
on	B-X
U2OS	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
USP21	B-X
is	B-X
the	B-X
first	B-X
ubiquitin-specific	B-X
protease	B-X
shown	B-X
to	B-X
have	B-X
dual	B-X
specificity	B-X
for	B-X
both	B-X
ubiquitin	B-X
and	B-X
NEDD8	B-X
and	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X

The	O
human	O
USP21	B-Protein
gene	O
is	O
located	O
on	O
chromosome	O
1q21	O
and	O
encodes	O
a	O
member	O
of	O
the	O
ubiquitin	B-Protein
-	O
specific	O
protease	O
family	O
with	O
highly	O
conserved	O
Cys	O
and	O
His	O
domains	O
.	O
<EOS>	B-X
Covalent	B-X
conjugation	B-X
of	B-X
proteins	B-X
by	B-X
ubiquitin	B-X
or	B-X
ubiquitin-like	B-X
molecules	B-X
is	B-X
an	B-X
important	B-X
form	B-X
of	B-X
post-translational	B-X
modification	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
many	B-X
cellular	B-X
processes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
cloning	B-X
of	B-X
a	B-X
2,141-base	B-X
pair	B-X
DNA	B-X
fragment	B-X
from	B-X
human	B-X
placenta	B-X
cDNA	B-X
library	B-X
by	B-X
a	B-X
strategy	B-X
that	B-X
involves	B-X
expressed	B-X
sequence	B-X
tag	B-X
data	B-X
base	B-X
searching	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
and	B-X
rapid	B-X
amplification	B-X
of	B-X
cDNA	B-X
ends	B-X
.	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
cloned	B-X
cDNA	B-X
contains	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
1,143	B-X
base	B-X
pairs	B-X
encoding	B-X
a	B-X
novel	B-X
protease	B-X
,	B-X
USP21	B-X
,	B-X
which	B-X
is	B-X
composed	B-X
of	B-X
381	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
43	B-X
kDa	B-X
.	B-X
The	B-X
human	B-X
USP21	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
1q21	B-X
and	B-X
encodes	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
family	B-X
with	B-X
highly	B-X
conserved	B-X
Cys	B-X
and	B-X
His	B-X
domains	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
specificity	B-X
of	B-X
USP21	B-X
were	B-X
determined	B-X
by	B-X
using	B-X
a	B-X
COS	B-X
cell	B-X
expression	B-X
system	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
ubiquitin	B-X
from	B-X
ubiquitinated	B-X
proteins	B-X
as	B-X
expected	B-X
.	B-X
Furthermore	B-X
,	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
NEDD8	B-X
from	B-X
NEDD8	B-X
conjugates	B-X
but	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
Sentrin-1	B-X
conjugates	B-X
.	B-X
As	B-X
expected	B-X
from	B-X
its	B-X
biochemical	B-X
activity	B-X
,	B-X
overexpression	B-X
of	B-X
USP21	B-X
has	B-X
a	B-X
profound	B-X
growth	B-X
inhibitory	B-X
effect	B-X
on	B-X
U2OS	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
USP21	B-X
is	B-X
the	B-X
first	B-X
ubiquitin-specific	B-X
protease	B-X
shown	B-X
to	B-X
have	B-X
dual	B-X
specificity	B-X
for	B-X
both	B-X
ubiquitin	B-X
and	B-X
NEDD8	B-X
and	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X

The	O
activity	O
and	O
specificity	O
of	O
USP21	B-Protein
were	O
determined	O
by	O
using	O
a	O
COS	O
cell	O
expression	O
system	O
in	O
vivo	O
.	O
<EOS>	B-X
Covalent	B-X
conjugation	B-X
of	B-X
proteins	B-X
by	B-X
ubiquitin	B-X
or	B-X
ubiquitin-like	B-X
molecules	B-X
is	B-X
an	B-X
important	B-X
form	B-X
of	B-X
post-translational	B-X
modification	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
many	B-X
cellular	B-X
processes	B-X
.	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
cloned	B-X
cDNA	B-X
contains	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
1,143	B-X
base	B-X
pairs	B-X
encoding	B-X
a	B-X
novel	B-X
protease	B-X
,	B-X
USP21	B-X
,	B-X
which	B-X
is	B-X
composed	B-X
of	B-X
381	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
43	B-X
kDa	B-X
.	B-X
The	B-X
human	B-X
USP21	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
1q21	B-X
and	B-X
encodes	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
family	B-X
with	B-X
highly	B-X
conserved	B-X
Cys	B-X
and	B-X
His	B-X
domains	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
specificity	B-X
of	B-X
USP21	B-X
were	B-X
determined	B-X
by	B-X
using	B-X
a	B-X
COS	B-X
cell	B-X
expression	B-X
system	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
ubiquitin	B-X
from	B-X
ubiquitinated	B-X
proteins	B-X
as	B-X
expected	B-X
.	B-X
Furthermore	B-X
,	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
NEDD8	B-X
from	B-X
NEDD8	B-X
conjugates	B-X
but	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
Sentrin-1	B-X
conjugates	B-X
.	B-X
As	B-X
expected	B-X
from	B-X
its	B-X
biochemical	B-X
activity	B-X
,	B-X
overexpression	B-X
of	B-X
USP21	B-X
has	B-X
a	B-X
profound	B-X
growth	B-X
inhibitory	B-X
effect	B-X
on	B-X
U2OS	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
USP21	B-X
is	B-X
the	B-X
first	B-X
ubiquitin-specific	B-X
protease	B-X
shown	B-X
to	B-X
have	B-X
dual	B-X
specificity	B-X
for	B-X
both	B-X
ubiquitin	B-X
and	B-X
NEDD8	B-X
and	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X

We	O
showed	O
that	O
USP21	B-Protein
is	O
capable	O
of	O
removing	O
ubiquitin	B-Protein
from	O
ubiquitinated	O
proteins	O
as	O
expected	O
.	O
<EOS>	B-X
Covalent	B-X
conjugation	B-X
of	B-X
proteins	B-X
by	B-X
ubiquitin	B-X
or	B-X
ubiquitin-like	B-X
molecules	B-X
is	B-X
an	B-X
important	B-X
form	B-X
of	B-X
post-translational	B-X
modification	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
many	B-X
cellular	B-X
processes	B-X
.	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
cloned	B-X
cDNA	B-X
contains	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
1,143	B-X
base	B-X
pairs	B-X
encoding	B-X
a	B-X
novel	B-X
protease	B-X
,	B-X
USP21	B-X
,	B-X
which	B-X
is	B-X
composed	B-X
of	B-X
381	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
43	B-X
kDa	B-X
.	B-X
The	B-X
human	B-X
USP21	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
1q21	B-X
and	B-X
encodes	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
family	B-X
with	B-X
highly	B-X
conserved	B-X
Cys	B-X
and	B-X
His	B-X
domains	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
specificity	B-X
of	B-X
USP21	B-X
were	B-X
determined	B-X
by	B-X
using	B-X
a	B-X
COS	B-X
cell	B-X
expression	B-X
system	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
ubiquitin	B-X
from	B-X
ubiquitinated	B-X
proteins	B-X
as	B-X
expected	B-X
.	B-X
Furthermore	B-X
,	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
NEDD8	B-X
from	B-X
NEDD8	B-X
conjugates	B-X
but	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
Sentrin-1	B-X
conjugates	B-X
.	B-X
As	B-X
expected	B-X
from	B-X
its	B-X
biochemical	B-X
activity	B-X
,	B-X
overexpression	B-X
of	B-X
USP21	B-X
has	B-X
a	B-X
profound	B-X
growth	B-X
inhibitory	B-X
effect	B-X
on	B-X
U2OS	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
USP21	B-X
is	B-X
the	B-X
first	B-X
ubiquitin-specific	B-X
protease	B-X
shown	B-X
to	B-X
have	B-X
dual	B-X
specificity	B-X
for	B-X
both	B-X
ubiquitin	B-X
and	B-X
NEDD8	B-X
and	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X

Furthermore	O
,	O
USP21	B-Protein
is	O
capable	O
of	O
removing	O
NEDD8	B-Protein
from	O
NEDD8	B-Protein
conjugates	O
but	O
has	O
no	O
effect	O
on	O
Sentrin	B-Protein
-	I-Protein
1	I-Protein
conjugates	O
.	O
<EOS>	B-X
Similar	B-X
to	B-X
the	B-X
concept	B-X
of	B-X
phosphorylation	B-X
and	B-X
dephosphorylation	B-X
,	B-X
these	B-X
conjugates	B-X
are	B-X
regulated	B-X
by	B-X
a	B-X
large	B-X
number	B-X
of	B-X
deconjugating	B-X
enzymes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
cloning	B-X
of	B-X
a	B-X
2,141-base	B-X
pair	B-X
DNA	B-X
fragment	B-X
from	B-X
human	B-X
placenta	B-X
cDNA	B-X
library	B-X
by	B-X
a	B-X
strategy	B-X
that	B-X
involves	B-X
expressed	B-X
sequence	B-X
tag	B-X
data	B-X
base	B-X
searching	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
and	B-X
rapid	B-X
amplification	B-X
of	B-X
cDNA	B-X
ends	B-X
.	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
cloned	B-X
cDNA	B-X
contains	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
1,143	B-X
base	B-X
pairs	B-X
encoding	B-X
a	B-X
novel	B-X
protease	B-X
,	B-X
USP21	B-X
,	B-X
which	B-X
is	B-X
composed	B-X
of	B-X
381	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
43	B-X
kDa	B-X
.	B-X
The	B-X
human	B-X
USP21	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
1q21	B-X
and	B-X
encodes	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
family	B-X
with	B-X
highly	B-X
conserved	B-X
Cys	B-X
and	B-X
His	B-X
domains	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
specificity	B-X
of	B-X
USP21	B-X
were	B-X
determined	B-X
by	B-X
using	B-X
a	B-X
COS	B-X
cell	B-X
expression	B-X
system	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
ubiquitin	B-X
from	B-X
ubiquitinated	B-X
proteins	B-X
as	B-X
expected	B-X
.	B-X
Furthermore	B-X
,	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
NEDD8	B-X
from	B-X
NEDD8	B-X
conjugates	B-X
but	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
Sentrin-1	B-X
conjugates	B-X
.	B-X
As	B-X
expected	B-X
from	B-X
its	B-X
biochemical	B-X
activity	B-X
,	B-X
overexpression	B-X
of	B-X
USP21	B-X
has	B-X
a	B-X
profound	B-X
growth	B-X
inhibitory	B-X
effect	B-X
on	B-X
U2OS	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
USP21	B-X
is	B-X
the	B-X
first	B-X
ubiquitin-specific	B-X
protease	B-X
shown	B-X
to	B-X
have	B-X
dual	B-X
specificity	B-X
for	B-X
both	B-X
ubiquitin	B-X
and	B-X
NEDD8	B-X
and	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X

As	O
expected	O
from	O
its	O
biochemical	O
activity	O
,	O
overexpression	O
of	O
USP21	B-Protein
has	O
a	O
profound	O
growth	O
inhibitory	O
effect	O
on	O
U2OS	O
cells	O
.	O

Thus	O
,	O
USP21	B-Protein
is	O
the	O
first	O
ubiquitin	B-Protein
-	O
specific	O
protease	O
shown	O
to	O
have	O
dual	O
specificity	O
for	O
both	O
ubiquitin	B-Protein
and	O
NEDD8	B-Protein
and	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
.	O
<EOS>	B-X
Covalent	B-X
conjugation	B-X
of	B-X
proteins	B-X
by	B-X
ubiquitin	B-X
or	B-X
ubiquitin-like	B-X
molecules	B-X
is	B-X
an	B-X
important	B-X
form	B-X
of	B-X
post-translational	B-X
modification	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
many	B-X
cellular	B-X
processes	B-X
.	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
cloned	B-X
cDNA	B-X
contains	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
of	B-X
1,143	B-X
base	B-X
pairs	B-X
encoding	B-X
a	B-X
novel	B-X
protease	B-X
,	B-X
USP21	B-X
,	B-X
which	B-X
is	B-X
composed	B-X
of	B-X
381	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
43	B-X
kDa	B-X
.	B-X
The	B-X
human	B-X
USP21	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
1q21	B-X
and	B-X
encodes	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
family	B-X
with	B-X
highly	B-X
conserved	B-X
Cys	B-X
and	B-X
His	B-X
domains	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
specificity	B-X
of	B-X
USP21	B-X
were	B-X
determined	B-X
by	B-X
using	B-X
a	B-X
COS	B-X
cell	B-X
expression	B-X
system	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
ubiquitin	B-X
from	B-X
ubiquitinated	B-X
proteins	B-X
as	B-X
expected	B-X
.	B-X
Furthermore	B-X
,	B-X
USP21	B-X
is	B-X
capable	B-X
of	B-X
removing	B-X
NEDD8	B-X
from	B-X
NEDD8	B-X
conjugates	B-X
but	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
Sentrin-1	B-X
conjugates	B-X
.	B-X
As	B-X
expected	B-X
from	B-X
its	B-X
biochemical	B-X
activity	B-X
,	B-X
overexpression	B-X
of	B-X
USP21	B-X
has	B-X
a	B-X
profound	B-X
growth	B-X
inhibitory	B-X
effect	B-X
on	B-X
U2OS	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
USP21	B-X
is	B-X
the	B-X
first	B-X
ubiquitin-specific	B-X
protease	B-X
shown	B-X
to	B-X
have	B-X
dual	B-X
specificity	B-X
for	B-X
both	B-X
ubiquitin	B-X
and	B-X
NEDD8	B-X
and	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X

Activation	O
of	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
-	O
specific	O
signaling	O
pathways	O
does	O
not	O
require	O
posttranslational	O
processing	O
of	O
H	B-Protein
-	I-Protein
ras	I-Protein
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
retained	O
transforming	O
activity	O
when	O
lacking	O
C	O
-	O
terminal	O
lipid	O
modifications	O
,	O
provided	O
that	O
plasma	O
membrane	O
localization	O
was	O
restored	O
by	O
an	O
N	O
-	O
terminal	O
transmembrane	O
domain	O
.	O

Since	O
several	O
ras	O
-	O
activated	O
pathways	O
contribute	O
to	O
the	O
transformed	O
phenotype	O
,	O
we	O
utilized	O
a	O
novel	O
set	O
of	O
transmembrane	O
domain	O
-	O
anchored	O
H	B-Protein
-	I-Protein
ras	I-Protein
derivatives	O
to	O
examine	O
if	O
lipids	O
are	O
required	O
for	O
activation	O
of	O
any	O
specific	O
signaling	O
pathways	O
.	O

We	O
demonstrate	O
here	O
that	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
-	O
induced	O
activation	O
of	O
the	O
Raf	B-Protein
/	O
MEK	O
/	O
MAPK	O
pathway	O
,	O
including	O
recruitment	O
of	O
Raf	B-Protein
to	O
the	O
plasma	O
membrane	O
and	O
activation	O
of	O
Raf	B-Protein
and	O
MAPK	O
,	O
does	O
not	O
require	O
C	O
-	O
terminal	O
processing	O
of	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
.	O

Biochemical	O
fractionation	O
experiments	O
confirm	O
the	O
localization	O
of	O
TM	O
-	O
ras	O
derivatives	O
to	O
the	O
plasma	O
membrane	O
,	O
as	O
well	O
as	O
the	O
ras	O
-	O
mediated	O
recruitment	O
of	O
c	B-Protein
-	I-Protein
Raf	I-Protein
-	I-Protein
1	I-Protein
.	O

Changes	O
in	O
the	O
actin	O
cytoskeleton	O
,	O
controlled	O
by	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
-	O
mediated	O
activation	O
of	O
the	O
Rac	O
/	O
Rho	O
pathway	O
,	O
as	O
well	O
as	O
PI	O
3	O
-	O
kinase	O
activation	O
,	O
can	O
also	O
occur	O
in	O
the	O
absence	O
of	O
C	O
-	O
terminal	O
lipid	O
modifications	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
H-ras61L	B-X
retained	B-X
transforming	B-X
activity	B-X
when	B-X
lacking	B-X
C-terminal	B-X
lipid	B-X
modifications	B-X
,	B-X
provided	B-X
that	B-X
plasma	B-X
membrane	B-X
localization	B-X
was	B-X
restored	B-X
by	B-X
an	B-X
N-terminal	B-X
transmembrane	B-X
domain	B-X
.	B-X
Since	B-X
several	B-X
ras-activated	B-X
pathways	B-X
contribute	B-X
to	B-X
the	B-X
transformed	B-X
phenotype	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
novel	B-X
set	B-X
of	B-X
transmembrane	B-X
domain-anchored	B-X
H-ras	B-X
derivatives	B-X
to	B-X
examine	B-X
if	B-X
lipids	B-X
are	B-X
required	B-X
for	B-X
activation	B-X
of	B-X
any	B-X
specific	B-X
signaling	B-X
pathways	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
H-ras61L-induced	B-X
activation	B-X
of	B-X
the	B-X
Raf/MEK/MAPK	B-X
pathway	B-X
,	B-X
including	B-X
recruitment	B-X
of	B-X
Raf	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
activation	B-X
of	B-X
Raf	B-X
and	B-X
MAPK	B-X
,	B-X
does	B-X
not	B-X
require	B-X
C-terminal	B-X
processing	B-X
of	B-X
H-ras61L	B-X
.	B-X
Biochemical	B-X
fractionation	B-X
experiments	B-X
confirm	B-X
the	B-X
localization	B-X
of	B-X
TM-ras	B-X
derivatives	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
ras-mediated	B-X
recruitment	B-X
of	B-X
c-Raf-1	B-X
.	B-X
Changes	B-X
in	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
,	B-X
controlled	B-X
by	B-X
H-ras61L-mediated	B-X
activation	B-X
of	B-X
the	B-X
Rac/	B-X
Rho	B-X
pathway	B-X
,	B-X
as	B-X
well	B-X
as	B-X
PI	B-X
3-kinase	B-X
activation	B-X
,	B-X
can	B-X
also	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
C-terminal	B-X
lipid	B-X
modifications	B-X
.	B-X
Finally	B-X
,	B-X
downstream	B-X
events	B-X
,	B-X
such	B-X
as	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
immediate-early	B-X
gene	B-X
c-fos	B-X
or	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC12	B-X
cells	B-X
,	B-X
are	B-X
stimulated	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
plasma	B-X
membrane-anchored	B-X
,	B-X
nonlipidated	B-X
H-ras6lL	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
H-ras	B-X
can	B-X
be	B-X
functionally	B-X
targeted	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
using	B-X
a	B-X
transmembrane	B-X
domain	B-X
sequence	B-X
and	B-X
that	B-X
several	B-X
signal	B-X
transduction	B-X
pathways	B-X
downstream	B-X
of	B-X
H-ras	B-X
can	B-X
be	B-X
activated	B-X
without	B-X
the	B-X
presence	B-X
of	B-X
normal	B-X
lipid	B-X
modifications	B-X
.	B-X

Finally	O
,	O
downstream	O
events	O
,	O
such	O
as	O
the	O
induction	O
of	O
the	O
immediate	O
-	O
early	O
gene	O
c	B-Protein
-	I-Protein
fos	I-Protein
or	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
are	O
stimulated	O
by	O
the	O
expression	O
of	O
plasma	O
membrane	O
-	O
anchored	O
,	O
nonlipidated	O
H	B-Protein
-	I-Protein
ras6lL	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
H-ras61L	B-X
retained	B-X
transforming	B-X
activity	B-X
when	B-X
lacking	B-X
C-terminal	B-X
lipid	B-X
modifications	B-X
,	B-X
provided	B-X
that	B-X
plasma	B-X
membrane	B-X
localization	B-X
was	B-X
restored	B-X
by	B-X
an	B-X
N-terminal	B-X
transmembrane	B-X
domain	B-X
.	B-X
Since	B-X
several	B-X
ras-activated	B-X
pathways	B-X
contribute	B-X
to	B-X
the	B-X
transformed	B-X
phenotype	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
novel	B-X
set	B-X
of	B-X
transmembrane	B-X
domain-anchored	B-X
H-ras	B-X
derivatives	B-X
to	B-X
examine	B-X
if	B-X
lipids	B-X
are	B-X
required	B-X
for	B-X
activation	B-X
of	B-X
any	B-X
specific	B-X
signaling	B-X
pathways	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
H-ras61L-induced	B-X
activation	B-X
of	B-X
the	B-X
Raf/MEK/MAPK	B-X
pathway	B-X
,	B-X
including	B-X
recruitment	B-X
of	B-X
Raf	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
activation	B-X
of	B-X
Raf	B-X
and	B-X
MAPK	B-X
,	B-X
does	B-X
not	B-X
require	B-X
C-terminal	B-X
processing	B-X
of	B-X
H-ras61L	B-X
.	B-X
Biochemical	B-X
fractionation	B-X
experiments	B-X
confirm	B-X
the	B-X
localization	B-X
of	B-X
TM-ras	B-X
derivatives	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
ras-mediated	B-X
recruitment	B-X
of	B-X
c-Raf-1	B-X
.	B-X
Changes	B-X
in	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
,	B-X
controlled	B-X
by	B-X
H-ras61L-mediated	B-X
activation	B-X
of	B-X
the	B-X
Rac/	B-X
Rho	B-X
pathway	B-X
,	B-X
as	B-X
well	B-X
as	B-X
PI	B-X
3-kinase	B-X
activation	B-X
,	B-X
can	B-X
also	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
C-terminal	B-X
lipid	B-X
modifications	B-X
.	B-X
Finally	B-X
,	B-X
downstream	B-X
events	B-X
,	B-X
such	B-X
as	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
immediate-early	B-X
gene	B-X
c-fos	B-X
or	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC12	B-X
cells	B-X
,	B-X
are	B-X
stimulated	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
plasma	B-X
membrane-anchored	B-X
,	B-X
nonlipidated	B-X
H-ras6lL	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
H-ras	B-X
can	B-X
be	B-X
functionally	B-X
targeted	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
using	B-X
a	B-X
transmembrane	B-X
domain	B-X
sequence	B-X
and	B-X
that	B-X
several	B-X
signal	B-X
transduction	B-X
pathways	B-X
downstream	B-X
of	B-X
H-ras	B-X
can	B-X
be	B-X
activated	B-X
without	B-X
the	B-X
presence	B-X
of	B-X
normal	B-X
lipid	B-X
modifications	B-X
.	B-X

These	O
results	O
demonstrate	O
that	O
H	B-Protein
-	I-Protein
ras	I-Protein
can	O
be	O
functionally	O
targeted	O
to	O
the	O
plasma	O
membrane	O
using	O
a	O
transmembrane	O
domain	O
sequence	O
and	O
that	O
several	O
signal	O
transduction	O
pathways	O
downstream	O
of	O
H	B-Protein
-	I-Protein
ras	I-Protein
can	O
be	O
activated	O
without	O
the	O
presence	O
of	O
normal	O
lipid	O
modifications	O
.	O

Membrane	O
pore	O
architecture	O
of	O
a	O
cytolytic	O
toxin	O
from	O
Bacillus	O
thuringiensis	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
membrane	B-X
pore	B-X
structure	B-X
of	B-X
Cyt2Aa1	B-X
toxin	B-X
from	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
14	B-X
single-cysteine	B-X
substitutions	B-X
of	B-X
the	B-X
toxin	B-X
were	B-X
constructed	B-X
.	B-X
Mutants	B-X
that	B-X
yielded	B-X
characteristic	B-X
proteolysed	B-X
products	B-X
and	B-X
wild-type	B-X
toxin	B-X
were	B-X
labelled	B-X
with	B-X
polarity-sensitive	B-X
acrylodan	B-X
(	B-X
6-acryloyl-2-dimethylaminonaphthalene	B-X
)	B-X
at	B-X
the	B-X
thiol	B-X
group	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
A	B-X
green-blue	B-X
shift	B-X
in	B-X
the	B-X
emission	B-X
spectra	B-X
was	B-X
observed	B-X
with	B-X
all	B-X
labelled	B-X
toxins	B-X
on	B-X
transfer	B-X
from	B-X
an	B-X
aqueous	B-X
solution	B-X
into	B-X
a	B-X
solution	B-X
containing	B-X
membranes	B-X
or	B-X
liposomes	B-X
from	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X

To	O
investigate	O
the	O
membrane	O
pore	O
structure	O
of	O
Cyt2Aa1	B-Protein
toxin	O
from	O
Bacillus	O
thuringiensis	O
,	O
14	O
single	O
-	O
cysteine	O
substitutions	O
of	O
the	O
toxin	O
were	O
constructed	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
membrane	B-X
pore	B-X
structure	B-X
of	B-X
Cyt2Aa1	B-X
toxin	B-X
from	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
14	B-X
single-cysteine	B-X
substitutions	B-X
of	B-X
the	B-X
toxin	B-X
were	B-X
constructed	B-X
.	B-X
Five	B-X
of	B-X
these	B-X
mutants	B-X
(	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
)	B-X
yielded	B-X
characteristic	B-X
products	B-X
when	B-X
processed	B-X
by	B-X
proteinase	B-X
K	B-X
;	B-X
other	B-X
mutants	B-X
were	B-X
degraded	B-X
by	B-X
this	B-X
enzyme	B-X
.	B-X
Mutants	B-X
that	B-X
yielded	B-X
characteristic	B-X
proteolysed	B-X
products	B-X
and	B-X
wild-type	B-X
toxin	B-X
were	B-X
labelled	B-X
with	B-X
polarity-sensitive	B-X
acrylodan	B-X
(	B-X
6-acryloyl-2-dimethylaminonaphthalene	B-X
)	B-X
at	B-X
the	B-X
thiol	B-X
group	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
A	B-X
green-blue	B-X
shift	B-X
in	B-X
the	B-X
emission	B-X
spectra	B-X
was	B-X
observed	B-X
with	B-X
all	B-X
labelled	B-X
toxins	B-X
on	B-X
transfer	B-X
from	B-X
an	B-X
aqueous	B-X
solution	B-X
into	B-X
a	B-X
solution	B-X
containing	B-X
membranes	B-X
or	B-X
liposomes	B-X
from	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
label	B-X
moved	B-X
into	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
membrane	B-X
or	B-X
became	B-X
buried	B-X
within	B-X
hydrophobic	B-X
regions	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
are	B-X
inserted	B-X
into	B-X
the	B-X
membrane	B-X
and	B-X
are	B-X
therefore	B-X
protected	B-X
from	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X

Five	O
of	O
these	O
mutants	O
(	O
L172C	O
,	O
V186C	O
,	O
L189C	O
,	O
E214C	O
and	O
L220C	O
)	O
yielded	O
characteristic	O
products	O
when	O
processed	O
by	O
proteinase	B-Protein
K	I-Protein
;	O
other	O
mutants	O
were	O
degraded	O
by	O
this	O
enzyme	O
.	O
<EOS>	B-X
Five	B-X
of	B-X
these	B-X
mutants	B-X
(	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
)	B-X
yielded	B-X
characteristic	B-X
products	B-X
when	B-X
processed	B-X
by	B-X
proteinase	B-X
K	B-X
;	B-X
other	B-X
mutants	B-X
were	B-X
degraded	B-X
by	B-X
this	B-X
enzyme	B-X
.	B-X
Mutants	B-X
that	B-X
yielded	B-X
characteristic	B-X
proteolysed	B-X
products	B-X
and	B-X
wild-type	B-X
toxin	B-X
were	B-X
labelled	B-X
with	B-X
polarity-sensitive	B-X
acrylodan	B-X
(	B-X
6-acryloyl-2-dimethylaminonaphthalene	B-X
)	B-X
at	B-X
the	B-X
thiol	B-X
group	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
are	B-X
inserted	B-X
into	B-X
the	B-X
membrane	B-X
and	B-X
are	B-X
therefore	B-X
protected	B-X
from	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X

Mutants	O
that	O
yielded	O
characteristic	O
proteolysed	O
products	O
and	O
wild	O
-	O
type	O
toxin	O
were	O
labelled	O
with	O
polarity	O
-	O
sensitive	O
acrylodan	O
(	O
6	O
-	O
acryloyl	O
-	O
2	O
-	O
dimethylaminonaphthalene	O
)	O
at	O
the	O
thiol	O
group	O
of	O
cysteine	O
residues	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
membrane	B-X
pore	B-X
structure	B-X
of	B-X
Cyt2Aa1	B-X
toxin	B-X
from	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
14	B-X
single-cysteine	B-X
substitutions	B-X
of	B-X
the	B-X
toxin	B-X
were	B-X
constructed	B-X
.	B-X
Five	B-X
of	B-X
these	B-X
mutants	B-X
(	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
)	B-X
yielded	B-X
characteristic	B-X
products	B-X
when	B-X
processed	B-X
by	B-X
proteinase	B-X
K	B-X
;	B-X
other	B-X
mutants	B-X
were	B-X
degraded	B-X
by	B-X
this	B-X
enzyme	B-X
.	B-X
Mutants	B-X
that	B-X
yielded	B-X
characteristic	B-X
proteolysed	B-X
products	B-X
and	B-X
wild-type	B-X
toxin	B-X
were	B-X
labelled	B-X
with	B-X
polarity-sensitive	B-X
acrylodan	B-X
(	B-X
6-acryloyl-2-dimethylaminonaphthalene	B-X
)	B-X
at	B-X
the	B-X
thiol	B-X
group	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
A	B-X
green-blue	B-X
shift	B-X
in	B-X
the	B-X
emission	B-X
spectra	B-X
was	B-X
observed	B-X
with	B-X
all	B-X
labelled	B-X
toxins	B-X
on	B-X
transfer	B-X
from	B-X
an	B-X
aqueous	B-X
solution	B-X
into	B-X
a	B-X
solution	B-X
containing	B-X
membranes	B-X
or	B-X
liposomes	B-X
from	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
are	B-X
inserted	B-X
into	B-X
the	B-X
membrane	B-X
and	B-X
are	B-X
therefore	B-X
protected	B-X
from	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
Cys-19	B-X
from	B-X
wild-type	B-X
molecules	B-X
is	B-X
enclosed	B-X
within	B-X
the	B-X
hydrophobic	B-X
pockets	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X

A	O
green	O
-	O
blue	O
shift	O
in	O
the	O
emission	O
spectra	O
was	O
observed	O
with	O
all	O
labelled	O
toxins	O
on	O
transfer	O
from	O
an	O
aqueous	O
solution	O
into	O
a	O
solution	O
containing	O
membranes	O
or	O
liposomes	O
from	O
red	O
blood	O
cells	O
.	O
<EOS>	B-X
Drug	B-X
delivery	B-X
research	B-X
pursues	B-X
many	B-X
types	B-X
of	B-X
carriers	B-X
including	B-X
proteins	B-X
and	B-X
other	B-X
macromolecules	B-X
,	B-X
natural	B-X
and	B-X
synthetic	B-X
polymeric	B-X
structures	B-X
,	B-X
nanocarriers	B-X
of	B-X
diverse	B-X
compositions	B-X
and	B-X
cells	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
liposomes	B-X
and	B-X
lipid	B-X
nanoparticles	B-X
represent	B-X
arguably	B-X
the	B-X
most	B-X
advanced	B-X
and	B-X
popular	B-X
human-made	B-X
nanocarriers	B-X
,	B-X
already	B-X
in	B-X
multiple	B-X
clinical	B-X
applications	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
red	B-X
blood	B-X
cells	B-X
(	B-X
RBCs	B-X
)	B-X
represent	B-X
attractive	B-X
natural	B-X
carriers	B-X
for	B-X
the	B-X
vascular	B-X
route	B-X
,	B-X
featuring	B-X
at	B-X
least	B-X
two	B-X
distinct	B-X
compartments	B-X
for	B-X
loading	B-X
pharmacological	B-X
cargoes	B-X
,	B-X
namely	B-X
inner	B-X
space	B-X
enclosed	B-X
by	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
the	B-X
outer	B-X
surface	B-X
of	B-X
this	B-X
membrane	B-X
.	B-X
Historically	B-X
,	B-X
studies	B-X
of	B-X
liposomal	B-X
drug	B-X
delivery	B-X
systems	B-X
(	B-X
DDS	B-X
)	B-X
astronomically	B-X
outnumbered	B-X
and	B-X
surpassed	B-X
the	B-X
RBC-based	B-X
DDS	B-X
.	B-X
Furthermore	B-X
,	B-X
RBC	B-X
carriage	B-X
cardinally	B-X
alters	B-X
behavior	B-X
and	B-X
effect	B-X
of	B-X
nanocarriers	B-X
in	B-X
the	B-X
bloodstream	B-X
,	B-X
so	B-X
called	B-X
RBC	B-X
hitchhiking	B-X
(	B-X
RBC-HH	B-X
)	B-X
.	B-X

These	O
results	O
suggested	O
that	O
the	O
label	O
moved	O
into	O
the	O
hydrophobic	O
environment	O
of	O
the	O
membrane	O
or	O
became	O
buried	O
within	O
hydrophobic	O
regions	O
of	O
the	O
protein	O
oligomers	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
membrane	B-X
pore	B-X
structure	B-X
of	B-X
Cyt2Aa1	B-X
toxin	B-X
from	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
14	B-X
single-cysteine	B-X
substitutions	B-X
of	B-X
the	B-X
toxin	B-X
were	B-X
constructed	B-X
.	B-X
Five	B-X
of	B-X
these	B-X
mutants	B-X
(	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
)	B-X
yielded	B-X
characteristic	B-X
products	B-X
when	B-X
processed	B-X
by	B-X
proteinase	B-X
K	B-X
;	B-X
other	B-X
mutants	B-X
were	B-X
degraded	B-X
by	B-X
this	B-X
enzyme	B-X
.	B-X
Mutants	B-X
that	B-X
yielded	B-X
characteristic	B-X
proteolysed	B-X
products	B-X
and	B-X
wild-type	B-X
toxin	B-X
were	B-X
labelled	B-X
with	B-X
polarity-sensitive	B-X
acrylodan	B-X
(	B-X
6-acryloyl-2-dimethylaminonaphthalene	B-X
)	B-X
at	B-X
the	B-X
thiol	B-X
group	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
A	B-X
green-blue	B-X
shift	B-X
in	B-X
the	B-X
emission	B-X
spectra	B-X
was	B-X
observed	B-X
with	B-X
all	B-X
labelled	B-X
toxins	B-X
on	B-X
transfer	B-X
from	B-X
an	B-X
aqueous	B-X
solution	B-X
into	B-X
a	B-X
solution	B-X
containing	B-X
membranes	B-X
or	B-X
liposomes	B-X
from	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
label	B-X
moved	B-X
into	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
membrane	B-X
or	B-X
became	B-X
buried	B-X
within	B-X
hydrophobic	B-X
regions	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
are	B-X
inserted	B-X
into	B-X
the	B-X
membrane	B-X
and	B-X
are	B-X
therefore	B-X
protected	B-X
from	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
Cys-19	B-X
from	B-X
wild-type	B-X
molecules	B-X
is	B-X
enclosed	B-X
within	B-X
the	B-X
hydrophobic	B-X
pockets	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X

Digestion	O
of	O
membrane	O
-	O
bound	O
labelled	O
toxin	O
with	O
proteinase	B-Protein
K	I-Protein
did	O
not	O
cause	O
a	O
significant	O
decrease	O
in	O
emission	O
intensity	O
from	O
any	O
of	O
the	O
labelled	O
mutants	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
membrane	B-X
pore	B-X
structure	B-X
of	B-X
Cyt2Aa1	B-X
toxin	B-X
from	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
14	B-X
single-cysteine	B-X
substitutions	B-X
of	B-X
the	B-X
toxin	B-X
were	B-X
constructed	B-X
.	B-X
Five	B-X
of	B-X
these	B-X
mutants	B-X
(	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
)	B-X
yielded	B-X
characteristic	B-X
products	B-X
when	B-X
processed	B-X
by	B-X
proteinase	B-X
K	B-X
;	B-X
other	B-X
mutants	B-X
were	B-X
degraded	B-X
by	B-X
this	B-X
enzyme	B-X
.	B-X
Mutants	B-X
that	B-X
yielded	B-X
characteristic	B-X
proteolysed	B-X
products	B-X
and	B-X
wild-type	B-X
toxin	B-X
were	B-X
labelled	B-X
with	B-X
polarity-sensitive	B-X
acrylodan	B-X
(	B-X
6-acryloyl-2-dimethylaminonaphthalene	B-X
)	B-X
at	B-X
the	B-X
thiol	B-X
group	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
A	B-X
green-blue	B-X
shift	B-X
in	B-X
the	B-X
emission	B-X
spectra	B-X
was	B-X
observed	B-X
with	B-X
all	B-X
labelled	B-X
toxins	B-X
on	B-X
transfer	B-X
from	B-X
an	B-X
aqueous	B-X
solution	B-X
into	B-X
a	B-X
solution	B-X
containing	B-X
membranes	B-X
or	B-X
liposomes	B-X
from	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
label	B-X
moved	B-X
into	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
membrane	B-X
or	B-X
became	B-X
buried	B-X
within	B-X
hydrophobic	B-X
regions	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
are	B-X
inserted	B-X
into	B-X
the	B-X
membrane	B-X
and	B-X
are	B-X
therefore	B-X
protected	B-X
from	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X

This	O
suggests	O
that	O
L172C	O
,	O
V186C	O
,	O
L189C	O
,	O
E214C	O
and	O
L220C	O
are	O
inserted	O
into	O
the	O
membrane	O
and	O
are	O
therefore	O
protected	O
from	O
proteolysis	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
membrane	B-X
pore	B-X
structure	B-X
of	B-X
Cyt2Aa1	B-X
toxin	B-X
from	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
14	B-X
single-cysteine	B-X
substitutions	B-X
of	B-X
the	B-X
toxin	B-X
were	B-X
constructed	B-X
.	B-X
Five	B-X
of	B-X
these	B-X
mutants	B-X
(	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
)	B-X
yielded	B-X
characteristic	B-X
products	B-X
when	B-X
processed	B-X
by	B-X
proteinase	B-X
K	B-X
;	B-X
other	B-X
mutants	B-X
were	B-X
degraded	B-X
by	B-X
this	B-X
enzyme	B-X
.	B-X
A	B-X
green-blue	B-X
shift	B-X
in	B-X
the	B-X
emission	B-X
spectra	B-X
was	B-X
observed	B-X
with	B-X
all	B-X
labelled	B-X
toxins	B-X
on	B-X
transfer	B-X
from	B-X
an	B-X
aqueous	B-X
solution	B-X
into	B-X
a	B-X
solution	B-X
containing	B-X
membranes	B-X
or	B-X
liposomes	B-X
from	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
label	B-X
moved	B-X
into	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
membrane	B-X
or	B-X
became	B-X
buried	B-X
within	B-X
hydrophobic	B-X
regions	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
are	B-X
inserted	B-X
into	B-X
the	B-X
membrane	B-X
and	B-X
are	B-X
therefore	B-X
protected	B-X
from	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X

In	O
contrast	O
,	O
a	O
marked	O
decrease	O
in	O
emission	O
intensity	O
was	O
observed	O
when	O
membrane	O
-	O
bound	O
labelled	O
wild	O
-	O
type	O
toxin	O
was	O
digested	O
with	O
proteinase	B-Protein
K	I-Protein
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
membrane	B-X
pore	B-X
structure	B-X
of	B-X
Cyt2Aa1	B-X
toxin	B-X
from	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
14	B-X
single-cysteine	B-X
substitutions	B-X
of	B-X
the	B-X
toxin	B-X
were	B-X
constructed	B-X
.	B-X
Five	B-X
of	B-X
these	B-X
mutants	B-X
(	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
)	B-X
yielded	B-X
characteristic	B-X
products	B-X
when	B-X
processed	B-X
by	B-X
proteinase	B-X
K	B-X
;	B-X
other	B-X
mutants	B-X
were	B-X
degraded	B-X
by	B-X
this	B-X
enzyme	B-X
.	B-X
Mutants	B-X
that	B-X
yielded	B-X
characteristic	B-X
proteolysed	B-X
products	B-X
and	B-X
wild-type	B-X
toxin	B-X
were	B-X
labelled	B-X
with	B-X
polarity-sensitive	B-X
acrylodan	B-X
(	B-X
6-acryloyl-2-dimethylaminonaphthalene	B-X
)	B-X
at	B-X
the	B-X
thiol	B-X
group	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
A	B-X
green-blue	B-X
shift	B-X
in	B-X
the	B-X
emission	B-X
spectra	B-X
was	B-X
observed	B-X
with	B-X
all	B-X
labelled	B-X
toxins	B-X
on	B-X
transfer	B-X
from	B-X
an	B-X
aqueous	B-X
solution	B-X
into	B-X
a	B-X
solution	B-X
containing	B-X
membranes	B-X
or	B-X
liposomes	B-X
from	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
label	B-X
moved	B-X
into	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
membrane	B-X
or	B-X
became	B-X
buried	B-X
within	B-X
hydrophobic	B-X
regions	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
are	B-X
inserted	B-X
into	B-X
the	B-X
membrane	B-X
and	B-X
are	B-X
therefore	B-X
protected	B-X
from	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
Cys-19	B-X
from	B-X
wild-type	B-X
molecules	B-X
is	B-X
enclosed	B-X
within	B-X
the	B-X
hydrophobic	B-X
pockets	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X

This	O
suggests	O
that	O
Cys	O
-	O
19	O
does	O
not	O
insert	O
into	O
the	O
membrane	O
.	O

Fluorimetric	O
analysis	O
of	O
delipidated	O
pore	O
complexes	O
suggests	O
that	O
L172C	O
,	O
V186C	O
,	O
L189C	O
and	O
E214C	O
point	O
towards	O
the	O
lipid	O
in	O
the	O
membrane	O
,	O
whereas	O
L220C	O
is	O
either	O
within	O
the	O
hydrophobic	O
environment	O
of	O
the	O
protein	O
oligomers	O
or	O
exposed	O
to	O
the	O
membrane	O
lipids	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
membrane	B-X
pore	B-X
structure	B-X
of	B-X
Cyt2Aa1	B-X
toxin	B-X
from	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
14	B-X
single-cysteine	B-X
substitutions	B-X
of	B-X
the	B-X
toxin	B-X
were	B-X
constructed	B-X
.	B-X
Five	B-X
of	B-X
these	B-X
mutants	B-X
(	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
)	B-X
yielded	B-X
characteristic	B-X
products	B-X
when	B-X
processed	B-X
by	B-X
proteinase	B-X
K	B-X
;	B-X
other	B-X
mutants	B-X
were	B-X
degraded	B-X
by	B-X
this	B-X
enzyme	B-X
.	B-X
A	B-X
green-blue	B-X
shift	B-X
in	B-X
the	B-X
emission	B-X
spectra	B-X
was	B-X
observed	B-X
with	B-X
all	B-X
labelled	B-X
toxins	B-X
on	B-X
transfer	B-X
from	B-X
an	B-X
aqueous	B-X
solution	B-X
into	B-X
a	B-X
solution	B-X
containing	B-X
membranes	B-X
or	B-X
liposomes	B-X
from	B-X
red	B-X
blood	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
label	B-X
moved	B-X
into	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
membrane	B-X
or	B-X
became	B-X
buried	B-X
within	B-X
hydrophobic	B-X
regions	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X
Digestion	B-X
of	B-X
membrane-bound	B-X
labelled	B-X
toxin	B-X
with	B-X
proteinase	B-X
K	B-X
did	B-X
not	B-X
cause	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
from	B-X
any	B-X
of	B-X
the	B-X
labelled	B-X
mutants	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
,	B-X
E214C	B-X
and	B-X
L220C	B-X
are	B-X
inserted	B-X
into	B-X
the	B-X
membrane	B-X
and	B-X
are	B-X
therefore	B-X
protected	B-X
from	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
emission	B-X
intensity	B-X
was	B-X
observed	B-X
when	B-X
membrane-bound	B-X
labelled	B-X
wild-type	B-X
toxin	B-X
was	B-X
digested	B-X
with	B-X
proteinase	B-X
K.	B-X
This	B-X
suggests	B-X
that	B-X
Cys-19	B-X
does	B-X
not	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
.	B-X
Fluorimetric	B-X
analysis	B-X
of	B-X
delipidated	B-X
pore	B-X
complexes	B-X
suggests	B-X
that	B-X
L172C	B-X
,	B-X
V186C	B-X
,	B-X
L189C	B-X
and	B-X
E214C	B-X
point	B-X
towards	B-X
the	B-X
lipid	B-X
in	B-X
the	B-X
membrane	B-X
,	B-X
whereas	B-X
L220C	B-X
is	B-X
either	B-X
within	B-X
the	B-X
hydrophobic	B-X
environment	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
or	B-X
exposed	B-X
to	B-X
the	B-X
membrane	B-X
lipids	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
Cys-19	B-X
from	B-X
wild-type	B-X
molecules	B-X
is	B-X
enclosed	B-X
within	B-X
the	B-X
hydrophobic	B-X
pockets	B-X
of	B-X
the	B-X
protein	B-X
oligomers	B-X
.	B-X

Most	O
of	O
the	O
Cys	O
-	O
19	O
from	O
wild	O
-	O
type	O
molecules	O
is	O
enclosed	O
within	O
the	O
hydrophobic	O
pockets	O
of	O
the	O
protein	O
oligomers	O
.	O

Escherichia	O
coli	O
alpha	B-Protein
-	I-Protein
hemolysin	I-Protein
(	O
HlyA	B-Protein
)	O
is	O
heterogeneously	O
acylated	O
in	O
vivo	O
with	O
14	O
-	O
,	O
15	O
-	O
,	O
and	O
17	O
-	O
carbon	O
fatty	O
acids	O
.	O
<EOS>	B-X
alpha-Hemolysin	B-X
(	B-X
HlyA	B-X
)	B-X
is	B-X
a	B-X
secreted	B-X
protein	B-X
virulence	B-X
factor	B-X
observed	B-X
in	B-X
certain	B-X
uropathogenic	B-X
strains	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
active	B-X
,	B-X
mature	B-X
form	B-X
of	B-X
HlyA	B-X
is	B-X
produced	B-X
by	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protoxin	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
acyl	B-X
carrier	B-X
protein	B-X
and	B-X
an	B-X
acyltransferase	B-X
,	B-X
HlyC	B-X
.	B-X
We	B-X
have	B-X
now	B-X
shown	B-X
using	B-X
mass	B-X
spectrometry	B-X
that	B-X
these	B-X
modifications	B-X
,	B-X
when	B-X
observed	B-X
in	B-X
protein	B-X
isolated	B-X
in	B-X
vivo	B-X
,	B-X
consist	B-X
of	B-X
acylation	B-X
at	B-X
the	B-X
epsilon-amino	B-X
groups	B-X
of	B-X
two	B-X
internal	B-X
lysine	B-X
residues	B-X
,	B-X
at	B-X
positions	B-X
564	B-X
and	B-X
690	B-X
,	B-X
with	B-X
saturated	B-X
14-	B-X
(	B-X
68	B-X
%	B-X
)	B-X
,	B-X
15-	B-X
(	B-X
26	B-X
%	B-X
)	B-X
,	B-X
and	B-X
17-	B-X
(	B-X
6	B-X
%	B-X
)	B-X
carbon	B-X
amide-linked	B-X
side	B-X
chains	B-X
.	B-X
Thus	B-X
,	B-X
HlyA	B-X
activated	B-X
in	B-X
vivo	B-X
consists	B-X
of	B-X
a	B-X
heterogeneous	B-X
family	B-X
of	B-X
up	B-X
to	B-X
nine	B-X
different	B-X
covalent	B-X
structures	B-X
,	B-X
and	B-X
the	B-X
substrate	B-X
specificity	B-X
of	B-X
the	B-X
HlyC	B-X
acyltransferase	B-X
appears	B-X
to	B-X
differ	B-X
from	B-X
that	B-X
of	B-X
the	B-X
closely	B-X
related	B-X
CyaC	B-X
acyltransferase	B-X
expressed	B-X
by	B-X
Bordetella	B-X
pertussis	B-X
.	B-X

alpha	B-Protein
-	I-Protein
Hemolysin	I-Protein
(	O
HlyA	B-Protein
)	O
is	O
a	O
secreted	O
protein	O
virulence	O
factor	O
observed	O
in	O
certain	O
uropathogenic	O
strains	O
of	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
alpha-Hemolysin	B-X
(	B-X
HlyA	B-X
)	B-X
is	B-X
a	B-X
secreted	B-X
protein	B-X
virulence	B-X
factor	B-X
observed	B-X
in	B-X
certain	B-X
uropathogenic	B-X
strains	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
active	B-X
,	B-X
mature	B-X
form	B-X
of	B-X
HlyA	B-X
is	B-X
produced	B-X
by	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protoxin	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
acyl	B-X
carrier	B-X
protein	B-X
and	B-X
an	B-X
acyltransferase	B-X
,	B-X
HlyC	B-X
.	B-X
We	B-X
have	B-X
now	B-X
shown	B-X
using	B-X
mass	B-X
spectrometry	B-X
that	B-X
these	B-X
modifications	B-X
,	B-X
when	B-X
observed	B-X
in	B-X
protein	B-X
isolated	B-X
in	B-X
vivo	B-X
,	B-X
consist	B-X
of	B-X
acylation	B-X
at	B-X
the	B-X
epsilon-amino	B-X
groups	B-X
of	B-X
two	B-X
internal	B-X
lysine	B-X
residues	B-X
,	B-X
at	B-X
positions	B-X
564	B-X
and	B-X
690	B-X
,	B-X
with	B-X
saturated	B-X
14-	B-X
(	B-X
68	B-X
%	B-X
)	B-X
,	B-X
15-	B-X
(	B-X
26	B-X
%	B-X
)	B-X
,	B-X
and	B-X
17-	B-X
(	B-X
6	B-X
%	B-X
)	B-X
carbon	B-X
amide-linked	B-X
side	B-X
chains	B-X
.	B-X
Thus	B-X
,	B-X
HlyA	B-X
activated	B-X
in	B-X
vivo	B-X
consists	B-X
of	B-X
a	B-X
heterogeneous	B-X
family	B-X
of	B-X
up	B-X
to	B-X
nine	B-X
different	B-X
covalent	B-X
structures	B-X
,	B-X
and	B-X
the	B-X
substrate	B-X
specificity	B-X
of	B-X
the	B-X
HlyC	B-X
acyltransferase	B-X
appears	B-X
to	B-X
differ	B-X
from	B-X
that	B-X
of	B-X
the	B-X
closely	B-X
related	B-X
CyaC	B-X
acyltransferase	B-X
expressed	B-X
by	B-X
Bordetella	B-X
pertussis	B-X
.	B-X

The	O
active	O
,	O
mature	O
form	O
of	O
HlyA	B-Protein
is	O
produced	O
by	O
posttranslational	O
modification	O
of	O
the	O
protoxin	O
that	O
is	O
mediated	O
by	O
acyl	O
carrier	O
protein	O
and	O
an	O
acyltransferase	O
,	O
HlyC	B-Protein
.	O

We	O
have	O
now	O
shown	O
using	O
mass	O
spectrometry	O
that	O
these	O
modifications	O
,	O
when	O
observed	O
in	O
protein	O
isolated	O
in	O
vivo	O
,	O
consist	O
of	O
acylation	O
at	O
the	O
epsilon	O
-	O
amino	O
groups	O
of	O
two	O
internal	O
lysine	O
residues	O
,	O
at	O
positions	O
564	O
and	O
690	O
,	O
with	O
saturated	O
14	O
-	O
(	O
68	O
%	O
)	O
,	O
15	O
-	O
(	O
26	O
%	O
)	O
,	O
and	O
17	O
-	O
(	O
6	O
%	O
)	O
carbon	O
amide	O
-	O
linked	O
side	O
chains	O
.	O

Thus	O
,	O
HlyA	B-Protein
activated	O
in	O
vivo	O
consists	O
of	O
a	O
heterogeneous	O
family	O
of	O
up	O
to	O
nine	O
different	O
covalent	O
structures	O
,	O
and	O
the	O
substrate	O
specificity	O
of	O
the	O
HlyC	B-Protein
acyltransferase	O
appears	O
to	O
differ	O
from	O
that	O
of	O
the	O
closely	O
related	O
CyaC	B-Protein
acyltransferase	O
expressed	O
by	O
Bordetella	O
pertussis	O
.	O
<EOS>	B-X
alpha-Hemolysin	B-X
(	B-X
HlyA	B-X
)	B-X
is	B-X
a	B-X
secreted	B-X
protein	B-X
virulence	B-X
factor	B-X
observed	B-X
in	B-X
certain	B-X
uropathogenic	B-X
strains	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
active	B-X
,	B-X
mature	B-X
form	B-X
of	B-X
HlyA	B-X
is	B-X
produced	B-X
by	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protoxin	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
acyl	B-X
carrier	B-X
protein	B-X
and	B-X
an	B-X
acyltransferase	B-X
,	B-X
HlyC	B-X
.	B-X
We	B-X
have	B-X
now	B-X
shown	B-X
using	B-X
mass	B-X
spectrometry	B-X
that	B-X
these	B-X
modifications	B-X
,	B-X
when	B-X
observed	B-X
in	B-X
protein	B-X
isolated	B-X
in	B-X
vivo	B-X
,	B-X
consist	B-X
of	B-X
acylation	B-X
at	B-X
the	B-X
epsilon-amino	B-X
groups	B-X
of	B-X
two	B-X
internal	B-X
lysine	B-X
residues	B-X
,	B-X
at	B-X
positions	B-X
564	B-X
and	B-X
690	B-X
,	B-X
with	B-X
saturated	B-X
14-	B-X
(	B-X
68	B-X
%	B-X
)	B-X
,	B-X
15-	B-X
(	B-X
26	B-X
%	B-X
)	B-X
,	B-X
and	B-X
17-	B-X
(	B-X
6	B-X
%	B-X
)	B-X
carbon	B-X
amide-linked	B-X
side	B-X
chains	B-X
.	B-X
Thus	B-X
,	B-X
HlyA	B-X
activated	B-X
in	B-X
vivo	B-X
consists	B-X
of	B-X
a	B-X
heterogeneous	B-X
family	B-X
of	B-X
up	B-X
to	B-X
nine	B-X
different	B-X
covalent	B-X
structures	B-X
,	B-X
and	B-X
the	B-X
substrate	B-X
specificity	B-X
of	B-X
the	B-X
HlyC	B-X
acyltransferase	B-X
appears	B-X
to	B-X
differ	B-X
from	B-X
that	B-X
of	B-X
the	B-X
closely	B-X
related	B-X
CyaC	B-X
acyltransferase	B-X
expressed	B-X
by	B-X
Bordetella	B-X
pertussis	B-X
.	B-X

Association	O
of	O
prenylated	O
proteins	O
with	O
the	O
plasma	O
membrane	O
and	O
the	O
inner	B-Protein
nuclear	I-Protein
membrane	I-Protein
is	O
mediated	O
by	O
the	O
same	O
membrane	O
-	O
targeting	O
motifs	O
.	O
<EOS>	B-X
Targeting	B-X
of	B-X
nuclear	B-X
lamins	B-X
to	B-X
the	B-X
inner	B-X
nuclear	B-X
envelope	B-X
membrane	B-X
requires	B-X
a	B-X
nuclear	B-X
localization	B-X
signal	B-X
and	B-X
CaaX	B-X
motif-dependent	B-X
posttranslational	B-X
modifications	B-X
,	B-X
including	B-X
isoprenylation	B-X
and	B-X
carboxyl	B-X
methylation	B-X
.	B-X
These	B-X
modifications	B-X
,	B-X
although	B-X
necessary	B-X
for	B-X
membrane	B-X
targeting	B-X
,	B-X
are	B-X
not	B-X
sufficient	B-X
to	B-X
mediate	B-X
stable	B-X
association	B-X
with	B-X
membranes	B-X
.	B-X
The	B-X
two	B-X
lamin	B-X
variants	B-X
differ	B-X
greatly	B-X
in	B-X
their	B-X
membrane	B-X
association	B-X
in	B-X
meiotically	B-X
matured	B-X
eggs	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
extra	B-X
cysteine	B-X
residue	B-X
(	B-X
as	B-X
a	B-X
potential	B-X
palmitoylation	B-X
site	B-X
)	B-X
and	B-X
a	B-X
basic	B-X
cluster	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
CaaX	B-X
motif	B-X
function	B-X
as	B-X
secondary	B-X
targeting	B-X
signals	B-X
responsible	B-X
for	B-X
the	B-X
stable	B-X
membrane	B-X
association	B-X
of	B-X
lamin	B-X
B3b	B-X
in	B-X
Xenopus	B-X
eggs	B-X
.	B-X
Moreover	B-X
,	B-X
transfection	B-X
experiments	B-X
with	B-X
Green	B-X
Fluorescent	B-X
Protein	B-X
lamin	B-X
tail	B-X
chimeras	B-X
and	B-X
with	B-X
a	B-X
Green	B-X
Fluorescent	B-X
Protein	B-X
N-Ras	B-X
chimera	B-X
show	B-X
that	B-X
these	B-X
secondary	B-X
motifs	B-X
are	B-X
sufficient	B-X
to	B-X
target	B-X
proteins	B-X
to	B-X
the	B-X
inner	B-X
nuclear	B-X
membrane	B-X
and/or	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Implications	B-X
for	B-X
the	B-X
intracellular	B-X
trafficking	B-X
of	B-X
doubly	B-X
lipidated	B-X
proteins	B-X
are	B-X
discussed	B-X
.	B-X

Targeting	O
of	O
nuclear	O
lamins	O
to	O
the	O
inner	O
nuclear	O
envelope	O
membrane	O
requires	O
a	O
nuclear	O
localization	O
signal	O
and	O
CaaX	O
motif	O
-	O
dependent	O
posttranslational	O
modifications	O
,	O
including	O
isoprenylation	O
and	O
carboxyl	O
methylation	O
.	O

These	O
modifications	O
,	O
although	O
necessary	O
for	O
membrane	O
targeting	O
,	O
are	O
not	O
sufficient	O
to	O
mediate	O
stable	O
association	O
with	O
membranes	O
.	O
<EOS>	B-X
Both	B-X
processes	B-X
are	B-X
necessary	B-X
to	B-X
mediate	B-X
protein-protein	B-X
and	B-X
membrane-protein	B-X
associations	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
regulating	B-X
the	B-X
localisation	B-X
and	B-X
function	B-X
of	B-X
proteins	B-X
.	B-X
Recent	B-X
studies	B-X
on	B-X
isoprenylation	B-X
and	B-X
postprenylation	B-X
processing	B-X
in	B-X
pathological	B-X
conditions	B-X
have	B-X
unveiled	B-X
surprising	B-X
aspects	B-X
of	B-X
these	B-X
modifications	B-X
and	B-X
their	B-X
roles	B-X
in	B-X
different	B-X
cellular	B-X
pathways	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
significant	B-X
increase	B-X
in	B-X
the	B-X
incidence	B-X
of	B-X
cancer	B-X
within	B-X
world	B-X
population	B-X
,	B-X
together	B-X
with	B-X
the	B-X
complexity	B-X
of	B-X
such	B-X
disease	B-X
,	B-X
featured	B-X
with	B-X
a	B-X
multifactorial	B-X
nature	B-X
,	B-X
access	B-X
to	B-X
new	B-X
drugs	B-X
targeting	B-X
different	B-X
biological	B-X
targets	B-X
connected	B-X
to	B-X
cancer	B-X
is	B-X
highly	B-X
necessary	B-X
.	B-X
The	B-X
preparation	B-X
of	B-X
glycoconjugates	B-X
in	B-X
which	B-X
the	B-X
carbohydrate	B-X
is	B-X
tethered	B-X
to	B-X
a	B-X
pharmacophore	B-X
has	B-X
also	B-X
allowed	B-X
a	B-X
better	B-X
permeation	B-X
of	B-X
the	B-X
drug	B-X
through	B-X
cellular	B-X
membranes	B-X
,	B-X
in	B-X
which	B-X
selective	B-X
interactions	B-X
with	B-X
the	B-X
carbohydrate	B-X
motifs	B-X
are	B-X
involved	B-X
.	B-X

We	O
show	O
that	O
two	O
variants	O
of	O
lamin	B-Protein
B3	I-Protein
(	O
i	O
.	O
e	O
.	O
,	O
B3a	B-Protein
and	O
B3b	B-Protein
)	O
exist	O
in	O
Xenopus	O
oocytes	O
.	O

They	O
are	O
encoded	O
by	O
two	O
alternatively	O
spliced	O
,	O
developmentally	O
regulated	O
mRNAs	O
.	O
<EOS>	B-X
The	B-X
two	B-X
proteins	B-X
are	B-X
encoded	B-X
by	B-X
separate	B-X
mRNAs	B-X
which	B-X
are	B-X
derived	B-X
from	B-X
a	B-X
single	B-X
gene	B-X
by	B-X
alternative	B-X
splicing	B-X
.	B-X
The	B-X
rise	B-X
in	B-X
the	B-X
steady-state	B-X
levels	B-X
of	B-X
both	B-X
mRNAs	B-X
began	B-X
on	B-X
day	B-X
9	B-X
of	B-X
gestation	B-X
.	B-X
By	B-X
elucidating	B-X
the	B-X
temporal	B-X
changes	B-X
in	B-X
GHR	B-X
and	B-X
GHBP	B-X
mRNA	B-X
abundance	B-X
during	B-X
pregnancy	B-X
and	B-X
lactation	B-X
in	B-X
multiple	B-X
maternal	B-X
tissues	B-X
and	B-X
by	B-X
assessing	B-X
the	B-X
ontogeny	B-X
of	B-X
these	B-X
mRNAs	B-X
in	B-X
fetal	B-X
and	B-X
early	B-X
postnatal	B-X
mouse	B-X
liver	B-X
,	B-X
our	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
the	B-X
alternative	B-X
splicing	B-X
of	B-X
mouse	B-X
GHR/GHBP	B-X
mRNA	B-X
precursor	B-X
is	B-X
regulated	B-X
in	B-X
a	B-X
tissue-	B-X
,	B-X
developmental	B-X
stage-	B-X
and	B-X
physiological	B-X
state-specific	B-X
manner	B-X
.	B-X
However	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
E2	B-X
and	B-X
GH	B-X
up-regulated	B-X
the	B-X
cellular	B-X
concentrations	B-X
of	B-X
GHBP	B-X
and	B-X
GHR	B-X
2-	B-X
to	B-X
3-fold	B-X
.	B-X
GHBP	B-X
and	B-X
GHR	B-X
mRNA	B-X
concentrations	B-X
were	B-X
also	B-X
up-regulated	B-X
2-	B-X
to	B-X
3-fold	B-X
.	B-X

The	O
two	O
lamin	O
variants	O
differ	O
greatly	O
in	O
their	O
membrane	O
association	O
in	O
meiotically	O
matured	O
eggs	O
.	O
<EOS>	B-X
Targeting	B-X
of	B-X
nuclear	B-X
lamins	B-X
to	B-X
the	B-X
inner	B-X
nuclear	B-X
envelope	B-X
membrane	B-X
requires	B-X
a	B-X
nuclear	B-X
localization	B-X
signal	B-X
and	B-X
CaaX	B-X
motif-dependent	B-X
posttranslational	B-X
modifications	B-X
,	B-X
including	B-X
isoprenylation	B-X
and	B-X
carboxyl	B-X
methylation	B-X
.	B-X
These	B-X
modifications	B-X
,	B-X
although	B-X
necessary	B-X
for	B-X
membrane	B-X
targeting	B-X
,	B-X
are	B-X
not	B-X
sufficient	B-X
to	B-X
mediate	B-X
stable	B-X
association	B-X
with	B-X
membranes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
two	B-X
variants	B-X
of	B-X
lamin	B-X
B3	B-X
(	B-X
i.e.	B-X
,	B-X
B3a	B-X
and	B-X
B3b	B-X
)	B-X
exist	B-X
in	B-X
Xenopus	B-X
oocytes	B-X
.	B-X
They	B-X
are	B-X
encoded	B-X
by	B-X
two	B-X
alternatively	B-X
spliced	B-X
,	B-X
developmentally	B-X
regulated	B-X
mRNAs	B-X
.	B-X
The	B-X
two	B-X
lamin	B-X
variants	B-X
differ	B-X
greatly	B-X
in	B-X
their	B-X
membrane	B-X
association	B-X
in	B-X
meiotically	B-X
matured	B-X
eggs	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
extra	B-X
cysteine	B-X
residue	B-X
(	B-X
as	B-X
a	B-X
potential	B-X
palmitoylation	B-X
site	B-X
)	B-X
and	B-X
a	B-X
basic	B-X
cluster	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
CaaX	B-X
motif	B-X
function	B-X
as	B-X
secondary	B-X
targeting	B-X
signals	B-X
responsible	B-X
for	B-X
the	B-X
stable	B-X
membrane	B-X
association	B-X
of	B-X
lamin	B-X
B3b	B-X
in	B-X
Xenopus	B-X
eggs	B-X
.	B-X
Moreover	B-X
,	B-X
transfection	B-X
experiments	B-X
with	B-X
Green	B-X
Fluorescent	B-X
Protein	B-X
lamin	B-X
tail	B-X
chimeras	B-X
and	B-X
with	B-X
a	B-X
Green	B-X
Fluorescent	B-X
Protein	B-X
N-Ras	B-X
chimera	B-X
show	B-X
that	B-X
these	B-X
secondary	B-X
motifs	B-X
are	B-X
sufficient	B-X
to	B-X
target	B-X
proteins	B-X
to	B-X
the	B-X
inner	B-X
nuclear	B-X
membrane	B-X
and/or	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

The	O
presence	O
of	O
an	O
extra	O
cysteine	O
residue	O
(	O
as	O
a	O
potential	O
palmitoylation	O
site	O
)	O
and	O
a	O
basic	O
cluster	O
in	O
conjunction	O
with	O
the	O
CaaX	O
motif	O
function	O
as	O
secondary	O
targeting	O
signals	O
responsible	O
for	O
the	O
stable	O
membrane	O
association	O
of	O
lamin	B-Protein
B3b	I-Protein
in	O
Xenopus	O
eggs	O
.	O

Moreover	O
,	O
transfection	O
experiments	O
with	O
Green	B-Protein
Fluorescent	I-Protein
Protein	I-Protein
lamin	O
tail	O
chimeras	O
and	O
with	O
a	O
Green	B-Protein
Fluorescent	I-Protein
Protein	I-Protein
N	B-Protein
-	I-Protein
Ras	I-Protein
chimera	O
show	O
that	O
these	O
secondary	O
motifs	O
are	O
sufficient	O
to	O
target	O
proteins	O
to	O
the	O
inner	O
nuclear	O
membrane	O
and	O
/	O
or	O
the	O
plasma	O
membrane	O
.	O
<EOS>	B-X
There	B-X
is	B-X
,	B-X
however	B-X
,	B-X
an	B-X
equally	B-X
important	B-X
process	B-X
that	B-X
happens	B-X
at	B-X
the	B-X
single	B-X
cell	B-X
level	B-X
,	B-X
when	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
compromised	B-X
.	B-X
Individual	B-X
eukaryotic	B-X
cells	B-X
can	B-X
rapidly	B-X
repair	B-X
their	B-X
plasma	B-X
membrane	B-X
after	B-X
injury	B-X
,	B-X
through	B-X
a	B-X
process	B-X
that	B-X
restores	B-X
internal	B-X
homeostasis	B-X
and	B-X
prevents	B-X
cell	B-X
death	B-X
.	B-X
Only	B-X
recently	B-X
have	B-X
we	B-X
begun	B-X
to	B-X
understand	B-X
that	B-X
plasma-membrane	B-X
repair	B-X
resembles	B-X
tissue	B-X
healing	B-X
,	B-X
in	B-X
the	B-X
sense	B-X
that	B-X
it	B-X
also	B-X
involves	B-X
sequential	B-X
,	B-X
highly	B-X
localized	B-X
remodeling	B-X
steps	B-X
that	B-X
ultimately	B-X
eliminate	B-X
all	B-X
traces	B-X
of	B-X
the	B-X
injury	B-X
.	B-X
Biological	B-X
membranes	B-X
are	B-X
key	B-X
elements	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
cell	B-X
architecture	B-X
and	B-X
physiology	B-X
.	B-X
Beyond	B-X
a	B-X
pure	B-X
barrier	B-X
separating	B-X
the	B-X
inner	B-X
space	B-X
of	B-X
the	B-X
cell	B-X
from	B-X
the	B-X
outer	B-X
,	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
a	B-X
scaffold	B-X
and	B-X
player	B-X
in	B-X
cell-to-cell	B-X
communication	B-X
and	B-X
the	B-X
initiation	B-X
of	B-X
intracellular	B-X
signals	B-X
among	B-X
other	B-X
functions	B-X
.	B-X
Critical	B-X
to	B-X
this	B-X
function	B-X
is	B-X
the	B-X
plasma	B-X
membrane	B-X
compartmentalization	B-X
in	B-X
lipid	B-X
microdomains	B-X
that	B-X
control	B-X
the	B-X
localization	B-X
and	B-X
productive	B-X
interactions	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
signal	B-X
propagation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
cells	B-X
are	B-X
divided	B-X
into	B-X
compartments	B-X
limited	B-X
by	B-X
other	B-X
membranes	B-X
whose	B-X
integrity	B-X
and	B-X
homeostasis	B-X
are	B-X
finely	B-X
controlled	B-X
,	B-X
and	B-X
which	B-X
determine	B-X
the	B-X
identity	B-X
and	B-X
function	B-X
of	B-X
the	B-X
different	B-X
organelles	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
current	B-X
knowledge	B-X
on	B-X
membrane	B-X
lipid	B-X
composition	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
endomembrane	B-X
compartments	B-X
,	B-X
emphasizing	B-X
its	B-X
role	B-X
in	B-X
sustaining	B-X
organelle	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
The	B-X
correct	B-X
composition	B-X
and	B-X
structure	B-X
of	B-X
cell	B-X
membranes	B-X
define	B-X
key	B-X
pathophysiological	B-X
aspects	B-X
of	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
therapeutic	B-X
potential	B-X
of	B-X
manipulating	B-X
membrane	B-X
lipid	B-X
composition	B-X
with	B-X
approaches	B-X
like	B-X
membrane	B-X
lipid	B-X
therapy	B-X
,	B-X
aiming	B-X
to	B-X
normalize	B-X
cell	B-X
functions	B-X
through	B-X
the	B-X
modification	B-X
of	B-X
membrane	B-X
lipid	B-X
bilayers	B-X
.	B-X

Implications	O
for	O
the	O
intracellular	O
trafficking	O
of	O
doubly	O
lipidated	O
proteins	O
are	O
discussed	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
transfection	B-X
experiments	B-X
with	B-X
Green	B-X
Fluorescent	B-X
Protein	B-X
lamin	B-X
tail	B-X
chimeras	B-X
and	B-X
with	B-X
a	B-X
Green	B-X
Fluorescent	B-X
Protein	B-X
N-Ras	B-X
chimera	B-X
show	B-X
that	B-X
these	B-X
secondary	B-X
motifs	B-X
are	B-X
sufficient	B-X
to	B-X
target	B-X
proteins	B-X
to	B-X
the	B-X
inner	B-X
nuclear	B-X
membrane	B-X
and/or	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Implications	B-X
for	B-X
the	B-X
intracellular	B-X
trafficking	B-X
of	B-X
doubly	B-X
lipidated	B-X
proteins	B-X
are	B-X
discussed	B-X
.	B-X

TcRho1	B-Protein
,	O
a	O
farnesylated	O
Rho	O
family	O
homologue	O
from	O
Trypanosoma	O
cruzi	O
:	O
cloning	O
,	O
trans	O
-	O
splicing	O
,	O
and	O
prenylation	O
studies	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
including	B-X
maintenance	B-X
of	B-X
cell	B-X
morphology	B-X
and	B-X
motility	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
transcription	B-X
activation	B-X
.	B-X
We	B-X
report	B-X
the	B-X
molecular	B-X
identification	B-X
in	B-X
trypanosomatids	B-X
(	B-X
Trypanosoma	B-X
cruzi	B-X
)	B-X
of	B-X
the	B-X
first	B-X
member	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
The	B-X
cloned	B-X
Rho	B-X
protein	B-X
,	B-X
TcRho1	B-X
,	B-X
shares	B-X
approximately	B-X
40	B-X
%	B-X
homology	B-X
with	B-X
other	B-X
members	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
Southern	B-X
blot	B-X
analysis	B-X
revealed	B-X
that	B-X
TcRHO1	B-X
is	B-X
a	B-X
single	B-X
copy	B-X
gene	B-X
per	B-X
haploid	B-X
genome	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
assays	B-X
showed	B-X
a	B-X
transcript	B-X
of	B-X
1200	B-X
nucleotides	B-X
in	B-X
length	B-X
.	B-X
Mapping	B-X
the	B-X
5'-untranslated	B-X
region	B-X
of	B-X
TcRHO1	B-X
transcripts	B-X
revealed	B-X
at	B-X
least	B-X
five	B-X
different	B-X
transcripts	B-X
derived	B-X
from	B-X
differential	B-X
trans-splicing	B-X
.	B-X
Three	B-X
of	B-X
the	B-X
five	B-X
transcripts	B-X
contain	B-X
the	B-X
trans-splicing	B-X
site	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
TcRHO1	B-X
gene	B-X
.	B-X
TcRho1	B-X
also	B-X
contains	B-X
the	B-X
C-terminal	B-X
sequence	B-X
CQLF	B-X
(	B-X
CAAX	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
direct	B-X
post-translation	B-X
prenylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
containing	B-X
this	B-X
C-terminal	B-X
motif	B-X
,	B-X
when	B-X
tested	B-X
against	B-X
Q-Sepharose	B-X
chromatography	B-X
fractions	B-X
from	B-X
T.	B-X
cruzi	B-X
cytosol	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
efficiently	B-X
farnesylated	B-X
,	B-X
but	B-X
not	B-X
geranylgeranylated	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
CAAX	B-X
motif	B-X
with	B-X
X	B-X
=	B-X
Phe	B-X
specifies	B-X
geranylgeranylation	B-X
by	B-X
mammalian	B-X
protein	B-X
geranylgeranyltransferase	B-X
I	B-X
.	B-X
Furthermore	B-X
,	B-X
immunoblot	B-X
analyses	B-X
of	B-X
epimastigote	B-X
protein	B-X
with	B-X
anti-S-farnesylcysteine	B-X
methyl	B-X
ester	B-X
and	B-X
anti-TcRho1	B-X
antisera	B-X
strongly	B-X
suggested	B-X
that	B-X
TcRho1	B-X
is	B-X
farnesylated	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
farnesylation	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
Rho	B-X
GTPases	B-X
could	B-X
be	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
selective	B-X
cytotoxic	B-X
action	B-X
of	B-X
protein	B-X
farnesyltransferase	B-X
inhibitors	B-X
on	B-X
trypanosomatids	B-X
versus	B-X
mammalian	B-X
cells	B-X
.	B-X

Rho	O
GTPases	O
are	O
members	O
of	O
the	O
Ras	O
superfamily	O
and	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
,	O
including	O
maintenance	O
of	O
cell	O
morphology	O
and	O
motility	O
,	O
cell	O
cycle	O
progression	O
,	O
and	O
transcription	O
activation	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
including	B-X
maintenance	B-X
of	B-X
cell	B-X
morphology	B-X
and	B-X
motility	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
transcription	B-X
activation	B-X
.	B-X
We	B-X
report	B-X
the	B-X
molecular	B-X
identification	B-X
in	B-X
trypanosomatids	B-X
(	B-X
Trypanosoma	B-X
cruzi	B-X
)	B-X
of	B-X
the	B-X
first	B-X
member	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
The	B-X
cloned	B-X
Rho	B-X
protein	B-X
,	B-X
TcRho1	B-X
,	B-X
shares	B-X
approximately	B-X
40	B-X
%	B-X
homology	B-X
with	B-X
other	B-X
members	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
TcRho1	B-X
also	B-X
contains	B-X
the	B-X
C-terminal	B-X
sequence	B-X
CQLF	B-X
(	B-X
CAAX	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
direct	B-X
post-translation	B-X
prenylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
.	B-X
Furthermore	B-X
,	B-X
immunoblot	B-X
analyses	B-X
of	B-X
epimastigote	B-X
protein	B-X
with	B-X
anti-S-farnesylcysteine	B-X
methyl	B-X
ester	B-X
and	B-X
anti-TcRho1	B-X
antisera	B-X
strongly	B-X
suggested	B-X
that	B-X
TcRho1	B-X
is	B-X
farnesylated	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
farnesylation	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
Rho	B-X
GTPases	B-X
could	B-X
be	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
selective	B-X
cytotoxic	B-X
action	B-X
of	B-X
protein	B-X
farnesyltransferase	B-X
inhibitors	B-X
on	B-X
trypanosomatids	B-X
versus	B-X
mammalian	B-X
cells	B-X
.	B-X

We	O
report	O
the	O
molecular	O
identification	O
in	O
trypanosomatids	O
(	O
Trypanosoma	O
cruzi	O
)	O
of	O
the	O
first	O
member	O
of	O
the	O
Rho	O
family	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
including	B-X
maintenance	B-X
of	B-X
cell	B-X
morphology	B-X
and	B-X
motility	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
transcription	B-X
activation	B-X
.	B-X
We	B-X
report	B-X
the	B-X
molecular	B-X
identification	B-X
in	B-X
trypanosomatids	B-X
(	B-X
Trypanosoma	B-X
cruzi	B-X
)	B-X
of	B-X
the	B-X
first	B-X
member	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
The	B-X
cloned	B-X
Rho	B-X
protein	B-X
,	B-X
TcRho1	B-X
,	B-X
shares	B-X
approximately	B-X
40	B-X
%	B-X
homology	B-X
with	B-X
other	B-X
members	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
TcRho1	B-X
also	B-X
contains	B-X
the	B-X
C-terminal	B-X
sequence	B-X
CQLF	B-X
(	B-X
CAAX	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
direct	B-X
post-translation	B-X
prenylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
containing	B-X
this	B-X
C-terminal	B-X
motif	B-X
,	B-X
when	B-X
tested	B-X
against	B-X
Q-Sepharose	B-X
chromatography	B-X
fractions	B-X
from	B-X
T.	B-X
cruzi	B-X
cytosol	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
efficiently	B-X
farnesylated	B-X
,	B-X
but	B-X
not	B-X
geranylgeranylated	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
CAAX	B-X
motif	B-X
with	B-X
X	B-X
=	B-X
Phe	B-X
specifies	B-X
geranylgeranylation	B-X
by	B-X
mammalian	B-X
protein	B-X
geranylgeranyltransferase	B-X
I	B-X
.	B-X
Furthermore	B-X
,	B-X
immunoblot	B-X
analyses	B-X
of	B-X
epimastigote	B-X
protein	B-X
with	B-X
anti-S-farnesylcysteine	B-X
methyl	B-X
ester	B-X
and	B-X
anti-TcRho1	B-X
antisera	B-X
strongly	B-X
suggested	B-X
that	B-X
TcRho1	B-X
is	B-X
farnesylated	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
farnesylation	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
Rho	B-X
GTPases	B-X
could	B-X
be	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
selective	B-X
cytotoxic	B-X
action	B-X
of	B-X
protein	B-X
farnesyltransferase	B-X
inhibitors	B-X
on	B-X
trypanosomatids	B-X
versus	B-X
mammalian	B-X
cells	B-X
.	B-X

The	O
cloned	O
Rho	O
protein	O
,	O
TcRho1	B-Protein
,	O
shares	O
approximately	O
40	O
%	O
homology	O
with	O
other	O
members	O
of	O
the	O
Rho	O
family	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
including	B-X
maintenance	B-X
of	B-X
cell	B-X
morphology	B-X
and	B-X
motility	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
transcription	B-X
activation	B-X
.	B-X
We	B-X
report	B-X
the	B-X
molecular	B-X
identification	B-X
in	B-X
trypanosomatids	B-X
(	B-X
Trypanosoma	B-X
cruzi	B-X
)	B-X
of	B-X
the	B-X
first	B-X
member	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
The	B-X
cloned	B-X
Rho	B-X
protein	B-X
,	B-X
TcRho1	B-X
,	B-X
shares	B-X
approximately	B-X
40	B-X
%	B-X
homology	B-X
with	B-X
other	B-X
members	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
TcRho1	B-X
also	B-X
contains	B-X
the	B-X
C-terminal	B-X
sequence	B-X
CQLF	B-X
(	B-X
CAAX	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
direct	B-X
post-translation	B-X
prenylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
containing	B-X
this	B-X
C-terminal	B-X
motif	B-X
,	B-X
when	B-X
tested	B-X
against	B-X
Q-Sepharose	B-X
chromatography	B-X
fractions	B-X
from	B-X
T.	B-X
cruzi	B-X
cytosol	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
efficiently	B-X
farnesylated	B-X
,	B-X
but	B-X
not	B-X
geranylgeranylated	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
CAAX	B-X
motif	B-X
with	B-X
X	B-X
=	B-X
Phe	B-X
specifies	B-X
geranylgeranylation	B-X
by	B-X
mammalian	B-X
protein	B-X
geranylgeranyltransferase	B-X
I	B-X
.	B-X
Furthermore	B-X
,	B-X
immunoblot	B-X
analyses	B-X
of	B-X
epimastigote	B-X
protein	B-X
with	B-X
anti-S-farnesylcysteine	B-X
methyl	B-X
ester	B-X
and	B-X
anti-TcRho1	B-X
antisera	B-X
strongly	B-X
suggested	B-X
that	B-X
TcRho1	B-X
is	B-X
farnesylated	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
farnesylation	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
Rho	B-X
GTPases	B-X
could	B-X
be	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
selective	B-X
cytotoxic	B-X
action	B-X
of	B-X
protein	B-X
farnesyltransferase	B-X
inhibitors	B-X
on	B-X
trypanosomatids	B-X
versus	B-X
mammalian	B-X
cells	B-X
.	B-X

Southern	O
blot	O
analysis	O
revealed	O
that	O
TcRHO1	B-Protein
is	O
a	O
single	O
copy	O
gene	O
per	O
haploid	O
genome	O
,	O
and	O
Northern	O
blot	O
assays	O
showed	O
a	O
transcript	O
of	O
1200	O
nucleotides	O
in	O
length	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
including	B-X
maintenance	B-X
of	B-X
cell	B-X
morphology	B-X
and	B-X
motility	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
transcription	B-X
activation	B-X
.	B-X
Southern	B-X
blot	B-X
analysis	B-X
revealed	B-X
that	B-X
TcRHO1	B-X
is	B-X
a	B-X
single	B-X
copy	B-X
gene	B-X
per	B-X
haploid	B-X
genome	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
assays	B-X
showed	B-X
a	B-X
transcript	B-X
of	B-X
1200	B-X
nucleotides	B-X
in	B-X
length	B-X
.	B-X
Mapping	B-X
the	B-X
5'-untranslated	B-X
region	B-X
of	B-X
TcRHO1	B-X
transcripts	B-X
revealed	B-X
at	B-X
least	B-X
five	B-X
different	B-X
transcripts	B-X
derived	B-X
from	B-X
differential	B-X
trans-splicing	B-X
.	B-X
Three	B-X
of	B-X
the	B-X
five	B-X
transcripts	B-X
contain	B-X
the	B-X
trans-splicing	B-X
site	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
TcRHO1	B-X
gene	B-X
.	B-X
Furthermore	B-X
,	B-X
immunoblot	B-X
analyses	B-X
of	B-X
epimastigote	B-X
protein	B-X
with	B-X
anti-S-farnesylcysteine	B-X
methyl	B-X
ester	B-X
and	B-X
anti-TcRho1	B-X
antisera	B-X
strongly	B-X
suggested	B-X
that	B-X
TcRho1	B-X
is	B-X
farnesylated	B-X
in	B-X
vivo	B-X
.	B-X

Mapping	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
TcRHO1	B-Protein
transcripts	O
revealed	O
at	O
least	O
five	O
different	O
transcripts	O
derived	O
from	O
differential	O
trans	O
-	O
splicing	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
including	B-X
maintenance	B-X
of	B-X
cell	B-X
morphology	B-X
and	B-X
motility	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
transcription	B-X
activation	B-X
.	B-X
Southern	B-X
blot	B-X
analysis	B-X
revealed	B-X
that	B-X
TcRHO1	B-X
is	B-X
a	B-X
single	B-X
copy	B-X
gene	B-X
per	B-X
haploid	B-X
genome	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
assays	B-X
showed	B-X
a	B-X
transcript	B-X
of	B-X
1200	B-X
nucleotides	B-X
in	B-X
length	B-X
.	B-X
Mapping	B-X
the	B-X
5'-untranslated	B-X
region	B-X
of	B-X
TcRHO1	B-X
transcripts	B-X
revealed	B-X
at	B-X
least	B-X
five	B-X
different	B-X
transcripts	B-X
derived	B-X
from	B-X
differential	B-X
trans-splicing	B-X
.	B-X
Three	B-X
of	B-X
the	B-X
five	B-X
transcripts	B-X
contain	B-X
the	B-X
trans-splicing	B-X
site	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
TcRHO1	B-X
gene	B-X
.	B-X
TcRho1	B-X
also	B-X
contains	B-X
the	B-X
C-terminal	B-X
sequence	B-X
CQLF	B-X
(	B-X
CAAX	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
direct	B-X
post-translation	B-X
prenylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
containing	B-X
this	B-X
C-terminal	B-X
motif	B-X
,	B-X
when	B-X
tested	B-X
against	B-X
Q-Sepharose	B-X
chromatography	B-X
fractions	B-X
from	B-X
T.	B-X
cruzi	B-X
cytosol	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
efficiently	B-X
farnesylated	B-X
,	B-X
but	B-X
not	B-X
geranylgeranylated	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
CAAX	B-X
motif	B-X
with	B-X
X	B-X
=	B-X
Phe	B-X
specifies	B-X
geranylgeranylation	B-X
by	B-X
mammalian	B-X
protein	B-X
geranylgeranyltransferase	B-X
I	B-X
.	B-X
The	B-X
farnesylation	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
Rho	B-X
GTPases	B-X
could	B-X
be	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
selective	B-X
cytotoxic	B-X
action	B-X
of	B-X
protein	B-X
farnesyltransferase	B-X
inhibitors	B-X
on	B-X
trypanosomatids	B-X
versus	B-X
mammalian	B-X
cells	B-X
.	B-X

Three	O
of	O
the	O
five	O
transcripts	O
contain	O
the	O
trans	O
-	O
splicing	O
site	O
within	O
the	O
coding	O
region	O
of	O
the	O
TcRHO1	B-Protein
gene	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
including	B-X
maintenance	B-X
of	B-X
cell	B-X
morphology	B-X
and	B-X
motility	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
transcription	B-X
activation	B-X
.	B-X
Southern	B-X
blot	B-X
analysis	B-X
revealed	B-X
that	B-X
TcRHO1	B-X
is	B-X
a	B-X
single	B-X
copy	B-X
gene	B-X
per	B-X
haploid	B-X
genome	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
assays	B-X
showed	B-X
a	B-X
transcript	B-X
of	B-X
1200	B-X
nucleotides	B-X
in	B-X
length	B-X
.	B-X
Mapping	B-X
the	B-X
5'-untranslated	B-X
region	B-X
of	B-X
TcRHO1	B-X
transcripts	B-X
revealed	B-X
at	B-X
least	B-X
five	B-X
different	B-X
transcripts	B-X
derived	B-X
from	B-X
differential	B-X
trans-splicing	B-X
.	B-X
Three	B-X
of	B-X
the	B-X
five	B-X
transcripts	B-X
contain	B-X
the	B-X
trans-splicing	B-X
site	B-X
within	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
TcRHO1	B-X
gene	B-X
.	B-X
TcRho1	B-X
also	B-X
contains	B-X
the	B-X
C-terminal	B-X
sequence	B-X
CQLF	B-X
(	B-X
CAAX	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
direct	B-X
post-translation	B-X
prenylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
containing	B-X
this	B-X
C-terminal	B-X
motif	B-X
,	B-X
when	B-X
tested	B-X
against	B-X
Q-Sepharose	B-X
chromatography	B-X
fractions	B-X
from	B-X
T.	B-X
cruzi	B-X
cytosol	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
efficiently	B-X
farnesylated	B-X
,	B-X
but	B-X
not	B-X
geranylgeranylated	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
CAAX	B-X
motif	B-X
with	B-X
X	B-X
=	B-X
Phe	B-X
specifies	B-X
geranylgeranylation	B-X
by	B-X
mammalian	B-X
protein	B-X
geranylgeranyltransferase	B-X
I	B-X
.	B-X
The	B-X
farnesylation	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
Rho	B-X
GTPases	B-X
could	B-X
be	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
selective	B-X
cytotoxic	B-X
action	B-X
of	B-X
protein	B-X
farnesyltransferase	B-X
inhibitors	B-X
on	B-X
trypanosomatids	B-X
versus	B-X
mammalian	B-X
cells	B-X
.	B-X

TcRho1	B-Protein
also	O
contains	O
the	O
C	O
-	O
terminal	O
sequence	O
CQLF	O
(	O
CAAX	O
motif	O
)	O
,	O
which	O
is	O
predicted	O
to	O
direct	O
post	O
-	O
translation	O
prenylation	O
of	O
the	O
cysteine	O
residue	O
.	O

A	O
synthetic	O
peptide	O
containing	O
this	O
C	O
-	O
terminal	O
motif	O
,	O
when	O
tested	O
against	O
Q	O
-	O
Sepharose	O
chromatography	O
fractions	O
from	O
T	O
.	O
cruzi	O
cytosol	O
,	O
was	O
shown	O
to	O
be	O
efficiently	O
farnesylated	O
,	O
but	O
not	O
geranylgeranylated	O
,	O
despite	O
the	O
fact	O
that	O
the	O
CAAX	O
motif	O
with	O
X	O
=	O
Phe	O
specifies	O
geranylgeranylation	O
by	O
mammalian	O
protein	O
geranylgeranyltransferase	O
I	O
.	O

Furthermore	O
,	O
immunoblot	O
analyses	O
of	O
epimastigote	O
protein	O
with	O
anti	O
-	O
S	O
-	O
farnesylcysteine	O
methyl	O
ester	O
and	O
anti	O
-	O
TcRho1	B-Protein
antisera	O
strongly	O
suggested	O
that	O
TcRho1	B-Protein
is	O
farnesylated	O
in	O
vivo	O
.	O

The	O
farnesylation	O
of	O
proteins	O
such	O
as	O
Rho	O
GTPases	O
could	O
be	O
the	O
basis	O
for	O
the	O
selective	O
cytotoxic	O
action	O
of	O
protein	O
farnesyltransferase	O
inhibitors	O
on	O
trypanosomatids	O
versus	O
mammalian	O
cells	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
including	B-X
maintenance	B-X
of	B-X
cell	B-X
morphology	B-X
and	B-X
motility	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
transcription	B-X
activation	B-X
.	B-X
We	B-X
report	B-X
the	B-X
molecular	B-X
identification	B-X
in	B-X
trypanosomatids	B-X
(	B-X
Trypanosoma	B-X
cruzi	B-X
)	B-X
of	B-X
the	B-X
first	B-X
member	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
The	B-X
cloned	B-X
Rho	B-X
protein	B-X
,	B-X
TcRho1	B-X
,	B-X
shares	B-X
approximately	B-X
40	B-X
%	B-X
homology	B-X
with	B-X
other	B-X
members	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
.	B-X
TcRho1	B-X
also	B-X
contains	B-X
the	B-X
C-terminal	B-X
sequence	B-X
CQLF	B-X
(	B-X
CAAX	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
direct	B-X
post-translation	B-X
prenylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
containing	B-X
this	B-X
C-terminal	B-X
motif	B-X
,	B-X
when	B-X
tested	B-X
against	B-X
Q-Sepharose	B-X
chromatography	B-X
fractions	B-X
from	B-X
T.	B-X
cruzi	B-X
cytosol	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
efficiently	B-X
farnesylated	B-X
,	B-X
but	B-X
not	B-X
geranylgeranylated	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
CAAX	B-X
motif	B-X
with	B-X
X	B-X
=	B-X
Phe	B-X
specifies	B-X
geranylgeranylation	B-X
by	B-X
mammalian	B-X
protein	B-X
geranylgeranyltransferase	B-X
I	B-X
.	B-X
Furthermore	B-X
,	B-X
immunoblot	B-X
analyses	B-X
of	B-X
epimastigote	B-X
protein	B-X
with	B-X
anti-S-farnesylcysteine	B-X
methyl	B-X
ester	B-X
and	B-X
anti-TcRho1	B-X
antisera	B-X
strongly	B-X
suggested	B-X
that	B-X
TcRho1	B-X
is	B-X
farnesylated	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
farnesylation	B-X
of	B-X
proteins	B-X
such	B-X
as	B-X
Rho	B-X
GTPases	B-X
could	B-X
be	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
selective	B-X
cytotoxic	B-X
action	B-X
of	B-X
protein	B-X
farnesyltransferase	B-X
inhibitors	B-X
on	B-X
trypanosomatids	B-X
versus	B-X
mammalian	B-X
cells	B-X
.	B-X

Thiopalmitoylation	O
of	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
epitopes	O
enhances	O
immunogenicity	O
and	O
encephalitogenicity	O
.	O
<EOS>	B-X
Proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
protein	B-X
of	B-X
CNS	B-X
myelin	B-X
,	B-X
and	B-X
is	B-X
posttranslationally	B-X
acylated	B-X
by	B-X
covalent	B-X
attachment	B-X
of	B-X
long	B-X
chain	B-X
fatty	B-X
acids	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
a	B-X
thioester	B-X
linkage	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
acylation	B-X
sites	B-X
are	B-X
within	B-X
epitopes	B-X
of	B-X
PLP	B-X
that	B-X
are	B-X
encephalitogenic	B-X
in	B-X
SJL/J	B-X
mice	B-X
(	B-X
PLP	B-X
(	B-X
104-117	B-X
)	B-X
and	B-X
PLP	B-X
(	B-X
139-151	B-X
)	B-X
)	B-X
and	B-X
against	B-X
which	B-X
increased	B-X
immune	B-X
responses	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
some	B-X
multiple	B-X
sclerosis	B-X
patients	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
attachment	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
lipid	B-X
side	B-X
chains	B-X
to	B-X
peptides	B-X
can	B-X
result	B-X
in	B-X
their	B-X
enhanced	B-X
immunogenicity	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
thioacylated	B-X
PLP	B-X
peptides	B-X
,	B-X
as	B-X
occur	B-X
in	B-X
the	B-X
native	B-X
protein	B-X
,	B-X
are	B-X
more	B-X
immunogenic	B-X
than	B-X
their	B-X
nonacylated	B-X
counterparts	B-X
,	B-X
and	B-X
whether	B-X
thioacylation	B-X
influences	B-X
the	B-X
development	B-X
of	B-X
autoreactivity	B-X
and	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
immune	B-X
responses	B-X
induced	B-X
by	B-X
endogenous	B-X
thioacylated	B-X
lipopeptides	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
immunopathogenesis	B-X
of	B-X
chronic	B-X
experimental	B-X
demyelinating	B-X
diseases	B-X
and	B-X
multiple	B-X
sclerosis	B-X
.	B-X

Proteolipid	B-Protein
protein	I-Protein
(	O
PLP	B-Protein
)	O
is	O
the	O
most	O
abundant	O
protein	O
of	O
CNS	O
myelin	O
,	O
and	O
is	O
posttranslationally	O
acylated	O
by	O
covalent	O
attachment	O
of	O
long	O
chain	O
fatty	O
acids	O
to	O
cysteine	O
residues	O
via	O
a	O
thioester	O
linkage	O
.	O

Two	O
of	O
the	O
acylation	O
sites	O
are	O
within	O
epitopes	O
of	O
PLP	B-Protein
that	O
are	O
encephalitogenic	O
in	O
SJL	O
/	O
J	O
mice	O
(	O
PLP	B-Protein
(	O
104	O
-	O
117	O
)	O
and	O
PLP	B-Protein
(	O
139	O
-	O
151	O
)	O
)	O
and	O
against	O
which	O
increased	O
immune	O
responses	O
have	O
been	O
detected	O
in	O
some	O
multiple	O
sclerosis	O
patients	O
.	O

It	O
is	O
known	O
that	O
attachment	O
of	O
certain	O
types	O
of	O
lipid	O
side	O
chains	O
to	O
peptides	O
can	O
result	O
in	O
their	O
enhanced	O
immunogenicity	O
.	O
<EOS>	B-X
Proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
protein	B-X
of	B-X
CNS	B-X
myelin	B-X
,	B-X
and	B-X
is	B-X
posttranslationally	B-X
acylated	B-X
by	B-X
covalent	B-X
attachment	B-X
of	B-X
long	B-X
chain	B-X
fatty	B-X
acids	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
a	B-X
thioester	B-X
linkage	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
attachment	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
lipid	B-X
side	B-X
chains	B-X
to	B-X
peptides	B-X
can	B-X
result	B-X
in	B-X
their	B-X
enhanced	B-X
immunogenicity	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
thioacylated	B-X
PLP	B-X
peptides	B-X
,	B-X
as	B-X
occur	B-X
in	B-X
the	B-X
native	B-X
protein	B-X
,	B-X
are	B-X
more	B-X
immunogenic	B-X
than	B-X
their	B-X
nonacylated	B-X
counterparts	B-X
,	B-X
and	B-X
whether	B-X
thioacylation	B-X
influences	B-X
the	B-X
development	B-X
of	B-X
autoreactivity	B-X
and	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
in	B-X
comparison	B-X
with	B-X
nonacylated	B-X
peptides	B-X
,	B-X
thioacylated	B-X
PLP	B-X
lipopeptides	B-X
can	B-X
induce	B-X
greater	B-X
T	B-X
cell	B-X
and	B-X
Ab	B-X
responses	B-X
to	B-X
both	B-X
the	B-X
acylated	B-X
and	B-X
nonacylated	B-X
peptides	B-X
.	B-X
They	B-X
also	B-X
enhanced	B-X
the	B-X
development	B-X
and	B-X
chronicity	B-X
of	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
Synthetic	B-X
peptides	B-X
in	B-X
which	B-X
the	B-X
fatty	B-X
acid	B-X
was	B-X
attached	B-X
via	B-X
an	B-X
amide	B-X
linkage	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
were	B-X
not	B-X
encephalitogenic	B-X
,	B-X
and	B-X
they	B-X
induced	B-X
greater	B-X
proportions	B-X
of	B-X
CD8+	B-X
cells	B-X
in	B-X
initial	B-X
in	B-X
vitro	B-X
stimulation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
immune	B-X
responses	B-X
induced	B-X
by	B-X
endogenous	B-X
thioacylated	B-X
lipopeptides	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
immunopathogenesis	B-X
of	B-X
chronic	B-X
experimental	B-X
demyelinating	B-X
diseases	B-X
and	B-X
multiple	B-X
sclerosis	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
thioacylated	O
PLP	B-Protein
peptides	O
,	O
as	O
occur	O
in	O
the	O
native	O
protein	O
,	O
are	O
more	O
immunogenic	O
than	O
their	O
nonacylated	O
counterparts	O
,	O
and	O
whether	O
thioacylation	O
influences	O
the	O
development	O
of	O
autoreactivity	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O
<EOS>	B-X
Proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
protein	B-X
of	B-X
CNS	B-X
myelin	B-X
,	B-X
and	B-X
is	B-X
posttranslationally	B-X
acylated	B-X
by	B-X
covalent	B-X
attachment	B-X
of	B-X
long	B-X
chain	B-X
fatty	B-X
acids	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
a	B-X
thioester	B-X
linkage	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
acylation	B-X
sites	B-X
are	B-X
within	B-X
epitopes	B-X
of	B-X
PLP	B-X
that	B-X
are	B-X
encephalitogenic	B-X
in	B-X
SJL/J	B-X
mice	B-X
(	B-X
PLP	B-X
(	B-X
104-117	B-X
)	B-X
and	B-X
PLP	B-X
(	B-X
139-151	B-X
)	B-X
)	B-X
and	B-X
against	B-X
which	B-X
increased	B-X
immune	B-X
responses	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
some	B-X
multiple	B-X
sclerosis	B-X
patients	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
attachment	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
lipid	B-X
side	B-X
chains	B-X
to	B-X
peptides	B-X
can	B-X
result	B-X
in	B-X
their	B-X
enhanced	B-X
immunogenicity	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
thioacylated	B-X
PLP	B-X
peptides	B-X
,	B-X
as	B-X
occur	B-X
in	B-X
the	B-X
native	B-X
protein	B-X
,	B-X
are	B-X
more	B-X
immunogenic	B-X
than	B-X
their	B-X
nonacylated	B-X
counterparts	B-X
,	B-X
and	B-X
whether	B-X
thioacylation	B-X
influences	B-X
the	B-X
development	B-X
of	B-X
autoreactivity	B-X
and	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
in	B-X
comparison	B-X
with	B-X
nonacylated	B-X
peptides	B-X
,	B-X
thioacylated	B-X
PLP	B-X
lipopeptides	B-X
can	B-X
induce	B-X
greater	B-X
T	B-X
cell	B-X
and	B-X
Ab	B-X
responses	B-X
to	B-X
both	B-X
the	B-X
acylated	B-X
and	B-X
nonacylated	B-X
peptides	B-X
.	B-X
They	B-X
also	B-X
enhanced	B-X
the	B-X
development	B-X
and	B-X
chronicity	B-X
of	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
Synthetic	B-X
peptides	B-X
in	B-X
which	B-X
the	B-X
fatty	B-X
acid	B-X
was	B-X
attached	B-X
via	B-X
an	B-X
amide	B-X
linkage	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
were	B-X
not	B-X
encephalitogenic	B-X
,	B-X
and	B-X
they	B-X
induced	B-X
greater	B-X
proportions	B-X
of	B-X
CD8+	B-X
cells	B-X
in	B-X
initial	B-X
in	B-X
vitro	B-X
stimulation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
immune	B-X
responses	B-X
induced	B-X
by	B-X
endogenous	B-X
thioacylated	B-X
lipopeptides	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
immunopathogenesis	B-X
of	B-X
chronic	B-X
experimental	B-X
demyelinating	B-X
diseases	B-X
and	B-X
multiple	B-X
sclerosis	B-X
.	B-X

The	O
results	O
show	O
that	O
in	O
comparison	O
with	O
nonacylated	O
peptides	O
,	O
thioacylated	O
PLP	B-Protein
lipopeptides	O
can	O
induce	O
greater	O
T	O
cell	O
and	O
Ab	O
responses	O
to	O
both	O
the	O
acylated	O
and	O
nonacylated	O
peptides	O
.	O
<EOS>	B-X
Proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
protein	B-X
of	B-X
CNS	B-X
myelin	B-X
,	B-X
and	B-X
is	B-X
posttranslationally	B-X
acylated	B-X
by	B-X
covalent	B-X
attachment	B-X
of	B-X
long	B-X
chain	B-X
fatty	B-X
acids	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
a	B-X
thioester	B-X
linkage	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
acylation	B-X
sites	B-X
are	B-X
within	B-X
epitopes	B-X
of	B-X
PLP	B-X
that	B-X
are	B-X
encephalitogenic	B-X
in	B-X
SJL/J	B-X
mice	B-X
(	B-X
PLP	B-X
(	B-X
104-117	B-X
)	B-X
and	B-X
PLP	B-X
(	B-X
139-151	B-X
)	B-X
)	B-X
and	B-X
against	B-X
which	B-X
increased	B-X
immune	B-X
responses	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
some	B-X
multiple	B-X
sclerosis	B-X
patients	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
attachment	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
lipid	B-X
side	B-X
chains	B-X
to	B-X
peptides	B-X
can	B-X
result	B-X
in	B-X
their	B-X
enhanced	B-X
immunogenicity	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
thioacylated	B-X
PLP	B-X
peptides	B-X
,	B-X
as	B-X
occur	B-X
in	B-X
the	B-X
native	B-X
protein	B-X
,	B-X
are	B-X
more	B-X
immunogenic	B-X
than	B-X
their	B-X
nonacylated	B-X
counterparts	B-X
,	B-X
and	B-X
whether	B-X
thioacylation	B-X
influences	B-X
the	B-X
development	B-X
of	B-X
autoreactivity	B-X
and	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
in	B-X
comparison	B-X
with	B-X
nonacylated	B-X
peptides	B-X
,	B-X
thioacylated	B-X
PLP	B-X
lipopeptides	B-X
can	B-X
induce	B-X
greater	B-X
T	B-X
cell	B-X
and	B-X
Ab	B-X
responses	B-X
to	B-X
both	B-X
the	B-X
acylated	B-X
and	B-X
nonacylated	B-X
peptides	B-X
.	B-X
Synthetic	B-X
peptides	B-X
in	B-X
which	B-X
the	B-X
fatty	B-X
acid	B-X
was	B-X
attached	B-X
via	B-X
an	B-X
amide	B-X
linkage	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
were	B-X
not	B-X
encephalitogenic	B-X
,	B-X
and	B-X
they	B-X
induced	B-X
greater	B-X
proportions	B-X
of	B-X
CD8+	B-X
cells	B-X
in	B-X
initial	B-X
in	B-X
vitro	B-X
stimulation	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
lability	B-X
and	B-X
the	B-X
site	B-X
of	B-X
the	B-X
linkage	B-X
between	B-X
the	B-X
peptide	B-X
and	B-X
fatty	B-X
acid	B-X
may	B-X
be	B-X
important	B-X
for	B-X
induction	B-X
of	B-X
encephalitogenic	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
immune	B-X
responses	B-X
induced	B-X
by	B-X
endogenous	B-X
thioacylated	B-X
lipopeptides	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
immunopathogenesis	B-X
of	B-X
chronic	B-X
experimental	B-X
demyelinating	B-X
diseases	B-X
and	B-X
multiple	B-X
sclerosis	B-X
.	B-X

They	O
also	O
enhanced	O
the	O
development	O
and	O
chronicity	O
of	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O
<EOS>	B-X
Both	B-X
autoimmune	B-X
diseases	B-X
are	B-X
thought	B-X
to	B-X
result	B-X
from	B-X
loss	B-X
of	B-X
self-tolerance	B-X
,	B-X
which	B-X
allows	B-X
for	B-X
the	B-X
development	B-X
and	B-X
function	B-X
of	B-X
autoreactive	B-X
lymphocytes	B-X
.	B-X
Although	B-X
the	B-X
mechanisms	B-X
underlying	B-X
compromised	B-X
self-tolerance	B-X
in	B-X
these	B-X
and	B-X
other	B-X
autoimmune	B-X
diseases	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
,	B-X
one	B-X
possibility	B-X
is	B-X
numerical	B-X
,	B-X
functional	B-X
,	B-X
and/or	B-X
migratory	B-X
deficits	B-X
in	B-X
T	B-X
regulatory	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
.	B-X
It	B-X
is	B-X
believed	B-X
that	B-X
Tregs	B-X
function	B-X
by	B-X
suppressing	B-X
the	B-X
effector	B-X
CD4+	B-X
T	B-X
cell	B-X
subsets	B-X
that	B-X
mediate	B-X
autoimmune	B-X
responses	B-X
.	B-X
In	B-X
pre-clinical	B-X
animal	B-X
models	B-X
of	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
and	B-X
experimental	B-X
autoimmune	B-X
myasthenia	B-X
gravis	B-X
(	B-X
EAMG	B-X
)	B-X
,	B-X
several	B-X
strategies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
ameliorate	B-X
the	B-X
disease	B-X
and	B-X
thus	B-X
appear	B-X
promising	B-X
for	B-X
treating	B-X
patients	B-X
with	B-X
MS	B-X
or	B-X
MG	B-X
.	B-X

Synthetic	O
peptides	O
in	O
which	O
the	O
fatty	O
acid	O
was	O
attached	O
via	O
an	O
amide	O
linkage	O
at	O
the	O
N	O
terminus	O
were	O
not	O
encephalitogenic	O
,	O
and	O
they	O
induced	O
greater	O
proportions	O
of	O
CD8	O
+	O
cells	O
in	O
initial	O
in	O
vitro	O
stimulation	O
.	O

Therefore	O
,	O
the	O
lability	O
and	O
the	O
site	O
of	O
the	O
linkage	O
between	O
the	O
peptide	O
and	O
fatty	O
acid	O
may	O
be	O
important	O
for	O
induction	O
of	O
encephalitogenic	O
CD4	B-Protein
+	O
T	O
cells	O
.	O
<EOS>	B-X
Proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
protein	B-X
of	B-X
CNS	B-X
myelin	B-X
,	B-X
and	B-X
is	B-X
posttranslationally	B-X
acylated	B-X
by	B-X
covalent	B-X
attachment	B-X
of	B-X
long	B-X
chain	B-X
fatty	B-X
acids	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
a	B-X
thioester	B-X
linkage	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
acylation	B-X
sites	B-X
are	B-X
within	B-X
epitopes	B-X
of	B-X
PLP	B-X
that	B-X
are	B-X
encephalitogenic	B-X
in	B-X
SJL/J	B-X
mice	B-X
(	B-X
PLP	B-X
(	B-X
104-117	B-X
)	B-X
and	B-X
PLP	B-X
(	B-X
139-151	B-X
)	B-X
)	B-X
and	B-X
against	B-X
which	B-X
increased	B-X
immune	B-X
responses	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
some	B-X
multiple	B-X
sclerosis	B-X
patients	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
attachment	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
lipid	B-X
side	B-X
chains	B-X
to	B-X
peptides	B-X
can	B-X
result	B-X
in	B-X
their	B-X
enhanced	B-X
immunogenicity	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
thioacylated	B-X
PLP	B-X
peptides	B-X
,	B-X
as	B-X
occur	B-X
in	B-X
the	B-X
native	B-X
protein	B-X
,	B-X
are	B-X
more	B-X
immunogenic	B-X
than	B-X
their	B-X
nonacylated	B-X
counterparts	B-X
,	B-X
and	B-X
whether	B-X
thioacylation	B-X
influences	B-X
the	B-X
development	B-X
of	B-X
autoreactivity	B-X
and	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
in	B-X
comparison	B-X
with	B-X
nonacylated	B-X
peptides	B-X
,	B-X
thioacylated	B-X
PLP	B-X
lipopeptides	B-X
can	B-X
induce	B-X
greater	B-X
T	B-X
cell	B-X
and	B-X
Ab	B-X
responses	B-X
to	B-X
both	B-X
the	B-X
acylated	B-X
and	B-X
nonacylated	B-X
peptides	B-X
.	B-X
Synthetic	B-X
peptides	B-X
in	B-X
which	B-X
the	B-X
fatty	B-X
acid	B-X
was	B-X
attached	B-X
via	B-X
an	B-X
amide	B-X
linkage	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
were	B-X
not	B-X
encephalitogenic	B-X
,	B-X
and	B-X
they	B-X
induced	B-X
greater	B-X
proportions	B-X
of	B-X
CD8+	B-X
cells	B-X
in	B-X
initial	B-X
in	B-X
vitro	B-X
stimulation	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
lability	B-X
and	B-X
the	B-X
site	B-X
of	B-X
the	B-X
linkage	B-X
between	B-X
the	B-X
peptide	B-X
and	B-X
fatty	B-X
acid	B-X
may	B-X
be	B-X
important	B-X
for	B-X
induction	B-X
of	B-X
encephalitogenic	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
immune	B-X
responses	B-X
induced	B-X
by	B-X
endogenous	B-X
thioacylated	B-X
lipopeptides	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
immunopathogenesis	B-X
of	B-X
chronic	B-X
experimental	B-X
demyelinating	B-X
diseases	B-X
and	B-X
multiple	B-X
sclerosis	B-X
.	B-X

These	O
results	O
suggest	O
that	O
immune	O
responses	O
induced	O
by	O
endogenous	O
thioacylated	O
lipopeptides	O
may	O
contribute	O
to	O
the	O
immunopathogenesis	O
of	O
chronic	O
experimental	O
demyelinating	O
diseases	O
and	O
multiple	O
sclerosis	O
.	O

COP9	O
signalosome	O
revisited	O
:	O
a	O
novel	O
mediator	O
of	O
protein	O
degradation	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
multiprotein	B-X
complex	B-X
that	B-X
was	B-X
first	B-X
identified	B-X
as	B-X
an	B-X
essential	B-X
complex	B-X
that	B-X
represses	B-X
light-regulated	B-X
development	B-X
in	B-X
Arabidopsis	B-X
.	B-X
The	B-X
COP9	B-X
signalosome	B-X
has	B-X
similarity	B-X
to	B-X
the	B-X
lid	B-X
of	B-X
the	B-X
19S	B-X
regulatory	B-X
particle	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
and	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
SCF-type	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
Although	B-X
its	B-X
precise	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
protein	B-X
degradation	B-X
remains	B-X
to	B-X
be	B-X
established	B-X
,	B-X
the	B-X
COP9	B-X
signalosome	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
that	B-X
functions	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
mediating	B-X
the	B-X
deconjugation	B-X
of	B-X
the	B-X
NEDD8/RUB-modification	B-X
from	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
SCF-type	B-X
E3	B-X
complexes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
these	B-X
recent	B-X
findings	B-X
,	B-X
which	B-X
add	B-X
an	B-X
additional	B-X
component	B-X
to	B-X
the	B-X
biology	B-X
of	B-X
substrate-specific	B-X
protein	B-X
degradation	B-X
.	B-X

The	O
COP9	O
signalosome	O
is	O
an	O
evolutionarily	O
conserved	O
multiprotein	O
complex	O
that	O
was	O
first	O
identified	O
as	O
an	O
essential	O
complex	O
that	O
represses	O
light	O
-	O
regulated	O
development	O
in	O
Arabidopsis	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
multiprotein	B-X
complex	B-X
that	B-X
was	B-X
first	B-X
identified	B-X
as	B-X
an	B-X
essential	B-X
complex	B-X
that	B-X
represses	B-X
light-regulated	B-X
development	B-X
in	B-X
Arabidopsis	B-X
.	B-X
The	B-X
COP9	B-X
signalosome	B-X
has	B-X
similarity	B-X
to	B-X
the	B-X
lid	B-X
of	B-X
the	B-X
19S	B-X
regulatory	B-X
particle	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
and	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
SCF-type	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
Although	B-X
its	B-X
precise	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
protein	B-X
degradation	B-X
remains	B-X
to	B-X
be	B-X
established	B-X
,	B-X
the	B-X
COP9	B-X
signalosome	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
that	B-X
functions	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
mediating	B-X
the	B-X
deconjugation	B-X
of	B-X
the	B-X
NEDD8/RUB-modification	B-X
from	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
SCF-type	B-X
E3	B-X
complexes	B-X
.	B-X

The	O
COP9	O
signalosome	O
has	O
similarity	O
to	O
the	O
lid	O
of	O
the	O
19S	O
regulatory	O
particle	O
of	O
the	O
26S	O
proteasome	O
and	O
has	O
recently	O
been	O
shown	O
to	O
interact	O
with	O
SCF	O
-	O
type	O
E3	O
ubiquitin	B-Protein
ligases	O
.	O

Although	O
its	O
precise	O
role	O
in	O
the	O
process	O
of	O
protein	O
degradation	O
remains	O
to	O
be	O
established	O
,	O
the	O
COP9	O
signalosome	O
is	O
a	O
positive	O
regulator	O
of	O
E3	O
ubiquitin	B-Protein
ligases	O
that	O
functions	O
at	O
least	O
in	O
part	O
by	O
mediating	O
the	O
deconjugation	O
of	O
the	O
NEDD8	B-Protein
/	O
RUB	O
-	O
modification	O
from	O
the	O
cullin	O
subunit	O
of	O
SCF	O
-	O
type	O
E3	O
complexes	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
multiprotein	B-X
complex	B-X
that	B-X
was	B-X
first	B-X
identified	B-X
as	B-X
an	B-X
essential	B-X
complex	B-X
that	B-X
represses	B-X
light-regulated	B-X
development	B-X
in	B-X
Arabidopsis	B-X
.	B-X
The	B-X
COP9	B-X
signalosome	B-X
has	B-X
similarity	B-X
to	B-X
the	B-X
lid	B-X
of	B-X
the	B-X
19S	B-X
regulatory	B-X
particle	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
and	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
SCF-type	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
Although	B-X
its	B-X
precise	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
protein	B-X
degradation	B-X
remains	B-X
to	B-X
be	B-X
established	B-X
,	B-X
the	B-X
COP9	B-X
signalosome	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
that	B-X
functions	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
mediating	B-X
the	B-X
deconjugation	B-X
of	B-X
the	B-X
NEDD8/RUB-modification	B-X
from	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
SCF-type	B-X
E3	B-X
complexes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
these	B-X
recent	B-X
findings	B-X
,	B-X
which	B-X
add	B-X
an	B-X
additional	B-X
component	B-X
to	B-X
the	B-X
biology	B-X
of	B-X
substrate-specific	B-X
protein	B-X
degradation	B-X
.	B-X

Here	O
,	O
we	O
discuss	O
these	O
recent	O
findings	O
,	O
which	O
add	O
an	O
additional	O
component	O
to	O
the	O
biology	O
of	O
substrate	O
-	O
specific	O
protein	O
degradation	O
.	O

Lovastatin	O
-	O
induced	O
cytoskeletal	O
reorganization	O
in	O
lens	O
epithelial	O
cells	O
:	O
role	O
of	O
Rho	O
GTPases	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
involvement	B-X
of	B-X
isoprenylated	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
GTPases	B-X
)	B-X
in	B-X
lovastatin-induced	B-X
cataractogenesis	B-X
,	B-X
Rho-	B-X
and	B-X
Rac-mediated	B-X
cell	B-X
adhesion	B-X
and	B-X
actin	B-X
cytoskeletal	B-X
reorganization	B-X
were	B-X
investigated	B-X
in	B-X
lovastatin-treated	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
involvement	B-X
of	B-X
the	B-X
Rho	B-X
GTPases-mediated	B-X
signaling	B-X
pathway	B-X
in	B-X
growth	B-X
factor-stimulated	B-X
actomyosin	B-X
cytoskeletal	B-X
organization	B-X
and	B-X
focal	B-X
adhesion	B-X
formation	B-X
in	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X

PURPOSE	O
:	O
To	O
understand	O
the	O
involvement	O
of	O
isoprenylated	O
small	O
guanosine	O
triphosphatases	O
(	O
GTPases	O
)	O
in	O
lovastatin	O
-	O
induced	O
cataractogenesis	O
,	O
Rho	O
-	O
and	O
Rac	O
-	O
mediated	O
cell	O
adhesion	O
and	O
actin	O
cytoskeletal	O
reorganization	O
were	O
investigated	O
in	O
lovastatin	O
-	O
treated	O
lens	O
epithelial	O
cells	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
involvement	B-X
of	B-X
isoprenylated	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
GTPases	B-X
)	B-X
in	B-X
lovastatin-induced	B-X
cataractogenesis	B-X
,	B-X
Rho-	B-X
and	B-X
Rac-mediated	B-X
cell	B-X
adhesion	B-X
and	B-X
actin	B-X
cytoskeletal	B-X
reorganization	B-X
were	B-X
investigated	B-X
in	B-X
lovastatin-treated	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X

METHODS	O
:	O
The	O
effects	O
of	O
lovastatin	O
on	O
F	O
-	O
actin	O
reorganization	O
(	O
phalloidin	O
staining	O
)	O
,	O
focal	O
adhesion	O
formation	O
(	O
paxillin	B-Protein
or	O
vinculin	B-Protein
)	O
,	O
cell	O
-	O
cell	O
adhesions	O
(	O
cadherin	O
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
)	O
,	O
and	O
protein	O
tyrosine	O
phosphorylation	O
were	O
evaluated	O
in	O
human	O
and	O
porcine	O
lens	O
epithelial	O
cells	O
by	O
immunocytochemical	O
staining	O
with	O
specific	O
antibodies	O
.	O

To	O
explore	O
the	O
involvement	O
of	O
the	O
Rho	O
and	O
Rac	O
GTPases	O
in	O
lovastatin	O
-	O
mediated	O
effects	O
,	O
changes	O
in	O
distribution	O
of	O
Rho	O
and	O
Rac	O
GTPases	O
were	O
analyzed	O
by	O
Western	O
blot	O
analysis	O
,	O
and	O
the	O
effects	O
of	O
C3	B-Protein
-	I-Protein
exoenzyme	I-Protein
on	O
lovastatin	O
-	O
induced	O
cytoskeletal	O
changes	O
were	O
evaluated	O
by	O
immunocytochemical	O
analysis	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
involvement	B-X
of	B-X
isoprenylated	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
GTPases	B-X
)	B-X
in	B-X
lovastatin-induced	B-X
cataractogenesis	B-X
,	B-X
Rho-	B-X
and	B-X
Rac-mediated	B-X
cell	B-X
adhesion	B-X
and	B-X
actin	B-X
cytoskeletal	B-X
reorganization	B-X
were	B-X
investigated	B-X
in	B-X
lovastatin-treated	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X

RESULTS	O
:	O
Lovastatin	O
induced	O
drastic	O
changes	O
in	O
cell	O
shape	O
in	O
both	O
human	O
and	O
porcine	O
lens	O
epithelial	O
cells	O
,	O
including	O
a	O
profound	O
loss	O
of	O
actin	O
stress	O
fibers	O
,	O
focal	O
adhesions	O
,	O
protein	O
phosphotyrosine	O
,	O
and	O
cell	O
-	O
cell	O
adhesions	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
involvement	B-X
of	B-X
isoprenylated	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
GTPases	B-X
)	B-X
in	B-X
lovastatin-induced	B-X
cataractogenesis	B-X
,	B-X
Rho-	B-X
and	B-X
Rac-mediated	B-X
cell	B-X
adhesion	B-X
and	B-X
actin	B-X
cytoskeletal	B-X
reorganization	B-X
were	B-X
investigated	B-X
in	B-X
lovastatin-treated	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X

Lovastatin	O
treatment	O
also	O
led	O
to	O
the	O
accumulation	O
of	O
nonisoprenylated	O
Rho	O
and	O
Rac	O
GTPases	O
in	O
cytosolic	O
fraction	O
.	O

Supplementation	O
of	O
culture	O
media	O
with	O
geranylgeranyl	O
pyrophosphate	O
dramatically	O
reversed	O
the	O
lovastatin	O
-	O
induced	O
morphologic	O
and	O
cytoskeletal	O
changes	O
,	O
whereas	O
farnesyl	O
pyrophosphate	O
was	O
ineffective	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
involvement	B-X
of	B-X
isoprenylated	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
GTPases	B-X
)	B-X
in	B-X
lovastatin-induced	B-X
cataractogenesis	B-X
,	B-X
Rho-	B-X
and	B-X
Rac-mediated	B-X
cell	B-X
adhesion	B-X
and	B-X
actin	B-X
cytoskeletal	B-X
reorganization	B-X
were	B-X
investigated	B-X
in	B-X
lovastatin-treated	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X

Treatment	O
of	O
cells	O
with	O
C3	B-Protein
-	I-Protein
exoenzyme	I-Protein
(	O
a	O
Rho	O
GTPase	O
-	O
specific	O
inhibitor	O
)	O
,	O
however	O
,	O
abolished	O
the	O
geranylgeranyl	O
-	O
supplementation	O
-	O
induced	O
recovery	O
from	O
the	O
morphologic	O
and	O
cytoskeletal	O
effects	O
of	O
lovastatin	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
involvement	B-X
of	B-X
isoprenylated	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
GTPases	B-X
)	B-X
in	B-X
lovastatin-induced	B-X
cataractogenesis	B-X
,	B-X
Rho-	B-X
and	B-X
Rac-mediated	B-X
cell	B-X
adhesion	B-X
and	B-X
actin	B-X
cytoskeletal	B-X
reorganization	B-X
were	B-X
investigated	B-X
in	B-X
lovastatin-treated	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
inhibition	O
of	O
protein	O
prenylation	O
by	O
lovastatin	O
leads	O
to	O
disruption	O
of	O
actin	O
cytoskeletal	O
organization	O
,	O
and	O
to	O
loss	O
of	O
integrin	O
-	O
mediated	O
focal	O
adhesions	O
and	O
cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesions	O
in	O
lens	O
epithelial	O
cells	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
involvement	B-X
of	B-X
isoprenylated	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
GTPases	B-X
)	B-X
in	B-X
lovastatin-induced	B-X
cataractogenesis	B-X
,	B-X
Rho-	B-X
and	B-X
Rac-mediated	B-X
cell	B-X
adhesion	B-X
and	B-X
actin	B-X
cytoskeletal	B-X
reorganization	B-X
were	B-X
investigated	B-X
in	B-X
lovastatin-treated	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X

Based	O
on	O
isoprenoid	O
supplementation	O
studies	O
,	O
it	O
could	O
be	O
concluded	O
that	O
impairment	O
of	O
geranylgeranylated	O
Rho	O
and	O
Rac	O
GTPase	O
function	O
is	O
most	O
likely	O
responsible	O
for	O
lovastatin	O
-	O
induced	O
cytoskeletal	O
changes	O
in	O
lens	O
epithelial	O
cells	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
involvement	B-X
of	B-X
isoprenylated	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
GTPases	B-X
)	B-X
in	B-X
lovastatin-induced	B-X
cataractogenesis	B-X
,	B-X
Rho-	B-X
and	B-X
Rac-mediated	B-X
cell	B-X
adhesion	B-X
and	B-X
actin	B-X
cytoskeletal	B-X
reorganization	B-X
were	B-X
investigated	B-X
in	B-X
lovastatin-treated	B-X
lens	B-X
epithelial	B-X
cells	B-X
.	B-X

Impairment	O
of	O
mineralocorticoid	B-Protein
receptor	I-Protein
(	O
MR	B-Protein
)	O
-	O
dependent	O
biological	O
response	O
by	O
oxidative	O
stress	O
and	O
aging	O
:	O
correlation	O
with	O
post	O
-	O
translational	O
modification	O
of	O
MR	B-Protein
and	O
decreased	O
ADP	O
-	O
ribosylatable	O
level	O
of	O
elongating	B-Protein
factor	I-Protein
2	I-Protein
in	O
kidney	O
cells	O
.	O
<EOS>	B-X
Acute	B-X
and	B-X
chronic	B-X
treatments	B-X
of	B-X
mice	B-X
with	B-X
the	B-X
glutathione-depleting	B-X
agent	B-X
,	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
,	B-X
impaired	B-X
the	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
MR	B-X
)	B-X
-dependent	B-X
biological	B-X
response	B-X
by	B-X
inhibiting	B-X
aldosterone	B-X
binding	B-X
.	B-X
This	B-X
steroid-binding	B-X
inhibition	B-X
was	B-X
fully	B-X
reversed	B-X
when	B-X
reducing	B-X
agents	B-X
were	B-X
added	B-X
to	B-X
kidney	B-X
cytosol	B-X
obtained	B-X
from	B-X
mice	B-X
treated	B-X
for	B-X
5	B-X
h	B-X
,	B-X
but	B-X
it	B-X
was	B-X
only	B-X
partially	B-X
reversed	B-X
in	B-X
cytosol	B-X
obtained	B-X
from	B-X
mice	B-X
treated	B-X
for	B-X
10	B-X
days	B-X
.	B-X
Although	B-X
the	B-X
oligomeric	B-X
structure	B-X
of	B-X
the	B-X
MR-hsp90	B-X
heterocomplex	B-X
was	B-X
always	B-X
unaffected	B-X
,	B-X
a	B-X
decreased	B-X
amount	B-X
of	B-X
MR	B-X
protein	B-X
was	B-X
evidenced	B-X
after	B-X
the	B-X
long	B-X
term	B-X
treatment	B-X
.	B-X
Such	B-X
a	B-X
deleterious	B-X
effect	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
post-translational	B-X
modification	B-X
of	B-X
MR	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
receptor	B-X
carbonylation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
failure	B-X
at	B-X
the	B-X
elongation/termination	B-X
step	B-X
was	B-X
also	B-X
observed	B-X
during	B-X
the	B-X
receptor	B-X
translation	B-X
process	B-X
in	B-X
a	B-X
reticulocyte	B-X
lysate	B-X
system	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
high	B-X
polyribosomes/monomers	B-X
ratio	B-X
and	B-X
both	B-X
increased	B-X
proteolysis	B-X
and	B-X
decreased	B-X
ADP-ribosylatable	B-X
concentration	B-X
of	B-X
elongation	B-X
factor	B-X
2	B-X
(	B-X
EF-2	B-X
)	B-X
were	B-X
shown	B-X
.	B-X
Notwithstanding	B-X
the	B-X
EF-2	B-X
functional	B-X
disruption	B-X
,	B-X
not	B-X
all	B-X
renal	B-X
proteins	B-X
were	B-X
equally	B-X
affected	B-X
as	B-X
the	B-X
MR.	B-X
Interestingly	B-X
,	B-X
both	B-X
EF-2	B-X
and	B-X
MR	B-X
expressed	B-X
in	B-X
old	B-X
mice	B-X
were	B-X
similarly	B-X
affected	B-X
as	B-X
in	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine-treated	B-X
young	B-X
mice	B-X
.	B-X
We	B-X
therefore	B-X
propose	B-X
that	B-X
a	B-X
dramatic	B-X
depletion	B-X
of	B-X
glutathione	B-X
in	B-X
kidney	B-X
cells	B-X
mimics	B-X
the	B-X
cumulative	B-X
effect	B-X
of	B-X
aging	B-X
which	B-X
,	B-X
at	B-X
the	B-X
end	B-X
,	B-X
may	B-X
lead	B-X
to	B-X
a	B-X
renal	B-X
mineralocorticoid	B-X
dysfunction	B-X
.	B-X

Acute	O
and	O
chronic	O
treatments	O
of	O
mice	O
with	O
the	O
glutathione	O
-	O
depleting	O
agent	O
,	O
L	O
-	O
buthionine	O
-	O
(	O
SR	O
)	O
-	O
sulfoximine	O
(	O
BSO	O
)	O
,	O
impaired	O
the	O
mineralocorticoid	B-Protein
receptor	I-Protein
(	O
MR	B-Protein
)	O
-	O
dependent	O
biological	O
response	O
by	O
inhibiting	O
aldosterone	O
binding	O
.	O
<EOS>	B-X
Acute	B-X
and	B-X
chronic	B-X
treatments	B-X
of	B-X
mice	B-X
with	B-X
the	B-X
glutathione-depleting	B-X
agent	B-X
,	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
,	B-X
impaired	B-X
the	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
MR	B-X
)	B-X
-dependent	B-X
biological	B-X
response	B-X
by	B-X
inhibiting	B-X
aldosterone	B-X
binding	B-X
.	B-X
This	B-X
steroid-binding	B-X
inhibition	B-X
was	B-X
fully	B-X
reversed	B-X
when	B-X
reducing	B-X
agents	B-X
were	B-X
added	B-X
to	B-X
kidney	B-X
cytosol	B-X
obtained	B-X
from	B-X
mice	B-X
treated	B-X
for	B-X
5	B-X
h	B-X
,	B-X
but	B-X
it	B-X
was	B-X
only	B-X
partially	B-X
reversed	B-X
in	B-X
cytosol	B-X
obtained	B-X
from	B-X
mice	B-X
treated	B-X
for	B-X
10	B-X
days	B-X
.	B-X
Although	B-X
the	B-X
oligomeric	B-X
structure	B-X
of	B-X
the	B-X
MR-hsp90	B-X
heterocomplex	B-X
was	B-X
always	B-X
unaffected	B-X
,	B-X
a	B-X
decreased	B-X
amount	B-X
of	B-X
MR	B-X
protein	B-X
was	B-X
evidenced	B-X
after	B-X
the	B-X
long	B-X
term	B-X
treatment	B-X
.	B-X
Such	B-X
a	B-X
deleterious	B-X
effect	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
post-translational	B-X
modification	B-X
of	B-X
MR	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
receptor	B-X
carbonylation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
failure	B-X
at	B-X
the	B-X
elongation/termination	B-X
step	B-X
was	B-X
also	B-X
observed	B-X
during	B-X
the	B-X
receptor	B-X
translation	B-X
process	B-X
in	B-X
a	B-X
reticulocyte	B-X
lysate	B-X
system	B-X
.	B-X
Importantly	B-X
,	B-X
similar	B-X
observations	B-X
were	B-X
also	B-X
performed	B-X
in	B-X
vivo	B-X
after	B-X
depletion	B-X
of	B-X
glutathione	B-X
.	B-X
Notwithstanding	B-X
the	B-X
EF-2	B-X
functional	B-X
disruption	B-X
,	B-X
not	B-X
all	B-X
renal	B-X
proteins	B-X
were	B-X
equally	B-X
affected	B-X
as	B-X
the	B-X
MR.	B-X
Interestingly	B-X
,	B-X
both	B-X
EF-2	B-X
and	B-X
MR	B-X
expressed	B-X
in	B-X
old	B-X
mice	B-X
were	B-X
similarly	B-X
affected	B-X
as	B-X
in	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine-treated	B-X
young	B-X
mice	B-X
.	B-X
We	B-X
therefore	B-X
propose	B-X
that	B-X
a	B-X
dramatic	B-X
depletion	B-X
of	B-X
glutathione	B-X
in	B-X
kidney	B-X
cells	B-X
mimics	B-X
the	B-X
cumulative	B-X
effect	B-X
of	B-X
aging	B-X
which	B-X
,	B-X
at	B-X
the	B-X
end	B-X
,	B-X
may	B-X
lead	B-X
to	B-X
a	B-X
renal	B-X
mineralocorticoid	B-X
dysfunction	B-X
.	B-X

This	O
steroid	O
-	O
binding	O
inhibition	O
was	O
fully	O
reversed	O
when	O
reducing	O
agents	O
were	O
added	O
to	O
kidney	O
cytosol	O
obtained	O
from	O
mice	O
treated	O
for	O
5	O
h	O
,	O
but	O
it	O
was	O
only	O
partially	O
reversed	O
in	O
cytosol	O
obtained	O
from	O
mice	O
treated	O
for	O
10	O
days	O
.	O
<EOS>	B-X
Acute	B-X
and	B-X
chronic	B-X
treatments	B-X
of	B-X
mice	B-X
with	B-X
the	B-X
glutathione-depleting	B-X
agent	B-X
,	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
,	B-X
impaired	B-X
the	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
MR	B-X
)	B-X
-dependent	B-X
biological	B-X
response	B-X
by	B-X
inhibiting	B-X
aldosterone	B-X
binding	B-X
.	B-X
This	B-X
steroid-binding	B-X
inhibition	B-X
was	B-X
fully	B-X
reversed	B-X
when	B-X
reducing	B-X
agents	B-X
were	B-X
added	B-X
to	B-X
kidney	B-X
cytosol	B-X
obtained	B-X
from	B-X
mice	B-X
treated	B-X
for	B-X
5	B-X
h	B-X
,	B-X
but	B-X
it	B-X
was	B-X
only	B-X
partially	B-X
reversed	B-X
in	B-X
cytosol	B-X
obtained	B-X
from	B-X
mice	B-X
treated	B-X
for	B-X
10	B-X
days	B-X
.	B-X
Although	B-X
the	B-X
oligomeric	B-X
structure	B-X
of	B-X
the	B-X
MR-hsp90	B-X
heterocomplex	B-X
was	B-X
always	B-X
unaffected	B-X
,	B-X
a	B-X
decreased	B-X
amount	B-X
of	B-X
MR	B-X
protein	B-X
was	B-X
evidenced	B-X
after	B-X
the	B-X
long	B-X
term	B-X
treatment	B-X
.	B-X
Such	B-X
a	B-X
deleterious	B-X
effect	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
post-translational	B-X
modification	B-X
of	B-X
MR	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
receptor	B-X
carbonylation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
failure	B-X
at	B-X
the	B-X
elongation/termination	B-X
step	B-X
was	B-X
also	B-X
observed	B-X
during	B-X
the	B-X
receptor	B-X
translation	B-X
process	B-X
in	B-X
a	B-X
reticulocyte	B-X
lysate	B-X
system	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
high	B-X
polyribosomes/monomers	B-X
ratio	B-X
and	B-X
both	B-X
increased	B-X
proteolysis	B-X
and	B-X
decreased	B-X
ADP-ribosylatable	B-X
concentration	B-X
of	B-X
elongation	B-X
factor	B-X
2	B-X
(	B-X
EF-2	B-X
)	B-X
were	B-X
shown	B-X
.	B-X
Importantly	B-X
,	B-X
similar	B-X
observations	B-X
were	B-X
also	B-X
performed	B-X
in	B-X
vivo	B-X
after	B-X
depletion	B-X
of	B-X
glutathione	B-X
.	B-X
Notwithstanding	B-X
the	B-X
EF-2	B-X
functional	B-X
disruption	B-X
,	B-X
not	B-X
all	B-X
renal	B-X
proteins	B-X
were	B-X
equally	B-X
affected	B-X
as	B-X
the	B-X
MR.	B-X
Interestingly	B-X
,	B-X
both	B-X
EF-2	B-X
and	B-X
MR	B-X
expressed	B-X
in	B-X
old	B-X
mice	B-X
were	B-X
similarly	B-X
affected	B-X
as	B-X
in	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine-treated	B-X
young	B-X
mice	B-X
.	B-X
We	B-X
therefore	B-X
propose	B-X
that	B-X
a	B-X
dramatic	B-X
depletion	B-X
of	B-X
glutathione	B-X
in	B-X
kidney	B-X
cells	B-X
mimics	B-X
the	B-X
cumulative	B-X
effect	B-X
of	B-X
aging	B-X
which	B-X
,	B-X
at	B-X
the	B-X
end	B-X
,	B-X
may	B-X
lead	B-X
to	B-X
a	B-X
renal	B-X
mineralocorticoid	B-X
dysfunction	B-X
.	B-X

Although	O
the	O
oligomeric	O
structure	O
of	O
the	O
MR	B-Protein
-	O
hsp90	B-Protein
heterocomplex	O
was	O
always	O
unaffected	O
,	O
a	O
decreased	O
amount	O
of	O
MR	B-Protein
protein	O
was	O
evidenced	O
after	O
the	O
long	O
term	O
treatment	O
.	O

Such	O
a	O
deleterious	O
effect	O
was	O
correlated	O
with	O
a	O
post	O
-	O
translational	O
modification	O
of	O
MR	B-Protein
,	O
as	O
demonstrated	O
by	O
an	O
increased	O
level	O
of	O
receptor	O
carbonylation	O
.	O
<EOS>	B-X
Acute	B-X
and	B-X
chronic	B-X
treatments	B-X
of	B-X
mice	B-X
with	B-X
the	B-X
glutathione-depleting	B-X
agent	B-X
,	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
,	B-X
impaired	B-X
the	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
MR	B-X
)	B-X
-dependent	B-X
biological	B-X
response	B-X
by	B-X
inhibiting	B-X
aldosterone	B-X
binding	B-X
.	B-X
Although	B-X
the	B-X
oligomeric	B-X
structure	B-X
of	B-X
the	B-X
MR-hsp90	B-X
heterocomplex	B-X
was	B-X
always	B-X
unaffected	B-X
,	B-X
a	B-X
decreased	B-X
amount	B-X
of	B-X
MR	B-X
protein	B-X
was	B-X
evidenced	B-X
after	B-X
the	B-X
long	B-X
term	B-X
treatment	B-X
.	B-X
Such	B-X
a	B-X
deleterious	B-X
effect	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
post-translational	B-X
modification	B-X
of	B-X
MR	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
receptor	B-X
carbonylation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
failure	B-X
at	B-X
the	B-X
elongation/termination	B-X
step	B-X
was	B-X
also	B-X
observed	B-X
during	B-X
the	B-X
receptor	B-X
translation	B-X
process	B-X
in	B-X
a	B-X
reticulocyte	B-X
lysate	B-X
system	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
high	B-X
polyribosomes/monomers	B-X
ratio	B-X
and	B-X
both	B-X
increased	B-X
proteolysis	B-X
and	B-X
decreased	B-X
ADP-ribosylatable	B-X
concentration	B-X
of	B-X
elongation	B-X
factor	B-X
2	B-X
(	B-X
EF-2	B-X
)	B-X
were	B-X
shown	B-X
.	B-X
Notwithstanding	B-X
the	B-X
EF-2	B-X
functional	B-X
disruption	B-X
,	B-X
not	B-X
all	B-X
renal	B-X
proteins	B-X
were	B-X
equally	B-X
affected	B-X
as	B-X
the	B-X
MR.	B-X
Interestingly	B-X
,	B-X
both	B-X
EF-2	B-X
and	B-X
MR	B-X
expressed	B-X
in	B-X
old	B-X
mice	B-X
were	B-X
similarly	B-X
affected	B-X
as	B-X
in	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine-treated	B-X
young	B-X
mice	B-X
.	B-X
We	B-X
therefore	B-X
propose	B-X
that	B-X
a	B-X
dramatic	B-X
depletion	B-X
of	B-X
glutathione	B-X
in	B-X
kidney	B-X
cells	B-X
mimics	B-X
the	B-X
cumulative	B-X
effect	B-X
of	B-X
aging	B-X
which	B-X
,	B-X
at	B-X
the	B-X
end	B-X
,	B-X
may	B-X
lead	B-X
to	B-X
a	B-X
renal	B-X
mineralocorticoid	B-X
dysfunction	B-X
.	B-X

In	O
addition	O
,	O
a	O
failure	O
at	O
the	O
elongation	O
/	O
termination	O
step	O
was	O
also	O
observed	O
during	O
the	O
receptor	O
translation	O
process	O
in	O
a	O
reticulocyte	O
lysate	O
system	O
.	O

Thus	O
,	O
a	O
high	O
polyribosomes	O
/	O
monomers	O
ratio	O
and	O
both	O
increased	O
proteolysis	O
and	O
decreased	O
ADP	O
-	O
ribosylatable	O
concentration	O
of	O
elongation	B-Protein
factor	I-Protein
2	I-Protein
(	O
EF	B-Protein
-	I-Protein
2	I-Protein
)	O
were	O
shown	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
oligomeric	B-X
structure	B-X
of	B-X
the	B-X
MR-hsp90	B-X
heterocomplex	B-X
was	B-X
always	B-X
unaffected	B-X
,	B-X
a	B-X
decreased	B-X
amount	B-X
of	B-X
MR	B-X
protein	B-X
was	B-X
evidenced	B-X
after	B-X
the	B-X
long	B-X
term	B-X
treatment	B-X
.	B-X
Such	B-X
a	B-X
deleterious	B-X
effect	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
post-translational	B-X
modification	B-X
of	B-X
MR	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
receptor	B-X
carbonylation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
failure	B-X
at	B-X
the	B-X
elongation/termination	B-X
step	B-X
was	B-X
also	B-X
observed	B-X
during	B-X
the	B-X
receptor	B-X
translation	B-X
process	B-X
in	B-X
a	B-X
reticulocyte	B-X
lysate	B-X
system	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
high	B-X
polyribosomes/monomers	B-X
ratio	B-X
and	B-X
both	B-X
increased	B-X
proteolysis	B-X
and	B-X
decreased	B-X
ADP-ribosylatable	B-X
concentration	B-X
of	B-X
elongation	B-X
factor	B-X
2	B-X
(	B-X
EF-2	B-X
)	B-X
were	B-X
shown	B-X
.	B-X
Notwithstanding	B-X
the	B-X
EF-2	B-X
functional	B-X
disruption	B-X
,	B-X
not	B-X
all	B-X
renal	B-X
proteins	B-X
were	B-X
equally	B-X
affected	B-X
as	B-X
the	B-X
MR.	B-X
Interestingly	B-X
,	B-X
both	B-X
EF-2	B-X
and	B-X
MR	B-X
expressed	B-X
in	B-X
old	B-X
mice	B-X
were	B-X
similarly	B-X
affected	B-X
as	B-X
in	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine-treated	B-X
young	B-X
mice	B-X
.	B-X

Importantly	O
,	O
similar	O
observations	O
were	O
also	O
performed	O
in	O
vivo	O
after	O
depletion	O
of	O
glutathione	O
.	O
<EOS>	B-X
Acute	B-X
and	B-X
chronic	B-X
treatments	B-X
of	B-X
mice	B-X
with	B-X
the	B-X
glutathione-depleting	B-X
agent	B-X
,	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
,	B-X
impaired	B-X
the	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
MR	B-X
)	B-X
-dependent	B-X
biological	B-X
response	B-X
by	B-X
inhibiting	B-X
aldosterone	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
failure	B-X
at	B-X
the	B-X
elongation/termination	B-X
step	B-X
was	B-X
also	B-X
observed	B-X
during	B-X
the	B-X
receptor	B-X
translation	B-X
process	B-X
in	B-X
a	B-X
reticulocyte	B-X
lysate	B-X
system	B-X
.	B-X
Importantly	B-X
,	B-X
similar	B-X
observations	B-X
were	B-X
also	B-X
performed	B-X
in	B-X
vivo	B-X
after	B-X
depletion	B-X
of	B-X
glutathione	B-X
.	B-X
Notwithstanding	B-X
the	B-X
EF-2	B-X
functional	B-X
disruption	B-X
,	B-X
not	B-X
all	B-X
renal	B-X
proteins	B-X
were	B-X
equally	B-X
affected	B-X
as	B-X
the	B-X
MR.	B-X
Interestingly	B-X
,	B-X
both	B-X
EF-2	B-X
and	B-X
MR	B-X
expressed	B-X
in	B-X
old	B-X
mice	B-X
were	B-X
similarly	B-X
affected	B-X
as	B-X
in	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine-treated	B-X
young	B-X
mice	B-X
.	B-X
We	B-X
therefore	B-X
propose	B-X
that	B-X
a	B-X
dramatic	B-X
depletion	B-X
of	B-X
glutathione	B-X
in	B-X
kidney	B-X
cells	B-X
mimics	B-X
the	B-X
cumulative	B-X
effect	B-X
of	B-X
aging	B-X
which	B-X
,	B-X
at	B-X
the	B-X
end	B-X
,	B-X
may	B-X
lead	B-X
to	B-X
a	B-X
renal	B-X
mineralocorticoid	B-X
dysfunction	B-X
.	B-X

Notwithstanding	O
the	O
EF	B-Protein
-	I-Protein
2	I-Protein
functional	O
disruption	O
,	O
not	O
all	O
renal	O
proteins	O
were	O
equally	O
affected	O
as	O
the	O
MR	B-Protein
.	O

Interestingly	O
,	O
both	O
EF	B-Protein
-	I-Protein
2	I-Protein
and	O
MR	B-Protein
expressed	O
in	O
old	O
mice	O
were	O
similarly	O
affected	O
as	O
in	O
L	O
-	O
buthionine	O
-	O
(	O
SR	O
)	O
-	O
sulfoximine	O
-	O
treated	O
young	O
mice	O
.	O

We	O
therefore	O
propose	O
that	O
a	O
dramatic	O
depletion	O
of	O
glutathione	O
in	O
kidney	O
cells	O
mimics	O
the	O
cumulative	O
effect	O
of	O
aging	O
which	O
,	O
at	O
the	O
end	O
,	O
may	O
lead	O
to	O
a	O
renal	O
mineralocorticoid	O
dysfunction	O
.	O
<EOS>	B-X
Acute	B-X
and	B-X
chronic	B-X
treatments	B-X
of	B-X
mice	B-X
with	B-X
the	B-X
glutathione-depleting	B-X
agent	B-X
,	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
,	B-X
impaired	B-X
the	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
MR	B-X
)	B-X
-dependent	B-X
biological	B-X
response	B-X
by	B-X
inhibiting	B-X
aldosterone	B-X
binding	B-X
.	B-X
This	B-X
steroid-binding	B-X
inhibition	B-X
was	B-X
fully	B-X
reversed	B-X
when	B-X
reducing	B-X
agents	B-X
were	B-X
added	B-X
to	B-X
kidney	B-X
cytosol	B-X
obtained	B-X
from	B-X
mice	B-X
treated	B-X
for	B-X
5	B-X
h	B-X
,	B-X
but	B-X
it	B-X
was	B-X
only	B-X
partially	B-X
reversed	B-X
in	B-X
cytosol	B-X
obtained	B-X
from	B-X
mice	B-X
treated	B-X
for	B-X
10	B-X
days	B-X
.	B-X
Such	B-X
a	B-X
deleterious	B-X
effect	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
post-translational	B-X
modification	B-X
of	B-X
MR	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
receptor	B-X
carbonylation	B-X
.	B-X
Importantly	B-X
,	B-X
similar	B-X
observations	B-X
were	B-X
also	B-X
performed	B-X
in	B-X
vivo	B-X
after	B-X
depletion	B-X
of	B-X
glutathione	B-X
.	B-X
Notwithstanding	B-X
the	B-X
EF-2	B-X
functional	B-X
disruption	B-X
,	B-X
not	B-X
all	B-X
renal	B-X
proteins	B-X
were	B-X
equally	B-X
affected	B-X
as	B-X
the	B-X
MR.	B-X
Interestingly	B-X
,	B-X
both	B-X
EF-2	B-X
and	B-X
MR	B-X
expressed	B-X
in	B-X
old	B-X
mice	B-X
were	B-X
similarly	B-X
affected	B-X
as	B-X
in	B-X
L-buthionine-	B-X
(	B-X
SR	B-X
)	B-X
-sulfoximine-treated	B-X
young	B-X
mice	B-X
.	B-X
We	B-X
therefore	B-X
propose	B-X
that	B-X
a	B-X
dramatic	B-X
depletion	B-X
of	B-X
glutathione	B-X
in	B-X
kidney	B-X
cells	B-X
mimics	B-X
the	B-X
cumulative	B-X
effect	B-X
of	B-X
aging	B-X
which	B-X
,	B-X
at	B-X
the	B-X
end	B-X
,	B-X
may	B-X
lead	B-X
to	B-X
a	B-X
renal	B-X
mineralocorticoid	B-X
dysfunction	B-X
.	B-X

Time	O
-	O
dependent	O
potentiation	O
of	O
the	O
beta	O
-	O
cell	O
is	O
a	O
Ca2	O
+	O
-	O
independent	O
phenomenon	O
.	O
<EOS>	B-X
When	B-X
isolated	B-X
rat	B-X
pancreatic	B-X
islets	B-X
are	B-X
treated	B-X
with	B-X
16.7	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
time-dependent	B-X
potentiation	B-X
(	B-X
TDP	B-X
)	B-X
of	B-X
insulin	B-X
release	B-X
occurs	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
subsequent	B-X
treatment	B-X
with	B-X
50	B-X
mM	B-X
KCl	B-X
.	B-X
It	B-X
has	B-X
been	B-X
thought	B-X
that	B-X
TDP	B-X
by	B-X
glucose	B-X
is	B-X
a	B-X
Ca2+-dependent	B-X
phenomenon	B-X
and	B-X
only	B-X
occurs	B-X
when	B-X
exposure	B-X
to	B-X
glucose	B-X
is	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
(	B-X
Ca2+-free	B-X
buffer	B-X
containing	B-X
1	B-X
mM	B-X
EGTA	B-X
)	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
under	B-X
these	B-X
Ca2+-free	B-X
conditions	B-X
glucose	B-X
caused	B-X
an	B-X
even	B-X
stronger	B-X
TDP	B-X
than	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
TDP	B-X
induced	B-X
by	B-X
glucose	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
was	B-X
unaffected	B-X
by	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
The	B-X
TDP	B-X
by	B-X
glucose	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
cytosolic	B-X
free	B-X
Ca2+	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
during	B-X
subsequent	B-X
treatment	B-X
with	B-X
high	B-X
K+	B-X
.	B-X
Exposure	B-X
of	B-X
islets	B-X
to	B-X
forskolin	B-X
under	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-free	B-X
conditions	B-X
did	B-X
not	B-X
cause	B-X
TDP	B-X
despite	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
cellular	B-X
cAMP	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
glucose	B-X
alone	B-X
induces	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
when	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
was	B-X
significantly	B-X
lowered	B-X
.	B-X

When	O
isolated	O
rat	O
pancreatic	O
islets	O
are	O
treated	O
with	O
16	O
.	O
7	O
mM	O
glucose	O
,	O
a	O
time	O
-	O
dependent	O
potentiation	O
(	O
TDP	O
)	O
of	O
insulin	B-Protein
release	O
occurs	O
that	O
can	O
be	O
detected	O
by	O
subsequent	O
treatment	O
with	O
50	O
mM	O
KCl	O
.	O
<EOS>	B-X
When	B-X
isolated	B-X
rat	B-X
pancreatic	B-X
islets	B-X
are	B-X
treated	B-X
with	B-X
16.7	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
time-dependent	B-X
potentiation	B-X
(	B-X
TDP	B-X
)	B-X
of	B-X
insulin	B-X
release	B-X
occurs	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
subsequent	B-X
treatment	B-X
with	B-X
50	B-X
mM	B-X
KCl	B-X
.	B-X
It	B-X
has	B-X
been	B-X
thought	B-X
that	B-X
TDP	B-X
by	B-X
glucose	B-X
is	B-X
a	B-X
Ca2+-dependent	B-X
phenomenon	B-X
and	B-X
only	B-X
occurs	B-X
when	B-X
exposure	B-X
to	B-X
glucose	B-X
is	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
(	B-X
Ca2+-free	B-X
buffer	B-X
containing	B-X
1	B-X
mM	B-X
EGTA	B-X
)	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
under	B-X
these	B-X
Ca2+-free	B-X
conditions	B-X
glucose	B-X
caused	B-X
an	B-X
even	B-X
stronger	B-X
TDP	B-X
than	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
TDP	B-X
induced	B-X
by	B-X
glucose	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
was	B-X
unaffected	B-X
by	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
cerulenin	B-X
or	B-X
tunicamycin	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
protein	B-X
acylation	B-X
,	B-X
eradicated	B-X
TDP	B-X
without	B-X
affecting	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
TDP	B-X
by	B-X
glucose	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
cytosolic	B-X
free	B-X
Ca2+	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
during	B-X
subsequent	B-X
treatment	B-X
with	B-X
high	B-X
K+	B-X
.	B-X
Exposure	B-X
of	B-X
islets	B-X
to	B-X
forskolin	B-X
under	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-free	B-X
conditions	B-X
did	B-X
not	B-X
cause	B-X
TDP	B-X
despite	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
cellular	B-X
cAMP	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
glucose	B-X
alone	B-X
induces	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
when	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
was	B-X
significantly	B-X
lowered	B-X
.	B-X
Protein	B-X
acylation	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
TDP	B-X
.	B-X

It	O
has	O
been	O
thought	O
that	O
TDP	O
by	O
glucose	O
is	O
a	O
Ca2	O
+	O
-	O
dependent	O
phenomenon	O
and	O
only	O
occurs	O
when	O
exposure	O
to	O
glucose	O
is	O
carried	O
out	O
in	O
the	O
presence	O
of	O
Ca2	O
+	O
.	O
<EOS>	B-X
When	B-X
isolated	B-X
rat	B-X
pancreatic	B-X
islets	B-X
are	B-X
treated	B-X
with	B-X
16.7	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
time-dependent	B-X
potentiation	B-X
(	B-X
TDP	B-X
)	B-X
of	B-X
insulin	B-X
release	B-X
occurs	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
subsequent	B-X
treatment	B-X
with	B-X
50	B-X
mM	B-X
KCl	B-X
.	B-X
It	B-X
has	B-X
been	B-X
thought	B-X
that	B-X
TDP	B-X
by	B-X
glucose	B-X
is	B-X
a	B-X
Ca2+-dependent	B-X
phenomenon	B-X
and	B-X
only	B-X
occurs	B-X
when	B-X
exposure	B-X
to	B-X
glucose	B-X
is	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
(	B-X
Ca2+-free	B-X
buffer	B-X
containing	B-X
1	B-X
mM	B-X
EGTA	B-X
)	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
under	B-X
these	B-X
Ca2+-free	B-X
conditions	B-X
glucose	B-X
caused	B-X
an	B-X
even	B-X
stronger	B-X
TDP	B-X
than	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
TDP	B-X
induced	B-X
by	B-X
glucose	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
was	B-X
unaffected	B-X
by	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
cerulenin	B-X
or	B-X
tunicamycin	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
protein	B-X
acylation	B-X
,	B-X
eradicated	B-X
TDP	B-X
without	B-X
affecting	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
TDP	B-X
by	B-X
glucose	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
cytosolic	B-X
free	B-X
Ca2+	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
during	B-X
subsequent	B-X
treatment	B-X
with	B-X
high	B-X
K+	B-X
.	B-X
Exposure	B-X
of	B-X
islets	B-X
to	B-X
forskolin	B-X
under	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-free	B-X
conditions	B-X
did	B-X
not	B-X
cause	B-X
TDP	B-X
despite	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
cellular	B-X
cAMP	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
glucose	B-X
alone	B-X
induces	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
when	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
was	B-X
significantly	B-X
lowered	B-X
.	B-X
Protein	B-X
acylation	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
TDP	B-X
.	B-X

In	O
contrast	O
to	O
this	O
,	O
we	O
now	O
demonstrate	O
TDP	O
under	O
stringent	O
Ca2	O
+	O
-	O
free	O
conditions	O
(	O
Ca2	O
+	O
-	O
free	O
buffer	O
containing	O
1	O
mM	O
EGTA	O
)	O
.	O
<EOS>	B-X
When	B-X
isolated	B-X
rat	B-X
pancreatic	B-X
islets	B-X
are	B-X
treated	B-X
with	B-X
16.7	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
time-dependent	B-X
potentiation	B-X
(	B-X
TDP	B-X
)	B-X
of	B-X
insulin	B-X
release	B-X
occurs	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
subsequent	B-X
treatment	B-X
with	B-X
50	B-X
mM	B-X
KCl	B-X
.	B-X
It	B-X
has	B-X
been	B-X
thought	B-X
that	B-X
TDP	B-X
by	B-X
glucose	B-X
is	B-X
a	B-X
Ca2+-dependent	B-X
phenomenon	B-X
and	B-X
only	B-X
occurs	B-X
when	B-X
exposure	B-X
to	B-X
glucose	B-X
is	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
(	B-X
Ca2+-free	B-X
buffer	B-X
containing	B-X
1	B-X
mM	B-X
EGTA	B-X
)	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
under	B-X
these	B-X
Ca2+-free	B-X
conditions	B-X
glucose	B-X
caused	B-X
an	B-X
even	B-X
stronger	B-X
TDP	B-X
than	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
TDP	B-X
induced	B-X
by	B-X
glucose	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
was	B-X
unaffected	B-X
by	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
cerulenin	B-X
or	B-X
tunicamycin	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
protein	B-X
acylation	B-X
,	B-X
eradicated	B-X
TDP	B-X
without	B-X
affecting	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
TDP	B-X
by	B-X
glucose	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
cytosolic	B-X
free	B-X
Ca2+	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
during	B-X
subsequent	B-X
treatment	B-X
with	B-X
high	B-X
K+	B-X
.	B-X
Exposure	B-X
of	B-X
islets	B-X
to	B-X
forskolin	B-X
under	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-free	B-X
conditions	B-X
did	B-X
not	B-X
cause	B-X
TDP	B-X
despite	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
cellular	B-X
cAMP	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
glucose	B-X
alone	B-X
induces	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
when	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
was	B-X
significantly	B-X
lowered	B-X
.	B-X
Protein	B-X
acylation	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
TDP	B-X
.	B-X

In	O
fact	O
,	O
under	O
these	O
Ca2	O
+	O
-	O
free	O
conditions	O
glucose	O
caused	O
an	O
even	O
stronger	O
TDP	O
than	O
in	O
the	O
presence	O
of	O
Ca2	O
+	O
.	O
<EOS>	B-X
When	B-X
isolated	B-X
rat	B-X
pancreatic	B-X
islets	B-X
are	B-X
treated	B-X
with	B-X
16.7	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
time-dependent	B-X
potentiation	B-X
(	B-X
TDP	B-X
)	B-X
of	B-X
insulin	B-X
release	B-X
occurs	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
subsequent	B-X
treatment	B-X
with	B-X
50	B-X
mM	B-X
KCl	B-X
.	B-X
It	B-X
has	B-X
been	B-X
thought	B-X
that	B-X
TDP	B-X
by	B-X
glucose	B-X
is	B-X
a	B-X
Ca2+-dependent	B-X
phenomenon	B-X
and	B-X
only	B-X
occurs	B-X
when	B-X
exposure	B-X
to	B-X
glucose	B-X
is	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
(	B-X
Ca2+-free	B-X
buffer	B-X
containing	B-X
1	B-X
mM	B-X
EGTA	B-X
)	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
under	B-X
these	B-X
Ca2+-free	B-X
conditions	B-X
glucose	B-X
caused	B-X
an	B-X
even	B-X
stronger	B-X
TDP	B-X
than	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
TDP	B-X
induced	B-X
by	B-X
glucose	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
was	B-X
unaffected	B-X
by	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
cerulenin	B-X
or	B-X
tunicamycin	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
protein	B-X
acylation	B-X
,	B-X
eradicated	B-X
TDP	B-X
without	B-X
affecting	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
TDP	B-X
by	B-X
glucose	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
cytosolic	B-X
free	B-X
Ca2+	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
during	B-X
subsequent	B-X
treatment	B-X
with	B-X
high	B-X
K+	B-X
.	B-X
Exposure	B-X
of	B-X
islets	B-X
to	B-X
forskolin	B-X
under	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-free	B-X
conditions	B-X
did	B-X
not	B-X
cause	B-X
TDP	B-X
despite	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
cellular	B-X
cAMP	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
glucose	B-X
alone	B-X
induces	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
when	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
was	B-X
significantly	B-X
lowered	B-X
.	B-X
Protein	B-X
acylation	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
TDP	B-X
.	B-X

TDP	O
induced	O
by	O
glucose	O
in	O
the	O
absence	O
of	O
extracellular	O
Ca2	O
+	O
was	O
unaffected	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O
<EOS>	B-X
When	B-X
isolated	B-X
rat	B-X
pancreatic	B-X
islets	B-X
are	B-X
treated	B-X
with	B-X
16.7	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
time-dependent	B-X
potentiation	B-X
(	B-X
TDP	B-X
)	B-X
of	B-X
insulin	B-X
release	B-X
occurs	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
subsequent	B-X
treatment	B-X
with	B-X
50	B-X
mM	B-X
KCl	B-X
.	B-X
It	B-X
has	B-X
been	B-X
thought	B-X
that	B-X
TDP	B-X
by	B-X
glucose	B-X
is	B-X
a	B-X
Ca2+-dependent	B-X
phenomenon	B-X
and	B-X
only	B-X
occurs	B-X
when	B-X
exposure	B-X
to	B-X
glucose	B-X
is	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
(	B-X
Ca2+-free	B-X
buffer	B-X
containing	B-X
1	B-X
mM	B-X
EGTA	B-X
)	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
under	B-X
these	B-X
Ca2+-free	B-X
conditions	B-X
glucose	B-X
caused	B-X
an	B-X
even	B-X
stronger	B-X
TDP	B-X
than	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
TDP	B-X
induced	B-X
by	B-X
glucose	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
was	B-X
unaffected	B-X
by	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
cerulenin	B-X
or	B-X
tunicamycin	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
protein	B-X
acylation	B-X
,	B-X
eradicated	B-X
TDP	B-X
without	B-X
affecting	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
TDP	B-X
by	B-X
glucose	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
cytosolic	B-X
free	B-X
Ca2+	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
during	B-X
subsequent	B-X
treatment	B-X
with	B-X
high	B-X
K+	B-X
.	B-X
Exposure	B-X
of	B-X
islets	B-X
to	B-X
forskolin	B-X
under	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-free	B-X
conditions	B-X
did	B-X
not	B-X
cause	B-X
TDP	B-X
despite	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
cellular	B-X
cAMP	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
glucose	B-X
alone	B-X
induces	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
when	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
was	B-X
significantly	B-X
lowered	B-X
.	B-X
Protein	B-X
acylation	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
TDP	B-X
.	B-X

However	O
,	O
cerulenin	O
or	O
tunicamycin	O
,	O
two	O
inhibitors	O
of	O
protein	O
acylation	O
,	O
eradicated	O
TDP	O
without	O
affecting	O
glucose	O
metabolism	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
found	B-X
that	B-X
cerulenin	B-X
inhibits	B-X
the	B-X
glycolysis	B-X
and	B-X
migration	B-X
of	B-X
SK-BR-3	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
effect	B-X
of	B-X
cerulenin	B-X
on	B-X
other	B-X
malignant	B-X
phenotypes	B-X
of	B-X
breast	B-X
cancer	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
cerulenin	B-X
displays	B-X
its	B-X
inhibitory	B-X
effects	B-X
is	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
systematically	B-X
investigate	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
cerulenin	B-X
on	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
invasion	B-X
and	B-X
glycolysis	B-X
of	B-X
ErbB2-overexpressing	B-X
breast	B-X
cancer	B-X
cells	B-X
and	B-X
its	B-X
molecular	B-X
mechanism	B-X
.	B-X
We	B-X
found	B-X
that	B-X
cerulenin	B-X
obviously	B-X
suppresses	B-X
the	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
invasion	B-X
as	B-X
well	B-X
as	B-X
glycolysis	B-X
.	B-X
Through	B-X
bioinformatic	B-X
analyses	B-X
,	B-X
we	B-X
found	B-X
that	B-X
PKM2	B-X
might	B-X
be	B-X
a	B-X
target	B-X
of	B-X
cerulenin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
ErbB2	B-X
and	B-X
its	B-X
signaling	B-X
pathway	B-X
upregulated	B-X
PKM2	B-X
protein	B-X
levels	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
cerulenin	B-X
downregulated	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
ErbB2	B-X
,	B-X
PKM2	B-X
and	B-X
EMT	B-X
markers	B-X
(	B-X
MMP9	B-X
,	B-X
MMP2	B-X
and	B-X
Snail2	B-X
)	B-X
in	B-X
a	B-X
dose-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
inhibitory	B-X
of	B-X
cerulenin	B-X
on	B-X
colony	B-X
formation	B-X
,	B-X
migration	B-X
,	B-X
invasion	B-X
and	B-X
glycolysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
protein	B-X
levels	B-X
of	B-X
EMT	B-X
markers	B-X
were	B-X
rescued	B-X
by	B-X
replenishing	B-X
with	B-X
PKM2	B-X
.	B-X
These	B-X
findings	B-X
illustrated	B-X
that	B-X
cerulenin	B-X
inhibits	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
invasion	B-X
and	B-X
glycolysis	B-X
by	B-X
targeting	B-X
ErbB2/PKM2	B-X
pathway	B-X
in	B-X
ErbB2-overexpressing	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

The	O
TDP	O
by	O
glucose	O
was	O
not	O
associated	O
with	O
an	O
increase	O
in	O
the	O
cytosolic	O
free	O
Ca2	O
+	O
concentration	O
(	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
during	O
subsequent	O
treatment	O
with	O
high	O
K	O
+	O
.	O
<EOS>	B-X
Abbreviations	B-X
:	B-X
ALS	B-X
:	B-X
amyotrophic	B-X
lateral	B-X
sclerosis	B-X
;	B-X
AR	B-X
:	B-X
androgen	B-X
receptor	B-X
;	B-X
ATG	B-X
:	B-X
autophagy	B-X
related	B-X
;	B-X
AV	B-X
:	B-X
autophagic	B-X
vacuole	B-X
;	B-X
BAG3	B-X
:	B-X
BCL2-associated	B-X
athanogene	B-X
3	B-X
;	B-X
BECN1	B-X
:	B-X
beclin	B-X
1	B-X
,	B-X
autophagy	B-X
related	B-X
;	B-X
CASA	B-X
:	B-X
chaperone-assisted	B-X
selective	B-X
autophagy	B-X
;	B-X
CTSB	B-X
:	B-X
cathepsin	B-X
b	B-X
;	B-X
DAPI	B-X
:	B-X
4',6-diamidino-2-phenylindole	B-X
;	B-X
DMEM	B-X
:	B-X
Dulbecco	B-X
's	B-X
modified	B-X
Eagle	B-X
's	B-X
medium	B-X
;	B-X
EGFP	B-X
:	B-X
enhanced	B-X
green	B-X
fluorescent	B-X
protein	B-X
;	B-X
fALS	B-X
,	B-X
familial	B-X
amyotrophic	B-X
lateral	B-X
sclerosis	B-X
;	B-X
FRA	B-X
:	B-X
filter	B-X
retardation	B-X
assay	B-X
;	B-X
GAPDH	B-X
:	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
;	B-X
GLA	B-X
:	B-X
galactosidase	B-X
,	B-X
alpha	B-X
;	B-X
HD	B-X
:	B-X
Huntington	B-X
disease	B-X
;	B-X
hIPSCs	B-X
:	B-X
human	B-X
induced	B-X
pluripotent	B-X
stem	B-X
cells	B-X
;	B-X
HSPA8	B-X
:	B-X
heat	B-X
shock	B-X
protein	B-X
A8	B-X
;	B-X
HSPB8	B-X
:	B-X
heat	B-X
shock	B-X
protein	B-X
B8	B-X
;	B-X
IF	B-X
:	B-X
immunofluorescence	B-X
analysis	B-X
;	B-X
LAMP1	B-X
:	B-X
lysosomal-associated	B-X
membrane	B-X
protein	B-X
1	B-X
;	B-X
LAMP2A	B-X
:	B-X
lysosomal-associated	B-X
membrane	B-X
protein	B-X
2A	B-X
;	B-X
LGALS3	B-X
:	B-X
lectin	B-X
,	B-X
galactose	B-X
binding	B-X
,	B-X
soluble	B-X
3	B-X
;	B-X
LLOMe	B-X
:	B-X
L-leucyl-L-leucine	B-X
methyl	B-X
ester	B-X
;	B-X
LMP	B-X
:	B-X
lysosomal	B-X
membrane	B-X
permeabilization	B-X
;	B-X
Lys	B-X
:	B-X
lysosomes	B-X
;	B-X
MAP1LC3B	B-X
:	B-X
microtubule-associated	B-X
protein	B-X
1	B-X
light	B-X
chain	B-X
3	B-X
beta	B-X
;	B-X
MCOLN1	B-X
:	B-X
mucolipin	B-X
1	B-X
;	B-X
mRNA	B-X
:	B-X
messenger	B-X
RNA	B-X
;	B-X
MTOR	B-X
:	B-X
mechanistic	B-X
target	B-X
of	B-X
rapamycin	B-X
kinase	B-X
;	B-X
NDs	B-X
:	B-X
neurodegenerative	B-X
diseases	B-X
;	B-X
NSC34	B-X
:	B-X
neuroblastoma	B-X
x	B-X
spinal	B-X
cord	B-X
34	B-X
;	B-X
PBS	B-X
:	B-X
phosphate-buffered	B-X
saline	B-X
;	B-X
PD	B-X
:	B-X
Parkinson	B-X
disease	B-X
;	B-X
polyQ	B-X
:	B-X
polyglutamine	B-X
;	B-X
PPARGC1A	B-X
:	B-X
peroxisome	B-X
proliferative	B-X
activated	B-X
receptor	B-X
,	B-X
gamma	B-X
,	B-X
coactivator	B-X
1	B-X
alpha	B-X
;	B-X
PPP3CB	B-X
:	B-X
protein	B-X
phosphatase	B-X
3	B-X
,	B-X
catalytic	B-X
subunit	B-X
,	B-X
beta	B-X
isoform	B-X
;	B-X
RT-qPCR	B-X
:	B-X
real-time	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
;	B-X
SBMA	B-X
:	B-X
spinal	B-X
and	B-X
bulbar	B-X
muscular	B-X
atrophy	B-X
;	B-X
SCAs	B-X
:	B-X
spinocerebellar	B-X
ataxias	B-X
;	B-X
siRNA	B-X
:	B-X
small	B-X
interfering	B-X
RNA	B-X
;	B-X
SLC2A8	B-X
:	B-X
solute	B-X
carrier	B-X
family	B-X
2	B-X
,	B-X
(	B-X
facilitated	B-X
glucose	B-X
transporter	B-X
)	B-X
,	B-X
member	B-X
8	B-X
;	B-X
smNPCs	B-X
:	B-X
small	B-X
molecules	B-X
neural	B-X
progenitors	B-X
cells	B-X
;	B-X
SOD1	B-X
:	B-X
superoxide	B-X
dismutase	B-X
1	B-X
;	B-X
SQSTM1/p62	B-X
:	B-X
sequestosome	B-X
1	B-X
;	B-X
STED	B-X
:	B-X
stimulated	B-X
emission	B-X
depletion	B-X
;	B-X
STUB1	B-X
:	B-X
STIP1	B-X
homology	B-X
and	B-X
U-box	B-X
containing	B-X
protein	B-X
1	B-X
;	B-X
TARDBP/TDP-43	B-X
:	B-X
TAR	B-X
DNA	B-X
binding	B-X
protein	B-X
;	B-X
TFEB	B-X
:	B-X
transcription	B-X
factor	B-X
EB	B-X
;	B-X
TPP1	B-X
:	B-X
tripeptidyl	B-X
peptidase	B-X
I	B-X
;	B-X
TREH	B-X
:	B-X
trehalase	B-X
(	B-X
brush-border	B-X
membrane	B-X
glycoprotein	B-X
)	B-X
;	B-X
WB	B-X
:	B-X
western	B-X
blotting	B-X
;	B-X
ZKSCAN3	B-X
:	B-X
zinc	B-X
finger	B-X
with	B-X
KRAB	B-X
and	B-X
SCAN	B-X
domains	B-X
3	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
efficient	B-X
disease-modifying	B-X
treatment	B-X
and	B-X
ideal	B-X
diagnostic	B-X
method	B-X
for	B-X
AD	B-X
are	B-X
unavailable	B-X
.	B-X
Perturbed	B-X
cerebral	B-X
glucose	B-X
metabolism	B-X
,	B-X
an	B-X
invariant	B-X
pathophysiological	B-X
feature	B-X
of	B-X
AD	B-X
,	B-X
may	B-X
be	B-X
a	B-X
critical	B-X
contributor	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
this	B-X
disease	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
firstly	B-X
discussed	B-X
the	B-X
features	B-X
of	B-X
cerebral	B-X
glucose	B-X
metabolism	B-X
in	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
further	B-X
reviewed	B-X
the	B-X
contribution	B-X
of	B-X
glucose	B-X
transportation	B-X
abnormality	B-X
and	B-X
intracellular	B-X
glucose	B-X
catabolism	B-X
dysfunction	B-X
in	B-X
AD	B-X
pathophysiology	B-X
,	B-X
and	B-X
proposed	B-X
a	B-X
hypothesis	B-X
that	B-X
multiple	B-X
pathogenic	B-X
cascades	B-X
induced	B-X
by	B-X
impaired	B-X
cerebral	B-X
glucose	B-X
metabolism	B-X
could	B-X
result	B-X
in	B-X
neuronal	B-X
degeneration	B-X
and	B-X
consequently	B-X
cognitive	B-X
deficits	B-X
in	B-X
AD	B-X
patients	B-X
.	B-X
Among	B-X
these	B-X
pathogenic	B-X
processes	B-X
,	B-X
altered	B-X

Exposure	O
of	O
islets	O
to	O
forskolin	O
under	O
Ca	O
(	O
2	O
+	O
)	O
-	O
free	O
conditions	O
did	O
not	O
cause	O
TDP	O
despite	O
a	O
large	O
increase	O
in	O
the	O
cellular	O
cAMP	O
levels	O
.	O

In	O
conclusion	O
,	O
glucose	O
alone	O
induces	O
TDP	O
under	O
stringent	O
Ca2	O
+	O
-	O
free	O
conditions	O
when	O
[	O
Ca2	O
+	O
]	O
i	O
was	O
significantly	O
lowered	O
.	O
<EOS>	B-X
When	B-X
isolated	B-X
rat	B-X
pancreatic	B-X
islets	B-X
are	B-X
treated	B-X
with	B-X
16.7	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
time-dependent	B-X
potentiation	B-X
(	B-X
TDP	B-X
)	B-X
of	B-X
insulin	B-X
release	B-X
occurs	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
subsequent	B-X
treatment	B-X
with	B-X
50	B-X
mM	B-X
KCl	B-X
.	B-X
It	B-X
has	B-X
been	B-X
thought	B-X
that	B-X
TDP	B-X
by	B-X
glucose	B-X
is	B-X
a	B-X
Ca2+-dependent	B-X
phenomenon	B-X
and	B-X
only	B-X
occurs	B-X
when	B-X
exposure	B-X
to	B-X
glucose	B-X
is	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
(	B-X
Ca2+-free	B-X
buffer	B-X
containing	B-X
1	B-X
mM	B-X
EGTA	B-X
)	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
under	B-X
these	B-X
Ca2+-free	B-X
conditions	B-X
glucose	B-X
caused	B-X
an	B-X
even	B-X
stronger	B-X
TDP	B-X
than	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
TDP	B-X
induced	B-X
by	B-X
glucose	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
was	B-X
unaffected	B-X
by	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
cerulenin	B-X
or	B-X
tunicamycin	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
protein	B-X
acylation	B-X
,	B-X
eradicated	B-X
TDP	B-X
without	B-X
affecting	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
TDP	B-X
by	B-X
glucose	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
cytosolic	B-X
free	B-X
Ca2+	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
during	B-X
subsequent	B-X
treatment	B-X
with	B-X
high	B-X
K+	B-X
.	B-X
Exposure	B-X
of	B-X
islets	B-X
to	B-X
forskolin	B-X
under	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-free	B-X
conditions	B-X
did	B-X
not	B-X
cause	B-X
TDP	B-X
despite	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
cellular	B-X
cAMP	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
glucose	B-X
alone	B-X
induces	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
when	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
was	B-X
significantly	B-X
lowered	B-X
.	B-X
Protein	B-X
acylation	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
TDP	B-X
.	B-X

Protein	O
acylation	O
is	O
implicated	O
in	O
the	O
underlying	O
mechanism	O
of	O
TDP	O
.	O
<EOS>	B-X
When	B-X
isolated	B-X
rat	B-X
pancreatic	B-X
islets	B-X
are	B-X
treated	B-X
with	B-X
16.7	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
time-dependent	B-X
potentiation	B-X
(	B-X
TDP	B-X
)	B-X
of	B-X
insulin	B-X
release	B-X
occurs	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
subsequent	B-X
treatment	B-X
with	B-X
50	B-X
mM	B-X
KCl	B-X
.	B-X
It	B-X
has	B-X
been	B-X
thought	B-X
that	B-X
TDP	B-X
by	B-X
glucose	B-X
is	B-X
a	B-X
Ca2+-dependent	B-X
phenomenon	B-X
and	B-X
only	B-X
occurs	B-X
when	B-X
exposure	B-X
to	B-X
glucose	B-X
is	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
(	B-X
Ca2+-free	B-X
buffer	B-X
containing	B-X
1	B-X
mM	B-X
EGTA	B-X
)	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
under	B-X
these	B-X
Ca2+-free	B-X
conditions	B-X
glucose	B-X
caused	B-X
an	B-X
even	B-X
stronger	B-X
TDP	B-X
than	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca2+	B-X
.	B-X
TDP	B-X
induced	B-X
by	B-X
glucose	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
was	B-X
unaffected	B-X
by	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
cerulenin	B-X
or	B-X
tunicamycin	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
protein	B-X
acylation	B-X
,	B-X
eradicated	B-X
TDP	B-X
without	B-X
affecting	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
TDP	B-X
by	B-X
glucose	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
cytosolic	B-X
free	B-X
Ca2+	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
during	B-X
subsequent	B-X
treatment	B-X
with	B-X
high	B-X
K+	B-X
.	B-X
Exposure	B-X
of	B-X
islets	B-X
to	B-X
forskolin	B-X
under	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-free	B-X
conditions	B-X
did	B-X
not	B-X
cause	B-X
TDP	B-X
despite	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
cellular	B-X
cAMP	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
glucose	B-X
alone	B-X
induces	B-X
TDP	B-X
under	B-X
stringent	B-X
Ca2+-free	B-X
conditions	B-X
when	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
was	B-X
significantly	B-X
lowered	B-X
.	B-X
Protein	B-X
acylation	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
TDP	B-X
.	B-X

Sumoylation	O
of	O
topoisomerase	B-Protein
I	I-Protein
is	O
involved	O
in	O
its	O
partitioning	O
between	O
nucleoli	O
and	O
nucleoplasm	O
and	O
its	O
clearing	O
from	O
nucleoli	O
in	O
response	O
to	O
camptothecin	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
identified	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
putatively	B-X
sumoylated	B-X
topoisomerase	B-X
I	B-X
(	B-X
TOP1	B-X
)	B-X
under	B-X
basal	B-X
conditions	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
,	B-X
and	B-X
anticancer	B-X
camptothecins	B-X
that	B-X
trap	B-X
the	B-X
TOP1-DNA	B-X
covalent	B-X
intermediate	B-X
markedly	B-X
increase	B-X
the	B-X
sumoylation	B-X
of	B-X
TOP1	B-X
(	B-X
<	B-X
or=10	B-X
%	B-X
)	B-X
.	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
sumoylation	B-X
of	B-X
TOP1	B-X
,	B-X
we	B-X
mutated	B-X
sites	B-X
on	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
-TOP1	B-X
corresponding	B-X
to	B-X
the	B-X
consensus	B-X
sequence	B-X
for	B-X
protein	B-X
sumoylation	B-X
(	B-X
PsiKXE	B-X
,	B-X
where	B-X
Psi	B-X
is	B-X
a	B-X
hydrophobic	B-X
residue	B-X
)	B-X
and	B-X
assayed	B-X
the	B-X
mutants	B-X
for	B-X
basal	B-X
and	B-X
camptothecin-induced	B-X
sumoylation	B-X
.	B-X
Only	B-X
one	B-X
of	B-X
the	B-X
eight	B-X
mutants	B-X
,	B-X
K117R	B-X
,	B-X
located	B-X
in	B-X
the	B-X
highly	B-X
charged	B-X
NH2-terminal	B-X
region	B-X
,	B-X
showed	B-X
a	B-X
substantial	B-X
reduction	B-X
(	B-X
approximately	B-X
5-fold	B-X
)	B-X
in	B-X
basal	B-X
and	B-X
camptothecin-induced	B-X
sumoylation	B-X
;	B-X
thus	B-X
,	B-X
Lys-117	B-X
appears	B-X
to	B-X
be	B-X
the	B-X
major	B-X
sumoylation	B-X
site	B-X
.	B-X
A	B-X
triple	B-X
mutant	B-X
having	B-X
the	B-X
PsiKXE	B-X
sequences	B-X
flanking	B-X
K117R	B-X
additionally	B-X
mutated	B-X
(	B-X
K103R/K117R/K153R	B-X
)	B-X
showed	B-X
little	B-X
if	B-X
any	B-X
sumoylation	B-X
,	B-X
but	B-X
was	B-X
degraded	B-X
like	B-X
wild-type	B-X
GFP-TOP1	B-X
during	B-X
camptothecin	B-X
treatment	B-X
.	B-X
However	B-X
,	B-X
K103R/K117R/K153R-GFP-TOP1	B-X
was	B-X
markedly	B-X
concentrated	B-X
within	B-X
nucleoli	B-X
,	B-X
depleted	B-X
from	B-X
the	B-X
remainder	B-X
of	B-X
nucleus	B-X
,	B-X
and	B-X
failed	B-X
to	B-X
be	B-X
cleared	B-X
from	B-X
nucleoli	B-X
in	B-X
response	B-X
to	B-X
camptothecin	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
wherein	B-X
basal	B-X
transient	B-X
sumoylation	B-X
of	B-X
the	B-X
NH2-terminal	B-X
,	B-X
highly	B-X
charged	B-X
,	B-X
disordered	B-X
region	B-X
prevents	B-X
TOP1	B-X
binding	B-X
to	B-X
sites	B-X
in	B-X
nucleoli	B-X
,	B-X
thus	B-X
driving	B-X
it	B-X
to	B-X
bind	B-X
in	B-X
the	B-X
nucleoplasm	B-X
;	B-X
and	B-X
camptothecin	B-X
treatment	B-X
,	B-X
which	B-X
increases	B-X
TOP1	B-X
sumoylation	B-X
,	B-X
further	B-X
shifts	B-X
the	B-X
binding	B-X
resulting	B-X
in	B-X
delocalization	B-X
of	B-X
TOP1	B-X
from	B-X
nucleoli	B-X
to	B-X
nucleoplasm	B-X
.	B-X

Previous	O
studies	O
identified	O
a	O
small	O
fraction	O
of	O
putatively	O
sumoylated	O
topoisomerase	B-Protein
I	I-Protein
(	O
TOP1	B-Protein
)	O
under	O
basal	O
conditions	O
(	O
approximately	O
1	O
%	O
)	O
,	O
and	O
anticancer	O
camptothecins	O
that	O
trap	O
the	O
TOP1	B-Protein
-	O
DNA	O
covalent	O
intermediate	O
markedly	O
increase	O
the	O
sumoylation	O
of	O
TOP1	B-Protein
(	O
<	O
or	O
=	O
10	O
%	O
)	O
.	O

To	O
study	O
the	O
role	O
of	O
the	O
sumoylation	O
of	O
TOP1	B-Protein
,	O
we	O
mutated	O
sites	O
on	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
-	O
TOP1	B-Protein
corresponding	O
to	O
the	O
consensus	O
sequence	O
for	O
protein	O
sumoylation	O
(	O
PsiKXE	O
,	O
where	O
Psi	O
is	O
a	O
hydrophobic	O
residue	O
)	O
and	O
assayed	O
the	O
mutants	O
for	O
basal	O
and	O
camptothecin	O
-	O
induced	O
sumoylation	O
.	O

Only	O
one	O
of	O
the	O
eight	O
mutants	O
,	O
K117R	O
,	O
located	O
in	O
the	O
highly	O
charged	O
NH2	O
-	O
terminal	O
region	O
,	O
showed	O
a	O
substantial	O
reduction	O
(	O
approximately	O
5	O
-	O
fold	O
)	O
in	O
basal	O
and	O
camptothecin	O
-	O
induced	O
sumoylation	O
;	O
thus	O
,	O
Lys	O
-	O
117	O
appears	O
to	O
be	O
the	O
major	O
sumoylation	O
site	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
identified	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
putatively	B-X
sumoylated	B-X
topoisomerase	B-X
I	B-X
(	B-X
TOP1	B-X
)	B-X
under	B-X
basal	B-X
conditions	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
,	B-X
and	B-X
anticancer	B-X
camptothecins	B-X
that	B-X
trap	B-X
the	B-X
TOP1-DNA	B-X
covalent	B-X
intermediate	B-X
markedly	B-X
increase	B-X
the	B-X
sumoylation	B-X
of	B-X
TOP1	B-X
(	B-X
<	B-X
or=10	B-X
%	B-X
)	B-X
.	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
sumoylation	B-X
of	B-X
TOP1	B-X
,	B-X
we	B-X
mutated	B-X
sites	B-X
on	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
-TOP1	B-X
corresponding	B-X
to	B-X
the	B-X
consensus	B-X
sequence	B-X
for	B-X
protein	B-X
sumoylation	B-X
(	B-X
PsiKXE	B-X
,	B-X
where	B-X
Psi	B-X
is	B-X
a	B-X
hydrophobic	B-X
residue	B-X
)	B-X
and	B-X
assayed	B-X
the	B-X
mutants	B-X
for	B-X
basal	B-X
and	B-X
camptothecin-induced	B-X
sumoylation	B-X
.	B-X
Only	B-X
one	B-X
of	B-X
the	B-X
eight	B-X
mutants	B-X
,	B-X
K117R	B-X
,	B-X
located	B-X
in	B-X
the	B-X
highly	B-X
charged	B-X
NH2-terminal	B-X
region	B-X
,	B-X
showed	B-X
a	B-X
substantial	B-X
reduction	B-X
(	B-X
approximately	B-X
5-fold	B-X
)	B-X
in	B-X
basal	B-X
and	B-X
camptothecin-induced	B-X
sumoylation	B-X
;	B-X
thus	B-X
,	B-X
Lys-117	B-X
appears	B-X
to	B-X
be	B-X
the	B-X
major	B-X
sumoylation	B-X
site	B-X
.	B-X
A	B-X
triple	B-X
mutant	B-X
having	B-X
the	B-X
PsiKXE	B-X
sequences	B-X
flanking	B-X
K117R	B-X
additionally	B-X
mutated	B-X
(	B-X
K103R/K117R/K153R	B-X
)	B-X
showed	B-X
little	B-X
if	B-X
any	B-X
sumoylation	B-X
,	B-X
but	B-X
was	B-X
degraded	B-X
like	B-X
wild-type	B-X
GFP-TOP1	B-X
during	B-X
camptothecin	B-X
treatment	B-X
.	B-X
However	B-X
,	B-X
K103R/K117R/K153R-GFP-TOP1	B-X
was	B-X
markedly	B-X
concentrated	B-X
within	B-X
nucleoli	B-X
,	B-X
depleted	B-X
from	B-X
the	B-X
remainder	B-X
of	B-X
nucleus	B-X
,	B-X
and	B-X
failed	B-X
to	B-X
be	B-X
cleared	B-X
from	B-X
nucleoli	B-X
in	B-X
response	B-X
to	B-X
camptothecin	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
wherein	B-X
basal	B-X
transient	B-X
sumoylation	B-X
of	B-X
the	B-X
NH2-terminal	B-X
,	B-X
highly	B-X
charged	B-X
,	B-X
disordered	B-X
region	B-X
prevents	B-X
TOP1	B-X
binding	B-X
to	B-X
sites	B-X
in	B-X
nucleoli	B-X
,	B-X
thus	B-X
driving	B-X
it	B-X
to	B-X
bind	B-X
in	B-X
the	B-X
nucleoplasm	B-X
;	B-X
and	B-X
camptothecin	B-X
treatment	B-X
,	B-X
which	B-X
increases	B-X
TOP1	B-X
sumoylation	B-X
,	B-X
further	B-X
shifts	B-X
the	B-X
binding	B-X
resulting	B-X
in	B-X
delocalization	B-X
of	B-X
TOP1	B-X
from	B-X
nucleoli	B-X
to	B-X
nucleoplasm	B-X
.	B-X

A	O
triple	O
mutant	O
having	O
the	O
PsiKXE	O
sequences	O
flanking	O
K117R	O
additionally	O
mutated	O
(	O
K103R	O
/	O
K117R	O
/	O
K153R	O
)	O
showed	O
little	O
if	O
any	O
sumoylation	O
,	O
but	O
was	O
degraded	O
like	O
wild	O
-	O
type	O
GFP	B-Protein
-	O
TOP1	B-Protein
during	O
camptothecin	O
treatment	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
identified	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
putatively	B-X
sumoylated	B-X
topoisomerase	B-X
I	B-X
(	B-X
TOP1	B-X
)	B-X
under	B-X
basal	B-X
conditions	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
,	B-X
and	B-X
anticancer	B-X
camptothecins	B-X
that	B-X
trap	B-X
the	B-X
TOP1-DNA	B-X
covalent	B-X
intermediate	B-X
markedly	B-X
increase	B-X
the	B-X
sumoylation	B-X
of	B-X
TOP1	B-X
(	B-X
<	B-X
or=10	B-X
%	B-X
)	B-X
.	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
sumoylation	B-X
of	B-X
TOP1	B-X
,	B-X
we	B-X
mutated	B-X
sites	B-X
on	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
-TOP1	B-X
corresponding	B-X
to	B-X
the	B-X
consensus	B-X
sequence	B-X
for	B-X
protein	B-X
sumoylation	B-X
(	B-X
PsiKXE	B-X
,	B-X
where	B-X
Psi	B-X
is	B-X
a	B-X
hydrophobic	B-X
residue	B-X
)	B-X
and	B-X
assayed	B-X
the	B-X
mutants	B-X
for	B-X
basal	B-X
and	B-X
camptothecin-induced	B-X
sumoylation	B-X
.	B-X
Only	B-X
one	B-X
of	B-X
the	B-X
eight	B-X
mutants	B-X
,	B-X
K117R	B-X
,	B-X
located	B-X
in	B-X
the	B-X
highly	B-X
charged	B-X
NH2-terminal	B-X
region	B-X
,	B-X
showed	B-X
a	B-X
substantial	B-X
reduction	B-X
(	B-X
approximately	B-X
5-fold	B-X
)	B-X
in	B-X
basal	B-X
and	B-X
camptothecin-induced	B-X
sumoylation	B-X
;	B-X
thus	B-X
,	B-X
Lys-117	B-X
appears	B-X
to	B-X
be	B-X
the	B-X
major	B-X
sumoylation	B-X
site	B-X
.	B-X
A	B-X
triple	B-X
mutant	B-X
having	B-X
the	B-X
PsiKXE	B-X
sequences	B-X
flanking	B-X
K117R	B-X
additionally	B-X
mutated	B-X
(	B-X
K103R/K117R/K153R	B-X
)	B-X
showed	B-X
little	B-X
if	B-X
any	B-X
sumoylation	B-X
,	B-X
but	B-X
was	B-X
degraded	B-X
like	B-X
wild-type	B-X
GFP-TOP1	B-X
during	B-X
camptothecin	B-X
treatment	B-X
.	B-X
However	B-X
,	B-X
K103R/K117R/K153R-GFP-TOP1	B-X
was	B-X
markedly	B-X
concentrated	B-X
within	B-X
nucleoli	B-X
,	B-X
depleted	B-X
from	B-X
the	B-X
remainder	B-X
of	B-X
nucleus	B-X
,	B-X
and	B-X
failed	B-X
to	B-X
be	B-X
cleared	B-X
from	B-X
nucleoli	B-X
in	B-X
response	B-X
to	B-X
camptothecin	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
wherein	B-X
basal	B-X
transient	B-X
sumoylation	B-X
of	B-X
the	B-X
NH2-terminal	B-X
,	B-X
highly	B-X
charged	B-X
,	B-X
disordered	B-X
region	B-X
prevents	B-X
TOP1	B-X
binding	B-X
to	B-X
sites	B-X
in	B-X
nucleoli	B-X
,	B-X
thus	B-X
driving	B-X
it	B-X
to	B-X
bind	B-X
in	B-X
the	B-X
nucleoplasm	B-X
;	B-X
and	B-X
camptothecin	B-X
treatment	B-X
,	B-X
which	B-X
increases	B-X
TOP1	B-X
sumoylation	B-X
,	B-X
further	B-X
shifts	B-X
the	B-X
binding	B-X
resulting	B-X
in	B-X
delocalization	B-X
of	B-X
TOP1	B-X
from	B-X
nucleoli	B-X
to	B-X
nucleoplasm	B-X
.	B-X

However	O
,	O
K103R	O
/	O
K117R	O
/	O
K153R	O
-	O
GFP	B-Protein
-	O
TOP1	B-Protein
was	O
markedly	O
concentrated	O
within	O
nucleoli	O
,	O
depleted	O
from	O
the	O
remainder	O
of	O
nucleus	O
,	O
and	O
failed	O
to	O
be	O
cleared	O
from	O
nucleoli	O
in	O
response	O
to	O
camptothecin	O
treatment	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
identified	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
putatively	B-X
sumoylated	B-X
topoisomerase	B-X
I	B-X
(	B-X
TOP1	B-X
)	B-X
under	B-X
basal	B-X
conditions	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
,	B-X
and	B-X
anticancer	B-X
camptothecins	B-X
that	B-X
trap	B-X
the	B-X
TOP1-DNA	B-X
covalent	B-X
intermediate	B-X
markedly	B-X
increase	B-X
the	B-X
sumoylation	B-X
of	B-X
TOP1	B-X
(	B-X
<	B-X
or=10	B-X
%	B-X
)	B-X
.	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
sumoylation	B-X
of	B-X
TOP1	B-X
,	B-X
we	B-X
mutated	B-X
sites	B-X
on	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
-TOP1	B-X
corresponding	B-X
to	B-X
the	B-X
consensus	B-X
sequence	B-X
for	B-X
protein	B-X
sumoylation	B-X
(	B-X
PsiKXE	B-X
,	B-X
where	B-X
Psi	B-X
is	B-X
a	B-X
hydrophobic	B-X
residue	B-X
)	B-X
and	B-X
assayed	B-X
the	B-X
mutants	B-X
for	B-X
basal	B-X
and	B-X
camptothecin-induced	B-X
sumoylation	B-X
.	B-X
Only	B-X
one	B-X
of	B-X
the	B-X
eight	B-X
mutants	B-X
,	B-X
K117R	B-X
,	B-X
located	B-X
in	B-X
the	B-X
highly	B-X
charged	B-X
NH2-terminal	B-X
region	B-X
,	B-X
showed	B-X
a	B-X
substantial	B-X
reduction	B-X
(	B-X
approximately	B-X
5-fold	B-X
)	B-X
in	B-X
basal	B-X
and	B-X
camptothecin-induced	B-X
sumoylation	B-X
;	B-X
thus	B-X
,	B-X
Lys-117	B-X
appears	B-X
to	B-X
be	B-X
the	B-X
major	B-X
sumoylation	B-X
site	B-X
.	B-X
A	B-X
triple	B-X
mutant	B-X
having	B-X
the	B-X
PsiKXE	B-X
sequences	B-X
flanking	B-X
K117R	B-X
additionally	B-X
mutated	B-X
(	B-X
K103R/K117R/K153R	B-X
)	B-X
showed	B-X
little	B-X
if	B-X
any	B-X
sumoylation	B-X
,	B-X
but	B-X
was	B-X
degraded	B-X
like	B-X
wild-type	B-X
GFP-TOP1	B-X
during	B-X
camptothecin	B-X
treatment	B-X
.	B-X
However	B-X
,	B-X
K103R/K117R/K153R-GFP-TOP1	B-X
was	B-X
markedly	B-X
concentrated	B-X
within	B-X
nucleoli	B-X
,	B-X
depleted	B-X
from	B-X
the	B-X
remainder	B-X
of	B-X
nucleus	B-X
,	B-X
and	B-X
failed	B-X
to	B-X
be	B-X
cleared	B-X
from	B-X
nucleoli	B-X
in	B-X
response	B-X
to	B-X
camptothecin	B-X
treatment	B-X
.	B-X
These	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
wherein	B-X
basal	B-X
transient	B-X
sumoylation	B-X
of	B-X
the	B-X
NH2-terminal	B-X
,	B-X
highly	B-X
charged	B-X
,	B-X
disordered	B-X
region	B-X
prevents	B-X
TOP1	B-X
binding	B-X
to	B-X
sites	B-X
in	B-X
nucleoli	B-X
,	B-X
thus	B-X
driving	B-X
it	B-X
to	B-X
bind	B-X
in	B-X
the	B-X
nucleoplasm	B-X
;	B-X
and	B-X
camptothecin	B-X
treatment	B-X
,	B-X
which	B-X
increases	B-X
TOP1	B-X
sumoylation	B-X
,	B-X
further	B-X
shifts	B-X
the	B-X
binding	B-X
resulting	B-X
in	B-X
delocalization	B-X
of	B-X
TOP1	B-X
from	B-X
nucleoli	B-X
to	B-X
nucleoplasm	B-X
.	B-X

These	O
data	O
are	O
consistent	O
with	O
a	O
model	O
wherein	O
basal	O
transient	O
sumoylation	O
of	O
the	O
NH2	O
-	O
terminal	O
,	O
highly	O
charged	O
,	O
disordered	O
region	O
prevents	O
TOP1	B-Protein
binding	O
to	O
sites	O
in	O
nucleoli	O
,	O
thus	O
driving	O
it	O
to	O
bind	O
in	O
the	O
nucleoplasm	O
;	O
and	O
camptothecin	O
treatment	O
,	O
which	O
increases	O
TOP1	B-Protein
sumoylation	O
,	O
further	O
shifts	O
the	O
binding	O
resulting	O
in	O
delocalization	O
of	O
TOP1	B-Protein
from	O
nucleoli	O
to	O
nucleoplasm	O
.	O

Age	O
-	O
related	O
changes	O
in	O
human	O
bone	O
proteoglycan	O
structure	O
.	O
<EOS>	B-X
PG	B-X
composition	B-X
and	B-X
structure	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
alter	B-X
with	B-X
age	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
the	B-X
post-translational	B-X
modifications	B-X
to	B-X
PGs	B-X
can	B-X
serve	B-X
as	B-X
in	B-X
vitro	B-X
surrogate	B-X
end	B-X
point	B-X
markers	B-X
for	B-X
chronological	B-X
age	B-X
,	B-X
the	B-X
extent	B-X
of	B-X
GAG	B-X
modifications	B-X
was	B-X
determined	B-X
for	B-X
PGs	B-X
derived	B-X
from	B-X
normal	B-X
human	B-X
bone	B-X
cells	B-X
of	B-X
14	B-X
donors	B-X
(	B-X
age	B-X
range	B-X
,	B-X
fetal	B-X
to	B-X
60	B-X
years	B-X
)	B-X
.	B-X
For	B-X
biglycan	B-X
and	B-X
decorin	B-X
,	B-X
iduronate	B-X
content	B-X
was	B-X
linearly	B-X
correlated	B-X
with	B-X
age	B-X
(	B-X
increased	B-X
1.5x	B-X
between	B-X
fetal	B-X
and	B-X
age	B-X
60	B-X
years	B-X
)	B-X
.	B-X
These	B-X
age-related	B-X
changes	B-X
in	B-X
post-translational	B-X
modifications	B-X
were	B-X
then	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
osteoblasts	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
osteogenesis	B-X
imperfecta	B-X
did	B-X
not	B-X
exhibit	B-X
facets	B-X
of	B-X
a	B-X
pre-mature	B-X
aging	B-X
,	B-X
but	B-X
rather	B-X
were	B-X
arrested	B-X
in	B-X
a	B-X
fetal-like	B-X
phenotypic	B-X
state	B-X
.	B-X
No	B-X
other	B-X
Arg-Gly-Asp	B-X
protein	B-X
(	B-X
fibronectin	B-X
,	B-X
vitronectin	B-X
,	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
osteopontin	B-X
,	B-X
and	B-X
bone	B-X
sialoprotein	B-X
)	B-X
showed	B-X
any	B-X
detectable	B-X
effect	B-X
on	B-X
PG	B-X
metabolism	B-X
in	B-X
bone	B-X
cells	B-X
.	B-X

Impact	O
of	O
osteogenesis	O
imperfecta	O
.	O
<EOS>	B-X
Osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
is	B-X
a	B-X
heritable	B-X
connective	B-X
tissue	B-X
disorder	B-X
of	B-X
severe	B-X
bone	B-X
fragility	B-X
and	B-X
recently	B-X
recognized	B-X
skeletal	B-X
muscle	B-X
weakness	B-X
.	B-X
Osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
describes	B-X
a	B-X
series	B-X
of	B-X
genetic	B-X
bone	B-X
fragility	B-X
disorders	B-X
that	B-X
can	B-X
have	B-X
a	B-X
substantive	B-X
impact	B-X
on	B-X
patient	B-X
quality	B-X
of	B-X
life	B-X
.	B-X
Osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
heritable	B-X
connective	B-X
tissue	B-X
disorder	B-X
primarily	B-X
characterised	B-X
by	B-X
skeletal	B-X
deformity	B-X
and	B-X
fragility	B-X
,	B-X
and	B-X
an	B-X
array	B-X
of	B-X
secondary	B-X
features	B-X
.	B-X
Osteogenesis	B-X
imperfecta	B-X
(	B-X
OI	B-X
)	B-X
,	B-X
which	B-X
is	B-X
most	B-X
often	B-X
due	B-X
to	B-X
a	B-X
collagen	B-X
type	B-X
1	B-X
gene	B-X
mutation	B-X
,	B-X
is	B-X
characterized	B-X
by	B-X
low	B-X
bone	B-X
density	B-X
and	B-X
bone	B-X
fragility	B-X
.	B-X

Proteoglycans	O
(	O
PGs	O
)	O
are	O
a	O
family	O
of	O
molecules	O
that	O
undergo	O
extensive	O
post	O
-	O
translational	O
modifications	O
that	O
include	O
addition	O
of	O
glycosaminoglycan	O
(	O
GAG	O
)	O
chains	O
as	O
well	O
as	O
N	O
-	O
and	O
O	O
-	O
linked	O
oligosaccharides	O
to	O
the	O
protein	O
core	O
.	O

PG	O
composition	O
and	O
structure	O
have	O
been	O
reported	O
to	O
alter	O
with	O
age	O
.	O
<EOS>	B-X
Proteoglycans	B-X
(	B-X
PGs	B-X
)	B-X
are	B-X
a	B-X
family	B-X
of	B-X
molecules	B-X
that	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
modifications	B-X
that	B-X
include	B-X
addition	B-X
of	B-X
glycosaminoglycan	B-X
(	B-X
GAG	B-X
)	B-X
chains	B-X
as	B-X
well	B-X
as	B-X
N-	B-X
and	B-X
O-linked	B-X
oligosaccharides	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
.	B-X
PG	B-X
composition	B-X
and	B-X
structure	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
alter	B-X
with	B-X
age	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
the	B-X
post-translational	B-X
modifications	B-X
to	B-X
PGs	B-X
can	B-X
serve	B-X
as	B-X
in	B-X
vitro	B-X
surrogate	B-X
end	B-X
point	B-X
markers	B-X
for	B-X
chronological	B-X
age	B-X
,	B-X
the	B-X
extent	B-X
of	B-X
GAG	B-X
modifications	B-X
was	B-X
determined	B-X
for	B-X
PGs	B-X
derived	B-X
from	B-X
normal	B-X
human	B-X
bone	B-X
cells	B-X
of	B-X
14	B-X
donors	B-X
(	B-X
age	B-X
range	B-X
,	B-X
fetal	B-X
to	B-X
60	B-X
years	B-X
)	B-X
.	B-X
For	B-X
biglycan	B-X
and	B-X
decorin	B-X
,	B-X
iduronate	B-X
content	B-X
was	B-X
linearly	B-X
correlated	B-X
with	B-X
age	B-X
(	B-X
increased	B-X
1.5x	B-X
between	B-X
fetal	B-X
and	B-X
age	B-X
60	B-X
years	B-X
)	B-X
.	B-X
For	B-X
the	B-X
syndecan-like	B-X
heparan	B-X
sulfate	B-X
PG	B-X
,	B-X
the	B-X
N-sulfation	B-X
of	B-X
post-natal	B-X
cells	B-X
increased	B-X
over	B-X
3.5-fold	B-X
until	B-X
reaching	B-X
a	B-X
plateau	B-X
during	B-X
the	B-X
4th	B-X
decade	B-X
of	B-X
life	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
O-linked	B-X
oligosaccharides	B-X
was	B-X
also	B-X
found	B-X
to	B-X
decrease	B-X
as	B-X
a	B-X
function	B-X
of	B-X
increasing	B-X
normal	B-X
donor	B-X
age	B-X
,	B-X
whereas	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
the	B-X
metabolic	B-X
precursor	B-X
pool	B-X
remained	B-X
constant	B-X
regardless	B-X
of	B-X
donor	B-X
age	B-X
.	B-X
These	B-X
age-related	B-X
changes	B-X
in	B-X
post-translational	B-X
modifications	B-X
were	B-X
then	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
osteoblasts	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
osteogenesis	B-X
imperfecta	B-X
did	B-X
not	B-X
exhibit	B-X
facets	B-X
of	B-X
a	B-X
pre-mature	B-X
aging	B-X
,	B-X
but	B-X
rather	B-X
were	B-X
arrested	B-X
in	B-X
a	B-X
fetal-like	B-X
phenotypic	B-X
state	B-X
.	B-X
A	B-X
growth	B-X
matrix	B-X
rich	B-X
in	B-X
thrombospondin	B-X
altered	B-X
PG	B-X
metabolism	B-X
in	B-X
osteoblastic	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
the	B-X
fetal-like	B-X
(	B-X
rich	B-X
in	B-X
O-linked	B-X
oligosaccharides	B-X
)	B-X
forms	B-X
of	B-X
decorin	B-X
and	B-X
biglycan	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
qualitatively	B-X
different	B-X
from	B-X
the	B-X
effect	B-X
of	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
,	B-X
which	B-X
predominantly	B-X
altered	B-X
GAGs	B-X
rather	B-X
than	B-X
O-linked	B-X
oligosaccharides	B-X
.	B-X
No	B-X
other	B-X
Arg-Gly-Asp	B-X
protein	B-X
(	B-X
fibronectin	B-X
,	B-X
vitronectin	B-X
,	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
osteopontin	B-X
,	B-X
and	B-X
bone	B-X
sialoprotein	B-X
)	B-X
showed	B-X
any	B-X
detectable	B-X
effect	B-X
on	B-X
PG	B-X
metabolism	B-X
in	B-X
bone	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
proper	B-X
matrix	B-X
stoichiometry	B-X
is	B-X
critical	B-X
for	B-X
metabolism	B-X
of	B-X
PGs	B-X
.	B-X

To	O
test	O
whether	O
the	O
post	O
-	O
translational	O
modifications	O
to	O
PGs	O
can	O
serve	O
as	O
in	O
vitro	O
surrogate	O
end	O
point	O
markers	O
for	O
chronological	O
age	O
,	O
the	O
extent	O
of	O
GAG	O
modifications	O
was	O
determined	O
for	O
PGs	O
derived	O
from	O
normal	O
human	O
bone	O
cells	O
of	O
14	O
donors	O
(	O
age	O
range	O
,	O
fetal	O
to	O
60	O
years	O
)	O
.	O
<EOS>	B-X
Proteoglycans	B-X
(	B-X
PGs	B-X
)	B-X
are	B-X
a	B-X
family	B-X
of	B-X
molecules	B-X
that	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
modifications	B-X
that	B-X
include	B-X
addition	B-X
of	B-X
glycosaminoglycan	B-X
(	B-X
GAG	B-X
)	B-X
chains	B-X
as	B-X
well	B-X
as	B-X
N-	B-X
and	B-X
O-linked	B-X
oligosaccharides	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
.	B-X
PG	B-X
composition	B-X
and	B-X
structure	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
alter	B-X
with	B-X
age	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
the	B-X
post-translational	B-X
modifications	B-X
to	B-X
PGs	B-X
can	B-X
serve	B-X
as	B-X
in	B-X
vitro	B-X
surrogate	B-X
end	B-X
point	B-X
markers	B-X
for	B-X
chronological	B-X
age	B-X
,	B-X
the	B-X
extent	B-X
of	B-X
GAG	B-X
modifications	B-X
was	B-X
determined	B-X
for	B-X
PGs	B-X
derived	B-X
from	B-X
normal	B-X
human	B-X
bone	B-X
cells	B-X
of	B-X
14	B-X
donors	B-X
(	B-X
age	B-X
range	B-X
,	B-X
fetal	B-X
to	B-X
60	B-X
years	B-X
)	B-X
.	B-X
Isolated	B-X
cells	B-X
were	B-X
steady	B-X
state	B-X
radiolabeled	B-X
with	B-X
(	B-X
35	B-X
)	B-X
SO	B-X
(	B-X
4	B-X
)	B-X
(	B-X
2-	B-X
)	B-X
and	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
GlcN	B-X
.	B-X
For	B-X
biglycan	B-X
and	B-X
decorin	B-X
,	B-X
iduronate	B-X
content	B-X
was	B-X
linearly	B-X
correlated	B-X
with	B-X
age	B-X
(	B-X
increased	B-X
1.5x	B-X
between	B-X
fetal	B-X
and	B-X
age	B-X
60	B-X
years	B-X
)	B-X
.	B-X
For	B-X
the	B-X
syndecan-like	B-X
heparan	B-X
sulfate	B-X
PG	B-X
,	B-X
the	B-X
N-sulfation	B-X
of	B-X
post-natal	B-X
cells	B-X
increased	B-X
over	B-X
3.5-fold	B-X
until	B-X
reaching	B-X
a	B-X
plateau	B-X
during	B-X
the	B-X
4th	B-X
decade	B-X
of	B-X
life	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
O-linked	B-X
oligosaccharides	B-X
was	B-X
also	B-X
found	B-X
to	B-X
decrease	B-X
as	B-X
a	B-X
function	B-X
of	B-X
increasing	B-X
normal	B-X
donor	B-X
age	B-X
,	B-X
whereas	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
the	B-X
metabolic	B-X
precursor	B-X
pool	B-X
remained	B-X
constant	B-X
regardless	B-X
of	B-X
donor	B-X
age	B-X
.	B-X
These	B-X
age-related	B-X
changes	B-X
in	B-X
post-translational	B-X
modifications	B-X
were	B-X
then	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
osteoblasts	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
osteogenesis	B-X
imperfecta	B-X
did	B-X
not	B-X
exhibit	B-X
facets	B-X
of	B-X
a	B-X
pre-mature	B-X
aging	B-X
,	B-X
but	B-X
rather	B-X
were	B-X
arrested	B-X
in	B-X
a	B-X
fetal-like	B-X
phenotypic	B-X
state	B-X
.	B-X
A	B-X
growth	B-X
matrix	B-X
rich	B-X
in	B-X
thrombospondin	B-X
altered	B-X
PG	B-X
metabolism	B-X
in	B-X
osteoblastic	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
the	B-X
fetal-like	B-X
(	B-X
rich	B-X
in	B-X
O-linked	B-X
oligosaccharides	B-X
)	B-X
forms	B-X
of	B-X
decorin	B-X
and	B-X
biglycan	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
qualitatively	B-X
different	B-X
from	B-X
the	B-X
effect	B-X
of	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
,	B-X
which	B-X
predominantly	B-X
altered	B-X
GAGs	B-X
rather	B-X
than	B-X
O-linked	B-X
oligosaccharides	B-X
.	B-X
No	B-X
other	B-X
Arg-Gly-Asp	B-X
protein	B-X
(	B-X
fibronectin	B-X
,	B-X
vitronectin	B-X
,	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
osteopontin	B-X
,	B-X
and	B-X
bone	B-X
sialoprotein	B-X
)	B-X
showed	B-X
any	B-X
detectable	B-X
effect	B-X
on	B-X
PG	B-X
metabolism	B-X
in	B-X
bone	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
proper	B-X
matrix	B-X
stoichiometry	B-X
is	B-X
critical	B-X
for	B-X
metabolism	B-X
of	B-X
PGs	B-X
.	B-X

Isolated	O
cells	O
were	O
steady	O
state	O
radiolabeled	O
with	O
(	O
35	O
)	O
SO	O
(	O
4	O
)	O
(	O
2	O
-	O
)	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
GlcN	O
.	O

For	O
biglycan	B-Protein
and	O
decorin	B-Protein
,	O
iduronate	O
content	O
was	O
linearly	O
correlated	O
with	O
age	O
(	O
increased	O
1	O
.	O
5x	O
between	O
fetal	O
and	O
age	O
60	O
years	O
)	O
.	O
<EOS>	B-X
PG	B-X
composition	B-X
and	B-X
structure	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
alter	B-X
with	B-X
age	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
the	B-X
post-translational	B-X
modifications	B-X
to	B-X
PGs	B-X
can	B-X
serve	B-X
as	B-X
in	B-X
vitro	B-X
surrogate	B-X
end	B-X
point	B-X
markers	B-X
for	B-X
chronological	B-X
age	B-X
,	B-X
the	B-X
extent	B-X
of	B-X
GAG	B-X
modifications	B-X
was	B-X
determined	B-X
for	B-X
PGs	B-X
derived	B-X
from	B-X
normal	B-X
human	B-X
bone	B-X
cells	B-X
of	B-X
14	B-X
donors	B-X
(	B-X
age	B-X
range	B-X
,	B-X
fetal	B-X
to	B-X
60	B-X
years	B-X
)	B-X
.	B-X
For	B-X
biglycan	B-X
and	B-X
decorin	B-X
,	B-X
iduronate	B-X
content	B-X
was	B-X
linearly	B-X
correlated	B-X
with	B-X
age	B-X
(	B-X
increased	B-X
1.5x	B-X
between	B-X
fetal	B-X
and	B-X
age	B-X
60	B-X
years	B-X
)	B-X
.	B-X
For	B-X
the	B-X
syndecan-like	B-X
heparan	B-X
sulfate	B-X
PG	B-X
,	B-X
the	B-X
N-sulfation	B-X
of	B-X
post-natal	B-X
cells	B-X
increased	B-X
over	B-X
3.5-fold	B-X
until	B-X
reaching	B-X
a	B-X
plateau	B-X
during	B-X
the	B-X
4th	B-X
decade	B-X
of	B-X
life	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
O-linked	B-X
oligosaccharides	B-X
was	B-X
also	B-X
found	B-X
to	B-X
decrease	B-X
as	B-X
a	B-X
function	B-X
of	B-X
increasing	B-X
normal	B-X
donor	B-X
age	B-X
,	B-X
whereas	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
the	B-X
metabolic	B-X
precursor	B-X
pool	B-X
remained	B-X
constant	B-X
regardless	B-X
of	B-X
donor	B-X
age	B-X
.	B-X
These	B-X
age-related	B-X
changes	B-X
in	B-X
post-translational	B-X
modifications	B-X
were	B-X
then	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
osteoblasts	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
osteogenesis	B-X
imperfecta	B-X
did	B-X
not	B-X
exhibit	B-X
facets	B-X
of	B-X
a	B-X
pre-mature	B-X
aging	B-X
,	B-X
but	B-X
rather	B-X
were	B-X
arrested	B-X
in	B-X
a	B-X
fetal-like	B-X
phenotypic	B-X
state	B-X
.	B-X
A	B-X
growth	B-X
matrix	B-X
rich	B-X
in	B-X
thrombospondin	B-X
altered	B-X
PG	B-X
metabolism	B-X
in	B-X
osteoblastic	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
the	B-X
fetal-like	B-X
(	B-X
rich	B-X
in	B-X
O-linked	B-X
oligosaccharides	B-X
)	B-X
forms	B-X
of	B-X
decorin	B-X
and	B-X
biglycan	B-X
.	B-X
No	B-X
other	B-X
Arg-Gly-Asp	B-X
protein	B-X
(	B-X
fibronectin	B-X
,	B-X
vitronectin	B-X
,	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
osteopontin	B-X
,	B-X
and	B-X
bone	B-X
sialoprotein	B-X
)	B-X
showed	B-X
any	B-X
detectable	B-X
effect	B-X
on	B-X
PG	B-X
metabolism	B-X
in	B-X
bone	B-X
cells	B-X
.	B-X

For	O
the	O
syndecan	O
-	O
like	O
heparan	O
sulfate	O
PG	O
,	O
the	O
N	O
-	O
sulfation	O
of	O
post	O
-	O
natal	O
cells	O
increased	O
over	O
3	O
.	O
5	O
-	O
fold	O
until	O
reaching	O
a	O
plateau	O
during	O
the	O
4th	O
decade	O
of	O
life	O
.	O

The	O
amount	O
of	O
O	O
-	O
linked	O
oligosaccharides	O
was	O
also	O
found	O
to	O
decrease	O
as	O
a	O
function	O
of	O
increasing	O
normal	O
donor	O
age	O
,	O
whereas	O
the	O
specific	O
activity	O
of	O
the	O
metabolic	O
precursor	O
pool	O
remained	O
constant	O
regardless	O
of	O
donor	O
age	O
.	O

These	O
age	O
-	O
related	O
changes	O
in	O
post	O
-	O
translational	O
modifications	O
were	O
then	O
used	O
to	O
demonstrate	O
that	O
osteoblasts	O
derived	O
from	O
patients	O
with	O
osteogenesis	O
imperfecta	O
did	O
not	O
exhibit	O
facets	O
of	O
a	O
pre	O
-	O
mature	O
aging	O
,	O
but	O
rather	O
were	O
arrested	O
in	O
a	O
fetal	O
-	O
like	O
phenotypic	O
state	O
.	O
<EOS>	B-X
Proteoglycans	B-X
(	B-X
PGs	B-X
)	B-X
are	B-X
a	B-X
family	B-X
of	B-X
molecules	B-X
that	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
modifications	B-X
that	B-X
include	B-X
addition	B-X
of	B-X
glycosaminoglycan	B-X
(	B-X
GAG	B-X
)	B-X
chains	B-X
as	B-X
well	B-X
as	B-X
N-	B-X
and	B-X
O-linked	B-X
oligosaccharides	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
.	B-X
PG	B-X
composition	B-X
and	B-X
structure	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
alter	B-X
with	B-X
age	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
the	B-X
post-translational	B-X
modifications	B-X
to	B-X
PGs	B-X
can	B-X
serve	B-X
as	B-X
in	B-X
vitro	B-X
surrogate	B-X
end	B-X
point	B-X
markers	B-X
for	B-X
chronological	B-X
age	B-X
,	B-X
the	B-X
extent	B-X
of	B-X
GAG	B-X
modifications	B-X
was	B-X
determined	B-X
for	B-X
PGs	B-X
derived	B-X
from	B-X
normal	B-X
human	B-X
bone	B-X
cells	B-X
of	B-X
14	B-X
donors	B-X
(	B-X
age	B-X
range	B-X
,	B-X
fetal	B-X
to	B-X
60	B-X
years	B-X
)	B-X
.	B-X
Isolated	B-X
cells	B-X
were	B-X
steady	B-X
state	B-X
radiolabeled	B-X
with	B-X
(	B-X
35	B-X
)	B-X
SO	B-X
(	B-X
4	B-X
)	B-X
(	B-X
2-	B-X
)	B-X
and	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
GlcN	B-X
.	B-X
For	B-X
biglycan	B-X
and	B-X
decorin	B-X
,	B-X
iduronate	B-X
content	B-X
was	B-X
linearly	B-X
correlated	B-X
with	B-X
age	B-X
(	B-X
increased	B-X
1.5x	B-X
between	B-X
fetal	B-X
and	B-X
age	B-X
60	B-X
years	B-X
)	B-X
.	B-X
For	B-X
the	B-X
syndecan-like	B-X
heparan	B-X
sulfate	B-X
PG	B-X
,	B-X
the	B-X
N-sulfation	B-X
of	B-X
post-natal	B-X
cells	B-X
increased	B-X
over	B-X
3.5-fold	B-X
until	B-X
reaching	B-X
a	B-X
plateau	B-X
during	B-X
the	B-X
4th	B-X
decade	B-X
of	B-X
life	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
O-linked	B-X
oligosaccharides	B-X
was	B-X
also	B-X
found	B-X
to	B-X
decrease	B-X
as	B-X
a	B-X
function	B-X
of	B-X
increasing	B-X
normal	B-X
donor	B-X
age	B-X
,	B-X
whereas	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
the	B-X
metabolic	B-X
precursor	B-X
pool	B-X
remained	B-X
constant	B-X
regardless	B-X
of	B-X
donor	B-X
age	B-X
.	B-X
These	B-X
age-related	B-X
changes	B-X
in	B-X
post-translational	B-X
modifications	B-X
were	B-X
then	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
osteoblasts	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
osteogenesis	B-X
imperfecta	B-X
did	B-X
not	B-X
exhibit	B-X
facets	B-X
of	B-X
a	B-X
pre-mature	B-X
aging	B-X
,	B-X
but	B-X
rather	B-X
were	B-X
arrested	B-X
in	B-X
a	B-X
fetal-like	B-X
phenotypic	B-X
state	B-X
.	B-X
A	B-X
growth	B-X
matrix	B-X
rich	B-X
in	B-X
thrombospondin	B-X
altered	B-X
PG	B-X
metabolism	B-X
in	B-X
osteoblastic	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
the	B-X
fetal-like	B-X
(	B-X
rich	B-X
in	B-X
O-linked	B-X
oligosaccharides	B-X
)	B-X
forms	B-X
of	B-X
decorin	B-X
and	B-X
biglycan	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
qualitatively	B-X
different	B-X
from	B-X
the	B-X
effect	B-X
of	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
,	B-X
which	B-X
predominantly	B-X
altered	B-X
GAGs	B-X
rather	B-X
than	B-X
O-linked	B-X
oligosaccharides	B-X
.	B-X
No	B-X
other	B-X
Arg-Gly-Asp	B-X
protein	B-X
(	B-X
fibronectin	B-X
,	B-X
vitronectin	B-X
,	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
osteopontin	B-X
,	B-X
and	B-X
bone	B-X
sialoprotein	B-X
)	B-X
showed	B-X
any	B-X
detectable	B-X
effect	B-X
on	B-X
PG	B-X
metabolism	B-X
in	B-X
bone	B-X
cells	B-X
.	B-X

A	O
growth	O
matrix	O
rich	O
in	O
thrombospondin	O
altered	O
PG	O
metabolism	O
in	O
osteoblastic	O
cells	O
,	O
resulting	O
in	O
the	O
production	O
and	O
secretion	O
of	O
the	O
fetal	O
-	O
like	O
(	O
rich	O
in	O
O	O
-	O
linked	O
oligosaccharides	O
)	O
forms	O
of	O
decorin	B-Protein
and	O
biglycan	B-Protein
.	O

This	O
effect	O
was	O
qualitatively	O
different	O
from	O
the	O
effect	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
,	O
which	O
predominantly	O
altered	O
GAGs	O
rather	O
than	O
O	O
-	O
linked	O
oligosaccharides	O
.	O
<EOS>	B-X
Proteoglycans	B-X
(	B-X
PGs	B-X
)	B-X
are	B-X
a	B-X
family	B-X
of	B-X
molecules	B-X
that	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
modifications	B-X
that	B-X
include	B-X
addition	B-X
of	B-X
glycosaminoglycan	B-X
(	B-X
GAG	B-X
)	B-X
chains	B-X
as	B-X
well	B-X
as	B-X
N-	B-X
and	B-X
O-linked	B-X
oligosaccharides	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
O-linked	B-X
oligosaccharides	B-X
was	B-X
also	B-X
found	B-X
to	B-X
decrease	B-X
as	B-X
a	B-X
function	B-X
of	B-X
increasing	B-X
normal	B-X
donor	B-X
age	B-X
,	B-X
whereas	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
the	B-X
metabolic	B-X
precursor	B-X
pool	B-X
remained	B-X
constant	B-X
regardless	B-X
of	B-X
donor	B-X
age	B-X
.	B-X
These	B-X
age-related	B-X
changes	B-X
in	B-X
post-translational	B-X
modifications	B-X
were	B-X
then	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
osteoblasts	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
osteogenesis	B-X
imperfecta	B-X
did	B-X
not	B-X
exhibit	B-X
facets	B-X
of	B-X
a	B-X
pre-mature	B-X
aging	B-X
,	B-X
but	B-X
rather	B-X
were	B-X
arrested	B-X
in	B-X
a	B-X
fetal-like	B-X
phenotypic	B-X
state	B-X
.	B-X
A	B-X
growth	B-X
matrix	B-X
rich	B-X
in	B-X
thrombospondin	B-X
altered	B-X
PG	B-X
metabolism	B-X
in	B-X
osteoblastic	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
the	B-X
fetal-like	B-X
(	B-X
rich	B-X
in	B-X
O-linked	B-X
oligosaccharides	B-X
)	B-X
forms	B-X
of	B-X
decorin	B-X
and	B-X
biglycan	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
qualitatively	B-X
different	B-X
from	B-X
the	B-X
effect	B-X
of	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
,	B-X
which	B-X
predominantly	B-X
altered	B-X
GAGs	B-X
rather	B-X
than	B-X
O-linked	B-X
oligosaccharides	B-X
.	B-X
No	B-X
other	B-X
Arg-Gly-Asp	B-X
protein	B-X
(	B-X
fibronectin	B-X
,	B-X
vitronectin	B-X
,	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
osteopontin	B-X
,	B-X
and	B-X
bone	B-X
sialoprotein	B-X
)	B-X
showed	B-X
any	B-X
detectable	B-X
effect	B-X
on	B-X
PG	B-X
metabolism	B-X
in	B-X
bone	B-X
cells	B-X
.	B-X

No	O
other	O
Arg	O
-	O
Gly	O
-	O
Asp	O
protein	O
(	O
fibronectin	B-Protein
,	O
vitronectin	B-Protein
,	O
type	O
I	O
collagen	O
,	O
osteopontin	B-Protein
,	O
and	O
bone	O
sialoprotein	O
)	O
showed	O
any	O
detectable	O
effect	O
on	O
PG	O
metabolism	O
in	O
bone	O
cells	O
.	O
<EOS>	B-X
Proteoglycans	B-X
(	B-X
PGs	B-X
)	B-X
are	B-X
a	B-X
family	B-X
of	B-X
molecules	B-X
that	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
modifications	B-X
that	B-X
include	B-X
addition	B-X
of	B-X
glycosaminoglycan	B-X
(	B-X
GAG	B-X
)	B-X
chains	B-X
as	B-X
well	B-X
as	B-X
N-	B-X
and	B-X
O-linked	B-X
oligosaccharides	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
.	B-X
PG	B-X
composition	B-X
and	B-X
structure	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
alter	B-X
with	B-X
age	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
the	B-X
post-translational	B-X
modifications	B-X
to	B-X
PGs	B-X
can	B-X
serve	B-X
as	B-X
in	B-X
vitro	B-X
surrogate	B-X
end	B-X
point	B-X
markers	B-X
for	B-X
chronological	B-X
age	B-X
,	B-X
the	B-X
extent	B-X
of	B-X
GAG	B-X
modifications	B-X
was	B-X
determined	B-X
for	B-X
PGs	B-X
derived	B-X
from	B-X
normal	B-X
human	B-X
bone	B-X
cells	B-X
of	B-X
14	B-X
donors	B-X
(	B-X
age	B-X
range	B-X
,	B-X
fetal	B-X
to	B-X
60	B-X
years	B-X
)	B-X
.	B-X
Isolated	B-X
cells	B-X
were	B-X
steady	B-X
state	B-X
radiolabeled	B-X
with	B-X
(	B-X
35	B-X
)	B-X
SO	B-X
(	B-X
4	B-X
)	B-X
(	B-X
2-	B-X
)	B-X
and	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
GlcN	B-X
.	B-X
For	B-X
the	B-X
syndecan-like	B-X
heparan	B-X
sulfate	B-X
PG	B-X
,	B-X
the	B-X
N-sulfation	B-X
of	B-X
post-natal	B-X
cells	B-X
increased	B-X
over	B-X
3.5-fold	B-X
until	B-X
reaching	B-X
a	B-X
plateau	B-X
during	B-X
the	B-X
4th	B-X
decade	B-X
of	B-X
life	B-X
.	B-X
A	B-X
growth	B-X
matrix	B-X
rich	B-X
in	B-X
thrombospondin	B-X
altered	B-X
PG	B-X
metabolism	B-X
in	B-X
osteoblastic	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
the	B-X
fetal-like	B-X
(	B-X
rich	B-X
in	B-X
O-linked	B-X
oligosaccharides	B-X
)	B-X
forms	B-X
of	B-X
decorin	B-X
and	B-X
biglycan	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
qualitatively	B-X
different	B-X
from	B-X
the	B-X
effect	B-X
of	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
,	B-X
which	B-X
predominantly	B-X
altered	B-X
GAGs	B-X
rather	B-X
than	B-X
O-linked	B-X
oligosaccharides	B-X
.	B-X
No	B-X
other	B-X
Arg-Gly-Asp	B-X
protein	B-X
(	B-X
fibronectin	B-X
,	B-X
vitronectin	B-X
,	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
osteopontin	B-X
,	B-X
and	B-X
bone	B-X
sialoprotein	B-X
)	B-X
showed	B-X
any	B-X
detectable	B-X
effect	B-X
on	B-X
PG	B-X
metabolism	B-X
in	B-X
bone	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
proper	B-X
matrix	B-X
stoichiometry	B-X
is	B-X
critical	B-X
for	B-X
metabolism	B-X
of	B-X
PGs	B-X
.	B-X

These	O
results	O
indicate	O
that	O
a	O
proper	O
matrix	O
stoichiometry	O
is	O
critical	O
for	O
metabolism	O
of	O
PGs	O
.	O
<EOS>	B-X
Proteoglycans	B-X
(	B-X
PGs	B-X
)	B-X
are	B-X
a	B-X
family	B-X
of	B-X
molecules	B-X
that	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
modifications	B-X
that	B-X
include	B-X
addition	B-X
of	B-X
glycosaminoglycan	B-X
(	B-X
GAG	B-X
)	B-X
chains	B-X
as	B-X
well	B-X
as	B-X
N-	B-X
and	B-X
O-linked	B-X
oligosaccharides	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
the	B-X
post-translational	B-X
modifications	B-X
to	B-X
PGs	B-X
can	B-X
serve	B-X
as	B-X
in	B-X
vitro	B-X
surrogate	B-X
end	B-X
point	B-X
markers	B-X
for	B-X
chronological	B-X
age	B-X
,	B-X
the	B-X
extent	B-X
of	B-X
GAG	B-X
modifications	B-X
was	B-X
determined	B-X
for	B-X
PGs	B-X
derived	B-X
from	B-X
normal	B-X
human	B-X
bone	B-X
cells	B-X
of	B-X
14	B-X
donors	B-X
(	B-X
age	B-X
range	B-X
,	B-X
fetal	B-X
to	B-X
60	B-X
years	B-X
)	B-X
.	B-X
A	B-X
growth	B-X
matrix	B-X
rich	B-X
in	B-X
thrombospondin	B-X
altered	B-X
PG	B-X
metabolism	B-X
in	B-X
osteoblastic	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
the	B-X
fetal-like	B-X
(	B-X
rich	B-X
in	B-X
O-linked	B-X
oligosaccharides	B-X
)	B-X
forms	B-X
of	B-X
decorin	B-X
and	B-X
biglycan	B-X
.	B-X
No	B-X
other	B-X
Arg-Gly-Asp	B-X
protein	B-X
(	B-X
fibronectin	B-X
,	B-X
vitronectin	B-X
,	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
osteopontin	B-X
,	B-X
and	B-X
bone	B-X
sialoprotein	B-X
)	B-X
showed	B-X
any	B-X
detectable	B-X
effect	B-X
on	B-X
PG	B-X
metabolism	B-X
in	B-X
bone	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
proper	B-X
matrix	B-X
stoichiometry	B-X
is	B-X
critical	B-X
for	B-X
metabolism	B-X
of	B-X
PGs	B-X
.	B-X

Expression	O
and	O
characterization	O
of	O
recombinant	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
glutamyl	I-Protein
carboxylase	I-Protein
from	O
an	O
invertebrate	O
,	O
Conus	O
textile	O
.	O
<EOS>	B-X
The	B-X
marine	B-X
snail	B-X
Conus	B-X
is	B-X
the	B-X
sole	B-X
invertebrate	B-X
wherein	B-X
both	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
and	B-X
its	B-X
product	B-X
,	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
To	B-X
examine	B-X
its	B-X
biosynthesis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
carboxylase	B-X
from	B-X
Conus	B-X
venom	B-X
ducts	B-X
.	B-X
The	B-X
carboxylase	B-X
cDNA	B-X
from	B-X
Conus	B-X
textile	B-X
has	B-X
an	B-X
ORF	B-X
that	B-X
encodes	B-X
a	B-X
811-amino-acid	B-X
protein	B-X
which	B-X
exhibits	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
vertebrate	B-X
carboxylases	B-X
,	B-X
with	B-X
41	B-X
%	B-X
identity	B-X
and	B-X
approximately	B-X
60	B-X
%	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
bovine	B-X
carboxylase	B-X
.	B-X
Expression	B-X
of	B-X
this	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
or	B-X
insect	B-X
cells	B-X
yielded	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
activity	B-X
and	B-X
vitamin	B-X
K-dependent	B-X
epoxidase	B-X
activity	B-X
.	B-X
The	B-X
recombinant	B-X
carboxylase	B-X
has	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
130	B-X
kDa	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
carboxylated	B-X
Phe-Leu-Glu-Glu-Leu	B-X
and	B-X
the	B-X
28-residue	B-X
peptides	B-X
based	B-X
on	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
human	B-X
proprothrombin	B-X
and	B-X
proFactor	B-X
IX	B-X
with	B-X
Km	B-X
values	B-X
of	B-X
420	B-X
micro	B-X
m	B-X
,	B-X
1.7	B-X
micro	B-X
m	B-X
and	B-X
6	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
;	B-X
the	B-X
Km	B-X
for	B-X
vitamin	B-X
K	B-X
is	B-X
52	B-X
micro	B-X
m.	B-X
The	B-X
Km	B-X
values	B-X
for	B-X
peptides	B-X
based	B-X
on	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
conotoxin	B-X
epsilon-TxIX	B-X
and	B-X
two	B-X
precursor	B-X
analogs	B-X
containing	B-X
12	B-X
or	B-X
29	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
propeptide	B-X
region	B-X
are	B-X
565	B-X
micro	B-X
m	B-X
,	B-X
75	B-X
micro	B-X
m	B-X
and	B-X
74	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
endogenous	B-X
substrates	B-X
,	B-X
is	B-X
stimulated	B-X
up	B-X
to	B-X
fivefold	B-X
by	B-X
vertebrate	B-X
propeptides	B-X
but	B-X
not	B-X
by	B-X
Conus	B-X
propeptides	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
two	B-X
propeptide-binding	B-X
sites	B-X
in	B-X
the	B-X
carboxylase	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
the	B-X
Conus	B-X
and	B-X
vertebrate	B-X
propeptides	B-X
and	B-X
is	B-X
required	B-X
for	B-X
substrate	B-X
binding	B-X
,	B-X
and	B-X
the	B-X
other	B-X
that	B-X
binds	B-X
only	B-X
the	B-X
vertebrate	B-X
propeptide	B-X
and	B-X
is	B-X
required	B-X
for	B-X
enzyme	B-X
stimulation	B-X
.	B-X
The	B-X
marked	B-X
functional	B-X
and	B-X
structural	B-X
similarities	B-X
between	B-X
the	B-X
Conus	B-X
carboxylase	B-X
and	B-X
vertebrate	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylases	B-X
argue	B-X
for	B-X
conservation	B-X
of	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
across	B-X
animal	B-X
species	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
synthesis	B-X
in	B-X
diverse	B-X
biological	B-X
systems	B-X
.	B-X

The	O
marine	O
snail	O
Conus	O
is	O
the	O
sole	O
invertebrate	O
wherein	O
both	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
and	O
its	O
product	O
,	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
have	O
been	O
identified	O
.	O
<EOS>	B-X
The	B-X
marine	B-X
snail	B-X
Conus	B-X
is	B-X
the	B-X
sole	B-X
invertebrate	B-X
wherein	B-X
both	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
and	B-X
its	B-X
product	B-X
,	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
To	B-X
examine	B-X
its	B-X
biosynthesis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
carboxylase	B-X
from	B-X
Conus	B-X
venom	B-X
ducts	B-X
.	B-X
The	B-X
carboxylase	B-X
cDNA	B-X
from	B-X
Conus	B-X
textile	B-X
has	B-X
an	B-X
ORF	B-X
that	B-X
encodes	B-X
a	B-X
811-amino-acid	B-X
protein	B-X
which	B-X
exhibits	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
vertebrate	B-X
carboxylases	B-X
,	B-X
with	B-X
41	B-X
%	B-X
identity	B-X
and	B-X
approximately	B-X
60	B-X
%	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
bovine	B-X
carboxylase	B-X
.	B-X
Expression	B-X
of	B-X
this	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
or	B-X
insect	B-X
cells	B-X
yielded	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
activity	B-X
and	B-X
vitamin	B-X
K-dependent	B-X
epoxidase	B-X
activity	B-X
.	B-X
The	B-X
recombinant	B-X
carboxylase	B-X
has	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
130	B-X
kDa	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
carboxylated	B-X
Phe-Leu-Glu-Glu-Leu	B-X
and	B-X
the	B-X
28-residue	B-X
peptides	B-X
based	B-X
on	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
human	B-X
proprothrombin	B-X
and	B-X
proFactor	B-X
IX	B-X
with	B-X
Km	B-X
values	B-X
of	B-X
420	B-X
micro	B-X
m	B-X
,	B-X
1.7	B-X
micro	B-X
m	B-X
and	B-X
6	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
;	B-X
the	B-X
Km	B-X
for	B-X
vitamin	B-X
K	B-X
is	B-X
52	B-X
micro	B-X
m.	B-X
The	B-X
Km	B-X
values	B-X
for	B-X
peptides	B-X
based	B-X
on	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
conotoxin	B-X
epsilon-TxIX	B-X
and	B-X
two	B-X
precursor	B-X
analogs	B-X
containing	B-X
12	B-X
or	B-X
29	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
propeptide	B-X
region	B-X
are	B-X
565	B-X
micro	B-X
m	B-X
,	B-X
75	B-X
micro	B-X
m	B-X
and	B-X
74	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
endogenous	B-X
substrates	B-X
,	B-X
is	B-X
stimulated	B-X
up	B-X
to	B-X
fivefold	B-X
by	B-X
vertebrate	B-X
propeptides	B-X
but	B-X
not	B-X
by	B-X
Conus	B-X
propeptides	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
two	B-X
propeptide-binding	B-X
sites	B-X
in	B-X
the	B-X
carboxylase	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
the	B-X
Conus	B-X
and	B-X
vertebrate	B-X
propeptides	B-X
and	B-X
is	B-X
required	B-X
for	B-X
substrate	B-X
binding	B-X
,	B-X
and	B-X
the	B-X
other	B-X
that	B-X
binds	B-X
only	B-X
the	B-X
vertebrate	B-X
propeptide	B-X
and	B-X
is	B-X
required	B-X
for	B-X
enzyme	B-X
stimulation	B-X
.	B-X
The	B-X
marked	B-X
functional	B-X
and	B-X
structural	B-X
similarities	B-X
between	B-X
the	B-X
Conus	B-X
carboxylase	B-X
and	B-X
vertebrate	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylases	B-X
argue	B-X
for	B-X
conservation	B-X
of	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
across	B-X
animal	B-X
species	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
synthesis	B-X
in	B-X
diverse	B-X
biological	B-X
systems	B-X
.	B-X

To	O
examine	O
its	O
biosynthesis	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
we	O
studied	O
the	O
carboxylase	B-Protein
from	O
Conus	O
venom	O
ducts	O
.	O
<EOS>	B-X
The	B-X
marine	B-X
snail	B-X
Conus	B-X
is	B-X
the	B-X
sole	B-X
invertebrate	B-X
wherein	B-X
both	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
and	B-X
its	B-X
product	B-X
,	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
To	B-X
examine	B-X
its	B-X
biosynthesis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
carboxylase	B-X
from	B-X
Conus	B-X
venom	B-X
ducts	B-X
.	B-X
The	B-X
carboxylase	B-X
cDNA	B-X
from	B-X
Conus	B-X
textile	B-X
has	B-X
an	B-X
ORF	B-X
that	B-X
encodes	B-X
a	B-X
811-amino-acid	B-X
protein	B-X
which	B-X
exhibits	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
vertebrate	B-X
carboxylases	B-X
,	B-X
with	B-X
41	B-X
%	B-X
identity	B-X
and	B-X
approximately	B-X
60	B-X
%	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
bovine	B-X
carboxylase	B-X
.	B-X
Expression	B-X
of	B-X
this	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
or	B-X
insect	B-X
cells	B-X
yielded	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
activity	B-X
and	B-X
vitamin	B-X
K-dependent	B-X
epoxidase	B-X
activity	B-X
.	B-X
The	B-X
recombinant	B-X
carboxylase	B-X
has	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
130	B-X
kDa	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
carboxylated	B-X
Phe-Leu-Glu-Glu-Leu	B-X
and	B-X
the	B-X
28-residue	B-X
peptides	B-X
based	B-X
on	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
human	B-X
proprothrombin	B-X
and	B-X
proFactor	B-X
IX	B-X
with	B-X
Km	B-X
values	B-X
of	B-X
420	B-X
micro	B-X
m	B-X
,	B-X
1.7	B-X
micro	B-X
m	B-X
and	B-X
6	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
;	B-X
the	B-X
Km	B-X
for	B-X
vitamin	B-X
K	B-X
is	B-X
52	B-X
micro	B-X
m.	B-X
The	B-X
Km	B-X
values	B-X
for	B-X
peptides	B-X
based	B-X
on	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
conotoxin	B-X
epsilon-TxIX	B-X
and	B-X
two	B-X
precursor	B-X
analogs	B-X
containing	B-X
12	B-X
or	B-X
29	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
propeptide	B-X
region	B-X
are	B-X
565	B-X
micro	B-X
m	B-X
,	B-X
75	B-X
micro	B-X
m	B-X
and	B-X
74	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
endogenous	B-X
substrates	B-X
,	B-X
is	B-X
stimulated	B-X
up	B-X
to	B-X
fivefold	B-X
by	B-X
vertebrate	B-X
propeptides	B-X
but	B-X
not	B-X
by	B-X
Conus	B-X
propeptides	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
two	B-X
propeptide-binding	B-X
sites	B-X
in	B-X
the	B-X
carboxylase	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
the	B-X
Conus	B-X
and	B-X
vertebrate	B-X
propeptides	B-X
and	B-X
is	B-X
required	B-X
for	B-X
substrate	B-X
binding	B-X
,	B-X
and	B-X
the	B-X
other	B-X
that	B-X
binds	B-X
only	B-X
the	B-X
vertebrate	B-X
propeptide	B-X
and	B-X
is	B-X
required	B-X
for	B-X
enzyme	B-X
stimulation	B-X
.	B-X
The	B-X
marked	B-X
functional	B-X
and	B-X
structural	B-X
similarities	B-X
between	B-X
the	B-X
Conus	B-X
carboxylase	B-X
and	B-X
vertebrate	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylases	B-X
argue	B-X
for	B-X
conservation	B-X
of	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
across	B-X
animal	B-X
species	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
synthesis	B-X
in	B-X
diverse	B-X
biological	B-X
systems	B-X
.	B-X

The	O
carboxylase	B-Protein
cDNA	O
from	O
Conus	O
textile	O
has	O
an	O
ORF	O
that	O
encodes	O
a	O
811	O
-	O
amino	O
-	O
acid	O
protein	O
which	O
exhibits	O
sequence	O
similarity	O
to	O
the	O
vertebrate	O
carboxylases	O
,	O
with	O
41	O
%	O
identity	O
and	O
approximately	O
60	O
%	O
sequence	O
similarity	O
to	O
the	O
bovine	O
carboxylase	O
.	O

Expression	O
of	O
this	O
cDNA	O
in	O
COS	O
cells	O
or	O
insect	O
cells	O
yielded	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
activity	O
and	O
vitamin	O
K	O
-	O
dependent	O
epoxidase	O
activity	O
.	O
<EOS>	B-X
Calmodulin-dependent	B-X
nitric-oxide	B-X
synthase	B-X
,	B-X
with	B-X
an	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
125	B-X
kDa	B-X
,	B-X
was	B-X
induced	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
rats	B-X
treated	B-X
with	B-X
Propionibacterium	B-X
acnes	B-X
and	B-X
Escherichia	B-X
coli	B-X
lipopolysaccharide	B-X
.	B-X
Clones	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
cDNA	B-X
library	B-X
obtained	B-X
from	B-X
induced	B-X
rat	B-X
liver	B-X
using	B-X
oligonucleotide	B-X
probes	B-X
which	B-X
were	B-X
synthesized	B-X
based	B-X
on	B-X
the	B-X
amino	B-X
acid	B-X
sequences	B-X
of	B-X
peptides	B-X
of	B-X
the	B-X
purified	B-X
enzyme	B-X
.	B-X
Four	B-X
overlapping	B-X
cDNA	B-X
clones	B-X
for	B-X
a	B-X
3.8-kbp	B-X
region	B-X
were	B-X
isolated	B-X
and	B-X
the	B-X
nucleotide	B-X
sequences	B-X
were	B-X
determined	B-X
.	B-X
The	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
cDNA	B-X
suggested	B-X
that	B-X
the	B-X
protein	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
NADPH	B-X
,	B-X
FAD	B-X
and	B-X
FMN	B-X
.	B-X
The	B-X
full-length	B-X
cDNA	B-X
was	B-X
expressed	B-X
in	B-X
COS	B-X
1	B-X
cells	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
cytomegalovirus	B-X
promoter	B-X
and	B-X
the	B-X
expressed	B-X
enzyme	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
calmodulin-dependent	B-X
nitric-oxide	B-X
synthase	B-X
.	B-X

The	O
recombinant	O
carboxylase	B-Protein
has	O
a	O
molecular	O
mass	O
of	O
approximately	O
130	O
kDa	O
.	O

The	O
recombinant	O
Conus	O
carboxylase	B-Protein
carboxylated	O
Phe	O
-	O
Leu	O
-	O
Glu	O
-	O
Glu	O
-	O
Leu	O
and	O
the	O
28	O
-	O
residue	O
peptides	O
based	O
on	O
residues	O
-	O
18	O
to	O
+	O
10	O
of	O
human	O
proprothrombin	B-Protein
and	O
proFactor	B-Protein
IX	I-Protein
with	O
Km	O
values	O
of	O
420	O
micro	O
m	O
,	O
1	O
.	O
7	O
micro	O
m	O
and	O
6	O
micro	O
m	O
,	O
respectively	O
;	O
the	O
Km	O
for	O
vitamin	O
K	O
is	O
52	O
micro	O
m	O
.	O
<EOS>	B-X
The	B-X
marine	B-X
snail	B-X
Conus	B-X
is	B-X
the	B-X
sole	B-X
invertebrate	B-X
wherein	B-X
both	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
and	B-X
its	B-X
product	B-X
,	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
To	B-X
examine	B-X
its	B-X
biosynthesis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
carboxylase	B-X
from	B-X
Conus	B-X
venom	B-X
ducts	B-X
.	B-X
The	B-X
carboxylase	B-X
cDNA	B-X
from	B-X
Conus	B-X
textile	B-X
has	B-X
an	B-X
ORF	B-X
that	B-X
encodes	B-X
a	B-X
811-amino-acid	B-X
protein	B-X
which	B-X
exhibits	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
vertebrate	B-X
carboxylases	B-X
,	B-X
with	B-X
41	B-X
%	B-X
identity	B-X
and	B-X
approximately	B-X
60	B-X
%	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
bovine	B-X
carboxylase	B-X
.	B-X
Expression	B-X
of	B-X
this	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
or	B-X
insect	B-X
cells	B-X
yielded	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
activity	B-X
and	B-X
vitamin	B-X
K-dependent	B-X
epoxidase	B-X
activity	B-X
.	B-X
The	B-X
recombinant	B-X
carboxylase	B-X
has	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
130	B-X
kDa	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
carboxylated	B-X
Phe-Leu-Glu-Glu-Leu	B-X
and	B-X
the	B-X
28-residue	B-X
peptides	B-X
based	B-X
on	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
human	B-X
proprothrombin	B-X
and	B-X
proFactor	B-X
IX	B-X
with	B-X
Km	B-X
values	B-X
of	B-X
420	B-X
micro	B-X
m	B-X
,	B-X
1.7	B-X
micro	B-X
m	B-X
and	B-X
6	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
;	B-X
the	B-X
Km	B-X
for	B-X
vitamin	B-X
K	B-X
is	B-X
52	B-X
micro	B-X
m.	B-X
The	B-X
Km	B-X
values	B-X
for	B-X
peptides	B-X
based	B-X
on	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
conotoxin	B-X
epsilon-TxIX	B-X
and	B-X
two	B-X
precursor	B-X
analogs	B-X
containing	B-X
12	B-X
or	B-X
29	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
propeptide	B-X
region	B-X
are	B-X
565	B-X
micro	B-X
m	B-X
,	B-X
75	B-X
micro	B-X
m	B-X
and	B-X
74	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
endogenous	B-X
substrates	B-X
,	B-X
is	B-X
stimulated	B-X
up	B-X
to	B-X
fivefold	B-X
by	B-X
vertebrate	B-X
propeptides	B-X
but	B-X
not	B-X
by	B-X
Conus	B-X
propeptides	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
two	B-X
propeptide-binding	B-X
sites	B-X
in	B-X
the	B-X
carboxylase	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
the	B-X
Conus	B-X
and	B-X
vertebrate	B-X
propeptides	B-X
and	B-X
is	B-X
required	B-X
for	B-X
substrate	B-X
binding	B-X
,	B-X
and	B-X
the	B-X
other	B-X
that	B-X
binds	B-X
only	B-X
the	B-X
vertebrate	B-X
propeptide	B-X
and	B-X
is	B-X
required	B-X
for	B-X
enzyme	B-X
stimulation	B-X
.	B-X
The	B-X
marked	B-X
functional	B-X
and	B-X
structural	B-X
similarities	B-X
between	B-X
the	B-X
Conus	B-X
carboxylase	B-X
and	B-X
vertebrate	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylases	B-X
argue	B-X
for	B-X
conservation	B-X
of	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
across	B-X
animal	B-X
species	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
synthesis	B-X
in	B-X
diverse	B-X
biological	B-X
systems	B-X
.	B-X

The	O
Km	O
values	O
for	O
peptides	O
based	O
on	O
the	O
sequence	O
of	O
the	O
conotoxin	B-Protein
epsilon	I-Protein
-	I-Protein
TxIX	I-Protein
and	O
two	O
precursor	O
analogs	O
containing	O
12	O
or	O
29	O
amino	O
acids	O
of	O
the	O
propeptide	O
region	O
are	O
565	O
micro	O
m	O
,	O
75	O
micro	O
m	O
and	O
74	O
micro	O
m	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
carboxylase	B-X
cDNA	B-X
from	B-X
Conus	B-X
textile	B-X
has	B-X
an	B-X
ORF	B-X
that	B-X
encodes	B-X
a	B-X
811-amino-acid	B-X
protein	B-X
which	B-X
exhibits	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
vertebrate	B-X
carboxylases	B-X
,	B-X
with	B-X
41	B-X
%	B-X
identity	B-X
and	B-X
approximately	B-X
60	B-X
%	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
bovine	B-X
carboxylase	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
carboxylated	B-X
Phe-Leu-Glu-Glu-Leu	B-X
and	B-X
the	B-X
28-residue	B-X
peptides	B-X
based	B-X
on	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
human	B-X
proprothrombin	B-X
and	B-X
proFactor	B-X
IX	B-X
with	B-X
Km	B-X
values	B-X
of	B-X
420	B-X
micro	B-X
m	B-X
,	B-X
1.7	B-X
micro	B-X
m	B-X
and	B-X
6	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
;	B-X
the	B-X
Km	B-X
for	B-X
vitamin	B-X
K	B-X
is	B-X
52	B-X
micro	B-X
m.	B-X
The	B-X
Km	B-X
values	B-X
for	B-X
peptides	B-X
based	B-X
on	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
conotoxin	B-X
epsilon-TxIX	B-X
and	B-X
two	B-X
precursor	B-X
analogs	B-X
containing	B-X
12	B-X
or	B-X
29	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
propeptide	B-X
region	B-X
are	B-X
565	B-X
micro	B-X
m	B-X
,	B-X
75	B-X
micro	B-X
m	B-X
and	B-X
74	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
endogenous	B-X
substrates	B-X
,	B-X
is	B-X
stimulated	B-X
up	B-X
to	B-X
fivefold	B-X
by	B-X
vertebrate	B-X
propeptides	B-X
but	B-X
not	B-X
by	B-X
Conus	B-X
propeptides	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
two	B-X
propeptide-binding	B-X
sites	B-X
in	B-X
the	B-X
carboxylase	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
the	B-X
Conus	B-X
and	B-X
vertebrate	B-X
propeptides	B-X
and	B-X
is	B-X
required	B-X
for	B-X
substrate	B-X
binding	B-X
,	B-X
and	B-X
the	B-X
other	B-X
that	B-X
binds	B-X
only	B-X
the	B-X
vertebrate	B-X
propeptide	B-X
and	B-X
is	B-X
required	B-X
for	B-X
enzyme	B-X
stimulation	B-X
.	B-X

The	O
recombinant	O
Conus	O
carboxylase	B-Protein
,	O
in	O
the	O
absence	O
of	O
endogenous	O
substrates	O
,	O
is	O
stimulated	O
up	O
to	O
fivefold	O
by	O
vertebrate	O
propeptides	O
but	O
not	O
by	O
Conus	O
propeptides	O
.	O

These	O
results	O
suggest	O
two	O
propeptide	O
-	O
binding	O
sites	O
in	O
the	O
carboxylase	B-Protein
,	O
one	O
that	O
binds	O
the	O
Conus	O
and	O
vertebrate	O
propeptides	O
and	O
is	O
required	O
for	O
substrate	O
binding	O
,	O
and	O
the	O
other	O
that	O
binds	O
only	O
the	O
vertebrate	O
propeptide	O
and	O
is	O
required	O
for	O
enzyme	O
stimulation	O
.	O
<EOS>	B-X
The	B-X
marine	B-X
snail	B-X
Conus	B-X
is	B-X
the	B-X
sole	B-X
invertebrate	B-X
wherein	B-X
both	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
and	B-X
its	B-X
product	B-X
,	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
To	B-X
examine	B-X
its	B-X
biosynthesis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
carboxylase	B-X
from	B-X
Conus	B-X
venom	B-X
ducts	B-X
.	B-X
The	B-X
carboxylase	B-X
cDNA	B-X
from	B-X
Conus	B-X
textile	B-X
has	B-X
an	B-X
ORF	B-X
that	B-X
encodes	B-X
a	B-X
811-amino-acid	B-X
protein	B-X
which	B-X
exhibits	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
vertebrate	B-X
carboxylases	B-X
,	B-X
with	B-X
41	B-X
%	B-X
identity	B-X
and	B-X
approximately	B-X
60	B-X
%	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
bovine	B-X
carboxylase	B-X
.	B-X
Expression	B-X
of	B-X
this	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
or	B-X
insect	B-X
cells	B-X
yielded	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
activity	B-X
and	B-X
vitamin	B-X
K-dependent	B-X
epoxidase	B-X
activity	B-X
.	B-X
The	B-X
recombinant	B-X
carboxylase	B-X
has	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
130	B-X
kDa	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
carboxylated	B-X
Phe-Leu-Glu-Glu-Leu	B-X
and	B-X
the	B-X
28-residue	B-X
peptides	B-X
based	B-X
on	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
human	B-X
proprothrombin	B-X
and	B-X
proFactor	B-X
IX	B-X
with	B-X
Km	B-X
values	B-X
of	B-X
420	B-X
micro	B-X
m	B-X
,	B-X
1.7	B-X
micro	B-X
m	B-X
and	B-X
6	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
;	B-X
the	B-X
Km	B-X
for	B-X
vitamin	B-X
K	B-X
is	B-X
52	B-X
micro	B-X
m.	B-X
The	B-X
Km	B-X
values	B-X
for	B-X
peptides	B-X
based	B-X
on	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
conotoxin	B-X
epsilon-TxIX	B-X
and	B-X
two	B-X
precursor	B-X
analogs	B-X
containing	B-X
12	B-X
or	B-X
29	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
propeptide	B-X
region	B-X
are	B-X
565	B-X
micro	B-X
m	B-X
,	B-X
75	B-X
micro	B-X
m	B-X
and	B-X
74	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
endogenous	B-X
substrates	B-X
,	B-X
is	B-X
stimulated	B-X
up	B-X
to	B-X
fivefold	B-X
by	B-X
vertebrate	B-X
propeptides	B-X
but	B-X
not	B-X
by	B-X
Conus	B-X
propeptides	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
two	B-X
propeptide-binding	B-X
sites	B-X
in	B-X
the	B-X
carboxylase	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
the	B-X
Conus	B-X
and	B-X
vertebrate	B-X
propeptides	B-X
and	B-X
is	B-X
required	B-X
for	B-X
substrate	B-X
binding	B-X
,	B-X
and	B-X
the	B-X
other	B-X
that	B-X
binds	B-X
only	B-X
the	B-X
vertebrate	B-X
propeptide	B-X
and	B-X
is	B-X
required	B-X
for	B-X
enzyme	B-X
stimulation	B-X
.	B-X
The	B-X
marked	B-X
functional	B-X
and	B-X
structural	B-X
similarities	B-X
between	B-X
the	B-X
Conus	B-X
carboxylase	B-X
and	B-X
vertebrate	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylases	B-X
argue	B-X
for	B-X
conservation	B-X
of	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
across	B-X
animal	B-X
species	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
synthesis	B-X
in	B-X
diverse	B-X
biological	B-X
systems	B-X
.	B-X

The	O
marked	O
functional	O
and	O
structural	O
similarities	O
between	O
the	O
Conus	O
carboxylase	B-Protein
and	O
vertebrate	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylases	I-Protein
argue	O
for	O
conservation	O
of	O
a	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
across	O
animal	O
species	O
and	O
the	O
importance	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
synthesis	O
in	O
diverse	O
biological	O
systems	O
.	O
<EOS>	B-X
The	B-X
marine	B-X
snail	B-X
Conus	B-X
is	B-X
the	B-X
sole	B-X
invertebrate	B-X
wherein	B-X
both	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
and	B-X
its	B-X
product	B-X
,	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
To	B-X
examine	B-X
its	B-X
biosynthesis	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
carboxylase	B-X
from	B-X
Conus	B-X
venom	B-X
ducts	B-X
.	B-X
The	B-X
carboxylase	B-X
cDNA	B-X
from	B-X
Conus	B-X
textile	B-X
has	B-X
an	B-X
ORF	B-X
that	B-X
encodes	B-X
a	B-X
811-amino-acid	B-X
protein	B-X
which	B-X
exhibits	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
vertebrate	B-X
carboxylases	B-X
,	B-X
with	B-X
41	B-X
%	B-X
identity	B-X
and	B-X
approximately	B-X
60	B-X
%	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
bovine	B-X
carboxylase	B-X
.	B-X
Expression	B-X
of	B-X
this	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
or	B-X
insect	B-X
cells	B-X
yielded	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
activity	B-X
and	B-X
vitamin	B-X
K-dependent	B-X
epoxidase	B-X
activity	B-X
.	B-X
The	B-X
recombinant	B-X
carboxylase	B-X
has	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
130	B-X
kDa	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
carboxylated	B-X
Phe-Leu-Glu-Glu-Leu	B-X
and	B-X
the	B-X
28-residue	B-X
peptides	B-X
based	B-X
on	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
human	B-X
proprothrombin	B-X
and	B-X
proFactor	B-X
IX	B-X
with	B-X
Km	B-X
values	B-X
of	B-X
420	B-X
micro	B-X
m	B-X
,	B-X
1.7	B-X
micro	B-X
m	B-X
and	B-X
6	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
;	B-X
the	B-X
Km	B-X
for	B-X
vitamin	B-X
K	B-X
is	B-X
52	B-X
micro	B-X
m.	B-X
The	B-X
Km	B-X
values	B-X
for	B-X
peptides	B-X
based	B-X
on	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
conotoxin	B-X
epsilon-TxIX	B-X
and	B-X
two	B-X
precursor	B-X
analogs	B-X
containing	B-X
12	B-X
or	B-X
29	B-X
amino	B-X
acids	B-X
of	B-X
the	B-X
propeptide	B-X
region	B-X
are	B-X
565	B-X
micro	B-X
m	B-X
,	B-X
75	B-X
micro	B-X
m	B-X
and	B-X
74	B-X
micro	B-X
m	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
recombinant	B-X
Conus	B-X
carboxylase	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
endogenous	B-X
substrates	B-X
,	B-X
is	B-X
stimulated	B-X
up	B-X
to	B-X
fivefold	B-X
by	B-X
vertebrate	B-X
propeptides	B-X
but	B-X
not	B-X
by	B-X
Conus	B-X
propeptides	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
two	B-X
propeptide-binding	B-X
sites	B-X
in	B-X
the	B-X
carboxylase	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
the	B-X
Conus	B-X
and	B-X
vertebrate	B-X
propeptides	B-X
and	B-X
is	B-X
required	B-X
for	B-X
substrate	B-X
binding	B-X
,	B-X
and	B-X
the	B-X
other	B-X
that	B-X
binds	B-X
only	B-X
the	B-X
vertebrate	B-X
propeptide	B-X
and	B-X
is	B-X
required	B-X
for	B-X
enzyme	B-X
stimulation	B-X
.	B-X
The	B-X
marked	B-X
functional	B-X
and	B-X
structural	B-X
similarities	B-X
between	B-X
the	B-X
Conus	B-X
carboxylase	B-X
and	B-X
vertebrate	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylases	B-X
argue	B-X
for	B-X
conservation	B-X
of	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
across	B-X
animal	B-X
species	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
synthesis	B-X
in	B-X
diverse	B-X
biological	B-X
systems	B-X
.	B-X

Cholesterol	O
-	O
modulating	O
agents	O
kill	O
acute	O
myeloid	O
leukemia	O
cells	O
and	O
sensitize	O
them	O
to	O
therapeutics	O
by	O
blocking	O
adaptive	O
cholesterol	O
responses	O
.	O
<EOS>	B-X
The	B-X
mevalonate	B-X
pathway	B-X
produces	B-X
many	B-X
critical	B-X
substances	B-X
in	B-X
cells	B-X
,	B-X
including	B-X
sterols	B-X
essential	B-X
for	B-X
membrane	B-X
structure	B-X
and	B-X
isoprenoids	B-X
vital	B-X
to	B-X
the	B-X
function	B-X
of	B-X
many	B-X
membrane	B-X
proteins	B-X
.	B-X
Because	B-X
cholesterol	B-X
is	B-X
a	B-X
product	B-X
of	B-X
this	B-X
pathway	B-X
,	B-X
HMG-CoA	B-X
reductase	B-X
inhibitors	B-X
(	B-X
statins	B-X
)	B-X
are	B-X
used	B-X
to	B-X
treat	B-X
hypercholesterolemia	B-X
.	B-X
Statins	B-X
are	B-X
also	B-X
toxic	B-X
to	B-X
several	B-X
malignancies	B-X
,	B-X
including	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
.	B-X
Although	B-X
this	B-X
toxicity	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
Ras/Rho	B-X
isoprenylation	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
statin	B-X
toxicity	B-X
in	B-X
primary	B-X
AML	B-X
cells	B-X
(	B-X
AMLs	B-X
)	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
Ras	B-X
isoprenylation	B-X
or	B-X
with	B-X
activating	B-X
Ras	B-X
mutations	B-X
.	B-X
In	B-X
other	B-X
studies	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
hypoxic	B-X
and	B-X
oxidant	B-X
injuries	B-X
induce	B-X
cholesterol	B-X
increments	B-X
in	B-X
renal	B-X
tubule	B-X
cells	B-X
and	B-X
that	B-X
statins	B-X
sensitize	B-X
these	B-X
cells	B-X
to	B-X
injury	B-X
by	B-X
blocking	B-X
protective	B-X
cholesterol	B-X
responses	B-X
.	B-X
We	B-X
now	B-X
demonstrate	B-X
that	B-X
exposing	B-X
particular	B-X
AMLs	B-X
to	B-X
radiochemotherapy	B-X
induces	B-X
much	B-X
greater	B-X
cellular	B-X
cholesterol	B-X
increments	B-X
than	B-X
those	B-X
seen	B-X
in	B-X
similarly	B-X
treated	B-X
normal	B-X
bone	B-X
marrow	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
AMLs	B-X
with	B-X
mevastatin	B-X
or	B-X
zaragozic	B-X
acid	B-X
(	B-X
which	B-X
inhibits	B-X
cholesterol	B-X
synthesis	B-X
but	B-X
not	B-X
isoprenoid	B-X
synthesis	B-X
)	B-X
attenuates	B-X
the	B-X
cholesterol	B-X
increments	B-X
and	B-X
sensitizes	B-X
cells	B-X
to	B-X
radiochemotherapy	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
toxicity	B-X
is	B-X
affected	B-X
by	B-X
the	B-X
availability	B-X
of	B-X
extracellular	B-X
lipoproteins	B-X
,	B-X
further	B-X
suggesting	B-X
that	B-X
cellular	B-X
cholesterol	B-X
is	B-X
critical	B-X
to	B-X
cell	B-X
survival	B-X
in	B-X
particular	B-X
AMLs	B-X
.	B-X
Because	B-X
zaragozic	B-X
acid	B-X
does	B-X
not	B-X
inhibit	B-X
isoprenoid	B-X
synthesis	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
cholesterol	B-X
modulation	B-X
is	B-X
an	B-X
important	B-X
mechanism	B-X
whereby	B-X
statins	B-X
exert	B-X
toxic	B-X
effects	B-X
on	B-X
some	B-X
AMLs	B-X
and	B-X
that	B-X
cholesterol	B-X
modulators	B-X
may	B-X
improve	B-X
therapeutic	B-X
ratios	B-X
in	B-X
AML	B-X
by	B-X
impacting	B-X
cholesterol-dependent	B-X
cytoresistance	B-X
.	B-X

The	O
mevalonate	O
pathway	O
produces	O
many	O
critical	O
substances	O
in	O
cells	O
,	O
including	O
sterols	O
essential	O
for	O
membrane	O
structure	O
and	O
isoprenoids	O
vital	O
to	O
the	O
function	O
of	O
many	O
membrane	O
proteins	O
.	O

3	B-Protein
-	I-Protein
Hydroxy	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
methylglutaryl	I-Protein
coenzyme	I-Protein
A	I-Protein
(	I-Protein
HMG	I-Protein
-	I-Protein
CoA	I-Protein
)	I-Protein
reductase	I-Protein
is	O
a	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
mevalonate	O
pathway	O
.	O
<EOS>	B-X
Simvastatin	B-X
is	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-coenzyme	B-X
A	B-X
(	B-X
CoA	B-X
)	B-X
reductase	B-X
(	B-X
HMGCR	B-X
)	B-X
,	B-X
the	B-X
rate-limiting	B-X
enzyme	B-X
of	B-X
the	B-X
mevalonate	B-X
(	B-X
MVA	B-X
)	B-X
pathway	B-X
for	B-X
the	B-X
cholesterol	B-X
biosynthesis	B-X
.	B-X
The	B-X
3-hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
reductase	B-X
(	B-X
HMGCR	B-X
)	B-X
is	B-X
the	B-X
rate-limiting	B-X
enzyme	B-X
in	B-X
the	B-X
biosynthesis	B-X
of	B-X
cholesterol	B-X
and	B-X
isoprenoids	B-X
,	B-X
which	B-X
are	B-X
substrates	B-X
required	B-X
for	B-X
post-translational	B-X
modification	B-X
of	B-X
signalling	B-X
proteins	B-X
that	B-X
can	B-X
potentially	B-X
regulate	B-X
various	B-X
aspects	B-X
of	B-X
embryonic	B-X
development	B-X
.	B-X
The	B-X
HMGCR	B-X
transcripts	B-X
are	B-X
detectable	B-X
during	B-X
early	B-X
embryogenesis	B-X
in	B-X
both	B-X
invertebrates	B-X
and	B-X
vertebrates	B-X
,	B-X
which	B-X
suggests	B-X
a	B-X
conserved	B-X
developmental	B-X
requirement	B-X
for	B-X
mevalonate	B-X
derivatives	B-X
.	B-X
Consistently	B-X
,	B-X
recent	B-X
animal	B-X
and	B-X
in	B-X
vitro	B-X
studies	B-X
have	B-X
yielded	B-X
valuable	B-X
insights	B-X
into	B-X
potential	B-X
morphogenic	B-X
parameters	B-X
that	B-X
are	B-X
modulated	B-X
by	B-X
HMGCR	B-X
activity	B-X
.	B-X
By	B-X
providing	B-X
a	B-X
synthesis	B-X
of	B-X
these	B-X
studies	B-X
,	B-X
we	B-X
hope	B-X
that	B-X
this	B-X
review	B-X
will	B-X
highlight	B-X
the	B-X
need	B-X
to	B-X
comprehensively	B-X
examine	B-X
the	B-X
entire	B-X
suite	B-X
of	B-X
developmental	B-X
processes	B-X
regulated	B-X
by	B-X
HMGCR	B-X
.	B-X

Because	O
cholesterol	O
is	O
a	O
product	O
of	O
this	O
pathway	O
,	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
inhibitors	O
(	O
statins	O
)	O
are	O
used	O
to	O
treat	O
hypercholesterolemia	O
.	O
<EOS>	B-X
Beyond	B-X
being	B-X
aging-related	B-X
diseases	B-X
,	B-X
atherosclerosis	B-X
and	B-X
osteoporosis	B-X
share	B-X
common	B-X
pathogenetic	B-X
pathways	B-X
implicated	B-X
in	B-X
bone	B-X
and	B-X
vascular	B-X
mineralization	B-X
.	B-X
Despite	B-X
the	B-X
high	B-X
data	B-X
heterogeneity	B-X
and	B-X
the	B-X
variable	B-X
quality	B-X
of	B-X
studies	B-X
,	B-X
dyslipidemia	B-X
,	B-X
mainly	B-X
elevated	B-X
total	B-X
and	B-X
low-density	B-X
lipoprotein	B-X
cholesterol	B-X
concentrations	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
low	B-X
bone	B-X
mass	B-X
and	B-X
increased	B-X
fracture	B-X
risk	B-X
.	B-X
Moreover	B-X
,	B-X
factors	B-X
such	B-X
as	B-X
estrogen	B-X
,	B-X
vitamin	B-X
D	B-X
and	B-X
K	B-X
deficiency	B-X
,	B-X
and	B-X
increased	B-X
concentrations	B-X
of	B-X
parathyroid	B-X
hormone	B-X
,	B-X
homocysteine	B-X
and	B-X
lipid	B-X
oxidation	B-X
products	B-X
,	B-X
can	B-X
also	B-X
contribute	B-X
.	B-X
Regarding	B-X
the	B-X
effect	B-X
of	B-X
hypolipidemic	B-X
medications	B-X
on	B-X
bone	B-X
metabolism	B-X
,	B-X
statins	B-X
may	B-X
slightly	B-X
increase	B-X
BMD	B-X
and	B-X
reduce	B-X
fracture	B-X
risk	B-X
,	B-X
although	B-X
the	B-X
evidence	B-X
is	B-X
not	B-X
robust	B-X
,	B-X
as	B-X
it	B-X
is	B-X
for	B-X
omega-3	B-X
fatty	B-X
acids	B-X
.	B-X

Statins	O
are	O
also	O
toxic	O
to	O
several	O
malignancies	O
,	O
including	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O
<EOS>	B-X
Since	B-X
then	B-X
,	B-X
several	B-X
single-arm	B-X
studies	B-X
have	B-X
convincingly	B-X
demonstrated	B-X
that	B-X
IFN-alpha2	B-X
is	B-X
a	B-X
highly	B-X
potent	B-X
anti-cancer	B-X
agent	B-X
in	B-X
several	B-X
cancer	B-X
types	B-X
but	B-X
unfortunately	B-X
not	B-X
being	B-X
explored	B-X
sufficiently	B-X
due	B-X
to	B-X
a	B-X
high	B-X
toxicity	B-X
profile	B-X
when	B-X
using	B-X
non-pegylated	B-X
IFN-alpha2	B-X
or	B-X
high	B-X
dosages	B-X
or	B-X
due	B-X
to	B-X
competitive	B-X
drugs	B-X
,	B-X
that	B-X
for	B-X
clinicians	B-X
at	B-X
first	B-X
glance	B-X
might	B-X
look	B-X
more	B-X
attractive	B-X
.	B-X
Within	B-X
the	B-X
hematological	B-X
malignancies	B-X
,	B-X
IFN-alpha2	B-X
has	B-X
only	B-X
recently	B-X
been	B-X
revived	B-X
in	B-X
patients	B-X
with	B-X
the	B-X
Philadelphia-negative	B-X
myeloproliferative	B-X
neoplasms-essential	B-X
thrombocytosis	B-X
,	B-X
polycythemia	B-X
vera	B-X
,	B-X
and	B-X
myelofibrosis	B-X
(	B-X
MPNs	B-X
)	B-X
-and	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
in	B-X
combination	B-X
with	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
advanced	B-X
and	B-X
transforming	B-X
disease	B-X
towards	B-X
leukemic	B-X
transformation	B-X
or	B-X
having	B-X
transformed	B-X
to	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
,	B-X
``	B-X
triple	B-X
therapy	B-X
''	B-X
is	B-X
proposed	B-X
as	B-X
a	B-X
novel	B-X
treatment	B-X
modality	B-X
to	B-X
be	B-X
tested	B-X
in	B-X
clinical	B-X
trials	B-X
combining	B-X
IFN-alpha2	B-X
,	B-X
DNA-hypomethylator	B-X
,	B-X
and	B-X
ruxolitinib	B-X
.	B-X
The	B-X
rationale	B-X
for	B-X
this	B-X
``	B-X
triple	B-X
therapy	B-X
''	B-X
is	B-X
given	B-X
,	B-X
including	B-X
the	B-X
fact	B-X
that	B-X
even	B-X
in	B-X
AML	B-X
,	B-X
IFN-alpha2	B-X
as	B-X
monotherapy	B-X
may	B-X
revert	B-X
disease	B-X
progression	B-X
.	B-X

Although	O
this	O
toxicity	O
has	O
been	O
attributed	O
to	O
the	O
inhibition	O
of	O
Ras	O
/	O
Rho	O
isoprenylation	O
,	O
we	O
have	O
previously	O
shown	O
that	O
statin	O
toxicity	O
in	O
primary	O
AML	O
cells	O
(	O
AMLs	O
)	O
does	O
not	O
correlate	O
with	O
Ras	O
isoprenylation	O
or	O
with	O
activating	O
Ras	O
mutations	O
.	O
<EOS>	B-X
Cancers	B-X
arise	B-X
owing	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
mutations	B-X
in	B-X
critical	B-X
genes	B-X
that	B-X
alter	B-X
normal	B-X
programmes	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
differentiation	B-X
and	B-X
death	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
BRAF	B-X
somatic	B-X
missense	B-X
mutations	B-X
in	B-X
66	B-X
%	B-X
of	B-X
malignant	B-X
melanomas	B-X
and	B-X
at	B-X
lower	B-X
frequency	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
All	B-X
mutations	B-X
are	B-X
within	B-X
the	B-X
kinase	B-X
domain	B-X
,	B-X
with	B-X
a	B-X
single	B-X
substitution	B-X
(	B-X
V599E	B-X
)	B-X
accounting	B-X
for	B-X
80	B-X
%	B-X
.	B-X
Mutated	B-X
BRAF	B-X
proteins	B-X
have	B-X
elevated	B-X
kinase	B-X
activity	B-X
and	B-X
are	B-X
transforming	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X

In	O
other	O
studies	O
,	O
we	O
have	O
shown	O
that	O
hypoxic	O
and	O
oxidant	O
injuries	O
induce	O
cholesterol	O
increments	O
in	O
renal	O
tubule	O
cells	O
and	O
that	O
statins	O
sensitize	O
these	O
cells	O
to	O
injury	O
by	O
blocking	O
protective	O
cholesterol	O
responses	O
.	O
<EOS>	B-X
The	B-X
mevalonate	B-X
pathway	B-X
produces	B-X
many	B-X
critical	B-X
substances	B-X
in	B-X
cells	B-X
,	B-X
including	B-X
sterols	B-X
essential	B-X
for	B-X
membrane	B-X
structure	B-X
and	B-X
isoprenoids	B-X
vital	B-X
to	B-X
the	B-X
function	B-X
of	B-X
many	B-X
membrane	B-X
proteins	B-X
.	B-X
Because	B-X
cholesterol	B-X
is	B-X
a	B-X
product	B-X
of	B-X
this	B-X
pathway	B-X
,	B-X
HMG-CoA	B-X
reductase	B-X
inhibitors	B-X
(	B-X
statins	B-X
)	B-X
are	B-X
used	B-X
to	B-X
treat	B-X
hypercholesterolemia	B-X
.	B-X
Although	B-X
this	B-X
toxicity	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
Ras/Rho	B-X
isoprenylation	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
statin	B-X
toxicity	B-X
in	B-X
primary	B-X
AML	B-X
cells	B-X
(	B-X
AMLs	B-X
)	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
Ras	B-X
isoprenylation	B-X
or	B-X
with	B-X
activating	B-X
Ras	B-X
mutations	B-X
.	B-X
In	B-X
other	B-X
studies	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
hypoxic	B-X
and	B-X
oxidant	B-X
injuries	B-X
induce	B-X
cholesterol	B-X
increments	B-X
in	B-X
renal	B-X
tubule	B-X
cells	B-X
and	B-X
that	B-X
statins	B-X
sensitize	B-X
these	B-X
cells	B-X
to	B-X
injury	B-X
by	B-X
blocking	B-X
protective	B-X
cholesterol	B-X
responses	B-X
.	B-X
We	B-X
now	B-X
demonstrate	B-X
that	B-X
exposing	B-X
particular	B-X
AMLs	B-X
to	B-X
radiochemotherapy	B-X
induces	B-X
much	B-X
greater	B-X
cellular	B-X
cholesterol	B-X
increments	B-X
than	B-X
those	B-X
seen	B-X
in	B-X
similarly	B-X
treated	B-X
normal	B-X
bone	B-X
marrow	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
AMLs	B-X
with	B-X
mevastatin	B-X
or	B-X
zaragozic	B-X
acid	B-X
(	B-X
which	B-X
inhibits	B-X
cholesterol	B-X
synthesis	B-X
but	B-X
not	B-X
isoprenoid	B-X
synthesis	B-X
)	B-X
attenuates	B-X
the	B-X
cholesterol	B-X
increments	B-X
and	B-X
sensitizes	B-X
cells	B-X
to	B-X
radiochemotherapy	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
toxicity	B-X
is	B-X
affected	B-X
by	B-X
the	B-X
availability	B-X
of	B-X
extracellular	B-X
lipoproteins	B-X
,	B-X
further	B-X
suggesting	B-X
that	B-X
cellular	B-X
cholesterol	B-X
is	B-X
critical	B-X
to	B-X
cell	B-X
survival	B-X
in	B-X
particular	B-X
AMLs	B-X
.	B-X
Because	B-X
zaragozic	B-X
acid	B-X
does	B-X
not	B-X
inhibit	B-X
isoprenoid	B-X
synthesis	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
cholesterol	B-X
modulation	B-X
is	B-X
an	B-X
important	B-X
mechanism	B-X
whereby	B-X
statins	B-X
exert	B-X
toxic	B-X
effects	B-X
on	B-X
some	B-X
AMLs	B-X
and	B-X
that	B-X
cholesterol	B-X
modulators	B-X
may	B-X
improve	B-X
therapeutic	B-X
ratios	B-X
in	B-X
AML	B-X
by	B-X
impacting	B-X
cholesterol-dependent	B-X
cytoresistance	B-X
.	B-X

We	O
now	O
demonstrate	O
that	O
exposing	O
particular	O
AMLs	O
to	O
radiochemotherapy	O
induces	O
much	O
greater	O
cellular	O
cholesterol	O
increments	O
than	O
those	O
seen	O
in	O
similarly	O
treated	O
normal	O
bone	O
marrow	O
.	O
<EOS>	B-X
Because	B-X
cholesterol	B-X
is	B-X
a	B-X
product	B-X
of	B-X
this	B-X
pathway	B-X
,	B-X
HMG-CoA	B-X
reductase	B-X
inhibitors	B-X
(	B-X
statins	B-X
)	B-X
are	B-X
used	B-X
to	B-X
treat	B-X
hypercholesterolemia	B-X
.	B-X
Although	B-X
this	B-X
toxicity	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
Ras/Rho	B-X
isoprenylation	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
statin	B-X
toxicity	B-X
in	B-X
primary	B-X
AML	B-X
cells	B-X
(	B-X
AMLs	B-X
)	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
Ras	B-X
isoprenylation	B-X
or	B-X
with	B-X
activating	B-X
Ras	B-X
mutations	B-X
.	B-X
In	B-X
other	B-X
studies	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
hypoxic	B-X
and	B-X
oxidant	B-X
injuries	B-X
induce	B-X
cholesterol	B-X
increments	B-X
in	B-X
renal	B-X
tubule	B-X
cells	B-X
and	B-X
that	B-X
statins	B-X
sensitize	B-X
these	B-X
cells	B-X
to	B-X
injury	B-X
by	B-X
blocking	B-X
protective	B-X
cholesterol	B-X
responses	B-X
.	B-X
We	B-X
now	B-X
demonstrate	B-X
that	B-X
exposing	B-X
particular	B-X
AMLs	B-X
to	B-X
radiochemotherapy	B-X
induces	B-X
much	B-X
greater	B-X
cellular	B-X
cholesterol	B-X
increments	B-X
than	B-X
those	B-X
seen	B-X
in	B-X
similarly	B-X
treated	B-X
normal	B-X
bone	B-X
marrow	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
AMLs	B-X
with	B-X
mevastatin	B-X
or	B-X
zaragozic	B-X
acid	B-X
(	B-X
which	B-X
inhibits	B-X
cholesterol	B-X
synthesis	B-X
but	B-X
not	B-X
isoprenoid	B-X
synthesis	B-X
)	B-X
attenuates	B-X
the	B-X
cholesterol	B-X
increments	B-X
and	B-X
sensitizes	B-X
cells	B-X
to	B-X
radiochemotherapy	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
toxicity	B-X
is	B-X
affected	B-X
by	B-X
the	B-X
availability	B-X
of	B-X
extracellular	B-X
lipoproteins	B-X
,	B-X
further	B-X
suggesting	B-X
that	B-X
cellular	B-X
cholesterol	B-X
is	B-X
critical	B-X
to	B-X
cell	B-X
survival	B-X
in	B-X
particular	B-X
AMLs	B-X
.	B-X
Because	B-X
zaragozic	B-X
acid	B-X
does	B-X
not	B-X
inhibit	B-X
isoprenoid	B-X
synthesis	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
cholesterol	B-X
modulation	B-X
is	B-X
an	B-X
important	B-X
mechanism	B-X
whereby	B-X
statins	B-X
exert	B-X
toxic	B-X
effects	B-X
on	B-X
some	B-X
AMLs	B-X
and	B-X
that	B-X
cholesterol	B-X
modulators	B-X
may	B-X
improve	B-X
therapeutic	B-X
ratios	B-X
in	B-X
AML	B-X
by	B-X
impacting	B-X
cholesterol-dependent	B-X
cytoresistance	B-X
.	B-X

Treatment	O
of	O
these	O
AMLs	O
with	O
mevastatin	O
or	O
zaragozic	O
acid	O
(	O
which	O
inhibits	O
cholesterol	O
synthesis	O
but	O
not	O
isoprenoid	O
synthesis	O
)	O
attenuates	O
the	O
cholesterol	O
increments	O
and	O
sensitizes	O
cells	O
to	O
radiochemotherapy	O
.	O

The	O
extent	O
of	O
toxicity	O
is	O
affected	O
by	O
the	O
availability	O
of	O
extracellular	O
lipoproteins	O
,	O
further	O
suggesting	O
that	O
cellular	O
cholesterol	O
is	O
critical	O
to	O
cell	O
survival	O
in	O
particular	O
AMLs	O
.	O
<EOS>	B-X
The	B-X
mevalonate	B-X
pathway	B-X
produces	B-X
many	B-X
critical	B-X
substances	B-X
in	B-X
cells	B-X
,	B-X
including	B-X
sterols	B-X
essential	B-X
for	B-X
membrane	B-X
structure	B-X
and	B-X
isoprenoids	B-X
vital	B-X
to	B-X
the	B-X
function	B-X
of	B-X
many	B-X
membrane	B-X
proteins	B-X
.	B-X
Because	B-X
cholesterol	B-X
is	B-X
a	B-X
product	B-X
of	B-X
this	B-X
pathway	B-X
,	B-X
HMG-CoA	B-X
reductase	B-X
inhibitors	B-X
(	B-X
statins	B-X
)	B-X
are	B-X
used	B-X
to	B-X
treat	B-X
hypercholesterolemia	B-X
.	B-X
Although	B-X
this	B-X
toxicity	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
Ras/Rho	B-X
isoprenylation	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
statin	B-X
toxicity	B-X
in	B-X
primary	B-X
AML	B-X
cells	B-X
(	B-X
AMLs	B-X
)	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
Ras	B-X
isoprenylation	B-X
or	B-X
with	B-X
activating	B-X
Ras	B-X
mutations	B-X
.	B-X
In	B-X
other	B-X
studies	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
hypoxic	B-X
and	B-X
oxidant	B-X
injuries	B-X
induce	B-X
cholesterol	B-X
increments	B-X
in	B-X
renal	B-X
tubule	B-X
cells	B-X
and	B-X
that	B-X
statins	B-X
sensitize	B-X
these	B-X
cells	B-X
to	B-X
injury	B-X
by	B-X
blocking	B-X
protective	B-X
cholesterol	B-X
responses	B-X
.	B-X
We	B-X
now	B-X
demonstrate	B-X
that	B-X
exposing	B-X
particular	B-X
AMLs	B-X
to	B-X
radiochemotherapy	B-X
induces	B-X
much	B-X
greater	B-X
cellular	B-X
cholesterol	B-X
increments	B-X
than	B-X
those	B-X
seen	B-X
in	B-X
similarly	B-X
treated	B-X
normal	B-X
bone	B-X
marrow	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
AMLs	B-X
with	B-X
mevastatin	B-X
or	B-X
zaragozic	B-X
acid	B-X
(	B-X
which	B-X
inhibits	B-X
cholesterol	B-X
synthesis	B-X
but	B-X
not	B-X
isoprenoid	B-X
synthesis	B-X
)	B-X
attenuates	B-X
the	B-X
cholesterol	B-X
increments	B-X
and	B-X
sensitizes	B-X
cells	B-X
to	B-X
radiochemotherapy	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
toxicity	B-X
is	B-X
affected	B-X
by	B-X
the	B-X
availability	B-X
of	B-X
extracellular	B-X
lipoproteins	B-X
,	B-X
further	B-X
suggesting	B-X
that	B-X
cellular	B-X
cholesterol	B-X
is	B-X
critical	B-X
to	B-X
cell	B-X
survival	B-X
in	B-X
particular	B-X
AMLs	B-X
.	B-X
Because	B-X
zaragozic	B-X
acid	B-X
does	B-X
not	B-X
inhibit	B-X
isoprenoid	B-X
synthesis	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
cholesterol	B-X
modulation	B-X
is	B-X
an	B-X
important	B-X
mechanism	B-X
whereby	B-X
statins	B-X
exert	B-X
toxic	B-X
effects	B-X
on	B-X
some	B-X
AMLs	B-X
and	B-X
that	B-X
cholesterol	B-X
modulators	B-X
may	B-X
improve	B-X
therapeutic	B-X
ratios	B-X
in	B-X
AML	B-X
by	B-X
impacting	B-X
cholesterol-dependent	B-X
cytoresistance	B-X
.	B-X

Because	O
zaragozic	O
acid	O
does	O
not	O
inhibit	O
isoprenoid	O
synthesis	O
,	O
these	O
data	O
suggest	O
that	O
cholesterol	O
modulation	O
is	O
an	O
important	O
mechanism	O
whereby	O
statins	O
exert	O
toxic	O
effects	O
on	O
some	O
AMLs	O
and	O
that	O
cholesterol	O
modulators	O
may	O
improve	O
therapeutic	O
ratios	O
in	O
AML	O
by	O
impacting	O
cholesterol	O
-	O
dependent	O
cytoresistance	O
.	O
<EOS>	B-X
Zaragozic	B-X
acids	B-X
and	B-X
squalestatins	B-X
were	B-X
documented	B-X
by	B-X
Merck	B-X
,	B-X
Glaxo	B-X
,	B-X
and	B-X
Tokyo	B-X
Noko	B-X
University/Mitsubishi	B-X
Kasei	B-X
Corporation	B-X
as	B-X
part	B-X
of	B-X
a	B-X
program	B-X
aimed	B-X
at	B-X
identifying	B-X
novel	B-X
inhibitors	B-X
of	B-X
squalene	B-X
synthase	B-X
,	B-X
as	B-X
well	B-X
as	B-X
farnesyl	B-X
transferase	B-X
.	B-X
These	B-X
natural	B-X
products	B-X
have	B-X
attracted	B-X
considerable	B-X
attention	B-X
from	B-X
numerous	B-X
synthetic	B-X
chemists	B-X
because	B-X
of	B-X
their	B-X
therapeutic	B-X
potential	B-X
and	B-X
novel	B-X
architecture	B-X
.	B-X
This	B-X
review	B-X
highlights	B-X
our	B-X
total	B-X
syntheses	B-X
of	B-X
zaragozic	B-X
acid	B-X
C	B-X
by	B-X
two	B-X
convergent	B-X
strategies	B-X
.	B-X
The	B-X
key	B-X
steps	B-X
in	B-X
our	B-X
first-generation	B-X
synthesis	B-X
involve	B-X
1	B-X
)	B-X
simultaneous	B-X
creation	B-X
of	B-X
the	B-X
C4	B-X
and	B-X
C5	B-X
quaternary	B-X
stereocenters	B-X
through	B-X
the	B-X
Sn	B-X
(	B-X
OTf	B-X
)	B-X
2-promoted	B-X
aldol	B-X
coupling	B-X
reaction	B-X
between	B-X
the	B-X
alpha-keto	B-X
ester	B-X
and	B-X
silyl	B-X
ketene	B-X
thioacetal	B-X
derived	B-X
from	B-X
L-	B-X
and	B-X
D-tartaric	B-X
acids	B-X
,	B-X
respectively	B-X
;	B-X
and	B-X
2	B-X
)	B-X
construction	B-X
of	B-X
the	B-X
bicyclic	B-X
core	B-X
structure	B-X
via	B-X
acid-catalyzed	B-X
internal	B-X
ketalization	B-X
under	B-X
kinetically	B-X
controlled	B-X
conditions	B-X
.	B-X

The	O
ABSCISIC	B-Protein
ACID	I-Protein
INSENSITIVE	I-Protein
3	I-Protein
(	O
ABI3	B-Protein
)	O
gene	O
is	O
modulated	O
by	O
farnesylation	O
and	O
is	O
involved	O
in	O
auxin	O
signaling	O
and	O
lateral	O
root	O
development	O
in	O
Arabidopsis	O
.	O
<EOS>	B-X
Genetic	B-X
screens	B-X
have	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
genes	B-X
that	B-X
regulate	B-X
abscisic	B-X
acid	B-X
(	B-X
ABA	B-X
)	B-X
responsiveness	B-X
in	B-X
Arabidopsis	B-X
.	B-X
Using	B-X
a	B-X
combination	B-X
of	B-X
suppressor	B-X
screens	B-X
and	B-X
double	B-X
mutant	B-X
analysis	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
a	B-X
genetic	B-X
relationship	B-X
for	B-X
a	B-X
number	B-X
of	B-X
these	B-X
ABA	B-X
response	B-X
loci	B-X
.	B-X
Based	B-X
on	B-X
germination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
exogenous	B-X
ABA	B-X
,	B-X
the	B-X
ABI1	B-X
and	B-X
ABI2	B-X
phosphatases	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
the	B-X
ERA1	B-X
farnesyl	B-X
transferase	B-X
and	B-X
the	B-X
ABI3	B-X
and	B-X
ABI5	B-X
transcription	B-X
factors	B-X
act	B-X
at	B-X
or	B-X
downstream	B-X
of	B-X
ERA1	B-X
.	B-X
In	B-X
contrast	B-X
with	B-X
ABI3	B-X
and	B-X
ABI5	B-X
,	B-X
the	B-X
ABI4	B-X
transcription	B-X
factor	B-X
appears	B-X
to	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
ERA1	B-X
.	B-X
Based	B-X
on	B-X
reporter	B-X
gene	B-X
constructs	B-X
,	B-X
the	B-X
upstream	B-X
regulation	B-X
of	B-X
ABI3	B-X
by	B-X
ERA1	B-X
occurs	B-X
at	B-X
least	B-X
partially	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
lipid	B-X
modification	B-X
is	B-X
required	B-X
to	B-X
attenuate	B-X
ABI3	B-X
expression	B-X
.	B-X
Similar	B-X
experiments	B-X
also	B-X
indicate	B-X
that	B-X
ABI3	B-X
is	B-X
auxin	B-X
inducible	B-X
in	B-X
lateral	B-X
root	B-X
primordia	B-X
.	B-X
Related	B-X
to	B-X
this	B-X
,	B-X
loss-of-function	B-X
abi3	B-X
alleles	B-X
show	B-X
reduced	B-X
lateral	B-X
root	B-X
responsiveness	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
auxin	B-X
and	B-X
an	B-X
auxin	B-X
transport	B-X
inhibitor	B-X
,	B-X
and	B-X
era1	B-X
mutants	B-X
have	B-X
increased	B-X
numbers	B-X
of	B-X
lateral	B-X
roots	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
the	B-X
possibility	B-X
that	B-X
genes	B-X
identified	B-X
through	B-X
ABA	B-X
responsive	B-X
germination	B-X
screens	B-X
such	B-X
as	B-X
ERA1	B-X
and	B-X
ABI3	B-X
have	B-X
functions	B-X
in	B-X
auxin	B-X
action	B-X
in	B-X
Arabidopsis	B-X
.	B-X

Genetic	O
screens	O
have	O
identified	O
a	O
number	O
of	O
genes	O
that	O
regulate	O
abscisic	O
acid	O
(	O
ABA	O
)	O
responsiveness	O
in	O
Arabidopsis	O
.	O
<EOS>	B-X
The	B-X
levels	B-X
of	B-X
soluble	B-X
sugars	B-X
,	B-X
such	B-X
as	B-X
glucose	B-X
and	B-X
sucrose	B-X
,	B-X
help	B-X
regulate	B-X
many	B-X
plant	B-X
metabolic	B-X
,	B-X
physiological	B-X
and	B-X
developmental	B-X
processes	B-X
.	B-X
Genetic	B-X
screens	B-X
are	B-X
helping	B-X
identify	B-X
some	B-X
of	B-X
the	B-X
loci	B-X
involved	B-X
in	B-X
plant	B-X
sugar	B-X
response	B-X
and	B-X
reveal	B-X
extensive	B-X
cross-talk	B-X
between	B-X
sugar	B-X
and	B-X
phytohormone	B-X
response	B-X
pathways	B-X
.	B-X
The	B-X
phytohormone	B-X
abscisic	B-X
acid	B-X
(	B-X
ABA	B-X
)	B-X
regulates	B-X
stress-responsive	B-X
gene	B-X
expression	B-X
during	B-X
vegetative	B-X
growth	B-X
.	B-X
The	B-X
ABA	B-X
regulation	B-X
of	B-X
many	B-X
genes	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
subfamily	B-X
of	B-X
basic	B-X
leucine	B-X
zipper	B-X
class	B-X
transcription	B-X
factors	B-X
referred	B-X
to	B-X
as	B-X
ABFs	B-X
(	B-X
i.e	B-X
.	B-X
ABF1-ABF4	B-X
)	B-X
,	B-X
whose	B-X
transcriptional	B-X
activity	B-X
is	B-X
induced	B-X
by	B-X
ABA	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
a	B-X
calcium-dependent	B-X
protein	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
ABA-dependent	B-X
activation	B-X
process	B-X
.	B-X
We	B-X
carried	B-X
out	B-X
yeast	B-X
two-hybrid	B-X
screens	B-X
to	B-X
identify	B-X
regulatory	B-X
components	B-X
of	B-X
ABF4	B-X
function	B-X
and	B-X
isolated	B-X
AtCPK32	B-X
as	B-X
an	B-X
ABF4-interacting	B-X
protein	B-X
.	B-X
Furthermore	B-X
,	B-X
its	B-X
overexpression	B-X
affects	B-X
both	B-X
ABA	B-X
sensitivity	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
number	B-X
of	B-X
ABF4-regulated	B-X
genes	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
AtCPK32	B-X
is	B-X
an	B-X
ABA	B-X
signaling	B-X
component	B-X
that	B-X
regulates	B-X
the	B-X
ABA-responsive	B-X
gene	B-X
expression	B-X
via	B-X
ABF4	B-X
.	B-X

Using	O
a	O
combination	O
of	O
suppressor	O
screens	O
and	O
double	O
mutant	O
analysis	O
,	O
we	O
have	O
determined	O
a	O
genetic	O
relationship	O
for	O
a	O
number	O
of	O
these	O
ABA	O
response	O
loci	O
.	O
<EOS>	B-X
Genetic	B-X
screens	B-X
have	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
genes	B-X
that	B-X
regulate	B-X
abscisic	B-X
acid	B-X
(	B-X
ABA	B-X
)	B-X
responsiveness	B-X
in	B-X
Arabidopsis	B-X
.	B-X
Using	B-X
a	B-X
combination	B-X
of	B-X
suppressor	B-X
screens	B-X
and	B-X
double	B-X
mutant	B-X
analysis	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
a	B-X
genetic	B-X
relationship	B-X
for	B-X
a	B-X
number	B-X
of	B-X
these	B-X
ABA	B-X
response	B-X
loci	B-X
.	B-X
Based	B-X
on	B-X
germination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
exogenous	B-X
ABA	B-X
,	B-X
the	B-X
ABI1	B-X
and	B-X
ABI2	B-X
phosphatases	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
the	B-X
ERA1	B-X
farnesyl	B-X
transferase	B-X
and	B-X
the	B-X
ABI3	B-X
and	B-X
ABI5	B-X
transcription	B-X
factors	B-X
act	B-X
at	B-X
or	B-X
downstream	B-X
of	B-X
ERA1	B-X
.	B-X
Related	B-X
to	B-X
this	B-X
,	B-X
loss-of-function	B-X
abi3	B-X
alleles	B-X
show	B-X
reduced	B-X
lateral	B-X
root	B-X
responsiveness	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
auxin	B-X
and	B-X
an	B-X
auxin	B-X
transport	B-X
inhibitor	B-X
,	B-X
and	B-X
era1	B-X
mutants	B-X
have	B-X
increased	B-X
numbers	B-X
of	B-X
lateral	B-X
roots	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
the	B-X
possibility	B-X
that	B-X
genes	B-X
identified	B-X
through	B-X
ABA	B-X
responsive	B-X
germination	B-X
screens	B-X
such	B-X
as	B-X
ERA1	B-X
and	B-X
ABI3	B-X
have	B-X
functions	B-X
in	B-X
auxin	B-X
action	B-X
in	B-X
Arabidopsis	B-X
.	B-X

Based	O
on	O
germination	O
in	O
the	O
presence	O
of	O
exogenous	O
ABA	O
,	O
the	O
ABI1	B-Protein
and	O
ABI2	B-Protein
phosphatases	O
act	O
at	O
or	O
upstream	O
of	O
the	O
ERA1	B-Protein
farnesyl	O
transferase	O
and	O
the	O
ABI3	B-Protein
and	O
ABI5	B-Protein
transcription	O
factors	O
act	O
at	O
or	O
downstream	O
of	O
ERA1	B-Protein
.	O
<EOS>	B-X
Cytosolic	B-X
calcium	B-X
increases	B-X
were	B-X
analyzed	B-X
in	B-X
guard	B-X
cells	B-X
of	B-X
the	B-X
Arabidopsis	B-X
farnesyltransferase	B-X
deletion	B-X
mutant	B-X
era1-2	B-X
(	B-X
enhanced	B-X
response	B-X
to	B-X
abscisic	B-X
acid	B-X
)	B-X
.	B-X
At	B-X
low	B-X
abscisic	B-X
acid	B-X
(	B-X
ABA	B-X
)	B-X
concentrations	B-X
(	B-X
0.1	B-X
microM	B-X
)	B-X
,	B-X
increases	B-X
of	B-X
guard	B-X
cell	B-X
cytosolic	B-X
calcium	B-X
and	B-X
stomatal	B-X
closure	B-X
were	B-X
activated	B-X
to	B-X
a	B-X
greater	B-X
extent	B-X
in	B-X
the	B-X
era1-2	B-X
mutant	B-X
compared	B-X
with	B-X
the	B-X
wild	B-X
type	B-X
.	B-X
Patch	B-X
clamping	B-X
of	B-X
era1-2	B-X
guard	B-X
cells	B-X
showed	B-X
enhanced	B-X
ABA	B-X
sensitivity	B-X
of	B-X
plasma	B-X
membrane	B-X
calcium	B-X
channel	B-X
currents	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
ERA1	B-X
farnesyltransferase	B-X
targets	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
ABA	B-X
signaling	B-X
that	B-X
acts	B-X
between	B-X
the	B-X
points	B-X
of	B-X
ABA	B-X
perception	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
plasma	B-X
membrane	B-X
calcium	B-X
influx	B-X
channels	B-X
.	B-X
Experimental	B-X
increases	B-X
of	B-X
cytosolic	B-X
calcium	B-X
showed	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
S-type	B-X
anion	B-X
currents	B-X
downstream	B-X
of	B-X
cytosolic	B-X
calcium	B-X
and	B-X
extracellular	B-X
calcium-induced	B-X
stomatal	B-X
closure	B-X
were	B-X
unaffected	B-X
in	B-X
era1-2	B-X
,	B-X
further	B-X
supporting	B-X
the	B-X
positioning	B-X
of	B-X
era1-2	B-X
upstream	B-X
of	B-X
cytosolic	B-X
calcium	B-X
in	B-X
the	B-X
guard	B-X
cell	B-X
ABA	B-X
signaling	B-X
cascade	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
suppression	B-X
of	B-X
ABA-induced	B-X
calcium	B-X
increases	B-X
in	B-X
guard	B-X
cells	B-X
by	B-X
the	B-X
dominant	B-X
protein	B-X
phosphatase	B-X
2C	B-X
mutant	B-X
abi2-1	B-X
was	B-X
rescued	B-X
partially	B-X
in	B-X
era1-2	B-X
abi2-1	B-X
double	B-X
mutant	B-X
guard	B-X
cells	B-X
,	B-X
further	B-X
reinforcing	B-X
the	B-X
notion	B-X
that	B-X
ERA1	B-X
functions	B-X
upstream	B-X
of	B-X
cytosolic	B-X
calcium	B-X
and	B-X
indicating	B-X
the	B-X
genetic	B-X
interaction	B-X
of	B-X
these	B-X
two	B-X
mutations	B-X
upstream	B-X
of	B-X
ABA-induced	B-X
calcium	B-X
increases	B-X
.	B-X

In	O
contrast	O
with	O
ABI3	B-Protein
and	O
ABI5	B-Protein
,	O
the	O
ABI4	B-Protein
transcription	O
factor	O
appears	O
to	O
act	O
at	O
or	O
upstream	O
of	O
ERA1	B-Protein
.	O
<EOS>	B-X
At	B-X
low	B-X
abscisic	B-X
acid	B-X
(	B-X
ABA	B-X
)	B-X
concentrations	B-X
(	B-X
0.1	B-X
microM	B-X
)	B-X
,	B-X
increases	B-X
of	B-X
guard	B-X
cell	B-X
cytosolic	B-X
calcium	B-X
and	B-X
stomatal	B-X
closure	B-X
were	B-X
activated	B-X
to	B-X
a	B-X
greater	B-X
extent	B-X
in	B-X
the	B-X
era1-2	B-X
mutant	B-X
compared	B-X
with	B-X
the	B-X
wild	B-X
type	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
ERA1	B-X
farnesyltransferase	B-X
targets	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
ABA	B-X
signaling	B-X
that	B-X
acts	B-X
between	B-X
the	B-X
points	B-X
of	B-X
ABA	B-X
perception	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
plasma	B-X
membrane	B-X
calcium	B-X
influx	B-X
channels	B-X
.	B-X
Experimental	B-X
increases	B-X
of	B-X
cytosolic	B-X
calcium	B-X
showed	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
S-type	B-X
anion	B-X
currents	B-X
downstream	B-X
of	B-X
cytosolic	B-X
calcium	B-X
and	B-X
extracellular	B-X
calcium-induced	B-X
stomatal	B-X
closure	B-X
were	B-X
unaffected	B-X
in	B-X
era1-2	B-X
,	B-X
further	B-X
supporting	B-X
the	B-X
positioning	B-X
of	B-X
era1-2	B-X
upstream	B-X
of	B-X
cytosolic	B-X
calcium	B-X
in	B-X
the	B-X
guard	B-X
cell	B-X
ABA	B-X
signaling	B-X
cascade	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
suppression	B-X
of	B-X
ABA-induced	B-X
calcium	B-X
increases	B-X
in	B-X
guard	B-X
cells	B-X
by	B-X
the	B-X
dominant	B-X
protein	B-X
phosphatase	B-X
2C	B-X
mutant	B-X
abi2-1	B-X
was	B-X
rescued	B-X
partially	B-X
in	B-X
era1-2	B-X
abi2-1	B-X
double	B-X
mutant	B-X
guard	B-X
cells	B-X
,	B-X
further	B-X
reinforcing	B-X
the	B-X
notion	B-X
that	B-X
ERA1	B-X
functions	B-X
upstream	B-X
of	B-X
cytosolic	B-X
calcium	B-X
and	B-X
indicating	B-X
the	B-X
genetic	B-X
interaction	B-X
of	B-X
these	B-X
two	B-X
mutations	B-X
upstream	B-X
of	B-X
ABA-induced	B-X
calcium	B-X
increases	B-X
.	B-X

Based	O
on	O
reporter	O
gene	O
constructs	O
,	O
the	O
upstream	O
regulation	O
of	O
ABI3	B-Protein
by	O
ERA1	B-Protein
occurs	O
at	O
least	O
partially	O
at	O
the	O
level	O
of	O
transcription	O
,	O
suggesting	O
that	O
this	O
lipid	O
modification	O
is	O
required	O
to	O
attenuate	O
ABI3	B-Protein
expression	O
.	O
<EOS>	B-X
Genetic	B-X
screens	B-X
have	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
genes	B-X
that	B-X
regulate	B-X
abscisic	B-X
acid	B-X
(	B-X
ABA	B-X
)	B-X
responsiveness	B-X
in	B-X
Arabidopsis	B-X
.	B-X
Using	B-X
a	B-X
combination	B-X
of	B-X
suppressor	B-X
screens	B-X
and	B-X
double	B-X
mutant	B-X
analysis	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
a	B-X
genetic	B-X
relationship	B-X
for	B-X
a	B-X
number	B-X
of	B-X
these	B-X
ABA	B-X
response	B-X
loci	B-X
.	B-X
Based	B-X
on	B-X
germination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
exogenous	B-X
ABA	B-X
,	B-X
the	B-X
ABI1	B-X
and	B-X
ABI2	B-X
phosphatases	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
the	B-X
ERA1	B-X
farnesyl	B-X
transferase	B-X
and	B-X
the	B-X
ABI3	B-X
and	B-X
ABI5	B-X
transcription	B-X
factors	B-X
act	B-X
at	B-X
or	B-X
downstream	B-X
of	B-X
ERA1	B-X
.	B-X
In	B-X
contrast	B-X
with	B-X
ABI3	B-X
and	B-X
ABI5	B-X
,	B-X
the	B-X
ABI4	B-X
transcription	B-X
factor	B-X
appears	B-X
to	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
ERA1	B-X
.	B-X
Based	B-X
on	B-X
reporter	B-X
gene	B-X
constructs	B-X
,	B-X
the	B-X
upstream	B-X
regulation	B-X
of	B-X
ABI3	B-X
by	B-X
ERA1	B-X
occurs	B-X
at	B-X
least	B-X
partially	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
lipid	B-X
modification	B-X
is	B-X
required	B-X
to	B-X
attenuate	B-X
ABI3	B-X
expression	B-X
.	B-X
Similar	B-X
experiments	B-X
also	B-X
indicate	B-X
that	B-X
ABI3	B-X
is	B-X
auxin	B-X
inducible	B-X
in	B-X
lateral	B-X
root	B-X
primordia	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
the	B-X
possibility	B-X
that	B-X
genes	B-X
identified	B-X
through	B-X
ABA	B-X
responsive	B-X
germination	B-X
screens	B-X
such	B-X
as	B-X
ERA1	B-X
and	B-X
ABI3	B-X
have	B-X
functions	B-X
in	B-X
auxin	B-X
action	B-X
in	B-X
Arabidopsis	B-X
.	B-X

Similar	O
experiments	O
also	O
indicate	O
that	O
ABI3	B-Protein
is	O
auxin	O
inducible	O
in	O
lateral	O
root	O
primordia	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
germination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
exogenous	B-X
ABA	B-X
,	B-X
the	B-X
ABI1	B-X
and	B-X
ABI2	B-X
phosphatases	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
the	B-X
ERA1	B-X
farnesyl	B-X
transferase	B-X
and	B-X
the	B-X
ABI3	B-X
and	B-X
ABI5	B-X
transcription	B-X
factors	B-X
act	B-X
at	B-X
or	B-X
downstream	B-X
of	B-X
ERA1	B-X
.	B-X
In	B-X
contrast	B-X
with	B-X
ABI3	B-X
and	B-X
ABI5	B-X
,	B-X
the	B-X
ABI4	B-X
transcription	B-X
factor	B-X
appears	B-X
to	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
ERA1	B-X
.	B-X
Based	B-X
on	B-X
reporter	B-X
gene	B-X
constructs	B-X
,	B-X
the	B-X
upstream	B-X
regulation	B-X
of	B-X
ABI3	B-X
by	B-X
ERA1	B-X
occurs	B-X
at	B-X
least	B-X
partially	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
lipid	B-X
modification	B-X
is	B-X
required	B-X
to	B-X
attenuate	B-X
ABI3	B-X
expression	B-X
.	B-X
Similar	B-X
experiments	B-X
also	B-X
indicate	B-X
that	B-X
ABI3	B-X
is	B-X
auxin	B-X
inducible	B-X
in	B-X
lateral	B-X
root	B-X
primordia	B-X
.	B-X
Related	B-X
to	B-X
this	B-X
,	B-X
loss-of-function	B-X
abi3	B-X
alleles	B-X
show	B-X
reduced	B-X
lateral	B-X
root	B-X
responsiveness	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
auxin	B-X
and	B-X
an	B-X
auxin	B-X
transport	B-X
inhibitor	B-X
,	B-X
and	B-X
era1	B-X
mutants	B-X
have	B-X
increased	B-X
numbers	B-X
of	B-X
lateral	B-X
roots	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
the	B-X
possibility	B-X
that	B-X
genes	B-X
identified	B-X
through	B-X
ABA	B-X
responsive	B-X
germination	B-X
screens	B-X
such	B-X
as	B-X
ERA1	B-X
and	B-X
ABI3	B-X
have	B-X
functions	B-X
in	B-X
auxin	B-X
action	B-X
in	B-X
Arabidopsis	B-X
.	B-X

Related	O
to	O
this	O
,	O
loss	O
-	O
of	O
-	O
function	O
abi3	B-Protein
alleles	O
show	O
reduced	O
lateral	O
root	O
responsiveness	O
in	O
the	O
presence	O
of	O
auxin	O
and	O
an	O
auxin	O
transport	O
inhibitor	O
,	O
and	O
era1	B-Protein
mutants	O
have	O
increased	O
numbers	O
of	O
lateral	O
roots	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
that	O
genes	O
identified	O
through	O
ABA	O
responsive	O
germination	O
screens	O
such	O
as	O
ERA1	B-Protein
and	O
ABI3	B-Protein
have	O
functions	O
in	O
auxin	O
action	O
in	O
Arabidopsis	O
.	O
<EOS>	B-X
Genetic	B-X
screens	B-X
have	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
genes	B-X
that	B-X
regulate	B-X
abscisic	B-X
acid	B-X
(	B-X
ABA	B-X
)	B-X
responsiveness	B-X
in	B-X
Arabidopsis	B-X
.	B-X
Using	B-X
a	B-X
combination	B-X
of	B-X
suppressor	B-X
screens	B-X
and	B-X
double	B-X
mutant	B-X
analysis	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
a	B-X
genetic	B-X
relationship	B-X
for	B-X
a	B-X
number	B-X
of	B-X
these	B-X
ABA	B-X
response	B-X
loci	B-X
.	B-X
Based	B-X
on	B-X
germination	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
exogenous	B-X
ABA	B-X
,	B-X
the	B-X
ABI1	B-X
and	B-X
ABI2	B-X
phosphatases	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
the	B-X
ERA1	B-X
farnesyl	B-X
transferase	B-X
and	B-X
the	B-X
ABI3	B-X
and	B-X
ABI5	B-X
transcription	B-X
factors	B-X
act	B-X
at	B-X
or	B-X
downstream	B-X
of	B-X
ERA1	B-X
.	B-X
In	B-X
contrast	B-X
with	B-X
ABI3	B-X
and	B-X
ABI5	B-X
,	B-X
the	B-X
ABI4	B-X
transcription	B-X
factor	B-X
appears	B-X
to	B-X
act	B-X
at	B-X
or	B-X
upstream	B-X
of	B-X
ERA1	B-X
.	B-X
Based	B-X
on	B-X
reporter	B-X
gene	B-X
constructs	B-X
,	B-X
the	B-X
upstream	B-X
regulation	B-X
of	B-X
ABI3	B-X
by	B-X
ERA1	B-X
occurs	B-X
at	B-X
least	B-X
partially	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
lipid	B-X
modification	B-X
is	B-X
required	B-X
to	B-X
attenuate	B-X
ABI3	B-X
expression	B-X
.	B-X
Similar	B-X
experiments	B-X
also	B-X
indicate	B-X
that	B-X
ABI3	B-X
is	B-X
auxin	B-X
inducible	B-X
in	B-X
lateral	B-X
root	B-X
primordia	B-X
.	B-X
Related	B-X
to	B-X
this	B-X
,	B-X
loss-of-function	B-X
abi3	B-X
alleles	B-X
show	B-X
reduced	B-X
lateral	B-X
root	B-X
responsiveness	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
auxin	B-X
and	B-X
an	B-X
auxin	B-X
transport	B-X
inhibitor	B-X
,	B-X
and	B-X
era1	B-X
mutants	B-X
have	B-X
increased	B-X
numbers	B-X
of	B-X
lateral	B-X
roots	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
the	B-X
possibility	B-X
that	B-X
genes	B-X
identified	B-X
through	B-X
ABA	B-X
responsive	B-X
germination	B-X
screens	B-X
such	B-X
as	B-X
ERA1	B-X
and	B-X
ABI3	B-X
have	B-X
functions	B-X
in	B-X
auxin	B-X
action	B-X
in	B-X
Arabidopsis	B-X
.	B-X

The	O
COP9	O
signalosome	O
interacts	O
with	O
SCF	O
UFO	B-Protein
and	O
participates	O
in	O
Arabidopsis	O
flower	O
development	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
multiple	B-X
developmental	B-X
processes	B-X
.	B-X
It	B-X
interacts	B-X
with	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
and	B-X
deconjugates	B-X
Nedd8/Rub1	B-X
from	B-X
cullins	B-X
(	B-X
deneddylation	B-X
)	B-X
.	B-X
CSN	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
Arabidopsis	B-X
floral	B-X
tissues	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
flower	B-X
development	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CSN	B-X
in	B-X
developing	B-X
flowers	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
two	B-X
csn1	B-X
partially	B-X
deficient	B-X
Arabidopsis	B-X
strains	B-X
exhibit	B-X
aberrant	B-X
development	B-X
of	B-X
floral	B-X
organs	B-X
,	B-X
decline	B-X
of	B-X
APETALA3	B-X
(	B-X
AP3	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
low	B-X
fertility	B-X
in	B-X
addition	B-X
to	B-X
defects	B-X
in	B-X
shoot	B-X
and	B-X
inflorescence	B-X
meristems	B-X
.	B-X
We	B-X
show	B-X
that	B-X
UNUSUAL	B-X
FLORAL	B-X
ORGANS	B-X
(	B-X
UFO	B-X
)	B-X
forms	B-X
a	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
complex	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
CSN	B-X
in	B-X
vivo	B-X
.	B-X
Genetic	B-X
interaction	B-X
analysis	B-X
indicates	B-X
that	B-X
CSN	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
gain-of-function	B-X
activity	B-X
of	B-X
the	B-X
F-box	B-X
protein	B-X
UFO	B-X
in	B-X
AP3	B-X
activation	B-X
and	B-X
in	B-X
floral	B-X
organ	B-X
transformation	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
previously	B-X
reported	B-X
csn5	B-X
antisense	B-X
and	B-X
csn1	B-X
null	B-X
mutants	B-X
,	B-X
partial	B-X
deficiency	B-X
of	B-X
CSN1	B-X
causes	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
level	B-X
of	B-X
CUL1	B-X
in	B-X
the	B-X
mutant	B-X
flowers	B-X
without	B-X
an	B-X
obvious	B-X
defect	B-X
in	B-X
CUL1	B-X
deneddylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CSN	B-X
is	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
and	B-X
suggest	B-X
that	B-X
CSN	B-X
regulates	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
in	B-X
part	B-X
by	B-X
modulating	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
-mediated	B-X
AP3	B-X
activation	B-X
.	B-X

The	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
is	O
involved	O
in	O
multiple	O
developmental	O
processes	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
,	B-X
once	B-X
defined	B-X
as	B-X
a	B-X
repressor	B-X
complex	B-X
of	B-X
light-activated	B-X
development	B-X
in	B-X
Arabidopsis	B-X
,	B-X
has	B-X
recently	B-X
been	B-X
found	B-X
in	B-X
humans	B-X
and	B-X
is	B-X
probably	B-X
present	B-X
in	B-X
most	B-X
multicellular	B-X
organisms	B-X
.	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
lid	B-X
sub-complex	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
in	B-X
structural	B-X
composition	B-X
and	B-X
probably	B-X
shares	B-X
a	B-X
common	B-X
evolutionary	B-X
ancestor	B-X
.	B-X
A	B-X
multifaceted	B-X
role	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
in	B-X
cell-signaling	B-X
processes	B-X
is	B-X
hinted	B-X
at	B-X
by	B-X
its	B-X
associated	B-X
novel	B-X
kinase	B-X
activity	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
involvement	B-X
of	B-X
its	B-X
subunits	B-X
in	B-X
regulating	B-X
multiple	B-X
cell-signaling	B-X
pathways	B-X
and	B-X
cell-cycle	B-X
progression	B-X
.	B-X
Moreover	B-X
,	B-X
coimmunoprecipitation	B-X
assays	B-X
showed	B-X
that	B-X
DCAF1	B-X
associates	B-X
with	B-X
DDB1	B-X
,	B-X
RELATED	B-X
TO	B-X
UBIQUITIN-modified	B-X
CUL4	B-X
,	B-X
and	B-X
the	B-X
COP9	B-X
signalosome	B-X
in	B-X
vivo	B-X
but	B-X
not	B-X
with	B-X
CULLIN-ASSOCIATED	B-X
and	B-X
NEDDYLATION-DISSOCIATED1	B-X
,	B-X
CONSTITUTIVE	B-X
PHOTOMORPHOGENIC1	B-X
(	B-X
COP1	B-X
)	B-X
,	B-X
or	B-X
the	B-X
COP10-DET1-DDB1	B-X
complex	B-X
,	B-X
supporting	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
distinct	B-X
Arabidopsis	B-X
CUL4	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
the	B-X
CUL4-DDB1-DCAF1	B-X
complex	B-X
.	B-X
Reducing	B-X
the	B-X
levels	B-X
of	B-X
DCAF1	B-X
leads	B-X
to	B-X
diverse	B-X
developmental	B-X
defects	B-X
,	B-X
implying	B-X
that	B-X
DCAF1	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
multiple	B-X
developmental	B-X
pathways	B-X
.	B-X

It	O
interacts	O
with	O
SCF	O
ubiquitin	B-Protein
ligases	O
and	O
deconjugates	O
Nedd8	B-Protein
/	O
Rub1	B-Protein
from	O
cullins	O
(	O
deneddylation	O
)	O
.	O
<EOS>	B-X
It	B-X
interacts	B-X
with	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
and	B-X
deconjugates	B-X
Nedd8/Rub1	B-X
from	B-X
cullins	B-X
(	B-X
deneddylation	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
UNUSUAL	B-X
FLORAL	B-X
ORGANS	B-X
(	B-X
UFO	B-X
)	B-X
forms	B-X
a	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
complex	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
CSN	B-X
in	B-X
vivo	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
previously	B-X
reported	B-X
csn5	B-X
antisense	B-X
and	B-X
csn1	B-X
null	B-X
mutants	B-X
,	B-X
partial	B-X
deficiency	B-X
of	B-X
CSN1	B-X
causes	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
level	B-X
of	B-X
CUL1	B-X
in	B-X
the	B-X
mutant	B-X
flowers	B-X
without	B-X
an	B-X
obvious	B-X
defect	B-X
in	B-X
CUL1	B-X
deneddylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CSN	B-X
is	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
and	B-X
suggest	B-X
that	B-X
CSN	B-X
regulates	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
in	B-X
part	B-X
by	B-X
modulating	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
-mediated	B-X
AP3	B-X
activation	B-X
.	B-X

CSN	O
is	O
highly	O
expressed	O
in	O
Arabidopsis	O
floral	O
tissues	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
multiple	B-X
developmental	B-X
processes	B-X
.	B-X
CSN	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
Arabidopsis	B-X
floral	B-X
tissues	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
flower	B-X
development	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CSN	B-X
in	B-X
developing	B-X
flowers	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
two	B-X
csn1	B-X
partially	B-X
deficient	B-X
Arabidopsis	B-X
strains	B-X
exhibit	B-X
aberrant	B-X
development	B-X
of	B-X
floral	B-X
organs	B-X
,	B-X
decline	B-X
of	B-X
APETALA3	B-X
(	B-X
AP3	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
low	B-X
fertility	B-X
in	B-X
addition	B-X
to	B-X
defects	B-X
in	B-X
shoot	B-X
and	B-X
inflorescence	B-X
meristems	B-X
.	B-X
We	B-X
show	B-X
that	B-X
UNUSUAL	B-X
FLORAL	B-X
ORGANS	B-X
(	B-X
UFO	B-X
)	B-X
forms	B-X
a	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
complex	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
CSN	B-X
in	B-X
vivo	B-X
.	B-X
Genetic	B-X
interaction	B-X
analysis	B-X
indicates	B-X
that	B-X
CSN	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
gain-of-function	B-X
activity	B-X
of	B-X
the	B-X
F-box	B-X
protein	B-X
UFO	B-X
in	B-X
AP3	B-X
activation	B-X
and	B-X
in	B-X
floral	B-X
organ	B-X
transformation	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
previously	B-X
reported	B-X
csn5	B-X
antisense	B-X
and	B-X
csn1	B-X
null	B-X
mutants	B-X
,	B-X
partial	B-X
deficiency	B-X
of	B-X
CSN1	B-X
causes	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
level	B-X
of	B-X
CUL1	B-X
in	B-X
the	B-X
mutant	B-X
flowers	B-X
without	B-X
an	B-X
obvious	B-X
defect	B-X
in	B-X
CUL1	B-X
deneddylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CSN	B-X
is	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
and	B-X
suggest	B-X
that	B-X
CSN	B-X
regulates	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
in	B-X
part	B-X
by	B-X
modulating	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
-mediated	B-X
AP3	B-X
activation	B-X
.	B-X

To	O
investigate	O
the	O
role	O
of	O
CSN	O
in	O
flower	O
development	O
,	O
we	O
examined	O
the	O
expression	O
pattern	O
of	O
CSN	O
in	O
developing	O
flowers	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
multiple	B-X
developmental	B-X
processes	B-X
.	B-X
CSN	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
Arabidopsis	B-X
floral	B-X
tissues	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
flower	B-X
development	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CSN	B-X
in	B-X
developing	B-X
flowers	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
two	B-X
csn1	B-X
partially	B-X
deficient	B-X
Arabidopsis	B-X
strains	B-X
exhibit	B-X
aberrant	B-X
development	B-X
of	B-X
floral	B-X
organs	B-X
,	B-X
decline	B-X
of	B-X
APETALA3	B-X
(	B-X
AP3	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
low	B-X
fertility	B-X
in	B-X
addition	B-X
to	B-X
defects	B-X
in	B-X
shoot	B-X
and	B-X
inflorescence	B-X
meristems	B-X
.	B-X
We	B-X
show	B-X
that	B-X
UNUSUAL	B-X
FLORAL	B-X
ORGANS	B-X
(	B-X
UFO	B-X
)	B-X
forms	B-X
a	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
complex	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
CSN	B-X
in	B-X
vivo	B-X
.	B-X
Genetic	B-X
interaction	B-X
analysis	B-X
indicates	B-X
that	B-X
CSN	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
gain-of-function	B-X
activity	B-X
of	B-X
the	B-X
F-box	B-X
protein	B-X
UFO	B-X
in	B-X
AP3	B-X
activation	B-X
and	B-X
in	B-X
floral	B-X
organ	B-X
transformation	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
previously	B-X
reported	B-X
csn5	B-X
antisense	B-X
and	B-X
csn1	B-X
null	B-X
mutants	B-X
,	B-X
partial	B-X
deficiency	B-X
of	B-X
CSN1	B-X
causes	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
level	B-X
of	B-X
CUL1	B-X
in	B-X
the	B-X
mutant	B-X
flowers	B-X
without	B-X
an	B-X
obvious	B-X
defect	B-X
in	B-X
CUL1	B-X
deneddylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CSN	B-X
is	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
and	B-X
suggest	B-X
that	B-X
CSN	B-X
regulates	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
in	B-X
part	B-X
by	B-X
modulating	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
-mediated	B-X
AP3	B-X
activation	B-X
.	B-X

We	O
report	O
here	O
that	O
two	O
csn1	B-Protein
partially	O
deficient	O
Arabidopsis	O
strains	O
exhibit	O
aberrant	O
development	O
of	O
floral	O
organs	O
,	O
decline	O
of	O
APETALA3	B-Protein
(	O
AP3	B-Protein
)	O
expression	O
,	O
and	O
low	O
fertility	O
in	O
addition	O
to	O
defects	O
in	O
shoot	O
and	O
inflorescence	O
meristems	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
multiple	B-X
developmental	B-X
processes	B-X
.	B-X
CSN	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
Arabidopsis	B-X
floral	B-X
tissues	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
flower	B-X
development	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CSN	B-X
in	B-X
developing	B-X
flowers	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
two	B-X
csn1	B-X
partially	B-X
deficient	B-X
Arabidopsis	B-X
strains	B-X
exhibit	B-X
aberrant	B-X
development	B-X
of	B-X
floral	B-X
organs	B-X
,	B-X
decline	B-X
of	B-X
APETALA3	B-X
(	B-X
AP3	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
low	B-X
fertility	B-X
in	B-X
addition	B-X
to	B-X
defects	B-X
in	B-X
shoot	B-X
and	B-X
inflorescence	B-X
meristems	B-X
.	B-X
Genetic	B-X
interaction	B-X
analysis	B-X
indicates	B-X
that	B-X
CSN	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
gain-of-function	B-X
activity	B-X
of	B-X
the	B-X
F-box	B-X
protein	B-X
UFO	B-X
in	B-X
AP3	B-X
activation	B-X
and	B-X
in	B-X
floral	B-X
organ	B-X
transformation	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
previously	B-X
reported	B-X
csn5	B-X
antisense	B-X
and	B-X
csn1	B-X
null	B-X
mutants	B-X
,	B-X
partial	B-X
deficiency	B-X
of	B-X
CSN1	B-X
causes	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
level	B-X
of	B-X
CUL1	B-X
in	B-X
the	B-X
mutant	B-X
flowers	B-X
without	B-X
an	B-X
obvious	B-X
defect	B-X
in	B-X
CUL1	B-X
deneddylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CSN	B-X
is	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
and	B-X
suggest	B-X
that	B-X
CSN	B-X
regulates	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
in	B-X
part	B-X
by	B-X
modulating	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
-mediated	B-X
AP3	B-X
activation	B-X
.	B-X

We	O
show	O
that	O
UNUSUAL	B-Protein
FLORAL	I-Protein
ORGANS	I-Protein
(	O
UFO	B-Protein
)	O
forms	O
a	O
SCF	O
(	O
UFO	B-Protein
)	O
complex	O
,	O
which	O
is	O
associated	O
with	O
CSN	O
in	O
vivo	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
multiple	B-X
developmental	B-X
processes	B-X
.	B-X
It	B-X
interacts	B-X
with	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
and	B-X
deconjugates	B-X
Nedd8/Rub1	B-X
from	B-X
cullins	B-X
(	B-X
deneddylation	B-X
)	B-X
.	B-X
CSN	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
Arabidopsis	B-X
floral	B-X
tissues	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
flower	B-X
development	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CSN	B-X
in	B-X
developing	B-X
flowers	B-X
.	B-X
We	B-X
show	B-X
that	B-X
UNUSUAL	B-X
FLORAL	B-X
ORGANS	B-X
(	B-X
UFO	B-X
)	B-X
forms	B-X
a	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
complex	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
CSN	B-X
in	B-X
vivo	B-X
.	B-X
Genetic	B-X
interaction	B-X
analysis	B-X
indicates	B-X
that	B-X
CSN	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
gain-of-function	B-X
activity	B-X
of	B-X
the	B-X
F-box	B-X
protein	B-X
UFO	B-X
in	B-X
AP3	B-X
activation	B-X
and	B-X
in	B-X
floral	B-X
organ	B-X
transformation	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
previously	B-X
reported	B-X
csn5	B-X
antisense	B-X
and	B-X
csn1	B-X
null	B-X
mutants	B-X
,	B-X
partial	B-X
deficiency	B-X
of	B-X
CSN1	B-X
causes	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
level	B-X
of	B-X
CUL1	B-X
in	B-X
the	B-X
mutant	B-X
flowers	B-X
without	B-X
an	B-X
obvious	B-X
defect	B-X
in	B-X
CUL1	B-X
deneddylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CSN	B-X
is	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
and	B-X
suggest	B-X
that	B-X
CSN	B-X
regulates	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
in	B-X
part	B-X
by	B-X
modulating	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
-mediated	B-X
AP3	B-X
activation	B-X
.	B-X

Genetic	O
interaction	O
analysis	O
indicates	O
that	O
CSN	O
is	O
necessary	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
activity	O
of	O
the	O
F	O
-	O
box	O
protein	O
UFO	B-Protein
in	O
AP3	B-Protein
activation	O
and	O
in	O
floral	O
organ	O
transformation	O
.	O

Compared	O
with	O
the	O
previously	O
reported	O
csn5	B-Protein
antisense	O
and	O
csn1	B-Protein
null	O
mutants	O
,	O
partial	O
deficiency	O
of	O
CSN1	B-Protein
causes	O
a	O
reduction	O
in	O
the	O
level	O
of	O
CUL1	B-Protein
in	O
the	O
mutant	O
flowers	O
without	O
an	O
obvious	O
defect	O
in	O
CUL1	B-Protein
deneddylation	O
.	O
<EOS>	B-X
It	B-X
interacts	B-X
with	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
and	B-X
deconjugates	B-X
Nedd8/Rub1	B-X
from	B-X
cullins	B-X
(	B-X
deneddylation	B-X
)	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
flower	B-X
development	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CSN	B-X
in	B-X
developing	B-X
flowers	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
two	B-X
csn1	B-X
partially	B-X
deficient	B-X
Arabidopsis	B-X
strains	B-X
exhibit	B-X
aberrant	B-X
development	B-X
of	B-X
floral	B-X
organs	B-X
,	B-X
decline	B-X
of	B-X
APETALA3	B-X
(	B-X
AP3	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
low	B-X
fertility	B-X
in	B-X
addition	B-X
to	B-X
defects	B-X
in	B-X
shoot	B-X
and	B-X
inflorescence	B-X
meristems	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
previously	B-X
reported	B-X
csn5	B-X
antisense	B-X
and	B-X
csn1	B-X
null	B-X
mutants	B-X
,	B-X
partial	B-X
deficiency	B-X
of	B-X
CSN1	B-X
causes	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
level	B-X
of	B-X
CUL1	B-X
in	B-X
the	B-X
mutant	B-X
flowers	B-X
without	B-X
an	B-X
obvious	B-X
defect	B-X
in	B-X
CUL1	B-X
deneddylation	B-X
.	B-X

We	O
conclude	O
that	O
CSN	O
is	O
an	O
essential	O
regulator	O
of	O
Arabidopsis	O
flower	O
development	O
and	O
suggest	O
that	O
CSN	O
regulates	O
Arabidopsis	O
flower	O
development	O
in	O
part	O
by	O
modulating	O
SCF	O
(	O
UFO	B-Protein
)	O
-	O
mediated	O
AP3	B-Protein
activation	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
multiple	B-X
developmental	B-X
processes	B-X
.	B-X
It	B-X
interacts	B-X
with	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
and	B-X
deconjugates	B-X
Nedd8/Rub1	B-X
from	B-X
cullins	B-X
(	B-X
deneddylation	B-X
)	B-X
.	B-X
CSN	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
Arabidopsis	B-X
floral	B-X
tissues	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
flower	B-X
development	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CSN	B-X
in	B-X
developing	B-X
flowers	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
two	B-X
csn1	B-X
partially	B-X
deficient	B-X
Arabidopsis	B-X
strains	B-X
exhibit	B-X
aberrant	B-X
development	B-X
of	B-X
floral	B-X
organs	B-X
,	B-X
decline	B-X
of	B-X
APETALA3	B-X
(	B-X
AP3	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
low	B-X
fertility	B-X
in	B-X
addition	B-X
to	B-X
defects	B-X
in	B-X
shoot	B-X
and	B-X
inflorescence	B-X
meristems	B-X
.	B-X
We	B-X
show	B-X
that	B-X
UNUSUAL	B-X
FLORAL	B-X
ORGANS	B-X
(	B-X
UFO	B-X
)	B-X
forms	B-X
a	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
complex	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
CSN	B-X
in	B-X
vivo	B-X
.	B-X
Genetic	B-X
interaction	B-X
analysis	B-X
indicates	B-X
that	B-X
CSN	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
gain-of-function	B-X
activity	B-X
of	B-X
the	B-X
F-box	B-X
protein	B-X
UFO	B-X
in	B-X
AP3	B-X
activation	B-X
and	B-X
in	B-X
floral	B-X
organ	B-X
transformation	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
previously	B-X
reported	B-X
csn5	B-X
antisense	B-X
and	B-X
csn1	B-X
null	B-X
mutants	B-X
,	B-X
partial	B-X
deficiency	B-X
of	B-X
CSN1	B-X
causes	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
level	B-X
of	B-X
CUL1	B-X
in	B-X
the	B-X
mutant	B-X
flowers	B-X
without	B-X
an	B-X
obvious	B-X
defect	B-X
in	B-X
CUL1	B-X
deneddylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CSN	B-X
is	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
and	B-X
suggest	B-X
that	B-X
CSN	B-X
regulates	B-X
Arabidopsis	B-X
flower	B-X
development	B-X
in	B-X
part	B-X
by	B-X
modulating	B-X
SCF	B-X
(	B-X
UFO	B-X
)	B-X
-mediated	B-X
AP3	B-X
activation	B-X
.	B-X

A	O
comparative	O
kinetic	O
study	O
on	O
the	O
singlet	O
molecular	O
oxygen	O
-	O
mediated	O
photoxidation	O
of	O
alpha	B-Protein
-	I-Protein
and	O
beta	B-Protein
-	I-Protein
chymotrypsins	I-Protein
.	O

Kinetic	O
aspects	O
of	O
the	O
sensitized	O
photooxidation	O
of	O
alpha	B-Protein
-	I-Protein
and	O
beta	B-Protein
-	I-Protein
chymotrypsins	I-Protein
have	O
been	O
studied	O
at	O
pH	O
6	O
and	O
8	O
.	O
<EOS>	B-X
Kinetic	B-X
aspects	B-X
of	B-X
the	B-X
sensitized	B-X
photooxidation	B-X
of	B-X
alpha-	B-X
and	B-X
beta-chymotrypsins	B-X
have	B-X
been	B-X
studied	B-X
at	B-X
pH	B-X
6	B-X
and	B-X
8	B-X
.	B-X
Overall	B-X
and	B-X
reactive	B-X
rate	B-X
constants	B-X
for	B-X
the	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
-quenching	B-X
(	B-X
in	B-X
the	B-X
order	B-X
of	B-X
108	B-X
and	B-X
107/M/s	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
and	B-X
rates	B-X
of	B-X
oxygen	B-X
consumption	B-X
determined	B-X
by	B-X
time-resolved	B-X
,	B-X
spectroscopic	B-X
and	B-X
polarographic	B-X
methods	B-X
indicate	B-X
that	B-X
alpha-	B-X
and	B-X
beta-chymotrypsins	B-X
are	B-X
less	B-X
photooxidizable	B-X
at	B-X
pH	B-X
6	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
an	B-X
enhancement	B-X
of	B-X
the	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
-physical	B-X
quenching	B-X
component	B-X
.	B-X
In	B-X
general	B-X
terms	B-X
,	B-X
beta-chymotrypsin	B-X
exhibits	B-X
the	B-X
greater	B-X
overall	B-X
proclivity	B-X
to	B-X
interact	B-X
with	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
,	B-X
whereas	B-X
structural	B-X
factors	B-X
,	B-X
possibly	B-X
evidenced	B-X
by	B-X
a	B-X
higher	B-X
exposure	B-X
of	B-X
the	B-X
reactive	B-X
tryptophan	B-X
residues	B-X
,	B-X
impart	B-X
an	B-X
increased	B-X
photooxidation	B-X
degree	B-X
to	B-X
the	B-X
proteins	B-X
at	B-X
pH	B-X
8	B-X
,	B-X
specially	B-X
to	B-X
the	B-X
alpha-chymotrypsin	B-X
.	B-X

The	O
sensitization	O
,	O
employing	O
classical	O
O2	O
(	O
1Deltag	O
)	O
-	O
photogenerators	O
,	O
such	O
as	O
xanthene	O
dyes	O
,	O
is	O
a	O
kinetically	O
intricate	O
process	O
because	O
of	O
the	O
presence	O
of	O
ground	O
state	O
dye	O
-	O
protein	O
associations	O
and	O
to	O
the	O
simultaneous	O
participation	O
of	O
superoxide	O
ion	O
and	O
singlet	O
molecular	O
oxygen	O
[	O
O2	O
(	O
1Deltag	O
)	O
]	O
.	O

Both	O
proteins	O
,	O
that	O
possess	O
the	O
same	O
distribution	O
pattern	O
of	O
photooxidizable	O
amino	O
acids	O
,	O
suffer	O
a	O
pure	O
O2	O
(	O
1Deltag	O
)	O
-	O
mediated	O
photodynamic	O
attack	O
,	O
using	O
the	O
carbonylic	O
sensitizer	O
Perinaphthenone	O
.	O
<EOS>	B-X
The	B-X
sensitization	B-X
,	B-X
employing	B-X
classical	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
-photogenerators	B-X
,	B-X
such	B-X
as	B-X
xanthene	B-X
dyes	B-X
,	B-X
is	B-X
a	B-X
kinetically	B-X
intricate	B-X
process	B-X
because	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
ground	B-X
state	B-X
dye-protein	B-X
associations	B-X
and	B-X
to	B-X
the	B-X
simultaneous	B-X
participation	B-X
of	B-X
superoxide	B-X
ion	B-X
and	B-X
singlet	B-X
molecular	B-X
oxygen	B-X
[	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
]	B-X
.	B-X
Both	B-X
proteins	B-X
,	B-X
that	B-X
possess	B-X
the	B-X
same	B-X
distribution	B-X
pattern	B-X
of	B-X
photooxidizable	B-X
amino	B-X
acids	B-X
,	B-X
suffer	B-X
a	B-X
pure	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
-mediated	B-X
photodynamic	B-X
attack	B-X
,	B-X
using	B-X
the	B-X
carbonylic	B-X
sensitizer	B-X
Perinaphthenone	B-X
.	B-X
Overall	B-X
and	B-X
reactive	B-X
rate	B-X
constants	B-X
for	B-X
the	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
-quenching	B-X
(	B-X
in	B-X
the	B-X
order	B-X
of	B-X
108	B-X
and	B-X
107/M/s	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
and	B-X
rates	B-X
of	B-X
oxygen	B-X
consumption	B-X
determined	B-X
by	B-X
time-resolved	B-X
,	B-X
spectroscopic	B-X
and	B-X
polarographic	B-X
methods	B-X
indicate	B-X
that	B-X
alpha-	B-X
and	B-X
beta-chymotrypsins	B-X
are	B-X
less	B-X
photooxidizable	B-X
at	B-X
pH	B-X
6	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
an	B-X
enhancement	B-X
of	B-X
the	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
-physical	B-X
quenching	B-X
component	B-X
.	B-X
In	B-X
general	B-X
terms	B-X
,	B-X
beta-chymotrypsin	B-X
exhibits	B-X
the	B-X
greater	B-X
overall	B-X
proclivity	B-X
to	B-X
interact	B-X
with	B-X
O2	B-X
(	B-X
1Deltag	B-X
)	B-X
,	B-X
whereas	B-X
structural	B-X
factors	B-X
,	B-X
possibly	B-X
evidenced	B-X
by	B-X
a	B-X
higher	B-X
exposure	B-X
of	B-X
the	B-X
reactive	B-X
tryptophan	B-X
residues	B-X
,	B-X
impart	B-X
an	B-X
increased	B-X
photooxidation	B-X
degree	B-X
to	B-X
the	B-X
proteins	B-X
at	B-X
pH	B-X
8	B-X
,	B-X
specially	B-X
to	B-X
the	B-X
alpha-chymotrypsin	B-X
.	B-X

Overall	O
and	O
reactive	O
rate	O
constants	O
for	O
the	O
O2	O
(	O
1Deltag	O
)	O
-	O
quenching	O
(	O
in	O
the	O
order	O
of	O
108	O
and	O
107	O
/	O
M	O
/	O
s	O
,	O
respectively	O
)	O
,	O
and	O
rates	O
of	O
oxygen	O
consumption	O
determined	O
by	O
time	O
-	O
resolved	O
,	O
spectroscopic	O
and	O
polarographic	O
methods	O
indicate	O
that	O
alpha	B-Protein
-	I-Protein
and	O
beta	B-Protein
-	I-Protein
chymotrypsins	I-Protein
are	O
less	O
photooxidizable	O
at	O
pH	O
6	O
,	O
as	O
a	O
result	O
of	O
an	O
enhancement	O
of	O
the	O
O2	O
(	O
1Deltag	O
)	O
-	O
physical	O
quenching	O
component	O
.	O

In	O
general	O
terms	O
,	O
beta	B-Protein
-	I-Protein
chymotrypsin	I-Protein
exhibits	O
the	O
greater	O
overall	O
proclivity	O
to	O
interact	O
with	O
O2	O
(	O
1Deltag	O
)	O
,	O
whereas	O
structural	O
factors	O
,	O
possibly	O
evidenced	O
by	O
a	O
higher	O
exposure	O
of	O
the	O
reactive	O
tryptophan	O
residues	O
,	O
impart	O
an	O
increased	O
photooxidation	O
degree	O
to	O
the	O
proteins	O
at	O
pH	O
8	O
,	O
specially	O
to	O
the	O
alpha	B-Protein
-	I-Protein
chymotrypsin	I-Protein
.	O

Sequence	O
analysis	O
of	O
a	O
gene	O
product	O
synthesized	O
by	O
Xanthomonas	O
sp	O
.	O
during	O
growth	O
on	O
natural	O
rubber	O
latex	O
.	O
<EOS>	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
secretes	B-X
an	B-X
extracellular	B-X
protein	B-X
(	B-X
Mr	B-X
approximately	B-X
70+/-5	B-X
kDa	B-X
)	B-X
during	B-X
growth	B-X
on	B-X
purified	B-X
natural	B-X
rubber	B-X
[	B-X
poly	B-X
(	B-X
1,4-cis-isoprene	B-X
)	B-X
]	B-X
but	B-X
not	B-X
during	B-X
growth	B-X
on	B-X
water-soluble	B-X
carbon	B-X
sources	B-X
such	B-X
as	B-X
glucose	B-X
or	B-X
gluconate	B-X
.	B-X
A	B-X
1.3	B-X
kbp	B-X
DNA	B-X
fragment	B-X
coding	B-X
for	B-X
an	B-X
internal	B-X
part	B-X
of	B-X
the	B-X
structural	B-X
gene	B-X
of	B-X
the	B-X
70	B-X
kDa	B-X
protein	B-X
was	B-X
amplified	B-X
by	B-X
nested	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
using	B-X
amino	B-X
acid	B-X
sequence	B-X
information	B-X
obtained	B-X
after	B-X
Edman	B-X
degradation	B-X
of	B-X
selected	B-X
trypsin-generated	B-X
peptides	B-X
of	B-X
the	B-X
purified	B-X
70	B-X
kDa	B-X
protein	B-X
.	B-X
The	B-X
PCR	B-X
product	B-X
was	B-X
used	B-X
as	B-X
a	B-X
DNA	B-X
probe	B-X
to	B-X
clone	B-X
the	B-X
complete	B-X
structural	B-X
gene	B-X
from	B-X
genomic	B-X
DNA	B-X
of	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
This	B-X
region	B-X
includes	B-X
a	B-X
histidine	B-X
residue	B-X
(	B-X
H519	B-X
in	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
and	B-X
H265	B-X
and	B-X
H271	B-X
in	B-X
the	B-X
Pseudomonas	B-X
strains	B-X
,	B-X
respectively	B-X
)	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
activity	B-X
in	B-X
CCPs	B-X
and	B-X
that	B-X
is	B-X
also	B-X
conserved	B-X
in	B-X
other	B-X
bacterial	B-X
oxidases	B-X
.	B-X
Blast	B-X
analysis	B-X
confirmed	B-X
the	B-X
relatedness	B-X
of	B-X
the	B-X
70	B-X
kDa	B-X
protein	B-X
to	B-X
heme-containing	B-X
oxidases	B-X
and	B-X
suggested	B-X
that	B-X
it	B-X
is	B-X
a	B-X
member	B-X
of	B-X
a	B-X
new	B-X
family	B-X
of	B-X
relatively	B-X
large	B-X
(	B-X
approximately	B-X
500	B-X
to	B-X
approximately	B-X
1000	B-X
amino	B-X
acids	B-X
)	B-X
extracellular	B-X
proteins	B-X
with	B-X
so	B-X
far	B-X
unknown	B-X
function	B-X
being	B-X
only	B-X
far	B-X
related	B-X
in	B-X
amino	B-X
acid	B-X
sequence	B-X
to	B-X
P.	B-X
denitrificans	B-X
and	B-X
P.	B-X
aeruginosa	B-X
CCPs	B-X
.	B-X

Xanthomonas	O
sp	O
.	O
secretes	O
an	O
extracellular	O
protein	O
(	O
Mr	O
approximately	O
70	O
+	O
/	O
-	O
5	O
kDa	O
)	O
during	O
growth	O
on	O
purified	O
natural	O
rubber	O
[	O
poly	O
(	O
1	O
,	O
4	O
-	O
cis	O
-	O
isoprene	O
)	O
]	O
but	O
not	O
during	O
growth	O
on	O
water	O
-	O
soluble	O
carbon	O
sources	O
such	O
as	O
glucose	O
or	O
gluconate	O
.	O
<EOS>	B-X
Lithium	B-X
inhibits	B-X
many	B-X
enzymes	B-X
:	B-X
Na/K	B-X
ATPase	B-X
,	B-X
adenylcyclase	B-X
,	B-X
enzymes	B-X
of	B-X
the	B-X
prostaglandines	B-X
E1	B-X
synthesis	B-X
,	B-X
inositol-1-phosphatase	B-X
.	B-X
Topical	B-X
lithium	B-X
succinate	B-X
associated	B-X
with	B-X
zinc	B-X
sulfate	B-X
and	B-X
lithium	B-X
gluconate	B-X
had	B-X
a	B-X
greater	B-X
efficacy	B-X
than	B-X
placebo	B-X
.	B-X
Comparison	B-X
with	B-X
topical	B-X
ketoconazole	B-X
showed	B-X
a	B-X
non	B-X
inferiority	B-X
of	B-X
lithium	B-X
gluconate	B-X
.	B-X
Lithium	B-X
gluconate	B-X
treatment	B-X
of	B-X
seborrhoeic	B-X
dermatitis	B-X
is	B-X
a	B-X
bid	B-X
application	B-X
during	B-X
at	B-X
least	B-X
8	B-X
weeks	B-X
.	B-X

A	O
1	O
.	O
3	O
kbp	O
DNA	O
fragment	O
coding	O
for	O
an	O
internal	O
part	O
of	O
the	O
structural	O
gene	O
of	O
the	O
70	O
kDa	O
protein	O
was	O
amplified	O
by	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
amino	O
acid	O
sequence	O
information	O
obtained	O
after	O
Edman	O
degradation	O
of	O
selected	O
trypsin	O
-	O
generated	O
peptides	O
of	O
the	O
purified	O
70	O
kDa	O
protein	O
.	O
<EOS>	B-X
secretes	B-X
an	B-X
extracellular	B-X
protein	B-X
(	B-X
Mr	B-X
approximately	B-X
70+/-5	B-X
kDa	B-X
)	B-X
during	B-X
growth	B-X
on	B-X
purified	B-X
natural	B-X
rubber	B-X
[	B-X
poly	B-X
(	B-X
1,4-cis-isoprene	B-X
)	B-X
]	B-X
but	B-X
not	B-X
during	B-X
growth	B-X
on	B-X
water-soluble	B-X
carbon	B-X
sources	B-X
such	B-X
as	B-X
glucose	B-X
or	B-X
gluconate	B-X
.	B-X
A	B-X
1.3	B-X
kbp	B-X
DNA	B-X
fragment	B-X
coding	B-X
for	B-X
an	B-X
internal	B-X
part	B-X
of	B-X
the	B-X
structural	B-X
gene	B-X
of	B-X
the	B-X
70	B-X
kDa	B-X
protein	B-X
was	B-X
amplified	B-X
by	B-X
nested	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
using	B-X
amino	B-X
acid	B-X
sequence	B-X
information	B-X
obtained	B-X
after	B-X
Edman	B-X
degradation	B-X
of	B-X
selected	B-X
trypsin-generated	B-X
peptides	B-X
of	B-X
the	B-X
purified	B-X
70	B-X
kDa	B-X
protein	B-X
.	B-X
The	B-X
PCR	B-X
product	B-X
was	B-X
used	B-X
as	B-X
a	B-X
DNA	B-X
probe	B-X
to	B-X
clone	B-X
the	B-X
complete	B-X
structural	B-X
gene	B-X
from	B-X
genomic	B-X
DNA	B-X
of	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
The	B-X
sequenced	B-X
DNA	B-X
contained	B-X
a	B-X
2037	B-X
bp	B-X
open	B-X
reading	B-X
frame	B-X
which	B-X
coded	B-X
for	B-X
a	B-X
polypeptide	B-X
of	B-X
678	B-X
amino	B-X
acids	B-X
(	B-X
Mr	B-X
74.6	B-X
kDa	B-X
)	B-X
and	B-X
which	B-X
included	B-X
the	B-X
features	B-X
of	B-X
the	B-X
N-terminal	B-X
signal	B-X
peptidase	B-X
cleavage	B-X
site	B-X
(	B-X
Mr	B-X
approximately	B-X
72.9	B-X
kDa	B-X
for	B-X
the	B-X
mature	B-X
protein	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
two	B-X
heme	B-X
binding	B-X
motifs	B-X
(	B-X
CXXCH	B-X
)	B-X
and	B-X
a	B-X
approximately	B-X
20	B-X
amino	B-X
acids	B-X
long	B-X
sequence	B-X
that	B-X
is	B-X
conserved	B-X
in	B-X
the	B-X
Paracoccus	B-X
denitrificans	B-X
and	B-X
Pseudomonas	B-X
aeruginosa	B-X
diheme	B-X
cytochrome	B-X
c	B-X
peroxidases	B-X
(	B-X
CCPs	B-X
)	B-X
.	B-X
This	B-X
region	B-X
includes	B-X
a	B-X
histidine	B-X
residue	B-X
(	B-X
H519	B-X
in	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
and	B-X
H265	B-X
and	B-X
H271	B-X
in	B-X
the	B-X
Pseudomonas	B-X
strains	B-X
,	B-X
respectively	B-X
)	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
activity	B-X
in	B-X
CCPs	B-X
and	B-X
that	B-X
is	B-X
also	B-X
conserved	B-X
in	B-X
other	B-X
bacterial	B-X
oxidases	B-X
.	B-X
Blast	B-X
analysis	B-X
confirmed	B-X
the	B-X
relatedness	B-X
of	B-X
the	B-X
70	B-X
kDa	B-X
protein	B-X
to	B-X
heme-containing	B-X
oxidases	B-X
and	B-X
suggested	B-X
that	B-X
it	B-X
is	B-X
a	B-X
member	B-X
of	B-X
a	B-X
new	B-X
family	B-X
of	B-X
relatively	B-X
large	B-X
(	B-X
approximately	B-X
500	B-X
to	B-X
approximately	B-X
1000	B-X
amino	B-X
acids	B-X
)	B-X
extracellular	B-X
proteins	B-X
with	B-X
so	B-X
far	B-X
unknown	B-X
function	B-X
being	B-X
only	B-X
far	B-X
related	B-X
in	B-X
amino	B-X
acid	B-X
sequence	B-X
to	B-X
P.	B-X
denitrificans	B-X
and	B-X
P.	B-X
aeruginosa	B-X
CCPs	B-X
.	B-X

The	O
PCR	O
product	O
was	O
used	O
as	O
a	O
DNA	O
probe	O
to	O
clone	O
the	O
complete	O
structural	O
gene	O
from	O
genomic	O
DNA	O
of	O
Xanthomonas	O
sp	O
.	O
<EOS>	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
A	B-X
1.3	B-X
kbp	B-X
DNA	B-X
fragment	B-X
coding	B-X
for	B-X
an	B-X
internal	B-X
part	B-X
of	B-X
the	B-X
structural	B-X
gene	B-X
of	B-X
the	B-X
70	B-X
kDa	B-X
protein	B-X
was	B-X
amplified	B-X
by	B-X
nested	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
using	B-X
amino	B-X
acid	B-X
sequence	B-X
information	B-X
obtained	B-X
after	B-X
Edman	B-X
degradation	B-X
of	B-X
selected	B-X
trypsin-generated	B-X
peptides	B-X
of	B-X
the	B-X
purified	B-X
70	B-X
kDa	B-X
protein	B-X
.	B-X
The	B-X
PCR	B-X
product	B-X
was	B-X
used	B-X
as	B-X
a	B-X
DNA	B-X
probe	B-X
to	B-X
clone	B-X
the	B-X
complete	B-X
structural	B-X
gene	B-X
from	B-X
genomic	B-X
DNA	B-X
of	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
The	B-X
sequenced	B-X
DNA	B-X
contained	B-X
a	B-X
2037	B-X
bp	B-X
open	B-X
reading	B-X
frame	B-X
which	B-X
coded	B-X
for	B-X
a	B-X
polypeptide	B-X
of	B-X
678	B-X
amino	B-X
acids	B-X
(	B-X
Mr	B-X
74.6	B-X
kDa	B-X
)	B-X
and	B-X
which	B-X
included	B-X
the	B-X
features	B-X
of	B-X
the	B-X
N-terminal	B-X
signal	B-X
peptidase	B-X
cleavage	B-X
site	B-X
(	B-X
Mr	B-X
approximately	B-X
72.9	B-X
kDa	B-X
for	B-X
the	B-X
mature	B-X
protein	B-X
)	B-X
.	B-X
This	B-X
region	B-X
includes	B-X
a	B-X
histidine	B-X
residue	B-X
(	B-X
H519	B-X
in	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
and	B-X
H265	B-X
and	B-X
H271	B-X
in	B-X
the	B-X
Pseudomonas	B-X
strains	B-X
,	B-X
respectively	B-X
)	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
activity	B-X
in	B-X
CCPs	B-X
and	B-X
that	B-X
is	B-X
also	B-X
conserved	B-X
in	B-X
other	B-X
bacterial	B-X
oxidases	B-X
.	B-X

The	O
sequenced	O
DNA	O
contained	O
a	O
2037	O
bp	O
open	O
reading	O
frame	O
which	O
coded	O
for	O
a	O
polypeptide	O
of	O
678	O
amino	O
acids	O
(	O
Mr	O
74	O
.	O
6	O
kDa	O
)	O
and	O
which	O
included	O
the	O
features	O
of	O
the	O
N	O
-	O
terminal	O
signal	O
peptidase	O
cleavage	O
site	O
(	O
Mr	O
approximately	O
72	O
.	O
9	O
kDa	O
for	O
the	O
mature	O
protein	O
)	O
.	O

Analysis	O
of	O
the	O
amino	O
acid	O
sequence	O
revealed	O
the	O
presence	O
of	O
two	O
heme	O
binding	O
motifs	O
(	O
CXXCH	O
)	O
and	O
a	O
approximately	O
20	O
amino	O
acids	O
long	O
sequence	O
that	O
is	O
conserved	O
in	O
the	O
Paracoccus	O
denitrificans	O
and	O
Pseudomonas	O
aeruginosa	O
diheme	O
cytochrome	B-Protein
c	I-Protein
peroxidases	I-Protein
(	O
CCPs	B-Protein
)	O
.	O

This	O
region	O
includes	O
a	O
histidine	O
residue	O
(	O
H519	O
in	O
Xanthomonas	O
sp	O
.	O
and	O
H265	O
and	O
H271	O
in	O
the	O
Pseudomonas	O
strains	O
,	O
respectively	O
)	O
that	O
is	O
essential	O
for	O
activity	O
in	O
CCPs	B-Protein
and	O
that	O
is	O
also	O
conserved	O
in	O
other	O
bacterial	O
oxidases	O
.	O
<EOS>	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
The	B-X
PCR	B-X
product	B-X
was	B-X
used	B-X
as	B-X
a	B-X
DNA	B-X
probe	B-X
to	B-X
clone	B-X
the	B-X
complete	B-X
structural	B-X
gene	B-X
from	B-X
genomic	B-X
DNA	B-X
of	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
two	B-X
heme	B-X
binding	B-X
motifs	B-X
(	B-X
CXXCH	B-X
)	B-X
and	B-X
a	B-X
approximately	B-X
20	B-X
amino	B-X
acids	B-X
long	B-X
sequence	B-X
that	B-X
is	B-X
conserved	B-X
in	B-X
the	B-X
Paracoccus	B-X
denitrificans	B-X
and	B-X
Pseudomonas	B-X
aeruginosa	B-X
diheme	B-X
cytochrome	B-X
c	B-X
peroxidases	B-X
(	B-X
CCPs	B-X
)	B-X
.	B-X
This	B-X
region	B-X
includes	B-X
a	B-X
histidine	B-X
residue	B-X
(	B-X
H519	B-X
in	B-X
Xanthomonas	B-X
sp	B-X
.	B-X
and	B-X
H265	B-X
and	B-X
H271	B-X
in	B-X
the	B-X
Pseudomonas	B-X
strains	B-X
,	B-X
respectively	B-X
)	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
activity	B-X
in	B-X
CCPs	B-X
and	B-X
that	B-X
is	B-X
also	B-X
conserved	B-X
in	B-X
other	B-X
bacterial	B-X
oxidases	B-X
.	B-X
Blast	B-X
analysis	B-X
confirmed	B-X
the	B-X
relatedness	B-X
of	B-X
the	B-X
70	B-X
kDa	B-X
protein	B-X
to	B-X
heme-containing	B-X
oxidases	B-X
and	B-X
suggested	B-X
that	B-X
it	B-X
is	B-X
a	B-X
member	B-X
of	B-X
a	B-X
new	B-X
family	B-X
of	B-X
relatively	B-X
large	B-X
(	B-X
approximately	B-X
500	B-X
to	B-X
approximately	B-X
1000	B-X
amino	B-X
acids	B-X
)	B-X
extracellular	B-X
proteins	B-X
with	B-X
so	B-X
far	B-X
unknown	B-X
function	B-X
being	B-X
only	B-X
far	B-X
related	B-X
in	B-X
amino	B-X
acid	B-X
sequence	B-X
to	B-X
P.	B-X
denitrificans	B-X
and	B-X
P.	B-X
aeruginosa	B-X
CCPs	B-X
.	B-X

Blast	O
analysis	O
confirmed	O
the	O
relatedness	O
of	O
the	O
70	O
kDa	O
protein	O
to	O
heme	O
-	O
containing	O
oxidases	O
and	O
suggested	O
that	O
it	O
is	O
a	O
member	O
of	O
a	O
new	O
family	O
of	O
relatively	O
large	O
(	O
approximately	O
500	O
to	O
approximately	O
1000	O
amino	O
acids	O
)	O
extracellular	O
proteins	O
with	O
so	O
far	O
unknown	O
function	O
being	O
only	O
far	O
related	O
in	O
amino	O
acid	O
sequence	O
to	O
P	O
.	O
denitrificans	O
and	O
P	O
.	O
aeruginosa	O
CCPs	B-Protein
.	O

High	O
affinity	O
for	O
farnesyltransferase	O
and	O
alternative	O
prenylation	O
contribute	O
individually	O
to	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
resistance	O
to	O
farnesyltransferase	O
inhibitors	O
.	O

Farnesyltransferase	O
inhibitors	O
(	O
FTIs	O
)	O
block	O
Ras	O
farnesylation	O
,	O
subcellular	O
localization	O
and	O
activity	O
,	O
and	O
inhibit	O
the	O
growth	O
of	O
Ras	O
-	O
transformed	O
cells	O
.	O
<EOS>	B-X
Farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
block	B-X
Ras	B-X
farnesylation	B-X
,	B-X
subcellular	B-X
localization	B-X
and	B-X
activity	B-X
,	B-X
and	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
Ras-transformed	B-X
cells	B-X
.	B-X
Although	B-X
FTIs	B-X
are	B-X
ineffective	B-X
against	B-X
K-Ras4B	B-X
,	B-X
the	B-X
Ras	B-X
isoform	B-X
most	B-X
commonly	B-X
mutated	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
they	B-X
can	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
tumors	B-X
containing	B-X
oncogenic	B-X
K-Ras4B	B-X
,	B-X
implicating	B-X
other	B-X
farnesylated	B-X
proteins	B-X
or	B-X
suggesting	B-X
distinct	B-X
functions	B-X
for	B-X
farnesylated	B-X
and	B-X
for	B-X
geranylgeranylated	B-X
K-Ras	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
when	B-X
farnesyltransferase	B-X
is	B-X
inhibited	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
bypassing	B-X
FTI	B-X
blockade	B-X
through	B-X
geranylgeranylation	B-X
,	B-X
K-Ras4B	B-X
resistance	B-X
to	B-X
FTIs	B-X
may	B-X
also	B-X
result	B-X
from	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
farnesyltransferase	B-X
.	B-X
Using	B-X
chimeric	B-X
Ras	B-X
proteins	B-X
containing	B-X
all	B-X
combinations	B-X
of	B-X
Ras	B-X
background	B-X
,	B-X
CAAX	B-X
motif	B-X
,	B-X
and	B-X
K-Ras	B-X
polybasic	B-X
domain	B-X
,	B-X
we	B-X
show	B-X
that	B-X
either	B-X
a	B-X
polybasic	B-X
domain	B-X
or	B-X
an	B-X
alternatively	B-X
prenylated	B-X
CAAX	B-X
renders	B-X
Ras	B-X
prenylation	B-X
,	B-X
Ras-induced	B-X
Elk-1	B-X
activation	B-X
,	B-X
and	B-X
anchorage-independent	B-X
cell	B-X
growth	B-X
FTI-resistant	B-X
.	B-X
The	B-X
polybasic	B-X
domain	B-X
alone	B-X
increases	B-X
the	B-X
affinity	B-X
of	B-X
Ras	B-X
for	B-X
farnesyltransferase	B-X
,	B-X
implying	B-X
independent	B-X
roles	B-X
for	B-X
each	B-X
K-Ras4B	B-X
sequence	B-X
element	B-X
in	B-X
FTI	B-X
resistance	B-X
.	B-X
Using	B-X
microarray	B-X
analysis	B-X
and	B-X
colony	B-X
formation	B-X
assays	B-X
,	B-X
we	B-X
confirm	B-X
that	B-X
K-Ras	B-X
function	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
prenyl	B-X
group	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
that	B-X
FTI	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
transformed	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
K-Ras	B-X
inhibition	B-X
.	B-X

Although	O
FTIs	O
are	O
ineffective	O
against	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
,	O
the	O
Ras	O
isoform	O
most	O
commonly	O
mutated	O
in	O
human	O
cancers	O
,	O
they	O
can	O
inhibit	O
the	O
growth	O
of	O
tumors	O
containing	O
oncogenic	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
,	O
implicating	O
other	O
farnesylated	O
proteins	O
or	O
suggesting	O
distinct	O
functions	O
for	O
farnesylated	O
and	O
for	O
geranylgeranylated	O
K	B-Protein
-	I-Protein
Ras	I-Protein
,	O
which	O
is	O
generated	O
when	O
farnesyltransferase	O
is	O
inhibited	O
.	O
<EOS>	B-X
Farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
block	B-X
Ras	B-X
farnesylation	B-X
,	B-X
subcellular	B-X
localization	B-X
and	B-X
activity	B-X
,	B-X
and	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
Ras-transformed	B-X
cells	B-X
.	B-X
Although	B-X
FTIs	B-X
are	B-X
ineffective	B-X
against	B-X
K-Ras4B	B-X
,	B-X
the	B-X
Ras	B-X
isoform	B-X
most	B-X
commonly	B-X
mutated	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
they	B-X
can	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
tumors	B-X
containing	B-X
oncogenic	B-X
K-Ras4B	B-X
,	B-X
implicating	B-X
other	B-X
farnesylated	B-X
proteins	B-X
or	B-X
suggesting	B-X
distinct	B-X
functions	B-X
for	B-X
farnesylated	B-X
and	B-X
for	B-X
geranylgeranylated	B-X
K-Ras	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
when	B-X
farnesyltransferase	B-X
is	B-X
inhibited	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
bypassing	B-X
FTI	B-X
blockade	B-X
through	B-X
geranylgeranylation	B-X
,	B-X
K-Ras4B	B-X
resistance	B-X
to	B-X
FTIs	B-X
may	B-X
also	B-X
result	B-X
from	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
farnesyltransferase	B-X
.	B-X
Using	B-X
chimeric	B-X
Ras	B-X
proteins	B-X
containing	B-X
all	B-X
combinations	B-X
of	B-X
Ras	B-X
background	B-X
,	B-X
CAAX	B-X
motif	B-X
,	B-X
and	B-X
K-Ras	B-X
polybasic	B-X
domain	B-X
,	B-X
we	B-X
show	B-X
that	B-X
either	B-X
a	B-X
polybasic	B-X
domain	B-X
or	B-X
an	B-X
alternatively	B-X
prenylated	B-X
CAAX	B-X
renders	B-X
Ras	B-X
prenylation	B-X
,	B-X
Ras-induced	B-X
Elk-1	B-X
activation	B-X
,	B-X
and	B-X
anchorage-independent	B-X
cell	B-X
growth	B-X
FTI-resistant	B-X
.	B-X
The	B-X
polybasic	B-X
domain	B-X
alone	B-X
increases	B-X
the	B-X
affinity	B-X
of	B-X
Ras	B-X
for	B-X
farnesyltransferase	B-X
,	B-X
implying	B-X
independent	B-X
roles	B-X
for	B-X
each	B-X
K-Ras4B	B-X
sequence	B-X
element	B-X
in	B-X
FTI	B-X
resistance	B-X
.	B-X
Using	B-X
microarray	B-X
analysis	B-X
and	B-X
colony	B-X
formation	B-X
assays	B-X
,	B-X
we	B-X
confirm	B-X
that	B-X
K-Ras	B-X
function	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
prenyl	B-X
group	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
that	B-X
FTI	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
transformed	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
K-Ras	B-X
inhibition	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
relevant	B-X
FTI	B-X
targets	B-X
will	B-X
lack	B-X
both	B-X
polybasic	B-X
and	B-X
potentially	B-X
geranylgeranylated	B-X
methionine-CAAX	B-X
motifs	B-X
.	B-X

In	O
addition	O
to	O
bypassing	O
FTI	O
blockade	O
through	O
geranylgeranylation	O
,	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
resistance	O
to	O
FTIs	O
may	O
also	O
result	O
from	O
its	O
higher	O
affinity	O
for	O
farnesyltransferase	O
.	O
<EOS>	B-X
Farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
block	B-X
Ras	B-X
farnesylation	B-X
,	B-X
subcellular	B-X
localization	B-X
and	B-X
activity	B-X
,	B-X
and	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
Ras-transformed	B-X
cells	B-X
.	B-X
Although	B-X
FTIs	B-X
are	B-X
ineffective	B-X
against	B-X
K-Ras4B	B-X
,	B-X
the	B-X
Ras	B-X
isoform	B-X
most	B-X
commonly	B-X
mutated	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
they	B-X
can	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
tumors	B-X
containing	B-X
oncogenic	B-X
K-Ras4B	B-X
,	B-X
implicating	B-X
other	B-X
farnesylated	B-X
proteins	B-X
or	B-X
suggesting	B-X
distinct	B-X
functions	B-X
for	B-X
farnesylated	B-X
and	B-X
for	B-X
geranylgeranylated	B-X
K-Ras	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
when	B-X
farnesyltransferase	B-X
is	B-X
inhibited	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
bypassing	B-X
FTI	B-X
blockade	B-X
through	B-X
geranylgeranylation	B-X
,	B-X
K-Ras4B	B-X
resistance	B-X
to	B-X
FTIs	B-X
may	B-X
also	B-X
result	B-X
from	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
farnesyltransferase	B-X
.	B-X
Using	B-X
chimeric	B-X
Ras	B-X
proteins	B-X
containing	B-X
all	B-X
combinations	B-X
of	B-X
Ras	B-X
background	B-X
,	B-X
CAAX	B-X
motif	B-X
,	B-X
and	B-X
K-Ras	B-X
polybasic	B-X
domain	B-X
,	B-X
we	B-X
show	B-X
that	B-X
either	B-X
a	B-X
polybasic	B-X
domain	B-X
or	B-X
an	B-X
alternatively	B-X
prenylated	B-X
CAAX	B-X
renders	B-X
Ras	B-X
prenylation	B-X
,	B-X
Ras-induced	B-X
Elk-1	B-X
activation	B-X
,	B-X
and	B-X
anchorage-independent	B-X
cell	B-X
growth	B-X
FTI-resistant	B-X
.	B-X
The	B-X
polybasic	B-X
domain	B-X
alone	B-X
increases	B-X
the	B-X
affinity	B-X
of	B-X
Ras	B-X
for	B-X
farnesyltransferase	B-X
,	B-X
implying	B-X
independent	B-X
roles	B-X
for	B-X
each	B-X
K-Ras4B	B-X
sequence	B-X
element	B-X
in	B-X
FTI	B-X
resistance	B-X
.	B-X
Using	B-X
microarray	B-X
analysis	B-X
and	B-X
colony	B-X
formation	B-X
assays	B-X
,	B-X
we	B-X
confirm	B-X
that	B-X
K-Ras	B-X
function	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
prenyl	B-X
group	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
that	B-X
FTI	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
transformed	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
K-Ras	B-X
inhibition	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
relevant	B-X
FTI	B-X
targets	B-X
will	B-X
lack	B-X
both	B-X
polybasic	B-X
and	B-X
potentially	B-X
geranylgeranylated	B-X
methionine-CAAX	B-X
motifs	B-X
.	B-X

Using	O
chimeric	O
Ras	O
proteins	O
containing	O
all	O
combinations	O
of	O
Ras	O
background	O
,	O
CAAX	O
motif	O
,	O
and	O
K	B-Protein
-	I-Protein
Ras	I-Protein
polybasic	O
domain	O
,	O
we	O
show	O
that	O
either	O
a	O
polybasic	O
domain	O
or	O
an	O
alternatively	O
prenylated	O
CAAX	O
renders	O
Ras	O
prenylation	O
,	O
Ras	O
-	O
induced	O
Elk	B-Protein
-	I-Protein
1	I-Protein
activation	O
,	O
and	O
anchorage	O
-	O
independent	O
cell	O
growth	O
FTI	O
-	O
resistant	O
.	O
<EOS>	B-X
Farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
block	B-X
Ras	B-X
farnesylation	B-X
,	B-X
subcellular	B-X
localization	B-X
and	B-X
activity	B-X
,	B-X
and	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
Ras-transformed	B-X
cells	B-X
.	B-X
Although	B-X
FTIs	B-X
are	B-X
ineffective	B-X
against	B-X
K-Ras4B	B-X
,	B-X
the	B-X
Ras	B-X
isoform	B-X
most	B-X
commonly	B-X
mutated	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
they	B-X
can	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
tumors	B-X
containing	B-X
oncogenic	B-X
K-Ras4B	B-X
,	B-X
implicating	B-X
other	B-X
farnesylated	B-X
proteins	B-X
or	B-X
suggesting	B-X
distinct	B-X
functions	B-X
for	B-X
farnesylated	B-X
and	B-X
for	B-X
geranylgeranylated	B-X
K-Ras	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
when	B-X
farnesyltransferase	B-X
is	B-X
inhibited	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
bypassing	B-X
FTI	B-X
blockade	B-X
through	B-X
geranylgeranylation	B-X
,	B-X
K-Ras4B	B-X
resistance	B-X
to	B-X
FTIs	B-X
may	B-X
also	B-X
result	B-X
from	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
farnesyltransferase	B-X
.	B-X
Using	B-X
chimeric	B-X
Ras	B-X
proteins	B-X
containing	B-X
all	B-X
combinations	B-X
of	B-X
Ras	B-X
background	B-X
,	B-X
CAAX	B-X
motif	B-X
,	B-X
and	B-X
K-Ras	B-X
polybasic	B-X
domain	B-X
,	B-X
we	B-X
show	B-X
that	B-X
either	B-X
a	B-X
polybasic	B-X
domain	B-X
or	B-X
an	B-X
alternatively	B-X
prenylated	B-X
CAAX	B-X
renders	B-X
Ras	B-X
prenylation	B-X
,	B-X
Ras-induced	B-X
Elk-1	B-X
activation	B-X
,	B-X
and	B-X
anchorage-independent	B-X
cell	B-X
growth	B-X
FTI-resistant	B-X
.	B-X
The	B-X
polybasic	B-X
domain	B-X
alone	B-X
increases	B-X
the	B-X
affinity	B-X
of	B-X
Ras	B-X
for	B-X
farnesyltransferase	B-X
,	B-X
implying	B-X
independent	B-X
roles	B-X
for	B-X
each	B-X
K-Ras4B	B-X
sequence	B-X
element	B-X
in	B-X
FTI	B-X
resistance	B-X
.	B-X
Using	B-X
microarray	B-X
analysis	B-X
and	B-X
colony	B-X
formation	B-X
assays	B-X
,	B-X
we	B-X
confirm	B-X
that	B-X
K-Ras	B-X
function	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
prenyl	B-X
group	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
that	B-X
FTI	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
transformed	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
K-Ras	B-X
inhibition	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
relevant	B-X
FTI	B-X
targets	B-X
will	B-X
lack	B-X
both	B-X
polybasic	B-X
and	B-X
potentially	B-X
geranylgeranylated	B-X
methionine-CAAX	B-X
motifs	B-X
.	B-X

The	O
polybasic	O
domain	O
alone	O
increases	O
the	O
affinity	O
of	O
Ras	O
for	O
farnesyltransferase	O
,	O
implying	O
independent	O
roles	O
for	O
each	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
sequence	O
element	O
in	O
FTI	O
resistance	O
.	O
<EOS>	B-X
Farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
block	B-X
Ras	B-X
farnesylation	B-X
,	B-X
subcellular	B-X
localization	B-X
and	B-X
activity	B-X
,	B-X
and	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
Ras-transformed	B-X
cells	B-X
.	B-X
Although	B-X
FTIs	B-X
are	B-X
ineffective	B-X
against	B-X
K-Ras4B	B-X
,	B-X
the	B-X
Ras	B-X
isoform	B-X
most	B-X
commonly	B-X
mutated	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
they	B-X
can	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
tumors	B-X
containing	B-X
oncogenic	B-X
K-Ras4B	B-X
,	B-X
implicating	B-X
other	B-X
farnesylated	B-X
proteins	B-X
or	B-X
suggesting	B-X
distinct	B-X
functions	B-X
for	B-X
farnesylated	B-X
and	B-X
for	B-X
geranylgeranylated	B-X
K-Ras	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
when	B-X
farnesyltransferase	B-X
is	B-X
inhibited	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
bypassing	B-X
FTI	B-X
blockade	B-X
through	B-X
geranylgeranylation	B-X
,	B-X
K-Ras4B	B-X
resistance	B-X
to	B-X
FTIs	B-X
may	B-X
also	B-X
result	B-X
from	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
farnesyltransferase	B-X
.	B-X
Using	B-X
chimeric	B-X
Ras	B-X
proteins	B-X
containing	B-X
all	B-X
combinations	B-X
of	B-X
Ras	B-X
background	B-X
,	B-X
CAAX	B-X
motif	B-X
,	B-X
and	B-X
K-Ras	B-X
polybasic	B-X
domain	B-X
,	B-X
we	B-X
show	B-X
that	B-X
either	B-X
a	B-X
polybasic	B-X
domain	B-X
or	B-X
an	B-X
alternatively	B-X
prenylated	B-X
CAAX	B-X
renders	B-X
Ras	B-X
prenylation	B-X
,	B-X
Ras-induced	B-X
Elk-1	B-X
activation	B-X
,	B-X
and	B-X
anchorage-independent	B-X
cell	B-X
growth	B-X
FTI-resistant	B-X
.	B-X
The	B-X
polybasic	B-X
domain	B-X
alone	B-X
increases	B-X
the	B-X
affinity	B-X
of	B-X
Ras	B-X
for	B-X
farnesyltransferase	B-X
,	B-X
implying	B-X
independent	B-X
roles	B-X
for	B-X
each	B-X
K-Ras4B	B-X
sequence	B-X
element	B-X
in	B-X
FTI	B-X
resistance	B-X
.	B-X
Using	B-X
microarray	B-X
analysis	B-X
and	B-X
colony	B-X
formation	B-X
assays	B-X
,	B-X
we	B-X
confirm	B-X
that	B-X
K-Ras	B-X
function	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
prenyl	B-X
group	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
that	B-X
FTI	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
transformed	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
K-Ras	B-X
inhibition	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
relevant	B-X
FTI	B-X
targets	B-X
will	B-X
lack	B-X
both	B-X
polybasic	B-X
and	B-X
potentially	B-X
geranylgeranylated	B-X
methionine-CAAX	B-X
motifs	B-X
.	B-X

Using	O
microarray	O
analysis	O
and	O
colony	O
formation	O
assays	O
,	O
we	O
confirm	O
that	O
K	B-Protein
-	I-Protein
Ras	I-Protein
function	O
is	O
independent	O
of	O
the	O
identity	O
of	O
the	O
prenyl	O
group	O
and	O
,	O
therefore	O
,	O
that	O
FTI	O
inhibition	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
transformed	O
cells	O
is	O
likely	O
to	O
be	O
independent	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
inhibition	O
.	O

Our	O
results	O
imply	O
that	O
relevant	O
FTI	O
targets	O
will	O
lack	O
both	O
polybasic	O
and	O
potentially	O
geranylgeranylated	O
methionine	O
-	O
CAAX	O
motifs	O
.	O
<EOS>	B-X
Farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
block	B-X
Ras	B-X
farnesylation	B-X
,	B-X
subcellular	B-X
localization	B-X
and	B-X
activity	B-X
,	B-X
and	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
Ras-transformed	B-X
cells	B-X
.	B-X
Although	B-X
FTIs	B-X
are	B-X
ineffective	B-X
against	B-X
K-Ras4B	B-X
,	B-X
the	B-X
Ras	B-X
isoform	B-X
most	B-X
commonly	B-X
mutated	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
they	B-X
can	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
tumors	B-X
containing	B-X
oncogenic	B-X
K-Ras4B	B-X
,	B-X
implicating	B-X
other	B-X
farnesylated	B-X
proteins	B-X
or	B-X
suggesting	B-X
distinct	B-X
functions	B-X
for	B-X
farnesylated	B-X
and	B-X
for	B-X
geranylgeranylated	B-X
K-Ras	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
when	B-X
farnesyltransferase	B-X
is	B-X
inhibited	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
bypassing	B-X
FTI	B-X
blockade	B-X
through	B-X
geranylgeranylation	B-X
,	B-X
K-Ras4B	B-X
resistance	B-X
to	B-X
FTIs	B-X
may	B-X
also	B-X
result	B-X
from	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
farnesyltransferase	B-X
.	B-X
Using	B-X
chimeric	B-X
Ras	B-X
proteins	B-X
containing	B-X
all	B-X
combinations	B-X
of	B-X
Ras	B-X
background	B-X
,	B-X
CAAX	B-X
motif	B-X
,	B-X
and	B-X
K-Ras	B-X
polybasic	B-X
domain	B-X
,	B-X
we	B-X
show	B-X
that	B-X
either	B-X
a	B-X
polybasic	B-X
domain	B-X
or	B-X
an	B-X
alternatively	B-X
prenylated	B-X
CAAX	B-X
renders	B-X
Ras	B-X
prenylation	B-X
,	B-X
Ras-induced	B-X
Elk-1	B-X
activation	B-X
,	B-X
and	B-X
anchorage-independent	B-X
cell	B-X
growth	B-X
FTI-resistant	B-X
.	B-X
The	B-X
polybasic	B-X
domain	B-X
alone	B-X
increases	B-X
the	B-X
affinity	B-X
of	B-X
Ras	B-X
for	B-X
farnesyltransferase	B-X
,	B-X
implying	B-X
independent	B-X
roles	B-X
for	B-X
each	B-X
K-Ras4B	B-X
sequence	B-X
element	B-X
in	B-X
FTI	B-X
resistance	B-X
.	B-X
Using	B-X
microarray	B-X
analysis	B-X
and	B-X
colony	B-X
formation	B-X
assays	B-X
,	B-X
we	B-X
confirm	B-X
that	B-X
K-Ras	B-X
function	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
prenyl	B-X
group	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
that	B-X
FTI	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
transformed	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
K-Ras	B-X
inhibition	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
relevant	B-X
FTI	B-X
targets	B-X
will	B-X
lack	B-X
both	B-X
polybasic	B-X
and	B-X
potentially	B-X
geranylgeranylated	B-X
methionine-CAAX	B-X
motifs	B-X
.	B-X

Disruption	O
of	O
the	O
COP9	O
signalosome	O
Csn2	B-Protein
subunit	O
in	O
mice	O
causes	O
deficient	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
p53	B-Protein
and	O
cyclin	O
E	O
,	O
and	O
early	O
embryonic	O
death	O
.	O
<EOS>	B-X
Csn2	B-X
(	B-X
Trip15/Cops2/Alien	B-X
)	B-X
encodes	B-X
the	B-X
second	B-X
subunit	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
an	B-X
eight-subunit	B-X
heteromeric	B-X
complex	B-X
homologous	B-X
to	B-X
the	B-X
lid	B-X
subcomplex	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
CSN	B-X
associates	B-X
with	B-X
protein	B-X
kinase	B-X
activities	B-X
targeting	B-X
p53	B-X
,	B-X
c-Jun	B-X
,	B-X
and	B-X
IkappaB	B-X
for	B-X
phosphorylation	B-X
.	B-X
Csn2	B-X
also	B-X
interacts	B-X
with	B-X
and	B-X
regulates	B-X
a	B-X
subset	B-X
of	B-X
nuclear	B-X
hormone	B-X
receptors	B-X
and	B-X
is	B-X
considered	B-X
a	B-X
novel	B-X
corepressor	B-X
.	B-X
We	B-X
report	B-X
that	B-X
targeted	B-X
disruption	B-X
of	B-X
Csn2	B-X
in	B-X
mice	B-X
caused	B-X
arrest	B-X
of	B-X
embryo	B-X
development	B-X
at	B-X
the	B-X
peri-implantation	B-X
stage	B-X
.	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
blastocysts	B-X
failed	B-X
to	B-X
outgrow	B-X
in	B-X
culture	B-X
and	B-X
exhibited	B-X
a	B-X
cell	B-X
proliferation	B-X
defect	B-X
in	B-X
inner	B-X
cell	B-X
mass	B-X
,	B-X
accompanied	B-X
by	B-X
a	B-X
slight	B-X
decrease	B-X
in	B-X
Oct4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
lack	B-X
of	B-X
Csn2	B-X
disrupted	B-X
the	B-X
CSN	B-X
complex	B-X
and	B-X
resulted	B-X
in	B-X
a	B-X
drastic	B-X
increase	B-X
in	B-X
cyclin	B-X
E	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
CSN	B-X
in	B-X
cooperating	B-X
with	B-X
the	B-X
SCF-ubiquitin-proteasome	B-X
system	B-X
to	B-X
regulate	B-X
protein	B-X
turnover	B-X
.	B-X
Furthermore	B-X
,	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
embryos	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
p53	B-X
and	B-X
p21	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
premature	B-X
cell	B-X
cycle	B-X
arrest	B-X
of	B-X
the	B-X
mutant	B-X
.	B-X

Csn2	B-Protein
(	O
Trip15	B-Protein
/	O
Cops2	B-Protein
/	O
Alien	B-Protein
)	O
encodes	O
the	O
second	O
subunit	O
of	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
an	O
eight	O
-	O
subunit	O
heteromeric	O
complex	O
homologous	O
to	O
the	O
lid	O
subcomplex	O
of	O
the	O
26S	O
proteasome	O
.	O

CSN	O
is	O
a	O
regulator	O
of	O
SCF	O
(	O
Skp1	B-Protein
-	O
cullin	O
-	O
F	O
-	O
box	O
protein	O
)	O
ubiquitin	B-Protein
ligases	O
,	O
mostly	O
through	O
the	O
enzymatic	O
activity	O
that	O
deconjugates	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
from	O
the	O
SCF	O
Cul1	B-Protein
component	O
.	O

In	O
addition	O
,	O
CSN	O
associates	O
with	O
protein	O
kinase	O
activities	O
targeting	O
p53	B-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
and	O
IkappaB	O
for	O
phosphorylation	O
.	O
<EOS>	B-X
Csn2	B-X
(	B-X
Trip15/Cops2/Alien	B-X
)	B-X
encodes	B-X
the	B-X
second	B-X
subunit	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
an	B-X
eight-subunit	B-X
heteromeric	B-X
complex	B-X
homologous	B-X
to	B-X
the	B-X
lid	B-X
subcomplex	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
CSN	B-X
is	B-X
a	B-X
regulator	B-X
of	B-X
SCF	B-X
(	B-X
Skp1-cullin-F-box	B-X
protein	B-X
)	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
mostly	B-X
through	B-X
the	B-X
enzymatic	B-X
activity	B-X
that	B-X
deconjugates	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
from	B-X
the	B-X
SCF	B-X
Cul1	B-X
component	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
CSN	B-X
associates	B-X
with	B-X
protein	B-X
kinase	B-X
activities	B-X
targeting	B-X
p53	B-X
,	B-X
c-Jun	B-X
,	B-X
and	B-X
IkappaB	B-X
for	B-X
phosphorylation	B-X
.	B-X
Csn2	B-X
also	B-X
interacts	B-X
with	B-X
and	B-X
regulates	B-X
a	B-X
subset	B-X
of	B-X
nuclear	B-X
hormone	B-X
receptors	B-X
and	B-X
is	B-X
considered	B-X
a	B-X
novel	B-X
corepressor	B-X
.	B-X
We	B-X
report	B-X
that	B-X
targeted	B-X
disruption	B-X
of	B-X
Csn2	B-X
in	B-X
mice	B-X
caused	B-X
arrest	B-X
of	B-X
embryo	B-X
development	B-X
at	B-X
the	B-X
peri-implantation	B-X
stage	B-X
.	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
blastocysts	B-X
failed	B-X
to	B-X
outgrow	B-X
in	B-X
culture	B-X
and	B-X
exhibited	B-X
a	B-X
cell	B-X
proliferation	B-X
defect	B-X
in	B-X
inner	B-X
cell	B-X
mass	B-X
,	B-X
accompanied	B-X
by	B-X
a	B-X
slight	B-X
decrease	B-X
in	B-X
Oct4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
lack	B-X
of	B-X
Csn2	B-X
disrupted	B-X
the	B-X
CSN	B-X
complex	B-X
and	B-X
resulted	B-X
in	B-X
a	B-X
drastic	B-X
increase	B-X
in	B-X
cyclin	B-X
E	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
CSN	B-X
in	B-X
cooperating	B-X
with	B-X
the	B-X
SCF-ubiquitin-proteasome	B-X
system	B-X
to	B-X
regulate	B-X
protein	B-X
turnover	B-X
.	B-X
Furthermore	B-X
,	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
embryos	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
p53	B-X
and	B-X
p21	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
premature	B-X
cell	B-X
cycle	B-X
arrest	B-X
of	B-X
the	B-X
mutant	B-X
.	B-X

Csn2	B-Protein
also	O
interacts	O
with	O
and	O
regulates	O
a	O
subset	O
of	O
nuclear	O
hormone	O
receptors	O
and	O
is	O
considered	O
a	O
novel	O
corepressor	O
.	O
<EOS>	B-X
Csn2	B-X
(	B-X
Trip15/Cops2/Alien	B-X
)	B-X
encodes	B-X
the	B-X
second	B-X
subunit	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
an	B-X
eight-subunit	B-X
heteromeric	B-X
complex	B-X
homologous	B-X
to	B-X
the	B-X
lid	B-X
subcomplex	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Csn2	B-X
also	B-X
interacts	B-X
with	B-X
and	B-X
regulates	B-X
a	B-X
subset	B-X
of	B-X
nuclear	B-X
hormone	B-X
receptors	B-X
and	B-X
is	B-X
considered	B-X
a	B-X
novel	B-X
corepressor	B-X
.	B-X
We	B-X
report	B-X
that	B-X
targeted	B-X
disruption	B-X
of	B-X
Csn2	B-X
in	B-X
mice	B-X
caused	B-X
arrest	B-X
of	B-X
embryo	B-X
development	B-X
at	B-X
the	B-X
peri-implantation	B-X
stage	B-X
.	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
blastocysts	B-X
failed	B-X
to	B-X
outgrow	B-X
in	B-X
culture	B-X
and	B-X
exhibited	B-X
a	B-X
cell	B-X
proliferation	B-X
defect	B-X
in	B-X
inner	B-X
cell	B-X
mass	B-X
,	B-X
accompanied	B-X
by	B-X
a	B-X
slight	B-X
decrease	B-X
in	B-X
Oct4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
lack	B-X
of	B-X
Csn2	B-X
disrupted	B-X
the	B-X
CSN	B-X
complex	B-X
and	B-X
resulted	B-X
in	B-X
a	B-X
drastic	B-X
increase	B-X
in	B-X
cyclin	B-X
E	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
CSN	B-X
in	B-X
cooperating	B-X
with	B-X
the	B-X
SCF-ubiquitin-proteasome	B-X
system	B-X
to	B-X
regulate	B-X
protein	B-X
turnover	B-X
.	B-X
Furthermore	B-X
,	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
embryos	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
p53	B-X
and	B-X
p21	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
premature	B-X
cell	B-X
cycle	B-X
arrest	B-X
of	B-X
the	B-X
mutant	B-X
.	B-X

We	O
report	O
that	O
targeted	O
disruption	O
of	O
Csn2	B-Protein
in	O
mice	O
caused	O
arrest	O
of	O
embryo	O
development	O
at	O
the	O
peri	O
-	O
implantation	O
stage	O
.	O
<EOS>	B-X
Csn2	B-X
(	B-X
Trip15/Cops2/Alien	B-X
)	B-X
encodes	B-X
the	B-X
second	B-X
subunit	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
an	B-X
eight-subunit	B-X
heteromeric	B-X
complex	B-X
homologous	B-X
to	B-X
the	B-X
lid	B-X
subcomplex	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Csn2	B-X
also	B-X
interacts	B-X
with	B-X
and	B-X
regulates	B-X
a	B-X
subset	B-X
of	B-X
nuclear	B-X
hormone	B-X
receptors	B-X
and	B-X
is	B-X
considered	B-X
a	B-X
novel	B-X
corepressor	B-X
.	B-X
We	B-X
report	B-X
that	B-X
targeted	B-X
disruption	B-X
of	B-X
Csn2	B-X
in	B-X
mice	B-X
caused	B-X
arrest	B-X
of	B-X
embryo	B-X
development	B-X
at	B-X
the	B-X
peri-implantation	B-X
stage	B-X
.	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
blastocysts	B-X
failed	B-X
to	B-X
outgrow	B-X
in	B-X
culture	B-X
and	B-X
exhibited	B-X
a	B-X
cell	B-X
proliferation	B-X
defect	B-X
in	B-X
inner	B-X
cell	B-X
mass	B-X
,	B-X
accompanied	B-X
by	B-X
a	B-X
slight	B-X
decrease	B-X
in	B-X
Oct4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
lack	B-X
of	B-X
Csn2	B-X
disrupted	B-X
the	B-X
CSN	B-X
complex	B-X
and	B-X
resulted	B-X
in	B-X
a	B-X
drastic	B-X
increase	B-X
in	B-X
cyclin	B-X
E	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
CSN	B-X
in	B-X
cooperating	B-X
with	B-X
the	B-X
SCF-ubiquitin-proteasome	B-X
system	B-X
to	B-X
regulate	B-X
protein	B-X
turnover	B-X
.	B-X
Furthermore	B-X
,	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
embryos	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
p53	B-X
and	B-X
p21	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
premature	B-X
cell	B-X
cycle	B-X
arrest	B-X
of	B-X
the	B-X
mutant	B-X
.	B-X

Csn2	B-Protein
(	O
-	O
/	O
-	O
)	O
blastocysts	O
failed	O
to	O
outgrow	O
in	O
culture	O
and	O
exhibited	O
a	O
cell	O
proliferation	O
defect	O
in	O
inner	O
cell	O
mass	O
,	O
accompanied	O
by	O
a	O
slight	O
decrease	O
in	O
Oct4	B-Protein
.	O
<EOS>	B-X
Csn2	B-X
(	B-X
Trip15/Cops2/Alien	B-X
)	B-X
encodes	B-X
the	B-X
second	B-X
subunit	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
an	B-X
eight-subunit	B-X
heteromeric	B-X
complex	B-X
homologous	B-X
to	B-X
the	B-X
lid	B-X
subcomplex	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Csn2	B-X
also	B-X
interacts	B-X
with	B-X
and	B-X
regulates	B-X
a	B-X
subset	B-X
of	B-X
nuclear	B-X
hormone	B-X
receptors	B-X
and	B-X
is	B-X
considered	B-X
a	B-X
novel	B-X
corepressor	B-X
.	B-X
We	B-X
report	B-X
that	B-X
targeted	B-X
disruption	B-X
of	B-X
Csn2	B-X
in	B-X
mice	B-X
caused	B-X
arrest	B-X
of	B-X
embryo	B-X
development	B-X
at	B-X
the	B-X
peri-implantation	B-X
stage	B-X
.	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
blastocysts	B-X
failed	B-X
to	B-X
outgrow	B-X
in	B-X
culture	B-X
and	B-X
exhibited	B-X
a	B-X
cell	B-X
proliferation	B-X
defect	B-X
in	B-X
inner	B-X
cell	B-X
mass	B-X
,	B-X
accompanied	B-X
by	B-X
a	B-X
slight	B-X
decrease	B-X
in	B-X
Oct4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
lack	B-X
of	B-X
Csn2	B-X
disrupted	B-X
the	B-X
CSN	B-X
complex	B-X
and	B-X
resulted	B-X
in	B-X
a	B-X
drastic	B-X
increase	B-X
in	B-X
cyclin	B-X
E	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
CSN	B-X
in	B-X
cooperating	B-X
with	B-X
the	B-X
SCF-ubiquitin-proteasome	B-X
system	B-X
to	B-X
regulate	B-X
protein	B-X
turnover	B-X
.	B-X
Furthermore	B-X
,	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
embryos	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
p53	B-X
and	B-X
p21	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
premature	B-X
cell	B-X
cycle	B-X
arrest	B-X
of	B-X
the	B-X
mutant	B-X
.	B-X

In	O
addition	O
,	O
lack	O
of	O
Csn2	B-Protein
disrupted	O
the	O
CSN	O
complex	O
and	O
resulted	O
in	O
a	O
drastic	O
increase	O
in	O
cyclin	O
E	O
,	O
supporting	O
a	O
role	O
for	O
CSN	O
in	O
cooperating	O
with	O
the	O
SCF	O
-	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
to	O
regulate	O
protein	O
turnover	O
.	O

Furthermore	O
,	O
Csn2	B-Protein
(	O
-	O
/	O
-	O
)	O
embryos	O
contained	O
elevated	O
levels	O
of	O
p53	B-Protein
and	O
p21	B-Protein
,	O
which	O
may	O
contribute	O
to	O
premature	O
cell	O
cycle	O
arrest	O
of	O
the	O
mutant	O
.	O
<EOS>	B-X
Csn2	B-X
(	B-X
Trip15/Cops2/Alien	B-X
)	B-X
encodes	B-X
the	B-X
second	B-X
subunit	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
an	B-X
eight-subunit	B-X
heteromeric	B-X
complex	B-X
homologous	B-X
to	B-X
the	B-X
lid	B-X
subcomplex	B-X
of	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
CSN	B-X
associates	B-X
with	B-X
protein	B-X
kinase	B-X
activities	B-X
targeting	B-X
p53	B-X
,	B-X
c-Jun	B-X
,	B-X
and	B-X
IkappaB	B-X
for	B-X
phosphorylation	B-X
.	B-X
Csn2	B-X
also	B-X
interacts	B-X
with	B-X
and	B-X
regulates	B-X
a	B-X
subset	B-X
of	B-X
nuclear	B-X
hormone	B-X
receptors	B-X
and	B-X
is	B-X
considered	B-X
a	B-X
novel	B-X
corepressor	B-X
.	B-X
We	B-X
report	B-X
that	B-X
targeted	B-X
disruption	B-X
of	B-X
Csn2	B-X
in	B-X
mice	B-X
caused	B-X
arrest	B-X
of	B-X
embryo	B-X
development	B-X
at	B-X
the	B-X
peri-implantation	B-X
stage	B-X
.	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
blastocysts	B-X
failed	B-X
to	B-X
outgrow	B-X
in	B-X
culture	B-X
and	B-X
exhibited	B-X
a	B-X
cell	B-X
proliferation	B-X
defect	B-X
in	B-X
inner	B-X
cell	B-X
mass	B-X
,	B-X
accompanied	B-X
by	B-X
a	B-X
slight	B-X
decrease	B-X
in	B-X
Oct4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
lack	B-X
of	B-X
Csn2	B-X
disrupted	B-X
the	B-X
CSN	B-X
complex	B-X
and	B-X
resulted	B-X
in	B-X
a	B-X
drastic	B-X
increase	B-X
in	B-X
cyclin	B-X
E	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
CSN	B-X
in	B-X
cooperating	B-X
with	B-X
the	B-X
SCF-ubiquitin-proteasome	B-X
system	B-X
to	B-X
regulate	B-X
protein	B-X
turnover	B-X
.	B-X
Furthermore	B-X
,	B-X
Csn2	B-X
(	B-X
-/-	B-X
)	B-X
embryos	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
p53	B-X
and	B-X
p21	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
premature	B-X
cell	B-X
cycle	B-X
arrest	B-X
of	B-X
the	B-X
mutant	B-X
.	B-X

On	O
again	O
-	O
off	O
again	O
:	O
COP9	O
signalosome	O
turns	O
the	O
key	O
on	O
protein	O
degradation	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
an	B-X
eight-subunit	B-X
protein	B-X
complex	B-X
that	B-X
regulates	B-X
protein	B-X
ubiquitination	B-X
and	B-X
protein	B-X
turnover	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
plant	B-X
developmental	B-X
and	B-X
physiological	B-X
contexts	B-X
,	B-X
including	B-X
light-regulated	B-X
development	B-X
,	B-X
hormone	B-X
signaling	B-X
,	B-X
and	B-X
defense	B-X
against	B-X
pathogens	B-X
.	B-X
In	B-X
all	B-X
eukaryotes	B-X
tested	B-X
,	B-X
the	B-X
COP9	B-X
signalosome	B-X
is	B-X
able	B-X
to	B-X
posttranslationally	B-X
modify	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
E3-ubiquitin-ligase	B-X
complexes	B-X
by	B-X
cleaving	B-X
off	B-X
the	B-X
covalently	B-X
coupled	B-X
peptide	B-X
,	B-X
Nedd8	B-X
.	B-X
Two	B-X
contrasting	B-X
models	B-X
ascribe	B-X
stimulatory	B-X
or	B-X
inhibitory	B-X
roles	B-X
to	B-X
the	B-X
modification	B-X
of	B-X
cullin/E3	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
.	B-X
There	B-X
is	B-X
considerable	B-X
disagreement	B-X
as	B-X
to	B-X
whether	B-X
Nedd8	B-X
cleavage	B-X
underlies	B-X
all	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
's	B-X
numerous	B-X
cellular	B-X
and	B-X
phenotypic	B-X
effects	B-X
.	B-X
This	B-X
is	B-X
because	B-X
macroscopic	B-X
phenotypes	B-X
do	B-X
not	B-X
always	B-X
correlate	B-X
with	B-X
biochemical	B-X
defects	B-X
in	B-X
COP9	B-X
signalosome	B-X
mutants	B-X
.	B-X
Additional	B-X
biochemical	B-X
activities	B-X
,	B-X
including	B-X
protein	B-X
interactions	B-X
with	B-X
the	B-X
cellular	B-X
machineries	B-X
for	B-X
protein	B-X
phosphorylation	B-X
,	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
protein	B-X
translation	B-X
,	B-X
have	B-X
been	B-X
proposed	B-X
to	B-X
account	B-X
for	B-X
the	B-X
role	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
in	B-X
development	B-X
and	B-X
disease	B-X
.	B-X

The	O
COP9	O
signalosome	O
is	O
an	O
eight	O
-	O
subunit	O
protein	O
complex	O
that	O
regulates	O
protein	O
ubiquitination	O
and	O
protein	O
turnover	O
in	O
a	O
variety	O
of	O
plant	O
developmental	O
and	O
physiological	O
contexts	O
,	O
including	O
light	O
-	O
regulated	O
development	O
,	O
hormone	O
signaling	O
,	O
and	O
defense	O
against	O
pathogens	O
.	O

In	O
all	O
eukaryotes	O
tested	O
,	O
the	O
COP9	O
signalosome	O
is	O
able	O
to	O
posttranslationally	O
modify	O
the	O
cullin	O
subunit	O
of	O
E3	O
-	O
ubiquitin	B-Protein
-	O
ligase	O
complexes	O
by	O
cleaving	O
off	O
the	O
covalently	O
coupled	O
peptide	O
,	O
Nedd8	B-Protein
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
an	B-X
eight-subunit	B-X
protein	B-X
complex	B-X
that	B-X
regulates	B-X
protein	B-X
ubiquitination	B-X
and	B-X
protein	B-X
turnover	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
plant	B-X
developmental	B-X
and	B-X
physiological	B-X
contexts	B-X
,	B-X
including	B-X
light-regulated	B-X
development	B-X
,	B-X
hormone	B-X
signaling	B-X
,	B-X
and	B-X
defense	B-X
against	B-X
pathogens	B-X
.	B-X
In	B-X
all	B-X
eukaryotes	B-X
tested	B-X
,	B-X
the	B-X
COP9	B-X
signalosome	B-X
is	B-X
able	B-X
to	B-X
posttranslationally	B-X
modify	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
E3-ubiquitin-ligase	B-X
complexes	B-X
by	B-X
cleaving	B-X
off	B-X
the	B-X
covalently	B-X
coupled	B-X
peptide	B-X
,	B-X
Nedd8	B-X
.	B-X
Two	B-X
contrasting	B-X
models	B-X
ascribe	B-X
stimulatory	B-X
or	B-X
inhibitory	B-X
roles	B-X
to	B-X
the	B-X
modification	B-X
of	B-X
cullin/E3	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
.	B-X
There	B-X
is	B-X
considerable	B-X
disagreement	B-X
as	B-X
to	B-X
whether	B-X
Nedd8	B-X
cleavage	B-X
underlies	B-X
all	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
's	B-X
numerous	B-X
cellular	B-X
and	B-X
phenotypic	B-X
effects	B-X
.	B-X
This	B-X
is	B-X
because	B-X
macroscopic	B-X
phenotypes	B-X
do	B-X
not	B-X
always	B-X
correlate	B-X
with	B-X
biochemical	B-X
defects	B-X
in	B-X
COP9	B-X
signalosome	B-X
mutants	B-X
.	B-X
Additional	B-X
biochemical	B-X
activities	B-X
,	B-X
including	B-X
protein	B-X
interactions	B-X
with	B-X
the	B-X
cellular	B-X
machineries	B-X
for	B-X
protein	B-X
phosphorylation	B-X
,	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
protein	B-X
translation	B-X
,	B-X
have	B-X
been	B-X
proposed	B-X
to	B-X
account	B-X
for	B-X
the	B-X
role	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
in	B-X
development	B-X
and	B-X
disease	B-X
.	B-X

Two	O
contrasting	O
models	O
ascribe	O
stimulatory	O
or	O
inhibitory	O
roles	O
to	O
the	O
modification	O
of	O
cullin	O
/	O
E3	O
that	O
is	O
mediated	O
by	O
the	O
COP9	O
signalosome	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
an	B-X
eight-subunit	B-X
protein	B-X
complex	B-X
that	B-X
regulates	B-X
protein	B-X
ubiquitination	B-X
and	B-X
protein	B-X
turnover	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
plant	B-X
developmental	B-X
and	B-X
physiological	B-X
contexts	B-X
,	B-X
including	B-X
light-regulated	B-X
development	B-X
,	B-X
hormone	B-X
signaling	B-X
,	B-X
and	B-X
defense	B-X
against	B-X
pathogens	B-X
.	B-X
In	B-X
all	B-X
eukaryotes	B-X
tested	B-X
,	B-X
the	B-X
COP9	B-X
signalosome	B-X
is	B-X
able	B-X
to	B-X
posttranslationally	B-X
modify	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
E3-ubiquitin-ligase	B-X
complexes	B-X
by	B-X
cleaving	B-X
off	B-X
the	B-X
covalently	B-X
coupled	B-X
peptide	B-X
,	B-X
Nedd8	B-X
.	B-X
Two	B-X
contrasting	B-X
models	B-X
ascribe	B-X
stimulatory	B-X
or	B-X
inhibitory	B-X
roles	B-X
to	B-X
the	B-X
modification	B-X
of	B-X
cullin/E3	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
.	B-X
There	B-X
is	B-X
considerable	B-X
disagreement	B-X
as	B-X
to	B-X
whether	B-X
Nedd8	B-X
cleavage	B-X
underlies	B-X
all	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
's	B-X
numerous	B-X
cellular	B-X
and	B-X
phenotypic	B-X
effects	B-X
.	B-X
This	B-X
is	B-X
because	B-X
macroscopic	B-X
phenotypes	B-X
do	B-X
not	B-X
always	B-X
correlate	B-X
with	B-X
biochemical	B-X
defects	B-X
in	B-X
COP9	B-X
signalosome	B-X
mutants	B-X
.	B-X
Additional	B-X
biochemical	B-X
activities	B-X
,	B-X
including	B-X
protein	B-X
interactions	B-X
with	B-X
the	B-X
cellular	B-X
machineries	B-X
for	B-X
protein	B-X
phosphorylation	B-X
,	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
protein	B-X
translation	B-X
,	B-X
have	B-X
been	B-X
proposed	B-X
to	B-X
account	B-X
for	B-X
the	B-X
role	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
in	B-X
development	B-X
and	B-X
disease	B-X
.	B-X

There	O
is	O
considerable	O
disagreement	O
as	O
to	O
whether	O
Nedd8	B-Protein
cleavage	O
underlies	O
all	O
of	O
the	O
COP9	O
signalosome	O
'	O
s	O
numerous	O
cellular	O
and	O
phenotypic	O
effects	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
an	B-X
eight-subunit	B-X
protein	B-X
complex	B-X
that	B-X
regulates	B-X
protein	B-X
ubiquitination	B-X
and	B-X
protein	B-X
turnover	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
plant	B-X
developmental	B-X
and	B-X
physiological	B-X
contexts	B-X
,	B-X
including	B-X
light-regulated	B-X
development	B-X
,	B-X
hormone	B-X
signaling	B-X
,	B-X
and	B-X
defense	B-X
against	B-X
pathogens	B-X
.	B-X
In	B-X
all	B-X
eukaryotes	B-X
tested	B-X
,	B-X
the	B-X
COP9	B-X
signalosome	B-X
is	B-X
able	B-X
to	B-X
posttranslationally	B-X
modify	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
E3-ubiquitin-ligase	B-X
complexes	B-X
by	B-X
cleaving	B-X
off	B-X
the	B-X
covalently	B-X
coupled	B-X
peptide	B-X
,	B-X
Nedd8	B-X
.	B-X
Two	B-X
contrasting	B-X
models	B-X
ascribe	B-X
stimulatory	B-X
or	B-X
inhibitory	B-X
roles	B-X
to	B-X
the	B-X
modification	B-X
of	B-X
cullin/E3	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
.	B-X
There	B-X
is	B-X
considerable	B-X
disagreement	B-X
as	B-X
to	B-X
whether	B-X
Nedd8	B-X
cleavage	B-X
underlies	B-X
all	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
's	B-X
numerous	B-X
cellular	B-X
and	B-X
phenotypic	B-X
effects	B-X
.	B-X
This	B-X
is	B-X
because	B-X
macroscopic	B-X
phenotypes	B-X
do	B-X
not	B-X
always	B-X
correlate	B-X
with	B-X
biochemical	B-X
defects	B-X
in	B-X
COP9	B-X
signalosome	B-X
mutants	B-X
.	B-X
Additional	B-X
biochemical	B-X
activities	B-X
,	B-X
including	B-X
protein	B-X
interactions	B-X
with	B-X
the	B-X
cellular	B-X
machineries	B-X
for	B-X
protein	B-X
phosphorylation	B-X
,	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
protein	B-X
translation	B-X
,	B-X
have	B-X
been	B-X
proposed	B-X
to	B-X
account	B-X
for	B-X
the	B-X
role	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
in	B-X
development	B-X
and	B-X
disease	B-X
.	B-X

This	O
is	O
because	O
macroscopic	O
phenotypes	O
do	O
not	O
always	O
correlate	O
with	O
biochemical	O
defects	O
in	O
COP9	O
signalosome	O
mutants	O
.	O
<EOS>	B-X
A	B-X
major	B-X
challenge	B-X
in	B-X
developing	B-X
new	B-X
therapies	B-X
for	B-X
autism	B-X
has	B-X
been	B-X
the	B-X
inability	B-X
to	B-X
identify	B-X
convergent	B-X
neural	B-X
phenotypes	B-X
that	B-X
could	B-X
explain	B-X
the	B-X
common	B-X
set	B-X
of	B-X
symptoms	B-X
that	B-X
result	B-X
in	B-X
the	B-X
diagnosis	B-X
.	B-X
Although	B-X
no	B-X
striking	B-X
macroscopic	B-X
neuropathological	B-X
changes	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
autism	B-X
,	B-X
there	B-X
is	B-X
growing	B-X
evidence	B-X
that	B-X
inhibitory	B-X
interneurons	B-X
(	B-X
INs	B-X
)	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
its	B-X
neural	B-X
basis	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
PV	B-X
,	B-X
the	B-X
phenotypes	B-X
of	B-X
PP	B-X
are	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
This	B-X
work	B-X
reviews	B-X
historical	B-X
aspects	B-X
of	B-X
these	B-X
conditions	B-X
,	B-X
new	B-X
genetic	B-X
findings	B-X
and	B-X
presents	B-X
our	B-X
initial	B-X
considerations	B-X
on	B-X
the	B-X
phenotypes	B-X
of	B-X
PP	B-X
and	B-X
a	B-X
consensus	B-X
classification	B-X
of	B-X
clinical	B-X
phenotypes	B-X
that	B-X
will	B-X
be	B-X
used	B-X
as	B-X
a	B-X
baseline	B-X
for	B-X
further	B-X
,	B-X
prospective	B-X
studies	B-X
of	B-X
PP	B-X
.	B-X
Generalized	B-X
pustular	B-X
psoriasis	B-X
(	B-X
GPP	B-X
)	B-X
is	B-X
defined	B-X
as	B-X
primary	B-X
,	B-X
sterile	B-X
,	B-X
macroscopically	B-X
visible	B-X
pustules	B-X
on	B-X
non-acral	B-X
skin	B-X
(	B-X
excluding	B-X
cases	B-X
where	B-X
pustulation	B-X
is	B-X
restricted	B-X
to	B-X
psoriatic	B-X
plaques	B-X
)	B-X
.	B-X
Acrodermatitis	B-X
continua	B-X
of	B-X
Hallopeau	B-X
(	B-X
ACH	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
primary	B-X
,	B-X
persistent	B-X
(	B-X
>	B-X
3	B-X
months	B-X
)	B-X
,	B-X
sterile	B-X
,	B-X
macroscopically	B-X
visible	B-X
pustules	B-X
affecting	B-X
the	B-X
nail	B-X
apparatus	B-X
.	B-X
Palmoplantar	B-X
pustulosis	B-X
(	B-X
PPP	B-X
)	B-X
has	B-X
primary	B-X
,	B-X
persistent	B-X
(	B-X
>	B-X
3	B-X
months	B-X
)	B-X
,	B-X
sterile	B-X
,	B-X
macroscopically	B-X
visible	B-X
pustules	B-X
on	B-X
palms	B-X
and/or	B-X
soles	B-X
and	B-X
can	B-X
occur	B-X
with	B-X
or	B-X
without	B-X
PV	B-X
.	B-X

Additional	O
biochemical	O
activities	O
,	O
including	O
protein	O
interactions	O
with	O
the	O
cellular	O
machineries	O
for	O
protein	O
phosphorylation	O
,	O
protein	O
turnover	O
,	O
and	O
protein	O
translation	O
,	O
have	O
been	O
proposed	O
to	O
account	O
for	O
the	O
role	O
of	O
the	O
COP9	O
signalosome	O
in	O
development	O
and	O
disease	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
is	B-X
an	B-X
eight-subunit	B-X
protein	B-X
complex	B-X
that	B-X
regulates	B-X
protein	B-X
ubiquitination	B-X
and	B-X
protein	B-X
turnover	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
plant	B-X
developmental	B-X
and	B-X
physiological	B-X
contexts	B-X
,	B-X
including	B-X
light-regulated	B-X
development	B-X
,	B-X
hormone	B-X
signaling	B-X
,	B-X
and	B-X
defense	B-X
against	B-X
pathogens	B-X
.	B-X
In	B-X
all	B-X
eukaryotes	B-X
tested	B-X
,	B-X
the	B-X
COP9	B-X
signalosome	B-X
is	B-X
able	B-X
to	B-X
posttranslationally	B-X
modify	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
E3-ubiquitin-ligase	B-X
complexes	B-X
by	B-X
cleaving	B-X
off	B-X
the	B-X
covalently	B-X
coupled	B-X
peptide	B-X
,	B-X
Nedd8	B-X
.	B-X
Two	B-X
contrasting	B-X
models	B-X
ascribe	B-X
stimulatory	B-X
or	B-X
inhibitory	B-X
roles	B-X
to	B-X
the	B-X
modification	B-X
of	B-X
cullin/E3	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
.	B-X
There	B-X
is	B-X
considerable	B-X
disagreement	B-X
as	B-X
to	B-X
whether	B-X
Nedd8	B-X
cleavage	B-X
underlies	B-X
all	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
's	B-X
numerous	B-X
cellular	B-X
and	B-X
phenotypic	B-X
effects	B-X
.	B-X
This	B-X
is	B-X
because	B-X
macroscopic	B-X
phenotypes	B-X
do	B-X
not	B-X
always	B-X
correlate	B-X
with	B-X
biochemical	B-X
defects	B-X
in	B-X
COP9	B-X
signalosome	B-X
mutants	B-X
.	B-X
Additional	B-X
biochemical	B-X
activities	B-X
,	B-X
including	B-X
protein	B-X
interactions	B-X
with	B-X
the	B-X
cellular	B-X
machineries	B-X
for	B-X
protein	B-X
phosphorylation	B-X
,	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
protein	B-X
translation	B-X
,	B-X
have	B-X
been	B-X
proposed	B-X
to	B-X
account	B-X
for	B-X
the	B-X
role	B-X
of	B-X
the	B-X
COP9	B-X
signalosome	B-X
in	B-X
development	B-X
and	B-X
disease	B-X
.	B-X

But1	B-Protein
and	O
But2	B-Protein
proteins	O
bind	O
to	O
Uba3	B-Protein
,	O
a	O
catalytic	O
subunit	O
of	O
E1	O
for	O
neddylation	O
,	O
in	O
fission	O
yeast	O
.	O
<EOS>	B-X
NEDD8/Rub1	B-X
is	B-X
the	B-X
most	B-X
homologous	B-X
protein	B-X
to	B-X
ubiquitin	B-X
among	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
,	B-X
and	B-X
it	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
target	B-X
proteins	B-X
via	B-X
the	B-X
C-terminal	B-X
glycine	B-X
residue	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitylation	B-X
.	B-X
Using	B-X
the	B-X
two-hybrid	B-X
system	B-X
,	B-X
we	B-X
isolated	B-X
novel	B-X
genes	B-X
from	B-X
the	B-X
Schizosaccharomyces	B-X
pombe	B-X
cDNA	B-X
library	B-X
whose	B-X
products	B-X
bind	B-X
to	B-X
Uba3	B-X
,	B-X
which	B-X
is	B-X
a	B-X
catalytic	B-X
protein	B-X
for	B-X
E1-like	B-X
activity	B-X
of	B-X
the	B-X
NEDD8	B-X
pathway	B-X
.	B-X
We	B-X
designated	B-X
these	B-X
genes	B-X
but1	B-X
(	B-X
+	B-X
)	B-X
and	B-X
but2	B-X
(	B-X
+	B-X
)	B-X
(	B-X
for	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
Uba	B-X
three	B-X
)	B-X
.	B-X
But1	B-X
is	B-X
a	B-X
nuclear	B-X
protein	B-X
and	B-X
its	B-X
overexpression	B-X
caused	B-X
cell	B-X
elongation	B-X
,	B-X
which	B-X
is	B-X
a	B-X
common	B-X
phenotype	B-X
of	B-X
the	B-X
NEDD8	B-X
pathway	B-X
defective	B-X
mutant	B-X
in	B-X
S.	B-X
pombe	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
But1	B-X
may	B-X
have	B-X
an	B-X
inhibitory	B-X
role	B-X
in	B-X
the	B-X
NEDD8	B-X
pathway	B-X
.	B-X

NEDD8	B-Protein
/	O
Rub1	B-Protein
is	O
the	O
most	O
homologous	O
protein	O
to	O
ubiquitin	B-Protein
among	O
the	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
,	O
and	O
it	O
is	O
covalently	O
linked	O
to	O
target	O
proteins	O
via	O
the	O
C	O
-	O
terminal	O
glycine	O
residue	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitylation	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
NEDD8	B-Protein
ligation	O
pathway	O
remains	O
elusive	O
.	O
<EOS>	B-X
An	B-X
emerging	B-X
mechanism	B-X
of	B-X
ubiquitylation	B-X
involves	B-X
partnering	B-X
of	B-X
two	B-X
distinct	B-X
E3	B-X
ligases	B-X
.	B-X
In	B-X
the	B-X
best-characterized	B-X
E3-E3	B-X
pathways	B-X
,	B-X
ARIH-family	B-X
RING-between-RING	B-X
(	B-X
RBR	B-X
)	B-X
E3s	B-X
ligate	B-X
ubiquitin	B-X
to	B-X
substrates	B-X
of	B-X
neddylated	B-X
cullin-RING	B-X
E3s	B-X
.	B-X
However	B-X
,	B-X
the	B-X
structural	B-X
mechanisms	B-X
remained	B-X
elusive	B-X
.	B-X
Comparison	B-X
to	B-X
structures	B-X
of	B-X
E3-E3	B-X
assemblies	B-X
comprising	B-X
ARIH1	B-X
and	B-X
neddylated	B-X
CUL1-RBX1-based	B-X
E3s	B-X
shows	B-X
cullin-specific	B-X
regulation	B-X
by	B-X
NEDD8	B-X
.	B-X
Whereas	B-X
CUL1-linked	B-X
NEDD8	B-X
directly	B-X
recruits	B-X
ARIH1	B-X
,	B-X
CUL5-linked	B-X
NEDD8	B-X
does	B-X
not	B-X
bind	B-X
ARIH2	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
data	B-X
reveal	B-X
an	B-X
allosteric	B-X
mechanism	B-X
.	B-X
NEDD8	B-X
uniquely	B-X
contacts	B-X
covalently	B-X
linked	B-X
CUL5	B-X
,	B-X
and	B-X
elicits	B-X
structural	B-X
rearrangements	B-X
that	B-X
unveil	B-X
cryptic	B-X
ARIH2-binding	B-X
sites	B-X
.	B-X

Using	O
the	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
isolated	O
novel	O
genes	O
from	O
the	O
Schizosaccharomyces	O
pombe	O
cDNA	O
library	O
whose	O
products	O
bind	O
to	O
Uba3	B-Protein
,	O
which	O
is	O
a	O
catalytic	O
protein	O
for	O
E1	O
-	O
like	O
activity	O
of	O
the	O
NEDD8	B-Protein
pathway	O
.	O
<EOS>	B-X
NEDD8/Rub1	B-X
is	B-X
the	B-X
most	B-X
homologous	B-X
protein	B-X
to	B-X
ubiquitin	B-X
among	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
,	B-X
and	B-X
it	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
target	B-X
proteins	B-X
via	B-X
the	B-X
C-terminal	B-X
glycine	B-X
residue	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitylation	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
NEDD8	B-X
ligation	B-X
pathway	B-X
remains	B-X
elusive	B-X
.	B-X
Using	B-X
the	B-X
two-hybrid	B-X
system	B-X
,	B-X
we	B-X
isolated	B-X
novel	B-X
genes	B-X
from	B-X
the	B-X
Schizosaccharomyces	B-X
pombe	B-X
cDNA	B-X
library	B-X
whose	B-X
products	B-X
bind	B-X
to	B-X
Uba3	B-X
,	B-X
which	B-X
is	B-X
a	B-X
catalytic	B-X
protein	B-X
for	B-X
E1-like	B-X
activity	B-X
of	B-X
the	B-X
NEDD8	B-X
pathway	B-X
.	B-X
We	B-X
designated	B-X
these	B-X
genes	B-X
but1	B-X
(	B-X
+	B-X
)	B-X
and	B-X
but2	B-X
(	B-X
+	B-X
)	B-X
(	B-X
for	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
Uba	B-X
three	B-X
)	B-X
.	B-X
But1	B-X
is	B-X
a	B-X
nuclear	B-X
protein	B-X
and	B-X
its	B-X
overexpression	B-X
caused	B-X
cell	B-X
elongation	B-X
,	B-X
which	B-X
is	B-X
a	B-X
common	B-X
phenotype	B-X
of	B-X
the	B-X
NEDD8	B-X
pathway	B-X
defective	B-X
mutant	B-X
in	B-X
S.	B-X
pombe	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
But1	B-X
may	B-X
have	B-X
an	B-X
inhibitory	B-X
role	B-X
in	B-X
the	B-X
NEDD8	B-X
pathway	B-X
.	B-X

We	O
designated	O
these	O
genes	O
but1	B-Protein
(	O
+	O
)	O
and	O
but2	B-Protein
(	O
+	O
)	O
(	O
for	O
proteins	O
that	O
bind	O
to	O
Uba	B-Protein
three	I-Protein
)	O
.	O
<EOS>	B-X
NEDD8/Rub1	B-X
is	B-X
the	B-X
most	B-X
homologous	B-X
protein	B-X
to	B-X
ubiquitin	B-X
among	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
,	B-X
and	B-X
it	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
target	B-X
proteins	B-X
via	B-X
the	B-X
C-terminal	B-X
glycine	B-X
residue	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitylation	B-X
.	B-X
Using	B-X
the	B-X
two-hybrid	B-X
system	B-X
,	B-X
we	B-X
isolated	B-X
novel	B-X
genes	B-X
from	B-X
the	B-X
Schizosaccharomyces	B-X
pombe	B-X
cDNA	B-X
library	B-X
whose	B-X
products	B-X
bind	B-X
to	B-X
Uba3	B-X
,	B-X
which	B-X
is	B-X
a	B-X
catalytic	B-X
protein	B-X
for	B-X
E1-like	B-X
activity	B-X
of	B-X
the	B-X
NEDD8	B-X
pathway	B-X
.	B-X
We	B-X
designated	B-X
these	B-X
genes	B-X
but1	B-X
(	B-X
+	B-X
)	B-X
and	B-X
but2	B-X
(	B-X
+	B-X
)	B-X
(	B-X
for	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
Uba	B-X
three	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
but1	B-X
(	B-X
+	B-X
)	B-X
in	B-X
ned8-temperature	B-X
sensitive	B-X
mutant	B-X
had	B-X
a	B-X
deleterious	B-X
effect	B-X
even	B-X
under	B-X
permissive	B-X
temperatures	B-X
.	B-X

But1	B-Protein
is	O
a	O
nuclear	O
protein	O
and	O
its	O
overexpression	O
caused	O
cell	O
elongation	O
,	O
which	O
is	O
a	O
common	O
phenotype	O
of	O
the	O
NEDD8	B-Protein
pathway	O
defective	O
mutant	O
in	O
S	O
.	O
pombe	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
but1	B-Protein
(	O
+	O
)	O
in	O
ned8	B-Protein
-	O
temperature	O
sensitive	O
mutant	O
had	O
a	O
deleterious	O
effect	O
even	O
under	O
permissive	O
temperatures	O
.	O
<EOS>	B-X
We	B-X
designated	B-X
these	B-X
genes	B-X
but1	B-X
(	B-X
+	B-X
)	B-X
and	B-X
but2	B-X
(	B-X
+	B-X
)	B-X
(	B-X
for	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
Uba	B-X
three	B-X
)	B-X
.	B-X
But1	B-X
is	B-X
a	B-X
nuclear	B-X
protein	B-X
and	B-X
its	B-X
overexpression	B-X
caused	B-X
cell	B-X
elongation	B-X
,	B-X
which	B-X
is	B-X
a	B-X
common	B-X
phenotype	B-X
of	B-X
the	B-X
NEDD8	B-X
pathway	B-X
defective	B-X
mutant	B-X
in	B-X
S.	B-X
pombe	B-X
.	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
but1	B-X
(	B-X
+	B-X
)	B-X
in	B-X
ned8-temperature	B-X
sensitive	B-X
mutant	B-X
had	B-X
a	B-X
deleterious	B-X
effect	B-X
even	B-X
under	B-X
permissive	B-X
temperatures	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
But1	B-Protein
may	O
have	O
an	O
inhibitory	O
role	O
in	O
the	O
NEDD8	B-Protein
pathway	O
.	O
<EOS>	B-X
NEDD8/Rub1	B-X
is	B-X
the	B-X
most	B-X
homologous	B-X
protein	B-X
to	B-X
ubiquitin	B-X
among	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
,	B-X
and	B-X
it	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
target	B-X
proteins	B-X
via	B-X
the	B-X
C-terminal	B-X
glycine	B-X
residue	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitylation	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
NEDD8	B-X
ligation	B-X
pathway	B-X
remains	B-X
elusive	B-X
.	B-X
Using	B-X
the	B-X
two-hybrid	B-X
system	B-X
,	B-X
we	B-X
isolated	B-X
novel	B-X
genes	B-X
from	B-X
the	B-X
Schizosaccharomyces	B-X
pombe	B-X
cDNA	B-X
library	B-X
whose	B-X
products	B-X
bind	B-X
to	B-X
Uba3	B-X
,	B-X
which	B-X
is	B-X
a	B-X
catalytic	B-X
protein	B-X
for	B-X
E1-like	B-X
activity	B-X
of	B-X
the	B-X
NEDD8	B-X
pathway	B-X
.	B-X
But1	B-X
is	B-X
a	B-X
nuclear	B-X
protein	B-X
and	B-X
its	B-X
overexpression	B-X
caused	B-X
cell	B-X
elongation	B-X
,	B-X
which	B-X
is	B-X
a	B-X
common	B-X
phenotype	B-X
of	B-X
the	B-X
NEDD8	B-X
pathway	B-X
defective	B-X
mutant	B-X
in	B-X
S.	B-X
pombe	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
But1	B-X
may	B-X
have	B-X
an	B-X
inhibitory	B-X
role	B-X
in	B-X
the	B-X
NEDD8	B-X
pathway	B-X
.	B-X

Rac	O
GTPase	O
instructs	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
by	O
conveying	O
the	O
SCF	O
complex	O
and	O
IkBalpha	B-Protein
to	O
the	O
ruffling	O
membranes	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
ubiquitously	O
expressed	O
transcription	O
factor	O
that	O
plays	O
a	O
central	O
role	O
in	O
directing	O
a	O
vast	O
range	O
of	O
cellular	O
functions	O
.	O

Its	O
activation	O
is	O
controlled	O
by	O
the	O
Rac	O
GTPase	O
and	O
relies	O
on	O
the	O
coordinated	O
cooperation	O
of	O
the	O
E3	O
-	O
ligase	O
complex	O
SCF	O
(	O
betaTrCP	B-Protein
)	O
,	O
composed	O
by	O
Skp	B-Protein
-	I-Protein
1	I-Protein
/	O
Cullin	B-Protein
-	I-Protein
1	I-Protein
,	O
Rbx	B-Protein
/	O
Roc1	B-Protein
,	O
and	O
the	O
beta	B-Protein
-	I-Protein
TrCP	I-Protein
proteins	O
.	O
<EOS>	B-X
Its	B-X
activation	B-X
is	B-X
controlled	B-X
by	B-X
the	B-X
Rac	B-X
GTPase	B-X
and	B-X
relies	B-X
on	B-X
the	B-X
coordinated	B-X
cooperation	B-X
of	B-X
the	B-X
E3-ligase	B-X
complex	B-X
SCF	B-X
(	B-X
betaTrCP	B-X
)	B-X
,	B-X
composed	B-X
by	B-X
Skp-1/Cullin-1	B-X
,	B-X
Rbx/Roc1	B-X
,	B-X
and	B-X
the	B-X
beta-TrCP	B-X
proteins	B-X
.	B-X
Recently	B-X
,	B-X
Cullin-1	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
activated	B-X
Rac	B-X
GTPase	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
specific	B-X
activation	B-X
of	B-X
the	B-X
Rac	B-X
GTPase	B-X
,	B-X
besides	B-X
directing	B-X
its	B-X
own	B-X
positioning	B-X
,	B-X
induces	B-X
the	B-X
relocalization	B-X
of	B-X
the	B-X
SCF	B-X
component	B-X
Cullin-1	B-X
to	B-X
the	B-X
ruffling	B-X
membranes	B-X
.	B-X
This	B-X
occurred	B-X
only	B-X
if	B-X
the	B-X
ruffles	B-X
were	B-X
stimulated	B-X
by	B-X
the	B-X
Rac	B-X
GTPase	B-X
and	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
repositioning	B-X
to	B-X
the	B-X
same	B-X
intracellular	B-X
compartment	B-X
of	B-X
the	B-X
SCF	B-X
protein	B-X
Skp-1	B-X
and	B-X
the	B-X
ubiquitin-like	B-X
molecule	B-X
Nedd-8	B-X
.	B-X
The	B-X
SCF	B-X
substrate	B-X
IkBalpha	B-X
was	B-X
also	B-X
directed	B-X
to	B-X
the	B-X
ruffling	B-X
membranes	B-X
in	B-X
a	B-X
Rac-dependent	B-X
way	B-X
.	B-X
The	B-X
novelty	B-X
of	B-X
these	B-X
findings	B-X
is	B-X
in	B-X
respect	B-X
to	B-X
the	B-X
demonstration	B-X
that	B-X
the	B-X
correct	B-X
positioning	B-X
at	B-X
the	B-X
ruffling	B-X
membranes	B-X
is	B-X
crucial	B-X
for	B-X
the	B-X
subsequent	B-X
series	B-X
of	B-X
events	B-X
that	B-X
leads	B-X
to	B-X
IkBalpha	B-X
proteasomal	B-X
degradation	B-X
and	B-X
the	B-X
resultant	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
Consequently	B-X
,	B-X
this	B-X
points	B-X
to	B-X
the	B-X
role	B-X
of	B-X
Rac	B-X
as	B-X
a	B-X
docking	B-X
molecule	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
.	B-X

Recently	O
,	O
Cullin	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
reported	O
to	O
form	O
a	O
complex	O
with	O
the	O
activated	O
Rac	O
GTPase	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
specific	O
activation	O
of	O
the	O
Rac	O
GTPase	O
,	O
besides	O
directing	O
its	O
own	O
positioning	O
,	O
induces	O
the	O
relocalization	O
of	O
the	O
SCF	O
component	O
Cullin	B-Protein
-	I-Protein
1	I-Protein
to	O
the	O
ruffling	O
membranes	O
.	O

This	O
occurred	O
only	O
if	O
the	O
ruffles	O
were	O
stimulated	O
by	O
the	O
Rac	O
GTPase	O
and	O
was	O
accompanied	O
by	O
the	O
repositioning	O
to	O
the	O
same	O
intracellular	O
compartment	O
of	O
the	O
SCF	O
protein	O
Skp	B-Protein
-	I-Protein
1	I-Protein
and	O
the	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
Nedd	B-Protein
-	I-Protein
8	I-Protein
.	O

The	O
SCF	O
substrate	O
IkBalpha	B-Protein
was	O
also	O
directed	O
to	O
the	O
ruffling	O
membranes	O
in	O
a	O
Rac	O
-	O
dependent	O
way	O
.	O

The	O
novelty	O
of	O
these	O
findings	O
is	O
in	O
respect	O
to	O
the	O
demonstration	O
that	O
the	O
correct	O
positioning	O
at	O
the	O
ruffling	O
membranes	O
is	O
crucial	O
for	O
the	O
subsequent	O
series	O
of	O
events	O
that	O
leads	O
to	O
IkBalpha	B-Protein
proteasomal	O
degradation	O
and	O
the	O
resultant	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Consequently	O
,	O
this	O
points	O
to	O
the	O
role	O
of	O
Rac	O
as	O
a	O
docking	O
molecule	O
in	O
NF	O
-	O
kappaB	O
activation	O
.	O

PIASy	B-Protein
-	O
mediated	O
repression	O
of	O
the	O
androgen	B-Protein
receptor	I-Protein
is	O
independent	O
of	O
sumoylation	O
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

PIASy	B-Protein
,	O
a	O
member	O
of	O
the	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
(	O
PIAS	O
)	O
family	O
,	O
represses	O
the	O
transcriptional	O
activity	O
of	O
the	O
androgen	B-Protein
receptor	I-Protein
(	O
AR	B-Protein
)	O
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
PIAS	B-X
proteins	B-X
possess	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
Conjugation	B-X
of	B-X
SUMO-1	B-X
to	B-X
AR	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
AR	B-X
activity	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

In	O
this	O
report	O
,	O
we	O
investigate	O
the	O
mechanism	O
of	O
PIASy	B-Protein
-	O
mediated	O
repression	O
of	O
AR	B-Protein
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
Conjugation	B-X
of	B-X
SUMO-1	B-X
to	B-X
AR	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
AR	B-X
activity	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

We	O
show	O
that	O
AR	B-Protein
binds	O
to	O
the	O
RING	O
-	O
finger	O
like	O
domain	O
of	O
PIASy	B-Protein
.	O

PIASy	B-Protein
contains	O
two	O
transcriptional	O
repression	O
domains	O
,	O
RD1	O
and	O
RD2	O
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

RD1	O
,	O
but	O
not	O
RD2	O
,	O
is	O
required	O
for	O
PIASy	B-Protein
-	O
mediated	O
repression	O
of	O
AR	B-Protein
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
cytotoxicity	B-X
of	B-X
Lactiplantibacillus	B-X
plantarum	B-X
strain	B-X
RD1	B-X
(	B-X
Lpb	B-X
RD1	B-X
)	B-X
,	B-X
which	B-X
was	B-X
isolated	B-X
and	B-X
identified	B-X
from	B-X
the	B-X
curd	B-X
by	B-X
16	B-X
S	B-X
rRNA	B-X
sequencing	B-X
.	B-X
The	B-X
probiotic	B-X
properties	B-X
of	B-X
the	B-X
isolated	B-X
strain	B-X
were	B-X
studied	B-X
by	B-X
bile	B-X
and	B-X
NaCl	B-X
tolerance	B-X
and	B-X
the	B-X
ethyl	B-X
acetate	B-X
extract	B-X
of	B-X
Ea-LpRD1	B-X
,	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
toxicity	B-X
against	B-X
human	B-X
breast	B-X
cancer	B-X
(	B-X
MCF-7	B-X
)	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
embryonic	B-X
kidney	B-X
(	B-X
HEK-293	B-X
)	B-X
cell	B-X
lines	B-X
by	B-X
MTT	B-X
assay	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
interferon-gamma	B-X
assays	B-X
that	B-X
use	B-X
Mycobacterium	B-X
tuberculosis-specific	B-X
region	B-X
of	B-X
difference	B-X
1	B-X
(	B-X
RD1	B-X
)	B-X
antigens	B-X
(	B-X
such	B-X
as	B-X
early	B-X
secretory	B-X
antigenic	B-X
target	B-X
6	B-X
and	B-X
culture	B-X
filtrate	B-X
protein	B-X
10	B-X
)	B-X
may	B-X
have	B-X
advantages	B-X
over	B-X
the	B-X
TST	B-X
,	B-X
in	B-X
terms	B-X
of	B-X
higher	B-X
specificity	B-X
,	B-X
better	B-X
correlation	B-X
with	B-X
exposure	B-X
to	B-X
M	B-X
tuberculosis	B-X
,	B-X
and	B-X
less	B-X
cross-reactivity	B-X
due	B-X
to	B-X
BCG	B-X
vaccination	B-X
and	B-X
non-tuberculous	B-X
mycobacterial	B-X
infection	B-X
.	B-X
However	B-X
,	B-X
interferon-gamma	B-X
assays	B-X
that	B-X
use	B-X
RD1	B-X
antigens	B-X
in	B-X
isolation	B-X
may	B-X
maximise	B-X
specificity	B-X
at	B-X
the	B-X
cost	B-X
of	B-X
sensitivity	B-X
.	B-X
Assays	B-X
that	B-X
use	B-X
cocktails	B-X
of	B-X
RD1	B-X
antigens	B-X
seem	B-X
to	B-X
overcome	B-X
this	B-X
problem	B-X
,	B-X
and	B-X
such	B-X
assays	B-X
have	B-X
the	B-X
highest	B-X
accuracy	B-X
.	B-X
RD1-based	B-X
interferon-gamma	B-X
assays	B-X
can	B-X
potentially	B-X
identify	B-X
those	B-X
with	B-X
latent	B-X
tuberculosis	B-X
who	B-X
are	B-X
at	B-X
high	B-X
risk	B-X
for	B-X
developing	B-X
active	B-X
disease	B-X
,	B-X
but	B-X
this	B-X
requires	B-X
confirmation	B-X
.	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
interferon-gamma	B-X
assays	B-X
based	B-X
on	B-X
cocktails	B-X
of	B-X
RD1	B-X
antigens	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
become	B-X
useful	B-X
diagnostic	B-X
tools	B-X
.	B-X

We	O
show	O
that	O
the	O
RD1	O
domain	O
binds	O
HDAC1	B-Protein
and	O
HDAC2	B-Protein
and	O
that	O
HDAC	O
activity	O
is	O
required	O
for	O
PIASy	B-Protein
-	O
mediated	O
AR	B-Protein
repression	O
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
PIAS	B-X
proteins	B-X
possess	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
Conjugation	B-X
of	B-X
SUMO-1	B-X
to	B-X
AR	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
AR	B-X
activity	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

PIAS	O
proteins	O
possess	O
small	O
ubiquitin	B-Protein
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
E3	O
ligase	O
activity	O
.	O
<EOS>	B-X
Transcriptional	B-X
activity	B-X
of	B-X
signal-dependent	B-X
transcription	B-X
factors	B-X
,	B-X
including	B-X
nuclear	B-X
receptors	B-X
,	B-X
relies	B-X
on	B-X
interacting	B-X
co-regulator	B-X
proteins	B-X
,	B-X
many	B-X
of	B-X
which	B-X
possess	B-X
protein-modifying	B-X
activity	B-X
.	B-X
SUMOs	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifiers	B-X
)	B-X
and	B-X
their	B-X
conjugation	B-X
pathway	B-X
components	B-X
act	B-X
as	B-X
co-regulator	B-X
proteins	B-X
for	B-X
numerous	B-X
transcription	B-X
factors	B-X
that	B-X
also	B-X
are	B-X
often	B-X
targets	B-X
for	B-X
SUMO	B-X
modification	B-X
.	B-X
PIAS	B-X
[	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
)	B-X
]	B-X
proteins	B-X
promote	B-X
SUMOylation	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
resembles	B-X
the	B-X
action	B-X
of	B-X
RING-type	B-X
ubiquitin	B-X
E3	B-X
ligases	B-X
.	B-X
PIAS	B-X
proteins	B-X
were	B-X
initially	B-X
named	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
STAT	B-X
proteins	B-X
and	B-X
inhibit	B-X
their	B-X
activity	B-X
,	B-X
but	B-X
their	B-X
interactions	B-X
and	B-X
functions	B-X
are	B-X
not	B-X
restricted	B-X
to	B-X
the	B-X
STATs	B-X
.	B-X
Moreover	B-X
,	B-X
PIAS	B-X
proteins	B-X
do	B-X
not	B-X
operate	B-X
merely	B-X
as	B-X
SUMO	B-X
E3s	B-X
,	B-X
since	B-X
their	B-X
co-regulator	B-X
effects	B-X
are	B-X
often	B-X
independent	B-X
of	B-X
their	B-X
RING	B-X
finger	B-X
but	B-X
dependent	B-X
on	B-X
their	B-X
SIM	B-X
(	B-X
SUMO-interacting	B-X
motif	B-X
)	B-X
or	B-X
SAP	B-X
(	B-X
scaffold	B-X
attachment	B-X
factor-A/B/acinus/PIAS	B-X
)	B-X
domain	B-X
capable	B-X
of	B-X
interacting	B-X
with	B-X
DNA	B-X
.	B-X
The	B-X
modulator	B-X
activity	B-X
imparted	B-X
by	B-X
the	B-X
PIAS/SUMO	B-X
system	B-X
involves	B-X
altered	B-X
subnuclear	B-X
targeting	B-X
and/or	B-X
assembly	B-X
of	B-X
transcription	B-X
complexes	B-X
.	B-X
PIAS	B-X
proteins	B-X
may	B-X
act	B-X
as	B-X
platforms	B-X
that	B-X
facilitate	B-X
both	B-X
removal	B-X
and	B-X
recruitment	B-X
of	B-X
other	B-X
regulatory	B-X
proteins	B-X
in	B-X
the	B-X
transcription	B-X
complexes	B-X
.	B-X

Conjugation	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
to	O
AR	B-Protein
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
AR	B-Protein
activity	O
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
PIAS	B-X
proteins	B-X
possess	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
Conjugation	B-X
of	B-X
SUMO-1	B-X
to	B-X
AR	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
AR	B-X
activity	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

We	O
examine	O
if	O
the	O
SUMO	O
ligase	O
activity	O
of	O
PIASy	B-Protein
is	O
required	O
for	O
PIASy	B-Protein
to	O
repress	O
AR	B-Protein
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
PIAS	B-X
proteins	B-X
possess	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
Conjugation	B-X
of	B-X
SUMO-1	B-X
to	B-X
AR	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
AR	B-X
activity	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

We	O
show	O
that	O
a	O
mutant	O
PIASy	B-Protein
,	O
defective	O
in	O
promoting	O
sumoylation	O
,	O
retains	O
the	O
ability	O
to	O
repress	O
AR	B-Protein
transcription	O
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
Conjugation	B-X
of	B-X
SUMO-1	B-X
to	B-X
AR	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
AR	B-X
activity	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

In	O
addition	O
,	O
mutation	O
of	O
all	O
the	O
known	O
sumoylation	O
acceptor	O
sites	O
of	O
AR	B-Protein
does	O
not	O
affect	O
the	O
transrepression	O
activity	O
of	O
PIASy	B-Protein
on	O
AR	B-Protein
.	O

Our	O
results	O
suggest	O
that	O
PIASy	B-Protein
may	O
repress	O
AR	B-Protein
by	O
recruiting	O
histone	O
deacetylases	O
,	O
independent	O
of	O
its	O
SUMO	O
ligase	O
activity	O
.	O
<EOS>	B-X
PIASy	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
(	B-X
PIAS	B-X
)	B-X
family	B-X
,	B-X
represses	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
AR	B-X
binds	B-X
to	B-X
the	B-X
RING-finger	B-X
like	B-X
domain	B-X
of	B-X
PIASy	B-X
.	B-X
PIASy	B-X
contains	B-X
two	B-X
transcriptional	B-X
repression	B-X
domains	B-X
,	B-X
RD1	B-X
and	B-X
RD2	B-X
.	B-X
RD1	B-X
,	B-X
but	B-X
not	B-X
RD2	B-X
,	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
repression	B-X
of	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
RD1	B-X
domain	B-X
binds	B-X
HDAC1	B-X
and	B-X
HDAC2	B-X
and	B-X
that	B-X
HDAC	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
PIASy-mediated	B-X
AR	B-X
repression	B-X
.	B-X
PIAS	B-X
proteins	B-X
possess	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
Conjugation	B-X
of	B-X
SUMO-1	B-X
to	B-X
AR	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
AR	B-X
activity	B-X
.	B-X
We	B-X
examine	B-X
if	B-X
the	B-X
SUMO	B-X
ligase	B-X
activity	B-X
of	B-X
PIASy	B-X
is	B-X
required	B-X
for	B-X
PIASy	B-X
to	B-X
repress	B-X
AR	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
mutant	B-X
PIASy	B-X
,	B-X
defective	B-X
in	B-X
promoting	B-X
sumoylation	B-X
,	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
repress	B-X
AR	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mutation	B-X
of	B-X
all	B-X
the	B-X
known	B-X
sumoylation	B-X
acceptor	B-X
sites	B-X
of	B-X
AR	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
transrepression	B-X
activity	B-X
of	B-X
PIASy	B-X
on	B-X
AR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
PIASy	B-X
may	B-X
repress	B-X
AR	B-X
by	B-X
recruiting	B-X
histone	B-X
deacetylases	B-X
,	B-X
independent	B-X
of	B-X
its	B-X
SUMO	B-X
ligase	B-X
activity	B-X
.	B-X

pVHL	B-Protein
modification	O
by	O
NEDD8	B-Protein
is	O
required	O
for	O
fibronectin	B-Protein
matrix	O
assembly	O
and	O
suppression	O
of	O
tumor	O
development	O
.	O
<EOS>	B-X
Functional	B-X
inactivation	B-X
of	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
is	B-X
the	B-X
cause	B-X
of	B-X
the	B-X
familial	B-X
VHL	B-X
disease	B-X
and	B-X
most	B-X
sporadic	B-X
renal	B-X
clear-cell	B-X
carcinomas	B-X
(	B-X
RCC	B-X
)	B-X
.	B-X
pVHL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
alpha	B-X
(	B-X
HIF-alpha	B-X
)	B-X
subunits	B-X
via	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
and	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
most	B-X
disease-causing	B-X
pVHL	B-X
mutations	B-X
hinder	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
HIF	B-X
pathway	B-X
,	B-X
every	B-X
disease-causing	B-X
pVHL	B-X
mutant	B-X
tested	B-X
to	B-X
date	B-X
has	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
,	B-X
underscoring	B-X
its	B-X
potential	B-X
importance	B-X
in	B-X
VHL	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
called	B-X
NEDD8	B-X
covalently	B-X
modifies	B-X
pVHL	B-X
.	B-X
A	B-X
nonneddylateable	B-X
pVHL	B-X
mutant	B-X
,	B-X
while	B-X
retaining	B-X
its	B-X
ability	B-X
to	B-X
ubiquitylate	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
bind	B-X
to	B-X
and	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
neddylation-defective	B-X
pVHL	B-X
in	B-X
RCC	B-X
cells	B-X
,	B-X
while	B-X
restoring	B-X
the	B-X
regulation	B-X
of	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
differentiated	B-X
morphology	B-X
in	B-X
a	B-X
three-dimensional	B-X
growth	B-X
assay	B-X
and	B-X
was	B-X
insufficient	B-X
to	B-X
suppress	B-X
the	B-X
formation	B-X
of	B-X
tumors	B-X
in	B-X
SCID	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
NEDD8	B-X
modification	B-X
of	B-X
pVHL	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
and	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
such	B-X
regulation	B-X
,	B-X
an	B-X
intact	B-X
HIF	B-X
pathway	B-X
is	B-X
insufficient	B-X
to	B-X
prevent	B-X
VHL-associated	B-X
tumorigenesis	B-X
.	B-X

Functional	O
inactivation	O
of	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumor	I-Protein
suppressor	I-Protein
gene	O
is	O
the	O
cause	O
of	O
the	O
familial	O
VHL	O
disease	O
and	O
most	O
sporadic	O
renal	O
clear	O
-	O
cell	O
carcinomas	O
(	O
RCC	O
)	O
.	O

pVHL	B-Protein
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
the	O
destruction	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
subunits	O
via	O
ubiquitin	B-Protein
-	O
mediated	O
proteolysis	O
and	O
in	O
the	O
regulation	O
of	O
fibronectin	B-Protein
matrix	O
assembly	O
.	O
<EOS>	B-X
pVHL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
alpha	B-X
(	B-X
HIF-alpha	B-X
)	B-X
subunits	B-X
via	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
and	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
most	B-X
disease-causing	B-X
pVHL	B-X
mutations	B-X
hinder	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
HIF	B-X
pathway	B-X
,	B-X
every	B-X
disease-causing	B-X
pVHL	B-X
mutant	B-X
tested	B-X
to	B-X
date	B-X
has	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
,	B-X
underscoring	B-X
its	B-X
potential	B-X
importance	B-X
in	B-X
VHL	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
called	B-X
NEDD8	B-X
covalently	B-X
modifies	B-X
pVHL	B-X
.	B-X
A	B-X
nonneddylateable	B-X
pVHL	B-X
mutant	B-X
,	B-X
while	B-X
retaining	B-X
its	B-X
ability	B-X
to	B-X
ubiquitylate	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
bind	B-X
to	B-X
and	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
neddylation-defective	B-X
pVHL	B-X
in	B-X
RCC	B-X
cells	B-X
,	B-X
while	B-X
restoring	B-X
the	B-X
regulation	B-X
of	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
differentiated	B-X
morphology	B-X
in	B-X
a	B-X
three-dimensional	B-X
growth	B-X
assay	B-X
and	B-X
was	B-X
insufficient	B-X
to	B-X
suppress	B-X
the	B-X
formation	B-X
of	B-X
tumors	B-X
in	B-X
SCID	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
NEDD8	B-X
modification	B-X
of	B-X
pVHL	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
and	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
such	B-X
regulation	B-X
,	B-X
an	B-X
intact	B-X
HIF	B-X
pathway	B-X
is	B-X
insufficient	B-X
to	B-X
prevent	B-X
VHL-associated	B-X
tumorigenesis	B-X
.	B-X

Although	O
most	O
disease	O
-	O
causing	O
pVHL	B-Protein
mutations	O
hinder	O
the	O
regulation	O
of	O
the	O
HIF	O
pathway	O
,	O
every	O
disease	O
-	O
causing	O
pVHL	B-Protein
mutant	O
tested	O
to	O
date	O
has	O
failed	O
to	O
promote	O
the	O
assembly	O
of	O
the	O
fibronectin	B-Protein
matrix	O
,	O
underscoring	O
its	O
potential	O
importance	O
in	O
VHL	O
disease	O
.	O
<EOS>	B-X
Functional	B-X
inactivation	B-X
of	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
is	B-X
the	B-X
cause	B-X
of	B-X
the	B-X
familial	B-X
VHL	B-X
disease	B-X
and	B-X
most	B-X
sporadic	B-X
renal	B-X
clear-cell	B-X
carcinomas	B-X
(	B-X
RCC	B-X
)	B-X
.	B-X
pVHL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
alpha	B-X
(	B-X
HIF-alpha	B-X
)	B-X
subunits	B-X
via	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
and	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
most	B-X
disease-causing	B-X
pVHL	B-X
mutations	B-X
hinder	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
HIF	B-X
pathway	B-X
,	B-X
every	B-X
disease-causing	B-X
pVHL	B-X
mutant	B-X
tested	B-X
to	B-X
date	B-X
has	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
,	B-X
underscoring	B-X
its	B-X
potential	B-X
importance	B-X
in	B-X
VHL	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
called	B-X
NEDD8	B-X
covalently	B-X
modifies	B-X
pVHL	B-X
.	B-X
A	B-X
nonneddylateable	B-X
pVHL	B-X
mutant	B-X
,	B-X
while	B-X
retaining	B-X
its	B-X
ability	B-X
to	B-X
ubiquitylate	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
bind	B-X
to	B-X
and	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
neddylation-defective	B-X
pVHL	B-X
in	B-X
RCC	B-X
cells	B-X
,	B-X
while	B-X
restoring	B-X
the	B-X
regulation	B-X
of	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
differentiated	B-X
morphology	B-X
in	B-X
a	B-X
three-dimensional	B-X
growth	B-X
assay	B-X
and	B-X
was	B-X
insufficient	B-X
to	B-X
suppress	B-X
the	B-X
formation	B-X
of	B-X
tumors	B-X
in	B-X
SCID	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
NEDD8	B-X
modification	B-X
of	B-X
pVHL	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
and	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
such	B-X
regulation	B-X
,	B-X
an	B-X
intact	B-X
HIF	B-X
pathway	B-X
is	B-X
insufficient	B-X
to	B-X
prevent	B-X
VHL-associated	B-X
tumorigenesis	B-X
.	B-X

Here	O
,	O
we	O
report	O
that	O
a	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
called	O
NEDD8	B-Protein
covalently	O
modifies	O
pVHL	B-Protein
.	O
<EOS>	B-X
pVHL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
alpha	B-X
(	B-X
HIF-alpha	B-X
)	B-X
subunits	B-X
via	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
and	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
most	B-X
disease-causing	B-X
pVHL	B-X
mutations	B-X
hinder	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
HIF	B-X
pathway	B-X
,	B-X
every	B-X
disease-causing	B-X
pVHL	B-X
mutant	B-X
tested	B-X
to	B-X
date	B-X
has	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
,	B-X
underscoring	B-X
its	B-X
potential	B-X
importance	B-X
in	B-X
VHL	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
called	B-X
NEDD8	B-X
covalently	B-X
modifies	B-X
pVHL	B-X
.	B-X
A	B-X
nonneddylateable	B-X
pVHL	B-X
mutant	B-X
,	B-X
while	B-X
retaining	B-X
its	B-X
ability	B-X
to	B-X
ubiquitylate	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
bind	B-X
to	B-X
and	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
neddylation-defective	B-X
pVHL	B-X
in	B-X
RCC	B-X
cells	B-X
,	B-X
while	B-X
restoring	B-X
the	B-X
regulation	B-X
of	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
differentiated	B-X
morphology	B-X
in	B-X
a	B-X
three-dimensional	B-X
growth	B-X
assay	B-X
and	B-X
was	B-X
insufficient	B-X
to	B-X
suppress	B-X
the	B-X
formation	B-X
of	B-X
tumors	B-X
in	B-X
SCID	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
NEDD8	B-X
modification	B-X
of	B-X
pVHL	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
and	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
such	B-X
regulation	B-X
,	B-X
an	B-X
intact	B-X
HIF	B-X
pathway	B-X
is	B-X
insufficient	B-X
to	B-X
prevent	B-X
VHL-associated	B-X
tumorigenesis	B-X
.	B-X

A	O
nonneddylateable	O
pVHL	B-Protein
mutant	O
,	O
while	O
retaining	O
its	O
ability	O
to	O
ubiquitylate	O
HIF	O
,	O
failed	O
to	O
bind	O
to	O
and	O
promote	O
the	O
assembly	O
of	O
the	O
fibronectin	B-Protein
matrix	O
.	O
<EOS>	B-X
pVHL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
alpha	B-X
(	B-X
HIF-alpha	B-X
)	B-X
subunits	B-X
via	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
and	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
most	B-X
disease-causing	B-X
pVHL	B-X
mutations	B-X
hinder	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
HIF	B-X
pathway	B-X
,	B-X
every	B-X
disease-causing	B-X
pVHL	B-X
mutant	B-X
tested	B-X
to	B-X
date	B-X
has	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
,	B-X
underscoring	B-X
its	B-X
potential	B-X
importance	B-X
in	B-X
VHL	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
called	B-X
NEDD8	B-X
covalently	B-X
modifies	B-X
pVHL	B-X
.	B-X
A	B-X
nonneddylateable	B-X
pVHL	B-X
mutant	B-X
,	B-X
while	B-X
retaining	B-X
its	B-X
ability	B-X
to	B-X
ubiquitylate	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
bind	B-X
to	B-X
and	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
neddylation-defective	B-X
pVHL	B-X
in	B-X
RCC	B-X
cells	B-X
,	B-X
while	B-X
restoring	B-X
the	B-X
regulation	B-X
of	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
differentiated	B-X
morphology	B-X
in	B-X
a	B-X
three-dimensional	B-X
growth	B-X
assay	B-X
and	B-X
was	B-X
insufficient	B-X
to	B-X
suppress	B-X
the	B-X
formation	B-X
of	B-X
tumors	B-X
in	B-X
SCID	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
NEDD8	B-X
modification	B-X
of	B-X
pVHL	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
and	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
such	B-X
regulation	B-X
,	B-X
an	B-X
intact	B-X
HIF	B-X
pathway	B-X
is	B-X
insufficient	B-X
to	B-X
prevent	B-X
VHL-associated	B-X
tumorigenesis	B-X
.	B-X

Expression	O
of	O
the	O
neddylation	O
-	O
defective	O
pVHL	B-Protein
in	O
RCC	O
cells	O
,	O
while	O
restoring	O
the	O
regulation	O
of	O
HIF	O
,	O
failed	O
to	O
promote	O
the	O
differentiated	O
morphology	O
in	O
a	O
three	O
-	O
dimensional	O
growth	O
assay	O
and	O
was	O
insufficient	O
to	O
suppress	O
the	O
formation	O
of	O
tumors	O
in	O
SCID	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
NEDD8	B-Protein
modification	O
of	O
pVHL	B-Protein
plays	O
an	O
important	O
role	O
in	O
fibronectin	B-Protein
matrix	O
assembly	O
and	O
that	O
in	O
the	O
absence	O
of	O
such	O
regulation	O
,	O
an	O
intact	O
HIF	O
pathway	O
is	O
insufficient	O
to	O
prevent	O
VHL	B-Protein
-	O
associated	O
tumorigenesis	O
.	O
<EOS>	B-X
Functional	B-X
inactivation	B-X
of	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
is	B-X
the	B-X
cause	B-X
of	B-X
the	B-X
familial	B-X
VHL	B-X
disease	B-X
and	B-X
most	B-X
sporadic	B-X
renal	B-X
clear-cell	B-X
carcinomas	B-X
(	B-X
RCC	B-X
)	B-X
.	B-X
pVHL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
alpha	B-X
(	B-X
HIF-alpha	B-X
)	B-X
subunits	B-X
via	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
and	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
most	B-X
disease-causing	B-X
pVHL	B-X
mutations	B-X
hinder	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
HIF	B-X
pathway	B-X
,	B-X
every	B-X
disease-causing	B-X
pVHL	B-X
mutant	B-X
tested	B-X
to	B-X
date	B-X
has	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
,	B-X
underscoring	B-X
its	B-X
potential	B-X
importance	B-X
in	B-X
VHL	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
called	B-X
NEDD8	B-X
covalently	B-X
modifies	B-X
pVHL	B-X
.	B-X
A	B-X
nonneddylateable	B-X
pVHL	B-X
mutant	B-X
,	B-X
while	B-X
retaining	B-X
its	B-X
ability	B-X
to	B-X
ubiquitylate	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
bind	B-X
to	B-X
and	B-X
promote	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
fibronectin	B-X
matrix	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
neddylation-defective	B-X
pVHL	B-X
in	B-X
RCC	B-X
cells	B-X
,	B-X
while	B-X
restoring	B-X
the	B-X
regulation	B-X
of	B-X
HIF	B-X
,	B-X
failed	B-X
to	B-X
promote	B-X
the	B-X
differentiated	B-X
morphology	B-X
in	B-X
a	B-X
three-dimensional	B-X
growth	B-X
assay	B-X
and	B-X
was	B-X
insufficient	B-X
to	B-X
suppress	B-X
the	B-X
formation	B-X
of	B-X
tumors	B-X
in	B-X
SCID	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
NEDD8	B-X
modification	B-X
of	B-X
pVHL	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
fibronectin	B-X
matrix	B-X
assembly	B-X
and	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
such	B-X
regulation	B-X
,	B-X
an	B-X
intact	B-X
HIF	B-X
pathway	B-X
is	B-X
insufficient	B-X
to	B-X
prevent	B-X
VHL-associated	B-X
tumorigenesis	B-X
.	B-X

Role	O
of	O
the	O
isoprenyl	O
pocket	O
of	O
the	O
G	O
protein	O
beta	O
gamma	O
subunit	O
complex	O
in	O
the	O
binding	O
of	O
phosducin	B-Protein
and	O
phosducin	B-Protein
-	I-Protein
like	I-Protein
protein	O
.	O

Phosducin	B-Protein
(	O
Pdc	B-Protein
)	O
and	O
phosducin	B-Protein
-	I-Protein
like	I-Protein
protein	I-Protein
(	O
PhLP	B-Protein
)	O
regulate	O
G	O
protein	O
-	O
mediated	O
signaling	O
by	O
binding	O
to	O
the	O
betagamma	O
subunit	O
complex	O
of	O
heterotrimeric	O
G	O
proteins	O
(	O
Gbetagamma	O
)	O
and	O
removing	O
the	O
dimer	O
from	O
cell	O
membranes	O
.	O

The	O
binding	O
of	O
Pdc	B-Protein
induces	O
a	O
conformational	O
change	O
in	O
the	O
beta	O
-	O
propeller	O
structure	O
of	O
Gbetagamma	O
,	O
creating	O
a	O
pocket	O
between	O
blades	O
6	O
and	O
7	O
.	O
<EOS>	B-X
Phosducin	B-X
(	B-X
Pdc	B-X
)	B-X
and	B-X
phosducin-like	B-X
protein	B-X
(	B-X
PhLP	B-X
)	B-X
regulate	B-X
G	B-X
protein-mediated	B-X
signaling	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
betagamma	B-X
subunit	B-X
complex	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
(	B-X
Gbetagamma	B-X
)	B-X
and	B-X
removing	B-X
the	B-X
dimer	B-X
from	B-X
cell	B-X
membranes	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
Pdc	B-X
induces	B-X
a	B-X
conformational	B-X
change	B-X
in	B-X
the	B-X
beta-propeller	B-X
structure	B-X
of	B-X
Gbetagamma	B-X
,	B-X
creating	B-X
a	B-X
pocket	B-X
between	B-X
blades	B-X
6	B-X
and	B-X
7	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
the	B-X
isoprenyl	B-X
group	B-X
of	B-X
Gbetagamma	B-X
inserts	B-X
into	B-X
this	B-X
pocket	B-X
,	B-X
stabilizing	B-X
the	B-X
Pdc.Gbetagamma	B-X
structure	B-X
and	B-X
decreasing	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
complex	B-X
for	B-X
the	B-X
lipid	B-X
bilayer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
Pdc	B-X
and	B-X
PhLP	B-X
to	B-X
several	B-X
Gbetagamma	B-X
dimers	B-X
containing	B-X
variants	B-X
of	B-X
the	B-X
beta	B-X
or	B-X
gamma	B-X
subunit	B-X
was	B-X
measured	B-X
.	B-X
These	B-X
variants	B-X
included	B-X
modifications	B-X
of	B-X
the	B-X
isoprenyl	B-X
group	B-X
(	B-X
gamma	B-X
)	B-X
,	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
beta	B-X
)	B-X
,	B-X
and	B-X
residues	B-X
lining	B-X
the	B-X
proposed	B-X
prenyl	B-X
pocket	B-X
(	B-X
beta	B-X
)	B-X
.	B-X
Switching	B-X
prenyl	B-X
groups	B-X
from	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
or	B-X
vice	B-X
versa	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
binding	B-X
.	B-X
However	B-X
,	B-X
alanine	B-X
substitution	B-X
of	B-X
one	B-X
residue	B-X
in	B-X
the	B-X
beta	B-X
subunit	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
W332	B-X
)	B-X
decreased	B-X
binding	B-X
5-fold	B-X
.	B-X
Alanine	B-X
substitution	B-X
of	B-X
certain	B-X
residues	B-X
within	B-X
the	B-X
prenyl	B-X
pocket	B-X
caused	B-X
only	B-X
minor	B-X
decreases	B-X
in	B-X
binding	B-X
,	B-X
while	B-X
a	B-X
lysine	B-X
substitution	B-X
of	B-X
T329	B-X
within	B-X
the	B-X
pocket	B-X
inhibited	B-X
binding	B-X
10-fold	B-X
.	B-X
Molecular	B-X
modeling	B-X
of	B-X
the	B-X
binding	B-X
energy	B-X
of	B-X
the	B-X
Pdc.Gbeta	B-X
(	B-X
1	B-X
)	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
complex	B-X
required	B-X
insertion	B-X
of	B-X
the	B-X
geranylgeranyl	B-X
group	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
in	B-X
order	B-X
to	B-X
accurately	B-X
predict	B-X
the	B-X
effects	B-X
of	B-X
prenyl	B-X
pocket	B-X
amino	B-X
acid	B-X
substitutions	B-X
.	B-X
Finally	B-X
,	B-X
a	B-X
dimer	B-X
containing	B-X
a	B-X
gamma	B-X
subunit	B-X
with	B-X
no	B-X
prenyl	B-X
group	B-X
(	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
-C68S	B-X
)	B-X
decreased	B-X
binding	B-X
by	B-X
nearly	B-X
20-fold	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
structural	B-X
model	B-X
in	B-X
which	B-X
the	B-X
prenyl	B-X
group	B-X
escapes	B-X
contact	B-X
with	B-X
the	B-X
aqueous	B-X
milieu	B-X
by	B-X
inserting	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
and	B-X
stabilizing	B-X
the	B-X
Pdc-binding	B-X
conformation	B-X
of	B-X
Gbetagamma	B-X
.	B-X

It	O
has	O
been	O
proposed	O
that	O
the	O
isoprenyl	O
group	O
of	O
Gbetagamma	O
inserts	O
into	O
this	O
pocket	O
,	O
stabilizing	O
the	O
Pdc	B-Protein
.	O
Gbetagamma	O
structure	O
and	O
decreasing	O
the	O
affinity	O
of	O
the	O
complex	O
for	O
the	O
lipid	O
bilayer	O
.	O
<EOS>	B-X
Phosducin	B-X
(	B-X
Pdc	B-X
)	B-X
and	B-X
phosducin-like	B-X
protein	B-X
(	B-X
PhLP	B-X
)	B-X
regulate	B-X
G	B-X
protein-mediated	B-X
signaling	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
betagamma	B-X
subunit	B-X
complex	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
(	B-X
Gbetagamma	B-X
)	B-X
and	B-X
removing	B-X
the	B-X
dimer	B-X
from	B-X
cell	B-X
membranes	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
Pdc	B-X
induces	B-X
a	B-X
conformational	B-X
change	B-X
in	B-X
the	B-X
beta-propeller	B-X
structure	B-X
of	B-X
Gbetagamma	B-X
,	B-X
creating	B-X
a	B-X
pocket	B-X
between	B-X
blades	B-X
6	B-X
and	B-X
7	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
the	B-X
isoprenyl	B-X
group	B-X
of	B-X
Gbetagamma	B-X
inserts	B-X
into	B-X
this	B-X
pocket	B-X
,	B-X
stabilizing	B-X
the	B-X
Pdc.Gbetagamma	B-X
structure	B-X
and	B-X
decreasing	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
complex	B-X
for	B-X
the	B-X
lipid	B-X
bilayer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
Pdc	B-X
and	B-X
PhLP	B-X
to	B-X
several	B-X
Gbetagamma	B-X
dimers	B-X
containing	B-X
variants	B-X
of	B-X
the	B-X
beta	B-X
or	B-X
gamma	B-X
subunit	B-X
was	B-X
measured	B-X
.	B-X
These	B-X
variants	B-X
included	B-X
modifications	B-X
of	B-X
the	B-X
isoprenyl	B-X
group	B-X
(	B-X
gamma	B-X
)	B-X
,	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
beta	B-X
)	B-X
,	B-X
and	B-X
residues	B-X
lining	B-X
the	B-X
proposed	B-X
prenyl	B-X
pocket	B-X
(	B-X
beta	B-X
)	B-X
.	B-X
Switching	B-X
prenyl	B-X
groups	B-X
from	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
or	B-X
vice	B-X
versa	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
binding	B-X
.	B-X
Alanine	B-X
substitution	B-X
of	B-X
certain	B-X
residues	B-X
within	B-X
the	B-X
prenyl	B-X
pocket	B-X
caused	B-X
only	B-X
minor	B-X
decreases	B-X
in	B-X
binding	B-X
,	B-X
while	B-X
a	B-X
lysine	B-X
substitution	B-X
of	B-X
T329	B-X
within	B-X
the	B-X
pocket	B-X
inhibited	B-X
binding	B-X
10-fold	B-X
.	B-X
Molecular	B-X
modeling	B-X
of	B-X
the	B-X
binding	B-X
energy	B-X
of	B-X
the	B-X
Pdc.Gbeta	B-X
(	B-X
1	B-X
)	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
complex	B-X
required	B-X
insertion	B-X
of	B-X
the	B-X
geranylgeranyl	B-X
group	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
in	B-X
order	B-X
to	B-X
accurately	B-X
predict	B-X
the	B-X
effects	B-X
of	B-X
prenyl	B-X
pocket	B-X
amino	B-X
acid	B-X
substitutions	B-X
.	B-X
Finally	B-X
,	B-X
a	B-X
dimer	B-X
containing	B-X
a	B-X
gamma	B-X
subunit	B-X
with	B-X
no	B-X
prenyl	B-X
group	B-X
(	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
-C68S	B-X
)	B-X
decreased	B-X
binding	B-X
by	B-X
nearly	B-X
20-fold	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
structural	B-X
model	B-X
in	B-X
which	B-X
the	B-X
prenyl	B-X
group	B-X
escapes	B-X
contact	B-X
with	B-X
the	B-X
aqueous	B-X
milieu	B-X
by	B-X
inserting	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
and	B-X
stabilizing	B-X
the	B-X
Pdc-binding	B-X
conformation	B-X
of	B-X
Gbetagamma	B-X
.	B-X

To	O
test	O
this	O
hypothesis	O
,	O
the	O
binding	O
of	O
Pdc	B-Protein
and	O
PhLP	B-Protein
to	O
several	O
Gbetagamma	O
dimers	O
containing	O
variants	O
of	O
the	O
beta	O
or	O
gamma	O
subunit	O
was	O
measured	O
.	O
<EOS>	B-X
Auxiliary	B-X
subunits	B-X
of	B-X
the	B-X
HVA	B-X
calcium	B-X
channels	B-X
contribute	B-X
significantly	B-X
to	B-X
biophysical	B-X
properties	B-X
of	B-X
the	B-X
channels	B-X
.	B-X
We	B-X
have	B-X
cloned	B-X
and	B-X
characterized	B-X
members	B-X
of	B-X
two	B-X
families	B-X
of	B-X
auxiliary	B-X
subunits	B-X
:	B-X
alpha2delta	B-X
and	B-X
gamma	B-X
.	B-X
Two	B-X
new	B-X
alpha2delta	B-X
subunits	B-X
,	B-X
alpha2delta-2	B-X
and	B-X
alpha2delta-3	B-X
,	B-X
regulate	B-X
all	B-X
classes	B-X
of	B-X
HVA	B-X
calcium	B-X
channels	B-X
.	B-X
While	B-X
the	B-X
ubiquitous	B-X
alpha2delta-2	B-X
modulates	B-X
both	B-X
neuronal	B-X
and	B-X
non-neuronal	B-X
channels	B-X
with	B-X
similar	B-X
efficiency	B-X
,	B-X
the	B-X
alpha2delta-3	B-X
subunit	B-X
regulates	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.3	B-X
channels	B-X
more	B-X
effectively	B-X
.	B-X
Four	B-X
new	B-X
gamma	B-X
subunits	B-X
,	B-X
gamma-2	B-X
,	B-X
gamma-3	B-X
,	B-X
gamma-4	B-X
and	B-X
gamma-5	B-X
,	B-X
were	B-X
characterized	B-X
.	B-X
The	B-X
gamma-2	B-X
subunit	B-X
modulated	B-X
both	B-X
the	B-X
non-neuronal	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
1.2	B-X
channel	B-X
and	B-X
the	B-X
neuronal	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.1	B-X
channel	B-X
.	B-X
The	B-X
gamma-4	B-X
subunit	B-X
affected	B-X
only	B-X
the	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.1	B-X
channel	B-X
.	B-X
The	B-X
gamma-5	B-X
subunit	B-X
may	B-X
be	B-X
a	B-X
regulatory	B-X
subunit	B-X
of	B-X
the	B-X
LVA	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
3.1	B-X
channel	B-X
.	B-X
Experiments	B-X
with	B-X
a	B-X
permanently	B-X
charged	B-X
DHP	B-X
suggested	B-X
that	B-X
there	B-X
is	B-X
another	B-X
low-affinity	B-X
interaction	B-X
site	B-X
on	B-X
the	B-X
alpha	B-X
(	B-X
1	B-X
)	B-X
subunit	B-X
.	B-X

These	O
variants	O
included	O
modifications	O
of	O
the	O
isoprenyl	O
group	O
(	O
gamma	O
)	O
,	O
residues	O
involved	O
in	O
the	O
conformational	O
change	O
(	O
beta	O
)	O
,	O
and	O
residues	O
lining	O
the	O
proposed	O
prenyl	O
pocket	O
(	O
beta	O
)	O
.	O
<EOS>	B-X
Phosducin	B-X
(	B-X
Pdc	B-X
)	B-X
and	B-X
phosducin-like	B-X
protein	B-X
(	B-X
PhLP	B-X
)	B-X
regulate	B-X
G	B-X
protein-mediated	B-X
signaling	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
betagamma	B-X
subunit	B-X
complex	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
(	B-X
Gbetagamma	B-X
)	B-X
and	B-X
removing	B-X
the	B-X
dimer	B-X
from	B-X
cell	B-X
membranes	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
Pdc	B-X
induces	B-X
a	B-X
conformational	B-X
change	B-X
in	B-X
the	B-X
beta-propeller	B-X
structure	B-X
of	B-X
Gbetagamma	B-X
,	B-X
creating	B-X
a	B-X
pocket	B-X
between	B-X
blades	B-X
6	B-X
and	B-X
7	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
the	B-X
isoprenyl	B-X
group	B-X
of	B-X
Gbetagamma	B-X
inserts	B-X
into	B-X
this	B-X
pocket	B-X
,	B-X
stabilizing	B-X
the	B-X
Pdc.Gbetagamma	B-X
structure	B-X
and	B-X
decreasing	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
complex	B-X
for	B-X
the	B-X
lipid	B-X
bilayer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
Pdc	B-X
and	B-X
PhLP	B-X
to	B-X
several	B-X
Gbetagamma	B-X
dimers	B-X
containing	B-X
variants	B-X
of	B-X
the	B-X
beta	B-X
or	B-X
gamma	B-X
subunit	B-X
was	B-X
measured	B-X
.	B-X
These	B-X
variants	B-X
included	B-X
modifications	B-X
of	B-X
the	B-X
isoprenyl	B-X
group	B-X
(	B-X
gamma	B-X
)	B-X
,	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
beta	B-X
)	B-X
,	B-X
and	B-X
residues	B-X
lining	B-X
the	B-X
proposed	B-X
prenyl	B-X
pocket	B-X
(	B-X
beta	B-X
)	B-X
.	B-X
Switching	B-X
prenyl	B-X
groups	B-X
from	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
or	B-X
vice	B-X
versa	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
binding	B-X
.	B-X
However	B-X
,	B-X
alanine	B-X
substitution	B-X
of	B-X
one	B-X
residue	B-X
in	B-X
the	B-X
beta	B-X
subunit	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
W332	B-X
)	B-X
decreased	B-X
binding	B-X
5-fold	B-X
.	B-X
Alanine	B-X
substitution	B-X
of	B-X
certain	B-X
residues	B-X
within	B-X
the	B-X
prenyl	B-X
pocket	B-X
caused	B-X
only	B-X
minor	B-X
decreases	B-X
in	B-X
binding	B-X
,	B-X
while	B-X
a	B-X
lysine	B-X
substitution	B-X
of	B-X
T329	B-X
within	B-X
the	B-X
pocket	B-X
inhibited	B-X
binding	B-X
10-fold	B-X
.	B-X
Molecular	B-X
modeling	B-X
of	B-X
the	B-X
binding	B-X
energy	B-X
of	B-X
the	B-X
Pdc.Gbeta	B-X
(	B-X
1	B-X
)	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
complex	B-X
required	B-X
insertion	B-X
of	B-X
the	B-X
geranylgeranyl	B-X
group	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
in	B-X
order	B-X
to	B-X
accurately	B-X
predict	B-X
the	B-X
effects	B-X
of	B-X
prenyl	B-X
pocket	B-X
amino	B-X
acid	B-X
substitutions	B-X
.	B-X
Finally	B-X
,	B-X
a	B-X
dimer	B-X
containing	B-X
a	B-X
gamma	B-X
subunit	B-X
with	B-X
no	B-X
prenyl	B-X
group	B-X
(	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
-C68S	B-X
)	B-X
decreased	B-X
binding	B-X
by	B-X
nearly	B-X
20-fold	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
structural	B-X
model	B-X
in	B-X
which	B-X
the	B-X
prenyl	B-X
group	B-X
escapes	B-X
contact	B-X
with	B-X
the	B-X
aqueous	B-X
milieu	B-X
by	B-X
inserting	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
and	B-X
stabilizing	B-X
the	B-X
Pdc-binding	B-X
conformation	B-X
of	B-X
Gbetagamma	B-X
.	B-X

Switching	O
prenyl	O
groups	O
from	O
farnesyl	O
to	O
geranylgeranyl	O
or	O
vice	O
versa	O
had	O
little	O
effect	O
on	O
binding	O
.	O
<EOS>	B-X
The	B-X
attachment	B-X
of	B-X
functional	B-X
groups	B-X
like	B-X
lipids	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
a	B-X
robust	B-X
and	B-X
effective	B-X
strategy	B-X
for	B-X
improving	B-X
their	B-X
therapeutic	B-X
potential	B-X
.	B-X
These	B-X
lipids	B-X
are	B-X
attached	B-X
by	B-X
the	B-X
F	B-X
superfamily	B-X
of	B-X
peptide	B-X
prenyltransferase	B-X
enzymes	B-X
that	B-X
utilize	B-X
5-carbon	B-X
(	B-X
prenylation	B-X
)	B-X
or	B-X
10-carbon	B-X
(	B-X
geranylation	B-X
)	B-X
donors	B-X
.	B-X
Biochemical	B-X
characterization	B-X
of	B-X
the	B-X
F	B-X
prenyltransferases	B-X
from	B-X
the	B-X
corresponding	B-X
clusters	B-X
shows	B-X
that	B-X
the	B-X
different	B-X
enzymes	B-X
have	B-X
different	B-X
acceptor	B-X
residue	B-X
specificities	B-X
but	B-X
are	B-X
otherwise	B-X
remarkably	B-X
sequence	B-X
tolerant	B-X
.	B-X
Recoverin	B-X
,	B-X
a	B-X
recently	B-X
discovered	B-X
member	B-X
of	B-X
the	B-X
EF-hand	B-X
superfamily	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-binding	B-X
proteins	B-X
,	B-X
serves	B-X
as	B-X
a	B-X
Ca2+	B-X
sensor	B-X
in	B-X
vision	B-X
.	B-X
Ca2+	B-X
induces	B-X
the	B-X
binding	B-X
of	B-X
both	B-X
the	B-X
unmyristoylated	B-X
and	B-X
myristoylated	B-X
proteins	B-X
to	B-X
phenyl-agarose	B-X
,	B-X
a	B-X
hydrophobic	B-X
support	B-X
.	B-X
The	B-X
Hill	B-X
coefficients	B-X
of	B-X
1.8	B-X
and	B-X
1.7	B-X
,	B-X
respectively	B-X
,	B-X
indicate	B-X
that	B-X
binding	B-X
was	B-X
cooperative	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Ca2+	B-X
induced	B-X
the	B-X
binding	B-X
of	B-X
myristoylated	B-X
but	B-X
not	B-X
of	B-X
unmyristoylated	B-X
recoverin	B-X
to	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
.	B-X
Likewise	B-X
,	B-X
myristoylated	B-X
but	B-X
not	B-X
unmyristoylated	B-X
recoverin	B-X
exhibited	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-induced	B-X
binding	B-X
to	B-X
phosphatidylcholine	B-X
vesicles	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
Ca2+	B-X
to	B-X
recoverin	B-X
has	B-X
two	B-X
effects	B-X
:	B-X
(	B-X
i	B-X
)	B-X
hydrophobic	B-X
surfaces	B-X
are	B-X
exposed	B-X
,	B-X
allowing	B-X
the	B-X
protein	B-X
to	B-X
interact	B-X
with	B-X
complementary	B-X
nonpolar	B-X
sites	B-X
,	B-X
such	B-X
as	B-X
the	B-X
aromatic	B-X
rings	B-X
of	B-X
phenyl-agarose	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
the	B-X
myristoyl	B-X
group	B-X
is	B-X
extruded	B-X
,	B-X
enabling	B-X
recoverin	B-X
to	B-X
insert	B-X
into	B-X
a	B-X
lipid	B-X
bilayer	B-X
membrane	B-X
.	B-X

However	O
,	O
alanine	O
substitution	O
of	O
one	O
residue	O
in	O
the	O
beta	O
subunit	O
involved	O
in	O
the	O
conformational	O
change	O
(	O
W332	O
)	O
decreased	O
binding	O
5	O
-	O
fold	O
.	O
<EOS>	B-X
Phosducin	B-X
(	B-X
Pdc	B-X
)	B-X
and	B-X
phosducin-like	B-X
protein	B-X
(	B-X
PhLP	B-X
)	B-X
regulate	B-X
G	B-X
protein-mediated	B-X
signaling	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
betagamma	B-X
subunit	B-X
complex	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
(	B-X
Gbetagamma	B-X
)	B-X
and	B-X
removing	B-X
the	B-X
dimer	B-X
from	B-X
cell	B-X
membranes	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
Pdc	B-X
induces	B-X
a	B-X
conformational	B-X
change	B-X
in	B-X
the	B-X
beta-propeller	B-X
structure	B-X
of	B-X
Gbetagamma	B-X
,	B-X
creating	B-X
a	B-X
pocket	B-X
between	B-X
blades	B-X
6	B-X
and	B-X
7	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
the	B-X
isoprenyl	B-X
group	B-X
of	B-X
Gbetagamma	B-X
inserts	B-X
into	B-X
this	B-X
pocket	B-X
,	B-X
stabilizing	B-X
the	B-X
Pdc.Gbetagamma	B-X
structure	B-X
and	B-X
decreasing	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
complex	B-X
for	B-X
the	B-X
lipid	B-X
bilayer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
Pdc	B-X
and	B-X
PhLP	B-X
to	B-X
several	B-X
Gbetagamma	B-X
dimers	B-X
containing	B-X
variants	B-X
of	B-X
the	B-X
beta	B-X
or	B-X
gamma	B-X
subunit	B-X
was	B-X
measured	B-X
.	B-X
These	B-X
variants	B-X
included	B-X
modifications	B-X
of	B-X
the	B-X
isoprenyl	B-X
group	B-X
(	B-X
gamma	B-X
)	B-X
,	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
beta	B-X
)	B-X
,	B-X
and	B-X
residues	B-X
lining	B-X
the	B-X
proposed	B-X
prenyl	B-X
pocket	B-X
(	B-X
beta	B-X
)	B-X
.	B-X
Switching	B-X
prenyl	B-X
groups	B-X
from	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
or	B-X
vice	B-X
versa	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
binding	B-X
.	B-X
However	B-X
,	B-X
alanine	B-X
substitution	B-X
of	B-X
one	B-X
residue	B-X
in	B-X
the	B-X
beta	B-X
subunit	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
W332	B-X
)	B-X
decreased	B-X
binding	B-X
5-fold	B-X
.	B-X
Alanine	B-X
substitution	B-X
of	B-X
certain	B-X
residues	B-X
within	B-X
the	B-X
prenyl	B-X
pocket	B-X
caused	B-X
only	B-X
minor	B-X
decreases	B-X
in	B-X
binding	B-X
,	B-X
while	B-X
a	B-X
lysine	B-X
substitution	B-X
of	B-X
T329	B-X
within	B-X
the	B-X
pocket	B-X
inhibited	B-X
binding	B-X
10-fold	B-X
.	B-X
Molecular	B-X
modeling	B-X
of	B-X
the	B-X
binding	B-X
energy	B-X
of	B-X
the	B-X
Pdc.Gbeta	B-X
(	B-X
1	B-X
)	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
complex	B-X
required	B-X
insertion	B-X
of	B-X
the	B-X
geranylgeranyl	B-X
group	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
in	B-X
order	B-X
to	B-X
accurately	B-X
predict	B-X
the	B-X
effects	B-X
of	B-X
prenyl	B-X
pocket	B-X
amino	B-X
acid	B-X
substitutions	B-X
.	B-X
Finally	B-X
,	B-X
a	B-X
dimer	B-X
containing	B-X
a	B-X
gamma	B-X
subunit	B-X
with	B-X
no	B-X
prenyl	B-X
group	B-X
(	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
-C68S	B-X
)	B-X
decreased	B-X
binding	B-X
by	B-X
nearly	B-X
20-fold	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
structural	B-X
model	B-X
in	B-X
which	B-X
the	B-X
prenyl	B-X
group	B-X
escapes	B-X
contact	B-X
with	B-X
the	B-X
aqueous	B-X
milieu	B-X
by	B-X
inserting	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
and	B-X
stabilizing	B-X
the	B-X
Pdc-binding	B-X
conformation	B-X
of	B-X
Gbetagamma	B-X
.	B-X

Alanine	O
substitution	O
of	O
certain	O
residues	O
within	O
the	O
prenyl	O
pocket	O
caused	O
only	O
minor	O
decreases	O
in	O
binding	O
,	O
while	O
a	O
lysine	O
substitution	O
of	O
T329	O
within	O
the	O
pocket	O
inhibited	O
binding	O
10	O
-	O
fold	O
.	O
<EOS>	B-X
Phosducin	B-X
(	B-X
Pdc	B-X
)	B-X
and	B-X
phosducin-like	B-X
protein	B-X
(	B-X
PhLP	B-X
)	B-X
regulate	B-X
G	B-X
protein-mediated	B-X
signaling	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
betagamma	B-X
subunit	B-X
complex	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
(	B-X
Gbetagamma	B-X
)	B-X
and	B-X
removing	B-X
the	B-X
dimer	B-X
from	B-X
cell	B-X
membranes	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
Pdc	B-X
induces	B-X
a	B-X
conformational	B-X
change	B-X
in	B-X
the	B-X
beta-propeller	B-X
structure	B-X
of	B-X
Gbetagamma	B-X
,	B-X
creating	B-X
a	B-X
pocket	B-X
between	B-X
blades	B-X
6	B-X
and	B-X
7	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
the	B-X
isoprenyl	B-X
group	B-X
of	B-X
Gbetagamma	B-X
inserts	B-X
into	B-X
this	B-X
pocket	B-X
,	B-X
stabilizing	B-X
the	B-X
Pdc.Gbetagamma	B-X
structure	B-X
and	B-X
decreasing	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
complex	B-X
for	B-X
the	B-X
lipid	B-X
bilayer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
Pdc	B-X
and	B-X
PhLP	B-X
to	B-X
several	B-X
Gbetagamma	B-X
dimers	B-X
containing	B-X
variants	B-X
of	B-X
the	B-X
beta	B-X
or	B-X
gamma	B-X
subunit	B-X
was	B-X
measured	B-X
.	B-X
These	B-X
variants	B-X
included	B-X
modifications	B-X
of	B-X
the	B-X
isoprenyl	B-X
group	B-X
(	B-X
gamma	B-X
)	B-X
,	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
beta	B-X
)	B-X
,	B-X
and	B-X
residues	B-X
lining	B-X
the	B-X
proposed	B-X
prenyl	B-X
pocket	B-X
(	B-X
beta	B-X
)	B-X
.	B-X
Switching	B-X
prenyl	B-X
groups	B-X
from	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
or	B-X
vice	B-X
versa	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
binding	B-X
.	B-X
However	B-X
,	B-X
alanine	B-X
substitution	B-X
of	B-X
one	B-X
residue	B-X
in	B-X
the	B-X
beta	B-X
subunit	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
W332	B-X
)	B-X
decreased	B-X
binding	B-X
5-fold	B-X
.	B-X
Alanine	B-X
substitution	B-X
of	B-X
certain	B-X
residues	B-X
within	B-X
the	B-X
prenyl	B-X
pocket	B-X
caused	B-X
only	B-X
minor	B-X
decreases	B-X
in	B-X
binding	B-X
,	B-X
while	B-X
a	B-X
lysine	B-X
substitution	B-X
of	B-X
T329	B-X
within	B-X
the	B-X
pocket	B-X
inhibited	B-X
binding	B-X
10-fold	B-X
.	B-X
Molecular	B-X
modeling	B-X
of	B-X
the	B-X
binding	B-X
energy	B-X
of	B-X
the	B-X
Pdc.Gbeta	B-X
(	B-X
1	B-X
)	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
complex	B-X
required	B-X
insertion	B-X
of	B-X
the	B-X
geranylgeranyl	B-X
group	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
in	B-X
order	B-X
to	B-X
accurately	B-X
predict	B-X
the	B-X
effects	B-X
of	B-X
prenyl	B-X
pocket	B-X
amino	B-X
acid	B-X
substitutions	B-X
.	B-X
Finally	B-X
,	B-X
a	B-X
dimer	B-X
containing	B-X
a	B-X
gamma	B-X
subunit	B-X
with	B-X
no	B-X
prenyl	B-X
group	B-X
(	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
-C68S	B-X
)	B-X
decreased	B-X
binding	B-X
by	B-X
nearly	B-X
20-fold	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
structural	B-X
model	B-X
in	B-X
which	B-X
the	B-X
prenyl	B-X
group	B-X
escapes	B-X
contact	B-X
with	B-X
the	B-X
aqueous	B-X
milieu	B-X
by	B-X
inserting	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
and	B-X
stabilizing	B-X
the	B-X
Pdc-binding	B-X
conformation	B-X
of	B-X
Gbetagamma	B-X
.	B-X

Molecular	O
modeling	O
of	O
the	O
binding	O
energy	O
of	O
the	O
Pdc	B-Protein
.	O
Gbeta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
gamma	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
complex	O
required	O
insertion	O
of	O
the	O
geranylgeranyl	O
group	O
into	O
the	O
prenyl	O
pocket	O
in	O
order	O
to	O
accurately	O
predict	O
the	O
effects	O
of	O
prenyl	O
pocket	O
amino	O
acid	O
substitutions	O
.	O

Finally	O
,	O
a	O
dimer	O
containing	O
a	O
gamma	O
subunit	O
with	O
no	O
prenyl	O
group	O
(	O
gamma	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
-	O
C68S	O
)	O
decreased	O
binding	O
by	O
nearly	O
20	O
-	O
fold	O
.	O

These	O
results	O
support	O
the	O
structural	O
model	O
in	O
which	O
the	O
prenyl	O
group	O
escapes	O
contact	O
with	O
the	O
aqueous	O
milieu	O
by	O
inserting	O
into	O
the	O
prenyl	O
pocket	O
and	O
stabilizing	O
the	O
Pdc	B-Protein
-	O
binding	O
conformation	O
of	O
Gbetagamma	O
.	O
<EOS>	B-X
Phosducin	B-X
(	B-X
Pdc	B-X
)	B-X
and	B-X
phosducin-like	B-X
protein	B-X
(	B-X
PhLP	B-X
)	B-X
regulate	B-X
G	B-X
protein-mediated	B-X
signaling	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
betagamma	B-X
subunit	B-X
complex	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
(	B-X
Gbetagamma	B-X
)	B-X
and	B-X
removing	B-X
the	B-X
dimer	B-X
from	B-X
cell	B-X
membranes	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
Pdc	B-X
induces	B-X
a	B-X
conformational	B-X
change	B-X
in	B-X
the	B-X
beta-propeller	B-X
structure	B-X
of	B-X
Gbetagamma	B-X
,	B-X
creating	B-X
a	B-X
pocket	B-X
between	B-X
blades	B-X
6	B-X
and	B-X
7	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
the	B-X
isoprenyl	B-X
group	B-X
of	B-X
Gbetagamma	B-X
inserts	B-X
into	B-X
this	B-X
pocket	B-X
,	B-X
stabilizing	B-X
the	B-X
Pdc.Gbetagamma	B-X
structure	B-X
and	B-X
decreasing	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
complex	B-X
for	B-X
the	B-X
lipid	B-X
bilayer	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
Pdc	B-X
and	B-X
PhLP	B-X
to	B-X
several	B-X
Gbetagamma	B-X
dimers	B-X
containing	B-X
variants	B-X
of	B-X
the	B-X
beta	B-X
or	B-X
gamma	B-X
subunit	B-X
was	B-X
measured	B-X
.	B-X
These	B-X
variants	B-X
included	B-X
modifications	B-X
of	B-X
the	B-X
isoprenyl	B-X
group	B-X
(	B-X
gamma	B-X
)	B-X
,	B-X
residues	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
beta	B-X
)	B-X
,	B-X
and	B-X
residues	B-X
lining	B-X
the	B-X
proposed	B-X
prenyl	B-X
pocket	B-X
(	B-X
beta	B-X
)	B-X
.	B-X
Switching	B-X
prenyl	B-X
groups	B-X
from	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
or	B-X
vice	B-X
versa	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
binding	B-X
.	B-X
However	B-X
,	B-X
alanine	B-X
substitution	B-X
of	B-X
one	B-X
residue	B-X
in	B-X
the	B-X
beta	B-X
subunit	B-X
involved	B-X
in	B-X
the	B-X
conformational	B-X
change	B-X
(	B-X
W332	B-X
)	B-X
decreased	B-X
binding	B-X
5-fold	B-X
.	B-X
Alanine	B-X
substitution	B-X
of	B-X
certain	B-X
residues	B-X
within	B-X
the	B-X
prenyl	B-X
pocket	B-X
caused	B-X
only	B-X
minor	B-X
decreases	B-X
in	B-X
binding	B-X
,	B-X
while	B-X
a	B-X
lysine	B-X
substitution	B-X
of	B-X
T329	B-X
within	B-X
the	B-X
pocket	B-X
inhibited	B-X
binding	B-X
10-fold	B-X
.	B-X
Molecular	B-X
modeling	B-X
of	B-X
the	B-X
binding	B-X
energy	B-X
of	B-X
the	B-X
Pdc.Gbeta	B-X
(	B-X
1	B-X
)	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
complex	B-X
required	B-X
insertion	B-X
of	B-X
the	B-X
geranylgeranyl	B-X
group	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
in	B-X
order	B-X
to	B-X
accurately	B-X
predict	B-X
the	B-X
effects	B-X
of	B-X
prenyl	B-X
pocket	B-X
amino	B-X
acid	B-X
substitutions	B-X
.	B-X
Finally	B-X
,	B-X
a	B-X
dimer	B-X
containing	B-X
a	B-X
gamma	B-X
subunit	B-X
with	B-X
no	B-X
prenyl	B-X
group	B-X
(	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
-C68S	B-X
)	B-X
decreased	B-X
binding	B-X
by	B-X
nearly	B-X
20-fold	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
structural	B-X
model	B-X
in	B-X
which	B-X
the	B-X
prenyl	B-X
group	B-X
escapes	B-X
contact	B-X
with	B-X
the	B-X
aqueous	B-X
milieu	B-X
by	B-X
inserting	B-X
into	B-X
the	B-X
prenyl	B-X
pocket	B-X
and	B-X
stabilizing	B-X
the	B-X
Pdc-binding	B-X
conformation	B-X
of	B-X
Gbetagamma	B-X
.	B-X

Atg21	B-Protein
is	O
a	O
phosphoinositide	O
binding	O
protein	O
required	O
for	O
efficient	O
lipidation	O
and	O
localization	O
of	O
Atg8	B-Protein
during	O
uptake	O
of	O
aminopeptidase	B-Protein
I	I-Protein
by	O
selective	O
autophagy	O
.	O
<EOS>	B-X
Delivery	B-X
of	B-X
proteins	B-X
and	B-X
organelles	B-X
to	B-X
the	B-X
vacuole	B-X
by	B-X
autophagy	B-X
and	B-X
the	B-X
cytoplasm	B-X
to	B-X
vacuole	B-X
targeting	B-X
(	B-X
Cvt	B-X
)	B-X
pathway	B-X
involves	B-X
novel	B-X
rearrangements	B-X
of	B-X
membrane	B-X
resulting	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
vesicles	B-X
that	B-X
fuse	B-X
with	B-X
the	B-X
vacuole	B-X
.	B-X
Atg18	B-X
and	B-X
Atg21	B-X
are	B-X
proteins	B-X
essential	B-X
to	B-X
vesicle	B-X
formation	B-X
and	B-X
together	B-X
with	B-X
Ygr223c	B-X
form	B-X
a	B-X
novel	B-X
family	B-X
of	B-X
phosphoinositide	B-X
binding	B-X
proteins	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
vacuole	B-X
and	B-X
perivacuolar	B-X
structures	B-X
.	B-X
Their	B-X
localization	B-X
requires	B-X
the	B-X
activity	B-X
of	B-X
Vps34	B-X
,	B-X
suggesting	B-X
that	B-X
phosphatidylinositol	B-X
(	B-X
3	B-X
)	B-X
phosphate	B-X
may	B-X
be	B-X
essential	B-X
for	B-X
their	B-X
function	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
Atg18	B-X
is	B-X
vital	B-X
for	B-X
all	B-X
forms	B-X
of	B-X
autophagy	B-X
,	B-X
whereas	B-X
Atg21	B-X
is	B-X
required	B-X
for	B-X
the	B-X
Cvt	B-X
pathway	B-X
but	B-X
not	B-X
for	B-X
nitrogen	B-X
starvation-induced	B-X
autophagy	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
Atg21	B-X
results	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
Atg8	B-X
from	B-X
the	B-X
pre-autophagosomal	B-X
structure	B-X
(	B-X
PAS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
reduced	B-X
rate	B-X
of	B-X
conjugation	B-X
of	B-X
Atg8	B-X
to	B-X
phosphatidylethanolamine	B-X
.	B-X
A	B-X
similar	B-X
defect	B-X
in	B-X
localization	B-X
of	B-X
a	B-X
second	B-X
ubiquitin-like	B-X
conjugate	B-X
,	B-X
Atg12-Atg5	B-X
,	B-X
suggests	B-X
that	B-X
Atg21	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
membrane	B-X
to	B-X
the	B-X
PAS	B-X
.	B-X

Delivery	O
of	O
proteins	O
and	O
organelles	O
to	O
the	O
vacuole	O
by	O
autophagy	O
and	O
the	O
cytoplasm	O
to	O
vacuole	O
targeting	O
(	O
Cvt	O
)	O
pathway	O
involves	O
novel	O
rearrangements	O
of	O
membrane	O
resulting	O
in	O
the	O
formation	O
of	O
vesicles	O
that	O
fuse	O
with	O
the	O
vacuole	O
.	O

The	O
mechanism	O
of	O
vesicle	O
formation	O
and	O
the	O
origin	O
of	O
the	O
membrane	O
are	O
complex	O
issues	O
still	O
to	O
be	O
resolved	O
.	O
<EOS>	B-X
Delivery	B-X
of	B-X
proteins	B-X
and	B-X
organelles	B-X
to	B-X
the	B-X
vacuole	B-X
by	B-X
autophagy	B-X
and	B-X
the	B-X
cytoplasm	B-X
to	B-X
vacuole	B-X
targeting	B-X
(	B-X
Cvt	B-X
)	B-X
pathway	B-X
involves	B-X
novel	B-X
rearrangements	B-X
of	B-X
membrane	B-X
resulting	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
vesicles	B-X
that	B-X
fuse	B-X
with	B-X
the	B-X
vacuole	B-X
.	B-X
The	B-X
mechanism	B-X
of	B-X
vesicle	B-X
formation	B-X
and	B-X
the	B-X
origin	B-X
of	B-X
the	B-X
membrane	B-X
are	B-X
complex	B-X
issues	B-X
still	B-X
to	B-X
be	B-X
resolved	B-X
.	B-X
Atg18	B-X
and	B-X
Atg21	B-X
are	B-X
proteins	B-X
essential	B-X
to	B-X
vesicle	B-X
formation	B-X
and	B-X
together	B-X
with	B-X
Ygr223c	B-X
form	B-X
a	B-X
novel	B-X
family	B-X
of	B-X
phosphoinositide	B-X
binding	B-X
proteins	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
vacuole	B-X
and	B-X
perivacuolar	B-X
structures	B-X
.	B-X
A	B-X
similar	B-X
defect	B-X
in	B-X
localization	B-X
of	B-X
a	B-X
second	B-X
ubiquitin-like	B-X
conjugate	B-X
,	B-X
Atg12-Atg5	B-X
,	B-X
suggests	B-X
that	B-X
Atg21	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
membrane	B-X
to	B-X
the	B-X
PAS	B-X
.	B-X

Atg18	B-Protein
and	O
Atg21	B-Protein
are	O
proteins	O
essential	O
to	O
vesicle	O
formation	O
and	O
together	O
with	O
Ygr223c	B-Protein
form	O
a	O
novel	O
family	O
of	O
phosphoinositide	O
binding	O
proteins	O
that	O
are	O
associated	O
with	O
the	O
vacuole	O
and	O
perivacuolar	O
structures	O
.	O

Their	O
localization	O
requires	O
the	O
activity	O
of	O
Vps34	B-Protein
,	O
suggesting	O
that	O
phosphatidylinositol	O
(	O
3	O
)	O
phosphate	O
may	O
be	O
essential	O
for	O
their	O
function	O
.	O
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
stepwise	B-X
formation	B-X
of	B-X
phosphatidylinositol	B-X
3-phosphate	B-X
(	B-X
PI	B-X
(	B-X
3	B-X
)	B-X
P	B-X
)	B-X
and	B-X
phosphatidylinositol	B-X
3,5-bisphosphate	B-X
(	B-X
PI	B-X
(	B-X
3,5	B-X
)	B-X
P	B-X
(	B-X
2	B-X
)	B-X
)	B-X
regulates	B-X
the	B-X
cell	B-X
type-specific	B-X
activation	B-X
and	B-X
localization	B-X
of	B-X
mTORC1	B-X
.	B-X
PI	B-X
(	B-X
3	B-X
)	B-X
P	B-X
formation	B-X
depends	B-X
on	B-X
the	B-X
class	B-X
II	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
PI3K-C2α	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
class	B-X
III	B-X
PI3K	B-X
Vps34	B-X
,	B-X
while	B-X
PI	B-X
(	B-X
3,5	B-X
)	B-X
P	B-X
(	B-X
2	B-X
)	B-X
requires	B-X
the	B-X
phosphatidylinositol-3-phosphate-5-kinase	B-X
PIKFYVE	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
show	B-X
that	B-X
PIKFYVE	B-X
and	B-X
PI3K-C2α	B-X
are	B-X
necessary	B-X
for	B-X
activation	B-X
of	B-X
mTORC1	B-X
and	B-X
its	B-X
translocation	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
in	B-X
3T3-L1	B-X
adipocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
mTORC1	B-X
component	B-X
Raptor	B-X
directly	B-X
interacts	B-X
with	B-X
PI	B-X
(	B-X
3,5	B-X
)	B-X
P	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
PI	B-X
(	B-X
3,5	B-X
)	B-X
P	B-X
(	B-X
2	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
mTORC1	B-X
regulator	B-X
that	B-X
defines	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
complex	B-X
.	B-X

The	O
activity	O
of	O
Atg18	B-Protein
is	O
vital	O
for	O
all	O
forms	O
of	O
autophagy	O
,	O
whereas	O
Atg21	B-Protein
is	O
required	O
for	O
the	O
Cvt	O
pathway	O
but	O
not	O
for	O
nitrogen	O
starvation	O
-	O
induced	O
autophagy	O
.	O

The	O
loss	O
of	O
Atg21	B-Protein
results	O
in	O
the	O
absence	O
of	O
Atg8	B-Protein
from	O
the	O
pre	O
-	O
autophagosomal	O
structure	O
(	O
PAS	O
)	O
,	O
which	O
may	O
be	O
ascribed	O
to	O
a	O
reduced	O
rate	O
of	O
conjugation	O
of	O
Atg8	B-Protein
to	O
phosphatidylethanolamine	O
.	O
<EOS>	B-X
Atg18	B-X
and	B-X
Atg21	B-X
are	B-X
proteins	B-X
essential	B-X
to	B-X
vesicle	B-X
formation	B-X
and	B-X
together	B-X
with	B-X
Ygr223c	B-X
form	B-X
a	B-X
novel	B-X
family	B-X
of	B-X
phosphoinositide	B-X
binding	B-X
proteins	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
vacuole	B-X
and	B-X
perivacuolar	B-X
structures	B-X
.	B-X
Their	B-X
localization	B-X
requires	B-X
the	B-X
activity	B-X
of	B-X
Vps34	B-X
,	B-X
suggesting	B-X
that	B-X
phosphatidylinositol	B-X
(	B-X
3	B-X
)	B-X
phosphate	B-X
may	B-X
be	B-X
essential	B-X
for	B-X
their	B-X
function	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
Atg18	B-X
is	B-X
vital	B-X
for	B-X
all	B-X
forms	B-X
of	B-X
autophagy	B-X
,	B-X
whereas	B-X
Atg21	B-X
is	B-X
required	B-X
for	B-X
the	B-X
Cvt	B-X
pathway	B-X
but	B-X
not	B-X
for	B-X
nitrogen	B-X
starvation-induced	B-X
autophagy	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
Atg21	B-X
results	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
Atg8	B-X
from	B-X
the	B-X
pre-autophagosomal	B-X
structure	B-X
(	B-X
PAS	B-X
)	B-X
,	B-X
which	B-X
may	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
reduced	B-X
rate	B-X
of	B-X
conjugation	B-X
of	B-X
Atg8	B-X
to	B-X
phosphatidylethanolamine	B-X
.	B-X
A	B-X
similar	B-X
defect	B-X
in	B-X
localization	B-X
of	B-X
a	B-X
second	B-X
ubiquitin-like	B-X
conjugate	B-X
,	B-X
Atg12-Atg5	B-X
,	B-X
suggests	B-X
that	B-X
Atg21	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
membrane	B-X
to	B-X
the	B-X
PAS	B-X
.	B-X

A	O
similar	O
defect	O
in	O
localization	O
of	O
a	O
second	O
ubiquitin	B-Protein
-	O
like	O
conjugate	O
,	O
Atg12	B-Protein
-	O
Atg5	B-Protein
,	O
suggests	O
that	O
Atg21	B-Protein
may	O
be	O
involved	O
in	O
the	O
recruitment	O
of	O
membrane	O
to	O
the	O
PAS	O
.	O

Effect	O
of	O
the	O
statin	O
atorvastatin	O
on	O
intracellular	O
signalling	O
by	O
the	O
prostacyclin	B-Protein
receptor	I-Protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
established	B-X
that	B-X
the	B-X
prostacyclin	B-X
receptor	B-X
(	B-X
IP	B-X
)	B-X
undergoes	B-X
isoprenylation	B-X
,	B-X
a	B-X
lipid	B-X
modification	B-X
obligate	B-X
for	B-X
its	B-X
function	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
current	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
hydroxy	B-X
methyl	B-X
glutaryl	B-X
co-enzyme	B-X
A	B-X
reductase	B-X
inhibitor	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
and	B-X
function	B-X
of	B-X
the	B-X
IP	B-X
expressed	B-X
in	B-X
mammalian	B-X
whole	B-X
cells	B-X
and	B-X
in	B-X
platelets	B-X
isolated	B-X
from	B-X
patients	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
.	B-X
Initially	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
human	B-X
(	B-X
h	B-X
)	B-X
and	B-X
mouse	B-X
(	B-X
m	B-X
)	B-X
IP	B-X
overexpressed	B-X
in	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
and	B-X
the	B-X
hIP	B-X
endogenously	B-X
expressed	B-X
in	B-X
human	B-X
erythroleukaemic	B-X
92.1.7	B-X
cells	B-X
was	B-X
investigated	B-X
.	B-X
Atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
6.6-11.1	B-X
microm	B-X
)	B-X
and	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
mobilization	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
7.2-16.4	B-X
microm	B-X
)	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
nonisoprenylated	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
adrenergic	B-X
receptor	B-X
or	B-X
the	B-X
alpha	B-X
or	B-X
beta	B-X
isoforms	B-X
of	B-X
the	B-X
human	B-X
thromboxane	B-X
A	B-X
(	B-X
2	B-X
)	B-X
receptor	B-X
(	B-X
TP	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
crossdesensitization	B-X
of	B-X
signalling	B-X
by	B-X
TP	B-X
alpha	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
10.4	B-X
microm	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
TP	B-X
beta	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
whole-cell	B-X
data	B-X
,	B-X
atorvastatin	B-X
therapy	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
or	B-X
IP-induced	B-X
inhibition	B-X
of	B-X
TP-mediated	B-X
aggregation	B-X
of	B-X
platelets	B-X
isolated	B-X
from	B-X
human	B-X
volunteers	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
(	B-X
10-80	B-X
mg	B-X
per	B-X
daily	B-X
dose	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
while	B-X
data	B-X
generated	B-X
in	B-X
whole	B-X
cells	B-X
indicated	B-X
that	B-X
atorvastatin	B-X
significantly	B-X
impairs	B-X
signalling	B-X
by	B-X
both	B-X
the	B-X
hIP	B-X
and	B-X
mP	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
clinical	B-X
data	B-X
indicated	B-X
that	B-X
,	B-X
at	B-X
the	B-X
administered	B-X
therapeutic	B-X
dose	B-X
,	B-X
atorvastatin	B-X
does	B-X
not	B-X
significantly	B-X
compromise	B-X
IP	B-X
signalling	B-X
and	B-X
function	B-X
in	B-X
humans	B-X
.	B-X

Prostacyclin	O
plays	O
a	O
central	O
role	O
within	O
the	O
vasculature	O
.	O

We	O
have	O
previously	O
established	O
that	O
the	O
prostacyclin	B-Protein
receptor	I-Protein
(	O
IP	B-Protein
)	O
undergoes	O
isoprenylation	O
,	O
a	O
lipid	O
modification	O
obligate	O
for	O
its	O
function	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
established	B-X
that	B-X
the	B-X
prostacyclin	B-X
receptor	B-X
(	B-X
IP	B-X
)	B-X
undergoes	B-X
isoprenylation	B-X
,	B-X
a	B-X
lipid	B-X
modification	B-X
obligate	B-X
for	B-X
its	B-X
function	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
current	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
hydroxy	B-X
methyl	B-X
glutaryl	B-X
co-enzyme	B-X
A	B-X
reductase	B-X
inhibitor	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
and	B-X
function	B-X
of	B-X
the	B-X
IP	B-X
expressed	B-X
in	B-X
mammalian	B-X
whole	B-X
cells	B-X
and	B-X
in	B-X
platelets	B-X
isolated	B-X
from	B-X
patients	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
.	B-X
Initially	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
human	B-X
(	B-X
h	B-X
)	B-X
and	B-X
mouse	B-X
(	B-X
m	B-X
)	B-X
IP	B-X
overexpressed	B-X
in	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
and	B-X
the	B-X
hIP	B-X
endogenously	B-X
expressed	B-X
in	B-X
human	B-X
erythroleukaemic	B-X
92.1.7	B-X
cells	B-X
was	B-X
investigated	B-X
.	B-X
Atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
6.6-11.1	B-X
microm	B-X
)	B-X
and	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
mobilization	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
7.2-16.4	B-X
microm	B-X
)	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
nonisoprenylated	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
adrenergic	B-X
receptor	B-X
or	B-X
the	B-X
alpha	B-X
or	B-X
beta	B-X
isoforms	B-X
of	B-X
the	B-X
human	B-X
thromboxane	B-X
A	B-X
(	B-X
2	B-X
)	B-X
receptor	B-X
(	B-X
TP	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
crossdesensitization	B-X
of	B-X
signalling	B-X
by	B-X
TP	B-X
alpha	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
10.4	B-X
microm	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
TP	B-X
beta	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
whole-cell	B-X
data	B-X
,	B-X
atorvastatin	B-X
therapy	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
or	B-X
IP-induced	B-X
inhibition	B-X
of	B-X
TP-mediated	B-X
aggregation	B-X
of	B-X
platelets	B-X
isolated	B-X
from	B-X
human	B-X
volunteers	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
(	B-X
10-80	B-X
mg	B-X
per	B-X
daily	B-X
dose	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
while	B-X
data	B-X
generated	B-X
in	B-X
whole	B-X
cells	B-X
indicated	B-X
that	B-X
atorvastatin	B-X
significantly	B-X
impairs	B-X
signalling	B-X
by	B-X
both	B-X
the	B-X
hIP	B-X
and	B-X
mP	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
clinical	B-X
data	B-X
indicated	B-X
that	B-X
,	B-X
at	B-X
the	B-X
administered	B-X
therapeutic	B-X
dose	B-X
,	B-X
atorvastatin	B-X
does	B-X
not	B-X
significantly	B-X
compromise	B-X
IP	B-X
signalling	B-X
and	B-X
function	B-X
in	B-X
humans	B-X
.	B-X

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
hydroxy	O
methyl	O
glutaryl	O
co	O
-	O
enzyme	O
A	O
reductase	O
inhibitor	O
atorvastatin	O
on	O
signalling	O
and	O
function	O
of	O
the	O
IP	B-Protein
expressed	O
in	O
mammalian	O
whole	O
cells	O
and	O
in	O
platelets	O
isolated	O
from	O
patients	O
undergoing	O
therapeutic	O
intervention	O
with	O
atorvastatin	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
established	B-X
that	B-X
the	B-X
prostacyclin	B-X
receptor	B-X
(	B-X
IP	B-X
)	B-X
undergoes	B-X
isoprenylation	B-X
,	B-X
a	B-X
lipid	B-X
modification	B-X
obligate	B-X
for	B-X
its	B-X
function	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
current	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
hydroxy	B-X
methyl	B-X
glutaryl	B-X
co-enzyme	B-X
A	B-X
reductase	B-X
inhibitor	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
and	B-X
function	B-X
of	B-X
the	B-X
IP	B-X
expressed	B-X
in	B-X
mammalian	B-X
whole	B-X
cells	B-X
and	B-X
in	B-X
platelets	B-X
isolated	B-X
from	B-X
patients	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
.	B-X
Initially	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
human	B-X
(	B-X
h	B-X
)	B-X
and	B-X
mouse	B-X
(	B-X
m	B-X
)	B-X
IP	B-X
overexpressed	B-X
in	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
and	B-X
the	B-X
hIP	B-X
endogenously	B-X
expressed	B-X
in	B-X
human	B-X
erythroleukaemic	B-X
92.1.7	B-X
cells	B-X
was	B-X
investigated	B-X
.	B-X
Atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
6.6-11.1	B-X
microm	B-X
)	B-X
and	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
mobilization	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
7.2-16.4	B-X
microm	B-X
)	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
nonisoprenylated	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
adrenergic	B-X
receptor	B-X
or	B-X
the	B-X
alpha	B-X
or	B-X
beta	B-X
isoforms	B-X
of	B-X
the	B-X
human	B-X
thromboxane	B-X
A	B-X
(	B-X
2	B-X
)	B-X
receptor	B-X
(	B-X
TP	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
crossdesensitization	B-X
of	B-X
signalling	B-X
by	B-X
TP	B-X
alpha	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
10.4	B-X
microm	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
TP	B-X
beta	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
whole-cell	B-X
data	B-X
,	B-X
atorvastatin	B-X
therapy	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
or	B-X
IP-induced	B-X
inhibition	B-X
of	B-X
TP-mediated	B-X
aggregation	B-X
of	B-X
platelets	B-X
isolated	B-X
from	B-X
human	B-X
volunteers	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
(	B-X
10-80	B-X
mg	B-X
per	B-X
daily	B-X
dose	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
while	B-X
data	B-X
generated	B-X
in	B-X
whole	B-X
cells	B-X
indicated	B-X
that	B-X
atorvastatin	B-X
significantly	B-X
impairs	B-X
signalling	B-X
by	B-X
both	B-X
the	B-X
hIP	B-X
and	B-X
mP	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
clinical	B-X
data	B-X
indicated	B-X
that	B-X
,	B-X
at	B-X
the	B-X
administered	B-X
therapeutic	B-X
dose	B-X
,	B-X
atorvastatin	B-X
does	B-X
not	B-X
significantly	B-X
compromise	B-X
IP	B-X
signalling	B-X
and	B-X
function	B-X
in	B-X
humans	B-X
.	B-X

Initially	O
,	O
the	O
effect	O
of	O
atorvastatin	O
on	O
signalling	O
by	O
the	O
human	O
(	O
h	O
)	O
and	O
mouse	O
(	O
m	O
)	O
IP	B-Protein
overexpressed	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
and	O
the	O
hIP	B-Protein
endogenously	O
expressed	O
in	O
human	O
erythroleukaemic	O
92	O
.	O
1	O
.	O
7	O
cells	O
was	O
investigated	O
.	O
<EOS>	B-X
Prostacyclin	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
within	B-X
the	B-X
vasculature	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
established	B-X
that	B-X
the	B-X
prostacyclin	B-X
receptor	B-X
(	B-X
IP	B-X
)	B-X
undergoes	B-X
isoprenylation	B-X
,	B-X
a	B-X
lipid	B-X
modification	B-X
obligate	B-X
for	B-X
its	B-X
function	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
current	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
hydroxy	B-X
methyl	B-X
glutaryl	B-X
co-enzyme	B-X
A	B-X
reductase	B-X
inhibitor	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
and	B-X
function	B-X
of	B-X
the	B-X
IP	B-X
expressed	B-X
in	B-X
mammalian	B-X
whole	B-X
cells	B-X
and	B-X
in	B-X
platelets	B-X
isolated	B-X
from	B-X
patients	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
.	B-X
Initially	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
human	B-X
(	B-X
h	B-X
)	B-X
and	B-X
mouse	B-X
(	B-X
m	B-X
)	B-X
IP	B-X
overexpressed	B-X
in	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
and	B-X
the	B-X
hIP	B-X
endogenously	B-X
expressed	B-X
in	B-X
human	B-X
erythroleukaemic	B-X
92.1.7	B-X
cells	B-X
was	B-X
investigated	B-X
.	B-X
Atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
6.6-11.1	B-X
microm	B-X
)	B-X
and	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
mobilization	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
7.2-16.4	B-X
microm	B-X
)	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
nonisoprenylated	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
adrenergic	B-X
receptor	B-X
or	B-X
the	B-X
alpha	B-X
or	B-X
beta	B-X
isoforms	B-X
of	B-X
the	B-X
human	B-X
thromboxane	B-X
A	B-X
(	B-X
2	B-X
)	B-X
receptor	B-X
(	B-X
TP	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
crossdesensitization	B-X
of	B-X
signalling	B-X
by	B-X
TP	B-X
alpha	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
10.4	B-X
microm	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
TP	B-X
beta	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
whole-cell	B-X
data	B-X
,	B-X
atorvastatin	B-X
therapy	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
or	B-X
IP-induced	B-X
inhibition	B-X
of	B-X
TP-mediated	B-X
aggregation	B-X
of	B-X
platelets	B-X
isolated	B-X
from	B-X
human	B-X
volunteers	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
(	B-X
10-80	B-X
mg	B-X
per	B-X
daily	B-X
dose	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
while	B-X
data	B-X
generated	B-X
in	B-X
whole	B-X
cells	B-X
indicated	B-X
that	B-X
atorvastatin	B-X
significantly	B-X
impairs	B-X
signalling	B-X
by	B-X
both	B-X
the	B-X
hIP	B-X
and	B-X
mP	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
clinical	B-X
data	B-X
indicated	B-X
that	B-X
,	B-X
at	B-X
the	B-X
administered	B-X
therapeutic	B-X
dose	B-X
,	B-X
atorvastatin	B-X
does	B-X
not	B-X
significantly	B-X
compromise	B-X
IP	B-X
signalling	B-X
and	B-X
function	B-X
in	B-X
humans	B-X
.	B-X

Atorvastatin	O
significantly	O
reduced	O
IP	B-Protein
-	O
mediated	O
cAMP	O
generation	O
(	O
IC	O
(	O
50	O
)	O
6	O
.	O
6	O
-	O
11	O
.	O
1	O
microm	O
)	O
and	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
mobilization	O
(	O
IC	O
(	O
50	O
)	O
7	O
.	O
2	O
-	O
16	O
.	O
4	O
microm	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
but	O
had	O
no	O
effect	O
on	O
signalling	O
by	O
the	O
nonisoprenylated	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
adrenergic	I-Protein
receptor	I-Protein
or	O
the	O
alpha	O
or	O
beta	O
isoforms	O
of	O
the	O
human	O
thromboxane	B-Protein
A	I-Protein
(	I-Protein
2	I-Protein
)	I-Protein
receptor	I-Protein
(	O
TP	B-Protein
)	O
.	O

Moreover	O
,	O
atorvastatin	O
significantly	O
reduced	O
IP	B-Protein
-	O
mediated	O
crossdesensitization	O
of	O
signalling	O
by	O
TP	B-Protein
alpha	I-Protein
(	O
IC	O
(	O
50	O
)	O
10	O
.	O
4	O
microm	O
)	O
,	O
but	O
not	O
by	O
TP	B-Protein
beta	I-Protein
.	O

In	O
contrast	O
to	O
the	O
whole	O
-	O
cell	O
data	O
,	O
atorvastatin	O
therapy	O
did	O
not	O
interfere	O
with	O
IP	B-Protein
-	O
mediated	O
cAMP	O
generation	O
or	O
IP	B-Protein
-	O
induced	O
inhibition	O
of	O
TP	B-Protein
-	O
mediated	O
aggregation	O
of	O
platelets	O
isolated	O
from	O
human	O
volunteers	O
undergoing	O
therapeutic	O
intervention	O
with	O
atorvastatin	O
(	O
10	O
-	O
80	O
mg	O
per	O
daily	O
dose	O
)	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
established	B-X
that	B-X
the	B-X
prostacyclin	B-X
receptor	B-X
(	B-X
IP	B-X
)	B-X
undergoes	B-X
isoprenylation	B-X
,	B-X
a	B-X
lipid	B-X
modification	B-X
obligate	B-X
for	B-X
its	B-X
function	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
current	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
hydroxy	B-X
methyl	B-X
glutaryl	B-X
co-enzyme	B-X
A	B-X
reductase	B-X
inhibitor	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
and	B-X
function	B-X
of	B-X
the	B-X
IP	B-X
expressed	B-X
in	B-X
mammalian	B-X
whole	B-X
cells	B-X
and	B-X
in	B-X
platelets	B-X
isolated	B-X
from	B-X
patients	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
.	B-X
Initially	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
atorvastatin	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
human	B-X
(	B-X
h	B-X
)	B-X
and	B-X
mouse	B-X
(	B-X
m	B-X
)	B-X
IP	B-X
overexpressed	B-X
in	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
and	B-X
the	B-X
hIP	B-X
endogenously	B-X
expressed	B-X
in	B-X
human	B-X
erythroleukaemic	B-X
92.1.7	B-X
cells	B-X
was	B-X
investigated	B-X
.	B-X
Atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
6.6-11.1	B-X
microm	B-X
)	B-X
and	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
mobilization	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
7.2-16.4	B-X
microm	B-X
)	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
signalling	B-X
by	B-X
the	B-X
nonisoprenylated	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
adrenergic	B-X
receptor	B-X
or	B-X
the	B-X
alpha	B-X
or	B-X
beta	B-X
isoforms	B-X
of	B-X
the	B-X
human	B-X
thromboxane	B-X
A	B-X
(	B-X
2	B-X
)	B-X
receptor	B-X
(	B-X
TP	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
atorvastatin	B-X
significantly	B-X
reduced	B-X
IP-mediated	B-X
crossdesensitization	B-X
of	B-X
signalling	B-X
by	B-X
TP	B-X
alpha	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
10.4	B-X
microm	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
TP	B-X
beta	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
whole-cell	B-X
data	B-X
,	B-X
atorvastatin	B-X
therapy	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
IP-mediated	B-X
cAMP	B-X
generation	B-X
or	B-X
IP-induced	B-X
inhibition	B-X
of	B-X
TP-mediated	B-X
aggregation	B-X
of	B-X
platelets	B-X
isolated	B-X
from	B-X
human	B-X
volunteers	B-X
undergoing	B-X
therapeutic	B-X
intervention	B-X
with	B-X
atorvastatin	B-X
(	B-X
10-80	B-X
mg	B-X
per	B-X
daily	B-X
dose	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
while	B-X
data	B-X
generated	B-X
in	B-X
whole	B-X
cells	B-X
indicated	B-X
that	B-X
atorvastatin	B-X
significantly	B-X
impairs	B-X
signalling	B-X
by	B-X
both	B-X
the	B-X
hIP	B-X
and	B-X
mP	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
clinical	B-X
data	B-X
indicated	B-X
that	B-X
,	B-X
at	B-X
the	B-X
administered	B-X
therapeutic	B-X
dose	B-X
,	B-X
atorvastatin	B-X
does	B-X
not	B-X
significantly	B-X
compromise	B-X
IP	B-X
signalling	B-X
and	B-X
function	B-X
in	B-X
humans	B-X
.	B-X

In	O
conclusion	O
,	O
while	O
data	O
generated	O
in	O
whole	O
cells	O
indicated	O
that	O
atorvastatin	O
significantly	O
impairs	O
signalling	O
by	O
both	O
the	O
hIP	B-Protein
and	O
mP	O
,	O
the	O
in	O
vivo	O
clinical	O
data	O
indicated	O
that	O
,	O
at	O
the	O
administered	O
therapeutic	O
dose	O
,	O
atorvastatin	O
does	O
not	O
significantly	O
compromise	O
IP	B-Protein
signalling	O
and	O
function	O
in	O
humans	O
.	O

Novel	O
role	O
of	O
ARF6	B-Protein
in	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
induced	O
signaling	O
and	O
angiogenesis	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
The	B-X
small	B-X
GTPase	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
membrane	B-X
trafficking	B-X
and	B-X
cell	B-X
motility	B-X
;	B-X
however	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
VEGF	B-X
signaling	B-X
and	B-X
physiological	B-X
responses	B-X
in	B-X
ECs	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
significantly	B-X
inhibits	B-X
both	B-X
VEGF-induced	B-X
responses	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Moreover	B-X
,	B-X
ARF6	B-X
expression	B-X
is	B-X
markedly	B-X
upregulated	B-X
in	B-X
association	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
capillary	B-X
density	B-X
in	B-X
a	B-X
mouse	B-X
hindlimb	B-X
ischemia	B-X
model	B-X
of	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
stimulates	O
endothelial	O
cell	O
(	O
EC	O
)	O
migration	O
and	O
proliferation	O
primarily	O
through	O
the	O
VEGF	B-Protein
receptor	I-Protein
-	I-Protein
2	I-Protein
(	O
VEGFR2	B-Protein
)	O
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
essential	B-X
for	B-X
tumor	B-X
growth	B-X
,	B-X
metastasis	B-X
,	B-X
arteriosclerosis	B-X
as	B-X
well	B-X
as	B-X
embryonic	B-X
development	B-X
and	B-X
wound	B-X
healing	B-X
.	B-X
Its	B-X
process	B-X
is	B-X
dependent	B-X
on	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
and	B-X
capillary	B-X
tube	B-X
formation	B-X
in	B-X
endothelia	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
such	B-X
as	B-X
superoxide	B-X
and	B-X
H2O2	B-X
are	B-X
observed	B-X
in	B-X
various	B-X
cancer	B-X
cells	B-X
.	B-X
Accumulating	B-X
evidence	B-X
suggests	B-X
that	B-X
ROS	B-X
function	B-X
as	B-X
signaling	B-X
molecules	B-X
to	B-X
mediate	B-X
various	B-X
growth-related	B-X
responses	B-X
including	B-X
angiogenesis	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
major	B-X
angiogenesis	B-X
factor	B-X
,	B-X
is	B-X
induced	B-X
in	B-X
growing	B-X
tumors	B-X
and	B-X
stimulates	B-X
EC	B-X
proliferation	B-X
and	B-X
migration	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor	B-X
type2	B-X
(	B-X
VEGFR2	B-X
,	B-X
Flk1/KDR	B-X
)	B-X
.	B-X
Major	B-X
source	B-X
of	B-X
ROS	B-X
in	B-X
ECs	B-X
is	B-X
a	B-X
NADPH	B-X
oxidase	B-X
which	B-X
consists	B-X
of	B-X
Nox1	B-X
,	B-X
Nox2	B-X
,	B-X
Nox4	B-X
,	B-X
Nox5	B-X
,	B-X
p22phox	B-X
,	B-X
p47phox	B-X
and	B-X
the	B-X
small	B-X
G-protein	B-X
Rac1	B-X
.	B-X
NADPH	B-X
oxidase	B-X
is	B-X
activated	B-X
by	B-X
various	B-X
growth	B-X
factors	B-X
including	B-X
VEGF	B-X
and	B-X
angiopoietin-1	B-X
as	B-X
well	B-X
as	B-X
hypoxia	B-X
and	B-X
ischemia	B-X
,	B-X
and	B-X
ROS	B-X
derived	B-X
from	B-X
this	B-X
oxidase	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
,	B-X
and	B-X
diverse	B-X
redox	B-X
signaling	B-X
pathways	B-X
leading	B-X
to	B-X
induction	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
genes	B-X
involved	B-X
in	B-X
angiogenesis	B-X
.	B-X

We	O
have	O
shown	O
that	O
VEGF	O
stimulates	O
a	O
Rac1	B-Protein
-	O
dependent	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
to	O
produce	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
that	O
are	O
involved	O
in	O
VEGFR2	B-Protein
autophosphorylation	O
and	O
angiogenic	O
-	O
related	O
responses	O
in	O
ECs	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
VEGF	B-X
stimulates	B-X
a	B-X
Rac1-dependent	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
oxidase	B-X
to	B-X
produce	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
and	B-X
angiogenic-related	B-X
responses	B-X
in	B-X
ECs	B-X
.	B-X
The	B-X
small	B-X
GTPase	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
membrane	B-X
trafficking	B-X
and	B-X
cell	B-X
motility	B-X
;	B-X
however	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
VEGF	B-X
signaling	B-X
and	B-X
physiological	B-X
responses	B-X
in	B-X
ECs	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
The	B-X
egress	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
is	B-X
contemporaneous	B-X
with	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
caveolin-1	B-X
(	B-X
Tyr14	B-X
)	B-X
and	B-X
VEGFR2	B-X
and	B-X
with	B-X
their	B-X
association	B-X
with	B-X
each	B-X
other	B-X
.	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
significantly	B-X
inhibits	B-X
both	B-X
VEGF-induced	B-X
responses	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
show	B-X
that	B-X
activated	B-X
VEGFR2	B-X
and	B-X
phosphocaveolin	B-X
colocalize	B-X
at	B-X
focal	B-X
complexes/adhesions	B-X
after	B-X
VEGF	B-X
stimulation	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

The	O
small	O
GTPase	O
ARF6	B-Protein
is	O
involved	O
in	O
membrane	O
trafficking	O
and	O
cell	O
motility	O
;	O
however	O
,	O
its	O
roles	O
in	O
VEGF	O
signaling	O
and	O
physiological	O
responses	O
in	O
ECs	O
are	O
unknown	O
.	O
<EOS>	B-X
A	B-X
wide	B-X
range	B-X
of	B-X
cellular	B-X
activities	B-X
depends	B-X
upon	B-X
endocytic	B-X
recycling	B-X
.	B-X
ARF6	B-X
,	B-X
a	B-X
small	B-X
molecular	B-X
weight	B-X
GTPase	B-X
,	B-X
regulates	B-X
the	B-X
processes	B-X
of	B-X
endocytosis	B-X
and	B-X
endocytic	B-X
recycling	B-X
in	B-X
concert	B-X
with	B-X
various	B-X
effector	B-X
molecules	B-X
and	B-X
other	B-X
small	B-X
GTPases	B-X
.	B-X
This	B-X
review	B-X
highlights	B-X
three	B-X
critical	B-X
processes	B-X
that	B-X
involve	B-X
ARF6-mediated	B-X
endosomal	B-X
membrane	B-X
trafficking-cell	B-X
motility	B-X
,	B-X
cytokinesis	B-X
,	B-X
and	B-X
cholesterol	B-X
homeostasis	B-X
.	B-X
In	B-X
each	B-X
case	B-X
,	B-X
the	B-X
function	B-X
of	B-X
ARF6-mediated	B-X
trafficking	B-X
varies-including	B-X
localization	B-X
of	B-X
specific	B-X
protein	B-X
and	B-X
lipid	B-X
cargo	B-X
,	B-X
regulation	B-X
of	B-X
bulk	B-X
membrane	B-X
movement	B-X
,	B-X
and	B-X
modulation	B-X
of	B-X
intracellular	B-X
signaling	B-X
.	B-X
As	B-X
described	B-X
in	B-X
this	B-X
review	B-X
,	B-X
mis-regulation	B-X
of	B-X
endocytic	B-X
traffic	B-X
can	B-X
result	B-X
in	B-X
human	B-X
disease	B-X
when	B-X
it	B-X
compromises	B-X
the	B-X
cell	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
cell	B-X
movement	B-X
and	B-X
invasion	B-X
,	B-X
cell	B-X
division	B-X
,	B-X
and	B-X
lipid	B-X
homeostasis	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
dominant	O
-	O
negative	O
ARF6	B-Protein
[	O
ARF6	B-Protein
(	O
T27N	O
)	O
]	O
almost	O
completely	O
inhibits	O
VEGF	O
-	O
induced	O
Rac1	B-Protein
activation	O
,	O
ROS	O
production	O
,	O
and	O
VEGFR2	B-Protein
autophosphorylation	O
in	O
ECs	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
VEGF	B-X
stimulates	B-X
a	B-X
Rac1-dependent	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
oxidase	B-X
to	B-X
produce	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
and	B-X
angiogenic-related	B-X
responses	B-X
in	B-X
ECs	B-X
.	B-X
The	B-X
small	B-X
GTPase	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
membrane	B-X
trafficking	B-X
and	B-X
cell	B-X
motility	B-X
;	B-X
however	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
VEGF	B-X
signaling	B-X
and	B-X
physiological	B-X
responses	B-X
in	B-X
ECs	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
The	B-X
egress	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
is	B-X
contemporaneous	B-X
with	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
caveolin-1	B-X
(	B-X
Tyr14	B-X
)	B-X
and	B-X
VEGFR2	B-X
and	B-X
with	B-X
their	B-X
association	B-X
with	B-X
each	B-X
other	B-X
.	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
significantly	B-X
inhibits	B-X
both	B-X
VEGF-induced	B-X
responses	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
show	B-X
that	B-X
activated	B-X
VEGFR2	B-X
and	B-X
phosphocaveolin	B-X
colocalize	B-X
at	B-X
focal	B-X
complexes/adhesions	B-X
after	B-X
VEGF	B-X
stimulation	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Moreover	B-X
,	B-X
ARF6	B-X
expression	B-X
is	B-X
markedly	B-X
upregulated	B-X
in	B-X
association	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
capillary	B-X
density	B-X
in	B-X
a	B-X
mouse	B-X
hindlimb	B-X
ischemia	B-X
model	B-X
of	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

Fractionation	O
of	O
caveolae	O
/	O
lipid	O
raft	O
membranes	O
demonstrates	O
that	O
ARF6	B-Protein
,	O
Rac1	B-Protein
,	O
and	O
VEGFR2	B-Protein
are	O
localized	O
in	O
caveolin	O
-	O
enriched	O
fractions	O
basally	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
VEGF	B-X
stimulates	B-X
a	B-X
Rac1-dependent	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
oxidase	B-X
to	B-X
produce	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
and	B-X
angiogenic-related	B-X
responses	B-X
in	B-X
ECs	B-X
.	B-X
The	B-X
small	B-X
GTPase	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
membrane	B-X
trafficking	B-X
and	B-X
cell	B-X
motility	B-X
;	B-X
however	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
VEGF	B-X
signaling	B-X
and	B-X
physiological	B-X
responses	B-X
in	B-X
ECs	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
The	B-X
egress	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
is	B-X
contemporaneous	B-X
with	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
caveolin-1	B-X
(	B-X
Tyr14	B-X
)	B-X
and	B-X
VEGFR2	B-X
and	B-X
with	B-X
their	B-X
association	B-X
with	B-X
each	B-X
other	B-X
.	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
significantly	B-X
inhibits	B-X
both	B-X
VEGF-induced	B-X
responses	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
show	B-X
that	B-X
activated	B-X
VEGFR2	B-X
and	B-X
phosphocaveolin	B-X
colocalize	B-X
at	B-X
focal	B-X
complexes/adhesions	B-X
after	B-X
VEGF	B-X
stimulation	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Moreover	B-X
,	B-X
ARF6	B-X
expression	B-X
is	B-X
markedly	B-X
upregulated	B-X
in	B-X
association	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
capillary	B-X
density	B-X
in	B-X
a	B-X
mouse	B-X
hindlimb	B-X
ischemia	B-X
model	B-X
of	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

VEGF	O
stimulation	O
results	O
in	O
the	O
release	O
of	O
VEGFR2	B-Protein
from	O
caveolae	O
/	O
lipid	O
rafts	O
and	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
without	O
affecting	O
localization	O
of	O
ARF6	B-Protein
,	O
Rac1	B-Protein
,	O
or	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
in	O
these	O
fractions	O
.	O
<EOS>	B-X
The	B-X
Long	B-X
Noncoding	B-X
RNA	B-X
DNM3OS	B-X
Is	B-X
a	B-X
Reservoir	B-X
of	B-X
FibromiRs	B-X
with	B-X
Major	B-X
Functions	B-X
in	B-X
Lung	B-X
Fibroblast	B-X
Response	B-X
to	B-X
TGF-β	B-X
and	B-X
Pulmonary	B-X
Fibrosis	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
aetiology	B-X
of	B-X
diabetic	B-X
cardiomyopathy	B-X
and	B-X
explore	B-X
the	B-X
involvement	B-X
of	B-X
the	B-X
protein	B-X
caveolin-3	B-X
(	B-X
Cav3	B-X
)	B-X
.	B-X
Caveolae	B-X
are	B-X
invaginations	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
where	B-X
ER-α	B-X
is	B-X
known	B-X
to	B-X
localize	B-X
and	B-X
directly	B-X
interacts	B-X
with	B-X
the	B-X
caveolar	B-X
protein	B-X
caveolin-1	B-X
(	B-X
CAV1	B-X
)	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
the	B-X
effects	B-X
of	B-X
simvastatin	B-X
on	B-X
plasma	B-X
membrane	B-X
caveolae	B-X
and	B-X
the	B-X
expression	B-X
and	B-X
palmitoylation	B-X
of	B-X
CAV1	B-X
in	B-X
human	B-X
leiomyomas	B-X
which	B-X
may	B-X
influence	B-X
ER-α	B-X
signaling	B-X
.	B-X

The	O
egress	O
of	O
VEGFR2	B-Protein
from	O
caveolae	O
/	O
lipid	O
rafts	O
is	O
contemporaneous	O
with	O
the	O
tyrosine	O
phosphorylation	O
of	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
(	O
Tyr14	O
)	O
and	O
VEGFR2	B-Protein
and	O
with	O
their	O
association	O
with	O
each	O
other	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
VEGF	B-X
stimulates	B-X
a	B-X
Rac1-dependent	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
oxidase	B-X
to	B-X
produce	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
and	B-X
angiogenic-related	B-X
responses	B-X
in	B-X
ECs	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
The	B-X
egress	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
is	B-X
contemporaneous	B-X
with	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
caveolin-1	B-X
(	B-X
Tyr14	B-X
)	B-X
and	B-X
VEGFR2	B-X
and	B-X
with	B-X
their	B-X
association	B-X
with	B-X
each	B-X
other	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
show	B-X
that	B-X
activated	B-X
VEGFR2	B-X
and	B-X
phosphocaveolin	B-X
colocalize	B-X
at	B-X
focal	B-X
complexes/adhesions	B-X
after	B-X
VEGF	B-X
stimulation	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Moreover	B-X
,	B-X
ARF6	B-X
expression	B-X
is	B-X
markedly	B-X
upregulated	B-X
in	B-X
association	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
capillary	B-X
density	B-X
in	B-X
a	B-X
mouse	B-X
hindlimb	B-X
ischemia	B-X
model	B-X
of	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

ARF6	B-Protein
(	O
T27N	O
)	O
significantly	O
inhibits	O
both	O
VEGF	O
-	O
induced	O
responses	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
VEGF	B-X
stimulates	B-X
a	B-X
Rac1-dependent	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
oxidase	B-X
to	B-X
produce	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
and	B-X
angiogenic-related	B-X
responses	B-X
in	B-X
ECs	B-X
.	B-X
The	B-X
small	B-X
GTPase	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
membrane	B-X
trafficking	B-X
and	B-X
cell	B-X
motility	B-X
;	B-X
however	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
VEGF	B-X
signaling	B-X
and	B-X
physiological	B-X
responses	B-X
in	B-X
ECs	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
The	B-X
egress	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
is	B-X
contemporaneous	B-X
with	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
caveolin-1	B-X
(	B-X
Tyr14	B-X
)	B-X
and	B-X
VEGFR2	B-X
and	B-X
with	B-X
their	B-X
association	B-X
with	B-X
each	B-X
other	B-X
.	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
significantly	B-X
inhibits	B-X
both	B-X
VEGF-induced	B-X
responses	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
show	B-X
that	B-X
activated	B-X
VEGFR2	B-X
and	B-X
phosphocaveolin	B-X
colocalize	B-X
at	B-X
focal	B-X
complexes/adhesions	B-X
after	B-X
VEGF	B-X
stimulation	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Moreover	B-X
,	B-X
ARF6	B-X
expression	B-X
is	B-X
markedly	B-X
upregulated	B-X
in	B-X
association	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
capillary	B-X
density	B-X
in	B-X
a	B-X
mouse	B-X
hindlimb	B-X
ischemia	B-X
model	B-X
of	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

Immunofluorescence	O
studies	O
show	O
that	O
activated	O
VEGFR2	B-Protein
and	O
phosphocaveolin	O
colocalize	O
at	O
focal	O
complexes	O
/	O
adhesions	O
after	O
VEGF	O
stimulation	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
VEGF	B-X
stimulates	B-X
a	B-X
Rac1-dependent	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
oxidase	B-X
to	B-X
produce	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
and	B-X
angiogenic-related	B-X
responses	B-X
in	B-X
ECs	B-X
.	B-X
The	B-X
small	B-X
GTPase	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
membrane	B-X
trafficking	B-X
and	B-X
cell	B-X
motility	B-X
;	B-X
however	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
VEGF	B-X
signaling	B-X
and	B-X
physiological	B-X
responses	B-X
in	B-X
ECs	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
The	B-X
egress	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
is	B-X
contemporaneous	B-X
with	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
caveolin-1	B-X
(	B-X
Tyr14	B-X
)	B-X
and	B-X
VEGFR2	B-X
and	B-X
with	B-X
their	B-X
association	B-X
with	B-X
each	B-X
other	B-X
.	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
significantly	B-X
inhibits	B-X
both	B-X
VEGF-induced	B-X
responses	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
show	B-X
that	B-X
activated	B-X
VEGFR2	B-X
and	B-X
phosphocaveolin	B-X
colocalize	B-X
at	B-X
focal	B-X
complexes/adhesions	B-X
after	B-X
VEGF	B-X
stimulation	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

Both	O
overexpression	O
of	O
ARF6	B-Protein
(	O
T27N	O
)	O
and	O
mutant	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
(	O
Y14F	O
)	O
,	O
which	O
cannot	O
be	O
phosphorylated	O
,	O
block	O
VEGF	O
-	O
stimulated	O
EC	O
migration	O
and	O
proliferation	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
VEGF	B-X
stimulates	B-X
a	B-X
Rac1-dependent	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
oxidase	B-X
to	B-X
produce	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
and	B-X
angiogenic-related	B-X
responses	B-X
in	B-X
ECs	B-X
.	B-X
The	B-X
small	B-X
GTPase	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
membrane	B-X
trafficking	B-X
and	B-X
cell	B-X
motility	B-X
;	B-X
however	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
VEGF	B-X
signaling	B-X
and	B-X
physiological	B-X
responses	B-X
in	B-X
ECs	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
The	B-X
egress	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
is	B-X
contemporaneous	B-X
with	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
caveolin-1	B-X
(	B-X
Tyr14	B-X
)	B-X
and	B-X
VEGFR2	B-X
and	B-X
with	B-X
their	B-X
association	B-X
with	B-X
each	B-X
other	B-X
.	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
significantly	B-X
inhibits	B-X
both	B-X
VEGF-induced	B-X
responses	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
show	B-X
that	B-X
activated	B-X
VEGFR2	B-X
and	B-X
phosphocaveolin	B-X
colocalize	B-X
at	B-X
focal	B-X
complexes/adhesions	B-X
after	B-X
VEGF	B-X
stimulation	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Moreover	B-X
,	B-X
ARF6	B-X
expression	B-X
is	B-X
markedly	B-X
upregulated	B-X
in	B-X
association	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
capillary	B-X
density	B-X
in	B-X
a	B-X
mouse	B-X
hindlimb	B-X
ischemia	B-X
model	B-X
of	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

Moreover	O
,	O
ARF6	B-Protein
expression	O
is	O
markedly	O
upregulated	O
in	O
association	O
with	O
an	O
increase	O
in	O
capillary	O
density	O
in	O
a	O
mouse	O
hindlimb	O
ischemia	O
model	O
of	O
angiogenesis	O
.	O

Thus	O
,	O
ARF6	B-Protein
is	O
involved	O
in	O
the	O
temporal	O
-	O
spatial	O
organization	O
of	O
caveolae	O
/	O
lipid	O
rafts	O
-	O
and	O
ROS	O
-	O
dependent	O
VEGF	O
signaling	O
in	O
ECs	O
as	O
well	O
as	O
in	O
angiogenesis	O
in	O
vivo	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
migration	B-X
and	B-X
proliferation	B-X
primarily	B-X
through	B-X
the	B-X
VEGF	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
VEGF	B-X
stimulates	B-X
a	B-X
Rac1-dependent	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
oxidase	B-X
to	B-X
produce	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
VEGFR2	B-X
autophosphorylation	B-X
and	B-X
angiogenic-related	B-X
responses	B-X
in	B-X
ECs	B-X
.	B-X
The	B-X
small	B-X
GTPase	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
membrane	B-X
trafficking	B-X
and	B-X
cell	B-X
motility	B-X
;	B-X
however	B-X
,	B-X
its	B-X
roles	B-X
in	B-X
VEGF	B-X
signaling	B-X
and	B-X
physiological	B-X
responses	B-X
in	B-X
ECs	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
ARF6	B-X
[	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
]	B-X
almost	B-X
completely	B-X
inhibits	B-X
VEGF-induced	B-X
Rac1	B-X
activation	B-X
,	B-X
ROS	B-X
production	B-X
,	B-X
and	B-X
VEGFR2	B-X
autophosphorylation	B-X
in	B-X
ECs	B-X
.	B-X
Fractionation	B-X
of	B-X
caveolae/lipid	B-X
raft	B-X
membranes	B-X
demonstrates	B-X
that	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
VEGFR2	B-X
are	B-X
localized	B-X
in	B-X
caveolin-enriched	B-X
fractions	B-X
basally	B-X
.	B-X
VEGF	B-X
stimulation	B-X
results	B-X
in	B-X
the	B-X
release	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
and	B-X
caveolin-1	B-X
without	B-X
affecting	B-X
localization	B-X
of	B-X
ARF6	B-X
,	B-X
Rac1	B-X
,	B-X
or	B-X
caveolin-1	B-X
in	B-X
these	B-X
fractions	B-X
.	B-X
The	B-X
egress	B-X
of	B-X
VEGFR2	B-X
from	B-X
caveolae/lipid	B-X
rafts	B-X
is	B-X
contemporaneous	B-X
with	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
caveolin-1	B-X
(	B-X
Tyr14	B-X
)	B-X
and	B-X
VEGFR2	B-X
and	B-X
with	B-X
their	B-X
association	B-X
with	B-X
each	B-X
other	B-X
.	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
significantly	B-X
inhibits	B-X
both	B-X
VEGF-induced	B-X
responses	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
show	B-X
that	B-X
activated	B-X
VEGFR2	B-X
and	B-X
phosphocaveolin	B-X
colocalize	B-X
at	B-X
focal	B-X
complexes/adhesions	B-X
after	B-X
VEGF	B-X
stimulation	B-X
.	B-X
Both	B-X
overexpression	B-X
of	B-X
ARF6	B-X
(	B-X
T27N	B-X
)	B-X
and	B-X
mutant	B-X
caveolin-1	B-X
(	B-X
Y14F	B-X
)	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
,	B-X
block	B-X
VEGF-stimulated	B-X
EC	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
Moreover	B-X
,	B-X
ARF6	B-X
expression	B-X
is	B-X
markedly	B-X
upregulated	B-X
in	B-X
association	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
capillary	B-X
density	B-X
in	B-X
a	B-X
mouse	B-X
hindlimb	B-X
ischemia	B-X
model	B-X
of	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
ARF6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
temporal-spatial	B-X
organization	B-X
of	B-X
caveolae/lipid	B-X
rafts-	B-X
and	B-X
ROS-dependent	B-X
VEGF	B-X
signaling	B-X
in	B-X
ECs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X

Golgi	O
targeting	O
of	O
human	O
guanylate	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
requires	O
nucleotide	O
binding	O
,	O
isoprenylation	O
,	O
and	O
an	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
inducible	O
cofactor	O
.	O

Human	O
guanylate	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
a	O
large	O
GTPase	O
,	O
similar	O
in	O
structure	O
to	O
the	O
dynamins	O
.	O

Like	O
many	O
smaller	O
GTPases	O
of	O
the	O
Ras	O
/	O
Rab	O
family	O
,	O
it	O
is	O
farnesylated	O
,	O
suggesting	O
it	O
may	O
dock	O
into	O
membranes	O
and	O
perhaps	O
play	O
a	O
role	O
in	O
intracellular	O
trafficking	O
.	O
<EOS>	B-X
Like	B-X
many	B-X
smaller	B-X
GTPases	B-X
of	B-X
the	B-X
Ras/Rab	B-X
family	B-X
,	B-X
it	B-X
is	B-X
farnesylated	B-X
,	B-X
suggesting	B-X
it	B-X
may	B-X
dock	B-X
into	B-X
membranes	B-X
and	B-X
perhaps	B-X
play	B-X
a	B-X
role	B-X
in	B-X
intracellular	B-X
trafficking	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
hGBP-1	B-X
has	B-X
never	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
specific	B-X
intracellular	B-X
compartment	B-X
.	B-X
Redistribution	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
Golgi	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
and	B-X
subcellular	B-X
fractionation	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
occurs	B-X
when	B-X
hGBP-1	B-X
is	B-X
in	B-X
its	B-X
GTP-bound	B-X
state	B-X
.	B-X
The	B-X
C589S	B-X
mutant	B-X
of	B-X
hGBP-1	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
farnesylated	B-X
,	B-X
and	B-X
the	B-X
previously	B-X
uncharacterized	B-X
R48P	B-X
mutant	B-X
,	B-X
which	B-X
can	B-X
not	B-X
bind	B-X
GTP	B-X
,	B-X
both	B-X
failed	B-X
to	B-X
localize	B-X
to	B-X
the	B-X
Golgi	B-X
.	B-X
Finally	B-X
,	B-X
two	B-X
nonhydrolyzing	B-X
mutants	B-X
of	B-X
hGBP-1	B-X
,	B-X
corresponding	B-X
to	B-X
active	B-X
mutants	B-X
of	B-X
Ras	B-X
family	B-X
proteins	B-X
,	B-X
failed	B-X
to	B-X
constitutively	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
;	B-X
we	B-X
propose	B-X
three	B-X
possible	B-X
explanations	B-X
for	B-X
this	B-X
surprising	B-X
result	B-X
.	B-X

To	O
date	O
,	O
however	O
,	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
has	O
never	O
been	O
associated	O
with	O
a	O
specific	O
intracellular	O
compartment	O
.	O
<EOS>	B-X
Human	B-X
guanylate-binding	B-X
protein-1	B-X
(	B-X
hGBP-1	B-X
)	B-X
is	B-X
a	B-X
large	B-X
GTPase	B-X
,	B-X
similar	B-X
in	B-X
structure	B-X
to	B-X
the	B-X
dynamins	B-X
.	B-X
Like	B-X
many	B-X
smaller	B-X
GTPases	B-X
of	B-X
the	B-X
Ras/Rab	B-X
family	B-X
,	B-X
it	B-X
is	B-X
farnesylated	B-X
,	B-X
suggesting	B-X
it	B-X
may	B-X
dock	B-X
into	B-X
membranes	B-X
and	B-X
perhaps	B-X
play	B-X
a	B-X
role	B-X
in	B-X
intracellular	B-X
trafficking	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
hGBP-1	B-X
has	B-X
never	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
specific	B-X
intracellular	B-X
compartment	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
evidence	B-X
that	B-X
hGBP-1	B-X
can	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
Redistribution	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
Golgi	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
and	B-X
subcellular	B-X
fractionation	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
occurs	B-X
when	B-X
hGBP-1	B-X
is	B-X
in	B-X
its	B-X
GTP-bound	B-X
state	B-X
.	B-X
The	B-X
C589S	B-X
mutant	B-X
of	B-X
hGBP-1	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
farnesylated	B-X
,	B-X
and	B-X
the	B-X
previously	B-X
uncharacterized	B-X
R48P	B-X
mutant	B-X
,	B-X
which	B-X
can	B-X
not	B-X
bind	B-X
GTP	B-X
,	B-X
both	B-X
failed	B-X
to	B-X
localize	B-X
to	B-X
the	B-X
Golgi	B-X
.	B-X
These	B-X
two	B-X
mutants	B-X
had	B-X
a	B-X
dominant-negative	B-X
effect	B-X
,	B-X
preventing	B-X
endogenous	B-X
wild-type	B-X
hGBP-1	B-X
from	B-X
efficiently	B-X
redistributing	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
.	B-X
Furthermore	B-X
,	B-X
hGBP-1	B-X
requires	B-X
another	B-X
IFN-gamma-induced	B-X
factor	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
the	B-X
Golgi	B-X
,	B-X
because	B-X
constitutively	B-X
expressed	B-X
hGBP-1	B-X
remained	B-X
cytosolic	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
aluminum	B-X
fluoride	B-X
unless	B-X
the	B-X
cells	B-X
were	B-X
preincubated	B-X
with	B-X
IFN-gamma	B-X
.	B-X
Finally	B-X
,	B-X
two	B-X
nonhydrolyzing	B-X
mutants	B-X
of	B-X
hGBP-1	B-X
,	B-X
corresponding	B-X
to	B-X
active	B-X
mutants	B-X
of	B-X
Ras	B-X
family	B-X
proteins	B-X
,	B-X
failed	B-X
to	B-X
constitutively	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
;	B-X
we	B-X
propose	B-X
three	B-X
possible	B-X
explanations	B-X
for	B-X
this	B-X
surprising	B-X
result	B-X
.	B-X

Here	O
we	O
present	O
evidence	O
that	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
can	O
associate	O
with	O
the	O
Golgi	O
apparatus	O
.	O
<EOS>	B-X
Human	B-X
guanylate-binding	B-X
protein-1	B-X
(	B-X
hGBP-1	B-X
)	B-X
is	B-X
a	B-X
large	B-X
GTPase	B-X
,	B-X
similar	B-X
in	B-X
structure	B-X
to	B-X
the	B-X
dynamins	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
hGBP-1	B-X
has	B-X
never	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
specific	B-X
intracellular	B-X
compartment	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
evidence	B-X
that	B-X
hGBP-1	B-X
can	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
Redistribution	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
Golgi	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
and	B-X
subcellular	B-X
fractionation	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
occurs	B-X
when	B-X
hGBP-1	B-X
is	B-X
in	B-X
its	B-X
GTP-bound	B-X
state	B-X
.	B-X
The	B-X
C589S	B-X
mutant	B-X
of	B-X
hGBP-1	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
farnesylated	B-X
,	B-X
and	B-X
the	B-X
previously	B-X
uncharacterized	B-X
R48P	B-X
mutant	B-X
,	B-X
which	B-X
can	B-X
not	B-X
bind	B-X
GTP	B-X
,	B-X
both	B-X
failed	B-X
to	B-X
localize	B-X
to	B-X
the	B-X
Golgi	B-X
.	B-X
These	B-X
two	B-X
mutants	B-X
had	B-X
a	B-X
dominant-negative	B-X
effect	B-X
,	B-X
preventing	B-X
endogenous	B-X
wild-type	B-X
hGBP-1	B-X
from	B-X
efficiently	B-X
redistributing	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
.	B-X
Furthermore	B-X
,	B-X
hGBP-1	B-X
requires	B-X
another	B-X
IFN-gamma-induced	B-X
factor	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
the	B-X
Golgi	B-X
,	B-X
because	B-X
constitutively	B-X
expressed	B-X
hGBP-1	B-X
remained	B-X
cytosolic	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
aluminum	B-X
fluoride	B-X
unless	B-X
the	B-X
cells	B-X
were	B-X
preincubated	B-X
with	B-X
IFN-gamma	B-X
.	B-X
Finally	B-X
,	B-X
two	B-X
nonhydrolyzing	B-X
mutants	B-X
of	B-X
hGBP-1	B-X
,	B-X
corresponding	B-X
to	B-X
active	B-X
mutants	B-X
of	B-X
Ras	B-X
family	B-X
proteins	B-X
,	B-X
failed	B-X
to	B-X
constitutively	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
;	B-X
we	B-X
propose	B-X
three	B-X
possible	B-X
explanations	B-X
for	B-X
this	B-X
surprising	B-X
result	B-X
.	B-X

Redistribution	O
from	O
the	O
cytosol	O
to	O
the	O
Golgi	O
was	O
observed	O
by	O
immunofluorescence	O
and	O
subcellular	O
fractionation	O
after	O
aluminum	O
fluoride	O
treatment	O
,	O
suggesting	O
that	O
it	O
occurs	O
when	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
is	O
in	O
its	O
GTP	O
-	O
bound	O
state	O
.	O

Relocalization	O
was	O
blocked	O
by	O
a	O
farnesyl	O
transferase	O
inhibitor	O
.	O
<EOS>	B-X
Supplementation	B-X
with	B-X
the	B-X
isoprenoid	B-X
precursor	B-X
,	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
(	B-X
GGPP	B-X
)	B-X
,	B-X
a	B-X
downstream	B-X
product	B-X
of	B-X
HMG	B-X
Co-A	B-X
reductase	B-X
,	B-X
reversed	B-X
statin-induced	B-X
glycosyltransferase	B-X
and	B-X
GSL	B-X
elevation	B-X
.	B-X
The	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
3-PEHPC	B-X
,	B-X
but	B-X
not	B-X
specific	B-X
inhibitors	B-X
of	B-X
farnesyl	B-X
transferase	B-X
,	B-X
or	B-X
geranylgeranyl	B-X
transferase	B-X
I	B-X
,	B-X
was	B-X
sufficient	B-X
to	B-X
replicate	B-X
statin-induced	B-X
GlcCer	B-X
and	B-X
Lc3Cer	B-X
synthesis	B-X
,	B-X
supporting	B-X
a	B-X
Rab	B-X
prenylation-dependent	B-X
mechanism	B-X
.	B-X
GSL-dependent	B-X
vesicular	B-X
retrograde	B-X
transport	B-X
of	B-X
Verotoxin	B-X
and	B-X
cholera	B-X
toxin	B-X
to	B-X
the	B-X
Golgi/endoplasmic	B-X
reticulum	B-X
were	B-X
blocked	B-X
after	B-X
statin	B-X
or	B-X
3-PEHPC	B-X
treatment	B-X
,	B-X
suggesting	B-X
aberrant	B-X
,	B-X
prenylation-dependent	B-X
vesicular	B-X
traffic	B-X
as	B-X
a	B-X
basis	B-X
of	B-X
glycosyltransferase	B-X
increase	B-X
and	B-X
GSL	B-X
remodeling	B-X
.	B-X
WT	B-X
prelamin	B-X
A	B-X
is	B-X
anchored	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
by	B-X
a	B-X
farnesyl	B-X
isoprenoid	B-X
lipid	B-X
.	B-X
Cleavage	B-X
of	B-X
the	B-X
terminal	B-X
15	B-X
aa	B-X
and	B-X
the	B-X
farnesyl	B-X
group	B-X
releases	B-X
mature	B-X
lamin	B-X
A	B-X
from	B-X
this	B-X
tether	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
retention	B-X
of	B-X
the	B-X
farnesyl	B-X
group	B-X
causes	B-X
progerin	B-X
to	B-X
become	B-X
permanently	B-X
anchored	B-X
in	B-X
the	B-X
nuclear	B-X
membrane	B-X
,	B-X
disrupting	B-X
proper	B-X
nuclear	B-X
scaffolding	B-X
and	B-X
causing	B-X
the	B-X
characteristic	B-X
nuclear	B-X
blebbing	B-X
seen	B-X
in	B-X
HGPS	B-X
cells	B-X
.	B-X
Also	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
blocking	B-X
farnesylation	B-X
would	B-X
decrease	B-X
progerin	B-X
toxicity	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
terminal	B-X
CSIM	B-X
sequence	B-X
in	B-X
progerin	B-X
was	B-X
mutated	B-X
to	B-X
SSIM	B-X
,	B-X
a	B-X
sequence	B-X
that	B-X
can	B-X
not	B-X
be	B-X
farnesylated	B-X
.	B-X
Also	B-X
,	B-X
blocking	B-X
farnesylation	B-X
of	B-X
authentic	B-X
progerin	B-X
in	B-X
transiently	B-X
transfected	B-X
HeLa	B-X
,	B-X
HEK	B-X
293	B-X
,	B-X
and	B-X
NIH	B-X
3T3	B-X
cells	B-X
with	B-X
farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
restored	B-X
normal	B-X
nuclear	B-X
architecture	B-X
.	B-X

The	O
C589S	O
mutant	O
of	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
,	O
which	O
cannot	O
be	O
farnesylated	O
,	O
and	O
the	O
previously	O
uncharacterized	O
R48P	O
mutant	O
,	O
which	O
cannot	O
bind	O
GTP	O
,	O
both	O
failed	O
to	O
localize	O
to	O
the	O
Golgi	O
.	O

These	O
two	O
mutants	O
had	O
a	O
dominant	O
-	O
negative	O
effect	O
,	O
preventing	O
endogenous	O
wild	O
-	O
type	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
from	O
efficiently	O
redistributing	O
after	O
aluminum	O
fluoride	O
treatment	O
.	O
<EOS>	B-X
Human	B-X
guanylate-binding	B-X
protein-1	B-X
(	B-X
hGBP-1	B-X
)	B-X
is	B-X
a	B-X
large	B-X
GTPase	B-X
,	B-X
similar	B-X
in	B-X
structure	B-X
to	B-X
the	B-X
dynamins	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
hGBP-1	B-X
has	B-X
never	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
specific	B-X
intracellular	B-X
compartment	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
evidence	B-X
that	B-X
hGBP-1	B-X
can	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
Redistribution	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
Golgi	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
and	B-X
subcellular	B-X
fractionation	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
occurs	B-X
when	B-X
hGBP-1	B-X
is	B-X
in	B-X
its	B-X
GTP-bound	B-X
state	B-X
.	B-X
The	B-X
C589S	B-X
mutant	B-X
of	B-X
hGBP-1	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
farnesylated	B-X
,	B-X
and	B-X
the	B-X
previously	B-X
uncharacterized	B-X
R48P	B-X
mutant	B-X
,	B-X
which	B-X
can	B-X
not	B-X
bind	B-X
GTP	B-X
,	B-X
both	B-X
failed	B-X
to	B-X
localize	B-X
to	B-X
the	B-X
Golgi	B-X
.	B-X
These	B-X
two	B-X
mutants	B-X
had	B-X
a	B-X
dominant-negative	B-X
effect	B-X
,	B-X
preventing	B-X
endogenous	B-X
wild-type	B-X
hGBP-1	B-X
from	B-X
efficiently	B-X
redistributing	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
.	B-X
Furthermore	B-X
,	B-X
hGBP-1	B-X
requires	B-X
another	B-X
IFN-gamma-induced	B-X
factor	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
the	B-X
Golgi	B-X
,	B-X
because	B-X
constitutively	B-X
expressed	B-X
hGBP-1	B-X
remained	B-X
cytosolic	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
aluminum	B-X
fluoride	B-X
unless	B-X
the	B-X
cells	B-X
were	B-X
preincubated	B-X
with	B-X
IFN-gamma	B-X
.	B-X
Finally	B-X
,	B-X
two	B-X
nonhydrolyzing	B-X
mutants	B-X
of	B-X
hGBP-1	B-X
,	B-X
corresponding	B-X
to	B-X
active	B-X
mutants	B-X
of	B-X
Ras	B-X
family	B-X
proteins	B-X
,	B-X
failed	B-X
to	B-X
constitutively	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
;	B-X
we	B-X
propose	B-X
three	B-X
possible	B-X
explanations	B-X
for	B-X
this	B-X
surprising	B-X
result	B-X
.	B-X

Furthermore	O
,	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
requires	O
another	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
induced	O
factor	O
to	O
be	O
targeted	O
to	O
the	O
Golgi	O
,	O
because	O
constitutively	O
expressed	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
remained	O
cytosolic	O
in	O
cells	O
treated	O
with	O
aluminum	O
fluoride	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O

Finally	O
,	O
two	O
nonhydrolyzing	O
mutants	O
of	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
,	O
corresponding	O
to	O
active	O
mutants	O
of	O
Ras	O
family	O
proteins	O
,	O
failed	O
to	O
constitutively	O
associate	O
with	O
the	O
Golgi	O
;	O
we	O
propose	O
three	O
possible	O
explanations	O
for	O
this	O
surprising	O
result	O
.	O
<EOS>	B-X
Human	B-X
guanylate-binding	B-X
protein-1	B-X
(	B-X
hGBP-1	B-X
)	B-X
is	B-X
a	B-X
large	B-X
GTPase	B-X
,	B-X
similar	B-X
in	B-X
structure	B-X
to	B-X
the	B-X
dynamins	B-X
.	B-X
Like	B-X
many	B-X
smaller	B-X
GTPases	B-X
of	B-X
the	B-X
Ras/Rab	B-X
family	B-X
,	B-X
it	B-X
is	B-X
farnesylated	B-X
,	B-X
suggesting	B-X
it	B-X
may	B-X
dock	B-X
into	B-X
membranes	B-X
and	B-X
perhaps	B-X
play	B-X
a	B-X
role	B-X
in	B-X
intracellular	B-X
trafficking	B-X
.	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
hGBP-1	B-X
has	B-X
never	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
specific	B-X
intracellular	B-X
compartment	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
evidence	B-X
that	B-X
hGBP-1	B-X
can	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
Redistribution	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
Golgi	B-X
was	B-X
observed	B-X
by	B-X
immunofluorescence	B-X
and	B-X
subcellular	B-X
fractionation	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
occurs	B-X
when	B-X
hGBP-1	B-X
is	B-X
in	B-X
its	B-X
GTP-bound	B-X
state	B-X
.	B-X
The	B-X
C589S	B-X
mutant	B-X
of	B-X
hGBP-1	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
farnesylated	B-X
,	B-X
and	B-X
the	B-X
previously	B-X
uncharacterized	B-X
R48P	B-X
mutant	B-X
,	B-X
which	B-X
can	B-X
not	B-X
bind	B-X
GTP	B-X
,	B-X
both	B-X
failed	B-X
to	B-X
localize	B-X
to	B-X
the	B-X
Golgi	B-X
.	B-X
These	B-X
two	B-X
mutants	B-X
had	B-X
a	B-X
dominant-negative	B-X
effect	B-X
,	B-X
preventing	B-X
endogenous	B-X
wild-type	B-X
hGBP-1	B-X
from	B-X
efficiently	B-X
redistributing	B-X
after	B-X
aluminum	B-X
fluoride	B-X
treatment	B-X
.	B-X
Furthermore	B-X
,	B-X
hGBP-1	B-X
requires	B-X
another	B-X
IFN-gamma-induced	B-X
factor	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
the	B-X
Golgi	B-X
,	B-X
because	B-X
constitutively	B-X
expressed	B-X
hGBP-1	B-X
remained	B-X
cytosolic	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
aluminum	B-X
fluoride	B-X
unless	B-X
the	B-X
cells	B-X
were	B-X
preincubated	B-X
with	B-X
IFN-gamma	B-X
.	B-X
Finally	B-X
,	B-X
two	B-X
nonhydrolyzing	B-X
mutants	B-X
of	B-X
hGBP-1	B-X
,	B-X
corresponding	B-X
to	B-X
active	B-X
mutants	B-X
of	B-X
Ras	B-X
family	B-X
proteins	B-X
,	B-X
failed	B-X
to	B-X
constitutively	B-X
associate	B-X
with	B-X
the	B-X
Golgi	B-X
;	B-X
we	B-X
propose	B-X
three	B-X
possible	B-X
explanations	B-X
for	B-X
this	B-X
surprising	B-X
result	B-X
.	B-X

Pc2	B-Protein
-	O
mediated	O
sumoylation	O
of	O
Smad	B-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
1	I-Protein
attenuates	O
transcriptional	O
repression	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
.	O
<EOS>	B-X
Epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
is	B-X
important	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
tumorigenesis	B-X
.	B-X
Smad-interacting	B-X
protein	B-X
1	B-X
(	B-X
SIP1	B-X
)	B-X
can	B-X
induce	B-X
EMT	B-X
by	B-X
repressing	B-X
the	B-X
transcription	B-X
of	B-X
E-cadherin	B-X
through	B-X
recruitment	B-X
of	B-X
the	B-X
corepressor	B-X
C-terminal-binding	B-X
protein	B-X
(	B-X
CtBP	B-X
)	B-X
.	B-X
How	B-X
the	B-X
activity	B-X
of	B-X
SIP1	B-X
is	B-X
regulated	B-X
still	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
that	B-X
SIP1	B-X
is	B-X
covalently	B-X
modified	B-X
by	B-X
sumoylation	B-X
at	B-X
two	B-X
conserved	B-X
sites	B-X
,	B-X
Lys391	B-X
and	B-X
Lys866	B-X
.	B-X
The	B-X
polycomb	B-X
protein	B-X
Pc2	B-X
,	B-X
but	B-X
not	B-X
the	B-X
PIAS	B-X
(	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
)	B-X
family	B-X
proteins	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
Small	B-X
ubiquitin-like	B-X
modifier	B-X
E3	B-X
ligase	B-X
for	B-X
SIP1	B-X
.	B-X
Sumoylation	B-X
of	B-X
SIP1	B-X
does	B-X
not	B-X
affect	B-X
its	B-X
subcellular	B-X
localization	B-X
,	B-X
but	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
wild-type	B-X
,	B-X
a	B-X
SIP1	B-X
sumoylation	B-X
null	B-X
mutant	B-X
shows	B-X
more	B-X
potent	B-X
repression	B-X
on	B-X
E-cadherin	B-X
transcription	B-X
but	B-X
similar	B-X
repression	B-X
on	B-X
two	B-X
transforming	B-X
growth	B-X
factor-beta-responsive	B-X
reporter	B-X
genes	B-X
and	B-X
comparable	B-X
activation	B-X
on	B-X
vitamin	B-X
D3	B-X
receptor	B-X
transcription	B-X
.	B-X
Coexpression	B-X
of	B-X
SIP1	B-X
with	B-X
Pc2	B-X
can	B-X
partially	B-X
relieve	B-X
E-cadherin	B-X
repression	B-X
by	B-X
SIP1	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
SIP1	B-X
sumoylation	B-X
disrupts	B-X
the	B-X
recruitment	B-X
of	B-X
CtBP	B-X
.	B-X
Thus	B-X
SIP1	B-X
sumoylation	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
promoter	B-X
context-dependent	B-X
manner	B-X
and	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
intervention	B-X
target	B-X
to	B-X
modulate	B-X
EMT	B-X
in	B-X
tumorigenesis	B-X
.	B-X

Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
important	O
in	O
embryonic	O
development	O
and	O
tumorigenesis	O
.	O
<EOS>	B-X
The	B-X
lineage	B-X
transition	B-X
between	B-X
epithelium	B-X
and	B-X
mesenchyme	B-X
is	B-X
a	B-X
process	B-X
known	B-X
as	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
by	B-X
which	B-X
polarized	B-X
epithelial	B-X
cells	B-X
lose	B-X
their	B-X
adhesion	B-X
property	B-X
and	B-X
obtain	B-X
mesenchymal	B-X
cell	B-X
phenotypes	B-X
.	B-X
EMT	B-X
is	B-X
a	B-X
biological	B-X
process	B-X
that	B-X
is	B-X
often	B-X
involved	B-X
in	B-X
embryogenesis	B-X
and	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
cancer	B-X
invasion	B-X
and	B-X
metastasis	B-X
.	B-X
The	B-X
EMT	B-X
and	B-X
the	B-X
reverse	B-X
process	B-X
,	B-X
mesenchymal-epithelial	B-X
transition	B-X
(	B-X
MET	B-X
)	B-X
,	B-X
also	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
stem	B-X
cell	B-X
differentiation	B-X
and	B-X
de-differentiation	B-X
(	B-X
or	B-X
reprogramming	B-X
)	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
current	B-X
research	B-X
progress	B-X
of	B-X
EMT	B-X
in	B-X
embryonic	B-X
development	B-X
,	B-X
cellular	B-X
differentiation	B-X
and	B-X
reprogramming	B-X
,	B-X
and	B-X
cancer	B-X
progression	B-X
,	B-X
all	B-X
of	B-X
which	B-X
are	B-X
representative	B-X
models	B-X
for	B-X
researches	B-X
of	B-X
stem	B-X
cell	B-X
biology	B-X
in	B-X
normal	B-X
and	B-X
in	B-X
diseases	B-X
.	B-X
Understanding	B-X
of	B-X
EMT	B-X
and	B-X
MET	B-X
may	B-X
help	B-X
to	B-X
identify	B-X
specific	B-X
markers	B-X
to	B-X
distinguish	B-X
normal	B-X
stem	B-X
cells	B-X
from	B-X
cancer	B-X
stem	B-X
cells	B-X
in	B-X
future	B-X
.	B-X

Smad	B-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
1	I-Protein
(	O
SIP1	B-Protein
)	O
can	O
induce	O
EMT	O
by	O
repressing	O
the	O
transcription	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
through	O
recruitment	O
of	O
the	O
corepressor	O
C	B-Protein
-	I-Protein
terminal	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CtBP	B-Protein
)	O
.	O
<EOS>	B-X
Epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
is	B-X
important	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
tumorigenesis	B-X
.	B-X
Smad-interacting	B-X
protein	B-X
1	B-X
(	B-X
SIP1	B-X
)	B-X
can	B-X
induce	B-X
EMT	B-X
by	B-X
repressing	B-X
the	B-X
transcription	B-X
of	B-X
E-cadherin	B-X
through	B-X
recruitment	B-X
of	B-X
the	B-X
corepressor	B-X
C-terminal-binding	B-X
protein	B-X
(	B-X
CtBP	B-X
)	B-X
.	B-X
How	B-X
the	B-X
activity	B-X
of	B-X
SIP1	B-X
is	B-X
regulated	B-X
still	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
that	B-X
SIP1	B-X
is	B-X
covalently	B-X
modified	B-X
by	B-X
sumoylation	B-X
at	B-X
two	B-X
conserved	B-X
sites	B-X
,	B-X
Lys391	B-X
and	B-X
Lys866	B-X
.	B-X
The	B-X
polycomb	B-X
protein	B-X
Pc2	B-X
,	B-X
but	B-X
not	B-X
the	B-X
PIAS	B-X
(	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
)	B-X
family	B-X
proteins	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
Small	B-X
ubiquitin-like	B-X
modifier	B-X
E3	B-X
ligase	B-X
for	B-X
SIP1	B-X
.	B-X
Sumoylation	B-X
of	B-X
SIP1	B-X
does	B-X
not	B-X
affect	B-X
its	B-X
subcellular	B-X
localization	B-X
,	B-X
but	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
wild-type	B-X
,	B-X
a	B-X
SIP1	B-X
sumoylation	B-X
null	B-X
mutant	B-X
shows	B-X
more	B-X
potent	B-X
repression	B-X
on	B-X
E-cadherin	B-X
transcription	B-X
but	B-X
similar	B-X
repression	B-X
on	B-X
two	B-X
transforming	B-X
growth	B-X
factor-beta-responsive	B-X
reporter	B-X
genes	B-X
and	B-X
comparable	B-X
activation	B-X
on	B-X
vitamin	B-X
D3	B-X
receptor	B-X
transcription	B-X
.	B-X
Coexpression	B-X
of	B-X
SIP1	B-X
with	B-X
Pc2	B-X
can	B-X
partially	B-X
relieve	B-X
E-cadherin	B-X
repression	B-X
by	B-X
SIP1	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
SIP1	B-X
sumoylation	B-X
disrupts	B-X
the	B-X
recruitment	B-X
of	B-X
CtBP	B-X
.	B-X
Thus	B-X
SIP1	B-X
sumoylation	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
promoter	B-X
context-dependent	B-X
manner	B-X
and	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
intervention	B-X
target	B-X
to	B-X
modulate	B-X
EMT	B-X
in	B-X
tumorigenesis	B-X
.	B-X

How	O
the	O
activity	O
of	O
SIP1	B-Protein
is	O
regulated	O
still	O
remains	O
unclear	O
.	O
<EOS>	B-X
Smad-interacting	B-X
protein	B-X
1	B-X
(	B-X
SIP1	B-X
)	B-X
can	B-X
induce	B-X
EMT	B-X
by	B-X
repressing	B-X
the	B-X
transcription	B-X
of	B-X
E-cadherin	B-X
through	B-X
recruitment	B-X
of	B-X
the	B-X
corepressor	B-X
C-terminal-binding	B-X
protein	B-X
(	B-X
CtBP	B-X
)	B-X
.	B-X
How	B-X
the	B-X
activity	B-X
of	B-X
SIP1	B-X
is	B-X
regulated	B-X
still	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
that	B-X
SIP1	B-X
is	B-X
covalently	B-X
modified	B-X
by	B-X
sumoylation	B-X
at	B-X
two	B-X
conserved	B-X
sites	B-X
,	B-X
Lys391	B-X
and	B-X
Lys866	B-X
.	B-X
The	B-X
polycomb	B-X
protein	B-X
Pc2	B-X
,	B-X
but	B-X
not	B-X
the	B-X
PIAS	B-X
(	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
)	B-X
family	B-X
proteins	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
Small	B-X
ubiquitin-like	B-X
modifier	B-X
E3	B-X
ligase	B-X
for	B-X
SIP1	B-X
.	B-X
Sumoylation	B-X
of	B-X
SIP1	B-X
does	B-X
not	B-X
affect	B-X
its	B-X
subcellular	B-X
localization	B-X
,	B-X
but	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
wild-type	B-X
,	B-X
a	B-X
SIP1	B-X
sumoylation	B-X
null	B-X
mutant	B-X
shows	B-X
more	B-X
potent	B-X
repression	B-X
on	B-X
E-cadherin	B-X
transcription	B-X
but	B-X
similar	B-X
repression	B-X
on	B-X
two	B-X
transforming	B-X
growth	B-X
factor-beta-responsive	B-X
reporter	B-X
genes	B-X
and	B-X
comparable	B-X
activation	B-X
on	B-X
vitamin	B-X
D3	B-X
receptor	B-X
transcription	B-X
.	B-X
Coexpression	B-X
of	B-X
SIP1	B-X
with	B-X
Pc2	B-X
can	B-X
partially	B-X
relieve	B-X
E-cadherin	B-X
repression	B-X
by	B-X
SIP1	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
SIP1	B-X
sumoylation	B-X
disrupts	B-X
the	B-X
recruitment	B-X
of	B-X
CtBP	B-X
.	B-X
Thus	B-X
SIP1	B-X
sumoylation	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
promoter	B-X
context-dependent	B-X
manner	B-X
and	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
intervention	B-X
target	B-X
to	B-X
modulate	B-X
EMT	B-X
in	B-X
tumorigenesis	B-X
.	B-X

Here	O
we	O
show	O
in	O
vivo	O
and	O
in	O
vitro	O
that	O
SIP1	B-Protein
is	O
covalently	O
modified	O
by	O
sumoylation	O
at	O
two	O
conserved	O
sites	O
,	O
Lys391	O
and	O
Lys866	O
.	O
<EOS>	B-X
Smad-interacting	B-X
protein	B-X
1	B-X
(	B-X
SIP1	B-X
)	B-X
can	B-X
induce	B-X
EMT	B-X
by	B-X
repressing	B-X
the	B-X
transcription	B-X
of	B-X
E-cadherin	B-X
through	B-X
recruitment	B-X
of	B-X
the	B-X
corepressor	B-X
C-terminal-binding	B-X
protein	B-X
(	B-X
CtBP	B-X
)	B-X
.	B-X
How	B-X
the	B-X
activity	B-X
of	B-X
SIP1	B-X
is	B-X
regulated	B-X
still	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
that	B-X
SIP1	B-X
is	B-X
covalently	B-X
modified	B-X
by	B-X
sumoylation	B-X
at	B-X
two	B-X
conserved	B-X
sites	B-X
,	B-X
Lys391	B-X
and	B-X
Lys866	B-X
.	B-X
The	B-X
polycomb	B-X
protein	B-X
Pc2	B-X
,	B-X
but	B-X
not	B-X
the	B-X
PIAS	B-X
(	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
)	B-X
family	B-X
proteins	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
Small	B-X
ubiquitin-like	B-X
modifier	B-X
E3	B-X
ligase	B-X
for	B-X
SIP1	B-X
.	B-X
Sumoylation	B-X
of	B-X
SIP1	B-X
does	B-X
not	B-X
affect	B-X
its	B-X
subcellular	B-X
localization	B-X
,	B-X
but	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
wild-type	B-X
,	B-X
a	B-X
SIP1	B-X
sumoylation	B-X
null	B-X
mutant	B-X
shows	B-X
more	B-X
potent	B-X
repression	B-X
on	B-X
E-cadherin	B-X
transcription	B-X
but	B-X
similar	B-X
repression	B-X
on	B-X
two	B-X
transforming	B-X
growth	B-X
factor-beta-responsive	B-X
reporter	B-X
genes	B-X
and	B-X
comparable	B-X
activation	B-X
on	B-X
vitamin	B-X
D3	B-X
receptor	B-X
transcription	B-X
.	B-X
Coexpression	B-X
of	B-X
SIP1	B-X
with	B-X
Pc2	B-X
can	B-X
partially	B-X
relieve	B-X
E-cadherin	B-X
repression	B-X
by	B-X
SIP1	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
SIP1	B-X
sumoylation	B-X
disrupts	B-X
the	B-X
recruitment	B-X
of	B-X
CtBP	B-X
.	B-X
Thus	B-X
SIP1	B-X
sumoylation	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
promoter	B-X
context-dependent	B-X
manner	B-X
and	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
intervention	B-X
target	B-X
to	B-X
modulate	B-X
EMT	B-X
in	B-X
tumorigenesis	B-X
.	B-X

The	O
polycomb	O
protein	O
Pc2	B-Protein
,	O
but	O
not	O
the	O
PIAS	O
(	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
)	O
family	O
proteins	O
,	O
acts	O
as	O
a	O
Small	O
ubiquitin	O
-	O
like	O
modifier	O
E3	O
ligase	O
for	O
SIP1	B-Protein
.	O
<EOS>	B-X
Polycomb	B-X
proteins	B-X
are	B-X
key	B-X
regulators	B-X
of	B-X
transcription	B-X
in	B-X
metazoan	B-X
organisms	B-X
.	B-X
Recent	B-X
work	B-X
has	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
polycomb	B-X
protein	B-X
complexes	B-X
in	B-X
flies	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Multiple	B-X
enzymatic	B-X
activities	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
associate	B-X
with	B-X
polycomb	B-X
complexes	B-X
,	B-X
including	B-X
histone	B-X
methyltransferase	B-X
,	B-X
histone	B-X
deacetylase	B-X
and	B-X
ubiquitination	B-X
activities	B-X
,	B-X
which	B-X
are	B-X
primarily	B-X
directed	B-X
towards	B-X
the	B-X
modification	B-X
of	B-X
chromatin	B-X
structure	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
chromatin-based	B-X
functions	B-X
,	B-X
other	B-X
potential	B-X
roles	B-X
for	B-X
polycomb	B-X
proteins	B-X
exist	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
a	B-X
comparison	B-X
of	B-X
vertebrate	B-X
Pc2	B-X
(	B-X
polycomb	B-X
2	B-X
protein	B-X
)	B-X
homologues	B-X
,	B-X
and	B-X
review	B-X
the	B-X
known	B-X
functions	B-X
of	B-X
the	B-X
mammalian	B-X
Pc2	B-X
focusing	B-X
on	B-X
its	B-X
role	B-X
as	B-X
a	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
E3	B-X
ligase	B-X
.	B-X
Pc2	B-X
is	B-X
an	B-X
E3	B-X
for	B-X
several	B-X
SUMO	B-X
substrates	B-X
,	B-X
but	B-X
still	B-X
appears	B-X
to	B-X
have	B-X
a	B-X
more	B-X
limited	B-X
repertoire	B-X
than	B-X
other	B-X
SUMO	B-X
E3s	B-X
,	B-X
perhaps	B-X
due	B-X
to	B-X
its	B-X
association	B-X
with	B-X
polycomb	B-X
complexes	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
Pc2	B-X
represents	B-X
a	B-X
relatively	B-X
specialized	B-X
polycomb	B-X
protein	B-X
,	B-X
which	B-X
has	B-X
additional	B-X
functions	B-X
to	B-X
those	B-X
associated	B-X
with	B-X
other	B-X
mammalian	B-X
Pc	B-X
(	B-X
polycomb	B-X
protein	B-X
)	B-X
paralogues	B-X
.	B-X

Sumoylation	O
of	O
SIP1	B-Protein
does	O
not	O
affect	O
its	O
subcellular	O
localization	O
,	O
but	O
regulates	O
its	O
transcriptional	O
activity	O
.	O

Compared	O
with	O
the	O
wild	O
-	O
type	O
,	O
a	O
SIP1	B-Protein
sumoylation	O
null	O
mutant	O
shows	O
more	O
potent	O
repression	O
on	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
transcription	O
but	O
similar	O
repression	O
on	O
two	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
-	O
responsive	O
reporter	O
genes	O
and	O
comparable	O
activation	O
on	O
vitamin	B-Protein
D3	I-Protein
receptor	I-Protein
transcription	O
.	O

Coexpression	O
of	O
SIP1	B-Protein
with	O
Pc2	B-Protein
can	O
partially	O
relieve	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
repression	O
by	O
SIP1	B-Protein
.	O
<EOS>	B-X
Epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
is	B-X
important	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
tumorigenesis	B-X
.	B-X
Smad-interacting	B-X
protein	B-X
1	B-X
(	B-X
SIP1	B-X
)	B-X
can	B-X
induce	B-X
EMT	B-X
by	B-X
repressing	B-X
the	B-X
transcription	B-X
of	B-X
E-cadherin	B-X
through	B-X
recruitment	B-X
of	B-X
the	B-X
corepressor	B-X
C-terminal-binding	B-X
protein	B-X
(	B-X
CtBP	B-X
)	B-X
.	B-X
How	B-X
the	B-X
activity	B-X
of	B-X
SIP1	B-X
is	B-X
regulated	B-X
still	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
that	B-X
SIP1	B-X
is	B-X
covalently	B-X
modified	B-X
by	B-X
sumoylation	B-X
at	B-X
two	B-X
conserved	B-X
sites	B-X
,	B-X
Lys391	B-X
and	B-X
Lys866	B-X
.	B-X
The	B-X
polycomb	B-X
protein	B-X
Pc2	B-X
,	B-X
but	B-X
not	B-X
the	B-X
PIAS	B-X
(	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
)	B-X
family	B-X
proteins	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
Small	B-X
ubiquitin-like	B-X
modifier	B-X
E3	B-X
ligase	B-X
for	B-X
SIP1	B-X
.	B-X
Sumoylation	B-X
of	B-X
SIP1	B-X
does	B-X
not	B-X
affect	B-X
its	B-X
subcellular	B-X
localization	B-X
,	B-X
but	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
wild-type	B-X
,	B-X
a	B-X
SIP1	B-X
sumoylation	B-X
null	B-X
mutant	B-X
shows	B-X
more	B-X
potent	B-X
repression	B-X
on	B-X
E-cadherin	B-X
transcription	B-X
but	B-X
similar	B-X
repression	B-X
on	B-X
two	B-X
transforming	B-X
growth	B-X
factor-beta-responsive	B-X
reporter	B-X
genes	B-X
and	B-X
comparable	B-X
activation	B-X
on	B-X
vitamin	B-X
D3	B-X
receptor	B-X
transcription	B-X
.	B-X
Coexpression	B-X
of	B-X
SIP1	B-X
with	B-X
Pc2	B-X
can	B-X
partially	B-X
relieve	B-X
E-cadherin	B-X
repression	B-X
by	B-X
SIP1	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
SIP1	B-X
sumoylation	B-X
disrupts	B-X
the	B-X
recruitment	B-X
of	B-X
CtBP	B-X
.	B-X
Thus	B-X
SIP1	B-X
sumoylation	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
promoter	B-X
context-dependent	B-X
manner	B-X
and	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
intervention	B-X
target	B-X
to	B-X
modulate	B-X
EMT	B-X
in	B-X
tumorigenesis	B-X
.	B-X

We	O
further	O
show	O
that	O
SIP1	B-Protein
sumoylation	O
disrupts	O
the	O
recruitment	O
of	O
CtBP	B-Protein
.	O
<EOS>	B-X
Smad-interacting	B-X
protein	B-X
1	B-X
(	B-X
SIP1	B-X
)	B-X
can	B-X
induce	B-X
EMT	B-X
by	B-X
repressing	B-X
the	B-X
transcription	B-X
of	B-X
E-cadherin	B-X
through	B-X
recruitment	B-X
of	B-X
the	B-X
corepressor	B-X
C-terminal-binding	B-X
protein	B-X
(	B-X
CtBP	B-X
)	B-X
.	B-X
How	B-X
the	B-X
activity	B-X
of	B-X
SIP1	B-X
is	B-X
regulated	B-X
still	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
that	B-X
SIP1	B-X
is	B-X
covalently	B-X
modified	B-X
by	B-X
sumoylation	B-X
at	B-X
two	B-X
conserved	B-X
sites	B-X
,	B-X
Lys391	B-X
and	B-X
Lys866	B-X
.	B-X
The	B-X
polycomb	B-X
protein	B-X
Pc2	B-X
,	B-X
but	B-X
not	B-X
the	B-X
PIAS	B-X
(	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
)	B-X
family	B-X
proteins	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
Small	B-X
ubiquitin-like	B-X
modifier	B-X
E3	B-X
ligase	B-X
for	B-X
SIP1	B-X
.	B-X
Sumoylation	B-X
of	B-X
SIP1	B-X
does	B-X
not	B-X
affect	B-X
its	B-X
subcellular	B-X
localization	B-X
,	B-X
but	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
wild-type	B-X
,	B-X
a	B-X
SIP1	B-X
sumoylation	B-X
null	B-X
mutant	B-X
shows	B-X
more	B-X
potent	B-X
repression	B-X
on	B-X
E-cadherin	B-X
transcription	B-X
but	B-X
similar	B-X
repression	B-X
on	B-X
two	B-X
transforming	B-X
growth	B-X
factor-beta-responsive	B-X
reporter	B-X
genes	B-X
and	B-X
comparable	B-X
activation	B-X
on	B-X
vitamin	B-X
D3	B-X
receptor	B-X
transcription	B-X
.	B-X
Coexpression	B-X
of	B-X
SIP1	B-X
with	B-X
Pc2	B-X
can	B-X
partially	B-X
relieve	B-X
E-cadherin	B-X
repression	B-X
by	B-X
SIP1	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
SIP1	B-X
sumoylation	B-X
disrupts	B-X
the	B-X
recruitment	B-X
of	B-X
CtBP	B-X
.	B-X
Thus	B-X
SIP1	B-X
sumoylation	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
promoter	B-X
context-dependent	B-X
manner	B-X
and	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
intervention	B-X
target	B-X
to	B-X
modulate	B-X
EMT	B-X
in	B-X
tumorigenesis	B-X
.	B-X

Thus	O
SIP1	B-Protein
sumoylation	O
regulates	O
its	O
transcriptional	O
activity	O
in	O
a	O
promoter	O
context	O
-	O
dependent	O
manner	O
and	O
may	O
represent	O
an	O
important	O
intervention	O
target	O
to	O
modulate	O
EMT	O
in	O
tumorigenesis	O
.	O

Regulation	O
of	O
MEF2	B-Protein
by	O
histone	B-Protein
deacetylase	I-Protein
4	I-Protein
-	O
and	O
SIRT1	B-Protein
deacetylase	O
-	O
mediated	O
lysine	O
modifications	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
deacetylase	B-X
histone	B-X
deacetylase	B-X
4	B-X
(	B-X
HDAC4	B-X
)	B-X
negatively	B-X
regulates	B-X
the	B-X
transcription	B-X
factor	B-X
MEF2	B-X
.	B-X
HDAC4	B-X
is	B-X
believed	B-X
to	B-X
repress	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
binding	B-X
to	B-X
MEF2	B-X
and	B-X
catalyzing	B-X
local	B-X
histone	B-X
deacetylation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
HDAC4	B-X
also	B-X
controls	B-X
MEF2	B-X
by	B-X
a	B-X
novel	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
HDAC4	B-X
interacts	B-X
with	B-X
the	B-X
SUMO	B-X
E2	B-X
conjugating	B-X
enzyme	B-X
Ubc9	B-X
and	B-X
is	B-X
itself	B-X
sumoylated	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
HDAC4	B-X
leads	B-X
to	B-X
prominent	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
recombinant	B-X
HDAC4	B-X
stimulates	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
a	B-X
reconstituted	B-X
system	B-X
in	B-X
vitro	B-X
.	B-X
Importantly	B-X
,	B-X
HDAC4	B-X
promotes	B-X
sumoylation	B-X
on	B-X
a	B-X
lysine	B-X
residue	B-X
that	B-X
is	B-X
also	B-X
subject	B-X
to	B-X
acetylation	B-X
by	B-X
a	B-X
MEF2	B-X
coactivator	B-X
,	B-X
the	B-X
acetyltransferase	B-X
CBP	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
interplay	B-X
between	B-X
acetylation	B-X
and	B-X
sumoylation	B-X
in	B-X
regulating	B-X
MEF2	B-X
activity	B-X
.	B-X
Indeed	B-X
,	B-X
MEF2	B-X
acetylation	B-X
is	B-X
correlated	B-X
with	B-X
MEF2	B-X
activation	B-X
and	B-X
dynamically	B-X
induced	B-X
upon	B-X
muscle	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
sumoylation	B-X
inhibits	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HDAC4	B-X
does	B-X
not	B-X
function	B-X
as	B-X
a	B-X
MEF2	B-X
deacetylase	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
NAD+-dependent	B-X
deacetylase	B-X
SIRT1	B-X
can	B-X
potently	B-X
induce	B-X
MEF2	B-X
deacetylation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
two	B-X
distinct	B-X
classes	B-X
of	B-X
deacetylases	B-X
that	B-X
affect	B-X
MEF2	B-X
sumoylation	B-X
and	B-X
acetylation	B-X
.	B-X

The	O
class	O
II	O
deacetylase	O
histone	B-Protein
deacetylase	I-Protein
4	I-Protein
(	O
HDAC4	B-Protein
)	O
negatively	O
regulates	O
the	O
transcription	O
factor	O
MEF2	B-Protein
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
deacetylase	B-X
histone	B-X
deacetylase	B-X
4	B-X
(	B-X
HDAC4	B-X
)	B-X
negatively	B-X
regulates	B-X
the	B-X
transcription	B-X
factor	B-X
MEF2	B-X
.	B-X
HDAC4	B-X
is	B-X
believed	B-X
to	B-X
repress	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
binding	B-X
to	B-X
MEF2	B-X
and	B-X
catalyzing	B-X
local	B-X
histone	B-X
deacetylation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
HDAC4	B-X
also	B-X
controls	B-X
MEF2	B-X
by	B-X
a	B-X
novel	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
HDAC4	B-X
interacts	B-X
with	B-X
the	B-X
SUMO	B-X
E2	B-X
conjugating	B-X
enzyme	B-X
Ubc9	B-X
and	B-X
is	B-X
itself	B-X
sumoylated	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
HDAC4	B-X
leads	B-X
to	B-X
prominent	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
recombinant	B-X
HDAC4	B-X
stimulates	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
a	B-X
reconstituted	B-X
system	B-X
in	B-X
vitro	B-X
.	B-X
Importantly	B-X
,	B-X
HDAC4	B-X
promotes	B-X
sumoylation	B-X
on	B-X
a	B-X
lysine	B-X
residue	B-X
that	B-X
is	B-X
also	B-X
subject	B-X
to	B-X
acetylation	B-X
by	B-X
a	B-X
MEF2	B-X
coactivator	B-X
,	B-X
the	B-X
acetyltransferase	B-X
CBP	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
interplay	B-X
between	B-X
acetylation	B-X
and	B-X
sumoylation	B-X
in	B-X
regulating	B-X
MEF2	B-X
activity	B-X
.	B-X
Indeed	B-X
,	B-X
MEF2	B-X
acetylation	B-X
is	B-X
correlated	B-X
with	B-X
MEF2	B-X
activation	B-X
and	B-X
dynamically	B-X
induced	B-X
upon	B-X
muscle	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
sumoylation	B-X
inhibits	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HDAC4	B-X
does	B-X
not	B-X
function	B-X
as	B-X
a	B-X
MEF2	B-X
deacetylase	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
NAD+-dependent	B-X
deacetylase	B-X
SIRT1	B-X
can	B-X
potently	B-X
induce	B-X
MEF2	B-X
deacetylation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
two	B-X
distinct	B-X
classes	B-X
of	B-X
deacetylases	B-X
that	B-X
affect	B-X
MEF2	B-X
sumoylation	B-X
and	B-X
acetylation	B-X
.	B-X

HDAC4	B-Protein
is	O
believed	O
to	O
repress	O
MEF2	B-Protein
transcriptional	O
activity	O
by	O
binding	O
to	O
MEF2	B-Protein
and	O
catalyzing	O
local	O
histone	B-Protein
deacetylation	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
deacetylase	B-X
histone	B-X
deacetylase	B-X
4	B-X
(	B-X
HDAC4	B-X
)	B-X
negatively	B-X
regulates	B-X
the	B-X
transcription	B-X
factor	B-X
MEF2	B-X
.	B-X
HDAC4	B-X
is	B-X
believed	B-X
to	B-X
repress	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
binding	B-X
to	B-X
MEF2	B-X
and	B-X
catalyzing	B-X
local	B-X
histone	B-X
deacetylation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
HDAC4	B-X
also	B-X
controls	B-X
MEF2	B-X
by	B-X
a	B-X
novel	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
HDAC4	B-X
interacts	B-X
with	B-X
the	B-X
SUMO	B-X
E2	B-X
conjugating	B-X
enzyme	B-X
Ubc9	B-X
and	B-X
is	B-X
itself	B-X
sumoylated	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
HDAC4	B-X
leads	B-X
to	B-X
prominent	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
recombinant	B-X
HDAC4	B-X
stimulates	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
a	B-X
reconstituted	B-X
system	B-X
in	B-X
vitro	B-X
.	B-X
Importantly	B-X
,	B-X
HDAC4	B-X
promotes	B-X
sumoylation	B-X
on	B-X
a	B-X
lysine	B-X
residue	B-X
that	B-X
is	B-X
also	B-X
subject	B-X
to	B-X
acetylation	B-X
by	B-X
a	B-X
MEF2	B-X
coactivator	B-X
,	B-X
the	B-X
acetyltransferase	B-X
CBP	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
interplay	B-X
between	B-X
acetylation	B-X
and	B-X
sumoylation	B-X
in	B-X
regulating	B-X
MEF2	B-X
activity	B-X
.	B-X
Indeed	B-X
,	B-X
MEF2	B-X
acetylation	B-X
is	B-X
correlated	B-X
with	B-X
MEF2	B-X
activation	B-X
and	B-X
dynamically	B-X
induced	B-X
upon	B-X
muscle	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
sumoylation	B-X
inhibits	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HDAC4	B-X
does	B-X
not	B-X
function	B-X
as	B-X
a	B-X
MEF2	B-X
deacetylase	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
NAD+-dependent	B-X
deacetylase	B-X
SIRT1	B-X
can	B-X
potently	B-X
induce	B-X
MEF2	B-X
deacetylation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
two	B-X
distinct	B-X
classes	B-X
of	B-X
deacetylases	B-X
that	B-X
affect	B-X
MEF2	B-X
sumoylation	B-X
and	B-X
acetylation	B-X
.	B-X

Here	O
we	O
report	O
that	O
HDAC4	B-Protein
also	O
controls	O
MEF2	B-Protein
by	O
a	O
novel	O
SUMO	O
E3	O
ligase	O
activity	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
deacetylase	B-X
histone	B-X
deacetylase	B-X
4	B-X
(	B-X
HDAC4	B-X
)	B-X
negatively	B-X
regulates	B-X
the	B-X
transcription	B-X
factor	B-X
MEF2	B-X
.	B-X
HDAC4	B-X
is	B-X
believed	B-X
to	B-X
repress	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
binding	B-X
to	B-X
MEF2	B-X
and	B-X
catalyzing	B-X
local	B-X
histone	B-X
deacetylation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
HDAC4	B-X
also	B-X
controls	B-X
MEF2	B-X
by	B-X
a	B-X
novel	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
HDAC4	B-X
interacts	B-X
with	B-X
the	B-X
SUMO	B-X
E2	B-X
conjugating	B-X
enzyme	B-X
Ubc9	B-X
and	B-X
is	B-X
itself	B-X
sumoylated	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
HDAC4	B-X
leads	B-X
to	B-X
prominent	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
recombinant	B-X
HDAC4	B-X
stimulates	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
a	B-X
reconstituted	B-X
system	B-X
in	B-X
vitro	B-X
.	B-X
Importantly	B-X
,	B-X
HDAC4	B-X
promotes	B-X
sumoylation	B-X
on	B-X
a	B-X
lysine	B-X
residue	B-X
that	B-X
is	B-X
also	B-X
subject	B-X
to	B-X
acetylation	B-X
by	B-X
a	B-X
MEF2	B-X
coactivator	B-X
,	B-X
the	B-X
acetyltransferase	B-X
CBP	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
interplay	B-X
between	B-X
acetylation	B-X
and	B-X
sumoylation	B-X
in	B-X
regulating	B-X
MEF2	B-X
activity	B-X
.	B-X
Indeed	B-X
,	B-X
MEF2	B-X
acetylation	B-X
is	B-X
correlated	B-X
with	B-X
MEF2	B-X
activation	B-X
and	B-X
dynamically	B-X
induced	B-X
upon	B-X
muscle	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
sumoylation	B-X
inhibits	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HDAC4	B-X
does	B-X
not	B-X
function	B-X
as	B-X
a	B-X
MEF2	B-X
deacetylase	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
NAD+-dependent	B-X
deacetylase	B-X
SIRT1	B-X
can	B-X
potently	B-X
induce	B-X
MEF2	B-X
deacetylation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
two	B-X
distinct	B-X
classes	B-X
of	B-X
deacetylases	B-X
that	B-X
affect	B-X
MEF2	B-X
sumoylation	B-X
and	B-X
acetylation	B-X
.	B-X

We	O
show	O
that	O
HDAC4	B-Protein
interacts	O
with	O
the	O
SUMO	O
E2	O
conjugating	O
enzyme	O
Ubc9	B-Protein
and	O
is	O
itself	O
sumoylated	O
.	O
<EOS>	B-X
HDAC4	B-X
is	B-X
a	B-X
potent	B-X
memory	B-X
repressor	B-X
with	B-X
overexpression	B-X
of	B-X
wild	B-X
type	B-X
or	B-X
a	B-X
nuclear-restricted	B-X
mutant	B-X
resulting	B-X
in	B-X
memory	B-X
deficits	B-X
.	B-X
Interestingly	B-X
,	B-X
reduction	B-X
of	B-X
HDAC4	B-X
also	B-X
impairs	B-X
memory	B-X
via	B-X
an	B-X
as	B-X
yet	B-X
unknown	B-X
mechanism	B-X
.	B-X
Although	B-X
histone	B-X
deacetylase	B-X
family	B-X
members	B-X
are	B-X
important	B-X
mediators	B-X
of	B-X
epigenetic	B-X
mechanisms	B-X
in	B-X
neurons	B-X
,	B-X
HDAC4	B-X
is	B-X
predominantly	B-X
cytoplasmic	B-X
in	B-X
the	B-X
brain	B-X
and	B-X
there	B-X
is	B-X
increasing	B-X
evidence	B-X
for	B-X
interactions	B-X
with	B-X
nonhistone	B-X
proteins	B-X
,	B-X
suggesting	B-X
HDAC4	B-X
has	B-X
roles	B-X
beyond	B-X
transcriptional	B-X
regulation	B-X
.	B-X
To	B-X
that	B-X
end	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
genetic	B-X
interaction	B-X
screen	B-X
in	B-X
Drosophila	B-X
and	B-X
identified	B-X
26	B-X
genes	B-X
that	B-X
interacted	B-X
with	B-X
HDAC4	B-X
,	B-X
including	B-X
Ubc9	B-X
,	B-X
the	B-X
sole	B-X
SUMO	B-X
E2-conjugating	B-X
enzyme	B-X
.	B-X
RNA	B-X
interference-induced	B-X
reduction	B-X
of	B-X
Ubc9	B-X
in	B-X
the	B-X
adult	B-X
brain	B-X
impaired	B-X
long-term	B-X
memory	B-X
in	B-X
the	B-X
courtship	B-X
suppression	B-X
assay	B-X
,	B-X
a	B-X
Drosophila	B-X
model	B-X
of	B-X
associative	B-X
memory	B-X
.	B-X
We	B-X
also	B-X
demonstrate	B-X
that	B-X
HDAC4	B-X
and	B-X
Ubc9	B-X
interact	B-X
genetically	B-X
during	B-X
memory	B-X
formation	B-X
,	B-X
opening	B-X
new	B-X
avenues	B-X
for	B-X
investigating	B-X
the	B-X
mechanisms	B-X
through	B-X
which	B-X
HDAC4	B-X
regulates	B-X
memory	B-X
formation	B-X
and	B-X
other	B-X
neurological	B-X
processes	B-X
.	B-X

The	O
overexpression	O
of	O
HDAC4	B-Protein
leads	O
to	O
prominent	O
MEF2	B-Protein
sumoylation	O
in	O
vivo	O
,	O
whereas	O
recombinant	O
HDAC4	B-Protein
stimulates	O
MEF2	B-Protein
sumoylation	O
in	O
a	O
reconstituted	O
system	O
in	O
vitro	O
.	O

Importantly	O
,	O
HDAC4	B-Protein
promotes	O
sumoylation	O
on	O
a	O
lysine	O
residue	O
that	O
is	O
also	O
subject	O
to	O
acetylation	O
by	O
a	O
MEF2	B-Protein
coactivator	O
,	O
the	O
acetyltransferase	O
CBP	B-Protein
,	O
suggesting	O
a	O
possible	O
interplay	O
between	O
acetylation	O
and	O
sumoylation	O
in	O
regulating	O
MEF2	B-Protein
activity	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
deacetylase	B-X
histone	B-X
deacetylase	B-X
4	B-X
(	B-X
HDAC4	B-X
)	B-X
negatively	B-X
regulates	B-X
the	B-X
transcription	B-X
factor	B-X
MEF2	B-X
.	B-X
HDAC4	B-X
is	B-X
believed	B-X
to	B-X
repress	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
binding	B-X
to	B-X
MEF2	B-X
and	B-X
catalyzing	B-X
local	B-X
histone	B-X
deacetylation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
HDAC4	B-X
also	B-X
controls	B-X
MEF2	B-X
by	B-X
a	B-X
novel	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
HDAC4	B-X
interacts	B-X
with	B-X
the	B-X
SUMO	B-X
E2	B-X
conjugating	B-X
enzyme	B-X
Ubc9	B-X
and	B-X
is	B-X
itself	B-X
sumoylated	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
HDAC4	B-X
leads	B-X
to	B-X
prominent	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
recombinant	B-X
HDAC4	B-X
stimulates	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
a	B-X
reconstituted	B-X
system	B-X
in	B-X
vitro	B-X
.	B-X
Importantly	B-X
,	B-X
HDAC4	B-X
promotes	B-X
sumoylation	B-X
on	B-X
a	B-X
lysine	B-X
residue	B-X
that	B-X
is	B-X
also	B-X
subject	B-X
to	B-X
acetylation	B-X
by	B-X
a	B-X
MEF2	B-X
coactivator	B-X
,	B-X
the	B-X
acetyltransferase	B-X
CBP	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
interplay	B-X
between	B-X
acetylation	B-X
and	B-X
sumoylation	B-X
in	B-X
regulating	B-X
MEF2	B-X
activity	B-X
.	B-X
Indeed	B-X
,	B-X
MEF2	B-X
acetylation	B-X
is	B-X
correlated	B-X
with	B-X
MEF2	B-X
activation	B-X
and	B-X
dynamically	B-X
induced	B-X
upon	B-X
muscle	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
sumoylation	B-X
inhibits	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HDAC4	B-X
does	B-X
not	B-X
function	B-X
as	B-X
a	B-X
MEF2	B-X
deacetylase	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
NAD+-dependent	B-X
deacetylase	B-X
SIRT1	B-X
can	B-X
potently	B-X
induce	B-X
MEF2	B-X
deacetylation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
two	B-X
distinct	B-X
classes	B-X
of	B-X
deacetylases	B-X
that	B-X
affect	B-X
MEF2	B-X
sumoylation	B-X
and	B-X
acetylation	B-X
.	B-X

Indeed	O
,	O
MEF2	B-Protein
acetylation	O
is	O
correlated	O
with	O
MEF2	B-Protein
activation	O
and	O
dynamically	O
induced	O
upon	O
muscle	O
cell	O
differentiation	O
,	O
while	O
sumoylation	O
inhibits	O
MEF2	B-Protein
transcriptional	O
activity	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
deacetylase	B-X
histone	B-X
deacetylase	B-X
4	B-X
(	B-X
HDAC4	B-X
)	B-X
negatively	B-X
regulates	B-X
the	B-X
transcription	B-X
factor	B-X
MEF2	B-X
.	B-X
HDAC4	B-X
is	B-X
believed	B-X
to	B-X
repress	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
binding	B-X
to	B-X
MEF2	B-X
and	B-X
catalyzing	B-X
local	B-X
histone	B-X
deacetylation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
HDAC4	B-X
also	B-X
controls	B-X
MEF2	B-X
by	B-X
a	B-X
novel	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
HDAC4	B-X
leads	B-X
to	B-X
prominent	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
recombinant	B-X
HDAC4	B-X
stimulates	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
a	B-X
reconstituted	B-X
system	B-X
in	B-X
vitro	B-X
.	B-X
Importantly	B-X
,	B-X
HDAC4	B-X
promotes	B-X
sumoylation	B-X
on	B-X
a	B-X
lysine	B-X
residue	B-X
that	B-X
is	B-X
also	B-X
subject	B-X
to	B-X
acetylation	B-X
by	B-X
a	B-X
MEF2	B-X
coactivator	B-X
,	B-X
the	B-X
acetyltransferase	B-X
CBP	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
interplay	B-X
between	B-X
acetylation	B-X
and	B-X
sumoylation	B-X
in	B-X
regulating	B-X
MEF2	B-X
activity	B-X
.	B-X
Indeed	B-X
,	B-X
MEF2	B-X
acetylation	B-X
is	B-X
correlated	B-X
with	B-X
MEF2	B-X
activation	B-X
and	B-X
dynamically	B-X
induced	B-X
upon	B-X
muscle	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
sumoylation	B-X
inhibits	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HDAC4	B-X
does	B-X
not	B-X
function	B-X
as	B-X
a	B-X
MEF2	B-X
deacetylase	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
NAD+-dependent	B-X
deacetylase	B-X
SIRT1	B-X
can	B-X
potently	B-X
induce	B-X
MEF2	B-X
deacetylation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
two	B-X
distinct	B-X
classes	B-X
of	B-X
deacetylases	B-X
that	B-X
affect	B-X
MEF2	B-X
sumoylation	B-X
and	B-X
acetylation	B-X
.	B-X

Unexpectedly	O
,	O
we	O
found	O
that	O
HDAC4	B-Protein
does	O
not	O
function	O
as	O
a	O
MEF2	B-Protein
deacetylase	O
.	O
<EOS>	B-X
While	B-X
it	B-X
converts	B-X
drug-resistance	B-X
to	B-X
cisplatin	B-X
(	B-X
CDDP	B-X
)	B-X
,	B-X
we	B-X
unexpectedly	B-X
found	B-X
that	B-X
ZIP4	B-X
induced	B-X
sensitization	B-X
of	B-X
HGSOC	B-X
cells	B-X
to	B-X
histone	B-X
deacetylase	B-X
inhibitors	B-X
(	B-X
HDACis	B-X
)	B-X
.	B-X
HDAC4	B-X
knockdown	B-X
(	B-X
KD	B-X
)	B-X
and	B-X
LMK-235	B-X
inhibited	B-X
spheroid	B-X
formation	B-X
in	B-X
vitro	B-X
and	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
,	B-X
with	B-X
hypoxia	B-X
inducible	B-X
factor-1	B-X
alpha	B-X
(	B-X
HIF1α	B-X
)	B-X
and	B-X
endothelial	B-X
growth	B-X
factor	B-X
A	B-X
(	B-X
VEGFA	B-X
)	B-X
as	B-X
functional	B-X
downstream	B-X
mediators	B-X
of	B-X
HDAC4	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
found	B-X
that	B-X
ZIP4	B-X
,	B-X
HDAC4	B-X
,	B-X
and	B-X
HIF1α	B-X
were	B-X
involved	B-X
in	B-X
regulating	B-X
secreted	B-X
VEGFA	B-X
in	B-X
HGSOC	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
tested	B-X
our	B-X
hypothesis	B-X
that	B-X
co-targeting	B-X
CSC	B-X
via	B-X
the	B-X
ZIP4-HDAC4	B-X
axis	B-X
and	B-X
non-CSC	B-X
using	B-X
CDDP	B-X
is	B-X
necessary	B-X
and	B-X
highly	B-X
effective	B-X
by	B-X
comparing	B-X
the	B-X
effects	B-X
of	B-X
ZIP4-knockout/KD	B-X
,	B-X
HDAC4-KD	B-X
,	B-X
and	B-X
HDACis	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
CDDP	B-X
on	B-X
tumorigenesis	B-X
in	B-X
mouse	B-X
models	B-X
.	B-X
Finally	B-X
,	B-X
data	B-X
from	B-X
human	B-X
HGSOC	B-X
tissues	B-X
showed	B-X
that	B-X
ZIP4	B-X
and	B-X
HDAC4	B-X
were	B-X
upregulated	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
recurrent	B-X
tumors	B-X
,	B-X
justifying	B-X
the	B-X
clinical	B-X
relevance	B-X
of	B-X
the	B-X
study	B-X
.	B-X

Instead	O
,	O
the	O
NAD	O
+	O
-	O
dependent	O
deacetylase	O
SIRT1	B-Protein
can	O
potently	O
induce	O
MEF2	B-Protein
deacetylation	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
deacetylase	B-X
histone	B-X
deacetylase	B-X
4	B-X
(	B-X
HDAC4	B-X
)	B-X
negatively	B-X
regulates	B-X
the	B-X
transcription	B-X
factor	B-X
MEF2	B-X
.	B-X
HDAC4	B-X
is	B-X
believed	B-X
to	B-X
repress	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
binding	B-X
to	B-X
MEF2	B-X
and	B-X
catalyzing	B-X
local	B-X
histone	B-X
deacetylation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
HDAC4	B-X
also	B-X
controls	B-X
MEF2	B-X
by	B-X
a	B-X
novel	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
HDAC4	B-X
leads	B-X
to	B-X
prominent	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
recombinant	B-X
HDAC4	B-X
stimulates	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
a	B-X
reconstituted	B-X
system	B-X
in	B-X
vitro	B-X
.	B-X
Importantly	B-X
,	B-X
HDAC4	B-X
promotes	B-X
sumoylation	B-X
on	B-X
a	B-X
lysine	B-X
residue	B-X
that	B-X
is	B-X
also	B-X
subject	B-X
to	B-X
acetylation	B-X
by	B-X
a	B-X
MEF2	B-X
coactivator	B-X
,	B-X
the	B-X
acetyltransferase	B-X
CBP	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
interplay	B-X
between	B-X
acetylation	B-X
and	B-X
sumoylation	B-X
in	B-X
regulating	B-X
MEF2	B-X
activity	B-X
.	B-X
Indeed	B-X
,	B-X
MEF2	B-X
acetylation	B-X
is	B-X
correlated	B-X
with	B-X
MEF2	B-X
activation	B-X
and	B-X
dynamically	B-X
induced	B-X
upon	B-X
muscle	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
sumoylation	B-X
inhibits	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HDAC4	B-X
does	B-X
not	B-X
function	B-X
as	B-X
a	B-X
MEF2	B-X
deacetylase	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
NAD+-dependent	B-X
deacetylase	B-X
SIRT1	B-X
can	B-X
potently	B-X
induce	B-X
MEF2	B-X
deacetylation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
two	B-X
distinct	B-X
classes	B-X
of	B-X
deacetylases	B-X
that	B-X
affect	B-X
MEF2	B-X
sumoylation	B-X
and	B-X
acetylation	B-X
.	B-X

Our	O
studies	O
reveal	O
a	O
novel	O
regulation	O
of	O
MEF2	B-Protein
transcriptional	O
activity	O
by	O
two	O
distinct	O
classes	O
of	O
deacetylases	O
that	O
affect	O
MEF2	B-Protein
sumoylation	O
and	O
acetylation	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
deacetylase	B-X
histone	B-X
deacetylase	B-X
4	B-X
(	B-X
HDAC4	B-X
)	B-X
negatively	B-X
regulates	B-X
the	B-X
transcription	B-X
factor	B-X
MEF2	B-X
.	B-X
HDAC4	B-X
is	B-X
believed	B-X
to	B-X
repress	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
binding	B-X
to	B-X
MEF2	B-X
and	B-X
catalyzing	B-X
local	B-X
histone	B-X
deacetylation	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
HDAC4	B-X
also	B-X
controls	B-X
MEF2	B-X
by	B-X
a	B-X
novel	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
HDAC4	B-X
leads	B-X
to	B-X
prominent	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
recombinant	B-X
HDAC4	B-X
stimulates	B-X
MEF2	B-X
sumoylation	B-X
in	B-X
a	B-X
reconstituted	B-X
system	B-X
in	B-X
vitro	B-X
.	B-X
Importantly	B-X
,	B-X
HDAC4	B-X
promotes	B-X
sumoylation	B-X
on	B-X
a	B-X
lysine	B-X
residue	B-X
that	B-X
is	B-X
also	B-X
subject	B-X
to	B-X
acetylation	B-X
by	B-X
a	B-X
MEF2	B-X
coactivator	B-X
,	B-X
the	B-X
acetyltransferase	B-X
CBP	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
interplay	B-X
between	B-X
acetylation	B-X
and	B-X
sumoylation	B-X
in	B-X
regulating	B-X
MEF2	B-X
activity	B-X
.	B-X
Indeed	B-X
,	B-X
MEF2	B-X
acetylation	B-X
is	B-X
correlated	B-X
with	B-X
MEF2	B-X
activation	B-X
and	B-X
dynamically	B-X
induced	B-X
upon	B-X
muscle	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
sumoylation	B-X
inhibits	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HDAC4	B-X
does	B-X
not	B-X
function	B-X
as	B-X
a	B-X
MEF2	B-X
deacetylase	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
NAD+-dependent	B-X
deacetylase	B-X
SIRT1	B-X
can	B-X
potently	B-X
induce	B-X
MEF2	B-X
deacetylation	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
a	B-X
novel	B-X
regulation	B-X
of	B-X
MEF2	B-X
transcriptional	B-X
activity	B-X
by	B-X
two	B-X
distinct	B-X
classes	B-X
of	B-X
deacetylases	B-X
that	B-X
affect	B-X
MEF2	B-X
sumoylation	B-X
and	B-X
acetylation	B-X
.	B-X

Different	O
transition	O
-	O
state	O
structures	O
for	O
the	O
reactions	O
of	O
beta	O
-	O
lactams	O
and	O
analogous	O
beta	O
-	O
sultams	O
with	O
serine	O
beta	O
-	O
lactamases	O
.	O
<EOS>	B-X
Beta-sultams	B-X
are	B-X
the	B-X
sulfonyl	B-X
analogues	B-X
of	B-X
beta-lactams	B-X
,	B-X
and	B-X
N-acyl	B-X
beta-sultams	B-X
are	B-X
novel	B-X
inactivators	B-X
of	B-X
the	B-X
class	B-X
C	B-X
beta-lactamase	B-X
of	B-X
Enterobacter	B-X
cloacae	B-X
P99	B-X
.	B-X
They	B-X
sulfonylate	B-X
the	B-X
active	B-X
site	B-X
serine	B-X
residue	B-X
to	B-X
form	B-X
a	B-X
sulfonate	B-X
ester	B-X
which	B-X
subsequently	B-X
undergoes	B-X
C-O	B-X
bond	B-X
fission	B-X
and	B-X
formation	B-X
of	B-X
a	B-X
dehydroalanine	B-X
residue	B-X
by	B-X
elimination	B-X
of	B-X
the	B-X
sulfonate	B-X
anion	B-X
as	B-X
shown	B-X
by	B-X
electrospray	B-X
ionization	B-X
mass	B-X
spectroscopy	B-X
.	B-X
The	B-X
analogous	B-X
N-acyl	B-X
beta-lactams	B-X
are	B-X
substrates	B-X
for	B-X
beta-lactamase	B-X
and	B-X
undergo	B-X
enzyme-catalyzed	B-X
hydrolysis	B-X
presumably	B-X
by	B-X
the	B-X
normal	B-X
acylation-deacylation	B-X
process	B-X
.	B-X
The	B-X
rates	B-X
of	B-X
acylation	B-X
of	B-X
the	B-X
enzyme	B-X
by	B-X
the	B-X
beta-lactams	B-X
,	B-X
measured	B-X
by	B-X
the	B-X
second-order	B-X
rate	B-X
constant	B-X
for	B-X
hydrolysis	B-X
,	B-X
kcat/K	B-X
(	B-X
m	B-X
)	B-X
,	B-X
and	B-X
those	B-X
of	B-X
sulfonylation	B-X
by	B-X
the	B-X
beta-sultams	B-X
,	B-X
measured	B-X
by	B-X
the	B-X
second-order	B-X
rate	B-X
constant	B-X
for	B-X
inactivation	B-X
,	B-X
k	B-X
(	B-X
i	B-X
)	B-X
,	B-X
both	B-X
show	B-X
a	B-X
similar	B-X
pH	B-X
dependence	B-X
to	B-X
that	B-X
exhibited	B-X
by	B-X
the	B-X
beta-lactamase-catalyzed	B-X
hydrolysis	B-X
of	B-X
beta-lactam	B-X
antibiotics	B-X
.	B-X
Electron-withdrawing	B-X
groups	B-X
in	B-X
the	B-X
aryl	B-X
residue	B-X
of	B-X
the	B-X
leaving	B-X
group	B-X
of	B-X
N-aroyl	B-X
beta-lactams	B-X
increase	B-X
the	B-X
rate	B-X
of	B-X
alkaline	B-X
hydrolysis	B-X
and	B-X
give	B-X
a	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
of	B-X
-0.55	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
late	B-X
transition	B-X
state	B-X
for	B-X
rate-limiting	B-X
formation	B-X
of	B-X
the	B-X
tetrahedral	B-X
intermediate	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
corresponding	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
for	B-X
the	B-X
beta-lactamase-catalyzed	B-X
hydrolysis	B-X
of	B-X
the	B-X
same	B-X
substrates	B-X
is	B-X
-0.06	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
earlier	B-X
transition	B-X
state	B-X
for	B-X
the	B-X
enzyme-catalyzed	B-X
reaction	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
although	B-X
the	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
for	B-X
the	B-X
alkaline	B-X
hydrolysis	B-X
of	B-X
N-aroyl	B-X
beta-sultams	B-X
is	B-X
-0.73	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
for	B-X
the	B-X
beta-lactams	B-X
,	B-X
that	B-X
for	B-X
the	B-X
sulfonylation	B-X
of	B-X
beta-lactamase	B-X
by	B-X
these	B-X
compounds	B-X
is	B-X
-1.46	B-X
,	B-X
compatible	B-X
with	B-X
significant	B-X
amide	B-X
anion	B-X
expulsion/S-N	B-X
fission	B-X
in	B-X
the	B-X
transition	B-X
state	B-X
.	B-X
In	B-X
this	B-X
case	B-X
,	B-X
the	B-X
enzyme	B-X
reaction	B-X
displays	B-X
a	B-X
later	B-X
transition	B-X
state	B-X
compared	B-X
with	B-X
hydroxide-ion-catalyzed	B-X
hydrolysis	B-X
of	B-X
the	B-X
beta-sultam	B-X
.	B-X

Beta	O
-	O
sultams	O
are	O
the	O
sulfonyl	O
analogues	O
of	O
beta	O
-	O
lactams	O
,	O
and	O
N	O
-	O
acyl	O
beta	O
-	O
sultams	O
are	O
novel	O
inactivators	O
of	O
the	O
class	O
C	O
beta	O
-	O
lactamase	O
of	O
Enterobacter	O
cloacae	O
P99	O
.	O

They	O
sulfonylate	O
the	O
active	O
site	O
serine	O
residue	O
to	O
form	O
a	O
sulfonate	O
ester	O
which	O
subsequently	O
undergoes	O
C	O
-	O
O	O
bond	O
fission	O
and	O
formation	O
of	O
a	O
dehydroalanine	O
residue	O
by	O
elimination	O
of	O
the	O
sulfonate	O
anion	O
as	O
shown	O
by	O
electrospray	O
ionization	O
mass	O
spectroscopy	O
.	O

The	O
analogous	O
N	O
-	O
acyl	O
beta	O
-	O
lactams	O
are	O
substrates	O
for	O
beta	O
-	O
lactamase	O
and	O
undergo	O
enzyme	O
-	O
catalyzed	O
hydrolysis	O
presumably	O
by	O
the	O
normal	O
acylation	O
-	O
deacylation	O
process	O
.	O
<EOS>	B-X
Beta-sultams	B-X
are	B-X
the	B-X
sulfonyl	B-X
analogues	B-X
of	B-X
beta-lactams	B-X
,	B-X
and	B-X
N-acyl	B-X
beta-sultams	B-X
are	B-X
novel	B-X
inactivators	B-X
of	B-X
the	B-X
class	B-X
C	B-X
beta-lactamase	B-X
of	B-X
Enterobacter	B-X
cloacae	B-X
P99	B-X
.	B-X
They	B-X
sulfonylate	B-X
the	B-X
active	B-X
site	B-X
serine	B-X
residue	B-X
to	B-X
form	B-X
a	B-X
sulfonate	B-X
ester	B-X
which	B-X
subsequently	B-X
undergoes	B-X
C-O	B-X
bond	B-X
fission	B-X
and	B-X
formation	B-X
of	B-X
a	B-X
dehydroalanine	B-X
residue	B-X
by	B-X
elimination	B-X
of	B-X
the	B-X
sulfonate	B-X
anion	B-X
as	B-X
shown	B-X
by	B-X
electrospray	B-X
ionization	B-X
mass	B-X
spectroscopy	B-X
.	B-X
The	B-X
analogous	B-X
N-acyl	B-X
beta-lactams	B-X
are	B-X
substrates	B-X
for	B-X
beta-lactamase	B-X
and	B-X
undergo	B-X
enzyme-catalyzed	B-X
hydrolysis	B-X
presumably	B-X
by	B-X
the	B-X
normal	B-X
acylation-deacylation	B-X
process	B-X
.	B-X
The	B-X
rates	B-X
of	B-X
acylation	B-X
of	B-X
the	B-X
enzyme	B-X
by	B-X
the	B-X
beta-lactams	B-X
,	B-X
measured	B-X
by	B-X
the	B-X
second-order	B-X
rate	B-X
constant	B-X
for	B-X
hydrolysis	B-X
,	B-X
kcat/K	B-X
(	B-X
m	B-X
)	B-X
,	B-X
and	B-X
those	B-X
of	B-X
sulfonylation	B-X
by	B-X
the	B-X
beta-sultams	B-X
,	B-X
measured	B-X
by	B-X
the	B-X
second-order	B-X
rate	B-X
constant	B-X
for	B-X
inactivation	B-X
,	B-X
k	B-X
(	B-X
i	B-X
)	B-X
,	B-X
both	B-X
show	B-X
a	B-X
similar	B-X
pH	B-X
dependence	B-X
to	B-X
that	B-X
exhibited	B-X
by	B-X
the	B-X
beta-lactamase-catalyzed	B-X
hydrolysis	B-X
of	B-X
beta-lactam	B-X
antibiotics	B-X
.	B-X
Electron-withdrawing	B-X
groups	B-X
in	B-X
the	B-X
aryl	B-X
residue	B-X
of	B-X
the	B-X
leaving	B-X
group	B-X
of	B-X
N-aroyl	B-X
beta-lactams	B-X
increase	B-X
the	B-X
rate	B-X
of	B-X
alkaline	B-X
hydrolysis	B-X
and	B-X
give	B-X
a	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
of	B-X
-0.55	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
late	B-X
transition	B-X
state	B-X
for	B-X
rate-limiting	B-X
formation	B-X
of	B-X
the	B-X
tetrahedral	B-X
intermediate	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
corresponding	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
for	B-X
the	B-X
beta-lactamase-catalyzed	B-X
hydrolysis	B-X
of	B-X
the	B-X
same	B-X
substrates	B-X
is	B-X
-0.06	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
earlier	B-X
transition	B-X
state	B-X
for	B-X
the	B-X
enzyme-catalyzed	B-X
reaction	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
although	B-X
the	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
for	B-X
the	B-X
alkaline	B-X
hydrolysis	B-X
of	B-X
N-aroyl	B-X
beta-sultams	B-X
is	B-X
-0.73	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
for	B-X
the	B-X
beta-lactams	B-X
,	B-X
that	B-X
for	B-X
the	B-X
sulfonylation	B-X
of	B-X
beta-lactamase	B-X
by	B-X
these	B-X
compounds	B-X
is	B-X
-1.46	B-X
,	B-X
compatible	B-X
with	B-X
significant	B-X
amide	B-X
anion	B-X
expulsion/S-N	B-X
fission	B-X
in	B-X
the	B-X
transition	B-X
state	B-X
.	B-X
In	B-X
this	B-X
case	B-X
,	B-X
the	B-X
enzyme	B-X
reaction	B-X
displays	B-X
a	B-X
later	B-X
transition	B-X
state	B-X
compared	B-X
with	B-X
hydroxide-ion-catalyzed	B-X
hydrolysis	B-X
of	B-X
the	B-X
beta-sultam	B-X
.	B-X

The	O
rates	O
of	O
acylation	O
of	O
the	O
enzyme	O
by	O
the	O
beta	O
-	O
lactams	O
,	O
measured	O
by	O
the	O
second	O
-	O
order	O
rate	O
constant	O
for	O
hydrolysis	O
,	O
kcat	O
/	O
K	O
(	O
m	O
)	O
,	O
and	O
those	O
of	O
sulfonylation	O
by	O
the	O
beta	O
-	O
sultams	O
,	O
measured	O
by	O
the	O
second	O
-	O
order	O
rate	O
constant	O
for	O
inactivation	O
,	O
k	O
(	O
i	O
)	O
,	O
both	O
show	O
a	O
similar	O
pH	O
dependence	O
to	O
that	O
exhibited	O
by	O
the	O
beta	O
-	O
lactamase	O
-	O
catalyzed	O
hydrolysis	O
of	O
beta	O
-	O
lactam	O
antibiotics	O
.	O

Electron	O
-	O
withdrawing	O
groups	O
in	O
the	O
aryl	O
residue	O
of	O
the	O
leaving	O
group	O
of	O
N	O
-	O
aroyl	O
beta	O
-	O
lactams	O
increase	O
the	O
rate	O
of	O
alkaline	O
hydrolysis	O
and	O
give	O
a	O
Bronsted	O
beta	O
(	O
lg	O
)	O
of	O
-	O
0	O
.	O
55	O
,	O
indicative	O
of	O
a	O
late	O
transition	O
state	O
for	O
rate	O
-	O
limiting	O
formation	O
of	O
the	O
tetrahedral	O
intermediate	O
.	O

Interestingly	O
,	O
the	O
corresponding	O
Bronsted	O
beta	O
(	O
lg	O
)	O
for	O
the	O
beta	O
-	O
lactamase	O
-	O
catalyzed	O
hydrolysis	O
of	O
the	O
same	O
substrates	O
is	O
-	O
0	O
.	O
06	O
,	O
indicative	O
of	O
an	O
earlier	O
transition	O
state	O
for	O
the	O
enzyme	O
-	O
catalyzed	O
reaction	O
.	O

By	O
contrast	O
,	O
although	O
the	O
Bronsted	O
beta	O
(	O
lg	O
)	O
for	O
the	O
alkaline	O
hydrolysis	O
of	O
N	O
-	O
aroyl	O
beta	O
-	O
sultams	O
is	O
-	O
0	O
.	O
73	O
,	O
similar	O
to	O
that	O
for	O
the	O
beta	O
-	O
lactams	O
,	O
that	O
for	O
the	O
sulfonylation	O
of	O
beta	O
-	O
lactamase	O
by	O
these	O
compounds	O
is	O
-	O
1	O
.	O
46	O
,	O
compatible	O
with	O
significant	O
amide	O
anion	O
expulsion	O
/	O
S	O
-	O
N	O
fission	O
in	O
the	O
transition	O
state	O
.	O

In	O
this	O
case	O
,	O
the	O
enzyme	O
reaction	O
displays	O
a	O
later	O
transition	O
state	O
compared	O
with	O
hydroxide	O
-	O
ion	O
-	O
catalyzed	O
hydrolysis	O
of	O
the	O
beta	O
-	O
sultam	O
.	O
<EOS>	B-X
Beta-sultams	B-X
are	B-X
the	B-X
sulfonyl	B-X
analogues	B-X
of	B-X
beta-lactams	B-X
,	B-X
and	B-X
N-acyl	B-X
beta-sultams	B-X
are	B-X
novel	B-X
inactivators	B-X
of	B-X
the	B-X
class	B-X
C	B-X
beta-lactamase	B-X
of	B-X
Enterobacter	B-X
cloacae	B-X
P99	B-X
.	B-X
They	B-X
sulfonylate	B-X
the	B-X
active	B-X
site	B-X
serine	B-X
residue	B-X
to	B-X
form	B-X
a	B-X
sulfonate	B-X
ester	B-X
which	B-X
subsequently	B-X
undergoes	B-X
C-O	B-X
bond	B-X
fission	B-X
and	B-X
formation	B-X
of	B-X
a	B-X
dehydroalanine	B-X
residue	B-X
by	B-X
elimination	B-X
of	B-X
the	B-X
sulfonate	B-X
anion	B-X
as	B-X
shown	B-X
by	B-X
electrospray	B-X
ionization	B-X
mass	B-X
spectroscopy	B-X
.	B-X
The	B-X
analogous	B-X
N-acyl	B-X
beta-lactams	B-X
are	B-X
substrates	B-X
for	B-X
beta-lactamase	B-X
and	B-X
undergo	B-X
enzyme-catalyzed	B-X
hydrolysis	B-X
presumably	B-X
by	B-X
the	B-X
normal	B-X
acylation-deacylation	B-X
process	B-X
.	B-X
The	B-X
rates	B-X
of	B-X
acylation	B-X
of	B-X
the	B-X
enzyme	B-X
by	B-X
the	B-X
beta-lactams	B-X
,	B-X
measured	B-X
by	B-X
the	B-X
second-order	B-X
rate	B-X
constant	B-X
for	B-X
hydrolysis	B-X
,	B-X
kcat/K	B-X
(	B-X
m	B-X
)	B-X
,	B-X
and	B-X
those	B-X
of	B-X
sulfonylation	B-X
by	B-X
the	B-X
beta-sultams	B-X
,	B-X
measured	B-X
by	B-X
the	B-X
second-order	B-X
rate	B-X
constant	B-X
for	B-X
inactivation	B-X
,	B-X
k	B-X
(	B-X
i	B-X
)	B-X
,	B-X
both	B-X
show	B-X
a	B-X
similar	B-X
pH	B-X
dependence	B-X
to	B-X
that	B-X
exhibited	B-X
by	B-X
the	B-X
beta-lactamase-catalyzed	B-X
hydrolysis	B-X
of	B-X
beta-lactam	B-X
antibiotics	B-X
.	B-X
Electron-withdrawing	B-X
groups	B-X
in	B-X
the	B-X
aryl	B-X
residue	B-X
of	B-X
the	B-X
leaving	B-X
group	B-X
of	B-X
N-aroyl	B-X
beta-lactams	B-X
increase	B-X
the	B-X
rate	B-X
of	B-X
alkaline	B-X
hydrolysis	B-X
and	B-X
give	B-X
a	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
of	B-X
-0.55	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
late	B-X
transition	B-X
state	B-X
for	B-X
rate-limiting	B-X
formation	B-X
of	B-X
the	B-X
tetrahedral	B-X
intermediate	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
corresponding	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
for	B-X
the	B-X
beta-lactamase-catalyzed	B-X
hydrolysis	B-X
of	B-X
the	B-X
same	B-X
substrates	B-X
is	B-X
-0.06	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
earlier	B-X
transition	B-X
state	B-X
for	B-X
the	B-X
enzyme-catalyzed	B-X
reaction	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
although	B-X
the	B-X
Bronsted	B-X
beta	B-X
(	B-X
lg	B-X
)	B-X
for	B-X
the	B-X
alkaline	B-X
hydrolysis	B-X
of	B-X
N-aroyl	B-X
beta-sultams	B-X
is	B-X
-0.73	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
for	B-X
the	B-X
beta-lactams	B-X
,	B-X
that	B-X
for	B-X
the	B-X
sulfonylation	B-X
of	B-X
beta-lactamase	B-X
by	B-X
these	B-X
compounds	B-X
is	B-X
-1.46	B-X
,	B-X
compatible	B-X
with	B-X
significant	B-X
amide	B-X
anion	B-X
expulsion/S-N	B-X
fission	B-X
in	B-X
the	B-X
transition	B-X
state	B-X
.	B-X
In	B-X
this	B-X
case	B-X
,	B-X
the	B-X
enzyme	B-X
reaction	B-X
displays	B-X
a	B-X
later	B-X
transition	B-X
state	B-X
compared	B-X
with	B-X
hydroxide-ion-catalyzed	B-X
hydrolysis	B-X
of	B-X
the	B-X
beta-sultam	B-X
.	B-X

Atorvastatin	O
desensitizes	O
beta	O
-	O
adrenergic	O
signaling	O
in	O
cardiac	O
myocytes	O
via	O
reduced	O
isoprenylation	O
of	O
G	O
-	O
protein	O
gamma	O
-	O
subunits	O
.	O
<EOS>	B-X
Statins	B-X
exert	B-X
pleiotropic	B-X
,	B-X
cholesterol-independent	B-X
effects	B-X
by	B-X
reducing	B-X
isoprenylation	B-X
of	B-X
monomeric	B-X
GTPases	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
statins	B-X
also	B-X
reduce	B-X
isoprenylation	B-X
of	B-X
gamma-subunits	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
and	B-X
thereby	B-X
affect	B-X
beta-adrenergic	B-X
signaling	B-X
and	B-X
regulation	B-X
of	B-X
force	B-X
in	B-X
cardiac	B-X
myocytes	B-X
.	B-X
Neonatal	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
(	B-X
NRCM	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
atorvastatin	B-X
(	B-X
0.1-10	B-X
micromol/l	B-X
;	B-X
12-48	B-X
h	B-X
)	B-X
and	B-X
examined	B-X
for	B-X
adenylyl	B-X
cyclase	B-X
regulating	B-X
G-protein	B-X
alpha-	B-X
(	B-X
Galpha	B-X
)	B-X
,	B-X
beta-	B-X
(	B-X
Gbeta	B-X
)	B-X
,	B-X
and	B-X
gamma-	B-X
(	B-X
Ggamma	B-X
)	B-X
subunits	B-X
and	B-X
cAMP	B-X
accumulation	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
a	B-X
second	B-X
band	B-X
of	B-X
Ggamma3	B-X
with	B-X
a	B-X
lower	B-X
apparent	B-X
molecular	B-X
weight	B-X
appeared	B-X
in	B-X
cytosol	B-X
and	B-X
particulate	B-X
fractions	B-X
that	B-X
was	B-X
absent	B-X
in	B-X
vehicle-treated	B-X
NRCM	B-X
,	B-X
but	B-X
also	B-X
seen	B-X
after	B-X
GGTI-298	B-X
,	B-X
a	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
Gbeta	B-X
accumulated	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
total	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
was	B-X
reduced	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
the	B-X
cAMP-increasing	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
reduced	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
positive	B-X
inotropic	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
desensitized	B-X
and	B-X
reduced	B-X
after	B-X
treatment	B-X
with	B-X
atorvastatin	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

Statins	O
exert	O
pleiotropic	O
,	O
cholesterol	O
-	O
independent	O
effects	O
by	O
reducing	O
isoprenylation	O
of	O
monomeric	O
GTPases	O
.	O
<EOS>	B-X
Statins	B-X
exert	B-X
pleiotropic	B-X
,	B-X
cholesterol-independent	B-X
effects	B-X
by	B-X
reducing	B-X
isoprenylation	B-X
of	B-X
monomeric	B-X
GTPases	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
statins	B-X
also	B-X
reduce	B-X
isoprenylation	B-X
of	B-X
gamma-subunits	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
and	B-X
thereby	B-X
affect	B-X
beta-adrenergic	B-X
signaling	B-X
and	B-X
regulation	B-X
of	B-X
force	B-X
in	B-X
cardiac	B-X
myocytes	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
atorvastatin	B-X
were	B-X
abolished	B-X
by	B-X
mevalonate	B-X
and/or	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
farnesyl	B-X
pyrophosphate	B-X
or	B-X
squalene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

Here	O
we	O
examined	O
whether	O
statins	O
also	O
reduce	O
isoprenylation	O
of	O
gamma	O
-	O
subunits	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
and	O
thereby	O
affect	O
beta	O
-	O
adrenergic	O
signaling	O
and	O
regulation	O
of	O
force	O
in	O
cardiac	O
myocytes	O
.	O
<EOS>	B-X
Statins	B-X
exert	B-X
pleiotropic	B-X
,	B-X
cholesterol-independent	B-X
effects	B-X
by	B-X
reducing	B-X
isoprenylation	B-X
of	B-X
monomeric	B-X
GTPases	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
statins	B-X
also	B-X
reduce	B-X
isoprenylation	B-X
of	B-X
gamma-subunits	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
and	B-X
thereby	B-X
affect	B-X
beta-adrenergic	B-X
signaling	B-X
and	B-X
regulation	B-X
of	B-X
force	B-X
in	B-X
cardiac	B-X
myocytes	B-X
.	B-X
Neonatal	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
(	B-X
NRCM	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
atorvastatin	B-X
(	B-X
0.1-10	B-X
micromol/l	B-X
;	B-X
12-48	B-X
h	B-X
)	B-X
and	B-X
examined	B-X
for	B-X
adenylyl	B-X
cyclase	B-X
regulating	B-X
G-protein	B-X
alpha-	B-X
(	B-X
Galpha	B-X
)	B-X
,	B-X
beta-	B-X
(	B-X
Gbeta	B-X
)	B-X
,	B-X
and	B-X
gamma-	B-X
(	B-X
Ggamma	B-X
)	B-X
subunits	B-X
and	B-X
cAMP	B-X
accumulation	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
a	B-X
second	B-X
band	B-X
of	B-X
Ggamma3	B-X
with	B-X
a	B-X
lower	B-X
apparent	B-X
molecular	B-X
weight	B-X
appeared	B-X
in	B-X
cytosol	B-X
and	B-X
particulate	B-X
fractions	B-X
that	B-X
was	B-X
absent	B-X
in	B-X
vehicle-treated	B-X
NRCM	B-X
,	B-X
but	B-X
also	B-X
seen	B-X
after	B-X
GGTI-298	B-X
,	B-X
a	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
Gbeta	B-X
accumulated	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
total	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
was	B-X
reduced	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
the	B-X
cAMP-increasing	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
reduced	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
positive	B-X
inotropic	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
desensitized	B-X
and	B-X
reduced	B-X
after	B-X
treatment	B-X
with	B-X
atorvastatin	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

Neonatal	O
rat	O
cardiac	O
myocytes	O
(	O
NRCM	O
)	O
were	O
treated	O
with	O
atorvastatin	O
(	O
0	O
.	O
1	O
-	O
10	O
micromol	O
/	O
l	O
;	O
12	O
-	O
48	O
h	O
)	O
and	O
examined	O
for	O
adenylyl	O
cyclase	O
regulating	O
G	O
-	O
protein	O
alpha	O
-	O
(	O
Galpha	O
)	O
,	O
beta	O
-	O
(	O
Gbeta	O
)	O
,	O
and	O
gamma	O
-	O
(	O
Ggamma	O
)	O
subunits	O
and	O
cAMP	O
accumulation	O
.	O

Engineered	O
heart	O
tissue	O
(	O
EHT	O
)	O
from	O
NRCM	O
was	O
used	O
to	O
evaluate	O
contractile	O
consequences	O
.	O
<EOS>	B-X
Neonatal	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
(	B-X
NRCM	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
atorvastatin	B-X
(	B-X
0.1-10	B-X
micromol/l	B-X
;	B-X
12-48	B-X
h	B-X
)	B-X
and	B-X
examined	B-X
for	B-X
adenylyl	B-X
cyclase	B-X
regulating	B-X
G-protein	B-X
alpha-	B-X
(	B-X
Galpha	B-X
)	B-X
,	B-X
beta-	B-X
(	B-X
Gbeta	B-X
)	B-X
,	B-X
and	B-X
gamma-	B-X
(	B-X
Ggamma	B-X
)	B-X
subunits	B-X
and	B-X
cAMP	B-X
accumulation	B-X
.	B-X
Engineered	B-X
heart	B-X
tissue	B-X
(	B-X
EHT	B-X
)	B-X
from	B-X
NRCM	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
contractile	B-X
consequences	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
a	B-X
second	B-X
band	B-X
of	B-X
Ggamma3	B-X
with	B-X
a	B-X
lower	B-X
apparent	B-X
molecular	B-X
weight	B-X
appeared	B-X
in	B-X
cytosol	B-X
and	B-X
particulate	B-X
fractions	B-X
that	B-X
was	B-X
absent	B-X
in	B-X
vehicle-treated	B-X
NRCM	B-X
,	B-X
but	B-X
also	B-X
seen	B-X
after	B-X
GGTI-298	B-X
,	B-X
a	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
the	B-X
cAMP-increasing	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
reduced	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

In	O
atorvastatin	O
-	O
treated	O
NRCM	O
,	O
a	O
second	O
band	O
of	O
Ggamma3	B-Protein
with	O
a	O
lower	O
apparent	O
molecular	O
weight	O
appeared	O
in	O
cytosol	O
and	O
particulate	O
fractions	O
that	O
was	O
absent	O
in	O
vehicle	O
-	O
treated	O
NRCM	O
,	O
but	O
also	O
seen	O
after	O
GGTI	O
-	O
298	O
,	O
a	O
geranylgeranyl	O
transferase	O
inhibitor	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
statins	B-X
also	B-X
reduce	B-X
isoprenylation	B-X
of	B-X
gamma-subunits	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
and	B-X
thereby	B-X
affect	B-X
beta-adrenergic	B-X
signaling	B-X
and	B-X
regulation	B-X
of	B-X
force	B-X
in	B-X
cardiac	B-X
myocytes	B-X
.	B-X
Neonatal	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
(	B-X
NRCM	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
atorvastatin	B-X
(	B-X
0.1-10	B-X
micromol/l	B-X
;	B-X
12-48	B-X
h	B-X
)	B-X
and	B-X
examined	B-X
for	B-X
adenylyl	B-X
cyclase	B-X
regulating	B-X
G-protein	B-X
alpha-	B-X
(	B-X
Galpha	B-X
)	B-X
,	B-X
beta-	B-X
(	B-X
Gbeta	B-X
)	B-X
,	B-X
and	B-X
gamma-	B-X
(	B-X
Ggamma	B-X
)	B-X
subunits	B-X
and	B-X
cAMP	B-X
accumulation	B-X
.	B-X
Engineered	B-X
heart	B-X
tissue	B-X
(	B-X
EHT	B-X
)	B-X
from	B-X
NRCM	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
contractile	B-X
consequences	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
a	B-X
second	B-X
band	B-X
of	B-X
Ggamma3	B-X
with	B-X
a	B-X
lower	B-X
apparent	B-X
molecular	B-X
weight	B-X
appeared	B-X
in	B-X
cytosol	B-X
and	B-X
particulate	B-X
fractions	B-X
that	B-X
was	B-X
absent	B-X
in	B-X
vehicle-treated	B-X
NRCM	B-X
,	B-X
but	B-X
also	B-X
seen	B-X
after	B-X
GGTI-298	B-X
,	B-X
a	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
Gbeta	B-X
accumulated	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
total	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
was	B-X
reduced	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
the	B-X
cAMP-increasing	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
reduced	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
positive	B-X
inotropic	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
desensitized	B-X
and	B-X
reduced	B-X
after	B-X
treatment	B-X
with	B-X
atorvastatin	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
atorvastatin	B-X
were	B-X
abolished	B-X
by	B-X
mevalonate	B-X
and/or	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
farnesyl	B-X
pyrophosphate	B-X
or	B-X
squalene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

In	O
parallel	O
,	O
Gbeta	O
accumulated	O
in	O
the	O
cytosol	O
and	O
total	O
cellular	O
content	O
of	O
Galphas	O
was	O
reduced	O
.	O
<EOS>	B-X
Neonatal	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
(	B-X
NRCM	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
atorvastatin	B-X
(	B-X
0.1-10	B-X
micromol/l	B-X
;	B-X
12-48	B-X
h	B-X
)	B-X
and	B-X
examined	B-X
for	B-X
adenylyl	B-X
cyclase	B-X
regulating	B-X
G-protein	B-X
alpha-	B-X
(	B-X
Galpha	B-X
)	B-X
,	B-X
beta-	B-X
(	B-X
Gbeta	B-X
)	B-X
,	B-X
and	B-X
gamma-	B-X
(	B-X
Ggamma	B-X
)	B-X
subunits	B-X
and	B-X
cAMP	B-X
accumulation	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
a	B-X
second	B-X
band	B-X
of	B-X
Ggamma3	B-X
with	B-X
a	B-X
lower	B-X
apparent	B-X
molecular	B-X
weight	B-X
appeared	B-X
in	B-X
cytosol	B-X
and	B-X
particulate	B-X
fractions	B-X
that	B-X
was	B-X
absent	B-X
in	B-X
vehicle-treated	B-X
NRCM	B-X
,	B-X
but	B-X
also	B-X
seen	B-X
after	B-X
GGTI-298	B-X
,	B-X
a	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
Gbeta	B-X
accumulated	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
total	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
was	B-X
reduced	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
the	B-X
cAMP-increasing	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
reduced	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
positive	B-X
inotropic	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
desensitized	B-X
and	B-X
reduced	B-X
after	B-X
treatment	B-X
with	B-X
atorvastatin	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

In	O
atorvastatin	O
-	O
treated	O
NRCM	O
,	O
the	O
cAMP	O
-	O
increasing	O
effect	O
of	O
isoprenaline	O
was	O
reduced	O
.	O
<EOS>	B-X
Statins	B-X
exert	B-X
pleiotropic	B-X
,	B-X
cholesterol-independent	B-X
effects	B-X
by	B-X
reducing	B-X
isoprenylation	B-X
of	B-X
monomeric	B-X
GTPases	B-X
.	B-X
Neonatal	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
(	B-X
NRCM	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
atorvastatin	B-X
(	B-X
0.1-10	B-X
micromol/l	B-X
;	B-X
12-48	B-X
h	B-X
)	B-X
and	B-X
examined	B-X
for	B-X
adenylyl	B-X
cyclase	B-X
regulating	B-X
G-protein	B-X
alpha-	B-X
(	B-X
Galpha	B-X
)	B-X
,	B-X
beta-	B-X
(	B-X
Gbeta	B-X
)	B-X
,	B-X
and	B-X
gamma-	B-X
(	B-X
Ggamma	B-X
)	B-X
subunits	B-X
and	B-X
cAMP	B-X
accumulation	B-X
.	B-X
Engineered	B-X
heart	B-X
tissue	B-X
(	B-X
EHT	B-X
)	B-X
from	B-X
NRCM	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
contractile	B-X
consequences	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
a	B-X
second	B-X
band	B-X
of	B-X
Ggamma3	B-X
with	B-X
a	B-X
lower	B-X
apparent	B-X
molecular	B-X
weight	B-X
appeared	B-X
in	B-X
cytosol	B-X
and	B-X
particulate	B-X
fractions	B-X
that	B-X
was	B-X
absent	B-X
in	B-X
vehicle-treated	B-X
NRCM	B-X
,	B-X
but	B-X
also	B-X
seen	B-X
after	B-X
GGTI-298	B-X
,	B-X
a	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
Gbeta	B-X
accumulated	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
total	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
was	B-X
reduced	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
the	B-X
cAMP-increasing	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
reduced	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
positive	B-X
inotropic	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
desensitized	B-X
and	B-X
reduced	B-X
after	B-X
treatment	B-X
with	B-X
atorvastatin	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
atorvastatin	B-X
were	B-X
abolished	B-X
by	B-X
mevalonate	B-X
and/or	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
farnesyl	B-X
pyrophosphate	B-X
or	B-X
squalene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

Likewise	O
,	O
the	O
positive	O
inotropic	O
effect	O
of	O
isoprenaline	O
was	O
desensitized	O
and	O
reduced	O
after	O
treatment	O
with	O
atorvastatin	O
.	O
<EOS>	B-X
Statins	B-X
exert	B-X
pleiotropic	B-X
,	B-X
cholesterol-independent	B-X
effects	B-X
by	B-X
reducing	B-X
isoprenylation	B-X
of	B-X
monomeric	B-X
GTPases	B-X
.	B-X
Neonatal	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
(	B-X
NRCM	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
atorvastatin	B-X
(	B-X
0.1-10	B-X
micromol/l	B-X
;	B-X
12-48	B-X
h	B-X
)	B-X
and	B-X
examined	B-X
for	B-X
adenylyl	B-X
cyclase	B-X
regulating	B-X
G-protein	B-X
alpha-	B-X
(	B-X
Galpha	B-X
)	B-X
,	B-X
beta-	B-X
(	B-X
Gbeta	B-X
)	B-X
,	B-X
and	B-X
gamma-	B-X
(	B-X
Ggamma	B-X
)	B-X
subunits	B-X
and	B-X
cAMP	B-X
accumulation	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
a	B-X
second	B-X
band	B-X
of	B-X
Ggamma3	B-X
with	B-X
a	B-X
lower	B-X
apparent	B-X
molecular	B-X
weight	B-X
appeared	B-X
in	B-X
cytosol	B-X
and	B-X
particulate	B-X
fractions	B-X
that	B-X
was	B-X
absent	B-X
in	B-X
vehicle-treated	B-X
NRCM	B-X
,	B-X
but	B-X
also	B-X
seen	B-X
after	B-X
GGTI-298	B-X
,	B-X
a	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
Gbeta	B-X
accumulated	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
total	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
was	B-X
reduced	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
the	B-X
cAMP-increasing	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
reduced	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
positive	B-X
inotropic	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
desensitized	B-X
and	B-X
reduced	B-X
after	B-X
treatment	B-X
with	B-X
atorvastatin	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
atorvastatin	B-X
were	B-X
abolished	B-X
by	B-X
mevalonate	B-X
and/or	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
farnesyl	B-X
pyrophosphate	B-X
or	B-X
squalene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

The	O
effects	O
of	O
atorvastatin	O
were	O
abolished	O
by	O
mevalonate	O
and	O
/	O
or	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
by	O
farnesyl	O
pyrophosphate	O
or	O
squalene	O
.	O
<EOS>	B-X
Human	B-X
sebum	B-X
also	B-X
contains	B-X
13	B-X
%	B-X
squalene	B-X
as	B-X
one	B-X
of	B-X
its	B-X
major	B-X
constituents	B-X
.	B-X
Squalane	B-X
is	B-X
a	B-X
saturated	B-X
derivative	B-X
of	B-X
squalene	B-X
and	B-X
also	B-X
found	B-X
in	B-X
these	B-X
sources	B-X
.	B-X
Interest	B-X
in	B-X
squalene	B-X
has	B-X
been	B-X
raised	B-X
after	B-X
its	B-X
characterization	B-X
in	B-X
shark	B-X
liver	B-X
oil	B-X
which	B-X
is	B-X
used	B-X
as	B-X
a	B-X
traditional	B-X
medicine	B-X
for	B-X
decades	B-X
.	B-X
Several	B-X
studies	B-X
exhibited	B-X
results	B-X
that	B-X
prove	B-X
certain	B-X
bioactivities	B-X
for	B-X
squalene	B-X
and	B-X
squalane	B-X
.	B-X
According	B-X
to	B-X
promising	B-X
results	B-X
from	B-X
recent	B-X
studies	B-X
,	B-X
squalene	B-X
and	B-X
squalane	B-X
are	B-X
considered	B-X
important	B-X
substances	B-X
in	B-X
practical	B-X
and	B-X
clinical	B-X
uses	B-X
with	B-X
a	B-X
huge	B-X
potential	B-X
in	B-X
nutraceutical	B-X
and	B-X
pharmaceutical	B-X
industries	B-X
.	B-X

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
show	O
that	O
atorvastatin	O
desensitizes	O
NRCM	O
to	O
beta	O
-	O
adrenergic	O
stimulation	O
by	O
a	O
mechanism	O
that	O
involves	O
reduced	O
isoprenylation	O
of	O
Ggamma	O
and	O
subsequent	O
reductions	O
in	O
the	O
cellular	O
content	O
of	O
Galphas	O
.	O
<EOS>	B-X
Statins	B-X
exert	B-X
pleiotropic	B-X
,	B-X
cholesterol-independent	B-X
effects	B-X
by	B-X
reducing	B-X
isoprenylation	B-X
of	B-X
monomeric	B-X
GTPases	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
statins	B-X
also	B-X
reduce	B-X
isoprenylation	B-X
of	B-X
gamma-subunits	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
and	B-X
thereby	B-X
affect	B-X
beta-adrenergic	B-X
signaling	B-X
and	B-X
regulation	B-X
of	B-X
force	B-X
in	B-X
cardiac	B-X
myocytes	B-X
.	B-X
Neonatal	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
(	B-X
NRCM	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
atorvastatin	B-X
(	B-X
0.1-10	B-X
micromol/l	B-X
;	B-X
12-48	B-X
h	B-X
)	B-X
and	B-X
examined	B-X
for	B-X
adenylyl	B-X
cyclase	B-X
regulating	B-X
G-protein	B-X
alpha-	B-X
(	B-X
Galpha	B-X
)	B-X
,	B-X
beta-	B-X
(	B-X
Gbeta	B-X
)	B-X
,	B-X
and	B-X
gamma-	B-X
(	B-X
Ggamma	B-X
)	B-X
subunits	B-X
and	B-X
cAMP	B-X
accumulation	B-X
.	B-X
Engineered	B-X
heart	B-X
tissue	B-X
(	B-X
EHT	B-X
)	B-X
from	B-X
NRCM	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
contractile	B-X
consequences	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
a	B-X
second	B-X
band	B-X
of	B-X
Ggamma3	B-X
with	B-X
a	B-X
lower	B-X
apparent	B-X
molecular	B-X
weight	B-X
appeared	B-X
in	B-X
cytosol	B-X
and	B-X
particulate	B-X
fractions	B-X
that	B-X
was	B-X
absent	B-X
in	B-X
vehicle-treated	B-X
NRCM	B-X
,	B-X
but	B-X
also	B-X
seen	B-X
after	B-X
GGTI-298	B-X
,	B-X
a	B-X
geranylgeranyl	B-X
transferase	B-X
inhibitor	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
Gbeta	B-X
accumulated	B-X
in	B-X
the	B-X
cytosol	B-X
and	B-X
total	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
was	B-X
reduced	B-X
.	B-X
In	B-X
atorvastatin-treated	B-X
NRCM	B-X
,	B-X
the	B-X
cAMP-increasing	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
reduced	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
positive	B-X
inotropic	B-X
effect	B-X
of	B-X
isoprenaline	B-X
was	B-X
desensitized	B-X
and	B-X
reduced	B-X
after	B-X
treatment	B-X
with	B-X
atorvastatin	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
atorvastatin	B-X
were	B-X
abolished	B-X
by	B-X
mevalonate	B-X
and/or	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
farnesyl	B-X
pyrophosphate	B-X
or	B-X
squalene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
atorvastatin	B-X
desensitizes	B-X
NRCM	B-X
to	B-X
beta-adrenergic	B-X
stimulation	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
reduced	B-X
isoprenylation	B-X
of	B-X
Ggamma	B-X
and	B-X
subsequent	B-X
reductions	B-X
in	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
Galphas	B-X
.	B-X

The	O
proprotein	O
convertase	O
(	O
PC	O
)	O
PCSK9	B-Protein
is	O
inactivated	O
by	O
furin	B-Protein
and	O
/	O
or	O
PC5	B-Protein
/	O
6A	B-Protein
:	O
functional	O
consequences	O
of	O
natural	O
mutations	O
and	O
post	O
-	O
translational	O
modifications	O
.	O
<EOS>	B-X
PCSK9	B-X
is	B-X
the	B-X
ninth	B-X
member	B-X
of	B-X
the	B-X
proprotein	B-X
convertase	B-X
(	B-X
PC	B-X
)	B-X
family	B-X
.	B-X
Some	B-X
of	B-X
its	B-X
natural	B-X
mutations	B-X
have	B-X
been	B-X
genetically	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
familial	B-X
hyper-	B-X
or	B-X
hypocholesterolemia	B-X
.	B-X
The	B-X
exact	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
PCSK9	B-X
is	B-X
not	B-X
clear	B-X
,	B-X
although	B-X
it	B-X
is	B-X
known	B-X
to	B-X
enhance	B-X
the	B-X
intracellular	B-X
degradation	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
in	B-X
acidic	B-X
compartments	B-X
,	B-X
likely	B-X
the	B-X
endosomes/lysosomes	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
post-translational	B-X
modifications	B-X
of	B-X
PCSK9	B-X
and	B-X
show	B-X
that	B-X
it	B-X
is	B-X
sulfated	B-X
within	B-X
its	B-X
prosegment	B-X
at	B-X
Tyr38	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
susceptibility	B-X
of	B-X
PCSK9	B-X
to	B-X
proteolytic	B-X
cleavage	B-X
by	B-X
the	B-X
other	B-X
members	B-X
of	B-X
the	B-X
PC	B-X
family	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
natural	B-X
gain-of-function	B-X
mutations	B-X
R218S	B-X
,	B-X
F216L	B-X
,	B-X
and	B-X
D374Y	B-X
associated	B-X
with	B-X
hypercholesterolemia	B-X
result	B-X
in	B-X
total	B-X
or	B-X
partial	B-X
loss	B-X
of	B-X
furin/PC5/6A	B-X
processing	B-X
at	B-X
the	B-X
motif	B-X
RFHR218	B-X
downward	B-X
arrow	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss-of-function	B-X
mutations	B-X
A443T	B-X
and	B-X
C679X	B-X
lead	B-X
either	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
trans-Golgi	B-X
network/recycling	B-X
endosome	B-X
localization	B-X
and	B-X
an	B-X
enhanced	B-X
susceptibility	B-X
to	B-X
furin	B-X
cleavage	B-X
(	B-X
A443T	B-X
)	B-X
or	B-X
to	B-X
the	B-X
inability	B-X
of	B-X
PCSK9	B-X
to	B-X
exit	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
C679X	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
report	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
native	B-X
and	B-X
furin-like	B-X
cleaved	B-X
forms	B-X
of	B-X
PCSK9	B-X
in	B-X
circulating	B-X
human	B-X
plasma	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PCSK9	B-X
levels	B-X
are	B-X
finely	B-X
regulated	B-X
by	B-X
the	B-X
basic	B-X
amino	B-X
acid	B-X
convertases	B-X
furin	B-X
and	B-X
PC5/6A	B-X
.	B-X

PCSK9	B-Protein
is	O
the	O
ninth	O
member	O
of	O
the	O
proprotein	O
convertase	O
(	O
PC	O
)	O
family	O
.	O
<EOS>	B-X
PCSK9	B-X
is	B-X
the	B-X
ninth	B-X
member	B-X
of	B-X
the	B-X
proprotein	B-X
convertase	B-X
(	B-X
PC	B-X
)	B-X
family	B-X
.	B-X
The	B-X
exact	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
PCSK9	B-X
is	B-X
not	B-X
clear	B-X
,	B-X
although	B-X
it	B-X
is	B-X
known	B-X
to	B-X
enhance	B-X
the	B-X
intracellular	B-X
degradation	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
in	B-X
acidic	B-X
compartments	B-X
,	B-X
likely	B-X
the	B-X
endosomes/lysosomes	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
post-translational	B-X
modifications	B-X
of	B-X
PCSK9	B-X
and	B-X
show	B-X
that	B-X
it	B-X
is	B-X
sulfated	B-X
within	B-X
its	B-X
prosegment	B-X
at	B-X
Tyr38	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
susceptibility	B-X
of	B-X
PCSK9	B-X
to	B-X
proteolytic	B-X
cleavage	B-X
by	B-X
the	B-X
other	B-X
members	B-X
of	B-X
the	B-X
PC	B-X
family	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
natural	B-X
gain-of-function	B-X
mutations	B-X
R218S	B-X
,	B-X
F216L	B-X
,	B-X
and	B-X
D374Y	B-X
associated	B-X
with	B-X
hypercholesterolemia	B-X
result	B-X
in	B-X
total	B-X
or	B-X
partial	B-X
loss	B-X
of	B-X
furin/PC5/6A	B-X
processing	B-X
at	B-X
the	B-X
motif	B-X
RFHR218	B-X
downward	B-X
arrow	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss-of-function	B-X
mutations	B-X
A443T	B-X
and	B-X
C679X	B-X
lead	B-X
either	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
trans-Golgi	B-X
network/recycling	B-X
endosome	B-X
localization	B-X
and	B-X
an	B-X
enhanced	B-X
susceptibility	B-X
to	B-X
furin	B-X
cleavage	B-X
(	B-X
A443T	B-X
)	B-X
or	B-X
to	B-X
the	B-X
inability	B-X
of	B-X
PCSK9	B-X
to	B-X
exit	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
C679X	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
report	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
native	B-X
and	B-X
furin-like	B-X
cleaved	B-X
forms	B-X
of	B-X
PCSK9	B-X
in	B-X
circulating	B-X
human	B-X
plasma	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PCSK9	B-X
levels	B-X
are	B-X
finely	B-X
regulated	B-X
by	B-X
the	B-X
basic	B-X
amino	B-X
acid	B-X
convertases	B-X
furin	B-X
and	B-X
PC5/6A	B-X
.	B-X

Some	O
of	O
its	O
natural	O
mutations	O
have	O
been	O
genetically	O
associated	O
with	O
the	O
development	O
of	O
a	O
dominant	O
form	O
of	O
familial	O
hyper	O
-	O
or	O
hypocholesterolemia	O
.	O
<EOS>	B-X
Multiple	B-X
studies	B-X
have	B-X
demonstrated	B-X
hypocholesterolemia	B-X
in	B-X
sepsis	B-X
,	B-X
the	B-X
degree	B-X
of	B-X
which	B-X
is	B-X
an	B-X
excellent	B-X
prognosticator	B-X
of	B-X
poor	B-X
outcomes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
clinical	B-X
significance	B-X
of	B-X
hypocholesterolemia	B-X
has	B-X
been	B-X
largely	B-X
unrecognized	B-X
.	B-X
Low	B-X
plasma	B-X
concentrations	B-X
are	B-X
associated	B-X
with	B-X
wider	B-X
changes	B-X
in	B-X
cholesterol	B-X
metabolism	B-X
and	B-X
its	B-X
functional	B-X
roles	B-X
,	B-X
and	B-X
these	B-X
appear	B-X
to	B-X
play	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
sepsis	B-X
pathophysiology	B-X
.	B-X
Risk	B-X
factors	B-X
of	B-X
ICH	B-X
are	B-X
hypertension	B-X
,	B-X
current	B-X
smoking	B-X
,	B-X
excessive	B-X
alcohol	B-X
consumption	B-X
,	B-X
hypocholesterolemia	B-X
,	B-X
and	B-X
drugs	B-X
.	B-X
As	B-X
non-vitamin	B-X
K	B-X
antagonist	B-X
oral	B-X
anticoagulants	B-X
(	B-X
NOACs	B-X
)	B-X
are	B-X
currently	B-X
replacing	B-X
warfarin	B-X
,	B-X
management	B-X
of	B-X
NOAC-associated	B-X
ICH	B-X
has	B-X
become	B-X
an	B-X
emerging	B-X
issue	B-X
.	B-X

The	O
exact	O
mechanism	O
of	O
action	O
of	O
PCSK9	B-Protein
is	O
not	O
clear	O
,	O
although	O
it	O
is	O
known	O
to	O
enhance	O
the	O
intracellular	O
degradation	O
of	O
the	O
low	B-Protein
density	I-Protein
lipoprotein	I-Protein
(	I-Protein
LDL	I-Protein
)	I-Protein
receptor	I-Protein
in	O
acidic	O
compartments	O
,	O
likely	O
the	O
endosomes	O
/	O
lysosomes	O
.	O
<EOS>	B-X
Our	B-X
primary	B-X
objective	B-X
is	B-X
to	B-X
review	B-X
the	B-X
most	B-X
recent	B-X
findings	B-X
on	B-X
the	B-X
biology	B-X
of	B-X
PCSK9	B-X
and	B-X
on	B-X
two	B-X
key	B-X
aspects	B-X
of	B-X
PCSK9	B-X
inhibition	B-X
beyond	B-X
LDL	B-X
control	B-X
of	B-X
great	B-X
clinical	B-X
relevance	B-X
:	B-X
the	B-X
regulation	B-X
of	B-X
lipoprotein	B-X
(	B-X
a	B-X
)	B-X
circulating	B-X
levels	B-X
by	B-X
PCSK9	B-X
inhibitors	B-X
and	B-X
the	B-X
putative	B-X
diabetogenic	B-X
effects	B-X
of	B-X
these	B-X
novel	B-X
therapies	B-X
.	B-X
Proprotein	B-X
convertase	B-X
subtilisin	B-X
kexin	B-X
9	B-X
(	B-X
PCSK9	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
low-density	B-X
lipoprotein	B-X
receptor	B-X
levels	B-X
and	B-X
LDL-cholesterol	B-X
levels	B-X
.	B-X
Loss-of-function	B-X
mutations	B-X
in	B-X
PCSK9	B-X
gene	B-X
are	B-X
associated	B-X
with	B-X
hypocholesterolaemia	B-X
and	B-X
protection	B-X
against	B-X
cardiovascular	B-X
disease	B-X
,	B-X
identifying	B-X
PCSK9	B-X
inhibition	B-X
as	B-X
a	B-X
valid	B-X
therapeutic	B-X
approach	B-X
to	B-X
manage	B-X
hypercholesterolaemia	B-X
and	B-X
related	B-X
diseases	B-X
.	B-X
Although	B-X
PCSK9	B-X
is	B-X
expressed	B-X
mainly	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
it	B-X
is	B-X
present	B-X
also	B-X
in	B-X
other	B-X
tissues	B-X
and	B-X
organs	B-X
with	B-X
specific	B-X
functions	B-X
,	B-X
raising	B-X
the	B-X
question	B-X
of	B-X
whether	B-X
a	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
PCSK9	B-X
to	B-X
treat	B-X
hypercholesterolaemia	B-X
and	B-X
associated	B-X
cardiovascular	B-X
diseases	B-X
might	B-X
be	B-X
helpful	B-X
or	B-X
deleterious	B-X
in	B-X
non-hepatic	B-X
tissues	B-X
.	B-X
For	B-X
example	B-X
,	B-X
PCSK9	B-X
is	B-X
expressed	B-X
in	B-X
the	B-X
vascular	B-X
wall	B-X
,	B-X
in	B-X
the	B-X
kidneys	B-X
,	B-X
and	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
where	B-X
it	B-X
was	B-X
proposed	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
development	B-X
,	B-X
neurocognitive	B-X
process	B-X
,	B-X
and	B-X
neuronal	B-X
apoptosis	B-X
.	B-X
A	B-X
link	B-X
between	B-X
PCSK9	B-X
and	B-X
immunity	B-X
was	B-X
also	B-X
proposed	B-X
as	B-X
both	B-X
sepsis	B-X
and	B-X
viral	B-X
infections	B-X
are	B-X
differentially	B-X
affected	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
PCSK9	B-X
.	B-X
Despite	B-X
the	B-X
increasing	B-X
number	B-X
of	B-X
observations	B-X
,	B-X
the	B-X
debate	B-X
on	B-X
the	B-X
exact	B-X
roles	B-X
of	B-X
PCSK9	B-X
in	B-X
extrahepatic	B-X
tissues	B-X
is	B-X
still	B-X
ongoing	B-X
,	B-X
and	B-X
as	B-X
very	B-X
effective	B-X
drugs	B-X
that	B-X
inhibit	B-X
PCSK9	B-X
have	B-X
become	B-X
available	B-X
to	B-X
the	B-X
clinician	B-X
,	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
biological	B-X
roles	B-X
of	B-X
PCSK9	B-X
is	B-X
warranted	B-X
.	B-X

We	O
analyzed	O
the	O
post	O
-	O
translational	O
modifications	O
of	O
PCSK9	B-Protein
and	O
show	O
that	O
it	O
is	O
sulfated	O
within	O
its	O
prosegment	O
at	O
Tyr38	O
.	O
<EOS>	B-X
PCSK9	B-X
is	B-X
the	B-X
ninth	B-X
member	B-X
of	B-X
the	B-X
proprotein	B-X
convertase	B-X
(	B-X
PC	B-X
)	B-X
family	B-X
.	B-X
The	B-X
exact	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
PCSK9	B-X
is	B-X
not	B-X
clear	B-X
,	B-X
although	B-X
it	B-X
is	B-X
known	B-X
to	B-X
enhance	B-X
the	B-X
intracellular	B-X
degradation	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
in	B-X
acidic	B-X
compartments	B-X
,	B-X
likely	B-X
the	B-X
endosomes/lysosomes	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
post-translational	B-X
modifications	B-X
of	B-X
PCSK9	B-X
and	B-X
show	B-X
that	B-X
it	B-X
is	B-X
sulfated	B-X
within	B-X
its	B-X
prosegment	B-X
at	B-X
Tyr38	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
susceptibility	B-X
of	B-X
PCSK9	B-X
to	B-X
proteolytic	B-X
cleavage	B-X
by	B-X
the	B-X
other	B-X
members	B-X
of	B-X
the	B-X
PC	B-X
family	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
natural	B-X
gain-of-function	B-X
mutations	B-X
R218S	B-X
,	B-X
F216L	B-X
,	B-X
and	B-X
D374Y	B-X
associated	B-X
with	B-X
hypercholesterolemia	B-X
result	B-X
in	B-X
total	B-X
or	B-X
partial	B-X
loss	B-X
of	B-X
furin/PC5/6A	B-X
processing	B-X
at	B-X
the	B-X
motif	B-X
RFHR218	B-X
downward	B-X
arrow	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss-of-function	B-X
mutations	B-X
A443T	B-X
and	B-X
C679X	B-X
lead	B-X
either	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
trans-Golgi	B-X
network/recycling	B-X
endosome	B-X
localization	B-X
and	B-X
an	B-X
enhanced	B-X
susceptibility	B-X
to	B-X
furin	B-X
cleavage	B-X
(	B-X
A443T	B-X
)	B-X
or	B-X
to	B-X
the	B-X
inability	B-X
of	B-X
PCSK9	B-X
to	B-X
exit	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
C679X	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
report	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
native	B-X
and	B-X
furin-like	B-X
cleaved	B-X
forms	B-X
of	B-X
PCSK9	B-X
in	B-X
circulating	B-X
human	B-X
plasma	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PCSK9	B-X
levels	B-X
are	B-X
finely	B-X
regulated	B-X
by	B-X
the	B-X
basic	B-X
amino	B-X
acid	B-X
convertases	B-X
furin	B-X
and	B-X
PC5/6A	B-X
.	B-X

We	O
also	O
examined	O
the	O
susceptibility	O
of	O
PCSK9	B-Protein
to	O
proteolytic	O
cleavage	O
by	O
the	O
other	O
members	O
of	O
the	O
PC	O
family	O
.	O
<EOS>	B-X
PCSK9	B-X
is	B-X
the	B-X
ninth	B-X
member	B-X
of	B-X
the	B-X
proprotein	B-X
convertase	B-X
(	B-X
PC	B-X
)	B-X
family	B-X
.	B-X
The	B-X
exact	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
PCSK9	B-X
is	B-X
not	B-X
clear	B-X
,	B-X
although	B-X
it	B-X
is	B-X
known	B-X
to	B-X
enhance	B-X
the	B-X
intracellular	B-X
degradation	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
in	B-X
acidic	B-X
compartments	B-X
,	B-X
likely	B-X
the	B-X
endosomes/lysosomes	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
post-translational	B-X
modifications	B-X
of	B-X
PCSK9	B-X
and	B-X
show	B-X
that	B-X
it	B-X
is	B-X
sulfated	B-X
within	B-X
its	B-X
prosegment	B-X
at	B-X
Tyr38	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
susceptibility	B-X
of	B-X
PCSK9	B-X
to	B-X
proteolytic	B-X
cleavage	B-X
by	B-X
the	B-X
other	B-X
members	B-X
of	B-X
the	B-X
PC	B-X
family	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
natural	B-X
gain-of-function	B-X
mutations	B-X
R218S	B-X
,	B-X
F216L	B-X
,	B-X
and	B-X
D374Y	B-X
associated	B-X
with	B-X
hypercholesterolemia	B-X
result	B-X
in	B-X
total	B-X
or	B-X
partial	B-X
loss	B-X
of	B-X
furin/PC5/6A	B-X
processing	B-X
at	B-X
the	B-X
motif	B-X
RFHR218	B-X
downward	B-X
arrow	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss-of-function	B-X
mutations	B-X
A443T	B-X
and	B-X
C679X	B-X
lead	B-X
either	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
trans-Golgi	B-X
network/recycling	B-X
endosome	B-X
localization	B-X
and	B-X
an	B-X
enhanced	B-X
susceptibility	B-X
to	B-X
furin	B-X
cleavage	B-X
(	B-X
A443T	B-X
)	B-X
or	B-X
to	B-X
the	B-X
inability	B-X
of	B-X
PCSK9	B-X
to	B-X
exit	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
C679X	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
report	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
native	B-X
and	B-X
furin-like	B-X
cleaved	B-X
forms	B-X
of	B-X
PCSK9	B-X
in	B-X
circulating	B-X
human	B-X
plasma	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PCSK9	B-X
levels	B-X
are	B-X
finely	B-X
regulated	B-X
by	B-X
the	B-X
basic	B-X
amino	B-X
acid	B-X
convertases	B-X
furin	B-X
and	B-X
PC5/6A	B-X
.	B-X

The	O
data	O
show	O
that	O
the	O
natural	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
R218S	O
,	O
F216L	O
,	O
and	O
D374Y	O
associated	O
with	O
hypercholesterolemia	O
result	O
in	O
total	O
or	O
partial	O
loss	O
of	O
furin	B-Protein
/	O
PC5	B-Protein
/	O
6A	B-Protein
processing	O
at	O
the	O
motif	O
RFHR218	O
downward	O
arrow	O
.	O
<EOS>	B-X
Some	B-X
of	B-X
its	B-X
natural	B-X
mutations	B-X
have	B-X
been	B-X
genetically	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
familial	B-X
hyper-	B-X
or	B-X
hypocholesterolemia	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
post-translational	B-X
modifications	B-X
of	B-X
PCSK9	B-X
and	B-X
show	B-X
that	B-X
it	B-X
is	B-X
sulfated	B-X
within	B-X
its	B-X
prosegment	B-X
at	B-X
Tyr38	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
natural	B-X
gain-of-function	B-X
mutations	B-X
R218S	B-X
,	B-X
F216L	B-X
,	B-X
and	B-X
D374Y	B-X
associated	B-X
with	B-X
hypercholesterolemia	B-X
result	B-X
in	B-X
total	B-X
or	B-X
partial	B-X
loss	B-X
of	B-X
furin/PC5/6A	B-X
processing	B-X
at	B-X
the	B-X
motif	B-X
RFHR218	B-X
downward	B-X
arrow	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss-of-function	B-X
mutations	B-X
A443T	B-X
and	B-X
C679X	B-X
lead	B-X
either	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
trans-Golgi	B-X
network/recycling	B-X
endosome	B-X
localization	B-X
and	B-X
an	B-X
enhanced	B-X
susceptibility	B-X
to	B-X
furin	B-X
cleavage	B-X
(	B-X
A443T	B-X
)	B-X
or	B-X
to	B-X
the	B-X
inability	B-X
of	B-X
PCSK9	B-X
to	B-X
exit	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
C679X	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
report	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
native	B-X
and	B-X
furin-like	B-X
cleaved	B-X
forms	B-X
of	B-X
PCSK9	B-X
in	B-X
circulating	B-X
human	B-X
plasma	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PCSK9	B-X
levels	B-X
are	B-X
finely	B-X
regulated	B-X
by	B-X
the	B-X
basic	B-X
amino	B-X
acid	B-X
convertases	B-X
furin	B-X
and	B-X
PC5/6A	B-X
.	B-X

In	O
contrast	O
,	O
the	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
A443T	O
and	O
C679X	O
lead	O
either	O
to	O
the	O
lack	O
of	O
trans	O
-	O
Golgi	O
network	O
/	O
recycling	O
endosome	O
localization	O
and	O
an	O
enhanced	O
susceptibility	O
to	O
furin	B-Protein
cleavage	O
(	O
A443T	O
)	O
or	O
to	O
the	O
inability	O
of	O
PCSK9	B-Protein
to	O
exit	O
the	O
endoplasmic	O
reticulum	O
(	O
C679X	O
)	O
.	O

Furthermore	O
,	O
we	O
report	O
the	O
presence	O
of	O
both	O
native	O
and	O
furin	B-Protein
-	O
like	O
cleaved	O
forms	O
of	O
PCSK9	B-Protein
in	O
circulating	O
human	O
plasma	O
.	O
<EOS>	B-X
PCSK9	B-X
is	B-X
the	B-X
ninth	B-X
member	B-X
of	B-X
the	B-X
proprotein	B-X
convertase	B-X
(	B-X
PC	B-X
)	B-X
family	B-X
.	B-X
The	B-X
exact	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
PCSK9	B-X
is	B-X
not	B-X
clear	B-X
,	B-X
although	B-X
it	B-X
is	B-X
known	B-X
to	B-X
enhance	B-X
the	B-X
intracellular	B-X
degradation	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
in	B-X
acidic	B-X
compartments	B-X
,	B-X
likely	B-X
the	B-X
endosomes/lysosomes	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
post-translational	B-X
modifications	B-X
of	B-X
PCSK9	B-X
and	B-X
show	B-X
that	B-X
it	B-X
is	B-X
sulfated	B-X
within	B-X
its	B-X
prosegment	B-X
at	B-X
Tyr38	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
susceptibility	B-X
of	B-X
PCSK9	B-X
to	B-X
proteolytic	B-X
cleavage	B-X
by	B-X
the	B-X
other	B-X
members	B-X
of	B-X
the	B-X
PC	B-X
family	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
natural	B-X
gain-of-function	B-X
mutations	B-X
R218S	B-X
,	B-X
F216L	B-X
,	B-X
and	B-X
D374Y	B-X
associated	B-X
with	B-X
hypercholesterolemia	B-X
result	B-X
in	B-X
total	B-X
or	B-X
partial	B-X
loss	B-X
of	B-X
furin/PC5/6A	B-X
processing	B-X
at	B-X
the	B-X
motif	B-X
RFHR218	B-X
downward	B-X
arrow	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss-of-function	B-X
mutations	B-X
A443T	B-X
and	B-X
C679X	B-X
lead	B-X
either	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
trans-Golgi	B-X
network/recycling	B-X
endosome	B-X
localization	B-X
and	B-X
an	B-X
enhanced	B-X
susceptibility	B-X
to	B-X
furin	B-X
cleavage	B-X
(	B-X
A443T	B-X
)	B-X
or	B-X
to	B-X
the	B-X
inability	B-X
of	B-X
PCSK9	B-X
to	B-X
exit	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
C679X	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
report	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
native	B-X
and	B-X
furin-like	B-X
cleaved	B-X
forms	B-X
of	B-X
PCSK9	B-X
in	B-X
circulating	B-X
human	B-X
plasma	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PCSK9	B-X
levels	B-X
are	B-X
finely	B-X
regulated	B-X
by	B-X
the	B-X
basic	B-X
amino	B-X
acid	B-X
convertases	B-X
furin	B-X
and	B-X
PC5/6A	B-X
.	B-X
The	B-X
latter	B-X
may	B-X
reduce	B-X
the	B-X
lifetime	B-X
of	B-X
this	B-X
proteinase	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
degrade	B-X
the	B-X
cell-surface	B-X
LDL	B-X
receptor	B-X
,	B-X
thereby	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
circulating	B-X
LDL	B-X
cholesterol	B-X
.	B-X

Thus	O
,	O
we	O
propose	O
that	O
PCSK9	B-Protein
levels	O
are	O
finely	O
regulated	O
by	O
the	O
basic	O
amino	O
acid	O
convertases	O
furin	B-Protein
and	O
PC5	B-Protein
/	O
6A	O
.	O
<EOS>	B-X
PCSK9	B-X
is	B-X
the	B-X
ninth	B-X
member	B-X
of	B-X
the	B-X
proprotein	B-X
convertase	B-X
(	B-X
PC	B-X
)	B-X
family	B-X
.	B-X
The	B-X
exact	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
PCSK9	B-X
is	B-X
not	B-X
clear	B-X
,	B-X
although	B-X
it	B-X
is	B-X
known	B-X
to	B-X
enhance	B-X
the	B-X
intracellular	B-X
degradation	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
in	B-X
acidic	B-X
compartments	B-X
,	B-X
likely	B-X
the	B-X
endosomes/lysosomes	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
post-translational	B-X
modifications	B-X
of	B-X
PCSK9	B-X
and	B-X
show	B-X
that	B-X
it	B-X
is	B-X
sulfated	B-X
within	B-X
its	B-X
prosegment	B-X
at	B-X
Tyr38	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
susceptibility	B-X
of	B-X
PCSK9	B-X
to	B-X
proteolytic	B-X
cleavage	B-X
by	B-X
the	B-X
other	B-X
members	B-X
of	B-X
the	B-X
PC	B-X
family	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
natural	B-X
gain-of-function	B-X
mutations	B-X
R218S	B-X
,	B-X
F216L	B-X
,	B-X
and	B-X
D374Y	B-X
associated	B-X
with	B-X
hypercholesterolemia	B-X
result	B-X
in	B-X
total	B-X
or	B-X
partial	B-X
loss	B-X
of	B-X
furin/PC5/6A	B-X
processing	B-X
at	B-X
the	B-X
motif	B-X
RFHR218	B-X
downward	B-X
arrow	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss-of-function	B-X
mutations	B-X
A443T	B-X
and	B-X
C679X	B-X
lead	B-X
either	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
trans-Golgi	B-X
network/recycling	B-X
endosome	B-X
localization	B-X
and	B-X
an	B-X
enhanced	B-X
susceptibility	B-X
to	B-X
furin	B-X
cleavage	B-X
(	B-X
A443T	B-X
)	B-X
or	B-X
to	B-X
the	B-X
inability	B-X
of	B-X
PCSK9	B-X
to	B-X
exit	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
C679X	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
report	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
native	B-X
and	B-X
furin-like	B-X
cleaved	B-X
forms	B-X
of	B-X
PCSK9	B-X
in	B-X
circulating	B-X
human	B-X
plasma	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PCSK9	B-X
levels	B-X
are	B-X
finely	B-X
regulated	B-X
by	B-X
the	B-X
basic	B-X
amino	B-X
acid	B-X
convertases	B-X
furin	B-X
and	B-X
PC5/6A	B-X
.	B-X
The	B-X
latter	B-X
may	B-X
reduce	B-X
the	B-X
lifetime	B-X
of	B-X
this	B-X
proteinase	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
degrade	B-X
the	B-X
cell-surface	B-X
LDL	B-X
receptor	B-X
,	B-X
thereby	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
circulating	B-X
LDL	B-X
cholesterol	B-X
.	B-X

The	O
latter	O
may	O
reduce	O
the	O
lifetime	O
of	O
this	O
proteinase	O
and	O
its	O
ability	O
to	O
degrade	O
the	O
cell	O
-	O
surface	O
LDL	B-Protein
receptor	I-Protein
,	O
thereby	O
regulating	O
the	O
levels	O
of	O
circulating	O
LDL	O
cholesterol	O
.	O
<EOS>	B-X
Some	B-X
of	B-X
its	B-X
natural	B-X
mutations	B-X
have	B-X
been	B-X
genetically	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
familial	B-X
hyper-	B-X
or	B-X
hypocholesterolemia	B-X
.	B-X
The	B-X
exact	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
PCSK9	B-X
is	B-X
not	B-X
clear	B-X
,	B-X
although	B-X
it	B-X
is	B-X
known	B-X
to	B-X
enhance	B-X
the	B-X
intracellular	B-X
degradation	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
in	B-X
acidic	B-X
compartments	B-X
,	B-X
likely	B-X
the	B-X
endosomes/lysosomes	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
natural	B-X
gain-of-function	B-X
mutations	B-X
R218S	B-X
,	B-X
F216L	B-X
,	B-X
and	B-X
D374Y	B-X
associated	B-X
with	B-X
hypercholesterolemia	B-X
result	B-X
in	B-X
total	B-X
or	B-X
partial	B-X
loss	B-X
of	B-X
furin/PC5/6A	B-X
processing	B-X
at	B-X
the	B-X
motif	B-X
RFHR218	B-X
downward	B-X
arrow	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss-of-function	B-X
mutations	B-X
A443T	B-X
and	B-X
C679X	B-X
lead	B-X
either	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
trans-Golgi	B-X
network/recycling	B-X
endosome	B-X
localization	B-X
and	B-X
an	B-X
enhanced	B-X
susceptibility	B-X
to	B-X
furin	B-X
cleavage	B-X
(	B-X
A443T	B-X
)	B-X
or	B-X
to	B-X
the	B-X
inability	B-X
of	B-X
PCSK9	B-X
to	B-X
exit	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
C679X	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
report	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
native	B-X
and	B-X
furin-like	B-X
cleaved	B-X
forms	B-X
of	B-X
PCSK9	B-X
in	B-X
circulating	B-X
human	B-X
plasma	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PCSK9	B-X
levels	B-X
are	B-X
finely	B-X
regulated	B-X
by	B-X
the	B-X
basic	B-X
amino	B-X
acid	B-X
convertases	B-X
furin	B-X
and	B-X
PC5/6A	B-X
.	B-X
The	B-X
latter	B-X
may	B-X
reduce	B-X
the	B-X
lifetime	B-X
of	B-X
this	B-X
proteinase	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
degrade	B-X
the	B-X
cell-surface	B-X
LDL	B-X
receptor	B-X
,	B-X
thereby	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
circulating	B-X
LDL	B-X
cholesterol	B-X
.	B-X

Identification	O
by	O
functional	O
proteomics	O
of	O
a	O
deubiquitinating	O
/	O
deNeddylating	O
enzyme	O
in	O
Plasmodium	O
falciparum	O
.	O
<EOS>	B-X
Ubiquitin	B-X
and	B-X
the	B-X
enzymes	B-X
that	B-X
act	B-X
on	B-X
it	B-X
,	B-X
although	B-X
conserved	B-X
and	B-X
essential	B-X
in	B-X
eukaryotes	B-X
,	B-X
have	B-X
not	B-X
been	B-X
well	B-X
studied	B-X
in	B-X
parasites	B-X
,	B-X
despite	B-X
sequencing	B-X
of	B-X
several	B-X
parasite	B-X
genomes	B-X
.	B-X
Several	B-X
putative	B-X
ubiquitin	B-X
hydrolases	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
Plasmodium	B-X
falciparum	B-X
based	B-X
on	B-X
sequence	B-X
homology	B-X
alone	B-X
,	B-X
with	B-X
no	B-X
evidence	B-X
of	B-X
expression	B-X
or	B-X
function	B-X
.	B-X
Here	B-X
we	B-X
identify	B-X
the	B-X
first	B-X
deubiquitinating	B-X
enzyme	B-X
in	B-X
P.	B-X
falciparum	B-X
,	B-X
PfUCH54	B-X
,	B-X
by	B-X
its	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PfUCH54	B-X
also	B-X
has	B-X
deNeddylating	B-X
activity	B-X
,	B-X
as	B-X
assayed	B-X
by	B-X
a	B-X
mammalian	B-X
Nedd8-based	B-X
probe	B-X
.	B-X
Given	B-X
the	B-X
importance	B-X
of	B-X
parasitic	B-X
membrane	B-X
protein	B-X
trafficking	B-X
as	B-X
well	B-X
as	B-X
protein	B-X
degradation	B-X
in	B-X
the	B-X
virulence	B-X
of	B-X
this	B-X
parasite	B-X
,	B-X
this	B-X
family	B-X
of	B-X
enzymes	B-X
may	B-X
represent	B-X
a	B-X
target	B-X
for	B-X
pharmacological	B-X
intervention	B-X
with	B-X
this	B-X
disease	B-X
.	B-X

Ubiquitination	O
is	O
a	O
post	O
-	O
translational	O
modification	O
implicated	O
in	O
a	O
variety	O
of	O
cellular	O
functions	O
,	O
including	O
transcriptional	O
regulation	O
,	O
protein	O
degradation	O
and	O
membrane	O
protein	O
trafficking	O
.	O

Ubiquitin	B-Protein
and	O
the	O
enzymes	O
that	O
act	O
on	O
it	O
,	O
although	O
conserved	O
and	O
essential	O
in	O
eukaryotes	O
,	O
have	O
not	O
been	O
well	O
studied	O
in	O
parasites	O
,	O
despite	O
sequencing	O
of	O
several	O
parasite	O
genomes	O
.	O

Several	O
putative	O
ubiquitin	B-Protein
hydrolases	O
have	O
been	O
identified	O
in	O
Plasmodium	O
falciparum	O
based	O
on	O
sequence	O
homology	O
alone	O
,	O
with	O
no	O
evidence	O
of	O
expression	O
or	O
function	O
.	O
<EOS>	B-X
The	B-X
heart	B-X
is	B-X
a	B-X
rhythmic	B-X
electromechanical	B-X
pump	B-X
,	B-X
the	B-X
functioning	B-X
of	B-X
which	B-X
depends	B-X
on	B-X
action	B-X
potential	B-X
generation	B-X
and	B-X
propagation	B-X
,	B-X
followed	B-X
by	B-X
relaxation	B-X
and	B-X
a	B-X
period	B-X
of	B-X
refractoriness	B-X
until	B-X
the	B-X
next	B-X
impulse	B-X
is	B-X
generated	B-X
.	B-X
In	B-X
different	B-X
regions	B-X
of	B-X
the	B-X
heart	B-X
,	B-X
action	B-X
potential	B-X
waveforms	B-X
are	B-X
distinct	B-X
,	B-X
owing	B-X
to	B-X
differences	B-X
in	B-X
Na	B-X
(	B-X
+	B-X
)	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
and	B-X
K	B-X
(	B-X
+	B-X
)	B-X
channel	B-X
expression	B-X
,	B-X
and	B-X
these	B-X
differences	B-X
contribute	B-X
to	B-X
the	B-X
normal	B-X
,	B-X
unidirectional	B-X
propagation	B-X
of	B-X
activity	B-X
and	B-X
to	B-X
the	B-X
generation	B-X
of	B-X
normal	B-X
cardiac	B-X
rhythms	B-X
.	B-X
Changes	B-X
in	B-X
channel	B-X
functioning	B-X
,	B-X
resulting	B-X
from	B-X
inherited	B-X
or	B-X
acquired	B-X
disease	B-X
,	B-X
affect	B-X
action	B-X
potential	B-X
repolarization	B-X
and	B-X
can	B-X
lead	B-X
to	B-X
the	B-X
generation	B-X
of	B-X
life-threatening	B-X
arrhythmias	B-X
.	B-X
Considerable	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
in	B-X
defining	B-X
the	B-X
functional	B-X
roles	B-X
of	B-X
the	B-X
various	B-X
channels	B-X
and	B-X
in	B-X
identifying	B-X
the	B-X
alpha-subunits	B-X
encoding	B-X
these	B-X
channels	B-X
.	B-X
Much	B-X
less	B-X
is	B-X
known	B-X
,	B-X
however	B-X
,	B-X
about	B-X
the	B-X
functioning	B-X
of	B-X
channel	B-X
accessory	B-X
subunits	B-X
and/or	B-X
posttranslational	B-X
processing	B-X
of	B-X
the	B-X
channel	B-X
proteins	B-X
.	B-X
It	B-X
has	B-X
also	B-X
become	B-X
clear	B-X
that	B-X
cardiac	B-X
ion	B-X
channels	B-X
function	B-X
as	B-X
components	B-X
of	B-X
macromolecular	B-X
complexes	B-X
,	B-X
comprising	B-X
the	B-X
alpha-subunits	B-X
,	B-X
one	B-X
or	B-X
more	B-X
accessory	B-X
subunit	B-X
,	B-X
and	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
regulatory	B-X
proteins	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
macromolecular	B-X
channel	B-X
protein	B-X
complexes	B-X
appear	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
and/or	B-X
the	B-X
extracellular	B-X
matrix	B-X
,	B-X
suggesting	B-X
important	B-X
functional	B-X
links	B-X
between	B-X
channel	B-X
complexes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
between	B-X
cardiac	B-X
structure	B-X
and	B-X
electrical	B-X
functioning	B-X
.	B-X
Important	B-X
areas	B-X
of	B-X
future	B-X
research	B-X
will	B-X
be	B-X
the	B-X
identification	B-X
of	B-X
(	B-X
all	B-X
of	B-X
)	B-X
the	B-X
molecular	B-X
components	B-X
of	B-X
functional	B-X
cardiac	B-X
ion	B-X
channels	B-X
and	B-X
delineation	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
and	B-X
the	B-X
functioning	B-X
of	B-X
these	B-X
channels	B-X
in	B-X
the	B-X
normal	B-X
and	B-X
the	B-X
diseased	B-X
myocardium	B-X
.	B-X

Here	O
we	O
identify	O
the	O
first	O
deubiquitinating	O
enzyme	O
in	O
P	O
.	O
falciparum	O
,	O
PfUCH54	B-Protein
,	O
by	O
its	O
activity	O
.	O

We	O
show	O
that	O
PfUCH54	B-Protein
also	O
has	O
deNeddylating	O
activity	O
,	O
as	O
assayed	O
by	O
a	O
mammalian	O
Nedd8	B-Protein
-	O
based	O
probe	O
.	O
<EOS>	B-X
Several	B-X
putative	B-X
ubiquitin	B-X
hydrolases	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
Plasmodium	B-X
falciparum	B-X
based	B-X
on	B-X
sequence	B-X
homology	B-X
alone	B-X
,	B-X
with	B-X
no	B-X
evidence	B-X
of	B-X
expression	B-X
or	B-X
function	B-X
.	B-X
Here	B-X
we	B-X
identify	B-X
the	B-X
first	B-X
deubiquitinating	B-X
enzyme	B-X
in	B-X
P.	B-X
falciparum	B-X
,	B-X
PfUCH54	B-X
,	B-X
by	B-X
its	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PfUCH54	B-X
also	B-X
has	B-X
deNeddylating	B-X
activity	B-X
,	B-X
as	B-X
assayed	B-X
by	B-X
a	B-X
mammalian	B-X
Nedd8-based	B-X
probe	B-X
.	B-X
This	B-X
activity	B-X
is	B-X
absent	B-X
from	B-X
mammalian	B-X
homologues	B-X
of	B-X
PfUCH54	B-X
.	B-X

This	O
activity	O
is	O
absent	O
from	O
mammalian	O
homologues	O
of	O
PfUCH54	B-Protein
.	O
<EOS>	B-X
Here	B-X
we	B-X
identify	B-X
the	B-X
first	B-X
deubiquitinating	B-X
enzyme	B-X
in	B-X
P.	B-X
falciparum	B-X
,	B-X
PfUCH54	B-X
,	B-X
by	B-X
its	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PfUCH54	B-X
also	B-X
has	B-X
deNeddylating	B-X
activity	B-X
,	B-X
as	B-X
assayed	B-X
by	B-X
a	B-X
mammalian	B-X
Nedd8-based	B-X
probe	B-X
.	B-X
This	B-X
activity	B-X
is	B-X
absent	B-X
from	B-X
mammalian	B-X
homologues	B-X
of	B-X
PfUCH54	B-X
.	B-X

Given	O
the	O
importance	O
of	O
parasitic	O
membrane	O
protein	O
trafficking	O
as	O
well	O
as	O
protein	O
degradation	O
in	O
the	O
virulence	O
of	O
this	O
parasite	O
,	O
this	O
family	O
of	O
enzymes	O
may	O
represent	O
a	O
target	O
for	O
pharmacological	O
intervention	O
with	O
this	O
disease	O
.	O
<EOS>	B-X
Ubiquitination	B-X
is	B-X
a	B-X
post-translational	B-X
modification	B-X
implicated	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
functions	B-X
,	B-X
including	B-X
transcriptional	B-X
regulation	B-X
,	B-X
protein	B-X
degradation	B-X
and	B-X
membrane	B-X
protein	B-X
trafficking	B-X
.	B-X
Ubiquitin	B-X
and	B-X
the	B-X
enzymes	B-X
that	B-X
act	B-X
on	B-X
it	B-X
,	B-X
although	B-X
conserved	B-X
and	B-X
essential	B-X
in	B-X
eukaryotes	B-X
,	B-X
have	B-X
not	B-X
been	B-X
well	B-X
studied	B-X
in	B-X
parasites	B-X
,	B-X
despite	B-X
sequencing	B-X
of	B-X
several	B-X
parasite	B-X
genomes	B-X
.	B-X
Given	B-X
the	B-X
importance	B-X
of	B-X
parasitic	B-X
membrane	B-X
protein	B-X
trafficking	B-X
as	B-X
well	B-X
as	B-X
protein	B-X
degradation	B-X
in	B-X
the	B-X
virulence	B-X
of	B-X
this	B-X
parasite	B-X
,	B-X
this	B-X
family	B-X
of	B-X
enzymes	B-X
may	B-X
represent	B-X
a	B-X
target	B-X
for	B-X
pharmacological	B-X
intervention	B-X
with	B-X
this	B-X
disease	B-X
.	B-X

Ubiquitin	B-Protein
and	O
ubiquitin	B-Protein
-	O
like	O
modifications	O
of	O
the	O
p53	B-Protein
family	O
.	O
<EOS>	B-X
Post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
phosphorylation	B-X
,	B-X
ubiquitination	B-X
and	B-X
acetylation	B-X
,	B-X
play	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
autophagy	B-X
.	B-X
Recent	B-X
advancements	B-X
in	B-X
the	B-X
rapidly	B-X
evolving	B-X
field	B-X
of	B-X
cancer	B-X
epigenetics	B-X
have	B-X
shown	B-X
extensive	B-X
reprogramming	B-X
of	B-X
every	B-X
component	B-X
of	B-X
the	B-X
epigenetic	B-X
machinery	B-X
in	B-X
cancer	B-X
,	B-X
including	B-X
DNA	B-X
methylation	B-X
,	B-X
histone	B-X
modifications	B-X
,	B-X
nucleosome	B-X
positioning	B-X
,	B-X
noncoding	B-X
RNAs	B-X
,	B-X
and	B-X
microRNAs	B-X
.	B-X
Regulation	B-X
of	B-X
p53	B-X
by	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
has	B-X
been	B-X
studied	B-X
considerably	B-X
.	B-X
Studies	B-X
have	B-X
also	B-X
demonstrated	B-X
that	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
SUMO-1	B-X
and	B-X
NEDD8	B-X
modify	B-X
p53	B-X
.	B-X
Similarly	B-X
,	B-X
p63	B-X
and	B-X
p73	B-X
are	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
modifications	B-X
,	B-X
and	B-X
perturbations	B-X
of	B-X
these	B-X
pathways	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
tumorigenesis	B-X
and	B-X
developmental	B-X
abnormalities	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
by	B-X
covalent	B-X
modification	B-X
by	B-X
ubiquitin	B-X
,	B-X
SUMO-1	B-X
,	B-X
and	B-X
NEDD8	B-X
.	B-X

Regulation	O
of	O
p53	B-Protein
by	O
the	O
ubiquitin	B-Protein
-	O
proteasomal	O
pathway	O
has	O
been	O
studied	O
considerably	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
p53	B-X
by	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
has	B-X
been	B-X
studied	B-X
considerably	B-X
.	B-X
Studies	B-X
have	B-X
also	B-X
demonstrated	B-X
that	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
SUMO-1	B-X
and	B-X
NEDD8	B-X
modify	B-X
p53	B-X
.	B-X
Similarly	B-X
,	B-X
p63	B-X
and	B-X
p73	B-X
are	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
modifications	B-X
,	B-X
and	B-X
perturbations	B-X
of	B-X
these	B-X
pathways	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
tumorigenesis	B-X
and	B-X
developmental	B-X
abnormalities	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
by	B-X
covalent	B-X
modification	B-X
by	B-X
ubiquitin	B-X
,	B-X
SUMO-1	B-X
,	B-X
and	B-X
NEDD8	B-X
.	B-X

Studies	O
have	O
also	O
demonstrated	O
that	O
the	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
and	O
NEDD8	B-Protein
modify	O
p53	B-Protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
p53	B-X
by	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
has	B-X
been	B-X
studied	B-X
considerably	B-X
.	B-X
Studies	B-X
have	B-X
also	B-X
demonstrated	B-X
that	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
SUMO-1	B-X
and	B-X
NEDD8	B-X
modify	B-X
p53	B-X
.	B-X
Similarly	B-X
,	B-X
p63	B-X
and	B-X
p73	B-X
are	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
modifications	B-X
,	B-X
and	B-X
perturbations	B-X
of	B-X
these	B-X
pathways	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
tumorigenesis	B-X
and	B-X
developmental	B-X
abnormalities	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
by	B-X
covalent	B-X
modification	B-X
by	B-X
ubiquitin	B-X
,	B-X
SUMO-1	B-X
,	B-X
and	B-X
NEDD8	B-X
.	B-X

Similarly	O
,	O
p63	B-Protein
and	O
p73	B-Protein
are	O
subject	O
to	O
regulation	O
by	O
ubiquitin	B-Protein
and	O
ubiquitin	B-Protein
-	O
like	O
modifications	O
,	O
and	O
perturbations	O
of	O
these	O
pathways	O
in	O
the	O
regulation	O
of	O
the	O
p53	B-Protein
family	O
have	O
been	O
implicated	O
in	O
tumorigenesis	O
and	O
developmental	O
abnormalities	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
p53	B-X
by	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
has	B-X
been	B-X
studied	B-X
considerably	B-X
.	B-X
Studies	B-X
have	B-X
also	B-X
demonstrated	B-X
that	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
SUMO-1	B-X
and	B-X
NEDD8	B-X
modify	B-X
p53	B-X
.	B-X
Similarly	B-X
,	B-X
p63	B-X
and	B-X
p73	B-X
are	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
modifications	B-X
,	B-X
and	B-X
perturbations	B-X
of	B-X
these	B-X
pathways	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
tumorigenesis	B-X
and	B-X
developmental	B-X
abnormalities	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
by	B-X
covalent	B-X
modification	B-X
by	B-X
ubiquitin	B-X
,	B-X
SUMO-1	B-X
,	B-X
and	B-X
NEDD8	B-X
.	B-X

Here	O
,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
regulation	O
of	O
the	O
p53	B-Protein
family	O
by	O
covalent	O
modification	O
by	O
ubiquitin	B-Protein
,	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
NEDD8	B-Protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
p53	B-X
by	B-X
the	B-X
ubiquitin-proteasomal	B-X
pathway	B-X
has	B-X
been	B-X
studied	B-X
considerably	B-X
.	B-X
Studies	B-X
have	B-X
also	B-X
demonstrated	B-X
that	B-X
the	B-X
ubiquitin-like	B-X
proteins	B-X
SUMO-1	B-X
and	B-X
NEDD8	B-X
modify	B-X
p53	B-X
.	B-X
Similarly	B-X
,	B-X
p63	B-X
and	B-X
p73	B-X
are	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
modifications	B-X
,	B-X
and	B-X
perturbations	B-X
of	B-X
these	B-X
pathways	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
tumorigenesis	B-X
and	B-X
developmental	B-X
abnormalities	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p53	B-X
family	B-X
by	B-X
covalent	B-X
modification	B-X
by	B-X
ubiquitin	B-X
,	B-X
SUMO-1	B-X
,	B-X
and	B-X
NEDD8	B-X
.	B-X

Transport	O
and	O
assembly	O
of	O
gag	B-Protein
proteins	O
into	O
Moloney	O
murine	O
leukemia	O
virus	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
process	B-X
of	B-X
Moloney	B-X
murine	B-X
leukemia	B-X
virus	B-X
(	B-X
M-MuLV	B-X
)	B-X
assembly	B-X
by	B-X
characterization	B-X
of	B-X
core	B-X
(	B-X
gag	B-X
)	B-X
protein	B-X
mutants	B-X
and	B-X
analysis	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
gag	B-X
proteins	B-X
produced	B-X
by	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ionophore	B-X
monensin	B-X
.	B-X
Our	B-X
genetic	B-X
studies	B-X
involved	B-X
examination	B-X
of	B-X
linker	B-X
insertion	B-X
mutants	B-X
of	B-X
a	B-X
Gag-beta-galactosidase	B-X
(	B-X
Gag-beta-gal	B-X
)	B-X
fusion	B-X
protein	B-X
,	B-X
GBG2051	B-X
,	B-X
which	B-X
is	B-X
incorporated	B-X
into	B-X
virus	B-X
particles	B-X
when	B-X
expressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
wt	B-X
viral	B-X
proteins	B-X
.	B-X
Analysis	B-X
indicated	B-X
that	B-X
the	B-X
amino-terminal	B-X
two-thirds	B-X
of	B-X
the	B-X
gag	B-X
matrix	B-X
domain	B-X
is	B-X
essential	B-X
for	B-X
targeting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
;	B-X
mutant	B-X
proteins	B-X
localized	B-X
to	B-X
the	B-X
cytoplasm	B-X
or	B-X
were	B-X
trapped	B-X
on	B-X
intracellular	B-X
membranes	B-X
.	B-X
Mutations	B-X
through	B-X
most	B-X
of	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
gag	B-X
capsid	B-X
domain	B-X
generated	B-X
proteins	B-X
which	B-X
were	B-X
released	B-X
from	B-X
cells	B-X
in	B-X
membrane	B-X
vesicles	B-X
but	B-X
not	B-X
in	B-X
virions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
linker	B-X
insertions	B-X
into	B-X
p12gag	B-X
or	B-X
carboxy-terminal	B-X
portions	B-X
of	B-X
the	B-X
matrix	B-X
or	B-X
capsid	B-X
coding	B-X
regions	B-X
did	B-X
not	B-X
affect	B-X
assembly	B-X
of	B-X
fusion	B-X
proteins	B-X
into	B-X
virus	B-X
particles	B-X
.	B-X
Monensin	B-X
,	B-X
which	B-X
blocks	B-X
vesicular	B-X
transport	B-X
,	B-X
inhibited	B-X
gag	B-X
protein	B-X
intracellular	B-X
transport	B-X
and	B-X
release	B-X
from	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
M-MuLV	B-X
myristylated	B-X
gag	B-X
proteins	B-X
travel	B-X
via	B-X
vesicles	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Specific	B-X
matrix	B-X
protein	B-X
polypeptide	B-X
regions	B-X
and	B-X
myristic	B-X
acid	B-X
modification	B-X
are	B-X
both	B-X
necessary	B-X
for	B-X
appropriate	B-X
gag	B-X
protein	B-X
transport	B-X
,	B-X
while	B-X
capsid	B-X
protein	B-X
interactions	B-X
appear	B-X
to	B-X
mediate	B-X
the	B-X
final	B-X
phase	B-X
of	B-X
virion	B-X
formation	B-X
.	B-X

We	O
have	O
studied	O
the	O
process	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
(	O
M	O
-	O
MuLV	O
)	O
assembly	O
by	O
characterization	O
of	O
core	O
(	O
gag	B-Protein
)	O
protein	O
mutants	O
and	O
analysis	O
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
gag	B-Protein
proteins	O
produced	O
by	O
cells	O
in	O
the	O
presence	O
of	O
the	O
ionophore	O
monensin	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
process	B-X
of	B-X
Moloney	B-X
murine	B-X
leukemia	B-X
virus	B-X
(	B-X
M-MuLV	B-X
)	B-X
assembly	B-X
by	B-X
characterization	B-X
of	B-X
core	B-X
(	B-X
gag	B-X
)	B-X
protein	B-X
mutants	B-X
and	B-X
analysis	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
gag	B-X
proteins	B-X
produced	B-X
by	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ionophore	B-X
monensin	B-X
.	B-X
Our	B-X
genetic	B-X
studies	B-X
involved	B-X
examination	B-X
of	B-X
linker	B-X
insertion	B-X
mutants	B-X
of	B-X
a	B-X
Gag-beta-galactosidase	B-X
(	B-X
Gag-beta-gal	B-X
)	B-X
fusion	B-X
protein	B-X
,	B-X
GBG2051	B-X
,	B-X
which	B-X
is	B-X
incorporated	B-X
into	B-X
virus	B-X
particles	B-X
when	B-X
expressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
wt	B-X
viral	B-X
proteins	B-X
.	B-X
Analysis	B-X
indicated	B-X
that	B-X
the	B-X
amino-terminal	B-X
two-thirds	B-X
of	B-X
the	B-X
gag	B-X
matrix	B-X
domain	B-X
is	B-X
essential	B-X
for	B-X
targeting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
;	B-X
mutant	B-X
proteins	B-X
localized	B-X
to	B-X
the	B-X
cytoplasm	B-X
or	B-X
were	B-X
trapped	B-X
on	B-X
intracellular	B-X
membranes	B-X
.	B-X
Mutations	B-X
through	B-X
most	B-X
of	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
gag	B-X
capsid	B-X
domain	B-X
generated	B-X
proteins	B-X
which	B-X
were	B-X
released	B-X
from	B-X
cells	B-X
in	B-X
membrane	B-X
vesicles	B-X
but	B-X
not	B-X
in	B-X
virions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
linker	B-X
insertions	B-X
into	B-X
p12gag	B-X
or	B-X
carboxy-terminal	B-X
portions	B-X
of	B-X
the	B-X
matrix	B-X
or	B-X
capsid	B-X
coding	B-X
regions	B-X
did	B-X
not	B-X
affect	B-X
assembly	B-X
of	B-X
fusion	B-X
proteins	B-X
into	B-X
virus	B-X
particles	B-X
.	B-X
Monensin	B-X
,	B-X
which	B-X
blocks	B-X
vesicular	B-X
transport	B-X
,	B-X
inhibited	B-X
gag	B-X
protein	B-X
intracellular	B-X
transport	B-X
and	B-X
release	B-X
from	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
M-MuLV	B-X
myristylated	B-X
gag	B-X
proteins	B-X
travel	B-X
via	B-X
vesicles	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Specific	B-X
matrix	B-X
protein	B-X
polypeptide	B-X
regions	B-X
and	B-X
myristic	B-X
acid	B-X
modification	B-X
are	B-X
both	B-X
necessary	B-X
for	B-X
appropriate	B-X
gag	B-X
protein	B-X
transport	B-X
,	B-X
while	B-X
capsid	B-X
protein	B-X
interactions	B-X
appear	B-X
to	B-X
mediate	B-X
the	B-X
final	B-X
phase	B-X
of	B-X
virion	B-X
formation	B-X
.	B-X

Our	O
genetic	O
studies	O
involved	O
examination	O
of	O
linker	O
insertion	O
mutants	O
of	O
a	O
Gag	B-Protein
-	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
(	O
Gag	B-Protein
-	I-Protein
beta	I-Protein
-	I-Protein
gal	I-Protein
)	O
fusion	O
protein	O
,	O
GBG2051	O
,	O
which	O
is	O
incorporated	O
into	O
virus	O
particles	O
when	O
expressed	O
in	O
the	O
presence	O
of	O
wt	O
viral	O
proteins	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
process	B-X
of	B-X
Moloney	B-X
murine	B-X
leukemia	B-X
virus	B-X
(	B-X
M-MuLV	B-X
)	B-X
assembly	B-X
by	B-X
characterization	B-X
of	B-X
core	B-X
(	B-X
gag	B-X
)	B-X
protein	B-X
mutants	B-X
and	B-X
analysis	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
gag	B-X
proteins	B-X
produced	B-X
by	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ionophore	B-X
monensin	B-X
.	B-X
Our	B-X
genetic	B-X
studies	B-X
involved	B-X
examination	B-X
of	B-X
linker	B-X
insertion	B-X
mutants	B-X
of	B-X
a	B-X
Gag-beta-galactosidase	B-X
(	B-X
Gag-beta-gal	B-X
)	B-X
fusion	B-X
protein	B-X
,	B-X
GBG2051	B-X
,	B-X
which	B-X
is	B-X
incorporated	B-X
into	B-X
virus	B-X
particles	B-X
when	B-X
expressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
wt	B-X
viral	B-X
proteins	B-X
.	B-X
Analysis	B-X
indicated	B-X
that	B-X
the	B-X
amino-terminal	B-X
two-thirds	B-X
of	B-X
the	B-X
gag	B-X
matrix	B-X
domain	B-X
is	B-X
essential	B-X
for	B-X
targeting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
;	B-X
mutant	B-X
proteins	B-X
localized	B-X
to	B-X
the	B-X
cytoplasm	B-X
or	B-X
were	B-X
trapped	B-X
on	B-X
intracellular	B-X
membranes	B-X
.	B-X
Mutations	B-X
through	B-X
most	B-X
of	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
gag	B-X
capsid	B-X
domain	B-X
generated	B-X
proteins	B-X
which	B-X
were	B-X
released	B-X
from	B-X
cells	B-X
in	B-X
membrane	B-X
vesicles	B-X
but	B-X
not	B-X
in	B-X
virions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
linker	B-X
insertions	B-X
into	B-X
p12gag	B-X
or	B-X
carboxy-terminal	B-X
portions	B-X
of	B-X
the	B-X
matrix	B-X
or	B-X
capsid	B-X
coding	B-X
regions	B-X
did	B-X
not	B-X
affect	B-X
assembly	B-X
of	B-X
fusion	B-X
proteins	B-X
into	B-X
virus	B-X
particles	B-X
.	B-X
Monensin	B-X
,	B-X
which	B-X
blocks	B-X
vesicular	B-X
transport	B-X
,	B-X
inhibited	B-X
gag	B-X
protein	B-X
intracellular	B-X
transport	B-X
and	B-X
release	B-X
from	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
M-MuLV	B-X
myristylated	B-X
gag	B-X
proteins	B-X
travel	B-X
via	B-X
vesicles	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Specific	B-X
matrix	B-X
protein	B-X
polypeptide	B-X
regions	B-X
and	B-X
myristic	B-X
acid	B-X
modification	B-X
are	B-X
both	B-X
necessary	B-X
for	B-X
appropriate	B-X
gag	B-X
protein	B-X
transport	B-X
,	B-X
while	B-X
capsid	B-X
protein	B-X
interactions	B-X
appear	B-X
to	B-X
mediate	B-X
the	B-X
final	B-X
phase	B-X
of	B-X
virion	B-X
formation	B-X
.	B-X

Analysis	O
indicated	O
that	O
the	O
amino	O
-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
gag	B-Protein
matrix	O
domain	O
is	O
essential	O
for	O
targeting	O
of	O
proteins	O
to	O
the	O
plasma	O
membrane	O
;	O
mutant	O
proteins	O
localized	O
to	O
the	O
cytoplasm	O
or	O
were	O
trapped	O
on	O
intracellular	O
membranes	O
.	O

Mutations	O
through	O
most	O
of	O
the	O
coding	O
region	O
of	O
the	O
gag	B-Protein
capsid	O
domain	O
generated	O
proteins	O
which	O
were	O
released	O
from	O
cells	O
in	O
membrane	O
vesicles	O
but	O
not	O
in	O
virions	O
.	O

In	O
contrast	O
,	O
linker	O
insertions	O
into	O
p12gag	B-Protein
or	O
carboxy	O
-	O
terminal	O
portions	O
of	O
the	O
matrix	O
or	O
capsid	O
coding	O
regions	O
did	O
not	O
affect	O
assembly	O
of	O
fusion	O
proteins	O
into	O
virus	O
particles	O
.	O
<EOS>	B-X
With	B-X
a	B-X
limited	B-X
coding	B-X
capacity	B-X
of	B-X
4.7	B-X
kb	B-X
,	B-X
adeno-associated	B-X
virus	B-X
(	B-X
AAV	B-X
)	B-X
genome	B-X
has	B-X
evolved	B-X
over-lapping	B-X
genes	B-X
to	B-X
maximise	B-X
the	B-X
usage	B-X
of	B-X
its	B-X
genome	B-X
.	B-X
An	B-X
example	B-X
is	B-X
the	B-X
recently	B-X
found	B-X
ORF	B-X
in	B-X
the	B-X
cap	B-X
gene	B-X
,	B-X
encoding	B-X
membrane-associated	B-X
accessory	B-X
protein	B-X
(	B-X
MAAP	B-X
)	B-X
,	B-X
located	B-X
in	B-X
the	B-X
same	B-X
genomic	B-X
region	B-X
as	B-X
the	B-X
VP1/2	B-X
unique	B-X
domain	B-X
,	B-X
but	B-X
in	B-X
a	B-X
different	B-X
reading	B-X
frame	B-X
.	B-X
This	B-X
13	B-X
KDa	B-X
protein	B-X
,	B-X
unique	B-X
to	B-X
the	B-X
dependovirus	B-X
genus	B-X
,	B-X
is	B-X
not	B-X
homologous	B-X
to	B-X
any	B-X
known	B-X
protein	B-X
.	B-X
We	B-X
have	B-X
further	B-X
observed	B-X
MAAP	B-X
localised	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
in	B-X
the	B-X
membranous	B-X
structures	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
by	B-X
co-transfecting	B-X
with	B-X
plasmids	B-X
encoding	B-X
the	B-X
wild-type	B-X
AAV	B-X
(	B-X
wt-AAV	B-X
)	B-X
genome	B-X
and	B-X
adenovirus	B-X
(	B-X
Ad	B-X
)	B-X
helper	B-X
genes	B-X
.	B-X
While	B-X
keeping	B-X
VP1/2	B-X
protein	B-X
sequence	B-X
identical	B-X
,	B-X
both	B-X
inactivation	B-X
and	B-X
truncation	B-X
of	B-X
MAAP	B-X
translation	B-X
affected	B-X
the	B-X
emergence	B-X
and	B-X
intracellular	B-X
distribution	B-X
of	B-X
the	B-X
AAV	B-X
capsid	B-X
proteins	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
were	B-X
able	B-X
to	B-X
improve	B-X
virus	B-X
production	B-X
and	B-X
capsid	B-X
integrity	B-X
through	B-X
a	B-X
C-terminal	B-X
truncation	B-X
of	B-X
MAAP	B-X
while	B-X
other	B-X
modifications	B-X
led	B-X
to	B-X
increased	B-X
packaging	B-X
of	B-X
contaminating	B-X
,	B-X
non-viral	B-X
DNA	B-X
.	B-X

Monensin	O
,	O
which	O
blocks	O
vesicular	O
transport	O
,	O
inhibited	O
gag	B-Protein
protein	O
intracellular	O
transport	O
and	O
release	O
from	O
cells	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
process	B-X
of	B-X
Moloney	B-X
murine	B-X
leukemia	B-X
virus	B-X
(	B-X
M-MuLV	B-X
)	B-X
assembly	B-X
by	B-X
characterization	B-X
of	B-X
core	B-X
(	B-X
gag	B-X
)	B-X
protein	B-X
mutants	B-X
and	B-X
analysis	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
gag	B-X
proteins	B-X
produced	B-X
by	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ionophore	B-X
monensin	B-X
.	B-X
Our	B-X
genetic	B-X
studies	B-X
involved	B-X
examination	B-X
of	B-X
linker	B-X
insertion	B-X
mutants	B-X
of	B-X
a	B-X
Gag-beta-galactosidase	B-X
(	B-X
Gag-beta-gal	B-X
)	B-X
fusion	B-X
protein	B-X
,	B-X
GBG2051	B-X
,	B-X
which	B-X
is	B-X
incorporated	B-X
into	B-X
virus	B-X
particles	B-X
when	B-X
expressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
wt	B-X
viral	B-X
proteins	B-X
.	B-X
Analysis	B-X
indicated	B-X
that	B-X
the	B-X
amino-terminal	B-X
two-thirds	B-X
of	B-X
the	B-X
gag	B-X
matrix	B-X
domain	B-X
is	B-X
essential	B-X
for	B-X
targeting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
;	B-X
mutant	B-X
proteins	B-X
localized	B-X
to	B-X
the	B-X
cytoplasm	B-X
or	B-X
were	B-X
trapped	B-X
on	B-X
intracellular	B-X
membranes	B-X
.	B-X
Mutations	B-X
through	B-X
most	B-X
of	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
gag	B-X
capsid	B-X
domain	B-X
generated	B-X
proteins	B-X
which	B-X
were	B-X
released	B-X
from	B-X
cells	B-X
in	B-X
membrane	B-X
vesicles	B-X
but	B-X
not	B-X
in	B-X
virions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
linker	B-X
insertions	B-X
into	B-X
p12gag	B-X
or	B-X
carboxy-terminal	B-X
portions	B-X
of	B-X
the	B-X
matrix	B-X
or	B-X
capsid	B-X
coding	B-X
regions	B-X
did	B-X
not	B-X
affect	B-X
assembly	B-X
of	B-X
fusion	B-X
proteins	B-X
into	B-X
virus	B-X
particles	B-X
.	B-X
Monensin	B-X
,	B-X
which	B-X
blocks	B-X
vesicular	B-X
transport	B-X
,	B-X
inhibited	B-X
gag	B-X
protein	B-X
intracellular	B-X
transport	B-X
and	B-X
release	B-X
from	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
M-MuLV	B-X
myristylated	B-X
gag	B-X
proteins	B-X
travel	B-X
via	B-X
vesicles	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Specific	B-X
matrix	B-X
protein	B-X
polypeptide	B-X
regions	B-X
and	B-X
myristic	B-X
acid	B-X
modification	B-X
are	B-X
both	B-X
necessary	B-X
for	B-X
appropriate	B-X
gag	B-X
protein	B-X
transport	B-X
,	B-X
while	B-X
capsid	B-X
protein	B-X
interactions	B-X
appear	B-X
to	B-X
mediate	B-X
the	B-X
final	B-X
phase	B-X
of	B-X
virion	B-X
formation	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
a	O
significant	O
proportion	O
of	O
M	O
-	O
MuLV	O
myristylated	O
gag	B-Protein
proteins	O
travel	O
via	O
vesicles	O
to	O
the	O
cell	O
surface	O
.	O

Specific	O
matrix	O
protein	O
polypeptide	O
regions	O
and	O
myristic	O
acid	O
modification	O
are	O
both	O
necessary	O
for	O
appropriate	O
gag	B-Protein
protein	O
transport	O
,	O
while	O
capsid	O
protein	O
interactions	O
appear	O
to	O
mediate	O
the	O
final	O
phase	O
of	O
virion	O
formation	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
process	B-X
of	B-X
Moloney	B-X
murine	B-X
leukemia	B-X
virus	B-X
(	B-X
M-MuLV	B-X
)	B-X
assembly	B-X
by	B-X
characterization	B-X
of	B-X
core	B-X
(	B-X
gag	B-X
)	B-X
protein	B-X
mutants	B-X
and	B-X
analysis	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
gag	B-X
proteins	B-X
produced	B-X
by	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ionophore	B-X
monensin	B-X
.	B-X
Our	B-X
genetic	B-X
studies	B-X
involved	B-X
examination	B-X
of	B-X
linker	B-X
insertion	B-X
mutants	B-X
of	B-X
a	B-X
Gag-beta-galactosidase	B-X
(	B-X
Gag-beta-gal	B-X
)	B-X
fusion	B-X
protein	B-X
,	B-X
GBG2051	B-X
,	B-X
which	B-X
is	B-X
incorporated	B-X
into	B-X
virus	B-X
particles	B-X
when	B-X
expressed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
wt	B-X
viral	B-X
proteins	B-X
.	B-X
Analysis	B-X
indicated	B-X
that	B-X
the	B-X
amino-terminal	B-X
two-thirds	B-X
of	B-X
the	B-X
gag	B-X
matrix	B-X
domain	B-X
is	B-X
essential	B-X
for	B-X
targeting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
;	B-X
mutant	B-X
proteins	B-X
localized	B-X
to	B-X
the	B-X
cytoplasm	B-X
or	B-X
were	B-X
trapped	B-X
on	B-X
intracellular	B-X
membranes	B-X
.	B-X
Mutations	B-X
through	B-X
most	B-X
of	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
gag	B-X
capsid	B-X
domain	B-X
generated	B-X
proteins	B-X
which	B-X
were	B-X
released	B-X
from	B-X
cells	B-X
in	B-X
membrane	B-X
vesicles	B-X
but	B-X
not	B-X
in	B-X
virions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
linker	B-X
insertions	B-X
into	B-X
p12gag	B-X
or	B-X
carboxy-terminal	B-X
portions	B-X
of	B-X
the	B-X
matrix	B-X
or	B-X
capsid	B-X
coding	B-X
regions	B-X
did	B-X
not	B-X
affect	B-X
assembly	B-X
of	B-X
fusion	B-X
proteins	B-X
into	B-X
virus	B-X
particles	B-X
.	B-X
Monensin	B-X
,	B-X
which	B-X
blocks	B-X
vesicular	B-X
transport	B-X
,	B-X
inhibited	B-X
gag	B-X
protein	B-X
intracellular	B-X
transport	B-X
and	B-X
release	B-X
from	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
M-MuLV	B-X
myristylated	B-X
gag	B-X
proteins	B-X
travel	B-X
via	B-X
vesicles	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Specific	B-X
matrix	B-X
protein	B-X
polypeptide	B-X
regions	B-X
and	B-X
myristic	B-X
acid	B-X
modification	B-X
are	B-X
both	B-X
necessary	B-X
for	B-X
appropriate	B-X
gag	B-X
protein	B-X
transport	B-X
,	B-X
while	B-X
capsid	B-X
protein	B-X
interactions	B-X
appear	B-X
to	B-X
mediate	B-X
the	B-X
final	B-X
phase	B-X
of	B-X
virion	B-X
formation	B-X
.	B-X

Endothelial	O
cell	O
response	O
to	O
lactate	O
:	O
implication	O
of	O
PAR	O
modification	O
of	O
VEGF	O
.	O
<EOS>	B-X
Angiogenesis	B-X
,	B-X
the	B-X
process	B-X
of	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
from	B-X
pre-existing	B-X
one	B-X
,	B-X
occurs	B-X
in	B-X
many	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
,	B-X
most	B-X
of	B-X
which	B-X
are	B-X
underlined	B-X
by	B-X
hypoxia	B-X
and	B-X
resultant	B-X
accumulation	B-X
of	B-X
lactate	B-X
.	B-X
Although	B-X
lactate	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
angiogenesis	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
its	B-X
action	B-X
on	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
is	B-X
not	B-X
known	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
examine	B-X
the	B-X
response	B-X
of	B-X
ECs	B-X
to	B-X
lactate	B-X
.	B-X
Morphological	B-X
analysis	B-X
revealed	B-X
that	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
in	B-X
culture	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
switching	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
concomitant	B-X
with	B-X
upregulation	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
as	B-X
determined	B-X
by	B-X
reverse	B-X
transcription-PCR	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
Apart	B-X
from	B-X
increase	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
VEGF	B-X
protein	B-X
as	B-X
determined	B-X
by	B-X
ELISA	B-X
,	B-X
chorio	B-X
allantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
assay	B-X
using	B-X
the	B-X
cell	B-X
extracts	B-X
revealed	B-X
that	B-X
lactate	B-X
also	B-X
increased	B-X
the	B-X
angiogenic	B-X
potency	B-X
of	B-X
VEGF	B-X
.	B-X
Isolated	B-X
VEGF	B-X
,	B-X
when	B-X
blotted	B-X
and	B-X
subsequently	B-X
probed	B-X
with	B-X
anti-PAR	B-X
antibody	B-X
,	B-X
revealed	B-X
considerable	B-X
reduction	B-X
in	B-X
poly-adenosyl	B-X
ribosylation	B-X
of	B-X
VEGF	B-X
associated	B-X
with	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
NAD	B-X
(	B-X
+	B-X
)	B-X
,	B-X
in	B-X
presence	B-X
of	B-X
lactate	B-X
.	B-X
Thus	B-X
it	B-X
appears	B-X
that	B-X
ECs	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
increasing	B-X
the	B-X
production	B-X
of	B-X
VEGF	B-X
and	B-X
modulating	B-X
its	B-X
angiogenic	B-X
potency	B-X
through	B-X
poly-ADP	B-X
ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
-dependent	B-X
mechanism	B-X
and	B-X
thereby	B-X
switch	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
.	B-X

Angiogenesis	O
,	O
the	O
process	O
of	O
formation	O
of	O
new	O
blood	O
vessels	O
from	O
pre	O
-	O
existing	O
one	O
,	O
occurs	O
in	O
many	O
physiological	O
and	O
pathological	O
conditions	O
,	O
most	O
of	O
which	O
are	O
underlined	O
by	O
hypoxia	O
and	O
resultant	O
accumulation	O
of	O
lactate	O
.	O
<EOS>	B-X
Angiogenesis	B-X
,	B-X
the	B-X
process	B-X
of	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
from	B-X
pre-existing	B-X
one	B-X
,	B-X
occurs	B-X
in	B-X
many	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
,	B-X
most	B-X
of	B-X
which	B-X
are	B-X
underlined	B-X
by	B-X
hypoxia	B-X
and	B-X
resultant	B-X
accumulation	B-X
of	B-X
lactate	B-X
.	B-X
Although	B-X
lactate	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
angiogenesis	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
its	B-X
action	B-X
on	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
is	B-X
not	B-X
known	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
examine	B-X
the	B-X
response	B-X
of	B-X
ECs	B-X
to	B-X
lactate	B-X
.	B-X
Morphological	B-X
analysis	B-X
revealed	B-X
that	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
in	B-X
culture	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
switching	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
concomitant	B-X
with	B-X
upregulation	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
as	B-X
determined	B-X
by	B-X
reverse	B-X
transcription-PCR	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
Apart	B-X
from	B-X
increase	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
VEGF	B-X
protein	B-X
as	B-X
determined	B-X
by	B-X
ELISA	B-X
,	B-X
chorio	B-X
allantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
assay	B-X
using	B-X
the	B-X
cell	B-X
extracts	B-X
revealed	B-X
that	B-X
lactate	B-X
also	B-X
increased	B-X
the	B-X
angiogenic	B-X
potency	B-X
of	B-X
VEGF	B-X
.	B-X
Isolated	B-X
VEGF	B-X
,	B-X
when	B-X
blotted	B-X
and	B-X
subsequently	B-X
probed	B-X
with	B-X
anti-PAR	B-X
antibody	B-X
,	B-X
revealed	B-X
considerable	B-X
reduction	B-X
in	B-X
poly-adenosyl	B-X
ribosylation	B-X
of	B-X
VEGF	B-X
associated	B-X
with	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
NAD	B-X
(	B-X
+	B-X
)	B-X
,	B-X
in	B-X
presence	B-X
of	B-X
lactate	B-X
.	B-X
Thus	B-X
it	B-X
appears	B-X
that	B-X
ECs	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
increasing	B-X
the	B-X
production	B-X
of	B-X
VEGF	B-X
and	B-X
modulating	B-X
its	B-X
angiogenic	B-X
potency	B-X
through	B-X
poly-ADP	B-X
ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
-dependent	B-X
mechanism	B-X
and	B-X
thereby	B-X
switch	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
.	B-X

Although	O
lactate	O
is	O
known	O
to	O
induce	O
angiogenesis	O
,	O
the	O
mechanism	O
of	O
its	O
action	O
on	O
endothelial	O
cells	O
(	O
ECs	O
)	O
is	O
not	O
known	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
response	O
of	O
ECs	O
to	O
lactate	O
.	O
<EOS>	B-X
Angiogenesis	B-X
,	B-X
the	B-X
process	B-X
of	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
from	B-X
pre-existing	B-X
one	B-X
,	B-X
occurs	B-X
in	B-X
many	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
,	B-X
most	B-X
of	B-X
which	B-X
are	B-X
underlined	B-X
by	B-X
hypoxia	B-X
and	B-X
resultant	B-X
accumulation	B-X
of	B-X
lactate	B-X
.	B-X
Although	B-X
lactate	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
angiogenesis	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
its	B-X
action	B-X
on	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
is	B-X
not	B-X
known	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
examine	B-X
the	B-X
response	B-X
of	B-X
ECs	B-X
to	B-X
lactate	B-X
.	B-X
Morphological	B-X
analysis	B-X
revealed	B-X
that	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
in	B-X
culture	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
switching	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
concomitant	B-X
with	B-X
upregulation	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
as	B-X
determined	B-X
by	B-X
reverse	B-X
transcription-PCR	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
Apart	B-X
from	B-X
increase	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
VEGF	B-X
protein	B-X
as	B-X
determined	B-X
by	B-X
ELISA	B-X
,	B-X
chorio	B-X
allantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
assay	B-X
using	B-X
the	B-X
cell	B-X
extracts	B-X
revealed	B-X
that	B-X
lactate	B-X
also	B-X
increased	B-X
the	B-X
angiogenic	B-X
potency	B-X
of	B-X
VEGF	B-X
.	B-X
Isolated	B-X
VEGF	B-X
,	B-X
when	B-X
blotted	B-X
and	B-X
subsequently	B-X
probed	B-X
with	B-X
anti-PAR	B-X
antibody	B-X
,	B-X
revealed	B-X
considerable	B-X
reduction	B-X
in	B-X
poly-adenosyl	B-X
ribosylation	B-X
of	B-X
VEGF	B-X
associated	B-X
with	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
NAD	B-X
(	B-X
+	B-X
)	B-X
,	B-X
in	B-X
presence	B-X
of	B-X
lactate	B-X
.	B-X
Thus	B-X
it	B-X
appears	B-X
that	B-X
ECs	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
increasing	B-X
the	B-X
production	B-X
of	B-X
VEGF	B-X
and	B-X
modulating	B-X
its	B-X
angiogenic	B-X
potency	B-X
through	B-X
poly-ADP	B-X
ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
-dependent	B-X
mechanism	B-X
and	B-X
thereby	B-X
switch	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
.	B-X

Morphological	O
analysis	O
revealed	O
that	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
in	O
culture	O
respond	O
to	O
lactate	O
by	O
switching	O
over	O
to	O
angiogenic	O
phenotype	O
concomitant	O
with	O
upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
2	I-Protein
(	O
VEGFR2	B-Protein
)	O
as	O
determined	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
.	O
<EOS>	B-X
Angiogenesis	B-X
,	B-X
the	B-X
process	B-X
of	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
from	B-X
pre-existing	B-X
one	B-X
,	B-X
occurs	B-X
in	B-X
many	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
,	B-X
most	B-X
of	B-X
which	B-X
are	B-X
underlined	B-X
by	B-X
hypoxia	B-X
and	B-X
resultant	B-X
accumulation	B-X
of	B-X
lactate	B-X
.	B-X
Although	B-X
lactate	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
angiogenesis	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
its	B-X
action	B-X
on	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
is	B-X
not	B-X
known	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
examine	B-X
the	B-X
response	B-X
of	B-X
ECs	B-X
to	B-X
lactate	B-X
.	B-X
Morphological	B-X
analysis	B-X
revealed	B-X
that	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
in	B-X
culture	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
switching	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
concomitant	B-X
with	B-X
upregulation	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
as	B-X
determined	B-X
by	B-X
reverse	B-X
transcription-PCR	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
Apart	B-X
from	B-X
increase	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
VEGF	B-X
protein	B-X
as	B-X
determined	B-X
by	B-X
ELISA	B-X
,	B-X
chorio	B-X
allantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
assay	B-X
using	B-X
the	B-X
cell	B-X
extracts	B-X
revealed	B-X
that	B-X
lactate	B-X
also	B-X
increased	B-X
the	B-X
angiogenic	B-X
potency	B-X
of	B-X
VEGF	B-X
.	B-X
Isolated	B-X
VEGF	B-X
,	B-X
when	B-X
blotted	B-X
and	B-X
subsequently	B-X
probed	B-X
with	B-X
anti-PAR	B-X
antibody	B-X
,	B-X
revealed	B-X
considerable	B-X
reduction	B-X
in	B-X
poly-adenosyl	B-X
ribosylation	B-X
of	B-X
VEGF	B-X
associated	B-X
with	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
NAD	B-X
(	B-X
+	B-X
)	B-X
,	B-X
in	B-X
presence	B-X
of	B-X
lactate	B-X
.	B-X
Thus	B-X
it	B-X
appears	B-X
that	B-X
ECs	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
increasing	B-X
the	B-X
production	B-X
of	B-X
VEGF	B-X
and	B-X
modulating	B-X
its	B-X
angiogenic	B-X
potency	B-X
through	B-X
poly-ADP	B-X
ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
-dependent	B-X
mechanism	B-X
and	B-X
thereby	B-X
switch	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
.	B-X

Apart	O
from	O
increase	O
in	O
the	O
levels	O
of	O
VEGF	O
protein	O
as	O
determined	O
by	O
ELISA	O
,	O
chorio	O
allantoic	O
membrane	O
(	O
CAM	O
)	O
assay	O
using	O
the	O
cell	O
extracts	O
revealed	O
that	O
lactate	O
also	O
increased	O
the	O
angiogenic	O
potency	O
of	O
VEGF	O
.	O
<EOS>	B-X
Angiogenesis	B-X
,	B-X
the	B-X
process	B-X
of	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
from	B-X
pre-existing	B-X
one	B-X
,	B-X
occurs	B-X
in	B-X
many	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
,	B-X
most	B-X
of	B-X
which	B-X
are	B-X
underlined	B-X
by	B-X
hypoxia	B-X
and	B-X
resultant	B-X
accumulation	B-X
of	B-X
lactate	B-X
.	B-X
Although	B-X
lactate	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
angiogenesis	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
its	B-X
action	B-X
on	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
is	B-X
not	B-X
known	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
examine	B-X
the	B-X
response	B-X
of	B-X
ECs	B-X
to	B-X
lactate	B-X
.	B-X
Morphological	B-X
analysis	B-X
revealed	B-X
that	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
in	B-X
culture	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
switching	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
concomitant	B-X
with	B-X
upregulation	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
as	B-X
determined	B-X
by	B-X
reverse	B-X
transcription-PCR	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
Apart	B-X
from	B-X
increase	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
VEGF	B-X
protein	B-X
as	B-X
determined	B-X
by	B-X
ELISA	B-X
,	B-X
chorio	B-X
allantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
assay	B-X
using	B-X
the	B-X
cell	B-X
extracts	B-X
revealed	B-X
that	B-X
lactate	B-X
also	B-X
increased	B-X
the	B-X
angiogenic	B-X
potency	B-X
of	B-X
VEGF	B-X
.	B-X
Isolated	B-X
VEGF	B-X
,	B-X
when	B-X
blotted	B-X
and	B-X
subsequently	B-X
probed	B-X
with	B-X
anti-PAR	B-X
antibody	B-X
,	B-X
revealed	B-X
considerable	B-X
reduction	B-X
in	B-X
poly-adenosyl	B-X
ribosylation	B-X
of	B-X
VEGF	B-X
associated	B-X
with	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
NAD	B-X
(	B-X
+	B-X
)	B-X
,	B-X
in	B-X
presence	B-X
of	B-X
lactate	B-X
.	B-X
Thus	B-X
it	B-X
appears	B-X
that	B-X
ECs	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
increasing	B-X
the	B-X
production	B-X
of	B-X
VEGF	B-X
and	B-X
modulating	B-X
its	B-X
angiogenic	B-X
potency	B-X
through	B-X
poly-ADP	B-X
ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
-dependent	B-X
mechanism	B-X
and	B-X
thereby	B-X
switch	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
.	B-X

Isolated	O
VEGF	O
,	O
when	O
blotted	O
and	O
subsequently	O
probed	O
with	O
anti	O
-	O
PAR	O
antibody	O
,	O
revealed	O
considerable	O
reduction	O
in	O
poly	O
-	O
adenosyl	O
ribosylation	O
of	O
VEGF	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
NAD	O
(	O
+	O
)	O
,	O
in	O
presence	O
of	O
lactate	O
.	O
<EOS>	B-X
Angiogenesis	B-X
,	B-X
the	B-X
process	B-X
of	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
from	B-X
pre-existing	B-X
one	B-X
,	B-X
occurs	B-X
in	B-X
many	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
,	B-X
most	B-X
of	B-X
which	B-X
are	B-X
underlined	B-X
by	B-X
hypoxia	B-X
and	B-X
resultant	B-X
accumulation	B-X
of	B-X
lactate	B-X
.	B-X
Although	B-X
lactate	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
angiogenesis	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
its	B-X
action	B-X
on	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
is	B-X
not	B-X
known	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
examine	B-X
the	B-X
response	B-X
of	B-X
ECs	B-X
to	B-X
lactate	B-X
.	B-X
Morphological	B-X
analysis	B-X
revealed	B-X
that	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
in	B-X
culture	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
switching	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
concomitant	B-X
with	B-X
upregulation	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
as	B-X
determined	B-X
by	B-X
reverse	B-X
transcription-PCR	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
Apart	B-X
from	B-X
increase	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
VEGF	B-X
protein	B-X
as	B-X
determined	B-X
by	B-X
ELISA	B-X
,	B-X
chorio	B-X
allantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
assay	B-X
using	B-X
the	B-X
cell	B-X
extracts	B-X
revealed	B-X
that	B-X
lactate	B-X
also	B-X
increased	B-X
the	B-X
angiogenic	B-X
potency	B-X
of	B-X
VEGF	B-X
.	B-X
Isolated	B-X
VEGF	B-X
,	B-X
when	B-X
blotted	B-X
and	B-X
subsequently	B-X
probed	B-X
with	B-X
anti-PAR	B-X
antibody	B-X
,	B-X
revealed	B-X
considerable	B-X
reduction	B-X
in	B-X
poly-adenosyl	B-X
ribosylation	B-X
of	B-X
VEGF	B-X
associated	B-X
with	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
NAD	B-X
(	B-X
+	B-X
)	B-X
,	B-X
in	B-X
presence	B-X
of	B-X
lactate	B-X
.	B-X
Thus	B-X
it	B-X
appears	B-X
that	B-X
ECs	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
increasing	B-X
the	B-X
production	B-X
of	B-X
VEGF	B-X
and	B-X
modulating	B-X
its	B-X
angiogenic	B-X
potency	B-X
through	B-X
poly-ADP	B-X
ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
-dependent	B-X
mechanism	B-X
and	B-X
thereby	B-X
switch	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
.	B-X

Thus	O
it	O
appears	O
that	O
ECs	O
respond	O
to	O
lactate	O
by	O
increasing	O
the	O
production	O
of	O
VEGF	O
and	O
modulating	O
its	O
angiogenic	O
potency	O
through	O
poly	O
-	O
ADP	O
ribosylation	O
(	O
PAR	O
)	O
-	O
dependent	O
mechanism	O
and	O
thereby	O
switch	O
over	O
to	O
angiogenic	O
phenotype	O
.	O
<EOS>	B-X
Angiogenesis	B-X
,	B-X
the	B-X
process	B-X
of	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
from	B-X
pre-existing	B-X
one	B-X
,	B-X
occurs	B-X
in	B-X
many	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
,	B-X
most	B-X
of	B-X
which	B-X
are	B-X
underlined	B-X
by	B-X
hypoxia	B-X
and	B-X
resultant	B-X
accumulation	B-X
of	B-X
lactate	B-X
.	B-X
Although	B-X
lactate	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
angiogenesis	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
its	B-X
action	B-X
on	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
is	B-X
not	B-X
known	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
examine	B-X
the	B-X
response	B-X
of	B-X
ECs	B-X
to	B-X
lactate	B-X
.	B-X
Morphological	B-X
analysis	B-X
revealed	B-X
that	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
in	B-X
culture	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
switching	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
concomitant	B-X
with	B-X
upregulation	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor-2	B-X
(	B-X
VEGFR2	B-X
)	B-X
as	B-X
determined	B-X
by	B-X
reverse	B-X
transcription-PCR	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
Apart	B-X
from	B-X
increase	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
VEGF	B-X
protein	B-X
as	B-X
determined	B-X
by	B-X
ELISA	B-X
,	B-X
chorio	B-X
allantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
assay	B-X
using	B-X
the	B-X
cell	B-X
extracts	B-X
revealed	B-X
that	B-X
lactate	B-X
also	B-X
increased	B-X
the	B-X
angiogenic	B-X
potency	B-X
of	B-X
VEGF	B-X
.	B-X
Isolated	B-X
VEGF	B-X
,	B-X
when	B-X
blotted	B-X
and	B-X
subsequently	B-X
probed	B-X
with	B-X
anti-PAR	B-X
antibody	B-X
,	B-X
revealed	B-X
considerable	B-X
reduction	B-X
in	B-X
poly-adenosyl	B-X
ribosylation	B-X
of	B-X
VEGF	B-X
associated	B-X
with	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
NAD	B-X
(	B-X
+	B-X
)	B-X
,	B-X
in	B-X
presence	B-X
of	B-X
lactate	B-X
.	B-X
Thus	B-X
it	B-X
appears	B-X
that	B-X
ECs	B-X
respond	B-X
to	B-X
lactate	B-X
by	B-X
increasing	B-X
the	B-X
production	B-X
of	B-X
VEGF	B-X
and	B-X
modulating	B-X
its	B-X
angiogenic	B-X
potency	B-X
through	B-X
poly-ADP	B-X
ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
-dependent	B-X
mechanism	B-X
and	B-X
thereby	B-X
switch	B-X
over	B-X
to	B-X
angiogenic	B-X
phenotype	B-X
.	B-X

Tyrosine	O
sulfation	O
of	O
statherin	B-Protein
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
TPST	B-X
)	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
secretory	B-X
and	B-X
membrane	B-X
proteins	B-X
,	B-X
has	B-X
been	B-X
identified	B-X
and	B-X
characterized	B-X
in	B-X
submandibular	B-X
salivary	B-X
glands	B-X
(	B-X
William	B-X
et	B-X
al	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
,	B-X
statherin	B-X
,	B-X
by	B-X
the	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
present	B-X
in	B-X
human	B-X
saliva	B-X
.	B-X
Optimum	B-X
statherin	B-X
sulfation	B-X
was	B-X
observed	B-X
at	B-X
pH	B-X
6.5	B-X
and	B-X
at	B-X
20	B-X
mm	B-X
MnCl	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
total	B-X
sulfation	B-X
was	B-X
observed	B-X
with	B-X
increasing	B-X
statherin	B-X
concentration	B-X
.	B-X
The	B-X
K	B-X
(	B-X
m	B-X
)	B-X
value	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
for	B-X
statherin	B-X
was	B-X
40	B-X
microM	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
product	B-X
on	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
autoradiography	B-X
revealed	B-X
(	B-X
35	B-X
)	B-X
S-labelling	B-X
of	B-X
a	B-X
5	B-X
kDa	B-X
statherin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
revealed	B-X
the	B-X
sulfation	B-X
on	B-X
tyrosyl	B-X
residue	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
report	B-X
demonstrating	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
sulfation	B-X
of	B-X
statherin	B-X
in	B-X
hydroxyapatite	B-X
binding	B-X
and	B-X
Actinomyces	B-X
viscosus	B-X
interactions	B-X
are	B-X
discussed	B-X
.	B-X

Tyrosylprotein	O
sulfotransferase	O
(	O
TPST	O
)	O
,	O
responsible	O
for	O
the	O
sulfation	O
of	O
a	O
variety	O
of	O
secretory	O
and	O
membrane	O
proteins	O
,	O
has	O
been	O
identified	O
and	O
characterized	O
in	O
submandibular	O
salivary	O
glands	O
(	O
William	O
et	O
al	O
.	O
Arch	O
Biochem	O
Biophys	O
1997	O
;	O
338	O
:	O
90	O
-	O
96	O
)	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
TPST	B-X
)	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
secretory	B-X
and	B-X
membrane	B-X
proteins	B-X
,	B-X
has	B-X
been	B-X
identified	B-X
and	B-X
characterized	B-X
in	B-X
submandibular	B-X
salivary	B-X
glands	B-X
(	B-X
William	B-X
et	B-X
al	B-X
.	B-X
Arch	B-X
Biochem	B-X
Biophys	B-X
1997	B-X
;	B-X
338	B-X
:	B-X
90-96	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
,	B-X
statherin	B-X
,	B-X
by	B-X
the	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
present	B-X
in	B-X
human	B-X
saliva	B-X
.	B-X
Optimum	B-X
statherin	B-X
sulfation	B-X
was	B-X
observed	B-X
at	B-X
pH	B-X
6.5	B-X
and	B-X
at	B-X
20	B-X
mm	B-X
MnCl	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
total	B-X
sulfation	B-X
was	B-X
observed	B-X
with	B-X
increasing	B-X
statherin	B-X
concentration	B-X
.	B-X
The	B-X
K	B-X
(	B-X
m	B-X
)	B-X
value	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
for	B-X
statherin	B-X
was	B-X
40	B-X
microM	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
product	B-X
on	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
autoradiography	B-X
revealed	B-X
(	B-X
35	B-X
)	B-X
S-labelling	B-X
of	B-X
a	B-X
5	B-X
kDa	B-X
statherin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
revealed	B-X
the	B-X
sulfation	B-X
on	B-X
tyrosyl	B-X
residue	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
report	B-X
demonstrating	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
sulfation	B-X
of	B-X
statherin	B-X
in	B-X
hydroxyapatite	B-X
binding	B-X
and	B-X
Actinomyces	B-X
viscosus	B-X
interactions	B-X
are	B-X
discussed	B-X
.	B-X

In	O
the	O
present	O
study	O
we	O
demonstrate	O
the	O
sulfation	O
of	O
a	O
salivary	O
secretory	O
protein	O
,	O
statherin	B-Protein
,	O
by	O
the	O
tyrosylprotein	O
sulfotransferase	O
present	O
in	O
human	O
saliva	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
TPST	B-X
)	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
secretory	B-X
and	B-X
membrane	B-X
proteins	B-X
,	B-X
has	B-X
been	B-X
identified	B-X
and	B-X
characterized	B-X
in	B-X
submandibular	B-X
salivary	B-X
glands	B-X
(	B-X
William	B-X
et	B-X
al	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
,	B-X
statherin	B-X
,	B-X
by	B-X
the	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
present	B-X
in	B-X
human	B-X
saliva	B-X
.	B-X
Optimum	B-X
statherin	B-X
sulfation	B-X
was	B-X
observed	B-X
at	B-X
pH	B-X
6.5	B-X
and	B-X
at	B-X
20	B-X
mm	B-X
MnCl	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
total	B-X
sulfation	B-X
was	B-X
observed	B-X
with	B-X
increasing	B-X
statherin	B-X
concentration	B-X
.	B-X
The	B-X
K	B-X
(	B-X
m	B-X
)	B-X
value	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
for	B-X
statherin	B-X
was	B-X
40	B-X
microM	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
product	B-X
on	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
autoradiography	B-X
revealed	B-X
(	B-X
35	B-X
)	B-X
S-labelling	B-X
of	B-X
a	B-X
5	B-X
kDa	B-X
statherin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
revealed	B-X
the	B-X
sulfation	B-X
on	B-X
tyrosyl	B-X
residue	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
report	B-X
demonstrating	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
sulfation	B-X
of	B-X
statherin	B-X
in	B-X
hydroxyapatite	B-X
binding	B-X
and	B-X
Actinomyces	B-X
viscosus	B-X
interactions	B-X
are	B-X
discussed	B-X
.	B-X

Optimum	O
statherin	B-Protein
sulfation	O
was	O
observed	O
at	O
pH	O
6	O
.	O
5	O
and	O
at	O
20	O
mm	O
MnCl	O
(	O
2	O
)	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
TPST	B-X
)	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
secretory	B-X
and	B-X
membrane	B-X
proteins	B-X
,	B-X
has	B-X
been	B-X
identified	B-X
and	B-X
characterized	B-X
in	B-X
submandibular	B-X
salivary	B-X
glands	B-X
(	B-X
William	B-X
et	B-X
al	B-X
.	B-X
Arch	B-X
Biochem	B-X
Biophys	B-X
1997	B-X
;	B-X
338	B-X
:	B-X
90-96	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
,	B-X
statherin	B-X
,	B-X
by	B-X
the	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
present	B-X
in	B-X
human	B-X
saliva	B-X
.	B-X
Optimum	B-X
statherin	B-X
sulfation	B-X
was	B-X
observed	B-X
at	B-X
pH	B-X
6.5	B-X
and	B-X
at	B-X
20	B-X
mm	B-X
MnCl	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
total	B-X
sulfation	B-X
was	B-X
observed	B-X
with	B-X
increasing	B-X
statherin	B-X
concentration	B-X
.	B-X
The	B-X
K	B-X
(	B-X
m	B-X
)	B-X
value	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
for	B-X
statherin	B-X
was	B-X
40	B-X
microM	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
product	B-X
on	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
autoradiography	B-X
revealed	B-X
(	B-X
35	B-X
)	B-X
S-labelling	B-X
of	B-X
a	B-X
5	B-X
kDa	B-X
statherin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
revealed	B-X
the	B-X
sulfation	B-X
on	B-X
tyrosyl	B-X
residue	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
report	B-X
demonstrating	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
sulfation	B-X
of	B-X
statherin	B-X
in	B-X
hydroxyapatite	B-X
binding	B-X
and	B-X
Actinomyces	B-X
viscosus	B-X
interactions	B-X
are	B-X
discussed	B-X
.	B-X

Increase	O
in	O
the	O
level	O
of	O
total	O
sulfation	O
was	O
observed	O
with	O
increasing	O
statherin	B-Protein
concentration	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
TPST	B-X
)	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
secretory	B-X
and	B-X
membrane	B-X
proteins	B-X
,	B-X
has	B-X
been	B-X
identified	B-X
and	B-X
characterized	B-X
in	B-X
submandibular	B-X
salivary	B-X
glands	B-X
(	B-X
William	B-X
et	B-X
al	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
,	B-X
statherin	B-X
,	B-X
by	B-X
the	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
present	B-X
in	B-X
human	B-X
saliva	B-X
.	B-X
Optimum	B-X
statherin	B-X
sulfation	B-X
was	B-X
observed	B-X
at	B-X
pH	B-X
6.5	B-X
and	B-X
at	B-X
20	B-X
mm	B-X
MnCl	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
total	B-X
sulfation	B-X
was	B-X
observed	B-X
with	B-X
increasing	B-X
statherin	B-X
concentration	B-X
.	B-X
The	B-X
K	B-X
(	B-X
m	B-X
)	B-X
value	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
for	B-X
statherin	B-X
was	B-X
40	B-X
microM	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
product	B-X
on	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
autoradiography	B-X
revealed	B-X
(	B-X
35	B-X
)	B-X
S-labelling	B-X
of	B-X
a	B-X
5	B-X
kDa	B-X
statherin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
revealed	B-X
the	B-X
sulfation	B-X
on	B-X
tyrosyl	B-X
residue	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
report	B-X
demonstrating	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
sulfation	B-X
of	B-X
statherin	B-X
in	B-X
hydroxyapatite	B-X
binding	B-X
and	B-X
Actinomyces	B-X
viscosus	B-X
interactions	B-X
are	B-X
discussed	B-X
.	B-X

The	O
K	O
(	O
m	O
)	O
value	O
of	O
tyrosylprotein	O
sulfotransferase	O
for	O
statherin	B-Protein
was	O
40	O
microM	O
.	O

Analysis	O
of	O
the	O
sulfated	O
statherin	B-Protein
product	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
followed	O
by	O
autoradiography	O
revealed	O
(	O
35	O
)	O
S	O
-	O
labelling	O
of	O
a	O
5	O
kDa	O
statherin	B-Protein
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
,	B-X
statherin	B-X
,	B-X
by	B-X
the	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
present	B-X
in	B-X
human	B-X
saliva	B-X
.	B-X
Optimum	B-X
statherin	B-X
sulfation	B-X
was	B-X
observed	B-X
at	B-X
pH	B-X
6.5	B-X
and	B-X
at	B-X
20	B-X
mm	B-X
MnCl	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
total	B-X
sulfation	B-X
was	B-X
observed	B-X
with	B-X
increasing	B-X
statherin	B-X
concentration	B-X
.	B-X
The	B-X
K	B-X
(	B-X
m	B-X
)	B-X
value	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
for	B-X
statherin	B-X
was	B-X
40	B-X
microM	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
product	B-X
on	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
autoradiography	B-X
revealed	B-X
(	B-X
35	B-X
)	B-X
S-labelling	B-X
of	B-X
a	B-X
5	B-X
kDa	B-X
statherin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
revealed	B-X
the	B-X
sulfation	B-X
on	B-X
tyrosyl	B-X
residue	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
sulfation	B-X
of	B-X
statherin	B-X
in	B-X
hydroxyapatite	B-X
binding	B-X
and	B-X
Actinomyces	B-X
viscosus	B-X
interactions	B-X
are	B-X
discussed	B-X
.	B-X

Further	O
analysis	O
of	O
the	O
sulfated	O
statherin	B-Protein
revealed	O
the	O
sulfation	O
on	O
tyrosyl	O
residue	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
TPST	B-X
)	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
secretory	B-X
and	B-X
membrane	B-X
proteins	B-X
,	B-X
has	B-X
been	B-X
identified	B-X
and	B-X
characterized	B-X
in	B-X
submandibular	B-X
salivary	B-X
glands	B-X
(	B-X
William	B-X
et	B-X
al	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
,	B-X
statherin	B-X
,	B-X
by	B-X
the	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
present	B-X
in	B-X
human	B-X
saliva	B-X
.	B-X
Optimum	B-X
statherin	B-X
sulfation	B-X
was	B-X
observed	B-X
at	B-X
pH	B-X
6.5	B-X
and	B-X
at	B-X
20	B-X
mm	B-X
MnCl	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
total	B-X
sulfation	B-X
was	B-X
observed	B-X
with	B-X
increasing	B-X
statherin	B-X
concentration	B-X
.	B-X
The	B-X
K	B-X
(	B-X
m	B-X
)	B-X
value	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
for	B-X
statherin	B-X
was	B-X
40	B-X
microM	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
product	B-X
on	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
autoradiography	B-X
revealed	B-X
(	B-X
35	B-X
)	B-X
S-labelling	B-X
of	B-X
a	B-X
5	B-X
kDa	B-X
statherin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
revealed	B-X
the	B-X
sulfation	B-X
on	B-X
tyrosyl	B-X
residue	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
report	B-X
demonstrating	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
sulfation	B-X
of	B-X
statherin	B-X
in	B-X
hydroxyapatite	B-X
binding	B-X
and	B-X
Actinomyces	B-X
viscosus	B-X
interactions	B-X
are	B-X
discussed	B-X
.	B-X

This	O
study	O
is	O
the	O
first	O
report	O
demonstrating	O
tyrosine	O
sulfation	O
of	O
a	O
salivary	O
secretory	O
protein	O
.	O

The	O
implications	O
of	O
this	O
sulfation	O
of	O
statherin	B-Protein
in	O
hydroxyapatite	O
binding	O
and	O
Actinomyces	O
viscosus	O
interactions	O
are	O
discussed	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
TPST	B-X
)	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
secretory	B-X
and	B-X
membrane	B-X
proteins	B-X
,	B-X
has	B-X
been	B-X
identified	B-X
and	B-X
characterized	B-X
in	B-X
submandibular	B-X
salivary	B-X
glands	B-X
(	B-X
William	B-X
et	B-X
al	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
,	B-X
statherin	B-X
,	B-X
by	B-X
the	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
present	B-X
in	B-X
human	B-X
saliva	B-X
.	B-X
Optimum	B-X
statherin	B-X
sulfation	B-X
was	B-X
observed	B-X
at	B-X
pH	B-X
6.5	B-X
and	B-X
at	B-X
20	B-X
mm	B-X
MnCl	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
total	B-X
sulfation	B-X
was	B-X
observed	B-X
with	B-X
increasing	B-X
statherin	B-X
concentration	B-X
.	B-X
The	B-X
K	B-X
(	B-X
m	B-X
)	B-X
value	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
for	B-X
statherin	B-X
was	B-X
40	B-X
microM	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
product	B-X
on	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
autoradiography	B-X
revealed	B-X
(	B-X
35	B-X
)	B-X
S-labelling	B-X
of	B-X
a	B-X
5	B-X
kDa	B-X
statherin	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
the	B-X
sulfated	B-X
statherin	B-X
revealed	B-X
the	B-X
sulfation	B-X
on	B-X
tyrosyl	B-X
residue	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
report	B-X
demonstrating	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
a	B-X
salivary	B-X
secretory	B-X
protein	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
sulfation	B-X
of	B-X
statherin	B-X
in	B-X
hydroxyapatite	B-X
binding	B-X
and	B-X
Actinomyces	B-X
viscosus	B-X
interactions	B-X
are	B-X
discussed	B-X
.	B-X

Substrate	O
-	O
mediated	O
regulation	O
of	O
cullin	O
neddylation	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
of	B-X
neddylation	B-X
pathway	B-X
in	B-X
ischemic	B-X
stroke	B-X
remain	B-X
elusive	B-X
.	B-X
Inhibition	B-X
of	B-X
neddylation	B-X
by	B-X
MLN4924	B-X
,	B-X
also	B-X
known	B-X
as	B-X
pevonedistat	B-X
,	B-X
inactivated	B-X
cullin-RING	B-X
E3	B-X
ligase	B-X
(	B-X
CRL	B-X
)	B-X
,	B-X
and	B-X
reduced	B-X
brain	B-X
infarction	B-X
and	B-X
improved	B-X
functional	B-X
outcomes	B-X
.	B-X
By	B-X
using	B-X
virus-mediated	B-X
NF1	B-X
silencing	B-X
,	B-X
we	B-X
show	B-X
that	B-X
NF1	B-X
knockdown	B-X
abolished	B-X
MLN4924-dependent	B-X
inhibition	B-X
of	B-X
neutrophil	B-X
trafficking	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
mediated	B-X
through	B-X
activation	B-X
of	B-X
endothelial	B-X
P-selectin	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
(	B-X
ICAM-1	B-X
)	B-X
,	B-X
and	B-X
blocking	B-X
antibodies	B-X
against	B-X
P-selectin	B-X
or	B-X
anti-ICAM-1	B-X
antibodies	B-X
reversed	B-X
NF1	B-X
silencing-induced	B-X
increase	B-X
in	B-X
neutrophil	B-X
infiltration	B-X
in	B-X
MLN4924-treated	B-X
mice	B-X
.	B-X
Our	B-X
study	B-X
demonstrated	B-X
that	B-X
increased	B-X
neddylation	B-X
promoted	B-X
neutrophil	B-X
trafficking	B-X
and	B-X
thus	B-X
exacerbated	B-X
injury	B-X
of	B-X
the	B-X
BBB	B-X
and	B-X
stroke	B-X
outcomes	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
the	B-X
neddylation	B-X
inhibition	B-X
may	B-X
be	B-X
beneficial	B-X
in	B-X
ischemic	B-X
stroke	B-X
.	B-X

Cullin	O
-	O
based	O
E3	O
ligases	O
are	O
a	O
large	O
family	O
of	O
multi	O
-	O
subunit	O
ubiquitin	B-Protein
ligases	O
with	O
diverse	O
cellular	O
functions	O
,	O
including	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
,	O
of	O
the	O
DNA	O
damage	O
response	O
,	O
and	O
of	O
various	O
transcription	O
factors	O
.	O
<EOS>	B-X
Cullin-based	B-X
E3	B-X
ligases	B-X
are	B-X
a	B-X
large	B-X
family	B-X
of	B-X
multi-subunit	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
diverse	B-X
cellular	B-X
functions	B-X
,	B-X
including	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
response	B-X
,	B-X
and	B-X
of	B-X
various	B-X
transcription	B-X
factors	B-X
.	B-X
These	B-X
ligases	B-X
are	B-X
composed	B-X
of	B-X
one	B-X
of	B-X
six	B-X
mammalian	B-X
cullin	B-X
homologs	B-X
(	B-X
Cul1	B-X
,	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
Cul4a	B-X
,	B-X
Cul4b	B-X
,	B-X
and	B-X
Cul5	B-X
)	B-X
,	B-X
the	B-X
Ring	B-X
finger	B-X
containing	B-X
protein	B-X
Roc1/Rbx1	B-X
,	B-X
and	B-X
cullin	B-X
homolog-specific	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
To	B-X
be	B-X
active	B-X
,	B-X
cullin-based	B-X
ligases	B-X
require	B-X
the	B-X
covalent	B-X
modification	B-X
of	B-X
a	B-X
conserved	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
cullin	B-X
protein	B-X
with	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
.	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
that	B-X
in	B-X
intact	B-X
cells	B-X
Cul1	B-X
neddylation	B-X
is	B-X
dependent	B-X
on	B-X
binding	B-X
to	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
Mutant	B-X
Cul1	B-X
that	B-X
is	B-X
unable	B-X
to	B-X
recruit	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
exhibits	B-X
markedly	B-X
reduced	B-X
neddylation	B-X
,	B-X
and	B-X
inhibiting	B-X
binding	B-X
of	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
to	B-X
wild	B-X
type	B-X
Cul1	B-X
reduces	B-X
Nedd8	B-X
modification	B-X
.	B-X
This	B-X
regulatory	B-X
mechanism	B-X
also	B-X
extends	B-X
to	B-X
other	B-X
cullin-based	B-X
E3	B-X
ligases	B-X
,	B-X
including	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
and	B-X
Cul4a	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
cullin	B-X
neddylation	B-X
by	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
in	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
both	B-X
CAND1	B-X
and	B-X
the	B-X
COP9	B-X
signalosome	B-X
,	B-X
two	B-X
negative	B-X
regulators	B-X
of	B-X
cullin	B-X
Nedd8	B-X
modification	B-X
.	B-X
Using	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
,	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
Elongin	B-X
B/C-Cul2-VHL	B-X
ligase	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
substrate	B-X
binding	B-X
to	B-X
promote	B-X
Cul2	B-X
neddylation	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
require	B-X
substrate	B-X
ubiquitination	B-X
but	B-X
may	B-X
involve	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
availability	B-X
of	B-X
substrate	B-X
recognition	B-X
subunits	B-X
and	B-X
substrates	B-X
can	B-X
regulate	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X

These	O
ligases	O
are	O
composed	O
of	O
one	O
of	O
six	O
mammalian	O
cullin	O
homologs	O
(	O
Cul1	B-Protein
,	O
Cul2	B-Protein
,	O
Cul3	B-Protein
,	O
Cul4a	B-Protein
,	O
Cul4b	B-Protein
,	O
and	O
Cul5	B-Protein
)	O
,	O
the	O
Ring	O
finger	O
containing	O
protein	O
Roc1	B-Protein
/	O
Rbx1	B-Protein
,	O
and	O
cullin	O
homolog	O
-	O
specific	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
.	O
<EOS>	B-X
Cullin-based	B-X
E3	B-X
ligases	B-X
are	B-X
a	B-X
large	B-X
family	B-X
of	B-X
multi-subunit	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
diverse	B-X
cellular	B-X
functions	B-X
,	B-X
including	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
response	B-X
,	B-X
and	B-X
of	B-X
various	B-X
transcription	B-X
factors	B-X
.	B-X
These	B-X
ligases	B-X
are	B-X
composed	B-X
of	B-X
one	B-X
of	B-X
six	B-X
mammalian	B-X
cullin	B-X
homologs	B-X
(	B-X
Cul1	B-X
,	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
Cul4a	B-X
,	B-X
Cul4b	B-X
,	B-X
and	B-X
Cul5	B-X
)	B-X
,	B-X
the	B-X
Ring	B-X
finger	B-X
containing	B-X
protein	B-X
Roc1/Rbx1	B-X
,	B-X
and	B-X
cullin	B-X
homolog-specific	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
To	B-X
be	B-X
active	B-X
,	B-X
cullin-based	B-X
ligases	B-X
require	B-X
the	B-X
covalent	B-X
modification	B-X
of	B-X
a	B-X
conserved	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
cullin	B-X
protein	B-X
with	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
.	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
that	B-X
in	B-X
intact	B-X
cells	B-X
Cul1	B-X
neddylation	B-X
is	B-X
dependent	B-X
on	B-X
binding	B-X
to	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
Mutant	B-X
Cul1	B-X
that	B-X
is	B-X
unable	B-X
to	B-X
recruit	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
exhibits	B-X
markedly	B-X
reduced	B-X
neddylation	B-X
,	B-X
and	B-X
inhibiting	B-X
binding	B-X
of	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
to	B-X
wild	B-X
type	B-X
Cul1	B-X
reduces	B-X
Nedd8	B-X
modification	B-X
.	B-X
This	B-X
regulatory	B-X
mechanism	B-X
also	B-X
extends	B-X
to	B-X
other	B-X
cullin-based	B-X
E3	B-X
ligases	B-X
,	B-X
including	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
and	B-X
Cul4a	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
cullin	B-X
neddylation	B-X
by	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
in	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
both	B-X
CAND1	B-X
and	B-X
the	B-X
COP9	B-X
signalosome	B-X
,	B-X
two	B-X
negative	B-X
regulators	B-X
of	B-X
cullin	B-X
Nedd8	B-X
modification	B-X
.	B-X
Using	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
,	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
Elongin	B-X
B/C-Cul2-VHL	B-X
ligase	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
substrate	B-X
binding	B-X
to	B-X
promote	B-X
Cul2	B-X
neddylation	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
require	B-X
substrate	B-X
ubiquitination	B-X
but	B-X
may	B-X
involve	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
availability	B-X
of	B-X
substrate	B-X
recognition	B-X
subunits	B-X
and	B-X
substrates	B-X
can	B-X
regulate	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X

To	O
be	O
active	O
,	O
cullin	O
-	O
based	O
ligases	O
require	O
the	O
covalent	O
modification	O
of	O
a	O
conserved	O
lysine	O
residue	O
in	O
the	O
cullin	O
protein	O
with	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
.	O
<EOS>	B-X
Cullin-based	B-X
E3	B-X
ligases	B-X
are	B-X
a	B-X
large	B-X
family	B-X
of	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
diverse	B-X
cellular	B-X
functions	B-X
.	B-X
They	B-X
are	B-X
composed	B-X
of	B-X
one	B-X
of	B-X
six	B-X
mammalian	B-X
cullin	B-X
homologues	B-X
,	B-X
the	B-X
Ring	B-X
finger	B-X
containing	B-X
protein	B-X
Roc1/Rbx1	B-X
and	B-X
cullin	B-X
homologue-specific	B-X
adapter	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
To	B-X
be	B-X
active	B-X
,	B-X
cullin-based	B-X
ligases	B-X
require	B-X
the	B-X
covalent	B-X
modification	B-X
of	B-X
a	B-X
conserved	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
cullin	B-X
protein	B-X
with	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
.	B-X
To	B-X
characterize	B-X
this	B-X
family	B-X
of	B-X
E3	B-X
ligases	B-X
in	B-X
intact	B-X
cells	B-X
,	B-X
we	B-X
generated	B-X
a	B-X
cell	B-X
line	B-X
with	B-X
tetracycline-inducible	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Ubc12	B-X
,	B-X
a	B-X
reported	B-X
inhibitor	B-X
of	B-X
cullin	B-X
neddylation	B-X
.	B-X
Using	B-X
this	B-X
cell	B-X
line	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
substrate	B-X
recognition	B-X
subunit	B-X
Skp2	B-X
and	B-X
the	B-X
adaptor	B-X
protein	B-X
Skp1	B-X
are	B-X
subject	B-X
to	B-X
Ubc12-dependent	B-X
autoubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
cullin	B-X
protein	B-X
stability	B-X
is	B-X
not	B-X
regulated	B-X
by	B-X
neddylation	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
provide	B-X
evidence	B-X
that	B-X
Cul1	B-X
and	B-X
Cul3	B-X
,	B-X
as	B-X
well	B-X
as	B-X
their	B-X
associated	B-X
substrate	B-X
recognition	B-X
subunits	B-X
Skp2	B-X
and	B-X
Keap1	B-X
,	B-X
respectively	B-X
,	B-X
homooligomerize	B-X
in	B-X
intact	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
cullin-based	B-X
ligases	B-X
are	B-X
dimeric	B-X
.	B-X
As	B-X
shown	B-X
for	B-X
other	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
dimerization	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
activity	B-X
of	B-X
cullin-based	B-X
E3	B-X
ligases	B-X
.	B-X

We	O
show	O
in	O
this	O
study	O
that	O
in	O
intact	O
cells	O
Cul1	B-Protein
neddylation	O
is	O
dependent	O
on	O
binding	O
to	O
adaptor	O
proteins	O
and	O
substrate	O
recognition	O
subunits	O
.	O
<EOS>	B-X
These	B-X
ligases	B-X
are	B-X
composed	B-X
of	B-X
one	B-X
of	B-X
six	B-X
mammalian	B-X
cullin	B-X
homologs	B-X
(	B-X
Cul1	B-X
,	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
Cul4a	B-X
,	B-X
Cul4b	B-X
,	B-X
and	B-X
Cul5	B-X
)	B-X
,	B-X
the	B-X
Ring	B-X
finger	B-X
containing	B-X
protein	B-X
Roc1/Rbx1	B-X
,	B-X
and	B-X
cullin	B-X
homolog-specific	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
that	B-X
in	B-X
intact	B-X
cells	B-X
Cul1	B-X
neddylation	B-X
is	B-X
dependent	B-X
on	B-X
binding	B-X
to	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
Mutant	B-X
Cul1	B-X
that	B-X
is	B-X
unable	B-X
to	B-X
recruit	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
exhibits	B-X
markedly	B-X
reduced	B-X
neddylation	B-X
,	B-X
and	B-X
inhibiting	B-X
binding	B-X
of	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
to	B-X
wild	B-X
type	B-X
Cul1	B-X
reduces	B-X
Nedd8	B-X
modification	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
cullin	B-X
neddylation	B-X
by	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
in	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
both	B-X
CAND1	B-X
and	B-X
the	B-X
COP9	B-X
signalosome	B-X
,	B-X
two	B-X
negative	B-X
regulators	B-X
of	B-X
cullin	B-X
Nedd8	B-X
modification	B-X
.	B-X
Using	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
,	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
Elongin	B-X
B/C-Cul2-VHL	B-X
ligase	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
substrate	B-X
binding	B-X
to	B-X
promote	B-X
Cul2	B-X
neddylation	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
require	B-X
substrate	B-X
ubiquitination	B-X
but	B-X
may	B-X
involve	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
availability	B-X
of	B-X
substrate	B-X
recognition	B-X
subunits	B-X
and	B-X
substrates	B-X
can	B-X
regulate	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X

Mutant	O
Cul1	B-Protein
that	O
is	O
unable	O
to	O
recruit	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
exhibits	O
markedly	O
reduced	O
neddylation	O
,	O
and	O
inhibiting	O
binding	O
of	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
to	O
wild	O
type	O
Cul1	B-Protein
reduces	O
Nedd8	B-Protein
modification	O
.	O
<EOS>	B-X
These	B-X
ligases	B-X
are	B-X
composed	B-X
of	B-X
one	B-X
of	B-X
six	B-X
mammalian	B-X
cullin	B-X
homologs	B-X
(	B-X
Cul1	B-X
,	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
Cul4a	B-X
,	B-X
Cul4b	B-X
,	B-X
and	B-X
Cul5	B-X
)	B-X
,	B-X
the	B-X
Ring	B-X
finger	B-X
containing	B-X
protein	B-X
Roc1/Rbx1	B-X
,	B-X
and	B-X
cullin	B-X
homolog-specific	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
To	B-X
be	B-X
active	B-X
,	B-X
cullin-based	B-X
ligases	B-X
require	B-X
the	B-X
covalent	B-X
modification	B-X
of	B-X
a	B-X
conserved	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
cullin	B-X
protein	B-X
with	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
.	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
that	B-X
in	B-X
intact	B-X
cells	B-X
Cul1	B-X
neddylation	B-X
is	B-X
dependent	B-X
on	B-X
binding	B-X
to	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
Mutant	B-X
Cul1	B-X
that	B-X
is	B-X
unable	B-X
to	B-X
recruit	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
exhibits	B-X
markedly	B-X
reduced	B-X
neddylation	B-X
,	B-X
and	B-X
inhibiting	B-X
binding	B-X
of	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
to	B-X
wild	B-X
type	B-X
Cul1	B-X
reduces	B-X
Nedd8	B-X
modification	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
cullin	B-X
neddylation	B-X
by	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
in	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
both	B-X
CAND1	B-X
and	B-X
the	B-X
COP9	B-X
signalosome	B-X
,	B-X
two	B-X
negative	B-X
regulators	B-X
of	B-X
cullin	B-X
Nedd8	B-X
modification	B-X
.	B-X
Using	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
,	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
Elongin	B-X
B/C-Cul2-VHL	B-X
ligase	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
substrate	B-X
binding	B-X
to	B-X
promote	B-X
Cul2	B-X
neddylation	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
require	B-X
substrate	B-X
ubiquitination	B-X
but	B-X
may	B-X
involve	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
availability	B-X
of	B-X
substrate	B-X
recognition	B-X
subunits	B-X
and	B-X
substrates	B-X
can	B-X
regulate	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X

This	O
regulatory	O
mechanism	O
also	O
extends	O
to	O
other	O
cullin	O
-	O
based	O
E3	O
ligases	O
,	O
including	O
Cul2	B-Protein
,	O
Cul3	B-Protein
,	O
and	O
Cul4a	B-Protein
.	O
<EOS>	B-X
Cullin-based	B-X
E3	B-X
ligases	B-X
are	B-X
a	B-X
large	B-X
family	B-X
of	B-X
multi-subunit	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
diverse	B-X
cellular	B-X
functions	B-X
,	B-X
including	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
response	B-X
,	B-X
and	B-X
of	B-X
various	B-X
transcription	B-X
factors	B-X
.	B-X
These	B-X
ligases	B-X
are	B-X
composed	B-X
of	B-X
one	B-X
of	B-X
six	B-X
mammalian	B-X
cullin	B-X
homologs	B-X
(	B-X
Cul1	B-X
,	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
Cul4a	B-X
,	B-X
Cul4b	B-X
,	B-X
and	B-X
Cul5	B-X
)	B-X
,	B-X
the	B-X
Ring	B-X
finger	B-X
containing	B-X
protein	B-X
Roc1/Rbx1	B-X
,	B-X
and	B-X
cullin	B-X
homolog-specific	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
To	B-X
be	B-X
active	B-X
,	B-X
cullin-based	B-X
ligases	B-X
require	B-X
the	B-X
covalent	B-X
modification	B-X
of	B-X
a	B-X
conserved	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
cullin	B-X
protein	B-X
with	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
.	B-X
This	B-X
regulatory	B-X
mechanism	B-X
also	B-X
extends	B-X
to	B-X
other	B-X
cullin-based	B-X
E3	B-X
ligases	B-X
,	B-X
including	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
and	B-X
Cul4a	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
cullin	B-X
neddylation	B-X
by	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
in	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
both	B-X
CAND1	B-X
and	B-X
the	B-X
COP9	B-X
signalosome	B-X
,	B-X
two	B-X
negative	B-X
regulators	B-X
of	B-X
cullin	B-X
Nedd8	B-X
modification	B-X
.	B-X
Using	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
,	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
Elongin	B-X
B/C-Cul2-VHL	B-X
ligase	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
substrate	B-X
binding	B-X
to	B-X
promote	B-X
Cul2	B-X
neddylation	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
require	B-X
substrate	B-X
ubiquitination	B-X
but	B-X
may	B-X
involve	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
availability	B-X
of	B-X
substrate	B-X
recognition	B-X
subunits	B-X
and	B-X
substrates	B-X
can	B-X
regulate	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X

The	O
regulation	O
of	O
cullin	O
neddylation	O
by	O
adaptor	O
proteins	O
and	O
substrate	O
recognition	O
subunits	O
in	O
cells	O
was	O
found	O
to	O
be	O
independent	O
of	O
both	O
CAND1	B-Protein
and	O
the	O
COP9	O
signalosome	O
,	O
two	O
negative	O
regulators	O
of	O
cullin	O
Nedd8	B-Protein
modification	O
.	O
<EOS>	B-X
Cullin-based	B-X
E3	B-X
ligases	B-X
are	B-X
a	B-X
large	B-X
family	B-X
of	B-X
multi-subunit	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
diverse	B-X
cellular	B-X
functions	B-X
,	B-X
including	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
response	B-X
,	B-X
and	B-X
of	B-X
various	B-X
transcription	B-X
factors	B-X
.	B-X
These	B-X
ligases	B-X
are	B-X
composed	B-X
of	B-X
one	B-X
of	B-X
six	B-X
mammalian	B-X
cullin	B-X
homologs	B-X
(	B-X
Cul1	B-X
,	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
Cul4a	B-X
,	B-X
Cul4b	B-X
,	B-X
and	B-X
Cul5	B-X
)	B-X
,	B-X
the	B-X
Ring	B-X
finger	B-X
containing	B-X
protein	B-X
Roc1/Rbx1	B-X
,	B-X
and	B-X
cullin	B-X
homolog-specific	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
To	B-X
be	B-X
active	B-X
,	B-X
cullin-based	B-X
ligases	B-X
require	B-X
the	B-X
covalent	B-X
modification	B-X
of	B-X
a	B-X
conserved	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
cullin	B-X
protein	B-X
with	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
.	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
that	B-X
in	B-X
intact	B-X
cells	B-X
Cul1	B-X
neddylation	B-X
is	B-X
dependent	B-X
on	B-X
binding	B-X
to	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
Mutant	B-X
Cul1	B-X
that	B-X
is	B-X
unable	B-X
to	B-X
recruit	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
exhibits	B-X
markedly	B-X
reduced	B-X
neddylation	B-X
,	B-X
and	B-X
inhibiting	B-X
binding	B-X
of	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
to	B-X
wild	B-X
type	B-X
Cul1	B-X
reduces	B-X
Nedd8	B-X
modification	B-X
.	B-X
This	B-X
regulatory	B-X
mechanism	B-X
also	B-X
extends	B-X
to	B-X
other	B-X
cullin-based	B-X
E3	B-X
ligases	B-X
,	B-X
including	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
and	B-X
Cul4a	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
cullin	B-X
neddylation	B-X
by	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
in	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
both	B-X
CAND1	B-X
and	B-X
the	B-X
COP9	B-X
signalosome	B-X
,	B-X
two	B-X
negative	B-X
regulators	B-X
of	B-X
cullin	B-X
Nedd8	B-X
modification	B-X
.	B-X
Using	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
,	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
Elongin	B-X
B/C-Cul2-VHL	B-X
ligase	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
substrate	B-X
binding	B-X
to	B-X
promote	B-X
Cul2	B-X
neddylation	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
require	B-X
substrate	B-X
ubiquitination	B-X
but	B-X
may	B-X
involve	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
availability	B-X
of	B-X
substrate	B-X
recognition	B-X
subunits	B-X
and	B-X
substrates	B-X
can	B-X
regulate	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X

Using	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
,	O
a	O
substrate	O
of	O
the	O
Elongin	B-Protein
B	I-Protein
/	O
C	B-Protein
-	O
Cul2	B-Protein
-	O
VHL	B-Protein
ligase	O
,	O
we	O
demonstrate	O
the	O
critical	O
role	O
of	O
substrate	O
binding	O
to	O
promote	O
Cul2	B-Protein
neddylation	O
in	O
a	O
manner	O
that	O
does	O
not	O
require	O
substrate	O
ubiquitination	O
but	O
may	O
involve	O
a	O
conformational	O
change	O
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
through	O
which	O
availability	O
of	O
substrate	O
recognition	O
subunits	O
and	O
substrates	O
can	O
regulate	O
the	O
ubiquitin	B-Protein
ligase	O
activity	O
.	O
<EOS>	B-X
Cullin-based	B-X
E3	B-X
ligases	B-X
are	B-X
a	B-X
large	B-X
family	B-X
of	B-X
multi-subunit	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
diverse	B-X
cellular	B-X
functions	B-X
,	B-X
including	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
response	B-X
,	B-X
and	B-X
of	B-X
various	B-X
transcription	B-X
factors	B-X
.	B-X
These	B-X
ligases	B-X
are	B-X
composed	B-X
of	B-X
one	B-X
of	B-X
six	B-X
mammalian	B-X
cullin	B-X
homologs	B-X
(	B-X
Cul1	B-X
,	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
Cul4a	B-X
,	B-X
Cul4b	B-X
,	B-X
and	B-X
Cul5	B-X
)	B-X
,	B-X
the	B-X
Ring	B-X
finger	B-X
containing	B-X
protein	B-X
Roc1/Rbx1	B-X
,	B-X
and	B-X
cullin	B-X
homolog-specific	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
To	B-X
be	B-X
active	B-X
,	B-X
cullin-based	B-X
ligases	B-X
require	B-X
the	B-X
covalent	B-X
modification	B-X
of	B-X
a	B-X
conserved	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
cullin	B-X
protein	B-X
with	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
.	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
that	B-X
in	B-X
intact	B-X
cells	B-X
Cul1	B-X
neddylation	B-X
is	B-X
dependent	B-X
on	B-X
binding	B-X
to	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
.	B-X
Mutant	B-X
Cul1	B-X
that	B-X
is	B-X
unable	B-X
to	B-X
recruit	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
exhibits	B-X
markedly	B-X
reduced	B-X
neddylation	B-X
,	B-X
and	B-X
inhibiting	B-X
binding	B-X
of	B-X
adaptor	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
to	B-X
wild	B-X
type	B-X
Cul1	B-X
reduces	B-X
Nedd8	B-X
modification	B-X
.	B-X
This	B-X
regulatory	B-X
mechanism	B-X
also	B-X
extends	B-X
to	B-X
other	B-X
cullin-based	B-X
E3	B-X
ligases	B-X
,	B-X
including	B-X
Cul2	B-X
,	B-X
Cul3	B-X
,	B-X
and	B-X
Cul4a	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
cullin	B-X
neddylation	B-X
by	B-X
adaptor	B-X
proteins	B-X
and	B-X
substrate	B-X
recognition	B-X
subunits	B-X
in	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
both	B-X
CAND1	B-X
and	B-X
the	B-X
COP9	B-X
signalosome	B-X
,	B-X
two	B-X
negative	B-X
regulators	B-X
of	B-X
cullin	B-X
Nedd8	B-X
modification	B-X
.	B-X
Using	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
,	B-X
a	B-X
substrate	B-X
of	B-X
the	B-X
Elongin	B-X
B/C-Cul2-VHL	B-X
ligase	B-X
,	B-X
we	B-X
demonstrate	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
substrate	B-X
binding	B-X
to	B-X
promote	B-X
Cul2	B-X
neddylation	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
does	B-X
not	B-X
require	B-X
substrate	B-X
ubiquitination	B-X
but	B-X
may	B-X
involve	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
availability	B-X
of	B-X
substrate	B-X
recognition	B-X
subunits	B-X
and	B-X
substrates	B-X
can	B-X
regulate	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X

Pro	O
-	O
oxidant	O
activity	O
of	O
histatin	B-Protein
5	I-Protein
related	O
Cu	O
(	O
II	O
)	O
-	O
model	O
peptide	O
probed	O
by	O
mass	O
spectrometry	O
.	O
<EOS>	B-X
Histatin	B-X
5	B-X
is	B-X
a	B-X
cationic	B-X
salivary	B-X
peptide	B-X
with	B-X
strong	B-X
candidacidal	B-X
and	B-X
bactericidal	B-X
activity	B-X
at	B-X
physiological	B-X
concentration	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
demonstrate	B-X
by	B-X
optical	B-X
spectroscopy	B-X
and	B-X
ESI-IT-MS	B-X
experiments	B-X
that	B-X
a	B-X
synthetic	B-X
peptide	B-X
related	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
histatin	B-X
5	B-X
specifically	B-X
binds	B-X
copper	B-X
ions	B-X
in	B-X
vitro	B-X
and	B-X
that	B-X
the	B-X
complex	B-X
metal-peptide	B-X
generates	B-X
reactive	B-X
oxygen	B-X
species	B-X
at	B-X
physiological	B-X
concentration	B-X
of	B-X
ascorbate	B-X
,	B-X
leading	B-X
to	B-X
significant	B-X
auto-oxidation	B-X
of	B-X
the	B-X
peptide	B-X
within	B-X
short	B-X
reaction	B-X
time	B-X
.	B-X
The	B-X
oxidative	B-X
activity	B-X
of	B-X
this	B-X
peptide	B-X
is	B-X
associated	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
specific	B-X
metal	B-X
binding	B-X
site	B-X
present	B-X
at	B-X
its	B-X
N-terminus	B-X
.	B-X
The	B-X
results	B-X
of	B-X
the	B-X
study	B-X
suggest	B-X
that	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
can	B-X
be	B-X
an	B-X
intrinsic	B-X
property	B-X
of	B-X
histatin	B-X
5	B-X
connected	B-X
to	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
metals	B-X
.	B-X

Histatin	B-Protein
5	I-Protein
is	O
a	O
cationic	O
salivary	O
peptide	O
with	O
strong	O
candidacidal	O
and	O
bactericidal	O
activity	O
at	O
physiological	O
concentration	O
.	O
<EOS>	B-X
Histatin	B-X
5	B-X
is	B-X
a	B-X
cationic	B-X
salivary	B-X
peptide	B-X
with	B-X
strong	B-X
candidacidal	B-X
and	B-X
bactericidal	B-X
activity	B-X
at	B-X
physiological	B-X
concentration	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
demonstrate	B-X
by	B-X
optical	B-X
spectroscopy	B-X
and	B-X
ESI-IT-MS	B-X
experiments	B-X
that	B-X
a	B-X
synthetic	B-X
peptide	B-X
related	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
histatin	B-X
5	B-X
specifically	B-X
binds	B-X
copper	B-X
ions	B-X
in	B-X
vitro	B-X
and	B-X
that	B-X
the	B-X
complex	B-X
metal-peptide	B-X
generates	B-X
reactive	B-X
oxygen	B-X
species	B-X
at	B-X
physiological	B-X
concentration	B-X
of	B-X
ascorbate	B-X
,	B-X
leading	B-X
to	B-X
significant	B-X
auto-oxidation	B-X
of	B-X
the	B-X
peptide	B-X
within	B-X
short	B-X
reaction	B-X
time	B-X
.	B-X
The	B-X
oxidative	B-X
activity	B-X
of	B-X
this	B-X
peptide	B-X
is	B-X
associated	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
specific	B-X
metal	B-X
binding	B-X
site	B-X
present	B-X
at	B-X
its	B-X
N-terminus	B-X
.	B-X
The	B-X
results	B-X
of	B-X
the	B-X
study	B-X
suggest	B-X
that	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
can	B-X
be	B-X
an	B-X
intrinsic	B-X
property	B-X
of	B-X
histatin	B-X
5	B-X
connected	B-X
to	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
metals	B-X
.	B-X

In	O
this	O
paper	O
we	O
demonstrate	O
by	O
optical	O
spectroscopy	O
and	O
ESI	O
-	O
IT	O
-	O
MS	O
experiments	O
that	O
a	O
synthetic	O
peptide	O
related	O
to	O
the	O
N	O
-	O
terminus	O
of	O
histatin	B-Protein
5	I-Protein
specifically	O
binds	O
copper	O
ions	O
in	O
vitro	O
and	O
that	O
the	O
complex	O
metal	O
-	O
peptide	O
generates	O
reactive	O
oxygen	O
species	O
at	O
physiological	O
concentration	O
of	O
ascorbate	O
,	O
leading	O
to	O
significant	O
auto	O
-	O
oxidation	O
of	O
the	O
peptide	O
within	O
short	O
reaction	O
time	O
.	O

The	O
oxidative	O
activity	O
of	O
this	O
peptide	O
is	O
associated	O
to	O
the	O
presence	O
of	O
a	O
specific	O
metal	O
binding	O
site	O
present	O
at	O
its	O
N	O
-	O
terminus	O
.	O

The	O
motif	O
is	O
constituted	O
by	O
the	O
amino	O
acid	O
sequence	O
NH	O
(	O
2	O
)	O
-	O
Asp	O
-	O
Ser	O
-	O
His	O
,	O
representing	O
a	O
copper	O
and	O
nickel	O
amino	O
terminal	O
binding	O
site	O
,	O
known	O
as	O
"	O
ATCUN	O
motif	O
"	O
.	O
<EOS>	B-X
Histatin	B-X
5	B-X
is	B-X
a	B-X
cationic	B-X
salivary	B-X
peptide	B-X
with	B-X
strong	B-X
candidacidal	B-X
and	B-X
bactericidal	B-X
activity	B-X
at	B-X
physiological	B-X
concentration	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
demonstrate	B-X
by	B-X
optical	B-X
spectroscopy	B-X
and	B-X
ESI-IT-MS	B-X
experiments	B-X
that	B-X
a	B-X
synthetic	B-X
peptide	B-X
related	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
histatin	B-X
5	B-X
specifically	B-X
binds	B-X
copper	B-X
ions	B-X
in	B-X
vitro	B-X
and	B-X
that	B-X
the	B-X
complex	B-X
metal-peptide	B-X
generates	B-X
reactive	B-X
oxygen	B-X
species	B-X
at	B-X
physiological	B-X
concentration	B-X
of	B-X
ascorbate	B-X
,	B-X
leading	B-X
to	B-X
significant	B-X
auto-oxidation	B-X
of	B-X
the	B-X
peptide	B-X
within	B-X
short	B-X
reaction	B-X
time	B-X
.	B-X
The	B-X
oxidative	B-X
activity	B-X
of	B-X
this	B-X
peptide	B-X
is	B-X
associated	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
specific	B-X
metal	B-X
binding	B-X
site	B-X
present	B-X
at	B-X
its	B-X
N-terminus	B-X
.	B-X
The	B-X
motif	B-X
is	B-X
constituted	B-X
by	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
-Asp-Ser-His	B-X
,	B-X
representing	B-X
a	B-X
copper	B-X
and	B-X
nickel	B-X
amino	B-X
terminal	B-X
binding	B-X
site	B-X
,	B-X
known	B-X
as	B-X
``	B-X
ATCUN	B-X
motif	B-X
''	B-X
.	B-X

The	O
results	O
of	O
the	O
study	O
suggest	O
that	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
can	O
be	O
an	O
intrinsic	O
property	O
of	O
histatin	B-Protein
5	I-Protein
connected	O
to	O
its	O
ability	O
to	O
bind	O
metals	O
.	O

Roles	O
for	O
negative	O
cell	O
regulator	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
in	O
control	O
of	O
MDM2	B-Protein
activities	O
.	O
<EOS>	B-X
The	B-X
14-3-3sigma	B-X
,	B-X
upregulated	B-X
by	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
can	B-X
have	B-X
a	B-X
positive-feedback	B-X
impact	B-X
driving	B-X
p53	B-X
activities	B-X
and	B-X
is	B-X
a	B-X
human	B-X
cancer	B-X
epithelial	B-X
marker	B-X
downregulated	B-X
in	B-X
various	B-X
tumors	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
14-3-3sigma	B-X
during	B-X
tumorigenesis	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
oncogene	B-X
(	B-X
MDM2	B-X
)	B-X
.	B-X
14-3-3sigma	B-X
interacts	B-X
with	B-X
MDM2	B-X
at	B-X
the	B-X
RING	B-X
domain	B-X
.	B-X
The	B-X
C-terminal	B-X
region	B-X
of	B-X
14-3-3sigma	B-X
binds	B-X
to	B-X
MDM2	B-X
very	B-X
efficiently	B-X
.	B-X
Importantly	B-X
,	B-X
14-3-3sigma	B-X
overexpression	B-X
leads	B-X
to	B-X
destabilization	B-X
of	B-X
MDM2	B-X
through	B-X
enhancing	B-X
MDM2	B-X
self-ubiquitination	B-X
and	B-X
accelerating	B-X
turnover	B-X
rate	B-X
.	B-X
Conversely	B-X
,	B-X
loss	B-X
of	B-X
14-3-3sigma	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
MDM2	B-X
protein	B-X
.	B-X
Moreover	B-X
,	B-X
live-cell	B-X
images	B-X
indicated	B-X
that	B-X
14-3-3sigma	B-X
can	B-X
affect	B-X
the	B-X
location	B-X
of	B-X
MDM2	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
that	B-X
MDM2-mediated	B-X
cytoplasmic	B-X
localization	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
14-3-3sigma	B-X
.	B-X
Significantly	B-X
,	B-X
we	B-X
further	B-X
showed	B-X
that	B-X
14-3-3sigma	B-X
causes	B-X
MDM2	B-X
downregulation	B-X
,	B-X
thereby	B-X
stabilizing	B-X
p53	B-X
and	B-X
inhibiting	B-X
tumor	B-X
growth	B-X
in	B-X
animal	B-X
tumors	B-X
.	B-X
Also	B-X
,	B-X
14-3-3sigma	B-X
blocks	B-X
MDM2-mediated	B-X
retinoblastoma	B-X
degradation	B-X
and	B-X
p53	B-X
NEDDylation	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
pivotal	B-X
MDM2	B-X
regulator	B-X
involved	B-X
in	B-X
blocking	B-X
a	B-X
variety	B-X
of	B-X
activities	B-X
of	B-X
MDM2	B-X
.	B-X

The	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
,	O
upregulated	O
by	O
p53	B-Protein
in	O
response	O
to	O
DNA	O
damage	O
,	O
can	O
have	O
a	O
positive	O
-	O
feedback	O
impact	O
driving	O
p53	B-Protein
activities	O
and	O
is	O
a	O
human	O
cancer	O
epithelial	O
marker	O
downregulated	O
in	O
various	O
tumors	O
.	O
<EOS>	B-X
The	B-X
14-3-3sigma	B-X
,	B-X
upregulated	B-X
by	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
can	B-X
have	B-X
a	B-X
positive-feedback	B-X
impact	B-X
driving	B-X
p53	B-X
activities	B-X
and	B-X
is	B-X
a	B-X
human	B-X
cancer	B-X
epithelial	B-X
marker	B-X
downregulated	B-X
in	B-X
various	B-X
tumors	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
14-3-3sigma	B-X
during	B-X
tumorigenesis	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
oncogene	B-X
(	B-X
MDM2	B-X
)	B-X
.	B-X
14-3-3sigma	B-X
interacts	B-X
with	B-X
MDM2	B-X
at	B-X
the	B-X
RING	B-X
domain	B-X
.	B-X
The	B-X
C-terminal	B-X
region	B-X
of	B-X
14-3-3sigma	B-X
binds	B-X
to	B-X
MDM2	B-X
very	B-X
efficiently	B-X
.	B-X
Importantly	B-X
,	B-X
14-3-3sigma	B-X
overexpression	B-X
leads	B-X
to	B-X
destabilization	B-X
of	B-X
MDM2	B-X
through	B-X
enhancing	B-X
MDM2	B-X
self-ubiquitination	B-X
and	B-X
accelerating	B-X
turnover	B-X
rate	B-X
.	B-X
Conversely	B-X
,	B-X
loss	B-X
of	B-X
14-3-3sigma	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
MDM2	B-X
protein	B-X
.	B-X
Moreover	B-X
,	B-X
live-cell	B-X
images	B-X
indicated	B-X
that	B-X
14-3-3sigma	B-X
can	B-X
affect	B-X
the	B-X
location	B-X
of	B-X
MDM2	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
that	B-X
MDM2-mediated	B-X
cytoplasmic	B-X
localization	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
14-3-3sigma	B-X
.	B-X
Significantly	B-X
,	B-X
we	B-X
further	B-X
showed	B-X
that	B-X
14-3-3sigma	B-X
causes	B-X
MDM2	B-X
downregulation	B-X
,	B-X
thereby	B-X
stabilizing	B-X
p53	B-X
and	B-X
inhibiting	B-X
tumor	B-X
growth	B-X
in	B-X
animal	B-X
tumors	B-X
.	B-X
Also	B-X
,	B-X
14-3-3sigma	B-X
blocks	B-X
MDM2-mediated	B-X
retinoblastoma	B-X
degradation	B-X
and	B-X
p53	B-X
NEDDylation	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
pivotal	B-X
MDM2	B-X
regulator	B-X
involved	B-X
in	B-X
blocking	B-X
a	B-X
variety	B-X
of	B-X
activities	B-X
of	B-X
MDM2	B-X
.	B-X

However	O
,	O
the	O
precise	O
roles	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
during	O
tumorigenesis	O
are	O
not	O
well	O
characterized	O
.	O

Here	O
,	O
we	O
show	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
is	O
a	O
critical	O
regulator	O
of	O
murine	O
double	O
minute	O
oncogene	O
(	O
MDM2	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
14-3-3sigma	B-X
,	B-X
upregulated	B-X
by	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
can	B-X
have	B-X
a	B-X
positive-feedback	B-X
impact	B-X
driving	B-X
p53	B-X
activities	B-X
and	B-X
is	B-X
a	B-X
human	B-X
cancer	B-X
epithelial	B-X
marker	B-X
downregulated	B-X
in	B-X
various	B-X
tumors	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
14-3-3sigma	B-X
during	B-X
tumorigenesis	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
oncogene	B-X
(	B-X
MDM2	B-X
)	B-X
.	B-X
14-3-3sigma	B-X
interacts	B-X
with	B-X
MDM2	B-X
at	B-X
the	B-X
RING	B-X
domain	B-X
.	B-X
The	B-X
C-terminal	B-X
region	B-X
of	B-X
14-3-3sigma	B-X
binds	B-X
to	B-X
MDM2	B-X
very	B-X
efficiently	B-X
.	B-X
Importantly	B-X
,	B-X
14-3-3sigma	B-X
overexpression	B-X
leads	B-X
to	B-X
destabilization	B-X
of	B-X
MDM2	B-X
through	B-X
enhancing	B-X
MDM2	B-X
self-ubiquitination	B-X
and	B-X
accelerating	B-X
turnover	B-X
rate	B-X
.	B-X
Conversely	B-X
,	B-X
loss	B-X
of	B-X
14-3-3sigma	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
MDM2	B-X
protein	B-X
.	B-X
Moreover	B-X
,	B-X
live-cell	B-X
images	B-X
indicated	B-X
that	B-X
14-3-3sigma	B-X
can	B-X
affect	B-X
the	B-X
location	B-X
of	B-X
MDM2	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
that	B-X
MDM2-mediated	B-X
cytoplasmic	B-X
localization	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
14-3-3sigma	B-X
.	B-X
Significantly	B-X
,	B-X
we	B-X
further	B-X
showed	B-X
that	B-X
14-3-3sigma	B-X
causes	B-X
MDM2	B-X
downregulation	B-X
,	B-X
thereby	B-X
stabilizing	B-X
p53	B-X
and	B-X
inhibiting	B-X
tumor	B-X
growth	B-X
in	B-X
animal	B-X
tumors	B-X
.	B-X
Also	B-X
,	B-X
14-3-3sigma	B-X
blocks	B-X
MDM2-mediated	B-X
retinoblastoma	B-X
degradation	B-X
and	B-X
p53	B-X
NEDDylation	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
pivotal	B-X
MDM2	B-X
regulator	B-X
involved	B-X
in	B-X
blocking	B-X
a	B-X
variety	B-X
of	B-X
activities	B-X
of	B-X
MDM2	B-X
.	B-X

14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
interacts	O
with	O
MDM2	B-Protein
at	O
the	O
RING	O
domain	O
.	O
<EOS>	B-X
The	B-X
14-3-3sigma	B-X
,	B-X
upregulated	B-X
by	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
can	B-X
have	B-X
a	B-X
positive-feedback	B-X
impact	B-X
driving	B-X
p53	B-X
activities	B-X
and	B-X
is	B-X
a	B-X
human	B-X
cancer	B-X
epithelial	B-X
marker	B-X
downregulated	B-X
in	B-X
various	B-X
tumors	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
14-3-3sigma	B-X
during	B-X
tumorigenesis	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
oncogene	B-X
(	B-X
MDM2	B-X
)	B-X
.	B-X
14-3-3sigma	B-X
interacts	B-X
with	B-X
MDM2	B-X
at	B-X
the	B-X
RING	B-X
domain	B-X
.	B-X
The	B-X
C-terminal	B-X
region	B-X
of	B-X
14-3-3sigma	B-X
binds	B-X
to	B-X
MDM2	B-X
very	B-X
efficiently	B-X
.	B-X
Importantly	B-X
,	B-X
14-3-3sigma	B-X
overexpression	B-X
leads	B-X
to	B-X
destabilization	B-X
of	B-X
MDM2	B-X
through	B-X
enhancing	B-X
MDM2	B-X
self-ubiquitination	B-X
and	B-X
accelerating	B-X
turnover	B-X
rate	B-X
.	B-X
Conversely	B-X
,	B-X
loss	B-X
of	B-X
14-3-3sigma	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
MDM2	B-X
protein	B-X
.	B-X
Moreover	B-X
,	B-X
live-cell	B-X
images	B-X
indicated	B-X
that	B-X
14-3-3sigma	B-X
can	B-X
affect	B-X
the	B-X
location	B-X
of	B-X
MDM2	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
that	B-X
MDM2-mediated	B-X
cytoplasmic	B-X
localization	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
14-3-3sigma	B-X
.	B-X
Significantly	B-X
,	B-X
we	B-X
further	B-X
showed	B-X
that	B-X
14-3-3sigma	B-X
causes	B-X
MDM2	B-X
downregulation	B-X
,	B-X
thereby	B-X
stabilizing	B-X
p53	B-X
and	B-X
inhibiting	B-X
tumor	B-X
growth	B-X
in	B-X
animal	B-X
tumors	B-X
.	B-X
Also	B-X
,	B-X
14-3-3sigma	B-X
blocks	B-X
MDM2-mediated	B-X
retinoblastoma	B-X
degradation	B-X
and	B-X
p53	B-X
NEDDylation	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
pivotal	B-X
MDM2	B-X
regulator	B-X
involved	B-X
in	B-X
blocking	B-X
a	B-X
variety	B-X
of	B-X
activities	B-X
of	B-X
MDM2	B-X
.	B-X

The	O
C	O
-	O
terminal	O
region	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
binds	O
to	O
MDM2	B-Protein
very	O
efficiently	O
.	O

Importantly	O
,	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
overexpression	O
leads	O
to	O
destabilization	O
of	O
MDM2	B-Protein
through	O
enhancing	O
MDM2	B-Protein
self	O
-	O
ubiquitination	O
and	O
accelerating	O
turnover	O
rate	O
.	O
<EOS>	B-X
The	B-X
14-3-3sigma	B-X
,	B-X
upregulated	B-X
by	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
can	B-X
have	B-X
a	B-X
positive-feedback	B-X
impact	B-X
driving	B-X
p53	B-X
activities	B-X
and	B-X
is	B-X
a	B-X
human	B-X
cancer	B-X
epithelial	B-X
marker	B-X
downregulated	B-X
in	B-X
various	B-X
tumors	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
14-3-3sigma	B-X
during	B-X
tumorigenesis	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
oncogene	B-X
(	B-X
MDM2	B-X
)	B-X
.	B-X
14-3-3sigma	B-X
interacts	B-X
with	B-X
MDM2	B-X
at	B-X
the	B-X
RING	B-X
domain	B-X
.	B-X
The	B-X
C-terminal	B-X
region	B-X
of	B-X
14-3-3sigma	B-X
binds	B-X
to	B-X
MDM2	B-X
very	B-X
efficiently	B-X
.	B-X
Importantly	B-X
,	B-X
14-3-3sigma	B-X
overexpression	B-X
leads	B-X
to	B-X
destabilization	B-X
of	B-X
MDM2	B-X
through	B-X
enhancing	B-X
MDM2	B-X
self-ubiquitination	B-X
and	B-X
accelerating	B-X
turnover	B-X
rate	B-X
.	B-X
Conversely	B-X
,	B-X
loss	B-X
of	B-X
14-3-3sigma	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
MDM2	B-X
protein	B-X
.	B-X
Moreover	B-X
,	B-X
live-cell	B-X
images	B-X
indicated	B-X
that	B-X
14-3-3sigma	B-X
can	B-X
affect	B-X
the	B-X
location	B-X
of	B-X
MDM2	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
that	B-X
MDM2-mediated	B-X
cytoplasmic	B-X
localization	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
14-3-3sigma	B-X
.	B-X
Significantly	B-X
,	B-X
we	B-X
further	B-X
showed	B-X
that	B-X
14-3-3sigma	B-X
causes	B-X
MDM2	B-X
downregulation	B-X
,	B-X
thereby	B-X
stabilizing	B-X
p53	B-X
and	B-X
inhibiting	B-X
tumor	B-X
growth	B-X
in	B-X
animal	B-X
tumors	B-X
.	B-X
Also	B-X
,	B-X
14-3-3sigma	B-X
blocks	B-X
MDM2-mediated	B-X
retinoblastoma	B-X
degradation	B-X
and	B-X
p53	B-X
NEDDylation	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
pivotal	B-X
MDM2	B-X
regulator	B-X
involved	B-X
in	B-X
blocking	B-X
a	B-X
variety	B-X
of	B-X
activities	B-X
of	B-X
MDM2	B-X
.	B-X

Conversely	O
,	O
loss	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
results	O
in	O
a	O
significant	O
increase	O
in	O
MDM2	B-Protein
protein	O
.	O

Moreover	O
,	O
live	O
-	O
cell	O
images	O
indicated	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
can	O
affect	O
the	O
location	O
of	O
MDM2	B-Protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
and	O
that	O
MDM2	B-Protein
-	O
mediated	O
cytoplasmic	O
localization	O
of	O
p53	B-Protein
can	O
be	O
reversed	O
by	O
the	O
presence	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
.	O

Significantly	O
,	O
we	O
further	O
showed	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
causes	O
MDM2	B-Protein
downregulation	O
,	O
thereby	O
stabilizing	O
p53	B-Protein
and	O
inhibiting	O
tumor	O
growth	O
in	O
animal	O
tumors	O
.	O
<EOS>	B-X
The	B-X
14-3-3sigma	B-X
,	B-X
upregulated	B-X
by	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
can	B-X
have	B-X
a	B-X
positive-feedback	B-X
impact	B-X
driving	B-X
p53	B-X
activities	B-X
and	B-X
is	B-X
a	B-X
human	B-X
cancer	B-X
epithelial	B-X
marker	B-X
downregulated	B-X
in	B-X
various	B-X
tumors	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
14-3-3sigma	B-X
during	B-X
tumorigenesis	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
oncogene	B-X
(	B-X
MDM2	B-X
)	B-X
.	B-X
14-3-3sigma	B-X
interacts	B-X
with	B-X
MDM2	B-X
at	B-X
the	B-X
RING	B-X
domain	B-X
.	B-X
The	B-X
C-terminal	B-X
region	B-X
of	B-X
14-3-3sigma	B-X
binds	B-X
to	B-X
MDM2	B-X
very	B-X
efficiently	B-X
.	B-X
Importantly	B-X
,	B-X
14-3-3sigma	B-X
overexpression	B-X
leads	B-X
to	B-X
destabilization	B-X
of	B-X
MDM2	B-X
through	B-X
enhancing	B-X
MDM2	B-X
self-ubiquitination	B-X
and	B-X
accelerating	B-X
turnover	B-X
rate	B-X
.	B-X
Conversely	B-X
,	B-X
loss	B-X
of	B-X
14-3-3sigma	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
MDM2	B-X
protein	B-X
.	B-X
Moreover	B-X
,	B-X
live-cell	B-X
images	B-X
indicated	B-X
that	B-X
14-3-3sigma	B-X
can	B-X
affect	B-X
the	B-X
location	B-X
of	B-X
MDM2	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
that	B-X
MDM2-mediated	B-X
cytoplasmic	B-X
localization	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
14-3-3sigma	B-X
.	B-X
Significantly	B-X
,	B-X
we	B-X
further	B-X
showed	B-X
that	B-X
14-3-3sigma	B-X
causes	B-X
MDM2	B-X
downregulation	B-X
,	B-X
thereby	B-X
stabilizing	B-X
p53	B-X
and	B-X
inhibiting	B-X
tumor	B-X
growth	B-X
in	B-X
animal	B-X
tumors	B-X
.	B-X
Also	B-X
,	B-X
14-3-3sigma	B-X
blocks	B-X
MDM2-mediated	B-X
retinoblastoma	B-X
degradation	B-X
and	B-X
p53	B-X
NEDDylation	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
pivotal	B-X
MDM2	B-X
regulator	B-X
involved	B-X
in	B-X
blocking	B-X
a	B-X
variety	B-X
of	B-X
activities	B-X
of	B-X
MDM2	B-X
.	B-X

Also	O
,	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
blocks	O
MDM2	B-Protein
-	O
mediated	O
retinoblastoma	O
degradation	O
and	O
p53	B-Protein
NEDDylation	O
.	O
<EOS>	B-X
The	B-X
14-3-3sigma	B-X
,	B-X
upregulated	B-X
by	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
can	B-X
have	B-X
a	B-X
positive-feedback	B-X
impact	B-X
driving	B-X
p53	B-X
activities	B-X
and	B-X
is	B-X
a	B-X
human	B-X
cancer	B-X
epithelial	B-X
marker	B-X
downregulated	B-X
in	B-X
various	B-X
tumors	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
14-3-3sigma	B-X
during	B-X
tumorigenesis	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
oncogene	B-X
(	B-X
MDM2	B-X
)	B-X
.	B-X
14-3-3sigma	B-X
interacts	B-X
with	B-X
MDM2	B-X
at	B-X
the	B-X
RING	B-X
domain	B-X
.	B-X
The	B-X
C-terminal	B-X
region	B-X
of	B-X
14-3-3sigma	B-X
binds	B-X
to	B-X
MDM2	B-X
very	B-X
efficiently	B-X
.	B-X
Importantly	B-X
,	B-X
14-3-3sigma	B-X
overexpression	B-X
leads	B-X
to	B-X
destabilization	B-X
of	B-X
MDM2	B-X
through	B-X
enhancing	B-X
MDM2	B-X
self-ubiquitination	B-X
and	B-X
accelerating	B-X
turnover	B-X
rate	B-X
.	B-X
Conversely	B-X
,	B-X
loss	B-X
of	B-X
14-3-3sigma	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
MDM2	B-X
protein	B-X
.	B-X
Moreover	B-X
,	B-X
live-cell	B-X
images	B-X
indicated	B-X
that	B-X
14-3-3sigma	B-X
can	B-X
affect	B-X
the	B-X
location	B-X
of	B-X
MDM2	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
that	B-X
MDM2-mediated	B-X
cytoplasmic	B-X
localization	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
14-3-3sigma	B-X
.	B-X
Significantly	B-X
,	B-X
we	B-X
further	B-X
showed	B-X
that	B-X
14-3-3sigma	B-X
causes	B-X
MDM2	B-X
downregulation	B-X
,	B-X
thereby	B-X
stabilizing	B-X
p53	B-X
and	B-X
inhibiting	B-X
tumor	B-X
growth	B-X
in	B-X
animal	B-X
tumors	B-X
.	B-X
Also	B-X
,	B-X
14-3-3sigma	B-X
blocks	B-X
MDM2-mediated	B-X
retinoblastoma	B-X
degradation	B-X
and	B-X
p53	B-X
NEDDylation	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
pivotal	B-X
MDM2	B-X
regulator	B-X
involved	B-X
in	B-X
blocking	B-X
a	B-X
variety	B-X
of	B-X
activities	B-X
of	B-X
MDM2	B-X
.	B-X

Our	O
results	O
provide	O
evidence	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
is	O
a	O
pivotal	O
MDM2	B-Protein
regulator	O
involved	O
in	O
blocking	O
a	O
variety	O
of	O
activities	O
of	O
MDM2	B-Protein
.	O
<EOS>	B-X
The	B-X
14-3-3sigma	B-X
,	B-X
upregulated	B-X
by	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
can	B-X
have	B-X
a	B-X
positive-feedback	B-X
impact	B-X
driving	B-X
p53	B-X
activities	B-X
and	B-X
is	B-X
a	B-X
human	B-X
cancer	B-X
epithelial	B-X
marker	B-X
downregulated	B-X
in	B-X
various	B-X
tumors	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
roles	B-X
of	B-X
14-3-3sigma	B-X
during	B-X
tumorigenesis	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
oncogene	B-X
(	B-X
MDM2	B-X
)	B-X
.	B-X
14-3-3sigma	B-X
interacts	B-X
with	B-X
MDM2	B-X
at	B-X
the	B-X
RING	B-X
domain	B-X
.	B-X
The	B-X
C-terminal	B-X
region	B-X
of	B-X
14-3-3sigma	B-X
binds	B-X
to	B-X
MDM2	B-X
very	B-X
efficiently	B-X
.	B-X
Importantly	B-X
,	B-X
14-3-3sigma	B-X
overexpression	B-X
leads	B-X
to	B-X
destabilization	B-X
of	B-X
MDM2	B-X
through	B-X
enhancing	B-X
MDM2	B-X
self-ubiquitination	B-X
and	B-X
accelerating	B-X
turnover	B-X
rate	B-X
.	B-X
Conversely	B-X
,	B-X
loss	B-X
of	B-X
14-3-3sigma	B-X
results	B-X
in	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
MDM2	B-X
protein	B-X
.	B-X
Moreover	B-X
,	B-X
live-cell	B-X
images	B-X
indicated	B-X
that	B-X
14-3-3sigma	B-X
can	B-X
affect	B-X
the	B-X
location	B-X
of	B-X
MDM2	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
that	B-X
MDM2-mediated	B-X
cytoplasmic	B-X
localization	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
14-3-3sigma	B-X
.	B-X
Significantly	B-X
,	B-X
we	B-X
further	B-X
showed	B-X
that	B-X
14-3-3sigma	B-X
causes	B-X
MDM2	B-X
downregulation	B-X
,	B-X
thereby	B-X
stabilizing	B-X
p53	B-X
and	B-X
inhibiting	B-X
tumor	B-X
growth	B-X
in	B-X
animal	B-X
tumors	B-X
.	B-X
Also	B-X
,	B-X
14-3-3sigma	B-X
blocks	B-X
MDM2-mediated	B-X
retinoblastoma	B-X
degradation	B-X
and	B-X
p53	B-X
NEDDylation	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
14-3-3sigma	B-X
is	B-X
a	B-X
pivotal	B-X
MDM2	B-X
regulator	B-X
involved	B-X
in	B-X
blocking	B-X
a	B-X
variety	B-X
of	B-X
activities	B-X
of	B-X
MDM2	B-X
.	B-X

Caspase	B-Protein
-	I-Protein
3	I-Protein
cleavage	O
of	O
GGA3	B-Protein
stabilizes	O
BACE	B-Protein
:	O
implications	O
for	O
Alzheimer	O
'	O
s	O
disease	O
.	O
<EOS>	B-X
BACE	B-X
initiates	B-X
the	B-X
production	B-X
of	B-X
beta-amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
the	B-X
likely	B-X
cause	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
show	B-X
that	B-X
during	B-X
apoptosis	B-X
caspase-3	B-X
cleaves	B-X
the	B-X
adaptor	B-X
protein	B-X
GGA3	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
BACE	B-X
lysosomal	B-X
degradation	B-X
,	B-X
consequently	B-X
stabilizing	B-X
BACE	B-X
and	B-X
elevating	B-X
Abeta	B-X
generation	B-X
.	B-X

BACE	B-Protein
initiates	O
the	O
production	O
of	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
(	O
Abeta	B-Protein
)	O
,	O
the	O
likely	O
cause	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O
<EOS>	B-X
The	B-X
beta-amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
peptide	B-X
is	B-X
the	B-X
major	B-X
constituent	B-X
of	B-X
amyloid	B-X
plaques	B-X
in	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
brain	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
this	B-X
devastating	B-X
neurodegenerative	B-X
disorder	B-X
.	B-X
The	B-X
beta-secretase	B-X
,	B-X
beta-site	B-X
amyloid	B-X
precursor	B-X
protein	B-X
cleaving	B-X
enzyme	B-X
(	B-X
BACE1	B-X
;	B-X
also	B-X
called	B-X
Asp2	B-X
,	B-X
memapsin	B-X
2	B-X
)	B-X
,	B-X
is	B-X
the	B-X
enzyme	B-X
responsible	B-X
for	B-X
initiating	B-X
Abeta	B-X
generation	B-X
.	B-X
Thus	B-X
,	B-X
BACE	B-X
is	B-X
a	B-X
prime	B-X
drug	B-X
target	B-X
for	B-X
the	B-X
therapeutic	B-X
inhibition	B-X
of	B-X
Abeta	B-X
production	B-X
in	B-X
AD	B-X
.	B-X
Since	B-X
its	B-X
discovery	B-X
10	B-X
years	B-X
ago	B-X
,	B-X
much	B-X
has	B-X
been	B-X
learned	B-X
about	B-X
BACE	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
BACE	B-X
properties	B-X
,	B-X
describes	B-X
BACE	B-X
translation	B-X
dysregulation	B-X
in	B-X
AD	B-X
,	B-X
and	B-X
discusses	B-X
BACE	B-X
physiological	B-X
functions	B-X
in	B-X
sodium	B-X
current	B-X
,	B-X
synaptic	B-X
transmission	B-X
,	B-X
myelination	B-X
,	B-X
and	B-X
schizophrenia	B-X
.	B-X
The	B-X
therapeutic	B-X
potential	B-X
of	B-X
BACE	B-X
will	B-X
also	B-X
be	B-X
considered	B-X
.	B-X
This	B-X
is	B-X
a	B-X
summary	B-X
of	B-X
topics	B-X
covered	B-X
at	B-X
a	B-X
symposium	B-X
held	B-X
at	B-X
the	B-X
39th	B-X
annual	B-X
meeting	B-X
of	B-X
the	B-X
Society	B-X
for	B-X
Neuroscience	B-X
and	B-X
is	B-X
not	B-X
meant	B-X
to	B-X
be	B-X
a	B-X
comprehensive	B-X
review	B-X
of	B-X
BACE	B-X
.	B-X

In	O
this	O
issue	O
of	O
Neuron	O
,	O
Tesco	O
et	O
al	O
.	O
show	O
that	O
during	O
apoptosis	O
caspase	B-Protein
-	I-Protein
3	I-Protein
cleaves	O
the	O
adaptor	O
protein	O
GGA3	B-Protein
,	O
which	O
is	O
required	O
for	O
BACE	B-Protein
lysosomal	O
degradation	O
,	O
consequently	O
stabilizing	O
BACE	B-Protein
and	O
elevating	O
Abeta	B-Protein
generation	O
.	O
<EOS>	B-X
BACE	B-X
initiates	B-X
the	B-X
production	B-X
of	B-X
beta-amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
the	B-X
likely	B-X
cause	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
In	B-X
this	B-X
issue	B-X
of	B-X
Neuron	B-X
,	B-X
Tesco	B-X
et	B-X
al	B-X
.	B-X
show	B-X
that	B-X
during	B-X
apoptosis	B-X
caspase-3	B-X
cleaves	B-X
the	B-X
adaptor	B-X
protein	B-X
GGA3	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
BACE	B-X
lysosomal	B-X
degradation	B-X
,	B-X
consequently	B-X
stabilizing	B-X
BACE	B-X
and	B-X
elevating	B-X
Abeta	B-X
generation	B-X
.	B-X

N	O
-	O
acylation	O
of	O
Aplysia	O
egg	B-Protein
-	I-Protein
laying	I-Protein
hormone	I-Protein
with	O
biotin	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
the	B-X
egg-laying	B-X
hormone	B-X
(	B-X
ELH	B-X
)	B-X
of	B-X
Aplysia	B-X
by	B-X
reaction	B-X
with	B-X
the	B-X
N-hydroxysuccinimide	B-X
ester	B-X
of	B-X
biotin	B-X
,	B-X
which	B-X
contained	B-X
6-aminohexanoic	B-X
acid	B-X
as	B-X
spacer	B-X
,	B-X
yielded	B-X
seven	B-X
distinct	B-X
derivatives	B-X
that	B-X
were	B-X
readily	B-X
separated	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
The	B-X
seven	B-X
derivatives	B-X
resulted	B-X
from	B-X
combinations	B-X
of	B-X
differential	B-X
modification	B-X
of	B-X
the	B-X
three	B-X
amino	B-X
groups	B-X
in	B-X
the	B-X
ELH	B-X
molecule	B-X
located	B-X
at	B-X
Ile1	B-X
(	B-X
alpha-NH2	B-X
)	B-X
,	B-X
Lys8	B-X
,	B-X
and	B-X
Lys36	B-X
.	B-X
Of	B-X
the	B-X
seven	B-X
derivatives	B-X
formed	B-X
,	B-X
only	B-X
one	B-X
,	B-X
monobiotinyl	B-X
Lys36-ELH	B-X
,	B-X
was	B-X
biologically	B-X
active	B-X
in	B-X
eliciting	B-X
egg-laying	B-X
activity	B-X
and	B-X
altering	B-X
the	B-X
electrophysiological	B-X
activity	B-X
of	B-X
the	B-X
abdominal	B-X
ganglion	B-X
neuron	B-X
R15	B-X
and	B-X
LB	B-X
and	B-X
LC	B-X
cluster	B-X
neurons	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
evaluation	B-X
of	B-X
the	B-X
time	B-X
course	B-X
of	B-X
biotinylation	B-X
of	B-X
ELH	B-X
revealed	B-X
that	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
amino	B-X
group	B-X
reactivity	B-X
was	B-X
epsilon-NH2-Lys36	B-X
greater	B-X
than	B-X
epsilon-NH2-Lys8	B-X
much	B-X
greater	B-X
than	B-X
alpha-NH2-Ile1	B-X
.	B-X
The	B-X
slow	B-X
rate	B-X
of	B-X
reaction	B-X
of	B-X
the	B-X
terminal	B-X
alpha-amino	B-X
group	B-X
suggested	B-X
that	B-X
it	B-X
was	B-X
relatively	B-X
inaccessible	B-X
to	B-X
biotinylation	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
conformational	B-X
factors	B-X
or	B-X
to	B-X
ion-pair	B-X
formation	B-X
with	B-X
an	B-X
unidentified	B-X
carboxyl	B-X
group	B-X
.	B-X
Loss	B-X
of	B-X
bioactivity	B-X
of	B-X
ELH	B-X
monobiotinylated	B-X
on	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
coupled	B-X
with	B-X
the	B-X
unusually	B-X
low	B-X
reactivity	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
provided	B-X
strong	B-X
evidence	B-X
for	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
in	B-X
ELH	B-X
function	B-X
.	B-X

Characterization	O
of	O
bioactive	O
and	O
inactive	O
derivatives	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
bioactive	B-X
long-acting	B-X
structurally	B-X
modified	B-X
FSH	B-X
analogs	B-X
is	B-X
desirable	B-X
for	B-X
human	B-X
and	B-X
veterinary	B-X
use	B-X
.	B-X
These	B-X
include	B-X
strategies	B-X
to	B-X
increase	B-X
the	B-X
mass	B-X
and/or	B-X
charge	B-X
of	B-X
FSH	B-X
and	B-X
to	B-X
prevent	B-X
the	B-X
dissociation	B-X
of	B-X
the	B-X
hormone	B-X
to	B-X
inactive	B-X
subunits	B-X
components	B-X
.	B-X
The	B-X
processing	B-X
of	B-X
these	B-X
mature	B-X
bioactive	B-X
cytokines	B-X
from	B-X
their	B-X
inactive	B-X
precursor	B-X
polypeptides	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
enzyme	B-X
Caspase-1	B-X
,	B-X
which	B-X
is	B-X
part	B-X
of	B-X
multiprotein	B-X
complexes	B-X
called	B-X
``	B-X
inflammasomes	B-X
.	B-X
''	B-X
Food	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
source	B-X
of	B-X
bioactive	B-X
peptides	B-X
.	B-X
These	B-X
peptides	B-X
are	B-X
inactive	B-X
within	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
parent	B-X
protein	B-X
and	B-X
must	B-X
be	B-X
released	B-X
during	B-X
gastrointestinal	B-X
digestion	B-X
,	B-X
fermentation	B-X
,	B-X
or	B-X
food	B-X
processing	B-X
.	B-X
Of	B-X
bioactive	B-X
peptides	B-X
,	B-X
multifunctional	B-X
cationic	B-X
peptides	B-X
are	B-X
more	B-X
useful	B-X
than	B-X
other	B-X
peptides	B-X
that	B-X
have	B-X
specific	B-X
activity	B-X
in	B-X
promotion	B-X
of	B-X
health	B-X
and/or	B-X
the	B-X
treatment	B-X
of	B-X
diseases	B-X
.	B-X
Further	B-X
,	B-X
we	B-X
have	B-X
discussed	B-X
the	B-X
critical	B-X
parameters	B-X
,	B-X
particularly	B-X
proteinase	B-X
preparations	B-X
and	B-X
fractionation	B-X
or	B-X
purification	B-X
,	B-X
in	B-X
the	B-X
enzymatic	B-X
hydrolysis	B-X
process	B-X
for	B-X
producing	B-X
bioactive	B-X
peptides	B-X
from	B-X
food	B-X
proteins	B-X
.	B-X

Chemical	O
modification	O
of	O
the	O
egg	B-Protein
-	I-Protein
laying	I-Protein
hormone	I-Protein
(	O
ELH	B-Protein
)	O
of	O
Aplysia	O
by	O
reaction	O
with	O
the	O
N	O
-	O
hydroxysuccinimide	O
ester	O
of	O
biotin	O
,	O
which	O
contained	O
6	O
-	O
aminohexanoic	O
acid	O
as	O
spacer	O
,	O
yielded	O
seven	O
distinct	O
derivatives	O
that	O
were	O
readily	O
separated	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

The	O
derivatives	O
were	O
chemically	O
characterized	O
by	O
amino	O
acid	O
compositional	O
analysis	O
,	O
sequence	O
analysis	O
,	O
and	O
mass	O
spectrometry	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
initial	B-X
steps	B-X
of	B-X
proteomic	B-X
analysis	B-X
is	B-X
peptide	B-X
separation	B-X
.	B-X
Meanwhile	B-X
,	B-X
prediction	B-X
of	B-X
the	B-X
retention	B-X
time	B-X
for	B-X
a	B-X
given	B-X
peptide	B-X
,	B-X
combined	B-X
with	B-X
routine	B-X
MS/MS	B-X
data	B-X
analysis	B-X
,	B-X
could	B-X
help	B-X
to	B-X
improve	B-X
the	B-X
confidence	B-X
of	B-X
peptide	B-X
identifications	B-X
.	B-X
The	B-X
chromatographic	B-X
behavior	B-X
of	B-X
peptides	B-X
has	B-X
usually	B-X
been	B-X
related	B-X
to	B-X
their	B-X
amino	B-X
acid	B-X
composition	B-X
.	B-X
However	B-X
,	B-X
different	B-X
values	B-X
of	B-X
retention	B-X
coefficients	B-X
of	B-X
the	B-X
same	B-X
amino	B-X
acid	B-X
in	B-X
different	B-X
peptides	B-X
at	B-X
different	B-X
neighborhoods	B-X
were	B-X
commonly	B-X
observed	B-X
.	B-X
Therefore	B-X
,	B-X
specific	B-X
retention	B-X
coefficients	B-X
were	B-X
derived	B-X
by	B-X
regression	B-X
analysis	B-X
or	B-X
by	B-X
artificial	B-X
neural	B-X
networks	B-X
(	B-X
ANNs	B-X
)	B-X
with	B-X
the	B-X
use	B-X
of	B-X
a	B-X
set	B-X
of	B-X
peptides	B-X
retention	B-X
.	B-X
The	B-X
contribution	B-X
of	B-X
sequence	B-X
dependent	B-X
parameters	B-X
(	B-X
e.g.	B-X
,	B-X
amphipathicity	B-X
or	B-X
peptide	B-X
sequence	B-X
)	B-X
and	B-X
peptide	B-X
physicochemical	B-X
descriptors	B-X
(	B-X
e.g.	B-X
,	B-X
hydrophobicity	B-X
or	B-X
peptide	B-X
length	B-X
)	B-X
that	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
affect	B-X
the	B-X
peptide	B-X
retention	B-X
time	B-X
in	B-X
LC	B-X
are	B-X
considered	B-X
and	B-X
analyzed	B-X
.	B-X

The	O
seven	O
derivatives	O
resulted	O
from	O
combinations	O
of	O
differential	O
modification	O
of	O
the	O
three	O
amino	O
groups	O
in	O
the	O
ELH	B-Protein
molecule	O
located	O
at	O
Ile1	O
(	O
alpha	O
-	O
NH2	O
)	O
,	O
Lys8	O
,	O
and	O
Lys36	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
the	B-X
egg-laying	B-X
hormone	B-X
(	B-X
ELH	B-X
)	B-X
of	B-X
Aplysia	B-X
by	B-X
reaction	B-X
with	B-X
the	B-X
N-hydroxysuccinimide	B-X
ester	B-X
of	B-X
biotin	B-X
,	B-X
which	B-X
contained	B-X
6-aminohexanoic	B-X
acid	B-X
as	B-X
spacer	B-X
,	B-X
yielded	B-X
seven	B-X
distinct	B-X
derivatives	B-X
that	B-X
were	B-X
readily	B-X
separated	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
The	B-X
derivatives	B-X
were	B-X
chemically	B-X
characterized	B-X
by	B-X
amino	B-X
acid	B-X
compositional	B-X
analysis	B-X
,	B-X
sequence	B-X
analysis	B-X
,	B-X
and	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
seven	B-X
derivatives	B-X
resulted	B-X
from	B-X
combinations	B-X
of	B-X
differential	B-X
modification	B-X
of	B-X
the	B-X
three	B-X
amino	B-X
groups	B-X
in	B-X
the	B-X
ELH	B-X
molecule	B-X
located	B-X
at	B-X
Ile1	B-X
(	B-X
alpha-NH2	B-X
)	B-X
,	B-X
Lys8	B-X
,	B-X
and	B-X
Lys36	B-X
.	B-X
Of	B-X
the	B-X
seven	B-X
derivatives	B-X
formed	B-X
,	B-X
only	B-X
one	B-X
,	B-X
monobiotinyl	B-X
Lys36-ELH	B-X
,	B-X
was	B-X
biologically	B-X
active	B-X
in	B-X
eliciting	B-X
egg-laying	B-X
activity	B-X
and	B-X
altering	B-X
the	B-X
electrophysiological	B-X
activity	B-X
of	B-X
the	B-X
abdominal	B-X
ganglion	B-X
neuron	B-X
R15	B-X
and	B-X
LB	B-X
and	B-X
LC	B-X
cluster	B-X
neurons	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
evaluation	B-X
of	B-X
the	B-X
time	B-X
course	B-X
of	B-X
biotinylation	B-X
of	B-X
ELH	B-X
revealed	B-X
that	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
amino	B-X
group	B-X
reactivity	B-X
was	B-X
epsilon-NH2-Lys36	B-X
greater	B-X
than	B-X
epsilon-NH2-Lys8	B-X
much	B-X
greater	B-X
than	B-X
alpha-NH2-Ile1	B-X
.	B-X
The	B-X
slow	B-X
rate	B-X
of	B-X
reaction	B-X
of	B-X
the	B-X
terminal	B-X
alpha-amino	B-X
group	B-X
suggested	B-X
that	B-X
it	B-X
was	B-X
relatively	B-X
inaccessible	B-X
to	B-X
biotinylation	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
conformational	B-X
factors	B-X
or	B-X
to	B-X
ion-pair	B-X
formation	B-X
with	B-X
an	B-X
unidentified	B-X
carboxyl	B-X
group	B-X
.	B-X
Loss	B-X
of	B-X
bioactivity	B-X
of	B-X
ELH	B-X
monobiotinylated	B-X
on	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
coupled	B-X
with	B-X
the	B-X
unusually	B-X
low	B-X
reactivity	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
provided	B-X
strong	B-X
evidence	B-X
for	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
in	B-X
ELH	B-X
function	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
development	B-X
and	B-X
availability	B-X
of	B-X
a	B-X
bioactive	B-X
ELH	B-X
probe	B-X
should	B-X
greatly	B-X
facilitate	B-X
the	B-X
isolation	B-X
,	B-X
characterization	B-X
,	B-X
and	B-X
localization	B-X
of	B-X
the	B-X
ELH	B-X
receptor	B-X
.	B-X

Of	O
the	O
seven	O
derivatives	O
formed	O
,	O
only	O
one	O
,	O
monobiotinyl	O
Lys36	O
-	O
ELH	B-Protein
,	O
was	O
biologically	O
active	O
in	O
eliciting	O
egg	O
-	O
laying	O
activity	O
and	O
altering	O
the	O
electrophysiological	O
activity	O
of	O
the	O
abdominal	O
ganglion	O
neuron	O
R15	O
and	O
LB	O
and	O
LC	O
cluster	O
neurons	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
the	B-X
egg-laying	B-X
hormone	B-X
(	B-X
ELH	B-X
)	B-X
of	B-X
Aplysia	B-X
by	B-X
reaction	B-X
with	B-X
the	B-X
N-hydroxysuccinimide	B-X
ester	B-X
of	B-X
biotin	B-X
,	B-X
which	B-X
contained	B-X
6-aminohexanoic	B-X
acid	B-X
as	B-X
spacer	B-X
,	B-X
yielded	B-X
seven	B-X
distinct	B-X
derivatives	B-X
that	B-X
were	B-X
readily	B-X
separated	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
The	B-X
derivatives	B-X
were	B-X
chemically	B-X
characterized	B-X
by	B-X
amino	B-X
acid	B-X
compositional	B-X
analysis	B-X
,	B-X
sequence	B-X
analysis	B-X
,	B-X
and	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
seven	B-X
derivatives	B-X
resulted	B-X
from	B-X
combinations	B-X
of	B-X
differential	B-X
modification	B-X
of	B-X
the	B-X
three	B-X
amino	B-X
groups	B-X
in	B-X
the	B-X
ELH	B-X
molecule	B-X
located	B-X
at	B-X
Ile1	B-X
(	B-X
alpha-NH2	B-X
)	B-X
,	B-X
Lys8	B-X
,	B-X
and	B-X
Lys36	B-X
.	B-X
Of	B-X
the	B-X
seven	B-X
derivatives	B-X
formed	B-X
,	B-X
only	B-X
one	B-X
,	B-X
monobiotinyl	B-X
Lys36-ELH	B-X
,	B-X
was	B-X
biologically	B-X
active	B-X
in	B-X
eliciting	B-X
egg-laying	B-X
activity	B-X
and	B-X
altering	B-X
the	B-X
electrophysiological	B-X
activity	B-X
of	B-X
the	B-X
abdominal	B-X
ganglion	B-X
neuron	B-X
R15	B-X
and	B-X
LB	B-X
and	B-X
LC	B-X
cluster	B-X
neurons	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
evaluation	B-X
of	B-X
the	B-X
time	B-X
course	B-X
of	B-X
biotinylation	B-X
of	B-X
ELH	B-X
revealed	B-X
that	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
amino	B-X
group	B-X
reactivity	B-X
was	B-X
epsilon-NH2-Lys36	B-X
greater	B-X
than	B-X
epsilon-NH2-Lys8	B-X
much	B-X
greater	B-X
than	B-X
alpha-NH2-Ile1	B-X
.	B-X
Loss	B-X
of	B-X
bioactivity	B-X
of	B-X
ELH	B-X
monobiotinylated	B-X
on	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
coupled	B-X
with	B-X
the	B-X
unusually	B-X
low	B-X
reactivity	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
provided	B-X
strong	B-X
evidence	B-X
for	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
in	B-X
ELH	B-X
function	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
development	B-X
and	B-X
availability	B-X
of	B-X
a	B-X
bioactive	B-X
ELH	B-X
probe	B-X
should	B-X
greatly	B-X
facilitate	B-X
the	B-X
isolation	B-X
,	B-X
characterization	B-X
,	B-X
and	B-X
localization	B-X
of	B-X
the	B-X
ELH	B-X
receptor	B-X
.	B-X

In	O
addition	O
,	O
evaluation	O
of	O
the	O
time	O
course	O
of	O
biotinylation	O
of	O
ELH	B-Protein
revealed	O
that	O
the	O
relative	O
rate	O
of	O
amino	O
group	O
reactivity	O
was	O
epsilon	O
-	O
NH2	O
-	O
Lys36	O
greater	O
than	O
epsilon	O
-	O
NH2	O
-	O
Lys8	O
much	O
greater	O
than	O
alpha	O
-	O
NH2	O
-	O
Ile1	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
the	B-X
egg-laying	B-X
hormone	B-X
(	B-X
ELH	B-X
)	B-X
of	B-X
Aplysia	B-X
by	B-X
reaction	B-X
with	B-X
the	B-X
N-hydroxysuccinimide	B-X
ester	B-X
of	B-X
biotin	B-X
,	B-X
which	B-X
contained	B-X
6-aminohexanoic	B-X
acid	B-X
as	B-X
spacer	B-X
,	B-X
yielded	B-X
seven	B-X
distinct	B-X
derivatives	B-X
that	B-X
were	B-X
readily	B-X
separated	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
The	B-X
derivatives	B-X
were	B-X
chemically	B-X
characterized	B-X
by	B-X
amino	B-X
acid	B-X
compositional	B-X
analysis	B-X
,	B-X
sequence	B-X
analysis	B-X
,	B-X
and	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
seven	B-X
derivatives	B-X
resulted	B-X
from	B-X
combinations	B-X
of	B-X
differential	B-X
modification	B-X
of	B-X
the	B-X
three	B-X
amino	B-X
groups	B-X
in	B-X
the	B-X
ELH	B-X
molecule	B-X
located	B-X
at	B-X
Ile1	B-X
(	B-X
alpha-NH2	B-X
)	B-X
,	B-X
Lys8	B-X
,	B-X
and	B-X
Lys36	B-X
.	B-X
Of	B-X
the	B-X
seven	B-X
derivatives	B-X
formed	B-X
,	B-X
only	B-X
one	B-X
,	B-X
monobiotinyl	B-X
Lys36-ELH	B-X
,	B-X
was	B-X
biologically	B-X
active	B-X
in	B-X
eliciting	B-X
egg-laying	B-X
activity	B-X
and	B-X
altering	B-X
the	B-X
electrophysiological	B-X
activity	B-X
of	B-X
the	B-X
abdominal	B-X
ganglion	B-X
neuron	B-X
R15	B-X
and	B-X
LB	B-X
and	B-X
LC	B-X
cluster	B-X
neurons	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
evaluation	B-X
of	B-X
the	B-X
time	B-X
course	B-X
of	B-X
biotinylation	B-X
of	B-X
ELH	B-X
revealed	B-X
that	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
amino	B-X
group	B-X
reactivity	B-X
was	B-X
epsilon-NH2-Lys36	B-X
greater	B-X
than	B-X
epsilon-NH2-Lys8	B-X
much	B-X
greater	B-X
than	B-X
alpha-NH2-Ile1	B-X
.	B-X
The	B-X
slow	B-X
rate	B-X
of	B-X
reaction	B-X
of	B-X
the	B-X
terminal	B-X
alpha-amino	B-X
group	B-X
suggested	B-X
that	B-X
it	B-X
was	B-X
relatively	B-X
inaccessible	B-X
to	B-X
biotinylation	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
conformational	B-X
factors	B-X
or	B-X
to	B-X
ion-pair	B-X
formation	B-X
with	B-X
an	B-X
unidentified	B-X
carboxyl	B-X
group	B-X
.	B-X
Loss	B-X
of	B-X
bioactivity	B-X
of	B-X
ELH	B-X
monobiotinylated	B-X
on	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
coupled	B-X
with	B-X
the	B-X
unusually	B-X
low	B-X
reactivity	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
provided	B-X
strong	B-X
evidence	B-X
for	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
in	B-X
ELH	B-X
function	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
development	B-X
and	B-X
availability	B-X
of	B-X
a	B-X
bioactive	B-X
ELH	B-X
probe	B-X
should	B-X
greatly	B-X
facilitate	B-X
the	B-X
isolation	B-X
,	B-X
characterization	B-X
,	B-X
and	B-X
localization	B-X
of	B-X
the	B-X
ELH	B-X
receptor	B-X
.	B-X

The	O
slow	O
rate	O
of	O
reaction	O
of	O
the	O
terminal	O
alpha	O
-	O
amino	O
group	O
suggested	O
that	O
it	O
was	O
relatively	O
inaccessible	O
to	O
biotinylation	O
,	O
possibly	O
due	O
to	O
conformational	O
factors	O
or	O
to	O
ion	O
-	O
pair	O
formation	O
with	O
an	O
unidentified	O
carboxyl	O
group	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
the	B-X
egg-laying	B-X
hormone	B-X
(	B-X
ELH	B-X
)	B-X
of	B-X
Aplysia	B-X
by	B-X
reaction	B-X
with	B-X
the	B-X
N-hydroxysuccinimide	B-X
ester	B-X
of	B-X
biotin	B-X
,	B-X
which	B-X
contained	B-X
6-aminohexanoic	B-X
acid	B-X
as	B-X
spacer	B-X
,	B-X
yielded	B-X
seven	B-X
distinct	B-X
derivatives	B-X
that	B-X
were	B-X
readily	B-X
separated	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
The	B-X
derivatives	B-X
were	B-X
chemically	B-X
characterized	B-X
by	B-X
amino	B-X
acid	B-X
compositional	B-X
analysis	B-X
,	B-X
sequence	B-X
analysis	B-X
,	B-X
and	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
seven	B-X
derivatives	B-X
resulted	B-X
from	B-X
combinations	B-X
of	B-X
differential	B-X
modification	B-X
of	B-X
the	B-X
three	B-X
amino	B-X
groups	B-X
in	B-X
the	B-X
ELH	B-X
molecule	B-X
located	B-X
at	B-X
Ile1	B-X
(	B-X
alpha-NH2	B-X
)	B-X
,	B-X
Lys8	B-X
,	B-X
and	B-X
Lys36	B-X
.	B-X
Of	B-X
the	B-X
seven	B-X
derivatives	B-X
formed	B-X
,	B-X
only	B-X
one	B-X
,	B-X
monobiotinyl	B-X
Lys36-ELH	B-X
,	B-X
was	B-X
biologically	B-X
active	B-X
in	B-X
eliciting	B-X
egg-laying	B-X
activity	B-X
and	B-X
altering	B-X
the	B-X
electrophysiological	B-X
activity	B-X
of	B-X
the	B-X
abdominal	B-X
ganglion	B-X
neuron	B-X
R15	B-X
and	B-X
LB	B-X
and	B-X
LC	B-X
cluster	B-X
neurons	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
evaluation	B-X
of	B-X
the	B-X
time	B-X
course	B-X
of	B-X
biotinylation	B-X
of	B-X
ELH	B-X
revealed	B-X
that	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
amino	B-X
group	B-X
reactivity	B-X
was	B-X
epsilon-NH2-Lys36	B-X
greater	B-X
than	B-X
epsilon-NH2-Lys8	B-X
much	B-X
greater	B-X
than	B-X
alpha-NH2-Ile1	B-X
.	B-X
The	B-X
slow	B-X
rate	B-X
of	B-X
reaction	B-X
of	B-X
the	B-X
terminal	B-X
alpha-amino	B-X
group	B-X
suggested	B-X
that	B-X
it	B-X
was	B-X
relatively	B-X
inaccessible	B-X
to	B-X
biotinylation	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
conformational	B-X
factors	B-X
or	B-X
to	B-X
ion-pair	B-X
formation	B-X
with	B-X
an	B-X
unidentified	B-X
carboxyl	B-X
group	B-X
.	B-X
Loss	B-X
of	B-X
bioactivity	B-X
of	B-X
ELH	B-X
monobiotinylated	B-X
on	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
coupled	B-X
with	B-X
the	B-X
unusually	B-X
low	B-X
reactivity	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
provided	B-X
strong	B-X
evidence	B-X
for	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
in	B-X
ELH	B-X
function	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
development	B-X
and	B-X
availability	B-X
of	B-X
a	B-X
bioactive	B-X
ELH	B-X
probe	B-X
should	B-X
greatly	B-X
facilitate	B-X
the	B-X
isolation	B-X
,	B-X
characterization	B-X
,	B-X
and	B-X
localization	B-X
of	B-X
the	B-X
ELH	B-X
receptor	B-X
.	B-X

Loss	O
of	O
bioactivity	O
of	O
ELH	B-Protein
monobiotinylated	O
on	O
the	O
alpha	O
-	O
amino	O
group	O
,	O
coupled	O
with	O
the	O
unusually	O
low	O
reactivity	O
of	O
the	O
alpha	O
-	O
amino	O
group	O
,	O
provided	O
strong	O
evidence	O
for	O
the	O
importance	O
of	O
the	O
alpha	O
-	O
amino	O
group	O
in	O
ELH	B-Protein
function	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
the	B-X
egg-laying	B-X
hormone	B-X
(	B-X
ELH	B-X
)	B-X
of	B-X
Aplysia	B-X
by	B-X
reaction	B-X
with	B-X
the	B-X
N-hydroxysuccinimide	B-X
ester	B-X
of	B-X
biotin	B-X
,	B-X
which	B-X
contained	B-X
6-aminohexanoic	B-X
acid	B-X
as	B-X
spacer	B-X
,	B-X
yielded	B-X
seven	B-X
distinct	B-X
derivatives	B-X
that	B-X
were	B-X
readily	B-X
separated	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
The	B-X
derivatives	B-X
were	B-X
chemically	B-X
characterized	B-X
by	B-X
amino	B-X
acid	B-X
compositional	B-X
analysis	B-X
,	B-X
sequence	B-X
analysis	B-X
,	B-X
and	B-X
mass	B-X
spectrometry	B-X
.	B-X
The	B-X
seven	B-X
derivatives	B-X
resulted	B-X
from	B-X
combinations	B-X
of	B-X
differential	B-X
modification	B-X
of	B-X
the	B-X
three	B-X
amino	B-X
groups	B-X
in	B-X
the	B-X
ELH	B-X
molecule	B-X
located	B-X
at	B-X
Ile1	B-X
(	B-X
alpha-NH2	B-X
)	B-X
,	B-X
Lys8	B-X
,	B-X
and	B-X
Lys36	B-X
.	B-X
Of	B-X
the	B-X
seven	B-X
derivatives	B-X
formed	B-X
,	B-X
only	B-X
one	B-X
,	B-X
monobiotinyl	B-X
Lys36-ELH	B-X
,	B-X
was	B-X
biologically	B-X
active	B-X
in	B-X
eliciting	B-X
egg-laying	B-X
activity	B-X
and	B-X
altering	B-X
the	B-X
electrophysiological	B-X
activity	B-X
of	B-X
the	B-X
abdominal	B-X
ganglion	B-X
neuron	B-X
R15	B-X
and	B-X
LB	B-X
and	B-X
LC	B-X
cluster	B-X
neurons	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
evaluation	B-X
of	B-X
the	B-X
time	B-X
course	B-X
of	B-X
biotinylation	B-X
of	B-X
ELH	B-X
revealed	B-X
that	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
amino	B-X
group	B-X
reactivity	B-X
was	B-X
epsilon-NH2-Lys36	B-X
greater	B-X
than	B-X
epsilon-NH2-Lys8	B-X
much	B-X
greater	B-X
than	B-X
alpha-NH2-Ile1	B-X
.	B-X
The	B-X
slow	B-X
rate	B-X
of	B-X
reaction	B-X
of	B-X
the	B-X
terminal	B-X
alpha-amino	B-X
group	B-X
suggested	B-X
that	B-X
it	B-X
was	B-X
relatively	B-X
inaccessible	B-X
to	B-X
biotinylation	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
conformational	B-X
factors	B-X
or	B-X
to	B-X
ion-pair	B-X
formation	B-X
with	B-X
an	B-X
unidentified	B-X
carboxyl	B-X
group	B-X
.	B-X
Loss	B-X
of	B-X
bioactivity	B-X
of	B-X
ELH	B-X
monobiotinylated	B-X
on	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
coupled	B-X
with	B-X
the	B-X
unusually	B-X
low	B-X
reactivity	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
provided	B-X
strong	B-X
evidence	B-X
for	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
in	B-X
ELH	B-X
function	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
development	B-X
and	B-X
availability	B-X
of	B-X
a	B-X
bioactive	B-X
ELH	B-X
probe	B-X
should	B-X
greatly	B-X
facilitate	B-X
the	B-X
isolation	B-X
,	B-X
characterization	B-X
,	B-X
and	B-X
localization	B-X
of	B-X
the	B-X
ELH	B-X
receptor	B-X
.	B-X

Furthermore	O
,	O
the	O
development	O
and	O
availability	O
of	O
a	O
bioactive	O
ELH	B-Protein
probe	O
should	O
greatly	O
facilitate	O
the	O
isolation	O
,	O
characterization	O
,	O
and	O
localization	O
of	O
the	O
ELH	B-Protein
receptor	O
.	O
<EOS>	B-X
Chemical	B-X
modification	B-X
of	B-X
the	B-X
egg-laying	B-X
hormone	B-X
(	B-X
ELH	B-X
)	B-X
of	B-X
Aplysia	B-X
by	B-X
reaction	B-X
with	B-X
the	B-X
N-hydroxysuccinimide	B-X
ester	B-X
of	B-X
biotin	B-X
,	B-X
which	B-X
contained	B-X
6-aminohexanoic	B-X
acid	B-X
as	B-X
spacer	B-X
,	B-X
yielded	B-X
seven	B-X
distinct	B-X
derivatives	B-X
that	B-X
were	B-X
readily	B-X
separated	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
The	B-X
seven	B-X
derivatives	B-X
resulted	B-X
from	B-X
combinations	B-X
of	B-X
differential	B-X
modification	B-X
of	B-X
the	B-X
three	B-X
amino	B-X
groups	B-X
in	B-X
the	B-X
ELH	B-X
molecule	B-X
located	B-X
at	B-X
Ile1	B-X
(	B-X
alpha-NH2	B-X
)	B-X
,	B-X
Lys8	B-X
,	B-X
and	B-X
Lys36	B-X
.	B-X
Of	B-X
the	B-X
seven	B-X
derivatives	B-X
formed	B-X
,	B-X
only	B-X
one	B-X
,	B-X
monobiotinyl	B-X
Lys36-ELH	B-X
,	B-X
was	B-X
biologically	B-X
active	B-X
in	B-X
eliciting	B-X
egg-laying	B-X
activity	B-X
and	B-X
altering	B-X
the	B-X
electrophysiological	B-X
activity	B-X
of	B-X
the	B-X
abdominal	B-X
ganglion	B-X
neuron	B-X
R15	B-X
and	B-X
LB	B-X
and	B-X
LC	B-X
cluster	B-X
neurons	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
evaluation	B-X
of	B-X
the	B-X
time	B-X
course	B-X
of	B-X
biotinylation	B-X
of	B-X
ELH	B-X
revealed	B-X
that	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
amino	B-X
group	B-X
reactivity	B-X
was	B-X
epsilon-NH2-Lys36	B-X
greater	B-X
than	B-X
epsilon-NH2-Lys8	B-X
much	B-X
greater	B-X
than	B-X
alpha-NH2-Ile1	B-X
.	B-X
Loss	B-X
of	B-X
bioactivity	B-X
of	B-X
ELH	B-X
monobiotinylated	B-X
on	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
coupled	B-X
with	B-X
the	B-X
unusually	B-X
low	B-X
reactivity	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
,	B-X
provided	B-X
strong	B-X
evidence	B-X
for	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
alpha-amino	B-X
group	B-X
in	B-X
ELH	B-X
function	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
development	B-X
and	B-X
availability	B-X
of	B-X
a	B-X
bioactive	B-X
ELH	B-X
probe	B-X
should	B-X
greatly	B-X
facilitate	B-X
the	B-X
isolation	B-X
,	B-X
characterization	B-X
,	B-X
and	B-X
localization	B-X
of	B-X
the	B-X
ELH	B-X
receptor	B-X
.	B-X

Identification	O
of	O
differentially	O
expressed	O
genes	O
in	O
human	O
varicose	O
veins	O
:	O
involvement	O
of	O
matrix	B-Protein
gla	I-Protein
protein	I-Protein
in	O
extracellular	O
matrix	O
remodeling	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
Using	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
,	B-X
we	B-X
identified	B-X
overexpression	B-X
of	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
including	B-X
collagen	B-X
III	B-X
,	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
I	B-X
,	B-X
dermatopontin	B-X
,	B-X
matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
and	B-X
tenascin	B-X
C.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
confirmed	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
MGP	B-X
transcript	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
MGP	B-X
level	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
undercarboxylated	B-X
form	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Smooth	B-X
muscle	B-X
cells	B-X
from	B-X
varicose	B-X
veins	B-X
showed	B-X
increased	B-X
proliferation	B-X
rate	B-X
and	B-X
enhanced	B-X
matrix	B-X
mineralization	B-X
.	B-X
This	B-X
observation	B-X
correlated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
ectopic	B-X
mineralization	B-X
areas	B-X
in	B-X
the	B-X
varicose	B-X
vein	B-X
walls	B-X
.	B-X
The	B-X
use	B-X
of	B-X
warfarin	B-X
,	B-X
to	B-X
inhibit	B-X
MGP	B-X
activity	B-X
,	B-X
or	B-X
siRNA	B-X
targeting	B-X
MGP	B-X
transcript	B-X
induced	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
exacerbated	B-X
proliferation	B-X
of	B-X
varicose	B-X
vein	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X
Further	B-X
study	B-X
of	B-X
these	B-X
genes	B-X
will	B-X
provide	B-X
insights	B-X
into	B-X
their	B-X
specific	B-X
roles	B-X
in	B-X
the	B-X
etiology	B-X
of	B-X
venous	B-X
disease	B-X
.	B-X

This	O
study	O
was	O
designed	O
to	O
identify	O
the	O
global	O
pattern	O
of	O
differentially	O
expressed	O
genes	O
in	O
human	O
varicose	O
veins	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
Using	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
,	B-X
we	B-X
identified	B-X
overexpression	B-X
of	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
including	B-X
collagen	B-X
III	B-X
,	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
I	B-X
,	B-X
dermatopontin	B-X
,	B-X
matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
and	B-X
tenascin	B-X
C.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
confirmed	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
MGP	B-X
transcript	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
MGP	B-X
level	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
undercarboxylated	B-X
form	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Smooth	B-X
muscle	B-X
cells	B-X
from	B-X
varicose	B-X
veins	B-X
showed	B-X
increased	B-X
proliferation	B-X
rate	B-X
and	B-X
enhanced	B-X
matrix	B-X
mineralization	B-X
.	B-X
This	B-X
observation	B-X
correlated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
ectopic	B-X
mineralization	B-X
areas	B-X
in	B-X
the	B-X
varicose	B-X
vein	B-X
walls	B-X
.	B-X
The	B-X
use	B-X
of	B-X
warfarin	B-X
,	B-X
to	B-X
inhibit	B-X
MGP	B-X
activity	B-X
,	B-X
or	B-X
siRNA	B-X
targeting	B-X
MGP	B-X
transcript	B-X
induced	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
exacerbated	B-X
proliferation	B-X
of	B-X
varicose	B-X
vein	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X
Further	B-X
study	B-X
of	B-X
these	B-X
genes	B-X
will	B-X
provide	B-X
insights	B-X
into	B-X
their	B-X
specific	B-X
roles	B-X
in	B-X
the	B-X
etiology	B-X
of	B-X
venous	B-X
disease	B-X
.	B-X

Using	O
suppressive	O
subtractive	O
hybridization	O
,	O
we	O
identified	O
overexpression	O
of	O
genes	O
known	O
to	O
be	O
associated	O
with	O
extracellular	O
matrix	O
remodeling	O
,	O
including	O
collagen	B-Protein
III	I-Protein
,	O
tissue	B-Protein
inhibitor	I-Protein
of	I-Protein
metalloproteinases	I-Protein
I	I-Protein
,	O
dermatopontin	B-Protein
,	O
matrix	B-Protein
Gla	I-Protein
protein	I-Protein
(	O
MGP	B-Protein
)	O
and	O
tenascin	B-Protein
C	I-Protein
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
Using	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
,	B-X
we	B-X
identified	B-X
overexpression	B-X
of	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
including	B-X
collagen	B-X
III	B-X
,	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
I	B-X
,	B-X
dermatopontin	B-X
,	B-X
matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
and	B-X
tenascin	B-X
C.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
confirmed	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
MGP	B-X
transcript	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
MGP	B-X
level	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
undercarboxylated	B-X
form	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Smooth	B-X
muscle	B-X
cells	B-X
from	B-X
varicose	B-X
veins	B-X
showed	B-X
increased	B-X
proliferation	B-X
rate	B-X
and	B-X
enhanced	B-X
matrix	B-X
mineralization	B-X
.	B-X
The	B-X
use	B-X
of	B-X
warfarin	B-X
,	B-X
to	B-X
inhibit	B-X
MGP	B-X
activity	B-X
,	B-X
or	B-X
siRNA	B-X
targeting	B-X
MGP	B-X
transcript	B-X
induced	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
exacerbated	B-X
proliferation	B-X
of	B-X
varicose	B-X
vein	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X
Further	B-X
study	B-X
of	B-X
these	B-X
genes	B-X
will	B-X
provide	B-X
insights	B-X
into	B-X
their	B-X
specific	B-X
roles	B-X
in	B-X
the	B-X
etiology	B-X
of	B-X
venous	B-X
disease	B-X
.	B-X

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
confirmed	O
the	O
differential	O
expression	O
of	O
these	O
genes	O
.	O
<EOS>	B-X
Hepatic	B-X
drug	B-X
metabolizing	B-X
and	B-X
cytoprotective	B-X
genes	B-X
are	B-X
induced	B-X
as	B-X
an	B-X
adaptive	B-X
response	B-X
to	B-X
xenobiotics	B-X
and	B-X
reactive	B-X
intermediates	B-X
;	B-X
as	B-X
several	B-X
of	B-X
these	B-X
genes	B-X
are	B-X
present	B-X
in	B-X
skin	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
their	B-X
cutaneous	B-X
expression	B-X
and	B-X
regulation	B-X
may	B-X
be	B-X
implicated	B-X
in	B-X
responses	B-X
to	B-X
ultraviolet	B-X
radiation	B-X
.	B-X
We	B-X
used	B-X
quantitative	B-X
real-time	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
to	B-X
investigate	B-X
interindividual	B-X
differences	B-X
in	B-X
the	B-X
cutaneous	B-X
expression	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
drug	B-X
metabolizing	B-X
and	B-X
cytoprotective	B-X
genes	B-X
,	B-X
including	B-X
cytochrome	B-X
P450s	B-X
,	B-X
glutathione	B-X
S-transferases	B-X
and	B-X
drug	B-X
transporters	B-X
,	B-X
and	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
by	B-X
ultraviolet	B-X
radiation	B-X
and	B-X
in	B-X
lesional	B-X
psoriatic	B-X
skin	B-X
.	B-X
We	B-X
confirmed	B-X
significant	B-X
induction	B-X
of	B-X
cyclooxygenase	B-X
2	B-X
(	B-X
mean	B-X
3.63-fold	B-X
,	B-X
range	B-X
0.14-22.6	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
by	B-X
ultraviolet	B-X
radiation	B-X
and	B-X
showed	B-X
more	B-X
modest	B-X
(	B-X
approximately	B-X
2-fold	B-X
)	B-X
inductions	B-X
of	B-X
glutathione	B-X
peroxidase	B-X
,	B-X
and	B-X
novel	B-X
inductions	B-X
of	B-X
glutathione	B-X
S-transferase	B-X
P1	B-X
and	B-X
the	B-X
drug	B-X
transporter	B-X
multidrug	B-X
resistance	B-X
associated	B-X
protein-1	B-X
.	B-X
Glutathione	B-X
S-transferase	B-X
P1	B-X
(	B-X
3.74-fold	B-X
,	B-X
1.3-33.1	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
and	B-X
multidrug	B-X
resistance	B-X
associated	B-X
protein-1	B-X
(	B-X
4.06-fold	B-X
,	B-X
1.3-24.8	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
were	B-X
also	B-X
significantly	B-X
increased	B-X
in	B-X
psoriatic	B-X
plaque	B-X
,	B-X
as	B-X
were	B-X
P450	B-X
CYP2E1	B-X
(	B-X
3.64-fold	B-X
,	B-X
1-28.9	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
and	B-X
heme	B-X
oxygenase-1	B-X
(	B-X
10.19-fold	B-X
,	B-X
2.9-49.7	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
implying	B-X
a	B-X
differential	B-X
adaptive	B-X
response	B-X
to	B-X
oxidant	B-X
exposure	B-X
in	B-X
lesional	B-X
psoriatic	B-X
skin	B-X
.	B-X
We	B-X
found	B-X
considerable	B-X
interindividual	B-X
variation	B-X
in	B-X
constitutive	B-X
gene	B-X
expression	B-X
and	B-X
inducibility	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
genes	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
individuality	B-X
in	B-X
response	B-X
to	B-X
ultraviolet	B-X
radiation	B-X
.	B-X

The	O
overexpression	O
of	O
MGP	B-Protein
transcript	O
was	O
associated	O
with	O
increased	O
MGP	B-Protein
level	O
in	O
varicose	O
veins	O
,	O
in	O
particular	O
the	O
undercarboxylated	O
form	O
of	O
the	O
protein	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
Using	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
,	B-X
we	B-X
identified	B-X
overexpression	B-X
of	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
including	B-X
collagen	B-X
III	B-X
,	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
I	B-X
,	B-X
dermatopontin	B-X
,	B-X
matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
and	B-X
tenascin	B-X
C.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
confirmed	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
MGP	B-X
transcript	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
MGP	B-X
level	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
undercarboxylated	B-X
form	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Smooth	B-X
muscle	B-X
cells	B-X
from	B-X
varicose	B-X
veins	B-X
showed	B-X
increased	B-X
proliferation	B-X
rate	B-X
and	B-X
enhanced	B-X
matrix	B-X
mineralization	B-X
.	B-X
This	B-X
observation	B-X
correlated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
ectopic	B-X
mineralization	B-X
areas	B-X
in	B-X
the	B-X
varicose	B-X
vein	B-X
walls	B-X
.	B-X
The	B-X
use	B-X
of	B-X
warfarin	B-X
,	B-X
to	B-X
inhibit	B-X
MGP	B-X
activity	B-X
,	B-X
or	B-X
siRNA	B-X
targeting	B-X
MGP	B-X
transcript	B-X
induced	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
exacerbated	B-X
proliferation	B-X
of	B-X
varicose	B-X
vein	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X

Smooth	O
muscle	O
cells	O
from	O
varicose	O
veins	O
showed	O
increased	O
proliferation	O
rate	O
and	O
enhanced	O
matrix	O
mineralization	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
Using	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
,	B-X
we	B-X
identified	B-X
overexpression	B-X
of	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
including	B-X
collagen	B-X
III	B-X
,	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
I	B-X
,	B-X
dermatopontin	B-X
,	B-X
matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
and	B-X
tenascin	B-X
C.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
confirmed	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
MGP	B-X
transcript	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
MGP	B-X
level	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
undercarboxylated	B-X
form	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Smooth	B-X
muscle	B-X
cells	B-X
from	B-X
varicose	B-X
veins	B-X
showed	B-X
increased	B-X
proliferation	B-X
rate	B-X
and	B-X
enhanced	B-X
matrix	B-X
mineralization	B-X
.	B-X
This	B-X
observation	B-X
correlated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
ectopic	B-X
mineralization	B-X
areas	B-X
in	B-X
the	B-X
varicose	B-X
vein	B-X
walls	B-X
.	B-X
The	B-X
use	B-X
of	B-X
warfarin	B-X
,	B-X
to	B-X
inhibit	B-X
MGP	B-X
activity	B-X
,	B-X
or	B-X
siRNA	B-X
targeting	B-X
MGP	B-X
transcript	B-X
induced	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
exacerbated	B-X
proliferation	B-X
of	B-X
varicose	B-X
vein	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X

This	O
observation	O
correlated	O
with	O
the	O
presence	O
of	O
ectopic	O
mineralization	O
areas	O
in	O
the	O
varicose	O
vein	O
walls	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
MGP	B-X
transcript	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
MGP	B-X
level	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
undercarboxylated	B-X
form	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Smooth	B-X
muscle	B-X
cells	B-X
from	B-X
varicose	B-X
veins	B-X
showed	B-X
increased	B-X
proliferation	B-X
rate	B-X
and	B-X
enhanced	B-X
matrix	B-X
mineralization	B-X
.	B-X
This	B-X
observation	B-X
correlated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
ectopic	B-X
mineralization	B-X
areas	B-X
in	B-X
the	B-X
varicose	B-X
vein	B-X
walls	B-X
.	B-X
The	B-X
use	B-X
of	B-X
warfarin	B-X
,	B-X
to	B-X
inhibit	B-X
MGP	B-X
activity	B-X
,	B-X
or	B-X
siRNA	B-X
targeting	B-X
MGP	B-X
transcript	B-X
induced	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
exacerbated	B-X
proliferation	B-X
of	B-X
varicose	B-X
vein	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X

The	O
use	O
of	O
warfarin	O
,	O
to	O
inhibit	O
MGP	B-Protein
activity	O
,	O
or	O
siRNA	O
targeting	O
MGP	B-Protein
transcript	O
induced	O
a	O
reduction	O
in	O
the	O
exacerbated	O
proliferation	O
of	O
varicose	O
vein	O
smooth	O
muscle	O
cells	O
.	O
<EOS>	B-X
Vascular	B-X
calcification	B-X
is	B-X
intimately	B-X
associated	B-X
with	B-X
CV	B-X
events	B-X
and	B-X
mortality	B-X
and	B-X
is	B-X
a	B-X
chronic	B-X
inflammatory	B-X
process	B-X
in	B-X
which	B-X
activated	B-X
macrophages	B-X
promote	B-X
osteoblastic	B-X
differentiation	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
through	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
TNF-α	B-X
,	B-X
and	B-X
oncostatin	B-X
M	B-X
(	B-X
OSM	B-X
)	B-X
in	B-X
both	B-X
intimal	B-X
and	B-X
medial	B-X
layers	B-X
of	B-X
arterial	B-X
walls	B-X
.	B-X
Matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
is	B-X
a	B-X
major	B-X
inhibitor	B-X
of	B-X
soft	B-X
tissue	B-X
calcification	B-X
and	B-X
contributes	B-X
to	B-X
preventing	B-X
both	B-X
intimal	B-X
and	B-X
medial	B-X
vascular	B-X
calcification	B-X
.	B-X
Vitamin	B-X
K	B-X
may	B-X
also	B-X
inhibit	B-X
progression	B-X
of	B-X
vascular	B-X
calcification	B-X
by	B-X
enhancing	B-X
the	B-X
activity	B-X
of	B-X
MGP	B-X
through	B-X
facilitating	B-X
its	B-X
γ-carboxylation	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
procalcific	B-X
effects	B-X
of	B-X
warfarin	B-X
,	B-X
an	B-X
antagonist	B-X
of	B-X
vitamin	B-X
K	B-X
,	B-X
on	B-X
arterial	B-X
calcification	B-X
have	B-X
been	B-X
demonstrated	B-X
in	B-X
several	B-X
clinical	B-X
studies	B-X
.	B-X
Among	B-X
the	B-X
inactive	B-X
MGP	B-X
forms	B-X
,	B-X
dephospho-uncarboxylated	B-X
MGP	B-X
(	B-X
dp-ucMGP	B-X
)	B-X
may	B-X
be	B-X
regarded	B-X
as	B-X
the	B-X
most	B-X
useful	B-X
biomarker	B-X
of	B-X
not	B-X
only	B-X
vitamin	B-X
K	B-X
deficiency	B-X
,	B-X
but	B-X
also	B-X
vascular	B-X
calcification	B-X
and	B-X
CVD	B-X
.	B-X
There	B-X
have	B-X
been	B-X
several	B-X
studies	B-X
showing	B-X
the	B-X
association	B-X
of	B-X
circulating	B-X
levels	B-X
of	B-X
dp-ucMGP	B-X
with	B-X
vitamin	B-X
K	B-X
intake	B-X
,	B-X
vascular	B-X
calcification	B-X
,	B-X
mortality	B-X
,	B-X
and	B-X
CVD	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
high	O
expression	O
of	O
MGP	B-Protein
in	O
varicose	O
veins	O
may	O
contribute	O
to	O
venous	O
wall	O
remodeling	O
by	O
affecting	O
proliferation	O
and	O
mineralization	O
processes	O
probably	O
through	O
impaired	O
carboxylation	O
of	O
MGP	B-Protein
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
Using	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
,	B-X
we	B-X
identified	B-X
overexpression	B-X
of	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
including	B-X
collagen	B-X
III	B-X
,	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
I	B-X
,	B-X
dermatopontin	B-X
,	B-X
matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
and	B-X
tenascin	B-X
C.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
confirmed	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
MGP	B-X
transcript	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
MGP	B-X
level	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
undercarboxylated	B-X
form	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Smooth	B-X
muscle	B-X
cells	B-X
from	B-X
varicose	B-X
veins	B-X
showed	B-X
increased	B-X
proliferation	B-X
rate	B-X
and	B-X
enhanced	B-X
matrix	B-X
mineralization	B-X
.	B-X
This	B-X
observation	B-X
correlated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
ectopic	B-X
mineralization	B-X
areas	B-X
in	B-X
the	B-X
varicose	B-X
vein	B-X
walls	B-X
.	B-X
The	B-X
use	B-X
of	B-X
warfarin	B-X
,	B-X
to	B-X
inhibit	B-X
MGP	B-X
activity	B-X
,	B-X
or	B-X
siRNA	B-X
targeting	B-X
MGP	B-X
transcript	B-X
induced	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
exacerbated	B-X
proliferation	B-X
of	B-X
varicose	B-X
vein	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X
Further	B-X
study	B-X
of	B-X
these	B-X
genes	B-X
will	B-X
provide	B-X
insights	B-X
into	B-X
their	B-X
specific	B-X
roles	B-X
in	B-X
the	B-X
etiology	B-X
of	B-X
venous	B-X
disease	B-X
.	B-X

In	O
addition	O
,	O
suppressive	O
subtractive	O
hybridization	O
results	O
also	O
produce	O
a	O
profile	O
of	O
differentially	O
expressed	O
genes	O
in	O
varicose	O
veins	O
,	O
in	O
particular	O
extracellular	O
matrix	O
components	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
Using	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
,	B-X
we	B-X
identified	B-X
overexpression	B-X
of	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
including	B-X
collagen	B-X
III	B-X
,	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
I	B-X
,	B-X
dermatopontin	B-X
,	B-X
matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
and	B-X
tenascin	B-X
C.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
confirmed	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
The	B-X
overexpression	B-X
of	B-X
MGP	B-X
transcript	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
MGP	B-X
level	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
undercarboxylated	B-X
form	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Smooth	B-X
muscle	B-X
cells	B-X
from	B-X
varicose	B-X
veins	B-X
showed	B-X
increased	B-X
proliferation	B-X
rate	B-X
and	B-X
enhanced	B-X
matrix	B-X
mineralization	B-X
.	B-X
This	B-X
observation	B-X
correlated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
ectopic	B-X
mineralization	B-X
areas	B-X
in	B-X
the	B-X
varicose	B-X
vein	B-X
walls	B-X
.	B-X
The	B-X
use	B-X
of	B-X
warfarin	B-X
,	B-X
to	B-X
inhibit	B-X
MGP	B-X
activity	B-X
,	B-X
or	B-X
siRNA	B-X
targeting	B-X
MGP	B-X
transcript	B-X
induced	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
exacerbated	B-X
proliferation	B-X
of	B-X
varicose	B-X
vein	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X
Further	B-X
study	B-X
of	B-X
these	B-X
genes	B-X
will	B-X
provide	B-X
insights	B-X
into	B-X
their	B-X
specific	B-X
roles	B-X
in	B-X
the	B-X
etiology	B-X
of	B-X
venous	B-X
disease	B-X
.	B-X

Further	O
study	O
of	O
these	O
genes	O
will	O
provide	O
insights	O
into	O
their	O
specific	O
roles	O
in	O
the	O
etiology	O
of	O
venous	O
disease	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
human	B-X
varicose	B-X
veins	B-X
.	B-X
Using	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
,	B-X
we	B-X
identified	B-X
overexpression	B-X
of	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
including	B-X
collagen	B-X
III	B-X
,	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
I	B-X
,	B-X
dermatopontin	B-X
,	B-X
matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
and	B-X
tenascin	B-X
C.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
confirmed	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
expression	B-X
of	B-X
MGP	B-X
in	B-X
varicose	B-X
veins	B-X
may	B-X
contribute	B-X
to	B-X
venous	B-X
wall	B-X
remodeling	B-X
by	B-X
affecting	B-X
proliferation	B-X
and	B-X
mineralization	B-X
processes	B-X
probably	B-X
through	B-X
impaired	B-X
carboxylation	B-X
of	B-X
MGP	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
suppressive	B-X
subtractive	B-X
hybridization	B-X
results	B-X
also	B-X
produce	B-X
a	B-X
profile	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
varicose	B-X
veins	B-X
,	B-X
in	B-X
particular	B-X
extracellular	B-X
matrix	B-X
components	B-X
.	B-X
Further	B-X
study	B-X
of	B-X
these	B-X
genes	B-X
will	B-X
provide	B-X
insights	B-X
into	B-X
their	B-X
specific	B-X
roles	B-X
in	B-X
the	B-X
etiology	B-X
of	B-X
venous	B-X
disease	B-X
.	B-X

Statins	O
reduce	O
amyloid	B-Protein
-	I-Protein
beta	I-Protein
production	O
through	O
inhibition	O
of	O
protein	O
isoprenylation	O
.	O
<EOS>	B-X
The	B-X
Rho	B-X
and	B-X
Rab	B-X
family	B-X
small	B-X
G-proteins	B-X
require	B-X
addition	B-X
of	B-X
these	B-X
isoprenyl	B-X
moieties	B-X
at	B-X
their	B-X
C	B-X
termini	B-X
for	B-X
normal	B-X
GTPase	B-X
function	B-X
.	B-X
In	B-X
neuroblastoma	B-X
cell	B-X
lines	B-X
,	B-X
treatment	B-X
with	B-X
statins	B-X
inhibits	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
Rho	B-X
and	B-X
Rab	B-X
proteins	B-X
at	B-X
statin	B-X
doses	B-X
as	B-X
low	B-X
as	B-X
200	B-X
nm	B-X
,	B-X
without	B-X
affecting	B-X
cellular	B-X
cholesterol	B-X
levels	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
at	B-X
low	B-X
,	B-X
physiologically	B-X
relevant	B-X
,	B-X
doses	B-X
statins	B-X
preferentially	B-X
inhibit	B-X
the	B-X
isoprenylation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
GTPases	B-X
.	B-X
The	B-X
amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
is	B-X
proteolytically	B-X
cleaved	B-X
to	B-X
generate	B-X
beta-amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
which	B-X
is	B-X
the	B-X
major	B-X
component	B-X
of	B-X
senile	B-X
plaques	B-X
found	B-X
in	B-X
AD	B-X
.	B-X
We	B-X
show	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
by	B-X
statins	B-X
causes	B-X
the	B-X
accumulation	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
through	B-X
inhibition	B-X
of	B-X
Rab	B-X
family	B-X
proteins	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
.	B-X
Moreover	B-X
,	B-X
inhibition	B-X
of	B-X
Rho	B-X
family	B-X
protein	B-X
function	B-X
reduces	B-X
levels	B-X
of	B-X
APP	B-X
C-terminal	B-X
fragments	B-X
due	B-X
to	B-X
enhanced	B-X
lysosomal	B-X
dependent	B-X
degradation	B-X
.	B-X
Statin	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
results	B-X
in	B-X
decreased	B-X
Abeta	B-X
secretion	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
show	B-X
that	B-X
statins	B-X
selectively	B-X
inhibit	B-X
GTPase	B-X
isoprenylation	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
,	B-X
leading	B-X
to	B-X
reduced	B-X
Abeta	B-X
production	B-X
in	B-X
an	B-X
isoprenoid-dependent	B-X
manner	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
statins	B-X
may	B-X
reduce	B-X
AD	B-X
pathogenesis	B-X
.	B-X

Epidemiological	O
evidence	O
suggests	O
that	O
long	O
term	O
treatment	O
with	O
hydroxymethylglutaryl	O
-	O
CoA	O
reductase	O
inhibitors	O
,	O
or	O
statins	O
,	O
decreases	O
the	O
risk	O
for	O
developing	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O
<EOS>	B-X
The	B-X
aetiology	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
believed	B-X
to	B-X
involve	B-X
environmental	B-X
exposure	B-X
and	B-X
genetic	B-X
susceptibility	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
our	B-X
present	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
was	B-X
to	B-X
roundly	B-X
evaluate	B-X
the	B-X
association	B-X
between	B-X
AD	B-X
and	B-X
its	B-X
modifiable	B-X
risk	B-X
factors	B-X
.	B-X
In	B-X
2016	B-X
,	B-X
an	B-X
expert	B-X
consensus	B-X
panel	B-X
from	B-X
the	B-X
ACC	B-X
recommended	B-X
the	B-X
use	B-X
of	B-X
nonstatin	B-X
therapies	B-X
(	B-X
ezetimibe	B-X
and	B-X
PCSK9	B-X
inhibitors	B-X
)	B-X
in	B-X
addition	B-X
to	B-X
maximally	B-X
tolerated	B-X
statin	B-X
therapy	B-X
in	B-X
individuals	B-X
whose	B-X
LDL-cholesterol	B-X
and	B-X
non-HDL-cholesterol	B-X
levels	B-X
remained	B-X
above	B-X
certain	B-X
thresholds	B-X
after	B-X
statin	B-X
treatment	B-X
.	B-X
Given	B-X
the	B-X
substantial	B-X
benefits	B-X
of	B-X
statin	B-X
therapies	B-X
in	B-X
both	B-X
primary	B-X
and	B-X
secondary	B-X
prevention	B-X
of	B-X
cardiovascular	B-X
disease	B-X
,	B-X
their	B-X
long-term	B-X
safety	B-X
has	B-X
become	B-X
a	B-X
concern	B-X
.	B-X
The	B-X
potential	B-X
harmful	B-X
effects	B-X
of	B-X
statin	B-X
therapy	B-X
on	B-X
muscle	B-X
and	B-X
liver	B-X
have	B-X
been	B-X
known	B-X
for	B-X
some	B-X
time	B-X
,	B-X
but	B-X
new	B-X
concerns	B-X
have	B-X
emerged	B-X
regarding	B-X
the	B-X
risk	B-X
of	B-X
new-onset	B-X
diabetes	B-X
mellitus	B-X
,	B-X
cognitive	B-X
impairment	B-X
and	B-X
haemorrhagic	B-X
stroke	B-X
associated	B-X
with	B-X
the	B-X
use	B-X
of	B-X
statins	B-X
and	B-X
the	B-X
risks	B-X
of	B-X
achieving	B-X
very	B-X
low	B-X
levels	B-X
of	B-X
LDL	B-X
cholesterol	B-X
.	B-X
The	B-X
increased	B-X
media	B-X
attention	B-X
on	B-X
the	B-X
adverse	B-X
events	B-X
associated	B-X
with	B-X
statins	B-X
has	B-X
unfortunately	B-X
led	B-X
to	B-X
statin	B-X
therapy	B-X
discontinuation	B-X
,	B-X
nonadherence	B-X
to	B-X
therapy	B-X
or	B-X
concerns	B-X
about	B-X
initiating	B-X
statin	B-X
therapy	B-X
.	B-X
In	B-X
this	B-X
Review	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
safety	B-X
of	B-X
statin	B-X
therapy	B-X
in	B-X
light	B-X
of	B-X
the	B-X
latest	B-X
evidence	B-X
and	B-X
provide	B-X
clinicians	B-X
with	B-X
reassurance	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
statins	B-X
.	B-X
Overwhelming	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
benefits	B-X
of	B-X
statin	B-X
therapy	B-X
far	B-X
outweigh	B-X
any	B-X
real	B-X
or	B-X
perceived	B-X
risks	B-X
.	B-X

However	O
,	O
statin	O
-	O
mediated	O
AD	O
protection	O
cannot	O
be	O
fully	O
explained	O
by	O
reduction	O
of	O
cholesterol	O
levels	O
.	O
<EOS>	B-X
Epidemiological	B-X
evidence	B-X
suggests	B-X
that	B-X
long	B-X
term	B-X
treatment	B-X
with	B-X
hydroxymethylglutaryl-CoA	B-X
reductase	B-X
inhibitors	B-X
,	B-X
or	B-X
statins	B-X
,	B-X
decreases	B-X
the	B-X
risk	B-X
for	B-X
developing	B-X
Alzheimer	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
However	B-X
,	B-X
statin-mediated	B-X
AD	B-X
protection	B-X
can	B-X
not	B-X
be	B-X
fully	B-X
explained	B-X
by	B-X
reduction	B-X
of	B-X
cholesterol	B-X
levels	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
their	B-X
cholesterol	B-X
lowering	B-X
effects	B-X
,	B-X
statins	B-X
have	B-X
pleiotropic	B-X
actions	B-X
and	B-X
act	B-X
to	B-X
lower	B-X
the	B-X
concentrations	B-X
of	B-X
isoprenoid	B-X
intermediates	B-X
,	B-X
such	B-X
as	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
.	B-X
In	B-X
neuroblastoma	B-X
cell	B-X
lines	B-X
,	B-X
treatment	B-X
with	B-X
statins	B-X
inhibits	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
Rho	B-X
and	B-X
Rab	B-X
proteins	B-X
at	B-X
statin	B-X
doses	B-X
as	B-X
low	B-X
as	B-X
200	B-X
nm	B-X
,	B-X
without	B-X
affecting	B-X
cellular	B-X
cholesterol	B-X
levels	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
at	B-X
low	B-X
,	B-X
physiologically	B-X
relevant	B-X
,	B-X
doses	B-X
statins	B-X
preferentially	B-X
inhibit	B-X
the	B-X
isoprenylation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
GTPases	B-X
.	B-X
The	B-X
amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
is	B-X
proteolytically	B-X
cleaved	B-X
to	B-X
generate	B-X
beta-amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
which	B-X
is	B-X
the	B-X
major	B-X
component	B-X
of	B-X
senile	B-X
plaques	B-X
found	B-X
in	B-X
AD	B-X
.	B-X
We	B-X
show	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
by	B-X
statins	B-X
causes	B-X
the	B-X
accumulation	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
through	B-X
inhibition	B-X
of	B-X
Rab	B-X
family	B-X
proteins	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
.	B-X
Moreover	B-X
,	B-X
inhibition	B-X
of	B-X
Rho	B-X
family	B-X
protein	B-X
function	B-X
reduces	B-X
levels	B-X
of	B-X
APP	B-X
C-terminal	B-X
fragments	B-X
due	B-X
to	B-X
enhanced	B-X
lysosomal	B-X
dependent	B-X
degradation	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
show	B-X
that	B-X
statins	B-X
selectively	B-X
inhibit	B-X
GTPase	B-X
isoprenylation	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
,	B-X
leading	B-X
to	B-X
reduced	B-X
Abeta	B-X
production	B-X
in	B-X
an	B-X
isoprenoid-dependent	B-X
manner	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
statins	B-X
may	B-X
reduce	B-X
AD	B-X
pathogenesis	B-X
.	B-X

In	O
addition	O
to	O
their	O
cholesterol	O
lowering	O
effects	O
,	O
statins	O
have	O
pleiotropic	O
actions	O
and	O
act	O
to	O
lower	O
the	O
concentrations	O
of	O
isoprenoid	O
intermediates	O
,	O
such	O
as	O
geranylgeranyl	O
pyrophosphate	O
and	O
farnesyl	O
pyrophosphate	O
.	O
<EOS>	B-X
Epidemiological	B-X
evidence	B-X
suggests	B-X
that	B-X
long	B-X
term	B-X
treatment	B-X
with	B-X
hydroxymethylglutaryl-CoA	B-X
reductase	B-X
inhibitors	B-X
,	B-X
or	B-X
statins	B-X
,	B-X
decreases	B-X
the	B-X
risk	B-X
for	B-X
developing	B-X
Alzheimer	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
However	B-X
,	B-X
statin-mediated	B-X
AD	B-X
protection	B-X
can	B-X
not	B-X
be	B-X
fully	B-X
explained	B-X
by	B-X
reduction	B-X
of	B-X
cholesterol	B-X
levels	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
their	B-X
cholesterol	B-X
lowering	B-X
effects	B-X
,	B-X
statins	B-X
have	B-X
pleiotropic	B-X
actions	B-X
and	B-X
act	B-X
to	B-X
lower	B-X
the	B-X
concentrations	B-X
of	B-X
isoprenoid	B-X
intermediates	B-X
,	B-X
such	B-X
as	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
Rho	B-X
and	B-X
Rab	B-X
family	B-X
small	B-X
G-proteins	B-X
require	B-X
addition	B-X
of	B-X
these	B-X
isoprenyl	B-X
moieties	B-X
at	B-X
their	B-X
C	B-X
termini	B-X
for	B-X
normal	B-X
GTPase	B-X
function	B-X
.	B-X
In	B-X
neuroblastoma	B-X
cell	B-X
lines	B-X
,	B-X
treatment	B-X
with	B-X
statins	B-X
inhibits	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
Rho	B-X
and	B-X
Rab	B-X
proteins	B-X
at	B-X
statin	B-X
doses	B-X
as	B-X
low	B-X
as	B-X
200	B-X
nm	B-X
,	B-X
without	B-X
affecting	B-X
cellular	B-X
cholesterol	B-X
levels	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
at	B-X
low	B-X
,	B-X
physiologically	B-X
relevant	B-X
,	B-X
doses	B-X
statins	B-X
preferentially	B-X
inhibit	B-X
the	B-X
isoprenylation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
GTPases	B-X
.	B-X
We	B-X
show	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
by	B-X
statins	B-X
causes	B-X
the	B-X
accumulation	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
through	B-X
inhibition	B-X
of	B-X
Rab	B-X
family	B-X
proteins	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
show	B-X
that	B-X
statins	B-X
selectively	B-X
inhibit	B-X
GTPase	B-X
isoprenylation	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
,	B-X
leading	B-X
to	B-X
reduced	B-X
Abeta	B-X
production	B-X
in	B-X
an	B-X
isoprenoid-dependent	B-X
manner	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
statins	B-X
may	B-X
reduce	B-X
AD	B-X
pathogenesis	B-X
.	B-X

The	O
Rho	O
and	O
Rab	O
family	O
small	O
G	O
-	O
proteins	O
require	O
addition	O
of	O
these	O
isoprenyl	O
moieties	O
at	O
their	O
C	O
termini	O
for	O
normal	O
GTPase	O
function	O
.	O
<EOS>	B-X
Epidemiological	B-X
evidence	B-X
suggests	B-X
that	B-X
long	B-X
term	B-X
treatment	B-X
with	B-X
hydroxymethylglutaryl-CoA	B-X
reductase	B-X
inhibitors	B-X
,	B-X
or	B-X
statins	B-X
,	B-X
decreases	B-X
the	B-X
risk	B-X
for	B-X
developing	B-X
Alzheimer	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
their	B-X
cholesterol	B-X
lowering	B-X
effects	B-X
,	B-X
statins	B-X
have	B-X
pleiotropic	B-X
actions	B-X
and	B-X
act	B-X
to	B-X
lower	B-X
the	B-X
concentrations	B-X
of	B-X
isoprenoid	B-X
intermediates	B-X
,	B-X
such	B-X
as	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
Rho	B-X
and	B-X
Rab	B-X
family	B-X
small	B-X
G-proteins	B-X
require	B-X
addition	B-X
of	B-X
these	B-X
isoprenyl	B-X
moieties	B-X
at	B-X
their	B-X
C	B-X
termini	B-X
for	B-X
normal	B-X
GTPase	B-X
function	B-X
.	B-X
In	B-X
neuroblastoma	B-X
cell	B-X
lines	B-X
,	B-X
treatment	B-X
with	B-X
statins	B-X
inhibits	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
Rho	B-X
and	B-X
Rab	B-X
proteins	B-X
at	B-X
statin	B-X
doses	B-X
as	B-X
low	B-X
as	B-X
200	B-X
nm	B-X
,	B-X
without	B-X
affecting	B-X
cellular	B-X
cholesterol	B-X
levels	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
at	B-X
low	B-X
,	B-X
physiologically	B-X
relevant	B-X
,	B-X
doses	B-X
statins	B-X
preferentially	B-X
inhibit	B-X
the	B-X
isoprenylation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
GTPases	B-X
.	B-X
We	B-X
show	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
by	B-X
statins	B-X
causes	B-X
the	B-X
accumulation	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
through	B-X
inhibition	B-X
of	B-X
Rab	B-X
family	B-X
proteins	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
.	B-X
Moreover	B-X
,	B-X
inhibition	B-X
of	B-X
Rho	B-X
family	B-X
protein	B-X
function	B-X
reduces	B-X
levels	B-X
of	B-X
APP	B-X
C-terminal	B-X
fragments	B-X
due	B-X
to	B-X
enhanced	B-X
lysosomal	B-X
dependent	B-X
degradation	B-X
.	B-X
Statin	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
results	B-X
in	B-X
decreased	B-X
Abeta	B-X
secretion	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
show	B-X
that	B-X
statins	B-X
selectively	B-X
inhibit	B-X
GTPase	B-X
isoprenylation	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
,	B-X
leading	B-X
to	B-X
reduced	B-X
Abeta	B-X
production	B-X
in	B-X
an	B-X
isoprenoid-dependent	B-X
manner	B-X
.	B-X

In	O
neuroblastoma	O
cell	O
lines	O
,	O
treatment	O
with	O
statins	O
inhibits	O
the	O
membrane	O
localization	O
of	O
Rho	O
and	O
Rab	O
proteins	O
at	O
statin	O
doses	O
as	O
low	O
as	O
200	O
nm	O
,	O
without	O
affecting	O
cellular	O
cholesterol	O
levels	O
.	O

In	O
addition	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
at	O
low	O
,	O
physiologically	O
relevant	O
,	O
doses	O
statins	O
preferentially	O
inhibit	O
the	O
isoprenylation	O
of	O
a	O
subset	O
of	O
GTPases	O
.	O
<EOS>	B-X
Epidemiological	B-X
evidence	B-X
suggests	B-X
that	B-X
long	B-X
term	B-X
treatment	B-X
with	B-X
hydroxymethylglutaryl-CoA	B-X
reductase	B-X
inhibitors	B-X
,	B-X
or	B-X
statins	B-X
,	B-X
decreases	B-X
the	B-X
risk	B-X
for	B-X
developing	B-X
Alzheimer	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
their	B-X
cholesterol	B-X
lowering	B-X
effects	B-X
,	B-X
statins	B-X
have	B-X
pleiotropic	B-X
actions	B-X
and	B-X
act	B-X
to	B-X
lower	B-X
the	B-X
concentrations	B-X
of	B-X
isoprenoid	B-X
intermediates	B-X
,	B-X
such	B-X
as	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
Rho	B-X
and	B-X
Rab	B-X
family	B-X
small	B-X
G-proteins	B-X
require	B-X
addition	B-X
of	B-X
these	B-X
isoprenyl	B-X
moieties	B-X
at	B-X
their	B-X
C	B-X
termini	B-X
for	B-X
normal	B-X
GTPase	B-X
function	B-X
.	B-X
In	B-X
neuroblastoma	B-X
cell	B-X
lines	B-X
,	B-X
treatment	B-X
with	B-X
statins	B-X
inhibits	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
Rho	B-X
and	B-X
Rab	B-X
proteins	B-X
at	B-X
statin	B-X
doses	B-X
as	B-X
low	B-X
as	B-X
200	B-X
nm	B-X
,	B-X
without	B-X
affecting	B-X
cellular	B-X
cholesterol	B-X
levels	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
at	B-X
low	B-X
,	B-X
physiologically	B-X
relevant	B-X
,	B-X
doses	B-X
statins	B-X
preferentially	B-X
inhibit	B-X
the	B-X
isoprenylation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
GTPases	B-X
.	B-X
We	B-X
show	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
by	B-X
statins	B-X
causes	B-X
the	B-X
accumulation	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
through	B-X
inhibition	B-X
of	B-X
Rab	B-X
family	B-X
proteins	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
.	B-X
Moreover	B-X
,	B-X
inhibition	B-X
of	B-X
Rho	B-X
family	B-X
protein	B-X
function	B-X
reduces	B-X
levels	B-X
of	B-X
APP	B-X
C-terminal	B-X
fragments	B-X
due	B-X
to	B-X
enhanced	B-X
lysosomal	B-X
dependent	B-X
degradation	B-X
.	B-X
Statin	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
results	B-X
in	B-X
decreased	B-X
Abeta	B-X
secretion	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
show	B-X
that	B-X
statins	B-X
selectively	B-X
inhibit	B-X
GTPase	B-X
isoprenylation	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
,	B-X
leading	B-X
to	B-X
reduced	B-X
Abeta	B-X
production	B-X
in	B-X
an	B-X
isoprenoid-dependent	B-X
manner	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
statins	B-X
may	B-X
reduce	B-X
AD	B-X
pathogenesis	B-X
.	B-X

The	O
amyloid	B-Protein
precursor	I-Protein
protein	I-Protein
(	O
APP	B-Protein
)	O
is	O
proteolytically	O
cleaved	O
to	O
generate	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
(	O
Abeta	B-Protein
)	O
,	O
which	O
is	O
the	O
major	O
component	O
of	O
senile	O
plaques	O
found	O
in	O
AD	O
.	O
<EOS>	B-X
Amyloid-β	B-X
peptide	B-X
(	B-X
Aβ	B-X
)	B-X
and	B-X
tau	B-X
are	B-X
major	B-X
components	B-X
of	B-X
senile	B-X
plaques	B-X
and	B-X
neurofibrillary	B-X
tangles	B-X
,	B-X
respectively	B-X
,	B-X
deposited	B-X
in	B-X
the	B-X
brains	B-X
of	B-X
Alzheimer	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
patients	B-X
.	B-X
Aβ	B-X
is	B-X
derived	B-X
from	B-X
amyloid-β	B-X
precursor	B-X
protein	B-X
that	B-X
is	B-X
sequentially	B-X
cleaved	B-X
by	B-X
two	B-X
aspartate	B-X
proteases	B-X
,	B-X
β-	B-X
and	B-X
γ-secretases	B-X
.	B-X
Several	B-X
lines	B-X
of	B-X
evidence	B-X
suggest	B-X
that	B-X
accumulation	B-X
of	B-X
Aβ	B-X
by	B-X
increased	B-X
production	B-X
or	B-X
decreased	B-X
degradation	B-X
induces	B-X
the	B-X
tau-mediated	B-X
neuronal	B-X
toxicity	B-X
and	B-X
symptomatic	B-X
manifestations	B-X
of	B-X
AD	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
dynamics	B-X
of	B-X
cerebral	B-X
Aβ	B-X
,	B-X
called	B-X
as	B-X
``	B-X
Aβ	B-X
economy	B-X
''	B-X
,	B-X
would	B-X
be	B-X
the	B-X
mechanistic	B-X
basis	B-X
of	B-X
AD	B-X
pathogenesis	B-X
.	B-X
Partial	B-X
loss	B-X
of	B-X
γ-secretase	B-X
activity	B-X
leads	B-X
to	B-X
the	B-X
increased	B-X
generation	B-X
of	B-X
toxic	B-X
Aβ	B-X
isoforms	B-X
,	B-X
indicating	B-X
that	B-X
activation	B-X
of	B-X
γ-secretase	B-X
would	B-X
provide	B-X
a	B-X
beneficial	B-X
effect	B-X
for	B-X
AD	B-X
.	B-X
Recent	B-X
studies	B-X
revealed	B-X
the	B-X
decreased	B-X
clearance	B-X
of	B-X
Aβ	B-X
in	B-X
sporadic	B-X
AD	B-X
patients	B-X
,	B-X
suggesting	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
catabolic	B-X
mechanism	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
AD	B-X
.	B-X
I	B-X
will	B-X
discuss	B-X
with	B-X
these	B-X
proteolytic	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
Aβ	B-X
economy	B-X
,	B-X
and	B-X
development	B-X
of	B-X
effective	B-X
treatment	B-X
and	B-X
diagnostics	B-X
for	B-X
AD	B-X
.	B-X

We	O
show	O
that	O
inhibition	O
of	O
protein	O
isoprenylation	O
by	O
statins	O
causes	O
the	O
accumulation	O
of	O
APP	B-Protein
within	O
the	O
cell	O
through	O
inhibition	O
of	O
Rab	O
family	O
proteins	O
involved	O
in	O
vesicular	O
trafficking	O
.	O
<EOS>	B-X
Epidemiological	B-X
evidence	B-X
suggests	B-X
that	B-X
long	B-X
term	B-X
treatment	B-X
with	B-X
hydroxymethylglutaryl-CoA	B-X
reductase	B-X
inhibitors	B-X
,	B-X
or	B-X
statins	B-X
,	B-X
decreases	B-X
the	B-X
risk	B-X
for	B-X
developing	B-X
Alzheimer	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
their	B-X
cholesterol	B-X
lowering	B-X
effects	B-X
,	B-X
statins	B-X
have	B-X
pleiotropic	B-X
actions	B-X
and	B-X
act	B-X
to	B-X
lower	B-X
the	B-X
concentrations	B-X
of	B-X
isoprenoid	B-X
intermediates	B-X
,	B-X
such	B-X
as	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
Rho	B-X
and	B-X
Rab	B-X
family	B-X
small	B-X
G-proteins	B-X
require	B-X
addition	B-X
of	B-X
these	B-X
isoprenyl	B-X
moieties	B-X
at	B-X
their	B-X
C	B-X
termini	B-X
for	B-X
normal	B-X
GTPase	B-X
function	B-X
.	B-X
In	B-X
neuroblastoma	B-X
cell	B-X
lines	B-X
,	B-X
treatment	B-X
with	B-X
statins	B-X
inhibits	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
Rho	B-X
and	B-X
Rab	B-X
proteins	B-X
at	B-X
statin	B-X
doses	B-X
as	B-X
low	B-X
as	B-X
200	B-X
nm	B-X
,	B-X
without	B-X
affecting	B-X
cellular	B-X
cholesterol	B-X
levels	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
at	B-X
low	B-X
,	B-X
physiologically	B-X
relevant	B-X
,	B-X
doses	B-X
statins	B-X
preferentially	B-X
inhibit	B-X
the	B-X
isoprenylation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
GTPases	B-X
.	B-X
The	B-X
amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
is	B-X
proteolytically	B-X
cleaved	B-X
to	B-X
generate	B-X
beta-amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
which	B-X
is	B-X
the	B-X
major	B-X
component	B-X
of	B-X
senile	B-X
plaques	B-X
found	B-X
in	B-X
AD	B-X
.	B-X
We	B-X
show	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
by	B-X
statins	B-X
causes	B-X
the	B-X
accumulation	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
through	B-X
inhibition	B-X
of	B-X
Rab	B-X
family	B-X
proteins	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
.	B-X
Moreover	B-X
,	B-X
inhibition	B-X
of	B-X
Rho	B-X
family	B-X
protein	B-X
function	B-X
reduces	B-X
levels	B-X
of	B-X
APP	B-X
C-terminal	B-X
fragments	B-X
due	B-X
to	B-X
enhanced	B-X
lysosomal	B-X
dependent	B-X
degradation	B-X
.	B-X
Statin	B-X
inhibition	B-X
of	B-X
protein	B-X
isoprenylation	B-X
results	B-X
in	B-X
decreased	B-X
Abeta	B-X
secretion	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
show	B-X
that	B-X
statins	B-X
selectively	B-X
inhibit	B-X
GTPase	B-X
isoprenylation	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
,	B-X
leading	B-X
to	B-X
reduced	B-X
Abeta	B-X
production	B-X
in	B-X
an	B-X
isoprenoid-dependent	B-X
manner	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
statins	B-X
may	B-X
reduce	B-X
AD	B-X
pathogenesis	B-X
.	B-X

Moreover	O
,	O
inhibition	O
of	O
Rho	O
family	O
protein	O
function	O
reduces	O
levels	O
of	O
APP	B-Protein
C	O
-	O
terminal	O
fragments	O
due	O
to	O
enhanced	O
lysosomal	O
dependent	O
degradation	O
.	O

Statin	O
inhibition	O
of	O
protein	O
isoprenylation	O
results	O
in	O
decreased	O
Abeta	B-Protein
secretion	O
.	O
<EOS>	B-X
Meta-analysis	B-X
of	B-X
association	B-X
studies	B-X
relevant	B-X
to	B-X
AD	B-X
indicates	B-X
that	B-X
apolipoprotein	B-X
(	B-X
apo	B-X
)	B-X
E4	B-X
is	B-X
the	B-X
only	B-X
cholesterol-related	B-X
polymorphism	B-X
that	B-X
shows	B-X
clear	B-X
association	B-X
with	B-X
AD	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
apoE4	B-X
on	B-X
the	B-X
pathophysiology	B-X
of	B-X
AD	B-X
occurs	B-X
via	B-X
a	B-X
mechanism	B-X
that	B-X
is	B-X
not	B-X
directly	B-X
related	B-X
to	B-X
cholesterol	B-X
,	B-X
such	B-X
as	B-X
fibrillization	B-X
of	B-X
Abeta	B-X
.	B-X
Despite	B-X
the	B-X
lack	B-X
of	B-X
genetic	B-X
association	B-X
,	B-X
cholesterol	B-X
and	B-X
statins	B-X
clearly	B-X
modulate	B-X
amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
processing	B-X
in	B-X
cell	B-X
culture	B-X
and	B-X
animal	B-X
models	B-X
.	B-X
Statins	B-X
appear	B-X
to	B-X
act	B-X
by	B-X
a	B-X
pleiotropic	B-X
mechanism	B-X
,	B-X
involving	B-X
both	B-X
cholesterol	B-X
(	B-X
via	B-X
lipid	B-X
rafts	B-X
)	B-X
and	B-X
isoprenylation	B-X
.	B-X
The	B-X
pleiotropic	B-X
mechanism	B-X
of	B-X
statin	B-X
action	B-X
clarifies	B-X
conflicting	B-X
data	B-X
from	B-X
clinical	B-X
studies	B-X
,	B-X
where	B-X
statins	B-X
exert	B-X
an	B-X
action	B-X
on	B-X
Abeta	B-X
and	B-X
AD	B-X
that	B-X
might	B-X
be	B-X
dose	B-X
dependent	B-X
because	B-X
of	B-X
actions	B-X
on	B-X
both	B-X
cholesterol	B-X
and	B-X
isoprenylation	B-X
.	B-X
Reduced	B-X
isoprenylation	B-X
can	B-X
also	B-X
inhibit	B-X
inflammation	B-X
.	B-X
Our	B-X
own	B-X
studies	B-X
of	B-X
brains	B-X
from	B-X
Alzheimer	B-X
subjects	B-X
+/-	B-X
statins	B-X
indicate	B-X
that	B-X
statins	B-X
inhibit	B-X
inflammation	B-X
in	B-X
humans	B-X
but	B-X
might	B-X
not	B-X
reduce	B-X
cerebral	B-X
Abeta	B-X
load	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
primary	B-X
action	B-X
of	B-X
statins	B-X
in	B-X
humans	B-X
with	B-X
AD	B-X
might	B-X
be	B-X
to	B-X
reduce	B-X
inflammation	B-X
rather	B-X
than	B-X
decrease	B-X
Abeta	B-X
load	B-X
.	B-X

In	O
summary	O
,	O
we	O
show	O
that	O
statins	O
selectively	O
inhibit	O
GTPase	O
isoprenylation	O
at	O
clinically	O
relevant	O
doses	O
,	O
leading	O
to	O
reduced	O
Abeta	B-Protein
production	O
in	O
an	O
isoprenoid	O
-	O
dependent	O
manner	O
.	O

These	O
studies	O
provide	O
insight	O
into	O
the	O
mechanisms	O
by	O
which	O
statins	O
may	O
reduce	O
AD	O
pathogenesis	O
.	O
<EOS>	B-X
The	B-X
mechanisms	B-X
that	B-X
underlie	B-X
the	B-X
pathophysiology	B-X
of	B-X
aging	B-X
,	B-X
amyotrophic	B-X
lateral	B-X
sclerosis	B-X
(	B-X
ALS	B-X
)	B-X
,	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
and	B-X
stroke	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
and	B-X
have	B-X
been	B-X
the	B-X
focus	B-X
of	B-X
intense	B-X
and	B-X
constant	B-X
investigation	B-X
worldwide	B-X
.	B-X
Studies	B-X
that	B-X
provide	B-X
insights	B-X
on	B-X
aging	B-X
and	B-X
age-related	B-X
disease	B-X
mechanisms	B-X
are	B-X
critical	B-X
for	B-X
advancing	B-X
novel	B-X
therapies	B-X
that	B-X
promote	B-X
successful	B-X
aging	B-X
and	B-X
prevent	B-X
or	B-X
cure	B-X
multiple	B-X
age-related	B-X
diseases	B-X
.	B-X
The	B-X
April	B-X
2019	B-X
issue	B-X
of	B-X
the	B-X
journal	B-X
,	B-X
``	B-X
Aging	B-X
&	B-X
Disease	B-X
''	B-X
published	B-X
a	B-X
series	B-X
of	B-X
articles	B-X
that	B-X
confer	B-X
fresh	B-X
insights	B-X
on	B-X
numerous	B-X
age-related	B-X
conditions	B-X
and	B-X
diseases	B-X
.	B-X
The	B-X
topics	B-X
discussed	B-X
on	B-X
AD	B-X
implied	B-X
that	B-X
extracellular	B-X
amyloid	B-X
β42	B-X
is	B-X
likely	B-X
the	B-X
cause	B-X
of	B-X
intraneuronal	B-X
neurofibrillary	B-X
tangle	B-X
accumulation	B-X
in	B-X
familial	B-X
AD	B-X
and	B-X
traditional	B-X
oriental	B-X
concoctions	B-X
may	B-X
be	B-X
useful	B-X
for	B-X
slowing	B-X
down	B-X
the	B-X
progression	B-X
of	B-X
AD	B-X
.	B-X
The	B-X
significance	B-X
of	B-X
the	B-X
above	B-X
findings	B-X
for	B-X
understanding	B-X
the	B-X
pathogenesis	B-X
in	B-X
aging	B-X
,	B-X
ALS	B-X
,	B-X
AD	B-X
,	B-X
and	B-X
stroke	B-X
,	B-X
slowing	B-X
down	B-X
the	B-X
progression	B-X
of	B-X
aging	B-X
,	B-X
ALS	B-X
and	B-X
AD	B-X
,	B-X
and	B-X
promoting	B-X
brain	B-X
repair	B-X
after	B-X
stroke	B-X
are	B-X
discussed	B-X
.	B-X

Mint3	B-Protein
/	O
X11gamma	B-Protein
is	O
an	O
ADP	O
-	O
ribosylation	O
factor	O
-	O
dependent	O
adaptor	O
that	O
regulates	O
the	O
traffic	O
of	O
the	O
Alzheimer	O
'	O
s	O
Precursor	O
protein	O
from	O
the	O
trans	O
-	O
Golgi	O
network	O
.	O
<EOS>	B-X
Beta-amyloid	B-X
peptides	B-X
(	B-X
Abeta	B-X
)	B-X
are	B-X
the	B-X
major	B-X
component	B-X
of	B-X
plaques	B-X
in	B-X
brains	B-X
of	B-X
Alzheimer	B-X
's	B-X
patients	B-X
,	B-X
and	B-X
are	B-X
they	B-X
derived	B-X
from	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
the	B-X
beta-amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
.	B-X
We	B-X
proposed	B-X
previously	B-X
that	B-X
transport	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
its	B-X
sorting	B-X
into	B-X
Mint/X11-containing	B-X
carriers	B-X
.	B-X
To	B-X
test	B-X
our	B-X
hypothesis	B-X
,	B-X
we	B-X
purified	B-X
APP-containing	B-X
vesicles	B-X
from	B-X
human	B-X
neuroblastoma	B-X
SH-SY5Y	B-X
cells	B-X
,	B-X
and	B-X
we	B-X
showed	B-X
that	B-X
Mint2/3	B-X
are	B-X
specifically	B-X
enriched	B-X
and	B-X
that	B-X
Mint3	B-X
and	B-X
APP	B-X
are	B-X
present	B-X
in	B-X
the	B-X
same	B-X
vesicles	B-X
.	B-X
Increasing	B-X
cellular	B-X
APP	B-X
levels	B-X
increased	B-X
the	B-X
amounts	B-X
of	B-X
both	B-X
APP	B-X
and	B-X
Mint3	B-X
in	B-X
purified	B-X
vesicles	B-X
.	B-X
Additional	B-X
evidence	B-X
supporting	B-X
an	B-X
obligate	B-X
role	B-X
for	B-X
Mint3	B-X
in	B-X
traffic	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
trans-Golgi	B-X
network	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
include	B-X
the	B-X
observations	B-X
that	B-X
depletion	B-X
of	B-X
Mint3	B-X
by	B-X
small	B-X
interference	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
or	B-X
mutation	B-X
of	B-X
the	B-X
Mint	B-X
binding	B-X
domain	B-X
of	B-X
APP	B-X
changes	B-X
the	B-X
export	B-X
route	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
basolateral	B-X
to	B-X
the	B-X
endosomal/lysosomal	B-X
sorting	B-X
route	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
increased	B-X
expression	B-X
of	B-X
Mint3	B-X
decreased	B-X
and	B-X
siRNA-mediated	B-X
knockdowns	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
neurotoxic	B-X
beta-amyloid	B-X
peptide	B-X
,	B-X
Abeta	B-X
(	B-X
1-40	B-X
)	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
implicate	B-X
Mint3	B-X
activity	B-X
as	B-X
a	B-X
critical	B-X
determinant	B-X
of	B-X
post-Golgi	B-X
APP	B-X
traffic	B-X
.	B-X

Beta	B-Protein
-	I-Protein
amyloid	I-Protein
peptides	O
(	O
Abeta	B-Protein
)	O
are	O
the	O
major	O
component	O
of	O
plaques	O
in	O
brains	O
of	O
Alzheimer	O
'	O
s	O
patients	O
,	O
and	O
are	O
they	O
derived	O
from	O
the	O
proteolytic	O
processing	O
of	O
the	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
precursor	I-Protein
protein	I-Protein
(	O
APP	B-Protein
)	O
.	O
<EOS>	B-X
Amyloid-β	B-X
peptide	B-X
(	B-X
Aβ	B-X
)	B-X
and	B-X
tau	B-X
are	B-X
major	B-X
components	B-X
of	B-X
senile	B-X
plaques	B-X
and	B-X
neurofibrillary	B-X
tangles	B-X
,	B-X
respectively	B-X
,	B-X
deposited	B-X
in	B-X
the	B-X
brains	B-X
of	B-X
Alzheimer	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
patients	B-X
.	B-X
Aβ	B-X
is	B-X
derived	B-X
from	B-X
amyloid-β	B-X
precursor	B-X
protein	B-X
that	B-X
is	B-X
sequentially	B-X
cleaved	B-X
by	B-X
two	B-X
aspartate	B-X
proteases	B-X
,	B-X
β-	B-X
and	B-X
γ-secretases	B-X
.	B-X
Recent	B-X
studies	B-X
revealed	B-X
the	B-X
decreased	B-X
clearance	B-X
of	B-X
Aβ	B-X
in	B-X
sporadic	B-X
AD	B-X
patients	B-X
,	B-X
suggesting	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
catabolic	B-X
mechanism	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
AD	B-X
.	B-X
I	B-X
will	B-X
discuss	B-X
with	B-X
these	B-X
proteolytic	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
Aβ	B-X
economy	B-X
,	B-X
and	B-X
development	B-X
of	B-X
effective	B-X
treatment	B-X
and	B-X
diagnostics	B-X
for	B-X
AD	B-X
.	B-X

The	O
movement	O
of	O
APP	B-Protein
between	O
organelles	O
is	O
highly	O
regulated	O
,	O
and	O
it	O
is	O
tightly	O
connected	O
to	O
its	O
processing	O
by	O
secretases	O
.	O
<EOS>	B-X
Beta-amyloid	B-X
peptides	B-X
(	B-X
Abeta	B-X
)	B-X
are	B-X
the	B-X
major	B-X
component	B-X
of	B-X
plaques	B-X
in	B-X
brains	B-X
of	B-X
Alzheimer	B-X
's	B-X
patients	B-X
,	B-X
and	B-X
are	B-X
they	B-X
derived	B-X
from	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
the	B-X
beta-amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
.	B-X
The	B-X
movement	B-X
of	B-X
APP	B-X
between	B-X
organelles	B-X
is	B-X
highly	B-X
regulated	B-X
,	B-X
and	B-X
it	B-X
is	B-X
tightly	B-X
connected	B-X
to	B-X
its	B-X
processing	B-X
by	B-X
secretases	B-X
.	B-X
We	B-X
proposed	B-X
previously	B-X
that	B-X
transport	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
its	B-X
sorting	B-X
into	B-X
Mint/X11-containing	B-X
carriers	B-X
.	B-X
To	B-X
test	B-X
our	B-X
hypothesis	B-X
,	B-X
we	B-X
purified	B-X
APP-containing	B-X
vesicles	B-X
from	B-X
human	B-X
neuroblastoma	B-X
SH-SY5Y	B-X
cells	B-X
,	B-X
and	B-X
we	B-X
showed	B-X
that	B-X
Mint2/3	B-X
are	B-X
specifically	B-X
enriched	B-X
and	B-X
that	B-X
Mint3	B-X
and	B-X
APP	B-X
are	B-X
present	B-X
in	B-X
the	B-X
same	B-X
vesicles	B-X
.	B-X
Increasing	B-X
cellular	B-X
APP	B-X
levels	B-X
increased	B-X
the	B-X
amounts	B-X
of	B-X
both	B-X
APP	B-X
and	B-X
Mint3	B-X
in	B-X
purified	B-X
vesicles	B-X
.	B-X
Additional	B-X
evidence	B-X
supporting	B-X
an	B-X
obligate	B-X
role	B-X
for	B-X
Mint3	B-X
in	B-X
traffic	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
trans-Golgi	B-X
network	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
include	B-X
the	B-X
observations	B-X
that	B-X
depletion	B-X
of	B-X
Mint3	B-X
by	B-X
small	B-X
interference	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
or	B-X
mutation	B-X
of	B-X
the	B-X
Mint	B-X
binding	B-X
domain	B-X
of	B-X
APP	B-X
changes	B-X
the	B-X
export	B-X
route	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
basolateral	B-X
to	B-X
the	B-X
endosomal/lysosomal	B-X
sorting	B-X
route	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
implicate	B-X
Mint3	B-X
activity	B-X
as	B-X
a	B-X
critical	B-X
determinant	B-X
of	B-X
post-Golgi	B-X
APP	B-X
traffic	B-X
.	B-X

We	O
proposed	O
previously	O
that	O
transport	O
of	O
APP	B-Protein
within	O
the	O
cell	O
is	O
mediated	O
in	O
part	O
through	O
its	O
sorting	O
into	O
Mint	O
/	O
X11	O
-	O
containing	O
carriers	O
.	O
<EOS>	B-X
Beta-amyloid	B-X
peptides	B-X
(	B-X
Abeta	B-X
)	B-X
are	B-X
the	B-X
major	B-X
component	B-X
of	B-X
plaques	B-X
in	B-X
brains	B-X
of	B-X
Alzheimer	B-X
's	B-X
patients	B-X
,	B-X
and	B-X
are	B-X
they	B-X
derived	B-X
from	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
the	B-X
beta-amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
.	B-X
The	B-X
movement	B-X
of	B-X
APP	B-X
between	B-X
organelles	B-X
is	B-X
highly	B-X
regulated	B-X
,	B-X
and	B-X
it	B-X
is	B-X
tightly	B-X
connected	B-X
to	B-X
its	B-X
processing	B-X
by	B-X
secretases	B-X
.	B-X
We	B-X
proposed	B-X
previously	B-X
that	B-X
transport	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
its	B-X
sorting	B-X
into	B-X
Mint/X11-containing	B-X
carriers	B-X
.	B-X
To	B-X
test	B-X
our	B-X
hypothesis	B-X
,	B-X
we	B-X
purified	B-X
APP-containing	B-X
vesicles	B-X
from	B-X
human	B-X
neuroblastoma	B-X
SH-SY5Y	B-X
cells	B-X
,	B-X
and	B-X
we	B-X
showed	B-X
that	B-X
Mint2/3	B-X
are	B-X
specifically	B-X
enriched	B-X
and	B-X
that	B-X
Mint3	B-X
and	B-X
APP	B-X
are	B-X
present	B-X
in	B-X
the	B-X
same	B-X
vesicles	B-X
.	B-X
Increasing	B-X
cellular	B-X
APP	B-X
levels	B-X
increased	B-X
the	B-X
amounts	B-X
of	B-X
both	B-X
APP	B-X
and	B-X
Mint3	B-X
in	B-X
purified	B-X
vesicles	B-X
.	B-X
Additional	B-X
evidence	B-X
supporting	B-X
an	B-X
obligate	B-X
role	B-X
for	B-X
Mint3	B-X
in	B-X
traffic	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
trans-Golgi	B-X
network	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
include	B-X
the	B-X
observations	B-X
that	B-X
depletion	B-X
of	B-X
Mint3	B-X
by	B-X
small	B-X
interference	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
or	B-X
mutation	B-X
of	B-X
the	B-X
Mint	B-X
binding	B-X
domain	B-X
of	B-X
APP	B-X
changes	B-X
the	B-X
export	B-X
route	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
basolateral	B-X
to	B-X
the	B-X
endosomal/lysosomal	B-X
sorting	B-X
route	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
increased	B-X
expression	B-X
of	B-X
Mint3	B-X
decreased	B-X
and	B-X
siRNA-mediated	B-X
knockdowns	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
neurotoxic	B-X
beta-amyloid	B-X
peptide	B-X
,	B-X
Abeta	B-X
(	B-X
1-40	B-X
)	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
implicate	B-X
Mint3	B-X
activity	B-X
as	B-X
a	B-X
critical	B-X
determinant	B-X
of	B-X
post-Golgi	B-X
APP	B-X
traffic	B-X
.	B-X

To	O
test	O
our	O
hypothesis	O
,	O
we	O
purified	O
APP	B-Protein
-	O
containing	O
vesicles	O
from	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
,	O
and	O
we	O
showed	O
that	O
Mint2	B-Protein
/	O
3	B-Protein
are	O
specifically	O
enriched	O
and	O
that	O
Mint3	B-Protein
and	O
APP	B-Protein
are	O
present	O
in	O
the	O
same	O
vesicles	O
.	O
<EOS>	B-X
Beta-amyloid	B-X
peptides	B-X
(	B-X
Abeta	B-X
)	B-X
are	B-X
the	B-X
major	B-X
component	B-X
of	B-X
plaques	B-X
in	B-X
brains	B-X
of	B-X
Alzheimer	B-X
's	B-X
patients	B-X
,	B-X
and	B-X
are	B-X
they	B-X
derived	B-X
from	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
the	B-X
beta-amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
.	B-X
The	B-X
movement	B-X
of	B-X
APP	B-X
between	B-X
organelles	B-X
is	B-X
highly	B-X
regulated	B-X
,	B-X
and	B-X
it	B-X
is	B-X
tightly	B-X
connected	B-X
to	B-X
its	B-X
processing	B-X
by	B-X
secretases	B-X
.	B-X
We	B-X
proposed	B-X
previously	B-X
that	B-X
transport	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
its	B-X
sorting	B-X
into	B-X
Mint/X11-containing	B-X
carriers	B-X
.	B-X
To	B-X
test	B-X
our	B-X
hypothesis	B-X
,	B-X
we	B-X
purified	B-X
APP-containing	B-X
vesicles	B-X
from	B-X
human	B-X
neuroblastoma	B-X
SH-SY5Y	B-X
cells	B-X
,	B-X
and	B-X
we	B-X
showed	B-X
that	B-X
Mint2/3	B-X
are	B-X
specifically	B-X
enriched	B-X
and	B-X
that	B-X
Mint3	B-X
and	B-X
APP	B-X
are	B-X
present	B-X
in	B-X
the	B-X
same	B-X
vesicles	B-X
.	B-X
Increasing	B-X
cellular	B-X
APP	B-X
levels	B-X
increased	B-X
the	B-X
amounts	B-X
of	B-X
both	B-X
APP	B-X
and	B-X
Mint3	B-X
in	B-X
purified	B-X
vesicles	B-X
.	B-X
Additional	B-X
evidence	B-X
supporting	B-X
an	B-X
obligate	B-X
role	B-X
for	B-X
Mint3	B-X
in	B-X
traffic	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
trans-Golgi	B-X
network	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
include	B-X
the	B-X
observations	B-X
that	B-X
depletion	B-X
of	B-X
Mint3	B-X
by	B-X
small	B-X
interference	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
or	B-X
mutation	B-X
of	B-X
the	B-X
Mint	B-X
binding	B-X
domain	B-X
of	B-X
APP	B-X
changes	B-X
the	B-X
export	B-X
route	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
basolateral	B-X
to	B-X
the	B-X
endosomal/lysosomal	B-X
sorting	B-X
route	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
increased	B-X
expression	B-X
of	B-X
Mint3	B-X
decreased	B-X
and	B-X
siRNA-mediated	B-X
knockdowns	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
neurotoxic	B-X
beta-amyloid	B-X
peptide	B-X
,	B-X
Abeta	B-X
(	B-X
1-40	B-X
)	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
implicate	B-X
Mint3	B-X
activity	B-X
as	B-X
a	B-X
critical	B-X
determinant	B-X
of	B-X
post-Golgi	B-X
APP	B-X
traffic	B-X
.	B-X

Increasing	O
cellular	O
APP	B-Protein
levels	O
increased	O
the	O
amounts	O
of	O
both	O
APP	B-Protein
and	O
Mint3	B-Protein
in	O
purified	O
vesicles	O
.	O
<EOS>	B-X
Beta-amyloid	B-X
peptides	B-X
(	B-X
Abeta	B-X
)	B-X
are	B-X
the	B-X
major	B-X
component	B-X
of	B-X
plaques	B-X
in	B-X
brains	B-X
of	B-X
Alzheimer	B-X
's	B-X
patients	B-X
,	B-X
and	B-X
are	B-X
they	B-X
derived	B-X
from	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
the	B-X
beta-amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
.	B-X
The	B-X
movement	B-X
of	B-X
APP	B-X
between	B-X
organelles	B-X
is	B-X
highly	B-X
regulated	B-X
,	B-X
and	B-X
it	B-X
is	B-X
tightly	B-X
connected	B-X
to	B-X
its	B-X
processing	B-X
by	B-X
secretases	B-X
.	B-X
We	B-X
proposed	B-X
previously	B-X
that	B-X
transport	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
its	B-X
sorting	B-X
into	B-X
Mint/X11-containing	B-X
carriers	B-X
.	B-X
To	B-X
test	B-X
our	B-X
hypothesis	B-X
,	B-X
we	B-X
purified	B-X
APP-containing	B-X
vesicles	B-X
from	B-X
human	B-X
neuroblastoma	B-X
SH-SY5Y	B-X
cells	B-X
,	B-X
and	B-X
we	B-X
showed	B-X
that	B-X
Mint2/3	B-X
are	B-X
specifically	B-X
enriched	B-X
and	B-X
that	B-X
Mint3	B-X
and	B-X
APP	B-X
are	B-X
present	B-X
in	B-X
the	B-X
same	B-X
vesicles	B-X
.	B-X
Increasing	B-X
cellular	B-X
APP	B-X
levels	B-X
increased	B-X
the	B-X
amounts	B-X
of	B-X
both	B-X
APP	B-X
and	B-X
Mint3	B-X
in	B-X
purified	B-X
vesicles	B-X
.	B-X
Additional	B-X
evidence	B-X
supporting	B-X
an	B-X
obligate	B-X
role	B-X
for	B-X
Mint3	B-X
in	B-X
traffic	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
trans-Golgi	B-X
network	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
include	B-X
the	B-X
observations	B-X
that	B-X
depletion	B-X
of	B-X
Mint3	B-X
by	B-X
small	B-X
interference	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
or	B-X
mutation	B-X
of	B-X
the	B-X
Mint	B-X
binding	B-X
domain	B-X
of	B-X
APP	B-X
changes	B-X
the	B-X
export	B-X
route	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
basolateral	B-X
to	B-X
the	B-X
endosomal/lysosomal	B-X
sorting	B-X
route	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
increased	B-X
expression	B-X
of	B-X
Mint3	B-X
decreased	B-X
and	B-X
siRNA-mediated	B-X
knockdowns	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
neurotoxic	B-X
beta-amyloid	B-X
peptide	B-X
,	B-X
Abeta	B-X
(	B-X
1-40	B-X
)	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
implicate	B-X
Mint3	B-X
activity	B-X
as	B-X
a	B-X
critical	B-X
determinant	B-X
of	B-X
post-Golgi	B-X
APP	B-X
traffic	B-X
.	B-X

Additional	O
evidence	O
supporting	O
an	O
obligate	O
role	O
for	O
Mint3	B-Protein
in	O
traffic	O
of	O
APP	B-Protein
from	O
the	O
trans	O
-	O
Golgi	O
network	O
to	O
the	O
plasma	O
membrane	O
include	O
the	O
observations	O
that	O
depletion	O
of	O
Mint3	B-Protein
by	O
small	O
interference	O
RNA	O
(	O
siRNA	O
)	O
or	O
mutation	O
of	O
the	O
Mint	O
binding	O
domain	O
of	O
APP	B-Protein
changes	O
the	O
export	O
route	O
of	O
APP	B-Protein
from	O
the	O
basolateral	O
to	O
the	O
endosomal	O
/	O
lysosomal	O
sorting	O
route	O
.	O

Finally	O
,	O
we	O
show	O
that	O
increased	O
expression	O
of	O
Mint3	B-Protein
decreased	O
and	O
siRNA	O
-	O
mediated	O
knockdowns	O
increased	O
the	O
secretion	O
of	O
the	O
neurotoxic	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
peptide	O
,	O
Abeta	B-Protein
(	O
1	O
-	O
40	O
)	O
.	O
<EOS>	B-X
Beta-amyloid	B-X
peptides	B-X
(	B-X
Abeta	B-X
)	B-X
are	B-X
the	B-X
major	B-X
component	B-X
of	B-X
plaques	B-X
in	B-X
brains	B-X
of	B-X
Alzheimer	B-X
's	B-X
patients	B-X
,	B-X
and	B-X
are	B-X
they	B-X
derived	B-X
from	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
the	B-X
beta-amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
.	B-X
We	B-X
proposed	B-X
previously	B-X
that	B-X
transport	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
its	B-X
sorting	B-X
into	B-X
Mint/X11-containing	B-X
carriers	B-X
.	B-X
To	B-X
test	B-X
our	B-X
hypothesis	B-X
,	B-X
we	B-X
purified	B-X
APP-containing	B-X
vesicles	B-X
from	B-X
human	B-X
neuroblastoma	B-X
SH-SY5Y	B-X
cells	B-X
,	B-X
and	B-X
we	B-X
showed	B-X
that	B-X
Mint2/3	B-X
are	B-X
specifically	B-X
enriched	B-X
and	B-X
that	B-X
Mint3	B-X
and	B-X
APP	B-X
are	B-X
present	B-X
in	B-X
the	B-X
same	B-X
vesicles	B-X
.	B-X
Increasing	B-X
cellular	B-X
APP	B-X
levels	B-X
increased	B-X
the	B-X
amounts	B-X
of	B-X
both	B-X
APP	B-X
and	B-X
Mint3	B-X
in	B-X
purified	B-X
vesicles	B-X
.	B-X
Additional	B-X
evidence	B-X
supporting	B-X
an	B-X
obligate	B-X
role	B-X
for	B-X
Mint3	B-X
in	B-X
traffic	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
trans-Golgi	B-X
network	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
include	B-X
the	B-X
observations	B-X
that	B-X
depletion	B-X
of	B-X
Mint3	B-X
by	B-X
small	B-X
interference	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
or	B-X
mutation	B-X
of	B-X
the	B-X
Mint	B-X
binding	B-X
domain	B-X
of	B-X
APP	B-X
changes	B-X
the	B-X
export	B-X
route	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
basolateral	B-X
to	B-X
the	B-X
endosomal/lysosomal	B-X
sorting	B-X
route	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
increased	B-X
expression	B-X
of	B-X
Mint3	B-X
decreased	B-X
and	B-X
siRNA-mediated	B-X
knockdowns	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
neurotoxic	B-X
beta-amyloid	B-X
peptide	B-X
,	B-X
Abeta	B-X
(	B-X
1-40	B-X
)	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
implicate	B-X
Mint3	B-X
activity	B-X
as	B-X
a	B-X
critical	B-X
determinant	B-X
of	B-X
post-Golgi	B-X
APP	B-X
traffic	B-X
.	B-X

Together	O
,	O
our	O
data	O
implicate	O
Mint3	B-Protein
activity	O
as	O
a	O
critical	O
determinant	O
of	O
post	O
-	O
Golgi	O
APP	B-Protein
traffic	O
.	O
<EOS>	B-X
Beta-amyloid	B-X
peptides	B-X
(	B-X
Abeta	B-X
)	B-X
are	B-X
the	B-X
major	B-X
component	B-X
of	B-X
plaques	B-X
in	B-X
brains	B-X
of	B-X
Alzheimer	B-X
's	B-X
patients	B-X
,	B-X
and	B-X
are	B-X
they	B-X
derived	B-X
from	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
the	B-X
beta-amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
.	B-X
The	B-X
movement	B-X
of	B-X
APP	B-X
between	B-X
organelles	B-X
is	B-X
highly	B-X
regulated	B-X
,	B-X
and	B-X
it	B-X
is	B-X
tightly	B-X
connected	B-X
to	B-X
its	B-X
processing	B-X
by	B-X
secretases	B-X
.	B-X
We	B-X
proposed	B-X
previously	B-X
that	B-X
transport	B-X
of	B-X
APP	B-X
within	B-X
the	B-X
cell	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
its	B-X
sorting	B-X
into	B-X
Mint/X11-containing	B-X
carriers	B-X
.	B-X
To	B-X
test	B-X
our	B-X
hypothesis	B-X
,	B-X
we	B-X
purified	B-X
APP-containing	B-X
vesicles	B-X
from	B-X
human	B-X
neuroblastoma	B-X
SH-SY5Y	B-X
cells	B-X
,	B-X
and	B-X
we	B-X
showed	B-X
that	B-X
Mint2/3	B-X
are	B-X
specifically	B-X
enriched	B-X
and	B-X
that	B-X
Mint3	B-X
and	B-X
APP	B-X
are	B-X
present	B-X
in	B-X
the	B-X
same	B-X
vesicles	B-X
.	B-X
Increasing	B-X
cellular	B-X
APP	B-X
levels	B-X
increased	B-X
the	B-X
amounts	B-X
of	B-X
both	B-X
APP	B-X
and	B-X
Mint3	B-X
in	B-X
purified	B-X
vesicles	B-X
.	B-X
Additional	B-X
evidence	B-X
supporting	B-X
an	B-X
obligate	B-X
role	B-X
for	B-X
Mint3	B-X
in	B-X
traffic	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
trans-Golgi	B-X
network	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
include	B-X
the	B-X
observations	B-X
that	B-X
depletion	B-X
of	B-X
Mint3	B-X
by	B-X
small	B-X
interference	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
or	B-X
mutation	B-X
of	B-X
the	B-X
Mint	B-X
binding	B-X
domain	B-X
of	B-X
APP	B-X
changes	B-X
the	B-X
export	B-X
route	B-X
of	B-X
APP	B-X
from	B-X
the	B-X
basolateral	B-X
to	B-X
the	B-X
endosomal/lysosomal	B-X
sorting	B-X
route	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
increased	B-X
expression	B-X
of	B-X
Mint3	B-X
decreased	B-X
and	B-X
siRNA-mediated	B-X
knockdowns	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
neurotoxic	B-X
beta-amyloid	B-X
peptide	B-X
,	B-X
Abeta	B-X
(	B-X
1-40	B-X
)	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
implicate	B-X
Mint3	B-X
activity	B-X
as	B-X
a	B-X
critical	B-X
determinant	B-X
of	B-X
post-Golgi	B-X
APP	B-X
traffic	B-X
.	B-X

Fbx8	B-Protein
makes	O
Arf6	B-Protein
refractory	O
to	O
function	O
via	O
ubiquitination	O
.	O
<EOS>	B-X
The	B-X
small	B-X
GTP-binding	B-X
protein	B-X
Arf6	B-X
regulates	B-X
membrane	B-X
remodeling	B-X
at	B-X
cell	B-X
peripheries	B-X
and	B-X
plays	B-X
crucial	B-X
roles	B-X
in	B-X
higher	B-X
orders	B-X
of	B-X
cellular	B-X
functions	B-X
including	B-X
tumor	B-X
invasion	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Fbx8	B-X
,	B-X
an	B-X
F-box	B-X
protein	B-X
bearing	B-X
the	B-X
Sec7	B-X
domain	B-X
,	B-X
mediates	B-X
ubiquitination	B-X
of	B-X
Arf6	B-X
.	B-X
This	B-X
ubiquitination	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
immediate	B-X
proteasomal	B-X
degradation	B-X
of	B-X
Arf6	B-X
,	B-X
whereas	B-X
Fbx8	B-X
knockdown	B-X
caused	B-X
hyperactivation	B-X
of	B-X
Arf6	B-X
.	B-X
Expression	B-X
of	B-X
Fbx8	B-X
protein	B-X
was	B-X
substantially	B-X
lost	B-X
in	B-X
several	B-X
breast	B-X
tumor	B-X
cell	B-X
lines	B-X
,	B-X
in	B-X
which	B-X
Arf6	B-X
activity	B-X
is	B-X
pivotal	B-X
for	B-X
their	B-X
invasion	B-X
.	B-X
Forced	B-X
expression	B-X
of	B-X
Fbx8	B-X
in	B-X
these	B-X
cells	B-X
suppressed	B-X
their	B-X
Arf6	B-X
activities	B-X
and	B-X
invasive	B-X
activities	B-X
,	B-X
in	B-X
which	B-X
the	B-X
F-box	B-X
and	B-X
Sec7	B-X
domains	B-X
of	B-X
Fbx8	B-X
are	B-X
required	B-X
.	B-X
Together	B-X
with	B-X
the	B-X
possible	B-X
mechanism	B-X
as	B-X
to	B-X
how	B-X
Fbx8-mediated	B-X
ubiquitination	B-X
interferes	B-X
with	B-X
the	B-X
functions	B-X
of	B-X
Arf6	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Fbx8	B-X
provides	B-X
a	B-X
novel	B-X
suppressive	B-X
control	B-X
of	B-X
Arf6	B-X
activity	B-X
through	B-X
noncanonical	B-X
ubiquitination	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
dysfunction	B-X
of	B-X
Fbx8	B-X
expression	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
invasiveness	B-X
of	B-X
some	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

The	O
small	O
GTP	O
-	O
binding	O
protein	O
Arf6	B-Protein
regulates	O
membrane	O
remodeling	O
at	O
cell	O
peripheries	O
and	O
plays	O
crucial	O
roles	O
in	O
higher	O
orders	O
of	O
cellular	O
functions	O
including	O
tumor	O
invasion	O
.	O
<EOS>	B-X
The	B-X
small	B-X
GTP-binding	B-X
protein	B-X
Arf6	B-X
regulates	B-X
membrane	B-X
remodeling	B-X
at	B-X
cell	B-X
peripheries	B-X
and	B-X
plays	B-X
crucial	B-X
roles	B-X
in	B-X
higher	B-X
orders	B-X
of	B-X
cellular	B-X
functions	B-X
including	B-X
tumor	B-X
invasion	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Fbx8	B-X
,	B-X
an	B-X
F-box	B-X
protein	B-X
bearing	B-X
the	B-X
Sec7	B-X
domain	B-X
,	B-X
mediates	B-X
ubiquitination	B-X
of	B-X
Arf6	B-X
.	B-X
This	B-X
ubiquitination	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
immediate	B-X
proteasomal	B-X
degradation	B-X
of	B-X
Arf6	B-X
,	B-X
whereas	B-X
Fbx8	B-X
knockdown	B-X
caused	B-X
hyperactivation	B-X
of	B-X
Arf6	B-X
.	B-X
Expression	B-X
of	B-X
Fbx8	B-X
protein	B-X
was	B-X
substantially	B-X
lost	B-X
in	B-X
several	B-X
breast	B-X
tumor	B-X
cell	B-X
lines	B-X
,	B-X
in	B-X
which	B-X
Arf6	B-X
activity	B-X
is	B-X
pivotal	B-X
for	B-X
their	B-X
invasion	B-X
.	B-X
Forced	B-X
expression	B-X
of	B-X
Fbx8	B-X
in	B-X
these	B-X
cells	B-X
suppressed	B-X
their	B-X
Arf6	B-X
activities	B-X
and	B-X
invasive	B-X
activities	B-X
,	B-X
in	B-X
which	B-X
the	B-X
F-box	B-X
and	B-X
Sec7	B-X
domains	B-X
of	B-X
Fbx8	B-X
are	B-X
required	B-X
.	B-X
Together	B-X
with	B-X
the	B-X
possible	B-X
mechanism	B-X
as	B-X
to	B-X
how	B-X
Fbx8-mediated	B-X
ubiquitination	B-X
interferes	B-X
with	B-X
the	B-X
functions	B-X
of	B-X
Arf6	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Fbx8	B-X
provides	B-X
a	B-X
novel	B-X
suppressive	B-X
control	B-X
of	B-X
Arf6	B-X
activity	B-X
through	B-X
noncanonical	B-X
ubiquitination	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
dysfunction	B-X
of	B-X
Fbx8	B-X
expression	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
invasiveness	B-X
of	B-X
some	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

Here	O
we	O
show	O
that	O
Fbx8	B-Protein
,	O
an	O
F	O
-	O
box	O
protein	O
bearing	O
the	O
Sec7	O
domain	O
,	O
mediates	O
ubiquitination	O
of	O
Arf6	B-Protein
.	O

This	O
ubiquitination	O
did	O
not	O
appear	O
to	O
be	O
linked	O
to	O
immediate	O
proteasomal	O
degradation	O
of	O
Arf6	B-Protein
,	O
whereas	O
Fbx8	B-Protein
knockdown	O
caused	O
hyperactivation	O
of	O
Arf6	B-Protein
.	O
<EOS>	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
role	B-X
of	B-X
ubiquitination	B-X
in	B-X
the	B-X
onset	B-X
and	B-X
progression	B-X
of	B-X
cancer	B-X
,	B-X
metabolic	B-X
syndromes	B-X
,	B-X
neurodegenerative	B-X
diseases	B-X
,	B-X
autoimmunity	B-X
,	B-X
inflammatory	B-X
disorders	B-X
,	B-X
infection	B-X
and	B-X
muscle	B-X
dystrophies	B-X
.	B-X
Ubiquitination	B-X
has	B-X
long	B-X
been	B-X
recognised	B-X
as	B-X
a	B-X
key	B-X
determinator	B-X
of	B-X
protein	B-X
fate	B-X
by	B-X
tagging	B-X
proteins	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Autophagy	B-X
is	B-X
a	B-X
major	B-X
degradation	B-X
pathway	B-X
that	B-X
utilizes	B-X
lysosome	B-X
hydrolases	B-X
to	B-X
degrade	B-X
cellular	B-X
constituents	B-X
and	B-X
is	B-X
often	B-X
induced	B-X
under	B-X
cellular	B-X
stress	B-X
conditions	B-X
to	B-X
restore	B-X
cell	B-X
homeostasis	B-X
.	B-X
Another	B-X
prime	B-X
degradation	B-X
pathway	B-X
in	B-X
the	B-X
cells	B-X
is	B-X
ubiquitin-proteasome	B-X
system	B-X
(	B-X
UPS	B-X
)	B-X
,	B-X
in	B-X
which	B-X
proteins	B-X
tagged	B-X
by	B-X
certain	B-X
types	B-X
of	B-X
polyubiquitin	B-X
chains	B-X
are	B-X
selectively	B-X
recognized	B-X
and	B-X
removed	B-X
by	B-X
proteasome	B-X
.	B-X
Although	B-X
the	B-X
two	B-X
degradation	B-X
pathways	B-X
are	B-X
operated	B-X
independently	B-X
with	B-X
different	B-X
sets	B-X
of	B-X
players	B-X
,	B-X
recent	B-X
studies	B-X
have	B-X
revealed	B-X
reciprocal	B-X
cross	B-X
talks	B-X
between	B-X
UPS	B-X
and	B-X
autophagy	B-X
at	B-X
multiple	B-X
layers	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
roles	B-X
of	B-X
protein	B-X
ubiquitination	B-X
and	B-X
deubiquitination	B-X
in	B-X
controlling	B-X
the	B-X
initiation	B-X
,	B-X
execution	B-X
,	B-X
and	B-X
termination	B-X
of	B-X
bulk	B-X
autophagy	B-X
as	B-X
well	B-X
as	B-X
the	B-X
role	B-X
of	B-X
ubiquitination	B-X
in	B-X
signaling	B-X
certain	B-X
types	B-X
of	B-X
selective	B-X
autophagy	B-X
.	B-X

Expression	O
of	O
Fbx8	B-Protein
protein	O
was	O
substantially	O
lost	O
in	O
several	O
breast	O
tumor	O
cell	O
lines	O
,	O
in	O
which	O
Arf6	B-Protein
activity	O
is	O
pivotal	O
for	O
their	O
invasion	O
.	O
<EOS>	B-X
The	B-X
small	B-X
GTP-binding	B-X
protein	B-X
Arf6	B-X
regulates	B-X
membrane	B-X
remodeling	B-X
at	B-X
cell	B-X
peripheries	B-X
and	B-X
plays	B-X
crucial	B-X
roles	B-X
in	B-X
higher	B-X
orders	B-X
of	B-X
cellular	B-X
functions	B-X
including	B-X
tumor	B-X
invasion	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Fbx8	B-X
,	B-X
an	B-X
F-box	B-X
protein	B-X
bearing	B-X
the	B-X
Sec7	B-X
domain	B-X
,	B-X
mediates	B-X
ubiquitination	B-X
of	B-X
Arf6	B-X
.	B-X
This	B-X
ubiquitination	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
immediate	B-X
proteasomal	B-X
degradation	B-X
of	B-X
Arf6	B-X
,	B-X
whereas	B-X
Fbx8	B-X
knockdown	B-X
caused	B-X
hyperactivation	B-X
of	B-X
Arf6	B-X
.	B-X
Expression	B-X
of	B-X
Fbx8	B-X
protein	B-X
was	B-X
substantially	B-X
lost	B-X
in	B-X
several	B-X
breast	B-X
tumor	B-X
cell	B-X
lines	B-X
,	B-X
in	B-X
which	B-X
Arf6	B-X
activity	B-X
is	B-X
pivotal	B-X
for	B-X
their	B-X
invasion	B-X
.	B-X
Forced	B-X
expression	B-X
of	B-X
Fbx8	B-X
in	B-X
these	B-X
cells	B-X
suppressed	B-X
their	B-X
Arf6	B-X
activities	B-X
and	B-X
invasive	B-X
activities	B-X
,	B-X
in	B-X
which	B-X
the	B-X
F-box	B-X
and	B-X
Sec7	B-X
domains	B-X
of	B-X
Fbx8	B-X
are	B-X
required	B-X
.	B-X
Together	B-X
with	B-X
the	B-X
possible	B-X
mechanism	B-X
as	B-X
to	B-X
how	B-X
Fbx8-mediated	B-X
ubiquitination	B-X
interferes	B-X
with	B-X
the	B-X
functions	B-X
of	B-X
Arf6	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Fbx8	B-X
provides	B-X
a	B-X
novel	B-X
suppressive	B-X
control	B-X
of	B-X
Arf6	B-X
activity	B-X
through	B-X
noncanonical	B-X
ubiquitination	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
dysfunction	B-X
of	B-X
Fbx8	B-X
expression	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
invasiveness	B-X
of	B-X
some	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

Forced	O
expression	O
of	O
Fbx8	B-Protein
in	O
these	O
cells	O
suppressed	O
their	O
Arf6	B-Protein
activities	O
and	O
invasive	O
activities	O
,	O
in	O
which	O
the	O
F	O
-	O
box	O
and	O
Sec7	O
domains	O
of	O
Fbx8	B-Protein
are	O
required	O
.	O

Together	O
with	O
the	O
possible	O
mechanism	O
as	O
to	O
how	O
Fbx8	B-Protein
-	O
mediated	O
ubiquitination	O
interferes	O
with	O
the	O
functions	O
of	O
Arf6	B-Protein
,	O
we	O
propose	O
that	O
Fbx8	B-Protein
provides	O
a	O
novel	O
suppressive	O
control	O
of	O
Arf6	B-Protein
activity	O
through	O
noncanonical	O
ubiquitination	O
.	O
<EOS>	B-X
The	B-X
small	B-X
GTP-binding	B-X
protein	B-X
Arf6	B-X
regulates	B-X
membrane	B-X
remodeling	B-X
at	B-X
cell	B-X
peripheries	B-X
and	B-X
plays	B-X
crucial	B-X
roles	B-X
in	B-X
higher	B-X
orders	B-X
of	B-X
cellular	B-X
functions	B-X
including	B-X
tumor	B-X
invasion	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Fbx8	B-X
,	B-X
an	B-X
F-box	B-X
protein	B-X
bearing	B-X
the	B-X
Sec7	B-X
domain	B-X
,	B-X
mediates	B-X
ubiquitination	B-X
of	B-X
Arf6	B-X
.	B-X
This	B-X
ubiquitination	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
immediate	B-X
proteasomal	B-X
degradation	B-X
of	B-X
Arf6	B-X
,	B-X
whereas	B-X
Fbx8	B-X
knockdown	B-X
caused	B-X
hyperactivation	B-X
of	B-X
Arf6	B-X
.	B-X
Expression	B-X
of	B-X
Fbx8	B-X
protein	B-X
was	B-X
substantially	B-X
lost	B-X
in	B-X
several	B-X
breast	B-X
tumor	B-X
cell	B-X
lines	B-X
,	B-X
in	B-X
which	B-X
Arf6	B-X
activity	B-X
is	B-X
pivotal	B-X
for	B-X
their	B-X
invasion	B-X
.	B-X
Forced	B-X
expression	B-X
of	B-X
Fbx8	B-X
in	B-X
these	B-X
cells	B-X
suppressed	B-X
their	B-X
Arf6	B-X
activities	B-X
and	B-X
invasive	B-X
activities	B-X
,	B-X
in	B-X
which	B-X
the	B-X
F-box	B-X
and	B-X
Sec7	B-X
domains	B-X
of	B-X
Fbx8	B-X
are	B-X
required	B-X
.	B-X
Together	B-X
with	B-X
the	B-X
possible	B-X
mechanism	B-X
as	B-X
to	B-X
how	B-X
Fbx8-mediated	B-X
ubiquitination	B-X
interferes	B-X
with	B-X
the	B-X
functions	B-X
of	B-X
Arf6	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Fbx8	B-X
provides	B-X
a	B-X
novel	B-X
suppressive	B-X
control	B-X
of	B-X
Arf6	B-X
activity	B-X
through	B-X
noncanonical	B-X
ubiquitination	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
dysfunction	B-X
of	B-X
Fbx8	B-X
expression	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
invasiveness	B-X
of	B-X
some	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X

Our	O
results	O
indicate	O
that	O
dysfunction	O
of	O
Fbx8	B-Protein
expression	O
may	O
contribute	O
to	O
the	O
invasiveness	O
of	O
some	O
breast	O
cancer	O
cells	O
.	O

Acetylation	O
in	O
nuclear	O
receptor	O
signaling	O
and	O
the	O
role	O
of	O
sirtuins	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
the	B-X
role	B-X
of	B-X
dietary	B-X
polyphenols	B-X
in	B-X
the	B-X
prevention	B-X
of	B-X
obesity	B-X
and	B-X
obesity-related	B-X
chronic	B-X
diseases	B-X
.	B-X
Concomitantly	B-X
,	B-X
the	B-X
polyphenols	B-X
modulate	B-X
signaling	B-X
pathways	B-X
including	B-X
the	B-X
adenosine-monophosphate-activated	B-X
protein	B-X
kinase	B-X
,	B-X
peroxisome	B-X
proliferator	B-X
activated	B-X
receptor	B-X
γ	B-X
,	B-X
CCAAT/enhancer	B-X
binding	B-X
protein	B-X
α	B-X
,	B-X
peroxisome	B-X
proliferator	B-X
activator	B-X
receptor	B-X
gamma	B-X
activator	B-X
1-alpha	B-X
,	B-X
sirtuin	B-X
1	B-X
,	B-X
sterol	B-X
regulatory	B-X
element	B-X
binding	B-X
protein-1c	B-X
,	B-X
uncoupling	B-X
proteins	B-X
1	B-X
and	B-X
2	B-X
,	B-X
and	B-X
nuclear	B-X
factor-κB	B-X
that	B-X
regulate	B-X
adipogenesis	B-X
,	B-X
antioxidant	B-X
and	B-X
anti-inflammatory	B-X
responses	B-X
.	B-X
It	B-X
has	B-X
been	B-X
known	B-X
since	B-X
the	B-X
early	B-X
1970s	B-X
that	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
bind	B-X
DNA	B-X
in	B-X
association	B-X
with	B-X
coregulatory	B-X
proteins	B-X
.	B-X
Characterization	B-X
of	B-X
these	B-X
nuclear	B-X
receptor	B-X
coregulators	B-X
has	B-X
revealed	B-X
diverse	B-X
enzymatic	B-X
activities	B-X
that	B-X
temporally	B-X
and	B-X
spatially	B-X
coordinate	B-X
nuclear	B-X
receptor	B-X
activity	B-X
within	B-X
the	B-X
context	B-X
of	B-X
local	B-X
chromatin	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
hormone	B-X
signals	B-X
.	B-X
Chromatin-modifying	B-X
proteins	B-X
,	B-X
which	B-X
dictate	B-X
the	B-X
higher-order	B-X
chromatin	B-X
structure	B-X
in	B-X
which	B-X
DNA	B-X
is	B-X
packaged	B-X
,	B-X
in	B-X
turn	B-X
orchestrate	B-X
orderly	B-X
recruitment	B-X
of	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
.	B-X
At	B-X
this	B-X
time	B-X
,	B-X
we	B-X
understand	B-X
how	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
modifications	B-X
regulates	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
-dependent	B-X
histone	B-X
deacetylases	B-X
,	B-X
the	B-X
sirtuins	B-X
,	B-X
are	B-X
capable	B-X
of	B-X
deacetylating	B-X
nuclear	B-X
receptors	B-X
provides	B-X
a	B-X
new	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
control	B-X
of	B-X
nuclear	B-X
receptor	B-X
activity	B-X
in	B-X
which	B-X
local	B-X
intracellular	B-X
concentrations	B-X
of	B-X
NAD	B-X
may	B-X
regulate	B-X
nuclear	B-X
receptor	B-X
physiology	B-X
.	B-X

It	O
has	O
been	O
known	O
since	O
the	O
early	O
1970s	O
that	O
nuclear	O
receptor	O
complexes	O
bind	O
DNA	O
in	O
association	O
with	O
coregulatory	O
proteins	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
known	B-X
since	B-X
the	B-X
early	B-X
1970s	B-X
that	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
bind	B-X
DNA	B-X
in	B-X
association	B-X
with	B-X
coregulatory	B-X
proteins	B-X
.	B-X
Characterization	B-X
of	B-X
these	B-X
nuclear	B-X
receptor	B-X
coregulators	B-X
has	B-X
revealed	B-X
diverse	B-X
enzymatic	B-X
activities	B-X
that	B-X
temporally	B-X
and	B-X
spatially	B-X
coordinate	B-X
nuclear	B-X
receptor	B-X
activity	B-X
within	B-X
the	B-X
context	B-X
of	B-X
local	B-X
chromatin	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
hormone	B-X
signals	B-X
.	B-X
Chromatin-modifying	B-X
proteins	B-X
,	B-X
which	B-X
dictate	B-X
the	B-X
higher-order	B-X
chromatin	B-X
structure	B-X
in	B-X
which	B-X
DNA	B-X
is	B-X
packaged	B-X
,	B-X
in	B-X
turn	B-X
orchestrate	B-X
orderly	B-X
recruitment	B-X
of	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
.	B-X
At	B-X
this	B-X
time	B-X
,	B-X
we	B-X
understand	B-X
how	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
modifications	B-X
regulates	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
-dependent	B-X
histone	B-X
deacetylases	B-X
,	B-X
the	B-X
sirtuins	B-X
,	B-X
are	B-X
capable	B-X
of	B-X
deacetylating	B-X
nuclear	B-X
receptors	B-X
provides	B-X
a	B-X
new	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
control	B-X
of	B-X
nuclear	B-X
receptor	B-X
activity	B-X
in	B-X
which	B-X
local	B-X
intracellular	B-X
concentrations	B-X
of	B-X
NAD	B-X
may	B-X
regulate	B-X
nuclear	B-X
receptor	B-X
physiology	B-X
.	B-X

Characterization	O
of	O
these	O
nuclear	O
receptor	O
coregulators	O
has	O
revealed	O
diverse	O
enzymatic	O
activities	O
that	O
temporally	O
and	O
spatially	O
coordinate	O
nuclear	O
receptor	O
activity	O
within	O
the	O
context	O
of	O
local	O
chromatin	O
in	O
response	O
to	O
diverse	O
hormone	O
signals	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
known	B-X
since	B-X
the	B-X
early	B-X
1970s	B-X
that	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
bind	B-X
DNA	B-X
in	B-X
association	B-X
with	B-X
coregulatory	B-X
proteins	B-X
.	B-X
Characterization	B-X
of	B-X
these	B-X
nuclear	B-X
receptor	B-X
coregulators	B-X
has	B-X
revealed	B-X
diverse	B-X
enzymatic	B-X
activities	B-X
that	B-X
temporally	B-X
and	B-X
spatially	B-X
coordinate	B-X
nuclear	B-X
receptor	B-X
activity	B-X
within	B-X
the	B-X
context	B-X
of	B-X
local	B-X
chromatin	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
hormone	B-X
signals	B-X
.	B-X
Chromatin-modifying	B-X
proteins	B-X
,	B-X
which	B-X
dictate	B-X
the	B-X
higher-order	B-X
chromatin	B-X
structure	B-X
in	B-X
which	B-X
DNA	B-X
is	B-X
packaged	B-X
,	B-X
in	B-X
turn	B-X
orchestrate	B-X
orderly	B-X
recruitment	B-X
of	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
.	B-X
At	B-X
this	B-X
time	B-X
,	B-X
we	B-X
understand	B-X
how	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
modifications	B-X
regulates	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
-dependent	B-X
histone	B-X
deacetylases	B-X
,	B-X
the	B-X
sirtuins	B-X
,	B-X
are	B-X
capable	B-X
of	B-X
deacetylating	B-X
nuclear	B-X
receptors	B-X
provides	B-X
a	B-X
new	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
control	B-X
of	B-X
nuclear	B-X
receptor	B-X
activity	B-X
in	B-X
which	B-X
local	B-X
intracellular	B-X
concentrations	B-X
of	B-X
NAD	B-X
may	B-X
regulate	B-X
nuclear	B-X
receptor	B-X
physiology	B-X
.	B-X

Chromatin	O
-	O
modifying	O
proteins	O
,	O
which	O
dictate	O
the	O
higher	O
-	O
order	O
chromatin	O
structure	O
in	O
which	O
DNA	O
is	O
packaged	O
,	O
in	O
turn	O
orchestrate	O
orderly	O
recruitment	O
of	O
nuclear	O
receptor	O
complexes	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
known	B-X
since	B-X
the	B-X
early	B-X
1970s	B-X
that	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
bind	B-X
DNA	B-X
in	B-X
association	B-X
with	B-X
coregulatory	B-X
proteins	B-X
.	B-X
Characterization	B-X
of	B-X
these	B-X
nuclear	B-X
receptor	B-X
coregulators	B-X
has	B-X
revealed	B-X
diverse	B-X
enzymatic	B-X
activities	B-X
that	B-X
temporally	B-X
and	B-X
spatially	B-X
coordinate	B-X
nuclear	B-X
receptor	B-X
activity	B-X
within	B-X
the	B-X
context	B-X
of	B-X
local	B-X
chromatin	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
hormone	B-X
signals	B-X
.	B-X
Chromatin-modifying	B-X
proteins	B-X
,	B-X
which	B-X
dictate	B-X
the	B-X
higher-order	B-X
chromatin	B-X
structure	B-X
in	B-X
which	B-X
DNA	B-X
is	B-X
packaged	B-X
,	B-X
in	B-X
turn	B-X
orchestrate	B-X
orderly	B-X
recruitment	B-X
of	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
.	B-X
At	B-X
this	B-X
time	B-X
,	B-X
we	B-X
understand	B-X
how	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
modifications	B-X
regulates	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
-dependent	B-X
histone	B-X
deacetylases	B-X
,	B-X
the	B-X
sirtuins	B-X
,	B-X
are	B-X
capable	B-X
of	B-X
deacetylating	B-X
nuclear	B-X
receptors	B-X
provides	B-X
a	B-X
new	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
control	B-X
of	B-X
nuclear	B-X
receptor	B-X
activity	B-X
in	B-X
which	B-X
local	B-X
intracellular	B-X
concentrations	B-X
of	B-X
NAD	B-X
may	B-X
regulate	B-X
nuclear	B-X
receptor	B-X
physiology	B-X
.	B-X

Modifications	O
of	O
histones	B-Protein
include	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
,	O
ubiquitylation	O
,	O
sumoylation	O
,	O
ADP	O
ribosylation	O
,	O
deimination	O
,	O
and	O
proline	O
isomerization	O
.	O
<EOS>	B-X
Modifications	B-X
of	B-X
histones	B-X
include	B-X
acetylation	B-X
,	B-X
methylation	B-X
,	B-X
phosphorylation	B-X
,	B-X
ubiquitylation	B-X
,	B-X
sumoylation	B-X
,	B-X
ADP	B-X
ribosylation	B-X
,	B-X
deimination	B-X
,	B-X
and	B-X
proline	B-X
isomerization	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
,	B-X
particularly	B-X
of	B-X
acetylation	B-X
and	B-X
demethylation	B-X
,	B-X
are	B-X
profound	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X

At	O
this	O
time	O
,	O
we	O
understand	O
how	O
a	O
subset	O
of	O
these	O
modifications	O
regulates	O
nuclear	O
receptor	O
signaling	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
known	B-X
since	B-X
the	B-X
early	B-X
1970s	B-X
that	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
bind	B-X
DNA	B-X
in	B-X
association	B-X
with	B-X
coregulatory	B-X
proteins	B-X
.	B-X
Characterization	B-X
of	B-X
these	B-X
nuclear	B-X
receptor	B-X
coregulators	B-X
has	B-X
revealed	B-X
diverse	B-X
enzymatic	B-X
activities	B-X
that	B-X
temporally	B-X
and	B-X
spatially	B-X
coordinate	B-X
nuclear	B-X
receptor	B-X
activity	B-X
within	B-X
the	B-X
context	B-X
of	B-X
local	B-X
chromatin	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
hormone	B-X
signals	B-X
.	B-X
Chromatin-modifying	B-X
proteins	B-X
,	B-X
which	B-X
dictate	B-X
the	B-X
higher-order	B-X
chromatin	B-X
structure	B-X
in	B-X
which	B-X
DNA	B-X
is	B-X
packaged	B-X
,	B-X
in	B-X
turn	B-X
orchestrate	B-X
orderly	B-X
recruitment	B-X
of	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
.	B-X
At	B-X
this	B-X
time	B-X
,	B-X
we	B-X
understand	B-X
how	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
modifications	B-X
regulates	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
-dependent	B-X
histone	B-X
deacetylases	B-X
,	B-X
the	B-X
sirtuins	B-X
,	B-X
are	B-X
capable	B-X
of	B-X
deacetylating	B-X
nuclear	B-X
receptors	B-X
provides	B-X
a	B-X
new	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
control	B-X
of	B-X
nuclear	B-X
receptor	B-X
activity	B-X
in	B-X
which	B-X
local	B-X
intracellular	B-X
concentrations	B-X
of	B-X
NAD	B-X
may	B-X
regulate	B-X
nuclear	B-X
receptor	B-X
physiology	B-X
.	B-X

However	O
,	O
the	O
effects	O
,	O
particularly	O
of	O
acetylation	O
and	O
demethylation	O
,	O
are	O
profound	O
.	O
<EOS>	B-X
Modifications	B-X
of	B-X
histones	B-X
include	B-X
acetylation	B-X
,	B-X
methylation	B-X
,	B-X
phosphorylation	B-X
,	B-X
ubiquitylation	B-X
,	B-X
sumoylation	B-X
,	B-X
ADP	B-X
ribosylation	B-X
,	B-X
deimination	B-X
,	B-X
and	B-X
proline	B-X
isomerization	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
,	B-X
particularly	B-X
of	B-X
acetylation	B-X
and	B-X
demethylation	B-X
,	B-X
are	B-X
profound	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X

The	O
finding	O
that	O
nuclear	O
receptors	O
are	O
directly	O
acetylated	O
and	O
that	O
acetylation	O
in	O
turn	O
directly	O
regulates	O
contact	O
-	O
independent	O
growth	O
has	O
broad	O
therapeutic	O
implications	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
known	B-X
since	B-X
the	B-X
early	B-X
1970s	B-X
that	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
bind	B-X
DNA	B-X
in	B-X
association	B-X
with	B-X
coregulatory	B-X
proteins	B-X
.	B-X
Characterization	B-X
of	B-X
these	B-X
nuclear	B-X
receptor	B-X
coregulators	B-X
has	B-X
revealed	B-X
diverse	B-X
enzymatic	B-X
activities	B-X
that	B-X
temporally	B-X
and	B-X
spatially	B-X
coordinate	B-X
nuclear	B-X
receptor	B-X
activity	B-X
within	B-X
the	B-X
context	B-X
of	B-X
local	B-X
chromatin	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
hormone	B-X
signals	B-X
.	B-X
Chromatin-modifying	B-X
proteins	B-X
,	B-X
which	B-X
dictate	B-X
the	B-X
higher-order	B-X
chromatin	B-X
structure	B-X
in	B-X
which	B-X
DNA	B-X
is	B-X
packaged	B-X
,	B-X
in	B-X
turn	B-X
orchestrate	B-X
orderly	B-X
recruitment	B-X
of	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
.	B-X
Modifications	B-X
of	B-X
histones	B-X
include	B-X
acetylation	B-X
,	B-X
methylation	B-X
,	B-X
phosphorylation	B-X
,	B-X
ubiquitylation	B-X
,	B-X
sumoylation	B-X
,	B-X
ADP	B-X
ribosylation	B-X
,	B-X
deimination	B-X
,	B-X
and	B-X
proline	B-X
isomerization	B-X
.	B-X
At	B-X
this	B-X
time	B-X
,	B-X
we	B-X
understand	B-X
how	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
modifications	B-X
regulates	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
,	B-X
particularly	B-X
of	B-X
acetylation	B-X
and	B-X
demethylation	B-X
,	B-X
are	B-X
profound	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
-dependent	B-X
histone	B-X
deacetylases	B-X
,	B-X
the	B-X
sirtuins	B-X
,	B-X
are	B-X
capable	B-X
of	B-X
deacetylating	B-X
nuclear	B-X
receptors	B-X
provides	B-X
a	B-X
new	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
control	B-X
of	B-X
nuclear	B-X
receptor	B-X
activity	B-X
in	B-X
which	B-X
local	B-X
intracellular	B-X
concentrations	B-X
of	B-X
NAD	B-X
may	B-X
regulate	B-X
nuclear	B-X
receptor	B-X
physiology	B-X
.	B-X

Studies	O
over	O
the	O
past	O
7	O
yr	O
have	O
led	O
to	O
the	O
understanding	O
that	O
nuclear	O
receptor	O
acetylation	O
is	O
a	O
conserved	O
function	O
,	O
regulating	O
diverse	O
nuclear	O
receptor	O
activity	O
.	O

Furthermore	O
,	O
we	O
now	O
know	O
that	O
acetylation	O
of	O
multiple	O
and	O
distinct	O
substrates	O
within	O
nuclear	O
receptor	O
signaling	O
pathways	O
,	O
form	O
an	O
acetylation	O
signaling	O
network	O
from	O
the	O
cell	O
surface	O
to	O
the	O
nucleus	O
.	O

The	O
finding	O
that	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
)	O
-	O
dependent	O
histone	B-Protein
deacetylases	O
,	O
the	O
sirtuins	O
,	O
are	O
capable	O
of	O
deacetylating	O
nuclear	O
receptors	O
provides	O
a	O
new	O
level	O
of	O
complexity	O
in	O
the	O
control	O
of	O
nuclear	O
receptor	O
activity	O
in	O
which	O
local	O
intracellular	O
concentrations	O
of	O
NAD	O
may	O
regulate	O
nuclear	O
receptor	O
physiology	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
known	B-X
since	B-X
the	B-X
early	B-X
1970s	B-X
that	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
bind	B-X
DNA	B-X
in	B-X
association	B-X
with	B-X
coregulatory	B-X
proteins	B-X
.	B-X
Characterization	B-X
of	B-X
these	B-X
nuclear	B-X
receptor	B-X
coregulators	B-X
has	B-X
revealed	B-X
diverse	B-X
enzymatic	B-X
activities	B-X
that	B-X
temporally	B-X
and	B-X
spatially	B-X
coordinate	B-X
nuclear	B-X
receptor	B-X
activity	B-X
within	B-X
the	B-X
context	B-X
of	B-X
local	B-X
chromatin	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
hormone	B-X
signals	B-X
.	B-X
Chromatin-modifying	B-X
proteins	B-X
,	B-X
which	B-X
dictate	B-X
the	B-X
higher-order	B-X
chromatin	B-X
structure	B-X
in	B-X
which	B-X
DNA	B-X
is	B-X
packaged	B-X
,	B-X
in	B-X
turn	B-X
orchestrate	B-X
orderly	B-X
recruitment	B-X
of	B-X
nuclear	B-X
receptor	B-X
complexes	B-X
.	B-X
Modifications	B-X
of	B-X
histones	B-X
include	B-X
acetylation	B-X
,	B-X
methylation	B-X
,	B-X
phosphorylation	B-X
,	B-X
ubiquitylation	B-X
,	B-X
sumoylation	B-X
,	B-X
ADP	B-X
ribosylation	B-X
,	B-X
deimination	B-X
,	B-X
and	B-X
proline	B-X
isomerization	B-X
.	B-X
At	B-X
this	B-X
time	B-X
,	B-X
we	B-X
understand	B-X
how	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
modifications	B-X
regulates	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nuclear	B-X
receptors	B-X
are	B-X
directly	B-X
acetylated	B-X
and	B-X
that	B-X
acetylation	B-X
in	B-X
turn	B-X
directly	B-X
regulates	B-X
contact-independent	B-X
growth	B-X
has	B-X
broad	B-X
therapeutic	B-X
implications	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
7	B-X
yr	B-X
have	B-X
led	B-X
to	B-X
the	B-X
understanding	B-X
that	B-X
nuclear	B-X
receptor	B-X
acetylation	B-X
is	B-X
a	B-X
conserved	B-X
function	B-X
,	B-X
regulating	B-X
diverse	B-X
nuclear	B-X
receptor	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
now	B-X
know	B-X
that	B-X
acetylation	B-X
of	B-X
multiple	B-X
and	B-X
distinct	B-X
substrates	B-X
within	B-X
nuclear	B-X
receptor	B-X
signaling	B-X
pathways	B-X
,	B-X
form	B-X
an	B-X
acetylation	B-X
signaling	B-X
network	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
-dependent	B-X
histone	B-X
deacetylases	B-X
,	B-X
the	B-X
sirtuins	B-X
,	B-X
are	B-X
capable	B-X
of	B-X
deacetylating	B-X
nuclear	B-X
receptors	B-X
provides	B-X
a	B-X
new	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
control	B-X
of	B-X
nuclear	B-X
receptor	B-X
activity	B-X
in	B-X
which	B-X
local	B-X
intracellular	B-X
concentrations	B-X
of	B-X
NAD	B-X
may	B-X
regulate	B-X
nuclear	B-X
receptor	B-X
physiology	B-X
.	B-X

Trafficking	O
and	O
postsecretory	O
events	O
responsible	O
for	O
the	O
formation	O
of	O
secreted	O
human	O
salivary	O
peptides	O
:	O
a	O
proteomics	O
approach	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
localization	B-X
of	B-X
post-translational	B-X
modifications	B-X
of	B-X
different	B-X
classes	B-X
of	B-X
human	B-X
salivary	B-X
proteins	B-X
and	B-X
peptides	B-X
(	B-X
acidic	B-X
and	B-X
basic	B-X
proline-rich	B-X
proteins	B-X
(	B-X
PRPs	B-X
)	B-X
,	B-X
Histatins	B-X
,	B-X
Statherin	B-X
,	B-X
P-B	B-X
peptide	B-X
,	B-X
and	B-X
``	B-X
S	B-X
type	B-X
''	B-X
Cystatins	B-X
)	B-X
a	B-X
comparative	B-X
reversed	B-X
phase	B-X
HPLC-ESI-MS	B-X
analysis	B-X
on	B-X
intact	B-X
proteins	B-X
of	B-X
enriched	B-X
granule	B-X
preparations	B-X
from	B-X
parotid	B-X
and	B-X
submandibular	B-X
glands	B-X
as	B-X
well	B-X
as	B-X
parotid	B-X
,	B-X
submandibular/sublingual	B-X
(	B-X
Sm/Sl	B-X
)	B-X
,	B-X
and	B-X
whole	B-X
saliva	B-X
was	B-X
performed	B-X
.	B-X
(	B-X
i	B-X
)	B-X
Phosphorylation	B-X
of	B-X
all	B-X
salivary	B-X
peptides	B-X
,	B-X
sulfation	B-X
of	B-X
Histatin	B-X
1	B-X
,	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
acidic	B-X
and	B-X
precursor	B-X
basic	B-X
PRPs	B-X
occur	B-X
before	B-X
granule	B-X
storage	B-X
.	B-X
(	B-X
ii	B-X
)	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
,	B-X
basic	B-X
PRPs	B-X
are	B-X
secreted	B-X
by	B-X
the	B-X
parotid	B-X
gland	B-X
only	B-X
,	B-X
whereas	B-X
all	B-X
isoforms	B-X
of	B-X
acidic	B-X
PRPs	B-X
(	B-X
aPRPs	B-X
)	B-X
are	B-X
secreted	B-X
by	B-X
both	B-X
parotid	B-X
and	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
viii	B-X
)	B-X
Basic	B-X
PRPs	B-X
are	B-X
cleaved	B-X
in	B-X
the	B-X
oral	B-X
cavity	B-X
by	B-X
unknown	B-X
peptidases	B-X
,	B-X
generating	B-X
various	B-X
small	B-X
proline-rich	B-X
peptides	B-X
.	B-X
(	B-X
x	B-X
)	B-X
P-B	B-X
peptide	B-X
is	B-X
secreted	B-X
by	B-X
both	B-X
glands	B-X
,	B-X
and	B-X
its	B-X
relative	B-X
quantity	B-X
is	B-X
higher	B-X
in	B-X
submandibular/sublingual	B-X
secretion	B-X
.	B-X

To	O
elucidate	O
the	O
localization	O
of	O
post	O
-	O
translational	O
modifications	O
of	O
different	O
classes	O
of	O
human	O
salivary	O
proteins	O
and	O
peptides	O
(	O
acidic	O
and	O
basic	O
proline	O
-	O
rich	O
proteins	O
(	O
PRPs	O
)	O
,	O
Histatins	O
,	O
Statherin	B-Protein
,	O
P	B-Protein
-	I-Protein
B	I-Protein
peptide	O
,	O
and	O
"	O
S	O
type	O
"	O
Cystatins	O
)	O
a	O
comparative	O
reversed	O
phase	O
HPLC	O
-	O
ESI	O
-	O
MS	O
analysis	O
on	O
intact	O
proteins	O
of	O
enriched	O
granule	O
preparations	O
from	O
parotid	O
and	O
submandibular	O
glands	O
as	O
well	O
as	O
parotid	O
,	O
submandibular	O
/	O
sublingual	O
(	O
Sm	O
/	O
Sl	O
)	O
,	O
and	O
whole	O
saliva	O
was	O
performed	O
.	O

The	O
main	O
results	O
of	O
this	O
study	O
indicate	O
the	O
following	O
.	O
<EOS>	B-X
The	B-X
application	B-X
of	B-X
SLN	B-X
surgery	B-X
for	B-X
staging	B-X
the	B-X
axilla	B-X
following	B-X
chemotherapy	B-X
for	B-X
women	B-X
who	B-X
initially	B-X
had	B-X
node-positive	B-X
cN1	B-X
breast	B-X
cancer	B-X
is	B-X
unclear	B-X
because	B-X
of	B-X
high	B-X
false-negative	B-X
results	B-X
reported	B-X
in	B-X
previous	B-X
studies	B-X
.	B-X
Even	B-X
though	B-X
PSA	B-X
remains	B-X
the	B-X
only	B-X
biomarker	B-X
of	B-X
this	B-X
disease	B-X
in	B-X
clinical	B-X
practice	B-X
,	B-X
it	B-X
is	B-X
not	B-X
always	B-X
analogue	B-X
with	B-X
the	B-X
severity	B-X
of	B-X
the	B-X
disease	B-X
and	B-X
should	B-X
be	B-X
evaluated	B-X
along	B-X
with	B-X
the	B-X
clinical	B-X
and	B-X
diagnostic	B-X
imaging	B-X
findings	B-X
.	B-X
The	B-X
study	B-X
is	B-X
devoted	B-X
to	B-X
finding	B-X
the	B-X
relationship	B-X
between	B-X
EEG	B-X
entropy	B-X
indices	B-X
and	B-X
depression	B-X
,	B-X
assessed	B-X
using	B-X
the	B-X
Beck	B-X
Depression	B-X
Inventory	B-X
.	B-X
The	B-X
WHO	B-X
proposed	B-X
that	B-X
the	B-X
main	B-X
reason	B-X
for	B-X
the	B-X
failure	B-X
of	B-X
the	B-X
healthcare	B-X
system	B-X
in	B-X
developing	B-X
countries	B-X
is	B-X
poor	B-X
organisational	B-X
capabilities	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
study	B-X
aimed	B-X
to	B-X
develop	B-X
an	B-X
index	B-X
system	B-X
for	B-X
evaluating	B-X
the	B-X
organisational	B-X
capabilities	B-X
of	B-X
PMIs	B-X
.	B-X

(	O
i	O
)	O
Phosphorylation	O
of	O
all	O
salivary	O
peptides	O
,	O
sulfation	O
of	O
Histatin	B-Protein
1	I-Protein
,	O
proteolytic	O
cleavages	O
of	O
acidic	O
and	O
precursor	O
basic	O
PRPs	O
occur	O
before	O
granule	O
storage	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
localization	B-X
of	B-X
post-translational	B-X
modifications	B-X
of	B-X
different	B-X
classes	B-X
of	B-X
human	B-X
salivary	B-X
proteins	B-X
and	B-X
peptides	B-X
(	B-X
acidic	B-X
and	B-X
basic	B-X
proline-rich	B-X
proteins	B-X
(	B-X
PRPs	B-X
)	B-X
,	B-X
Histatins	B-X
,	B-X
Statherin	B-X
,	B-X
P-B	B-X
peptide	B-X
,	B-X
and	B-X
``	B-X
S	B-X
type	B-X
''	B-X
Cystatins	B-X
)	B-X
a	B-X
comparative	B-X
reversed	B-X
phase	B-X
HPLC-ESI-MS	B-X
analysis	B-X
on	B-X
intact	B-X
proteins	B-X
of	B-X
enriched	B-X
granule	B-X
preparations	B-X
from	B-X
parotid	B-X
and	B-X
submandibular	B-X
glands	B-X
as	B-X
well	B-X
as	B-X
parotid	B-X
,	B-X
submandibular/sublingual	B-X
(	B-X
Sm/Sl	B-X
)	B-X
,	B-X
and	B-X
whole	B-X
saliva	B-X
was	B-X
performed	B-X
.	B-X
(	B-X
i	B-X
)	B-X
Phosphorylation	B-X
of	B-X
all	B-X
salivary	B-X
peptides	B-X
,	B-X
sulfation	B-X
of	B-X
Histatin	B-X
1	B-X
,	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
acidic	B-X
and	B-X
precursor	B-X
basic	B-X
PRPs	B-X
occur	B-X
before	B-X
granule	B-X
storage	B-X
.	B-X
(	B-X
ii	B-X
)	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
,	B-X
basic	B-X
PRPs	B-X
are	B-X
secreted	B-X
by	B-X
the	B-X
parotid	B-X
gland	B-X
only	B-X
,	B-X
whereas	B-X
all	B-X
isoforms	B-X
of	B-X
acidic	B-X
PRPs	B-X
(	B-X
aPRPs	B-X
)	B-X
are	B-X
secreted	B-X
by	B-X
both	B-X
parotid	B-X
and	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
iii	B-X
)	B-X
Phosphorylation	B-X
levels	B-X
of	B-X
aPRPs	B-X
,	B-X
Histatin	B-X
1	B-X
,	B-X
and	B-X
Statherin	B-X
are	B-X
higher	B-X
in	B-X
the	B-X
parotid	B-X
gland	B-X
,	B-X
whereas	B-X
the	B-X
extent	B-X
of	B-X
cleavage	B-X
of	B-X
aPRP	B-X
is	B-X
higher	B-X
in	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
iv	B-X
)	B-X
O-Sulfation	B-X
of	B-X
tyrosines	B-X
of	B-X
Histatin	B-X
1	B-X
is	B-X
a	B-X
post-translational	B-X
modification	B-X
specific	B-X
for	B-X
the	B-X
submandibular	B-X
gland	B-X
.	B-X
(	B-X
v	B-X
)	B-X
The	B-X
concentration	B-X
of	B-X
Histatin	B-X
3	B-X
,	B-X
Histatin	B-X
5	B-X
,	B-X
and	B-X
Histatin	B-X
6	B-X
,	B-X
but	B-X
not	B-X
Histatin	B-X
1	B-X
,	B-X
is	B-X
higher	B-X
in	B-X
parotid	B-X
saliva	B-X
.	B-X
(	B-X
vi	B-X
)	B-X
Histatin	B-X
3	B-X
is	B-X
submitted	B-X
to	B-X
the	B-X
first	B-X
proteolytic	B-X
cleavage	B-X
(	B-X
generating	B-X
Histatins	B-X
6	B-X
and	B-X
5	B-X
)	B-X
during	B-X
granule	B-X
maturation	B-X
,	B-X
and	B-X
it	B-X
occurs	B-X
to	B-X
the	B-X
same	B-X
relative	B-X
extent	B-X
in	B-X
both	B-X
glands	B-X
.	B-X
(	B-X
vii	B-X
)	B-X
The	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
Histatin	B-X
5	B-X
and	B-X
6	B-X
,	B-X
generating	B-X
a	B-X
cascade	B-X
of	B-X
Histatin	B-X
3	B-X
fragments	B-X
,	B-X
take	B-X
place	B-X
after	B-X
granule	B-X
secretion	B-X
and	B-X
are	B-X
more	B-X
extensive	B-X
in	B-X
parotid	B-X
secretion	B-X
.	B-X
(	B-X
viii	B-X
)	B-X
Basic	B-X
PRPs	B-X
are	B-X
cleaved	B-X
in	B-X
the	B-X
oral	B-X
cavity	B-X
by	B-X
unknown	B-X
peptidases	B-X
,	B-X
generating	B-X
various	B-X
small	B-X
proline-rich	B-X
peptides	B-X
.	B-X

(	O
ii	O
)	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
basic	O
PRPs	O
are	O
secreted	O
by	O
the	O
parotid	O
gland	O
only	O
,	O
whereas	O
all	O
isoforms	O
of	O
acidic	O
PRPs	O
(	O
aPRPs	O
)	O
are	O
secreted	O
by	O
both	O
parotid	O
and	O
Sm	O
/	O
Sl	O
glands	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
localization	B-X
of	B-X
post-translational	B-X
modifications	B-X
of	B-X
different	B-X
classes	B-X
of	B-X
human	B-X
salivary	B-X
proteins	B-X
and	B-X
peptides	B-X
(	B-X
acidic	B-X
and	B-X
basic	B-X
proline-rich	B-X
proteins	B-X
(	B-X
PRPs	B-X
)	B-X
,	B-X
Histatins	B-X
,	B-X
Statherin	B-X
,	B-X
P-B	B-X
peptide	B-X
,	B-X
and	B-X
``	B-X
S	B-X
type	B-X
''	B-X
Cystatins	B-X
)	B-X
a	B-X
comparative	B-X
reversed	B-X
phase	B-X
HPLC-ESI-MS	B-X
analysis	B-X
on	B-X
intact	B-X
proteins	B-X
of	B-X
enriched	B-X
granule	B-X
preparations	B-X
from	B-X
parotid	B-X
and	B-X
submandibular	B-X
glands	B-X
as	B-X
well	B-X
as	B-X
parotid	B-X
,	B-X
submandibular/sublingual	B-X
(	B-X
Sm/Sl	B-X
)	B-X
,	B-X
and	B-X
whole	B-X
saliva	B-X
was	B-X
performed	B-X
.	B-X
(	B-X
i	B-X
)	B-X
Phosphorylation	B-X
of	B-X
all	B-X
salivary	B-X
peptides	B-X
,	B-X
sulfation	B-X
of	B-X
Histatin	B-X
1	B-X
,	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
acidic	B-X
and	B-X
precursor	B-X
basic	B-X
PRPs	B-X
occur	B-X
before	B-X
granule	B-X
storage	B-X
.	B-X
(	B-X
ii	B-X
)	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
,	B-X
basic	B-X
PRPs	B-X
are	B-X
secreted	B-X
by	B-X
the	B-X
parotid	B-X
gland	B-X
only	B-X
,	B-X
whereas	B-X
all	B-X
isoforms	B-X
of	B-X
acidic	B-X
PRPs	B-X
(	B-X
aPRPs	B-X
)	B-X
are	B-X
secreted	B-X
by	B-X
both	B-X
parotid	B-X
and	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
iii	B-X
)	B-X
Phosphorylation	B-X
levels	B-X
of	B-X
aPRPs	B-X
,	B-X
Histatin	B-X
1	B-X
,	B-X
and	B-X
Statherin	B-X
are	B-X
higher	B-X
in	B-X
the	B-X
parotid	B-X
gland	B-X
,	B-X
whereas	B-X
the	B-X
extent	B-X
of	B-X
cleavage	B-X
of	B-X
aPRP	B-X
is	B-X
higher	B-X
in	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
iv	B-X
)	B-X
O-Sulfation	B-X
of	B-X
tyrosines	B-X
of	B-X
Histatin	B-X
1	B-X
is	B-X
a	B-X
post-translational	B-X
modification	B-X
specific	B-X
for	B-X
the	B-X
submandibular	B-X
gland	B-X
.	B-X
(	B-X
v	B-X
)	B-X
The	B-X
concentration	B-X
of	B-X
Histatin	B-X
3	B-X
,	B-X
Histatin	B-X
5	B-X
,	B-X
and	B-X
Histatin	B-X
6	B-X
,	B-X
but	B-X
not	B-X
Histatin	B-X
1	B-X
,	B-X
is	B-X
higher	B-X
in	B-X
parotid	B-X
saliva	B-X
.	B-X
(	B-X
vi	B-X
)	B-X
Histatin	B-X
3	B-X
is	B-X
submitted	B-X
to	B-X
the	B-X
first	B-X
proteolytic	B-X
cleavage	B-X
(	B-X
generating	B-X
Histatins	B-X
6	B-X
and	B-X
5	B-X
)	B-X
during	B-X
granule	B-X
maturation	B-X
,	B-X
and	B-X
it	B-X
occurs	B-X
to	B-X
the	B-X
same	B-X
relative	B-X
extent	B-X
in	B-X
both	B-X
glands	B-X
.	B-X
(	B-X
vii	B-X
)	B-X
The	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
Histatin	B-X
5	B-X
and	B-X
6	B-X
,	B-X
generating	B-X
a	B-X
cascade	B-X
of	B-X
Histatin	B-X
3	B-X
fragments	B-X
,	B-X
take	B-X
place	B-X
after	B-X
granule	B-X
secretion	B-X
and	B-X
are	B-X
more	B-X
extensive	B-X
in	B-X
parotid	B-X
secretion	B-X
.	B-X
(	B-X
viii	B-X
)	B-X
Basic	B-X
PRPs	B-X
are	B-X
cleaved	B-X
in	B-X
the	B-X
oral	B-X
cavity	B-X
by	B-X
unknown	B-X
peptidases	B-X
,	B-X
generating	B-X
various	B-X
small	B-X
proline-rich	B-X
peptides	B-X
.	B-X
(	B-X
ix	B-X
)	B-X
C-terminal	B-X
removal	B-X
from	B-X
Statherin	B-X
is	B-X
more	B-X
extensive	B-X
in	B-X
parotid	B-X
saliva	B-X
.	B-X
(	B-X
x	B-X
)	B-X
P-B	B-X
peptide	B-X
is	B-X
secreted	B-X
by	B-X
both	B-X
glands	B-X
,	B-X
and	B-X
its	B-X
relative	B-X
quantity	B-X
is	B-X
higher	B-X
in	B-X
submandibular/sublingual	B-X
secretion	B-X
.	B-X
(	B-X
xi	B-X
)	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
,	B-X
S	B-X
type	B-X
Cystatins	B-X
are	B-X
mainly	B-X
the	B-X
product	B-X
of	B-X
Sm/Sl	B-X
glands	B-X
.	B-X

(	O
iii	O
)	O
Phosphorylation	O
levels	O
of	O
aPRPs	O
,	O
Histatin	B-Protein
1	I-Protein
,	O
and	O
Statherin	B-Protein
are	O
higher	O
in	O
the	O
parotid	O
gland	O
,	O
whereas	O
the	O
extent	O
of	O
cleavage	O
of	O
aPRP	O
is	O
higher	O
in	O
Sm	O
/	O
Sl	O
glands	O
.	O

(	O
iv	O
)	O
O	O
-	O
Sulfation	O
of	O
tyrosines	O
of	O
Histatin	B-Protein
1	I-Protein
is	O
a	O
post	O
-	O
translational	O
modification	O
specific	O
for	O
the	O
submandibular	O
gland	O
.	O

(	O
v	O
)	O
The	O
concentration	O
of	O
Histatin	B-Protein
3	I-Protein
,	O
Histatin	B-Protein
5	I-Protein
,	O
and	O
Histatin	B-Protein
6	I-Protein
,	O
but	O
not	O
Histatin	B-Protein
1	I-Protein
,	O
is	O
higher	O
in	O
parotid	O
saliva	O
.	O

(	O
vi	O
)	O
Histatin	B-Protein
3	I-Protein
is	O
submitted	O
to	O
the	O
first	O
proteolytic	O
cleavage	O
(	O
generating	O
Histatins	B-Protein
6	I-Protein
and	O
5	B-Protein
)	O
during	O
granule	O
maturation	O
,	O
and	O
it	O
occurs	O
to	O
the	O
same	O
relative	O
extent	O
in	O
both	O
glands	O
.	O

(	O
vii	O
)	O
The	O
proteolytic	O
cleavages	O
of	O
Histatin	B-Protein
5	I-Protein
and	O
6	B-Protein
,	O
generating	O
a	O
cascade	O
of	O
Histatin	B-Protein
3	I-Protein
fragments	O
,	O
take	O
place	O
after	O
granule	O
secretion	O
and	O
are	O
more	O
extensive	O
in	O
parotid	O
secretion	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
localization	B-X
of	B-X
post-translational	B-X
modifications	B-X
of	B-X
different	B-X
classes	B-X
of	B-X
human	B-X
salivary	B-X
proteins	B-X
and	B-X
peptides	B-X
(	B-X
acidic	B-X
and	B-X
basic	B-X
proline-rich	B-X
proteins	B-X
(	B-X
PRPs	B-X
)	B-X
,	B-X
Histatins	B-X
,	B-X
Statherin	B-X
,	B-X
P-B	B-X
peptide	B-X
,	B-X
and	B-X
``	B-X
S	B-X
type	B-X
''	B-X
Cystatins	B-X
)	B-X
a	B-X
comparative	B-X
reversed	B-X
phase	B-X
HPLC-ESI-MS	B-X
analysis	B-X
on	B-X
intact	B-X
proteins	B-X
of	B-X
enriched	B-X
granule	B-X
preparations	B-X
from	B-X
parotid	B-X
and	B-X
submandibular	B-X
glands	B-X
as	B-X
well	B-X
as	B-X
parotid	B-X
,	B-X
submandibular/sublingual	B-X
(	B-X
Sm/Sl	B-X
)	B-X
,	B-X
and	B-X
whole	B-X
saliva	B-X
was	B-X
performed	B-X
.	B-X
(	B-X
i	B-X
)	B-X
Phosphorylation	B-X
of	B-X
all	B-X
salivary	B-X
peptides	B-X
,	B-X
sulfation	B-X
of	B-X
Histatin	B-X
1	B-X
,	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
acidic	B-X
and	B-X
precursor	B-X
basic	B-X
PRPs	B-X
occur	B-X
before	B-X
granule	B-X
storage	B-X
.	B-X
(	B-X
ii	B-X
)	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
,	B-X
basic	B-X
PRPs	B-X
are	B-X
secreted	B-X
by	B-X
the	B-X
parotid	B-X
gland	B-X
only	B-X
,	B-X
whereas	B-X
all	B-X
isoforms	B-X
of	B-X
acidic	B-X
PRPs	B-X
(	B-X
aPRPs	B-X
)	B-X
are	B-X
secreted	B-X
by	B-X
both	B-X
parotid	B-X
and	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
iii	B-X
)	B-X
Phosphorylation	B-X
levels	B-X
of	B-X
aPRPs	B-X
,	B-X
Histatin	B-X
1	B-X
,	B-X
and	B-X
Statherin	B-X
are	B-X
higher	B-X
in	B-X
the	B-X
parotid	B-X
gland	B-X
,	B-X
whereas	B-X
the	B-X
extent	B-X
of	B-X
cleavage	B-X
of	B-X
aPRP	B-X
is	B-X
higher	B-X
in	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
iv	B-X
)	B-X
O-Sulfation	B-X
of	B-X
tyrosines	B-X
of	B-X
Histatin	B-X
1	B-X
is	B-X
a	B-X
post-translational	B-X
modification	B-X
specific	B-X
for	B-X
the	B-X
submandibular	B-X
gland	B-X
.	B-X
(	B-X
v	B-X
)	B-X
The	B-X
concentration	B-X
of	B-X
Histatin	B-X
3	B-X
,	B-X
Histatin	B-X
5	B-X
,	B-X
and	B-X
Histatin	B-X
6	B-X
,	B-X
but	B-X
not	B-X
Histatin	B-X
1	B-X
,	B-X
is	B-X
higher	B-X
in	B-X
parotid	B-X
saliva	B-X
.	B-X
(	B-X
vi	B-X
)	B-X
Histatin	B-X
3	B-X
is	B-X
submitted	B-X
to	B-X
the	B-X
first	B-X
proteolytic	B-X
cleavage	B-X
(	B-X
generating	B-X
Histatins	B-X
6	B-X
and	B-X
5	B-X
)	B-X
during	B-X
granule	B-X
maturation	B-X
,	B-X
and	B-X
it	B-X
occurs	B-X
to	B-X
the	B-X
same	B-X
relative	B-X
extent	B-X
in	B-X
both	B-X
glands	B-X
.	B-X
(	B-X
vii	B-X
)	B-X
The	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
Histatin	B-X
5	B-X
and	B-X
6	B-X
,	B-X
generating	B-X
a	B-X
cascade	B-X
of	B-X
Histatin	B-X
3	B-X
fragments	B-X
,	B-X
take	B-X
place	B-X
after	B-X
granule	B-X
secretion	B-X
and	B-X
are	B-X
more	B-X
extensive	B-X
in	B-X
parotid	B-X
secretion	B-X
.	B-X
(	B-X
viii	B-X
)	B-X
Basic	B-X
PRPs	B-X
are	B-X
cleaved	B-X
in	B-X
the	B-X
oral	B-X
cavity	B-X
by	B-X
unknown	B-X
peptidases	B-X
,	B-X
generating	B-X
various	B-X
small	B-X
proline-rich	B-X
peptides	B-X
.	B-X
(	B-X
ix	B-X
)	B-X
C-terminal	B-X
removal	B-X
from	B-X
Statherin	B-X
is	B-X
more	B-X
extensive	B-X
in	B-X
parotid	B-X
saliva	B-X
.	B-X
(	B-X
x	B-X
)	B-X
P-B	B-X
peptide	B-X
is	B-X
secreted	B-X
by	B-X
both	B-X
glands	B-X
,	B-X
and	B-X
its	B-X
relative	B-X
quantity	B-X
is	B-X
higher	B-X
in	B-X
submandibular/sublingual	B-X
secretion	B-X
.	B-X

(	O
viii	O
)	O
Basic	O
PRPs	O
are	O
cleaved	O
in	O
the	O
oral	O
cavity	O
by	O
unknown	O
peptidases	O
,	O
generating	O
various	O
small	O
proline	O
-	O
rich	O
peptides	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
localization	B-X
of	B-X
post-translational	B-X
modifications	B-X
of	B-X
different	B-X
classes	B-X
of	B-X
human	B-X
salivary	B-X
proteins	B-X
and	B-X
peptides	B-X
(	B-X
acidic	B-X
and	B-X
basic	B-X
proline-rich	B-X
proteins	B-X
(	B-X
PRPs	B-X
)	B-X
,	B-X
Histatins	B-X
,	B-X
Statherin	B-X
,	B-X
P-B	B-X
peptide	B-X
,	B-X
and	B-X
``	B-X
S	B-X
type	B-X
''	B-X
Cystatins	B-X
)	B-X
a	B-X
comparative	B-X
reversed	B-X
phase	B-X
HPLC-ESI-MS	B-X
analysis	B-X
on	B-X
intact	B-X
proteins	B-X
of	B-X
enriched	B-X
granule	B-X
preparations	B-X
from	B-X
parotid	B-X
and	B-X
submandibular	B-X
glands	B-X
as	B-X
well	B-X
as	B-X
parotid	B-X
,	B-X
submandibular/sublingual	B-X
(	B-X
Sm/Sl	B-X
)	B-X
,	B-X
and	B-X
whole	B-X
saliva	B-X
was	B-X
performed	B-X
.	B-X
(	B-X
i	B-X
)	B-X
Phosphorylation	B-X
of	B-X
all	B-X
salivary	B-X
peptides	B-X
,	B-X
sulfation	B-X
of	B-X
Histatin	B-X
1	B-X
,	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
acidic	B-X
and	B-X
precursor	B-X
basic	B-X
PRPs	B-X
occur	B-X
before	B-X
granule	B-X
storage	B-X
.	B-X
(	B-X
ii	B-X
)	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
,	B-X
basic	B-X
PRPs	B-X
are	B-X
secreted	B-X
by	B-X
the	B-X
parotid	B-X
gland	B-X
only	B-X
,	B-X
whereas	B-X
all	B-X
isoforms	B-X
of	B-X
acidic	B-X
PRPs	B-X
(	B-X
aPRPs	B-X
)	B-X
are	B-X
secreted	B-X
by	B-X
both	B-X
parotid	B-X
and	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
iii	B-X
)	B-X
Phosphorylation	B-X
levels	B-X
of	B-X
aPRPs	B-X
,	B-X
Histatin	B-X
1	B-X
,	B-X
and	B-X
Statherin	B-X
are	B-X
higher	B-X
in	B-X
the	B-X
parotid	B-X
gland	B-X
,	B-X
whereas	B-X
the	B-X
extent	B-X
of	B-X
cleavage	B-X
of	B-X
aPRP	B-X
is	B-X
higher	B-X
in	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
vi	B-X
)	B-X
Histatin	B-X
3	B-X
is	B-X
submitted	B-X
to	B-X
the	B-X
first	B-X
proteolytic	B-X
cleavage	B-X
(	B-X
generating	B-X
Histatins	B-X
6	B-X
and	B-X
5	B-X
)	B-X
during	B-X
granule	B-X
maturation	B-X
,	B-X
and	B-X
it	B-X
occurs	B-X
to	B-X
the	B-X
same	B-X
relative	B-X
extent	B-X
in	B-X
both	B-X
glands	B-X
.	B-X
(	B-X
vii	B-X
)	B-X
The	B-X
proteolytic	B-X
cleavages	B-X
of	B-X
Histatin	B-X
5	B-X
and	B-X
6	B-X
,	B-X
generating	B-X
a	B-X
cascade	B-X
of	B-X
Histatin	B-X
3	B-X
fragments	B-X
,	B-X
take	B-X
place	B-X
after	B-X
granule	B-X
secretion	B-X
and	B-X
are	B-X
more	B-X
extensive	B-X
in	B-X
parotid	B-X
secretion	B-X
.	B-X
(	B-X
viii	B-X
)	B-X
Basic	B-X
PRPs	B-X
are	B-X
cleaved	B-X
in	B-X
the	B-X
oral	B-X
cavity	B-X
by	B-X
unknown	B-X
peptidases	B-X
,	B-X
generating	B-X
various	B-X
small	B-X
proline-rich	B-X
peptides	B-X
.	B-X

(	O
ix	O
)	O
C	O
-	O
terminal	O
removal	O
from	O
Statherin	B-Protein
is	O
more	O
extensive	O
in	O
parotid	O
saliva	O
.	O

(	O
x	O
)	O
P	B-Protein
-	I-Protein
B	I-Protein
peptide	O
is	O
secreted	O
by	O
both	O
glands	O
,	O
and	O
its	O
relative	O
quantity	O
is	O
higher	O
in	O
submandibular	O
/	O
sublingual	O
secretion	O
.	O

(	O
xi	O
)	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
S	O
type	O
Cystatins	O
are	O
mainly	O
the	O
product	O
of	O
Sm	O
/	O
Sl	O
glands	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
localization	B-X
of	B-X
post-translational	B-X
modifications	B-X
of	B-X
different	B-X
classes	B-X
of	B-X
human	B-X
salivary	B-X
proteins	B-X
and	B-X
peptides	B-X
(	B-X
acidic	B-X
and	B-X
basic	B-X
proline-rich	B-X
proteins	B-X
(	B-X
PRPs	B-X
)	B-X
,	B-X
Histatins	B-X
,	B-X
Statherin	B-X
,	B-X
P-B	B-X
peptide	B-X
,	B-X
and	B-X
``	B-X
S	B-X
type	B-X
''	B-X
Cystatins	B-X
)	B-X
a	B-X
comparative	B-X
reversed	B-X
phase	B-X
HPLC-ESI-MS	B-X
analysis	B-X
on	B-X
intact	B-X
proteins	B-X
of	B-X
enriched	B-X
granule	B-X
preparations	B-X
from	B-X
parotid	B-X
and	B-X
submandibular	B-X
glands	B-X
as	B-X
well	B-X
as	B-X
parotid	B-X
,	B-X
submandibular/sublingual	B-X
(	B-X
Sm/Sl	B-X
)	B-X
,	B-X
and	B-X
whole	B-X
saliva	B-X
was	B-X
performed	B-X
.	B-X
(	B-X
ii	B-X
)	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
,	B-X
basic	B-X
PRPs	B-X
are	B-X
secreted	B-X
by	B-X
the	B-X
parotid	B-X
gland	B-X
only	B-X
,	B-X
whereas	B-X
all	B-X
isoforms	B-X
of	B-X
acidic	B-X
PRPs	B-X
(	B-X
aPRPs	B-X
)	B-X
are	B-X
secreted	B-X
by	B-X
both	B-X
parotid	B-X
and	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
iii	B-X
)	B-X
Phosphorylation	B-X
levels	B-X
of	B-X
aPRPs	B-X
,	B-X
Histatin	B-X
1	B-X
,	B-X
and	B-X
Statherin	B-X
are	B-X
higher	B-X
in	B-X
the	B-X
parotid	B-X
gland	B-X
,	B-X
whereas	B-X
the	B-X
extent	B-X
of	B-X
cleavage	B-X
of	B-X
aPRP	B-X
is	B-X
higher	B-X
in	B-X
Sm/Sl	B-X
glands	B-X
.	B-X
(	B-X
vi	B-X
)	B-X
Histatin	B-X
3	B-X
is	B-X
submitted	B-X
to	B-X
the	B-X
first	B-X
proteolytic	B-X
cleavage	B-X
(	B-X
generating	B-X
Histatins	B-X
6	B-X
and	B-X
5	B-X
)	B-X
during	B-X
granule	B-X
maturation	B-X
,	B-X
and	B-X
it	B-X
occurs	B-X
to	B-X
the	B-X
same	B-X
relative	B-X
extent	B-X
in	B-X
both	B-X
glands	B-X
.	B-X
(	B-X
x	B-X
)	B-X
P-B	B-X
peptide	B-X
is	B-X
secreted	B-X
by	B-X
both	B-X
glands	B-X
,	B-X
and	B-X
its	B-X
relative	B-X
quantity	B-X
is	B-X
higher	B-X
in	B-X
submandibular/sublingual	B-X
secretion	B-X
.	B-X
(	B-X
xi	B-X
)	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
,	B-X
S	B-X
type	B-X
Cystatins	B-X
are	B-X
mainly	B-X
the	B-X
product	B-X
of	B-X
Sm/Sl	B-X
glands	B-X
.	B-X

Functional	O
and	O
structural	O
roles	O
of	O
conserved	O
cysteine	O
residues	O
in	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
follicle	B-Protein
-	I-Protein
stimulating	I-Protein
hormone	I-Protein
receptor	I-Protein
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O
<EOS>	B-X
The	B-X
carboxyl-terminal	B-X
segment	B-X
of	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
has	B-X
one	B-X
or	B-X
more	B-X
conserved	B-X
cysteine	B-X
residues	B-X
that	B-X
are	B-X
potential	B-X
sites	B-X
for	B-X
palmitoylation	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
other	B-X
members	B-X
of	B-X
the	B-X
glycoprotein	B-X
hormone	B-X
receptor	B-X
family	B-X
(	B-X
the	B-X
LH	B-X
and	B-X
thyroid-stimulating	B-X
hormone	B-X
receptors	B-X
)	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
the	B-X
follicle-stimulating	B-X
hormone	B-X
receptor	B-X
(	B-X
FSHR	B-X
)	B-X
is	B-X
palmitoylated	B-X
and	B-X
what	B-X
are	B-X
the	B-X
effects	B-X
of	B-X
abolishing	B-X
its	B-X
potential	B-X
palmitoylation	B-X
sites	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
functional	B-X
analysis	B-X
of	B-X
the	B-X
FSHR	B-X
carboxyl-terminal	B-X
segment	B-X
cysteine	B-X
residues	B-X
was	B-X
carried	B-X
out	B-X
.	B-X
We	B-X
constructed	B-X
a	B-X
series	B-X
of	B-X
mutant	B-X
FSHRs	B-X
by	B-X
substituting	B-X
cysteine	B-X
residues	B-X
with	B-X
alanine	B-X
,	B-X
serine	B-X
,	B-X
or	B-X
threonine	B-X
individually	B-X
and	B-X
together	B-X
at	B-X
positions	B-X
629	B-X
and	B-X
655	B-X
(	B-X
conserved	B-X
cysteines	B-X
)	B-X
and	B-X
627	B-X
(	B-X
nonconserved	B-X
)	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
all	B-X
three	B-X
cysteine	B-X
residues	B-X
are	B-X
palmitoylated	B-X
but	B-X
that	B-X
only	B-X
modification	B-X
at	B-X
Cys629	B-X
is	B-X
functionally	B-X
relevant	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
palmitoylation	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
greatly	B-X
impair	B-X
coupling	B-X
to	B-X
G	B-X
(	B-X
s	B-X
)	B-X
but	B-X
,	B-X
when	B-X
absent	B-X
at	B-X
position	B-X
629	B-X
,	B-X
does	B-X
significantly	B-X
impair	B-X
cell	B-X
surface	B-X
membrane	B-X
expression	B-X
of	B-X
the	B-X
partially	B-X
palmitoylated	B-X
receptor	B-X
.	B-X
All	B-X
FSHR	B-X
Cys	B-X
mutants	B-X
were	B-X
capable	B-X
of	B-X
binding	B-X
agonist	B-X
with	B-X
the	B-X
same	B-X
affinity	B-X
as	B-X
the	B-X
wild-type	B-X
receptor	B-X
and	B-X
internalizing	B-X
on	B-X
agonist	B-X
stimulation	B-X
.	B-X
Molecular	B-X
dynamics	B-X
simulations	B-X
at	B-X
a	B-X
time	B-X
scale	B-X
of	B-X
approximately	B-X
100	B-X
nsec	B-X
revealed	B-X
that	B-X
replacement	B-X
of	B-X
Cys629	B-X
resulted	B-X
in	B-X
structures	B-X
that	B-X
differed	B-X
significantly	B-X
from	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
receptor	B-X
.	B-X
Thus	B-X
,	B-X
deviations	B-X
from	B-X
wild-type	B-X
conformation	B-X
may	B-X
potentially	B-X
contribute	B-X
to	B-X
the	B-X
severe	B-X
impairment	B-X
in	B-X
plasma	B-X
membrane	B-X
expression	B-X
and	B-X
the	B-X
modest	B-X
effects	B-X
on	B-X
signaling	B-X
exhibited	B-X
by	B-X
the	B-X
receptors	B-X
modified	B-X
in	B-X
this	B-X
particular	B-X
position	B-X
.	B-X

The	O
carboxyl	O
-	O
terminal	O
segment	O
of	O
G	O
protein	O
-	O
coupled	O
receptors	O
has	O
one	O
or	O
more	O
conserved	O
cysteine	O
residues	O
that	O
are	O
potential	O
sites	O
for	O
palmitoylation	O
.	O
<EOS>	B-X
The	B-X
V2b	B-X
variant	B-X
has	B-X
an	B-X
amino	B-X
acid	B-X
sequence	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
V2a	B-X
receptor	B-X
up	B-X
to	B-X
the	B-X
sixth	B-X
transmembrane	B-X
domain	B-X
,	B-X
but	B-X
the	B-X
V2b	B-X
sequences	B-X
corresponding	B-X
to	B-X
the	B-X
putative	B-X
seventh	B-X
transmembrane	B-X
domain	B-X
and	B-X
the	B-X
carboxyl	B-X
terminus	B-X
are	B-X
different	B-X
from	B-X
those	B-X
of	B-X
the	B-X
V2a	B-X
receptor	B-X
.	B-X
We	B-X
found	B-X
that	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
V2a	B-X
receptor	B-X
,	B-X
the	B-X
V2b	B-X
adopted	B-X
two	B-X
topologies	B-X
:	B-X
one	B-X
with	B-X
six	B-X
transmembrane	B-X
segments	B-X
with	B-X
the	B-X
C-terminus	B-X
on	B-X
the	B-X
extracellular	B-X
side	B-X
of	B-X
the	B-X
membrane	B-X
and	B-X
another	B-X
with	B-X
seven	B-X
transmembrane	B-X
segments	B-X
with	B-X
the	B-X
C-terminus	B-X
on	B-X
the	B-X
intracellular	B-X
side	B-X
,	B-X
similar	B-X
to	B-X
typical	B-X
G-protein-coupled	B-X
receptors	B-X
.	B-X
Unlike	B-X
the	B-X
V2a	B-X
receptor	B-X
,	B-X
V2b	B-X
did	B-X
not	B-X
move	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
but	B-X
it	B-X
is	B-X
retained	B-X
in	B-X
the	B-X
ER	B-X
--	B-X
Golgi	B-X
compartments	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
C-terminal	B-X
sequence	B-X
beyond	B-X
the	B-X
sixth	B-X
transmembrane	B-X
of	B-X
the	B-X
V2a	B-X
is	B-X
required	B-X
for	B-X
the	B-X
stabilization	B-X
of	B-X
the	B-X
seven-transmembrane	B-X
topology	B-X
of	B-X
the	B-X
receptor	B-X
and	B-X
is	B-X
also	B-X
essential	B-X
for	B-X
the	B-X
trafficking	B-X
of	B-X
the	B-X
receptor	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

This	O
posttranslational	O
modification	O
contributes	O
to	O
membrane	O
association	O
,	O
internalization	O
,	O
and	O
membrane	O
targeting	O
of	O
proteins	O
.	O
<EOS>	B-X
The	B-X
E	B-X
protein	B-X
contains	B-X
a	B-X
central	B-X
hydrophobic	B-X
domain	B-X
and	B-X
a	B-X
conserved	B-X
potential	B-X
site	B-X
for	B-X
N-terminal	B-X
myristoylation	B-X
,	B-X
a	B-X
hydrophobic	B-X
modification	B-X
usually	B-X
pivotal	B-X
for	B-X
membrane	B-X
targeting	B-X
of	B-X
the	B-X
modified	B-X
protein	B-X
.	B-X
Biochemical	B-X
fractionation	B-X
revealed	B-X
that	B-X
E-YFP	B-X
with	B-X
an	B-X
inactivated	B-X
acylation	B-X
site	B-X
was	B-X
still	B-X
completely	B-X
membrane-bound	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
putative	B-X
transmembrane	B-X
domain	B-X
of	B-X
E	B-X
mediates	B-X
membrane	B-X
targeting	B-X
.	B-X
Confocal	B-X
microscopy	B-X
showed	B-X
that	B-X
both	B-X
myristoylated	B-X
and	B-X
non-myristoylated	B-X
E-YFP	B-X
were	B-X
localized	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
complex	B-X
,	B-X
the	B-X
membranes	B-X
from	B-X
which	B-X
EAV	B-X
buds	B-X
.	B-X
Western	B-X
blotting	B-X
of	B-X
cell-culture	B-X
supernatants	B-X
showed	B-X
that	B-X
N	B-X
and	B-X
M	B-X
,	B-X
the	B-X
major	B-X
structural	B-X
proteins	B-X
of	B-X
EAV	B-X
,	B-X
are	B-X
released	B-X
in	B-X
similar	B-X
amounts	B-X
by	B-X
cells	B-X
transfected	B-X
with	B-X
wild-type	B-X
and	B-X
mutant	B-X
genomes	B-X
.	B-X

In	O
contrast	O
to	O
other	O
members	O
of	O
the	O
glycoprotein	O
hormone	O
receptor	O
family	O
(	O
the	O
LH	B-Protein
and	O
thyroid	B-Protein
-	I-Protein
stimulating	I-Protein
hormone	I-Protein
receptors	I-Protein
)	O
,	O
it	O
is	O
not	O
known	O
whether	O
the	O
follicle	B-Protein
-	I-Protein
stimulating	I-Protein
hormone	I-Protein
receptor	I-Protein
(	O
FSHR	B-Protein
)	O
is	O
palmitoylated	O
and	O
what	O
are	O
the	O
effects	O
of	O
abolishing	O
its	O
potential	O
palmitoylation	O
sites	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
functional	O
analysis	O
of	O
the	O
FSHR	B-Protein
carboxyl	O
-	O
terminal	O
segment	O
cysteine	O
residues	O
was	O
carried	O
out	O
.	O
<EOS>	B-X
The	B-X
carboxyl-terminal	B-X
segment	B-X
of	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
has	B-X
one	B-X
or	B-X
more	B-X
conserved	B-X
cysteine	B-X
residues	B-X
that	B-X
are	B-X
potential	B-X
sites	B-X
for	B-X
palmitoylation	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
other	B-X
members	B-X
of	B-X
the	B-X
glycoprotein	B-X
hormone	B-X
receptor	B-X
family	B-X
(	B-X
the	B-X
LH	B-X
and	B-X
thyroid-stimulating	B-X
hormone	B-X
receptors	B-X
)	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
the	B-X
follicle-stimulating	B-X
hormone	B-X
receptor	B-X
(	B-X
FSHR	B-X
)	B-X
is	B-X
palmitoylated	B-X
and	B-X
what	B-X
are	B-X
the	B-X
effects	B-X
of	B-X
abolishing	B-X
its	B-X
potential	B-X
palmitoylation	B-X
sites	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
functional	B-X
analysis	B-X
of	B-X
the	B-X
FSHR	B-X
carboxyl-terminal	B-X
segment	B-X
cysteine	B-X
residues	B-X
was	B-X
carried	B-X
out	B-X
.	B-X
We	B-X
constructed	B-X
a	B-X
series	B-X
of	B-X
mutant	B-X
FSHRs	B-X
by	B-X
substituting	B-X
cysteine	B-X
residues	B-X
with	B-X
alanine	B-X
,	B-X
serine	B-X
,	B-X
or	B-X
threonine	B-X
individually	B-X
and	B-X
together	B-X
at	B-X
positions	B-X
629	B-X
and	B-X
655	B-X
(	B-X
conserved	B-X
cysteines	B-X
)	B-X
and	B-X
627	B-X
(	B-X
nonconserved	B-X
)	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
all	B-X
three	B-X
cysteine	B-X
residues	B-X
are	B-X
palmitoylated	B-X
but	B-X
that	B-X
only	B-X
modification	B-X
at	B-X
Cys629	B-X
is	B-X
functionally	B-X
relevant	B-X
.	B-X
All	B-X
FSHR	B-X
Cys	B-X
mutants	B-X
were	B-X
capable	B-X
of	B-X
binding	B-X
agonist	B-X
with	B-X
the	B-X
same	B-X
affinity	B-X
as	B-X
the	B-X
wild-type	B-X
receptor	B-X
and	B-X
internalizing	B-X
on	B-X
agonist	B-X
stimulation	B-X
.	B-X

We	O
constructed	O
a	O
series	O
of	O
mutant	O
FSHRs	B-Protein
by	O
substituting	O
cysteine	O
residues	O
with	O
alanine	O
,	O
serine	O
,	O
or	O
threonine	O
individually	O
and	O
together	O
at	O
positions	O
629	O
and	O
655	O
(	O
conserved	O
cysteines	O
)	O
and	O
627	O
(	O
nonconserved	O
)	O
.	O
<EOS>	B-X
The	B-X
carboxyl-terminal	B-X
segment	B-X
of	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
has	B-X
one	B-X
or	B-X
more	B-X
conserved	B-X
cysteine	B-X
residues	B-X
that	B-X
are	B-X
potential	B-X
sites	B-X
for	B-X
palmitoylation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
functional	B-X
analysis	B-X
of	B-X
the	B-X
FSHR	B-X
carboxyl-terminal	B-X
segment	B-X
cysteine	B-X
residues	B-X
was	B-X
carried	B-X
out	B-X
.	B-X
We	B-X
constructed	B-X
a	B-X
series	B-X
of	B-X
mutant	B-X
FSHRs	B-X
by	B-X
substituting	B-X
cysteine	B-X
residues	B-X
with	B-X
alanine	B-X
,	B-X
serine	B-X
,	B-X
or	B-X
threonine	B-X
individually	B-X
and	B-X
together	B-X
at	B-X
positions	B-X
629	B-X
and	B-X
655	B-X
(	B-X
conserved	B-X
cysteines	B-X
)	B-X
and	B-X
627	B-X
(	B-X
nonconserved	B-X
)	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
all	B-X
three	B-X
cysteine	B-X
residues	B-X
are	B-X
palmitoylated	B-X
but	B-X
that	B-X
only	B-X
modification	B-X
at	B-X
Cys629	B-X
is	B-X
functionally	B-X
relevant	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
palmitoylation	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
greatly	B-X
impair	B-X
coupling	B-X
to	B-X
G	B-X
(	B-X
s	B-X
)	B-X
but	B-X
,	B-X
when	B-X
absent	B-X
at	B-X
position	B-X
629	B-X
,	B-X
does	B-X
significantly	B-X
impair	B-X
cell	B-X
surface	B-X
membrane	B-X
expression	B-X
of	B-X
the	B-X
partially	B-X
palmitoylated	B-X
receptor	B-X
.	B-X
All	B-X
FSHR	B-X
Cys	B-X
mutants	B-X
were	B-X
capable	B-X
of	B-X
binding	B-X
agonist	B-X
with	B-X
the	B-X
same	B-X
affinity	B-X
as	B-X
the	B-X
wild-type	B-X
receptor	B-X
and	B-X
internalizing	B-X
on	B-X
agonist	B-X
stimulation	B-X
.	B-X
Molecular	B-X
dynamics	B-X
simulations	B-X
at	B-X
a	B-X
time	B-X
scale	B-X
of	B-X
approximately	B-X
100	B-X
nsec	B-X
revealed	B-X
that	B-X
replacement	B-X
of	B-X
Cys629	B-X
resulted	B-X
in	B-X
structures	B-X
that	B-X
differed	B-X
significantly	B-X
from	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
receptor	B-X
.	B-X

The	O
results	O
showed	O
that	O
all	O
three	O
cysteine	O
residues	O
are	O
palmitoylated	O
but	O
that	O
only	O
modification	O
at	O
Cys629	O
is	O
functionally	O
relevant	O
.	O
<EOS>	B-X
The	B-X
carboxyl-terminal	B-X
segment	B-X
of	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
has	B-X
one	B-X
or	B-X
more	B-X
conserved	B-X
cysteine	B-X
residues	B-X
that	B-X
are	B-X
potential	B-X
sites	B-X
for	B-X
palmitoylation	B-X
.	B-X
This	B-X
posttranslational	B-X
modification	B-X
contributes	B-X
to	B-X
membrane	B-X
association	B-X
,	B-X
internalization	B-X
,	B-X
and	B-X
membrane	B-X
targeting	B-X
of	B-X
proteins	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
other	B-X
members	B-X
of	B-X
the	B-X
glycoprotein	B-X
hormone	B-X
receptor	B-X
family	B-X
(	B-X
the	B-X
LH	B-X
and	B-X
thyroid-stimulating	B-X
hormone	B-X
receptors	B-X
)	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
the	B-X
follicle-stimulating	B-X
hormone	B-X
receptor	B-X
(	B-X
FSHR	B-X
)	B-X
is	B-X
palmitoylated	B-X
and	B-X
what	B-X
are	B-X
the	B-X
effects	B-X
of	B-X
abolishing	B-X
its	B-X
potential	B-X
palmitoylation	B-X
sites	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
functional	B-X
analysis	B-X
of	B-X
the	B-X
FSHR	B-X
carboxyl-terminal	B-X
segment	B-X
cysteine	B-X
residues	B-X
was	B-X
carried	B-X
out	B-X
.	B-X
We	B-X
constructed	B-X
a	B-X
series	B-X
of	B-X
mutant	B-X
FSHRs	B-X
by	B-X
substituting	B-X
cysteine	B-X
residues	B-X
with	B-X
alanine	B-X
,	B-X
serine	B-X
,	B-X
or	B-X
threonine	B-X
individually	B-X
and	B-X
together	B-X
at	B-X
positions	B-X
629	B-X
and	B-X
655	B-X
(	B-X
conserved	B-X
cysteines	B-X
)	B-X
and	B-X
627	B-X
(	B-X
nonconserved	B-X
)	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
all	B-X
three	B-X
cysteine	B-X
residues	B-X
are	B-X
palmitoylated	B-X
but	B-X
that	B-X
only	B-X
modification	B-X
at	B-X
Cys629	B-X
is	B-X
functionally	B-X
relevant	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
palmitoylation	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
greatly	B-X
impair	B-X
coupling	B-X
to	B-X
G	B-X
(	B-X
s	B-X
)	B-X
but	B-X
,	B-X
when	B-X
absent	B-X
at	B-X
position	B-X
629	B-X
,	B-X
does	B-X
significantly	B-X
impair	B-X
cell	B-X
surface	B-X
membrane	B-X
expression	B-X
of	B-X
the	B-X
partially	B-X
palmitoylated	B-X
receptor	B-X
.	B-X
Molecular	B-X
dynamics	B-X
simulations	B-X
at	B-X
a	B-X
time	B-X
scale	B-X
of	B-X
approximately	B-X
100	B-X
nsec	B-X
revealed	B-X
that	B-X
replacement	B-X
of	B-X
Cys629	B-X
resulted	B-X
in	B-X
structures	B-X
that	B-X
differed	B-X
significantly	B-X
from	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
receptor	B-X
.	B-X

The	O
lack	O
of	O
palmitoylation	O
does	O
not	O
appear	O
to	O
greatly	O
impair	O
coupling	O
to	O
G	O
(	O
s	O
)	O
but	O
,	O
when	O
absent	O
at	O
position	O
629	O
,	O
does	O
significantly	O
impair	O
cell	O
surface	O
membrane	O
expression	O
of	O
the	O
partially	O
palmitoylated	O
receptor	O
.	O
<EOS>	B-X
The	B-X
most	B-X
important	B-X
risk	B-X
factors	B-X
are	B-X
dietary	B-X
pattern	B-X
,	B-X
genetics	B-X
,	B-X
old	B-X
age	B-X
,	B-X
lack	B-X
of	B-X
exercise	B-X
,	B-X
disrupted	B-X
biology	B-X
,	B-X
medication	B-X
usage	B-X
,	B-X
and	B-X
excessive	B-X
alcohol	B-X
consumption	B-X
,	B-X
but	B-X
pathophysiology	B-X
of	B-X
MS	B-X
has	B-X
not	B-X
been	B-X
completely	B-X
identified	B-X
.	B-X
Korean	B-X
Red	B-X
Ginseng	B-X
(	B-X
KRG	B-X
)	B-X
refers	B-X
to	B-X
steamed/dried	B-X
ginseng	B-X
,	B-X
traditionally	B-X
associated	B-X
with	B-X
beneficial	B-X
effects	B-X
such	B-X
as	B-X
anti-inflammation	B-X
,	B-X
anti-fatigue	B-X
,	B-X
anti-obesity	B-X
,	B-X
anti-oxidant	B-X
,	B-X
and	B-X
anti-cancer	B-X
effects	B-X
.	B-X
KRG	B-X
has	B-X
been	B-X
often	B-X
used	B-X
in	B-X
traditional	B-X
medicine	B-X
to	B-X
treat	B-X
multiple	B-X
metabolic	B-X
conditions	B-X
.	B-X
This	B-X
paper	B-X
summarizes	B-X
the	B-X
effects	B-X
of	B-X
KRG	B-X
in	B-X
MS	B-X
and	B-X
related	B-X
diseases	B-X
such	B-X
as	B-X
obesity	B-X
,	B-X
cardiovascular	B-X
disease	B-X
,	B-X
insulin	B-X
resistance	B-X
,	B-X
diabetes	B-X
,	B-X
dyslipidemia	B-X
,	B-X
or	B-X
non-alcoholic	B-X
fatty	B-X
liver	B-X
disease	B-X
based	B-X
on	B-X
experimental	B-X
research	B-X
and	B-X
clinical	B-X
studies	B-X
.	B-X

All	O
FSHR	B-Protein
Cys	O
mutants	O
were	O
capable	O
of	O
binding	O
agonist	O
with	O
the	O
same	O
affinity	O
as	O
the	O
wild	O
-	O
type	O
receptor	O
and	O
internalizing	O
on	O
agonist	O
stimulation	O
.	O
<EOS>	B-X
The	B-X
carboxyl-terminal	B-X
segment	B-X
of	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
has	B-X
one	B-X
or	B-X
more	B-X
conserved	B-X
cysteine	B-X
residues	B-X
that	B-X
are	B-X
potential	B-X
sites	B-X
for	B-X
palmitoylation	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
other	B-X
members	B-X
of	B-X
the	B-X
glycoprotein	B-X
hormone	B-X
receptor	B-X
family	B-X
(	B-X
the	B-X
LH	B-X
and	B-X
thyroid-stimulating	B-X
hormone	B-X
receptors	B-X
)	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
the	B-X
follicle-stimulating	B-X
hormone	B-X
receptor	B-X
(	B-X
FSHR	B-X
)	B-X
is	B-X
palmitoylated	B-X
and	B-X
what	B-X
are	B-X
the	B-X
effects	B-X
of	B-X
abolishing	B-X
its	B-X
potential	B-X
palmitoylation	B-X
sites	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
functional	B-X
analysis	B-X
of	B-X
the	B-X
FSHR	B-X
carboxyl-terminal	B-X
segment	B-X
cysteine	B-X
residues	B-X
was	B-X
carried	B-X
out	B-X
.	B-X
We	B-X
constructed	B-X
a	B-X
series	B-X
of	B-X
mutant	B-X
FSHRs	B-X
by	B-X
substituting	B-X
cysteine	B-X
residues	B-X
with	B-X
alanine	B-X
,	B-X
serine	B-X
,	B-X
or	B-X
threonine	B-X
individually	B-X
and	B-X
together	B-X
at	B-X
positions	B-X
629	B-X
and	B-X
655	B-X
(	B-X
conserved	B-X
cysteines	B-X
)	B-X
and	B-X
627	B-X
(	B-X
nonconserved	B-X
)	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
all	B-X
three	B-X
cysteine	B-X
residues	B-X
are	B-X
palmitoylated	B-X
but	B-X
that	B-X
only	B-X
modification	B-X
at	B-X
Cys629	B-X
is	B-X
functionally	B-X
relevant	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
palmitoylation	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
greatly	B-X
impair	B-X
coupling	B-X
to	B-X
G	B-X
(	B-X
s	B-X
)	B-X
but	B-X
,	B-X
when	B-X
absent	B-X
at	B-X
position	B-X
629	B-X
,	B-X
does	B-X
significantly	B-X
impair	B-X
cell	B-X
surface	B-X
membrane	B-X
expression	B-X
of	B-X
the	B-X
partially	B-X
palmitoylated	B-X
receptor	B-X
.	B-X
All	B-X
FSHR	B-X
Cys	B-X
mutants	B-X
were	B-X
capable	B-X
of	B-X
binding	B-X
agonist	B-X
with	B-X
the	B-X
same	B-X
affinity	B-X
as	B-X
the	B-X
wild-type	B-X
receptor	B-X
and	B-X
internalizing	B-X
on	B-X
agonist	B-X
stimulation	B-X
.	B-X
Molecular	B-X
dynamics	B-X
simulations	B-X
at	B-X
a	B-X
time	B-X
scale	B-X
of	B-X
approximately	B-X
100	B-X
nsec	B-X
revealed	B-X
that	B-X
replacement	B-X
of	B-X
Cys629	B-X
resulted	B-X
in	B-X
structures	B-X
that	B-X
differed	B-X
significantly	B-X
from	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
receptor	B-X
.	B-X
Thus	B-X
,	B-X
deviations	B-X
from	B-X
wild-type	B-X
conformation	B-X
may	B-X
potentially	B-X
contribute	B-X
to	B-X
the	B-X
severe	B-X
impairment	B-X
in	B-X
plasma	B-X
membrane	B-X
expression	B-X
and	B-X
the	B-X
modest	B-X
effects	B-X
on	B-X
signaling	B-X
exhibited	B-X
by	B-X
the	B-X
receptors	B-X
modified	B-X
in	B-X
this	B-X
particular	B-X
position	B-X
.	B-X

Molecular	O
dynamics	O
simulations	O
at	O
a	O
time	O
scale	O
of	O
approximately	O
100	O
nsec	O
revealed	O
that	O
replacement	O
of	O
Cys629	O
resulted	O
in	O
structures	O
that	O
differed	O
significantly	O
from	O
that	O
of	O
the	O
wild	O
-	O
type	O
receptor	O
.	O

Thus	O
,	O
deviations	O
from	O
wild	O
-	O
type	O
conformation	O
may	O
potentially	O
contribute	O
to	O
the	O
severe	O
impairment	O
in	O
plasma	O
membrane	O
expression	O
and	O
the	O
modest	O
effects	O
on	O
signaling	O
exhibited	O
by	O
the	O
receptors	O
modified	O
in	O
this	O
particular	O
position	O
.	O

Galectin	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
novel	O
structural	O
component	O
and	O
a	O
major	O
regulator	O
of	O
h	B-Protein
-	I-Protein
ras	I-Protein
nanoclusters	O
.	O

The	O
organization	O
of	O
Ras	O
proteins	O
into	O
nanoclusters	O
on	O
the	O
inner	O
plasma	O
membrane	O
is	O
essential	O
for	O
Ras	O
signal	O
transduction	O
,	O
but	O
the	O
mechanisms	O
that	O
drive	O
nanoclustering	O
are	O
unknown	O
.	O
<EOS>	B-X
The	B-X
organization	B-X
of	B-X
Ras	B-X
proteins	B-X
into	B-X
nanoclusters	B-X
on	B-X
the	B-X
inner	B-X
plasma	B-X
membrane	B-X
is	B-X
essential	B-X
for	B-X
Ras	B-X
signal	B-X
transduction	B-X
,	B-X
but	B-X
the	B-X
mechanisms	B-X
that	B-X
drive	B-X
nanoclustering	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
activation	B-X
stimulates	B-X
the	B-X
formation	B-X
of	B-X
H-Ras.GTP-Galectin-1	B-X
(	B-X
Gal-1	B-X
)	B-X
complexes	B-X
on	B-X
the	B-X
plasma	B-X
membrane	B-X
that	B-X
are	B-X
then	B-X
assembled	B-X
into	B-X
transient	B-X
nanoclusters	B-X
.	B-X
Gal-1	B-X
is	B-X
therefore	B-X
an	B-X
integral	B-X
structural	B-X
component	B-X
of	B-X
the	B-X
H-Ras-signaling	B-X
nanocluster	B-X
.	B-X
Increasing	B-X
Gal-1	B-X
levels	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
H-Ras	B-X
nanoclusters	B-X
,	B-X
leading	B-X
to	B-X
enhanced	B-X
effector	B-X
recruitment	B-X
and	B-X
signal	B-X
output	B-X
.	B-X
Elements	B-X
in	B-X
the	B-X
H-Ras	B-X
C-terminal	B-X
hypervariable	B-X
region	B-X
and	B-X
an	B-X
activated	B-X
G-domain	B-X
are	B-X
required	B-X
for	B-X
H-Ras-Gal-1	B-X
interaction	B-X
.	B-X
Palmitoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
H-Ras-Gal-1	B-X
complex	B-X
formation	B-X
,	B-X
but	B-X
is	B-X
required	B-X
to	B-X
anchor	B-X
H-Ras-Gal-1	B-X
complexes	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
a	B-X
mechanism	B-X
for	B-X
H-Ras	B-X
nanoclustering	B-X
that	B-X
involves	B-X
a	B-X
dual	B-X
role	B-X
for	B-X
Gal-1	B-X
as	B-X
a	B-X
critical	B-X
scaffolding	B-X
protein	B-X
and	B-X
a	B-X
molecular	B-X
chaperone	B-X
that	B-X
contributes	B-X
to	B-X
H-Ras	B-X
trafficking	B-X
by	B-X
returning	B-X
depalmitoylated	B-X
H-Ras	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
for	B-X
repalmitoylation	B-X
.	B-X

Here	O
we	O
show	O
that	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
activation	O
stimulates	O
the	O
formation	O
of	O
H	B-Protein
-	I-Protein
Ras	I-Protein
.	O
GTP	O
-	O
Galectin	B-Protein
-	I-Protein
1	I-Protein
(	O
Gal	B-Protein
-	I-Protein
1	I-Protein
)	O
complexes	O
on	O
the	O
plasma	O
membrane	O
that	O
are	O
then	O
assembled	O
into	O
transient	O
nanoclusters	O
.	O
<EOS>	B-X
The	B-X
organization	B-X
of	B-X
Ras	B-X
proteins	B-X
into	B-X
nanoclusters	B-X
on	B-X
the	B-X
inner	B-X
plasma	B-X
membrane	B-X
is	B-X
essential	B-X
for	B-X
Ras	B-X
signal	B-X
transduction	B-X
,	B-X
but	B-X
the	B-X
mechanisms	B-X
that	B-X
drive	B-X
nanoclustering	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
activation	B-X
stimulates	B-X
the	B-X
formation	B-X
of	B-X
H-Ras.GTP-Galectin-1	B-X
(	B-X
Gal-1	B-X
)	B-X
complexes	B-X
on	B-X
the	B-X
plasma	B-X
membrane	B-X
that	B-X
are	B-X
then	B-X
assembled	B-X
into	B-X
transient	B-X
nanoclusters	B-X
.	B-X
Gal-1	B-X
is	B-X
therefore	B-X
an	B-X
integral	B-X
structural	B-X
component	B-X
of	B-X
the	B-X
H-Ras-signaling	B-X
nanocluster	B-X
.	B-X
Increasing	B-X
Gal-1	B-X
levels	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
H-Ras	B-X
nanoclusters	B-X
,	B-X
leading	B-X
to	B-X
enhanced	B-X
effector	B-X
recruitment	B-X
and	B-X
signal	B-X
output	B-X
.	B-X
Elements	B-X
in	B-X
the	B-X
H-Ras	B-X
C-terminal	B-X
hypervariable	B-X
region	B-X
and	B-X
an	B-X
activated	B-X
G-domain	B-X
are	B-X
required	B-X
for	B-X
H-Ras-Gal-1	B-X
interaction	B-X
.	B-X
Palmitoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
H-Ras-Gal-1	B-X
complex	B-X
formation	B-X
,	B-X
but	B-X
is	B-X
required	B-X
to	B-X
anchor	B-X
H-Ras-Gal-1	B-X
complexes	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
a	B-X
mechanism	B-X
for	B-X
H-Ras	B-X
nanoclustering	B-X
that	B-X
involves	B-X
a	B-X
dual	B-X
role	B-X
for	B-X
Gal-1	B-X
as	B-X
a	B-X
critical	B-X
scaffolding	B-X
protein	B-X
and	B-X
a	B-X
molecular	B-X
chaperone	B-X
that	B-X
contributes	B-X
to	B-X
H-Ras	B-X
trafficking	B-X
by	B-X
returning	B-X
depalmitoylated	B-X
H-Ras	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
for	B-X
repalmitoylation	B-X
.	B-X

Gal	B-Protein
-	I-Protein
1	I-Protein
is	O
therefore	O
an	O
integral	O
structural	O
component	O
of	O
the	O
H	B-Protein
-	I-Protein
Ras	I-Protein
-	O
signaling	O
nanocluster	O
.	O

Increasing	O
Gal	B-Protein
-	I-Protein
1	I-Protein
levels	O
increases	O
the	O
stability	O
of	O
H	B-Protein
-	I-Protein
Ras	I-Protein
nanoclusters	O
,	O
leading	O
to	O
enhanced	O
effector	O
recruitment	O
and	O
signal	O
output	O
.	O
<EOS>	B-X
The	B-X
organization	B-X
of	B-X
Ras	B-X
proteins	B-X
into	B-X
nanoclusters	B-X
on	B-X
the	B-X
inner	B-X
plasma	B-X
membrane	B-X
is	B-X
essential	B-X
for	B-X
Ras	B-X
signal	B-X
transduction	B-X
,	B-X
but	B-X
the	B-X
mechanisms	B-X
that	B-X
drive	B-X
nanoclustering	B-X
are	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
activation	B-X
stimulates	B-X
the	B-X
formation	B-X
of	B-X
H-Ras.GTP-Galectin-1	B-X
(	B-X
Gal-1	B-X
)	B-X
complexes	B-X
on	B-X
the	B-X
plasma	B-X
membrane	B-X
that	B-X
are	B-X
then	B-X
assembled	B-X
into	B-X
transient	B-X
nanoclusters	B-X
.	B-X
Gal-1	B-X
is	B-X
therefore	B-X
an	B-X
integral	B-X
structural	B-X
component	B-X
of	B-X
the	B-X
H-Ras-signaling	B-X
nanocluster	B-X
.	B-X
Increasing	B-X
Gal-1	B-X
levels	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
H-Ras	B-X
nanoclusters	B-X
,	B-X
leading	B-X
to	B-X
enhanced	B-X
effector	B-X
recruitment	B-X
and	B-X
signal	B-X
output	B-X
.	B-X
Elements	B-X
in	B-X
the	B-X
H-Ras	B-X
C-terminal	B-X
hypervariable	B-X
region	B-X
and	B-X
an	B-X
activated	B-X
G-domain	B-X
are	B-X
required	B-X
for	B-X
H-Ras-Gal-1	B-X
interaction	B-X
.	B-X
Palmitoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
H-Ras-Gal-1	B-X
complex	B-X
formation	B-X
,	B-X
but	B-X
is	B-X
required	B-X
to	B-X
anchor	B-X
H-Ras-Gal-1	B-X
complexes	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
a	B-X
mechanism	B-X
for	B-X
H-Ras	B-X
nanoclustering	B-X
that	B-X
involves	B-X
a	B-X
dual	B-X
role	B-X
for	B-X
Gal-1	B-X
as	B-X
a	B-X
critical	B-X
scaffolding	B-X
protein	B-X
and	B-X
a	B-X
molecular	B-X
chaperone	B-X
that	B-X
contributes	B-X
to	B-X
H-Ras	B-X
trafficking	B-X
by	B-X
returning	B-X
depalmitoylated	B-X
H-Ras	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
for	B-X
repalmitoylation	B-X
.	B-X

Elements	O
in	O
the	O
H	B-Protein
-	I-Protein
Ras	I-Protein
C	O
-	O
terminal	O
hypervariable	O
region	O
and	O
an	O
activated	O
G	O
-	O
domain	O
are	O
required	O
for	O
H	B-Protein
-	I-Protein
Ras	I-Protein
-	O
Gal	B-Protein
-	I-Protein
1	I-Protein
interaction	O
.	O

Palmitoylation	O
is	O
not	O
required	O
for	O
H	B-Protein
-	I-Protein
Ras	I-Protein
-	O
Gal	B-Protein
-	I-Protein
1	I-Protein
complex	O
formation	O
,	O
but	O
is	O
required	O
to	O
anchor	O
H	B-Protein
-	I-Protein
Ras	I-Protein
-	O
Gal	B-Protein
-	I-Protein
1	I-Protein
complexes	O
to	O
the	O
plasma	O
membrane	O
.	O
<EOS>	B-X
S-palmitoylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
function	B-X
of	B-X
both	B-X
oncogenes	B-X
(	B-X
e.g.	B-X
,	B-X
NRAS	B-X
and	B-X
EGFR	B-X
)	B-X
and	B-X
tumor	B-X
suppressors	B-X
(	B-X
e.g.	B-X
,	B-X
SCRIB	B-X
,	B-X
melanocortin	B-X
1	B-X
receptor	B-X
)	B-X
.	B-X
In	B-X
mammalian	B-X
cells	B-X
,	B-X
the	B-X
thioesterification	B-X
of	B-X
palmitate	B-X
to	B-X
internal	B-X
cysteine	B-X
residues	B-X
is	B-X
catalyzed	B-X
by	B-X
23	B-X
Asp-His-His-Cys	B-X
(	B-X
DHHC	B-X
)	B-X
-family	B-X
palmitoyl	B-X
S-acyltransferases	B-X
while	B-X
the	B-X
removal	B-X
of	B-X
palmitate	B-X
is	B-X
catalyzed	B-X
by	B-X
serine	B-X
hydrolases	B-X
,	B-X
including	B-X
acyl-protein	B-X
thioesterases	B-X
(	B-X
APTs	B-X
)	B-X
.	B-X
Palmitoylation	B-X
is	B-X
an	B-X
important	B-X
post-translational	B-X
modification	B-X
(	B-X
PTM	B-X
)	B-X
catalyzed	B-X
by	B-X
DHHC-palmitoyl	B-X
transferases	B-X
,	B-X
which	B-X
participate	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
diverse	B-X
biological	B-X
processes	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
palmitoylation	B-X
regulates	B-X
cGAS	B-X
function	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
explored	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
found	B-X
that	B-X
palmitoylation	B-X
of	B-X
cGAS	B-X
at	B-X
C474	B-X
restricted	B-X
its	B-X
enzymatic	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
double-stranded	B-X
DNA	B-X
.	B-X
cGAS	B-X
palmitoylation	B-X
was	B-X
catalyzed	B-X
mainly	B-X
by	B-X
the	B-X
palmitoyltransferase	B-X
ZDHHC18	B-X
and	B-X
double-stranded	B-X
DNA	B-X
promoted	B-X
this	B-X
modification	B-X
.	B-X
Consistently	B-X
,	B-X
ZDHHC18	B-X
negatively	B-X
regulated	B-X
cGAS	B-X
activation	B-X
in	B-X
human	B-X
and	B-X
mouse	B-X
cell	B-X
lines	B-X
.	B-X
In	B-X
a	B-X
more	B-X
biologically	B-X
relevant	B-X
model	B-X
system	B-X
,	B-X
Zdhhc18-deficient	B-X
mice	B-X
were	B-X
found	B-X
to	B-X
be	B-X
resistant	B-X
to	B-X
infection	B-X
by	B-X
DNA	B-X
viruses	B-X
,	B-X
in	B-X
agreement	B-X
with	B-X
the	B-X
observation	B-X
that	B-X
ZDHHC18	B-X
negatively	B-X
regulated	B-X
cGAS	B-X
mediated	B-X
innate	B-X
immune	B-X
responses	B-X
in	B-X
human	B-X
and	B-X
mouse	B-X
primary	B-X
cells	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
the	B-X
negative	B-X
role	B-X
of	B-X
ZDHHC18-mediated	B-X
cGAS	B-X
palmitoylation	B-X
may	B-X
be	B-X
a	B-X
novel	B-X
regulatory	B-X
mechanism	B-X
in	B-X
the	B-X
fine-tuning	B-X
of	B-X
innate	B-X
immunity	B-X
.	B-X

Our	O
data	O
suggest	O
a	O
mechanism	O
for	O
H	B-Protein
-	I-Protein
Ras	I-Protein
nanoclustering	O
that	O
involves	O
a	O
dual	O
role	O
for	O
Gal	B-Protein
-	I-Protein
1	I-Protein
as	O
a	O
critical	O
scaffolding	O
protein	O
and	O
a	O
molecular	O
chaperone	O
that	O
contributes	O
to	O
H	B-Protein
-	I-Protein
Ras	I-Protein
trafficking	O
by	O
returning	O
depalmitoylated	O
H	B-Protein
-	I-Protein
Ras	I-Protein
to	O
the	O
Golgi	O
complex	O
for	O
repalmitoylation	O
.	O

A	O
targeted	O
proteomic	O
analysis	O
of	O
the	O
ubiquitin	B-Protein
-	O
like	O
modifier	O
nedd8	B-Protein
and	O
associated	O
proteins	O
.	O
<EOS>	B-X
Nedd8	B-X
is	B-X
a	B-X
small	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
can	B-X
be	B-X
conjugated	B-X
to	B-X
substrate-proteins	B-X
in	B-X
a	B-X
process	B-X
known	B-X
as	B-X
neddylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
neddylation	B-X
pathway	B-X
at	B-X
the	B-X
proteome	B-X
level	B-X
,	B-X
we	B-X
have	B-X
affinity	B-X
purified	B-X
Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
from	B-X
HEK293	B-X
cells	B-X
stably	B-X
expressing	B-X
GST-Nedd8	B-X
and	B-X
employed	B-X
LC-MS/MS	B-X
for	B-X
subsequent	B-X
protein	B-X
identification	B-X
.	B-X
A	B-X
total	B-X
of	B-X
496	B-X
GST-Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
including	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
cullin	B-X
family	B-X
members	B-X
(	B-X
i.e.	B-X
,	B-X
Cul-1	B-X
,	B-X
-2	B-X
,	B-X
-3	B-X
,	B-X
-4A	B-X
,	B-X
-4B	B-X
,	B-X
-5	B-X
,	B-X
-7	B-X
,	B-X
and	B-X
Parc	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
neddylation	B-X
and	B-X
ubiquitin-proteasome	B-X
degradation	B-X
pathway	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
group	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
transcription	B-X
,	B-X
DNA	B-X
repair	B-X
and	B-X
replication	B-X
,	B-X
cell	B-X
cycle	B-X
regulation	B-X
and	B-X
chromatin	B-X
organization	B-X
,	B-X
and	B-X
remodeling	B-X
have	B-X
been	B-X
copurified	B-X
and	B-X
identified	B-X
.	B-X
Apart	B-X
from	B-X
protein	B-X
identification	B-X
,	B-X
the	B-X
neddylation	B-X
sites	B-X
of	B-X
cullins	B-X
were	B-X
determined	B-X
by	B-X
MS/MS	B-X
analysis	B-X
,	B-X
which	B-X
agree	B-X
well	B-X
with	B-X
previous	B-X
mutagenesis	B-X
studies	B-X
.	B-X
These	B-X
results	B-X
present	B-X
the	B-X
first	B-X
molecular	B-X
evidence	B-X
for	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
polyneddylation	B-X
,	B-X
suggesting	B-X
that	B-X
chain	B-X
formation	B-X
of	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
proteins	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
for	B-X
these	B-X
modifications	B-X
.	B-X
The	B-X
vast	B-X
amount	B-X
of	B-X
proteomic	B-X
information	B-X
obtained	B-X
here	B-X
can	B-X
provide	B-X
clues	B-X
on	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
Nedd8	B-X
and	B-X
lay	B-X
the	B-X
foundation	B-X
for	B-X
an	B-X
in-depth	B-X
analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Nedd8	B-Protein
is	O
a	O
small	O
ubiquitin	B-Protein
-	O
like	O
protein	O
that	O
can	O
be	O
conjugated	O
to	O
substrate	O
-	O
proteins	O
in	O
a	O
process	O
known	O
as	O
neddylation	O
.	O

Although	O
neddylation	O
plays	O
a	O
critical	O
regulatory	O
role	O
in	O
cell	O
proliferation	O
and	O
development	O
,	O
the	O
spectrum	O
of	O
Nedd8	B-Protein
substrates	O
and	O
its	O
interaction	O
network	O
remain	O
poorly	O
understood	O
.	O

To	O
explore	O
the	O
neddylation	O
pathway	O
at	O
the	O
proteome	O
level	O
,	O
we	O
have	O
affinity	O
purified	O
Nedd8	B-Protein
modified	O
and	O
associated	O
proteins	O
from	O
HEK293	O
cells	O
stably	O
expressing	O
GST	O
-	O
Nedd8	B-Protein
and	O
employed	O
LC	O
-	O
MS	O
/	O
MS	O
for	O
subsequent	O
protein	O
identification	O
.	O

A	O
total	O
of	O
496	O
GST	O
-	O
Nedd8	B-Protein
modified	O
and	O
associated	O
proteins	O
have	O
been	O
identified	O
,	O
including	O
all	O
of	O
the	O
eight	O
cullin	O
family	O
members	O
(	O
i	O
.	O
e	O
.	O
,	O
Cul	B-Protein
-	I-Protein
1	I-Protein
,	O
-	B-Protein
2	I-Protein
,	O
-	B-Protein
3	I-Protein
,	O
-	B-Protein
4A	I-Protein
,	O
-	B-Protein
4B	I-Protein
,	O
-	B-Protein
5	I-Protein
,	O
-	B-Protein
7	I-Protein
,	O
and	O
Parc	B-Protein
)	O
that	O
are	O
involved	O
in	O
the	O
neddylation	O
and	O
ubiquitin	B-Protein
-	O
proteasome	O
degradation	O
pathway	O
.	O

In	O
addition	O
,	O
a	O
group	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
DNA	O
repair	O
and	O
replication	O
,	O
cell	O
cycle	O
regulation	O
and	O
chromatin	O
organization	O
,	O
and	O
remodeling	O
have	O
been	O
copurified	O
and	O
identified	O
.	O
<EOS>	B-X
Nedd8	B-X
is	B-X
a	B-X
small	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
can	B-X
be	B-X
conjugated	B-X
to	B-X
substrate-proteins	B-X
in	B-X
a	B-X
process	B-X
known	B-X
as	B-X
neddylation	B-X
.	B-X
Although	B-X
neddylation	B-X
plays	B-X
a	B-X
critical	B-X
regulatory	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
and	B-X
development	B-X
,	B-X
the	B-X
spectrum	B-X
of	B-X
Nedd8	B-X
substrates	B-X
and	B-X
its	B-X
interaction	B-X
network	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
neddylation	B-X
pathway	B-X
at	B-X
the	B-X
proteome	B-X
level	B-X
,	B-X
we	B-X
have	B-X
affinity	B-X
purified	B-X
Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
from	B-X
HEK293	B-X
cells	B-X
stably	B-X
expressing	B-X
GST-Nedd8	B-X
and	B-X
employed	B-X
LC-MS/MS	B-X
for	B-X
subsequent	B-X
protein	B-X
identification	B-X
.	B-X
A	B-X
total	B-X
of	B-X
496	B-X
GST-Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
including	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
cullin	B-X
family	B-X
members	B-X
(	B-X
i.e.	B-X
,	B-X
Cul-1	B-X
,	B-X
-2	B-X
,	B-X
-3	B-X
,	B-X
-4A	B-X
,	B-X
-4B	B-X
,	B-X
-5	B-X
,	B-X
-7	B-X
,	B-X
and	B-X
Parc	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
neddylation	B-X
and	B-X
ubiquitin-proteasome	B-X
degradation	B-X
pathway	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
group	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
transcription	B-X
,	B-X
DNA	B-X
repair	B-X
and	B-X
replication	B-X
,	B-X
cell	B-X
cycle	B-X
regulation	B-X
and	B-X
chromatin	B-X
organization	B-X
,	B-X
and	B-X
remodeling	B-X
have	B-X
been	B-X
copurified	B-X
and	B-X
identified	B-X
.	B-X
These	B-X
results	B-X
present	B-X
the	B-X
first	B-X
molecular	B-X
evidence	B-X
for	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
polyneddylation	B-X
,	B-X
suggesting	B-X
that	B-X
chain	B-X
formation	B-X
of	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
proteins	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
for	B-X
these	B-X
modifications	B-X
.	B-X
The	B-X
vast	B-X
amount	B-X
of	B-X
proteomic	B-X
information	B-X
obtained	B-X
here	B-X
can	B-X
provide	B-X
clues	B-X
on	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
Nedd8	B-X
and	B-X
lay	B-X
the	B-X
foundation	B-X
for	B-X
an	B-X
in-depth	B-X
analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Apart	O
from	O
protein	O
identification	O
,	O
the	O
neddylation	O
sites	O
of	O
cullins	O
were	O
determined	O
by	O
MS	O
/	O
MS	O
analysis	O
,	O
which	O
agree	O
well	O
with	O
previous	O
mutagenesis	O
studies	O
.	O

Furthermore	O
,	O
MS	O
analyses	O
revealed	O
that	O
Nedd8	B-Protein
K11	O
,	O
K22	O
,	O
K48	O
,	O
and	O
K60	O
can	O
form	O
chains	O
in	O
vivo	O
,	O
whereas	O
Nedd8	B-Protein
K22	O
and	O
K48	O
can	O
be	O
neddylated	O
in	O
vitro	O
.	O
<EOS>	B-X
Nedd8	B-X
is	B-X
a	B-X
small	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
can	B-X
be	B-X
conjugated	B-X
to	B-X
substrate-proteins	B-X
in	B-X
a	B-X
process	B-X
known	B-X
as	B-X
neddylation	B-X
.	B-X
Although	B-X
neddylation	B-X
plays	B-X
a	B-X
critical	B-X
regulatory	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
and	B-X
development	B-X
,	B-X
the	B-X
spectrum	B-X
of	B-X
Nedd8	B-X
substrates	B-X
and	B-X
its	B-X
interaction	B-X
network	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
neddylation	B-X
pathway	B-X
at	B-X
the	B-X
proteome	B-X
level	B-X
,	B-X
we	B-X
have	B-X
affinity	B-X
purified	B-X
Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
from	B-X
HEK293	B-X
cells	B-X
stably	B-X
expressing	B-X
GST-Nedd8	B-X
and	B-X
employed	B-X
LC-MS/MS	B-X
for	B-X
subsequent	B-X
protein	B-X
identification	B-X
.	B-X
A	B-X
total	B-X
of	B-X
496	B-X
GST-Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
including	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
cullin	B-X
family	B-X
members	B-X
(	B-X
i.e.	B-X
,	B-X
Cul-1	B-X
,	B-X
-2	B-X
,	B-X
-3	B-X
,	B-X
-4A	B-X
,	B-X
-4B	B-X
,	B-X
-5	B-X
,	B-X
-7	B-X
,	B-X
and	B-X
Parc	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
neddylation	B-X
and	B-X
ubiquitin-proteasome	B-X
degradation	B-X
pathway	B-X
.	B-X
Apart	B-X
from	B-X
protein	B-X
identification	B-X
,	B-X
the	B-X
neddylation	B-X
sites	B-X
of	B-X
cullins	B-X
were	B-X
determined	B-X
by	B-X
MS/MS	B-X
analysis	B-X
,	B-X
which	B-X
agree	B-X
well	B-X
with	B-X
previous	B-X
mutagenesis	B-X
studies	B-X
.	B-X
Furthermore	B-X
,	B-X
MS	B-X
analyses	B-X
revealed	B-X
that	B-X
Nedd8	B-X
K11	B-X
,	B-X
K22	B-X
,	B-X
K48	B-X
,	B-X
and	B-X
K60	B-X
can	B-X
form	B-X
chains	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
Nedd8	B-X
K22	B-X
and	B-X
K48	B-X
can	B-X
be	B-X
neddylated	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
present	B-X
the	B-X
first	B-X
molecular	B-X
evidence	B-X
for	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
polyneddylation	B-X
,	B-X
suggesting	B-X
that	B-X
chain	B-X
formation	B-X
of	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
proteins	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
for	B-X
these	B-X
modifications	B-X
.	B-X
Although	B-X
much	B-X
remains	B-X
to	B-X
be	B-X
explored	B-X
for	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
observations	B-X
,	B-X
this	B-X
work	B-X
provides	B-X
critically	B-X
important	B-X
information	B-X
regarding	B-X
Nedd8	B-X
chain	B-X
assembly	B-X
and	B-X
its	B-X
interaction	B-X
network	B-X
.	B-X
The	B-X
vast	B-X
amount	B-X
of	B-X
proteomic	B-X
information	B-X
obtained	B-X
here	B-X
can	B-X
provide	B-X
clues	B-X
on	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
Nedd8	B-X
and	B-X
lay	B-X
the	B-X
foundation	B-X
for	B-X
an	B-X
in-depth	B-X
analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

These	O
results	O
present	O
the	O
first	O
molecular	O
evidence	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
polyneddylation	O
,	O
suggesting	O
that	O
chain	O
formation	O
of	O
ubiquitin	B-Protein
and	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
may	O
be	O
a	O
general	O
phenomenon	O
for	O
these	O
modifications	O
.	O
<EOS>	B-X
Nedd8	B-X
is	B-X
a	B-X
small	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
can	B-X
be	B-X
conjugated	B-X
to	B-X
substrate-proteins	B-X
in	B-X
a	B-X
process	B-X
known	B-X
as	B-X
neddylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
neddylation	B-X
pathway	B-X
at	B-X
the	B-X
proteome	B-X
level	B-X
,	B-X
we	B-X
have	B-X
affinity	B-X
purified	B-X
Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
from	B-X
HEK293	B-X
cells	B-X
stably	B-X
expressing	B-X
GST-Nedd8	B-X
and	B-X
employed	B-X
LC-MS/MS	B-X
for	B-X
subsequent	B-X
protein	B-X
identification	B-X
.	B-X
A	B-X
total	B-X
of	B-X
496	B-X
GST-Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
including	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
cullin	B-X
family	B-X
members	B-X
(	B-X
i.e.	B-X
,	B-X
Cul-1	B-X
,	B-X
-2	B-X
,	B-X
-3	B-X
,	B-X
-4A	B-X
,	B-X
-4B	B-X
,	B-X
-5	B-X
,	B-X
-7	B-X
,	B-X
and	B-X
Parc	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
neddylation	B-X
and	B-X
ubiquitin-proteasome	B-X
degradation	B-X
pathway	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
group	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
transcription	B-X
,	B-X
DNA	B-X
repair	B-X
and	B-X
replication	B-X
,	B-X
cell	B-X
cycle	B-X
regulation	B-X
and	B-X
chromatin	B-X
organization	B-X
,	B-X
and	B-X
remodeling	B-X
have	B-X
been	B-X
copurified	B-X
and	B-X
identified	B-X
.	B-X
Furthermore	B-X
,	B-X
MS	B-X
analyses	B-X
revealed	B-X
that	B-X
Nedd8	B-X
K11	B-X
,	B-X
K22	B-X
,	B-X
K48	B-X
,	B-X
and	B-X
K60	B-X
can	B-X
form	B-X
chains	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
Nedd8	B-X
K22	B-X
and	B-X
K48	B-X
can	B-X
be	B-X
neddylated	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
present	B-X
the	B-X
first	B-X
molecular	B-X
evidence	B-X
for	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
polyneddylation	B-X
,	B-X
suggesting	B-X
that	B-X
chain	B-X
formation	B-X
of	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
proteins	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
for	B-X
these	B-X
modifications	B-X
.	B-X
Although	B-X
much	B-X
remains	B-X
to	B-X
be	B-X
explored	B-X
for	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
observations	B-X
,	B-X
this	B-X
work	B-X
provides	B-X
critically	B-X
important	B-X
information	B-X
regarding	B-X
Nedd8	B-X
chain	B-X
assembly	B-X
and	B-X
its	B-X
interaction	B-X
network	B-X
.	B-X
The	B-X
vast	B-X
amount	B-X
of	B-X
proteomic	B-X
information	B-X
obtained	B-X
here	B-X
can	B-X
provide	B-X
clues	B-X
on	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
Nedd8	B-X
and	B-X
lay	B-X
the	B-X
foundation	B-X
for	B-X
an	B-X
in-depth	B-X
analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Although	O
much	O
remains	O
to	O
be	O
explored	O
for	O
the	O
biological	O
significance	O
of	O
the	O
observations	O
,	O
this	O
work	O
provides	O
critically	O
important	O
information	O
regarding	O
Nedd8	B-Protein
chain	O
assembly	O
and	O
its	O
interaction	O
network	O
.	O
<EOS>	B-X
Nedd8	B-X
is	B-X
a	B-X
small	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
can	B-X
be	B-X
conjugated	B-X
to	B-X
substrate-proteins	B-X
in	B-X
a	B-X
process	B-X
known	B-X
as	B-X
neddylation	B-X
.	B-X
Although	B-X
neddylation	B-X
plays	B-X
a	B-X
critical	B-X
regulatory	B-X
role	B-X
in	B-X
cell	B-X
proliferation	B-X
and	B-X
development	B-X
,	B-X
the	B-X
spectrum	B-X
of	B-X
Nedd8	B-X
substrates	B-X
and	B-X
its	B-X
interaction	B-X
network	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
neddylation	B-X
pathway	B-X
at	B-X
the	B-X
proteome	B-X
level	B-X
,	B-X
we	B-X
have	B-X
affinity	B-X
purified	B-X
Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
from	B-X
HEK293	B-X
cells	B-X
stably	B-X
expressing	B-X
GST-Nedd8	B-X
and	B-X
employed	B-X
LC-MS/MS	B-X
for	B-X
subsequent	B-X
protein	B-X
identification	B-X
.	B-X
A	B-X
total	B-X
of	B-X
496	B-X
GST-Nedd8	B-X
modified	B-X
and	B-X
associated	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
including	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
cullin	B-X
family	B-X
members	B-X
(	B-X
i.e.	B-X
,	B-X
Cul-1	B-X
,	B-X
-2	B-X
,	B-X
-3	B-X
,	B-X
-4A	B-X
,	B-X
-4B	B-X
,	B-X
-5	B-X
,	B-X
-7	B-X
,	B-X
and	B-X
Parc	B-X
)	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
neddylation	B-X
and	B-X
ubiquitin-proteasome	B-X
degradation	B-X
pathway	B-X
.	B-X
Furthermore	B-X
,	B-X
MS	B-X
analyses	B-X
revealed	B-X
that	B-X
Nedd8	B-X
K11	B-X
,	B-X
K22	B-X
,	B-X
K48	B-X
,	B-X
and	B-X
K60	B-X
can	B-X
form	B-X
chains	B-X
in	B-X
vivo	B-X
,	B-X
whereas	B-X
Nedd8	B-X
K22	B-X
and	B-X
K48	B-X
can	B-X
be	B-X
neddylated	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
present	B-X
the	B-X
first	B-X
molecular	B-X
evidence	B-X
for	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
polyneddylation	B-X
,	B-X
suggesting	B-X
that	B-X
chain	B-X
formation	B-X
of	B-X
ubiquitin	B-X
and	B-X
ubiquitin-like	B-X
proteins	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
for	B-X
these	B-X
modifications	B-X
.	B-X
Although	B-X
much	B-X
remains	B-X
to	B-X
be	B-X
explored	B-X
for	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
observations	B-X
,	B-X
this	B-X
work	B-X
provides	B-X
critically	B-X
important	B-X
information	B-X
regarding	B-X
Nedd8	B-X
chain	B-X
assembly	B-X
and	B-X
its	B-X
interaction	B-X
network	B-X
.	B-X
The	B-X
vast	B-X
amount	B-X
of	B-X
proteomic	B-X
information	B-X
obtained	B-X
here	B-X
can	B-X
provide	B-X
clues	B-X
on	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
Nedd8	B-X
and	B-X
lay	B-X
the	B-X
foundation	B-X
for	B-X
an	B-X
in-depth	B-X
analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

The	O
vast	O
amount	O
of	O
proteomic	O
information	O
obtained	O
here	O
can	O
provide	O
clues	O
on	O
the	O
biological	O
role	O
of	O
Nedd8	B-Protein
and	O
lay	O
the	O
foundation	O
for	O
an	O
in	O
-	O
depth	O
analysis	O
of	O
the	O
regulation	O
of	O
the	O
Nedd8	B-Protein
pathway	O
.	O

Docking	O
of	O
fatty	O
acids	O
into	O
the	O
WIF	O
domain	O
of	O
the	O
human	O
Wnt	B-Protein
inhibitory	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Palmitoylated	B-X
Wnt	B-X
proteins	B-X
comprise	B-X
a	B-X
conserved	B-X
family	B-X
of	B-X
secreted	B-X
signaling	B-X
molecules	B-X
associated	B-X
with	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
WIF	B-X
domain	B-X
of	B-X
the	B-X
human	B-X
WIF	B-X
(	B-X
Wnt	B-X
inhibitory	B-X
factor	B-X
)	B-X
-1	B-X
is	B-X
sufficient	B-X
for	B-X
Wnt	B-X
binding	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X
Detailed	B-X
interactions	B-X
between	B-X
Wnt	B-X
and	B-X
WIF-1	B-X
are	B-X
not	B-X
known	B-X
.	B-X
Computational	B-X
docking	B-X
was	B-X
employed	B-X
to	B-X
identify	B-X
a	B-X
possible	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
WIF	B-X
domain	B-X
.	B-X
A	B-X
putative	B-X
binding	B-X
site	B-X
was	B-X
identified	B-X
inside	B-X
the	B-X
domain	B-X
.	B-X
WIF	B-X
domain	B-X
exhibited	B-X
the	B-X
highest	B-X
affinity	B-X
for	B-X
C16:0-C18:0	B-X
(	B-X
-22	B-X
kJ/mol	B-X
free	B-X
energy	B-X
of	B-X
binding	B-X
)	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
of	B-X
the	B-X
WIF	B-X
domain	B-X
as	B-X
a	B-X
palmitoyl	B-X
binding	B-X
domain	B-X
required	B-X
for	B-X
WIF-1	B-X
binding	B-X
to	B-X
palmitoylated	B-X
Wnt	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X

Palmitoylated	O
Wnt	O
proteins	O
comprise	O
a	O
conserved	O
family	O
of	O
secreted	O
signaling	O
molecules	O
associated	O
with	O
variety	O
of	O
human	O
cancers	O
.	O
<EOS>	B-X
Palmitoylated	B-X
Wnt	B-X
proteins	B-X
comprise	B-X
a	B-X
conserved	B-X
family	B-X
of	B-X
secreted	B-X
signaling	B-X
molecules	B-X
associated	B-X
with	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
WIF	B-X
domain	B-X
of	B-X
the	B-X
human	B-X
WIF	B-X
(	B-X
Wnt	B-X
inhibitory	B-X
factor	B-X
)	B-X
-1	B-X
is	B-X
sufficient	B-X
for	B-X
Wnt	B-X
binding	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X
Detailed	B-X
interactions	B-X
between	B-X
Wnt	B-X
and	B-X
WIF-1	B-X
are	B-X
not	B-X
known	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
of	B-X
the	B-X
WIF	B-X
domain	B-X
as	B-X
a	B-X
palmitoyl	B-X
binding	B-X
domain	B-X
required	B-X
for	B-X
WIF-1	B-X
binding	B-X
to	B-X
palmitoylated	B-X
Wnt	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X

WIF	O
domain	O
of	O
the	O
human	O
WIF	B-Protein
(	I-Protein
Wnt	I-Protein
inhibitory	I-Protein
factor	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
is	O
sufficient	O
for	O
Wnt	O
binding	O
and	O
signaling	O
inhibition	O
.	O
<EOS>	B-X
Palmitoylated	B-X
Wnt	B-X
proteins	B-X
comprise	B-X
a	B-X
conserved	B-X
family	B-X
of	B-X
secreted	B-X
signaling	B-X
molecules	B-X
associated	B-X
with	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
WIF	B-X
domain	B-X
of	B-X
the	B-X
human	B-X
WIF	B-X
(	B-X
Wnt	B-X
inhibitory	B-X
factor	B-X
)	B-X
-1	B-X
is	B-X
sufficient	B-X
for	B-X
Wnt	B-X
binding	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X
Detailed	B-X
interactions	B-X
between	B-X
Wnt	B-X
and	B-X
WIF-1	B-X
are	B-X
not	B-X
known	B-X
.	B-X
Computational	B-X
docking	B-X
was	B-X
employed	B-X
to	B-X
identify	B-X
a	B-X
possible	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
WIF	B-X
domain	B-X
.	B-X
A	B-X
putative	B-X
binding	B-X
site	B-X
was	B-X
identified	B-X
inside	B-X
the	B-X
domain	B-X
.	B-X
WIF	B-X
domain	B-X
exhibited	B-X
the	B-X
highest	B-X
affinity	B-X
for	B-X
C16:0-C18:0	B-X
(	B-X
-22	B-X
kJ/mol	B-X
free	B-X
energy	B-X
of	B-X
binding	B-X
)	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
of	B-X
the	B-X
WIF	B-X
domain	B-X
as	B-X
a	B-X
palmitoyl	B-X
binding	B-X
domain	B-X
required	B-X
for	B-X
WIF-1	B-X
binding	B-X
to	B-X
palmitoylated	B-X
Wnt	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X

Detailed	O
interactions	O
between	O
Wnt	O
and	O
WIF	B-Protein
-	I-Protein
1	I-Protein
are	O
not	O
known	O
.	O

Computational	O
docking	O
was	O
employed	O
to	O
identify	O
a	O
possible	O
fatty	O
acid	O
binding	O
site	O
in	O
the	O
WIF	O
domain	O
.	O
<EOS>	B-X
WIF	B-X
domain	B-X
of	B-X
the	B-X
human	B-X
WIF	B-X
(	B-X
Wnt	B-X
inhibitory	B-X
factor	B-X
)	B-X
-1	B-X
is	B-X
sufficient	B-X
for	B-X
Wnt	B-X
binding	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X
Detailed	B-X
interactions	B-X
between	B-X
Wnt	B-X
and	B-X
WIF-1	B-X
are	B-X
not	B-X
known	B-X
.	B-X
Computational	B-X
docking	B-X
was	B-X
employed	B-X
to	B-X
identify	B-X
a	B-X
possible	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
WIF	B-X
domain	B-X
.	B-X
A	B-X
putative	B-X
binding	B-X
site	B-X
was	B-X
identified	B-X
inside	B-X
the	B-X
domain	B-X
.	B-X
WIF	B-X
domain	B-X
exhibited	B-X
the	B-X
highest	B-X
affinity	B-X
for	B-X
C16:0-C18:0	B-X
(	B-X
-22	B-X
kJ/mol	B-X
free	B-X
energy	B-X
of	B-X
binding	B-X
)	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
of	B-X
the	B-X
WIF	B-X
domain	B-X
as	B-X
a	B-X
palmitoyl	B-X
binding	B-X
domain	B-X
required	B-X
for	B-X
WIF-1	B-X
binding	B-X
to	B-X
palmitoylated	B-X
Wnt	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X

A	O
putative	O
binding	O
site	O
was	O
identified	O
inside	O
the	O
domain	O
.	O
<EOS>	B-X
The	B-X
helicase	B-X
domain	B-X
of	B-X
nonstructural	B-X
protein	B-X
3	B-X
(	B-X
NS3H	B-X
)	B-X
unwinds	B-X
the	B-X
double-stranded	B-X
RNA	B-X
replication	B-X
intermediate	B-X
in	B-X
an	B-X
ATP-dependent	B-X
manner	B-X
during	B-X
the	B-X
flavivirus	B-X
life	B-X
cycle	B-X
.	B-X
Using	B-X
modeling	B-X
,	B-X
we	B-X
explored	B-X
plausible	B-X
allosteric	B-X
mechanisms	B-X
by	B-X
which	B-X
ssDNA	B-X
inhibits	B-X
the	B-X
ATPase	B-X
via	B-X
nonspecific	B-X
binding	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
active	B-X
site	B-X
and	B-X
ATP	B-X
repositioning	B-X
.	B-X
One	B-X
intermediate	B-X
,	B-X
in	B-X
which	B-X
the	B-X
inorganic	B-X
phosphate	B-X
and	B-X
ADP	B-X
remained	B-X
trapped	B-X
inside	B-X
the	B-X
ATPase	B-X
site	B-X
after	B-X
hydrolysis	B-X
,	B-X
suggests	B-X
that	B-X
inorganic	B-X
phosphate	B-X
release	B-X
is	B-X
the	B-X
rate-limiting	B-X
step	B-X
.	B-X
Using	B-X
structure-guided	B-X
modeling	B-X
and	B-X
molecular	B-X
dynamics	B-X
simulation	B-X
,	B-X
we	B-X
identified	B-X
putative	B-X
RNA-binding	B-X
residues	B-X
and	B-X
observed	B-X
that	B-X
the	B-X
opening	B-X
and	B-X
closing	B-X
of	B-X
the	B-X
ATP-binding	B-X
site	B-X
modulates	B-X
RNA	B-X
affinity	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
conserved	B-X
RNA-binding	B-X
residues	B-X
revealed	B-X
that	B-X
the	B-X
allosteric	B-X
activation	B-X
of	B-X
ATPase	B-X
activity	B-X
is	B-X
primarily	B-X
communicated	B-X
via	B-X
an	B-X
arginine	B-X
residue	B-X
in	B-X
domain	B-X
1	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
characterized	B-X
conformational	B-X
changes	B-X
associated	B-X
with	B-X
modulating	B-X
RNA	B-X
affinity	B-X
and	B-X
mapped	B-X
allosteric	B-X
communication	B-X
between	B-X
RNA-binding	B-X
groove	B-X
and	B-X
ATPase	B-X
site	B-X
of	B-X
tick-borne	B-X
encephalitis	B-X
virus	B-X
helicase	B-X
.	B-X

WIF	O
domain	O
exhibited	O
the	O
highest	O
affinity	O
for	O
C16	O
:	O
0	O
-	O
C18	O
:	O
0	O
(	O
-	O
22	O
kJ	O
/	O
mol	O
free	O
energy	O
of	O
binding	O
)	O
fatty	O
acids	O
.	O

The	O
results	O
suggest	O
a	O
role	O
of	O
the	O
WIF	O
domain	O
as	O
a	O
palmitoyl	O
binding	O
domain	O
required	O
for	O
WIF	B-Protein
-	I-Protein
1	I-Protein
binding	O
to	O
palmitoylated	O
Wnt	O
and	O
signaling	O
inhibition	O
.	O
<EOS>	B-X
Palmitoylated	B-X
Wnt	B-X
proteins	B-X
comprise	B-X
a	B-X
conserved	B-X
family	B-X
of	B-X
secreted	B-X
signaling	B-X
molecules	B-X
associated	B-X
with	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
WIF	B-X
domain	B-X
of	B-X
the	B-X
human	B-X
WIF	B-X
(	B-X
Wnt	B-X
inhibitory	B-X
factor	B-X
)	B-X
-1	B-X
is	B-X
sufficient	B-X
for	B-X
Wnt	B-X
binding	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X
Detailed	B-X
interactions	B-X
between	B-X
Wnt	B-X
and	B-X
WIF-1	B-X
are	B-X
not	B-X
known	B-X
.	B-X
Computational	B-X
docking	B-X
was	B-X
employed	B-X
to	B-X
identify	B-X
a	B-X
possible	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
WIF	B-X
domain	B-X
.	B-X
A	B-X
putative	B-X
binding	B-X
site	B-X
was	B-X
identified	B-X
inside	B-X
the	B-X
domain	B-X
.	B-X
WIF	B-X
domain	B-X
exhibited	B-X
the	B-X
highest	B-X
affinity	B-X
for	B-X
C16:0-C18:0	B-X
(	B-X
-22	B-X
kJ/mol	B-X
free	B-X
energy	B-X
of	B-X
binding	B-X
)	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
of	B-X
the	B-X
WIF	B-X
domain	B-X
as	B-X
a	B-X
palmitoyl	B-X
binding	B-X
domain	B-X
required	B-X
for	B-X
WIF-1	B-X
binding	B-X
to	B-X
palmitoylated	B-X
Wnt	B-X
and	B-X
signaling	B-X
inhibition	B-X
.	B-X

Palmitoylation	O
and	O
ubiquitination	O
regulate	O
exit	O
of	O
the	O
Wnt	O
signaling	O
protein	O
LRP6	B-Protein
from	O
the	O
endoplasmic	O
reticulum	O
.	O
<EOS>	B-X
Canonical	B-X
Wnt	B-X
signaling	B-X
is	B-X
initiated	B-X
by	B-X
binding	B-X
of	B-X
Wnt	B-X
proteins	B-X
to	B-X
members	B-X
of	B-X
the	B-X
Frizzled	B-X
family	B-X
and	B-X
subsequent	B-X
complex	B-X
formation	B-X
with	B-X
lipoprotein	B-X
receptor-related	B-X
proteins	B-X
5/6	B-X
(	B-X
LRP5/6	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LRP6	B-X
is	B-X
palmitoylated	B-X
on	B-X
a	B-X
juxtamembranous	B-X
cysteine	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
exit	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
palmitoylation	B-X
serves	B-X
to	B-X
tilt	B-X
the	B-X
long	B-X
,	B-X
23-residue	B-X
transmembrane	B-X
domain	B-X
of	B-X
LRP6	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
plane	B-X
of	B-X
membrane	B-X
to	B-X
prevent	B-X
a	B-X
hydrophobic	B-X
mismatch	B-X
and	B-X
subsequent	B-X
recognition	B-X
by	B-X
the	B-X
ER	B-X
quality	B-X
control	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
model	B-X
,	B-X
a	B-X
palmitoylation-deficient	B-X
LRP6	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
from	B-X
ER	B-X
retention	B-X
by	B-X
deletion	B-X
of	B-X
two	B-X
to	B-X
four	B-X
residues	B-X
in	B-X
the	B-X
transmembrane	B-X
domain	B-X
.	B-X
Importantly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
palmitoylation-deficient	B-X
LRP6	B-X
was	B-X
retained	B-X
in	B-X
the	B-X
ER	B-X
by	B-X
a	B-X
completely	B-X
novel	B-X
monoubiquitination-dependent	B-X
ER	B-X
retention	B-X
mechanism	B-X
.	B-X
Mutation	B-X
of	B-X
a	B-X
specific	B-X
lysine	B-X
indeed	B-X
abolished	B-X
ubiquitination	B-X
of	B-X
palmitoylation-deficient	B-X
LRP6	B-X
and	B-X
led	B-X
to	B-X
a	B-X
rescue	B-X
from	B-X
ER	B-X
retention	B-X
.	B-X
Finally	B-X
,	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
we	B-X
found	B-X
that	B-X
interplay	B-X
between	B-X
palmitoylation	B-X
and	B-X
ubiquitination	B-X
was	B-X
necessary	B-X
for	B-X
efficient	B-X
Wnt	B-X
signaling	B-X
.	B-X

Canonical	O
Wnt	O
signaling	O
is	O
initiated	O
by	O
binding	O
of	O
Wnt	O
proteins	O
to	O
members	O
of	O
the	O
Frizzled	B-Protein
family	O
and	O
subsequent	O
complex	O
formation	O
with	O
lipoprotein	B-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
proteins	I-Protein
5	I-Protein
/	O
6	B-Protein
(	O
LRP5	B-Protein
/	O
6	B-Protein
)	O
.	O
<EOS>	B-X
Canonical	B-X
Wnt	B-X
signaling	B-X
is	B-X
initiated	B-X
by	B-X
binding	B-X
of	B-X
Wnt	B-X
proteins	B-X
to	B-X
members	B-X
of	B-X
the	B-X
Frizzled	B-X
family	B-X
and	B-X
subsequent	B-X
complex	B-X
formation	B-X
with	B-X
lipoprotein	B-X
receptor-related	B-X
proteins	B-X
5/6	B-X
(	B-X
LRP5/6	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LRP6	B-X
is	B-X
palmitoylated	B-X
on	B-X
a	B-X
juxtamembranous	B-X
cysteine	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
exit	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
palmitoylation	B-X
serves	B-X
to	B-X
tilt	B-X
the	B-X
long	B-X
,	B-X
23-residue	B-X
transmembrane	B-X
domain	B-X
of	B-X
LRP6	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
plane	B-X
of	B-X
membrane	B-X
to	B-X
prevent	B-X
a	B-X
hydrophobic	B-X
mismatch	B-X
and	B-X
subsequent	B-X
recognition	B-X
by	B-X
the	B-X
ER	B-X
quality	B-X
control	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
model	B-X
,	B-X
a	B-X
palmitoylation-deficient	B-X
LRP6	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
from	B-X
ER	B-X
retention	B-X
by	B-X
deletion	B-X
of	B-X
two	B-X
to	B-X
four	B-X
residues	B-X
in	B-X
the	B-X
transmembrane	B-X
domain	B-X
.	B-X
Importantly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
palmitoylation-deficient	B-X
LRP6	B-X
was	B-X
retained	B-X
in	B-X
the	B-X
ER	B-X
by	B-X
a	B-X
completely	B-X
novel	B-X
monoubiquitination-dependent	B-X
ER	B-X
retention	B-X
mechanism	B-X
.	B-X
Mutation	B-X
of	B-X
a	B-X
specific	B-X
lysine	B-X
indeed	B-X
abolished	B-X
ubiquitination	B-X
of	B-X
palmitoylation-deficient	B-X
LRP6	B-X
and	B-X
led	B-X
to	B-X
a	B-X
rescue	B-X
from	B-X
ER	B-X
retention	B-X
.	B-X
Finally	B-X
,	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
we	B-X
found	B-X
that	B-X
interplay	B-X
between	B-X
palmitoylation	B-X
and	B-X
ubiquitination	B-X
was	B-X
necessary	B-X
for	B-X
efficient	B-X
Wnt	B-X
signaling	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
LRP6	B-Protein
is	O
palmitoylated	O
on	O
a	O
juxtamembranous	O
cysteine	O
and	O
that	O
palmitoylation	O
is	O
required	O
for	O
exit	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LRP6	B-X
is	B-X
palmitoylated	B-X
on	B-X
a	B-X
juxtamembranous	B-X
cysteine	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
exit	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
palmitoylation	B-X
serves	B-X
to	B-X
tilt	B-X
the	B-X
long	B-X
,	B-X
23-residue	B-X
transmembrane	B-X
domain	B-X
of	B-X
LRP6	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
plane	B-X
of	B-X
membrane	B-X
to	B-X
prevent	B-X
a	B-X
hydrophobic	B-X
mismatch	B-X
and	B-X
subsequent	B-X
recognition	B-X
by	B-X
the	B-X
ER	B-X
quality	B-X
control	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
model	B-X
,	B-X
a	B-X
palmitoylation-deficient	B-X
LRP6	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
from	B-X
ER	B-X
retention	B-X
by	B-X
deletion	B-X
of	B-X
two	B-X
to	B-X
four	B-X
residues	B-X
in	B-X
the	B-X
transmembrane	B-X
domain	B-X
.	B-X
Importantly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
palmitoylation-deficient	B-X
LRP6	B-X
was	B-X
retained	B-X
in	B-X
the	B-X
ER	B-X
by	B-X
a	B-X
completely	B-X
novel	B-X
monoubiquitination-dependent	B-X
ER	B-X
retention	B-X
mechanism	B-X
.	B-X
Mutation	B-X
of	B-X
a	B-X
specific	B-X
lysine	B-X
indeed	B-X
abolished	B-X
ubiquitination	B-X
of	B-X
palmitoylation-deficient	B-X
LRP6	B-X
and	B-X
led	B-X
to	B-X
a	B-X
rescue	B-X
from	B-X
ER	B-X
retention	B-X
.	B-X
Finally	B-X
,	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
we	B-X
found	B-X
that	B-X
interplay	B-X
between	B-X
palmitoylation	B-X
and	B-X
ubiquitination	B-X
was	B-X
necessary	B-X
for	B-X
efficient	B-X
Wnt	B-X
signaling	B-X
.	B-X

We	O
propose	O
that	O
palmitoylation	O
serves	O
to	O
tilt	O
the	O
long	O
,	O
23	O
-	O
residue	O
transmembrane	O
domain	O
of	O
LRP6	B-Protein
with	O
respect	O
to	O
the	O
plane	O
of	O
membrane	O
to	O
prevent	O
a	O
hydrophobic	O
mismatch	O
and	O
subsequent	O
recognition	O
by	O
the	O
ER	O
quality	O
control	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
a	O
palmitoylation	O
-	O
deficient	O
LRP6	B-Protein
mutant	O
could	O
be	O
rescued	O
from	O
ER	O
retention	O
by	O
deletion	O
of	O
two	O
to	O
four	O
residues	O
in	O
the	O
transmembrane	O
domain	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
palmitoylation	O
-	O
deficient	O
LRP6	B-Protein
was	O
retained	O
in	O
the	O
ER	O
by	O
a	O
completely	O
novel	O
monoubiquitination	O
-	O
dependent	O
ER	O
retention	O
mechanism	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LRP6	B-X
is	B-X
palmitoylated	B-X
on	B-X
a	B-X
juxtamembranous	B-X
cysteine	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
exit	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
palmitoylation	B-X
serves	B-X
to	B-X
tilt	B-X
the	B-X
long	B-X
,	B-X
23-residue	B-X
transmembrane	B-X
domain	B-X
of	B-X
LRP6	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
plane	B-X
of	B-X
membrane	B-X
to	B-X
prevent	B-X
a	B-X
hydrophobic	B-X
mismatch	B-X
and	B-X
subsequent	B-X
recognition	B-X
by	B-X
the	B-X
ER	B-X
quality	B-X
control	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
model	B-X
,	B-X
a	B-X
palmitoylation-deficient	B-X
LRP6	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
from	B-X
ER	B-X
retention	B-X
by	B-X
deletion	B-X
of	B-X
two	B-X
to	B-X
four	B-X
residues	B-X
in	B-X
the	B-X
transmembrane	B-X
domain	B-X
.	B-X
Importantly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
palmitoylation-deficient	B-X
LRP6	B-X
was	B-X
retained	B-X
in	B-X
the	B-X
ER	B-X
by	B-X
a	B-X
completely	B-X
novel	B-X
monoubiquitination-dependent	B-X
ER	B-X
retention	B-X
mechanism	B-X
.	B-X
Mutation	B-X
of	B-X
a	B-X
specific	B-X
lysine	B-X
indeed	B-X
abolished	B-X
ubiquitination	B-X
of	B-X
palmitoylation-deficient	B-X
LRP6	B-X
and	B-X
led	B-X
to	B-X
a	B-X
rescue	B-X
from	B-X
ER	B-X
retention	B-X
.	B-X
Finally	B-X
,	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
we	B-X
found	B-X
that	B-X
interplay	B-X
between	B-X
palmitoylation	B-X
and	B-X
ubiquitination	B-X
was	B-X
necessary	B-X
for	B-X
efficient	B-X
Wnt	B-X
signaling	B-X
.	B-X

Mutation	O
of	O
a	O
specific	O
lysine	O
indeed	O
abolished	O
ubiquitination	O
of	O
palmitoylation	O
-	O
deficient	O
LRP6	B-Protein
and	O
led	O
to	O
a	O
rescue	O
from	O
ER	O
retention	O
.	O
<EOS>	B-X
Canonical	B-X
Wnt	B-X
signaling	B-X
is	B-X
initiated	B-X
by	B-X
binding	B-X
of	B-X
Wnt	B-X
proteins	B-X
to	B-X
members	B-X
of	B-X
the	B-X
Frizzled	B-X
family	B-X
and	B-X
subsequent	B-X
complex	B-X
formation	B-X
with	B-X
lipoprotein	B-X
receptor-related	B-X
proteins	B-X
5/6	B-X
(	B-X
LRP5/6	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LRP6	B-X
is	B-X
palmitoylated	B-X
on	B-X
a	B-X
juxtamembranous	B-X
cysteine	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
exit	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
palmitoylation	B-X
serves	B-X
to	B-X
tilt	B-X
the	B-X
long	B-X
,	B-X
23-residue	B-X
transmembrane	B-X
domain	B-X
of	B-X
LRP6	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
plane	B-X
of	B-X
membrane	B-X
to	B-X
prevent	B-X
a	B-X
hydrophobic	B-X
mismatch	B-X
and	B-X
subsequent	B-X
recognition	B-X
by	B-X
the	B-X
ER	B-X
quality	B-X
control	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
model	B-X
,	B-X
a	B-X
palmitoylation-deficient	B-X
LRP6	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
from	B-X
ER	B-X
retention	B-X
by	B-X
deletion	B-X
of	B-X
two	B-X
to	B-X
four	B-X
residues	B-X
in	B-X
the	B-X
transmembrane	B-X
domain	B-X
.	B-X
Importantly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
palmitoylation-deficient	B-X
LRP6	B-X
was	B-X
retained	B-X
in	B-X
the	B-X
ER	B-X
by	B-X
a	B-X
completely	B-X
novel	B-X
monoubiquitination-dependent	B-X
ER	B-X
retention	B-X
mechanism	B-X
.	B-X
Mutation	B-X
of	B-X
a	B-X
specific	B-X
lysine	B-X
indeed	B-X
abolished	B-X
ubiquitination	B-X
of	B-X
palmitoylation-deficient	B-X
LRP6	B-X
and	B-X
led	B-X
to	B-X
a	B-X
rescue	B-X
from	B-X
ER	B-X
retention	B-X
.	B-X
Finally	B-X
,	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
we	B-X
found	B-X
that	B-X
interplay	B-X
between	B-X
palmitoylation	B-X
and	B-X
ubiquitination	B-X
was	B-X
necessary	B-X
for	B-X
efficient	B-X
Wnt	B-X
signaling	B-X
.	B-X

Finally	O
,	O
at	O
the	O
cell	O
surface	O
,	O
we	O
found	O
that	O
interplay	O
between	O
palmitoylation	O
and	O
ubiquitination	O
was	O
necessary	O
for	O
efficient	O
Wnt	O
signaling	O
.	O
<EOS>	B-X
Canonical	B-X
Wnt	B-X
signaling	B-X
is	B-X
initiated	B-X
by	B-X
binding	B-X
of	B-X
Wnt	B-X
proteins	B-X
to	B-X
members	B-X
of	B-X
the	B-X
Frizzled	B-X
family	B-X
and	B-X
subsequent	B-X
complex	B-X
formation	B-X
with	B-X
lipoprotein	B-X
receptor-related	B-X
proteins	B-X
5/6	B-X
(	B-X
LRP5/6	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LRP6	B-X
is	B-X
palmitoylated	B-X
on	B-X
a	B-X
juxtamembranous	B-X
cysteine	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
exit	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
palmitoylation	B-X
serves	B-X
to	B-X
tilt	B-X
the	B-X
long	B-X
,	B-X
23-residue	B-X
transmembrane	B-X
domain	B-X
of	B-X
LRP6	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
plane	B-X
of	B-X
membrane	B-X
to	B-X
prevent	B-X
a	B-X
hydrophobic	B-X
mismatch	B-X
and	B-X
subsequent	B-X
recognition	B-X
by	B-X
the	B-X
ER	B-X
quality	B-X
control	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
model	B-X
,	B-X
a	B-X
palmitoylation-deficient	B-X
LRP6	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
from	B-X
ER	B-X
retention	B-X
by	B-X
deletion	B-X
of	B-X
two	B-X
to	B-X
four	B-X
residues	B-X
in	B-X
the	B-X
transmembrane	B-X
domain	B-X
.	B-X
Importantly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
palmitoylation-deficient	B-X
LRP6	B-X
was	B-X
retained	B-X
in	B-X
the	B-X
ER	B-X
by	B-X
a	B-X
completely	B-X
novel	B-X
monoubiquitination-dependent	B-X
ER	B-X
retention	B-X
mechanism	B-X
.	B-X
Mutation	B-X
of	B-X
a	B-X
specific	B-X
lysine	B-X
indeed	B-X
abolished	B-X
ubiquitination	B-X
of	B-X
palmitoylation-deficient	B-X
LRP6	B-X
and	B-X
led	B-X
to	B-X
a	B-X
rescue	B-X
from	B-X
ER	B-X
retention	B-X
.	B-X
Finally	B-X
,	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
we	B-X
found	B-X
that	B-X
interplay	B-X
between	B-X
palmitoylation	B-X
and	B-X
ubiquitination	B-X
was	B-X
necessary	B-X
for	B-X
efficient	B-X
Wnt	B-X
signaling	B-X
.	B-X

Quantification	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
-	O
modified	O
proteins	O
in	O
cerebrospinal	O
fluid	O
from	O
infants	O
and	O
children	O
after	O
traumatic	O
brain	O
injury	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Both	B-X
peak	B-X
and	B-X
mean	B-X
CSF	B-X
PAR-modified	B-X
proteins	B-X
were	B-X
increased	B-X
in	B-X
TBI	B-X
patients	B-X
versus	B-X
controls	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
Increases	B-X
in	B-X
peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
concentrations	B-X
were	B-X
independently	B-X
associated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
but	B-X
not	B-X
initial	B-X
Glasgow	B-X
Coma	B-X
Scale	B-X
score	B-X
,	B-X
Glasgow	B-X
outcome	B-X
score	B-X
,	B-X
or	B-X
mechanism	B-X
of	B-X
injury	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

Poly	O
-	O
ADP	O
-	O
ribosylation	O
(	O
PAR	O
)	O
of	O
proteins	O
by	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerases	O
(	O
PARP	O
)	O
occurs	O
after	O
experimental	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
and	O
modulates	O
neurologic	O
outcome	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
Both	B-X
peak	B-X
and	B-X
mean	B-X
CSF	B-X
PAR-modified	B-X
proteins	B-X
were	B-X
increased	B-X
in	B-X
TBI	B-X
patients	B-X
versus	B-X
controls	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
Increases	B-X
in	B-X
peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
concentrations	B-X
were	B-X
independently	B-X
associated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
but	B-X
not	B-X
initial	B-X
Glasgow	B-X
Coma	B-X
Scale	B-X
score	B-X
,	B-X
Glasgow	B-X
outcome	B-X
score	B-X
,	B-X
or	B-X
mechanism	B-X
of	B-X
injury	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

Several	O
promising	O
pharmacological	O
PARP	O
inhibitors	O
have	O
been	O
developed	O
for	O
use	O
in	O
humans	O
,	O
but	O
there	O
is	O
currently	O
no	O
clinically	O
relevant	O
means	O
of	O
monitoring	O
treatment	O
effects	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

We	O
therefore	O
used	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
to	O
measure	O
PAR	O
-	O
modified	O
proteins	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
Both	B-X
peak	B-X
and	B-X
mean	B-X
CSF	B-X
PAR-modified	B-X
proteins	B-X
were	B-X
increased	B-X
in	B-X
TBI	B-X
patients	B-X
versus	B-X
controls	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
Increases	B-X
in	B-X
peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
concentrations	B-X
were	B-X
independently	B-X
associated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
but	B-X
not	B-X
initial	B-X
Glasgow	B-X
Coma	B-X
Scale	B-X
score	B-X
,	B-X
Glasgow	B-X
outcome	B-X
score	B-X
,	B-X
or	B-X
mechanism	B-X
of	B-X
injury	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

Cerebrospinal	O
fluid	O
samples	O
from	O
17	O
pediatric	O
TBI	O
patients	O
and	O
15	O
controls	O
were	O
plated	O
overnight	O
and	O
then	O
incubated	O
with	O
polyclonal	O
antibody	O
against	O
PAR	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
Both	B-X
peak	B-X
and	B-X
mean	B-X
CSF	B-X
PAR-modified	B-X
proteins	B-X
were	B-X
increased	B-X
in	B-X
TBI	B-X
patients	B-X
versus	B-X
controls	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
Increases	B-X
in	B-X
peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
concentrations	B-X
were	B-X
independently	B-X
associated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
but	B-X
not	B-X
initial	B-X
Glasgow	B-X
Coma	B-X
Scale	B-X
score	B-X
,	B-X
Glasgow	B-X
outcome	B-X
score	B-X
,	B-X
or	B-X
mechanism	B-X
of	B-X
injury	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

Histone	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
PARP	O
substrate	O
,	O
was	O
incubated	O
with	O
active	O
PARP	O
,	O
NAD	O
,	O
and	O
nicked	O
DNA	O
,	O
and	O
served	O
as	O
the	O
standard	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

Both	O
peak	O
and	O
mean	O
CSF	O
PAR	O
-	O
modified	O
proteins	O
were	O
increased	O
in	O
TBI	O
patients	O
versus	O
controls	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
Both	B-X
peak	B-X
and	B-X
mean	B-X
CSF	B-X
PAR-modified	B-X
proteins	B-X
were	B-X
increased	B-X
in	B-X
TBI	B-X
patients	B-X
versus	B-X
controls	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
Increases	B-X
in	B-X
peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
concentrations	B-X
were	B-X
independently	B-X
associated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
but	B-X
not	B-X
initial	B-X
Glasgow	B-X
Coma	B-X
Scale	B-X
score	B-X
,	B-X
Glasgow	B-X
outcome	B-X
score	B-X
,	B-X
or	B-X
mechanism	B-X
of	B-X
injury	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

Peak	O
CSF	O
PAR	O
-	O
modified	O
protein	O
levels	O
occurred	O
on	O
day	O
1	O
and	O
levels	O
remained	O
increased	O
on	O
day	O
2	O
after	O
TBI	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
Both	B-X
peak	B-X
and	B-X
mean	B-X
CSF	B-X
PAR-modified	B-X
proteins	B-X
were	B-X
increased	B-X
in	B-X
TBI	B-X
patients	B-X
versus	B-X
controls	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
Increases	B-X
in	B-X
peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
concentrations	B-X
were	B-X
independently	B-X
associated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
but	B-X
not	B-X
initial	B-X
Glasgow	B-X
Coma	B-X
Scale	B-X
score	B-X
,	B-X
Glasgow	B-X
outcome	B-X
score	B-X
,	B-X
or	B-X
mechanism	B-X
of	B-X
injury	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

Increases	O
in	O
peak	O
CSF	O
PAR	O
-	O
modified	O
protein	O
concentrations	O
were	O
independently	O
associated	O
with	O
age	O
and	O
male	O
sex	O
,	O
but	O
not	O
initial	O
Glasgow	O
Coma	O
Scale	O
score	O
,	O
Glasgow	O
outcome	O
score	O
,	O
or	O
mechanism	O
of	O
injury	O
.	O
<EOS>	B-X
Different	B-X
classification	B-X
systems	B-X
exist	B-X
,	B-X
some	B-X
are	B-X
based	B-X
on	B-X
the	B-X
mechanism	B-X
of	B-X
injury	B-X
,	B-X
some	B-X
on	B-X
anatomic	B-X
patterns	B-X
and	B-X
some	B-X
are	B-X
focusing	B-X
on	B-X
the	B-X
resulting	B-X
instability	B-X
requiring	B-X
operative	B-X
fixation	B-X
.	B-X
The	B-X
optimal	B-X
treatment	B-X
strategy	B-X
,	B-X
however	B-X
,	B-X
should	B-X
keep	B-X
into	B-X
consideration	B-X
the	B-X
hemodynamic	B-X
status	B-X
,	B-X
the	B-X
anatomic	B-X
impairment	B-X
of	B-X
pelvic	B-X
ring	B-X
function	B-X
and	B-X
the	B-X
associated	B-X
injuries	B-X
.	B-X
The	B-X
management	B-X
of	B-X
pelvic	B-X
trauma	B-X
patients	B-X
aims	B-X
definitively	B-X
to	B-X
restore	B-X
the	B-X
homeostasis	B-X
and	B-X
the	B-X
normal	B-X
physiopathology	B-X
associated	B-X
to	B-X
the	B-X
mechanical	B-X
stability	B-X
of	B-X
the	B-X
pelvic	B-X
ring	B-X
.	B-X
Thus	B-X
the	B-X
management	B-X
of	B-X
pelvic	B-X
trauma	B-X
must	B-X
be	B-X
multidisciplinary	B-X
and	B-X
should	B-X
be	B-X
ultimately	B-X
based	B-X
on	B-X
the	B-X
physiology	B-X
of	B-X
the	B-X
patient	B-X
and	B-X
the	B-X
anatomy	B-X
of	B-X
the	B-X
injury	B-X
.	B-X
This	B-X
paper	B-X
presents	B-X
the	B-X
World	B-X
Society	B-X
of	B-X
Emergency	B-X
Surgery	B-X
(	B-X
WSES	B-X
)	B-X
classification	B-X
of	B-X
pelvic	B-X
trauma	B-X
and	B-X
the	B-X
management	B-X
Guidelines	B-X
.	B-X

The	O
increase	O
in	O
PAR	O
-	O
modified	O
proteins	O
in	O
CSF	O
after	O
TBI	O
may	O
be	O
because	O
of	O
increased	O
PARP	O
activation	O
,	O
decreased	O
PAR	O
degradation	O
,	O
or	O
both	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
Both	B-X
peak	B-X
and	B-X
mean	B-X
CSF	B-X
PAR-modified	B-X
proteins	B-X
were	B-X
increased	B-X
in	B-X
TBI	B-X
patients	B-X
versus	B-X
controls	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
Increases	B-X
in	B-X
peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
concentrations	B-X
were	B-X
independently	B-X
associated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
but	B-X
not	B-X
initial	B-X
Glasgow	B-X
Coma	B-X
Scale	B-X
score	B-X
,	B-X
Glasgow	B-X
outcome	B-X
score	B-X
,	B-X
or	B-X
mechanism	B-X
of	B-X
injury	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

As	O
PAR	O
-	O
modified	O
protein	O
concentration	O
correlated	O
with	O
age	O
and	O
male	O
sex	O
,	O
developmental	O
and	O
sex	O
-	O
dependent	O
roles	O
for	O
PARP	O
after	O
TBI	O
are	O
implicated	O
.	O
<EOS>	B-X
Poly-ADP-ribosylation	B-X
(	B-X
PAR	B-X
)	B-X
of	B-X
proteins	B-X
by	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerases	B-X
(	B-X
PARP	B-X
)	B-X
occurs	B-X
after	B-X
experimental	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
and	B-X
modulates	B-X
neurologic	B-X
outcome	B-X
.	B-X
Several	B-X
promising	B-X
pharmacological	B-X
PARP	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
use	B-X
in	B-X
humans	B-X
,	B-X
but	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
clinically	B-X
relevant	B-X
means	B-X
of	B-X
monitoring	B-X
treatment	B-X
effects	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Cerebrospinal	B-X
fluid	B-X
samples	B-X
from	B-X
17	B-X
pediatric	B-X
TBI	B-X
patients	B-X
and	B-X
15	B-X
controls	B-X
were	B-X
plated	B-X
overnight	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
polyclonal	B-X
antibody	B-X
against	B-X
PAR	B-X
.	B-X
Histone-1	B-X
,	B-X
a	B-X
PARP	B-X
substrate	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
active	B-X
PARP	B-X
,	B-X
NAD	B-X
,	B-X
and	B-X
nicked	B-X
DNA	B-X
,	B-X
and	B-X
served	B-X
as	B-X
the	B-X
standard	B-X
.	B-X
Both	B-X
peak	B-X
and	B-X
mean	B-X
CSF	B-X
PAR-modified	B-X
proteins	B-X
were	B-X
increased	B-X
in	B-X
TBI	B-X
patients	B-X
versus	B-X
controls	B-X
.	B-X
Peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
levels	B-X
occurred	B-X
on	B-X
day	B-X
1	B-X
and	B-X
levels	B-X
remained	B-X
increased	B-X
on	B-X
day	B-X
2	B-X
after	B-X
TBI	B-X
.	B-X
Increases	B-X
in	B-X
peak	B-X
CSF	B-X
PAR-modified	B-X
protein	B-X
concentrations	B-X
were	B-X
independently	B-X
associated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
but	B-X
not	B-X
initial	B-X
Glasgow	B-X
Coma	B-X
Scale	B-X
score	B-X
,	B-X
Glasgow	B-X
outcome	B-X
score	B-X
,	B-X
or	B-X
mechanism	B-X
of	B-X
injury	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
PAR-modified	B-X
proteins	B-X
in	B-X
CSF	B-X
after	B-X
TBI	B-X
may	B-X
be	B-X
because	B-X
of	B-X
increased	B-X
PARP	B-X
activation	B-X
,	B-X
decreased	B-X
PAR	B-X
degradation	B-X
,	B-X
or	B-X
both	B-X
.	B-X
As	B-X
PAR-modified	B-X
protein	B-X
concentration	B-X
correlated	B-X
with	B-X
age	B-X
and	B-X
male	B-X
sex	B-X
,	B-X
developmental	B-X
and	B-X
sex-dependent	B-X
roles	B-X
for	B-X
PARP	B-X
after	B-X
TBI	B-X
are	B-X
implicated	B-X
.	B-X

Genetic	O
analysis	O
of	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interactions	O
in	O
Arabidopsis	O
supports	O
a	O
role	O
for	O
CAND1	B-Protein
-	O
mediated	O
cycling	O
of	O
the	O
SCFTIR1	B-Protein
complex	O
.	O
<EOS>	B-X
Cullin-Associated	B-X
and	B-X
Neddylation-Dissociated	B-X
(	B-X
CAND1	B-X
)	B-X
modulates	B-X
SCF	B-X
function	B-X
through	B-X
its	B-X
interactions	B-X
with	B-X
the	B-X
CUL1	B-X
subunit	B-X
.	B-X
Although	B-X
biochemical	B-X
studies	B-X
with	B-X
human	B-X
CAND1	B-X
suggested	B-X
that	B-X
CAND1	B-X
plays	B-X
a	B-X
negative	B-X
regulatory	B-X
role	B-X
by	B-X
sequestering	B-X
CUL1	B-X
and	B-X
preventing	B-X
SCF	B-X
complex	B-X
assembly	B-X
,	B-X
genetic	B-X
studies	B-X
in	B-X
Arabidopsis	B-X
have	B-X
shown	B-X
that	B-X
cand1	B-X
mutants	B-X
exhibit	B-X
reduced	B-X
SCF	B-X
activity	B-X
,	B-X
demonstrating	B-X
that	B-X
CAND1	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
genetic	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
suggested	B-X
a	B-X
model	B-X
of	B-X
CAND1-mediated	B-X
cycles	B-X
of	B-X
SCF	B-X
complex	B-X
assembly	B-X
and	B-X
disassembly	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
the	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
of	B-X
the	B-X
Arabidopsis	B-X
auxin	B-X
response	B-X
pathway	B-X
,	B-X
we	B-X
test	B-X
the	B-X
SCF	B-X
cycling	B-X
model	B-X
with	B-X
Arabidopsis	B-X
mutant	B-X
derivatives	B-X
of	B-X
CAND1	B-X
and	B-X
CUL1	B-X
that	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
disruption	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
results	B-X
in	B-X
an	B-X
increased	B-X
abundance	B-X
of	B-X
assembled	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
stabilization	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
diminishes	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
abundance	B-X
.	B-X
The	B-X
fact	B-X
that	B-X
both	B-X
decreased	B-X
and	B-X
increased	B-X
CAND1-CUL1	B-X
interactions	B-X
result	B-X
in	B-X
reduced	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
activity	B-X
in	B-X
vivo	B-X
strongly	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
CAND1-mediated	B-X
cycling	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
.	B-X

SKP1	B-Protein
-	O
Cullin1	B-Protein
-	O
F	O
-	O
box	O
protein	O
(	O
SCF	O
)	O
ubiquitin	B-Protein
-	O
ligases	O
regulate	O
numerous	O
aspects	O
of	O
eukaryotic	O
growth	O
and	O
development	O
.	O
<EOS>	B-X
Neuronal	B-X
development	B-X
requires	B-X
proper	B-X
migration	B-X
,	B-X
polarization	B-X
and	B-X
establishment	B-X
of	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Growing	B-X
evidence	B-X
identifies	B-X
the	B-X
ubiquitin	B-X
proteasome	B-X
system	B-X
(	B-X
UPS	B-X
)	B-X
with	B-X
its	B-X
numerous	B-X
components	B-X
as	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
various	B-X
aspects	B-X
of	B-X
neuronal	B-X
development	B-X
.	B-X
F-box	B-X
proteins	B-X
are	B-X
interchangeable	B-X
subunits	B-X
of	B-X
the	B-X
Cullin-1	B-X
based	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
but	B-X
only	B-X
a	B-X
few	B-X
family	B-X
members	B-X
have	B-X
been	B-X
studied	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
centrosomal	B-X
E3	B-X
ligase	B-X
FBXO31-SCF	B-X
(	B-X
Skp1/Cullin-1/F-box	B-X
protein	B-X
)	B-X
regulates	B-X
neuronal	B-X
morphogenesis	B-X
and	B-X
axonal	B-X
identity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
identified	B-X
the	B-X
polarity	B-X
protein	B-X
Par6c	B-X
as	B-X
a	B-X
novel	B-X
interaction	B-X
partner	B-X
and	B-X
substrate	B-X
targeted	B-X
for	B-X
proteasomal	B-X
degradation	B-X
in	B-X
the	B-X
control	B-X
of	B-X
axon	B-X
but	B-X
not	B-X
dendrite	B-X
growth	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
ascribe	B-X
a	B-X
role	B-X
for	B-X
FBXO31	B-X
in	B-X
dendrite	B-X
growth	B-X
and	B-X
neuronal	B-X
migration	B-X
in	B-X
the	B-X
developing	B-X
cerebellar	B-X
cortex	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
uncovered	B-X
the	B-X
centrosomal	B-X
E3	B-X
ligase	B-X
FBXO31-SCF	B-X
as	B-X
a	B-X
novel	B-X
regulator	B-X
of	B-X
neuronal	B-X
development	B-X
.	B-X

Cullin	O
-	O
Associated	O
and	O
Neddylation	O
-	O
Dissociated	O
(	O
CAND1	B-Protein
)	O
modulates	O
SCF	O
function	O
through	O
its	O
interactions	O
with	O
the	O
CUL1	B-Protein
subunit	O
.	O
<EOS>	B-X
SKP1-Cullin1-F-box	B-X
protein	B-X
(	B-X
SCF	B-X
)	B-X
ubiquitin-ligases	B-X
regulate	B-X
numerous	B-X
aspects	B-X
of	B-X
eukaryotic	B-X
growth	B-X
and	B-X
development	B-X
.	B-X
Cullin-Associated	B-X
and	B-X
Neddylation-Dissociated	B-X
(	B-X
CAND1	B-X
)	B-X
modulates	B-X
SCF	B-X
function	B-X
through	B-X
its	B-X
interactions	B-X
with	B-X
the	B-X
CUL1	B-X
subunit	B-X
.	B-X
Although	B-X
biochemical	B-X
studies	B-X
with	B-X
human	B-X
CAND1	B-X
suggested	B-X
that	B-X
CAND1	B-X
plays	B-X
a	B-X
negative	B-X
regulatory	B-X
role	B-X
by	B-X
sequestering	B-X
CUL1	B-X
and	B-X
preventing	B-X
SCF	B-X
complex	B-X
assembly	B-X
,	B-X
genetic	B-X
studies	B-X
in	B-X
Arabidopsis	B-X
have	B-X
shown	B-X
that	B-X
cand1	B-X
mutants	B-X
exhibit	B-X
reduced	B-X
SCF	B-X
activity	B-X
,	B-X
demonstrating	B-X
that	B-X
CAND1	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
genetic	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
suggested	B-X
a	B-X
model	B-X
of	B-X
CAND1-mediated	B-X
cycles	B-X
of	B-X
SCF	B-X
complex	B-X
assembly	B-X
and	B-X
disassembly	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
the	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
of	B-X
the	B-X
Arabidopsis	B-X
auxin	B-X
response	B-X
pathway	B-X
,	B-X
we	B-X
test	B-X
the	B-X
SCF	B-X
cycling	B-X
model	B-X
with	B-X
Arabidopsis	B-X
mutant	B-X
derivatives	B-X
of	B-X
CAND1	B-X
and	B-X
CUL1	B-X
that	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
disruption	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
results	B-X
in	B-X
an	B-X
increased	B-X
abundance	B-X
of	B-X
assembled	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
stabilization	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
diminishes	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
abundance	B-X
.	B-X
The	B-X
fact	B-X
that	B-X
both	B-X
decreased	B-X
and	B-X
increased	B-X
CAND1-CUL1	B-X
interactions	B-X
result	B-X
in	B-X
reduced	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
activity	B-X
in	B-X
vivo	B-X
strongly	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
CAND1-mediated	B-X
cycling	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
.	B-X

Although	O
biochemical	O
studies	O
with	O
human	O
CAND1	B-Protein
suggested	O
that	O
CAND1	B-Protein
plays	O
a	O
negative	O
regulatory	O
role	O
by	O
sequestering	O
CUL1	B-Protein
and	O
preventing	O
SCF	O
complex	O
assembly	O
,	O
genetic	O
studies	O
in	O
Arabidopsis	O
have	O
shown	O
that	O
cand1	B-Protein
mutants	O
exhibit	O
reduced	O
SCF	O
activity	O
,	O
demonstrating	O
that	O
CAND1	B-Protein
is	O
required	O
for	O
optimal	O
SCF	O
function	O
in	O
vivo	O
.	O

Together	O
,	O
these	O
genetic	O
and	O
biochemical	O
studies	O
have	O
suggested	O
a	O
model	O
of	O
CAND1	B-Protein
-	O
mediated	O
cycles	O
of	O
SCF	O
complex	O
assembly	O
and	O
disassembly	O
.	O

Here	O
,	O
using	O
the	O
SCF	O
(	O
TIR1	B-Protein
)	O
complex	O
of	O
the	O
Arabidopsis	O
auxin	O
response	O
pathway	O
,	O
we	O
test	O
the	O
SCF	O
cycling	O
model	O
with	O
Arabidopsis	O
mutant	O
derivatives	O
of	O
CAND1	B-Protein
and	O
CUL1	B-Protein
that	O
have	O
opposing	O
effects	O
on	O
the	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interaction	O
.	O
<EOS>	B-X
SKP1-Cullin1-F-box	B-X
protein	B-X
(	B-X
SCF	B-X
)	B-X
ubiquitin-ligases	B-X
regulate	B-X
numerous	B-X
aspects	B-X
of	B-X
eukaryotic	B-X
growth	B-X
and	B-X
development	B-X
.	B-X
Cullin-Associated	B-X
and	B-X
Neddylation-Dissociated	B-X
(	B-X
CAND1	B-X
)	B-X
modulates	B-X
SCF	B-X
function	B-X
through	B-X
its	B-X
interactions	B-X
with	B-X
the	B-X
CUL1	B-X
subunit	B-X
.	B-X
Although	B-X
biochemical	B-X
studies	B-X
with	B-X
human	B-X
CAND1	B-X
suggested	B-X
that	B-X
CAND1	B-X
plays	B-X
a	B-X
negative	B-X
regulatory	B-X
role	B-X
by	B-X
sequestering	B-X
CUL1	B-X
and	B-X
preventing	B-X
SCF	B-X
complex	B-X
assembly	B-X
,	B-X
genetic	B-X
studies	B-X
in	B-X
Arabidopsis	B-X
have	B-X
shown	B-X
that	B-X
cand1	B-X
mutants	B-X
exhibit	B-X
reduced	B-X
SCF	B-X
activity	B-X
,	B-X
demonstrating	B-X
that	B-X
CAND1	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
genetic	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
suggested	B-X
a	B-X
model	B-X
of	B-X
CAND1-mediated	B-X
cycles	B-X
of	B-X
SCF	B-X
complex	B-X
assembly	B-X
and	B-X
disassembly	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
the	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
of	B-X
the	B-X
Arabidopsis	B-X
auxin	B-X
response	B-X
pathway	B-X
,	B-X
we	B-X
test	B-X
the	B-X
SCF	B-X
cycling	B-X
model	B-X
with	B-X
Arabidopsis	B-X
mutant	B-X
derivatives	B-X
of	B-X
CAND1	B-X
and	B-X
CUL1	B-X
that	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
disruption	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
results	B-X
in	B-X
an	B-X
increased	B-X
abundance	B-X
of	B-X
assembled	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
stabilization	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
diminishes	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
abundance	B-X
.	B-X
The	B-X
fact	B-X
that	B-X
both	B-X
decreased	B-X
and	B-X
increased	B-X
CAND1-CUL1	B-X
interactions	B-X
result	B-X
in	B-X
reduced	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
activity	B-X
in	B-X
vivo	B-X
strongly	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
CAND1-mediated	B-X
cycling	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
.	B-X

We	O
find	O
that	O
the	O
disruption	O
of	O
the	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interaction	O
results	O
in	O
an	O
increased	O
abundance	O
of	O
assembled	O
SCF	O
(	O
TIR1	B-Protein
)	O
complex	O
.	O

In	O
contrast	O
,	O
stabilization	O
of	O
the	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interaction	O
diminishes	O
SCF	O
(	O
TIR1	B-Protein
)	O
complex	O
abundance	O
.	O
<EOS>	B-X
SKP1-Cullin1-F-box	B-X
protein	B-X
(	B-X
SCF	B-X
)	B-X
ubiquitin-ligases	B-X
regulate	B-X
numerous	B-X
aspects	B-X
of	B-X
eukaryotic	B-X
growth	B-X
and	B-X
development	B-X
.	B-X
Cullin-Associated	B-X
and	B-X
Neddylation-Dissociated	B-X
(	B-X
CAND1	B-X
)	B-X
modulates	B-X
SCF	B-X
function	B-X
through	B-X
its	B-X
interactions	B-X
with	B-X
the	B-X
CUL1	B-X
subunit	B-X
.	B-X
Although	B-X
biochemical	B-X
studies	B-X
with	B-X
human	B-X
CAND1	B-X
suggested	B-X
that	B-X
CAND1	B-X
plays	B-X
a	B-X
negative	B-X
regulatory	B-X
role	B-X
by	B-X
sequestering	B-X
CUL1	B-X
and	B-X
preventing	B-X
SCF	B-X
complex	B-X
assembly	B-X
,	B-X
genetic	B-X
studies	B-X
in	B-X
Arabidopsis	B-X
have	B-X
shown	B-X
that	B-X
cand1	B-X
mutants	B-X
exhibit	B-X
reduced	B-X
SCF	B-X
activity	B-X
,	B-X
demonstrating	B-X
that	B-X
CAND1	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
genetic	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
suggested	B-X
a	B-X
model	B-X
of	B-X
CAND1-mediated	B-X
cycles	B-X
of	B-X
SCF	B-X
complex	B-X
assembly	B-X
and	B-X
disassembly	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
the	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
of	B-X
the	B-X
Arabidopsis	B-X
auxin	B-X
response	B-X
pathway	B-X
,	B-X
we	B-X
test	B-X
the	B-X
SCF	B-X
cycling	B-X
model	B-X
with	B-X
Arabidopsis	B-X
mutant	B-X
derivatives	B-X
of	B-X
CAND1	B-X
and	B-X
CUL1	B-X
that	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
disruption	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
results	B-X
in	B-X
an	B-X
increased	B-X
abundance	B-X
of	B-X
assembled	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
stabilization	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
diminishes	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
abundance	B-X
.	B-X
The	B-X
fact	B-X
that	B-X
both	B-X
decreased	B-X
and	B-X
increased	B-X
CAND1-CUL1	B-X
interactions	B-X
result	B-X
in	B-X
reduced	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
activity	B-X
in	B-X
vivo	B-X
strongly	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
CAND1-mediated	B-X
cycling	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
.	B-X

The	O
fact	O
that	O
both	O
decreased	O
and	O
increased	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interactions	O
result	O
in	O
reduced	O
SCF	O
(	O
TIR1	B-Protein
)	O
activity	O
in	O
vivo	O
strongly	O
supports	O
the	O
hypothesis	O
that	O
CAND1	B-Protein
-	O
mediated	O
cycling	O
is	O
required	O
for	O
optimal	O
SCF	O
function	O
.	O
<EOS>	B-X
SKP1-Cullin1-F-box	B-X
protein	B-X
(	B-X
SCF	B-X
)	B-X
ubiquitin-ligases	B-X
regulate	B-X
numerous	B-X
aspects	B-X
of	B-X
eukaryotic	B-X
growth	B-X
and	B-X
development	B-X
.	B-X
Cullin-Associated	B-X
and	B-X
Neddylation-Dissociated	B-X
(	B-X
CAND1	B-X
)	B-X
modulates	B-X
SCF	B-X
function	B-X
through	B-X
its	B-X
interactions	B-X
with	B-X
the	B-X
CUL1	B-X
subunit	B-X
.	B-X
Although	B-X
biochemical	B-X
studies	B-X
with	B-X
human	B-X
CAND1	B-X
suggested	B-X
that	B-X
CAND1	B-X
plays	B-X
a	B-X
negative	B-X
regulatory	B-X
role	B-X
by	B-X
sequestering	B-X
CUL1	B-X
and	B-X
preventing	B-X
SCF	B-X
complex	B-X
assembly	B-X
,	B-X
genetic	B-X
studies	B-X
in	B-X
Arabidopsis	B-X
have	B-X
shown	B-X
that	B-X
cand1	B-X
mutants	B-X
exhibit	B-X
reduced	B-X
SCF	B-X
activity	B-X
,	B-X
demonstrating	B-X
that	B-X
CAND1	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
genetic	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
suggested	B-X
a	B-X
model	B-X
of	B-X
CAND1-mediated	B-X
cycles	B-X
of	B-X
SCF	B-X
complex	B-X
assembly	B-X
and	B-X
disassembly	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
the	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
of	B-X
the	B-X
Arabidopsis	B-X
auxin	B-X
response	B-X
pathway	B-X
,	B-X
we	B-X
test	B-X
the	B-X
SCF	B-X
cycling	B-X
model	B-X
with	B-X
Arabidopsis	B-X
mutant	B-X
derivatives	B-X
of	B-X
CAND1	B-X
and	B-X
CUL1	B-X
that	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
disruption	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
results	B-X
in	B-X
an	B-X
increased	B-X
abundance	B-X
of	B-X
assembled	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
stabilization	B-X
of	B-X
the	B-X
CAND1-CUL1	B-X
interaction	B-X
diminishes	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
complex	B-X
abundance	B-X
.	B-X
The	B-X
fact	B-X
that	B-X
both	B-X
decreased	B-X
and	B-X
increased	B-X
CAND1-CUL1	B-X
interactions	B-X
result	B-X
in	B-X
reduced	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
activity	B-X
in	B-X
vivo	B-X
strongly	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
CAND1-mediated	B-X
cycling	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
SCF	B-X
function	B-X
.	B-X

Palmitoylation	O
and	O
membrane	O
interactions	O
of	O
the	O
neuroprotective	O
chaperone	O
cysteine	B-Protein
-	I-Protein
string	I-Protein
protein	I-Protein
.	O
<EOS>	B-X
Cysteine-string	B-X
protein	B-X
(	B-X
CSP	B-X
)	B-X
is	B-X
an	B-X
extensively	B-X
palmitoylated	B-X
DnaJ-family	B-X
chaperone	B-X
,	B-X
which	B-X
exerts	B-X
an	B-X
important	B-X
neuroprotective	B-X
function	B-X
.	B-X
Palmitoylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
intracellular	B-X
sorting	B-X
and	B-X
function	B-X
of	B-X
CSP	B-X
,	B-X
and	B-X
thus	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
how	B-X
this	B-X
essential	B-X
modification	B-X
of	B-X
CSP	B-X
is	B-X
regulated	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
DHHC	B-X
proteins	B-X
promote	B-X
stable	B-X
membrane	B-X
attachment	B-X
of	B-X
CSP	B-X
,	B-X
which	B-X
is	B-X
otherwise	B-X
cytosolic	B-X
.	B-X
An	B-X
inverse	B-X
correlation	B-X
was	B-X
identified	B-X
between	B-X
membrane	B-X
affinity	B-X
of	B-X
unpalmitoylated	B-X
CSP	B-X
mutants	B-X
and	B-X
subsequent	B-X
palmitoylation	B-X
:	B-X
mutants	B-X
with	B-X
an	B-X
increased	B-X
membrane	B-X
affinity	B-X
localize	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
are	B-X
physically	B-X
separated	B-X
from	B-X
the	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
.	B-X
Palmitoylation	B-X
of	B-X
an	B-X
ER-localized	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
by	B-X
brefeldin	B-X
A	B-X
treatment	B-X
,	B-X
which	B-X
promotes	B-X
the	B-X
mixing	B-X
of	B-X
ER	B-X
and	B-X
Golgi	B-X
membranes	B-X
.	B-X
Interestingly	B-X
though	B-X
,	B-X
the	B-X
palmitoylated	B-X
mutant	B-X
remained	B-X
at	B-X
the	B-X
ER	B-X
following	B-X
brefeldin	B-X
A	B-X
washout	B-X
and	B-X
did	B-X
not	B-X
traffic	B-X
to	B-X
more	B-X
distal	B-X
membrane	B-X
compartments	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
CSP	B-X
has	B-X
a	B-X
weak	B-X
membrane	B-X
affinity	B-X
that	B-X
allows	B-X
the	B-X
protein	B-X
to	B-X
locate	B-X
its	B-X
partner	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
directly	B-X
by	B-X
membrane	B-X
``	B-X
sampling	B-X
.	B-X
''	B-X
Mutations	B-X
that	B-X
enhance	B-X
membrane	B-X
association	B-X
prevent	B-X
sampling	B-X
and	B-X
lead	B-X
to	B-X
accumulation	B-X
of	B-X
CSP	B-X
on	B-X
cellular	B-X
membranes	B-X
such	B-X
as	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
coupling	B-X
of	B-X
CSP	B-X
palmitoylation	B-X
to	B-X
Golgi	B-X
membranes	B-X
may	B-X
thus	B-X
be	B-X
an	B-X
important	B-X
requirement	B-X
for	B-X
subsequent	B-X
sorting	B-X
.	B-X

Cysteine	B-Protein
-	I-Protein
string	I-Protein
protein	I-Protein
(	O
CSP	B-Protein
)	O
is	O
an	O
extensively	O
palmitoylated	O
DnaJ	B-Protein
-	O
family	O
chaperone	O
,	O
which	O
exerts	O
an	O
important	O
neuroprotective	O
function	O
.	O
<EOS>	B-X
Cysteine-string	B-X
protein	B-X
(	B-X
CSP	B-X
)	B-X
is	B-X
an	B-X
extensively	B-X
palmitoylated	B-X
DnaJ-family	B-X
chaperone	B-X
,	B-X
which	B-X
exerts	B-X
an	B-X
important	B-X
neuroprotective	B-X
function	B-X
.	B-X
Palmitoylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
intracellular	B-X
sorting	B-X
and	B-X
function	B-X
of	B-X
CSP	B-X
,	B-X
and	B-X
thus	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
how	B-X
this	B-X
essential	B-X
modification	B-X
of	B-X
CSP	B-X
is	B-X
regulated	B-X
.	B-X
Recent	B-X
work	B-X
identified	B-X
23	B-X
putative	B-X
palmitoyl	B-X
transferases	B-X
containing	B-X
a	B-X
conserved	B-X
DHHC	B-X
domain	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
here	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
of	B-X
CSP	B-X
is	B-X
enhanced	B-X
specifically	B-X
by	B-X
co-expression	B-X
of	B-X
the	B-X
Golgi-localized	B-X
palmitoyl	B-X
transferases	B-X
DHHC3	B-X
,	B-X
DHHC7	B-X
,	B-X
DHHC15	B-X
,	B-X
or	B-X
DHHC17	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
DHHC	B-X
proteins	B-X
promote	B-X
stable	B-X
membrane	B-X
attachment	B-X
of	B-X
CSP	B-X
,	B-X
which	B-X
is	B-X
otherwise	B-X
cytosolic	B-X
.	B-X
An	B-X
inverse	B-X
correlation	B-X
was	B-X
identified	B-X
between	B-X
membrane	B-X
affinity	B-X
of	B-X
unpalmitoylated	B-X
CSP	B-X
mutants	B-X
and	B-X
subsequent	B-X
palmitoylation	B-X
:	B-X
mutants	B-X
with	B-X
an	B-X
increased	B-X
membrane	B-X
affinity	B-X
localize	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
are	B-X
physically	B-X
separated	B-X
from	B-X
the	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
.	B-X
Interestingly	B-X
though	B-X
,	B-X
the	B-X
palmitoylated	B-X
mutant	B-X
remained	B-X
at	B-X
the	B-X
ER	B-X
following	B-X
brefeldin	B-X
A	B-X
washout	B-X
and	B-X
did	B-X
not	B-X
traffic	B-X
to	B-X
more	B-X
distal	B-X
membrane	B-X
compartments	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
CSP	B-X
has	B-X
a	B-X
weak	B-X
membrane	B-X
affinity	B-X
that	B-X
allows	B-X
the	B-X
protein	B-X
to	B-X
locate	B-X
its	B-X
partner	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
directly	B-X
by	B-X
membrane	B-X
``	B-X
sampling	B-X
.	B-X
''	B-X
Mutations	B-X
that	B-X
enhance	B-X
membrane	B-X
association	B-X
prevent	B-X
sampling	B-X
and	B-X
lead	B-X
to	B-X
accumulation	B-X
of	B-X
CSP	B-X
on	B-X
cellular	B-X
membranes	B-X
such	B-X
as	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
coupling	B-X
of	B-X
CSP	B-X
palmitoylation	B-X
to	B-X
Golgi	B-X
membranes	B-X
may	B-X
thus	B-X
be	B-X
an	B-X
important	B-X
requirement	B-X
for	B-X
subsequent	B-X
sorting	B-X
.	B-X

Palmitoylation	O
is	O
required	O
for	O
the	O
intracellular	O
sorting	O
and	O
function	O
of	O
CSP	B-Protein
,	O
and	O
thus	O
it	O
is	O
important	O
to	O
understand	O
how	O
this	O
essential	O
modification	O
of	O
CSP	B-Protein
is	O
regulated	O
.	O
<EOS>	B-X
Cysteine-string	B-X
protein	B-X
(	B-X
CSP	B-X
)	B-X
is	B-X
an	B-X
extensively	B-X
palmitoylated	B-X
DnaJ-family	B-X
chaperone	B-X
,	B-X
which	B-X
exerts	B-X
an	B-X
important	B-X
neuroprotective	B-X
function	B-X
.	B-X
Palmitoylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
intracellular	B-X
sorting	B-X
and	B-X
function	B-X
of	B-X
CSP	B-X
,	B-X
and	B-X
thus	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
how	B-X
this	B-X
essential	B-X
modification	B-X
of	B-X
CSP	B-X
is	B-X
regulated	B-X
.	B-X
Recent	B-X
work	B-X
identified	B-X
23	B-X
putative	B-X
palmitoyl	B-X
transferases	B-X
containing	B-X
a	B-X
conserved	B-X
DHHC	B-X
domain	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
here	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
of	B-X
CSP	B-X
is	B-X
enhanced	B-X
specifically	B-X
by	B-X
co-expression	B-X
of	B-X
the	B-X
Golgi-localized	B-X
palmitoyl	B-X
transferases	B-X
DHHC3	B-X
,	B-X
DHHC7	B-X
,	B-X
DHHC15	B-X
,	B-X
or	B-X
DHHC17	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
DHHC	B-X
proteins	B-X
promote	B-X
stable	B-X
membrane	B-X
attachment	B-X
of	B-X
CSP	B-X
,	B-X
which	B-X
is	B-X
otherwise	B-X
cytosolic	B-X
.	B-X
An	B-X
inverse	B-X
correlation	B-X
was	B-X
identified	B-X
between	B-X
membrane	B-X
affinity	B-X
of	B-X
unpalmitoylated	B-X
CSP	B-X
mutants	B-X
and	B-X
subsequent	B-X
palmitoylation	B-X
:	B-X
mutants	B-X
with	B-X
an	B-X
increased	B-X
membrane	B-X
affinity	B-X
localize	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
are	B-X
physically	B-X
separated	B-X
from	B-X
the	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
.	B-X
Palmitoylation	B-X
of	B-X
an	B-X
ER-localized	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
by	B-X
brefeldin	B-X
A	B-X
treatment	B-X
,	B-X
which	B-X
promotes	B-X
the	B-X
mixing	B-X
of	B-X
ER	B-X
and	B-X
Golgi	B-X
membranes	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
CSP	B-X
has	B-X
a	B-X
weak	B-X
membrane	B-X
affinity	B-X
that	B-X
allows	B-X
the	B-X
protein	B-X
to	B-X
locate	B-X
its	B-X
partner	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
directly	B-X
by	B-X
membrane	B-X
``	B-X
sampling	B-X
.	B-X
''	B-X
Mutations	B-X
that	B-X
enhance	B-X
membrane	B-X
association	B-X
prevent	B-X
sampling	B-X
and	B-X
lead	B-X
to	B-X
accumulation	B-X
of	B-X
CSP	B-X
on	B-X
cellular	B-X
membranes	B-X
such	B-X
as	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
coupling	B-X
of	B-X
CSP	B-X
palmitoylation	B-X
to	B-X
Golgi	B-X
membranes	B-X
may	B-X
thus	B-X
be	B-X
an	B-X
important	B-X
requirement	B-X
for	B-X
subsequent	B-X
sorting	B-X
.	B-X

Recent	O
work	O
identified	O
23	O
putative	O
palmitoyl	O
transferases	O
containing	O
a	O
conserved	O
DHHC	O
domain	O
in	O
mammalian	O
cells	O
,	O
and	O
here	O
we	O
show	O
that	O
palmitoylation	O
of	O
CSP	B-Protein
is	O
enhanced	O
specifically	O
by	O
co	O
-	O
expression	O
of	O
the	O
Golgi	O
-	O
localized	O
palmitoyl	O
transferases	O
DHHC3	B-Protein
,	O
DHHC7	B-Protein
,	O
DHHC15	B-Protein
,	O
or	O
DHHC17	B-Protein
.	O
<EOS>	B-X
Protein	B-X
lipid	B-X
modification	B-X
,	B-X
including	B-X
palmitoylation	B-X
,	B-X
myristoylation	B-X
,	B-X
and	B-X
farnesyation	B-X
,	B-X
constitutes	B-X
a	B-X
crucial	B-X
mechanism	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
protein	B-X
dynamic	B-X
interactions	B-X
with	B-X
membranes	B-X
.	B-X
Among	B-X
the	B-X
three	B-X
subunits	B-X
of	B-X
the	B-X
AMPK	B-X
heterotrimeric	B-X
complex	B-X
,	B-X
the	B-X
structural	B-X
subunit	B-X
AMPKβ	B-X
is	B-X
myristoylated	B-X
and	B-X
the	B-X
catalytic	B-X
subunit	B-X
AMPKα	B-X
is	B-X
palmitoylated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
characterization	B-X
of	B-X
AMPKα	B-X
palmitoylation	B-X
.	B-X
We	B-X
found	B-X
that	B-X
AMKPα	B-X
was	B-X
palmitoylated	B-X
at	B-X
Cys209	B-X
and	B-X
Cys543	B-X
,	B-X
and	B-X
this	B-X
was	B-X
required	B-X
for	B-X
AMPK	B-X
activation	B-X
and	B-X
subcellular	B-X
membrane	B-X
compartmentalization	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
regulation	B-X
of	B-X
AMPKα	B-X
palmitoylation	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
DHHC17	B-X
as	B-X
a	B-X
candidate	B-X
palmitoyltransferase	B-X
for	B-X
AMPKα	B-X
and	B-X
found	B-X
that	B-X
DHHC17	B-X
,	B-X
by	B-X
palmitoylating	B-X
AMPKα	B-X
,	B-X
modulated	B-X
AMPK	B-X
membrane	B-X
association	B-X
and	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
energy	B-X
stress	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
DHHC17	B-X
in	B-X
cell	B-X
function	B-X
,	B-X
we	B-X
generated	B-X
DHHC17	B-X
liver-specific	B-X
knockout	B-X
mice	B-X
and	B-X
found	B-X
that	B-X
inactivation	B-X
of	B-X
DHHC17	B-X
in	B-X
the	B-X
mouse	B-X
liver	B-X
impaired	B-X
AMPK	B-X
activation	B-X
and	B-X
hepatic	B-X
autophagy	B-X
and	B-X
caused	B-X
a	B-X
type	B-X
2	B-X
diabetes-like	B-X
syndrome	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
studies	B-X
demonstrate	B-X
that	B-X
AMPKα	B-X
palmitoylation	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
AMPK	B-X
activation	B-X
and	B-X
that	B-X
DHHC17	B-X
,	B-X
through	B-X
its	B-X
modulation	B-X
of	B-X
AMPK	B-X
signaling	B-X
,	B-X
constitutes	B-X
a	B-X
new	B-X
regulator	B-X
of	B-X
hepatic	B-X
metabolism	B-X
.	B-X

Indeed	O
,	O
these	O
DHHC	O
proteins	O
promote	O
stable	O
membrane	O
attachment	O
of	O
CSP	B-Protein
,	O
which	O
is	O
otherwise	O
cytosolic	O
.	O
<EOS>	B-X
Cysteine-string	B-X
protein	B-X
(	B-X
CSP	B-X
)	B-X
is	B-X
an	B-X
extensively	B-X
palmitoylated	B-X
DnaJ-family	B-X
chaperone	B-X
,	B-X
which	B-X
exerts	B-X
an	B-X
important	B-X
neuroprotective	B-X
function	B-X
.	B-X
Palmitoylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
intracellular	B-X
sorting	B-X
and	B-X
function	B-X
of	B-X
CSP	B-X
,	B-X
and	B-X
thus	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
how	B-X
this	B-X
essential	B-X
modification	B-X
of	B-X
CSP	B-X
is	B-X
regulated	B-X
.	B-X
Recent	B-X
work	B-X
identified	B-X
23	B-X
putative	B-X
palmitoyl	B-X
transferases	B-X
containing	B-X
a	B-X
conserved	B-X
DHHC	B-X
domain	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
here	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
of	B-X
CSP	B-X
is	B-X
enhanced	B-X
specifically	B-X
by	B-X
co-expression	B-X
of	B-X
the	B-X
Golgi-localized	B-X
palmitoyl	B-X
transferases	B-X
DHHC3	B-X
,	B-X
DHHC7	B-X
,	B-X
DHHC15	B-X
,	B-X
or	B-X
DHHC17	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
DHHC	B-X
proteins	B-X
promote	B-X
stable	B-X
membrane	B-X
attachment	B-X
of	B-X
CSP	B-X
,	B-X
which	B-X
is	B-X
otherwise	B-X
cytosolic	B-X
.	B-X
An	B-X
inverse	B-X
correlation	B-X
was	B-X
identified	B-X
between	B-X
membrane	B-X
affinity	B-X
of	B-X
unpalmitoylated	B-X
CSP	B-X
mutants	B-X
and	B-X
subsequent	B-X
palmitoylation	B-X
:	B-X
mutants	B-X
with	B-X
an	B-X
increased	B-X
membrane	B-X
affinity	B-X
localize	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
are	B-X
physically	B-X
separated	B-X
from	B-X
the	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
.	B-X
Palmitoylation	B-X
of	B-X
an	B-X
ER-localized	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
by	B-X
brefeldin	B-X
A	B-X
treatment	B-X
,	B-X
which	B-X
promotes	B-X
the	B-X
mixing	B-X
of	B-X
ER	B-X
and	B-X
Golgi	B-X
membranes	B-X
.	B-X
Interestingly	B-X
though	B-X
,	B-X
the	B-X
palmitoylated	B-X
mutant	B-X
remained	B-X
at	B-X
the	B-X
ER	B-X
following	B-X
brefeldin	B-X
A	B-X
washout	B-X
and	B-X
did	B-X
not	B-X
traffic	B-X
to	B-X
more	B-X
distal	B-X
membrane	B-X
compartments	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
CSP	B-X
has	B-X
a	B-X
weak	B-X
membrane	B-X
affinity	B-X
that	B-X
allows	B-X
the	B-X
protein	B-X
to	B-X
locate	B-X
its	B-X
partner	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
directly	B-X
by	B-X
membrane	B-X
``	B-X
sampling	B-X
.	B-X
''	B-X
Mutations	B-X
that	B-X
enhance	B-X
membrane	B-X
association	B-X
prevent	B-X
sampling	B-X
and	B-X
lead	B-X
to	B-X
accumulation	B-X
of	B-X
CSP	B-X
on	B-X
cellular	B-X
membranes	B-X
such	B-X
as	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
coupling	B-X
of	B-X
CSP	B-X
palmitoylation	B-X
to	B-X
Golgi	B-X
membranes	B-X
may	B-X
thus	B-X
be	B-X
an	B-X
important	B-X
requirement	B-X
for	B-X
subsequent	B-X
sorting	B-X
.	B-X

An	O
inverse	O
correlation	O
was	O
identified	O
between	O
membrane	O
affinity	O
of	O
unpalmitoylated	O
CSP	B-Protein
mutants	O
and	O
subsequent	O
palmitoylation	O
:	O
mutants	O
with	O
an	O
increased	O
membrane	O
affinity	O
localize	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
are	O
physically	O
separated	O
from	O
the	O
Golgi	O
-	O
localized	O
DHHC	O
proteins	O
.	O

Palmitoylation	O
of	O
an	O
ER	O
-	O
localized	O
mutant	O
could	O
be	O
rescued	O
by	O
brefeldin	O
A	O
treatment	O
,	O
which	O
promotes	O
the	O
mixing	O
of	O
ER	O
and	O
Golgi	O
membranes	O
.	O
<EOS>	B-X
Palmitoylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
intracellular	B-X
sorting	B-X
and	B-X
function	B-X
of	B-X
CSP	B-X
,	B-X
and	B-X
thus	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
how	B-X
this	B-X
essential	B-X
modification	B-X
of	B-X
CSP	B-X
is	B-X
regulated	B-X
.	B-X
Recent	B-X
work	B-X
identified	B-X
23	B-X
putative	B-X
palmitoyl	B-X
transferases	B-X
containing	B-X
a	B-X
conserved	B-X
DHHC	B-X
domain	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
here	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
of	B-X
CSP	B-X
is	B-X
enhanced	B-X
specifically	B-X
by	B-X
co-expression	B-X
of	B-X
the	B-X
Golgi-localized	B-X
palmitoyl	B-X
transferases	B-X
DHHC3	B-X
,	B-X
DHHC7	B-X
,	B-X
DHHC15	B-X
,	B-X
or	B-X
DHHC17	B-X
.	B-X
An	B-X
inverse	B-X
correlation	B-X
was	B-X
identified	B-X
between	B-X
membrane	B-X
affinity	B-X
of	B-X
unpalmitoylated	B-X
CSP	B-X
mutants	B-X
and	B-X
subsequent	B-X
palmitoylation	B-X
:	B-X
mutants	B-X
with	B-X
an	B-X
increased	B-X
membrane	B-X
affinity	B-X
localize	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
are	B-X
physically	B-X
separated	B-X
from	B-X
the	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
.	B-X
Palmitoylation	B-X
of	B-X
an	B-X
ER-localized	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
by	B-X
brefeldin	B-X
A	B-X
treatment	B-X
,	B-X
which	B-X
promotes	B-X
the	B-X
mixing	B-X
of	B-X
ER	B-X
and	B-X
Golgi	B-X
membranes	B-X
.	B-X
Interestingly	B-X
though	B-X
,	B-X
the	B-X
palmitoylated	B-X
mutant	B-X
remained	B-X
at	B-X
the	B-X
ER	B-X
following	B-X
brefeldin	B-X
A	B-X
washout	B-X
and	B-X
did	B-X
not	B-X
traffic	B-X
to	B-X
more	B-X
distal	B-X
membrane	B-X
compartments	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
CSP	B-X
has	B-X
a	B-X
weak	B-X
membrane	B-X
affinity	B-X
that	B-X
allows	B-X
the	B-X
protein	B-X
to	B-X
locate	B-X
its	B-X
partner	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
directly	B-X
by	B-X
membrane	B-X
``	B-X
sampling	B-X
.	B-X
''	B-X
Mutations	B-X
that	B-X
enhance	B-X
membrane	B-X
association	B-X
prevent	B-X
sampling	B-X
and	B-X
lead	B-X
to	B-X
accumulation	B-X
of	B-X
CSP	B-X
on	B-X
cellular	B-X
membranes	B-X
such	B-X
as	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
coupling	B-X
of	B-X
CSP	B-X
palmitoylation	B-X
to	B-X
Golgi	B-X
membranes	B-X
may	B-X
thus	B-X
be	B-X
an	B-X
important	B-X
requirement	B-X
for	B-X
subsequent	B-X
sorting	B-X
.	B-X

Interestingly	O
though	O
,	O
the	O
palmitoylated	O
mutant	O
remained	O
at	O
the	O
ER	O
following	O
brefeldin	O
A	O
washout	O
and	O
did	O
not	O
traffic	O
to	O
more	O
distal	O
membrane	O
compartments	O
.	O

We	O
propose	O
that	O
CSP	B-Protein
has	O
a	O
weak	O
membrane	O
affinity	O
that	O
allows	O
the	O
protein	O
to	O
locate	O
its	O
partner	O
Golgi	O
-	O
localized	O
DHHC	O
proteins	O
directly	O
by	O
membrane	O
"	O
sampling	O
.	O
"	O
Mutations	O
that	O
enhance	O
membrane	O
association	O
prevent	O
sampling	O
and	O
lead	O
to	O
accumulation	O
of	O
CSP	B-Protein
on	O
cellular	O
membranes	O
such	O
as	O
the	O
ER	O
.	O

The	O
coupling	O
of	O
CSP	B-Protein
palmitoylation	O
to	O
Golgi	O
membranes	O
may	O
thus	O
be	O
an	O
important	O
requirement	O
for	O
subsequent	O
sorting	O
.	O
<EOS>	B-X
Cysteine-string	B-X
protein	B-X
(	B-X
CSP	B-X
)	B-X
is	B-X
an	B-X
extensively	B-X
palmitoylated	B-X
DnaJ-family	B-X
chaperone	B-X
,	B-X
which	B-X
exerts	B-X
an	B-X
important	B-X
neuroprotective	B-X
function	B-X
.	B-X
Palmitoylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
intracellular	B-X
sorting	B-X
and	B-X
function	B-X
of	B-X
CSP	B-X
,	B-X
and	B-X
thus	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
how	B-X
this	B-X
essential	B-X
modification	B-X
of	B-X
CSP	B-X
is	B-X
regulated	B-X
.	B-X
Recent	B-X
work	B-X
identified	B-X
23	B-X
putative	B-X
palmitoyl	B-X
transferases	B-X
containing	B-X
a	B-X
conserved	B-X
DHHC	B-X
domain	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
here	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
of	B-X
CSP	B-X
is	B-X
enhanced	B-X
specifically	B-X
by	B-X
co-expression	B-X
of	B-X
the	B-X
Golgi-localized	B-X
palmitoyl	B-X
transferases	B-X
DHHC3	B-X
,	B-X
DHHC7	B-X
,	B-X
DHHC15	B-X
,	B-X
or	B-X
DHHC17	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
DHHC	B-X
proteins	B-X
promote	B-X
stable	B-X
membrane	B-X
attachment	B-X
of	B-X
CSP	B-X
,	B-X
which	B-X
is	B-X
otherwise	B-X
cytosolic	B-X
.	B-X
An	B-X
inverse	B-X
correlation	B-X
was	B-X
identified	B-X
between	B-X
membrane	B-X
affinity	B-X
of	B-X
unpalmitoylated	B-X
CSP	B-X
mutants	B-X
and	B-X
subsequent	B-X
palmitoylation	B-X
:	B-X
mutants	B-X
with	B-X
an	B-X
increased	B-X
membrane	B-X
affinity	B-X
localize	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
are	B-X
physically	B-X
separated	B-X
from	B-X
the	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
.	B-X
Palmitoylation	B-X
of	B-X
an	B-X
ER-localized	B-X
mutant	B-X
could	B-X
be	B-X
rescued	B-X
by	B-X
brefeldin	B-X
A	B-X
treatment	B-X
,	B-X
which	B-X
promotes	B-X
the	B-X
mixing	B-X
of	B-X
ER	B-X
and	B-X
Golgi	B-X
membranes	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
CSP	B-X
has	B-X
a	B-X
weak	B-X
membrane	B-X
affinity	B-X
that	B-X
allows	B-X
the	B-X
protein	B-X
to	B-X
locate	B-X
its	B-X
partner	B-X
Golgi-localized	B-X
DHHC	B-X
proteins	B-X
directly	B-X
by	B-X
membrane	B-X
``	B-X
sampling	B-X
.	B-X
''	B-X
Mutations	B-X
that	B-X
enhance	B-X
membrane	B-X
association	B-X
prevent	B-X
sampling	B-X
and	B-X
lead	B-X
to	B-X
accumulation	B-X
of	B-X
CSP	B-X
on	B-X
cellular	B-X
membranes	B-X
such	B-X
as	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
coupling	B-X
of	B-X
CSP	B-X
palmitoylation	B-X
to	B-X
Golgi	B-X
membranes	B-X
may	B-X
thus	B-X
be	B-X
an	B-X
important	B-X
requirement	B-X
for	B-X
subsequent	B-X
sorting	B-X
.	B-X

The	O
HOOK	O
-	O
domain	O
between	O
the	O
SH3	O
and	O
the	O
GK	O
domains	O
of	O
Cavbeta	O
subunits	O
contains	O
key	O
determinants	O
controlling	O
calcium	O
channel	O
inactivation	O
.	O

Ca	O
(	O
v	O
)	O
beta	O
subunits	O
of	O
voltage	O
-	O
gated	O
calcium	O
channels	O
contain	O
two	O
conserved	O
domains	O
,	O
a	O
src	O
-	O
homology	O
-	O
3	O
(	O
SH3	O
)	O
-	O
domain	O
and	O
a	O
guanylate	O
kinase	O
-	O
like	O
(	O
GK	O
)	O
-	O
domain	O
.	O

The	O
SH3	O
-	O
domain	O
is	O
split	O
,	O
with	O
its	O
final	O
(	O
fifth	O
)	O
beta	O
-	O
strand	O
separated	O
from	O
the	O
rest	O
of	O
the	O
domain	O
by	O
an	O
intervening	O
sequence	O
termed	O
the	O
HOOK	O
-	O
domain	O
,	O
whose	O
sequence	O
varies	O
between	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
.	O
<EOS>	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
of	B-X
voltage-gated	B-X
calcium	B-X
channels	B-X
contain	B-X
two	B-X
conserved	B-X
domains	B-X
,	B-X
a	B-X
src-homology-3	B-X
(	B-X
SH3	B-X
)	B-X
-domain	B-X
and	B-X
a	B-X
guanylate	B-X
kinase-like	B-X
(	B-X
GK	B-X
)	B-X
-domain	B-X
.	B-X
The	B-X
SH3-domain	B-X
is	B-X
split	B-X
,	B-X
with	B-X
its	B-X
final	B-X
(	B-X
fifth	B-X
)	B-X
beta-strand	B-X
separated	B-X
from	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
domain	B-X
by	B-X
an	B-X
intervening	B-X
sequence	B-X
termed	B-X
the	B-X
HOOK-domain	B-X
,	B-X
whose	B-X
sequence	B-X
varies	B-X
between	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
been	B-X
guided	B-X
by	B-X
the	B-X
recent	B-X
structural	B-X
studies	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
design	B-X
of	B-X
specific	B-X
truncated	B-X
constructs	B-X
,	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
investigating	B-X
the	B-X
role	B-X
of	B-X
the	B-X
HOOK-domain	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
inactivation	B-X
of	B-X
N-type	B-X
calcium	B-X
channels	B-X
.	B-X
We	B-X
have	B-X
coexpressed	B-X
the	B-X
beta	B-X
subunit	B-X
constructs	B-X
with	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.2	B-X
and	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
delta-2	B-X
,	B-X
using	B-X
the	B-X
N-terminally	B-X
palmitoylated	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
subunit	B-X
,	B-X
because	B-X
it	B-X
supports	B-X
very	B-X
little	B-X
voltage-dependent	B-X
inactivation	B-X
,	B-X
and	B-X
made	B-X
comparisons	B-X
with	B-X
beta	B-X
(	B-X
1b	B-X
)	B-X
domains	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
variable	B-X
region	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
HOOK-domain	B-X
resulted	B-X
in	B-X
currents	B-X
with	B-X
a	B-X
rapidly	B-X
inactivating	B-X
component	B-X
,	B-X
and	B-X
additional	B-X
mutation	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
palmitoylation	B-X
motif	B-X
further	B-X
enhanced	B-X
inactivation	B-X
.	B-X
The	B-X
isolated	B-X
GK-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
alone	B-X
enhanced	B-X
current	B-X
amplitude	B-X
,	B-X
but	B-X
the	B-X
currents	B-X
were	B-X
rapidly	B-X
and	B-X
completely	B-X
inactivating	B-X
.	B-X
When	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
-GK-domain	B-X
construct	B-X
was	B-X
extended	B-X
proximally	B-X
,	B-X
by	B-X
including	B-X
the	B-X
HOOK-domain	B-X
and	B-X
the	B-X
epsilon-strand	B-X
of	B-X
the	B-X
SH3-domain	B-X
,	B-X
inactivation	B-X
was	B-X
about	B-X
four-fold	B-X
slower	B-X
than	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
HOOK	B-X
domain	B-X
.	B-X
When	B-X
the	B-X
SH3-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
truncated	B-X
prior	B-X
to	B-X
the	B-X
HOOK-domain	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
,	B-X
all	B-X
the	B-X
properties	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
were	B-X
restored	B-X
,	B-X
in	B-X
terms	B-X
of	B-X
loss	B-X
of	B-X
inactivation	B-X
.	B-X
Furthermore	B-X
,	B-X
removal	B-X
of	B-X
the	B-X
HOOK	B-X
sequence	B-X
from	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-beta	B-X
(	B-X
2a	B-X
)	B-X
construct	B-X
increased	B-X
inactivation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
HOOK	B-X
domain	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
inactivation	B-X
.	B-X

Here	O
we	O
have	O
been	O
guided	O
by	O
the	O
recent	O
structural	O
studies	O
of	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
in	O
the	O
design	O
of	O
specific	O
truncated	O
constructs	O
,	O
with	O
the	O
goal	O
of	O
investigating	O
the	O
role	O
of	O
the	O
HOOK	O
-	O
domain	O
of	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
in	O
the	O
modulation	O
of	O
inactivation	O
of	O
N	O
-	O
type	O
calcium	O
channels	O
.	O

We	O
have	O
coexpressed	O
the	O
beta	O
subunit	O
constructs	O
with	O
Ca	B-Protein
(	I-Protein
v	I-Protein
)	I-Protein
2	I-Protein
.	I-Protein
2	I-Protein
and	O
alpha	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
delta	B-Protein
-	I-Protein
2	I-Protein
,	O
using	O
the	O
N	O
-	O
terminally	O
palmitoylated	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
subunit	O
,	O
because	O
it	O
supports	O
very	O
little	O
voltage	O
-	O
dependent	O
inactivation	O
,	O
and	O
made	O
comparisons	O
with	O
beta	B-Protein
(	I-Protein
1b	I-Protein
)	I-Protein
domains	O
.	O

Deletion	O
of	O
the	O
variable	O
region	O
of	O
the	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
HOOK	O
-	O
domain	O
resulted	O
in	O
currents	O
with	O
a	O
rapidly	O
inactivating	O
component	O
,	O
and	O
additional	O
mutation	O
of	O
the	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
palmitoylation	O
motif	O
further	O
enhanced	O
inactivation	O
.	O
<EOS>	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
of	B-X
voltage-gated	B-X
calcium	B-X
channels	B-X
contain	B-X
two	B-X
conserved	B-X
domains	B-X
,	B-X
a	B-X
src-homology-3	B-X
(	B-X
SH3	B-X
)	B-X
-domain	B-X
and	B-X
a	B-X
guanylate	B-X
kinase-like	B-X
(	B-X
GK	B-X
)	B-X
-domain	B-X
.	B-X
The	B-X
SH3-domain	B-X
is	B-X
split	B-X
,	B-X
with	B-X
its	B-X
final	B-X
(	B-X
fifth	B-X
)	B-X
beta-strand	B-X
separated	B-X
from	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
domain	B-X
by	B-X
an	B-X
intervening	B-X
sequence	B-X
termed	B-X
the	B-X
HOOK-domain	B-X
,	B-X
whose	B-X
sequence	B-X
varies	B-X
between	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
been	B-X
guided	B-X
by	B-X
the	B-X
recent	B-X
structural	B-X
studies	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
design	B-X
of	B-X
specific	B-X
truncated	B-X
constructs	B-X
,	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
investigating	B-X
the	B-X
role	B-X
of	B-X
the	B-X
HOOK-domain	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
inactivation	B-X
of	B-X
N-type	B-X
calcium	B-X
channels	B-X
.	B-X
We	B-X
have	B-X
coexpressed	B-X
the	B-X
beta	B-X
subunit	B-X
constructs	B-X
with	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.2	B-X
and	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
delta-2	B-X
,	B-X
using	B-X
the	B-X
N-terminally	B-X
palmitoylated	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
subunit	B-X
,	B-X
because	B-X
it	B-X
supports	B-X
very	B-X
little	B-X
voltage-dependent	B-X
inactivation	B-X
,	B-X
and	B-X
made	B-X
comparisons	B-X
with	B-X
beta	B-X
(	B-X
1b	B-X
)	B-X
domains	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
variable	B-X
region	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
HOOK-domain	B-X
resulted	B-X
in	B-X
currents	B-X
with	B-X
a	B-X
rapidly	B-X
inactivating	B-X
component	B-X
,	B-X
and	B-X
additional	B-X
mutation	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
palmitoylation	B-X
motif	B-X
further	B-X
enhanced	B-X
inactivation	B-X
.	B-X
The	B-X
isolated	B-X
GK-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
alone	B-X
enhanced	B-X
current	B-X
amplitude	B-X
,	B-X
but	B-X
the	B-X
currents	B-X
were	B-X
rapidly	B-X
and	B-X
completely	B-X
inactivating	B-X
.	B-X
When	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
-GK-domain	B-X
construct	B-X
was	B-X
extended	B-X
proximally	B-X
,	B-X
by	B-X
including	B-X
the	B-X
HOOK-domain	B-X
and	B-X
the	B-X
epsilon-strand	B-X
of	B-X
the	B-X
SH3-domain	B-X
,	B-X
inactivation	B-X
was	B-X
about	B-X
four-fold	B-X
slower	B-X
than	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
HOOK	B-X
domain	B-X
.	B-X
When	B-X
the	B-X
SH3-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
truncated	B-X
prior	B-X
to	B-X
the	B-X
HOOK-domain	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
,	B-X
all	B-X
the	B-X
properties	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
were	B-X
restored	B-X
,	B-X
in	B-X
terms	B-X
of	B-X
loss	B-X
of	B-X
inactivation	B-X
.	B-X
Furthermore	B-X
,	B-X
removal	B-X
of	B-X
the	B-X
HOOK	B-X
sequence	B-X
from	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-beta	B-X
(	B-X
2a	B-X
)	B-X
construct	B-X
increased	B-X
inactivation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
HOOK	B-X
domain	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
inactivation	B-X
.	B-X

The	O
isolated	O
GK	O
-	O
domain	O
of	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
alone	O
enhanced	O
current	O
amplitude	O
,	O
but	O
the	O
currents	O
were	O
rapidly	O
and	O
completely	O
inactivating	O
.	O
<EOS>	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
of	B-X
voltage-gated	B-X
calcium	B-X
channels	B-X
contain	B-X
two	B-X
conserved	B-X
domains	B-X
,	B-X
a	B-X
src-homology-3	B-X
(	B-X
SH3	B-X
)	B-X
-domain	B-X
and	B-X
a	B-X
guanylate	B-X
kinase-like	B-X
(	B-X
GK	B-X
)	B-X
-domain	B-X
.	B-X
The	B-X
SH3-domain	B-X
is	B-X
split	B-X
,	B-X
with	B-X
its	B-X
final	B-X
(	B-X
fifth	B-X
)	B-X
beta-strand	B-X
separated	B-X
from	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
domain	B-X
by	B-X
an	B-X
intervening	B-X
sequence	B-X
termed	B-X
the	B-X
HOOK-domain	B-X
,	B-X
whose	B-X
sequence	B-X
varies	B-X
between	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
been	B-X
guided	B-X
by	B-X
the	B-X
recent	B-X
structural	B-X
studies	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
design	B-X
of	B-X
specific	B-X
truncated	B-X
constructs	B-X
,	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
investigating	B-X
the	B-X
role	B-X
of	B-X
the	B-X
HOOK-domain	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
inactivation	B-X
of	B-X
N-type	B-X
calcium	B-X
channels	B-X
.	B-X
We	B-X
have	B-X
coexpressed	B-X
the	B-X
beta	B-X
subunit	B-X
constructs	B-X
with	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.2	B-X
and	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
delta-2	B-X
,	B-X
using	B-X
the	B-X
N-terminally	B-X
palmitoylated	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
subunit	B-X
,	B-X
because	B-X
it	B-X
supports	B-X
very	B-X
little	B-X
voltage-dependent	B-X
inactivation	B-X
,	B-X
and	B-X
made	B-X
comparisons	B-X
with	B-X
beta	B-X
(	B-X
1b	B-X
)	B-X
domains	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
variable	B-X
region	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
HOOK-domain	B-X
resulted	B-X
in	B-X
currents	B-X
with	B-X
a	B-X
rapidly	B-X
inactivating	B-X
component	B-X
,	B-X
and	B-X
additional	B-X
mutation	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
palmitoylation	B-X
motif	B-X
further	B-X
enhanced	B-X
inactivation	B-X
.	B-X
The	B-X
isolated	B-X
GK-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
alone	B-X
enhanced	B-X
current	B-X
amplitude	B-X
,	B-X
but	B-X
the	B-X
currents	B-X
were	B-X
rapidly	B-X
and	B-X
completely	B-X
inactivating	B-X
.	B-X
When	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
-GK-domain	B-X
construct	B-X
was	B-X
extended	B-X
proximally	B-X
,	B-X
by	B-X
including	B-X
the	B-X
HOOK-domain	B-X
and	B-X
the	B-X
epsilon-strand	B-X
of	B-X
the	B-X
SH3-domain	B-X
,	B-X
inactivation	B-X
was	B-X
about	B-X
four-fold	B-X
slower	B-X
than	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
HOOK	B-X
domain	B-X
.	B-X
When	B-X
the	B-X
SH3-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
truncated	B-X
prior	B-X
to	B-X
the	B-X
HOOK-domain	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
,	B-X
all	B-X
the	B-X
properties	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
were	B-X
restored	B-X
,	B-X
in	B-X
terms	B-X
of	B-X
loss	B-X
of	B-X
inactivation	B-X
.	B-X
Furthermore	B-X
,	B-X
removal	B-X
of	B-X
the	B-X
HOOK	B-X
sequence	B-X
from	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-beta	B-X
(	B-X
2a	B-X
)	B-X
construct	B-X
increased	B-X
inactivation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
HOOK	B-X
domain	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
inactivation	B-X
.	B-X

When	O
the	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
-	O
GK	O
-	O
domain	O
construct	O
was	O
extended	O
proximally	O
,	O
by	O
including	O
the	O
HOOK	O
-	O
domain	O
and	O
the	O
epsilon	O
-	O
strand	O
of	O
the	O
SH3	O
-	O
domain	O
,	O
inactivation	O
was	O
about	O
four	O
-	O
fold	O
slower	O
than	O
in	O
the	O
absence	O
of	O
the	O
HOOK	O
domain	O
.	O
<EOS>	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
of	B-X
voltage-gated	B-X
calcium	B-X
channels	B-X
contain	B-X
two	B-X
conserved	B-X
domains	B-X
,	B-X
a	B-X
src-homology-3	B-X
(	B-X
SH3	B-X
)	B-X
-domain	B-X
and	B-X
a	B-X
guanylate	B-X
kinase-like	B-X
(	B-X
GK	B-X
)	B-X
-domain	B-X
.	B-X
The	B-X
SH3-domain	B-X
is	B-X
split	B-X
,	B-X
with	B-X
its	B-X
final	B-X
(	B-X
fifth	B-X
)	B-X
beta-strand	B-X
separated	B-X
from	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
domain	B-X
by	B-X
an	B-X
intervening	B-X
sequence	B-X
termed	B-X
the	B-X
HOOK-domain	B-X
,	B-X
whose	B-X
sequence	B-X
varies	B-X
between	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
been	B-X
guided	B-X
by	B-X
the	B-X
recent	B-X
structural	B-X
studies	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
design	B-X
of	B-X
specific	B-X
truncated	B-X
constructs	B-X
,	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
investigating	B-X
the	B-X
role	B-X
of	B-X
the	B-X
HOOK-domain	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
inactivation	B-X
of	B-X
N-type	B-X
calcium	B-X
channels	B-X
.	B-X
We	B-X
have	B-X
coexpressed	B-X
the	B-X
beta	B-X
subunit	B-X
constructs	B-X
with	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.2	B-X
and	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
delta-2	B-X
,	B-X
using	B-X
the	B-X
N-terminally	B-X
palmitoylated	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
subunit	B-X
,	B-X
because	B-X
it	B-X
supports	B-X
very	B-X
little	B-X
voltage-dependent	B-X
inactivation	B-X
,	B-X
and	B-X
made	B-X
comparisons	B-X
with	B-X
beta	B-X
(	B-X
1b	B-X
)	B-X
domains	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
variable	B-X
region	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
HOOK-domain	B-X
resulted	B-X
in	B-X
currents	B-X
with	B-X
a	B-X
rapidly	B-X
inactivating	B-X
component	B-X
,	B-X
and	B-X
additional	B-X
mutation	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
palmitoylation	B-X
motif	B-X
further	B-X
enhanced	B-X
inactivation	B-X
.	B-X
The	B-X
isolated	B-X
GK-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
alone	B-X
enhanced	B-X
current	B-X
amplitude	B-X
,	B-X
but	B-X
the	B-X
currents	B-X
were	B-X
rapidly	B-X
and	B-X
completely	B-X
inactivating	B-X
.	B-X
When	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
-GK-domain	B-X
construct	B-X
was	B-X
extended	B-X
proximally	B-X
,	B-X
by	B-X
including	B-X
the	B-X
HOOK-domain	B-X
and	B-X
the	B-X
epsilon-strand	B-X
of	B-X
the	B-X
SH3-domain	B-X
,	B-X
inactivation	B-X
was	B-X
about	B-X
four-fold	B-X
slower	B-X
than	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
HOOK	B-X
domain	B-X
.	B-X
When	B-X
the	B-X
SH3-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
truncated	B-X
prior	B-X
to	B-X
the	B-X
HOOK-domain	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
,	B-X
all	B-X
the	B-X
properties	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
were	B-X
restored	B-X
,	B-X
in	B-X
terms	B-X
of	B-X
loss	B-X
of	B-X
inactivation	B-X
.	B-X
Furthermore	B-X
,	B-X
removal	B-X
of	B-X
the	B-X
HOOK	B-X
sequence	B-X
from	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-beta	B-X
(	B-X
2a	B-X
)	B-X
construct	B-X
increased	B-X
inactivation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
HOOK	B-X
domain	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
inactivation	B-X
.	B-X

When	O
the	O
SH3	O
-	O
domain	O
of	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
truncated	O
prior	O
to	O
the	O
HOOK	O
-	O
domain	O
was	O
coexpressed	O
with	O
the	O
(	O
HOOK	O
+	O
epsilonSH3	O
+	O
GK	O
)	O
-	O
domain	O
of	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
,	O
all	O
the	O
properties	O
of	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
were	O
restored	O
,	O
in	O
terms	O
of	O
loss	O
of	O
inactivation	O
.	O

Furthermore	O
,	O
removal	O
of	O
the	O
HOOK	O
sequence	O
from	O
the	O
(	O
HOOK	O
+	O
epsilonSH3	O
+	O
GK	O
)	O
-	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
construct	O
increased	O
inactivation	O
.	O
<EOS>	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
of	B-X
voltage-gated	B-X
calcium	B-X
channels	B-X
contain	B-X
two	B-X
conserved	B-X
domains	B-X
,	B-X
a	B-X
src-homology-3	B-X
(	B-X
SH3	B-X
)	B-X
-domain	B-X
and	B-X
a	B-X
guanylate	B-X
kinase-like	B-X
(	B-X
GK	B-X
)	B-X
-domain	B-X
.	B-X
The	B-X
SH3-domain	B-X
is	B-X
split	B-X
,	B-X
with	B-X
its	B-X
final	B-X
(	B-X
fifth	B-X
)	B-X
beta-strand	B-X
separated	B-X
from	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
domain	B-X
by	B-X
an	B-X
intervening	B-X
sequence	B-X
termed	B-X
the	B-X
HOOK-domain	B-X
,	B-X
whose	B-X
sequence	B-X
varies	B-X
between	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
been	B-X
guided	B-X
by	B-X
the	B-X
recent	B-X
structural	B-X
studies	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
design	B-X
of	B-X
specific	B-X
truncated	B-X
constructs	B-X
,	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
investigating	B-X
the	B-X
role	B-X
of	B-X
the	B-X
HOOK-domain	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
inactivation	B-X
of	B-X
N-type	B-X
calcium	B-X
channels	B-X
.	B-X
We	B-X
have	B-X
coexpressed	B-X
the	B-X
beta	B-X
subunit	B-X
constructs	B-X
with	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.2	B-X
and	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
delta-2	B-X
,	B-X
using	B-X
the	B-X
N-terminally	B-X
palmitoylated	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
subunit	B-X
,	B-X
because	B-X
it	B-X
supports	B-X
very	B-X
little	B-X
voltage-dependent	B-X
inactivation	B-X
,	B-X
and	B-X
made	B-X
comparisons	B-X
with	B-X
beta	B-X
(	B-X
1b	B-X
)	B-X
domains	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
variable	B-X
region	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
HOOK-domain	B-X
resulted	B-X
in	B-X
currents	B-X
with	B-X
a	B-X
rapidly	B-X
inactivating	B-X
component	B-X
,	B-X
and	B-X
additional	B-X
mutation	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
palmitoylation	B-X
motif	B-X
further	B-X
enhanced	B-X
inactivation	B-X
.	B-X
The	B-X
isolated	B-X
GK-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
alone	B-X
enhanced	B-X
current	B-X
amplitude	B-X
,	B-X
but	B-X
the	B-X
currents	B-X
were	B-X
rapidly	B-X
and	B-X
completely	B-X
inactivating	B-X
.	B-X
When	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
-GK-domain	B-X
construct	B-X
was	B-X
extended	B-X
proximally	B-X
,	B-X
by	B-X
including	B-X
the	B-X
HOOK-domain	B-X
and	B-X
the	B-X
epsilon-strand	B-X
of	B-X
the	B-X
SH3-domain	B-X
,	B-X
inactivation	B-X
was	B-X
about	B-X
four-fold	B-X
slower	B-X
than	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
HOOK	B-X
domain	B-X
.	B-X
When	B-X
the	B-X
SH3-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
truncated	B-X
prior	B-X
to	B-X
the	B-X
HOOK-domain	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
,	B-X
all	B-X
the	B-X
properties	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
were	B-X
restored	B-X
,	B-X
in	B-X
terms	B-X
of	B-X
loss	B-X
of	B-X
inactivation	B-X
.	B-X
Furthermore	B-X
,	B-X
removal	B-X
of	B-X
the	B-X
HOOK	B-X
sequence	B-X
from	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-beta	B-X
(	B-X
2a	B-X
)	B-X
construct	B-X
increased	B-X
inactivation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
HOOK	B-X
domain	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
inactivation	B-X
.	B-X

Together	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
the	O
HOOK	O
domain	O
is	O
an	O
important	O
determinant	O
of	O
inactivation	O
.	O
<EOS>	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
of	B-X
voltage-gated	B-X
calcium	B-X
channels	B-X
contain	B-X
two	B-X
conserved	B-X
domains	B-X
,	B-X
a	B-X
src-homology-3	B-X
(	B-X
SH3	B-X
)	B-X
-domain	B-X
and	B-X
a	B-X
guanylate	B-X
kinase-like	B-X
(	B-X
GK	B-X
)	B-X
-domain	B-X
.	B-X
The	B-X
SH3-domain	B-X
is	B-X
split	B-X
,	B-X
with	B-X
its	B-X
final	B-X
(	B-X
fifth	B-X
)	B-X
beta-strand	B-X
separated	B-X
from	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
domain	B-X
by	B-X
an	B-X
intervening	B-X
sequence	B-X
termed	B-X
the	B-X
HOOK-domain	B-X
,	B-X
whose	B-X
sequence	B-X
varies	B-X
between	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
been	B-X
guided	B-X
by	B-X
the	B-X
recent	B-X
structural	B-X
studies	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
design	B-X
of	B-X
specific	B-X
truncated	B-X
constructs	B-X
,	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
investigating	B-X
the	B-X
role	B-X
of	B-X
the	B-X
HOOK-domain	B-X
of	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
beta	B-X
subunits	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
inactivation	B-X
of	B-X
N-type	B-X
calcium	B-X
channels	B-X
.	B-X
We	B-X
have	B-X
coexpressed	B-X
the	B-X
beta	B-X
subunit	B-X
constructs	B-X
with	B-X
Ca	B-X
(	B-X
v	B-X
)	B-X
2.2	B-X
and	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
delta-2	B-X
,	B-X
using	B-X
the	B-X
N-terminally	B-X
palmitoylated	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
subunit	B-X
,	B-X
because	B-X
it	B-X
supports	B-X
very	B-X
little	B-X
voltage-dependent	B-X
inactivation	B-X
,	B-X
and	B-X
made	B-X
comparisons	B-X
with	B-X
beta	B-X
(	B-X
1b	B-X
)	B-X
domains	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
variable	B-X
region	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
HOOK-domain	B-X
resulted	B-X
in	B-X
currents	B-X
with	B-X
a	B-X
rapidly	B-X
inactivating	B-X
component	B-X
,	B-X
and	B-X
additional	B-X
mutation	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
palmitoylation	B-X
motif	B-X
further	B-X
enhanced	B-X
inactivation	B-X
.	B-X
The	B-X
isolated	B-X
GK-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
alone	B-X
enhanced	B-X
current	B-X
amplitude	B-X
,	B-X
but	B-X
the	B-X
currents	B-X
were	B-X
rapidly	B-X
and	B-X
completely	B-X
inactivating	B-X
.	B-X
When	B-X
the	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
-GK-domain	B-X
construct	B-X
was	B-X
extended	B-X
proximally	B-X
,	B-X
by	B-X
including	B-X
the	B-X
HOOK-domain	B-X
and	B-X
the	B-X
epsilon-strand	B-X
of	B-X
the	B-X
SH3-domain	B-X
,	B-X
inactivation	B-X
was	B-X
about	B-X
four-fold	B-X
slower	B-X
than	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
HOOK	B-X
domain	B-X
.	B-X
When	B-X
the	B-X
SH3-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
truncated	B-X
prior	B-X
to	B-X
the	B-X
HOOK-domain	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-domain	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
,	B-X
all	B-X
the	B-X
properties	B-X
of	B-X
beta	B-X
(	B-X
2a	B-X
)	B-X
were	B-X
restored	B-X
,	B-X
in	B-X
terms	B-X
of	B-X
loss	B-X
of	B-X
inactivation	B-X
.	B-X
Furthermore	B-X
,	B-X
removal	B-X
of	B-X
the	B-X
HOOK	B-X
sequence	B-X
from	B-X
the	B-X
(	B-X
HOOK+epsilonSH3+GK	B-X
)	B-X
-beta	B-X
(	B-X
2a	B-X
)	B-X
construct	B-X
increased	B-X
inactivation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
HOOK	B-X
domain	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
inactivation	B-X
.	B-X

Membrane	O
binding	O
of	O
lipidated	O
Ras	O
peptides	O
and	O
proteins	O
-	O
-	O
the	O
structural	O
point	O
of	O
view	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
integral	B-X
membrane	B-X
proteins	B-X
,	B-X
a	B-X
number	B-X
of	B-X
proteins	B-X
bind	B-X
to	B-X
the	B-X
membrane	B-X
surface	B-X
and	B-X
associate	B-X
with	B-X
it	B-X
.	B-X
Membrane	B-X
binding	B-X
by	B-X
insertion	B-X
of	B-X
hydrophobic	B-X
lipid	B-X
moieties	B-X
is	B-X
relevant	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
of	B-X
all	B-X
cellular	B-X
proteins	B-X
.	B-X
A	B-X
particular	B-X
interesting	B-X
lipid-modified	B-X
protein	B-X
is	B-X
the	B-X
small	B-X
GTPase	B-X
Ras	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
cellular	B-X
signal	B-X
transduction	B-X
.	B-X
Until	B-X
recently	B-X
,	B-X
the	B-X
structural	B-X
basis	B-X
for	B-X
membrane	B-X
binding	B-X
of	B-X
Ras	B-X
was	B-X
not	B-X
well-defined	B-X
.	B-X
However	B-X
,	B-X
with	B-X
the	B-X
advent	B-X
of	B-X
new	B-X
synthesis	B-X
techniques	B-X
and	B-X
the	B-X
advancement	B-X
of	B-X
several	B-X
biophysical	B-X
methods	B-X
,	B-X
a	B-X
number	B-X
of	B-X
structural	B-X
and	B-X
dynamical	B-X
features	B-X
about	B-X
membrane	B-X
binding	B-X
of	B-X
Ras	B-X
proteins	B-X
have	B-X
been	B-X
revealed	B-X
.	B-X
This	B-X
review	B-X
will	B-X
summarize	B-X
the	B-X
chemical	B-X
biology	B-X
of	B-X
Ras	B-X
and	B-X
discuss	B-X
in	B-X
more	B-X
detail	B-X
the	B-X
biophysical	B-X
and	B-X
structural	B-X
features	B-X
of	B-X
the	B-X
membrane	B-X
bound	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X

Biological	O
membranes	O
are	O
interesting	O
interfaces	O
,	O
at	O
which	O
important	O
biological	O
processes	O
occur	O
.	O
<EOS>	B-X
Their	B-X
functions	B-X
are	B-X
versatile	B-X
and	B-X
important	B-X
,	B-X
being	B-X
responsible	B-X
for	B-X
forming	B-X
the	B-X
genetic	B-X
code	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
mineral	B-X
components	B-X
of	B-X
hard	B-X
tissue	B-X
.	B-X
Several	B-X
unfavorable	B-X
events	B-X
occur	B-X
at	B-X
the	B-X
interface	B-X
of	B-X
materials	B-X
and	B-X
living	B-X
organisms	B-X
because	B-X
most	B-X
of	B-X
these	B-X
materials	B-X
have	B-X
not	B-X
been	B-X
designed	B-X
while	B-X
taking	B-X
host	B-X
responses	B-X
into	B-X
account	B-X
.	B-X
Biomimetic	B-X
phosphorus-containing	B-X
polymers	B-X
can	B-X
improve	B-X
the	B-X
reliability	B-X
of	B-X
materials	B-X
in	B-X
biological	B-X
systems	B-X
.	B-X
It	B-X
occurs	B-X
through	B-X
assembly	B-X
of	B-X
coat	B-X
components	B-X
around	B-X
the	B-X
plasma	B-X
membrane	B-X
that	B-X
determine	B-X
vesicle	B-X
contents	B-X
and	B-X
facilitate	B-X
membrane	B-X
bending	B-X
to	B-X
form	B-X
a	B-X
clathrin-coated	B-X
transport	B-X
vesicle	B-X
.	B-X
Thus	B-X
,	B-X
key	B-X
mechanical	B-X
processes	B-X
driving	B-X
clathrin-mediated	B-X
endocytosis	B-X
have	B-X
been	B-X
captured	B-X
through	B-X
multiple	B-X
techniques	B-X
working	B-X
in	B-X
partnership	B-X
.	B-X

In	O
addition	O
to	O
integral	O
membrane	O
proteins	O
,	O
a	O
number	O
of	O
proteins	O
bind	O
to	O
the	O
membrane	O
surface	O
and	O
associate	O
with	O
it	O
.	O

Posttranslational	O
lipid	O
modification	O
is	O
one	O
important	O
mechanism	O
,	O
by	O
which	O
soluble	O
molecules	O
develop	O
a	O
propensity	O
towards	O
the	O
membrane	O
and	O
reversibly	O
bind	O
to	O
it	O
.	O
<EOS>	B-X
Biological	B-X
membranes	B-X
are	B-X
interesting	B-X
interfaces	B-X
,	B-X
at	B-X
which	B-X
important	B-X
biological	B-X
processes	B-X
occur	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
integral	B-X
membrane	B-X
proteins	B-X
,	B-X
a	B-X
number	B-X
of	B-X
proteins	B-X
bind	B-X
to	B-X
the	B-X
membrane	B-X
surface	B-X
and	B-X
associate	B-X
with	B-X
it	B-X
.	B-X
Posttranslational	B-X
lipid	B-X
modification	B-X
is	B-X
one	B-X
important	B-X
mechanism	B-X
,	B-X
by	B-X
which	B-X
soluble	B-X
molecules	B-X
develop	B-X
a	B-X
propensity	B-X
towards	B-X
the	B-X
membrane	B-X
and	B-X
reversibly	B-X
bind	B-X
to	B-X
it	B-X
.	B-X
Membrane	B-X
binding	B-X
by	B-X
insertion	B-X
of	B-X
hydrophobic	B-X
lipid	B-X
moieties	B-X
is	B-X
relevant	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
of	B-X
all	B-X
cellular	B-X
proteins	B-X
.	B-X
A	B-X
particular	B-X
interesting	B-X
lipid-modified	B-X
protein	B-X
is	B-X
the	B-X
small	B-X
GTPase	B-X
Ras	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
cellular	B-X
signal	B-X
transduction	B-X
.	B-X
Until	B-X
recently	B-X
,	B-X
the	B-X
structural	B-X
basis	B-X
for	B-X
membrane	B-X
binding	B-X
of	B-X
Ras	B-X
was	B-X
not	B-X
well-defined	B-X
.	B-X
However	B-X
,	B-X
with	B-X
the	B-X
advent	B-X
of	B-X
new	B-X
synthesis	B-X
techniques	B-X
and	B-X
the	B-X
advancement	B-X
of	B-X
several	B-X
biophysical	B-X
methods	B-X
,	B-X
a	B-X
number	B-X
of	B-X
structural	B-X
and	B-X
dynamical	B-X
features	B-X
about	B-X
membrane	B-X
binding	B-X
of	B-X
Ras	B-X
proteins	B-X
have	B-X
been	B-X
revealed	B-X
.	B-X
This	B-X
review	B-X
will	B-X
summarize	B-X
the	B-X
chemical	B-X
biology	B-X
of	B-X
Ras	B-X
and	B-X
discuss	B-X
in	B-X
more	B-X
detail	B-X
the	B-X
biophysical	B-X
and	B-X
structural	B-X
features	B-X
of	B-X
the	B-X
membrane	B-X
bound	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X

Membrane	O
binding	O
by	O
insertion	O
of	O
hydrophobic	O
lipid	O
moieties	O
is	O
relevant	O
for	O
up	O
to	O
10	O
%	O
of	O
all	O
cellular	O
proteins	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
integral	B-X
membrane	B-X
proteins	B-X
,	B-X
a	B-X
number	B-X
of	B-X
proteins	B-X
bind	B-X
to	B-X
the	B-X
membrane	B-X
surface	B-X
and	B-X
associate	B-X
with	B-X
it	B-X
.	B-X
Posttranslational	B-X
lipid	B-X
modification	B-X
is	B-X
one	B-X
important	B-X
mechanism	B-X
,	B-X
by	B-X
which	B-X
soluble	B-X
molecules	B-X
develop	B-X
a	B-X
propensity	B-X
towards	B-X
the	B-X
membrane	B-X
and	B-X
reversibly	B-X
bind	B-X
to	B-X
it	B-X
.	B-X
Membrane	B-X
binding	B-X
by	B-X
insertion	B-X
of	B-X
hydrophobic	B-X
lipid	B-X
moieties	B-X
is	B-X
relevant	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
of	B-X
all	B-X
cellular	B-X
proteins	B-X
.	B-X
A	B-X
particular	B-X
interesting	B-X
lipid-modified	B-X
protein	B-X
is	B-X
the	B-X
small	B-X
GTPase	B-X
Ras	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
cellular	B-X
signal	B-X
transduction	B-X
.	B-X
Until	B-X
recently	B-X
,	B-X
the	B-X
structural	B-X
basis	B-X
for	B-X
membrane	B-X
binding	B-X
of	B-X
Ras	B-X
was	B-X
not	B-X
well-defined	B-X
.	B-X
However	B-X
,	B-X
with	B-X
the	B-X
advent	B-X
of	B-X
new	B-X
synthesis	B-X
techniques	B-X
and	B-X
the	B-X
advancement	B-X
of	B-X
several	B-X
biophysical	B-X
methods	B-X
,	B-X
a	B-X
number	B-X
of	B-X
structural	B-X
and	B-X
dynamical	B-X
features	B-X
about	B-X
membrane	B-X
binding	B-X
of	B-X
Ras	B-X
proteins	B-X
have	B-X
been	B-X
revealed	B-X
.	B-X

A	O
particular	O
interesting	O
lipid	O
-	O
modified	O
protein	O
is	O
the	O
small	O
GTPase	O
Ras	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
cellular	O
signal	O
transduction	O
.	O

Until	O
recently	O
,	O
the	O
structural	O
basis	O
for	O
membrane	O
binding	O
of	O
Ras	O
was	O
not	O
well	O
-	O
defined	O
.	O

However	O
,	O
with	O
the	O
advent	O
of	O
new	O
synthesis	O
techniques	O
and	O
the	O
advancement	O
of	O
several	O
biophysical	O
methods	O
,	O
a	O
number	O
of	O
structural	O
and	O
dynamical	O
features	O
about	O
membrane	O
binding	O
of	O
Ras	O
proteins	O
have	O
been	O
revealed	O
.	O
<EOS>	B-X
Biological	B-X
membranes	B-X
are	B-X
interesting	B-X
interfaces	B-X
,	B-X
at	B-X
which	B-X
important	B-X
biological	B-X
processes	B-X
occur	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
integral	B-X
membrane	B-X
proteins	B-X
,	B-X
a	B-X
number	B-X
of	B-X
proteins	B-X
bind	B-X
to	B-X
the	B-X
membrane	B-X
surface	B-X
and	B-X
associate	B-X
with	B-X
it	B-X
.	B-X
Posttranslational	B-X
lipid	B-X
modification	B-X
is	B-X
one	B-X
important	B-X
mechanism	B-X
,	B-X
by	B-X
which	B-X
soluble	B-X
molecules	B-X
develop	B-X
a	B-X
propensity	B-X
towards	B-X
the	B-X
membrane	B-X
and	B-X
reversibly	B-X
bind	B-X
to	B-X
it	B-X
.	B-X
Membrane	B-X
binding	B-X
by	B-X
insertion	B-X
of	B-X
hydrophobic	B-X
lipid	B-X
moieties	B-X
is	B-X
relevant	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
of	B-X
all	B-X
cellular	B-X
proteins	B-X
.	B-X
A	B-X
particular	B-X
interesting	B-X
lipid-modified	B-X
protein	B-X
is	B-X
the	B-X
small	B-X
GTPase	B-X
Ras	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
cellular	B-X
signal	B-X
transduction	B-X
.	B-X
Until	B-X
recently	B-X
,	B-X
the	B-X
structural	B-X
basis	B-X
for	B-X
membrane	B-X
binding	B-X
of	B-X
Ras	B-X
was	B-X
not	B-X
well-defined	B-X
.	B-X
However	B-X
,	B-X
with	B-X
the	B-X
advent	B-X
of	B-X
new	B-X
synthesis	B-X
techniques	B-X
and	B-X
the	B-X
advancement	B-X
of	B-X
several	B-X
biophysical	B-X
methods	B-X
,	B-X
a	B-X
number	B-X
of	B-X
structural	B-X
and	B-X
dynamical	B-X
features	B-X
about	B-X
membrane	B-X
binding	B-X
of	B-X
Ras	B-X
proteins	B-X
have	B-X
been	B-X
revealed	B-X
.	B-X
This	B-X
review	B-X
will	B-X
summarize	B-X
the	B-X
chemical	B-X
biology	B-X
of	B-X
Ras	B-X
and	B-X
discuss	B-X
in	B-X
more	B-X
detail	B-X
the	B-X
biophysical	B-X
and	B-X
structural	B-X
features	B-X
of	B-X
the	B-X
membrane	B-X
bound	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X

This	O
review	O
will	O
summarize	O
the	O
chemical	O
biology	O
of	O
Ras	O
and	O
discuss	O
in	O
more	O
detail	O
the	O
biophysical	O
and	O
structural	O
features	O
of	O
the	O
membrane	O
bound	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

RanBP2	B-Protein
and	O
SENP3	B-Protein
function	O
in	O
a	O
mitotic	O
SUMO2	B-Protein
/	O
3	B-Protein
conjugation	O
-	O
deconjugation	O
cycle	O
on	O
Borealin	B-Protein
.	O

The	O
ubiquitin	B-Protein
-	O
like	O
SUMO	O
system	O
controls	O
cellular	O
key	O
functions	O
,	O
and	O
several	O
lines	O
of	O
evidence	O
point	O
to	O
a	O
critical	O
role	O
of	O
SUMO	O
for	O
mitotic	O
progression	O
.	O
<EOS>	B-X
The	B-X
ubiquitin-like	B-X
SUMO	B-X
system	B-X
controls	B-X
cellular	B-X
key	B-X
functions	B-X
,	B-X
and	B-X
several	B-X
lines	B-X
of	B-X
evidence	B-X
point	B-X
to	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
SUMO	B-X
for	B-X
mitotic	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
in	B-X
mammalian	B-X
cells	B-X
mitotic	B-X
substrates	B-X
of	B-X
sumoylation	B-X
and	B-X
the	B-X
regulatory	B-X
components	B-X
involved	B-X
are	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
Borealin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
chromosomal	B-X
passenger	B-X
complex	B-X
(	B-X
CPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
mitotic	B-X
target	B-X
of	B-X
SUMO	B-X
.	B-X
The	B-X
CPC	B-X
,	B-X
which	B-X
additionally	B-X
comprises	B-X
INCENP	B-X
,	B-X
Survivin	B-X
,	B-X
and	B-X
Aurora	B-X
B	B-X
,	B-X
regulates	B-X
key	B-X
mitotic	B-X
events	B-X
,	B-X
including	B-X
chromosome	B-X
congression	B-X
,	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
,	B-X
and	B-X
cytokinesis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Borealin	B-X
is	B-X
preferentially	B-X
modified	B-X
by	B-X
SUMO2/3	B-X
and	B-X
demonstrate	B-X
that	B-X
the	B-X
modification	B-X
is	B-X
dynamically	B-X
regulated	B-X
during	B-X
mitotic	B-X
progression	B-X
,	B-X
peaking	B-X
in	B-X
early	B-X
mitosis	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
SUMO	B-X
ligase	B-X
RanBP2	B-X
interacts	B-X
with	B-X
the	B-X
CPC	B-X
,	B-X
stimulates	B-X
SUMO	B-X
modification	B-X
of	B-X
Borealin	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
is	B-X
required	B-X
for	B-X
its	B-X
modification	B-X
in	B-X
vivo	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
SUMO	B-X
isopeptidase	B-X
SENP3	B-X
is	B-X
a	B-X
specific	B-X
interaction	B-X
partner	B-X
of	B-X
Borealin	B-X
and	B-X
catalyzes	B-X
the	B-X
removal	B-X
of	B-X
SUMO2/3	B-X
from	B-X
Borealin	B-X
.	B-X
These	B-X
data	B-X
thus	B-X
delineate	B-X
a	B-X
mitotic	B-X
SUMO2/3	B-X
conjugation-deconjugation	B-X
cycle	B-X
of	B-X
Borealin	B-X
and	B-X
further	B-X
assign	B-X
a	B-X
regulatory	B-X
function	B-X
of	B-X
RanBP2	B-X
and	B-X
SENP3	B-X
in	B-X
the	B-X
mitotic	B-X
SUMO	B-X
pathway	B-X
.	B-X

However	O
,	O
in	O
mammalian	O
cells	O
mitotic	O
substrates	O
of	O
sumoylation	O
and	O
the	O
regulatory	O
components	O
involved	O
are	O
not	O
well	O
defined	O
.	O
<EOS>	B-X
Post-translational	B-X
modification	B-X
by	B-X
SUMO	B-X
is	B-X
a	B-X
highly	B-X
conserved	B-X
pathway	B-X
in	B-X
eukaryotes	B-X
that	B-X
plays	B-X
very	B-X
important	B-X
regulatory	B-X
roles	B-X
in	B-X
many	B-X
cellular	B-X
processes	B-X
.	B-X
Therefore	B-X
,	B-X
identifying	B-X
additional	B-X
SUMO	B-X
substrates	B-X
and	B-X
studying	B-X
how	B-X
their	B-X
cellular	B-X
and	B-X
biological	B-X
functions	B-X
are	B-X
regulated	B-X
by	B-X
sumoylation	B-X
should	B-X
provide	B-X
new	B-X
insights	B-X
.	B-X
Our	B-X
studies	B-X
showed	B-X
that	B-X
sumoylation	B-X
activity	B-X
was	B-X
significant	B-X
in	B-X
Xenopus	B-X
egg	B-X
extracts	B-X
,	B-X
and	B-X
that	B-X
a	B-X
high	B-X
level	B-X
of	B-X
sumoylation	B-X
was	B-X
associated	B-X
with	B-X
sperm	B-X
chromatin	B-X
when	B-X
SUMO	B-X
was	B-X
incubated	B-X
with	B-X
Xenopus	B-X
egg	B-X
extracts	B-X
.	B-X
By	B-X
isolating	B-X
SUMO-conjugated	B-X
substrates	B-X
using	B-X
His-tagged	B-X
SUMO1	B-X
or	B-X
SUMO2	B-X
proteins	B-X
under	B-X
denaturing	B-X
conditions	B-X
,	B-X
we	B-X
identified	B-X
346	B-X
proteins	B-X
by	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
that	B-X
were	B-X
not	B-X
present	B-X
in	B-X
control	B-X
pull-downs	B-X
.	B-X
Among	B-X
them	B-X
,	B-X
167	B-X
proteins	B-X
were	B-X
identified	B-X
from	B-X
interphase	B-X
egg	B-X
extracts	B-X
,	B-X
86	B-X
proteins	B-X
from	B-X
mitotic	B-X
phase	B-X
egg	B-X
extracts	B-X
,	B-X
and	B-X
93	B-X
proteins	B-X
from	B-X
both	B-X
.	B-X
We	B-X
validated	B-X
the	B-X
sumoylation	B-X
of	B-X
five	B-X
candidates	B-X
,	B-X
CKB	B-X
,	B-X
ATXN10	B-X
,	B-X
BTF3	B-X
,	B-X
HABP4	B-X
,	B-X
and	B-X
BZW1	B-X
,	B-X
by	B-X
co-transfecting	B-X
them	B-X
along	B-X
with	B-X
SUMO	B-X
in	B-X
HEK293T	B-X
cells	B-X
.	B-X
Gene	B-X
ontology	B-X
analysis	B-X
showed	B-X
that	B-X
SUMO	B-X
substrates	B-X
identified	B-X
in	B-X
this	B-X
study	B-X
were	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
processes	B-X
.	B-X
Additionally	B-X
,	B-X
SUMO	B-X
substrates	B-X
identified	B-X
from	B-X
different	B-X
cell	B-X
cycle	B-X
stages	B-X
or	B-X
pulled	B-X
down	B-X
by	B-X
different	B-X
SUMO	B-X
homologs	B-X
were	B-X
enriched	B-X
for	B-X
distinct	B-X
cellular	B-X
components	B-X
and	B-X
functional	B-X
categories	B-X
.	B-X
Our	B-X
results	B-X
comprehensively	B-X
profile	B-X
the	B-X
sumoylation	B-X
occurring	B-X
in	B-X
the	B-X
Xenopus	B-X
egg	B-X
extract	B-X
system	B-X
.	B-X

Here	O
,	O
we	O
identify	O
Borealin	B-Protein
,	O
a	O
component	O
of	O
the	O
chromosomal	O
passenger	O
complex	O
(	O
CPC	O
)	O
,	O
as	O
a	O
mitotic	O
target	O
of	O
SUMO	O
.	O
<EOS>	B-X
The	B-X
ubiquitin-like	B-X
SUMO	B-X
system	B-X
controls	B-X
cellular	B-X
key	B-X
functions	B-X
,	B-X
and	B-X
several	B-X
lines	B-X
of	B-X
evidence	B-X
point	B-X
to	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
SUMO	B-X
for	B-X
mitotic	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
in	B-X
mammalian	B-X
cells	B-X
mitotic	B-X
substrates	B-X
of	B-X
sumoylation	B-X
and	B-X
the	B-X
regulatory	B-X
components	B-X
involved	B-X
are	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
Borealin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
chromosomal	B-X
passenger	B-X
complex	B-X
(	B-X
CPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
mitotic	B-X
target	B-X
of	B-X
SUMO	B-X
.	B-X
The	B-X
CPC	B-X
,	B-X
which	B-X
additionally	B-X
comprises	B-X
INCENP	B-X
,	B-X
Survivin	B-X
,	B-X
and	B-X
Aurora	B-X
B	B-X
,	B-X
regulates	B-X
key	B-X
mitotic	B-X
events	B-X
,	B-X
including	B-X
chromosome	B-X
congression	B-X
,	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
,	B-X
and	B-X
cytokinesis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Borealin	B-X
is	B-X
preferentially	B-X
modified	B-X
by	B-X
SUMO2/3	B-X
and	B-X
demonstrate	B-X
that	B-X
the	B-X
modification	B-X
is	B-X
dynamically	B-X
regulated	B-X
during	B-X
mitotic	B-X
progression	B-X
,	B-X
peaking	B-X
in	B-X
early	B-X
mitosis	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
SUMO	B-X
ligase	B-X
RanBP2	B-X
interacts	B-X
with	B-X
the	B-X
CPC	B-X
,	B-X
stimulates	B-X
SUMO	B-X
modification	B-X
of	B-X
Borealin	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
is	B-X
required	B-X
for	B-X
its	B-X
modification	B-X
in	B-X
vivo	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
SUMO	B-X
isopeptidase	B-X
SENP3	B-X
is	B-X
a	B-X
specific	B-X
interaction	B-X
partner	B-X
of	B-X
Borealin	B-X
and	B-X
catalyzes	B-X
the	B-X
removal	B-X
of	B-X
SUMO2/3	B-X
from	B-X
Borealin	B-X
.	B-X
These	B-X
data	B-X
thus	B-X
delineate	B-X
a	B-X
mitotic	B-X
SUMO2/3	B-X
conjugation-deconjugation	B-X
cycle	B-X
of	B-X
Borealin	B-X
and	B-X
further	B-X
assign	B-X
a	B-X
regulatory	B-X
function	B-X
of	B-X
RanBP2	B-X
and	B-X
SENP3	B-X
in	B-X
the	B-X
mitotic	B-X
SUMO	B-X
pathway	B-X
.	B-X

The	O
CPC	O
,	O
which	O
additionally	O
comprises	O
INCENP	B-Protein
,	O
Survivin	B-Protein
,	O
and	O
Aurora	B-Protein
B	I-Protein
,	O
regulates	O
key	O
mitotic	O
events	O
,	O
including	O
chromosome	O
congression	O
,	O
the	O
spindle	O
assembly	O
checkpoint	O
,	O
and	O
cytokinesis	O
.	O
<EOS>	B-X
The	B-X
ubiquitin-like	B-X
SUMO	B-X
system	B-X
controls	B-X
cellular	B-X
key	B-X
functions	B-X
,	B-X
and	B-X
several	B-X
lines	B-X
of	B-X
evidence	B-X
point	B-X
to	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
SUMO	B-X
for	B-X
mitotic	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
in	B-X
mammalian	B-X
cells	B-X
mitotic	B-X
substrates	B-X
of	B-X
sumoylation	B-X
and	B-X
the	B-X
regulatory	B-X
components	B-X
involved	B-X
are	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
Borealin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
chromosomal	B-X
passenger	B-X
complex	B-X
(	B-X
CPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
mitotic	B-X
target	B-X
of	B-X
SUMO	B-X
.	B-X
The	B-X
CPC	B-X
,	B-X
which	B-X
additionally	B-X
comprises	B-X
INCENP	B-X
,	B-X
Survivin	B-X
,	B-X
and	B-X
Aurora	B-X
B	B-X
,	B-X
regulates	B-X
key	B-X
mitotic	B-X
events	B-X
,	B-X
including	B-X
chromosome	B-X
congression	B-X
,	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
,	B-X
and	B-X
cytokinesis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Borealin	B-X
is	B-X
preferentially	B-X
modified	B-X
by	B-X
SUMO2/3	B-X
and	B-X
demonstrate	B-X
that	B-X
the	B-X
modification	B-X
is	B-X
dynamically	B-X
regulated	B-X
during	B-X
mitotic	B-X
progression	B-X
,	B-X
peaking	B-X
in	B-X
early	B-X
mitosis	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
SUMO	B-X
ligase	B-X
RanBP2	B-X
interacts	B-X
with	B-X
the	B-X
CPC	B-X
,	B-X
stimulates	B-X
SUMO	B-X
modification	B-X
of	B-X
Borealin	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
is	B-X
required	B-X
for	B-X
its	B-X
modification	B-X
in	B-X
vivo	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
SUMO	B-X
isopeptidase	B-X
SENP3	B-X
is	B-X
a	B-X
specific	B-X
interaction	B-X
partner	B-X
of	B-X
Borealin	B-X
and	B-X
catalyzes	B-X
the	B-X
removal	B-X
of	B-X
SUMO2/3	B-X
from	B-X
Borealin	B-X
.	B-X
These	B-X
data	B-X
thus	B-X
delineate	B-X
a	B-X
mitotic	B-X
SUMO2/3	B-X
conjugation-deconjugation	B-X
cycle	B-X
of	B-X
Borealin	B-X
and	B-X
further	B-X
assign	B-X
a	B-X
regulatory	B-X
function	B-X
of	B-X
RanBP2	B-X
and	B-X
SENP3	B-X
in	B-X
the	B-X
mitotic	B-X
SUMO	B-X
pathway	B-X
.	B-X

We	O
show	O
that	O
Borealin	B-Protein
is	O
preferentially	O
modified	O
by	O
SUMO2	B-Protein
/	O
3	B-Protein
and	O
demonstrate	O
that	O
the	O
modification	O
is	O
dynamically	O
regulated	O
during	O
mitotic	O
progression	O
,	O
peaking	O
in	O
early	O
mitosis	O
.	O
<EOS>	B-X
The	B-X
ubiquitin-like	B-X
SUMO	B-X
system	B-X
controls	B-X
cellular	B-X
key	B-X
functions	B-X
,	B-X
and	B-X
several	B-X
lines	B-X
of	B-X
evidence	B-X
point	B-X
to	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
SUMO	B-X
for	B-X
mitotic	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
in	B-X
mammalian	B-X
cells	B-X
mitotic	B-X
substrates	B-X
of	B-X
sumoylation	B-X
and	B-X
the	B-X
regulatory	B-X
components	B-X
involved	B-X
are	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
Borealin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
chromosomal	B-X
passenger	B-X
complex	B-X
(	B-X
CPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
mitotic	B-X
target	B-X
of	B-X
SUMO	B-X
.	B-X
The	B-X
CPC	B-X
,	B-X
which	B-X
additionally	B-X
comprises	B-X
INCENP	B-X
,	B-X
Survivin	B-X
,	B-X
and	B-X
Aurora	B-X
B	B-X
,	B-X
regulates	B-X
key	B-X
mitotic	B-X
events	B-X
,	B-X
including	B-X
chromosome	B-X
congression	B-X
,	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
,	B-X
and	B-X
cytokinesis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Borealin	B-X
is	B-X
preferentially	B-X
modified	B-X
by	B-X
SUMO2/3	B-X
and	B-X
demonstrate	B-X
that	B-X
the	B-X
modification	B-X
is	B-X
dynamically	B-X
regulated	B-X
during	B-X
mitotic	B-X
progression	B-X
,	B-X
peaking	B-X
in	B-X
early	B-X
mitosis	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
SUMO	B-X
ligase	B-X
RanBP2	B-X
interacts	B-X
with	B-X
the	B-X
CPC	B-X
,	B-X
stimulates	B-X
SUMO	B-X
modification	B-X
of	B-X
Borealin	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
is	B-X
required	B-X
for	B-X
its	B-X
modification	B-X
in	B-X
vivo	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
SUMO	B-X
isopeptidase	B-X
SENP3	B-X
is	B-X
a	B-X
specific	B-X
interaction	B-X
partner	B-X
of	B-X
Borealin	B-X
and	B-X
catalyzes	B-X
the	B-X
removal	B-X
of	B-X
SUMO2/3	B-X
from	B-X
Borealin	B-X
.	B-X
These	B-X
data	B-X
thus	B-X
delineate	B-X
a	B-X
mitotic	B-X
SUMO2/3	B-X
conjugation-deconjugation	B-X
cycle	B-X
of	B-X
Borealin	B-X
and	B-X
further	B-X
assign	B-X
a	B-X
regulatory	B-X
function	B-X
of	B-X
RanBP2	B-X
and	B-X
SENP3	B-X
in	B-X
the	B-X
mitotic	B-X
SUMO	B-X
pathway	B-X
.	B-X

Intriguingly	O
,	O
the	O
SUMO	O
ligase	O
RanBP2	B-Protein
interacts	O
with	O
the	O
CPC	O
,	O
stimulates	O
SUMO	O
modification	O
of	O
Borealin	B-Protein
in	O
vitro	O
,	O
and	O
is	O
required	O
for	O
its	O
modification	O
in	O
vivo	O
.	O
<EOS>	B-X
The	B-X
ubiquitin-like	B-X
SUMO	B-X
system	B-X
controls	B-X
cellular	B-X
key	B-X
functions	B-X
,	B-X
and	B-X
several	B-X
lines	B-X
of	B-X
evidence	B-X
point	B-X
to	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
SUMO	B-X
for	B-X
mitotic	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
Borealin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
chromosomal	B-X
passenger	B-X
complex	B-X
(	B-X
CPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
mitotic	B-X
target	B-X
of	B-X
SUMO	B-X
.	B-X
The	B-X
CPC	B-X
,	B-X
which	B-X
additionally	B-X
comprises	B-X
INCENP	B-X
,	B-X
Survivin	B-X
,	B-X
and	B-X
Aurora	B-X
B	B-X
,	B-X
regulates	B-X
key	B-X
mitotic	B-X
events	B-X
,	B-X
including	B-X
chromosome	B-X
congression	B-X
,	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
,	B-X
and	B-X
cytokinesis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Borealin	B-X
is	B-X
preferentially	B-X
modified	B-X
by	B-X
SUMO2/3	B-X
and	B-X
demonstrate	B-X
that	B-X
the	B-X
modification	B-X
is	B-X
dynamically	B-X
regulated	B-X
during	B-X
mitotic	B-X
progression	B-X
,	B-X
peaking	B-X
in	B-X
early	B-X
mitosis	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
SUMO	B-X
ligase	B-X
RanBP2	B-X
interacts	B-X
with	B-X
the	B-X
CPC	B-X
,	B-X
stimulates	B-X
SUMO	B-X
modification	B-X
of	B-X
Borealin	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
is	B-X
required	B-X
for	B-X
its	B-X
modification	B-X
in	B-X
vivo	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
SUMO	B-X
isopeptidase	B-X
SENP3	B-X
is	B-X
a	B-X
specific	B-X
interaction	B-X
partner	B-X
of	B-X
Borealin	B-X
and	B-X
catalyzes	B-X
the	B-X
removal	B-X
of	B-X
SUMO2/3	B-X
from	B-X
Borealin	B-X
.	B-X
These	B-X
data	B-X
thus	B-X
delineate	B-X
a	B-X
mitotic	B-X
SUMO2/3	B-X
conjugation-deconjugation	B-X
cycle	B-X
of	B-X
Borealin	B-X
and	B-X
further	B-X
assign	B-X
a	B-X
regulatory	B-X
function	B-X
of	B-X
RanBP2	B-X
and	B-X
SENP3	B-X
in	B-X
the	B-X
mitotic	B-X
SUMO	B-X
pathway	B-X
.	B-X

Moreover	O
,	O
the	O
SUMO	O
isopeptidase	O
SENP3	B-Protein
is	O
a	O
specific	O
interaction	O
partner	O
of	O
Borealin	B-Protein
and	O
catalyzes	O
the	O
removal	O
of	O
SUMO2	B-Protein
/	O
3	B-Protein
from	O
Borealin	B-Protein
.	O
<EOS>	B-X
The	B-X
ubiquitin-like	B-X
SUMO	B-X
system	B-X
controls	B-X
cellular	B-X
key	B-X
functions	B-X
,	B-X
and	B-X
several	B-X
lines	B-X
of	B-X
evidence	B-X
point	B-X
to	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
SUMO	B-X
for	B-X
mitotic	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
Borealin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
chromosomal	B-X
passenger	B-X
complex	B-X
(	B-X
CPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
mitotic	B-X
target	B-X
of	B-X
SUMO	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Borealin	B-X
is	B-X
preferentially	B-X
modified	B-X
by	B-X
SUMO2/3	B-X
and	B-X
demonstrate	B-X
that	B-X
the	B-X
modification	B-X
is	B-X
dynamically	B-X
regulated	B-X
during	B-X
mitotic	B-X
progression	B-X
,	B-X
peaking	B-X
in	B-X
early	B-X
mitosis	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
SUMO	B-X
ligase	B-X
RanBP2	B-X
interacts	B-X
with	B-X
the	B-X
CPC	B-X
,	B-X
stimulates	B-X
SUMO	B-X
modification	B-X
of	B-X
Borealin	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
is	B-X
required	B-X
for	B-X
its	B-X
modification	B-X
in	B-X
vivo	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
SUMO	B-X
isopeptidase	B-X
SENP3	B-X
is	B-X
a	B-X
specific	B-X
interaction	B-X
partner	B-X
of	B-X
Borealin	B-X
and	B-X
catalyzes	B-X
the	B-X
removal	B-X
of	B-X
SUMO2/3	B-X
from	B-X
Borealin	B-X
.	B-X
These	B-X
data	B-X
thus	B-X
delineate	B-X
a	B-X
mitotic	B-X
SUMO2/3	B-X
conjugation-deconjugation	B-X
cycle	B-X
of	B-X
Borealin	B-X
and	B-X
further	B-X
assign	B-X
a	B-X
regulatory	B-X
function	B-X
of	B-X
RanBP2	B-X
and	B-X
SENP3	B-X
in	B-X
the	B-X
mitotic	B-X
SUMO	B-X
pathway	B-X
.	B-X

These	O
data	O
thus	O
delineate	O
a	O
mitotic	O
SUMO2	B-Protein
/	O
3	B-Protein
conjugation	O
-	O
deconjugation	O
cycle	O
of	O
Borealin	B-Protein
and	O
further	O
assign	O
a	O
regulatory	O
function	O
of	O
RanBP2	B-Protein
and	O
SENP3	B-Protein
in	O
the	O
mitotic	O
SUMO	O
pathway	O
.	O
<EOS>	B-X
The	B-X
ubiquitin-like	B-X
SUMO	B-X
system	B-X
controls	B-X
cellular	B-X
key	B-X
functions	B-X
,	B-X
and	B-X
several	B-X
lines	B-X
of	B-X
evidence	B-X
point	B-X
to	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
SUMO	B-X
for	B-X
mitotic	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
in	B-X
mammalian	B-X
cells	B-X
mitotic	B-X
substrates	B-X
of	B-X
sumoylation	B-X
and	B-X
the	B-X
regulatory	B-X
components	B-X
involved	B-X
are	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
Borealin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
chromosomal	B-X
passenger	B-X
complex	B-X
(	B-X
CPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
mitotic	B-X
target	B-X
of	B-X
SUMO	B-X
.	B-X
The	B-X
CPC	B-X
,	B-X
which	B-X
additionally	B-X
comprises	B-X
INCENP	B-X
,	B-X
Survivin	B-X
,	B-X
and	B-X
Aurora	B-X
B	B-X
,	B-X
regulates	B-X
key	B-X
mitotic	B-X
events	B-X
,	B-X
including	B-X
chromosome	B-X
congression	B-X
,	B-X
the	B-X
spindle	B-X
assembly	B-X
checkpoint	B-X
,	B-X
and	B-X
cytokinesis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Borealin	B-X
is	B-X
preferentially	B-X
modified	B-X
by	B-X
SUMO2/3	B-X
and	B-X
demonstrate	B-X
that	B-X
the	B-X
modification	B-X
is	B-X
dynamically	B-X
regulated	B-X
during	B-X
mitotic	B-X
progression	B-X
,	B-X
peaking	B-X
in	B-X
early	B-X
mitosis	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
SUMO	B-X
ligase	B-X
RanBP2	B-X
interacts	B-X
with	B-X
the	B-X
CPC	B-X
,	B-X
stimulates	B-X
SUMO	B-X
modification	B-X
of	B-X
Borealin	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
is	B-X
required	B-X
for	B-X
its	B-X
modification	B-X
in	B-X
vivo	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
SUMO	B-X
isopeptidase	B-X
SENP3	B-X
is	B-X
a	B-X
specific	B-X
interaction	B-X
partner	B-X
of	B-X
Borealin	B-X
and	B-X
catalyzes	B-X
the	B-X
removal	B-X
of	B-X
SUMO2/3	B-X
from	B-X
Borealin	B-X
.	B-X
These	B-X
data	B-X
thus	B-X
delineate	B-X
a	B-X
mitotic	B-X
SUMO2/3	B-X
conjugation-deconjugation	B-X
cycle	B-X
of	B-X
Borealin	B-X
and	B-X
further	B-X
assign	B-X
a	B-X
regulatory	B-X
function	B-X
of	B-X
RanBP2	B-X
and	B-X
SENP3	B-X
in	B-X
the	B-X
mitotic	B-X
SUMO	B-X
pathway	B-X
.	B-X

Structural	O
basis	O
and	O
specificity	O
of	O
human	O
otubain	B-Protein
1	I-Protein
-	O
mediated	O
deubiquitination	O
.	O
<EOS>	B-X
OTUB	B-X
(	B-X
otubain	B-X
)	B-X
1	B-X
is	B-X
a	B-X
human	B-X
deubiquitinating	B-X
enzyme	B-X
that	B-X
is	B-X
implicated	B-X
in	B-X
mediating	B-X
lymphocyte	B-X
antigen	B-X
responsiveness	B-X
,	B-X
but	B-X
whose	B-X
molecular	B-X
function	B-X
is	B-X
generally	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
A	B-X
structural	B-X
analysis	B-X
of	B-X
OTUB1	B-X
shows	B-X
differences	B-X
in	B-X
accessibility	B-X
to	B-X
the	B-X
active	B-X
site	B-X
and	B-X
in	B-X
surface	B-X
properties	B-X
of	B-X
the	B-X
substrate-binding	B-X
regions	B-X
when	B-X
compared	B-X
with	B-X
its	B-X
close	B-X
homologue	B-X
,	B-X
OTUB2	B-X
,	B-X
suggesting	B-X
variations	B-X
in	B-X
regulatory	B-X
mechanisms	B-X
and	B-X
substrate	B-X
specificity	B-X
.	B-X
Biochemical	B-X
analysis	B-X
reveals	B-X
that	B-X
OTUB1	B-X
has	B-X
a	B-X
preference	B-X
for	B-X
cleaving	B-X
Lys	B-X
(	B-X
48	B-X
)	B-X
-linked	B-X
polyubiquitin	B-X
chains	B-X
over	B-X
Lys	B-X
(	B-X
63	B-X
)	B-X
-linked	B-X
polyubiquitin	B-X
chains	B-X
,	B-X
and	B-X
it	B-X
is	B-X
capable	B-X
of	B-X
cleaving	B-X
NEDD8	B-X
(	B-X
neural-precursor-cell-expressed	B-X
developmentally	B-X
down-regulated	B-X
8	B-X
)	B-X
,	B-X
but	B-X
not	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
1/2/3	B-X
and	B-X
ISG15	B-X
(	B-X
interferon-stimulated	B-X
gene	B-X
15	B-X
)	B-X
conjugates	B-X
.	B-X
A	B-X
functional	B-X
comparison	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
indicated	B-X
a	B-X
differential	B-X
reactivity	B-X
towards	B-X
ubiquitin-based	B-X
active-site	B-X
probes	B-X
carrying	B-X
a	B-X
vinyl	B-X
methyl	B-X
ester	B-X
,	B-X
a	B-X
2-chloroethyl	B-X
or	B-X
a	B-X
2-bromoethyl	B-X
group	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
Mutational	B-X
analysis	B-X
suggested	B-X
that	B-X
a	B-X
narrow	B-X
P1	B-X
'	B-X
site	B-X
,	B-X
as	B-X
observed	B-X
in	B-X
OTUB1	B-X
,	B-X
correlates	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
preferentially	B-X
cleave	B-X
Lys	B-X
(	B-X
48	B-X
)	B-X
-linked	B-X
ubiquitin	B-X
chains	B-X
.	B-X
Analysis	B-X
of	B-X
cellular	B-X
interaction	B-X
partners	B-X
of	B-X
OTUB1	B-X
by	B-X
co-immunoprecipitation	B-X
and	B-X
MS/MS	B-X
(	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
)	B-X
experiments	B-X
demonstrated	B-X
that	B-X
FUS	B-X
[	B-X
fusion	B-X
involved	B-X
in	B-X
t	B-X
(	B-X
12	B-X
;	B-X
6	B-X
)	B-X
in	B-X
malignant	B-X
liposarcoma	B-X
;	B-X
also	B-X
known	B-X
as	B-X
TLS	B-X
(	B-X
translocation	B-X
in	B-X
liposarcoma	B-X
)	B-X
or	B-X
CHOP	B-X
(	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
homologous	B-X
protein	B-X
)	B-X
]	B-X
and	B-X
RACK1	B-X
[	B-X
receptor	B-X
for	B-X
activated	B-X
kinase	B-X
1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
GNB2L1	B-X
(	B-X
guanine-nucleotide-binding	B-X
protein	B-X
beta	B-X
polypeptide	B-X
2-like	B-X
1	B-X
)	B-X
]	B-X
are	B-X
part	B-X
of	B-X
OTUB1-containing	B-X
complexes	B-X
,	B-X
pointing	B-X
towards	B-X
a	B-X
molecular	B-X
function	B-X
of	B-X
this	B-X
deubiquitinating	B-X
enzyme	B-X
in	B-X
RNA	B-X
processing	B-X
and	B-X
cell	B-X
adhesion/morphology	B-X
.	B-X

OTUB	B-Protein
(	I-Protein
otubain	I-Protein
)	I-Protein
1	I-Protein
is	O
a	O
human	O
deubiquitinating	O
enzyme	O
that	O
is	O
implicated	O
in	O
mediating	O
lymphocyte	O
antigen	O
responsiveness	O
,	O
but	O
whose	O
molecular	O
function	O
is	O
generally	O
not	O
well	O
defined	O
.	O

A	O
structural	O
analysis	O
of	O
OTUB1	B-Protein
shows	O
differences	O
in	O
accessibility	O
to	O
the	O
active	O
site	O
and	O
in	O
surface	O
properties	O
of	O
the	O
substrate	O
-	O
binding	O
regions	O
when	O
compared	O
with	O
its	O
close	O
homologue	O
,	O
OTUB2	B-Protein
,	O
suggesting	O
variations	O
in	O
regulatory	O
mechanisms	O
and	O
substrate	O
specificity	O
.	O

Biochemical	O
analysis	O
reveals	O
that	O
OTUB1	B-Protein
has	O
a	O
preference	O
for	O
cleaving	O
Lys	O
(	O
48	O
)	O
-	O
linked	O
polyubiquitin	B-Protein
chains	O
over	O
Lys	O
(	O
63	O
)	O
-	O
linked	O
polyubiquitin	B-Protein
chains	O
,	O
and	O
it	O
is	O
capable	O
of	O
cleaving	O
NEDD8	B-Protein
(	O
neural	B-Protein
-	I-Protein
precursor	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
expressed	I-Protein
developmentally	I-Protein
down	I-Protein
-	I-Protein
regulated	I-Protein
8	I-Protein
)	O
,	O
but	O
not	O
SUMO	B-Protein
(	I-Protein
small	I-Protein
ubiquitin	I-Protein
-	I-Protein
related	I-Protein
modifier	I-Protein
)	I-Protein
1	I-Protein
/	O
2	B-Protein
/	O
3	B-Protein
and	O
ISG15	B-Protein
(	O
interferon	O
-	O
stimulated	O
gene	O
15	O
)	O
conjugates	O
.	O

A	O
functional	O
comparison	O
of	O
OTUB1	B-Protein
and	O
OTUB2	B-Protein
indicated	O
a	O
differential	O
reactivity	O
towards	O
ubiquitin	B-Protein
-	O
based	O
active	O
-	O
site	O
probes	O
carrying	O
a	O
vinyl	O
methyl	O
ester	O
,	O
a	O
2	O
-	O
chloroethyl	O
or	O
a	O
2	O
-	O
bromoethyl	O
group	O
at	O
the	O
C	O
-	O
terminus	O
.	O

Mutational	O
analysis	O
suggested	O
that	O
a	O
narrow	O
P1	O
'	O
site	O
,	O
as	O
observed	O
in	O
OTUB1	B-Protein
,	O
correlates	O
with	O
its	O
ability	O
to	O
preferentially	O
cleave	O
Lys	O
(	O
48	O
)	O
-	O
linked	O
ubiquitin	B-Protein
chains	O
.	O
<EOS>	B-X
OTUB	B-X
(	B-X
otubain	B-X
)	B-X
1	B-X
is	B-X
a	B-X
human	B-X
deubiquitinating	B-X
enzyme	B-X
that	B-X
is	B-X
implicated	B-X
in	B-X
mediating	B-X
lymphocyte	B-X
antigen	B-X
responsiveness	B-X
,	B-X
but	B-X
whose	B-X
molecular	B-X
function	B-X
is	B-X
generally	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
A	B-X
structural	B-X
analysis	B-X
of	B-X
OTUB1	B-X
shows	B-X
differences	B-X
in	B-X
accessibility	B-X
to	B-X
the	B-X
active	B-X
site	B-X
and	B-X
in	B-X
surface	B-X
properties	B-X
of	B-X
the	B-X
substrate-binding	B-X
regions	B-X
when	B-X
compared	B-X
with	B-X
its	B-X
close	B-X
homologue	B-X
,	B-X
OTUB2	B-X
,	B-X
suggesting	B-X
variations	B-X
in	B-X
regulatory	B-X
mechanisms	B-X
and	B-X
substrate	B-X
specificity	B-X
.	B-X
Biochemical	B-X
analysis	B-X
reveals	B-X
that	B-X
OTUB1	B-X
has	B-X
a	B-X
preference	B-X
for	B-X
cleaving	B-X
Lys	B-X
(	B-X
48	B-X
)	B-X
-linked	B-X
polyubiquitin	B-X
chains	B-X
over	B-X
Lys	B-X
(	B-X
63	B-X
)	B-X
-linked	B-X
polyubiquitin	B-X
chains	B-X
,	B-X
and	B-X
it	B-X
is	B-X
capable	B-X
of	B-X
cleaving	B-X
NEDD8	B-X
(	B-X
neural-precursor-cell-expressed	B-X
developmentally	B-X
down-regulated	B-X
8	B-X
)	B-X
,	B-X
but	B-X
not	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
1/2/3	B-X
and	B-X
ISG15	B-X
(	B-X
interferon-stimulated	B-X
gene	B-X
15	B-X
)	B-X
conjugates	B-X
.	B-X
A	B-X
functional	B-X
comparison	B-X
of	B-X
OTUB1	B-X
and	B-X
OTUB2	B-X
indicated	B-X
a	B-X
differential	B-X
reactivity	B-X
towards	B-X
ubiquitin-based	B-X
active-site	B-X
probes	B-X
carrying	B-X
a	B-X
vinyl	B-X
methyl	B-X
ester	B-X
,	B-X
a	B-X
2-chloroethyl	B-X
or	B-X
a	B-X
2-bromoethyl	B-X
group	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
Mutational	B-X
analysis	B-X
suggested	B-X
that	B-X
a	B-X
narrow	B-X
P1	B-X
'	B-X
site	B-X
,	B-X
as	B-X
observed	B-X
in	B-X
OTUB1	B-X
,	B-X
correlates	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
preferentially	B-X
cleave	B-X
Lys	B-X
(	B-X
48	B-X
)	B-X
-linked	B-X
ubiquitin	B-X
chains	B-X
.	B-X
Analysis	B-X
of	B-X
cellular	B-X
interaction	B-X
partners	B-X
of	B-X
OTUB1	B-X
by	B-X
co-immunoprecipitation	B-X
and	B-X
MS/MS	B-X
(	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
)	B-X
experiments	B-X
demonstrated	B-X
that	B-X
FUS	B-X
[	B-X
fusion	B-X
involved	B-X
in	B-X
t	B-X
(	B-X
12	B-X
;	B-X
6	B-X
)	B-X
in	B-X
malignant	B-X
liposarcoma	B-X
;	B-X
also	B-X
known	B-X
as	B-X
TLS	B-X
(	B-X
translocation	B-X
in	B-X
liposarcoma	B-X
)	B-X
or	B-X
CHOP	B-X
(	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
homologous	B-X
protein	B-X
)	B-X
]	B-X
and	B-X
RACK1	B-X
[	B-X
receptor	B-X
for	B-X
activated	B-X
kinase	B-X
1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
GNB2L1	B-X
(	B-X
guanine-nucleotide-binding	B-X
protein	B-X
beta	B-X
polypeptide	B-X
2-like	B-X
1	B-X
)	B-X
]	B-X
are	B-X
part	B-X
of	B-X
OTUB1-containing	B-X
complexes	B-X
,	B-X
pointing	B-X
towards	B-X
a	B-X
molecular	B-X
function	B-X
of	B-X
this	B-X
deubiquitinating	B-X
enzyme	B-X
in	B-X
RNA	B-X
processing	B-X
and	B-X
cell	B-X
adhesion/morphology	B-X
.	B-X

Analysis	O
of	O
cellular	O
interaction	O
partners	O
of	O
OTUB1	B-Protein
by	O
co	O
-	O
immunoprecipitation	O
and	O
MS	O
/	O
MS	O
(	O
tandem	O
mass	O
spectrometry	O
)	O
experiments	O
demonstrated	O
that	O
FUS	B-Protein
[	O
fusion	B-Protein
involved	I-Protein
in	I-Protein
t	I-Protein
(	I-Protein
12	I-Protein
;	I-Protein
6	I-Protein
)	I-Protein
in	I-Protein
malignant	I-Protein
liposarcoma	I-Protein
;	O
also	O
known	O
as	O
TLS	B-Protein
(	O
translocation	B-Protein
in	I-Protein
liposarcoma	I-Protein
)	O
or	O
CHOP	B-Protein
(	O
CCAAT	B-Protein
/	I-Protein
enhancer	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
homologous	I-Protein
protein	I-Protein
)	O
]	O
and	O
RACK1	B-Protein
[	O
receptor	B-Protein
for	I-Protein
activated	I-Protein
kinase	I-Protein
1	I-Protein
;	O
also	O
known	O
as	O
GNB2L1	B-Protein
(	O
guanine	B-Protein
-	I-Protein
nucleotide	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
beta	I-Protein
polypeptide	I-Protein
2	I-Protein
-	I-Protein
like	I-Protein
1	I-Protein
)	O
]	O
are	O
part	O
of	O
OTUB1	B-Protein
-	O
containing	O
complexes	O
,	O
pointing	O
towards	O
a	O
molecular	O
function	O
of	O
this	O
deubiquitinating	O
enzyme	O
in	O
RNA	O
processing	O
and	O
cell	O
adhesion	O
/	O
morphology	O
.	O

O	O
-	O
linked	O
GlcNAc	O
modification	O
of	O
cardiac	O
myofilament	O
proteins	O
:	O
a	O
novel	O
regulator	O
of	O
myocardial	O
contractile	O
function	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
O-phosphorylation	B-X
,	B-X
O-linked	B-X
modifications	B-X
of	B-X
serine	B-X
and	B-X
threonine	B-X
by	B-X
beta-N-acetyl-D-glucosamine	B-X
(	B-X
GlcNAc	B-X
)	B-X
may	B-X
regulate	B-X
muscle	B-X
contractile	B-X
function	B-X
.	B-X
This	B-X
study	B-X
assessed	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
O-GlcNAcylation	B-X
in	B-X
cardiac	B-X
muscle	B-X
contractile	B-X
activation	B-X
.	B-X
To	B-X
identify	B-X
specific	B-X
sites	B-X
of	B-X
O-GlcNAcylation	B-X
in	B-X
cardiac	B-X
myofilament	B-X
proteins	B-X
,	B-X
a	B-X
recently	B-X
developed	B-X
methodology	B-X
based	B-X
on	B-X
GalNAz-biotin	B-X
labeling	B-X
followed	B-X
by	B-X
dithiothreitol	B-X
replacement	B-X
and	B-X
light	B-X
chromatography/tandem	B-X
mass	B-X
spectrometry	B-X
site	B-X
mapping	B-X
was	B-X
adopted	B-X
.	B-X
Thirty-two	B-X
O-GlcNAcylated	B-X
peptides	B-X
from	B-X
cardiac	B-X
myofilaments	B-X
were	B-X
identified	B-X
on	B-X
cardiac	B-X
myosin	B-X
heavy	B-X
chain	B-X
,	B-X
actin	B-X
,	B-X
myosin	B-X
light	B-X
chains	B-X
,	B-X
and	B-X
troponin	B-X
I	B-X
.	B-X
To	B-X
assess	B-X
the	B-X
potential	B-X
physiological	B-X
role	B-X
of	B-X
the	B-X
GlcNAc	B-X
,	B-X
force-	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
relationships	B-X
were	B-X
studied	B-X
in	B-X
skinned	B-X
rat	B-X
trabeculae	B-X
.	B-X
Exposure	B-X
to	B-X
GlcNAc	B-X
significantly	B-X
decreased	B-X
calcium	B-X
sensitivity	B-X
(	B-X
pCa50	B-X
)	B-X
,	B-X
whereas	B-X
maximal	B-X
force	B-X
(	B-X
F	B-X
(	B-X
max	B-X
)	B-X
)	B-X
and	B-X
Hill	B-X
coefficient	B-X
(	B-X
n	B-X
)	B-X
were	B-X
not	B-X
modified	B-X
.	B-X
Using	B-X
a	B-X
pan-specific	B-X
O-GlcNAc	B-X
antibody	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
acute	B-X
exposure	B-X
of	B-X
myofilaments	B-X
to	B-X
GlcNAc	B-X
induced	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
actin	B-X
O-GlcNAcylation	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
the	B-X
first	B-X
identification	B-X
of	B-X
O-GlcNAcylation	B-X
sites	B-X
in	B-X
cardiac	B-X
myofilament	B-X
proteins	B-X
and	B-X
demonstrates	B-X
their	B-X
potential	B-X
role	B-X
in	B-X
regulating	B-X
myocardial	B-X
contractile	B-X
function	B-X
.	B-X

In	O
addition	O
to	O
O	O
-	O
phosphorylation	O
,	O
O	O
-	O
linked	O
modifications	O
of	O
serine	O
and	O
threonine	O
by	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
D	O
-	O
glucosamine	O
(	O
GlcNAc	O
)	O
may	O
regulate	O
muscle	O
contractile	O
function	O
.	O

This	O
study	O
assessed	O
the	O
potential	O
role	O
of	O
O	O
-	O
GlcNAcylation	O
in	O
cardiac	O
muscle	O
contractile	O
activation	O
.	O

To	O
identify	O
specific	O
sites	O
of	O
O	O
-	O
GlcNAcylation	O
in	O
cardiac	O
myofilament	O
proteins	O
,	O
a	O
recently	O
developed	O
methodology	O
based	O
on	O
GalNAz	O
-	O
biotin	O
labeling	O
followed	O
by	O
dithiothreitol	O
replacement	O
and	O
light	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
site	O
mapping	O
was	O
adopted	O
.	O

Thirty	O
-	O
two	O
O	O
-	O
GlcNAcylated	O
peptides	O
from	O
cardiac	O
myofilaments	O
were	O
identified	O
on	O
cardiac	O
myosin	O
heavy	O
chain	O
,	O
actin	B-Protein
,	O
myosin	B-Protein
light	I-Protein
chains	I-Protein
,	O
and	O
troponin	B-Protein
I	I-Protein
.	O
<EOS>	B-X
This	B-X
study	B-X
assessed	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
O-GlcNAcylation	B-X
in	B-X
cardiac	B-X
muscle	B-X
contractile	B-X
activation	B-X
.	B-X
To	B-X
identify	B-X
specific	B-X
sites	B-X
of	B-X
O-GlcNAcylation	B-X
in	B-X
cardiac	B-X
myofilament	B-X
proteins	B-X
,	B-X
a	B-X
recently	B-X
developed	B-X
methodology	B-X
based	B-X
on	B-X
GalNAz-biotin	B-X
labeling	B-X
followed	B-X
by	B-X
dithiothreitol	B-X
replacement	B-X
and	B-X
light	B-X
chromatography/tandem	B-X
mass	B-X
spectrometry	B-X
site	B-X
mapping	B-X
was	B-X
adopted	B-X
.	B-X
Thirty-two	B-X
O-GlcNAcylated	B-X
peptides	B-X
from	B-X
cardiac	B-X
myofilaments	B-X
were	B-X
identified	B-X
on	B-X
cardiac	B-X
myosin	B-X
heavy	B-X
chain	B-X
,	B-X
actin	B-X
,	B-X
myosin	B-X
light	B-X
chains	B-X
,	B-X
and	B-X
troponin	B-X
I	B-X
.	B-X
Using	B-X
a	B-X
pan-specific	B-X
O-GlcNAc	B-X
antibody	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
acute	B-X
exposure	B-X
of	B-X
myofilaments	B-X
to	B-X
GlcNAc	B-X
induced	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
actin	B-X
O-GlcNAcylation	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
the	B-X
first	B-X
identification	B-X
of	B-X
O-GlcNAcylation	B-X
sites	B-X
in	B-X
cardiac	B-X
myofilament	B-X
proteins	B-X
and	B-X
demonstrates	B-X
their	B-X
potential	B-X
role	B-X
in	B-X
regulating	B-X
myocardial	B-X
contractile	B-X
function	B-X
.	B-X

To	O
assess	O
the	O
potential	O
physiological	O
role	O
of	O
the	O
GlcNAc	O
,	O
force	O
-	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
relationships	O
were	O
studied	O
in	O
skinned	O
rat	O
trabeculae	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
O-phosphorylation	B-X
,	B-X
O-linked	B-X
modifications	B-X
of	B-X
serine	B-X
and	B-X
threonine	B-X
by	B-X
beta-N-acetyl-D-glucosamine	B-X
(	B-X
GlcNAc	B-X
)	B-X
may	B-X
regulate	B-X
muscle	B-X
contractile	B-X
function	B-X
.	B-X
This	B-X
study	B-X
assessed	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
O-GlcNAcylation	B-X
in	B-X
cardiac	B-X
muscle	B-X
contractile	B-X
activation	B-X
.	B-X
To	B-X
identify	B-X
specific	B-X
sites	B-X
of	B-X
O-GlcNAcylation	B-X
in	B-X
cardiac	B-X
myofilament	B-X
proteins	B-X
,	B-X
a	B-X
recently	B-X
developed	B-X
methodology	B-X
based	B-X
on	B-X
GalNAz-biotin	B-X
labeling	B-X
followed	B-X
by	B-X
dithiothreitol	B-X
replacement	B-X
and	B-X
light	B-X
chromatography/tandem	B-X
mass	B-X
spectrometry	B-X
site	B-X
mapping	B-X
was	B-X
adopted	B-X
.	B-X
Thirty-two	B-X
O-GlcNAcylated	B-X
peptides	B-X
from	B-X
cardiac	B-X
myofilaments	B-X
were	B-X
identified	B-X
on	B-X
cardiac	B-X
myosin	B-X
heavy	B-X
chain	B-X
,	B-X
actin	B-X
,	B-X
myosin	B-X
light	B-X
chains	B-X
,	B-X
and	B-X
troponin	B-X
I	B-X
.	B-X
To	B-X
assess	B-X
the	B-X
potential	B-X
physiological	B-X
role	B-X
of	B-X
the	B-X
GlcNAc	B-X
,	B-X
force-	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
relationships	B-X
were	B-X
studied	B-X
in	B-X
skinned	B-X
rat	B-X
trabeculae	B-X
.	B-X
Exposure	B-X
to	B-X
GlcNAc	B-X
significantly	B-X
decreased	B-X
calcium	B-X
sensitivity	B-X
(	B-X
pCa50	B-X
)	B-X
,	B-X
whereas	B-X
maximal	B-X
force	B-X
(	B-X
F	B-X
(	B-X
max	B-X
)	B-X
)	B-X
and	B-X
Hill	B-X
coefficient	B-X
(	B-X
n	B-X
)	B-X
were	B-X
not	B-X
modified	B-X
.	B-X
Using	B-X
a	B-X
pan-specific	B-X
O-GlcNAc	B-X
antibody	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
acute	B-X
exposure	B-X
of	B-X
myofilaments	B-X
to	B-X
GlcNAc	B-X
induced	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
actin	B-X
O-GlcNAcylation	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
the	B-X
first	B-X
identification	B-X
of	B-X
O-GlcNAcylation	B-X
sites	B-X
in	B-X
cardiac	B-X
myofilament	B-X
proteins	B-X
and	B-X
demonstrates	B-X
their	B-X
potential	B-X
role	B-X
in	B-X
regulating	B-X
myocardial	B-X
contractile	B-X
function	B-X
.	B-X

Exposure	O
to	O
GlcNAc	O
significantly	O
decreased	O
calcium	O
sensitivity	O
(	O
pCa50	O
)	O
,	O
whereas	O
maximal	O
force	O
(	O
F	O
(	O
max	O
)	O
)	O
and	O
Hill	O
coefficient	O
(	O
n	O
)	O
were	O
not	O
modified	O
.	O

Using	O
a	O
pan	O
-	O
specific	O
O	O
-	O
GlcNAc	O
antibody	O
,	O
it	O
was	O
determined	O
that	O
acute	O
exposure	O
of	O
myofilaments	O
to	O
GlcNAc	O
induced	O
a	O
significant	O
increase	O
in	O
actin	O
O	O
-	O
GlcNAcylation	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
O-phosphorylation	B-X
,	B-X
O-linked	B-X
modifications	B-X
of	B-X
serine	B-X
and	B-X
threonine	B-X
by	B-X
beta-N-acetyl-D-glucosamine	B-X
(	B-X
GlcNAc	B-X
)	B-X
may	B-X
regulate	B-X
muscle	B-X
contractile	B-X
function	B-X
.	B-X
This	B-X
study	B-X
assessed	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
O-GlcNAcylation	B-X
in	B-X
cardiac	B-X
muscle	B-X
contractile	B-X
activation	B-X
.	B-X
To	B-X
identify	B-X
specific	B-X
sites	B-X
of	B-X
O-GlcNAcylation	B-X
in	B-X
cardiac	B-X
myofilament	B-X
proteins	B-X
,	B-X
a	B-X
recently	B-X
developed	B-X
methodology	B-X
based	B-X
on	B-X
GalNAz-biotin	B-X
labeling	B-X
followed	B-X
by	B-X
dithiothreitol	B-X
replacement	B-X
and	B-X
light	B-X
chromatography/tandem	B-X
mass	B-X
spectrometry	B-X
site	B-X
mapping	B-X
was	B-X
adopted	B-X
.	B-X
Thirty-two	B-X
O-GlcNAcylated	B-X
peptides	B-X
from	B-X
cardiac	B-X
myofilaments	B-X
were	B-X
identified	B-X
on	B-X
cardiac	B-X
myosin	B-X
heavy	B-X
chain	B-X
,	B-X
actin	B-X
,	B-X
myosin	B-X
light	B-X
chains	B-X
,	B-X
and	B-X
troponin	B-X
I	B-X
.	B-X
To	B-X
assess	B-X
the	B-X
potential	B-X
physiological	B-X
role	B-X
of	B-X
the	B-X
GlcNAc	B-X
,	B-X
force-	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
relationships	B-X
were	B-X
studied	B-X
in	B-X
skinned	B-X
rat	B-X
trabeculae	B-X
.	B-X
Exposure	B-X
to	B-X
GlcNAc	B-X
significantly	B-X
decreased	B-X
calcium	B-X
sensitivity	B-X
(	B-X
pCa50	B-X
)	B-X
,	B-X
whereas	B-X
maximal	B-X
force	B-X
(	B-X
F	B-X
(	B-X
max	B-X
)	B-X
)	B-X
and	B-X
Hill	B-X
coefficient	B-X
(	B-X
n	B-X
)	B-X
were	B-X
not	B-X
modified	B-X
.	B-X
Using	B-X
a	B-X
pan-specific	B-X
O-GlcNAc	B-X
antibody	B-X
,	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
acute	B-X
exposure	B-X
of	B-X
myofilaments	B-X
to	B-X
GlcNAc	B-X
induced	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
actin	B-X
O-GlcNAcylation	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
the	B-X
first	B-X
identification	B-X
of	B-X
O-GlcNAcylation	B-X
sites	B-X
in	B-X
cardiac	B-X
myofilament	B-X
proteins	B-X
and	B-X
demonstrates	B-X
their	B-X
potential	B-X
role	B-X
in	B-X
regulating	B-X
myocardial	B-X
contractile	B-X
function	B-X
.	B-X

This	O
study	O
provides	O
the	O
first	O
identification	O
of	O
O	O
-	O
GlcNAcylation	O
sites	O
in	O
cardiac	O
myofilament	O
proteins	O
and	O
demonstrates	O
their	O
potential	O
role	O
in	O
regulating	O
myocardial	O
contractile	O
function	O
.	O

Biochemical	O
characterization	O
of	O
plasma	O
-	O
derived	O
tissue	B-Protein
factor	I-Protein
pathway	I-Protein
inhibitor	I-Protein
:	O
post	O
-	O
translational	O
modification	O
of	O
free	O
,	O
full	O
-	O
length	O
form	O
with	O
particular	O
reference	O
to	O
the	O
sugar	O
chain	O
.	O

BACKGROUND	O
:	O
Tissue	B-Protein
factor	I-Protein
pathway	I-Protein
inhibitor	I-Protein
(	O
TFPI	B-Protein
)	O
is	O
a	O
physiological	O
protease	O
inhibitor	O
that	O
inhibits	O
the	O
initial	O
reactions	O
of	O
the	O
extrinsic	O
blood	O
coagulation	O
pathway	O
.	O
<EOS>	B-X
Tissue	B-X
factor	B-X
pathway	B-X
inhibitor	B-X
(	B-X
TFPI	B-X
)	B-X
is	B-X
a	B-X
physiological	B-X
protease	B-X
inhibitor	B-X
that	B-X
inhibits	B-X
the	B-X
initial	B-X
reactions	B-X
of	B-X
the	B-X
extrinsic	B-X
blood	B-X
coagulation	B-X
pathway	B-X
.	B-X
Most	B-X
TFPI	B-X
in	B-X
human	B-X
plasma	B-X
is	B-X
associated	B-X
with	B-X
lipoproteins	B-X
;	B-X
however	B-X
,	B-X
the	B-X
most	B-X
functionally	B-X
active	B-X
form	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
the	B-X
free	B-X
,	B-X
full-length	B-X
form	B-X
(	B-X
f-pTFPI	B-X
)	B-X
.	B-X
Cell	B-X
culture	B-X
derived	B-X
TFPI	B-X
and	B-X
recombinant	B-X
TFPI	B-X
(	B-X
rTFPI	B-X
)	B-X
exhibit	B-X
variations	B-X
in	B-X
their	B-X
respective	B-X
anticoagulant	B-X
activity	B-X
,	B-X
which	B-X
may	B-X
be	B-X
caused	B-X
by	B-X
post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
the	B-X
frequent	B-X
differences	B-X
in	B-X
sugar	B-X
chain	B-X
structures	B-X
among	B-X
recombinant	B-X
proteins	B-X
.	B-X
Sugar	B-X
chain	B-X
structures	B-X
in	B-X
rTFPI	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
previously	B-X
,	B-X
but	B-X
those	B-X
of	B-X
plasma	B-X
TFPI	B-X
have	B-X
not	B-X
been	B-X
.	B-X

Most	O
TFPI	B-Protein
in	O
human	O
plasma	O
is	O
associated	O
with	O
lipoproteins	O
;	O
however	O
,	O
the	O
most	O
functionally	O
active	O
form	O
is	O
thought	O
to	O
be	O
the	O
free	O
,	O
full	O
-	O
length	O
form	O
(	O
f	O
-	O
pTFPI	B-Protein
)	O
.	O
<EOS>	B-X
Protein	B-X
S	B-X
is	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
protein	B-X
that	B-X
acts	B-X
as	B-X
a	B-X
cofactor	B-X
of	B-X
the	B-X
anticoagulant	B-X
protein	B-X
APC	B-X
.	B-X
However	B-X
,	B-X
protein	B-X
S	B-X
also	B-X
exhibits	B-X
anticoagulant	B-X
activity	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
APC	B-X
.	B-X
Thrombin	B-X
generation	B-X
experiments	B-X
in	B-X
normal	B-X
plasma	B-X
and	B-X
in	B-X
plasma	B-X
deficient	B-X
in	B-X
tissue	B-X
factor	B-X
pathway	B-X
inhibitor	B-X
(	B-X
TFPI	B-X
)	B-X
and/or	B-X
protein	B-X
S	B-X
demonstrated	B-X
that	B-X
protein	B-X
S	B-X
stimulates	B-X
the	B-X
inhibition	B-X
of	B-X
TF	B-X
by	B-X
TFPI	B-X
.	B-X
Kinetic	B-X
analysis	B-X
in	B-X
model	B-X
systems	B-X
containing	B-X
purified	B-X
proteins	B-X
showed	B-X
that	B-X
protein	B-X
S	B-X
enhances	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
binary	B-X
FXa	B-X
:	B-X
TFPI	B-X
complex	B-X
by	B-X
reducing	B-X
the	B-X
Ki	B-X
of	B-X
TFPI	B-X
from	B-X
approximately	B-X
4	B-X
nM	B-X
to	B-X
approximately	B-X
0.5	B-X
nM	B-X
.	B-X
Enhancement	B-X
of	B-X
inhibitory	B-X
activity	B-X
of	B-X
TFPI	B-X
by	B-X
protein	B-X
S	B-X
is	B-X
only	B-X
observed	B-X
with	B-X
full-length	B-X
TFPI	B-X
and	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
negatively	B-X
charged	B-X
phospholipid	B-X
surface	B-X
.	B-X
The	B-X
Ki	B-X
decrease	B-X
brings	B-X
the	B-X
TFPI	B-X
concentration	B-X
necessary	B-X
for	B-X
FXa	B-X
:	B-X
TFPI	B-X
complex	B-X
formation	B-X
within	B-X
range	B-X
of	B-X
the	B-X
plasma	B-X
TFPI	B-X
concentration	B-X
which	B-X
increases	B-X
FXa	B-X
:	B-X
TFPI	B-X
complex	B-X
formation	B-X
and	B-X
accelerates	B-X
feedback	B-X
inhibition	B-X
of	B-X
the	B-X
TF	B-X
pathway	B-X
by	B-X
enhancing	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
quaternary	B-X
TFPI	B-X
:	B-X
FXa	B-X
:	B-X
TF	B-X
:	B-X
FVIIa	B-X
complex	B-X
.	B-X
Thus	B-X
,	B-X
protein	B-X
S	B-X
is	B-X
not	B-X
only	B-X
a	B-X
cofactor	B-X
of	B-X
APC	B-X
,	B-X
but	B-X
also	B-X
of	B-X
TFPI	B-X
.	B-X
A	B-X
reduced	B-X
TFPI	B-X
cofactor	B-X
activity	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
increased	B-X
risk	B-X
of	B-X
venous	B-X
thrombosis	B-X
in	B-X
protein-S	B-X
deficient	B-X
individuals	B-X
.	B-X
Using	B-X
calibrated	B-X
automated	B-X
thrombography	B-X
we	B-X
have	B-X
developed	B-X
two	B-X
assays	B-X
that	B-X
enable	B-X
quantification	B-X
of	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
TFPI/protein	B-X
S	B-X
system	B-X
in	B-X
plasma	B-X
.	B-X
These	B-X
assays	B-X
show	B-X
that	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
TFPI/protein	B-X
S	B-X
system	B-X
is	B-X
greatly	B-X
impaired	B-X
in	B-X
oral	B-X
contraceptive	B-X
users	B-X
.	B-X

Cell	O
culture	O
derived	O
TFPI	B-Protein
and	O
recombinant	O
TFPI	B-Protein
(	O
rTFPI	B-Protein
)	O
exhibit	O
variations	O
in	O
their	O
respective	O
anticoagulant	O
activity	O
,	O
which	O
may	O
be	O
caused	O
by	O
post	O
-	O
translational	O
modifications	O
,	O
such	O
as	O
the	O
frequent	O
differences	O
in	O
sugar	O
chain	O
structures	O
among	O
recombinant	O
proteins	O
.	O
<EOS>	B-X
Tissue	B-X
factor	B-X
pathway	B-X
inhibitor	B-X
(	B-X
TFPI	B-X
)	B-X
is	B-X
a	B-X
physiological	B-X
protease	B-X
inhibitor	B-X
that	B-X
inhibits	B-X
the	B-X
initial	B-X
reactions	B-X
of	B-X
the	B-X
extrinsic	B-X
blood	B-X
coagulation	B-X
pathway	B-X
.	B-X
Most	B-X
TFPI	B-X
in	B-X
human	B-X
plasma	B-X
is	B-X
associated	B-X
with	B-X
lipoproteins	B-X
;	B-X
however	B-X
,	B-X
the	B-X
most	B-X
functionally	B-X
active	B-X
form	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
the	B-X
free	B-X
,	B-X
full-length	B-X
form	B-X
(	B-X
f-pTFPI	B-X
)	B-X
.	B-X
Cell	B-X
culture	B-X
derived	B-X
TFPI	B-X
and	B-X
recombinant	B-X
TFPI	B-X
(	B-X
rTFPI	B-X
)	B-X
exhibit	B-X
variations	B-X
in	B-X
their	B-X
respective	B-X
anticoagulant	B-X
activity	B-X
,	B-X
which	B-X
may	B-X
be	B-X
caused	B-X
by	B-X
post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
the	B-X
frequent	B-X
differences	B-X
in	B-X
sugar	B-X
chain	B-X
structures	B-X
among	B-X
recombinant	B-X
proteins	B-X
.	B-X
Sugar	B-X
chain	B-X
structures	B-X
in	B-X
rTFPI	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
previously	B-X
,	B-X
but	B-X
those	B-X
of	B-X
plasma	B-X
TFPI	B-X
have	B-X
not	B-X
been	B-X
.	B-X

Sugar	O
chain	O
structures	O
in	O
rTFPI	B-Protein
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
have	O
been	O
reported	O
previously	O
,	O
but	O
those	O
of	O
plasma	O
TFPI	B-Protein
have	O
not	O
been	O
.	O
<EOS>	B-X
Tissue	B-X
factor	B-X
pathway	B-X
inhibitor	B-X
(	B-X
TFPI	B-X
)	B-X
is	B-X
a	B-X
physiological	B-X
protease	B-X
inhibitor	B-X
that	B-X
inhibits	B-X
the	B-X
initial	B-X
reactions	B-X
of	B-X
the	B-X
extrinsic	B-X
blood	B-X
coagulation	B-X
pathway	B-X
.	B-X
Most	B-X
TFPI	B-X
in	B-X
human	B-X
plasma	B-X
is	B-X
associated	B-X
with	B-X
lipoproteins	B-X
;	B-X
however	B-X
,	B-X
the	B-X
most	B-X
functionally	B-X
active	B-X
form	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
the	B-X
free	B-X
,	B-X
full-length	B-X
form	B-X
(	B-X
f-pTFPI	B-X
)	B-X
.	B-X
Cell	B-X
culture	B-X
derived	B-X
TFPI	B-X
and	B-X
recombinant	B-X
TFPI	B-X
(	B-X
rTFPI	B-X
)	B-X
exhibit	B-X
variations	B-X
in	B-X
their	B-X
respective	B-X
anticoagulant	B-X
activity	B-X
,	B-X
which	B-X
may	B-X
be	B-X
caused	B-X
by	B-X
post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
the	B-X
frequent	B-X
differences	B-X
in	B-X
sugar	B-X
chain	B-X
structures	B-X
among	B-X
recombinant	B-X
proteins	B-X
.	B-X
Sugar	B-X
chain	B-X
structures	B-X
in	B-X
rTFPI	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
previously	B-X
,	B-X
but	B-X
those	B-X
of	B-X
plasma	B-X
TFPI	B-X
have	B-X
not	B-X
been	B-X
.	B-X

OBJECTIVES	O
:	O
To	O
purify	O
f	O
-	O
pTFPI	B-Protein
and	O
analyze	O
the	O
sugar	O
chain	O
structures	O
.	O
<EOS>	B-X
Tissue	B-X
factor	B-X
pathway	B-X
inhibitor	B-X
(	B-X
TFPI	B-X
)	B-X
is	B-X
a	B-X
physiological	B-X
protease	B-X
inhibitor	B-X
that	B-X
inhibits	B-X
the	B-X
initial	B-X
reactions	B-X
of	B-X
the	B-X
extrinsic	B-X
blood	B-X
coagulation	B-X
pathway	B-X
.	B-X
Most	B-X
TFPI	B-X
in	B-X
human	B-X
plasma	B-X
is	B-X
associated	B-X
with	B-X
lipoproteins	B-X
;	B-X
however	B-X
,	B-X
the	B-X
most	B-X
functionally	B-X
active	B-X
form	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
the	B-X
free	B-X
,	B-X
full-length	B-X
form	B-X
(	B-X
f-pTFPI	B-X
)	B-X
.	B-X
Cell	B-X
culture	B-X
derived	B-X
TFPI	B-X
and	B-X
recombinant	B-X
TFPI	B-X
(	B-X
rTFPI	B-X
)	B-X
exhibit	B-X
variations	B-X
in	B-X
their	B-X
respective	B-X
anticoagulant	B-X
activity	B-X
,	B-X
which	B-X
may	B-X
be	B-X
caused	B-X
by	B-X
post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
the	B-X
frequent	B-X
differences	B-X
in	B-X
sugar	B-X
chain	B-X
structures	B-X
among	B-X
recombinant	B-X
proteins	B-X
.	B-X
Sugar	B-X
chain	B-X
structures	B-X
in	B-X
rTFPI	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
previously	B-X
,	B-X
but	B-X
those	B-X
of	B-X
plasma	B-X
TFPI	B-X
have	B-X
not	B-X
been	B-X
.	B-X

RESULTS	O
AND	O
CONCLUSION	O
:	O
f	O
-	O
pTFPI	B-Protein
was	O
purified	O
to	O
homogeneity	O
from	O
blood	O
plasma	O
using	O
a	O
combination	O
of	O
anion	O
-	O
exchange	O
,	O
heparin	O
affinity	O
,	O
immunoaffinity	O
,	O
and	O
reversed	O
-	O
phase	O
chromatographies	O
,	O
resulting	O
in	O
a	O
yield	O
of	O
76	O
%	O
.	O

f	O
-	O
pTFPI	B-Protein
showed	O
a	O
partially	O
phosphorylated	O
glycoprotein	O
comprising	O
a	O
total	O
of	O
276	O
amino	O
acids	O
by	O
peptide	O
mapping	O
.	O
<EOS>	B-X
Tissue	B-X
factor	B-X
pathway	B-X
inhibitor	B-X
(	B-X
TFPI	B-X
)	B-X
is	B-X
a	B-X
physiological	B-X
protease	B-X
inhibitor	B-X
that	B-X
inhibits	B-X
the	B-X
initial	B-X
reactions	B-X
of	B-X
the	B-X
extrinsic	B-X
blood	B-X
coagulation	B-X
pathway	B-X
.	B-X
Most	B-X
TFPI	B-X
in	B-X
human	B-X
plasma	B-X
is	B-X
associated	B-X
with	B-X
lipoproteins	B-X
;	B-X
however	B-X
,	B-X
the	B-X
most	B-X
functionally	B-X
active	B-X
form	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
the	B-X
free	B-X
,	B-X
full-length	B-X
form	B-X
(	B-X
f-pTFPI	B-X
)	B-X
.	B-X
Cell	B-X
culture	B-X
derived	B-X
TFPI	B-X
and	B-X
recombinant	B-X
TFPI	B-X
(	B-X
rTFPI	B-X
)	B-X
exhibit	B-X
variations	B-X
in	B-X
their	B-X
respective	B-X
anticoagulant	B-X
activity	B-X
,	B-X
which	B-X
may	B-X
be	B-X
caused	B-X
by	B-X
post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
the	B-X
frequent	B-X
differences	B-X
in	B-X
sugar	B-X
chain	B-X
structures	B-X
among	B-X
recombinant	B-X
proteins	B-X
.	B-X
Sugar	B-X
chain	B-X
structures	B-X
in	B-X
rTFPI	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
previously	B-X
,	B-X
but	B-X
those	B-X
of	B-X
plasma	B-X
TFPI	B-X
have	B-X
not	B-X
been	B-X
.	B-X

The	O
sugar	O
chain	O
structures	O
were	O
analyzed	O
by	O
two	O
-	O
dimensional	O
sugar	O
mapping	O
combined	O
with	O
exoglycosidase	O
digestion	O
of	O
the	O
pyridylamino	O
sugar	O
chains	O
and	O
the	O
following	O
results	O
were	O
obtained	O
.	O
<EOS>	B-X
Cell	B-X
culture	B-X
derived	B-X
TFPI	B-X
and	B-X
recombinant	B-X
TFPI	B-X
(	B-X
rTFPI	B-X
)	B-X
exhibit	B-X
variations	B-X
in	B-X
their	B-X
respective	B-X
anticoagulant	B-X
activity	B-X
,	B-X
which	B-X
may	B-X
be	B-X
caused	B-X
by	B-X
post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
the	B-X
frequent	B-X
differences	B-X
in	B-X
sugar	B-X
chain	B-X
structures	B-X
among	B-X
recombinant	B-X
proteins	B-X
.	B-X
Sugar	B-X
chain	B-X
structures	B-X
in	B-X
rTFPI	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
previously	B-X
,	B-X
but	B-X
those	B-X
of	B-X
plasma	B-X
TFPI	B-X
have	B-X
not	B-X
been	B-X
.	B-X

(	O
Sialyl	O
)	O
Galbeta1	O
-	O
3GalNAc	O
was	O
linked	O
to	O
Thr	O
(	O
175	O
)	O
,	O
partially	O
to	O
Thr	O
(	O
14	O
)	O
and	O
Ser	O
(	O
174	O
)	O
;	O
sialyl	O
complex	O
-	O
type	O
sugar	O
chains	O
to	O
Asn	O
(	O
117	O
)	O
and	O
Asn	O
(	O
167	O
)	O
,	O
whereas	O
Asn	O
(	O
228	O
)	O
was	O
not	O
glycosylated	O
.	O

Neuraminidase	O
-	O
resistant	O
acidic	O
sugar	O
chains	O
including	O
sulfated	O
sugar	O
chains	O
were	O
not	O
observed	O
significantly	O
.	O

The	O
protease	O
inhibitory	O
activities	O
of	O
f	O
-	O
pTFPI	B-Protein
towards	O
activated	O
factor	B-Protein
(	I-Protein
F	I-Protein
)	I-Protein
X	I-Protein
and	O
tissue	B-Protein
factor	I-Protein
-	O
activated	O
FVII	O
complex	O
were	O
identical	O
to	O
those	O
of	O
full	O
-	O
length	O
rTFPI	B-Protein
expressed	O
in	O
CHO	O
cells	O
.	O

Site	O
-	O
specific	O
mutagenesis	O
identifies	O
three	O
cysteine	O
residues	O
in	O
the	O
cytoplasmic	O
tail	O
as	O
acylation	O
sites	O
of	O
influenza	O
virus	O
hemagglutinin	B-Protein
.	O
<EOS>	B-X
The	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
of	B-X
influenza	B-X
virus	B-X
is	B-X
a	B-X
type	B-X
I	B-X
transmembrane	B-X
glycoprotein	B-X
which	B-X
is	B-X
acylated	B-X
with	B-X
long-chain	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
have	B-X
used	B-X
oligonucleotide-directed	B-X
mutagenesis	B-X
of	B-X
cloned	B-X
cDNA	B-X
and	B-X
a	B-X
simian	B-X
virus	B-X
40	B-X
expression	B-X
system	B-X
to	B-X
determine	B-X
the	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
HA	B-X
and	B-X
to	B-X
examine	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
HA	B-X
is	B-X
acylated	B-X
through	B-X
thioester	B-X
linkages	B-X
at	B-X
three	B-X
highly	B-X
conserved	B-X
cysteine	B-X
residues	B-X
located	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
and	B-X
at	B-X
the	B-X
carboxy-terminal	B-X
end	B-X
of	B-X
the	B-X
transmembrane	B-X
region	B-X
,	B-X
whereas	B-X
a	B-X
cysteine	B-X
located	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
the	B-X
membrane-spanning	B-X
domain	B-X
is	B-X
not	B-X
acylated	B-X
.	B-X
Mutants	B-X
lacking	B-X
fatty	B-X
acids	B-X
at	B-X
individual	B-X
or	B-X
all	B-X
three	B-X
attachment	B-X
sites	B-X
acquire	B-X
endoglycosidase	B-X
H-resistant	B-X
oligosaccharide	B-X
side	B-X
chains	B-X
,	B-X
are	B-X
cleaved	B-X
into	B-X
HA1	B-X
and	B-X
HA2	B-X
subunits	B-X
,	B-X
and	B-X
are	B-X
transported	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
at	B-X
rates	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
wild-type	B-X
HA	B-X
.	B-X
Furthermore	B-X
,	B-X
lack	B-X
of	B-X
acylation	B-X
has	B-X
no	B-X
obvious	B-X
influence	B-X
on	B-X
the	B-X
biological	B-X
activities	B-X
of	B-X
HA	B-X
:	B-X
cells	B-X
expressing	B-X
fatty	B-X
acid-free	B-X
HA	B-X
bind	B-X
to	B-X
and	B-X
,	B-X
after	B-X
brief	B-X
exposure	B-X
to	B-X
mildly	B-X
acidic	B-X
pH	B-X
,	B-X
fuse	B-X
with	B-X
erythrocytes	B-X
;	B-X
the	B-X
HA-induced	B-X
polykaryon	B-X
formation	B-X
is	B-X
not	B-X
impaired	B-X
,	B-X
either	B-X
.	B-X

The	O
hemagglutinin	B-Protein
(	O
HA	B-Protein
)	O
of	O
influenza	O
virus	O
is	O
a	O
type	O
I	O
transmembrane	O
glycoprotein	O
which	O
is	O
acylated	O
with	O
long	O
-	O
chain	O
fatty	O
acids	O
.	O
<EOS>	B-X
The	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
of	B-X
influenza	B-X
virus	B-X
is	B-X
a	B-X
type	B-X
I	B-X
transmembrane	B-X
glycoprotein	B-X
which	B-X
is	B-X
acylated	B-X
with	B-X
long-chain	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
have	B-X
used	B-X
oligonucleotide-directed	B-X
mutagenesis	B-X
of	B-X
cloned	B-X
cDNA	B-X
and	B-X
a	B-X
simian	B-X
virus	B-X
40	B-X
expression	B-X
system	B-X
to	B-X
determine	B-X
the	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
HA	B-X
and	B-X
to	B-X
examine	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
HA	B-X
is	B-X
acylated	B-X
through	B-X
thioester	B-X
linkages	B-X
at	B-X
three	B-X
highly	B-X
conserved	B-X
cysteine	B-X
residues	B-X
located	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
and	B-X
at	B-X
the	B-X
carboxy-terminal	B-X
end	B-X
of	B-X
the	B-X
transmembrane	B-X
region	B-X
,	B-X
whereas	B-X
a	B-X
cysteine	B-X
located	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
the	B-X
membrane-spanning	B-X
domain	B-X
is	B-X
not	B-X
acylated	B-X
.	B-X
Mutants	B-X
lacking	B-X
fatty	B-X
acids	B-X
at	B-X
individual	B-X
or	B-X
all	B-X
three	B-X
attachment	B-X
sites	B-X
acquire	B-X
endoglycosidase	B-X
H-resistant	B-X
oligosaccharide	B-X
side	B-X
chains	B-X
,	B-X
are	B-X
cleaved	B-X
into	B-X
HA1	B-X
and	B-X
HA2	B-X
subunits	B-X
,	B-X
and	B-X
are	B-X
transported	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
at	B-X
rates	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
wild-type	B-X
HA	B-X
.	B-X
These	B-X
results	B-X
exclude	B-X
transport	B-X
signal	B-X
and	B-X
membrane-anchoring	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
for	B-X
this	B-X
integral	B-X
membrane	B-X
glycoprotein	B-X
.	B-X
Furthermore	B-X
,	B-X
lack	B-X
of	B-X
acylation	B-X
has	B-X
no	B-X
obvious	B-X
influence	B-X
on	B-X
the	B-X
biological	B-X
activities	B-X
of	B-X
HA	B-X
:	B-X
cells	B-X
expressing	B-X
fatty	B-X
acid-free	B-X
HA	B-X
bind	B-X
to	B-X
and	B-X
,	B-X
after	B-X
brief	B-X
exposure	B-X
to	B-X
mildly	B-X
acidic	B-X
pH	B-X
,	B-X
fuse	B-X
with	B-X
erythrocytes	B-X
;	B-X
the	B-X
HA-induced	B-X
polykaryon	B-X
formation	B-X
is	B-X
not	B-X
impaired	B-X
,	B-X
either	B-X
.	B-X
Other	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
in	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
which	B-X
can	B-X
not	B-X
be	B-X
examined	B-X
in	B-X
conventional	B-X
cDNA	B-X
expression	B-X
systems	B-X
are	B-X
discussed	B-X
.	B-X

In	O
this	O
study	O
we	O
have	O
used	O
oligonucleotide	O
-	O
directed	O
mutagenesis	O
of	O
cloned	O
cDNA	O
and	O
a	O
simian	O
virus	O
40	O
expression	O
system	O
to	O
determine	O
the	O
fatty	O
acid	O
binding	O
site	O
in	O
HA	B-Protein
and	O
to	O
examine	O
possible	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
.	O

The	O
results	O
show	O
that	O
the	O
HA	B-Protein
is	O
acylated	O
through	O
thioester	O
linkages	O
at	O
three	O
highly	O
conserved	O
cysteine	O
residues	O
located	O
in	O
the	O
cytoplasmic	O
domain	O
and	O
at	O
the	O
carboxy	O
-	O
terminal	O
end	O
of	O
the	O
transmembrane	O
region	O
,	O
whereas	O
a	O
cysteine	O
located	O
in	O
the	O
middle	O
of	O
the	O
membrane	O
-	O
spanning	O
domain	O
is	O
not	O
acylated	O
.	O

Mutants	O
lacking	O
fatty	O
acids	O
at	O
individual	O
or	O
all	O
three	O
attachment	O
sites	O
acquire	O
endoglycosidase	B-Protein
H	I-Protein
-	O
resistant	O
oligosaccharide	O
side	O
chains	O
,	O
are	O
cleaved	O
into	O
HA1	B-Protein
and	O
HA2	B-Protein
subunits	O
,	O
and	O
are	O
transported	O
to	O
the	O
plasma	O
membrane	O
at	O
rates	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
HA	B-Protein
.	O
<EOS>	B-X
White	B-X
chanterelles	B-X
(	B-X
Basidiomycota	B-X
)	B-X
,	B-X
lacking	B-X
the	B-X
orange	B-X
pigments	B-X
and	B-X
apricot-like	B-X
odour	B-X
of	B-X
typical	B-X
chanterelles	B-X
,	B-X
were	B-X
found	B-X
recently	B-X
in	B-X
the	B-X
Canadian	B-X
provinces	B-X
of	B-X
Québec	B-X
(	B-X
QC	B-X
)	B-X
and	B-X
Newfoundland	B-X
&	B-X
Labrador	B-X
(	B-X
NL	B-X
)	B-X
.	B-X
White	B-X
mutants	B-X
of	B-X
C.	B-X
enelensis	B-X
lacked	B-X
detectable	B-X
β-carotene	B-X
,	B-X
confirmed	B-X
to	B-X
be	B-X
the	B-X
primary	B-X
pigment	B-X
of	B-X
wild-type	B-X
,	B-X
golden-orange	B-X
individuals	B-X
,	B-X
and	B-X
could	B-X
also	B-X
be	B-X
distinguished	B-X
by	B-X
their	B-X
profiles	B-X
of	B-X
fatty	B-X
acids	B-X
and	B-X
phenolic	B-X
acids	B-X
,	B-X
and	B-X
by	B-X
the	B-X
ketone	B-X
and	B-X
terpene	B-X
composition	B-X
of	B-X
their	B-X
volatiles	B-X
.	B-X
We	B-X
detected	B-X
single	B-X
base	B-X
substitutions	B-X
in	B-X
the	B-X
phytoene	B-X
desaturase	B-X
(	B-X
Al-1	B-X
)	B-X
and	B-X
phytoene	B-X
synthase	B-X
(	B-X
Al-2	B-X
)	B-X
genes	B-X
of	B-X
the	B-X
white	B-X
mutant	B-X
,	B-X
which	B-X
are	B-X
predicted	B-X
to	B-X
result	B-X
in	B-X
altered	B-X
amino	B-X
acids	B-X
in	B-X
their	B-X
gene	B-X
products	B-X
and	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
β-carotene	B-X
synthesis	B-X
in	B-X
that	B-X
form	B-X
.	B-X
Polyunsaturated	B-X
fatty	B-X
acids	B-X
(	B-X
PUFAs	B-X
)	B-X
,	B-X
including	B-X
essential	B-X
fatty	B-X
acids	B-X
linoleic	B-X
and	B-X
α-linolenic	B-X
acid	B-X
and	B-X
derived	B-X
long	B-X
chain	B-X
and	B-X
very	B-X
long	B-X
chain	B-X
ω3-and	B-X
ω6-polyunsaturated	B-X
fatty	B-X
acids	B-X
,	B-X
are	B-X
vital	B-X
structures	B-X
in	B-X
mammalian	B-X
membrane	B-X
systems	B-X
and	B-X
signaling	B-X
molecules	B-X
,	B-X
pivotal	B-X
in	B-X
brain	B-X
development	B-X
,	B-X
lipid	B-X
,	B-X
and	B-X
energy	B-X
metabolism	B-X
and	B-X
in	B-X
female	B-X
and	B-X
male	B-X
fertility	B-X
during	B-X
human	B-X
evolution	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
Δ6	B-X
fatty	B-X
acid	B-X
desaturase	B-X
(	B-X
FADS2	B-X
)	B-X
deficient	B-X
mouse	B-X
mutant	B-X
lacking	B-X
key	B-X
enzyme	B-X
activity	B-X
in	B-X
the	B-X
biosynthesis	B-X
of	B-X
ω3-and	B-X
ω6-PUFAs	B-X
from	B-X
EFAs	B-X
to	B-X
address	B-X
the	B-X
molecular	B-X
role	B-X
of	B-X
PUFAs	B-X
in	B-X
female	B-X
and	B-X
male	B-X
fertility	B-X
.	B-X
Infertility	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
the	B-X
pleiotropic	B-X
but	B-X
auxotrophic	B-X
fads2-/-	B-X
phenotype	B-X
and	B-X
is	B-X
therefore	B-X
helpful	B-X
for	B-X
stringent	B-X
dietary	B-X
studies	B-X
on	B-X
the	B-X
role	B-X
of	B-X
individual	B-X
PUFAs	B-X
.	B-X

All	O
mutants	O
are	O
membrane	O
bound	O
and	O
not	O
secreted	O
into	O
the	O
medium	O
.	O
<EOS>	B-X
We	B-X
used	B-X
Escherichia	B-X
coli	B-X
mutants	B-X
,	B-X
in	B-X
which	B-X
the	B-X
nuo-genes	B-X
coding	B-X
the	B-X
subunits	B-X
of	B-X
complex	B-X
I	B-X
were	B-X
individually	B-X
disrupted	B-X
by	B-X
an	B-X
insertion	B-X
of	B-X
a	B-X
resistance	B-X
cartridge	B-X
to	B-X
determine	B-X
whether	B-X
they	B-X
are	B-X
required	B-X
for	B-X
the	B-X
assembly	B-X
of	B-X
a	B-X
functional	B-X
complex	B-X
I	B-X
.	B-X
No	B-X
complex	B-X
I-mediated	B-X
enzyme	B-X
activity	B-X
was	B-X
detectable	B-X
in	B-X
the	B-X
mutant	B-X
membranes	B-X
and	B-X
it	B-X
was	B-X
not	B-X
possible	B-X
to	B-X
extract	B-X
a	B-X
structurally	B-X
intact	B-X
complex	B-X
I	B-X
from	B-X
the	B-X
mutant	B-X
membranes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
subunits	B-X
and	B-X
the	B-X
cofactors	B-X
of	B-X
the	B-X
soluble	B-X
NADH	B-X
dehydrogenase	B-X
fragment	B-X
of	B-X
the	B-X
complex	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
some	B-X
of	B-X
the	B-X
nuo-mutants	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
membrane-bound	B-X
fragment	B-X
exhibiting	B-X
NADH/ferricyanide	B-X
oxidoreductase	B-X
activity	B-X
and	B-X
containing	B-X
the	B-X
iron-sulfur	B-X
cluster	B-X
N2	B-X
was	B-X
detected	B-X
in	B-X
one	B-X
mutant	B-X
.	B-X

These	O
results	O
exclude	O
transport	O
signal	O
and	O
membrane	O
-	O
anchoring	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
for	O
this	O
integral	O
membrane	O
glycoprotein	O
.	O
<EOS>	B-X
The	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
of	B-X
influenza	B-X
virus	B-X
is	B-X
a	B-X
type	B-X
I	B-X
transmembrane	B-X
glycoprotein	B-X
which	B-X
is	B-X
acylated	B-X
with	B-X
long-chain	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
have	B-X
used	B-X
oligonucleotide-directed	B-X
mutagenesis	B-X
of	B-X
cloned	B-X
cDNA	B-X
and	B-X
a	B-X
simian	B-X
virus	B-X
40	B-X
expression	B-X
system	B-X
to	B-X
determine	B-X
the	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
HA	B-X
and	B-X
to	B-X
examine	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
HA	B-X
is	B-X
acylated	B-X
through	B-X
thioester	B-X
linkages	B-X
at	B-X
three	B-X
highly	B-X
conserved	B-X
cysteine	B-X
residues	B-X
located	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
and	B-X
at	B-X
the	B-X
carboxy-terminal	B-X
end	B-X
of	B-X
the	B-X
transmembrane	B-X
region	B-X
,	B-X
whereas	B-X
a	B-X
cysteine	B-X
located	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
the	B-X
membrane-spanning	B-X
domain	B-X
is	B-X
not	B-X
acylated	B-X
.	B-X
Mutants	B-X
lacking	B-X
fatty	B-X
acids	B-X
at	B-X
individual	B-X
or	B-X
all	B-X
three	B-X
attachment	B-X
sites	B-X
acquire	B-X
endoglycosidase	B-X
H-resistant	B-X
oligosaccharide	B-X
side	B-X
chains	B-X
,	B-X
are	B-X
cleaved	B-X
into	B-X
HA1	B-X
and	B-X
HA2	B-X
subunits	B-X
,	B-X
and	B-X
are	B-X
transported	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
at	B-X
rates	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
wild-type	B-X
HA	B-X
.	B-X
All	B-X
mutants	B-X
are	B-X
membrane	B-X
bound	B-X
and	B-X
not	B-X
secreted	B-X
into	B-X
the	B-X
medium	B-X
.	B-X
These	B-X
results	B-X
exclude	B-X
transport	B-X
signal	B-X
and	B-X
membrane-anchoring	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
for	B-X
this	B-X
integral	B-X
membrane	B-X
glycoprotein	B-X
.	B-X
Furthermore	B-X
,	B-X
lack	B-X
of	B-X
acylation	B-X
has	B-X
no	B-X
obvious	B-X
influence	B-X
on	B-X
the	B-X
biological	B-X
activities	B-X
of	B-X
HA	B-X
:	B-X
cells	B-X
expressing	B-X
fatty	B-X
acid-free	B-X
HA	B-X
bind	B-X
to	B-X
and	B-X
,	B-X
after	B-X
brief	B-X
exposure	B-X
to	B-X
mildly	B-X
acidic	B-X
pH	B-X
,	B-X
fuse	B-X
with	B-X
erythrocytes	B-X
;	B-X
the	B-X
HA-induced	B-X
polykaryon	B-X
formation	B-X
is	B-X
not	B-X
impaired	B-X
,	B-X
either	B-X
.	B-X
Other	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
in	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
which	B-X
can	B-X
not	B-X
be	B-X
examined	B-X
in	B-X
conventional	B-X
cDNA	B-X
expression	B-X
systems	B-X
are	B-X
discussed	B-X
.	B-X

Furthermore	O
,	O
lack	O
of	O
acylation	O
has	O
no	O
obvious	O
influence	O
on	O
the	O
biological	O
activities	O
of	O
HA	B-Protein
:	O
cells	O
expressing	O
fatty	O
acid	O
-	O
free	O
HA	B-Protein
bind	O
to	O
and	O
,	O
after	O
brief	O
exposure	O
to	O
mildly	O
acidic	O
pH	O
,	O
fuse	O
with	O
erythrocytes	O
;	O
the	O
HA	B-Protein
-	O
induced	O
polykaryon	O
formation	O
is	O
not	O
impaired	O
,	O
either	O
.	O
<EOS>	B-X
The	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
of	B-X
influenza	B-X
virus	B-X
is	B-X
a	B-X
type	B-X
I	B-X
transmembrane	B-X
glycoprotein	B-X
which	B-X
is	B-X
acylated	B-X
with	B-X
long-chain	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
have	B-X
used	B-X
oligonucleotide-directed	B-X
mutagenesis	B-X
of	B-X
cloned	B-X
cDNA	B-X
and	B-X
a	B-X
simian	B-X
virus	B-X
40	B-X
expression	B-X
system	B-X
to	B-X
determine	B-X
the	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
HA	B-X
and	B-X
to	B-X
examine	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
HA	B-X
is	B-X
acylated	B-X
through	B-X
thioester	B-X
linkages	B-X
at	B-X
three	B-X
highly	B-X
conserved	B-X
cysteine	B-X
residues	B-X
located	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
and	B-X
at	B-X
the	B-X
carboxy-terminal	B-X
end	B-X
of	B-X
the	B-X
transmembrane	B-X
region	B-X
,	B-X
whereas	B-X
a	B-X
cysteine	B-X
located	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
the	B-X
membrane-spanning	B-X
domain	B-X
is	B-X
not	B-X
acylated	B-X
.	B-X
Mutants	B-X
lacking	B-X
fatty	B-X
acids	B-X
at	B-X
individual	B-X
or	B-X
all	B-X
three	B-X
attachment	B-X
sites	B-X
acquire	B-X
endoglycosidase	B-X
H-resistant	B-X
oligosaccharide	B-X
side	B-X
chains	B-X
,	B-X
are	B-X
cleaved	B-X
into	B-X
HA1	B-X
and	B-X
HA2	B-X
subunits	B-X
,	B-X
and	B-X
are	B-X
transported	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
at	B-X
rates	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
wild-type	B-X
HA	B-X
.	B-X
These	B-X
results	B-X
exclude	B-X
transport	B-X
signal	B-X
and	B-X
membrane-anchoring	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
for	B-X
this	B-X
integral	B-X
membrane	B-X
glycoprotein	B-X
.	B-X
Furthermore	B-X
,	B-X
lack	B-X
of	B-X
acylation	B-X
has	B-X
no	B-X
obvious	B-X
influence	B-X
on	B-X
the	B-X
biological	B-X
activities	B-X
of	B-X
HA	B-X
:	B-X
cells	B-X
expressing	B-X
fatty	B-X
acid-free	B-X
HA	B-X
bind	B-X
to	B-X
and	B-X
,	B-X
after	B-X
brief	B-X
exposure	B-X
to	B-X
mildly	B-X
acidic	B-X
pH	B-X
,	B-X
fuse	B-X
with	B-X
erythrocytes	B-X
;	B-X
the	B-X
HA-induced	B-X
polykaryon	B-X
formation	B-X
is	B-X
not	B-X
impaired	B-X
,	B-X
either	B-X
.	B-X
Other	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
in	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
which	B-X
can	B-X
not	B-X
be	B-X
examined	B-X
in	B-X
conventional	B-X
cDNA	B-X
expression	B-X
systems	B-X
are	B-X
discussed	B-X
.	B-X

Other	O
possible	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
in	O
integral	O
membrane	O
glycoproteins	O
which	O
cannot	O
be	O
examined	O
in	O
conventional	O
cDNA	O
expression	O
systems	O
are	O
discussed	O
.	O
<EOS>	B-X
The	B-X
hemagglutinin	B-X
(	B-X
HA	B-X
)	B-X
of	B-X
influenza	B-X
virus	B-X
is	B-X
a	B-X
type	B-X
I	B-X
transmembrane	B-X
glycoprotein	B-X
which	B-X
is	B-X
acylated	B-X
with	B-X
long-chain	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
have	B-X
used	B-X
oligonucleotide-directed	B-X
mutagenesis	B-X
of	B-X
cloned	B-X
cDNA	B-X
and	B-X
a	B-X
simian	B-X
virus	B-X
40	B-X
expression	B-X
system	B-X
to	B-X
determine	B-X
the	B-X
fatty	B-X
acid	B-X
binding	B-X
site	B-X
in	B-X
HA	B-X
and	B-X
to	B-X
examine	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
HA	B-X
is	B-X
acylated	B-X
through	B-X
thioester	B-X
linkages	B-X
at	B-X
three	B-X
highly	B-X
conserved	B-X
cysteine	B-X
residues	B-X
located	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
and	B-X
at	B-X
the	B-X
carboxy-terminal	B-X
end	B-X
of	B-X
the	B-X
transmembrane	B-X
region	B-X
,	B-X
whereas	B-X
a	B-X
cysteine	B-X
located	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
the	B-X
membrane-spanning	B-X
domain	B-X
is	B-X
not	B-X
acylated	B-X
.	B-X
Mutants	B-X
lacking	B-X
fatty	B-X
acids	B-X
at	B-X
individual	B-X
or	B-X
all	B-X
three	B-X
attachment	B-X
sites	B-X
acquire	B-X
endoglycosidase	B-X
H-resistant	B-X
oligosaccharide	B-X
side	B-X
chains	B-X
,	B-X
are	B-X
cleaved	B-X
into	B-X
HA1	B-X
and	B-X
HA2	B-X
subunits	B-X
,	B-X
and	B-X
are	B-X
transported	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
at	B-X
rates	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
wild-type	B-X
HA	B-X
.	B-X
All	B-X
mutants	B-X
are	B-X
membrane	B-X
bound	B-X
and	B-X
not	B-X
secreted	B-X
into	B-X
the	B-X
medium	B-X
.	B-X
These	B-X
results	B-X
exclude	B-X
transport	B-X
signal	B-X
and	B-X
membrane-anchoring	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
for	B-X
this	B-X
integral	B-X
membrane	B-X
glycoprotein	B-X
.	B-X
Furthermore	B-X
,	B-X
lack	B-X
of	B-X
acylation	B-X
has	B-X
no	B-X
obvious	B-X
influence	B-X
on	B-X
the	B-X
biological	B-X
activities	B-X
of	B-X
HA	B-X
:	B-X
cells	B-X
expressing	B-X
fatty	B-X
acid-free	B-X
HA	B-X
bind	B-X
to	B-X
and	B-X
,	B-X
after	B-X
brief	B-X
exposure	B-X
to	B-X
mildly	B-X
acidic	B-X
pH	B-X
,	B-X
fuse	B-X
with	B-X
erythrocytes	B-X
;	B-X
the	B-X
HA-induced	B-X
polykaryon	B-X
formation	B-X
is	B-X
not	B-X
impaired	B-X
,	B-X
either	B-X
.	B-X
Other	B-X
possible	B-X
functions	B-X
of	B-X
covalently	B-X
linked	B-X
fatty	B-X
acids	B-X
in	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
which	B-X
can	B-X
not	B-X
be	B-X
examined	B-X
in	B-X
conventional	B-X
cDNA	B-X
expression	B-X
systems	B-X
are	B-X
discussed	B-X
.	B-X

Subcellular	O
localization	O
directs	O
signaling	O
specificity	O
of	O
the	O
Cryptococcus	O
neoformans	O
Ras1	B-Protein
protein	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
,	B-X
Ras	B-X
signaling	B-X
mediates	B-X
sexual	B-X
differentiation	B-X
,	B-X
morphogenesis	B-X
,	B-X
and	B-X
pathogenesis	B-X
.	B-X
By	B-X
studying	B-X
Ras	B-X
prenylation	B-X
and	B-X
palmitoylation	B-X
in	B-X
this	B-X
organism	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
this	B-X
protein	B-X
dictates	B-X
its	B-X
downstream	B-X
signaling	B-X
specificity	B-X
.	B-X
Inhibiting	B-X
C.	B-X
neoformans	B-X
Ras1	B-X
prenylation	B-X
results	B-X
in	B-X
the	B-X
defective	B-X
general	B-X
membrane	B-X
targeting	B-X
of	B-X
this	B-X
protein	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
all	B-X
Ras	B-X
function	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
palmitoylation	B-X
mediates	B-X
localization	B-X
of	B-X
Ras1	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
morphogenesis	B-X
and	B-X
survival	B-X
at	B-X
high	B-X
temperatures	B-X
.	B-X
However	B-X
,	B-X
palmitoylation	B-X
and	B-X
plasma	B-X
membrane	B-X
localization	B-X
are	B-X
not	B-X
required	B-X
for	B-X
Ras-dependent	B-X
sexual	B-X
differentiation	B-X
.	B-X
Likely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
its	B-X
effect	B-X
on	B-X
thermotolerance	B-X
,	B-X
Ras1	B-X
palmitoylation	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
pathogenesis	B-X
of	B-X
C.	B-X
neoformans	B-X
.	B-X
These	B-X
data	B-X
support	B-X
an	B-X
emerging	B-X
paradigm	B-X
of	B-X
compartmentalized	B-X
Ras	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
our	B-X
studies	B-X
also	B-X
demonstrate	B-X
fundamental	B-X
differences	B-X
between	B-X
the	B-X
Ras	B-X
pathways	B-X
in	B-X
different	B-X
organisms	B-X
that	B-X
emphasize	B-X
the	B-X
functional	B-X
flexibility	B-X
of	B-X
conserved	B-X
signaling	B-X
cascades	B-X
.	B-X

In	O
the	O
human	O
fungal	O
pathogen	O
Cryptococcus	O
neoformans	O
,	O
Ras	O
signaling	O
mediates	O
sexual	O
differentiation	O
,	O
morphogenesis	O
,	O
and	O
pathogenesis	O
.	O
<EOS>	B-X
The	B-X
localization	B-X
and	B-X
specialized	B-X
function	B-X
of	B-X
Ras-like	B-X
proteins	B-X
are	B-X
largely	B-X
determined	B-X
by	B-X
posttranslational	B-X
processing	B-X
events	B-X
.	B-X
In	B-X
the	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
,	B-X
Ras1	B-X
protein	B-X
palmitoylation	B-X
is	B-X
essential	B-X
for	B-X
growth	B-X
at	B-X
high	B-X
temperature	B-X
but	B-X
is	B-X
dispensable	B-X
for	B-X
sexual	B-X
differentiation	B-X
.	B-X
Ras1	B-X
palmitoylation	B-X
is	B-X
also	B-X
required	B-X
for	B-X
localization	B-X
of	B-X
this	B-X
protein	B-X
on	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
specific	B-X
Ras	B-X
functions	B-X
are	B-X
mediated	B-X
from	B-X
different	B-X
subcellular	B-X
locations	B-X
.	B-X
We	B-X
therefore	B-X
hypothesize	B-X
that	B-X
proteins	B-X
that	B-X
activate	B-X
Ras1	B-X
or	B-X
mediate	B-X
Ras1	B-X
localization	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
will	B-X
be	B-X
important	B-X
for	B-X
C.	B-X
neoformans	B-X
pathogenesis	B-X
.	B-X
To	B-X
further	B-X
characterize	B-X
the	B-X
Ras1	B-X
signaling	B-X
cascade	B-X
mediating	B-X
high-temperature	B-X
growth	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
family	B-X
of	B-X
protein	B-X
S-acyltransferases	B-X
(	B-X
PATs	B-X
)	B-X
,	B-X
enzymes	B-X
that	B-X
mediate	B-X
palmitoylation	B-X
,	B-X
in	B-X
the	B-X
C.	B-X
neoformans	B-X
genome	B-X
database	B-X
.	B-X
Deletion	B-X
strains	B-X
for	B-X
each	B-X
candidate	B-X
gene	B-X
were	B-X
generated	B-X
by	B-X
homogenous	B-X
recombination	B-X
,	B-X
and	B-X
each	B-X
mutant	B-X
strain	B-X
was	B-X
assessed	B-X
for	B-X
Ras1-mediated	B-X
phenotypes	B-X
,	B-X
including	B-X
high-temperature	B-X
growth	B-X
,	B-X
morphogenesis	B-X
,	B-X
and	B-X
sexual	B-X
development	B-X
.	B-X
We	B-X
found	B-X
that	B-X
full	B-X
Ras1	B-X
palmitoylation	B-X
and	B-X
function	B-X
required	B-X
one	B-X
particular	B-X
PAT	B-X
,	B-X
Pfa4	B-X
,	B-X
and	B-X
deletion	B-X
of	B-X
the	B-X
PFA4	B-X
gene	B-X
in	B-X
C.	B-X
neoformans	B-X
resulted	B-X
in	B-X
altered	B-X
Ras1	B-X
localization	B-X
to	B-X
membranes	B-X
,	B-X
impaired	B-X
growth	B-X
at	B-X
37°C	B-X
,	B-X
and	B-X
reduced	B-X
virulence	B-X
.	B-X

By	O
studying	O
Ras	O
prenylation	O
and	O
palmitoylation	O
in	O
this	O
organism	O
,	O
we	O
have	O
found	O
that	O
the	O
subcellular	O
localization	O
of	O
this	O
protein	O
dictates	O
its	O
downstream	O
signaling	O
specificity	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
,	B-X
Ras	B-X
signaling	B-X
mediates	B-X
sexual	B-X
differentiation	B-X
,	B-X
morphogenesis	B-X
,	B-X
and	B-X
pathogenesis	B-X
.	B-X
By	B-X
studying	B-X
Ras	B-X
prenylation	B-X
and	B-X
palmitoylation	B-X
in	B-X
this	B-X
organism	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
this	B-X
protein	B-X
dictates	B-X
its	B-X
downstream	B-X
signaling	B-X
specificity	B-X
.	B-X
Inhibiting	B-X
C.	B-X
neoformans	B-X
Ras1	B-X
prenylation	B-X
results	B-X
in	B-X
the	B-X
defective	B-X
general	B-X
membrane	B-X
targeting	B-X
of	B-X
this	B-X
protein	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
all	B-X
Ras	B-X
function	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
palmitoylation	B-X
mediates	B-X
localization	B-X
of	B-X
Ras1	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
morphogenesis	B-X
and	B-X
survival	B-X
at	B-X
high	B-X
temperatures	B-X
.	B-X
However	B-X
,	B-X
palmitoylation	B-X
and	B-X
plasma	B-X
membrane	B-X
localization	B-X
are	B-X
not	B-X
required	B-X
for	B-X
Ras-dependent	B-X
sexual	B-X
differentiation	B-X
.	B-X
Likely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
its	B-X
effect	B-X
on	B-X
thermotolerance	B-X
,	B-X
Ras1	B-X
palmitoylation	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
pathogenesis	B-X
of	B-X
C.	B-X
neoformans	B-X
.	B-X
These	B-X
data	B-X
support	B-X
an	B-X
emerging	B-X
paradigm	B-X
of	B-X
compartmentalized	B-X
Ras	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
our	B-X
studies	B-X
also	B-X
demonstrate	B-X
fundamental	B-X
differences	B-X
between	B-X
the	B-X
Ras	B-X
pathways	B-X
in	B-X
different	B-X
organisms	B-X
that	B-X
emphasize	B-X
the	B-X
functional	B-X
flexibility	B-X
of	B-X
conserved	B-X
signaling	B-X
cascades	B-X
.	B-X

Inhibiting	O
C	O
.	O
neoformans	O
Ras1	B-Protein
prenylation	O
results	O
in	O
the	O
defective	O
general	O
membrane	O
targeting	O
of	O
this	O
protein	O
and	O
the	O
loss	O
of	O
all	O
Ras	O
function	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
,	B-X
Ras	B-X
signaling	B-X
mediates	B-X
sexual	B-X
differentiation	B-X
,	B-X
morphogenesis	B-X
,	B-X
and	B-X
pathogenesis	B-X
.	B-X
By	B-X
studying	B-X
Ras	B-X
prenylation	B-X
and	B-X
palmitoylation	B-X
in	B-X
this	B-X
organism	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
this	B-X
protein	B-X
dictates	B-X
its	B-X
downstream	B-X
signaling	B-X
specificity	B-X
.	B-X
Inhibiting	B-X
C.	B-X
neoformans	B-X
Ras1	B-X
prenylation	B-X
results	B-X
in	B-X
the	B-X
defective	B-X
general	B-X
membrane	B-X
targeting	B-X
of	B-X
this	B-X
protein	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
all	B-X
Ras	B-X
function	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
palmitoylation	B-X
mediates	B-X
localization	B-X
of	B-X
Ras1	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
morphogenesis	B-X
and	B-X
survival	B-X
at	B-X
high	B-X
temperatures	B-X
.	B-X
However	B-X
,	B-X
palmitoylation	B-X
and	B-X
plasma	B-X
membrane	B-X
localization	B-X
are	B-X
not	B-X
required	B-X
for	B-X
Ras-dependent	B-X
sexual	B-X
differentiation	B-X
.	B-X
Likely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
its	B-X
effect	B-X
on	B-X
thermotolerance	B-X
,	B-X
Ras1	B-X
palmitoylation	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
pathogenesis	B-X
of	B-X
C.	B-X
neoformans	B-X
.	B-X
These	B-X
data	B-X
support	B-X
an	B-X
emerging	B-X
paradigm	B-X
of	B-X
compartmentalized	B-X
Ras	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
our	B-X
studies	B-X
also	B-X
demonstrate	B-X
fundamental	B-X
differences	B-X
between	B-X
the	B-X
Ras	B-X
pathways	B-X
in	B-X
different	B-X
organisms	B-X
that	B-X
emphasize	B-X
the	B-X
functional	B-X
flexibility	B-X
of	B-X
conserved	B-X
signaling	B-X
cascades	B-X
.	B-X

In	O
contrast	O
,	O
palmitoylation	O
mediates	O
localization	O
of	O
Ras1	B-Protein
to	O
the	O
plasma	O
membrane	O
and	O
is	O
required	O
for	O
normal	O
morphogenesis	O
and	O
survival	O
at	O
high	O
temperatures	O
.	O

However	O
,	O
palmitoylation	O
and	O
plasma	O
membrane	O
localization	O
are	O
not	O
required	O
for	O
Ras	O
-	O
dependent	O
sexual	O
differentiation	O
.	O
<EOS>	B-X
Glucose	B-X
transporter	B-X
GLUT1	B-X
is	B-X
a	B-X
transmembrane	B-X
protein	B-X
responsible	B-X
for	B-X
the	B-X
uptake	B-X
of	B-X
glucose	B-X
into	B-X
the	B-X
cells	B-X
of	B-X
many	B-X
tissues	B-X
through	B-X
facilitative	B-X
diffusion	B-X
.	B-X
Plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
localization	B-X
is	B-X
essential	B-X
for	B-X
glucose	B-X
uptake	B-X
by	B-X
GLUT1	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
GLUT1	B-X
PM	B-X
localization	B-X
remains	B-X
enigmatic	B-X
.	B-X
We	B-X
find	B-X
that	B-X
GLUT1	B-X
is	B-X
palmitoylated	B-X
at	B-X
Cys207	B-X
,	B-X
and	B-X
S-palmitoylation	B-X
is	B-X
required	B-X
for	B-X
maintaining	B-X
GLUT1	B-X
PM	B-X
localization	B-X
.	B-X
Knockout	B-X
of	B-X
DHHC9	B-X
or	B-X
mutation	B-X
of	B-X
GLUT1	B-X
Cys207	B-X
to	B-X
serine	B-X
abrogates	B-X
palmitoylation	B-X
and	B-X
PM	B-X
distribution	B-X
of	B-X
GLUT1	B-X
,	B-X
and	B-X
impairs	B-X
glycolysis	B-X
,	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
glioblastoma	B-X
(	B-X
GBM	B-X
)	B-X
tumorigenesis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
DHHC9	B-X
expression	B-X
positively	B-X
correlates	B-X
with	B-X
GLUT1	B-X
PM	B-X
localization	B-X
in	B-X
GBM	B-X
specimens	B-X
and	B-X
indicates	B-X
a	B-X
poor	B-X
prognosis	B-X
in	B-X
GBM	B-X
patients	B-X
.	B-X
These	B-X
findings	B-X
underscore	B-X
that	B-X
DHHC9-mediated	B-X
GLUT1	B-X
S-palmitoylation	B-X
is	B-X
critical	B-X
for	B-X
glucose	B-X
supply	B-X
during	B-X
GBM	B-X
tumorigenesis	B-X
.	B-X

Likely	O
as	O
a	O
result	O
of	O
its	O
effect	O
on	O
thermotolerance	O
,	O
Ras1	B-Protein
palmitoylation	O
is	O
also	O
required	O
for	O
the	O
pathogenesis	O
of	O
C	O
.	O
neoformans	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
,	B-X
Ras	B-X
signaling	B-X
mediates	B-X
sexual	B-X
differentiation	B-X
,	B-X
morphogenesis	B-X
,	B-X
and	B-X
pathogenesis	B-X
.	B-X
By	B-X
studying	B-X
Ras	B-X
prenylation	B-X
and	B-X
palmitoylation	B-X
in	B-X
this	B-X
organism	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
this	B-X
protein	B-X
dictates	B-X
its	B-X
downstream	B-X
signaling	B-X
specificity	B-X
.	B-X
Inhibiting	B-X
C.	B-X
neoformans	B-X
Ras1	B-X
prenylation	B-X
results	B-X
in	B-X
the	B-X
defective	B-X
general	B-X
membrane	B-X
targeting	B-X
of	B-X
this	B-X
protein	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
all	B-X
Ras	B-X
function	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
palmitoylation	B-X
mediates	B-X
localization	B-X
of	B-X
Ras1	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
morphogenesis	B-X
and	B-X
survival	B-X
at	B-X
high	B-X
temperatures	B-X
.	B-X
However	B-X
,	B-X
palmitoylation	B-X
and	B-X
plasma	B-X
membrane	B-X
localization	B-X
are	B-X
not	B-X
required	B-X
for	B-X
Ras-dependent	B-X
sexual	B-X
differentiation	B-X
.	B-X
Likely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
its	B-X
effect	B-X
on	B-X
thermotolerance	B-X
,	B-X
Ras1	B-X
palmitoylation	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
pathogenesis	B-X
of	B-X
C.	B-X
neoformans	B-X
.	B-X
However	B-X
,	B-X
our	B-X
studies	B-X
also	B-X
demonstrate	B-X
fundamental	B-X
differences	B-X
between	B-X
the	B-X
Ras	B-X
pathways	B-X
in	B-X
different	B-X
organisms	B-X
that	B-X
emphasize	B-X
the	B-X
functional	B-X
flexibility	B-X
of	B-X
conserved	B-X
signaling	B-X
cascades	B-X
.	B-X

These	O
data	O
support	O
an	O
emerging	O
paradigm	O
of	O
compartmentalized	O
Ras	O
signaling	O
.	O
<EOS>	B-X
Ras	B-X
GTPases	B-X
mediate	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cellular	B-X
processes	B-X
by	B-X
converting	B-X
a	B-X
multitude	B-X
of	B-X
extracellular	B-X
stimuli	B-X
into	B-X
specific	B-X
biological	B-X
responses	B-X
including	B-X
proliferation	B-X
,	B-X
differentiation	B-X
and	B-X
survival	B-X
.	B-X
In	B-X
mammalian	B-X
cells	B-X
,	B-X
three	B-X
ras	B-X
genes	B-X
encode	B-X
four	B-X
Ras	B-X
isoforms	B-X
(	B-X
H-Ras	B-X
,	B-X
K-Ras4A	B-X
,	B-X
K-Ras4B	B-X
and	B-X
N-Ras	B-X
)	B-X
that	B-X
are	B-X
highly	B-X
homologous	B-X
but	B-X
functionally	B-X
distinct	B-X
.	B-X
Differences	B-X
between	B-X
the	B-X
isoforms	B-X
,	B-X
including	B-X
their	B-X
post-translational	B-X
modifications	B-X
and	B-X
intracellular	B-X
sorting	B-X
,	B-X
mean	B-X
that	B-X
Ras	B-X
has	B-X
emerged	B-X
as	B-X
an	B-X
important	B-X
model	B-X
system	B-X
of	B-X
compartmentalised	B-X
signalling	B-X
and	B-X
membrane	B-X
biology	B-X
.	B-X
Ras	B-X
isoforms	B-X
in	B-X
different	B-X
subcellular	B-X
locations	B-X
are	B-X
proposed	B-X
to	B-X
recruit	B-X
distinct	B-X
upstream	B-X
and	B-X
downstream	B-X
accessory	B-X
proteins	B-X
and	B-X
activate	B-X
multiple	B-X
signalling	B-X
pathways	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarise	B-X
data	B-X
relating	B-X
to	B-X
isoform-specific	B-X
signalling	B-X
,	B-X
its	B-X
role	B-X
in	B-X
disease	B-X
and	B-X
the	B-X
mechanisms	B-X
promoting	B-X
compartmentalised	B-X
signalling	B-X
.	B-X
Further	B-X
understanding	B-X
of	B-X
this	B-X
field	B-X
will	B-X
reveal	B-X
the	B-X
role	B-X
of	B-X
Ras	B-X
signalling	B-X
in	B-X
development	B-X
,	B-X
cellular	B-X
homeostasis	B-X
and	B-X
cancer	B-X
and	B-X
may	B-X
suggest	B-X
new	B-X
therapeutic	B-X
approaches	B-X
.	B-X

However	O
,	O
our	O
studies	O
also	O
demonstrate	O
fundamental	O
differences	O
between	O
the	O
Ras	O
pathways	O
in	O
different	O
organisms	O
that	O
emphasize	O
the	O
functional	O
flexibility	O
of	O
conserved	O
signaling	O
cascades	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
,	B-X
Ras	B-X
signaling	B-X
mediates	B-X
sexual	B-X
differentiation	B-X
,	B-X
morphogenesis	B-X
,	B-X
and	B-X
pathogenesis	B-X
.	B-X
By	B-X
studying	B-X
Ras	B-X
prenylation	B-X
and	B-X
palmitoylation	B-X
in	B-X
this	B-X
organism	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
this	B-X
protein	B-X
dictates	B-X
its	B-X
downstream	B-X
signaling	B-X
specificity	B-X
.	B-X
Inhibiting	B-X
C.	B-X
neoformans	B-X
Ras1	B-X
prenylation	B-X
results	B-X
in	B-X
the	B-X
defective	B-X
general	B-X
membrane	B-X
targeting	B-X
of	B-X
this	B-X
protein	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
all	B-X
Ras	B-X
function	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
palmitoylation	B-X
mediates	B-X
localization	B-X
of	B-X
Ras1	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
morphogenesis	B-X
and	B-X
survival	B-X
at	B-X
high	B-X
temperatures	B-X
.	B-X
However	B-X
,	B-X
palmitoylation	B-X
and	B-X
plasma	B-X
membrane	B-X
localization	B-X
are	B-X
not	B-X
required	B-X
for	B-X
Ras-dependent	B-X
sexual	B-X
differentiation	B-X
.	B-X
Likely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
its	B-X
effect	B-X
on	B-X
thermotolerance	B-X
,	B-X
Ras1	B-X
palmitoylation	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
pathogenesis	B-X
of	B-X
C.	B-X
neoformans	B-X
.	B-X
These	B-X
data	B-X
support	B-X
an	B-X
emerging	B-X
paradigm	B-X
of	B-X
compartmentalized	B-X
Ras	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
our	B-X
studies	B-X
also	B-X
demonstrate	B-X
fundamental	B-X
differences	B-X
between	B-X
the	B-X
Ras	B-X
pathways	B-X
in	B-X
different	B-X
organisms	B-X
that	B-X
emphasize	B-X
the	B-X
functional	B-X
flexibility	B-X
of	B-X
conserved	B-X
signaling	B-X
cascades	B-X
.	B-X

Both	O
FMNH2	O
and	O
FADH2	O
can	O
be	O
utilized	O
by	O
the	O
dibenzothiophene	B-Protein
monooxygenase	I-Protein
from	O
a	O
desulfurizing	O
bacterium	O
Mycobacterium	O
goodii	O
X7B	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
flavin	B-X
utilization	B-X
by	B-X
dibenzothiophene	B-X
monooxygenase	B-X
(	B-X
DszC	B-X
)	B-X
,	B-X
DszC	B-X
of	B-X
a	B-X
desulfurizing	B-X
bacterium	B-X
Mycobacterium	B-X
goodii	B-X
X7B	B-X
was	B-X
purified	B-X
from	B-X
the	B-X
recombinant	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
DszC	B-X
should	B-X
be	B-X
reclassified	B-X
as	B-X
an	B-X
FMNH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
FADH	B-X
(	B-X
2	B-X
)	B-X
both-utilizing	B-X
monooxygenase	B-X
component	B-X
and	B-X
the	B-X
flavins	B-X
should	B-X
be	B-X
controlled	B-X
at	B-X
properly	B-X
reduced	B-X
levels	B-X
to	B-X
obtain	B-X
optimal	B-X
biodesulfurization	B-X
results	B-X
.	B-X

To	O
investigate	O
the	O
flavin	O
utilization	O
by	O
dibenzothiophene	B-Protein
monooxygenase	I-Protein
(	O
DszC	B-Protein
)	O
,	O
DszC	B-Protein
of	O
a	O
desulfurizing	O
bacterium	O
Mycobacterium	O
goodii	O
X7B	O
was	O
purified	O
from	O
the	O
recombinant	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
flavin	B-X
utilization	B-X
by	B-X
dibenzothiophene	B-X
monooxygenase	B-X
(	B-X
DszC	B-X
)	B-X
,	B-X
DszC	B-X
of	B-X
a	B-X
desulfurizing	B-X
bacterium	B-X
Mycobacterium	B-X
goodii	B-X
X7B	B-X
was	B-X
purified	B-X
from	B-X
the	B-X
recombinant	B-X
Escherichia	B-X
coli	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
able	B-X
to	B-X
utilize	B-X
either	B-X
FMNH	B-X
(	B-X
2	B-X
)	B-X
or	B-X
FADH	B-X
(	B-X
2	B-X
)	B-X
when	B-X
coupled	B-X
with	B-X
a	B-X
flavin	B-X
reductase	B-X
that	B-X
reduces	B-X
either	B-X
FMN	B-X
or	B-X
FAD	B-X
.	B-X
Sequence	B-X
analysis	B-X
indicated	B-X
that	B-X
DszC	B-X
was	B-X
similar	B-X
to	B-X
the	B-X
C	B-X
(	B-X
2	B-X
)	B-X
component	B-X
of	B-X
p-hydroxyphenylacetate	B-X
hydroxylase	B-X
from	B-X
Acinetobacter	B-X
baumannii	B-X
,	B-X
which	B-X
can	B-X
use	B-X
both	B-X
FADH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
FMNH	B-X
(	B-X
2	B-X
)	B-X
as	B-X
substrates	B-X
.	B-X
Both	B-X
flavins	B-X
at	B-X
high	B-X
concentrations	B-X
could	B-X
inhibit	B-X
the	B-X
activity	B-X
of	B-X
DszC	B-X
due	B-X
to	B-X
autocatalytic	B-X
oxidation	B-X
of	B-X
reduced	B-X
flavins	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
DszC	B-X
should	B-X
be	B-X
reclassified	B-X
as	B-X
an	B-X
FMNH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
FADH	B-X
(	B-X
2	B-X
)	B-X
both-utilizing	B-X
monooxygenase	B-X
component	B-X
and	B-X
the	B-X
flavins	B-X
should	B-X
be	B-X
controlled	B-X
at	B-X
properly	B-X
reduced	B-X
levels	B-X
to	B-X
obtain	B-X
optimal	B-X
biodesulfurization	B-X
results	B-X
.	B-X

It	O
was	O
shown	O
to	O
be	O
able	O
to	O
utilize	O
either	O
FMNH	O
(	O
2	O
)	O
or	O
FADH	O
(	O
2	O
)	O
when	O
coupled	O
with	O
a	O
flavin	B-Protein
reductase	I-Protein
that	O
reduces	O
either	O
FMN	O
or	O
FAD	O
.	O
<EOS>	B-X
The	B-X
riboflavin	B-X
derivatives	B-X
FMN	B-X
and	B-X
flavin	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
FAD	B-X
)	B-X
are	B-X
critical	B-X
cofactors	B-X
for	B-X
wide-ranging	B-X
biological	B-X
processes	B-X
across	B-X
all	B-X
kingdoms	B-X
of	B-X
life	B-X
.	B-X
Although	B-X
it	B-X
is	B-X
well	B-X
established	B-X
that	B-X
these	B-X
flavins	B-X
can	B-X
be	B-X
readily	B-X
interconverted	B-X
,	B-X
in	B-X
plants	B-X
,	B-X
the	B-X
responsible	B-X
catalysts	B-X
and	B-X
regulatory	B-X
mechanisms	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
cloning	B-X
and	B-X
biochemical	B-X
characterization	B-X
of	B-X
an	B-X
FAD	B-X
synthetase	B-X
encoded	B-X
by	B-X
the	B-X
gene	B-X
At5g03430	B-X
,	B-X
which	B-X
we	B-X
have	B-X
designated	B-X
AtFADS1	B-X
(	B-X
A.	B-X
thaliana	B-X
FADS1	B-X
)	B-X
.	B-X
The	B-X
catalytic	B-X
properties	B-X
of	B-X
the	B-X
FAD	B-X
synthetase	B-X
activity	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
reported	B-X
for	B-X
other	B-X
FAD	B-X
synthetases	B-X
,	B-X
except	B-X
that	B-X
we	B-X
observed	B-X
maximum	B-X
activity	B-X
with	B-X
Zn	B-X

Sequence	O
analysis	O
indicated	O
that	O
DszC	B-Protein
was	O
similar	O
to	O
the	O
C	O
(	O
2	O
)	O
component	O
of	O
p	O
-	O
hydroxyphenylacetate	O
hydroxylase	O
from	O
Acinetobacter	O
baumannii	O
,	O
which	O
can	O
use	O
both	O
FADH	O
(	O
2	O
)	O
and	O
FMNH	O
(	O
2	O
)	O
as	O
substrates	O
.	O

Both	O
flavins	O
at	O
high	O
concentrations	O
could	O
inhibit	O
the	O
activity	O
of	O
DszC	B-Protein
due	O
to	O
autocatalytic	O
oxidation	O
of	O
reduced	O
flavins	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
flavin	B-X
utilization	B-X
by	B-X
dibenzothiophene	B-X
monooxygenase	B-X
(	B-X
DszC	B-X
)	B-X
,	B-X
DszC	B-X
of	B-X
a	B-X
desulfurizing	B-X
bacterium	B-X
Mycobacterium	B-X
goodii	B-X
X7B	B-X
was	B-X
purified	B-X
from	B-X
the	B-X
recombinant	B-X
Escherichia	B-X
coli	B-X
.	B-X
Sequence	B-X
analysis	B-X
indicated	B-X
that	B-X
DszC	B-X
was	B-X
similar	B-X
to	B-X
the	B-X
C	B-X
(	B-X
2	B-X
)	B-X
component	B-X
of	B-X
p-hydroxyphenylacetate	B-X
hydroxylase	B-X
from	B-X
Acinetobacter	B-X
baumannii	B-X
,	B-X
which	B-X
can	B-X
use	B-X
both	B-X
FADH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
FMNH	B-X
(	B-X
2	B-X
)	B-X
as	B-X
substrates	B-X
.	B-X
Both	B-X
flavins	B-X
at	B-X
high	B-X
concentrations	B-X
could	B-X
inhibit	B-X
the	B-X
activity	B-X
of	B-X
DszC	B-X
due	B-X
to	B-X
autocatalytic	B-X
oxidation	B-X
of	B-X
reduced	B-X
flavins	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
DszC	B-X
should	B-X
be	B-X
reclassified	B-X
as	B-X
an	B-X
FMNH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
FADH	B-X
(	B-X
2	B-X
)	B-X
both-utilizing	B-X
monooxygenase	B-X
component	B-X
and	B-X
the	B-X
flavins	B-X
should	B-X
be	B-X
controlled	B-X
at	B-X
properly	B-X
reduced	B-X
levels	B-X
to	B-X
obtain	B-X
optimal	B-X
biodesulfurization	B-X
results	B-X
.	B-X

The	O
results	O
suggest	O
that	O
DszC	B-Protein
should	O
be	O
reclassified	O
as	O
an	O
FMNH	O
(	O
2	O
)	O
and	O
FADH	O
(	O
2	O
)	O
both	O
-	O
utilizing	O
monooxygenase	O
component	O
and	O
the	O
flavins	O
should	O
be	O
controlled	O
at	O
properly	O
reduced	O
levels	O
to	O
obtain	O
optimal	O
biodesulfurization	O
results	O
.	O

Generation	O
of	O
branched	O
-	O
chain	O
fatty	O
acids	O
through	O
lipoate	O
-	O
dependent	O
metabolism	O
facilitates	O
intracellular	O
growth	O
of	O
Listeria	O
monocytogenes	O
.	O
<EOS>	B-X
The	B-X
gram-positive	B-X
bacterial	B-X
pathogen	B-X
Listeria	B-X
monocytogenes	B-X
has	B-X
evolved	B-X
mechanisms	B-X
to	B-X
rapidly	B-X
replicate	B-X
in	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
implying	B-X
efficient	B-X
utilization	B-X
of	B-X
host-derived	B-X
nutrients	B-X
.	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
To	B-X
characterize	B-X
which	B-X
biosynthetic	B-X
pathways	B-X
support	B-X
replication	B-X
of	B-X
L.	B-X
monocytogenes	B-X
inside	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
we	B-X
impaired	B-X
lipoate-dependent	B-X
metabolism	B-X
by	B-X
disrupting	B-X
two	B-X
lipoate	B-X
ligase	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
bacterial	B-X
protein	B-X
lipoylation	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
BCFAs	B-X
alone	B-X
rescued	B-X
intracellular	B-X
growth	B-X
and	B-X
spread	B-X
in	B-X
L2	B-X
fibroblasts	B-X
of	B-X
the	B-X
A1A2-	B-X
mutant	B-X
.	B-X
Lipoate-dependent	B-X
metabolism	B-X
was	B-X
also	B-X
required	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
a	B-X
wild-type	B-X
strain	B-X
robustly	B-X
outcompeted	B-X
the	B-X
lipoylation-deficient	B-X
mutant	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
listeriosis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

The	O
gram	O
-	O
positive	O
bacterial	O
pathogen	O
Listeria	O
monocytogenes	O
has	O
evolved	O
mechanisms	O
to	O
rapidly	O
replicate	O
in	O
the	O
host	O
cytosol	O
,	O
implying	O
efficient	O
utilization	O
of	O
host	O
-	O
derived	O
nutrients	O
.	O
<EOS>	B-X
The	B-X
gram-positive	B-X
bacterial	B-X
pathogen	B-X
Listeria	B-X
monocytogenes	B-X
has	B-X
evolved	B-X
mechanisms	B-X
to	B-X
rapidly	B-X
replicate	B-X
in	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
implying	B-X
efficient	B-X
utilization	B-X
of	B-X
host-derived	B-X
nutrients	B-X
.	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
To	B-X
characterize	B-X
which	B-X
biosynthetic	B-X
pathways	B-X
support	B-X
replication	B-X
of	B-X
L.	B-X
monocytogenes	B-X
inside	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
we	B-X
impaired	B-X
lipoate-dependent	B-X
metabolism	B-X
by	B-X
disrupting	B-X
two	B-X
lipoate	B-X
ligase	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
bacterial	B-X
protein	B-X
lipoylation	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

However	O
,	O
the	O
contribution	O
of	O
host	O
nutrient	O
scavenging	O
versus	O
that	O
of	O
bacterial	O
biosynthesis	O
toward	O
rapid	O
intracellular	O
growth	O
remains	O
unclear	O
.	O
<EOS>	B-X
The	B-X
gram-positive	B-X
bacterial	B-X
pathogen	B-X
Listeria	B-X
monocytogenes	B-X
has	B-X
evolved	B-X
mechanisms	B-X
to	B-X
rapidly	B-X
replicate	B-X
in	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
implying	B-X
efficient	B-X
utilization	B-X
of	B-X
host-derived	B-X
nutrients	B-X
.	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
To	B-X
characterize	B-X
which	B-X
biosynthetic	B-X
pathways	B-X
support	B-X
replication	B-X
of	B-X
L.	B-X
monocytogenes	B-X
inside	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
we	B-X
impaired	B-X
lipoate-dependent	B-X
metabolism	B-X
by	B-X
disrupting	B-X
two	B-X
lipoate	B-X
ligase	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
bacterial	B-X
protein	B-X
lipoylation	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
BCFAs	B-X
alone	B-X
rescued	B-X
intracellular	B-X
growth	B-X
and	B-X
spread	B-X
in	B-X
L2	B-X
fibroblasts	B-X
of	B-X
the	B-X
A1A2-	B-X
mutant	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

Nutrients	O
that	O
contribute	O
to	O
growth	O
of	O
L	O
.	O
monocytogenes	O
include	O
branched	O
-	O
chain	O
fatty	O
acids	O
(	O
BCFAs	O
)	O
,	O
amino	O
acids	O
,	O
and	O
other	O
metabolic	O
intermediates	O
generated	O
from	O
acyl	O
-	O
coenzyme	O
A	O
,	O
which	O
is	O
synthesized	O
using	O
lipoylated	O
metabolic	O
enzyme	O
complexes	O
.	O
<EOS>	B-X
The	B-X
gram-positive	B-X
bacterial	B-X
pathogen	B-X
Listeria	B-X
monocytogenes	B-X
has	B-X
evolved	B-X
mechanisms	B-X
to	B-X
rapidly	B-X
replicate	B-X
in	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
implying	B-X
efficient	B-X
utilization	B-X
of	B-X
host-derived	B-X
nutrients	B-X
.	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
To	B-X
characterize	B-X
which	B-X
biosynthetic	B-X
pathways	B-X
support	B-X
replication	B-X
of	B-X
L.	B-X
monocytogenes	B-X
inside	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
we	B-X
impaired	B-X
lipoate-dependent	B-X
metabolism	B-X
by	B-X
disrupting	B-X
two	B-X
lipoate	B-X
ligase	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
bacterial	B-X
protein	B-X
lipoylation	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
BCFAs	B-X
alone	B-X
rescued	B-X
intracellular	B-X
growth	B-X
and	B-X
spread	B-X
in	B-X
L2	B-X
fibroblasts	B-X
of	B-X
the	B-X
A1A2-	B-X
mutant	B-X
.	B-X
Lipoate-dependent	B-X
metabolism	B-X
was	B-X
also	B-X
required	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
a	B-X
wild-type	B-X
strain	B-X
robustly	B-X
outcompeted	B-X
the	B-X
lipoylation-deficient	B-X
mutant	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
listeriosis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

To	O
characterize	O
which	O
biosynthetic	O
pathways	O
support	O
replication	O
of	O
L	O
.	O
monocytogenes	O
inside	O
the	O
host	O
cytosol	O
,	O
we	O
impaired	O
lipoate	O
-	O
dependent	O
metabolism	O
by	O
disrupting	O
two	O
lipoate	O
ligase	O
genes	O
that	O
are	O
responsible	O
for	O
bacterial	O
protein	O
lipoylation	O
.	O
<EOS>	B-X
The	B-X
gram-positive	B-X
bacterial	B-X
pathogen	B-X
Listeria	B-X
monocytogenes	B-X
has	B-X
evolved	B-X
mechanisms	B-X
to	B-X
rapidly	B-X
replicate	B-X
in	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
implying	B-X
efficient	B-X
utilization	B-X
of	B-X
host-derived	B-X
nutrients	B-X
.	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
To	B-X
characterize	B-X
which	B-X
biosynthetic	B-X
pathways	B-X
support	B-X
replication	B-X
of	B-X
L.	B-X
monocytogenes	B-X
inside	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
we	B-X
impaired	B-X
lipoate-dependent	B-X
metabolism	B-X
by	B-X
disrupting	B-X
two	B-X
lipoate	B-X
ligase	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
bacterial	B-X
protein	B-X
lipoylation	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
BCFAs	B-X
alone	B-X
rescued	B-X
intracellular	B-X
growth	B-X
and	B-X
spread	B-X
in	B-X
L2	B-X
fibroblasts	B-X
of	B-X
the	B-X
A1A2-	B-X
mutant	B-X
.	B-X
Lipoate-dependent	B-X
metabolism	B-X
was	B-X
also	B-X
required	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
a	B-X
wild-type	B-X
strain	B-X
robustly	B-X
outcompeted	B-X
the	B-X
lipoylation-deficient	B-X
mutant	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
listeriosis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

Interrupting	O
lipoate	O
-	O
dependent	O
metabolism	O
modestly	O
impaired	O
replication	O
in	O
rich	O
broth	O
medium	O
but	O
strongly	O
inhibited	O
growth	O
in	O
defined	O
medium	O
and	O
host	O
cells	O
and	O
impaired	O
the	O
generation	O
of	O
BCFAs	O
.	O
<EOS>	B-X
The	B-X
gram-positive	B-X
bacterial	B-X
pathogen	B-X
Listeria	B-X
monocytogenes	B-X
has	B-X
evolved	B-X
mechanisms	B-X
to	B-X
rapidly	B-X
replicate	B-X
in	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
implying	B-X
efficient	B-X
utilization	B-X
of	B-X
host-derived	B-X
nutrients	B-X
.	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
To	B-X
characterize	B-X
which	B-X
biosynthetic	B-X
pathways	B-X
support	B-X
replication	B-X
of	B-X
L.	B-X
monocytogenes	B-X
inside	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
we	B-X
impaired	B-X
lipoate-dependent	B-X
metabolism	B-X
by	B-X
disrupting	B-X
two	B-X
lipoate	B-X
ligase	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
bacterial	B-X
protein	B-X
lipoylation	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
BCFAs	B-X
alone	B-X
rescued	B-X
intracellular	B-X
growth	B-X
and	B-X
spread	B-X
in	B-X
L2	B-X
fibroblasts	B-X
of	B-X
the	B-X
A1A2-	B-X
mutant	B-X
.	B-X
Lipoate-dependent	B-X
metabolism	B-X
was	B-X
also	B-X
required	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
a	B-X
wild-type	B-X
strain	B-X
robustly	B-X
outcompeted	B-X
the	B-X
lipoylation-deficient	B-X
mutant	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
listeriosis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

Addition	O
of	O
short	O
BCFAs	O
and	O
amino	O
acids	O
restored	O
growth	O
of	O
the	O
A1A2	O
-	O
deficient	O
(	O
A1A2	O
-	O
)	O
mutant	O
in	O
minimal	O
medium	O
,	O
implying	O
that	O
lipoate	O
-	O
dependent	O
metabolism	O
generates	O
amino	O
acids	O
and	O
BCFAs	O
.	O
<EOS>	B-X
The	B-X
gram-positive	B-X
bacterial	B-X
pathogen	B-X
Listeria	B-X
monocytogenes	B-X
has	B-X
evolved	B-X
mechanisms	B-X
to	B-X
rapidly	B-X
replicate	B-X
in	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
implying	B-X
efficient	B-X
utilization	B-X
of	B-X
host-derived	B-X
nutrients	B-X
.	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
To	B-X
characterize	B-X
which	B-X
biosynthetic	B-X
pathways	B-X
support	B-X
replication	B-X
of	B-X
L.	B-X
monocytogenes	B-X
inside	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
we	B-X
impaired	B-X
lipoate-dependent	B-X
metabolism	B-X
by	B-X
disrupting	B-X
two	B-X
lipoate	B-X
ligase	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
bacterial	B-X
protein	B-X
lipoylation	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
BCFAs	B-X
alone	B-X
rescued	B-X
intracellular	B-X
growth	B-X
and	B-X
spread	B-X
in	B-X
L2	B-X
fibroblasts	B-X
of	B-X
the	B-X
A1A2-	B-X
mutant	B-X
.	B-X
Lipoate-dependent	B-X
metabolism	B-X
was	B-X
also	B-X
required	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
a	B-X
wild-type	B-X
strain	B-X
robustly	B-X
outcompeted	B-X
the	B-X
lipoylation-deficient	B-X
mutant	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
listeriosis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

BCFAs	O
alone	O
rescued	O
intracellular	O
growth	O
and	O
spread	O
in	O
L2	O
fibroblasts	O
of	O
the	O
A1A2	O
-	O
mutant	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
BCFAs	B-X
alone	B-X
rescued	B-X
intracellular	B-X
growth	B-X
and	B-X
spread	B-X
in	B-X
L2	B-X
fibroblasts	B-X
of	B-X
the	B-X
A1A2-	B-X
mutant	B-X
.	B-X
Lipoate-dependent	B-X
metabolism	B-X
was	B-X
also	B-X
required	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
a	B-X
wild-type	B-X
strain	B-X
robustly	B-X
outcompeted	B-X
the	B-X
lipoylation-deficient	B-X
mutant	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
listeriosis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

Lipoate	O
-	O
dependent	O
metabolism	O
was	O
also	O
required	O
in	O
vivo	O
,	O
as	O
a	O
wild	O
-	O
type	O
strain	O
robustly	O
outcompeted	O
the	O
lipoylation	O
-	O
deficient	O
mutant	O
in	O
a	O
murine	O
model	O
of	O
listeriosis	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
lipoate	O
-	O
dependent	O
metabolism	O
contributes	O
to	O
both	O
amino	O
acid	O
and	O
BCFA	O
biosynthesis	O
and	O
that	O
BCFA	O
biosynthesis	O
is	O
preferentially	O
required	O
for	O
intracellular	O
growth	O
of	O
L	O
.	O
monocytogenes	O
.	O
<EOS>	B-X
The	B-X
gram-positive	B-X
bacterial	B-X
pathogen	B-X
Listeria	B-X
monocytogenes	B-X
has	B-X
evolved	B-X
mechanisms	B-X
to	B-X
rapidly	B-X
replicate	B-X
in	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
implying	B-X
efficient	B-X
utilization	B-X
of	B-X
host-derived	B-X
nutrients	B-X
.	B-X
However	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
host	B-X
nutrient	B-X
scavenging	B-X
versus	B-X
that	B-X
of	B-X
bacterial	B-X
biosynthesis	B-X
toward	B-X
rapid	B-X
intracellular	B-X
growth	B-X
remains	B-X
unclear	B-X
.	B-X
Nutrients	B-X
that	B-X
contribute	B-X
to	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
include	B-X
branched-chain	B-X
fatty	B-X
acids	B-X
(	B-X
BCFAs	B-X
)	B-X
,	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
other	B-X
metabolic	B-X
intermediates	B-X
generated	B-X
from	B-X
acyl-coenzyme	B-X
A	B-X
,	B-X
which	B-X
is	B-X
synthesized	B-X
using	B-X
lipoylated	B-X
metabolic	B-X
enzyme	B-X
complexes	B-X
.	B-X
To	B-X
characterize	B-X
which	B-X
biosynthetic	B-X
pathways	B-X
support	B-X
replication	B-X
of	B-X
L.	B-X
monocytogenes	B-X
inside	B-X
the	B-X
host	B-X
cytosol	B-X
,	B-X
we	B-X
impaired	B-X
lipoate-dependent	B-X
metabolism	B-X
by	B-X
disrupting	B-X
two	B-X
lipoate	B-X
ligase	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
bacterial	B-X
protein	B-X
lipoylation	B-X
.	B-X
Interrupting	B-X
lipoate-dependent	B-X
metabolism	B-X
modestly	B-X
impaired	B-X
replication	B-X
in	B-X
rich	B-X
broth	B-X
medium	B-X
but	B-X
strongly	B-X
inhibited	B-X
growth	B-X
in	B-X
defined	B-X
medium	B-X
and	B-X
host	B-X
cells	B-X
and	B-X
impaired	B-X
the	B-X
generation	B-X
of	B-X
BCFAs	B-X
.	B-X
Addition	B-X
of	B-X
short	B-X
BCFAs	B-X
and	B-X
amino	B-X
acids	B-X
restored	B-X
growth	B-X
of	B-X
the	B-X
A1A2-deficient	B-X
(	B-X
A1A2-	B-X
)	B-X
mutant	B-X
in	B-X
minimal	B-X
medium	B-X
,	B-X
implying	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
generates	B-X
amino	B-X
acids	B-X
and	B-X
BCFAs	B-X
.	B-X
BCFAs	B-X
alone	B-X
rescued	B-X
intracellular	B-X
growth	B-X
and	B-X
spread	B-X
in	B-X
L2	B-X
fibroblasts	B-X
of	B-X
the	B-X
A1A2-	B-X
mutant	B-X
.	B-X
Lipoate-dependent	B-X
metabolism	B-X
was	B-X
also	B-X
required	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
a	B-X
wild-type	B-X
strain	B-X
robustly	B-X
outcompeted	B-X
the	B-X
lipoylation-deficient	B-X
mutant	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
listeriosis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
lipoate-dependent	B-X
metabolism	B-X
contributes	B-X
to	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
BCFA	B-X
biosynthesis	B-X
and	B-X
that	B-X
BCFA	B-X
biosynthesis	B-X
is	B-X
preferentially	B-X
required	B-X
for	B-X
intracellular	B-X
growth	B-X
of	B-X
L.	B-X
monocytogenes	B-X
.	B-X

Eliminylation	O
:	O
a	O
post	O
-	O
translational	O
modification	O
catalyzed	O
by	O
phosphothreonine	O
lyases	O
.	O
<EOS>	B-X
We	B-X
propose	B-X
the	B-X
classification	B-X
of	B-X
a	B-X
protein	B-X
post-translational	B-X
modification	B-X
,	B-X
eliminylation	B-X
,	B-X
based	B-X
on	B-X
the	B-X
recently	B-X
delineated	B-X
mechanism	B-X
of	B-X
the	B-X
Shigella	B-X
OspF	B-X
and	B-X
Salmonella	B-X
SpvC	B-X
phosphothreonine	B-X
lyases	B-X
.	B-X
Remarkably	B-X
,	B-X
they	B-X
employ	B-X
an	B-X
unusual	B-X
beta-elimination	B-X
reaction	B-X
,	B-X
removing	B-X
the	B-X
phosphate	B-X
from	B-X
phosphothreonine	B-X
and	B-X
converting	B-X
it	B-X
into	B-X
dehydrobutyrine	B-X
(	B-X
an	B-X
alkene	B-X
)	B-X
.	B-X
We	B-X
postulate	B-X
that	B-X
eliminylation	B-X
might	B-X
be	B-X
a	B-X
widespread	B-X
regulatory	B-X
modification	B-X
,	B-X
and	B-X
we	B-X
propose	B-X
the	B-X
use	B-X
of	B-X
phosphothreonine	B-X
lyases	B-X
as	B-X
in	B-X
vivo	B-X
MAPK	B-X
inhibitors	B-X
both	B-X
therapeutically	B-X
and	B-X
to	B-X
investigate	B-X
MAPK	B-X
signalling	B-X
regulation	B-X
.	B-X

We	O
propose	O
the	O
classification	O
of	O
a	O
protein	O
post	O
-	O
translational	O
modification	O
,	O
eliminylation	O
,	O
based	O
on	O
the	O
recently	O
delineated	O
mechanism	O
of	O
the	O
Shigella	O
OspF	B-Protein
and	O
Salmonella	O
SpvC	B-Protein
phosphothreonine	O
lyases	O
.	O
<EOS>	B-X
We	B-X
propose	B-X
the	B-X
classification	B-X
of	B-X
a	B-X
protein	B-X
post-translational	B-X
modification	B-X
,	B-X
eliminylation	B-X
,	B-X
based	B-X
on	B-X
the	B-X
recently	B-X
delineated	B-X
mechanism	B-X
of	B-X
the	B-X
Shigella	B-X
OspF	B-X
and	B-X
Salmonella	B-X
SpvC	B-X
phosphothreonine	B-X
lyases	B-X
.	B-X
These	B-X
bacterial	B-X
type-III	B-X
secretion-system	B-X
virulence	B-X
factors	B-X
are	B-X
injected	B-X
into	B-X
eukaryotic	B-X
cells	B-X
and	B-X
inhibit	B-X
signalling	B-X
by	B-X
irreversibly	B-X
inactivating	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
.	B-X
Remarkably	B-X
,	B-X
they	B-X
employ	B-X
an	B-X
unusual	B-X
beta-elimination	B-X
reaction	B-X
,	B-X
removing	B-X
the	B-X
phosphate	B-X
from	B-X
phosphothreonine	B-X
and	B-X
converting	B-X
it	B-X
into	B-X
dehydrobutyrine	B-X
(	B-X
an	B-X
alkene	B-X
)	B-X
.	B-X
We	B-X
postulate	B-X
that	B-X
eliminylation	B-X
might	B-X
be	B-X
a	B-X
widespread	B-X
regulatory	B-X
modification	B-X
,	B-X
and	B-X
we	B-X
propose	B-X
the	B-X
use	B-X
of	B-X
phosphothreonine	B-X
lyases	B-X
as	B-X
in	B-X
vivo	B-X
MAPK	B-X
inhibitors	B-X
both	B-X
therapeutically	B-X
and	B-X
to	B-X
investigate	B-X
MAPK	B-X
signalling	B-X
regulation	B-X
.	B-X

These	O
bacterial	O
type	O
-	O
III	O
secretion	O
-	O
system	O
virulence	O
factors	O
are	O
injected	O
into	O
eukaryotic	O
cells	O
and	O
inhibit	O
signalling	O
by	O
irreversibly	O
inactivating	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
.	O
<EOS>	B-X
We	B-X
propose	B-X
the	B-X
classification	B-X
of	B-X
a	B-X
protein	B-X
post-translational	B-X
modification	B-X
,	B-X
eliminylation	B-X
,	B-X
based	B-X
on	B-X
the	B-X
recently	B-X
delineated	B-X
mechanism	B-X
of	B-X
the	B-X
Shigella	B-X
OspF	B-X
and	B-X
Salmonella	B-X
SpvC	B-X
phosphothreonine	B-X
lyases	B-X
.	B-X
These	B-X
bacterial	B-X
type-III	B-X
secretion-system	B-X
virulence	B-X
factors	B-X
are	B-X
injected	B-X
into	B-X
eukaryotic	B-X
cells	B-X
and	B-X
inhibit	B-X
signalling	B-X
by	B-X
irreversibly	B-X
inactivating	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
.	B-X
Eliminylated	B-X
cysteine	B-X
can	B-X
also	B-X
be	B-X
produced	B-X
by	B-X
decarboxylation	B-X
and	B-X
eliminylated	B-X
serine	B-X
and	B-X
threonine	B-X
by	B-X
dehydration	B-X
;	B-X
these	B-X
residues	B-X
are	B-X
found	B-X
in	B-X
the	B-X
eye	B-X
lens	B-X
and	B-X
in	B-X
bacterial	B-X
lantibiotics	B-X
.	B-X
We	B-X
postulate	B-X
that	B-X
eliminylation	B-X
might	B-X
be	B-X
a	B-X
widespread	B-X
regulatory	B-X
modification	B-X
,	B-X
and	B-X
we	B-X
propose	B-X
the	B-X
use	B-X
of	B-X
phosphothreonine	B-X
lyases	B-X
as	B-X
in	B-X
vivo	B-X
MAPK	B-X
inhibitors	B-X
both	B-X
therapeutically	B-X
and	B-X
to	B-X
investigate	B-X
MAPK	B-X
signalling	B-X
regulation	B-X
.	B-X

Remarkably	O
,	O
they	O
employ	O
an	O
unusual	O
beta	O
-	O
elimination	O
reaction	O
,	O
removing	O
the	O
phosphate	O
from	O
phosphothreonine	O
and	O
converting	O
it	O
into	O
dehydrobutyrine	O
(	O
an	O
alkene	O
)	O
.	O
<EOS>	B-X
We	B-X
propose	B-X
the	B-X
classification	B-X
of	B-X
a	B-X
protein	B-X
post-translational	B-X
modification	B-X
,	B-X
eliminylation	B-X
,	B-X
based	B-X
on	B-X
the	B-X
recently	B-X
delineated	B-X
mechanism	B-X
of	B-X
the	B-X
Shigella	B-X
OspF	B-X
and	B-X
Salmonella	B-X
SpvC	B-X
phosphothreonine	B-X
lyases	B-X
.	B-X
Remarkably	B-X
,	B-X
they	B-X
employ	B-X
an	B-X
unusual	B-X
beta-elimination	B-X
reaction	B-X
,	B-X
removing	B-X
the	B-X
phosphate	B-X
from	B-X
phosphothreonine	B-X
and	B-X
converting	B-X
it	B-X
into	B-X
dehydrobutyrine	B-X
(	B-X
an	B-X
alkene	B-X
)	B-X
.	B-X
We	B-X
postulate	B-X
that	B-X
eliminylation	B-X
might	B-X
be	B-X
a	B-X
widespread	B-X
regulatory	B-X
modification	B-X
,	B-X
and	B-X
we	B-X
propose	B-X
the	B-X
use	B-X
of	B-X
phosphothreonine	B-X
lyases	B-X
as	B-X
in	B-X
vivo	B-X
MAPK	B-X
inhibitors	B-X
both	B-X
therapeutically	B-X
and	B-X
to	B-X
investigate	B-X
MAPK	B-X
signalling	B-X
regulation	B-X
.	B-X

Eliminylated	O
cysteine	O
can	O
also	O
be	O
produced	O
by	O
decarboxylation	O
and	O
eliminylated	O
serine	O
and	O
threonine	O
by	O
dehydration	O
;	O
these	O
residues	O
are	O
found	O
in	O
the	O
eye	O
lens	O
and	O
in	O
bacterial	O
lantibiotics	O
.	O
<EOS>	B-X
We	B-X
propose	B-X
the	B-X
classification	B-X
of	B-X
a	B-X
protein	B-X
post-translational	B-X
modification	B-X
,	B-X
eliminylation	B-X
,	B-X
based	B-X
on	B-X
the	B-X
recently	B-X
delineated	B-X
mechanism	B-X
of	B-X
the	B-X
Shigella	B-X
OspF	B-X
and	B-X
Salmonella	B-X
SpvC	B-X
phosphothreonine	B-X
lyases	B-X
.	B-X
These	B-X
bacterial	B-X
type-III	B-X
secretion-system	B-X
virulence	B-X
factors	B-X
are	B-X
injected	B-X
into	B-X
eukaryotic	B-X
cells	B-X
and	B-X
inhibit	B-X
signalling	B-X
by	B-X
irreversibly	B-X
inactivating	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
.	B-X
Remarkably	B-X
,	B-X
they	B-X
employ	B-X
an	B-X
unusual	B-X
beta-elimination	B-X
reaction	B-X
,	B-X
removing	B-X
the	B-X
phosphate	B-X
from	B-X
phosphothreonine	B-X
and	B-X
converting	B-X
it	B-X
into	B-X
dehydrobutyrine	B-X
(	B-X
an	B-X
alkene	B-X
)	B-X
.	B-X
Eliminylated	B-X
cysteine	B-X
can	B-X
also	B-X
be	B-X
produced	B-X
by	B-X
decarboxylation	B-X
and	B-X
eliminylated	B-X
serine	B-X
and	B-X
threonine	B-X
by	B-X
dehydration	B-X
;	B-X
these	B-X
residues	B-X
are	B-X
found	B-X
in	B-X
the	B-X
eye	B-X
lens	B-X
and	B-X
in	B-X
bacterial	B-X
lantibiotics	B-X
.	B-X
We	B-X
postulate	B-X
that	B-X
eliminylation	B-X
might	B-X
be	B-X
a	B-X
widespread	B-X
regulatory	B-X
modification	B-X
,	B-X
and	B-X
we	B-X
propose	B-X
the	B-X
use	B-X
of	B-X
phosphothreonine	B-X
lyases	B-X
as	B-X
in	B-X
vivo	B-X
MAPK	B-X
inhibitors	B-X
both	B-X
therapeutically	B-X
and	B-X
to	B-X
investigate	B-X
MAPK	B-X
signalling	B-X
regulation	B-X
.	B-X

We	O
postulate	O
that	O
eliminylation	O
might	O
be	O
a	O
widespread	O
regulatory	O
modification	O
,	O
and	O
we	O
propose	O
the	O
use	O
of	O
phosphothreonine	O
lyases	O
as	O
in	O
vivo	O
MAPK	O
inhibitors	O
both	O
therapeutically	O
and	O
to	O
investigate	O
MAPK	O
signalling	O
regulation	O
.	O
<EOS>	B-X
We	B-X
propose	B-X
the	B-X
classification	B-X
of	B-X
a	B-X
protein	B-X
post-translational	B-X
modification	B-X
,	B-X
eliminylation	B-X
,	B-X
based	B-X
on	B-X
the	B-X
recently	B-X
delineated	B-X
mechanism	B-X
of	B-X
the	B-X
Shigella	B-X
OspF	B-X
and	B-X
Salmonella	B-X
SpvC	B-X
phosphothreonine	B-X
lyases	B-X
.	B-X
These	B-X
bacterial	B-X
type-III	B-X
secretion-system	B-X
virulence	B-X
factors	B-X
are	B-X
injected	B-X
into	B-X
eukaryotic	B-X
cells	B-X
and	B-X
inhibit	B-X
signalling	B-X
by	B-X
irreversibly	B-X
inactivating	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
.	B-X
Remarkably	B-X
,	B-X
they	B-X
employ	B-X
an	B-X
unusual	B-X
beta-elimination	B-X
reaction	B-X
,	B-X
removing	B-X
the	B-X
phosphate	B-X
from	B-X
phosphothreonine	B-X
and	B-X
converting	B-X
it	B-X
into	B-X
dehydrobutyrine	B-X
(	B-X
an	B-X
alkene	B-X
)	B-X
.	B-X
We	B-X
postulate	B-X
that	B-X
eliminylation	B-X
might	B-X
be	B-X
a	B-X
widespread	B-X
regulatory	B-X
modification	B-X
,	B-X
and	B-X
we	B-X
propose	B-X
the	B-X
use	B-X
of	B-X
phosphothreonine	B-X
lyases	B-X
as	B-X
in	B-X
vivo	B-X
MAPK	B-X
inhibitors	B-X
both	B-X
therapeutically	B-X
and	B-X
to	B-X
investigate	B-X
MAPK	B-X
signalling	B-X
regulation	B-X
.	B-X

Antigenic	O
protein	O
modifications	O
in	O
Ehrlichia	O
.	O
<EOS>	B-X
To	B-X
develop	B-X
effective	B-X
vaccination	B-X
strategies	B-X
against	B-X
Ehrlichia	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
developing	B-X
an	B-X
animal	B-X
model	B-X
of	B-X
cross-protection	B-X
in	B-X
which	B-X
C57BL/6	B-X
mice	B-X
primed	B-X
with	B-X
E.	B-X
muris	B-X
were	B-X
resistant	B-X
to	B-X
lethal	B-X
infection	B-X
with	B-X
Ixodes	B-X
ovatus	B-X
ehrlichia	B-X
(	B-X
IOE	B-X
)	B-X
.	B-X
Polyclonal	B-X
antibody	B-X
produced	B-X
in	B-X
mice	B-X
after	B-X
priming	B-X
with	B-X
E.	B-X
muris	B-X
and	B-X
later	B-X
injected	B-X
with	B-X
IOE-detected	B-X
antigenic	B-X
proteins	B-X
in	B-X
E.	B-X
muris	B-X
and	B-X
IOE	B-X
cell	B-X
lysates	B-X
.	B-X
Cross-reaction	B-X
of	B-X
antigenic	B-X
proteins	B-X
was	B-X
observed	B-X
when	B-X
we	B-X
probed	B-X
both	B-X
the	B-X
E.	B-X
muris	B-X
and	B-X
IOE	B-X
cell	B-X
lysates	B-X
with	B-X
IOE	B-X
and	B-X
E.	B-X
muris-specific	B-X
polyclonal	B-X
antibody	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
total	B-X
proteins	B-X
of	B-X
E.	B-X
muris	B-X
and	B-X
IOE	B-X
by	B-X
two	B-X
dimensional	B-X
electrophoresis	B-X
showed	B-X
that	B-X
both	B-X
E.	B-X
muris	B-X
and	B-X
IOE	B-X
have	B-X
the	B-X
same	B-X
antigenic	B-X
proteins	B-X
.	B-X
Finally	B-X
,	B-X
studies	B-X
on	B-X
post-translational	B-X
protein	B-X
modifications	B-X
using	B-X
a	B-X
novel	B-X
technique	B-X
,	B-X
Eastern	B-X
blotting	B-X
,	B-X
showed	B-X
that	B-X
E.	B-X
muris	B-X
proteins	B-X
are	B-X
more	B-X
lipoylated	B-X
and	B-X
glycosylated	B-X
than	B-X
those	B-X
of	B-X
IOE	B-X
.	B-X

To	O
develop	O
effective	O
vaccination	O
strategies	O
against	O
Ehrlichia	O
,	O
we	O
have	O
previously	O
reported	O
developing	O
an	O
animal	O
model	O
of	O
cross	O
-	O
protection	O
in	O
which	O
C57BL	O
/	O
6	O
mice	O
primed	O
with	O
E	O
.	O
muris	O
were	O
resistant	O
to	O
lethal	O
infection	O
with	O
Ixodes	O
ovatus	O
ehrlichia	O
(	O
IOE	O
)	O
.	O

Polyclonal	O
antibody	O
produced	O
in	O
mice	O
after	O
priming	O
with	O
E	O
.	O
muris	O
and	O
later	O
injected	O
with	O
IOE	O
-	O
detected	O
antigenic	O
proteins	O
in	O
E	O
.	O
muris	O
and	O
IOE	O
cell	O
lysates	O
.	O

Cross	O
-	O
reaction	O
of	O
antigenic	O
proteins	O
was	O
observed	O
when	O
we	O
probed	O
both	O
the	O
E	O
.	O
muris	O
and	O
IOE	O
cell	O
lysates	O
with	O
IOE	O
and	O
E	O
.	O
muris	O
-	O
specific	O
polyclonal	O
antibody	O
.	O

Analysis	O
of	O
the	O
total	O
proteins	O
of	O
E	O
.	O
muris	O
and	O
IOE	O
by	O
two	O
dimensional	O
electrophoresis	O
showed	O
that	O
both	O
E	O
.	O
muris	O
and	O
IOE	O
have	O
the	O
same	O
antigenic	O
proteins	O
.	O

Finally	O
,	O
studies	O
on	O
post	O
-	O
translational	O
protein	O
modifications	O
using	O
a	O
novel	O
technique	O
,	O
Eastern	O
blotting	O
,	O
showed	O
that	O
E	O
.	O
muris	O
proteins	O
are	O
more	O
lipoylated	O
and	O
glycosylated	O
than	O
those	O
of	O
IOE	O
.	O
<EOS>	B-X
To	B-X
develop	B-X
effective	B-X
vaccination	B-X
strategies	B-X
against	B-X
Ehrlichia	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
developing	B-X
an	B-X
animal	B-X
model	B-X
of	B-X
cross-protection	B-X
in	B-X
which	B-X
C57BL/6	B-X
mice	B-X
primed	B-X
with	B-X
E.	B-X
muris	B-X
were	B-X
resistant	B-X
to	B-X
lethal	B-X
infection	B-X
with	B-X
Ixodes	B-X
ovatus	B-X
ehrlichia	B-X
(	B-X
IOE	B-X
)	B-X
.	B-X
Polyclonal	B-X
antibody	B-X
produced	B-X
in	B-X
mice	B-X
after	B-X
priming	B-X
with	B-X
E.	B-X
muris	B-X
and	B-X
later	B-X
injected	B-X
with	B-X
IOE-detected	B-X
antigenic	B-X
proteins	B-X
in	B-X
E.	B-X
muris	B-X
and	B-X
IOE	B-X
cell	B-X
lysates	B-X
.	B-X
Cross-reaction	B-X
of	B-X
antigenic	B-X
proteins	B-X
was	B-X
observed	B-X
when	B-X
we	B-X
probed	B-X
both	B-X
the	B-X
E.	B-X
muris	B-X
and	B-X
IOE	B-X
cell	B-X
lysates	B-X
with	B-X
IOE	B-X
and	B-X
E.	B-X
muris-specific	B-X
polyclonal	B-X
antibody	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
total	B-X
proteins	B-X
of	B-X
E.	B-X
muris	B-X
and	B-X
IOE	B-X
by	B-X
two	B-X
dimensional	B-X
electrophoresis	B-X
showed	B-X
that	B-X
both	B-X
E.	B-X
muris	B-X
and	B-X
IOE	B-X
have	B-X
the	B-X
same	B-X
antigenic	B-X
proteins	B-X
.	B-X
Finally	B-X
,	B-X
studies	B-X
on	B-X
post-translational	B-X
protein	B-X
modifications	B-X
using	B-X
a	B-X
novel	B-X
technique	B-X
,	B-X
Eastern	B-X
blotting	B-X
,	B-X
showed	B-X
that	B-X
E.	B-X
muris	B-X
proteins	B-X
are	B-X
more	B-X
lipoylated	B-X
and	B-X
glycosylated	B-X
than	B-X
those	B-X
of	B-X
IOE	B-X
.	B-X

Regulation	O
of	O
AMPA	O
receptor	O
extrasynaptic	O
insertion	O
by	O
4	B-Protein
.	I-Protein
1N	I-Protein
,	O
phosphorylation	O
and	O
palmitoylation	O
.	O
<EOS>	B-X
The	B-X
insertion	B-X
of	B-X
AMPA	B-X
receptors	B-X
(	B-X
AMPARs	B-X
)	B-X
into	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
the	B-X
synaptic	B-X
delivery	B-X
of	B-X
AMPARs	B-X
during	B-X
the	B-X
expression	B-X
of	B-X
synaptic	B-X
plasticity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
AMPAR	B-X
insertion	B-X
remain	B-X
elusive	B-X
.	B-X
By	B-X
directly	B-X
visualizing	B-X
individual	B-X
insertion	B-X
events	B-X
of	B-X
the	B-X
AMPAR	B-X
subunit	B-X
GluR1	B-X
in	B-X
rodents	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
4.1N	B-X
was	B-X
required	B-X
for	B-X
activity-dependent	B-X
GluR1	B-X
insertion	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
phosphorylation	B-X
of	B-X
the	B-X
serine	B-X
816	B-X
(	B-X
S816	B-X
)	B-X
and	B-X
S818	B-X
residues	B-X
of	B-X
GluR1	B-X
enhanced	B-X
4.1N	B-X
binding	B-X
to	B-X
GluR1	B-X
and	B-X
facilitated	B-X
GluR1	B-X
insertion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
palmitoylation	B-X
of	B-X
GluR1	B-X
C811	B-X
residue	B-X
modulated	B-X
PKC	B-X
phosphorylation	B-X
and	B-X
GluR1	B-X
insertion	B-X
.	B-X
Finally	B-X
,	B-X
disrupting	B-X
4.1N-dependent	B-X
GluR1	B-X
insertion	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
GluR1	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
long-term	B-X
potentiation	B-X
.	B-X
Our	B-X
study	B-X
uncovers	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
that	B-X
governs	B-X
activity-dependent	B-X
GluR1	B-X
trafficking	B-X
,	B-X
reveals	B-X
an	B-X
interaction	B-X
between	B-X
AMPAR	B-X
palmitoylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
and	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
4.1N	B-X
in	B-X
AMPAR	B-X
trafficking	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X

The	O
insertion	O
of	O
AMPA	O
receptors	O
(	O
AMPARs	O
)	O
into	O
the	O
plasma	O
membrane	O
is	O
an	O
important	O
step	O
in	O
the	O
synaptic	O
delivery	O
of	O
AMPARs	O
during	O
the	O
expression	O
of	O
synaptic	O
plasticity	O
.	O
<EOS>	B-X
The	B-X
insertion	B-X
of	B-X
AMPA	B-X
receptors	B-X
(	B-X
AMPARs	B-X
)	B-X
into	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
the	B-X
synaptic	B-X
delivery	B-X
of	B-X
AMPARs	B-X
during	B-X
the	B-X
expression	B-X
of	B-X
synaptic	B-X
plasticity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
AMPAR	B-X
insertion	B-X
remain	B-X
elusive	B-X
.	B-X
By	B-X
directly	B-X
visualizing	B-X
individual	B-X
insertion	B-X
events	B-X
of	B-X
the	B-X
AMPAR	B-X
subunit	B-X
GluR1	B-X
in	B-X
rodents	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
4.1N	B-X
was	B-X
required	B-X
for	B-X
activity-dependent	B-X
GluR1	B-X
insertion	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
phosphorylation	B-X
of	B-X
the	B-X
serine	B-X
816	B-X
(	B-X
S816	B-X
)	B-X
and	B-X
S818	B-X
residues	B-X
of	B-X
GluR1	B-X
enhanced	B-X
4.1N	B-X
binding	B-X
to	B-X
GluR1	B-X
and	B-X
facilitated	B-X
GluR1	B-X
insertion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
palmitoylation	B-X
of	B-X
GluR1	B-X
C811	B-X
residue	B-X
modulated	B-X
PKC	B-X
phosphorylation	B-X
and	B-X
GluR1	B-X
insertion	B-X
.	B-X
Finally	B-X
,	B-X
disrupting	B-X
4.1N-dependent	B-X
GluR1	B-X
insertion	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
GluR1	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
long-term	B-X
potentiation	B-X
.	B-X
Our	B-X
study	B-X
uncovers	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
that	B-X
governs	B-X
activity-dependent	B-X
GluR1	B-X
trafficking	B-X
,	B-X
reveals	B-X
an	B-X
interaction	B-X
between	B-X
AMPAR	B-X
palmitoylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
and	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
4.1N	B-X
in	B-X
AMPAR	B-X
trafficking	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X

However	O
,	O
the	O
molecular	O
mechanisms	O
regulating	O
AMPAR	O
insertion	O
remain	O
elusive	O
.	O
<EOS>	B-X
This	B-X
form	B-X
of	B-X
synaptic	B-X
plasticity	B-X
primarily	B-X
involves	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic	B-X
acid	B-X
receptor	B-X
(	B-X
AMPAR	B-X
)	B-X
abundance	B-X
and	B-X
properties	B-X
,	B-X
whereby	B-X
AMPARs	B-X
are	B-X
inserted	B-X
into	B-X
synapses	B-X
during	B-X
long-term	B-X
potentiation	B-X
(	B-X
LTP	B-X
)	B-X
or	B-X
removed	B-X
during	B-X
long-term	B-X
depression	B-X
(	B-X
LTD	B-X
)	B-X
.	B-X
The	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
AMPAR	B-X
trafficking	B-X
remain	B-X
elusive	B-X
,	B-X
however	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
glutamate	B-X
receptor	B-X
interacting	B-X
protein	B-X
1	B-X
(	B-X
GRIP1	B-X
)	B-X
,	B-X
an	B-X
AMPAR-binding	B-X
protein	B-X
shown	B-X
to	B-X
regulate	B-X
the	B-X
trafficking	B-X
and	B-X
synaptic	B-X
targeting	B-X
of	B-X
AMPARs	B-X
,	B-X
is	B-X
required	B-X
for	B-X
LTP	B-X
and	B-X
learning	B-X
and	B-X
memory	B-X
.	B-X
The	B-X
insertion	B-X
of	B-X
AMPA	B-X
receptors	B-X
(	B-X
AMPARs	B-X
)	B-X
into	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
the	B-X
synaptic	B-X
delivery	B-X
of	B-X
AMPARs	B-X
during	B-X
the	B-X
expression	B-X
of	B-X
synaptic	B-X
plasticity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
AMPAR	B-X
insertion	B-X
remain	B-X
elusive	B-X
.	B-X
By	B-X
directly	B-X
visualizing	B-X
individual	B-X
insertion	B-X
events	B-X
of	B-X
the	B-X
AMPAR	B-X
subunit	B-X
GluR1	B-X
in	B-X
rodents	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
4.1N	B-X
was	B-X
required	B-X
for	B-X
activity-dependent	B-X
GluR1	B-X
insertion	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
phosphorylation	B-X
of	B-X
the	B-X
serine	B-X
816	B-X
(	B-X
S816	B-X
)	B-X
and	B-X
S818	B-X
residues	B-X
of	B-X
GluR1	B-X
enhanced	B-X
4.1N	B-X
binding	B-X
to	B-X
GluR1	B-X
and	B-X
facilitated	B-X
GluR1	B-X
insertion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
palmitoylation	B-X
of	B-X
GluR1	B-X
C811	B-X
residue	B-X
modulated	B-X
PKC	B-X
phosphorylation	B-X
and	B-X
GluR1	B-X
insertion	B-X
.	B-X
Finally	B-X
,	B-X
disrupting	B-X
4.1N-dependent	B-X
GluR1	B-X
insertion	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
GluR1	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
long-term	B-X
potentiation	B-X
.	B-X
Our	B-X
study	B-X
uncovers	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
that	B-X
governs	B-X
activity-dependent	B-X
GluR1	B-X
trafficking	B-X
,	B-X
reveals	B-X
an	B-X
interaction	B-X
between	B-X
AMPAR	B-X
palmitoylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
and	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
4.1N	B-X
in	B-X
AMPAR	B-X
trafficking	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X

By	O
directly	O
visualizing	O
individual	O
insertion	O
events	O
of	O
the	O
AMPAR	O
subunit	O
GluR1	B-Protein
in	O
rodents	O
,	O
we	O
found	O
that	O
the	O
protein	O
4	B-Protein
.	I-Protein
1N	I-Protein
was	O
required	O
for	O
activity	O
-	O
dependent	O
GluR1	B-Protein
insertion	O
.	O
<EOS>	B-X
The	B-X
insertion	B-X
of	B-X
AMPA	B-X
receptors	B-X
(	B-X
AMPARs	B-X
)	B-X
into	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
the	B-X
synaptic	B-X
delivery	B-X
of	B-X
AMPARs	B-X
during	B-X
the	B-X
expression	B-X
of	B-X
synaptic	B-X
plasticity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
AMPAR	B-X
insertion	B-X
remain	B-X
elusive	B-X
.	B-X
By	B-X
directly	B-X
visualizing	B-X
individual	B-X
insertion	B-X
events	B-X
of	B-X
the	B-X
AMPAR	B-X
subunit	B-X
GluR1	B-X
in	B-X
rodents	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
4.1N	B-X
was	B-X
required	B-X
for	B-X
activity-dependent	B-X
GluR1	B-X
insertion	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
phosphorylation	B-X
of	B-X
the	B-X
serine	B-X
816	B-X
(	B-X
S816	B-X
)	B-X
and	B-X
S818	B-X
residues	B-X
of	B-X
GluR1	B-X
enhanced	B-X
4.1N	B-X
binding	B-X
to	B-X
GluR1	B-X
and	B-X
facilitated	B-X
GluR1	B-X
insertion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
palmitoylation	B-X
of	B-X
GluR1	B-X
C811	B-X
residue	B-X
modulated	B-X
PKC	B-X
phosphorylation	B-X
and	B-X
GluR1	B-X
insertion	B-X
.	B-X
Finally	B-X
,	B-X
disrupting	B-X
4.1N-dependent	B-X
GluR1	B-X
insertion	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
GluR1	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
long-term	B-X
potentiation	B-X
.	B-X
Our	B-X
study	B-X
uncovers	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
that	B-X
governs	B-X
activity-dependent	B-X
GluR1	B-X
trafficking	B-X
,	B-X
reveals	B-X
an	B-X
interaction	B-X
between	B-X
AMPAR	B-X
palmitoylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
and	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
4.1N	B-X
in	B-X
AMPAR	B-X
trafficking	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
phosphorylation	O
of	O
the	O
serine	O
816	O
(	O
S816	O
)	O
and	O
S818	O
residues	O
of	O
GluR1	B-Protein
enhanced	O
4	B-Protein
.	I-Protein
1N	I-Protein
binding	O
to	O
GluR1	B-Protein
and	O
facilitated	O
GluR1	B-Protein
insertion	O
.	O
<EOS>	B-X
The	B-X
insertion	B-X
of	B-X
AMPA	B-X
receptors	B-X
(	B-X
AMPARs	B-X
)	B-X
into	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
the	B-X
synaptic	B-X
delivery	B-X
of	B-X
AMPARs	B-X
during	B-X
the	B-X
expression	B-X
of	B-X
synaptic	B-X
plasticity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
AMPAR	B-X
insertion	B-X
remain	B-X
elusive	B-X
.	B-X
By	B-X
directly	B-X
visualizing	B-X
individual	B-X
insertion	B-X
events	B-X
of	B-X
the	B-X
AMPAR	B-X
subunit	B-X
GluR1	B-X
in	B-X
rodents	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
4.1N	B-X
was	B-X
required	B-X
for	B-X
activity-dependent	B-X
GluR1	B-X
insertion	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
phosphorylation	B-X
of	B-X
the	B-X
serine	B-X
816	B-X
(	B-X
S816	B-X
)	B-X
and	B-X
S818	B-X
residues	B-X
of	B-X
GluR1	B-X
enhanced	B-X
4.1N	B-X
binding	B-X
to	B-X
GluR1	B-X
and	B-X
facilitated	B-X
GluR1	B-X
insertion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
palmitoylation	B-X
of	B-X
GluR1	B-X
C811	B-X
residue	B-X
modulated	B-X
PKC	B-X
phosphorylation	B-X
and	B-X
GluR1	B-X
insertion	B-X
.	B-X
Finally	B-X
,	B-X
disrupting	B-X
4.1N-dependent	B-X
GluR1	B-X
insertion	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
GluR1	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
long-term	B-X
potentiation	B-X
.	B-X
Our	B-X
study	B-X
uncovers	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
that	B-X
governs	B-X
activity-dependent	B-X
GluR1	B-X
trafficking	B-X
,	B-X
reveals	B-X
an	B-X
interaction	B-X
between	B-X
AMPAR	B-X
palmitoylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
and	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
4.1N	B-X
in	B-X
AMPAR	B-X
trafficking	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X

In	O
addition	O
,	O
palmitoylation	O
of	O
GluR1	B-Protein
C811	O
residue	O
modulated	O
PKC	O
phosphorylation	O
and	O
GluR1	B-Protein
insertion	O
.	O
<EOS>	B-X
The	B-X
insertion	B-X
of	B-X
AMPA	B-X
receptors	B-X
(	B-X
AMPARs	B-X
)	B-X
into	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
the	B-X
synaptic	B-X
delivery	B-X
of	B-X
AMPARs	B-X
during	B-X
the	B-X
expression	B-X
of	B-X
synaptic	B-X
plasticity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
AMPAR	B-X
insertion	B-X
remain	B-X
elusive	B-X
.	B-X
By	B-X
directly	B-X
visualizing	B-X
individual	B-X
insertion	B-X
events	B-X
of	B-X
the	B-X
AMPAR	B-X
subunit	B-X
GluR1	B-X
in	B-X
rodents	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
4.1N	B-X
was	B-X
required	B-X
for	B-X
activity-dependent	B-X
GluR1	B-X
insertion	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
phosphorylation	B-X
of	B-X
the	B-X
serine	B-X
816	B-X
(	B-X
S816	B-X
)	B-X
and	B-X
S818	B-X
residues	B-X
of	B-X
GluR1	B-X
enhanced	B-X
4.1N	B-X
binding	B-X
to	B-X
GluR1	B-X
and	B-X
facilitated	B-X
GluR1	B-X
insertion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
palmitoylation	B-X
of	B-X
GluR1	B-X
C811	B-X
residue	B-X
modulated	B-X
PKC	B-X
phosphorylation	B-X
and	B-X
GluR1	B-X
insertion	B-X
.	B-X
Finally	B-X
,	B-X
disrupting	B-X
4.1N-dependent	B-X
GluR1	B-X
insertion	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
GluR1	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
long-term	B-X
potentiation	B-X
.	B-X
Our	B-X
study	B-X
uncovers	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
that	B-X
governs	B-X
activity-dependent	B-X
GluR1	B-X
trafficking	B-X
,	B-X
reveals	B-X
an	B-X
interaction	B-X
between	B-X
AMPAR	B-X
palmitoylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
and	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
4.1N	B-X
in	B-X
AMPAR	B-X
trafficking	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X

Finally	O
,	O
disrupting	O
4	B-Protein
.	I-Protein
1N	I-Protein
-	O
dependent	O
GluR1	B-Protein
insertion	O
decreased	O
surface	O
expression	O
of	O
GluR1	B-Protein
and	O
the	O
expression	O
of	O
long	O
-	O
term	O
potentiation	O
.	O
<EOS>	B-X
The	B-X
insertion	B-X
of	B-X
AMPA	B-X
receptors	B-X
(	B-X
AMPARs	B-X
)	B-X
into	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
the	B-X
synaptic	B-X
delivery	B-X
of	B-X
AMPARs	B-X
during	B-X
the	B-X
expression	B-X
of	B-X
synaptic	B-X
plasticity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
AMPAR	B-X
insertion	B-X
remain	B-X
elusive	B-X
.	B-X
By	B-X
directly	B-X
visualizing	B-X
individual	B-X
insertion	B-X
events	B-X
of	B-X
the	B-X
AMPAR	B-X
subunit	B-X
GluR1	B-X
in	B-X
rodents	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
4.1N	B-X
was	B-X
required	B-X
for	B-X
activity-dependent	B-X
GluR1	B-X
insertion	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
phosphorylation	B-X
of	B-X
the	B-X
serine	B-X
816	B-X
(	B-X
S816	B-X
)	B-X
and	B-X
S818	B-X
residues	B-X
of	B-X
GluR1	B-X
enhanced	B-X
4.1N	B-X
binding	B-X
to	B-X
GluR1	B-X
and	B-X
facilitated	B-X
GluR1	B-X
insertion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
palmitoylation	B-X
of	B-X
GluR1	B-X
C811	B-X
residue	B-X
modulated	B-X
PKC	B-X
phosphorylation	B-X
and	B-X
GluR1	B-X
insertion	B-X
.	B-X
Finally	B-X
,	B-X
disrupting	B-X
4.1N-dependent	B-X
GluR1	B-X
insertion	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
GluR1	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
long-term	B-X
potentiation	B-X
.	B-X
Our	B-X
study	B-X
uncovers	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
that	B-X
governs	B-X
activity-dependent	B-X
GluR1	B-X
trafficking	B-X
,	B-X
reveals	B-X
an	B-X
interaction	B-X
between	B-X
AMPAR	B-X
palmitoylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
and	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
4.1N	B-X
in	B-X
AMPAR	B-X
trafficking	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X

Our	O
study	O
uncovers	O
a	O
previously	O
unknown	O
mechanism	O
that	O
governs	O
activity	O
-	O
dependent	O
GluR1	B-Protein
trafficking	O
,	O
reveals	O
an	O
interaction	O
between	O
AMPAR	O
palmitoylation	O
and	O
phosphorylation	O
,	O
and	O
underscores	O
the	O
functional	O
importance	O
of	O
4	B-Protein
.	I-Protein
1N	I-Protein
in	O
AMPAR	O
trafficking	O
and	O
synaptic	O
plasticity	O
.	O
<EOS>	B-X
The	B-X
insertion	B-X
of	B-X
AMPA	B-X
receptors	B-X
(	B-X
AMPARs	B-X
)	B-X
into	B-X
the	B-X
plasma	B-X
membrane	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
the	B-X
synaptic	B-X
delivery	B-X
of	B-X
AMPARs	B-X
during	B-X
the	B-X
expression	B-X
of	B-X
synaptic	B-X
plasticity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
AMPAR	B-X
insertion	B-X
remain	B-X
elusive	B-X
.	B-X
By	B-X
directly	B-X
visualizing	B-X
individual	B-X
insertion	B-X
events	B-X
of	B-X
the	B-X
AMPAR	B-X
subunit	B-X
GluR1	B-X
in	B-X
rodents	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
4.1N	B-X
was	B-X
required	B-X
for	B-X
activity-dependent	B-X
GluR1	B-X
insertion	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
phosphorylation	B-X
of	B-X
the	B-X
serine	B-X
816	B-X
(	B-X
S816	B-X
)	B-X
and	B-X
S818	B-X
residues	B-X
of	B-X
GluR1	B-X
enhanced	B-X
4.1N	B-X
binding	B-X
to	B-X
GluR1	B-X
and	B-X
facilitated	B-X
GluR1	B-X
insertion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
palmitoylation	B-X
of	B-X
GluR1	B-X
C811	B-X
residue	B-X
modulated	B-X
PKC	B-X
phosphorylation	B-X
and	B-X
GluR1	B-X
insertion	B-X
.	B-X
Finally	B-X
,	B-X
disrupting	B-X
4.1N-dependent	B-X
GluR1	B-X
insertion	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
GluR1	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
long-term	B-X
potentiation	B-X
.	B-X
Our	B-X
study	B-X
uncovers	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
that	B-X
governs	B-X
activity-dependent	B-X
GluR1	B-X
trafficking	B-X
,	B-X
reveals	B-X
an	B-X
interaction	B-X
between	B-X
AMPAR	B-X
palmitoylation	B-X
and	B-X
phosphorylation	B-X
,	B-X
and	B-X
underscores	B-X
the	B-X
functional	B-X
importance	B-X
of	B-X
4.1N	B-X
in	B-X
AMPAR	B-X
trafficking	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X

Using	O
RNA	O
interference	O
to	O
identify	O
specific	O
modifiers	O
of	O
a	O
temperature	O
-	O
sensitive	O
,	O
embryonic	O
-	O
lethal	O
mutation	O
in	O
the	O
Caenorhabditis	O
elegans	O
ubiquitin	B-Protein
-	O
like	O
Nedd8	B-Protein
protein	O
modification	O
pathway	O
E1	O
-	O
activating	O
gene	O
rfl	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
essential	B-X
Caenorhabditis	B-X
elegans	B-X
gene	B-X
rfl-1	B-X
encodes	B-X
one	B-X
subunit	B-X
of	B-X
a	B-X
heterodimeric	B-X
E1-activating	B-X
enzyme	B-X
in	B-X
the	B-X
Nedd8	B-X
ubiquitin-like	B-X
protein	B-X
conjugation	B-X
pathway	B-X
.	B-X
This	B-X
pathway	B-X
modifies	B-X
the	B-X
Cullin	B-X
scaffolds	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
a	B-X
single	B-X
Nedd8	B-X
moiety	B-X
to	B-X
promote	B-X
ligase	B-X
function	B-X
.	B-X
To	B-X
identify	B-X
genes	B-X
that	B-X
influence	B-X
neddylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
synthetic	B-X
screen	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
,	B-X
when	B-X
depleted	B-X
with	B-X
RNAi	B-X
,	B-X
enhance	B-X
or	B-X
suppress	B-X
the	B-X
embryonic	B-X
lethality	B-X
caused	B-X
by	B-X
or198ts	B-X
,	B-X
a	B-X
temperature-sensitive	B-X
(	B-X
ts	B-X
)	B-X
mutation	B-X
in	B-X
rfl-1	B-X
.	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
specific	B-X
modifiers	B-X
are	B-X
conserved	B-X
in	B-X
other	B-X
organisms	B-X
,	B-X
and	B-X
most	B-X
are	B-X
nonessential	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

The	O
essential	O
Caenorhabditis	O
elegans	O
gene	O
rfl	B-Protein
-	I-Protein
1	I-Protein
encodes	O
one	O
subunit	O
of	O
a	O
heterodimeric	O
E1	O
-	O
activating	O
enzyme	O
in	O
the	O
Nedd8	B-Protein
ubiquitin	B-Protein
-	O
like	O
protein	O
conjugation	O
pathway	O
.	O
<EOS>	B-X
The	B-X
essential	B-X
Caenorhabditis	B-X
elegans	B-X
gene	B-X
rfl-1	B-X
encodes	B-X
one	B-X
subunit	B-X
of	B-X
a	B-X
heterodimeric	B-X
E1-activating	B-X
enzyme	B-X
in	B-X
the	B-X
Nedd8	B-X
ubiquitin-like	B-X
protein	B-X
conjugation	B-X
pathway	B-X
.	B-X
This	B-X
pathway	B-X
modifies	B-X
the	B-X
Cullin	B-X
scaffolds	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
a	B-X
single	B-X
Nedd8	B-X
moiety	B-X
to	B-X
promote	B-X
ligase	B-X
function	B-X
.	B-X
To	B-X
identify	B-X
genes	B-X
that	B-X
influence	B-X
neddylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
synthetic	B-X
screen	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
,	B-X
when	B-X
depleted	B-X
with	B-X
RNAi	B-X
,	B-X
enhance	B-X
or	B-X
suppress	B-X
the	B-X
embryonic	B-X
lethality	B-X
caused	B-X
by	B-X
or198ts	B-X
,	B-X
a	B-X
temperature-sensitive	B-X
(	B-X
ts	B-X
)	B-X
mutation	B-X
in	B-X
rfl-1	B-X
.	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
specific	B-X
modifiers	B-X
are	B-X
conserved	B-X
in	B-X
other	B-X
organisms	B-X
,	B-X
and	B-X
most	B-X
are	B-X
nonessential	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

This	O
pathway	O
modifies	O
the	O
Cullin	O
scaffolds	O
of	O
E3	O
ubiquitin	B-Protein
ligases	O
with	O
a	O
single	O
Nedd8	B-Protein
moiety	O
to	O
promote	O
ligase	O
function	O
.	O
<EOS>	B-X
The	B-X
essential	B-X
Caenorhabditis	B-X
elegans	B-X
gene	B-X
rfl-1	B-X
encodes	B-X
one	B-X
subunit	B-X
of	B-X
a	B-X
heterodimeric	B-X
E1-activating	B-X
enzyme	B-X
in	B-X
the	B-X
Nedd8	B-X
ubiquitin-like	B-X
protein	B-X
conjugation	B-X
pathway	B-X
.	B-X
This	B-X
pathway	B-X
modifies	B-X
the	B-X
Cullin	B-X
scaffolds	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
a	B-X
single	B-X
Nedd8	B-X
moiety	B-X
to	B-X
promote	B-X
ligase	B-X
function	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X

To	O
identify	O
genes	O
that	O
influence	O
neddylation	O
,	O
we	O
used	O
a	O
synthetic	O
screen	O
to	O
identify	O
genes	O
that	O
,	O
when	O
depleted	O
with	O
RNAi	O
,	O
enhance	O
or	O
suppress	O
the	O
embryonic	O
lethality	O
caused	O
by	O
or198ts	O
,	O
a	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
mutation	O
in	O
rfl	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
essential	B-X
Caenorhabditis	B-X
elegans	B-X
gene	B-X
rfl-1	B-X
encodes	B-X
one	B-X
subunit	B-X
of	B-X
a	B-X
heterodimeric	B-X
E1-activating	B-X
enzyme	B-X
in	B-X
the	B-X
Nedd8	B-X
ubiquitin-like	B-X
protein	B-X
conjugation	B-X
pathway	B-X
.	B-X
To	B-X
identify	B-X
genes	B-X
that	B-X
influence	B-X
neddylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
synthetic	B-X
screen	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
,	B-X
when	B-X
depleted	B-X
with	B-X
RNAi	B-X
,	B-X
enhance	B-X
or	B-X
suppress	B-X
the	B-X
embryonic	B-X
lethality	B-X
caused	B-X
by	B-X
or198ts	B-X
,	B-X
a	B-X
temperature-sensitive	B-X
(	B-X
ts	B-X
)	B-X
mutation	B-X
in	B-X
rfl-1	B-X
.	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

We	O
identified	O
reproducible	O
suppressor	O
and	O
enhancer	O
genes	O
and	O
employed	O
a	O
systematic	O
specificity	O
analysis	O
for	O
each	O
modifier	O
using	O
four	O
unrelated	O
ts	O
embryonic	O
lethal	O
mutants	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
genes	B-X
that	B-X
influence	B-X
neddylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
synthetic	B-X
screen	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
,	B-X
when	B-X
depleted	B-X
with	B-X
RNAi	B-X
,	B-X
enhance	B-X
or	B-X
suppress	B-X
the	B-X
embryonic	B-X
lethality	B-X
caused	B-X
by	B-X
or198ts	B-X
,	B-X
a	B-X
temperature-sensitive	B-X
(	B-X
ts	B-X
)	B-X
mutation	B-X
in	B-X
rfl-1	B-X
.	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
specific	B-X
modifiers	B-X
are	B-X
conserved	B-X
in	B-X
other	B-X
organisms	B-X
,	B-X
and	B-X
most	B-X
are	B-X
nonessential	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

Results	O
of	O
this	O
analysis	O
highlight	O
the	O
importance	O
of	O
specificity	O
controls	O
in	O
identifying	O
genetic	O
interactions	O
relevant	O
to	O
a	O
particular	O
biological	O
process	O
because	O
8	O
/	O
14	O
enhancers	O
and	O
7	O
/	O
21	O
suppressors	O
modified	O
lethality	O
in	O
other	O
mutants	O
.	O
<EOS>	B-X
The	B-X
essential	B-X
Caenorhabditis	B-X
elegans	B-X
gene	B-X
rfl-1	B-X
encodes	B-X
one	B-X
subunit	B-X
of	B-X
a	B-X
heterodimeric	B-X
E1-activating	B-X
enzyme	B-X
in	B-X
the	B-X
Nedd8	B-X
ubiquitin-like	B-X
protein	B-X
conjugation	B-X
pathway	B-X
.	B-X
This	B-X
pathway	B-X
modifies	B-X
the	B-X
Cullin	B-X
scaffolds	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
a	B-X
single	B-X
Nedd8	B-X
moiety	B-X
to	B-X
promote	B-X
ligase	B-X
function	B-X
.	B-X
To	B-X
identify	B-X
genes	B-X
that	B-X
influence	B-X
neddylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
synthetic	B-X
screen	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
,	B-X
when	B-X
depleted	B-X
with	B-X
RNAi	B-X
,	B-X
enhance	B-X
or	B-X
suppress	B-X
the	B-X
embryonic	B-X
lethality	B-X
caused	B-X
by	B-X
or198ts	B-X
,	B-X
a	B-X
temperature-sensitive	B-X
(	B-X
ts	B-X
)	B-X
mutation	B-X
in	B-X
rfl-1	B-X
.	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

Depletion	O
of	O
the	O
strongest	O
specific	O
suppressors	O
rescued	O
the	O
early	O
embryonic	O
cell	O
division	O
defects	O
in	O
rfl	B-Protein
-	I-Protein
1	I-Protein
(	O
or198ts	O
)	O
mutants	O
.	O
<EOS>	B-X
The	B-X
essential	B-X
Caenorhabditis	B-X
elegans	B-X
gene	B-X
rfl-1	B-X
encodes	B-X
one	B-X
subunit	B-X
of	B-X
a	B-X
heterodimeric	B-X
E1-activating	B-X
enzyme	B-X
in	B-X
the	B-X
Nedd8	B-X
ubiquitin-like	B-X
protein	B-X
conjugation	B-X
pathway	B-X
.	B-X
To	B-X
identify	B-X
genes	B-X
that	B-X
influence	B-X
neddylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
synthetic	B-X
screen	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
,	B-X
when	B-X
depleted	B-X
with	B-X
RNAi	B-X
,	B-X
enhance	B-X
or	B-X
suppress	B-X
the	B-X
embryonic	B-X
lethality	B-X
caused	B-X
by	B-X
or198ts	B-X
,	B-X
a	B-X
temperature-sensitive	B-X
(	B-X
ts	B-X
)	B-X
mutation	B-X
in	B-X
rfl-1	B-X
.	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
specific	B-X
modifiers	B-X
are	B-X
conserved	B-X
in	B-X
other	B-X
organisms	B-X
,	B-X
and	B-X
most	B-X
are	B-X
nonessential	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

RNAi	O
knockdown	O
of	O
some	O
specific	O
suppressors	O
partially	O
restored	O
Cullin	O
neddylation	O
in	O
rfl	B-Protein
-	I-Protein
1	I-Protein
(	O
or198ts	O
)	O
mutants	O
,	O
consistent	O
with	O
their	O
gene	O
products	O
normally	O
opposing	O
neddylation	O
,	O
and	O
GFP	B-Protein
fusions	O
to	O
several	O
suppressors	O
were	O
detected	O
in	O
the	O
cytoplasm	O
or	O
the	O
nucleus	O
,	O
similar	O
in	O
pattern	O
to	O
Nedd8	B-Protein
conjugation	O
pathway	O
components	O
in	O
early	O
embryonic	O
cells	O
.	O
<EOS>	B-X
The	B-X
essential	B-X
Caenorhabditis	B-X
elegans	B-X
gene	B-X
rfl-1	B-X
encodes	B-X
one	B-X
subunit	B-X
of	B-X
a	B-X
heterodimeric	B-X
E1-activating	B-X
enzyme	B-X
in	B-X
the	B-X
Nedd8	B-X
ubiquitin-like	B-X
protein	B-X
conjugation	B-X
pathway	B-X
.	B-X
This	B-X
pathway	B-X
modifies	B-X
the	B-X
Cullin	B-X
scaffolds	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
a	B-X
single	B-X
Nedd8	B-X
moiety	B-X
to	B-X
promote	B-X
ligase	B-X
function	B-X
.	B-X
To	B-X
identify	B-X
genes	B-X
that	B-X
influence	B-X
neddylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
synthetic	B-X
screen	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
,	B-X
when	B-X
depleted	B-X
with	B-X
RNAi	B-X
,	B-X
enhance	B-X
or	B-X
suppress	B-X
the	B-X
embryonic	B-X
lethality	B-X
caused	B-X
by	B-X
or198ts	B-X
,	B-X
a	B-X
temperature-sensitive	B-X
(	B-X
ts	B-X
)	B-X
mutation	B-X
in	B-X
rfl-1	B-X
.	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
specific	B-X
modifiers	B-X
are	B-X
conserved	B-X
in	B-X
other	B-X
organisms	B-X
,	B-X
and	B-X
most	B-X
are	B-X
nonessential	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

In	O
contrast	O
,	O
depletion	O
of	O
the	O
two	O
strongest	O
specific	O
enhancers	O
did	O
not	O
affect	O
the	O
early	O
embryonic	O
cell	O
division	O
defects	O
observed	O
in	O
rfl	B-Protein
-	I-Protein
1	I-Protein
(	O
or198ts	O
)	O
mutants	O
,	O
suggesting	O
that	O
they	O
may	O
act	O
at	O
later	O
times	O
in	O
other	O
essential	O
processes	O
.	O

Many	O
of	O
the	O
specific	O
modifiers	O
are	O
conserved	O
in	O
other	O
organisms	O
,	O
and	O
most	O
are	O
nonessential	O
.	O
<EOS>	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
specific	B-X
modifiers	B-X
are	B-X
conserved	B-X
in	B-X
other	B-X
organisms	B-X
,	B-X
and	B-X
most	B-X
are	B-X
nonessential	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

Thus	O
,	O
when	O
controlled	O
properly	O
for	O
specificity	O
,	O
modifier	O
screens	O
using	O
conditionally	O
lethal	O
C	O
.	O
elegans	O
mutants	O
can	O
identify	O
roles	O
for	O
nonessential	O
but	O
conserved	O
genes	O
in	O
essential	O
processes	O
.	O
<EOS>	B-X
The	B-X
essential	B-X
Caenorhabditis	B-X
elegans	B-X
gene	B-X
rfl-1	B-X
encodes	B-X
one	B-X
subunit	B-X
of	B-X
a	B-X
heterodimeric	B-X
E1-activating	B-X
enzyme	B-X
in	B-X
the	B-X
Nedd8	B-X
ubiquitin-like	B-X
protein	B-X
conjugation	B-X
pathway	B-X
.	B-X
This	B-X
pathway	B-X
modifies	B-X
the	B-X
Cullin	B-X
scaffolds	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
a	B-X
single	B-X
Nedd8	B-X
moiety	B-X
to	B-X
promote	B-X
ligase	B-X
function	B-X
.	B-X
To	B-X
identify	B-X
genes	B-X
that	B-X
influence	B-X
neddylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
synthetic	B-X
screen	B-X
to	B-X
identify	B-X
genes	B-X
that	B-X
,	B-X
when	B-X
depleted	B-X
with	B-X
RNAi	B-X
,	B-X
enhance	B-X
or	B-X
suppress	B-X
the	B-X
embryonic	B-X
lethality	B-X
caused	B-X
by	B-X
or198ts	B-X
,	B-X
a	B-X
temperature-sensitive	B-X
(	B-X
ts	B-X
)	B-X
mutation	B-X
in	B-X
rfl-1	B-X
.	B-X
We	B-X
identified	B-X
reproducible	B-X
suppressor	B-X
and	B-X
enhancer	B-X
genes	B-X
and	B-X
employed	B-X
a	B-X
systematic	B-X
specificity	B-X
analysis	B-X
for	B-X
each	B-X
modifier	B-X
using	B-X
four	B-X
unrelated	B-X
ts	B-X
embryonic	B-X
lethal	B-X
mutants	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
analysis	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
specificity	B-X
controls	B-X
in	B-X
identifying	B-X
genetic	B-X
interactions	B-X
relevant	B-X
to	B-X
a	B-X
particular	B-X
biological	B-X
process	B-X
because	B-X
8/14	B-X
enhancers	B-X
and	B-X
7/21	B-X
suppressors	B-X
modified	B-X
lethality	B-X
in	B-X
other	B-X
mutants	B-X
.	B-X
Depletion	B-X
of	B-X
the	B-X
strongest	B-X
specific	B-X
suppressors	B-X
rescued	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
.	B-X
RNAi	B-X
knockdown	B-X
of	B-X
some	B-X
specific	B-X
suppressors	B-X
partially	B-X
restored	B-X
Cullin	B-X
neddylation	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
consistent	B-X
with	B-X
their	B-X
gene	B-X
products	B-X
normally	B-X
opposing	B-X
neddylation	B-X
,	B-X
and	B-X
GFP	B-X
fusions	B-X
to	B-X
several	B-X
suppressors	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
cytoplasm	B-X
or	B-X
the	B-X
nucleus	B-X
,	B-X
similar	B-X
in	B-X
pattern	B-X
to	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
in	B-X
early	B-X
embryonic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
the	B-X
two	B-X
strongest	B-X
specific	B-X
enhancers	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
early	B-X
embryonic	B-X
cell	B-X
division	B-X
defects	B-X
observed	B-X
in	B-X
rfl-1	B-X
(	B-X
or198ts	B-X
)	B-X
mutants	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
act	B-X
at	B-X
later	B-X
times	B-X
in	B-X
other	B-X
essential	B-X
processes	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
specific	B-X
modifiers	B-X
are	B-X
conserved	B-X
in	B-X
other	B-X
organisms	B-X
,	B-X
and	B-X
most	B-X
are	B-X
nonessential	B-X
.	B-X
Thus	B-X
,	B-X
when	B-X
controlled	B-X
properly	B-X
for	B-X
specificity	B-X
,	B-X
modifier	B-X
screens	B-X
using	B-X
conditionally	B-X
lethal	B-X
C.	B-X
elegans	B-X
mutants	B-X
can	B-X
identify	B-X
roles	B-X
for	B-X
nonessential	B-X
but	B-X
conserved	B-X
genes	B-X
in	B-X
essential	B-X
processes	B-X
.	B-X

Characterization	O
of	O
subcellular	O
localization	O
of	O
duck	O
enteritis	O
virus	O
UL51	B-Protein
protein	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
a	B-X
protein	B-X
can	B-X
provide	B-X
useful	B-X
insights	B-X
about	B-X
its	B-X
function	B-X
.	B-X
While	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
many	B-X
alphaherpesvirus	B-X
UL51	B-X
proteins	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
where	B-X
duck	B-X
enteritis	B-X
virus	B-X
(	B-X
DEV	B-X
)	B-X
UL51	B-X
protein	B-X
(	B-X
pUL51	B-X
)	B-X
is	B-X
targeted	B-X
to	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
distribution	B-X
of	B-X
DEV	B-X
pUL51	B-X
by	B-X
computer	B-X
aided	B-X
analysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IIF	B-X
)	B-X
and	B-X
transmission	B-X
immunoelectron	B-X
microscopy	B-X
(	B-X
TIEM	B-X
)	B-X
approaches	B-X
in	B-X
DEV-infected	B-X
cells	B-X
.	B-X

BACKGROUND	O
:	O
Knowledge	O
of	O
the	O
subcellular	O
localization	O
of	O
a	O
protein	O
can	O
provide	O
useful	O
insights	O
about	O
its	O
function	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
a	B-X
protein	B-X
can	B-X
provide	B-X
useful	B-X
insights	B-X
about	B-X
its	B-X
function	B-X
.	B-X
While	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
many	B-X
alphaherpesvirus	B-X
UL51	B-X
proteins	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
where	B-X
duck	B-X
enteritis	B-X
virus	B-X
(	B-X
DEV	B-X
)	B-X
UL51	B-X
protein	B-X
(	B-X
pUL51	B-X
)	B-X
is	B-X
targeted	B-X
to	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
distribution	B-X
of	B-X
DEV	B-X
pUL51	B-X
by	B-X
computer	B-X
aided	B-X
analysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IIF	B-X
)	B-X
and	B-X
transmission	B-X
immunoelectron	B-X
microscopy	B-X
(	B-X
TIEM	B-X
)	B-X
approaches	B-X
in	B-X
DEV-infected	B-X
cells	B-X
.	B-X

While	O
the	O
subcellular	O
localization	O
of	O
many	O
alphaherpesvirus	O
UL51	B-Protein
proteins	O
has	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
where	O
duck	O
enteritis	O
virus	O
(	O
DEV	O
)	O
UL51	B-Protein
protein	O
(	O
pUL51	B-Protein
)	O
is	O
targeted	O
to	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
a	B-X
protein	B-X
can	B-X
provide	B-X
useful	B-X
insights	B-X
about	B-X
its	B-X
function	B-X
.	B-X
While	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
many	B-X
alphaherpesvirus	B-X
UL51	B-X
proteins	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
where	B-X
duck	B-X
enteritis	B-X
virus	B-X
(	B-X
DEV	B-X
)	B-X
UL51	B-X
protein	B-X
(	B-X
pUL51	B-X
)	B-X
is	B-X
targeted	B-X
to	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
distribution	B-X
of	B-X
DEV	B-X
pUL51	B-X
by	B-X
computer	B-X
aided	B-X
analysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IIF	B-X
)	B-X
and	B-X
transmission	B-X
immunoelectron	B-X
microscopy	B-X
(	B-X
TIEM	B-X
)	B-X
approaches	B-X
in	B-X
DEV-infected	B-X
cells	B-X
.	B-X

Thus	O
,	O
in	O
this	O
study	O
,	O
we	O
investigated	O
the	O
subcellular	O
localization	O
and	O
distribution	O
of	O
DEV	O
pUL51	B-Protein
by	O
computer	O
aided	O
analysis	O
,	O
as	O
well	O
as	O
indirect	O
immunofluorescence	O
(	O
IIF	O
)	O
and	O
transmission	O
immunoelectron	O
microscopy	O
(	O
TIEM	O
)	O
approaches	O
in	O
DEV	O
-	O
infected	O
cells	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
a	B-X
protein	B-X
can	B-X
provide	B-X
useful	B-X
insights	B-X
about	B-X
its	B-X
function	B-X
.	B-X
While	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
many	B-X
alphaherpesvirus	B-X
UL51	B-X
proteins	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
where	B-X
duck	B-X
enteritis	B-X
virus	B-X
(	B-X
DEV	B-X
)	B-X
UL51	B-X
protein	B-X
(	B-X
pUL51	B-X
)	B-X
is	B-X
targeted	B-X
to	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
distribution	B-X
of	B-X
DEV	B-X
pUL51	B-X
by	B-X
computer	B-X
aided	B-X
analysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IIF	B-X
)	B-X
and	B-X
transmission	B-X
immunoelectron	B-X
microscopy	B-X
(	B-X
TIEM	B-X
)	B-X
approaches	B-X
in	B-X
DEV-infected	B-X
cells	B-X
.	B-X

RESULTS	O
:	O
The	O
DEV	O
UL51	B-Protein
gene	O
product	O
was	O
identified	O
as	O
an	O
approximate	O
34	O
kDa	O
protein	O
in	O
DEV	O
-	O
infected	O
cells	O
analyzed	O
by	O
western	O
blotting	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
a	B-X
protein	B-X
can	B-X
provide	B-X
useful	B-X
insights	B-X
about	B-X
its	B-X
function	B-X
.	B-X
While	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
many	B-X
alphaherpesvirus	B-X
UL51	B-X
proteins	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
where	B-X
duck	B-X
enteritis	B-X
virus	B-X
(	B-X
DEV	B-X
)	B-X
UL51	B-X
protein	B-X
(	B-X
pUL51	B-X
)	B-X
is	B-X
targeted	B-X
to	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
distribution	B-X
of	B-X
DEV	B-X
pUL51	B-X
by	B-X
computer	B-X
aided	B-X
analysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IIF	B-X
)	B-X
and	B-X
transmission	B-X
immunoelectron	B-X
microscopy	B-X
(	B-X
TIEM	B-X
)	B-X
approaches	B-X
in	B-X
DEV-infected	B-X
cells	B-X
.	B-X

Computer	O
aided	O
analysis	O
suggested	O
that	O
DEV	O
pUL51	B-Protein
is	O
not	O
targeted	O
to	O
the	O
mitochondrial	O
,	O
extra	O
-	O
cellular	O
or	O
nucleus	O
,	O
but	O
be	O
targeted	O
to	O
the	O
cytoplasmic	O
in	O
host	O
cells	O
,	O
more	O
specifically	O
,	O
palmitoylation	O
of	O
the	O
pUL51	B-Protein
through	O
the	O
N	O
-	O
terminal	O
cysteine	O
at	O
position	O
9	O
makes	O
membrane	O
association	O
and	O
Golgi	O
localization	O
possible	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
a	B-X
protein	B-X
can	B-X
provide	B-X
useful	B-X
insights	B-X
about	B-X
its	B-X
function	B-X
.	B-X
While	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
many	B-X
alphaherpesvirus	B-X
UL51	B-X
proteins	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
where	B-X
duck	B-X
enteritis	B-X
virus	B-X
(	B-X
DEV	B-X
)	B-X
UL51	B-X
protein	B-X
(	B-X
pUL51	B-X
)	B-X
is	B-X
targeted	B-X
to	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
distribution	B-X
of	B-X
DEV	B-X
pUL51	B-X
by	B-X
computer	B-X
aided	B-X
analysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IIF	B-X
)	B-X
and	B-X
transmission	B-X
immunoelectron	B-X
microscopy	B-X
(	B-X
TIEM	B-X
)	B-X
approaches	B-X
in	B-X
DEV-infected	B-X
cells	B-X
.	B-X

Using	O
IIF	O
analysis	O
,	O
we	O
found	O
that	O
DEV	O
pUL51	B-Protein
was	O
first	O
detected	O
in	O
a	O
juxtanuclear	O
region	O
of	O
DEV	O
-	O
infected	O
cells	O
at	O
9	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.	O
)	O
,	O
and	O
then	O
was	O
detected	O
widely	O
distributed	O
in	O
the	O
cytoplasm	O
and	O
especially	O
was	O
stronger	O
in	O
the	O
juxtanuclear	O
region	O
from	O
12	O
to	O
60	O
h	O
p	O
.	O
i	O
.	O

TIEM	O
analysis	O
revealed	O
that	O
DEV	O
pUL51	B-Protein
was	O
mainly	O
associated	O
with	O
cytoplasmic	O
virions	O
and	O
also	O
with	O
some	O
membranous	O
structure	O
near	O
the	O
pUL51	B-Protein
-	O
specific	O
immuno	O
-	O
labeling	O
intracellular	O
virion	O
in	O
the	O
cytoplasmic	O
vesicles	O
;	O
moreover	O
,	O
the	O
pUL51	B-Protein
efficiently	O
accumulated	O
in	O
the	O
Golgi	O
apparatus	O
at	O
first	O
,	O
and	O
then	O
was	O
sent	O
to	O
the	O
plasma	O
membrane	O
from	O
the	O
Golgi	O
by	O
some	O
unknown	O
mechanism	O
.	O
<EOS>	B-X
While	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
many	B-X
alphaherpesvirus	B-X
UL51	B-X
proteins	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
where	B-X
duck	B-X
enteritis	B-X
virus	B-X
(	B-X
DEV	B-X
)	B-X
UL51	B-X
protein	B-X
(	B-X
pUL51	B-X
)	B-X
is	B-X
targeted	B-X
to	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
distribution	B-X
of	B-X
DEV	B-X
pUL51	B-X
by	B-X
computer	B-X
aided	B-X
analysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IIF	B-X
)	B-X
and	B-X
transmission	B-X
immunoelectron	B-X
microscopy	B-X
(	B-X
TIEM	B-X
)	B-X
approaches	B-X
in	B-X
DEV-infected	B-X
cells	B-X
.	B-X

CONCLUSION	O
:	O
In	O
this	O
work	O
,	O
we	O
described	O
the	O
basic	O
characteristics	O
of	O
pUL51	B-Protein
subcellular	O
localization	O
and	O
distribution	O
for	O
the	O
first	O
time	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
a	B-X
protein	B-X
can	B-X
provide	B-X
useful	B-X
insights	B-X
about	B-X
its	B-X
function	B-X
.	B-X
While	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
many	B-X
alphaherpesvirus	B-X
UL51	B-X
proteins	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
where	B-X
duck	B-X
enteritis	B-X
virus	B-X
(	B-X
DEV	B-X
)	B-X
UL51	B-X
protein	B-X
(	B-X
pUL51	B-X
)	B-X
is	B-X
targeted	B-X
to	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
distribution	B-X
of	B-X
DEV	B-X
pUL51	B-X
by	B-X
computer	B-X
aided	B-X
analysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IIF	B-X
)	B-X
and	B-X
transmission	B-X
immunoelectron	B-X
microscopy	B-X
(	B-X
TIEM	B-X
)	B-X
approaches	B-X
in	B-X
DEV-infected	B-X
cells	B-X
.	B-X

From	O
these	O
results	O
,	O
we	O
concluded	O
that	O
palmitoylation	O
at	O
the	O
N	O
-	O
terminal	O
cysteine	O
,	O
which	O
is	O
conserved	O
in	O
all	O
alphaherpesvirus	O
UL51	B-Protein
homologs	O
,	O
is	O
required	O
for	O
its	O
membrane	O
association	O
and	O
Golgi	O
localization	O
,	O
and	O
the	O
pUL51	B-Protein
mainly	O
localized	O
to	O
the	O
juxtanuclear	O
region	O
of	O
DEV	O
-	O
infected	O
cells	O
,	O
as	O
well	O
seemed	O
to	O
be	O
incorporated	O
into	O
mature	O
virions	O
as	O
a	O
component	O
of	O
the	O
tegument	O
.	O

The	O
research	O
will	O
provide	O
useful	O
clues	O
for	O
DEV	O
pUL51	B-Protein
functional	O
analysis	O
,	O
and	O
will	O
be	O
usefull	O
for	O
further	O
understanding	O
the	O
localization	O
properties	O
of	O
alphaherpesvirus	O
UL51	B-Protein
homologs	O
.	O

Palmitoylation	O
of	O
the	O
sphingosine	O
1	O
-	O
phosphate	O
receptor	O
S1P	O
is	O
involved	O
in	O
its	O
signaling	O
functions	O
and	O
internalization	O
.	O
<EOS>	B-X
The	B-X
lipid	B-X
mediator	B-X
sphingosine	B-X
1-phosphate	B-X
(	B-X
S1P	B-X
)	B-X
regulates	B-X
several	B-X
cellular	B-X
processes	B-X
through	B-X
binding	B-X
to	B-X
its	B-X
receptors	B-X
(	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
-S1P	B-X
(	B-X
5	B-X
)	B-X
)	B-X
,	B-X
which	B-X
are	B-X
heterotrimeric	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
all	B-X
S1P	B-X
receptors	B-X
are	B-X
palmitoylated	B-X
.	B-X
In	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
three	B-X
Cys	B-X
residues	B-X
in	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
are	B-X
palmitoylated	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
palmitoylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
using	B-X
model	B-X
cells	B-X
in	B-X
which	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
or	B-X
a	B-X
non-palmitoylated	B-X
mutant	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
overproduced	B-X
.	B-X
Compared	B-X
with	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
the	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
exhibited	B-X
binding	B-X
affinity	B-X
similar	B-X
to	B-X
the	B-X
natural	B-X
ligand	B-X
S1P	B-X
but	B-X
lower	B-X
to	B-X
the	B-X
synthetic	B-X
ligand	B-X
FTY720	B-X
phosphate	B-X
(	B-X
FTY720-P	B-X
)	B-X
,	B-X
the	B-X
active	B-X
form	B-X
of	B-X
the	B-X
immunomodulator	B-X
FTY720	B-X
.	B-X
However	B-X
,	B-X
downstream	B-X
signaling	B-X
of	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
similarly	B-X
affected	B-X
by	B-X
S1P	B-X
and	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Moreover	B-X
,	B-X
upon	B-X
stimulation	B-X
with	B-X
S1P	B-X
,	B-X
internalization	B-X
of	B-X
the	B-X
mutant	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
retarded	B-X
,	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
protein	B-X
.	B-X
Similar	B-X
differences	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
phosphorylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
and	B-X
its	B-X
mutant	B-X
.	B-X
Finally	B-X
,	B-X
palmitoylation	B-X
of	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
increased	B-X
upon	B-X
treatment	B-X
with	B-X
S1P	B-X
,	B-X
suggesting	B-X
that	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
undergoes	B-X
a	B-X
palmitoylation/depalmitoylation	B-X
cycle	B-X
after	B-X
stimulation	B-X
by	B-X
its	B-X
ligands	B-X
.	B-X

The	O
lipid	O
mediator	O
sphingosine	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
regulates	O
several	O
cellular	O
processes	O
through	O
binding	O
to	O
its	O
receptors	O
(	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
-	O
S1P	B-Protein
(	I-Protein
5	I-Protein
)	I-Protein
)	O
,	O
which	O
are	O
heterotrimeric	O
G	O
protein	O
-	O
coupled	O
receptors	O
.	O

Here	O
,	O
we	O
report	O
that	O
all	O
S1P	O
receptors	O
are	O
palmitoylated	O
.	O
<EOS>	B-X
The	B-X
lipid	B-X
mediator	B-X
sphingosine	B-X
1-phosphate	B-X
(	B-X
S1P	B-X
)	B-X
regulates	B-X
several	B-X
cellular	B-X
processes	B-X
through	B-X
binding	B-X
to	B-X
its	B-X
receptors	B-X
(	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
-S1P	B-X
(	B-X
5	B-X
)	B-X
)	B-X
,	B-X
which	B-X
are	B-X
heterotrimeric	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
all	B-X
S1P	B-X
receptors	B-X
are	B-X
palmitoylated	B-X
.	B-X
In	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
three	B-X
Cys	B-X
residues	B-X
in	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
are	B-X
palmitoylated	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
palmitoylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
using	B-X
model	B-X
cells	B-X
in	B-X
which	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
or	B-X
a	B-X
non-palmitoylated	B-X
mutant	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
overproduced	B-X
.	B-X
Compared	B-X
with	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
the	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
exhibited	B-X
binding	B-X
affinity	B-X
similar	B-X
to	B-X
the	B-X
natural	B-X
ligand	B-X
S1P	B-X
but	B-X
lower	B-X
to	B-X
the	B-X
synthetic	B-X
ligand	B-X
FTY720	B-X
phosphate	B-X
(	B-X
FTY720-P	B-X
)	B-X
,	B-X
the	B-X
active	B-X
form	B-X
of	B-X
the	B-X
immunomodulator	B-X
FTY720	B-X
.	B-X
However	B-X
,	B-X
downstream	B-X
signaling	B-X
of	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
similarly	B-X
affected	B-X
by	B-X
S1P	B-X
and	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Moreover	B-X
,	B-X
upon	B-X
stimulation	B-X
with	B-X
S1P	B-X
,	B-X
internalization	B-X
of	B-X
the	B-X
mutant	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
retarded	B-X
,	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
protein	B-X
.	B-X
Similar	B-X
differences	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
phosphorylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
and	B-X
its	B-X
mutant	B-X
.	B-X
Finally	B-X
,	B-X
palmitoylation	B-X
of	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
increased	B-X
upon	B-X
treatment	B-X
with	B-X
S1P	B-X
,	B-X
suggesting	B-X
that	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
undergoes	B-X
a	B-X
palmitoylation/depalmitoylation	B-X
cycle	B-X
after	B-X
stimulation	B-X
by	B-X
its	B-X
ligands	B-X
.	B-X

In	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
,	O
three	O
Cys	O
residues	O
in	O
the	O
cytoplasmic	O
tail	O
are	O
palmitoylated	O
.	O
<EOS>	B-X
The	B-X
lipid	B-X
mediator	B-X
sphingosine	B-X
1-phosphate	B-X
(	B-X
S1P	B-X
)	B-X
regulates	B-X
several	B-X
cellular	B-X
processes	B-X
through	B-X
binding	B-X
to	B-X
its	B-X
receptors	B-X
(	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
-S1P	B-X
(	B-X
5	B-X
)	B-X
)	B-X
,	B-X
which	B-X
are	B-X
heterotrimeric	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
all	B-X
S1P	B-X
receptors	B-X
are	B-X
palmitoylated	B-X
.	B-X
In	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
three	B-X
Cys	B-X
residues	B-X
in	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
are	B-X
palmitoylated	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
palmitoylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
using	B-X
model	B-X
cells	B-X
in	B-X
which	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
or	B-X
a	B-X
non-palmitoylated	B-X
mutant	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
overproduced	B-X
.	B-X
Compared	B-X
with	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
the	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
exhibited	B-X
binding	B-X
affinity	B-X
similar	B-X
to	B-X
the	B-X
natural	B-X
ligand	B-X
S1P	B-X
but	B-X
lower	B-X
to	B-X
the	B-X
synthetic	B-X
ligand	B-X
FTY720	B-X
phosphate	B-X
(	B-X
FTY720-P	B-X
)	B-X
,	B-X
the	B-X
active	B-X
form	B-X
of	B-X
the	B-X
immunomodulator	B-X
FTY720	B-X
.	B-X
However	B-X
,	B-X
downstream	B-X
signaling	B-X
of	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
similarly	B-X
affected	B-X
by	B-X
S1P	B-X
and	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Moreover	B-X
,	B-X
upon	B-X
stimulation	B-X
with	B-X
S1P	B-X
,	B-X
internalization	B-X
of	B-X
the	B-X
mutant	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
retarded	B-X
,	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
protein	B-X
.	B-X
Similar	B-X
differences	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
phosphorylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
and	B-X
its	B-X
mutant	B-X
.	B-X
Finally	B-X
,	B-X
palmitoylation	B-X
of	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
increased	B-X
upon	B-X
treatment	B-X
with	B-X
S1P	B-X
,	B-X
suggesting	B-X
that	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
undergoes	B-X
a	B-X
palmitoylation/depalmitoylation	B-X
cycle	B-X
after	B-X
stimulation	B-X
by	B-X
its	B-X
ligands	B-X
.	B-X

We	O
examined	O
the	O
roles	O
of	O
palmitoylation	O
of	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
using	O
model	O
cells	O
in	O
which	O
wild	O
-	O
type	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
or	O
a	O
non	O
-	O
palmitoylated	O
mutant	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
was	O
overproduced	O
.	O

Compared	O
with	O
wild	O
-	O
type	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
,	O
the	O
non	O
-	O
palmitoylated	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
exhibited	O
binding	O
affinity	O
similar	O
to	O
the	O
natural	O
ligand	O
S1P	O
but	O
lower	O
to	O
the	O
synthetic	O
ligand	O
FTY720	O
phosphate	O
(	O
FTY720	O
-	O
P	O
)	O
,	O
the	O
active	O
form	O
of	O
the	O
immunomodulator	O
FTY720	O
.	O

However	O
,	O
downstream	O
signaling	O
of	O
non	O
-	O
palmitoylated	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
was	O
similarly	O
affected	O
by	O
S1P	O
and	O
FTY720	O
-	O
P	O
stimulation	O
.	O
<EOS>	B-X
The	B-X
lipid	B-X
mediator	B-X
sphingosine	B-X
1-phosphate	B-X
(	B-X
S1P	B-X
)	B-X
regulates	B-X
several	B-X
cellular	B-X
processes	B-X
through	B-X
binding	B-X
to	B-X
its	B-X
receptors	B-X
(	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
-S1P	B-X
(	B-X
5	B-X
)	B-X
)	B-X
,	B-X
which	B-X
are	B-X
heterotrimeric	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
all	B-X
S1P	B-X
receptors	B-X
are	B-X
palmitoylated	B-X
.	B-X
In	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
three	B-X
Cys	B-X
residues	B-X
in	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
are	B-X
palmitoylated	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
palmitoylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
using	B-X
model	B-X
cells	B-X
in	B-X
which	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
or	B-X
a	B-X
non-palmitoylated	B-X
mutant	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
overproduced	B-X
.	B-X
Compared	B-X
with	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
the	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
exhibited	B-X
binding	B-X
affinity	B-X
similar	B-X
to	B-X
the	B-X
natural	B-X
ligand	B-X
S1P	B-X
but	B-X
lower	B-X
to	B-X
the	B-X
synthetic	B-X
ligand	B-X
FTY720	B-X
phosphate	B-X
(	B-X
FTY720-P	B-X
)	B-X
,	B-X
the	B-X
active	B-X
form	B-X
of	B-X
the	B-X
immunomodulator	B-X
FTY720	B-X
.	B-X
However	B-X
,	B-X
downstream	B-X
signaling	B-X
of	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
similarly	B-X
affected	B-X
by	B-X
S1P	B-X
and	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Moreover	B-X
,	B-X
upon	B-X
stimulation	B-X
with	B-X
S1P	B-X
,	B-X
internalization	B-X
of	B-X
the	B-X
mutant	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
retarded	B-X
,	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
protein	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
much	B-X
more	B-X
pronounced	B-X
with	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Similar	B-X
differences	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
phosphorylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
and	B-X
its	B-X
mutant	B-X
.	B-X
These	B-X
findings	B-X
may	B-X
provide	B-X
insights	B-X
into	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
the	B-X
pharmacological	B-X
effects	B-X
of	B-X
FTY720	B-X
.	B-X
Finally	B-X
,	B-X
palmitoylation	B-X
of	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
increased	B-X
upon	B-X
treatment	B-X
with	B-X
S1P	B-X
,	B-X
suggesting	B-X
that	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
undergoes	B-X
a	B-X
palmitoylation/depalmitoylation	B-X
cycle	B-X
after	B-X
stimulation	B-X
by	B-X
its	B-X
ligands	B-X
.	B-X

Moreover	O
,	O
upon	O
stimulation	O
with	O
S1P	O
,	O
internalization	O
of	O
the	O
mutant	O
non	O
-	O
palmitoylated	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
was	O
retarded	O
,	O
compared	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O
<EOS>	B-X
The	B-X
lipid	B-X
mediator	B-X
sphingosine	B-X
1-phosphate	B-X
(	B-X
S1P	B-X
)	B-X
regulates	B-X
several	B-X
cellular	B-X
processes	B-X
through	B-X
binding	B-X
to	B-X
its	B-X
receptors	B-X
(	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
-S1P	B-X
(	B-X
5	B-X
)	B-X
)	B-X
,	B-X
which	B-X
are	B-X
heterotrimeric	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
all	B-X
S1P	B-X
receptors	B-X
are	B-X
palmitoylated	B-X
.	B-X
In	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
three	B-X
Cys	B-X
residues	B-X
in	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
are	B-X
palmitoylated	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
palmitoylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
using	B-X
model	B-X
cells	B-X
in	B-X
which	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
or	B-X
a	B-X
non-palmitoylated	B-X
mutant	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
overproduced	B-X
.	B-X
Compared	B-X
with	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
the	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
exhibited	B-X
binding	B-X
affinity	B-X
similar	B-X
to	B-X
the	B-X
natural	B-X
ligand	B-X
S1P	B-X
but	B-X
lower	B-X
to	B-X
the	B-X
synthetic	B-X
ligand	B-X
FTY720	B-X
phosphate	B-X
(	B-X
FTY720-P	B-X
)	B-X
,	B-X
the	B-X
active	B-X
form	B-X
of	B-X
the	B-X
immunomodulator	B-X
FTY720	B-X
.	B-X
However	B-X
,	B-X
downstream	B-X
signaling	B-X
of	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
similarly	B-X
affected	B-X
by	B-X
S1P	B-X
and	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Moreover	B-X
,	B-X
upon	B-X
stimulation	B-X
with	B-X
S1P	B-X
,	B-X
internalization	B-X
of	B-X
the	B-X
mutant	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
retarded	B-X
,	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
protein	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
much	B-X
more	B-X
pronounced	B-X
with	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Similar	B-X
differences	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
phosphorylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
and	B-X
its	B-X
mutant	B-X
.	B-X
Finally	B-X
,	B-X
palmitoylation	B-X
of	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
increased	B-X
upon	B-X
treatment	B-X
with	B-X
S1P	B-X
,	B-X
suggesting	B-X
that	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
undergoes	B-X
a	B-X
palmitoylation/depalmitoylation	B-X
cycle	B-X
after	B-X
stimulation	B-X
by	B-X
its	B-X
ligands	B-X
.	B-X

This	O
effect	O
was	O
much	O
more	O
pronounced	O
with	O
FTY720	O
-	O
P	O
stimulation	O
.	O
<EOS>	B-X
The	B-X
lipid	B-X
mediator	B-X
sphingosine	B-X
1-phosphate	B-X
(	B-X
S1P	B-X
)	B-X
regulates	B-X
several	B-X
cellular	B-X
processes	B-X
through	B-X
binding	B-X
to	B-X
its	B-X
receptors	B-X
(	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
-S1P	B-X
(	B-X
5	B-X
)	B-X
)	B-X
,	B-X
which	B-X
are	B-X
heterotrimeric	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
all	B-X
S1P	B-X
receptors	B-X
are	B-X
palmitoylated	B-X
.	B-X
In	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
three	B-X
Cys	B-X
residues	B-X
in	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
are	B-X
palmitoylated	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
palmitoylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
using	B-X
model	B-X
cells	B-X
in	B-X
which	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
or	B-X
a	B-X
non-palmitoylated	B-X
mutant	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
overproduced	B-X
.	B-X
Compared	B-X
with	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
the	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
exhibited	B-X
binding	B-X
affinity	B-X
similar	B-X
to	B-X
the	B-X
natural	B-X
ligand	B-X
S1P	B-X
but	B-X
lower	B-X
to	B-X
the	B-X
synthetic	B-X
ligand	B-X
FTY720	B-X
phosphate	B-X
(	B-X
FTY720-P	B-X
)	B-X
,	B-X
the	B-X
active	B-X
form	B-X
of	B-X
the	B-X
immunomodulator	B-X
FTY720	B-X
.	B-X
However	B-X
,	B-X
downstream	B-X
signaling	B-X
of	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
similarly	B-X
affected	B-X
by	B-X
S1P	B-X
and	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Moreover	B-X
,	B-X
upon	B-X
stimulation	B-X
with	B-X
S1P	B-X
,	B-X
internalization	B-X
of	B-X
the	B-X
mutant	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
retarded	B-X
,	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
protein	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
much	B-X
more	B-X
pronounced	B-X
with	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Similar	B-X
differences	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
phosphorylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
and	B-X
its	B-X
mutant	B-X
.	B-X
These	B-X
findings	B-X
may	B-X
provide	B-X
insights	B-X
into	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
the	B-X
pharmacological	B-X
effects	B-X
of	B-X
FTY720	B-X
.	B-X
Finally	B-X
,	B-X
palmitoylation	B-X
of	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
increased	B-X
upon	B-X
treatment	B-X
with	B-X
S1P	B-X
,	B-X
suggesting	B-X
that	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
undergoes	B-X
a	B-X
palmitoylation/depalmitoylation	B-X
cycle	B-X
after	B-X
stimulation	B-X
by	B-X
its	B-X
ligands	B-X
.	B-X

Similar	O
differences	O
were	O
observed	O
for	O
the	O
phosphorylation	O
of	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
and	O
its	O
mutant	O
.	O
<EOS>	B-X
The	B-X
lipid	B-X
mediator	B-X
sphingosine	B-X
1-phosphate	B-X
(	B-X
S1P	B-X
)	B-X
regulates	B-X
several	B-X
cellular	B-X
processes	B-X
through	B-X
binding	B-X
to	B-X
its	B-X
receptors	B-X
(	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
-S1P	B-X
(	B-X
5	B-X
)	B-X
)	B-X
,	B-X
which	B-X
are	B-X
heterotrimeric	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
all	B-X
S1P	B-X
receptors	B-X
are	B-X
palmitoylated	B-X
.	B-X
In	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
three	B-X
Cys	B-X
residues	B-X
in	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
are	B-X
palmitoylated	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
palmitoylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
using	B-X
model	B-X
cells	B-X
in	B-X
which	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
or	B-X
a	B-X
non-palmitoylated	B-X
mutant	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
overproduced	B-X
.	B-X
Compared	B-X
with	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
the	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
exhibited	B-X
binding	B-X
affinity	B-X
similar	B-X
to	B-X
the	B-X
natural	B-X
ligand	B-X
S1P	B-X
but	B-X
lower	B-X
to	B-X
the	B-X
synthetic	B-X
ligand	B-X
FTY720	B-X
phosphate	B-X
(	B-X
FTY720-P	B-X
)	B-X
,	B-X
the	B-X
active	B-X
form	B-X
of	B-X
the	B-X
immunomodulator	B-X
FTY720	B-X
.	B-X
However	B-X
,	B-X
downstream	B-X
signaling	B-X
of	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
similarly	B-X
affected	B-X
by	B-X
S1P	B-X
and	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
Moreover	B-X
,	B-X
upon	B-X
stimulation	B-X
with	B-X
S1P	B-X
,	B-X
internalization	B-X
of	B-X
the	B-X
mutant	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
retarded	B-X
,	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
the	B-X
wild-type	B-X
protein	B-X
.	B-X
Similar	B-X
differences	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
phosphorylation	B-X
of	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
and	B-X
its	B-X
mutant	B-X
.	B-X
Finally	B-X
,	B-X
palmitoylation	B-X
of	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
increased	B-X
upon	B-X
treatment	B-X
with	B-X
S1P	B-X
,	B-X
suggesting	B-X
that	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
undergoes	B-X
a	B-X
palmitoylation/depalmitoylation	B-X
cycle	B-X
after	B-X
stimulation	B-X
by	B-X
its	B-X
ligands	B-X
.	B-X

These	O
findings	O
may	O
provide	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
of	O
the	O
pharmacological	O
effects	O
of	O
FTY720	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
chemotherapy-induced	B-X
painful	B-X
peripheral	B-X
neuropathy	B-X
is	B-X
a	B-X
major	B-X
dose-limiting	B-X
side	B-X
effect	B-X
of	B-X
many	B-X
chemotherapeutics	B-X
,	B-X
including	B-X
bortezomib	B-X
,	B-X
but	B-X
the	B-X
mechanisms	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
Accordingly	B-X
,	B-X
genetic	B-X
and	B-X
pharmacological	B-X
disruption	B-X
of	B-X
S1PR1	B-X
with	B-X
multiple	B-X
S1PR1	B-X
antagonists	B-X
,	B-X
including	B-X
FTY720	B-X
,	B-X
blocked	B-X
and	B-X
reversed	B-X
neuropathic	B-X
pain	B-X
.	B-X
Compared	B-X
with	B-X
wild-type	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
,	B-X
the	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
exhibited	B-X
binding	B-X
affinity	B-X
similar	B-X
to	B-X
the	B-X
natural	B-X
ligand	B-X
S1P	B-X
but	B-X
lower	B-X
to	B-X
the	B-X
synthetic	B-X
ligand	B-X
FTY720	B-X
phosphate	B-X
(	B-X
FTY720-P	B-X
)	B-X
,	B-X
the	B-X
active	B-X
form	B-X
of	B-X
the	B-X
immunomodulator	B-X
FTY720	B-X
.	B-X
However	B-X
,	B-X
downstream	B-X
signaling	B-X
of	B-X
non-palmitoylated	B-X
S1P	B-X
(	B-X
1	B-X
)	B-X
was	B-X
similarly	B-X
affected	B-X
by	B-X
S1P	B-X
and	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
much	B-X
more	B-X
pronounced	B-X
with	B-X
FTY720-P	B-X
stimulation	B-X
.	B-X
These	B-X
findings	B-X
may	B-X
provide	B-X
insights	B-X
into	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
the	B-X
pharmacological	B-X
effects	B-X
of	B-X
FTY720	B-X
.	B-X

Finally	O
,	O
palmitoylation	O
of	O
wild	O
-	O
type	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
increased	O
upon	O
treatment	O
with	O
S1P	O
,	O
suggesting	O
that	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
undergoes	O
a	O
palmitoylation	O
/	O
depalmitoylation	O
cycle	O
after	O
stimulation	O
by	O
its	O
ligands	O
.	O

Tyrosine	O
sulfation	O
:	O
an	O
increasingly	O
recognised	O
post	O
-	O
translational	O
modification	O
of	O
secreted	O
proteins	O
.	O
<EOS>	B-X
The	B-X
post-translational	B-X
sulfation	B-X
of	B-X
tyrosine	B-X
residues	B-X
occurs	B-X
in	B-X
numerous	B-X
secreted	B-X
and	B-X
integral	B-X
membrane	B-X
proteins	B-X
and	B-X
,	B-X
in	B-X
many	B-X
cases	B-X
,	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
controlling	B-X
the	B-X
interactions	B-X
of	B-X
these	B-X
proteins	B-X
with	B-X
physiological	B-X
binding	B-X
partners	B-X
as	B-X
well	B-X
as	B-X
invading	B-X
pathogens	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
protein	B-X
tyrosine	B-X
sulfation	B-X
have	B-X
come	B-X
about	B-X
owing	B-X
to	B-X
the	B-X
cloning	B-X
of	B-X
two	B-X
human	B-X
tyrosylprotein	B-X
sulfotransferases	B-X
(	B-X
TPST-1	B-X
and	B-X
TPST-2	B-X
)	B-X
,	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
analytical	B-X
and	B-X
synthetic	B-X
methodologies	B-X
and	B-X
detailed	B-X
studies	B-X
of	B-X
proteins	B-X
and	B-X
peptides	B-X
containing	B-X
sulfotyrosine	B-X
residues	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
TPST	B-X
enzymes	B-X
,	B-X
review	B-X
the	B-X
major	B-X
techniques	B-X
available	B-X
for	B-X
studying	B-X
the	B-X
presence	B-X
,	B-X
location	B-X
and	B-X
function	B-X
of	B-X
tyrosine	B-X
sulfation	B-X
in	B-X
proteins	B-X
and	B-X
discuss	B-X
the	B-X
biological	B-X
functions	B-X
and	B-X
biochemical	B-X
interactions	B-X
of	B-X
several	B-X
proteins	B-X
(	B-X
or	B-X
protein	B-X
families	B-X
)	B-X
in	B-X
which	B-X
tyrosine	B-X
sulfation	B-X
influences	B-X
the	B-X
protein	B-X
function	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
detailed	B-X
evidence	B-X
supporting	B-X
the	B-X
importance	B-X
of	B-X
tyrosine	B-X
sulfation	B-X
in	B-X
the	B-X
cellular	B-X
adhesion	B-X
function	B-X
of	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
,	B-X
the	B-X
leukocyte	B-X
trafficking	B-X
and	B-X
pathogen	B-X
invasion	B-X
functions	B-X
of	B-X
chemokine	B-X
receptors	B-X
and	B-X
the	B-X
ligand	B-X
binding	B-X
and	B-X
activation	B-X
of	B-X
other	B-X
G-protein-coupled	B-X
receptors	B-X
by	B-X
complement	B-X
proteins	B-X
,	B-X
phospholipdis	B-X
and	B-X
glycoprotein	B-X
hormones	B-X
.	B-X

The	O
post	O
-	O
translational	O
sulfation	O
of	O
tyrosine	O
residues	O
occurs	O
in	O
numerous	O
secreted	O
and	O
integral	O
membrane	O
proteins	O
and	O
,	O
in	O
many	O
cases	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
controlling	O
the	O
interactions	O
of	O
these	O
proteins	O
with	O
physiological	O
binding	O
partners	O
as	O
well	O
as	O
invading	O
pathogens	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
of	O
protein	O
tyrosine	O
sulfation	O
have	O
come	O
about	O
owing	O
to	O
the	O
cloning	O
of	O
two	O
human	O
tyrosylprotein	O
sulfotransferases	O
(	O
TPST	B-Protein
-	I-Protein
1	I-Protein
and	O
TPST	B-Protein
-	I-Protein
2	I-Protein
)	O
,	O
the	O
development	O
of	O
novel	O
analytical	O
and	O
synthetic	O
methodologies	O
and	O
detailed	O
studies	O
of	O
proteins	O
and	O
peptides	O
containing	O
sulfotyrosine	O
residues	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
TPST	O
enzymes	O
,	O
review	O
the	O
major	O
techniques	O
available	O
for	O
studying	O
the	O
presence	O
,	O
location	O
and	O
function	O
of	O
tyrosine	O
sulfation	O
in	O
proteins	O
and	O
discuss	O
the	O
biological	O
functions	O
and	O
biochemical	O
interactions	O
of	O
several	O
proteins	O
(	O
or	O
protein	O
families	O
)	O
in	O
which	O
tyrosine	O
sulfation	O
influences	O
the	O
protein	O
function	O
.	O
<EOS>	B-X
The	B-X
post-translational	B-X
sulfation	B-X
of	B-X
tyrosine	B-X
residues	B-X
occurs	B-X
in	B-X
numerous	B-X
secreted	B-X
and	B-X
integral	B-X
membrane	B-X
proteins	B-X
and	B-X
,	B-X
in	B-X
many	B-X
cases	B-X
,	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
controlling	B-X
the	B-X
interactions	B-X
of	B-X
these	B-X
proteins	B-X
with	B-X
physiological	B-X
binding	B-X
partners	B-X
as	B-X
well	B-X
as	B-X
invading	B-X
pathogens	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
protein	B-X
tyrosine	B-X
sulfation	B-X
have	B-X
come	B-X
about	B-X
owing	B-X
to	B-X
the	B-X
cloning	B-X
of	B-X
two	B-X
human	B-X
tyrosylprotein	B-X
sulfotransferases	B-X
(	B-X
TPST-1	B-X
and	B-X
TPST-2	B-X
)	B-X
,	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
analytical	B-X
and	B-X
synthetic	B-X
methodologies	B-X
and	B-X
detailed	B-X
studies	B-X
of	B-X
proteins	B-X
and	B-X
peptides	B-X
containing	B-X
sulfotyrosine	B-X
residues	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
TPST	B-X
enzymes	B-X
,	B-X
review	B-X
the	B-X
major	B-X
techniques	B-X
available	B-X
for	B-X
studying	B-X
the	B-X
presence	B-X
,	B-X
location	B-X
and	B-X
function	B-X
of	B-X
tyrosine	B-X
sulfation	B-X
in	B-X
proteins	B-X
and	B-X
discuss	B-X
the	B-X
biological	B-X
functions	B-X
and	B-X
biochemical	B-X
interactions	B-X
of	B-X
several	B-X
proteins	B-X
(	B-X
or	B-X
protein	B-X
families	B-X
)	B-X
in	B-X
which	B-X
tyrosine	B-X
sulfation	B-X
influences	B-X
the	B-X
protein	B-X
function	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
detailed	B-X
evidence	B-X
supporting	B-X
the	B-X
importance	B-X
of	B-X
tyrosine	B-X
sulfation	B-X
in	B-X
the	B-X
cellular	B-X
adhesion	B-X
function	B-X
of	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
,	B-X
the	B-X
leukocyte	B-X
trafficking	B-X
and	B-X
pathogen	B-X
invasion	B-X
functions	B-X
of	B-X
chemokine	B-X
receptors	B-X
and	B-X
the	B-X
ligand	B-X
binding	B-X
and	B-X
activation	B-X
of	B-X
other	B-X
G-protein-coupled	B-X
receptors	B-X
by	B-X
complement	B-X
proteins	B-X
,	B-X
phospholipdis	B-X
and	B-X
glycoprotein	B-X
hormones	B-X
.	B-X

In	O
particular	O
,	O
we	O
describe	O
the	O
detailed	O
evidence	O
supporting	O
the	O
importance	O
of	O
tyrosine	O
sulfation	O
in	O
the	O
cellular	O
adhesion	O
function	O
of	O
P	B-Protein
-	I-Protein
selectin	I-Protein
glycoprotein	I-Protein
ligand	I-Protein
-	I-Protein
1	I-Protein
,	O
the	O
leukocyte	O
trafficking	O
and	O
pathogen	O
invasion	O
functions	O
of	O
chemokine	O
receptors	O
and	O
the	O
ligand	O
binding	O
and	O
activation	O
of	O
other	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
by	O
complement	O
proteins	O
,	O
phospholipdis	O
and	O
glycoprotein	O
hormones	O
.	O
<EOS>	B-X
The	B-X
post-translational	B-X
sulfation	B-X
of	B-X
tyrosine	B-X
residues	B-X
occurs	B-X
in	B-X
numerous	B-X
secreted	B-X
and	B-X
integral	B-X
membrane	B-X
proteins	B-X
and	B-X
,	B-X
in	B-X
many	B-X
cases	B-X
,	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
controlling	B-X
the	B-X
interactions	B-X
of	B-X
these	B-X
proteins	B-X
with	B-X
physiological	B-X
binding	B-X
partners	B-X
as	B-X
well	B-X
as	B-X
invading	B-X
pathogens	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
protein	B-X
tyrosine	B-X
sulfation	B-X
have	B-X
come	B-X
about	B-X
owing	B-X
to	B-X
the	B-X
cloning	B-X
of	B-X
two	B-X
human	B-X
tyrosylprotein	B-X
sulfotransferases	B-X
(	B-X
TPST-1	B-X
and	B-X
TPST-2	B-X
)	B-X
,	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
analytical	B-X
and	B-X
synthetic	B-X
methodologies	B-X
and	B-X
detailed	B-X
studies	B-X
of	B-X
proteins	B-X
and	B-X
peptides	B-X
containing	B-X
sulfotyrosine	B-X
residues	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
TPST	B-X
enzymes	B-X
,	B-X
review	B-X
the	B-X
major	B-X
techniques	B-X
available	B-X
for	B-X
studying	B-X
the	B-X
presence	B-X
,	B-X
location	B-X
and	B-X
function	B-X
of	B-X
tyrosine	B-X
sulfation	B-X
in	B-X
proteins	B-X
and	B-X
discuss	B-X
the	B-X
biological	B-X
functions	B-X
and	B-X
biochemical	B-X
interactions	B-X
of	B-X
several	B-X
proteins	B-X
(	B-X
or	B-X
protein	B-X
families	B-X
)	B-X
in	B-X
which	B-X
tyrosine	B-X
sulfation	B-X
influences	B-X
the	B-X
protein	B-X
function	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
detailed	B-X
evidence	B-X
supporting	B-X
the	B-X
importance	B-X
of	B-X
tyrosine	B-X
sulfation	B-X
in	B-X
the	B-X
cellular	B-X
adhesion	B-X
function	B-X
of	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
,	B-X
the	B-X
leukocyte	B-X
trafficking	B-X
and	B-X
pathogen	B-X
invasion	B-X
functions	B-X
of	B-X
chemokine	B-X
receptors	B-X
and	B-X
the	B-X
ligand	B-X
binding	B-X
and	B-X
activation	B-X
of	B-X
other	B-X
G-protein-coupled	B-X
receptors	B-X
by	B-X
complement	B-X
proteins	B-X
,	B-X
phospholipdis	B-X
and	B-X
glycoprotein	B-X
hormones	B-X
.	B-X

Detection	O
of	O
protein	O
ubiquitination	O
.	O
<EOS>	B-X
Different	B-X
biochemical	B-X
techniques	B-X
are	B-X
well	B-X
established	B-X
to	B-X
investigate	B-X
target	B-X
's	B-X
ubiquitination	B-X
in	B-X
mammals	B-X
without	B-X
overexpressing	B-X
a	B-X
tagged	B-X
version	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
.	B-X
The	B-X
simplest	B-X
and	B-X
more	B-X
direct	B-X
approach	B-X
is	B-X
to	B-X
immunoprecipitate	B-X
(	B-X
IP	B-X
)	B-X
your	B-X
target	B-X
protein	B-X
from	B-X
cell	B-X
lysate	B-X
(	B-X
stimulated	B-X
and/or	B-X
properly	B-X
treated	B-X
)	B-X
,	B-X
followed	B-X
by	B-X
western	B-X
blot	B-X
analysis	B-X
utilizing	B-X
specific	B-X
antibodies	B-X
against	B-X
Ub	B-X
(	B-X
see	B-X
Subheading	B-X
3.1	B-X
)	B-X
.	B-X
This	B-X
approach	B-X
requires	B-X
a	B-X
good	B-X
antibody	B-X
against	B-X
the	B-X
target	B-X
working	B-X
in	B-X
IP	B-X
;	B-X
alternatively	B-X
,	B-X
one	B-X
could	B-X
express	B-X
a	B-X
tagged	B-X
version	B-X
of	B-X
the	B-X
protein	B-X
,	B-X
possibly	B-X
at	B-X
the	B-X
endogenous	B-X
level	B-X
.	B-X
Another	B-X
approach	B-X
consists	B-X
in	B-X
IP	B-X
ubiquitinated	B-X
proteins	B-X
from	B-X
total	B-X
cell	B-X
lysate	B-X
followed	B-X
by	B-X
detection	B-X
with	B-X
the	B-X
antibody	B-X
against	B-X
the	B-X
protein	B-X
of	B-X
interest	B-X
.	B-X
Cross-validation	B-X
with	B-X
more	B-X
than	B-X
one	B-X
approach	B-X
is	B-X
usually	B-X
recommended	B-X
in	B-X
order	B-X
to	B-X
prove	B-X
that	B-X
your	B-X
protein	B-X
is	B-X
modified	B-X
by	B-X
ubiquitin.Here	B-X
we	B-X
will	B-X
use	B-X
the	B-X
EGFR	B-X
as	B-X
model	B-X
system	B-X
but	B-X
protocols	B-X
can	B-X
be	B-X
easily	B-X
modified	B-X
according	B-X
to	B-X
the	B-X
protein	B-X
of	B-X
interest	B-X
.	B-X

Ubiquitination	O
,	O
the	O
covalent	O
attachment	O
of	O
the	O
polypeptide	O
ubiquitin	B-Protein
to	O
target	O
proteins	O
,	O
is	O
a	O
key	O
posttranslational	O
modification	O
carried	O
out	O
by	O
a	O
set	O
of	O
three	O
enzymes	O
.	O
<EOS>	B-X
Ubiquitination	B-X
,	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
polypeptide	B-X
ubiquitin	B-X
to	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
a	B-X
key	B-X
posttranslational	B-X
modification	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
set	B-X
of	B-X
three	B-X
enzymes	B-X
.	B-X
They	B-X
include	B-X
ubiquitin-activating	B-X
enzyme	B-X
E1	B-X
,	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
E2	B-X
,	B-X
and	B-X
ubiquitin	B-X
ligase	B-X
E3	B-X
.	B-X
Unlike	B-X
to	B-X
E1	B-X
and	B-X
E2	B-X
,	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
display	B-X
substrate	B-X
specificity	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
numerous	B-X
deubiquitylating	B-X
enzymes	B-X
have	B-X
roles	B-X
in	B-X
processing	B-X
polyubiquitinated	B-X
proteins	B-X
.	B-X
Ubiquitination	B-X
can	B-X
result	B-X
in	B-X
change	B-X
of	B-X
protein	B-X
stability	B-X
,	B-X
cellular	B-X
localization	B-X
,	B-X
and	B-X
biological	B-X
activity	B-X
.	B-X
Mutations	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
the	B-X
ubiquitination/deubiquitination	B-X
pathway	B-X
or	B-X
altered	B-X
ubiquitin	B-X
system	B-X
function	B-X
are	B-X
associated	B-X
with	B-X
many	B-X
different	B-X
human	B-X
diseases	B-X
such	B-X
as	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
,	B-X
neurodegeneration	B-X
,	B-X
and	B-X
metabolic	B-X
disorders	B-X
.	B-X
The	B-X
detection	B-X
of	B-X
altered	B-X
or	B-X
normal	B-X
ubiquitination	B-X
of	B-X
target	B-X
proteins	B-X
may	B-X
provide	B-X
a	B-X
better	B-X
understanding	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
these	B-X
diseases	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
protocols	B-X
to	B-X
detect	B-X
protein	B-X
ubiquitination	B-X
in	B-X
cultured	B-X
cells	B-X
in	B-X
vivo	B-X
and	B-X
test	B-X
tubes	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
protocols	B-X
are	B-X
also	B-X
useful	B-X
to	B-X
detect	B-X
other	B-X
ubiquitin-like	B-X
small	B-X
molecule	B-X
modification	B-X
such	B-X
as	B-X
sumolyation	B-X
and	B-X
neddylation	B-X
.	B-X

They	O
include	O
ubiquitin	B-Protein
-	O
activating	O
enzyme	O
E1	O
,	O
ubiquitin	B-Protein
-	O
conjugating	O
enzyme	O
E2	B-Protein
,	O
and	O
ubiquitin	B-Protein
ligase	O
E3	O
.	O
<EOS>	B-X
Ubiquitin-fold	B-X
modifier	B-X
1	B-X
(	B-X
UFM1	B-X
)	B-X
,	B-X
a	B-X
newly	B-X
identified	B-X
ubiquitin-like	B-X
molecule	B-X
(	B-X
UBLs	B-X
)	B-X
,	B-X
is	B-X
evolutionarily	B-X
expressed	B-X
in	B-X
multiple	B-X
species	B-X
except	B-X
yeast	B-X
.	B-X
Similarly	B-X
to	B-X
ubiquitin	B-X
,	B-X
UFM1	B-X
is	B-X
covalently	B-X
attached	B-X
to	B-X
its	B-X
substrates	B-X
through	B-X
a	B-X
well-orchestrated	B-X
three-step	B-X
enzymatic	B-X
reaction	B-X
involving	B-X
E1	B-X
,	B-X
the	B-X
UFM1-activating	B-X
enzyme	B-X
(	B-X
ubiquitin-like	B-X
modifier-activating	B-X
enzyme	B-X
5	B-X
,	B-X
UBA5	B-X
)	B-X
;	B-X
E2	B-X
,	B-X
the	B-X
UFM1-conjugating	B-X
enzyme	B-X
1	B-X
(	B-X
UFC1	B-X
)	B-X
;	B-X
and	B-X
E3	B-X
,	B-X
the	B-X
UFM1-specific	B-X
ligase	B-X
1	B-X
(	B-X
UFL1	B-X
)	B-X
.	B-X
Cellular	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
covalent	B-X
attachment	B-X
to	B-X
a	B-X
small	B-X
protein	B-X
known	B-X
as	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
through	B-X
ubiquitination	B-X
.	B-X
This	B-X
ubiquitination	B-X
process	B-X
serves	B-X
as	B-X
signal	B-X
for	B-X
protein	B-X
turnover	B-X
that	B-X
leads	B-X
to	B-X
rapid	B-X
muscle	B-X
mass	B-X
lack	B-X
.	B-X
This	B-X
process	B-X
is	B-X
carried	B-X
out	B-X
through	B-X
an	B-X
enzymatic	B-X
cascade	B-X
,	B-X
which	B-X
includes	B-X
three	B-X
groups	B-X
of	B-X
enzymes	B-X
termed	B-X
ubiquitin	B-X
E1	B-X
(	B-X
activating	B-X
enzyme	B-X
)	B-X
,	B-X
ubiquitin	B-X
E2	B-X
(	B-X
conjugating	B-X
enzyme	B-X
)	B-X
,	B-X
and	B-X
ubiquitin	B-X
E3	B-X
(	B-X
ligase	B-X
)	B-X
.	B-X
There	B-X
are	B-X
several	B-X
ways	B-X
of	B-X
ubiquitin	B-X
conjugation	B-X
driving	B-X
to	B-X
ubiquitination	B-X
of	B-X
specific	B-X
proteins	B-X
through	B-X
ubiquitin-proteasome	B-X
system	B-X
(	B-X
UPS	B-X
)	B-X
.	B-X
A	B-X
lot	B-X
of	B-X
UPS	B-X
genes	B-X
stated	B-X
to	B-X
be	B-X
included	B-X
in	B-X
skeletal	B-X
muscle	B-X
atrophy	B-X
.	B-X

Unlike	O
to	O
E1	O
and	O
E2	O
,	O
E3	O
ubiquitin	B-Protein
ligases	O
display	O
substrate	O
specificity	O
.	O
<EOS>	B-X
Ubiquitination	B-X
,	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
polypeptide	B-X
ubiquitin	B-X
to	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
a	B-X
key	B-X
posttranslational	B-X
modification	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
set	B-X
of	B-X
three	B-X
enzymes	B-X
.	B-X
They	B-X
include	B-X
ubiquitin-activating	B-X
enzyme	B-X
E1	B-X
,	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
E2	B-X
,	B-X
and	B-X
ubiquitin	B-X
ligase	B-X
E3	B-X
.	B-X
Unlike	B-X
to	B-X
E1	B-X
and	B-X
E2	B-X
,	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
display	B-X
substrate	B-X
specificity	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
numerous	B-X
deubiquitylating	B-X
enzymes	B-X
have	B-X
roles	B-X
in	B-X
processing	B-X
polyubiquitinated	B-X
proteins	B-X
.	B-X
Mutations	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
the	B-X
ubiquitination/deubiquitination	B-X
pathway	B-X
or	B-X
altered	B-X
ubiquitin	B-X
system	B-X
function	B-X
are	B-X
associated	B-X
with	B-X
many	B-X
different	B-X
human	B-X
diseases	B-X
such	B-X
as	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
,	B-X
neurodegeneration	B-X
,	B-X
and	B-X
metabolic	B-X
disorders	B-X
.	B-X
The	B-X
detection	B-X
of	B-X
altered	B-X
or	B-X
normal	B-X
ubiquitination	B-X
of	B-X
target	B-X
proteins	B-X
may	B-X
provide	B-X
a	B-X
better	B-X
understanding	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
these	B-X
diseases	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
protocols	B-X
to	B-X
detect	B-X
protein	B-X
ubiquitination	B-X
in	B-X
cultured	B-X
cells	B-X
in	B-X
vivo	B-X
and	B-X
test	B-X
tubes	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
protocols	B-X
are	B-X
also	B-X
useful	B-X
to	B-X
detect	B-X
other	B-X
ubiquitin-like	B-X
small	B-X
molecule	B-X
modification	B-X
such	B-X
as	B-X
sumolyation	B-X
and	B-X
neddylation	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
numerous	O
deubiquitylating	O
enzymes	O
have	O
roles	O
in	O
processing	O
polyubiquitinated	O
proteins	O
.	O
<EOS>	B-X
Ubiquitination	B-X
,	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
polypeptide	B-X
ubiquitin	B-X
to	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
a	B-X
key	B-X
posttranslational	B-X
modification	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
set	B-X
of	B-X
three	B-X
enzymes	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
numerous	B-X
deubiquitylating	B-X
enzymes	B-X
have	B-X
roles	B-X
in	B-X
processing	B-X
polyubiquitinated	B-X
proteins	B-X
.	B-X
The	B-X
detection	B-X
of	B-X
altered	B-X
or	B-X
normal	B-X
ubiquitination	B-X
of	B-X
target	B-X
proteins	B-X
may	B-X
provide	B-X
a	B-X
better	B-X
understanding	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
these	B-X
diseases	B-X
.	B-X

Ubiquitination	O
can	O
result	O
in	O
change	O
of	O
protein	O
stability	O
,	O
cellular	O
localization	O
,	O
and	O
biological	O
activity	O
.	O
<EOS>	B-X
SUMOylation	B-X
of	B-X
METTL3	B-X
does	B-X
not	B-X
alter	B-X
its	B-X
stability	B-X
,	B-X
localization	B-X
and	B-X
interaction	B-X
with	B-X
METTL14	B-X
and	B-X
WTAP	B-X
,	B-X
but	B-X
significantly	B-X
represses	B-X
its	B-X
m6A	B-X
methytransferase	B-X
activity	B-X
resulting	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
m6A	B-X
levels	B-X
in	B-X
mRNAs	B-X
.	B-X
The	B-X
alternation	B-X
of	B-X
m6A	B-X
in	B-X
mRNAs	B-X
and	B-X
subsequently	B-X
change	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
,	B-X
which	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
of	B-X
METTL3	B-X
,	B-X
may	B-X
directly	B-X
influence	B-X
the	B-X
soft-agar	B-X
colony	B-X
formation	B-X
and	B-X
xenografted	B-X
tumor	B-X
growth	B-X
of	B-X
H1299	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
uncover	B-X
an	B-X
important	B-X
mechanism	B-X
for	B-X
SUMOylation	B-X
of	B-X
METTL3	B-X
regulating	B-X
its	B-X
m6A	B-X
RNA	B-X
methyltransferase	B-X
activity	B-X
.	B-X
Long-non-coding	B-X
RNAs	B-X
(	B-X
lncRNAs	B-X
)	B-X
,	B-X
RNA	B-X
molecules	B-X
longer	B-X
than	B-X
200	B-X
nucleotides	B-X
,	B-X
have	B-X
been	B-X
involved	B-X
in	B-X
several	B-X
biological	B-X
processes	B-X
and	B-X
in	B-X
a	B-X
growing	B-X
number	B-X
of	B-X
diseases	B-X
,	B-X
controlling	B-X
gene	B-X
transcription	B-X
,	B-X
pre-mRNA	B-X
processing	B-X
,	B-X
the	B-X
transport	B-X
of	B-X
mature	B-X
mRNAs	B-X
to	B-X
specific	B-X
cellular	B-X
compartments	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
mRNA	B-X
stability	B-X
,	B-X
protein	B-X
translation	B-X
and	B-X
turnover	B-X
.	B-X
LncRNAs	B-X
are	B-X
abundantly	B-X
expressed	B-X
in	B-X
mammalian	B-X
CNS	B-X
in	B-X
a	B-X
specific	B-X
spatio-temporal	B-X
manner	B-X
allowing	B-X
a	B-X
quick	B-X
response	B-X
to	B-X
environmental/molecular	B-X
changes	B-X
.	B-X

Mutations	O
of	O
genes	O
involved	O
in	O
the	O
ubiquitination	O
/	O
deubiquitination	O
pathway	O
or	O
altered	O
ubiquitin	B-Protein
system	O
function	O
are	O
associated	O
with	O
many	O
different	O
human	O
diseases	O
such	O
as	O
various	O
types	O
of	O
cancer	O
,	O
neurodegeneration	O
,	O
and	O
metabolic	O
disorders	O
.	O
<EOS>	B-X
The	B-X
Wnt	B-X
signaling	B-X
pathway	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
embryonic	B-X
development	B-X
,	B-X
homeostatic	B-X
processes	B-X
,	B-X
cell	B-X
differentiation	B-X
,	B-X
cell	B-X
polarity	B-X
,	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
cell	B-X
migration	B-X
via	B-X
the	B-X
β-catenin	B-X
binding	B-X
of	B-X
Wnt	B-X
target	B-X
genes	B-X
.	B-X
Dysregulation	B-X
of	B-X
Wnt	B-X
signaling	B-X
is	B-X
associated	B-X
with	B-X
various	B-X
diseases	B-X
such	B-X
as	B-X
cancer	B-X
,	B-X
aging	B-X
,	B-X
Alzheimer	B-X
's	B-X
disease	B-X
,	B-X
metabolic	B-X
disease	B-X
,	B-X
and	B-X
pigmentation	B-X
disorders	B-X
.	B-X
Numerous	B-X
studies	B-X
entailing	B-X
the	B-X
Wnt	B-X
signaling	B-X
pathway	B-X
have	B-X
been	B-X
conducted	B-X
for	B-X
various	B-X
cancers	B-X
.	B-X
Diverse	B-X
signaling	B-X
factors	B-X
mediate	B-X
the	B-X
up-	B-X
or	B-X
down-regulation	B-X
of	B-X
Wnt	B-X
signaling	B-X
through	B-X
post-translational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
,	B-X
and	B-X
aberrant	B-X
regulation	B-X
is	B-X
associated	B-X
with	B-X
several	B-X
different	B-X
malignancies	B-X
in	B-X
humans	B-X
.	B-X
Of	B-X
the	B-X
numerous	B-X
PTMs	B-X
involved	B-X
,	B-X
most	B-X
Wnt	B-X
signaling	B-X
factors	B-X
are	B-X
regulated	B-X
by	B-X
ubiquitination	B-X
and	B-X
deubiquitination	B-X
.	B-X
Ubiquitination	B-X
by	B-X
E3	B-X
ligase	B-X
attaches	B-X
ubiquitins	B-X
to	B-X
target	B-X
proteins	B-X
and	B-X
usually	B-X
induces	B-X
proteasomal	B-X
degradation	B-X
of	B-X
Wnt	B-X
signaling	B-X
factors	B-X
such	B-X
as	B-X
β-catenin	B-X
,	B-X
Axin	B-X
,	B-X
GSK3	B-X
,	B-X
and	B-X
Dvl	B-X
.	B-X
Conversely	B-X
,	B-X
deubiquitination	B-X
induced	B-X
by	B-X
the	B-X
deubiquitinating	B-X
enzymes	B-X
(	B-X
DUBs	B-X
)	B-X
detaches	B-X
the	B-X
ubiquitins	B-X
and	B-X
modulates	B-X
the	B-X
stability	B-X
of	B-X
signaling	B-X
factors	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
effects	B-X
of	B-X
ubiquitination	B-X
and	B-X
deubiquitination	B-X
on	B-X
the	B-X
Wnt	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
the	B-X
inhibitors	B-X
of	B-X
DUBs	B-X
that	B-X
can	B-X
be	B-X
applied	B-X
for	B-X
cancer	B-X
therapeutic	B-X
strategies	B-X
.	B-X

The	O
detection	O
of	O
altered	O
or	O
normal	O
ubiquitination	O
of	O
target	O
proteins	O
may	O
provide	O
a	O
better	O
understanding	O
on	O
the	O
pathogenesis	O
of	O
these	O
diseases	O
.	O
<EOS>	B-X
Recognition	B-X
of	B-X
pathogens	B-X
and	B-X
altered	B-X
self	B-X
must	B-X
be	B-X
efficient	B-X
and	B-X
highly	B-X
specific	B-X
to	B-X
orchestrate	B-X
appropriate	B-X
responses	B-X
while	B-X
limiting	B-X
excessive	B-X
inflammation	B-X
and	B-X
autoimmune	B-X
reaction	B-X
to	B-X
normal	B-X
self	B-X
.	B-X
However	B-X
,	B-X
AIM2	B-X
achieves	B-X
specificity	B-X
by	B-X
detecting	B-X
altered	B-X
or	B-X
mislocalized	B-X
DNA	B-X
molecules	B-X
.	B-X
The	B-X
AIM2	B-X
inflammasome	B-X
contributes	B-X
to	B-X
physiological	B-X
responses	B-X
and	B-X
diseases	B-X
.	B-X
It	B-X
is	B-X
a	B-X
key	B-X
player	B-X
in	B-X
host	B-X
defenses	B-X
,	B-X
but	B-X
its	B-X
deregulation	B-X
can	B-X
contribute	B-X
immune-linked	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
autoinflammatory	B-X
and	B-X
autoimmune	B-X
pathologies	B-X
.	B-X
Moreover	B-X
,	B-X
AIM2	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cancer	B-X
development	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
detection	B-X
of	B-X
self-DNA	B-X
species	B-X
by	B-X
AIM2	B-X
is	B-X
an	B-X
important	B-X
factor	B-X
that	B-X
contributes	B-X
to	B-X
diseases	B-X
associated	B-X
with	B-X
perturbation	B-X
of	B-X
cellular	B-X
homeostasis	B-X
.	B-X

Here	O
,	O
we	O
describe	O
protocols	O
to	O
detect	O
protein	O
ubiquitination	O
in	O
cultured	O
cells	O
in	O
vivo	O
and	O
test	O
tubes	O
in	O
vitro	O
.	O
<EOS>	B-X
Ubiquitination	B-X
,	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
polypeptide	B-X
ubiquitin	B-X
to	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
a	B-X
key	B-X
posttranslational	B-X
modification	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
set	B-X
of	B-X
three	B-X
enzymes	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
numerous	B-X
deubiquitylating	B-X
enzymes	B-X
have	B-X
roles	B-X
in	B-X
processing	B-X
polyubiquitinated	B-X
proteins	B-X
.	B-X
Ubiquitination	B-X
can	B-X
result	B-X
in	B-X
change	B-X
of	B-X
protein	B-X
stability	B-X
,	B-X
cellular	B-X
localization	B-X
,	B-X
and	B-X
biological	B-X
activity	B-X
.	B-X
Mutations	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
the	B-X
ubiquitination/deubiquitination	B-X
pathway	B-X
or	B-X
altered	B-X
ubiquitin	B-X
system	B-X
function	B-X
are	B-X
associated	B-X
with	B-X
many	B-X
different	B-X
human	B-X
diseases	B-X
such	B-X
as	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
,	B-X
neurodegeneration	B-X
,	B-X
and	B-X
metabolic	B-X
disorders	B-X
.	B-X
The	B-X
detection	B-X
of	B-X
altered	B-X
or	B-X
normal	B-X
ubiquitination	B-X
of	B-X
target	B-X
proteins	B-X
may	B-X
provide	B-X
a	B-X
better	B-X
understanding	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
these	B-X
diseases	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
protocols	B-X
to	B-X
detect	B-X
protein	B-X
ubiquitination	B-X
in	B-X
cultured	B-X
cells	B-X
in	B-X
vivo	B-X
and	B-X
test	B-X
tubes	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
protocols	B-X
are	B-X
also	B-X
useful	B-X
to	B-X
detect	B-X
other	B-X
ubiquitin-like	B-X
small	B-X
molecule	B-X
modification	B-X
such	B-X
as	B-X
sumolyation	B-X
and	B-X
neddylation	B-X
.	B-X

These	O
protocols	O
are	O
also	O
useful	O
to	O
detect	O
other	O
ubiquitin	B-Protein
-	O
like	O
small	O
molecule	O
modification	O
such	O
as	O
sumolyation	O
and	O
neddylation	O
.	O
<EOS>	B-X
Ubiquitination	B-X
,	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
polypeptide	B-X
ubiquitin	B-X
to	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
a	B-X
key	B-X
posttranslational	B-X
modification	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
set	B-X
of	B-X
three	B-X
enzymes	B-X
.	B-X
They	B-X
include	B-X
ubiquitin-activating	B-X
enzyme	B-X
E1	B-X
,	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
E2	B-X
,	B-X
and	B-X
ubiquitin	B-X
ligase	B-X
E3	B-X
.	B-X
Unlike	B-X
to	B-X
E1	B-X
and	B-X
E2	B-X
,	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
display	B-X
substrate	B-X
specificity	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
numerous	B-X
deubiquitylating	B-X
enzymes	B-X
have	B-X
roles	B-X
in	B-X
processing	B-X
polyubiquitinated	B-X
proteins	B-X
.	B-X
Mutations	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
the	B-X
ubiquitination/deubiquitination	B-X
pathway	B-X
or	B-X
altered	B-X
ubiquitin	B-X
system	B-X
function	B-X
are	B-X
associated	B-X
with	B-X
many	B-X
different	B-X
human	B-X
diseases	B-X
such	B-X
as	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
,	B-X
neurodegeneration	B-X
,	B-X
and	B-X
metabolic	B-X
disorders	B-X
.	B-X
The	B-X
detection	B-X
of	B-X
altered	B-X
or	B-X
normal	B-X
ubiquitination	B-X
of	B-X
target	B-X
proteins	B-X
may	B-X
provide	B-X
a	B-X
better	B-X
understanding	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
these	B-X
diseases	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
protocols	B-X
to	B-X
detect	B-X
protein	B-X
ubiquitination	B-X
in	B-X
cultured	B-X
cells	B-X
in	B-X
vivo	B-X
and	B-X
test	B-X
tubes	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
protocols	B-X
are	B-X
also	B-X
useful	B-X
to	B-X
detect	B-X
other	B-X
ubiquitin-like	B-X
small	B-X
molecule	B-X
modification	B-X
such	B-X
as	B-X
sumolyation	B-X
and	B-X
neddylation	B-X
.	B-X

Resolving	O
the	O
CSN	O
and	O
CAND1	B-Protein
paradoxes	O
.	O
<EOS>	B-X
(	B-X
2009	B-X
)	B-X
untangle	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
cullin-associated	B-X
and	B-X
neddylation-dissociated	B-X
1	B-X
(	B-X
CAND1	B-X
)	B-X
protein	B-X
,	B-X
and	B-X
cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
.	B-X

In	O
this	O
issue	O
of	O
Molecular	O
Cell	O
,	O
Schmidt	O
et	O
al	O
.	O

(	O
2009	O
)	O
untangle	O
the	O
interplay	O
between	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
cullin	B-Protein
-	I-Protein
associated	I-Protein
and	I-Protein
neddylation	I-Protein
-	I-Protein
dissociated	I-Protein
1	I-Protein
(	O
CAND1	B-Protein
)	O
protein	O
,	O
and	O
cullin	O
-	O
RING	O
ubiquitin	B-Protein
ligases	O
(	O
CRLs	O
)	O
.	O
<EOS>	B-X
(	B-X
2009	B-X
)	B-X
untangle	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
cullin-associated	B-X
and	B-X
neddylation-dissociated	B-X
1	B-X
(	B-X
CAND1	B-X
)	B-X
protein	B-X
,	B-X
and	B-X
cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
.	B-X

PARP	B-Protein
-	I-Protein
1	I-Protein
transcriptional	O
activity	O
is	O
regulated	O
by	O
sumoylation	O
upon	O
heat	O
shock	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
and	B-X
other	B-X
environmental	B-X
stresses	B-X
rapidly	B-X
induce	B-X
transcriptional	B-X
responses	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
Among	B-X
these	B-X
,	B-X
poly	B-X
(	B-X
ADP-ribosyl	B-X
)	B-X
ation	B-X
and	B-X
sumoylation	B-X
have	B-X
received	B-X
growing	B-X
attention	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
SUMO	B-X
E3	B-X
ligase	B-X
PIASy	B-X
interacts	B-X
with	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
PARP-1	B-X
,	B-X
and	B-X
that	B-X
PIASy	B-X
mediates	B-X
heat	B-X
shock-induced	B-X
poly-sumoylation	B-X
of	B-X
PARP-1	B-X
.	B-X
Furthermore	B-X
,	B-X
PIASy	B-X
,	B-X
and	B-X
hence	B-X
sumoylation	B-X
,	B-X
appears	B-X
indispensable	B-X
for	B-X
full	B-X
activation	B-X
of	B-X
the	B-X
inducible	B-X
HSP70.1	B-X
gene	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
show	B-X
that	B-X
PIASy	B-X
,	B-X
SUMO	B-X
and	B-X
the	B-X
SUMO-conjugating	B-X
enzyme	B-X
Ubc9	B-X
are	B-X
rapidly	B-X
recruited	B-X
to	B-X
the	B-X
HSP70.1	B-X
promoter	B-X
upon	B-X
heat	B-X
shock	B-X
,	B-X
and	B-X
that	B-X
they	B-X
are	B-X
subsequently	B-X
released	B-X
with	B-X
kinetics	B-X
similar	B-X
to	B-X
PARP-1	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligase	B-X
RNF4	B-X
mediates	B-X
heat-shock-inducible	B-X
ubiquitination	B-X
of	B-X
PARP-1	B-X
,	B-X
regulates	B-X
the	B-X
stability	B-X
of	B-X
PARP-1	B-X
,	B-X
and	B-X
,	B-X
like	B-X
PIASy	B-X
,	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
HSP70.1	B-X
gene	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
,	B-X
thus	B-X
,	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
regulating	B-X
PARP-1	B-X
transcription	B-X
function	B-X
,	B-X
and	B-X
suggest	B-X
crosstalk	B-X
between	B-X
sumoylation	B-X
and	B-X
RNF4-mediated	B-X
ubiquitination	B-X
in	B-X
regulating	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
heat	B-X
shock	B-X
.	B-X

Heat	O
shock	O
and	O
other	O
environmental	O
stresses	O
rapidly	O
induce	O
transcriptional	O
responses	O
subject	O
to	O
regulation	O
by	O
a	O
variety	O
of	O
post	O
-	O
translational	O
modifications	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
and	B-X
other	B-X
environmental	B-X
stresses	B-X
rapidly	B-X
induce	B-X
transcriptional	B-X
responses	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
SUMO	B-X
E3	B-X
ligase	B-X
PIASy	B-X
interacts	B-X
with	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
PARP-1	B-X
,	B-X
and	B-X
that	B-X
PIASy	B-X
mediates	B-X
heat	B-X
shock-induced	B-X
poly-sumoylation	B-X
of	B-X
PARP-1	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
show	B-X
that	B-X
PIASy	B-X
,	B-X
SUMO	B-X
and	B-X
the	B-X
SUMO-conjugating	B-X
enzyme	B-X
Ubc9	B-X
are	B-X
rapidly	B-X
recruited	B-X
to	B-X
the	B-X
HSP70.1	B-X
promoter	B-X
upon	B-X
heat	B-X
shock	B-X
,	B-X
and	B-X
that	B-X
they	B-X
are	B-X
subsequently	B-X
released	B-X
with	B-X
kinetics	B-X
similar	B-X
to	B-X
PARP-1	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligase	B-X
RNF4	B-X
mediates	B-X
heat-shock-inducible	B-X
ubiquitination	B-X
of	B-X
PARP-1	B-X
,	B-X
regulates	B-X
the	B-X
stability	B-X
of	B-X
PARP-1	B-X
,	B-X
and	B-X
,	B-X
like	B-X
PIASy	B-X
,	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
HSP70.1	B-X
gene	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
,	B-X
thus	B-X
,	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
regulating	B-X
PARP-1	B-X
transcription	B-X
function	B-X
,	B-X
and	B-X
suggest	B-X
crosstalk	B-X
between	B-X
sumoylation	B-X
and	B-X
RNF4-mediated	B-X
ubiquitination	B-X
in	B-X
regulating	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
heat	B-X
shock	B-X
.	B-X

Among	O
these	O
,	O
poly	O
(	O
ADP	O
-	O
ribosyl	O
)	O
ation	O
and	O
sumoylation	O
have	O
received	O
growing	O
attention	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
and	B-X
other	B-X
environmental	B-X
stresses	B-X
rapidly	B-X
induce	B-X
transcriptional	B-X
responses	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
Among	B-X
these	B-X
,	B-X
poly	B-X
(	B-X
ADP-ribosyl	B-X
)	B-X
ation	B-X
and	B-X
sumoylation	B-X
have	B-X
received	B-X
growing	B-X
attention	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
SUMO	B-X
E3	B-X
ligase	B-X
PIASy	B-X
interacts	B-X
with	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
PARP-1	B-X
,	B-X
and	B-X
that	B-X
PIASy	B-X
mediates	B-X
heat	B-X
shock-induced	B-X
poly-sumoylation	B-X
of	B-X
PARP-1	B-X
.	B-X
Furthermore	B-X
,	B-X
PIASy	B-X
,	B-X
and	B-X
hence	B-X
sumoylation	B-X
,	B-X
appears	B-X
indispensable	B-X
for	B-X
full	B-X
activation	B-X
of	B-X
the	B-X
inducible	B-X
HSP70.1	B-X
gene	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
show	B-X
that	B-X
PIASy	B-X
,	B-X
SUMO	B-X
and	B-X
the	B-X
SUMO-conjugating	B-X
enzyme	B-X
Ubc9	B-X
are	B-X
rapidly	B-X
recruited	B-X
to	B-X
the	B-X
HSP70.1	B-X
promoter	B-X
upon	B-X
heat	B-X
shock	B-X
,	B-X
and	B-X
that	B-X
they	B-X
are	B-X
subsequently	B-X
released	B-X
with	B-X
kinetics	B-X
similar	B-X
to	B-X
PARP-1	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligase	B-X
RNF4	B-X
mediates	B-X
heat-shock-inducible	B-X
ubiquitination	B-X
of	B-X
PARP-1	B-X
,	B-X
regulates	B-X
the	B-X
stability	B-X
of	B-X
PARP-1	B-X
,	B-X
and	B-X
,	B-X
like	B-X
PIASy	B-X
,	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
HSP70.1	B-X
gene	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
,	B-X
thus	B-X
,	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
regulating	B-X
PARP-1	B-X
transcription	B-X
function	B-X
,	B-X
and	B-X
suggest	B-X
crosstalk	B-X
between	B-X
sumoylation	B-X
and	B-X
RNF4-mediated	B-X
ubiquitination	B-X
in	B-X
regulating	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
heat	B-X
shock	B-X
.	B-X

Here	O
we	O
show	O
that	O
the	O
SUMO	O
E3	O
ligase	O
PIASy	B-Protein
interacts	O
with	O
the	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
PARP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
that	O
PIASy	B-Protein
mediates	O
heat	O
shock	O
-	O
induced	O
poly	O
-	O
sumoylation	O
of	O
PARP	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
and	B-X
other	B-X
environmental	B-X
stresses	B-X
rapidly	B-X
induce	B-X
transcriptional	B-X
responses	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
Among	B-X
these	B-X
,	B-X
poly	B-X
(	B-X
ADP-ribosyl	B-X
)	B-X
ation	B-X
and	B-X
sumoylation	B-X
have	B-X
received	B-X
growing	B-X
attention	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
SUMO	B-X
E3	B-X
ligase	B-X
PIASy	B-X
interacts	B-X
with	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
PARP-1	B-X
,	B-X
and	B-X
that	B-X
PIASy	B-X
mediates	B-X
heat	B-X
shock-induced	B-X
poly-sumoylation	B-X
of	B-X
PARP-1	B-X
.	B-X
Furthermore	B-X
,	B-X
PIASy	B-X
,	B-X
and	B-X
hence	B-X
sumoylation	B-X
,	B-X
appears	B-X
indispensable	B-X
for	B-X
full	B-X
activation	B-X
of	B-X
the	B-X
inducible	B-X
HSP70.1	B-X
gene	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
show	B-X
that	B-X
PIASy	B-X
,	B-X
SUMO	B-X
and	B-X
the	B-X
SUMO-conjugating	B-X
enzyme	B-X
Ubc9	B-X
are	B-X
rapidly	B-X
recruited	B-X
to	B-X
the	B-X
HSP70.1	B-X
promoter	B-X
upon	B-X
heat	B-X
shock	B-X
,	B-X
and	B-X
that	B-X
they	B-X
are	B-X
subsequently	B-X
released	B-X
with	B-X
kinetics	B-X
similar	B-X
to	B-X
PARP-1	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligase	B-X
RNF4	B-X
mediates	B-X
heat-shock-inducible	B-X
ubiquitination	B-X
of	B-X
PARP-1	B-X
,	B-X
regulates	B-X
the	B-X
stability	B-X
of	B-X
PARP-1	B-X
,	B-X
and	B-X
,	B-X
like	B-X
PIASy	B-X
,	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
HSP70.1	B-X
gene	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
,	B-X
thus	B-X
,	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
regulating	B-X
PARP-1	B-X
transcription	B-X
function	B-X
,	B-X
and	B-X
suggest	B-X
crosstalk	B-X
between	B-X
sumoylation	B-X
and	B-X
RNF4-mediated	B-X
ubiquitination	B-X
in	B-X
regulating	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
heat	B-X
shock	B-X
.	B-X

Furthermore	O
,	O
PIASy	B-Protein
,	O
and	O
hence	O
sumoylation	O
,	O
appears	O
indispensable	O
for	O
full	O
activation	O
of	O
the	O
inducible	O
HSP70	B-Protein
.	I-Protein
1	I-Protein
gene	O
.	O
<EOS>	B-X
Among	B-X
these	B-X
,	B-X
poly	B-X
(	B-X
ADP-ribosyl	B-X
)	B-X
ation	B-X
and	B-X
sumoylation	B-X
have	B-X
received	B-X
growing	B-X
attention	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
SUMO	B-X
E3	B-X
ligase	B-X
PIASy	B-X
interacts	B-X
with	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
PARP-1	B-X
,	B-X
and	B-X
that	B-X
PIASy	B-X
mediates	B-X
heat	B-X
shock-induced	B-X
poly-sumoylation	B-X
of	B-X
PARP-1	B-X
.	B-X
Furthermore	B-X
,	B-X
PIASy	B-X
,	B-X
and	B-X
hence	B-X
sumoylation	B-X
,	B-X
appears	B-X
indispensable	B-X
for	B-X
full	B-X
activation	B-X
of	B-X
the	B-X
inducible	B-X
HSP70.1	B-X
gene	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
show	B-X
that	B-X
PIASy	B-X
,	B-X
SUMO	B-X
and	B-X
the	B-X
SUMO-conjugating	B-X
enzyme	B-X
Ubc9	B-X
are	B-X
rapidly	B-X
recruited	B-X
to	B-X
the	B-X
HSP70.1	B-X
promoter	B-X
upon	B-X
heat	B-X
shock	B-X
,	B-X
and	B-X
that	B-X
they	B-X
are	B-X
subsequently	B-X
released	B-X
with	B-X
kinetics	B-X
similar	B-X
to	B-X
PARP-1	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligase	B-X
RNF4	B-X
mediates	B-X
heat-shock-inducible	B-X
ubiquitination	B-X
of	B-X
PARP-1	B-X
,	B-X
regulates	B-X
the	B-X
stability	B-X
of	B-X
PARP-1	B-X
,	B-X
and	B-X
,	B-X
like	B-X
PIASy	B-X
,	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
HSP70.1	B-X
gene	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
,	B-X
thus	B-X
,	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
regulating	B-X
PARP-1	B-X
transcription	B-X
function	B-X
,	B-X
and	B-X
suggest	B-X
crosstalk	B-X
between	B-X
sumoylation	B-X
and	B-X
RNF4-mediated	B-X
ubiquitination	B-X
in	B-X
regulating	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
heat	B-X
shock	B-X
.	B-X

Chromatin	O
immunoprecipitation	O
experiments	O
show	O
that	O
PIASy	B-Protein
,	O
SUMO	O
and	O
the	O
SUMO	O
-	O
conjugating	O
enzyme	O
Ubc9	B-Protein
are	O
rapidly	O
recruited	O
to	O
the	O
HSP70	B-Protein
.	I-Protein
1	I-Protein
promoter	O
upon	O
heat	O
shock	O
,	O
and	O
that	O
they	O
are	O
subsequently	O
released	O
with	O
kinetics	O
similar	O
to	O
PARP	B-Protein
-	I-Protein
1	I-Protein
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
SUMO	O
-	O
targeted	O
ubiquitin	B-Protein
ligase	O
RNF4	B-Protein
mediates	O
heat	O
-	O
shock	O
-	O
inducible	O
ubiquitination	O
of	O
PARP	B-Protein
-	I-Protein
1	I-Protein
,	O
regulates	O
the	O
stability	O
of	O
PARP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
,	O
like	O
PIASy	B-Protein
,	O
is	O
a	O
positive	O
regulator	O
of	O
HSP70	B-Protein
.	I-Protein
1	I-Protein
gene	O
activity	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
and	B-X
other	B-X
environmental	B-X
stresses	B-X
rapidly	B-X
induce	B-X
transcriptional	B-X
responses	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
SUMO	B-X
E3	B-X
ligase	B-X
PIASy	B-X
interacts	B-X
with	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
PARP-1	B-X
,	B-X
and	B-X
that	B-X
PIASy	B-X
mediates	B-X
heat	B-X
shock-induced	B-X
poly-sumoylation	B-X
of	B-X
PARP-1	B-X
.	B-X
Furthermore	B-X
,	B-X
PIASy	B-X
,	B-X
and	B-X
hence	B-X
sumoylation	B-X
,	B-X
appears	B-X
indispensable	B-X
for	B-X
full	B-X
activation	B-X
of	B-X
the	B-X
inducible	B-X
HSP70.1	B-X
gene	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
show	B-X
that	B-X
PIASy	B-X
,	B-X
SUMO	B-X
and	B-X
the	B-X
SUMO-conjugating	B-X
enzyme	B-X
Ubc9	B-X
are	B-X
rapidly	B-X
recruited	B-X
to	B-X
the	B-X
HSP70.1	B-X
promoter	B-X
upon	B-X
heat	B-X
shock	B-X
,	B-X
and	B-X
that	B-X
they	B-X
are	B-X
subsequently	B-X
released	B-X
with	B-X
kinetics	B-X
similar	B-X
to	B-X
PARP-1	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligase	B-X
RNF4	B-X
mediates	B-X
heat-shock-inducible	B-X
ubiquitination	B-X
of	B-X
PARP-1	B-X
,	B-X
regulates	B-X
the	B-X
stability	B-X
of	B-X
PARP-1	B-X
,	B-X
and	B-X
,	B-X
like	B-X
PIASy	B-X
,	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
HSP70.1	B-X
gene	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
,	B-X
thus	B-X
,	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
regulating	B-X
PARP-1	B-X
transcription	B-X
function	B-X
,	B-X
and	B-X
suggest	B-X
crosstalk	B-X
between	B-X
sumoylation	B-X
and	B-X
RNF4-mediated	B-X
ubiquitination	B-X
in	B-X
regulating	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
heat	B-X
shock	B-X
.	B-X

These	O
results	O
,	O
thus	O
,	O
point	O
to	O
a	O
novel	O
mechanism	O
for	O
regulating	O
PARP	B-Protein
-	I-Protein
1	I-Protein
transcription	O
function	O
,	O
and	O
suggest	O
crosstalk	O
between	O
sumoylation	O
and	O
RNF4	B-Protein
-	O
mediated	O
ubiquitination	O
in	O
regulating	O
gene	O
expression	O
in	O
response	O
to	O
heat	O
shock	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
and	B-X
other	B-X
environmental	B-X
stresses	B-X
rapidly	B-X
induce	B-X
transcriptional	B-X
responses	B-X
subject	B-X
to	B-X
regulation	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
Among	B-X
these	B-X
,	B-X
poly	B-X
(	B-X
ADP-ribosyl	B-X
)	B-X
ation	B-X
and	B-X
sumoylation	B-X
have	B-X
received	B-X
growing	B-X
attention	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
SUMO	B-X
E3	B-X
ligase	B-X
PIASy	B-X
interacts	B-X
with	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
PARP-1	B-X
,	B-X
and	B-X
that	B-X
PIASy	B-X
mediates	B-X
heat	B-X
shock-induced	B-X
poly-sumoylation	B-X
of	B-X
PARP-1	B-X
.	B-X
Furthermore	B-X
,	B-X
PIASy	B-X
,	B-X
and	B-X
hence	B-X
sumoylation	B-X
,	B-X
appears	B-X
indispensable	B-X
for	B-X
full	B-X
activation	B-X
of	B-X
the	B-X
inducible	B-X
HSP70.1	B-X
gene	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
show	B-X
that	B-X
PIASy	B-X
,	B-X
SUMO	B-X
and	B-X
the	B-X
SUMO-conjugating	B-X
enzyme	B-X
Ubc9	B-X
are	B-X
rapidly	B-X
recruited	B-X
to	B-X
the	B-X
HSP70.1	B-X
promoter	B-X
upon	B-X
heat	B-X
shock	B-X
,	B-X
and	B-X
that	B-X
they	B-X
are	B-X
subsequently	B-X
released	B-X
with	B-X
kinetics	B-X
similar	B-X
to	B-X
PARP-1	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligase	B-X
RNF4	B-X
mediates	B-X
heat-shock-inducible	B-X
ubiquitination	B-X
of	B-X
PARP-1	B-X
,	B-X
regulates	B-X
the	B-X
stability	B-X
of	B-X
PARP-1	B-X
,	B-X
and	B-X
,	B-X
like	B-X
PIASy	B-X
,	B-X
is	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
HSP70.1	B-X
gene	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
,	B-X
thus	B-X
,	B-X
point	B-X
to	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
regulating	B-X
PARP-1	B-X
transcription	B-X
function	B-X
,	B-X
and	B-X
suggest	B-X
crosstalk	B-X
between	B-X
sumoylation	B-X
and	B-X
RNF4-mediated	B-X
ubiquitination	B-X
in	B-X
regulating	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
heat	B-X
shock	B-X
.	B-X

Distinct	O
domains	O
within	O
PSD	B-Protein
-	I-Protein
95	I-Protein
mediate	O
synaptic	O
incorporation	O
,	O
stabilization	O
,	O
and	O
activity	O
-	O
dependent	O
trafficking	O
.	O
<EOS>	B-X
The	B-X
postsynaptic	B-X
density	B-X
(	B-X
PSD	B-X
)	B-X
consists	B-X
of	B-X
a	B-X
lattice-like	B-X
array	B-X
of	B-X
interacting	B-X
proteins	B-X
that	B-X
organizes	B-X
and	B-X
stabilizes	B-X
receptors	B-X
,	B-X
ion	B-X
channels	B-X
,	B-X
structural	B-X
,	B-X
and	B-X
signaling	B-X
proteins	B-X
necessary	B-X
for	B-X
synaptic	B-X
function	B-X
.	B-X
To	B-X
study	B-X
the	B-X
stabilization	B-X
of	B-X
proteins	B-X
within	B-X
this	B-X
structure	B-X
and	B-X
the	B-X
contribution	B-X
of	B-X
these	B-X
proteins	B-X
to	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
PSD	B-X
,	B-X
we	B-X
tagged	B-X
synaptic	B-X
proteins	B-X
with	B-X
PAGFP	B-X
(	B-X
photoactivatable	B-X
green	B-X
fluorescent	B-X
protein	B-X
)	B-X
and	B-X
used	B-X
combined	B-X
two-photon	B-X
laser-scanning	B-X
microscopy	B-X
and	B-X
two-photon	B-X
laser	B-X
photoactivation	B-X
to	B-X
measure	B-X
their	B-X
rate	B-X
of	B-X
turnover	B-X
in	B-X
individual	B-X
spines	B-X
of	B-X
rat	B-X
CA1	B-X
pyramidal	B-X
neurons	B-X
.	B-X
We	B-X
find	B-X
that	B-X
PSD-95	B-X
is	B-X
highly	B-X
stable	B-X
within	B-X
the	B-X
spine	B-X
,	B-X
more	B-X
so	B-X
than	B-X
other	B-X
PSD-associated	B-X
proteins	B-X
such	B-X
as	B-X
CaMKIIalpha	B-X
,	B-X
CaMKIIbeta	B-X
,	B-X
GluR2	B-X
,	B-X
and	B-X
Stargazin	B-X
.	B-X
Analysis	B-X
of	B-X
a	B-X
series	B-X
of	B-X
PSD-95	B-X
mutants	B-X
revealed	B-X
that	B-X
distinct	B-X
domains	B-X
stabilize	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
and	B-X
contribute	B-X
to	B-X
PSD	B-X
formation	B-X
.	B-X
Stabilization	B-X
of	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
requires	B-X
N-terminal	B-X
palmitoylation	B-X
and	B-X
protein	B-X
interactions	B-X
mediated	B-X
by	B-X
the	B-X
first	B-X
and	B-X
second	B-X
PDZ	B-X
domains	B-X
,	B-X
whereas	B-X
formation	B-X
of	B-X
a	B-X
stable	B-X
lattice	B-X
of	B-X
PSD-95	B-X
molecules	B-X
within	B-X
the	B-X
PSD	B-X
additionally	B-X
requires	B-X
the	B-X
C-terminal	B-X
SH3	B-X
domain	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
a	B-X
PDZ	B-X
domain	B-X
1	B-X
and	B-X
2	B-X
dependent	B-X
manner	B-X
,	B-X
activation	B-X
of	B-X
NMDA	B-X
receptors	B-X
with	B-X
a	B-X
chemical	B-X
long-term	B-X
depression	B-X
protocol	B-X
rapidly	B-X
destabilizes	B-X
PSD-95	B-X
and	B-X
causes	B-X
a	B-X
subset	B-X
of	B-X
the	B-X
PSD-95	B-X
molecules	B-X
previously	B-X
anchored	B-X
in	B-X
the	B-X
spine	B-X
to	B-X
be	B-X
released	B-X
.	B-X
Thus	B-X
,	B-X
through	B-X
the	B-X
analysis	B-X
of	B-X
rates	B-X
of	B-X
exchange	B-X
of	B-X
synaptic	B-X
PSD-95	B-X
,	B-X
we	B-X
determine	B-X
separate	B-X
domains	B-X
of	B-X
PSD-95	B-X
that	B-X
play	B-X
specific	B-X
roles	B-X
in	B-X
establishing	B-X
a	B-X
stable	B-X
postsynaptic	B-X
lattice	B-X
,	B-X
in	B-X
allowing	B-X
proteins	B-X
to	B-X
enter	B-X
this	B-X
lattice	B-X
,	B-X
and	B-X
in	B-X
reorganizing	B-X
this	B-X
structure	B-X
in	B-X
response	B-X
to	B-X
plasticity-inducing	B-X
stimuli	B-X
.	B-X

The	O
postsynaptic	O
density	O
(	O
PSD	O
)	O
consists	O
of	O
a	O
lattice	O
-	O
like	O
array	O
of	O
interacting	O
proteins	O
that	O
organizes	O
and	O
stabilizes	O
receptors	O
,	O
ion	O
channels	O
,	O
structural	O
,	O
and	O
signaling	O
proteins	O
necessary	O
for	O
synaptic	O
function	O
.	O
<EOS>	B-X
The	B-X
postsynaptic	B-X
density	B-X
(	B-X
PSD	B-X
)	B-X
consists	B-X
of	B-X
a	B-X
lattice-like	B-X
array	B-X
of	B-X
interacting	B-X
proteins	B-X
that	B-X
organizes	B-X
and	B-X
stabilizes	B-X
receptors	B-X
,	B-X
ion	B-X
channels	B-X
,	B-X
structural	B-X
,	B-X
and	B-X
signaling	B-X
proteins	B-X
necessary	B-X
for	B-X
synaptic	B-X
function	B-X
.	B-X
To	B-X
study	B-X
the	B-X
stabilization	B-X
of	B-X
proteins	B-X
within	B-X
this	B-X
structure	B-X
and	B-X
the	B-X
contribution	B-X
of	B-X
these	B-X
proteins	B-X
to	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
PSD	B-X
,	B-X
we	B-X
tagged	B-X
synaptic	B-X
proteins	B-X
with	B-X
PAGFP	B-X
(	B-X
photoactivatable	B-X
green	B-X
fluorescent	B-X
protein	B-X
)	B-X
and	B-X
used	B-X
combined	B-X
two-photon	B-X
laser-scanning	B-X
microscopy	B-X
and	B-X
two-photon	B-X
laser	B-X
photoactivation	B-X
to	B-X
measure	B-X
their	B-X
rate	B-X
of	B-X
turnover	B-X
in	B-X
individual	B-X
spines	B-X
of	B-X
rat	B-X
CA1	B-X
pyramidal	B-X
neurons	B-X
.	B-X
We	B-X
find	B-X
that	B-X
PSD-95	B-X
is	B-X
highly	B-X
stable	B-X
within	B-X
the	B-X
spine	B-X
,	B-X
more	B-X
so	B-X
than	B-X
other	B-X
PSD-associated	B-X
proteins	B-X
such	B-X
as	B-X
CaMKIIalpha	B-X
,	B-X
CaMKIIbeta	B-X
,	B-X
GluR2	B-X
,	B-X
and	B-X
Stargazin	B-X
.	B-X
Analysis	B-X
of	B-X
a	B-X
series	B-X
of	B-X
PSD-95	B-X
mutants	B-X
revealed	B-X
that	B-X
distinct	B-X
domains	B-X
stabilize	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
and	B-X
contribute	B-X
to	B-X
PSD	B-X
formation	B-X
.	B-X
Stabilization	B-X
of	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
requires	B-X
N-terminal	B-X
palmitoylation	B-X
and	B-X
protein	B-X
interactions	B-X
mediated	B-X
by	B-X
the	B-X
first	B-X
and	B-X
second	B-X
PDZ	B-X
domains	B-X
,	B-X
whereas	B-X
formation	B-X
of	B-X
a	B-X
stable	B-X
lattice	B-X
of	B-X
PSD-95	B-X
molecules	B-X
within	B-X
the	B-X
PSD	B-X
additionally	B-X
requires	B-X
the	B-X
C-terminal	B-X
SH3	B-X
domain	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
a	B-X
PDZ	B-X
domain	B-X
1	B-X
and	B-X
2	B-X
dependent	B-X
manner	B-X
,	B-X
activation	B-X
of	B-X
NMDA	B-X
receptors	B-X
with	B-X
a	B-X
chemical	B-X
long-term	B-X
depression	B-X
protocol	B-X
rapidly	B-X
destabilizes	B-X
PSD-95	B-X
and	B-X
causes	B-X
a	B-X
subset	B-X
of	B-X
the	B-X
PSD-95	B-X
molecules	B-X
previously	B-X
anchored	B-X
in	B-X
the	B-X
spine	B-X
to	B-X
be	B-X
released	B-X
.	B-X
Thus	B-X
,	B-X
through	B-X
the	B-X
analysis	B-X
of	B-X
rates	B-X
of	B-X
exchange	B-X
of	B-X
synaptic	B-X
PSD-95	B-X
,	B-X
we	B-X
determine	B-X
separate	B-X
domains	B-X
of	B-X
PSD-95	B-X
that	B-X
play	B-X
specific	B-X
roles	B-X
in	B-X
establishing	B-X
a	B-X
stable	B-X
postsynaptic	B-X
lattice	B-X
,	B-X
in	B-X
allowing	B-X
proteins	B-X
to	B-X
enter	B-X
this	B-X
lattice	B-X
,	B-X
and	B-X
in	B-X
reorganizing	B-X
this	B-X
structure	B-X
in	B-X
response	B-X
to	B-X
plasticity-inducing	B-X
stimuli	B-X
.	B-X

To	O
study	O
the	O
stabilization	O
of	O
proteins	O
within	O
this	O
structure	O
and	O
the	O
contribution	O
of	O
these	O
proteins	O
to	O
the	O
integrity	O
of	O
the	O
PSD	O
,	O
we	O
tagged	O
synaptic	O
proteins	O
with	O
PAGFP	B-Protein
(	O
photoactivatable	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
)	O
and	O
used	O
combined	O
two	O
-	O
photon	O
laser	O
-	O
scanning	O
microscopy	O
and	O
two	O
-	O
photon	O
laser	O
photoactivation	O
to	O
measure	O
their	O
rate	O
of	O
turnover	O
in	O
individual	O
spines	O
of	O
rat	O
CA1	O
pyramidal	O
neurons	O
.	O

We	O
find	O
that	O
PSD	B-Protein
-	I-Protein
95	I-Protein
is	O
highly	O
stable	O
within	O
the	O
spine	O
,	O
more	O
so	O
than	O
other	O
PSD	O
-	O
associated	O
proteins	O
such	O
as	O
CaMKIIalpha	B-Protein
,	O
CaMKIIbeta	B-Protein
,	O
GluR2	B-Protein
,	O
and	O
Stargazin	B-Protein
.	O
<EOS>	B-X
The	B-X
postsynaptic	B-X
density	B-X
(	B-X
PSD	B-X
)	B-X
consists	B-X
of	B-X
a	B-X
lattice-like	B-X
array	B-X
of	B-X
interacting	B-X
proteins	B-X
that	B-X
organizes	B-X
and	B-X
stabilizes	B-X
receptors	B-X
,	B-X
ion	B-X
channels	B-X
,	B-X
structural	B-X
,	B-X
and	B-X
signaling	B-X
proteins	B-X
necessary	B-X
for	B-X
synaptic	B-X
function	B-X
.	B-X
To	B-X
study	B-X
the	B-X
stabilization	B-X
of	B-X
proteins	B-X
within	B-X
this	B-X
structure	B-X
and	B-X
the	B-X
contribution	B-X
of	B-X
these	B-X
proteins	B-X
to	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
PSD	B-X
,	B-X
we	B-X
tagged	B-X
synaptic	B-X
proteins	B-X
with	B-X
PAGFP	B-X
(	B-X
photoactivatable	B-X
green	B-X
fluorescent	B-X
protein	B-X
)	B-X
and	B-X
used	B-X
combined	B-X
two-photon	B-X
laser-scanning	B-X
microscopy	B-X
and	B-X
two-photon	B-X
laser	B-X
photoactivation	B-X
to	B-X
measure	B-X
their	B-X
rate	B-X
of	B-X
turnover	B-X
in	B-X
individual	B-X
spines	B-X
of	B-X
rat	B-X
CA1	B-X
pyramidal	B-X
neurons	B-X
.	B-X
We	B-X
find	B-X
that	B-X
PSD-95	B-X
is	B-X
highly	B-X
stable	B-X
within	B-X
the	B-X
spine	B-X
,	B-X
more	B-X
so	B-X
than	B-X
other	B-X
PSD-associated	B-X
proteins	B-X
such	B-X
as	B-X
CaMKIIalpha	B-X
,	B-X
CaMKIIbeta	B-X
,	B-X
GluR2	B-X
,	B-X
and	B-X
Stargazin	B-X
.	B-X
Analysis	B-X
of	B-X
a	B-X
series	B-X
of	B-X
PSD-95	B-X
mutants	B-X
revealed	B-X
that	B-X
distinct	B-X
domains	B-X
stabilize	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
and	B-X
contribute	B-X
to	B-X
PSD	B-X
formation	B-X
.	B-X
Stabilization	B-X
of	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
requires	B-X
N-terminal	B-X
palmitoylation	B-X
and	B-X
protein	B-X
interactions	B-X
mediated	B-X
by	B-X
the	B-X
first	B-X
and	B-X
second	B-X
PDZ	B-X
domains	B-X
,	B-X
whereas	B-X
formation	B-X
of	B-X
a	B-X
stable	B-X
lattice	B-X
of	B-X
PSD-95	B-X
molecules	B-X
within	B-X
the	B-X
PSD	B-X
additionally	B-X
requires	B-X
the	B-X
C-terminal	B-X
SH3	B-X
domain	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
a	B-X
PDZ	B-X
domain	B-X
1	B-X
and	B-X
2	B-X
dependent	B-X
manner	B-X
,	B-X
activation	B-X
of	B-X
NMDA	B-X
receptors	B-X
with	B-X
a	B-X
chemical	B-X
long-term	B-X
depression	B-X
protocol	B-X
rapidly	B-X
destabilizes	B-X
PSD-95	B-X
and	B-X
causes	B-X
a	B-X
subset	B-X
of	B-X
the	B-X
PSD-95	B-X
molecules	B-X
previously	B-X
anchored	B-X
in	B-X
the	B-X
spine	B-X
to	B-X
be	B-X
released	B-X
.	B-X
Thus	B-X
,	B-X
through	B-X
the	B-X
analysis	B-X
of	B-X
rates	B-X
of	B-X
exchange	B-X
of	B-X
synaptic	B-X
PSD-95	B-X
,	B-X
we	B-X
determine	B-X
separate	B-X
domains	B-X
of	B-X
PSD-95	B-X
that	B-X
play	B-X
specific	B-X
roles	B-X
in	B-X
establishing	B-X
a	B-X
stable	B-X
postsynaptic	B-X
lattice	B-X
,	B-X
in	B-X
allowing	B-X
proteins	B-X
to	B-X
enter	B-X
this	B-X
lattice	B-X
,	B-X
and	B-X
in	B-X
reorganizing	B-X
this	B-X
structure	B-X
in	B-X
response	B-X
to	B-X
plasticity-inducing	B-X
stimuli	B-X
.	B-X

Analysis	O
of	O
a	O
series	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
mutants	O
revealed	O
that	O
distinct	O
domains	O
stabilize	O
PSD	B-Protein
-	I-Protein
95	I-Protein
within	O
the	O
PSD	O
and	O
contribute	O
to	O
PSD	O
formation	O
.	O
<EOS>	B-X
The	B-X
postsynaptic	B-X
density	B-X
(	B-X
PSD	B-X
)	B-X
consists	B-X
of	B-X
a	B-X
lattice-like	B-X
array	B-X
of	B-X
interacting	B-X
proteins	B-X
that	B-X
organizes	B-X
and	B-X
stabilizes	B-X
receptors	B-X
,	B-X
ion	B-X
channels	B-X
,	B-X
structural	B-X
,	B-X
and	B-X
signaling	B-X
proteins	B-X
necessary	B-X
for	B-X
synaptic	B-X
function	B-X
.	B-X
To	B-X
study	B-X
the	B-X
stabilization	B-X
of	B-X
proteins	B-X
within	B-X
this	B-X
structure	B-X
and	B-X
the	B-X
contribution	B-X
of	B-X
these	B-X
proteins	B-X
to	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
PSD	B-X
,	B-X
we	B-X
tagged	B-X
synaptic	B-X
proteins	B-X
with	B-X
PAGFP	B-X
(	B-X
photoactivatable	B-X
green	B-X
fluorescent	B-X
protein	B-X
)	B-X
and	B-X
used	B-X
combined	B-X
two-photon	B-X
laser-scanning	B-X
microscopy	B-X
and	B-X
two-photon	B-X
laser	B-X
photoactivation	B-X
to	B-X
measure	B-X
their	B-X
rate	B-X
of	B-X
turnover	B-X
in	B-X
individual	B-X
spines	B-X
of	B-X
rat	B-X
CA1	B-X
pyramidal	B-X
neurons	B-X
.	B-X
We	B-X
find	B-X
that	B-X
PSD-95	B-X
is	B-X
highly	B-X
stable	B-X
within	B-X
the	B-X
spine	B-X
,	B-X
more	B-X
so	B-X
than	B-X
other	B-X
PSD-associated	B-X
proteins	B-X
such	B-X
as	B-X
CaMKIIalpha	B-X
,	B-X
CaMKIIbeta	B-X
,	B-X
GluR2	B-X
,	B-X
and	B-X
Stargazin	B-X
.	B-X
Analysis	B-X
of	B-X
a	B-X
series	B-X
of	B-X
PSD-95	B-X
mutants	B-X
revealed	B-X
that	B-X
distinct	B-X
domains	B-X
stabilize	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
and	B-X
contribute	B-X
to	B-X
PSD	B-X
formation	B-X
.	B-X
Stabilization	B-X
of	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
requires	B-X
N-terminal	B-X
palmitoylation	B-X
and	B-X
protein	B-X
interactions	B-X
mediated	B-X
by	B-X
the	B-X
first	B-X
and	B-X
second	B-X
PDZ	B-X
domains	B-X
,	B-X
whereas	B-X
formation	B-X
of	B-X
a	B-X
stable	B-X
lattice	B-X
of	B-X
PSD-95	B-X
molecules	B-X
within	B-X
the	B-X
PSD	B-X
additionally	B-X
requires	B-X
the	B-X
C-terminal	B-X
SH3	B-X
domain	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
a	B-X
PDZ	B-X
domain	B-X
1	B-X
and	B-X
2	B-X
dependent	B-X
manner	B-X
,	B-X
activation	B-X
of	B-X
NMDA	B-X
receptors	B-X
with	B-X
a	B-X
chemical	B-X
long-term	B-X
depression	B-X
protocol	B-X
rapidly	B-X
destabilizes	B-X
PSD-95	B-X
and	B-X
causes	B-X
a	B-X
subset	B-X
of	B-X
the	B-X
PSD-95	B-X
molecules	B-X
previously	B-X
anchored	B-X
in	B-X
the	B-X
spine	B-X
to	B-X
be	B-X
released	B-X
.	B-X
Thus	B-X
,	B-X
through	B-X
the	B-X
analysis	B-X
of	B-X
rates	B-X
of	B-X
exchange	B-X
of	B-X
synaptic	B-X
PSD-95	B-X
,	B-X
we	B-X
determine	B-X
separate	B-X
domains	B-X
of	B-X
PSD-95	B-X
that	B-X
play	B-X
specific	B-X
roles	B-X
in	B-X
establishing	B-X
a	B-X
stable	B-X
postsynaptic	B-X
lattice	B-X
,	B-X
in	B-X
allowing	B-X
proteins	B-X
to	B-X
enter	B-X
this	B-X
lattice	B-X
,	B-X
and	B-X
in	B-X
reorganizing	B-X
this	B-X
structure	B-X
in	B-X
response	B-X
to	B-X
plasticity-inducing	B-X
stimuli	B-X
.	B-X

Stabilization	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
within	O
the	O
PSD	O
requires	O
N	O
-	O
terminal	O
palmitoylation	O
and	O
protein	O
interactions	O
mediated	O
by	O
the	O
first	O
and	O
second	O
PDZ	O
domains	O
,	O
whereas	O
formation	O
of	O
a	O
stable	O
lattice	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
molecules	O
within	O
the	O
PSD	O
additionally	O
requires	O
the	O
C	O
-	O
terminal	O
SH3	O
domain	O
.	O

Furthermore	O
,	O
in	O
a	O
PDZ	O
domain	O
1	O
and	O
2	O
dependent	O
manner	O
,	O
activation	O
of	O
NMDA	O
receptors	O
with	O
a	O
chemical	O
long	O
-	O
term	O
depression	O
protocol	O
rapidly	O
destabilizes	O
PSD	B-Protein
-	I-Protein
95	I-Protein
and	O
causes	O
a	O
subset	O
of	O
the	O
PSD	B-Protein
-	I-Protein
95	I-Protein
molecules	O
previously	O
anchored	O
in	O
the	O
spine	O
to	O
be	O
released	O
.	O

Thus	O
,	O
through	O
the	O
analysis	O
of	O
rates	O
of	O
exchange	O
of	O
synaptic	O
PSD	B-Protein
-	I-Protein
95	I-Protein
,	O
we	O
determine	O
separate	O
domains	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
that	O
play	O
specific	O
roles	O
in	O
establishing	O
a	O
stable	O
postsynaptic	O
lattice	O
,	O
in	O
allowing	O
proteins	O
to	O
enter	O
this	O
lattice	O
,	O
and	O
in	O
reorganizing	O
this	O
structure	O
in	O
response	O
to	O
plasticity	O
-	O
inducing	O
stimuli	O
.	O
<EOS>	B-X
The	B-X
postsynaptic	B-X
density	B-X
(	B-X
PSD	B-X
)	B-X
consists	B-X
of	B-X
a	B-X
lattice-like	B-X
array	B-X
of	B-X
interacting	B-X
proteins	B-X
that	B-X
organizes	B-X
and	B-X
stabilizes	B-X
receptors	B-X
,	B-X
ion	B-X
channels	B-X
,	B-X
structural	B-X
,	B-X
and	B-X
signaling	B-X
proteins	B-X
necessary	B-X
for	B-X
synaptic	B-X
function	B-X
.	B-X
To	B-X
study	B-X
the	B-X
stabilization	B-X
of	B-X
proteins	B-X
within	B-X
this	B-X
structure	B-X
and	B-X
the	B-X
contribution	B-X
of	B-X
these	B-X
proteins	B-X
to	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
PSD	B-X
,	B-X
we	B-X
tagged	B-X
synaptic	B-X
proteins	B-X
with	B-X
PAGFP	B-X
(	B-X
photoactivatable	B-X
green	B-X
fluorescent	B-X
protein	B-X
)	B-X
and	B-X
used	B-X
combined	B-X
two-photon	B-X
laser-scanning	B-X
microscopy	B-X
and	B-X
two-photon	B-X
laser	B-X
photoactivation	B-X
to	B-X
measure	B-X
their	B-X
rate	B-X
of	B-X
turnover	B-X
in	B-X
individual	B-X
spines	B-X
of	B-X
rat	B-X
CA1	B-X
pyramidal	B-X
neurons	B-X
.	B-X
We	B-X
find	B-X
that	B-X
PSD-95	B-X
is	B-X
highly	B-X
stable	B-X
within	B-X
the	B-X
spine	B-X
,	B-X
more	B-X
so	B-X
than	B-X
other	B-X
PSD-associated	B-X
proteins	B-X
such	B-X
as	B-X
CaMKIIalpha	B-X
,	B-X
CaMKIIbeta	B-X
,	B-X
GluR2	B-X
,	B-X
and	B-X
Stargazin	B-X
.	B-X
Analysis	B-X
of	B-X
a	B-X
series	B-X
of	B-X
PSD-95	B-X
mutants	B-X
revealed	B-X
that	B-X
distinct	B-X
domains	B-X
stabilize	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
and	B-X
contribute	B-X
to	B-X
PSD	B-X
formation	B-X
.	B-X
Stabilization	B-X
of	B-X
PSD-95	B-X
within	B-X
the	B-X
PSD	B-X
requires	B-X
N-terminal	B-X
palmitoylation	B-X
and	B-X
protein	B-X
interactions	B-X
mediated	B-X
by	B-X
the	B-X
first	B-X
and	B-X
second	B-X
PDZ	B-X
domains	B-X
,	B-X
whereas	B-X
formation	B-X
of	B-X
a	B-X
stable	B-X
lattice	B-X
of	B-X
PSD-95	B-X
molecules	B-X
within	B-X
the	B-X
PSD	B-X
additionally	B-X
requires	B-X
the	B-X
C-terminal	B-X
SH3	B-X
domain	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
a	B-X
PDZ	B-X
domain	B-X
1	B-X
and	B-X
2	B-X
dependent	B-X
manner	B-X
,	B-X
activation	B-X
of	B-X
NMDA	B-X
receptors	B-X
with	B-X
a	B-X
chemical	B-X
long-term	B-X
depression	B-X
protocol	B-X
rapidly	B-X
destabilizes	B-X
PSD-95	B-X
and	B-X
causes	B-X
a	B-X
subset	B-X
of	B-X
the	B-X
PSD-95	B-X
molecules	B-X
previously	B-X
anchored	B-X
in	B-X
the	B-X
spine	B-X
to	B-X
be	B-X
released	B-X
.	B-X
Thus	B-X
,	B-X
through	B-X
the	B-X
analysis	B-X
of	B-X
rates	B-X
of	B-X
exchange	B-X
of	B-X
synaptic	B-X
PSD-95	B-X
,	B-X
we	B-X
determine	B-X
separate	B-X
domains	B-X
of	B-X
PSD-95	B-X
that	B-X
play	B-X
specific	B-X
roles	B-X
in	B-X
establishing	B-X
a	B-X
stable	B-X
postsynaptic	B-X
lattice	B-X
,	B-X
in	B-X
allowing	B-X
proteins	B-X
to	B-X
enter	B-X
this	B-X
lattice	B-X
,	B-X
and	B-X
in	B-X
reorganizing	B-X
this	B-X
structure	B-X
in	B-X
response	B-X
to	B-X
plasticity-inducing	B-X
stimuli	B-X
.	B-X

Avidin	B-Protein
acylation	O
prevents	O
the	O
complement	O
-	O
dependent	O
lysis	O
of	O
avidin	B-Protein
-	O
carrying	O
erythrocytes	O
.	O
<EOS>	B-X
Non-covalent	B-X
binding	B-X
of	B-X
avidin	B-X
to	B-X
biotinylated	B-X
erythrocytes	B-X
results	B-X
in	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
Biotinylated	B-X
erythrocytes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
native	B-X
cells	B-X
,	B-X
are	B-X
not	B-X
lysed	B-X
by	B-X
complement	B-X
.	B-X
Complement	B-X
activation	B-X
requires	B-X
a	B-X
tight	B-X
contact	B-X
between	B-X
avidin	B-X
and	B-X
the	B-X
erythrocyte	B-X
membrane	B-X
,	B-X
since	B-X
avidin	B-X
does	B-X
not	B-X
in	B-X
itself	B-X
activate	B-X
complement	B-X
and	B-X
does	B-X
not	B-X
inhibit	B-X
lysis	B-X
of	B-X
sensitized	B-X
sheep	B-X
erythrocytes	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
haemolysis	B-X
depends	B-X
on	B-X
avidin	B-X
's	B-X
surface	B-X
density	B-X
.	B-X
When	B-X
the	B-X
avidin	B-X
concentration	B-X
in	B-X
the	B-X
reaction	B-X
mixture	B-X
is	B-X
less	B-X
than	B-X
15	B-X
micrograms/ml	B-X
,	B-X
erythrocyte	B-X
lysis	B-X
is	B-X
not	B-X
induced	B-X
.	B-X
However	B-X
,	B-X
the	B-X
attachment	B-X
of	B-X
biotinylated	B-X
antibodies	B-X
to	B-X
avidin-carrying	B-X
erythrocytes	B-X
decreases	B-X
dramatically	B-X
.	B-X
Acylation	B-X
of	B-X
avidin	B-X
with	B-X
succinic	B-X
anhydride	B-X
strongly	B-X
decreases	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
avidin	B-X
to	B-X
cross-link	B-X
the	B-X
biotin-containing	B-X
structures	B-X
decreases	B-X
after	B-X
acylation	B-X
.	B-X
A	B-X
50	B-X
%	B-X
modification	B-X
of	B-X
avidin	B-X
by	B-X
succinic	B-X
anhydride	B-X
(	B-X
pI	B-X
about	B-X
7.0	B-X
)	B-X
allows	B-X
preparation	B-X
of	B-X
'immunoerythrocytes	B-X
'	B-X
,	B-X
which	B-X
retain	B-X
their	B-X
affinity	B-X
to	B-X
antigen	B-X
and	B-X
stability	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
.	B-X

Non	O
-	O
covalent	O
binding	O
of	O
avidin	B-Protein
to	O
biotinylated	O
erythrocytes	O
results	O
in	O
complement	O
-	O
dependent	O
haemolysis	O
.	O
<EOS>	B-X
Non-covalent	B-X
binding	B-X
of	B-X
avidin	B-X
to	B-X
biotinylated	B-X
erythrocytes	B-X
results	B-X
in	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
Biotinylated	B-X
erythrocytes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
native	B-X
cells	B-X
,	B-X
are	B-X
not	B-X
lysed	B-X
by	B-X
complement	B-X
.	B-X
Complement	B-X
activation	B-X
requires	B-X
a	B-X
tight	B-X
contact	B-X
between	B-X
avidin	B-X
and	B-X
the	B-X
erythrocyte	B-X
membrane	B-X
,	B-X
since	B-X
avidin	B-X
does	B-X
not	B-X
in	B-X
itself	B-X
activate	B-X
complement	B-X
and	B-X
does	B-X
not	B-X
inhibit	B-X
lysis	B-X
of	B-X
sensitized	B-X
sheep	B-X
erythrocytes	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
haemolysis	B-X
depends	B-X
on	B-X
avidin	B-X
's	B-X
surface	B-X
density	B-X
.	B-X
When	B-X
the	B-X
avidin	B-X
concentration	B-X
in	B-X
the	B-X
reaction	B-X
mixture	B-X
is	B-X
less	B-X
than	B-X
15	B-X
micrograms/ml	B-X
,	B-X
erythrocyte	B-X
lysis	B-X
is	B-X
not	B-X
induced	B-X
.	B-X
However	B-X
,	B-X
the	B-X
attachment	B-X
of	B-X
biotinylated	B-X
antibodies	B-X
to	B-X
avidin-carrying	B-X
erythrocytes	B-X
decreases	B-X
dramatically	B-X
.	B-X
Acylation	B-X
of	B-X
avidin	B-X
with	B-X
succinic	B-X
anhydride	B-X
strongly	B-X
decreases	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
avidin	B-X
to	B-X
cross-link	B-X
the	B-X
biotin-containing	B-X
structures	B-X
decreases	B-X
after	B-X
acylation	B-X
.	B-X
A	B-X
50	B-X
%	B-X
modification	B-X
of	B-X
avidin	B-X
by	B-X
succinic	B-X
anhydride	B-X
(	B-X
pI	B-X
about	B-X
7.0	B-X
)	B-X
allows	B-X
preparation	B-X
of	B-X
'immunoerythrocytes	B-X
'	B-X
,	B-X
which	B-X
retain	B-X
their	B-X
affinity	B-X
to	B-X
antigen	B-X
and	B-X
stability	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
.	B-X

Biotinylated	O
erythrocytes	O
,	O
as	O
well	O
as	O
native	O
cells	O
,	O
are	O
not	O
lysed	O
by	O
complement	O
.	O
<EOS>	B-X
Rosetting	B-X
,	B-X
namely	B-X
the	B-X
capacity	B-X
of	B-X
the	B-X
Plasmodium	B-X
falciparum-infected	B-X
red	B-X
blood	B-X
cells	B-X
to	B-X
bind	B-X
uninfected	B-X
RBCs	B-X
,	B-X
is	B-X
commonly	B-X
observed	B-X
in	B-X
African	B-X
children	B-X
with	B-X
severe	B-X
malaria	B-X
.	B-X

Complement	O
activation	O
requires	O
a	O
tight	O
contact	O
between	O
avidin	B-Protein
and	O
the	O
erythrocyte	O
membrane	O
,	O
since	O
avidin	B-Protein
does	O
not	O
in	O
itself	O
activate	O
complement	O
and	O
does	O
not	O
inhibit	O
lysis	O
of	O
sensitized	O
sheep	O
erythrocytes	O
.	O

The	O
efficiency	O
of	O
haemolysis	O
depends	O
on	O
avidin	B-Protein
'	O
s	O
surface	O
density	O
.	O
<EOS>	B-X
Non-covalent	B-X
binding	B-X
of	B-X
avidin	B-X
to	B-X
biotinylated	B-X
erythrocytes	B-X
results	B-X
in	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
Complement	B-X
activation	B-X
requires	B-X
a	B-X
tight	B-X
contact	B-X
between	B-X
avidin	B-X
and	B-X
the	B-X
erythrocyte	B-X
membrane	B-X
,	B-X
since	B-X
avidin	B-X
does	B-X
not	B-X
in	B-X
itself	B-X
activate	B-X
complement	B-X
and	B-X
does	B-X
not	B-X
inhibit	B-X
lysis	B-X
of	B-X
sensitized	B-X
sheep	B-X
erythrocytes	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
haemolysis	B-X
depends	B-X
on	B-X
avidin	B-X
's	B-X
surface	B-X
density	B-X
.	B-X
When	B-X
the	B-X
avidin	B-X
concentration	B-X
in	B-X
the	B-X
reaction	B-X
mixture	B-X
is	B-X
less	B-X
than	B-X
15	B-X
micrograms/ml	B-X
,	B-X
erythrocyte	B-X
lysis	B-X
is	B-X
not	B-X
induced	B-X
.	B-X
However	B-X
,	B-X
the	B-X
attachment	B-X
of	B-X
biotinylated	B-X
antibodies	B-X
to	B-X
avidin-carrying	B-X
erythrocytes	B-X
decreases	B-X
dramatically	B-X
.	B-X
Acylation	B-X
of	B-X
avidin	B-X
with	B-X
succinic	B-X
anhydride	B-X
strongly	B-X
decreases	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
avidin	B-X
to	B-X
cross-link	B-X
the	B-X
biotin-containing	B-X
structures	B-X
decreases	B-X
after	B-X
acylation	B-X
.	B-X
A	B-X
50	B-X
%	B-X
modification	B-X
of	B-X
avidin	B-X
by	B-X
succinic	B-X
anhydride	B-X
(	B-X
pI	B-X
about	B-X
7.0	B-X
)	B-X
allows	B-X
preparation	B-X
of	B-X
'immunoerythrocytes	B-X
'	B-X
,	B-X
which	B-X
retain	B-X
their	B-X
affinity	B-X
to	B-X
antigen	B-X
and	B-X
stability	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
.	B-X

When	O
the	O
avidin	B-Protein
concentration	O
in	O
the	O
reaction	O
mixture	O
is	O
less	O
than	O
15	O
micrograms	O
/	O
ml	O
,	O
erythrocyte	O
lysis	O
is	O
not	O
induced	O
.	O

However	O
,	O
the	O
attachment	O
of	O
biotinylated	O
antibodies	O
to	O
avidin	B-Protein
-	O
carrying	O
erythrocytes	O
decreases	O
dramatically	O
.	O
<EOS>	B-X
Non-covalent	B-X
binding	B-X
of	B-X
avidin	B-X
to	B-X
biotinylated	B-X
erythrocytes	B-X
results	B-X
in	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
Biotinylated	B-X
erythrocytes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
native	B-X
cells	B-X
,	B-X
are	B-X
not	B-X
lysed	B-X
by	B-X
complement	B-X
.	B-X
Complement	B-X
activation	B-X
requires	B-X
a	B-X
tight	B-X
contact	B-X
between	B-X
avidin	B-X
and	B-X
the	B-X
erythrocyte	B-X
membrane	B-X
,	B-X
since	B-X
avidin	B-X
does	B-X
not	B-X
in	B-X
itself	B-X
activate	B-X
complement	B-X
and	B-X
does	B-X
not	B-X
inhibit	B-X
lysis	B-X
of	B-X
sensitized	B-X
sheep	B-X
erythrocytes	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
haemolysis	B-X
depends	B-X
on	B-X
avidin	B-X
's	B-X
surface	B-X
density	B-X
.	B-X
When	B-X
the	B-X
avidin	B-X
concentration	B-X
in	B-X
the	B-X
reaction	B-X
mixture	B-X
is	B-X
less	B-X
than	B-X
15	B-X
micrograms/ml	B-X
,	B-X
erythrocyte	B-X
lysis	B-X
is	B-X
not	B-X
induced	B-X
.	B-X
However	B-X
,	B-X
the	B-X
attachment	B-X
of	B-X
biotinylated	B-X
antibodies	B-X
to	B-X
avidin-carrying	B-X
erythrocytes	B-X
decreases	B-X
dramatically	B-X
.	B-X
Acylation	B-X
of	B-X
avidin	B-X
with	B-X
succinic	B-X
anhydride	B-X
strongly	B-X
decreases	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
avidin	B-X
to	B-X
cross-link	B-X
the	B-X
biotin-containing	B-X
structures	B-X
decreases	B-X
after	B-X
acylation	B-X
.	B-X
A	B-X
50	B-X
%	B-X
modification	B-X
of	B-X
avidin	B-X
by	B-X
succinic	B-X
anhydride	B-X
(	B-X
pI	B-X
about	B-X
7.0	B-X
)	B-X
allows	B-X
preparation	B-X
of	B-X
'immunoerythrocytes	B-X
'	B-X
,	B-X
which	B-X
retain	B-X
their	B-X
affinity	B-X
to	B-X
antigen	B-X
and	B-X
stability	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
.	B-X

Acylation	O
of	O
avidin	B-Protein
with	O
succinic	O
anhydride	O
strongly	O
decreases	O
its	O
ability	O
to	O
induce	O
complement	O
-	O
dependent	O
haemolysis	O
.	O
<EOS>	B-X
Non-covalent	B-X
binding	B-X
of	B-X
avidin	B-X
to	B-X
biotinylated	B-X
erythrocytes	B-X
results	B-X
in	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
Biotinylated	B-X
erythrocytes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
native	B-X
cells	B-X
,	B-X
are	B-X
not	B-X
lysed	B-X
by	B-X
complement	B-X
.	B-X
Complement	B-X
activation	B-X
requires	B-X
a	B-X
tight	B-X
contact	B-X
between	B-X
avidin	B-X
and	B-X
the	B-X
erythrocyte	B-X
membrane	B-X
,	B-X
since	B-X
avidin	B-X
does	B-X
not	B-X
in	B-X
itself	B-X
activate	B-X
complement	B-X
and	B-X
does	B-X
not	B-X
inhibit	B-X
lysis	B-X
of	B-X
sensitized	B-X
sheep	B-X
erythrocytes	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
haemolysis	B-X
depends	B-X
on	B-X
avidin	B-X
's	B-X
surface	B-X
density	B-X
.	B-X
When	B-X
the	B-X
avidin	B-X
concentration	B-X
in	B-X
the	B-X
reaction	B-X
mixture	B-X
is	B-X
less	B-X
than	B-X
15	B-X
micrograms/ml	B-X
,	B-X
erythrocyte	B-X
lysis	B-X
is	B-X
not	B-X
induced	B-X
.	B-X
However	B-X
,	B-X
the	B-X
attachment	B-X
of	B-X
biotinylated	B-X
antibodies	B-X
to	B-X
avidin-carrying	B-X
erythrocytes	B-X
decreases	B-X
dramatically	B-X
.	B-X
Acylation	B-X
of	B-X
avidin	B-X
with	B-X
succinic	B-X
anhydride	B-X
strongly	B-X
decreases	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
avidin	B-X
to	B-X
cross-link	B-X
the	B-X
biotin-containing	B-X
structures	B-X
decreases	B-X
after	B-X
acylation	B-X
.	B-X
A	B-X
50	B-X
%	B-X
modification	B-X
of	B-X
avidin	B-X
by	B-X
succinic	B-X
anhydride	B-X
(	B-X
pI	B-X
about	B-X
7.0	B-X
)	B-X
allows	B-X
preparation	B-X
of	B-X
'immunoerythrocytes	B-X
'	B-X
,	B-X
which	B-X
retain	B-X
their	B-X
affinity	B-X
to	B-X
antigen	B-X
and	B-X
stability	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
.	B-X

However	O
,	O
the	O
ability	O
of	O
avidin	B-Protein
to	O
cross	O
-	O
link	O
the	O
biotin	O
-	O
containing	O
structures	O
decreases	O
after	O
acylation	O
.	O
<EOS>	B-X
Non-covalent	B-X
binding	B-X
of	B-X
avidin	B-X
to	B-X
biotinylated	B-X
erythrocytes	B-X
results	B-X
in	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
Complement	B-X
activation	B-X
requires	B-X
a	B-X
tight	B-X
contact	B-X
between	B-X
avidin	B-X
and	B-X
the	B-X
erythrocyte	B-X
membrane	B-X
,	B-X
since	B-X
avidin	B-X
does	B-X
not	B-X
in	B-X
itself	B-X
activate	B-X
complement	B-X
and	B-X
does	B-X
not	B-X
inhibit	B-X
lysis	B-X
of	B-X
sensitized	B-X
sheep	B-X
erythrocytes	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
haemolysis	B-X
depends	B-X
on	B-X
avidin	B-X
's	B-X
surface	B-X
density	B-X
.	B-X
When	B-X
the	B-X
avidin	B-X
concentration	B-X
in	B-X
the	B-X
reaction	B-X
mixture	B-X
is	B-X
less	B-X
than	B-X
15	B-X
micrograms/ml	B-X
,	B-X
erythrocyte	B-X
lysis	B-X
is	B-X
not	B-X
induced	B-X
.	B-X
However	B-X
,	B-X
the	B-X
attachment	B-X
of	B-X
biotinylated	B-X
antibodies	B-X
to	B-X
avidin-carrying	B-X
erythrocytes	B-X
decreases	B-X
dramatically	B-X
.	B-X
Acylation	B-X
of	B-X
avidin	B-X
with	B-X
succinic	B-X
anhydride	B-X
strongly	B-X
decreases	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
complement-dependent	B-X
haemolysis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
avidin	B-X
to	B-X
cross-link	B-X
the	B-X
biotin-containing	B-X
structures	B-X
decreases	B-X
after	B-X
acylation	B-X
.	B-X
A	B-X
50	B-X
%	B-X
modification	B-X
of	B-X
avidin	B-X
by	B-X
succinic	B-X
anhydride	B-X
(	B-X
pI	B-X
about	B-X
7.0	B-X
)	B-X
allows	B-X
preparation	B-X
of	B-X
'immunoerythrocytes	B-X
'	B-X
,	B-X
which	B-X
retain	B-X
their	B-X
affinity	B-X
to	B-X
antigen	B-X
and	B-X
stability	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
.	B-X

A	O
50	O
%	O
modification	O
of	O
avidin	B-Protein
by	O
succinic	O
anhydride	O
(	O
pI	O
about	O
7	O
.	O
0	O
)	O
allows	O
preparation	O
of	O
'	O
immunoerythrocytes	O
'	O
,	O
which	O
retain	O
their	O
affinity	O
to	O
antigen	O
and	O
stability	O
in	O
the	O
presence	O
of	O
complement	O
.	O

NUB1	B-Protein
promotes	O
cytoplasmic	O
localization	O
of	O
p53	B-Protein
through	O
cooperation	O
of	O
the	O
NEDD8	B-Protein
and	O
ubiquitin	B-Protein
pathways	O
.	O
<EOS>	B-X
Non-covalent	B-X
recognition	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
molecules	B-X
(	B-X
Ubls	B-X
)	B-X
by	B-X
interacting	B-X
proteins	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
protein	B-X
function	B-X
and	B-X
initiation	B-X
of	B-X
signalling	B-X
events	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
growing	B-X
evidence	B-X
suggests	B-X
that	B-X
regulation	B-X
of	B-X
p53	B-X
subcellular	B-X
localization	B-X
contributes	B-X
to	B-X
the	B-X
biological	B-X
outcome	B-X
of	B-X
the	B-X
p53	B-X
response	B-X
.	B-X
Cytoplasmic	B-X
p53	B-X
is	B-X
shown	B-X
to	B-X
promote	B-X
apoptosis	B-X
and	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
ultimate	B-X
buster	B-X
1	B-X
(	B-X
NUB1	B-X
)	B-X
,	B-X
a	B-X
non-covalent	B-X
interactor	B-X
of	B-X
the	B-X
Ubl	B-X
NEDD8	B-X
(	B-X
neural	B-X
precursor	B-X
cell	B-X
expressed	B-X
,	B-X
developmentally	B-X
downregulated	B-X
8	B-X
)	B-X
,	B-X
controls	B-X
the	B-X
localization	B-X
of	B-X
p53	B-X
.	B-X
Expression	B-X
of	B-X
NUB1	B-X
leads	B-X
to	B-X
decreased	B-X
modification	B-X
of	B-X
p53	B-X
with	B-X
NEDD8	B-X
and	B-X
stimulation	B-X
of	B-X
p53	B-X
ubiquitination	B-X
.	B-X
The	B-X
biological	B-X
outcome	B-X
is	B-X
the	B-X
cytoplasmic	B-X
localization	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
p53	B-X
.	B-X
Although	B-X
the	B-X
effects	B-X
of	B-X
NUB1	B-X
on	B-X
p53	B-X
depend	B-X
on	B-X
NEDDylation	B-X
and	B-X
the	B-X
murine	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
Mdm2	B-X
)	B-X
E3-ligase	B-X
,	B-X
the	B-X
cooperation	B-X
of	B-X
NEDD8	B-X
with	B-X
ubiquitin	B-X
is	B-X
required	B-X
.	B-X
The	B-X
data	B-X
identify	B-X
a	B-X
role	B-X
for	B-X
NEDD8	B-X
in	B-X
controlling	B-X
p53	B-X
localization	B-X
and	B-X
suggest	B-X
that	B-X
NEDD8	B-X
can	B-X
control	B-X
protein	B-X
function	B-X
through	B-X
its	B-X
non-covalent	B-X
recognition	B-X
by	B-X
interacting	B-X
proteins	B-X
.	B-X

Non	O
-	O
covalent	O
recognition	O
of	O
ubiquitin	B-Protein
(	O
Ub	B-Protein
)	O
and	O
ubiquitin	B-Protein
-	O
like	O
molecules	O
(	O
Ubls	O
)	O
by	O
interacting	O
proteins	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
protein	O
function	O
and	O
initiation	O
of	O
signalling	O
events	O
.	O
<EOS>	B-X
Non-covalent	B-X
recognition	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
molecules	B-X
(	B-X
Ubls	B-X
)	B-X
by	B-X
interacting	B-X
proteins	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
protein	B-X
function	B-X
and	B-X
initiation	B-X
of	B-X
signalling	B-X
events	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
growing	B-X
evidence	B-X
suggests	B-X
that	B-X
regulation	B-X
of	B-X
p53	B-X
subcellular	B-X
localization	B-X
contributes	B-X
to	B-X
the	B-X
biological	B-X
outcome	B-X
of	B-X
the	B-X
p53	B-X
response	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
ultimate	B-X
buster	B-X
1	B-X
(	B-X
NUB1	B-X
)	B-X
,	B-X
a	B-X
non-covalent	B-X
interactor	B-X
of	B-X
the	B-X
Ubl	B-X
NEDD8	B-X
(	B-X
neural	B-X
precursor	B-X
cell	B-X
expressed	B-X
,	B-X
developmentally	B-X
downregulated	B-X
8	B-X
)	B-X
,	B-X
controls	B-X
the	B-X
localization	B-X
of	B-X
p53	B-X
.	B-X
Expression	B-X
of	B-X
NUB1	B-X
leads	B-X
to	B-X
decreased	B-X
modification	B-X
of	B-X
p53	B-X
with	B-X
NEDD8	B-X
and	B-X
stimulation	B-X
of	B-X
p53	B-X
ubiquitination	B-X
.	B-X
Although	B-X
the	B-X
effects	B-X
of	B-X
NUB1	B-X
on	B-X
p53	B-X
depend	B-X
on	B-X
NEDDylation	B-X
and	B-X
the	B-X
murine	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
Mdm2	B-X
)	B-X
E3-ligase	B-X
,	B-X
the	B-X
cooperation	B-X
of	B-X
NEDD8	B-X
with	B-X
ubiquitin	B-X
is	B-X
required	B-X
.	B-X
The	B-X
data	B-X
identify	B-X
a	B-X
role	B-X
for	B-X
NEDD8	B-X
in	B-X
controlling	B-X
p53	B-X
localization	B-X
and	B-X
suggest	B-X
that	B-X
NEDD8	B-X
can	B-X
control	B-X
protein	B-X
function	B-X
through	B-X
its	B-X
non-covalent	B-X
recognition	B-X
by	B-X
interacting	B-X
proteins	B-X
.	B-X

In	O
addition	O
,	O
growing	O
evidence	O
suggests	O
that	O
regulation	O
of	O
p53	B-Protein
subcellular	O
localization	O
contributes	O
to	O
the	O
biological	O
outcome	O
of	O
the	O
p53	B-Protein
response	O
.	O

Cytoplasmic	O
p53	B-Protein
is	O
shown	O
to	O
promote	O
apoptosis	O
and	O
inhibit	O
the	O
induction	O
of	O
autophagy	O
.	O
<EOS>	B-X
The	B-X
interplay	B-X
between	B-X
p53	B-X
and	B-X
RAS	B-X
signaling	B-X
regulates	B-X
cancer	B-X
chemoresistance	B-X
,	B-X
but	B-X
the	B-X
detailed	B-X
mechanism	B-X
is	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
interactive	B-X
effects	B-X
of	B-X
p53	B-X
and	B-X
RAS	B-X
on	B-X
ovarian	B-X
cancer	B-X
cisplatin	B-X
resistance	B-X
to	B-X
explore	B-X
the	B-X
potential	B-X
therapeutic	B-X
targets	B-X
.	B-X
The	B-X
tumor	B-X
suppressor	B-X
p53	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulation	B-X
of	B-X
mitochondrial	B-X
integrity	B-X
and	B-X
mitophagy	B-X
in	B-X
several	B-X
forms	B-X
of	B-X
ALI	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
p53-regulated	B-X
mitophagy	B-X
in	B-X
HS-ALI	B-X
remains	B-X
unclear	B-X
.	B-X
Pretreatment	B-X
with	B-X
3-MA	B-X
or	B-X
Mdivi-1	B-X
significantly	B-X
exacerbated	B-X
ALI	B-X
by	B-X
inhibiting	B-X
mitophagy	B-X
in	B-X
HS-ALI	B-X
mice	B-X
.	B-X
Consistent	B-X
with	B-X
the	B-X
animal	B-X
HS-ALI	B-X
model	B-X
results	B-X
,	B-X
silencing	B-X
Parkin	B-X
aggravated	B-X
mitochondrial	B-X
damage	B-X
and	B-X
apoptosis	B-X
by	B-X
inhibiting	B-X
mitophagy	B-X
in	B-X
HS-treated	B-X
normal	B-X
human	B-X
liver	B-X
cell	B-X
line	B-X
(	B-X
LO2	B-X
cells	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
described	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
translocation	B-X
of	B-X
p53	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
and	B-X
cytosolic	B-X
p53	B-X
binds	B-X
to	B-X
Parkin	B-X
in	B-X
LO2	B-X
cells	B-X
following	B-X
HS	B-X
.	B-X
p53	B-X
overexpression	B-X
using	B-X
a	B-X
specific	B-X
adenovirus	B-X
or	B-X
Tenovin-6	B-X
exacerbated	B-X
HS-ALI	B-X
through	B-X
Parkin-dependent	B-X
mitophagy	B-X
both	B-X

In	O
this	O
study	O
we	O
show	O
that	O
NEDD8	B-Protein
ultimate	I-Protein
buster	I-Protein
1	I-Protein
(	O
NUB1	B-Protein
)	O
,	O
a	O
non	O
-	O
covalent	O
interactor	O
of	O
the	O
Ubl	O
NEDD8	B-Protein
(	O
neural	B-Protein
precursor	I-Protein
cell	I-Protein
expressed	I-Protein
,	I-Protein
developmentally	I-Protein
downregulated	I-Protein
8	I-Protein
)	O
,	O
controls	O
the	O
localization	O
of	O
p53	B-Protein
.	O
<EOS>	B-X
Non-covalent	B-X
recognition	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
molecules	B-X
(	B-X
Ubls	B-X
)	B-X
by	B-X
interacting	B-X
proteins	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
protein	B-X
function	B-X
and	B-X
initiation	B-X
of	B-X
signalling	B-X
events	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
growing	B-X
evidence	B-X
suggests	B-X
that	B-X
regulation	B-X
of	B-X
p53	B-X
subcellular	B-X
localization	B-X
contributes	B-X
to	B-X
the	B-X
biological	B-X
outcome	B-X
of	B-X
the	B-X
p53	B-X
response	B-X
.	B-X
Cytoplasmic	B-X
p53	B-X
is	B-X
shown	B-X
to	B-X
promote	B-X
apoptosis	B-X
and	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
ultimate	B-X
buster	B-X
1	B-X
(	B-X
NUB1	B-X
)	B-X
,	B-X
a	B-X
non-covalent	B-X
interactor	B-X
of	B-X
the	B-X
Ubl	B-X
NEDD8	B-X
(	B-X
neural	B-X
precursor	B-X
cell	B-X
expressed	B-X
,	B-X
developmentally	B-X
downregulated	B-X
8	B-X
)	B-X
,	B-X
controls	B-X
the	B-X
localization	B-X
of	B-X
p53	B-X
.	B-X
Expression	B-X
of	B-X
NUB1	B-X
leads	B-X
to	B-X
decreased	B-X
modification	B-X
of	B-X
p53	B-X
with	B-X
NEDD8	B-X
and	B-X
stimulation	B-X
of	B-X
p53	B-X
ubiquitination	B-X
.	B-X
The	B-X
biological	B-X
outcome	B-X
is	B-X
the	B-X
cytoplasmic	B-X
localization	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
p53	B-X
.	B-X
Although	B-X
the	B-X
effects	B-X
of	B-X
NUB1	B-X
on	B-X
p53	B-X
depend	B-X
on	B-X
NEDDylation	B-X
and	B-X
the	B-X
murine	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
Mdm2	B-X
)	B-X
E3-ligase	B-X
,	B-X
the	B-X
cooperation	B-X
of	B-X
NEDD8	B-X
with	B-X
ubiquitin	B-X
is	B-X
required	B-X
.	B-X
The	B-X
data	B-X
identify	B-X
a	B-X
role	B-X
for	B-X
NEDD8	B-X
in	B-X
controlling	B-X
p53	B-X
localization	B-X
and	B-X
suggest	B-X
that	B-X
NEDD8	B-X
can	B-X
control	B-X
protein	B-X
function	B-X
through	B-X
its	B-X
non-covalent	B-X
recognition	B-X
by	B-X
interacting	B-X
proteins	B-X
.	B-X

Expression	O
of	O
NUB1	B-Protein
leads	O
to	O
decreased	O
modification	O
of	O
p53	B-Protein
with	O
NEDD8	B-Protein
and	O
stimulation	O
of	O
p53	B-Protein
ubiquitination	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
growing	B-X
evidence	B-X
suggests	B-X
that	B-X
regulation	B-X
of	B-X
p53	B-X
subcellular	B-X
localization	B-X
contributes	B-X
to	B-X
the	B-X
biological	B-X
outcome	B-X
of	B-X
the	B-X
p53	B-X
response	B-X
.	B-X
Cytoplasmic	B-X
p53	B-X
is	B-X
shown	B-X
to	B-X
promote	B-X
apoptosis	B-X
and	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
ultimate	B-X
buster	B-X
1	B-X
(	B-X
NUB1	B-X
)	B-X
,	B-X
a	B-X
non-covalent	B-X
interactor	B-X
of	B-X
the	B-X
Ubl	B-X
NEDD8	B-X
(	B-X
neural	B-X
precursor	B-X
cell	B-X
expressed	B-X
,	B-X
developmentally	B-X
downregulated	B-X
8	B-X
)	B-X
,	B-X
controls	B-X
the	B-X
localization	B-X
of	B-X
p53	B-X
.	B-X
Expression	B-X
of	B-X
NUB1	B-X
leads	B-X
to	B-X
decreased	B-X
modification	B-X
of	B-X
p53	B-X
with	B-X
NEDD8	B-X
and	B-X
stimulation	B-X
of	B-X
p53	B-X
ubiquitination	B-X
.	B-X
The	B-X
biological	B-X
outcome	B-X
is	B-X
the	B-X
cytoplasmic	B-X
localization	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
p53	B-X
.	B-X
Although	B-X
the	B-X
effects	B-X
of	B-X
NUB1	B-X
on	B-X
p53	B-X
depend	B-X
on	B-X
NEDDylation	B-X
and	B-X
the	B-X
murine	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
Mdm2	B-X
)	B-X
E3-ligase	B-X
,	B-X
the	B-X
cooperation	B-X
of	B-X
NEDD8	B-X
with	B-X
ubiquitin	B-X
is	B-X
required	B-X
.	B-X
The	B-X
data	B-X
identify	B-X
a	B-X
role	B-X
for	B-X
NEDD8	B-X
in	B-X
controlling	B-X
p53	B-X
localization	B-X
and	B-X
suggest	B-X
that	B-X
NEDD8	B-X
can	B-X
control	B-X
protein	B-X
function	B-X
through	B-X
its	B-X
non-covalent	B-X
recognition	B-X
by	B-X
interacting	B-X
proteins	B-X
.	B-X

The	O
biological	O
outcome	O
is	O
the	O
cytoplasmic	O
localization	O
and	O
inhibition	O
of	O
the	O
transcriptional	O
activity	O
of	O
p53	B-Protein
.	O
<EOS>	B-X
A	B-X
transcription	B-X
factor	B-X
p53	B-X
is	B-X
activated	B-X
upon	B-X
cellular	B-X
exposure	B-X
to	B-X
endogenous	B-X
and	B-X
exogenous	B-X
stresses	B-X
,	B-X
triggering	B-X
either	B-X
homeostatic	B-X
correction	B-X
or	B-X
cell	B-X
death	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
stress	B-X
level	B-X
,	B-X
often	B-X
measurable	B-X
as	B-X
DNA	B-X
damage	B-X
,	B-X
the	B-X
dual	B-X
outcome	B-X
is	B-X
supported	B-X
by	B-X
p53	B-X
binding	B-X
to	B-X
a	B-X
number	B-X
of	B-X
regulatory	B-X
and	B-X
metabolic	B-X
proteins	B-X
.	B-X
Apart	B-X
from	B-X
the	B-X
nucleus	B-X
,	B-X
p53	B-X
localizes	B-X
to	B-X
mitochondria	B-X
,	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
cytosol	B-X
.	B-X
We	B-X
consider	B-X
non-nuclear	B-X
heterologous	B-X
protein	B-X
complexes	B-X
of	B-X
p53	B-X
,	B-X
their	B-X
structural	B-X
determinants	B-X
,	B-X
regulatory	B-X
post-translational	B-X
modifications	B-X
and	B-X
the	B-X
role	B-X
in	B-X
intricate	B-X
p53	B-X
functions	B-X
.	B-X
The	B-X
p53	B-X
heterologous	B-X
complexes	B-X
regulate	B-X
the	B-X
folding	B-X
,	B-X
trafficking	B-X
and/or	B-X
action	B-X
of	B-X
interacting	B-X
partners	B-X
in	B-X
cellular	B-X
compartments	B-X
.	B-X
Some	B-X
of	B-X
them	B-X
mainly	B-X
sequester	B-X
p53	B-X
(	B-X
HSP	B-X
proteins	B-X
,	B-X
G6PD	B-X
,	B-X
LONP1	B-X
)	B-X
or	B-X
its	B-X
partners	B-X
(	B-X
RRM2B	B-X
,	B-X
PRKN	B-X
)	B-X
in	B-X
specific	B-X
locations	B-X
.	B-X
Formation	B-X
of	B-X
other	B-X
complexes	B-X
(	B-X
with	B-X
ATP2A2	B-X
,	B-X
ATP5PO	B-X
,	B-X
BAX	B-X
,	B-X
BCL2L1	B-X
,	B-X
CHCHD4	B-X
,	B-X
PPIF	B-X
,	B-X
POLG	B-X
,	B-X
SOD2	B-X
,	B-X
SSBP1	B-X
,	B-X
TFAM	B-X
)	B-X
depends	B-X
on	B-X
p53	B-X
upregulation	B-X
according	B-X
to	B-X
the	B-X
stress	B-X
level	B-X
.	B-X
The	B-X
p53	B-X
complexes	B-X
with	B-X
SIRT2	B-X
,	B-X
MUL1	B-X
,	B-X
USP7	B-X
,	B-X
TXN	B-X
,	B-X
PIN1	B-X
and	B-X
PPIF	B-X
control	B-X
regulation	B-X
of	B-X
p53	B-X
function	B-X
through	B-X
post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
lysine	B-X
acetylation	B-X
or	B-X
ubiquitination	B-X
,	B-X
cysteine/cystine	B-X
redox	B-X
transformation	B-X
and	B-X
peptidyl-prolyl	B-X

Although	O
the	O
effects	O
of	O
NUB1	B-Protein
on	O
p53	B-Protein
depend	O
on	O
NEDDylation	O
and	O
the	O
murine	B-Protein
double	I-Protein
minute	I-Protein
2	I-Protein
(	O
Mdm2	B-Protein
)	O
E3	O
-	O
ligase	O
,	O
the	O
cooperation	O
of	O
NEDD8	B-Protein
with	O
ubiquitin	B-Protein
is	O
required	O
.	O
<EOS>	B-X
Non-covalent	B-X
recognition	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
molecules	B-X
(	B-X
Ubls	B-X
)	B-X
by	B-X
interacting	B-X
proteins	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
protein	B-X
function	B-X
and	B-X
initiation	B-X
of	B-X
signalling	B-X
events	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
growing	B-X
evidence	B-X
suggests	B-X
that	B-X
regulation	B-X
of	B-X
p53	B-X
subcellular	B-X
localization	B-X
contributes	B-X
to	B-X
the	B-X
biological	B-X
outcome	B-X
of	B-X
the	B-X
p53	B-X
response	B-X
.	B-X
Cytoplasmic	B-X
p53	B-X
is	B-X
shown	B-X
to	B-X
promote	B-X
apoptosis	B-X
and	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
ultimate	B-X
buster	B-X
1	B-X
(	B-X
NUB1	B-X
)	B-X
,	B-X
a	B-X
non-covalent	B-X
interactor	B-X
of	B-X
the	B-X
Ubl	B-X
NEDD8	B-X
(	B-X
neural	B-X
precursor	B-X
cell	B-X
expressed	B-X
,	B-X
developmentally	B-X
downregulated	B-X
8	B-X
)	B-X
,	B-X
controls	B-X
the	B-X
localization	B-X
of	B-X
p53	B-X
.	B-X
Expression	B-X
of	B-X
NUB1	B-X
leads	B-X
to	B-X
decreased	B-X
modification	B-X
of	B-X
p53	B-X
with	B-X
NEDD8	B-X
and	B-X
stimulation	B-X
of	B-X
p53	B-X
ubiquitination	B-X
.	B-X
The	B-X
biological	B-X
outcome	B-X
is	B-X
the	B-X
cytoplasmic	B-X
localization	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
p53	B-X
.	B-X
Although	B-X
the	B-X
effects	B-X
of	B-X
NUB1	B-X
on	B-X
p53	B-X
depend	B-X
on	B-X
NEDDylation	B-X
and	B-X
the	B-X
murine	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
Mdm2	B-X
)	B-X
E3-ligase	B-X
,	B-X
the	B-X
cooperation	B-X
of	B-X
NEDD8	B-X
with	B-X
ubiquitin	B-X
is	B-X
required	B-X
.	B-X
The	B-X
data	B-X
identify	B-X
a	B-X
role	B-X
for	B-X
NEDD8	B-X
in	B-X
controlling	B-X
p53	B-X
localization	B-X
and	B-X
suggest	B-X
that	B-X
NEDD8	B-X
can	B-X
control	B-X
protein	B-X
function	B-X
through	B-X
its	B-X
non-covalent	B-X
recognition	B-X
by	B-X
interacting	B-X
proteins	B-X
.	B-X

The	O
data	O
identify	O
a	O
role	O
for	O
NEDD8	B-Protein
in	O
controlling	O
p53	B-Protein
localization	O
and	O
suggest	O
that	O
NEDD8	B-Protein
can	O
control	O
protein	O
function	O
through	O
its	O
non	O
-	O
covalent	O
recognition	O
by	O
interacting	O
proteins	O
.	O
<EOS>	B-X
Non-covalent	B-X
recognition	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
molecules	B-X
(	B-X
Ubls	B-X
)	B-X
by	B-X
interacting	B-X
proteins	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
protein	B-X
function	B-X
and	B-X
initiation	B-X
of	B-X
signalling	B-X
events	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
growing	B-X
evidence	B-X
suggests	B-X
that	B-X
regulation	B-X
of	B-X
p53	B-X
subcellular	B-X
localization	B-X
contributes	B-X
to	B-X
the	B-X
biological	B-X
outcome	B-X
of	B-X
the	B-X
p53	B-X
response	B-X
.	B-X
Cytoplasmic	B-X
p53	B-X
is	B-X
shown	B-X
to	B-X
promote	B-X
apoptosis	B-X
and	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
ultimate	B-X
buster	B-X
1	B-X
(	B-X
NUB1	B-X
)	B-X
,	B-X
a	B-X
non-covalent	B-X
interactor	B-X
of	B-X
the	B-X
Ubl	B-X
NEDD8	B-X
(	B-X
neural	B-X
precursor	B-X
cell	B-X
expressed	B-X
,	B-X
developmentally	B-X
downregulated	B-X
8	B-X
)	B-X
,	B-X
controls	B-X
the	B-X
localization	B-X
of	B-X
p53	B-X
.	B-X
Expression	B-X
of	B-X
NUB1	B-X
leads	B-X
to	B-X
decreased	B-X
modification	B-X
of	B-X
p53	B-X
with	B-X
NEDD8	B-X
and	B-X
stimulation	B-X
of	B-X
p53	B-X
ubiquitination	B-X
.	B-X
The	B-X
biological	B-X
outcome	B-X
is	B-X
the	B-X
cytoplasmic	B-X
localization	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
p53	B-X
.	B-X
Although	B-X
the	B-X
effects	B-X
of	B-X
NUB1	B-X
on	B-X
p53	B-X
depend	B-X
on	B-X
NEDDylation	B-X
and	B-X
the	B-X
murine	B-X
double	B-X
minute	B-X
2	B-X
(	B-X
Mdm2	B-X
)	B-X
E3-ligase	B-X
,	B-X
the	B-X
cooperation	B-X
of	B-X
NEDD8	B-X
with	B-X
ubiquitin	B-X
is	B-X
required	B-X
.	B-X
The	B-X
data	B-X
identify	B-X
a	B-X
role	B-X
for	B-X
NEDD8	B-X
in	B-X
controlling	B-X
p53	B-X
localization	B-X
and	B-X
suggest	B-X
that	B-X
NEDD8	B-X
can	B-X
control	B-X
protein	B-X
function	B-X
through	B-X
its	B-X
non-covalent	B-X
recognition	B-X
by	B-X
interacting	B-X
proteins	B-X
.	B-X

Small	O
-	O
molecule	O
inhibition	O
of	O
APT1	B-Protein
affects	O
Ras	O
localization	O
and	O
signaling	O
.	O
<EOS>	B-X
Cycles	B-X
of	B-X
depalmitoylation	B-X
and	B-X
repalmitoylation	B-X
critically	B-X
control	B-X
the	B-X
steady-state	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
various	B-X
peripheral	B-X
membrane	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
Ras	B-X
proto-oncogene	B-X
products	B-X
.	B-X
Interference	B-X
with	B-X
acylation	B-X
using	B-X
small	B-X
molecules	B-X
is	B-X
a	B-X
strategy	B-X
to	B-X
modulate	B-X
cellular	B-X
localization	B-X
--	B-X
and	B-X
thereby	B-X
unregulated	B-X
signaling	B-X
--	B-X
caused	B-X
by	B-X
palmitoylated	B-X
Ras	B-X
proteins	B-X
.	B-X
We	B-X
present	B-X
the	B-X
knowledge-based	B-X
development	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
acyl	B-X
protein	B-X
thioesterase	B-X
1	B-X
(	B-X
APT1	B-X
)	B-X
,	B-X
a	B-X
bona	B-X
fide	B-X
depalmitoylating	B-X
enzyme	B-X
that	B-X
is	B-X
,	B-X
so	B-X
far	B-X
,	B-X
poorly	B-X
characterized	B-X
in	B-X
cells	B-X
.	B-X
The	B-X
inhibitor	B-X
,	B-X
palmostatin	B-X
B	B-X
,	B-X
perturbs	B-X
the	B-X
cellular	B-X
acylation	B-X
cycle	B-X
at	B-X
the	B-X
level	B-X
of	B-X
depalmitoylation	B-X
and	B-X
thereby	B-X
causes	B-X
a	B-X
loss	B-X
of	B-X
the	B-X
precise	B-X
steady-state	B-X
localization	B-X
of	B-X
palmitoylated	B-X
Ras	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
,	B-X
palmostatin	B-X
B	B-X
induces	B-X
partial	B-X
phenotypic	B-X
reversion	B-X
in	B-X
oncogenic	B-X
HRasG12V-transformed	B-X
fibroblasts	B-X
.	B-X
We	B-X
identify	B-X
APT1	B-X
as	B-X
one	B-X
of	B-X
the	B-X
thioesterases	B-X
in	B-X
the	B-X
acylation	B-X
cycle	B-X
and	B-X
show	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
a	B-X
cellular	B-X
target	B-X
of	B-X
the	B-X
inhibitor	B-X
.	B-X

Cycles	O
of	O
depalmitoylation	O
and	O
repalmitoylation	O
critically	O
control	O
the	O
steady	O
-	O
state	O
localization	O
and	O
function	O
of	O
various	O
peripheral	O
membrane	O
proteins	O
,	O
such	O
as	O
Ras	O
proto	O
-	O
oncogene	O
products	O
.	O
<EOS>	B-X
Cycles	B-X
of	B-X
depalmitoylation	B-X
and	B-X
repalmitoylation	B-X
critically	B-X
control	B-X
the	B-X
steady-state	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
various	B-X
peripheral	B-X
membrane	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
Ras	B-X
proto-oncogene	B-X
products	B-X
.	B-X
Interference	B-X
with	B-X
acylation	B-X
using	B-X
small	B-X
molecules	B-X
is	B-X
a	B-X
strategy	B-X
to	B-X
modulate	B-X
cellular	B-X
localization	B-X
--	B-X
and	B-X
thereby	B-X
unregulated	B-X
signaling	B-X
--	B-X
caused	B-X
by	B-X
palmitoylated	B-X
Ras	B-X
proteins	B-X
.	B-X
The	B-X
inhibitor	B-X
,	B-X
palmostatin	B-X
B	B-X
,	B-X
perturbs	B-X
the	B-X
cellular	B-X
acylation	B-X
cycle	B-X
at	B-X
the	B-X
level	B-X
of	B-X
depalmitoylation	B-X
and	B-X
thereby	B-X
causes	B-X
a	B-X
loss	B-X
of	B-X
the	B-X
precise	B-X
steady-state	B-X
localization	B-X
of	B-X
palmitoylated	B-X
Ras	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
,	B-X
palmostatin	B-X
B	B-X
induces	B-X
partial	B-X
phenotypic	B-X
reversion	B-X
in	B-X
oncogenic	B-X
HRasG12V-transformed	B-X
fibroblasts	B-X
.	B-X

Interference	O
with	O
acylation	O
using	O
small	O
molecules	O
is	O
a	O
strategy	O
to	O
modulate	O
cellular	O
localization	O
-	O
-	O
and	O
thereby	O
unregulated	O
signaling	O
-	O
-	O
caused	O
by	O
palmitoylated	O
Ras	O
proteins	O
.	O
<EOS>	B-X
Cycles	B-X
of	B-X
depalmitoylation	B-X
and	B-X
repalmitoylation	B-X
critically	B-X
control	B-X
the	B-X
steady-state	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
various	B-X
peripheral	B-X
membrane	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
Ras	B-X
proto-oncogene	B-X
products	B-X
.	B-X
Interference	B-X
with	B-X
acylation	B-X
using	B-X
small	B-X
molecules	B-X
is	B-X
a	B-X
strategy	B-X
to	B-X
modulate	B-X
cellular	B-X
localization	B-X
--	B-X
and	B-X
thereby	B-X
unregulated	B-X
signaling	B-X
--	B-X
caused	B-X
by	B-X
palmitoylated	B-X
Ras	B-X
proteins	B-X
.	B-X
The	B-X
inhibitor	B-X
,	B-X
palmostatin	B-X
B	B-X
,	B-X
perturbs	B-X
the	B-X
cellular	B-X
acylation	B-X
cycle	B-X
at	B-X
the	B-X
level	B-X
of	B-X
depalmitoylation	B-X
and	B-X
thereby	B-X
causes	B-X
a	B-X
loss	B-X
of	B-X
the	B-X
precise	B-X
steady-state	B-X
localization	B-X
of	B-X
palmitoylated	B-X
Ras	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
,	B-X
palmostatin	B-X
B	B-X
induces	B-X
partial	B-X
phenotypic	B-X
reversion	B-X
in	B-X
oncogenic	B-X
HRasG12V-transformed	B-X
fibroblasts	B-X
.	B-X
We	B-X
identify	B-X
APT1	B-X
as	B-X
one	B-X
of	B-X
the	B-X
thioesterases	B-X
in	B-X
the	B-X
acylation	B-X
cycle	B-X
and	B-X
show	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
a	B-X
cellular	B-X
target	B-X
of	B-X
the	B-X
inhibitor	B-X
.	B-X

We	O
present	O
the	O
knowledge	O
-	O
based	O
development	O
and	O
characterization	O
of	O
a	O
potent	O
inhibitor	O
of	O
acyl	B-Protein
protein	I-Protein
thioesterase	I-Protein
1	I-Protein
(	O
APT1	B-Protein
)	O
,	O
a	O
bona	O
fide	O
depalmitoylating	O
enzyme	O
that	O
is	O
,	O
so	O
far	O
,	O
poorly	O
characterized	O
in	O
cells	O
.	O
<EOS>	B-X
Cycles	B-X
of	B-X
depalmitoylation	B-X
and	B-X
repalmitoylation	B-X
critically	B-X
control	B-X
the	B-X
steady-state	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
various	B-X
peripheral	B-X
membrane	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
Ras	B-X
proto-oncogene	B-X
products	B-X
.	B-X
Interference	B-X
with	B-X
acylation	B-X
using	B-X
small	B-X
molecules	B-X
is	B-X
a	B-X
strategy	B-X
to	B-X
modulate	B-X
cellular	B-X
localization	B-X
--	B-X
and	B-X
thereby	B-X
unregulated	B-X
signaling	B-X
--	B-X
caused	B-X
by	B-X
palmitoylated	B-X
Ras	B-X
proteins	B-X
.	B-X
We	B-X
present	B-X
the	B-X
knowledge-based	B-X
development	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
acyl	B-X
protein	B-X
thioesterase	B-X
1	B-X
(	B-X
APT1	B-X
)	B-X
,	B-X
a	B-X
bona	B-X
fide	B-X
depalmitoylating	B-X
enzyme	B-X
that	B-X
is	B-X
,	B-X
so	B-X
far	B-X
,	B-X
poorly	B-X
characterized	B-X
in	B-X
cells	B-X
.	B-X
The	B-X
inhibitor	B-X
,	B-X
palmostatin	B-X
B	B-X
,	B-X
perturbs	B-X
the	B-X
cellular	B-X
acylation	B-X
cycle	B-X
at	B-X
the	B-X
level	B-X
of	B-X
depalmitoylation	B-X
and	B-X
thereby	B-X
causes	B-X
a	B-X
loss	B-X
of	B-X
the	B-X
precise	B-X
steady-state	B-X
localization	B-X
of	B-X
palmitoylated	B-X
Ras	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
,	B-X
palmostatin	B-X
B	B-X
induces	B-X
partial	B-X
phenotypic	B-X
reversion	B-X
in	B-X
oncogenic	B-X
HRasG12V-transformed	B-X
fibroblasts	B-X
.	B-X
We	B-X
identify	B-X
APT1	B-X
as	B-X
one	B-X
of	B-X
the	B-X
thioesterases	B-X
in	B-X
the	B-X
acylation	B-X
cycle	B-X
and	B-X
show	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
a	B-X
cellular	B-X
target	B-X
of	B-X
the	B-X
inhibitor	B-X
.	B-X

The	O
inhibitor	O
,	O
palmostatin	O
B	O
,	O
perturbs	O
the	O
cellular	O
acylation	O
cycle	O
at	O
the	O
level	O
of	O
depalmitoylation	O
and	O
thereby	O
causes	O
a	O
loss	O
of	O
the	O
precise	O
steady	O
-	O
state	O
localization	O
of	O
palmitoylated	O
Ras	O
.	O
<EOS>	B-X
Cycles	B-X
of	B-X
depalmitoylation	B-X
and	B-X
repalmitoylation	B-X
critically	B-X
control	B-X
the	B-X
steady-state	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
various	B-X
peripheral	B-X
membrane	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
Ras	B-X
proto-oncogene	B-X
products	B-X
.	B-X
Interference	B-X
with	B-X
acylation	B-X
using	B-X
small	B-X
molecules	B-X
is	B-X
a	B-X
strategy	B-X
to	B-X
modulate	B-X
cellular	B-X
localization	B-X
--	B-X
and	B-X
thereby	B-X
unregulated	B-X
signaling	B-X
--	B-X
caused	B-X
by	B-X
palmitoylated	B-X
Ras	B-X
proteins	B-X
.	B-X
We	B-X
present	B-X
the	B-X
knowledge-based	B-X
development	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
acyl	B-X
protein	B-X
thioesterase	B-X
1	B-X
(	B-X
APT1	B-X
)	B-X
,	B-X
a	B-X
bona	B-X
fide	B-X
depalmitoylating	B-X
enzyme	B-X
that	B-X
is	B-X
,	B-X
so	B-X
far	B-X
,	B-X
poorly	B-X
characterized	B-X
in	B-X
cells	B-X
.	B-X
The	B-X
inhibitor	B-X
,	B-X
palmostatin	B-X
B	B-X
,	B-X
perturbs	B-X
the	B-X
cellular	B-X
acylation	B-X
cycle	B-X
at	B-X
the	B-X
level	B-X
of	B-X
depalmitoylation	B-X
and	B-X
thereby	B-X
causes	B-X
a	B-X
loss	B-X
of	B-X
the	B-X
precise	B-X
steady-state	B-X
localization	B-X
of	B-X
palmitoylated	B-X
Ras	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
,	B-X
palmostatin	B-X
B	B-X
induces	B-X
partial	B-X
phenotypic	B-X
reversion	B-X
in	B-X
oncogenic	B-X
HRasG12V-transformed	B-X
fibroblasts	B-X
.	B-X
We	B-X
identify	B-X
APT1	B-X
as	B-X
one	B-X
of	B-X
the	B-X
thioesterases	B-X
in	B-X
the	B-X
acylation	B-X
cycle	B-X
and	B-X
show	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
a	B-X
cellular	B-X
target	B-X
of	B-X
the	B-X
inhibitor	B-X
.	B-X

As	O
a	O
consequence	O
,	O
palmostatin	O
B	O
induces	O
partial	O
phenotypic	O
reversion	O
in	O
oncogenic	O
HRasG12V	B-Protein
-	O
transformed	O
fibroblasts	O
.	O
<EOS>	B-X
The	B-X
inhibitor	B-X
,	B-X
palmostatin	B-X
B	B-X
,	B-X
perturbs	B-X
the	B-X
cellular	B-X
acylation	B-X
cycle	B-X
at	B-X
the	B-X
level	B-X
of	B-X
depalmitoylation	B-X
and	B-X
thereby	B-X
causes	B-X
a	B-X
loss	B-X
of	B-X
the	B-X
precise	B-X
steady-state	B-X
localization	B-X
of	B-X
palmitoylated	B-X
Ras	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
,	B-X
palmostatin	B-X
B	B-X
induces	B-X
partial	B-X
phenotypic	B-X
reversion	B-X
in	B-X
oncogenic	B-X
HRasG12V-transformed	B-X
fibroblasts	B-X
.	B-X

We	O
identify	O
APT1	B-Protein
as	O
one	O
of	O
the	O
thioesterases	O
in	O
the	O
acylation	O
cycle	O
and	O
show	O
that	O
this	O
protein	O
is	O
a	O
cellular	O
target	O
of	O
the	O
inhibitor	O
.	O
<EOS>	B-X
Cycles	B-X
of	B-X
depalmitoylation	B-X
and	B-X
repalmitoylation	B-X
critically	B-X
control	B-X
the	B-X
steady-state	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
various	B-X
peripheral	B-X
membrane	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
Ras	B-X
proto-oncogene	B-X
products	B-X
.	B-X
Interference	B-X
with	B-X
acylation	B-X
using	B-X
small	B-X
molecules	B-X
is	B-X
a	B-X
strategy	B-X
to	B-X
modulate	B-X
cellular	B-X
localization	B-X
--	B-X
and	B-X
thereby	B-X
unregulated	B-X
signaling	B-X
--	B-X
caused	B-X
by	B-X
palmitoylated	B-X
Ras	B-X
proteins	B-X
.	B-X
We	B-X
present	B-X
the	B-X
knowledge-based	B-X
development	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
acyl	B-X
protein	B-X
thioesterase	B-X
1	B-X
(	B-X
APT1	B-X
)	B-X
,	B-X
a	B-X
bona	B-X
fide	B-X
depalmitoylating	B-X
enzyme	B-X
that	B-X
is	B-X
,	B-X
so	B-X
far	B-X
,	B-X
poorly	B-X
characterized	B-X
in	B-X
cells	B-X
.	B-X
The	B-X
inhibitor	B-X
,	B-X
palmostatin	B-X
B	B-X
,	B-X
perturbs	B-X
the	B-X
cellular	B-X
acylation	B-X
cycle	B-X
at	B-X
the	B-X
level	B-X
of	B-X
depalmitoylation	B-X
and	B-X
thereby	B-X
causes	B-X
a	B-X
loss	B-X
of	B-X
the	B-X
precise	B-X
steady-state	B-X
localization	B-X
of	B-X
palmitoylated	B-X
Ras	B-X
.	B-X
We	B-X
identify	B-X
APT1	B-X
as	B-X
one	B-X
of	B-X
the	B-X
thioesterases	B-X
in	B-X
the	B-X
acylation	B-X
cycle	B-X
and	B-X
show	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
a	B-X
cellular	B-X
target	B-X
of	B-X
the	B-X
inhibitor	B-X
.	B-X

Ohr	O
(	O
organic	O
hydroperoxide	O
resistance	O
protein	O
)	O
possesses	O
a	O
previously	O
undescribed	O
activity	O
,	O
lipoyl	O
-	O
dependent	O
peroxidase	O
.	O
<EOS>	B-X
The	B-X
Ohr	B-X
(	B-X
organic	B-X
hydroperoxide	B-X
resistance	B-X
)	B-X
family	B-X
of	B-X
15-kDa	B-X
Cys-based	B-X
,	B-X
thiol-dependent	B-X
peroxidases	B-X
is	B-X
central	B-X
to	B-X
the	B-X
bacterial	B-X
response	B-X
to	B-X
stress	B-X
induced	B-X
by	B-X
organic	B-X
hydroperoxides	B-X
but	B-X
not	B-X
by	B-X
hydrogen	B-X
peroxide	B-X
.	B-X
Ohr	B-X
has	B-X
a	B-X
unique	B-X
three-dimensional	B-X
structure	B-X
and	B-X
requires	B-X
dithiols	B-X
,	B-X
but	B-X
not	B-X
monothiols	B-X
,	B-X
to	B-X
support	B-X
its	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
physiological	B-X
reducing	B-X
system	B-X
of	B-X
Ohr	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
identified	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
lipoylated	B-X
enzymes	B-X
present	B-X
in	B-X
the	B-X
bacterial	B-X
extracts	B-X
of	B-X
Xylella	B-X
fastidiosa	B-X
interacted	B-X
physically	B-X
and	B-X
functionally	B-X
with	B-X
this	B-X
Cys-based	B-X
peroxidase	B-X
,	B-X
whereas	B-X
thioredoxin	B-X
and	B-X
glutathione	B-X
systems	B-X
failed	B-X
to	B-X
support	B-X
Ohr	B-X
peroxidase	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
could	B-X
reconstitute	B-X
in	B-X
vitro	B-X
three	B-X
lipoyl-dependent	B-X
systems	B-X
as	B-X
the	B-X
Ohr	B-X
physiological	B-X
reducing	B-X
systems	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
that	B-X
OsmC	B-X
from	B-X
Escherichia	B-X
coli	B-X
,	B-X
an	B-X
orthologue	B-X
of	B-X
Ohr	B-X
from	B-X
Xylella	B-X
fastidiosa	B-X
,	B-X
is	B-X
specifically	B-X
reduced	B-X
by	B-X
lipoyl-dependent	B-X
systems	B-X
.	B-X
These	B-X
results	B-X
represent	B-X
the	B-X
first	B-X
description	B-X
of	B-X
a	B-X
Cys-based	B-X
peroxidase	B-X
that	B-X
is	B-X
directly	B-X
reduced	B-X
by	B-X
lipoylated	B-X
enzymes	B-X
.	B-X

The	O
Ohr	O
(	O
organic	O
hydroperoxide	O
resistance	O
)	O
family	O
of	O
15	O
-	O
kDa	O
Cys	O
-	O
based	O
,	O
thiol	O
-	O
dependent	O
peroxidases	O
is	O
central	O
to	O
the	O
bacterial	O
response	O
to	O
stress	O
induced	O
by	O
organic	O
hydroperoxides	O
but	O
not	O
by	O
hydrogen	O
peroxide	O
.	O

Ohr	O
has	O
a	O
unique	O
three	O
-	O
dimensional	O
structure	O
and	O
requires	O
dithiols	O
,	O
but	O
not	O
monothiols	O
,	O
to	O
support	O
its	O
activity	O
.	O

However	O
,	O
the	O
physiological	O
reducing	O
system	O
of	O
Ohr	O
has	O
not	O
yet	O
been	O
identified	O
.	O
<EOS>	B-X
Ohrs	B-X
(	B-X
organic	B-X
hydroperoxide	B-X
resistance	B-X
proteins	B-X
)	B-X
are	B-X
antioxidant	B-X
enzymes	B-X
that	B-X
play	B-X
central	B-X
roles	B-X
in	B-X
the	B-X
response	B-X
of	B-X
microorganisms	B-X
to	B-X
organic	B-X
peroxides	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
structure	B-X
,	B-X
catalysis	B-X
,	B-X
phylogeny	B-X
,	B-X
regulation	B-X
,	B-X
and	B-X
physiological	B-X
roles	B-X
of	B-X
Ohr	B-X
proteins	B-X
and	B-X
of	B-X
its	B-X
transcriptional	B-X
regulator	B-X
,	B-X
OhrR	B-X
,	B-X
highlighting	B-X
their	B-X
unique	B-X
features	B-X
.	B-X
Ohr	B-X
is	B-X
extremely	B-X
efficient	B-X
in	B-X
reducing	B-X
fatty	B-X
acid	B-X
peroxides	B-X
and	B-X
peroxynitrite	B-X
,	B-X
two	B-X
oxidants	B-X
relevant	B-X
in	B-X
host-pathogen	B-X
interactions	B-X
.	B-X
The	B-X
highly	B-X
reactive	B-X
Cys	B-X
residue	B-X
of	B-X
Ohr	B-X
,	B-X
named	B-X
peroxidatic	B-X
Cys	B-X
(	B-X
C	B-X

Here	O
we	O
show	O
that	O
lipoylated	O
enzymes	O
present	O
in	O
the	O
bacterial	O
extracts	O
of	O
Xylella	O
fastidiosa	O
interacted	O
physically	O
and	O
functionally	O
with	O
this	O
Cys	O
-	O
based	O
peroxidase	O
,	O
whereas	O
thioredoxin	O
and	O
glutathione	O
systems	O
failed	O
to	O
support	O
Ohr	O
peroxidase	O
activity	O
.	O
<EOS>	B-X
The	B-X
Ohr	B-X
(	B-X
organic	B-X
hydroperoxide	B-X
resistance	B-X
)	B-X
family	B-X
of	B-X
15-kDa	B-X
Cys-based	B-X
,	B-X
thiol-dependent	B-X
peroxidases	B-X
is	B-X
central	B-X
to	B-X
the	B-X
bacterial	B-X
response	B-X
to	B-X
stress	B-X
induced	B-X
by	B-X
organic	B-X
hydroperoxides	B-X
but	B-X
not	B-X
by	B-X
hydrogen	B-X
peroxide	B-X
.	B-X
Ohr	B-X
has	B-X
a	B-X
unique	B-X
three-dimensional	B-X
structure	B-X
and	B-X
requires	B-X
dithiols	B-X
,	B-X
but	B-X
not	B-X
monothiols	B-X
,	B-X
to	B-X
support	B-X
its	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
physiological	B-X
reducing	B-X
system	B-X
of	B-X
Ohr	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
identified	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
lipoylated	B-X
enzymes	B-X
present	B-X
in	B-X
the	B-X
bacterial	B-X
extracts	B-X
of	B-X
Xylella	B-X
fastidiosa	B-X
interacted	B-X
physically	B-X
and	B-X
functionally	B-X
with	B-X
this	B-X
Cys-based	B-X
peroxidase	B-X
,	B-X
whereas	B-X
thioredoxin	B-X
and	B-X
glutathione	B-X
systems	B-X
failed	B-X
to	B-X
support	B-X
Ohr	B-X
peroxidase	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
could	B-X
reconstitute	B-X
in	B-X
vitro	B-X
three	B-X
lipoyl-dependent	B-X
systems	B-X
as	B-X
the	B-X
Ohr	B-X
physiological	B-X
reducing	B-X
systems	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
that	B-X
OsmC	B-X
from	B-X
Escherichia	B-X
coli	B-X
,	B-X
an	B-X
orthologue	B-X
of	B-X
Ohr	B-X
from	B-X
Xylella	B-X
fastidiosa	B-X
,	B-X
is	B-X
specifically	B-X
reduced	B-X
by	B-X
lipoyl-dependent	B-X
systems	B-X
.	B-X
These	B-X
results	B-X
represent	B-X
the	B-X
first	B-X
description	B-X
of	B-X
a	B-X
Cys-based	B-X
peroxidase	B-X
that	B-X
is	B-X
directly	B-X
reduced	B-X
by	B-X
lipoylated	B-X
enzymes	B-X
.	B-X

Furthermore	O
,	O
we	O
could	O
reconstitute	O
in	O
vitro	O
three	O
lipoyl	O
-	O
dependent	O
systems	O
as	O
the	O
Ohr	O
physiological	O
reducing	O
systems	O
.	O
<EOS>	B-X
The	B-X
Ohr	B-X
(	B-X
organic	B-X
hydroperoxide	B-X
resistance	B-X
)	B-X
family	B-X
of	B-X
15-kDa	B-X
Cys-based	B-X
,	B-X
thiol-dependent	B-X
peroxidases	B-X
is	B-X
central	B-X
to	B-X
the	B-X
bacterial	B-X
response	B-X
to	B-X
stress	B-X
induced	B-X
by	B-X
organic	B-X
hydroperoxides	B-X
but	B-X
not	B-X
by	B-X
hydrogen	B-X
peroxide	B-X
.	B-X
Ohr	B-X
has	B-X
a	B-X
unique	B-X
three-dimensional	B-X
structure	B-X
and	B-X
requires	B-X
dithiols	B-X
,	B-X
but	B-X
not	B-X
monothiols	B-X
,	B-X
to	B-X
support	B-X
its	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
physiological	B-X
reducing	B-X
system	B-X
of	B-X
Ohr	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
identified	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
lipoylated	B-X
enzymes	B-X
present	B-X
in	B-X
the	B-X
bacterial	B-X
extracts	B-X
of	B-X
Xylella	B-X
fastidiosa	B-X
interacted	B-X
physically	B-X
and	B-X
functionally	B-X
with	B-X
this	B-X
Cys-based	B-X
peroxidase	B-X
,	B-X
whereas	B-X
thioredoxin	B-X
and	B-X
glutathione	B-X
systems	B-X
failed	B-X
to	B-X
support	B-X
Ohr	B-X
peroxidase	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
could	B-X
reconstitute	B-X
in	B-X
vitro	B-X
three	B-X
lipoyl-dependent	B-X
systems	B-X
as	B-X
the	B-X
Ohr	B-X
physiological	B-X
reducing	B-X
systems	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
that	B-X
OsmC	B-X
from	B-X
Escherichia	B-X
coli	B-X
,	B-X
an	B-X
orthologue	B-X
of	B-X
Ohr	B-X
from	B-X
Xylella	B-X
fastidiosa	B-X
,	B-X
is	B-X
specifically	B-X
reduced	B-X
by	B-X
lipoyl-dependent	B-X
systems	B-X
.	B-X
These	B-X
results	B-X
represent	B-X
the	B-X
first	B-X
description	B-X
of	B-X
a	B-X
Cys-based	B-X
peroxidase	B-X
that	B-X
is	B-X
directly	B-X
reduced	B-X
by	B-X
lipoylated	B-X
enzymes	B-X
.	B-X

We	O
also	O
showed	O
that	O
OsmC	B-Protein
from	O
Escherichia	O
coli	O
,	O
an	O
orthologue	O
of	O
Ohr	O
from	O
Xylella	O
fastidiosa	O
,	O
is	O
specifically	O
reduced	O
by	O
lipoyl	O
-	O
dependent	O
systems	O
.	O
<EOS>	B-X
The	B-X
Ohr	B-X
(	B-X
organic	B-X
hydroperoxide	B-X
resistance	B-X
)	B-X
family	B-X
of	B-X
15-kDa	B-X
Cys-based	B-X
,	B-X
thiol-dependent	B-X
peroxidases	B-X
is	B-X
central	B-X
to	B-X
the	B-X
bacterial	B-X
response	B-X
to	B-X
stress	B-X
induced	B-X
by	B-X
organic	B-X
hydroperoxides	B-X
but	B-X
not	B-X
by	B-X
hydrogen	B-X
peroxide	B-X
.	B-X
Ohr	B-X
has	B-X
a	B-X
unique	B-X
three-dimensional	B-X
structure	B-X
and	B-X
requires	B-X
dithiols	B-X
,	B-X
but	B-X
not	B-X
monothiols	B-X
,	B-X
to	B-X
support	B-X
its	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
physiological	B-X
reducing	B-X
system	B-X
of	B-X
Ohr	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
identified	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
lipoylated	B-X
enzymes	B-X
present	B-X
in	B-X
the	B-X
bacterial	B-X
extracts	B-X
of	B-X
Xylella	B-X
fastidiosa	B-X
interacted	B-X
physically	B-X
and	B-X
functionally	B-X
with	B-X
this	B-X
Cys-based	B-X
peroxidase	B-X
,	B-X
whereas	B-X
thioredoxin	B-X
and	B-X
glutathione	B-X
systems	B-X
failed	B-X
to	B-X
support	B-X
Ohr	B-X
peroxidase	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
could	B-X
reconstitute	B-X
in	B-X
vitro	B-X
three	B-X
lipoyl-dependent	B-X
systems	B-X
as	B-X
the	B-X
Ohr	B-X
physiological	B-X
reducing	B-X
systems	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
that	B-X
OsmC	B-X
from	B-X
Escherichia	B-X
coli	B-X
,	B-X
an	B-X
orthologue	B-X
of	B-X
Ohr	B-X
from	B-X
Xylella	B-X
fastidiosa	B-X
,	B-X
is	B-X
specifically	B-X
reduced	B-X
by	B-X
lipoyl-dependent	B-X
systems	B-X
.	B-X
These	B-X
results	B-X
represent	B-X
the	B-X
first	B-X
description	B-X
of	B-X
a	B-X
Cys-based	B-X
peroxidase	B-X
that	B-X
is	B-X
directly	B-X
reduced	B-X
by	B-X
lipoylated	B-X
enzymes	B-X
.	B-X

These	O
results	O
represent	O
the	O
first	O
description	O
of	O
a	O
Cys	O
-	O
based	O
peroxidase	O
that	O
is	O
directly	O
reduced	O
by	O
lipoylated	O
enzymes	O
.	O
<EOS>	B-X
The	B-X
Ohr	B-X
(	B-X
organic	B-X
hydroperoxide	B-X
resistance	B-X
)	B-X
family	B-X
of	B-X
15-kDa	B-X
Cys-based	B-X
,	B-X
thiol-dependent	B-X
peroxidases	B-X
is	B-X
central	B-X
to	B-X
the	B-X
bacterial	B-X
response	B-X
to	B-X
stress	B-X
induced	B-X
by	B-X
organic	B-X
hydroperoxides	B-X
but	B-X
not	B-X
by	B-X
hydrogen	B-X
peroxide	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
lipoylated	B-X
enzymes	B-X
present	B-X
in	B-X
the	B-X
bacterial	B-X
extracts	B-X
of	B-X
Xylella	B-X
fastidiosa	B-X
interacted	B-X
physically	B-X
and	B-X
functionally	B-X
with	B-X
this	B-X
Cys-based	B-X
peroxidase	B-X
,	B-X
whereas	B-X
thioredoxin	B-X
and	B-X
glutathione	B-X
systems	B-X
failed	B-X
to	B-X
support	B-X
Ohr	B-X
peroxidase	B-X
activity	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
that	B-X
OsmC	B-X
from	B-X
Escherichia	B-X
coli	B-X
,	B-X
an	B-X
orthologue	B-X
of	B-X
Ohr	B-X
from	B-X
Xylella	B-X
fastidiosa	B-X
,	B-X
is	B-X
specifically	B-X
reduced	B-X
by	B-X
lipoyl-dependent	B-X
systems	B-X
.	B-X
These	B-X
results	B-X
represent	B-X
the	B-X
first	B-X
description	B-X
of	B-X
a	B-X
Cys-based	B-X
peroxidase	B-X
that	B-X
is	B-X
directly	B-X
reduced	B-X
by	B-X
lipoylated	B-X
enzymes	B-X
.	B-X

One	O
SUMO	O
is	O
sufficient	O
to	O
silence	O
the	O
dimeric	O
potassium	O
channel	O
K2P1	B-Protein
.	O
<EOS>	B-X
Small	B-X
ubiquitin	B-X
modifier	B-X
1	B-X
(	B-X
SUMO1	B-X
)	B-X
is	B-X
shown	B-X
to	B-X
regulate	B-X
K2P1	B-X
background	B-X
channels	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
of	B-X
live	B-X
mammalian	B-X
cells	B-X
.	B-X
Confocal	B-X
microscopy	B-X
reveals	B-X
native	B-X
SUMO1	B-X
,	B-X
SAE1	B-X
,	B-X
and	B-X
Ubc9	B-X
(	B-X
the	B-X
enzymes	B-X
that	B-X
activate	B-X
and	B-X
conjugate	B-X
SUMO1	B-X
)	B-X
at	B-X
PM	B-X
where	B-X
SUMO1	B-X
and	B-X
expressed	B-X
human	B-X
K2P1	B-X
are	B-X
demonstrated	B-X
to	B-X
colocalize	B-X
.	B-X
Silent	B-X
K2P1	B-X
channels	B-X
in	B-X
excised	B-X
PM	B-X
patches	B-X
are	B-X
activated	B-X
by	B-X
SUMO	B-X
isopeptidase	B-X
(	B-X
SENP1	B-X
)	B-X
and	B-X
resilenced	B-X
by	B-X
SUMO1	B-X
.	B-X
K2P1-Lys274	B-X
is	B-X
crucial	B-X
:	B-X
when	B-X
mutated	B-X
to	B-X
Gln	B-X
,	B-X
Arg	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
,	B-X
Cys	B-X
,	B-X
or	B-X
Ala	B-X
,	B-X
the	B-X
channels	B-X
are	B-X
constitutively	B-X
active	B-X
and	B-X
insensitive	B-X
to	B-X
SUMO1	B-X
and	B-X
SENP1	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
confirms	B-X
conjugation	B-X
of	B-X
SUMO1	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
Lys274	B-X
in	B-X
vitro	B-X
.	B-X
FRET	B-X
microscopy	B-X
shows	B-X
that	B-X
assembly	B-X
of	B-X
K2P1	B-X
and	B-X
SUMO1	B-X
requires	B-X
Lys274	B-X
.	B-X
Single-particle	B-X
TIRF	B-X
microscopy	B-X
shows	B-X
that	B-X
wild-type	B-X
channels	B-X
in	B-X
PM	B-X
have	B-X
two	B-X
K2P1	B-X
subunits	B-X
and	B-X
assemble	B-X
with	B-X
two	B-X
SUMO1	B-X
monomers	B-X
.	B-X
Although	B-X
channels	B-X
engineered	B-X
with	B-X
one	B-X
Lys274	B-X
site	B-X
carry	B-X
just	B-X
one	B-X
SUMO1	B-X
they	B-X
are	B-X
activated	B-X
and	B-X
silenced	B-X
by	B-X
SENP1	B-X
and	B-X
SUMO1	B-X
like	B-X
wild-type	B-X
channels	B-X
.	B-X

Small	B-Protein
ubiquitin	I-Protein
modifier	I-Protein
1	I-Protein
(	O
SUMO1	B-Protein
)	O
is	O
shown	O
to	O
regulate	O
K2P1	B-Protein
background	O
channels	O
in	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
of	O
live	O
mammalian	O
cells	O
.	O
<EOS>	B-X
Small	B-X
ubiquitin	B-X
modifier	B-X
1	B-X
(	B-X
SUMO1	B-X
)	B-X
is	B-X
shown	B-X
to	B-X
regulate	B-X
K2P1	B-X
background	B-X
channels	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
of	B-X
live	B-X
mammalian	B-X
cells	B-X
.	B-X
Confocal	B-X
microscopy	B-X
reveals	B-X
native	B-X
SUMO1	B-X
,	B-X
SAE1	B-X
,	B-X
and	B-X
Ubc9	B-X
(	B-X
the	B-X
enzymes	B-X
that	B-X
activate	B-X
and	B-X
conjugate	B-X
SUMO1	B-X
)	B-X
at	B-X
PM	B-X
where	B-X
SUMO1	B-X
and	B-X
expressed	B-X
human	B-X
K2P1	B-X
are	B-X
demonstrated	B-X
to	B-X
colocalize	B-X
.	B-X
Silent	B-X
K2P1	B-X
channels	B-X
in	B-X
excised	B-X
PM	B-X
patches	B-X
are	B-X
activated	B-X
by	B-X
SUMO	B-X
isopeptidase	B-X
(	B-X
SENP1	B-X
)	B-X
and	B-X
resilenced	B-X
by	B-X
SUMO1	B-X
.	B-X
K2P1-Lys274	B-X
is	B-X
crucial	B-X
:	B-X
when	B-X
mutated	B-X
to	B-X
Gln	B-X
,	B-X
Arg	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
,	B-X
Cys	B-X
,	B-X
or	B-X
Ala	B-X
,	B-X
the	B-X
channels	B-X
are	B-X
constitutively	B-X
active	B-X
and	B-X
insensitive	B-X
to	B-X
SUMO1	B-X
and	B-X
SENP1	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
confirms	B-X
conjugation	B-X
of	B-X
SUMO1	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
Lys274	B-X
in	B-X
vitro	B-X
.	B-X
FRET	B-X
microscopy	B-X
shows	B-X
that	B-X
assembly	B-X
of	B-X
K2P1	B-X
and	B-X
SUMO1	B-X
requires	B-X
Lys274	B-X
.	B-X
Single-particle	B-X
TIRF	B-X
microscopy	B-X
shows	B-X
that	B-X
wild-type	B-X
channels	B-X
in	B-X
PM	B-X
have	B-X
two	B-X
K2P1	B-X
subunits	B-X
and	B-X
assemble	B-X
with	B-X
two	B-X
SUMO1	B-X
monomers	B-X
.	B-X
Although	B-X
channels	B-X
engineered	B-X
with	B-X
one	B-X
Lys274	B-X
site	B-X
carry	B-X
just	B-X
one	B-X
SUMO1	B-X
they	B-X
are	B-X
activated	B-X
and	B-X
silenced	B-X
by	B-X
SENP1	B-X
and	B-X
SUMO1	B-X
like	B-X
wild-type	B-X
channels	B-X
.	B-X

Confocal	O
microscopy	O
reveals	O
native	O
SUMO1	B-Protein
,	O
SAE1	B-Protein
,	O
and	O
Ubc9	B-Protein
(	O
the	O
enzymes	O
that	O
activate	O
and	O
conjugate	O
SUMO1	B-Protein
)	O
at	O
PM	O
where	O
SUMO1	B-Protein
and	O
expressed	O
human	O
K2P1	B-Protein
are	O
demonstrated	O
to	O
colocalize	O
.	O
<EOS>	B-X
Small	B-X
ubiquitin	B-X
modifier	B-X
1	B-X
(	B-X
SUMO1	B-X
)	B-X
is	B-X
shown	B-X
to	B-X
regulate	B-X
K2P1	B-X
background	B-X
channels	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
of	B-X
live	B-X
mammalian	B-X
cells	B-X
.	B-X
Confocal	B-X
microscopy	B-X
reveals	B-X
native	B-X
SUMO1	B-X
,	B-X
SAE1	B-X
,	B-X
and	B-X
Ubc9	B-X
(	B-X
the	B-X
enzymes	B-X
that	B-X
activate	B-X
and	B-X
conjugate	B-X
SUMO1	B-X
)	B-X
at	B-X
PM	B-X
where	B-X
SUMO1	B-X
and	B-X
expressed	B-X
human	B-X
K2P1	B-X
are	B-X
demonstrated	B-X
to	B-X
colocalize	B-X
.	B-X
Silent	B-X
K2P1	B-X
channels	B-X
in	B-X
excised	B-X
PM	B-X
patches	B-X
are	B-X
activated	B-X
by	B-X
SUMO	B-X
isopeptidase	B-X
(	B-X
SENP1	B-X
)	B-X
and	B-X
resilenced	B-X
by	B-X
SUMO1	B-X
.	B-X
K2P1-Lys274	B-X
is	B-X
crucial	B-X
:	B-X
when	B-X
mutated	B-X
to	B-X
Gln	B-X
,	B-X
Arg	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
,	B-X
Cys	B-X
,	B-X
or	B-X
Ala	B-X
,	B-X
the	B-X
channels	B-X
are	B-X
constitutively	B-X
active	B-X
and	B-X
insensitive	B-X
to	B-X
SUMO1	B-X
and	B-X
SENP1	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
confirms	B-X
conjugation	B-X
of	B-X
SUMO1	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
Lys274	B-X
in	B-X
vitro	B-X
.	B-X
FRET	B-X
microscopy	B-X
shows	B-X
that	B-X
assembly	B-X
of	B-X
K2P1	B-X
and	B-X
SUMO1	B-X
requires	B-X
Lys274	B-X
.	B-X
Single-particle	B-X
TIRF	B-X
microscopy	B-X
shows	B-X
that	B-X
wild-type	B-X
channels	B-X
in	B-X
PM	B-X
have	B-X
two	B-X
K2P1	B-X
subunits	B-X
and	B-X
assemble	B-X
with	B-X
two	B-X
SUMO1	B-X
monomers	B-X
.	B-X
Although	B-X
channels	B-X
engineered	B-X
with	B-X
one	B-X
Lys274	B-X
site	B-X
carry	B-X
just	B-X
one	B-X
SUMO1	B-X
they	B-X
are	B-X
activated	B-X
and	B-X
silenced	B-X
by	B-X
SENP1	B-X
and	B-X
SUMO1	B-X
like	B-X
wild-type	B-X
channels	B-X
.	B-X

Silent	O
K2P1	B-Protein
channels	O
in	O
excised	O
PM	O
patches	O
are	O
activated	O
by	O
SUMO	O
isopeptidase	O
(	O
SENP1	B-Protein
)	O
and	O
resilenced	O
by	O
SUMO1	B-Protein
.	O
<EOS>	B-X
Small	B-X
ubiquitin	B-X
modifier	B-X
1	B-X
(	B-X
SUMO1	B-X
)	B-X
is	B-X
shown	B-X
to	B-X
regulate	B-X
K2P1	B-X
background	B-X
channels	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
of	B-X
live	B-X
mammalian	B-X
cells	B-X
.	B-X
Confocal	B-X
microscopy	B-X
reveals	B-X
native	B-X
SUMO1	B-X
,	B-X
SAE1	B-X
,	B-X
and	B-X
Ubc9	B-X
(	B-X
the	B-X
enzymes	B-X
that	B-X
activate	B-X
and	B-X
conjugate	B-X
SUMO1	B-X
)	B-X
at	B-X
PM	B-X
where	B-X
SUMO1	B-X
and	B-X
expressed	B-X
human	B-X
K2P1	B-X
are	B-X
demonstrated	B-X
to	B-X
colocalize	B-X
.	B-X
Silent	B-X
K2P1	B-X
channels	B-X
in	B-X
excised	B-X
PM	B-X
patches	B-X
are	B-X
activated	B-X
by	B-X
SUMO	B-X
isopeptidase	B-X
(	B-X
SENP1	B-X
)	B-X
and	B-X
resilenced	B-X
by	B-X
SUMO1	B-X
.	B-X
K2P1-Lys274	B-X
is	B-X
crucial	B-X
:	B-X
when	B-X
mutated	B-X
to	B-X
Gln	B-X
,	B-X
Arg	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
,	B-X
Cys	B-X
,	B-X
or	B-X
Ala	B-X
,	B-X
the	B-X
channels	B-X
are	B-X
constitutively	B-X
active	B-X
and	B-X
insensitive	B-X
to	B-X
SUMO1	B-X
and	B-X
SENP1	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
confirms	B-X
conjugation	B-X
of	B-X
SUMO1	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
Lys274	B-X
in	B-X
vitro	B-X
.	B-X
FRET	B-X
microscopy	B-X
shows	B-X
that	B-X
assembly	B-X
of	B-X
K2P1	B-X
and	B-X
SUMO1	B-X
requires	B-X
Lys274	B-X
.	B-X
Single-particle	B-X
TIRF	B-X
microscopy	B-X
shows	B-X
that	B-X
wild-type	B-X
channels	B-X
in	B-X
PM	B-X
have	B-X
two	B-X
K2P1	B-X
subunits	B-X
and	B-X
assemble	B-X
with	B-X
two	B-X
SUMO1	B-X
monomers	B-X
.	B-X
Although	B-X
channels	B-X
engineered	B-X
with	B-X
one	B-X
Lys274	B-X
site	B-X
carry	B-X
just	B-X
one	B-X
SUMO1	B-X
they	B-X
are	B-X
activated	B-X
and	B-X
silenced	B-X
by	B-X
SENP1	B-X
and	B-X
SUMO1	B-X
like	B-X
wild-type	B-X
channels	B-X
.	B-X

K2P1	B-Protein
-	O
Lys274	O
is	O
crucial	O
:	O
when	O
mutated	O
to	O
Gln	O
,	O
Arg	O
,	O
Glu	O
,	O
Asp	O
,	O
Cys	O
,	O
or	O
Ala	O
,	O
the	O
channels	O
are	O
constitutively	O
active	O
and	O
insensitive	O
to	O
SUMO1	B-Protein
and	O
SENP1	B-Protein
.	O
<EOS>	B-X
Small	B-X
ubiquitin	B-X
modifier	B-X
1	B-X
(	B-X
SUMO1	B-X
)	B-X
is	B-X
shown	B-X
to	B-X
regulate	B-X
K2P1	B-X
background	B-X
channels	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
of	B-X
live	B-X
mammalian	B-X
cells	B-X
.	B-X
Confocal	B-X
microscopy	B-X
reveals	B-X
native	B-X
SUMO1	B-X
,	B-X
SAE1	B-X
,	B-X
and	B-X
Ubc9	B-X
(	B-X
the	B-X
enzymes	B-X
that	B-X
activate	B-X
and	B-X
conjugate	B-X
SUMO1	B-X
)	B-X
at	B-X
PM	B-X
where	B-X
SUMO1	B-X
and	B-X
expressed	B-X
human	B-X
K2P1	B-X
are	B-X
demonstrated	B-X
to	B-X
colocalize	B-X
.	B-X
Silent	B-X
K2P1	B-X
channels	B-X
in	B-X
excised	B-X
PM	B-X
patches	B-X
are	B-X
activated	B-X
by	B-X
SUMO	B-X
isopeptidase	B-X
(	B-X
SENP1	B-X
)	B-X
and	B-X
resilenced	B-X
by	B-X
SUMO1	B-X
.	B-X
K2P1-Lys274	B-X
is	B-X
crucial	B-X
:	B-X
when	B-X
mutated	B-X
to	B-X
Gln	B-X
,	B-X
Arg	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
,	B-X
Cys	B-X
,	B-X
or	B-X
Ala	B-X
,	B-X
the	B-X
channels	B-X
are	B-X
constitutively	B-X
active	B-X
and	B-X
insensitive	B-X
to	B-X
SUMO1	B-X
and	B-X
SENP1	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
confirms	B-X
conjugation	B-X
of	B-X
SUMO1	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
Lys274	B-X
in	B-X
vitro	B-X
.	B-X
FRET	B-X
microscopy	B-X
shows	B-X
that	B-X
assembly	B-X
of	B-X
K2P1	B-X
and	B-X
SUMO1	B-X
requires	B-X
Lys274	B-X
.	B-X
Single-particle	B-X
TIRF	B-X
microscopy	B-X
shows	B-X
that	B-X
wild-type	B-X
channels	B-X
in	B-X
PM	B-X
have	B-X
two	B-X
K2P1	B-X
subunits	B-X
and	B-X
assemble	B-X
with	B-X
two	B-X
SUMO1	B-X
monomers	B-X
.	B-X
Although	B-X
channels	B-X
engineered	B-X
with	B-X
one	B-X
Lys274	B-X
site	B-X
carry	B-X
just	B-X
one	B-X
SUMO1	B-X
they	B-X
are	B-X
activated	B-X
and	B-X
silenced	B-X
by	B-X
SENP1	B-X
and	B-X
SUMO1	B-X
like	B-X
wild-type	B-X
channels	B-X
.	B-X

Tandem	O
mass	O
spectrometry	O
confirms	O
conjugation	O
of	O
SUMO1	B-Protein
to	O
the	O
epsilon	O
-	O
amino	O
group	O
of	O
Lys274	O
in	O
vitro	O
.	O

FRET	O
microscopy	O
shows	O
that	O
assembly	O
of	O
K2P1	B-Protein
and	O
SUMO1	B-Protein
requires	O
Lys274	O
.	O
<EOS>	B-X
Small	B-X
ubiquitin	B-X
modifier	B-X
1	B-X
(	B-X
SUMO1	B-X
)	B-X
is	B-X
shown	B-X
to	B-X
regulate	B-X
K2P1	B-X
background	B-X
channels	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
of	B-X
live	B-X
mammalian	B-X
cells	B-X
.	B-X
Confocal	B-X
microscopy	B-X
reveals	B-X
native	B-X
SUMO1	B-X
,	B-X
SAE1	B-X
,	B-X
and	B-X
Ubc9	B-X
(	B-X
the	B-X
enzymes	B-X
that	B-X
activate	B-X
and	B-X
conjugate	B-X
SUMO1	B-X
)	B-X
at	B-X
PM	B-X
where	B-X
SUMO1	B-X
and	B-X
expressed	B-X
human	B-X
K2P1	B-X
are	B-X
demonstrated	B-X
to	B-X
colocalize	B-X
.	B-X
Silent	B-X
K2P1	B-X
channels	B-X
in	B-X
excised	B-X
PM	B-X
patches	B-X
are	B-X
activated	B-X
by	B-X
SUMO	B-X
isopeptidase	B-X
(	B-X
SENP1	B-X
)	B-X
and	B-X
resilenced	B-X
by	B-X
SUMO1	B-X
.	B-X
K2P1-Lys274	B-X
is	B-X
crucial	B-X
:	B-X
when	B-X
mutated	B-X
to	B-X
Gln	B-X
,	B-X
Arg	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
,	B-X
Cys	B-X
,	B-X
or	B-X
Ala	B-X
,	B-X
the	B-X
channels	B-X
are	B-X
constitutively	B-X
active	B-X
and	B-X
insensitive	B-X
to	B-X
SUMO1	B-X
and	B-X
SENP1	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
confirms	B-X
conjugation	B-X
of	B-X
SUMO1	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
Lys274	B-X
in	B-X
vitro	B-X
.	B-X
FRET	B-X
microscopy	B-X
shows	B-X
that	B-X
assembly	B-X
of	B-X
K2P1	B-X
and	B-X
SUMO1	B-X
requires	B-X
Lys274	B-X
.	B-X
Single-particle	B-X
TIRF	B-X
microscopy	B-X
shows	B-X
that	B-X
wild-type	B-X
channels	B-X
in	B-X
PM	B-X
have	B-X
two	B-X
K2P1	B-X
subunits	B-X
and	B-X
assemble	B-X
with	B-X
two	B-X
SUMO1	B-X
monomers	B-X
.	B-X
Although	B-X
channels	B-X
engineered	B-X
with	B-X
one	B-X
Lys274	B-X
site	B-X
carry	B-X
just	B-X
one	B-X
SUMO1	B-X
they	B-X
are	B-X
activated	B-X
and	B-X
silenced	B-X
by	B-X
SENP1	B-X
and	B-X
SUMO1	B-X
like	B-X
wild-type	B-X
channels	B-X
.	B-X

Single	O
-	O
particle	O
TIRF	O
microscopy	O
shows	O
that	O
wild	O
-	O
type	O
channels	O
in	O
PM	O
have	O
two	O
K2P1	B-Protein
subunits	O
and	O
assemble	O
with	O
two	O
SUMO1	B-Protein
monomers	O
.	O

Although	O
channels	O
engineered	O
with	O
one	O
Lys274	O
site	O
carry	O
just	O
one	O
SUMO1	B-Protein
they	O
are	O
activated	O
and	O
silenced	O
by	O
SENP1	B-Protein
and	O
SUMO1	B-Protein
like	O
wild	O
-	O
type	O
channels	O
.	O
<EOS>	B-X
Small	B-X
ubiquitin	B-X
modifier	B-X
1	B-X
(	B-X
SUMO1	B-X
)	B-X
is	B-X
shown	B-X
to	B-X
regulate	B-X
K2P1	B-X
background	B-X
channels	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
of	B-X
live	B-X
mammalian	B-X
cells	B-X
.	B-X
Confocal	B-X
microscopy	B-X
reveals	B-X
native	B-X
SUMO1	B-X
,	B-X
SAE1	B-X
,	B-X
and	B-X
Ubc9	B-X
(	B-X
the	B-X
enzymes	B-X
that	B-X
activate	B-X
and	B-X
conjugate	B-X
SUMO1	B-X
)	B-X
at	B-X
PM	B-X
where	B-X
SUMO1	B-X
and	B-X
expressed	B-X
human	B-X
K2P1	B-X
are	B-X
demonstrated	B-X
to	B-X
colocalize	B-X
.	B-X
Silent	B-X
K2P1	B-X
channels	B-X
in	B-X
excised	B-X
PM	B-X
patches	B-X
are	B-X
activated	B-X
by	B-X
SUMO	B-X
isopeptidase	B-X
(	B-X
SENP1	B-X
)	B-X
and	B-X
resilenced	B-X
by	B-X
SUMO1	B-X
.	B-X
K2P1-Lys274	B-X
is	B-X
crucial	B-X
:	B-X
when	B-X
mutated	B-X
to	B-X
Gln	B-X
,	B-X
Arg	B-X
,	B-X
Glu	B-X
,	B-X
Asp	B-X
,	B-X
Cys	B-X
,	B-X
or	B-X
Ala	B-X
,	B-X
the	B-X
channels	B-X
are	B-X
constitutively	B-X
active	B-X
and	B-X
insensitive	B-X
to	B-X
SUMO1	B-X
and	B-X
SENP1	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
confirms	B-X
conjugation	B-X
of	B-X
SUMO1	B-X
to	B-X
the	B-X
epsilon-amino	B-X
group	B-X
of	B-X
Lys274	B-X
in	B-X
vitro	B-X
.	B-X
FRET	B-X
microscopy	B-X
shows	B-X
that	B-X
assembly	B-X
of	B-X
K2P1	B-X
and	B-X
SUMO1	B-X
requires	B-X
Lys274	B-X
.	B-X
Single-particle	B-X
TIRF	B-X
microscopy	B-X
shows	B-X
that	B-X
wild-type	B-X
channels	B-X
in	B-X
PM	B-X
have	B-X
two	B-X
K2P1	B-X
subunits	B-X
and	B-X
assemble	B-X
with	B-X
two	B-X
SUMO1	B-X
monomers	B-X
.	B-X
Although	B-X
channels	B-X
engineered	B-X
with	B-X
one	B-X
Lys274	B-X
site	B-X
carry	B-X
just	B-X
one	B-X
SUMO1	B-X
they	B-X
are	B-X
activated	B-X
and	B-X
silenced	B-X
by	B-X
SENP1	B-X
and	B-X
SUMO1	B-X
like	B-X
wild-type	B-X
channels	B-X
.	B-X

Role	O
of	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
of	O
E1	O
in	O
SUMO	O
adenylation	O
.	O
<EOS>	B-X
In	B-X
these	B-X
modifications	B-X
an	B-X
E1	B-X
enzyme	B-X
activates	B-X
each	B-X
ubiquitin-like	B-X
protein	B-X
(	B-X
Ubl	B-X
)	B-X
by	B-X
adenylation	B-X
of	B-X
the	B-X
Ubl	B-X
C-terminal	B-X
COOH	B-X
group	B-X
and	B-X
then	B-X
forms	B-X
a	B-X
thioester	B-X
bond	B-X
with	B-X
the	B-X
adenylated	B-X
C-terminal	B-X
COOH	B-X
group	B-X
of	B-X
the	B-X
Ubl	B-X
.	B-X
Previous	B-X
x-ray	B-X
crystallography	B-X
studies	B-X
revealed	B-X
a	B-X
conserved	B-X
zinc	B-X
motif	B-X
in	B-X
the	B-X
SUMO	B-X
and	B-X
NEDD8	B-X
E1	B-X
;	B-X
however	B-X
,	B-X
the	B-X
function	B-X
of	B-X
this	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
quantitative	B-X
ATP	B-X
:	B-X
PPi	B-X
isotope	B-X
exchange	B-X
assays	B-X
in	B-X
combination	B-X
with	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
conserved	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
in	B-X
the	B-X
SUMO	B-X
E1	B-X
is	B-X
important	B-X
for	B-X
SUMO	B-X
adenylation	B-X
and	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
E1	B-X
pseudo-ordered	B-X
substrate	B-X
binding	B-X
mechanism	B-X
.	B-X
Furthermore	B-X
,	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
mutants	B-X
showed	B-X
significantly	B-X
reduced	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
values	B-X
for	B-X
ATP	B-X
:	B-X
PPi	B-X
isotope	B-X
exchange	B-X
assays	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
important	B-X
in	B-X
binding	B-X
and	B-X
preventing	B-X
SUMO	B-X
adenylate	B-X
from	B-X
dissociating	B-X
from	B-X
E1	B-X
before	B-X
formation	B-X
of	B-X
the	B-X
thioester	B-X
conjugate	B-X
.	B-X
Because	B-X
the	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
located	B-X
in	B-X
a	B-X
cross-over	B-X
loop	B-X
that	B-X
is	B-X
known	B-X
to	B-X
have	B-X
conformational	B-X
flexibility	B-X
,	B-X
the	B-X
results	B-X
described	B-X
here	B-X
suggest	B-X
that	B-X
this	B-X
cross-over	B-X
loop	B-X
interacts	B-X
with	B-X
Ubl	B-X
in	B-X
the	B-X
multistep	B-X
,	B-X
dynamic	B-X
process	B-X
of	B-X
Ubl	B-X
activation	B-X
by	B-X
E1s	B-X
.	B-X

Post	O
-	O
translational	O
modifications	O
by	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
are	O
among	O
the	O
most	O
important	O
mechanisms	O
for	O
regulating	O
a	O
wide	O
variety	O
of	O
cellular	O
functions	O
.	O
<EOS>	B-X
EZH2	B-X
(	B-X
the	B-X
Enhancer	B-X
of	B-X
Zeste	B-X
Homolog	B-X
2	B-X
)	B-X
,	B-X
as	B-X
a	B-X
key	B-X
epigenetic	B-X
regulator	B-X
and	B-X
EMT	B-X
inducer	B-X
,	B-X
participates	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cancer	B-X
metastasis	B-X
.	B-X
EZH2	B-X
stability	B-X
is	B-X
regulated	B-X
by	B-X
several	B-X
types	B-X
of	B-X
post-translational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
.The	B-X
long	B-X
non-coding	B-X
RNAs	B-X
(	B-X
lncRNA	B-X
)	B-X
have	B-X
been	B-X
implicated	B-X
to	B-X
have	B-X
critical	B-X
roles	B-X
in	B-X
multiple	B-X
carcinogenesis	B-X
through	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
mechanisms	B-X
,	B-X
including	B-X
modulating	B-X
the	B-X
stability	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
determined	B-X
that	B-X
ANCR	B-X
potentiated	B-X
the	B-X
CDK1-EZH2	B-X
interaction	B-X
,	B-X
which	B-X
then	B-X
increased	B-X
the	B-X
intensity	B-X
of	B-X
phosphorylation	B-X
at	B-X
Thr-345	B-X
and	B-X
Thr-487	B-X
sites	B-X
of	B-X
EZH2	B-X
,	B-X
facilitating	B-X
EZH2	B-X
ubiquitination	B-X
and	B-X
hence	B-X
its	B-X
degradation	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
also	B-X
uncover	B-X
ANCR	B-X
is	B-X
an	B-X
important	B-X
player	B-X
in	B-X
breast	B-X
cancer	B-X
progression	B-X
and	B-X
metastasis	B-X
mainly	B-X
through	B-X
decreasing	B-X
EZH2	B-X
stability	B-X
.	B-X

In	O
these	O
modifications	O
an	O
E1	O
enzyme	O
activates	O
each	O
ubiquitin	B-Protein
-	O
like	O
protein	O
(	O
Ubl	O
)	O
by	O
adenylation	O
of	O
the	O
Ubl	O
C	O
-	O
terminal	O
COOH	O
group	O
and	O
then	O
forms	O
a	O
thioester	O
bond	O
with	O
the	O
adenylated	O
C	O
-	O
terminal	O
COOH	O
group	O
of	O
the	O
Ubl	O
.	O
<EOS>	B-X
Post-translational	B-X
modifications	B-X
by	B-X
ubiquitin-like	B-X
proteins	B-X
are	B-X
among	B-X
the	B-X
most	B-X
important	B-X
mechanisms	B-X
for	B-X
regulating	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cellular	B-X
functions	B-X
.	B-X
In	B-X
these	B-X
modifications	B-X
an	B-X
E1	B-X
enzyme	B-X
activates	B-X
each	B-X
ubiquitin-like	B-X
protein	B-X
(	B-X
Ubl	B-X
)	B-X
by	B-X
adenylation	B-X
of	B-X
the	B-X
Ubl	B-X
C-terminal	B-X
COOH	B-X
group	B-X
and	B-X
then	B-X
forms	B-X
a	B-X
thioester	B-X
bond	B-X
with	B-X
the	B-X
adenylated	B-X
C-terminal	B-X
COOH	B-X
group	B-X
of	B-X
the	B-X
Ubl	B-X
.	B-X
Previous	B-X
x-ray	B-X
crystallography	B-X
studies	B-X
revealed	B-X
a	B-X
conserved	B-X
zinc	B-X
motif	B-X
in	B-X
the	B-X
SUMO	B-X
and	B-X
NEDD8	B-X
E1	B-X
;	B-X
however	B-X
,	B-X
the	B-X
function	B-X
of	B-X
this	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
quantitative	B-X
ATP	B-X
:	B-X
PPi	B-X
isotope	B-X
exchange	B-X
assays	B-X
in	B-X
combination	B-X
with	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
conserved	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
in	B-X
the	B-X
SUMO	B-X
E1	B-X
is	B-X
important	B-X
for	B-X
SUMO	B-X
adenylation	B-X
and	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
E1	B-X
pseudo-ordered	B-X
substrate	B-X
binding	B-X
mechanism	B-X
.	B-X
Furthermore	B-X
,	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
mutants	B-X
showed	B-X
significantly	B-X
reduced	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
values	B-X
for	B-X
ATP	B-X
:	B-X
PPi	B-X
isotope	B-X
exchange	B-X
assays	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
important	B-X
in	B-X
binding	B-X
and	B-X
preventing	B-X
SUMO	B-X
adenylate	B-X
from	B-X
dissociating	B-X
from	B-X
E1	B-X
before	B-X
formation	B-X
of	B-X
the	B-X
thioester	B-X
conjugate	B-X
.	B-X
Because	B-X
the	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
located	B-X
in	B-X
a	B-X
cross-over	B-X
loop	B-X
that	B-X
is	B-X
known	B-X
to	B-X
have	B-X
conformational	B-X
flexibility	B-X
,	B-X
the	B-X
results	B-X
described	B-X
here	B-X
suggest	B-X
that	B-X
this	B-X
cross-over	B-X
loop	B-X
interacts	B-X
with	B-X
Ubl	B-X
in	B-X
the	B-X
multistep	B-X
,	B-X
dynamic	B-X
process	B-X
of	B-X
Ubl	B-X
activation	B-X
by	B-X
E1s	B-X
.	B-X

Previous	O
x	O
-	O
ray	O
crystallography	O
studies	O
revealed	O
a	O
conserved	O
zinc	O
motif	O
in	O
the	O
SUMO	O
and	O
NEDD8	B-Protein
E1	O
;	O
however	O
,	O
the	O
function	O
of	O
this	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
unclear	O
.	O
<EOS>	B-X
Post-translational	B-X
modifications	B-X
by	B-X
ubiquitin-like	B-X
proteins	B-X
are	B-X
among	B-X
the	B-X
most	B-X
important	B-X
mechanisms	B-X
for	B-X
regulating	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cellular	B-X
functions	B-X
.	B-X
In	B-X
these	B-X
modifications	B-X
an	B-X
E1	B-X
enzyme	B-X
activates	B-X
each	B-X
ubiquitin-like	B-X
protein	B-X
(	B-X
Ubl	B-X
)	B-X
by	B-X
adenylation	B-X
of	B-X
the	B-X
Ubl	B-X
C-terminal	B-X
COOH	B-X
group	B-X
and	B-X
then	B-X
forms	B-X
a	B-X
thioester	B-X
bond	B-X
with	B-X
the	B-X
adenylated	B-X
C-terminal	B-X
COOH	B-X
group	B-X
of	B-X
the	B-X
Ubl	B-X
.	B-X
Previous	B-X
x-ray	B-X
crystallography	B-X
studies	B-X
revealed	B-X
a	B-X
conserved	B-X
zinc	B-X
motif	B-X
in	B-X
the	B-X
SUMO	B-X
and	B-X
NEDD8	B-X
E1	B-X
;	B-X
however	B-X
,	B-X
the	B-X
function	B-X
of	B-X
this	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
quantitative	B-X
ATP	B-X
:	B-X
PPi	B-X
isotope	B-X
exchange	B-X
assays	B-X
in	B-X
combination	B-X
with	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
conserved	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
in	B-X
the	B-X
SUMO	B-X
E1	B-X
is	B-X
important	B-X
for	B-X
SUMO	B-X
adenylation	B-X
and	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
E1	B-X
pseudo-ordered	B-X
substrate	B-X
binding	B-X
mechanism	B-X
.	B-X
Furthermore	B-X
,	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
mutants	B-X
showed	B-X
significantly	B-X
reduced	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
values	B-X
for	B-X
ATP	B-X
:	B-X
PPi	B-X
isotope	B-X
exchange	B-X
assays	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
important	B-X
in	B-X
binding	B-X
and	B-X
preventing	B-X
SUMO	B-X
adenylate	B-X
from	B-X
dissociating	B-X
from	B-X
E1	B-X
before	B-X
formation	B-X
of	B-X
the	B-X
thioester	B-X
conjugate	B-X
.	B-X
Because	B-X
the	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
located	B-X
in	B-X
a	B-X
cross-over	B-X
loop	B-X
that	B-X
is	B-X
known	B-X
to	B-X
have	B-X
conformational	B-X
flexibility	B-X
,	B-X
the	B-X
results	B-X
described	B-X
here	B-X
suggest	B-X
that	B-X
this	B-X
cross-over	B-X
loop	B-X
interacts	B-X
with	B-X
Ubl	B-X
in	B-X
the	B-X
multistep	B-X
,	B-X
dynamic	B-X
process	B-X
of	B-X
Ubl	B-X
activation	B-X
by	B-X
E1s	B-X
.	B-X

In	O
this	O
study	O
,	O
using	O
quantitative	O
ATP	O
:	O
PPi	O
isotope	O
exchange	O
assays	O
in	O
combination	O
with	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
show	O
that	O
the	O
conserved	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
in	O
the	O
SUMO	O
E1	O
is	O
important	O
for	O
SUMO	O
adenylation	O
and	O
is	O
critical	O
for	O
the	O
E1	O
pseudo	O
-	O
ordered	O
substrate	O
binding	O
mechanism	O
.	O
<EOS>	B-X
Post-translational	B-X
modifications	B-X
by	B-X
ubiquitin-like	B-X
proteins	B-X
are	B-X
among	B-X
the	B-X
most	B-X
important	B-X
mechanisms	B-X
for	B-X
regulating	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cellular	B-X
functions	B-X
.	B-X
In	B-X
these	B-X
modifications	B-X
an	B-X
E1	B-X
enzyme	B-X
activates	B-X
each	B-X
ubiquitin-like	B-X
protein	B-X
(	B-X
Ubl	B-X
)	B-X
by	B-X
adenylation	B-X
of	B-X
the	B-X
Ubl	B-X
C-terminal	B-X
COOH	B-X
group	B-X
and	B-X
then	B-X
forms	B-X
a	B-X
thioester	B-X
bond	B-X
with	B-X
the	B-X
adenylated	B-X
C-terminal	B-X
COOH	B-X
group	B-X
of	B-X
the	B-X
Ubl	B-X
.	B-X
Previous	B-X
x-ray	B-X
crystallography	B-X
studies	B-X
revealed	B-X
a	B-X
conserved	B-X
zinc	B-X
motif	B-X
in	B-X
the	B-X
SUMO	B-X
and	B-X
NEDD8	B-X
E1	B-X
;	B-X
however	B-X
,	B-X
the	B-X
function	B-X
of	B-X
this	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
quantitative	B-X
ATP	B-X
:	B-X
PPi	B-X
isotope	B-X
exchange	B-X
assays	B-X
in	B-X
combination	B-X
with	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
conserved	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
in	B-X
the	B-X
SUMO	B-X
E1	B-X
is	B-X
important	B-X
for	B-X
SUMO	B-X
adenylation	B-X
and	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
E1	B-X
pseudo-ordered	B-X
substrate	B-X
binding	B-X
mechanism	B-X
.	B-X
Furthermore	B-X
,	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
mutants	B-X
showed	B-X
significantly	B-X
reduced	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
values	B-X
for	B-X
ATP	B-X
:	B-X
PPi	B-X
isotope	B-X
exchange	B-X
assays	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
important	B-X
in	B-X
binding	B-X
and	B-X
preventing	B-X
SUMO	B-X
adenylate	B-X
from	B-X
dissociating	B-X
from	B-X
E1	B-X
before	B-X
formation	B-X
of	B-X
the	B-X
thioester	B-X
conjugate	B-X
.	B-X
Because	B-X
the	B-X
Zn	B-X
(	B-X
2+	B-X
)	B-X
motif	B-X
is	B-X
located	B-X
in	B-X
a	B-X
cross-over	B-X
loop	B-X
that	B-X
is	B-X
known	B-X
to	B-X
have	B-X
conformational	B-X
flexibility	B-X
,	B-X
the	B-X
results	B-X
described	B-X
here	B-X
suggest	B-X
that	B-X
this	B-X
cross-over	B-X
loop	B-X
interacts	B-X
with	B-X
Ubl	B-X
in	B-X
the	B-X
multistep	B-X
,	B-X
dynamic	B-X
process	B-X
of	B-X
Ubl	B-X
activation	B-X
by	B-X
E1s	B-X
.	B-X

Furthermore	O
,	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
mutants	O
showed	O
significantly	O
reduced	O
k	O
(	O
cat	O
)	O
values	O
for	O
ATP	O
:	O
PPi	O
isotope	O
exchange	O
assays	O
,	O
suggesting	O
that	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
important	O
in	O
binding	O
and	O
preventing	O
SUMO	O
adenylate	O
from	O
dissociating	O
from	O
E1	O
before	O
formation	O
of	O
the	O
thioester	O
conjugate	O
.	O

Because	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
located	O
in	O
a	O
cross	O
-	O
over	O
loop	O
that	O
is	O
known	O
to	O
have	O
conformational	O
flexibility	O
,	O
the	O
results	O
described	O
here	O
suggest	O
that	O
this	O
cross	O
-	O
over	O
loop	O
interacts	O
with	O
Ubl	O
in	O
the	O
multistep	O
,	O
dynamic	O
process	O
of	O
Ubl	O
activation	O
by	O
E1s	O
.	O

Transcriptional	O
repression	O
by	O
sumoylation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
BZLF1	B-Protein
protein	O
correlates	O
with	O
association	O
of	O
histone	O
deacetylase	O
.	O
<EOS>	B-X
The	B-X
transition	B-X
from	B-X
latent	B-X
to	B-X
lytic	B-X
phases	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
life	B-X
cycle	B-X
is	B-X
triggered	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
viral	B-X
transactivator	B-X
,	B-X
BZLF1	B-X
,	B-X
that	B-X
then	B-X
induces	B-X
expression	B-X
of	B-X
the	B-X
viral	B-X
immediate-early	B-X
and	B-X
early	B-X
genes	B-X
.	B-X
The	B-X
BZLF1	B-X
protein	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier-1	B-X
(	B-X
SUMO-1	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
BZLF1	B-X
is	B-X
conjugated	B-X
at	B-X
lysine	B-X
12	B-X
not	B-X
only	B-X
by	B-X
SUMO-1	B-X
but	B-X
also	B-X
by	B-X
SUMO-2	B-X
and	B-X
3	B-X
.	B-X
The	B-X
K12R	B-X
mutant	B-X
of	B-X
BZLF1	B-X
,	B-X
which	B-X
no	B-X
longer	B-X
becomes	B-X
sumoylated	B-X
,	B-X
exhibits	B-X
stronger	B-X
transactivation	B-X
than	B-X
the	B-X
wild-type	B-X
BZLF1	B-X
in	B-X
a	B-X
reporter	B-X
assay	B-X
system	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
virus	B-X
genome	B-X
with	B-X
nucleosomal	B-X
structures	B-X
.	B-X
Furthermore	B-X
,	B-X
exogenous	B-X
supply	B-X
of	B-X
a	B-X
SUMO-specific	B-X
protease	B-X
,	B-X
SENP	B-X
,	B-X
caused	B-X
de-sumoylation	B-X
of	B-X
BZLF1	B-X
and	B-X
enhanced	B-X
BZLF1-mediated	B-X
transactivation	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
proved	B-X
that	B-X
histone	B-X
deacetylase	B-X
3	B-X
preferentially	B-X
associated	B-X
with	B-X
the	B-X
sumoylated	B-X
form	B-X
of	B-X
BZLF1	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
sumoylated	B-X
BZLF1	B-X
increased	B-X
as	B-X
lytic	B-X
replication	B-X
progressed	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
sumoylation	B-X
of	B-X
BZLF1	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
through	B-X
histone	B-X
modification	B-X
during	B-X
Epstein-Barr	B-X
virus	B-X
productive	B-X
replication	B-X
.	B-X

The	O
transition	O
from	O
latent	O
to	O
lytic	O
phases	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
life	O
cycle	O
is	O
triggered	O
by	O
expression	O
of	O
a	O
viral	O
transactivator	O
,	O
BZLF1	B-Protein
,	O
that	O
then	O
induces	O
expression	O
of	O
the	O
viral	O
immediate	O
-	O
early	O
and	O
early	O
genes	O
.	O
<EOS>	B-X
The	B-X
transition	B-X
from	B-X
latent	B-X
to	B-X
lytic	B-X
phases	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
life	B-X
cycle	B-X
is	B-X
triggered	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
viral	B-X
transactivator	B-X
,	B-X
BZLF1	B-X
,	B-X
that	B-X
then	B-X
induces	B-X
expression	B-X
of	B-X
the	B-X
viral	B-X
immediate-early	B-X
and	B-X
early	B-X
genes	B-X
.	B-X
The	B-X
BZLF1	B-X
protein	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier-1	B-X
(	B-X
SUMO-1	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
BZLF1	B-X
is	B-X
conjugated	B-X
at	B-X
lysine	B-X
12	B-X
not	B-X
only	B-X
by	B-X
SUMO-1	B-X
but	B-X
also	B-X
by	B-X
SUMO-2	B-X
and	B-X
3	B-X
.	B-X
The	B-X
K12R	B-X
mutant	B-X
of	B-X
BZLF1	B-X
,	B-X
which	B-X
no	B-X
longer	B-X
becomes	B-X
sumoylated	B-X
,	B-X
exhibits	B-X
stronger	B-X
transactivation	B-X
than	B-X
the	B-X
wild-type	B-X
BZLF1	B-X
in	B-X
a	B-X
reporter	B-X
assay	B-X
system	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
virus	B-X
genome	B-X
with	B-X
nucleosomal	B-X
structures	B-X
.	B-X
Furthermore	B-X
,	B-X
exogenous	B-X
supply	B-X
of	B-X
a	B-X
SUMO-specific	B-X
protease	B-X
,	B-X
SENP	B-X
,	B-X
caused	B-X
de-sumoylation	B-X
of	B-X
BZLF1	B-X
and	B-X
enhanced	B-X
BZLF1-mediated	B-X
transactivation	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
proved	B-X
that	B-X
histone	B-X
deacetylase	B-X
3	B-X
preferentially	B-X
associated	B-X
with	B-X
the	B-X
sumoylated	B-X
form	B-X
of	B-X
BZLF1	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
sumoylated	B-X
BZLF1	B-X
increased	B-X
as	B-X
lytic	B-X
replication	B-X
progressed	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
sumoylation	B-X
of	B-X
BZLF1	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
through	B-X
histone	B-X
modification	B-X
during	B-X
Epstein-Barr	B-X
virus	B-X
productive	B-X
replication	B-X
.	B-X

The	O
BZLF1	B-Protein
protein	O
is	O
post	O
-	O
translationally	O
modified	O
by	O
a	O
small	B-Protein
ubiquitin	I-Protein
-	I-Protein
related	I-Protein
modifier	I-Protein
-	I-Protein
1	I-Protein
(	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
)	O
.	O
<EOS>	B-X
The	B-X
transition	B-X
from	B-X
latent	B-X
to	B-X
lytic	B-X
phases	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
life	B-X
cycle	B-X
is	B-X
triggered	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
viral	B-X
transactivator	B-X
,	B-X
BZLF1	B-X
,	B-X
that	B-X
then	B-X
induces	B-X
expression	B-X
of	B-X
the	B-X
viral	B-X
immediate-early	B-X
and	B-X
early	B-X
genes	B-X
.	B-X
The	B-X
BZLF1	B-X
protein	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier-1	B-X
(	B-X
SUMO-1	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
BZLF1	B-X
is	B-X
conjugated	B-X
at	B-X
lysine	B-X
12	B-X
not	B-X
only	B-X
by	B-X
SUMO-1	B-X
but	B-X
also	B-X
by	B-X
SUMO-2	B-X
and	B-X
3	B-X
.	B-X
The	B-X
K12R	B-X
mutant	B-X
of	B-X
BZLF1	B-X
,	B-X
which	B-X
no	B-X
longer	B-X
becomes	B-X
sumoylated	B-X
,	B-X
exhibits	B-X
stronger	B-X
transactivation	B-X
than	B-X
the	B-X
wild-type	B-X
BZLF1	B-X
in	B-X
a	B-X
reporter	B-X
assay	B-X
system	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
virus	B-X
genome	B-X
with	B-X
nucleosomal	B-X
structures	B-X
.	B-X
Furthermore	B-X
,	B-X
exogenous	B-X
supply	B-X
of	B-X
a	B-X
SUMO-specific	B-X
protease	B-X
,	B-X
SENP	B-X
,	B-X
caused	B-X
de-sumoylation	B-X
of	B-X
BZLF1	B-X
and	B-X
enhanced	B-X
BZLF1-mediated	B-X
transactivation	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
proved	B-X
that	B-X
histone	B-X
deacetylase	B-X
3	B-X
preferentially	B-X
associated	B-X
with	B-X
the	B-X
sumoylated	B-X
form	B-X
of	B-X
BZLF1	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
sumoylated	B-X
BZLF1	B-X
increased	B-X
as	B-X
lytic	B-X
replication	B-X
progressed	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
sumoylation	B-X
of	B-X
BZLF1	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
through	B-X
histone	B-X
modification	B-X
during	B-X
Epstein-Barr	B-X
virus	B-X
productive	B-X
replication	B-X
.	B-X

Here	O
we	O
found	O
that	O
BZLF1	B-Protein
is	O
conjugated	O
at	O
lysine	O
12	O
not	O
only	O
by	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
but	O
also	O
by	O
SUMO	B-Protein
-	I-Protein
2	I-Protein
and	O
3	B-Protein
.	O

The	O
K12R	O
mutant	O
of	O
BZLF1	B-Protein
,	O
which	O
no	O
longer	O
becomes	O
sumoylated	O
,	O
exhibits	O
stronger	O
transactivation	O
than	O
the	O
wild	O
-	O
type	O
BZLF1	B-Protein
in	O
a	O
reporter	O
assay	O
system	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
virus	O
genome	O
with	O
nucleosomal	O
structures	O
.	O

Furthermore	O
,	O
exogenous	O
supply	O
of	O
a	O
SUMO	O
-	O
specific	O
protease	O
,	O
SENP	B-Protein
,	O
caused	O
de	O
-	O
sumoylation	O
of	O
BZLF1	B-Protein
and	O
enhanced	O
BZLF1	B-Protein
-	O
mediated	O
transactivation	O
.	O
<EOS>	B-X
The	B-X
transition	B-X
from	B-X
latent	B-X
to	B-X
lytic	B-X
phases	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
life	B-X
cycle	B-X
is	B-X
triggered	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
viral	B-X
transactivator	B-X
,	B-X
BZLF1	B-X
,	B-X
that	B-X
then	B-X
induces	B-X
expression	B-X
of	B-X
the	B-X
viral	B-X
immediate-early	B-X
and	B-X
early	B-X
genes	B-X
.	B-X
The	B-X
BZLF1	B-X
protein	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier-1	B-X
(	B-X
SUMO-1	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
BZLF1	B-X
is	B-X
conjugated	B-X
at	B-X
lysine	B-X
12	B-X
not	B-X
only	B-X
by	B-X
SUMO-1	B-X
but	B-X
also	B-X
by	B-X
SUMO-2	B-X
and	B-X
3	B-X
.	B-X
The	B-X
K12R	B-X
mutant	B-X
of	B-X
BZLF1	B-X
,	B-X
which	B-X
no	B-X
longer	B-X
becomes	B-X
sumoylated	B-X
,	B-X
exhibits	B-X
stronger	B-X
transactivation	B-X
than	B-X
the	B-X
wild-type	B-X
BZLF1	B-X
in	B-X
a	B-X
reporter	B-X
assay	B-X
system	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
virus	B-X
genome	B-X
with	B-X
nucleosomal	B-X
structures	B-X
.	B-X
Furthermore	B-X
,	B-X
exogenous	B-X
supply	B-X
of	B-X
a	B-X
SUMO-specific	B-X
protease	B-X
,	B-X
SENP	B-X
,	B-X
caused	B-X
de-sumoylation	B-X
of	B-X
BZLF1	B-X
and	B-X
enhanced	B-X
BZLF1-mediated	B-X
transactivation	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
proved	B-X
that	B-X
histone	B-X
deacetylase	B-X
3	B-X
preferentially	B-X
associated	B-X
with	B-X
the	B-X
sumoylated	B-X
form	B-X
of	B-X
BZLF1	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
sumoylated	B-X
BZLF1	B-X
increased	B-X
as	B-X
lytic	B-X
replication	B-X
progressed	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
sumoylation	B-X
of	B-X
BZLF1	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
through	B-X
histone	B-X
modification	B-X
during	B-X
Epstein-Barr	B-X
virus	B-X
productive	B-X
replication	B-X
.	B-X

Immunoprecipitation	O
experiments	O
proved	O
that	O
histone	B-Protein
deacetylase	I-Protein
3	I-Protein
preferentially	O
associated	O
with	O
the	O
sumoylated	O
form	O
of	O
BZLF1	B-Protein
.	O
<EOS>	B-X
The	B-X
transition	B-X
from	B-X
latent	B-X
to	B-X
lytic	B-X
phases	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
life	B-X
cycle	B-X
is	B-X
triggered	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
viral	B-X
transactivator	B-X
,	B-X
BZLF1	B-X
,	B-X
that	B-X
then	B-X
induces	B-X
expression	B-X
of	B-X
the	B-X
viral	B-X
immediate-early	B-X
and	B-X
early	B-X
genes	B-X
.	B-X
The	B-X
BZLF1	B-X
protein	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier-1	B-X
(	B-X
SUMO-1	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
BZLF1	B-X
is	B-X
conjugated	B-X
at	B-X
lysine	B-X
12	B-X
not	B-X
only	B-X
by	B-X
SUMO-1	B-X
but	B-X
also	B-X
by	B-X
SUMO-2	B-X
and	B-X
3	B-X
.	B-X
The	B-X
K12R	B-X
mutant	B-X
of	B-X
BZLF1	B-X
,	B-X
which	B-X
no	B-X
longer	B-X
becomes	B-X
sumoylated	B-X
,	B-X
exhibits	B-X
stronger	B-X
transactivation	B-X
than	B-X
the	B-X
wild-type	B-X
BZLF1	B-X
in	B-X
a	B-X
reporter	B-X
assay	B-X
system	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
virus	B-X
genome	B-X
with	B-X
nucleosomal	B-X
structures	B-X
.	B-X
Furthermore	B-X
,	B-X
exogenous	B-X
supply	B-X
of	B-X
a	B-X
SUMO-specific	B-X
protease	B-X
,	B-X
SENP	B-X
,	B-X
caused	B-X
de-sumoylation	B-X
of	B-X
BZLF1	B-X
and	B-X
enhanced	B-X
BZLF1-mediated	B-X
transactivation	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
proved	B-X
that	B-X
histone	B-X
deacetylase	B-X
3	B-X
preferentially	B-X
associated	B-X
with	B-X
the	B-X
sumoylated	B-X
form	B-X
of	B-X
BZLF1	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
sumoylated	B-X
BZLF1	B-X
increased	B-X
as	B-X
lytic	B-X
replication	B-X
progressed	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
sumoylation	B-X
of	B-X
BZLF1	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
through	B-X
histone	B-X
modification	B-X
during	B-X
Epstein-Barr	B-X
virus	B-X
productive	B-X
replication	B-X
.	B-X

Levels	O
of	O
the	O
sumoylated	O
BZLF1	B-Protein
increased	O
as	O
lytic	O
replication	O
progressed	O
.	O
<EOS>	B-X
The	B-X
transition	B-X
from	B-X
latent	B-X
to	B-X
lytic	B-X
phases	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
life	B-X
cycle	B-X
is	B-X
triggered	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
viral	B-X
transactivator	B-X
,	B-X
BZLF1	B-X
,	B-X
that	B-X
then	B-X
induces	B-X
expression	B-X
of	B-X
the	B-X
viral	B-X
immediate-early	B-X
and	B-X
early	B-X
genes	B-X
.	B-X
The	B-X
BZLF1	B-X
protein	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier-1	B-X
(	B-X
SUMO-1	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
BZLF1	B-X
is	B-X
conjugated	B-X
at	B-X
lysine	B-X
12	B-X
not	B-X
only	B-X
by	B-X
SUMO-1	B-X
but	B-X
also	B-X
by	B-X
SUMO-2	B-X
and	B-X
3	B-X
.	B-X
The	B-X
K12R	B-X
mutant	B-X
of	B-X
BZLF1	B-X
,	B-X
which	B-X
no	B-X
longer	B-X
becomes	B-X
sumoylated	B-X
,	B-X
exhibits	B-X
stronger	B-X
transactivation	B-X
than	B-X
the	B-X
wild-type	B-X
BZLF1	B-X
in	B-X
a	B-X
reporter	B-X
assay	B-X
system	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
virus	B-X
genome	B-X
with	B-X
nucleosomal	B-X
structures	B-X
.	B-X
Furthermore	B-X
,	B-X
exogenous	B-X
supply	B-X
of	B-X
a	B-X
SUMO-specific	B-X
protease	B-X
,	B-X
SENP	B-X
,	B-X
caused	B-X
de-sumoylation	B-X
of	B-X
BZLF1	B-X
and	B-X
enhanced	B-X
BZLF1-mediated	B-X
transactivation	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
proved	B-X
that	B-X
histone	B-X
deacetylase	B-X
3	B-X
preferentially	B-X
associated	B-X
with	B-X
the	B-X
sumoylated	B-X
form	B-X
of	B-X
BZLF1	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
sumoylated	B-X
BZLF1	B-X
increased	B-X
as	B-X
lytic	B-X
replication	B-X
progressed	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
sumoylation	B-X
of	B-X
BZLF1	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
through	B-X
histone	B-X
modification	B-X
during	B-X
Epstein-Barr	B-X
virus	B-X
productive	B-X
replication	B-X
.	B-X

Based	O
on	O
these	O
observations	O
,	O
we	O
conclude	O
that	O
sumoylation	O
of	O
BZLF1	B-Protein
regulates	O
its	O
transcriptional	O
activity	O
through	O
histone	B-Protein
modification	O
during	O
Epstein	O
-	O
Barr	O
virus	O
productive	O
replication	O
.	O
<EOS>	B-X
The	B-X
transition	B-X
from	B-X
latent	B-X
to	B-X
lytic	B-X
phases	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
life	B-X
cycle	B-X
is	B-X
triggered	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
viral	B-X
transactivator	B-X
,	B-X
BZLF1	B-X
,	B-X
that	B-X
then	B-X
induces	B-X
expression	B-X
of	B-X
the	B-X
viral	B-X
immediate-early	B-X
and	B-X
early	B-X
genes	B-X
.	B-X
The	B-X
BZLF1	B-X
protein	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier-1	B-X
(	B-X
SUMO-1	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
BZLF1	B-X
is	B-X
conjugated	B-X
at	B-X
lysine	B-X
12	B-X
not	B-X
only	B-X
by	B-X
SUMO-1	B-X
but	B-X
also	B-X
by	B-X
SUMO-2	B-X
and	B-X
3	B-X
.	B-X
The	B-X
K12R	B-X
mutant	B-X
of	B-X
BZLF1	B-X
,	B-X
which	B-X
no	B-X
longer	B-X
becomes	B-X
sumoylated	B-X
,	B-X
exhibits	B-X
stronger	B-X
transactivation	B-X
than	B-X
the	B-X
wild-type	B-X
BZLF1	B-X
in	B-X
a	B-X
reporter	B-X
assay	B-X
system	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
virus	B-X
genome	B-X
with	B-X
nucleosomal	B-X
structures	B-X
.	B-X
Furthermore	B-X
,	B-X
exogenous	B-X
supply	B-X
of	B-X
a	B-X
SUMO-specific	B-X
protease	B-X
,	B-X
SENP	B-X
,	B-X
caused	B-X
de-sumoylation	B-X
of	B-X
BZLF1	B-X
and	B-X
enhanced	B-X
BZLF1-mediated	B-X
transactivation	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
proved	B-X
that	B-X
histone	B-X
deacetylase	B-X
3	B-X
preferentially	B-X
associated	B-X
with	B-X
the	B-X
sumoylated	B-X
form	B-X
of	B-X
BZLF1	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
sumoylated	B-X
BZLF1	B-X
increased	B-X
as	B-X
lytic	B-X
replication	B-X
progressed	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
sumoylation	B-X
of	B-X
BZLF1	B-X
regulates	B-X
its	B-X
transcriptional	B-X
activity	B-X
through	B-X
histone	B-X
modification	B-X
during	B-X
Epstein-Barr	B-X
virus	B-X
productive	B-X
replication	B-X
.	B-X

Sequential	O
and	O
gamma	O
-	O
secretase	O
-	O
dependent	O
processing	O
of	O
the	O
betacellulin	B-Protein
precursor	O
generates	O
a	O
palmitoylated	O
intracellular	O
-	O
domain	O
fragment	O
that	O
inhibits	O
cell	O
growth	O
.	O
<EOS>	B-X
Betacellulin	B-X
(	B-X
BTC	B-X
)	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
growth	B-X
factors	B-X
that	B-X
are	B-X
expressed	B-X
as	B-X
transmembrane	B-X
precursors	B-X
and	B-X
undergo	B-X
proteolytic	B-X
ectodomain	B-X
shedding	B-X
to	B-X
release	B-X
soluble	B-X
mature	B-X
ligands	B-X
.	B-X
BTC	B-X
is	B-X
a	B-X
dual-specificity	B-X
ligand	B-X
for	B-X
ErbB1	B-X
and	B-X
ErbB4	B-X
receptors	B-X
,	B-X
and	B-X
can	B-X
activate	B-X
unique	B-X
signal-transduction	B-X
pathways	B-X
that	B-X
are	B-X
beneficial	B-X
for	B-X
the	B-X
function	B-X
,	B-X
survival	B-X
and	B-X
regeneration	B-X
of	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
BTC	B-X
precursor	B-X
(	B-X
proBTC	B-X
)	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
generate	B-X
soluble	B-X
ligand	B-X
and	B-X
a	B-X
stable	B-X
,	B-X
transmembrane	B-X
remnant	B-X
(	B-X
BTC-CTF	B-X
)	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
proBTC	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
produce	B-X
BTC-CTF	B-X
,	B-X
which	B-X
then	B-X
undergoes	B-X
intramembrane	B-X
processing	B-X
by	B-X
presenilin-1-	B-X
and/or	B-X
presenilin-2-dependent	B-X
gamma-secretase	B-X
to	B-X
generate	B-X
an	B-X
intracellular-domain	B-X
fragment	B-X
(	B-X
BTC-ICD	B-X
)	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
proBTC	B-X
cytoplasmic	B-X
domain	B-X
is	B-X
palmitoylated	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
ADAM10-dependent	B-X
cleavage	B-X
but	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
stability	B-X
and	B-X
gamma-secretase-dependent	B-X
processing	B-X
of	B-X
BTC-CTF	B-X
to	B-X
generate	B-X
BTC-ICD	B-X
.	B-X
Additionally	B-X
,	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
nuclear-membrane	B-X
localization	B-X
of	B-X
BTC-ICD	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
redistribution	B-X
of	B-X
non-palmitoylated	B-X
BTC-ICD	B-X
mutant	B-X
to	B-X
the	B-X
nucleoplasm	B-X
.	B-X
Importantly	B-X
,	B-X
a	B-X
novel	B-X
receptor-independent	B-X
role	B-X
for	B-X
BTC-ICD	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
BTC-ICD	B-X
to	B-X
inhibit	B-X
cell	B-X
growth	B-X
in	B-X
vitro	B-X
.	B-X

Betacellulin	B-Protein
(	O
BTC	B-Protein
)	O
belongs	O
to	O
the	O
family	O
of	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	O
EGF	B-Protein
)	O
-	O
like	O
growth	O
factors	O
that	O
are	O
expressed	O
as	O
transmembrane	O
precursors	O
and	O
undergo	O
proteolytic	O
ectodomain	O
shedding	O
to	O
release	O
soluble	O
mature	O
ligands	O
.	O

BTC	B-Protein
is	O
a	O
dual	O
-	O
specificity	O
ligand	O
for	O
ErbB1	B-Protein
and	O
ErbB4	B-Protein
receptors	O
,	O
and	O
can	O
activate	O
unique	O
signal	O
-	O
transduction	O
pathways	O
that	O
are	O
beneficial	O
for	O
the	O
function	O
,	O
survival	O
and	O
regeneration	O
of	O
pancreatic	O
beta	O
-	O
cells	O
.	O
<EOS>	B-X
Betacellulin	B-X
(	B-X
BTC	B-X
)	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
growth	B-X
factors	B-X
that	B-X
are	B-X
expressed	B-X
as	B-X
transmembrane	B-X
precursors	B-X
and	B-X
undergo	B-X
proteolytic	B-X
ectodomain	B-X
shedding	B-X
to	B-X
release	B-X
soluble	B-X
mature	B-X
ligands	B-X
.	B-X
BTC	B-X
is	B-X
a	B-X
dual-specificity	B-X
ligand	B-X
for	B-X
ErbB1	B-X
and	B-X
ErbB4	B-X
receptors	B-X
,	B-X
and	B-X
can	B-X
activate	B-X
unique	B-X
signal-transduction	B-X
pathways	B-X
that	B-X
are	B-X
beneficial	B-X
for	B-X
the	B-X
function	B-X
,	B-X
survival	B-X
and	B-X
regeneration	B-X
of	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
BTC	B-X
precursor	B-X
(	B-X
proBTC	B-X
)	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
generate	B-X
soluble	B-X
ligand	B-X
and	B-X
a	B-X
stable	B-X
,	B-X
transmembrane	B-X
remnant	B-X
(	B-X
BTC-CTF	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
BTC-CTF	B-X
in	B-X
greater	B-X
detail	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
proBTC	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
produce	B-X
BTC-CTF	B-X
,	B-X
which	B-X
then	B-X
undergoes	B-X
intramembrane	B-X
processing	B-X
by	B-X
presenilin-1-	B-X
and/or	B-X
presenilin-2-dependent	B-X
gamma-secretase	B-X
to	B-X
generate	B-X
an	B-X
intracellular-domain	B-X
fragment	B-X
(	B-X
BTC-ICD	B-X
)	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
proBTC	B-X
cytoplasmic	B-X
domain	B-X
is	B-X
palmitoylated	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
ADAM10-dependent	B-X
cleavage	B-X
but	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
stability	B-X
and	B-X
gamma-secretase-dependent	B-X
processing	B-X
of	B-X
BTC-CTF	B-X
to	B-X
generate	B-X
BTC-ICD	B-X
.	B-X
Additionally	B-X
,	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
nuclear-membrane	B-X
localization	B-X
of	B-X
BTC-ICD	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
redistribution	B-X
of	B-X
non-palmitoylated	B-X
BTC-ICD	B-X
mutant	B-X
to	B-X
the	B-X
nucleoplasm	B-X
.	B-X
Importantly	B-X
,	B-X
a	B-X
novel	B-X
receptor-independent	B-X
role	B-X
for	B-X
BTC-ICD	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
BTC-ICD	B-X
to	B-X
inhibit	B-X
cell	B-X
growth	B-X
in	B-X
vitro	B-X
.	B-X

We	O
have	O
previously	O
shown	O
that	O
BTC	B-Protein
precursor	O
(	O
proBTC	B-Protein
)	O
is	O
cleaved	O
by	O
ADAM10	B-Protein
to	O
generate	O
soluble	O
ligand	O
and	O
a	O
stable	O
,	O
transmembrane	O
remnant	O
(	O
BTC	B-Protein
-	O
CTF	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
fate	O
of	O
the	O
BTC	B-Protein
-	O
CTF	O
in	O
greater	O
detail	O
.	O
<EOS>	B-X
Betacellulin	B-X
(	B-X
BTC	B-X
)	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
growth	B-X
factors	B-X
that	B-X
are	B-X
expressed	B-X
as	B-X
transmembrane	B-X
precursors	B-X
and	B-X
undergo	B-X
proteolytic	B-X
ectodomain	B-X
shedding	B-X
to	B-X
release	B-X
soluble	B-X
mature	B-X
ligands	B-X
.	B-X
BTC	B-X
is	B-X
a	B-X
dual-specificity	B-X
ligand	B-X
for	B-X
ErbB1	B-X
and	B-X
ErbB4	B-X
receptors	B-X
,	B-X
and	B-X
can	B-X
activate	B-X
unique	B-X
signal-transduction	B-X
pathways	B-X
that	B-X
are	B-X
beneficial	B-X
for	B-X
the	B-X
function	B-X
,	B-X
survival	B-X
and	B-X
regeneration	B-X
of	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
BTC	B-X
precursor	B-X
(	B-X
proBTC	B-X
)	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
generate	B-X
soluble	B-X
ligand	B-X
and	B-X
a	B-X
stable	B-X
,	B-X
transmembrane	B-X
remnant	B-X
(	B-X
BTC-CTF	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
BTC-CTF	B-X
in	B-X
greater	B-X
detail	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
proBTC	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
produce	B-X
BTC-CTF	B-X
,	B-X
which	B-X
then	B-X
undergoes	B-X
intramembrane	B-X
processing	B-X
by	B-X
presenilin-1-	B-X
and/or	B-X
presenilin-2-dependent	B-X
gamma-secretase	B-X
to	B-X
generate	B-X
an	B-X
intracellular-domain	B-X
fragment	B-X
(	B-X
BTC-ICD	B-X
)	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
proBTC	B-X
cytoplasmic	B-X
domain	B-X
is	B-X
palmitoylated	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
ADAM10-dependent	B-X
cleavage	B-X
but	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
stability	B-X
and	B-X
gamma-secretase-dependent	B-X
processing	B-X
of	B-X
BTC-CTF	B-X
to	B-X
generate	B-X
BTC-ICD	B-X
.	B-X
Additionally	B-X
,	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
nuclear-membrane	B-X
localization	B-X
of	B-X
BTC-ICD	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
redistribution	B-X
of	B-X
non-palmitoylated	B-X
BTC-ICD	B-X
mutant	B-X
to	B-X
the	B-X
nucleoplasm	B-X
.	B-X
Importantly	B-X
,	B-X
a	B-X
novel	B-X
receptor-independent	B-X
role	B-X
for	B-X
BTC-ICD	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
BTC-ICD	B-X
to	B-X
inhibit	B-X
cell	B-X
growth	B-X
in	B-X
vitro	B-X
.	B-X

We	O
demonstrated	O
that	O
proBTC	B-Protein
is	O
cleaved	O
by	O
ADAM10	B-Protein
to	O
produce	O
BTC	B-Protein
-	O
CTF	O
,	O
which	O
then	O
undergoes	O
intramembrane	O
processing	O
by	O
presenilin	B-Protein
-	I-Protein
1	I-Protein
-	O
and	O
/	O
or	O
presenilin	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
gamma	O
-	O
secretase	O
to	O
generate	O
an	O
intracellular	O
-	O
domain	O
fragment	O
(	O
BTC	B-Protein
-	O
ICD	O
)	O
.	O
<EOS>	B-X
Betacellulin	B-X
(	B-X
BTC	B-X
)	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
growth	B-X
factors	B-X
that	B-X
are	B-X
expressed	B-X
as	B-X
transmembrane	B-X
precursors	B-X
and	B-X
undergo	B-X
proteolytic	B-X
ectodomain	B-X
shedding	B-X
to	B-X
release	B-X
soluble	B-X
mature	B-X
ligands	B-X
.	B-X
BTC	B-X
is	B-X
a	B-X
dual-specificity	B-X
ligand	B-X
for	B-X
ErbB1	B-X
and	B-X
ErbB4	B-X
receptors	B-X
,	B-X
and	B-X
can	B-X
activate	B-X
unique	B-X
signal-transduction	B-X
pathways	B-X
that	B-X
are	B-X
beneficial	B-X
for	B-X
the	B-X
function	B-X
,	B-X
survival	B-X
and	B-X
regeneration	B-X
of	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
BTC	B-X
precursor	B-X
(	B-X
proBTC	B-X
)	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
generate	B-X
soluble	B-X
ligand	B-X
and	B-X
a	B-X
stable	B-X
,	B-X
transmembrane	B-X
remnant	B-X
(	B-X
BTC-CTF	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
BTC-CTF	B-X
in	B-X
greater	B-X
detail	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
proBTC	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
produce	B-X
BTC-CTF	B-X
,	B-X
which	B-X
then	B-X
undergoes	B-X
intramembrane	B-X
processing	B-X
by	B-X
presenilin-1-	B-X
and/or	B-X
presenilin-2-dependent	B-X
gamma-secretase	B-X
to	B-X
generate	B-X
an	B-X
intracellular-domain	B-X
fragment	B-X
(	B-X
BTC-ICD	B-X
)	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
proBTC	B-X
cytoplasmic	B-X
domain	B-X
is	B-X
palmitoylated	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
ADAM10-dependent	B-X
cleavage	B-X
but	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
stability	B-X
and	B-X
gamma-secretase-dependent	B-X
processing	B-X
of	B-X
BTC-CTF	B-X
to	B-X
generate	B-X
BTC-ICD	B-X
.	B-X
Additionally	B-X
,	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
nuclear-membrane	B-X
localization	B-X
of	B-X
BTC-ICD	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
redistribution	B-X
of	B-X
non-palmitoylated	B-X
BTC-ICD	B-X
mutant	B-X
to	B-X
the	B-X
nucleoplasm	B-X
.	B-X
Importantly	B-X
,	B-X
a	B-X
novel	B-X
receptor-independent	B-X
role	B-X
for	B-X
BTC-ICD	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
BTC-ICD	B-X
to	B-X
inhibit	B-X
cell	B-X
growth	B-X
in	B-X
vitro	B-X
.	B-X

We	O
found	O
that	O
the	O
proBTC	B-Protein
cytoplasmic	O
domain	O
is	O
palmitoylated	O
and	O
that	O
palmitoylation	O
is	O
not	O
required	O
for	O
ADAM10	B-Protein
-	O
dependent	O
cleavage	O
but	O
is	O
necessary	O
for	O
the	O
stability	O
and	O
gamma	O
-	O
secretase	O
-	O
dependent	O
processing	O
of	O
BTC	B-Protein
-	O
CTF	O
to	O
generate	O
BTC	B-Protein
-	O
ICD	O
.	O

Additionally	O
,	O
palmitoylation	O
is	O
required	O
for	O
nuclear	O
-	O
membrane	O
localization	O
of	O
BTC	B-Protein
-	O
ICD	O
,	O
as	O
demonstrated	O
by	O
the	O
redistribution	O
of	O
non	O
-	O
palmitoylated	O
BTC	B-Protein
-	O
ICD	O
mutant	O
to	O
the	O
nucleoplasm	O
.	O

Importantly	O
,	O
a	O
novel	O
receptor	O
-	O
independent	O
role	O
for	O
BTC	B-Protein
-	O
ICD	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
BTC	B-Protein
-	O
ICD	O
to	O
inhibit	O
cell	O
growth	O
in	O
vitro	O
.	O
<EOS>	B-X
Betacellulin	B-X
(	B-X
BTC	B-X
)	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
-like	B-X
growth	B-X
factors	B-X
that	B-X
are	B-X
expressed	B-X
as	B-X
transmembrane	B-X
precursors	B-X
and	B-X
undergo	B-X
proteolytic	B-X
ectodomain	B-X
shedding	B-X
to	B-X
release	B-X
soluble	B-X
mature	B-X
ligands	B-X
.	B-X
BTC	B-X
is	B-X
a	B-X
dual-specificity	B-X
ligand	B-X
for	B-X
ErbB1	B-X
and	B-X
ErbB4	B-X
receptors	B-X
,	B-X
and	B-X
can	B-X
activate	B-X
unique	B-X
signal-transduction	B-X
pathways	B-X
that	B-X
are	B-X
beneficial	B-X
for	B-X
the	B-X
function	B-X
,	B-X
survival	B-X
and	B-X
regeneration	B-X
of	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
BTC	B-X
precursor	B-X
(	B-X
proBTC	B-X
)	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
generate	B-X
soluble	B-X
ligand	B-X
and	B-X
a	B-X
stable	B-X
,	B-X
transmembrane	B-X
remnant	B-X
(	B-X
BTC-CTF	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
BTC-CTF	B-X
in	B-X
greater	B-X
detail	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
proBTC	B-X
is	B-X
cleaved	B-X
by	B-X
ADAM10	B-X
to	B-X
produce	B-X
BTC-CTF	B-X
,	B-X
which	B-X
then	B-X
undergoes	B-X
intramembrane	B-X
processing	B-X
by	B-X
presenilin-1-	B-X
and/or	B-X
presenilin-2-dependent	B-X
gamma-secretase	B-X
to	B-X
generate	B-X
an	B-X
intracellular-domain	B-X
fragment	B-X
(	B-X
BTC-ICD	B-X
)	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
proBTC	B-X
cytoplasmic	B-X
domain	B-X
is	B-X
palmitoylated	B-X
and	B-X
that	B-X
palmitoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
ADAM10-dependent	B-X
cleavage	B-X
but	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
stability	B-X
and	B-X
gamma-secretase-dependent	B-X
processing	B-X
of	B-X
BTC-CTF	B-X
to	B-X
generate	B-X
BTC-ICD	B-X
.	B-X
Additionally	B-X
,	B-X
palmitoylation	B-X
is	B-X
required	B-X
for	B-X
nuclear-membrane	B-X
localization	B-X
of	B-X
BTC-ICD	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
redistribution	B-X
of	B-X
non-palmitoylated	B-X
BTC-ICD	B-X
mutant	B-X
to	B-X
the	B-X
nucleoplasm	B-X
.	B-X
Importantly	B-X
,	B-X
a	B-X
novel	B-X
receptor-independent	B-X
role	B-X
for	B-X
BTC-ICD	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
BTC-ICD	B-X
to	B-X
inhibit	B-X
cell	B-X
growth	B-X
in	B-X
vitro	B-X
.	B-X

Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	B-Protein
protein	I-Protein
is	O
necessary	O
for	O
partitioning	O
into	O
detergent	O
-	O
resistant	O
membranes	O
and	O
cell	O
-	O
cell	O
fusion	O
but	O
not	O
interaction	O
with	O
M	B-Protein
protein	I-Protein
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
recently	B-X
emerged	B-X
coronavirus	B-X
that	B-X
caused	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
(	B-X
SARS-CoV	B-X
)	B-X
is	B-X
the	B-X
most	B-X
pathogenic	B-X
human	B-X
coronavirus	B-X
discovered	B-X
to	B-X
date	B-X
.	B-X
The	B-X
SARS-CoV	B-X
spike	B-X
(	B-X
S	B-X
)	B-X
protein	B-X
mediates	B-X
virus	B-X
entry	B-X
by	B-X
binding	B-X
cellular	B-X
receptors	B-X
and	B-X
inducing	B-X
fusion	B-X
between	B-X
the	B-X
viral	B-X
envelope	B-X
and	B-X
the	B-X
host	B-X
cell	B-X
membrane	B-X
.	B-X
Coronavirus	B-X
S	B-X
proteins	B-X
are	B-X
palmitoylated	B-X
,	B-X
which	B-X
may	B-X
affect	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
created	B-X
a	B-X
non-palmitoylated	B-X
SARS-CoV	B-X
S	B-X
protein	B-X
by	B-X
mutating	B-X
all	B-X
nine	B-X
cytoplasmic	B-X
cysteine	B-X
residues	B-X
.	B-X
Palmitoylation	B-X
of	B-X
SARS-CoV	B-X
S	B-X
was	B-X
required	B-X
for	B-X
partitioning	B-X
into	B-X
detergent-resistant	B-X
membranes	B-X
and	B-X
for	B-X
cell-cell	B-X
fusion	B-X
.	B-X
Surprisingly	B-X
,	B-X
however	B-X
,	B-X
palmitoylation	B-X
of	B-X
S	B-X
was	B-X
not	B-X
required	B-X
for	B-X
interaction	B-X
with	B-X
SARS-CoV	B-X
M	B-X
protein	B-X
.	B-X
This	B-X
contrasts	B-X
with	B-X
the	B-X
requirement	B-X
for	B-X
palmitoylation	B-X
of	B-X
mouse	B-X
hepatitis	B-X
virus	B-X
S	B-X
protein	B-X
for	B-X
interaction	B-X
with	B-X
M	B-X
protein	B-X
and	B-X
may	B-X
point	B-X
to	B-X
important	B-X
differences	B-X
in	B-X
assembly	B-X
and	B-X
infectivity	B-X
of	B-X
these	B-X
two	B-X
coronaviruses	B-X
.	B-X

Coronaviruses	O
are	O
enveloped	O
RNA	O
viruses	O
that	O
generally	O
cause	O
mild	O
disease	O
in	O
humans	O
.	O
<EOS>	B-X
The	B-X
unprecedented	B-X
global	B-X
spread	B-X
of	B-X
the	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
(	B-X
SARS	B-X
)	B-X
caused	B-X
by	B-X
SARS-CoV-2	B-X
is	B-X
depicting	B-X
the	B-X
distressing	B-X
pandemic	B-X
consequence	B-X
on	B-X
human	B-X
health	B-X
,	B-X
economy	B-X
as	B-X
well	B-X
as	B-X
ecosystem	B-X
services	B-X
.	B-X
CoV	B-X
relates	B-X
to	B-X
the	B-X
enveloped	B-X
family	B-X
of	B-X
Betacoronavirus	B-X
(	B-X
βCoV	B-X
)	B-X
with	B-X
positive-sense	B-X
single-stranded	B-X
RNA	B-X
(	B-X
+ssRNA	B-X
)	B-X
.	B-X
In	B-X
this	B-X
realm	B-X
,	B-X
this	B-X
communication	B-X
attempted	B-X
to	B-X
review	B-X
the	B-X
possible	B-X
influx	B-X
route	B-X
of	B-X
the	B-X
enteric	B-X
enveloped	B-X
viral	B-X
transmission	B-X
in	B-X
the	B-X
environmental	B-X
settings	B-X
with	B-X
reference	B-X
to	B-X
its	B-X
occurrence	B-X
,	B-X
persistence	B-X
,	B-X
detection	B-X
,	B-X
and	B-X
inactivation	B-X
based	B-X
on	B-X
the	B-X
published	B-X
literature	B-X
so	B-X
far	B-X
.	B-X
The	B-X
possibilities	B-X
of	B-X
airborne	B-X
transmission	B-X
through	B-X
enteric	B-X
virus-laden	B-X
aerosols	B-X
,	B-X
environmental	B-X
factors	B-X
that	B-X
may	B-X
influence	B-X
the	B-X
viral	B-X
transmission	B-X
,	B-X
and	B-X
disinfection	B-X
methods	B-X
(	B-X
conventional	B-X
and	B-X
emerging	B-X
)	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inactivation	B-X
mechanism	B-X
with	B-X
reference	B-X
to	B-X
the	B-X
enveloped	B-X
virus	B-X
were	B-X
reviewed	B-X
.	B-X
This	B-X
communication	B-X
will	B-X
provide	B-X
a	B-X
basis	B-X
to	B-X
understand	B-X
the	B-X
SARS-CoV-2	B-X
as	B-X
well	B-X
as	B-X
other	B-X
viruses	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
environmental	B-X
engineering	B-X
perspective	B-X
to	B-X
design	B-X
effective	B-X
strategies	B-X
to	B-X
counter	B-X
the	B-X
enteric	B-X
virus	B-X
transmission	B-X
and	B-X
also	B-X
serves	B-X
as	B-X
a	B-X
working	B-X
paper	B-X
for	B-X
researchers	B-X
,	B-X
policy	B-X
makers	B-X
and	B-X
regulators	B-X
.	B-X

However	O
,	O
the	O
recently	O
emerged	O
coronavirus	O
that	O
caused	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
most	O
pathogenic	O
human	O
coronavirus	O
discovered	O
to	O
date	O
.	O
<EOS>	B-X
Coronavirus	B-X
infections	B-X
of	B-X
multiple	B-X
origins	B-X
have	B-X
spread	B-X
to	B-X
date	B-X
worldwide	B-X
,	B-X
causing	B-X
severe	B-X
respiratory	B-X
diseases	B-X
.	B-X
Seven	B-X
coronaviruses	B-X
that	B-X
infect	B-X
humans	B-X
have	B-X
been	B-X
identified	B-X
:	B-X
HCoV-229E	B-X
,	B-X
HCoV-OC43	B-X
,	B-X
HCoV-NL63	B-X
,	B-X
HCoV-HKU1	B-X
,	B-X
SARS-CoV	B-X
,	B-X
MERS-CoV	B-X
,	B-X
and	B-X
SARS-CoV-2	B-X
.	B-X
Among	B-X
them	B-X
,	B-X
SARS-CoV	B-X
and	B-X
MERS-CoV	B-X
caused	B-X
outbreaks	B-X
in	B-X
2002	B-X
and	B-X
2012	B-X
,	B-X
respectively	B-X
.	B-X
SARS-CoV-2	B-X
(	B-X
COVID-19	B-X
)	B-X
is	B-X
the	B-X
most	B-X
recently	B-X
discovered	B-X
.	B-X
It	B-X
has	B-X
created	B-X
a	B-X
severe	B-X
worldwide	B-X
outbreak	B-X
beginning	B-X
in	B-X
late	B-X
2019	B-X
,	B-X
leading	B-X
to	B-X
date	B-X
to	B-X
over	B-X
4	B-X
million	B-X
cases	B-X
globally	B-X
.	B-X
However	B-X
,	B-X
the	B-X
recent	B-X
outbreaks	B-X
of	B-X
SARS-CoV	B-X
and	B-X
MERS-CoV	B-X
,	B-X
and	B-X
the	B-X
ongoing	B-X
outbreak	B-X
of	B-X
SARS-CoV-2	B-X
,	B-X
indicate	B-X
that	B-X
there	B-X
remains	B-X
a	B-X
long	B-X
way	B-X
to	B-X
go	B-X
to	B-X
identify	B-X
and	B-X
develop	B-X
specific	B-X
therapeutic	B-X
treatments	B-X
.	B-X
Only	B-X
after	B-X
gaining	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
their	B-X
pathogenic	B-X
mechanisms	B-X
can	B-X
we	B-X
minimize	B-X
viral	B-X
pandemics	B-X
.	B-X
This	B-X
paper	B-X
mainly	B-X
focuses	B-X
on	B-X
SARS-CoV	B-X
,	B-X
MERS-CoV	B-X
,	B-X
and	B-X
SARS-CoV-2	B-X
.	B-X

The	O
SARS	O
-	O
CoV	O
spike	B-Protein
(	I-Protein
S	I-Protein
)	I-Protein
protein	I-Protein
mediates	O
virus	O
entry	O
by	O
binding	O
cellular	O
receptors	O
and	O
inducing	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
the	O
host	O
cell	O
membrane	O
.	O
<EOS>	B-X
The	B-X
zoonotic	B-X
transmission	B-X
of	B-X
highly	B-X
pathogenic	B-X
coronaviruses	B-X
into	B-X
the	B-X
human	B-X
population	B-X
is	B-X
a	B-X
pressing	B-X
concern	B-X
highlighted	B-X
by	B-X
the	B-X
ongoing	B-X
SARS-CoV-2	B-X
pandemic	B-X
.	B-X
Recent	B-X
work	B-X
has	B-X
helped	B-X
to	B-X
illuminate	B-X
much	B-X
about	B-X
the	B-X
mechanisms	B-X
of	B-X
SARS-CoV-2	B-X
entry	B-X
into	B-X
the	B-X
cell	B-X
,	B-X
which	B-X
determines	B-X
host-	B-X
and	B-X
tissue-specific	B-X
tropism	B-X
,	B-X
pathogenicity	B-X
,	B-X
and	B-X
zoonotic	B-X
transmission	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
current	B-X
findings	B-X
on	B-X
the	B-X
factors	B-X
governing	B-X
SARS-CoV-2	B-X
entry	B-X
.	B-X
We	B-X
first	B-X
reviewed	B-X
key	B-X
features	B-X
of	B-X
the	B-X
viral	B-X
spike	B-X
protein	B-X
(	B-X
S	B-X
)	B-X
mediating	B-X
fusion	B-X
of	B-X
the	B-X
viral	B-X
envelope	B-X
and	B-X
host	B-X
cell	B-X
membrane	B-X
through	B-X
binding	B-X
to	B-X
the	B-X
SARS-CoV-2	B-X
receptor	B-X
,	B-X
angiotensin-converting	B-X
enzyme	B-X
2	B-X
.	B-X
We	B-X
then	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
host	B-X
proteases	B-X
including	B-X
transmembrane	B-X
protease	B-X
serine	B-X
2	B-X
and	B-X
cathepsins	B-X
in	B-X
processing	B-X
S	B-X
for	B-X
virus	B-X
entry	B-X
and	B-X
the	B-X
impact	B-X
of	B-X
this	B-X
processing	B-X
on	B-X
endosomal	B-X
and	B-X
plasma	B-X
membrane	B-X
virus	B-X
entry	B-X
routes	B-X
.	B-X
We	B-X
further	B-X
discussed	B-X
recent	B-X
work	B-X
on	B-X
several	B-X
host	B-X
cofactors	B-X
that	B-X
enhance	B-X
SARS-CoV-2	B-X
entry	B-X
including	B-X
Neuropilin-1	B-X
,	B-X
CD147	B-X
,	B-X
phosphatidylserine	B-X
receptors	B-X
,	B-X
heparan	B-X
sulfate	B-X
proteoglycans	B-X
,	B-X
sialic	B-X
acids	B-X
,	B-X
and	B-X
C-type	B-X
lectins	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
discussed	B-X
two	B-X
key	B-X
host	B-X
restriction	B-X
factors	B-X
,	B-X
i.e.	B-X
,	B-X
interferon-induced	B-X
transmembrane	B-X
proteins	B-X
and	B-X
lymphocyte	B-X
antigen	B-X
6	B-X
complex	B-X
locus	B-X
E	B-X
,	B-X
which	B-X
can	B-X
disrupt	B-X
SARS-CoV-2	B-X
entry	B-X
.	B-X
The	B-X
features	B-X
of	B-X
SARS-CoV-2	B-X
are	B-X
presented	B-X
in	B-X
the	B-X
context	B-X
of	B-X
other	B-X
human	B-X
coronaviruses	B-X
,	B-X
highlighting	B-X
unique	B-X
aspects	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
identify	B-X
the	B-X
gaps	B-X
in	B-X
understanding	B-X
of	B-X
SARS-CoV-2	B-X
entry	B-X
that	B-X
will	B-X
need	B-X
to	B-X
be	B-X
addressed	B-X
by	B-X
future	B-X
studies	B-X
.	B-X

Coronavirus	O
S	O
proteins	O
are	O
palmitoylated	O
,	O
which	O
may	O
affect	O
function	O
.	O
<EOS>	B-X
SARS-CoV-2	B-X
can	B-X
cause	B-X
lung	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
pneumonia	B-X
and	B-X
acute	B-X
respiratory	B-X
distress	B-X
syndrome	B-X
,	B-X
and	B-X
multi-system	B-X
dysfunction	B-X
.	B-X
Succinylated	B-X
N	B-X
and	B-X
membrane	B-X
(	B-X
M	B-X
)	B-X
proteins	B-X
of	B-X
SARS-CoV-2	B-X
synergistically	B-X
affect	B-X
virus	B-X
particle	B-X
assembly	B-X
.	B-X
N	B-X
protein	B-X
regulates	B-X
its	B-X
affinity	B-X
for	B-X
other	B-X
proteins	B-X
and	B-X
the	B-X
viral	B-X
genome	B-X
through	B-X
acetylation	B-X
.	B-X
Both	B-X
palmitoylation	B-X
and	B-X
myristoylation	B-X
sites	B-X
on	B-X
S	B-X
protein	B-X
can	B-X
affect	B-X
the	B-X
virus	B-X
infectivity	B-X
.	B-X
NSP3	B-X
macrodomain	B-X
can	B-X
reverse	B-X
the	B-X
ADP-ribosylation	B-X
of	B-X
host	B-X
proteins	B-X
,	B-X
and	B-X
inhibit	B-X
the	B-X
cascade	B-X
immune	B-X
response	B-X
with	B-X
IFN	B-X
as	B-X
the	B-X
core	B-X
,	B-X
thereby	B-X
promoting	B-X
the	B-X
intracellular	B-X
replication	B-X
of	B-X
SARS-CoV-2	B-X
.	B-X

Here	O
,	O
we	O
created	O
a	O
non	O
-	O
palmitoylated	O
SARS	O
-	O
CoV	O
S	B-Protein
protein	I-Protein
by	O
mutating	O
all	O
nine	O
cytoplasmic	O
cysteine	O
residues	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
recently	B-X
emerged	B-X
coronavirus	B-X
that	B-X
caused	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
(	B-X
SARS-CoV	B-X
)	B-X
is	B-X
the	B-X
most	B-X
pathogenic	B-X
human	B-X
coronavirus	B-X
discovered	B-X
to	B-X
date	B-X
.	B-X
The	B-X
SARS-CoV	B-X
spike	B-X
(	B-X
S	B-X
)	B-X
protein	B-X
mediates	B-X
virus	B-X
entry	B-X
by	B-X
binding	B-X
cellular	B-X
receptors	B-X
and	B-X
inducing	B-X
fusion	B-X
between	B-X
the	B-X
viral	B-X
envelope	B-X
and	B-X
the	B-X
host	B-X
cell	B-X
membrane	B-X
.	B-X
Coronavirus	B-X
S	B-X
proteins	B-X
are	B-X
palmitoylated	B-X
,	B-X
which	B-X
may	B-X
affect	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
created	B-X
a	B-X
non-palmitoylated	B-X
SARS-CoV	B-X
S	B-X
protein	B-X
by	B-X
mutating	B-X
all	B-X
nine	B-X
cytoplasmic	B-X
cysteine	B-X
residues	B-X
.	B-X
Palmitoylation	B-X
of	B-X
SARS-CoV	B-X
S	B-X
was	B-X
required	B-X
for	B-X
partitioning	B-X
into	B-X
detergent-resistant	B-X
membranes	B-X
and	B-X
for	B-X
cell-cell	B-X
fusion	B-X
.	B-X
Surprisingly	B-X
,	B-X
however	B-X
,	B-X
palmitoylation	B-X
of	B-X
S	B-X
was	B-X
not	B-X
required	B-X
for	B-X
interaction	B-X
with	B-X
SARS-CoV	B-X
M	B-X
protein	B-X
.	B-X
This	B-X
contrasts	B-X
with	B-X
the	B-X
requirement	B-X
for	B-X
palmitoylation	B-X
of	B-X
mouse	B-X
hepatitis	B-X
virus	B-X
S	B-X
protein	B-X
for	B-X
interaction	B-X
with	B-X
M	B-X
protein	B-X
and	B-X
may	B-X
point	B-X
to	B-X
important	B-X
differences	B-X
in	B-X
assembly	B-X
and	B-X
infectivity	B-X
of	B-X
these	B-X
two	B-X
coronaviruses	B-X
.	B-X

Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	B-Protein
was	O
required	O
for	O
partitioning	O
into	O
detergent	O
-	O
resistant	O
membranes	O
and	O
for	O
cell	O
-	O
cell	O
fusion	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
recently	B-X
emerged	B-X
coronavirus	B-X
that	B-X
caused	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
(	B-X
SARS-CoV	B-X
)	B-X
is	B-X
the	B-X
most	B-X
pathogenic	B-X
human	B-X
coronavirus	B-X
discovered	B-X
to	B-X
date	B-X
.	B-X
The	B-X
SARS-CoV	B-X
spike	B-X
(	B-X
S	B-X
)	B-X
protein	B-X
mediates	B-X
virus	B-X
entry	B-X
by	B-X
binding	B-X
cellular	B-X
receptors	B-X
and	B-X
inducing	B-X
fusion	B-X
between	B-X
the	B-X
viral	B-X
envelope	B-X
and	B-X
the	B-X
host	B-X
cell	B-X
membrane	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
created	B-X
a	B-X
non-palmitoylated	B-X
SARS-CoV	B-X
S	B-X
protein	B-X
by	B-X
mutating	B-X
all	B-X
nine	B-X
cytoplasmic	B-X
cysteine	B-X
residues	B-X
.	B-X
Palmitoylation	B-X
of	B-X
SARS-CoV	B-X
S	B-X
was	B-X
required	B-X
for	B-X
partitioning	B-X
into	B-X
detergent-resistant	B-X
membranes	B-X
and	B-X
for	B-X
cell-cell	B-X
fusion	B-X
.	B-X
Surprisingly	B-X
,	B-X
however	B-X
,	B-X
palmitoylation	B-X
of	B-X
S	B-X
was	B-X
not	B-X
required	B-X
for	B-X
interaction	B-X
with	B-X
SARS-CoV	B-X
M	B-X
protein	B-X
.	B-X

Surprisingly	O
,	O
however	O
,	O
palmitoylation	O
of	O
S	B-Protein
was	O
not	O
required	O
for	O
interaction	O
with	O
SARS	O
-	O
CoV	O
M	B-Protein
protein	I-Protein
.	O
<EOS>	B-X
Notably	B-X
,	B-X
glutamine	B-X
synthetase	B-X
palmitoylates	B-X
itself	B-X
and	B-X
interacts	B-X
with	B-X
RHOJ	B-X
to	B-X
sustain	B-X
RHOJ	B-X
palmitoylation	B-X
,	B-X
membrane	B-X
localization	B-X
and	B-X
activation	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
that	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
known	B-X
formation	B-X
of	B-X
glutamine	B-X
,	B-X
the	B-X
enzyme	B-X
glutamine	B-X
synthetase	B-X
shows	B-X
unknown	B-X
activity	B-X
in	B-X
endothelial	B-X
cell	B-X
migration	B-X
during	B-X
pathological	B-X
angiogenesis	B-X
through	B-X
RHOJ	B-X
palmitoylation	B-X
.	B-X
Surprisingly	B-X
,	B-X
other	B-X
than	B-X
supplying	B-X
1C	B-X
units	B-X
,	B-X
we	B-X
found	B-X
that	B-X
GCS	B-X
is	B-X
important	B-X
for	B-X
maintaining	B-X
protein	B-X
lipoylation	B-X
and	B-X
mitochondrial	B-X
activity	B-X
.	B-X
Protein	B-X
S-acylation	B-X
,	B-X
also	B-X
known	B-X
as	B-X
palmitoylation	B-X
,	B-X
is	B-X
an	B-X
important	B-X
lipid	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
in	B-X
eukaryotes	B-X
.	B-X
S-acylation	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
protein	B-X
functions	B-X
involved	B-X
in	B-X
plant	B-X
development	B-X
and	B-X
responses	B-X
to	B-X
abiotic	B-X
and	B-X
biotic	B-X
stresses	B-X
.	B-X
The	B-X
status	B-X
of	B-X
S-acylation	B-X
on	B-X
proteins	B-X
is	B-X
dynamic	B-X
and	B-X
reversible	B-X
,	B-X
which	B-X
is	B-X
catalyzed	B-X
by	B-X
protein	B-X
S-acyltransferases	B-X
(	B-X
PATs	B-X
)	B-X
and	B-X
reversed	B-X
by	B-X
acyl	B-X
protein	B-X
thioesterases	B-X
.	B-X
The	B-X
cycle	B-X
of	B-X
S-acylation	B-X
and	B-X
de-S-acylation	B-X
provides	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
membrane-associated	B-X
proteins	B-X
to	B-X
undergo	B-X
cycling	B-X
and	B-X
trafficking	B-X
between	B-X
different	B-X
cell	B-X
compartments	B-X
and	B-X
thus	B-X
works	B-X
as	B-X
a	B-X
switch	B-X
to	B-X
initiate	B-X
or	B-X
terminate	B-X
particular	B-X
signaling	B-X
transductions	B-X
on	B-X
the	B-X
membrane	B-X
surface	B-X
.	B-X
In	B-X
plants	B-X
,	B-X
thousands	B-X
of	B-X
proteins	B-X
have	B-X
been	B-X
identified	B-X
to	B-X
be	B-X
S-acylated	B-X
through	B-X
proteomics	B-X
.	B-X
Many	B-X
S-acylated	B-X
proteins	B-X
and	B-X
quite	B-X
a	B-X
few	B-X
PAT-substrate	B-X
pairs	B-X
have	B-X
been	B-X
functionally	B-X
characterized	B-X
.	B-X
A	B-X
recently	B-X
characterized	B-X
acyl	B-X
protein	B-X
thioesterases	B-X
family	B-X
,	B-X
ABAPT	B-X
family	B-X
proteins	B-X
in	B-X

This	O
contrasts	O
with	O
the	O
requirement	O
for	O
palmitoylation	O
of	O
mouse	O
hepatitis	O
virus	O
S	B-Protein
protein	I-Protein
for	O
interaction	O
with	O
M	B-Protein
protein	I-Protein
and	O
may	O
point	O
to	O
important	O
differences	O
in	O
assembly	O
and	O
infectivity	O
of	O
these	O
two	O
coronaviruses	O
.	O

Elucidation	O
of	O
XA21	B-Protein
-	O
mediated	O
innate	O
immunity	O
.	O
<EOS>	B-X
In	B-X
1995	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
gene	B-X
controlling	B-X
this	B-X
resistance	B-X
and	B-X
in	B-X
2009	B-X
demonstrated	B-X
that	B-X
XA21	B-X
recognizes	B-X
a	B-X
highly	B-X
conserved	B-X
peptide	B-X
,	B-X
called	B-X
'Ax21	B-X
'	B-X
(	B-X
activator	B-X
of	B-X
XA21-mediated	B-X
immunity	B-X
)	B-X
.	B-X
Tyrosine	B-X
sulfation	B-X
of	B-X
Ax21	B-X
is	B-X
required	B-X
for	B-X
recognition	B-X
by	B-X
rice	B-X
XA21	B-X
.	B-X
A	B-X
decade	B-X
of	B-X
genetic	B-X
,	B-X
molecular	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
uncovered	B-X
key	B-X
components	B-X
of	B-X
the	B-X
XA21-mediated	B-X
signalling	B-X
cascade	B-X
.	B-X
Ax21	B-X
recognition	B-X
by	B-X
XA21	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
induces	B-X
phosphorylation-mediated	B-X
events	B-X
,	B-X
which	B-X
are	B-X
predicted	B-X
to	B-X
alter	B-X
subcellular	B-X
localization	B-X
and/or	B-X
DNA-binding	B-X
activity	B-X
of	B-X
a	B-X
WRKY	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Because	B-X
XA21	B-X
is	B-X
representative	B-X
of	B-X
the	B-X
large	B-X
number	B-X
of	B-X
predicted	B-X
pattern	B-X
recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
)	B-X
in	B-X
rice	B-X
(	B-X
n	B-X
=	B-X
328	B-X
)	B-X
,	B-X
Arabidopsis	B-X
(	B-X
n	B-X
=	B-X
35	B-X
)	B-X
and	B-X
other	B-X
plant	B-X
species	B-X
,	B-X
further	B-X
characterization	B-X
of	B-X
XA21-mediated	B-X
signalling	B-X
pathways	B-X
will	B-X
contribute	B-X
to	B-X
elucidation	B-X
of	B-X
these	B-X
important	B-X
defence	B-X
responses	B-X
.	B-X

In	O
the	O
early	O
1970s	O
,	O
the	O
Xa21	B-Protein
gene	O
from	O
the	O
wild	O
rice	O
species	O
Oryza	O
longistaminata	O
drew	O
attention	O
of	O
rice	O
breeders	O
because	O
of	O
its	O
broad	O
-	O
spectrum	O
resistance	O
to	O
diverse	O
strains	O
of	O
a	O
serious	O
bacterial	O
disease	O
of	O
rice	O
in	O
Asia	O
and	O
Africa	O
,	O
called	O
'	O
bacterial	O
blight	O
disease	O
'	O
,	O
caused	O
by	O
the	O
Gram	O
-	O
negative	O
bacterium	O
,	O
Xanthomonas	O
oryzae	O
pv	O
.	O
oryzae	O
(	O
Xoo	O
)	O
.	O
<EOS>	B-X
In	B-X
the	B-X
early	B-X
1970s	B-X
,	B-X
the	B-X
Xa21	B-X
gene	B-X
from	B-X
the	B-X
wild	B-X
rice	B-X
species	B-X
Oryza	B-X
longistaminata	B-X
drew	B-X
attention	B-X
of	B-X
rice	B-X
breeders	B-X
because	B-X
of	B-X
its	B-X
broad-spectrum	B-X
resistance	B-X
to	B-X
diverse	B-X
strains	B-X
of	B-X
a	B-X
serious	B-X
bacterial	B-X
disease	B-X
of	B-X
rice	B-X
in	B-X
Asia	B-X
and	B-X
Africa	B-X
,	B-X
called	B-X
'bacterial	B-X
blight	B-X
disease	B-X
'	B-X
,	B-X
caused	B-X
by	B-X
the	B-X
Gram-negative	B-X
bacterium	B-X
,	B-X
Xanthomonas	B-X
oryzae	B-X
pv	B-X
.	B-X
oryzae	B-X
(	B-X
Xoo	B-X
)	B-X
.	B-X
In	B-X
1995	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
gene	B-X
controlling	B-X
this	B-X
resistance	B-X
and	B-X
in	B-X
2009	B-X
demonstrated	B-X
that	B-X
XA21	B-X
recognizes	B-X
a	B-X
highly	B-X
conserved	B-X
peptide	B-X
,	B-X
called	B-X
'Ax21	B-X
'	B-X
(	B-X
activator	B-X
of	B-X
XA21-mediated	B-X
immunity	B-X
)	B-X
.	B-X
Tyrosine	B-X
sulfation	B-X
of	B-X
Ax21	B-X
is	B-X
required	B-X
for	B-X
recognition	B-X
by	B-X
rice	B-X
XA21	B-X
.	B-X
A	B-X
decade	B-X
of	B-X
genetic	B-X
,	B-X
molecular	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
uncovered	B-X
key	B-X
components	B-X
of	B-X
the	B-X
XA21-mediated	B-X
signalling	B-X
cascade	B-X
.	B-X
Because	B-X
XA21	B-X
is	B-X
representative	B-X
of	B-X
the	B-X
large	B-X
number	B-X
of	B-X
predicted	B-X
pattern	B-X
recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
)	B-X
in	B-X
rice	B-X
(	B-X
n	B-X
=	B-X
328	B-X
)	B-X
,	B-X
Arabidopsis	B-X
(	B-X
n	B-X
=	B-X
35	B-X
)	B-X
and	B-X
other	B-X
plant	B-X
species	B-X
,	B-X
further	B-X
characterization	B-X
of	B-X
XA21-mediated	B-X
signalling	B-X
pathways	B-X
will	B-X
contribute	B-X
to	B-X
elucidation	B-X
of	B-X
these	B-X
important	B-X
defence	B-X
responses	B-X
.	B-X

In	O
1995	O
,	O
we	O
isolated	O
the	O
gene	O
controlling	O
this	O
resistance	O
and	O
in	O
2009	O
demonstrated	O
that	O
XA21	B-Protein
recognizes	O
a	O
highly	O
conserved	O
peptide	O
,	O
called	O
'	O
Ax21	B-Protein
'	O
(	O
activator	B-Protein
of	I-Protein
XA21	I-Protein
-	I-Protein
mediated	I-Protein
immunity	I-Protein
)	O
.	O
<EOS>	B-X
In	B-X
the	B-X
early	B-X
1970s	B-X
,	B-X
the	B-X
Xa21	B-X
gene	B-X
from	B-X
the	B-X
wild	B-X
rice	B-X
species	B-X
Oryza	B-X
longistaminata	B-X
drew	B-X
attention	B-X
of	B-X
rice	B-X
breeders	B-X
because	B-X
of	B-X
its	B-X
broad-spectrum	B-X
resistance	B-X
to	B-X
diverse	B-X
strains	B-X
of	B-X
a	B-X
serious	B-X
bacterial	B-X
disease	B-X
of	B-X
rice	B-X
in	B-X
Asia	B-X
and	B-X
Africa	B-X
,	B-X
called	B-X
'bacterial	B-X
blight	B-X
disease	B-X
'	B-X
,	B-X
caused	B-X
by	B-X
the	B-X
Gram-negative	B-X
bacterium	B-X
,	B-X
Xanthomonas	B-X
oryzae	B-X
pv	B-X
.	B-X
In	B-X
1995	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
gene	B-X
controlling	B-X
this	B-X
resistance	B-X
and	B-X
in	B-X
2009	B-X
demonstrated	B-X
that	B-X
XA21	B-X
recognizes	B-X
a	B-X
highly	B-X
conserved	B-X
peptide	B-X
,	B-X
called	B-X
'Ax21	B-X
'	B-X
(	B-X
activator	B-X
of	B-X
XA21-mediated	B-X
immunity	B-X
)	B-X
.	B-X
Tyrosine	B-X
sulfation	B-X
of	B-X
Ax21	B-X
is	B-X
required	B-X
for	B-X
recognition	B-X
by	B-X
rice	B-X
XA21	B-X
.	B-X
A	B-X
decade	B-X
of	B-X
genetic	B-X
,	B-X
molecular	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
uncovered	B-X
key	B-X
components	B-X
of	B-X
the	B-X
XA21-mediated	B-X
signalling	B-X
cascade	B-X
.	B-X
Ax21	B-X
recognition	B-X
by	B-X
XA21	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
induces	B-X
phosphorylation-mediated	B-X
events	B-X
,	B-X
which	B-X
are	B-X
predicted	B-X
to	B-X
alter	B-X
subcellular	B-X
localization	B-X
and/or	B-X
DNA-binding	B-X
activity	B-X
of	B-X
a	B-X
WRKY	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Because	B-X
XA21	B-X
is	B-X
representative	B-X
of	B-X
the	B-X
large	B-X
number	B-X
of	B-X
predicted	B-X
pattern	B-X
recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
)	B-X
in	B-X
rice	B-X
(	B-X
n	B-X
=	B-X
328	B-X
)	B-X
,	B-X
Arabidopsis	B-X
(	B-X
n	B-X
=	B-X
35	B-X
)	B-X
and	B-X
other	B-X
plant	B-X
species	B-X
,	B-X
further	B-X
characterization	B-X
of	B-X
XA21-mediated	B-X
signalling	B-X
pathways	B-X
will	B-X
contribute	B-X
to	B-X
elucidation	B-X
of	B-X
these	B-X
important	B-X
defence	B-X
responses	B-X
.	B-X

Tyrosine	O
sulfation	O
of	O
Ax21	B-Protein
is	O
required	O
for	O
recognition	O
by	O
rice	O
XA21	B-Protein
.	O
<EOS>	B-X
In	B-X
the	B-X
early	B-X
1970s	B-X
,	B-X
the	B-X
Xa21	B-X
gene	B-X
from	B-X
the	B-X
wild	B-X
rice	B-X
species	B-X
Oryza	B-X
longistaminata	B-X
drew	B-X
attention	B-X
of	B-X
rice	B-X
breeders	B-X
because	B-X
of	B-X
its	B-X
broad-spectrum	B-X
resistance	B-X
to	B-X
diverse	B-X
strains	B-X
of	B-X
a	B-X
serious	B-X
bacterial	B-X
disease	B-X
of	B-X
rice	B-X
in	B-X
Asia	B-X
and	B-X
Africa	B-X
,	B-X
called	B-X
'bacterial	B-X
blight	B-X
disease	B-X
'	B-X
,	B-X
caused	B-X
by	B-X
the	B-X
Gram-negative	B-X
bacterium	B-X
,	B-X
Xanthomonas	B-X
oryzae	B-X
pv	B-X
.	B-X
In	B-X
1995	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
gene	B-X
controlling	B-X
this	B-X
resistance	B-X
and	B-X
in	B-X
2009	B-X
demonstrated	B-X
that	B-X
XA21	B-X
recognizes	B-X
a	B-X
highly	B-X
conserved	B-X
peptide	B-X
,	B-X
called	B-X
'Ax21	B-X
'	B-X
(	B-X
activator	B-X
of	B-X
XA21-mediated	B-X
immunity	B-X
)	B-X
.	B-X
Tyrosine	B-X
sulfation	B-X
of	B-X
Ax21	B-X
is	B-X
required	B-X
for	B-X
recognition	B-X
by	B-X
rice	B-X
XA21	B-X
.	B-X
A	B-X
decade	B-X
of	B-X
genetic	B-X
,	B-X
molecular	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
uncovered	B-X
key	B-X
components	B-X
of	B-X
the	B-X
XA21-mediated	B-X
signalling	B-X
cascade	B-X
.	B-X
Ax21	B-X
recognition	B-X
by	B-X
XA21	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
induces	B-X
phosphorylation-mediated	B-X
events	B-X
,	B-X
which	B-X
are	B-X
predicted	B-X
to	B-X
alter	B-X
subcellular	B-X
localization	B-X
and/or	B-X
DNA-binding	B-X
activity	B-X
of	B-X
a	B-X
WRKY	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Because	B-X
XA21	B-X
is	B-X
representative	B-X
of	B-X
the	B-X
large	B-X
number	B-X
of	B-X
predicted	B-X
pattern	B-X
recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
)	B-X
in	B-X
rice	B-X
(	B-X
n	B-X
=	B-X
328	B-X
)	B-X
,	B-X
Arabidopsis	B-X
(	B-X
n	B-X
=	B-X
35	B-X
)	B-X
and	B-X
other	B-X
plant	B-X
species	B-X
,	B-X
further	B-X
characterization	B-X
of	B-X
XA21-mediated	B-X
signalling	B-X
pathways	B-X
will	B-X
contribute	B-X
to	B-X
elucidation	B-X
of	B-X
these	B-X
important	B-X
defence	B-X
responses	B-X
.	B-X

A	O
decade	O
of	O
genetic	O
,	O
molecular	O
and	O
biochemical	O
studies	O
have	O
uncovered	O
key	O
components	O
of	O
the	O
XA21	B-Protein
-	O
mediated	O
signalling	O
cascade	O
.	O
<EOS>	B-X
In	B-X
1995	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
gene	B-X
controlling	B-X
this	B-X
resistance	B-X
and	B-X
in	B-X
2009	B-X
demonstrated	B-X
that	B-X
XA21	B-X
recognizes	B-X
a	B-X
highly	B-X
conserved	B-X
peptide	B-X
,	B-X
called	B-X
'Ax21	B-X
'	B-X
(	B-X
activator	B-X
of	B-X
XA21-mediated	B-X
immunity	B-X
)	B-X
.	B-X
Tyrosine	B-X
sulfation	B-X
of	B-X
Ax21	B-X
is	B-X
required	B-X
for	B-X
recognition	B-X
by	B-X
rice	B-X
XA21	B-X
.	B-X
A	B-X
decade	B-X
of	B-X
genetic	B-X
,	B-X
molecular	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
uncovered	B-X
key	B-X
components	B-X
of	B-X
the	B-X
XA21-mediated	B-X
signalling	B-X
cascade	B-X
.	B-X
Ax21	B-X
recognition	B-X
by	B-X
XA21	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
induces	B-X
phosphorylation-mediated	B-X
events	B-X
,	B-X
which	B-X
are	B-X
predicted	B-X
to	B-X
alter	B-X
subcellular	B-X
localization	B-X
and/or	B-X
DNA-binding	B-X
activity	B-X
of	B-X
a	B-X
WRKY	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Because	B-X
XA21	B-X
is	B-X
representative	B-X
of	B-X
the	B-X
large	B-X
number	B-X
of	B-X
predicted	B-X
pattern	B-X
recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
)	B-X
in	B-X
rice	B-X
(	B-X
n	B-X
=	B-X
328	B-X
)	B-X
,	B-X
Arabidopsis	B-X
(	B-X
n	B-X
=	B-X
35	B-X
)	B-X
and	B-X
other	B-X
plant	B-X
species	B-X
,	B-X
further	B-X
characterization	B-X
of	B-X
XA21-mediated	B-X
signalling	B-X
pathways	B-X
will	B-X
contribute	B-X
to	B-X
elucidation	B-X
of	B-X
these	B-X
important	B-X
defence	B-X
responses	B-X
.	B-X

Ax21	B-Protein
recognition	O
by	O
XA21	B-Protein
at	O
the	O
cell	O
surface	O
induces	O
phosphorylation	O
-	O
mediated	O
events	O
,	O
which	O
are	O
predicted	O
to	O
alter	O
subcellular	O
localization	O
and	O
/	O
or	O
DNA	O
-	O
binding	O
activity	O
of	O
a	O
WRKY	O
family	O
of	O
transcription	O
factors	O
.	O
<EOS>	B-X
In	B-X
1995	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
gene	B-X
controlling	B-X
this	B-X
resistance	B-X
and	B-X
in	B-X
2009	B-X
demonstrated	B-X
that	B-X
XA21	B-X
recognizes	B-X
a	B-X
highly	B-X
conserved	B-X
peptide	B-X
,	B-X
called	B-X
'Ax21	B-X
'	B-X
(	B-X
activator	B-X
of	B-X
XA21-mediated	B-X
immunity	B-X
)	B-X
.	B-X
Tyrosine	B-X
sulfation	B-X
of	B-X
Ax21	B-X
is	B-X
required	B-X
for	B-X
recognition	B-X
by	B-X
rice	B-X
XA21	B-X
.	B-X
A	B-X
decade	B-X
of	B-X
genetic	B-X
,	B-X
molecular	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
uncovered	B-X
key	B-X
components	B-X
of	B-X
the	B-X
XA21-mediated	B-X
signalling	B-X
cascade	B-X
.	B-X
Ax21	B-X
recognition	B-X
by	B-X
XA21	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
induces	B-X
phosphorylation-mediated	B-X
events	B-X
,	B-X
which	B-X
are	B-X
predicted	B-X
to	B-X
alter	B-X
subcellular	B-X
localization	B-X
and/or	B-X
DNA-binding	B-X
activity	B-X
of	B-X
a	B-X
WRKY	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Because	B-X
XA21	B-X
is	B-X
representative	B-X
of	B-X
the	B-X
large	B-X
number	B-X
of	B-X
predicted	B-X
pattern	B-X
recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
)	B-X
in	B-X
rice	B-X
(	B-X
n	B-X
=	B-X
328	B-X
)	B-X
,	B-X
Arabidopsis	B-X
(	B-X
n	B-X
=	B-X
35	B-X
)	B-X
and	B-X
other	B-X
plant	B-X
species	B-X
,	B-X
further	B-X
characterization	B-X
of	B-X
XA21-mediated	B-X
signalling	B-X
pathways	B-X
will	B-X
contribute	B-X
to	B-X
elucidation	B-X
of	B-X
these	B-X
important	B-X
defence	B-X
responses	B-X
.	B-X

Because	O
XA21	B-Protein
is	O
representative	O
of	O
the	O
large	O
number	O
of	O
predicted	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
in	O
rice	O
(	O
n	O
=	O
328	O
)	O
,	O
Arabidopsis	O
(	O
n	O
=	O
35	O
)	O
and	O
other	O
plant	O
species	O
,	O
further	O
characterization	O
of	O
XA21	B-Protein
-	O
mediated	O
signalling	O
pathways	O
will	O
contribute	O
to	O
elucidation	O
of	O
these	O
important	O
defence	O
responses	O
.	O
<EOS>	B-X
In	B-X
the	B-X
early	B-X
1970s	B-X
,	B-X
the	B-X
Xa21	B-X
gene	B-X
from	B-X
the	B-X
wild	B-X
rice	B-X
species	B-X
Oryza	B-X
longistaminata	B-X
drew	B-X
attention	B-X
of	B-X
rice	B-X
breeders	B-X
because	B-X
of	B-X
its	B-X
broad-spectrum	B-X
resistance	B-X
to	B-X
diverse	B-X
strains	B-X
of	B-X
a	B-X
serious	B-X
bacterial	B-X
disease	B-X
of	B-X
rice	B-X
in	B-X
Asia	B-X
and	B-X
Africa	B-X
,	B-X
called	B-X
'bacterial	B-X
blight	B-X
disease	B-X
'	B-X
,	B-X
caused	B-X
by	B-X
the	B-X
Gram-negative	B-X
bacterium	B-X
,	B-X
Xanthomonas	B-X
oryzae	B-X
pv	B-X
.	B-X
In	B-X
1995	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
gene	B-X
controlling	B-X
this	B-X
resistance	B-X
and	B-X
in	B-X
2009	B-X
demonstrated	B-X
that	B-X
XA21	B-X
recognizes	B-X
a	B-X
highly	B-X
conserved	B-X
peptide	B-X
,	B-X
called	B-X
'Ax21	B-X
'	B-X
(	B-X
activator	B-X
of	B-X
XA21-mediated	B-X
immunity	B-X
)	B-X
.	B-X
Tyrosine	B-X
sulfation	B-X
of	B-X
Ax21	B-X
is	B-X
required	B-X
for	B-X
recognition	B-X
by	B-X
rice	B-X
XA21	B-X
.	B-X
A	B-X
decade	B-X
of	B-X
genetic	B-X
,	B-X
molecular	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
uncovered	B-X
key	B-X
components	B-X
of	B-X
the	B-X
XA21-mediated	B-X
signalling	B-X
cascade	B-X
.	B-X
Ax21	B-X
recognition	B-X
by	B-X
XA21	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
induces	B-X
phosphorylation-mediated	B-X
events	B-X
,	B-X
which	B-X
are	B-X
predicted	B-X
to	B-X
alter	B-X
subcellular	B-X
localization	B-X
and/or	B-X
DNA-binding	B-X
activity	B-X
of	B-X
a	B-X
WRKY	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Because	B-X
XA21	B-X
is	B-X
representative	B-X
of	B-X
the	B-X
large	B-X
number	B-X
of	B-X
predicted	B-X
pattern	B-X
recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
)	B-X
in	B-X
rice	B-X
(	B-X
n	B-X
=	B-X
328	B-X
)	B-X
,	B-X
Arabidopsis	B-X
(	B-X
n	B-X
=	B-X
35	B-X
)	B-X
and	B-X
other	B-X
plant	B-X
species	B-X
,	B-X
further	B-X
characterization	B-X
of	B-X
XA21-mediated	B-X
signalling	B-X
pathways	B-X
will	B-X
contribute	B-X
to	B-X
elucidation	B-X
of	B-X
these	B-X
important	B-X
defence	B-X
responses	B-X
.	B-X

dHIP14	B-Protein
-	O
dependent	O
palmitoylation	O
promotes	O
secretion	O
of	O
the	O
BMP	O
antagonist	O
Sog	B-Protein
.	O
<EOS>	B-X
The	B-X
Short	B-X
Gastrulation	B-X
(	B-X
Sog	B-X
)	B-X
protein	B-X
is	B-X
another	B-X
secreted	B-X
Drosophila	B-X
protein	B-X
that	B-X
contains	B-X
a	B-X
type-II	B-X
signal	B-X
and	B-X
differs	B-X
from	B-X
its	B-X
vertebrate	B-X
ortholog	B-X
Chordin	B-X
which	B-X
contains	B-X
a	B-X
standard	B-X
signal	B-X
peptide	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulation	B-X
of	B-X
Sog	B-X
secretion	B-X
and	B-X
regulation	B-X
by	B-X
dHIP14	B-X
,	B-X
the	B-X
ortholog	B-X
of	B-X
a	B-X
mammalian	B-X
palmitoylase	B-X
first	B-X
identified	B-X
as	B-X
Huntington	B-X
Interacting	B-X
Protein	B-X
(	B-X
HIP	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
dHIP14	B-X
binds	B-X
to	B-X
Sog	B-X
and	B-X
that	B-X
Sog	B-X
is	B-X
palmitoylated	B-X
.	B-X
In	B-X
S2	B-X
cells	B-X
,	B-X
dHIP14	B-X
promotes	B-X
secretion	B-X
of	B-X
Sog	B-X
as	B-X
well	B-X
as	B-X
stabilizing	B-X
a	B-X
membrane	B-X
associated	B-X
form	B-X
of	B-X
Sog	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
find	B-X
that	B-X
dHIP14	B-X
promotes	B-X
the	B-X
activity	B-X
of	B-X
Sog	B-X
in	B-X
vivo	B-X
.	B-X

Analysis	O
of	O
diverse	O
signaling	O
systems	O
has	O
revealed	O
that	O
one	O
important	O
level	O
of	O
control	O
is	O
regulation	O
of	O
membrane	O
trafficking	O
of	O
ligands	O
and	O
receptors	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
diverse	B-X
signaling	B-X
systems	B-X
has	B-X
revealed	B-X
that	B-X
one	B-X
important	B-X
level	B-X
of	B-X
control	B-X
is	B-X
regulation	B-X
of	B-X
membrane	B-X
trafficking	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
The	B-X
activities	B-X
of	B-X
some	B-X
ligands	B-X
are	B-X
also	B-X
regulated	B-X
by	B-X
whether	B-X
they	B-X
are	B-X
membrane	B-X
bound	B-X
or	B-X
secreted	B-X
.	B-X
In	B-X
Drosophila	B-X
,	B-X
several	B-X
morphogenetic	B-X
signals	B-X
that	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
development	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
subject	B-X
to	B-X
such	B-X
regulation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulation	B-X
of	B-X
Sog	B-X
secretion	B-X
and	B-X
regulation	B-X
by	B-X
dHIP14	B-X
,	B-X
the	B-X
ortholog	B-X
of	B-X
a	B-X
mammalian	B-X
palmitoylase	B-X
first	B-X
identified	B-X
as	B-X
Huntington	B-X
Interacting	B-X
Protein	B-X
(	B-X
HIP	B-X
)	B-X
.	B-X
In	B-X
S2	B-X
cells	B-X
,	B-X
dHIP14	B-X
promotes	B-X
secretion	B-X
of	B-X
Sog	B-X
as	B-X
well	B-X
as	B-X
stabilizing	B-X
a	B-X
membrane	B-X
associated	B-X
form	B-X
of	B-X
Sog	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
These	B-X
studies	B-X
highlight	B-X
the	B-X
growing	B-X
importance	B-X
of	B-X
lipid	B-X
modification	B-X
in	B-X
regulating	B-X
signaling	B-X
at	B-X
the	B-X
level	B-X
of	B-X
ligand	B-X
production	B-X
and	B-X
localization	B-X
.	B-X

The	O
activities	O
of	O
some	O
ligands	O
are	O
also	O
regulated	O
by	O
whether	O
they	O
are	O
membrane	O
bound	O
or	O
secreted	O
.	O
<EOS>	B-X
These	B-X
are	B-X
natural	B-X
sexual	B-X
responses	B-X
but	B-X
may	B-X
also	B-X
represent	B-X
symptoms	B-X
of	B-X
urinary	B-X
incontinence	B-X
.	B-X
Women	B-X
expel	B-X
various	B-X
kinds	B-X
of	B-X
fluids	B-X
during	B-X
sexual	B-X
activities	B-X
.	B-X
HIV-1	B-X
Tat	B-X
was	B-X
also	B-X
found	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
other	B-X
HIV-1	B-X
proteins	B-X
including	B-X
Vpr	B-X
,	B-X
Nef	B-X
,	B-X
Nucleocapsid	B-X
(	B-X
NC	B-X
)	B-X
and	B-X
Rev	B-X
.	B-X
Research	B-X
in	B-X
the	B-X
recent	B-X
years	B-X
has	B-X
established	B-X
that	B-X
Tat	B-X
is	B-X
not	B-X
only	B-X
important	B-X
for	B-X
HIV-1	B-X
promoter	B-X
transactivation	B-X
and	B-X
virus	B-X
replication	B-X
but	B-X
also	B-X
modulating	B-X
multiple	B-X
cellular	B-X
and	B-X
molecular	B-X
functions	B-X
leading	B-X
to	B-X
HIV-1	B-X
pathogenicity	B-X
.	B-X

In	O
Drosophila	O
,	O
several	O
morphogenetic	O
signals	O
that	O
play	O
critical	O
roles	O
in	O
development	O
have	O
been	O
found	O
to	O
be	O
subject	O
to	O
such	O
regulation	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
diverse	B-X
signaling	B-X
systems	B-X
has	B-X
revealed	B-X
that	B-X
one	B-X
important	B-X
level	B-X
of	B-X
control	B-X
is	B-X
regulation	B-X
of	B-X
membrane	B-X
trafficking	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
In	B-X
Drosophila	B-X
,	B-X
several	B-X
morphogenetic	B-X
signals	B-X
that	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
development	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
subject	B-X
to	B-X
such	B-X
regulation	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
its	B-X
vertebrate	B-X
homologues	B-X
,	B-X
which	B-X
have	B-X
typical	B-X
N-terminal	B-X
signal	B-X
sequences	B-X
,	B-X
the	B-X
precursor	B-X
form	B-X
of	B-X
Drosophila	B-X
Hh	B-X
contains	B-X
an	B-X
internal	B-X
type-II	B-X
secretory	B-X
signal	B-X
motif	B-X
.	B-X
The	B-X
Short	B-X
Gastrulation	B-X
(	B-X
Sog	B-X
)	B-X
protein	B-X
is	B-X
another	B-X
secreted	B-X
Drosophila	B-X
protein	B-X
that	B-X
contains	B-X
a	B-X
type-II	B-X
signal	B-X
and	B-X
differs	B-X
from	B-X
its	B-X
vertebrate	B-X
ortholog	B-X
Chordin	B-X
which	B-X
contains	B-X
a	B-X
standard	B-X
signal	B-X
peptide	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulation	B-X
of	B-X
Sog	B-X
secretion	B-X
and	B-X
regulation	B-X
by	B-X
dHIP14	B-X
,	B-X
the	B-X
ortholog	B-X
of	B-X
a	B-X
mammalian	B-X
palmitoylase	B-X
first	B-X
identified	B-X
as	B-X
Huntington	B-X
Interacting	B-X
Protein	B-X
(	B-X
HIP	B-X
)	B-X
.	B-X

For	O
example	O
,	O
activity	O
of	O
the	O
Hedgehog	B-Protein
(	O
Hh	B-Protein
)	O
is	O
regulated	O
by	O
Raspberry	B-Protein
,	O
which	O
palmitoylates	O
Hh	B-Protein
.	O
<EOS>	B-X
The	B-X
activities	B-X
of	B-X
some	B-X
ligands	B-X
are	B-X
also	B-X
regulated	B-X
by	B-X
whether	B-X
they	B-X
are	B-X
membrane	B-X
bound	B-X
or	B-X
secreted	B-X
.	B-X
For	B-X
example	B-X
,	B-X
activity	B-X
of	B-X
the	B-X
Hedgehog	B-X
(	B-X
Hh	B-X
)	B-X
is	B-X
regulated	B-X
by	B-X
Raspberry	B-X
,	B-X
which	B-X
palmitoylates	B-X
Hh	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
palmitoylases	B-X
Porcupine	B-X
and	B-X
Raspberry	B-X
increase	B-X
the	B-X
activities	B-X
of	B-X
Wingless	B-X
(	B-X
Wg	B-X
)	B-X
and	B-X
the	B-X
EGF-ligand	B-X
Spitz	B-X
(	B-X
Spi	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
its	B-X
vertebrate	B-X
homologues	B-X
,	B-X
which	B-X
have	B-X
typical	B-X
N-terminal	B-X
signal	B-X
sequences	B-X
,	B-X
the	B-X
precursor	B-X
form	B-X
of	B-X
Drosophila	B-X
Hh	B-X
contains	B-X
an	B-X
internal	B-X
type-II	B-X
secretory	B-X
signal	B-X
motif	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
find	B-X
that	B-X
dHIP14	B-X
promotes	B-X
the	B-X
activity	B-X
of	B-X
Sog	B-X
in	B-X
vivo	B-X
.	B-X

Similarly	O
,	O
the	O
palmitoylases	O
Porcupine	B-Protein
and	O
Raspberry	B-Protein
increase	O
the	O
activities	O
of	O
Wingless	B-Protein
(	O
Wg	B-Protein
)	O
and	O
the	O
EGF	O
-	O
ligand	O
Spitz	B-Protein
(	O
Spi	B-Protein
)	O
,	O
respectively	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
diverse	B-X
signaling	B-X
systems	B-X
has	B-X
revealed	B-X
that	B-X
one	B-X
important	B-X
level	B-X
of	B-X
control	B-X
is	B-X
regulation	B-X
of	B-X
membrane	B-X
trafficking	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
The	B-X
activities	B-X
of	B-X
some	B-X
ligands	B-X
are	B-X
also	B-X
regulated	B-X
by	B-X
whether	B-X
they	B-X
are	B-X
membrane	B-X
bound	B-X
or	B-X
secreted	B-X
.	B-X
For	B-X
example	B-X
,	B-X
activity	B-X
of	B-X
the	B-X
Hedgehog	B-X
(	B-X
Hh	B-X
)	B-X
is	B-X
regulated	B-X
by	B-X
Raspberry	B-X
,	B-X
which	B-X
palmitoylates	B-X
Hh	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
palmitoylases	B-X
Porcupine	B-X
and	B-X
Raspberry	B-X
increase	B-X
the	B-X
activities	B-X
of	B-X
Wingless	B-X
(	B-X
Wg	B-X
)	B-X
and	B-X
the	B-X
EGF-ligand	B-X
Spitz	B-X
(	B-X
Spi	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
studies	B-X
highlight	B-X
the	B-X
growing	B-X
importance	B-X
of	B-X
lipid	B-X
modification	B-X
in	B-X
regulating	B-X
signaling	B-X
at	B-X
the	B-X
level	B-X
of	B-X
ligand	B-X
production	B-X
and	B-X
localization	B-X
.	B-X

In	O
contrast	O
to	O
its	O
vertebrate	O
homologues	O
,	O
which	O
have	O
typical	O
N	O
-	O
terminal	O
signal	O
sequences	O
,	O
the	O
precursor	O
form	O
of	O
Drosophila	O
Hh	B-Protein
contains	O
an	O
internal	O
type	O
-	O
II	O
secretory	O
signal	O
motif	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
diverse	B-X
signaling	B-X
systems	B-X
has	B-X
revealed	B-X
that	B-X
one	B-X
important	B-X
level	B-X
of	B-X
control	B-X
is	B-X
regulation	B-X
of	B-X
membrane	B-X
trafficking	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
In	B-X
Drosophila	B-X
,	B-X
several	B-X
morphogenetic	B-X
signals	B-X
that	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
development	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
subject	B-X
to	B-X
such	B-X
regulation	B-X
.	B-X
For	B-X
example	B-X
,	B-X
activity	B-X
of	B-X
the	B-X
Hedgehog	B-X
(	B-X
Hh	B-X
)	B-X
is	B-X
regulated	B-X
by	B-X
Raspberry	B-X
,	B-X
which	B-X
palmitoylates	B-X
Hh	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
its	B-X
vertebrate	B-X
homologues	B-X
,	B-X
which	B-X
have	B-X
typical	B-X
N-terminal	B-X
signal	B-X
sequences	B-X
,	B-X
the	B-X
precursor	B-X
form	B-X
of	B-X
Drosophila	B-X
Hh	B-X
contains	B-X
an	B-X
internal	B-X
type-II	B-X
secretory	B-X
signal	B-X
motif	B-X
.	B-X
The	B-X
Short	B-X
Gastrulation	B-X
(	B-X
Sog	B-X
)	B-X
protein	B-X
is	B-X
another	B-X
secreted	B-X
Drosophila	B-X
protein	B-X
that	B-X
contains	B-X
a	B-X
type-II	B-X
signal	B-X
and	B-X
differs	B-X
from	B-X
its	B-X
vertebrate	B-X
ortholog	B-X
Chordin	B-X
which	B-X
contains	B-X
a	B-X
standard	B-X
signal	B-X
peptide	B-X
.	B-X
In	B-X
S2	B-X
cells	B-X
,	B-X
dHIP14	B-X
promotes	B-X
secretion	B-X
of	B-X
Sog	B-X
as	B-X
well	B-X
as	B-X
stabilizing	B-X
a	B-X
membrane	B-X
associated	B-X
form	B-X
of	B-X
Sog	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
These	B-X
studies	B-X
highlight	B-X
the	B-X
growing	B-X
importance	B-X
of	B-X
lipid	B-X
modification	B-X
in	B-X
regulating	B-X
signaling	B-X
at	B-X
the	B-X
level	B-X
of	B-X
ligand	B-X
production	B-X
and	B-X
localization	B-X
.	B-X

The	O
Short	B-Protein
Gastrulation	I-Protein
(	O
Sog	B-Protein
)	O
protein	O
is	O
another	O
secreted	O
Drosophila	O
protein	O
that	O
contains	O
a	O
type	O
-	O
II	O
signal	O
and	O
differs	O
from	O
its	O
vertebrate	O
ortholog	O
Chordin	B-Protein
which	O
contains	O
a	O
standard	O
signal	O
peptide	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
diverse	B-X
signaling	B-X
systems	B-X
has	B-X
revealed	B-X
that	B-X
one	B-X
important	B-X
level	B-X
of	B-X
control	B-X
is	B-X
regulation	B-X
of	B-X
membrane	B-X
trafficking	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
The	B-X
activities	B-X
of	B-X
some	B-X
ligands	B-X
are	B-X
also	B-X
regulated	B-X
by	B-X
whether	B-X
they	B-X
are	B-X
membrane	B-X
bound	B-X
or	B-X
secreted	B-X
.	B-X
In	B-X
Drosophila	B-X
,	B-X
several	B-X
morphogenetic	B-X
signals	B-X
that	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
development	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
subject	B-X
to	B-X
such	B-X
regulation	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
its	B-X
vertebrate	B-X
homologues	B-X
,	B-X
which	B-X
have	B-X
typical	B-X
N-terminal	B-X
signal	B-X
sequences	B-X
,	B-X
the	B-X
precursor	B-X
form	B-X
of	B-X
Drosophila	B-X
Hh	B-X
contains	B-X
an	B-X
internal	B-X
type-II	B-X
secretory	B-X
signal	B-X
motif	B-X
.	B-X
The	B-X
Short	B-X
Gastrulation	B-X
(	B-X
Sog	B-X
)	B-X
protein	B-X
is	B-X
another	B-X
secreted	B-X
Drosophila	B-X
protein	B-X
that	B-X
contains	B-X
a	B-X
type-II	B-X
signal	B-X
and	B-X
differs	B-X
from	B-X
its	B-X
vertebrate	B-X
ortholog	B-X
Chordin	B-X
which	B-X
contains	B-X
a	B-X
standard	B-X
signal	B-X
peptide	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulation	B-X
of	B-X
Sog	B-X
secretion	B-X
and	B-X
regulation	B-X
by	B-X
dHIP14	B-X
,	B-X
the	B-X
ortholog	B-X
of	B-X
a	B-X
mammalian	B-X
palmitoylase	B-X
first	B-X
identified	B-X
as	B-X
Huntington	B-X
Interacting	B-X
Protein	B-X
(	B-X
HIP	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
dHIP14	B-X
binds	B-X
to	B-X
Sog	B-X
and	B-X
that	B-X
Sog	B-X
is	B-X
palmitoylated	B-X
.	B-X
In	B-X
S2	B-X
cells	B-X
,	B-X
dHIP14	B-X
promotes	B-X
secretion	B-X
of	B-X
Sog	B-X
as	B-X
well	B-X
as	B-X
stabilizing	B-X
a	B-X
membrane	B-X
associated	B-X
form	B-X
of	B-X
Sog	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
find	B-X
that	B-X
dHIP14	B-X
promotes	B-X
the	B-X
activity	B-X
of	B-X
Sog	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
studies	B-X
highlight	B-X
the	B-X
growing	B-X
importance	B-X
of	B-X
lipid	B-X
modification	B-X
in	B-X
regulating	B-X
signaling	B-X
at	B-X
the	B-X
level	B-X
of	B-X
ligand	B-X
production	B-X
and	B-X
localization	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
regulation	O
of	O
Sog	B-Protein
secretion	O
and	O
regulation	O
by	O
dHIP14	B-Protein
,	O
the	O
ortholog	O
of	O
a	O
mammalian	O
palmitoylase	O
first	O
identified	O
as	O
Huntington	O
Interacting	O
Protein	O
(	O
HIP	O
)	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
diverse	B-X
signaling	B-X
systems	B-X
has	B-X
revealed	B-X
that	B-X
one	B-X
important	B-X
level	B-X
of	B-X
control	B-X
is	B-X
regulation	B-X
of	B-X
membrane	B-X
trafficking	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
In	B-X
Drosophila	B-X
,	B-X
several	B-X
morphogenetic	B-X
signals	B-X
that	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
development	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
subject	B-X
to	B-X
such	B-X
regulation	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
palmitoylases	B-X
Porcupine	B-X
and	B-X
Raspberry	B-X
increase	B-X
the	B-X
activities	B-X
of	B-X
Wingless	B-X
(	B-X
Wg	B-X
)	B-X
and	B-X
the	B-X
EGF-ligand	B-X
Spitz	B-X
(	B-X
Spi	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Short	B-X
Gastrulation	B-X
(	B-X
Sog	B-X
)	B-X
protein	B-X
is	B-X
another	B-X
secreted	B-X
Drosophila	B-X
protein	B-X
that	B-X
contains	B-X
a	B-X
type-II	B-X
signal	B-X
and	B-X
differs	B-X
from	B-X
its	B-X
vertebrate	B-X
ortholog	B-X
Chordin	B-X
which	B-X
contains	B-X
a	B-X
standard	B-X
signal	B-X
peptide	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulation	B-X
of	B-X
Sog	B-X
secretion	B-X
and	B-X
regulation	B-X
by	B-X
dHIP14	B-X
,	B-X
the	B-X
ortholog	B-X
of	B-X
a	B-X
mammalian	B-X
palmitoylase	B-X
first	B-X
identified	B-X
as	B-X
Huntington	B-X
Interacting	B-X
Protein	B-X
(	B-X
HIP	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
dHIP14	B-X
binds	B-X
to	B-X
Sog	B-X
and	B-X
that	B-X
Sog	B-X
is	B-X
palmitoylated	B-X
.	B-X
In	B-X
S2	B-X
cells	B-X
,	B-X
dHIP14	B-X
promotes	B-X
secretion	B-X
of	B-X
Sog	B-X
as	B-X
well	B-X
as	B-X
stabilizing	B-X
a	B-X
membrane	B-X
associated	B-X
form	B-X
of	B-X
Sog	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
find	B-X
that	B-X
dHIP14	B-X
promotes	B-X
the	B-X
activity	B-X
of	B-X
Sog	B-X
in	B-X
vivo	B-X
.	B-X

We	O
show	O
that	O
dHIP14	B-Protein
binds	O
to	O
Sog	B-Protein
and	O
that	O
Sog	B-Protein
is	O
palmitoylated	O
.	O
<EOS>	B-X
The	B-X
Short	B-X
Gastrulation	B-X
(	B-X
Sog	B-X
)	B-X
protein	B-X
is	B-X
another	B-X
secreted	B-X
Drosophila	B-X
protein	B-X
that	B-X
contains	B-X
a	B-X
type-II	B-X
signal	B-X
and	B-X
differs	B-X
from	B-X
its	B-X
vertebrate	B-X
ortholog	B-X
Chordin	B-X
which	B-X
contains	B-X
a	B-X
standard	B-X
signal	B-X
peptide	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulation	B-X
of	B-X
Sog	B-X
secretion	B-X
and	B-X
regulation	B-X
by	B-X
dHIP14	B-X
,	B-X
the	B-X
ortholog	B-X
of	B-X
a	B-X
mammalian	B-X
palmitoylase	B-X
first	B-X
identified	B-X
as	B-X
Huntington	B-X
Interacting	B-X
Protein	B-X
(	B-X
HIP	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
dHIP14	B-X
binds	B-X
to	B-X
Sog	B-X
and	B-X
that	B-X
Sog	B-X
is	B-X
palmitoylated	B-X
.	B-X
In	B-X
S2	B-X
cells	B-X
,	B-X
dHIP14	B-X
promotes	B-X
secretion	B-X
of	B-X
Sog	B-X
as	B-X
well	B-X
as	B-X
stabilizing	B-X
a	B-X
membrane	B-X
associated	B-X
form	B-X
of	B-X
Sog	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
find	B-X
that	B-X
dHIP14	B-X
promotes	B-X
the	B-X
activity	B-X
of	B-X
Sog	B-X
in	B-X
vivo	B-X
.	B-X

In	O
S2	O
cells	O
,	O
dHIP14	B-Protein
promotes	O
secretion	O
of	O
Sog	B-Protein
as	O
well	O
as	O
stabilizing	O
a	O
membrane	O
associated	O
form	O
of	O
Sog	B-Protein
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
diverse	B-X
signaling	B-X
systems	B-X
has	B-X
revealed	B-X
that	B-X
one	B-X
important	B-X
level	B-X
of	B-X
control	B-X
is	B-X
regulation	B-X
of	B-X
membrane	B-X
trafficking	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
The	B-X
activities	B-X
of	B-X
some	B-X
ligands	B-X
are	B-X
also	B-X
regulated	B-X
by	B-X
whether	B-X
they	B-X
are	B-X
membrane	B-X
bound	B-X
or	B-X
secreted	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
its	B-X
vertebrate	B-X
homologues	B-X
,	B-X
which	B-X
have	B-X
typical	B-X
N-terminal	B-X
signal	B-X
sequences	B-X
,	B-X
the	B-X
precursor	B-X
form	B-X
of	B-X
Drosophila	B-X
Hh	B-X
contains	B-X
an	B-X
internal	B-X
type-II	B-X
secretory	B-X
signal	B-X
motif	B-X
.	B-X
The	B-X
Short	B-X
Gastrulation	B-X
(	B-X
Sog	B-X
)	B-X
protein	B-X
is	B-X
another	B-X
secreted	B-X
Drosophila	B-X
protein	B-X
that	B-X
contains	B-X
a	B-X
type-II	B-X
signal	B-X
and	B-X
differs	B-X
from	B-X
its	B-X
vertebrate	B-X
ortholog	B-X
Chordin	B-X
which	B-X
contains	B-X
a	B-X
standard	B-X
signal	B-X
peptide	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulation	B-X
of	B-X
Sog	B-X
secretion	B-X
and	B-X
regulation	B-X
by	B-X
dHIP14	B-X
,	B-X
the	B-X
ortholog	B-X
of	B-X
a	B-X
mammalian	B-X
palmitoylase	B-X
first	B-X
identified	B-X
as	B-X
Huntington	B-X
Interacting	B-X
Protein	B-X
(	B-X
HIP	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
dHIP14	B-X
binds	B-X
to	B-X
Sog	B-X
and	B-X
that	B-X
Sog	B-X
is	B-X
palmitoylated	B-X
.	B-X
In	B-X
S2	B-X
cells	B-X
,	B-X
dHIP14	B-X
promotes	B-X
secretion	B-X
of	B-X
Sog	B-X
as	B-X
well	B-X
as	B-X
stabilizing	B-X
a	B-X
membrane	B-X
associated	B-X
form	B-X
of	B-X
Sog	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
find	B-X
that	B-X
dHIP14	B-X
promotes	B-X
the	B-X
activity	B-X
of	B-X
Sog	B-X
in	B-X
vivo	B-X
.	B-X

We	O
examined	O
the	O
requirement	O
for	O
candidate	O
cysteine	O
residues	O
in	O
the	O
N	O
-	O
terminal	O
predicted	O
cytoplasmic	O
domain	O
of	O
Sog	B-Protein
and	O
find	O
that	O
Cys27	O
,	O
one	O
of	O
two	O
adjacent	O
cysteines	O
(	O
Cys27	O
and	O
Cys28	O
)	O
,	O
is	O
essential	O
for	O
the	O
full	O
activity	O
of	O
dHIP14	B-Protein
and	O
its	O
effect	O
on	O
Sog	B-Protein
.	O

Finally	O
,	O
we	O
find	O
that	O
dHIP14	B-Protein
promotes	O
the	O
activity	O
of	O
Sog	B-Protein
in	O
vivo	O
.	O
<EOS>	B-X
For	B-X
example	B-X
,	B-X
activity	B-X
of	B-X
the	B-X
Hedgehog	B-X
(	B-X
Hh	B-X
)	B-X
is	B-X
regulated	B-X
by	B-X
Raspberry	B-X
,	B-X
which	B-X
palmitoylates	B-X
Hh	B-X
.	B-X
The	B-X
Short	B-X
Gastrulation	B-X
(	B-X
Sog	B-X
)	B-X
protein	B-X
is	B-X
another	B-X
secreted	B-X
Drosophila	B-X
protein	B-X
that	B-X
contains	B-X
a	B-X
type-II	B-X
signal	B-X
and	B-X
differs	B-X
from	B-X
its	B-X
vertebrate	B-X
ortholog	B-X
Chordin	B-X
which	B-X
contains	B-X
a	B-X
standard	B-X
signal	B-X
peptide	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulation	B-X
of	B-X
Sog	B-X
secretion	B-X
and	B-X
regulation	B-X
by	B-X
dHIP14	B-X
,	B-X
the	B-X
ortholog	B-X
of	B-X
a	B-X
mammalian	B-X
palmitoylase	B-X
first	B-X
identified	B-X
as	B-X
Huntington	B-X
Interacting	B-X
Protein	B-X
(	B-X
HIP	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
dHIP14	B-X
binds	B-X
to	B-X
Sog	B-X
and	B-X
that	B-X
Sog	B-X
is	B-X
palmitoylated	B-X
.	B-X
In	B-X
S2	B-X
cells	B-X
,	B-X
dHIP14	B-X
promotes	B-X
secretion	B-X
of	B-X
Sog	B-X
as	B-X
well	B-X
as	B-X
stabilizing	B-X
a	B-X
membrane	B-X
associated	B-X
form	B-X
of	B-X
Sog	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
requirement	B-X
for	B-X
candidate	B-X
cysteine	B-X
residues	B-X
in	B-X
the	B-X
N-terminal	B-X
predicted	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
Sog	B-X
and	B-X
find	B-X
that	B-X
Cys27	B-X
,	B-X
one	B-X
of	B-X
two	B-X
adjacent	B-X
cysteines	B-X
(	B-X
Cys27	B-X
and	B-X
Cys28	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
dHIP14	B-X
and	B-X
its	B-X
effect	B-X
on	B-X
Sog	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
find	B-X
that	B-X
dHIP14	B-X
promotes	B-X
the	B-X
activity	B-X
of	B-X
Sog	B-X
in	B-X
vivo	B-X
.	B-X

These	O
studies	O
highlight	O
the	O
growing	O
importance	O
of	O
lipid	O
modification	O
in	O
regulating	O
signaling	O
at	O
the	O
level	O
of	O
ligand	O
production	O
and	O
localization	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
diverse	B-X
signaling	B-X
systems	B-X
has	B-X
revealed	B-X
that	B-X
one	B-X
important	B-X
level	B-X
of	B-X
control	B-X
is	B-X
regulation	B-X
of	B-X
membrane	B-X
trafficking	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
The	B-X
activities	B-X
of	B-X
some	B-X
ligands	B-X
are	B-X
also	B-X
regulated	B-X
by	B-X
whether	B-X
they	B-X
are	B-X
membrane	B-X
bound	B-X
or	B-X
secreted	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
palmitoylases	B-X
Porcupine	B-X
and	B-X
Raspberry	B-X
increase	B-X
the	B-X
activities	B-X
of	B-X
Wingless	B-X
(	B-X
Wg	B-X
)	B-X
and	B-X
the	B-X
EGF-ligand	B-X
Spitz	B-X
(	B-X
Spi	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
studies	B-X
highlight	B-X
the	B-X
growing	B-X
importance	B-X
of	B-X
lipid	B-X
modification	B-X
in	B-X
regulating	B-X
signaling	B-X
at	B-X
the	B-X
level	B-X
of	B-X
ligand	B-X
production	B-X
and	B-X
localization	B-X
.	B-X

GlcNAcylation	O
plays	O
an	O
essential	O
role	O
in	O
breast	O
cancer	O
metastasis	O
.	O
<EOS>	B-X
GlcNAcylation	B-X
,	B-X
a	B-X
dynamic	B-X
posttranslational	B-X
modification	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
processes	B-X
and	B-X
some	B-X
human	B-X
diseases	B-X
.	B-X
Although	B-X
there	B-X
is	B-X
emerging	B-X
evidence	B-X
that	B-X
some	B-X
tumor-associated	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
GlcNAcylation	B-X
,	B-X
the	B-X
role	B-X
of	B-X
GlcNAcylation	B-X
in	B-X
tumor	B-X
progression	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
GlcNAcylation	B-X
enhances	B-X
the	B-X
migration/invasion	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
lung	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
is	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
GlcNAcylation-induced	B-X
breast	B-X
cancer	B-X
metastasis	B-X
.	B-X
p120	B-X
and	B-X
beta-catenin	B-X
,	B-X
but	B-X
not	B-X
E-cadherin	B-X
,	B-X
are	B-X
GlcNAcylated	B-X
;	B-X
the	B-X
GlcNAcylation	B-X
of	B-X
p120	B-X
and	B-X
beta-catenin	B-X
might	B-X
play	B-X
roles	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
.	B-X
Moreover	B-X
,	B-X
immunohistochemistry	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
global	B-X
GlcNAcylation	B-X
level	B-X
in	B-X
breast	B-X
tumor	B-X
tissues	B-X
is	B-X
elevated	B-X
significantly	B-X
as	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
adjacent	B-X
tissues	B-X
;	B-X
further	B-X
,	B-X
GlcNAcylation	B-X
was	B-X
significantly	B-X
enhanced	B-X
in	B-X
metastatic	B-X
lymph	B-X
nodes	B-X
compared	B-X
with	B-X
their	B-X
corresponding	B-X
primary	B-X
tumor	B-X
tissues	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
clearly	B-X
elucidate	B-X
the	B-X
roles	B-X
and	B-X
mechanisms	B-X
whereby	B-X
GlcNAcylation	B-X
influences	B-X
the	B-X
malignant	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
GlcNAcylation	B-X
might	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X

GlcNAcylation	O
,	O
a	O
dynamic	O
posttranslational	O
modification	O
,	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
biological	O
processes	O
and	O
some	O
human	O
diseases	O
.	O

Although	O
there	O
is	O
emerging	O
evidence	O
that	O
some	O
tumor	O
-	O
associated	O
proteins	O
are	O
modified	O
by	O
GlcNAcylation	O
,	O
the	O
role	O
of	O
GlcNAcylation	O
in	O
tumor	O
progression	O
remains	O
unclear	O
.	O
<EOS>	B-X
GlcNAcylation	B-X
,	B-X
a	B-X
dynamic	B-X
posttranslational	B-X
modification	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
processes	B-X
and	B-X
some	B-X
human	B-X
diseases	B-X
.	B-X
Although	B-X
there	B-X
is	B-X
emerging	B-X
evidence	B-X
that	B-X
some	B-X
tumor-associated	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
GlcNAcylation	B-X
,	B-X
the	B-X
role	B-X
of	B-X
GlcNAcylation	B-X
in	B-X
tumor	B-X
progression	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
GlcNAcylation	B-X
enhances	B-X
the	B-X
migration/invasion	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
lung	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
is	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
GlcNAcylation-induced	B-X
breast	B-X
cancer	B-X
metastasis	B-X
.	B-X
p120	B-X
and	B-X
beta-catenin	B-X
,	B-X
but	B-X
not	B-X
E-cadherin	B-X
,	B-X
are	B-X
GlcNAcylated	B-X
;	B-X
the	B-X
GlcNAcylation	B-X
of	B-X
p120	B-X
and	B-X
beta-catenin	B-X
might	B-X
play	B-X
roles	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
.	B-X
Moreover	B-X
,	B-X
immunohistochemistry	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
global	B-X
GlcNAcylation	B-X
level	B-X
in	B-X
breast	B-X
tumor	B-X
tissues	B-X
is	B-X
elevated	B-X
significantly	B-X
as	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
adjacent	B-X
tissues	B-X
;	B-X
further	B-X
,	B-X
GlcNAcylation	B-X
was	B-X
significantly	B-X
enhanced	B-X
in	B-X
metastatic	B-X
lymph	B-X
nodes	B-X
compared	B-X
with	B-X
their	B-X
corresponding	B-X
primary	B-X
tumor	B-X
tissues	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
clearly	B-X
elucidate	B-X
the	B-X
roles	B-X
and	B-X
mechanisms	B-X
whereby	B-X
GlcNAcylation	B-X
influences	B-X
the	B-X
malignant	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
GlcNAcylation	B-X
might	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
GlcNAcylation	O
enhances	O
the	O
migration	O
/	O
invasion	O
of	O
breast	O
cancer	O
cells	O
in	O
vitro	O
and	O
lung	O
metastasis	O
in	O
vivo	O
.	O
<EOS>	B-X
GlcNAcylation	B-X
,	B-X
a	B-X
dynamic	B-X
posttranslational	B-X
modification	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
processes	B-X
and	B-X
some	B-X
human	B-X
diseases	B-X
.	B-X
Although	B-X
there	B-X
is	B-X
emerging	B-X
evidence	B-X
that	B-X
some	B-X
tumor-associated	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
GlcNAcylation	B-X
,	B-X
the	B-X
role	B-X
of	B-X
GlcNAcylation	B-X
in	B-X
tumor	B-X
progression	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
GlcNAcylation	B-X
enhances	B-X
the	B-X
migration/invasion	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
lung	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
is	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
GlcNAcylation-induced	B-X
breast	B-X
cancer	B-X
metastasis	B-X
.	B-X
p120	B-X
and	B-X
beta-catenin	B-X
,	B-X
but	B-X
not	B-X
E-cadherin	B-X
,	B-X
are	B-X
GlcNAcylated	B-X
;	B-X
the	B-X
GlcNAcylation	B-X
of	B-X
p120	B-X
and	B-X
beta-catenin	B-X
might	B-X
play	B-X
roles	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
.	B-X
Moreover	B-X
,	B-X
immunohistochemistry	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
global	B-X
GlcNAcylation	B-X
level	B-X
in	B-X
breast	B-X
tumor	B-X
tissues	B-X
is	B-X
elevated	B-X
significantly	B-X
as	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
adjacent	B-X
tissues	B-X
;	B-X
further	B-X
,	B-X
GlcNAcylation	B-X
was	B-X
significantly	B-X
enhanced	B-X
in	B-X
metastatic	B-X
lymph	B-X
nodes	B-X
compared	B-X
with	B-X
their	B-X
corresponding	B-X
primary	B-X
tumor	B-X
tissues	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
clearly	B-X
elucidate	B-X
the	B-X
roles	B-X
and	B-X
mechanisms	B-X
whereby	B-X
GlcNAcylation	B-X
influences	B-X
the	B-X
malignant	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
GlcNAcylation	B-X
might	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X

The	O
decrease	O
of	O
cell	O
surface	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
is	O
the	O
molecular	O
mechanism	O
underlying	O
GlcNAcylation	O
-	O
induced	O
breast	O
cancer	O
metastasis	O
.	O
<EOS>	B-X
GlcNAcylation	B-X
,	B-X
a	B-X
dynamic	B-X
posttranslational	B-X
modification	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
processes	B-X
and	B-X
some	B-X
human	B-X
diseases	B-X
.	B-X
Although	B-X
there	B-X
is	B-X
emerging	B-X
evidence	B-X
that	B-X
some	B-X
tumor-associated	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
GlcNAcylation	B-X
,	B-X
the	B-X
role	B-X
of	B-X
GlcNAcylation	B-X
in	B-X
tumor	B-X
progression	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
GlcNAcylation	B-X
enhances	B-X
the	B-X
migration/invasion	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
lung	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
is	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
GlcNAcylation-induced	B-X
breast	B-X
cancer	B-X
metastasis	B-X
.	B-X
p120	B-X
and	B-X
beta-catenin	B-X
,	B-X
but	B-X
not	B-X
E-cadherin	B-X
,	B-X
are	B-X
GlcNAcylated	B-X
;	B-X
the	B-X
GlcNAcylation	B-X
of	B-X
p120	B-X
and	B-X
beta-catenin	B-X
might	B-X
play	B-X
roles	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
.	B-X
Moreover	B-X
,	B-X
immunohistochemistry	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
global	B-X
GlcNAcylation	B-X
level	B-X
in	B-X
breast	B-X
tumor	B-X
tissues	B-X
is	B-X
elevated	B-X
significantly	B-X
as	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
adjacent	B-X
tissues	B-X
;	B-X
further	B-X
,	B-X
GlcNAcylation	B-X
was	B-X
significantly	B-X
enhanced	B-X
in	B-X
metastatic	B-X
lymph	B-X
nodes	B-X
compared	B-X
with	B-X
their	B-X
corresponding	B-X
primary	B-X
tumor	B-X
tissues	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
clearly	B-X
elucidate	B-X
the	B-X
roles	B-X
and	B-X
mechanisms	B-X
whereby	B-X
GlcNAcylation	B-X
influences	B-X
the	B-X
malignant	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
GlcNAcylation	B-X
might	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X

p120	B-Protein
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
,	O
but	O
not	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
,	O
are	O
GlcNAcylated	O
;	O
the	O
GlcNAcylation	O
of	O
p120	B-Protein
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
might	O
play	O
roles	O
in	O
the	O
decrease	O
of	O
cell	O
surface	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
.	O
<EOS>	B-X
Cadherins	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
tissue	B-X
homeostasis	B-X
,	B-X
as	B-X
they	B-X
are	B-X
responsible	B-X
for	B-X
cell-cell	B-X
adhesion	B-X
during	B-X
embryogenesis	B-X
,	B-X
tissue	B-X
morphogenesis	B-X
,	B-X
differentiation	B-X
and	B-X
carcinogenesis	B-X
.	B-X
Cadherins	B-X
are	B-X
inseparably	B-X
connected	B-X
with	B-X
catenins	B-X
,	B-X
forming	B-X
cadherin-catenin	B-X
complexes	B-X
,	B-X
which	B-X
are	B-X
crucial	B-X
for	B-X
cell-to-cell	B-X
adherence	B-X
.	B-X
Any	B-X
dysfunction	B-X
or	B-X
destabilization	B-X
of	B-X
cadherin-catenin	B-X
complex	B-X
may	B-X
result	B-X
in	B-X
tumor	B-X
progression	B-X
.	B-X
Epithelial	B-X
mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
is	B-X
a	B-X
mechanism	B-X
in	B-X
which	B-X
epithelial	B-X
cadherin	B-X
(	B-X
E-cadherin	B-X
)	B-X
expression	B-X
is	B-X
lost	B-X
during	B-X
tumor	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
during	B-X
tumorigenesis	B-X
,	B-X
many	B-X
processes	B-X
take	B-X
place	B-X
,	B-X
and	B-X
downregulation	B-X
of	B-X
E-cadherin	B-X
,	B-X
nuclear	B-X
β-catenin	B-X
and	B-X
p120	B-X
catenin	B-X
(	B-X
p120	B-X
)	B-X
signaling	B-X
are	B-X
among	B-X
the	B-X
most	B-X
critical	B-X
.	B-X
Additional	B-X
signaling	B-X
pathways	B-X
,	B-X
such	B-X
as	B-X
Receptor	B-X
tyrosine	B-X
kinase	B-X
(	B-X
RTK	B-X
)	B-X
,	B-X
Rho	B-X
GTPases	B-X
,	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
and	B-X
Hippo	B-X
affect	B-X
cadherin	B-X
cell-cell	B-X
adhesion	B-X
and	B-X
also	B-X
contribute	B-X
to	B-X
tumor	B-X
progression	B-X
and	B-X
metastasis	B-X
.	B-X
Many	B-X
signaling	B-X
pathways	B-X
may	B-X
be	B-X
activated	B-X
during	B-X
tumorigenesis	B-X
;	B-X
thus	B-X
,	B-X
cadherin-targeting	B-X
drugs	B-X
seem	B-X
to	B-X
limit	B-X
the	B-X
progression	B-X
of	B-X
malignant	B-X
tumor	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
role	B-X
of	B-X
cadherins	B-X
in	B-X
selected	B-X
signaling	B-X
mechanisms	B-X
involved	B-X
in	B-X
tumor	B-X
growth	B-X
.	B-X
The	B-X
clinical	B-X
importance	B-X
of	B-X
cadherin	B-X
will	B-X
be	B-X
discussed	B-X
in	B-X
cases	B-X
of	B-X
human	B-X
and	B-X
animal	B-X
cancers	B-X
.	B-X

Moreover	O
,	O
immunohistochemistry	O
analysis	O
indicated	O
that	O
the	O
global	O
GlcNAcylation	O
level	O
in	O
breast	O
tumor	O
tissues	O
is	O
elevated	O
significantly	O
as	O
compared	O
with	O
that	O
in	O
the	O
corresponding	O
adjacent	O
tissues	O
;	O
further	O
,	O
GlcNAcylation	O
was	O
significantly	O
enhanced	O
in	O
metastatic	O
lymph	O
nodes	O
compared	O
with	O
their	O
corresponding	O
primary	O
tumor	O
tissues	O
.	O
<EOS>	B-X
GlcNAcylation	B-X
,	B-X
a	B-X
dynamic	B-X
posttranslational	B-X
modification	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
processes	B-X
and	B-X
some	B-X
human	B-X
diseases	B-X
.	B-X
Although	B-X
there	B-X
is	B-X
emerging	B-X
evidence	B-X
that	B-X
some	B-X
tumor-associated	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
GlcNAcylation	B-X
,	B-X
the	B-X
role	B-X
of	B-X
GlcNAcylation	B-X
in	B-X
tumor	B-X
progression	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
GlcNAcylation	B-X
enhances	B-X
the	B-X
migration/invasion	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
lung	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
is	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
GlcNAcylation-induced	B-X
breast	B-X
cancer	B-X
metastasis	B-X
.	B-X
p120	B-X
and	B-X
beta-catenin	B-X
,	B-X
but	B-X
not	B-X
E-cadherin	B-X
,	B-X
are	B-X
GlcNAcylated	B-X
;	B-X
the	B-X
GlcNAcylation	B-X
of	B-X
p120	B-X
and	B-X
beta-catenin	B-X
might	B-X
play	B-X
roles	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
.	B-X
Moreover	B-X
,	B-X
immunohistochemistry	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
global	B-X
GlcNAcylation	B-X
level	B-X
in	B-X
breast	B-X
tumor	B-X
tissues	B-X
is	B-X
elevated	B-X
significantly	B-X
as	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
adjacent	B-X
tissues	B-X
;	B-X
further	B-X
,	B-X
GlcNAcylation	B-X
was	B-X
significantly	B-X
enhanced	B-X
in	B-X
metastatic	B-X
lymph	B-X
nodes	B-X
compared	B-X
with	B-X
their	B-X
corresponding	B-X
primary	B-X
tumor	B-X
tissues	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
clearly	B-X
elucidate	B-X
the	B-X
roles	B-X
and	B-X
mechanisms	B-X
whereby	B-X
GlcNAcylation	B-X
influences	B-X
the	B-X
malignant	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
GlcNAcylation	B-X
might	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X

This	O
is	O
the	O
first	O
report	O
to	O
clearly	O
elucidate	O
the	O
roles	O
and	O
mechanisms	O
whereby	O
GlcNAcylation	O
influences	O
the	O
malignant	O
properties	O
of	O
breast	O
cancer	O
cells	O
.	O
<EOS>	B-X
GlcNAcylation	B-X
,	B-X
a	B-X
dynamic	B-X
posttranslational	B-X
modification	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
processes	B-X
and	B-X
some	B-X
human	B-X
diseases	B-X
.	B-X
Although	B-X
there	B-X
is	B-X
emerging	B-X
evidence	B-X
that	B-X
some	B-X
tumor-associated	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
GlcNAcylation	B-X
,	B-X
the	B-X
role	B-X
of	B-X
GlcNAcylation	B-X
in	B-X
tumor	B-X
progression	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
GlcNAcylation	B-X
enhances	B-X
the	B-X
migration/invasion	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
lung	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
is	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
GlcNAcylation-induced	B-X
breast	B-X
cancer	B-X
metastasis	B-X
.	B-X
p120	B-X
and	B-X
beta-catenin	B-X
,	B-X
but	B-X
not	B-X
E-cadherin	B-X
,	B-X
are	B-X
GlcNAcylated	B-X
;	B-X
the	B-X
GlcNAcylation	B-X
of	B-X
p120	B-X
and	B-X
beta-catenin	B-X
might	B-X
play	B-X
roles	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
.	B-X
Moreover	B-X
,	B-X
immunohistochemistry	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
global	B-X
GlcNAcylation	B-X
level	B-X
in	B-X
breast	B-X
tumor	B-X
tissues	B-X
is	B-X
elevated	B-X
significantly	B-X
as	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
adjacent	B-X
tissues	B-X
;	B-X
further	B-X
,	B-X
GlcNAcylation	B-X
was	B-X
significantly	B-X
enhanced	B-X
in	B-X
metastatic	B-X
lymph	B-X
nodes	B-X
compared	B-X
with	B-X
their	B-X
corresponding	B-X
primary	B-X
tumor	B-X
tissues	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
clearly	B-X
elucidate	B-X
the	B-X
roles	B-X
and	B-X
mechanisms	B-X
whereby	B-X
GlcNAcylation	B-X
influences	B-X
the	B-X
malignant	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
GlcNAcylation	B-X
might	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X

These	O
results	O
also	O
suggest	O
that	O
GlcNAcylation	O
might	O
be	O
a	O
potential	O
target	O
for	O
the	O
diagnosis	O
and	O
therapy	O
of	O
breast	O
cancer	O
.	O
<EOS>	B-X
GlcNAcylation	B-X
,	B-X
a	B-X
dynamic	B-X
posttranslational	B-X
modification	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
processes	B-X
and	B-X
some	B-X
human	B-X
diseases	B-X
.	B-X
Although	B-X
there	B-X
is	B-X
emerging	B-X
evidence	B-X
that	B-X
some	B-X
tumor-associated	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
GlcNAcylation	B-X
,	B-X
the	B-X
role	B-X
of	B-X
GlcNAcylation	B-X
in	B-X
tumor	B-X
progression	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
GlcNAcylation	B-X
enhances	B-X
the	B-X
migration/invasion	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
lung	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
is	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
GlcNAcylation-induced	B-X
breast	B-X
cancer	B-X
metastasis	B-X
.	B-X
p120	B-X
and	B-X
beta-catenin	B-X
,	B-X
but	B-X
not	B-X
E-cadherin	B-X
,	B-X
are	B-X
GlcNAcylated	B-X
;	B-X
the	B-X
GlcNAcylation	B-X
of	B-X
p120	B-X
and	B-X
beta-catenin	B-X
might	B-X
play	B-X
roles	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
cell	B-X
surface	B-X
E-cadherin	B-X
.	B-X
Moreover	B-X
,	B-X
immunohistochemistry	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
global	B-X
GlcNAcylation	B-X
level	B-X
in	B-X
breast	B-X
tumor	B-X
tissues	B-X
is	B-X
elevated	B-X
significantly	B-X
as	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
adjacent	B-X
tissues	B-X
;	B-X
further	B-X
,	B-X
GlcNAcylation	B-X
was	B-X
significantly	B-X
enhanced	B-X
in	B-X
metastatic	B-X
lymph	B-X
nodes	B-X
compared	B-X
with	B-X
their	B-X
corresponding	B-X
primary	B-X
tumor	B-X
tissues	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
clearly	B-X
elucidate	B-X
the	B-X
roles	B-X
and	B-X
mechanisms	B-X
whereby	B-X
GlcNAcylation	B-X
influences	B-X
the	B-X
malignant	B-X
properties	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
also	B-X
suggest	B-X
that	B-X
GlcNAcylation	B-X
might	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X

C	O
.	O
elegans	O
CAND	B-Protein
-	I-Protein
1	I-Protein
regulates	O
cullin	O
neddylation	O
,	O
cell	O
proliferation	O
and	O
morphogenesis	O
in	O
specific	O
tissues	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
are	B-X
critical	B-X
regulators	B-X
of	B-X
multiple	B-X
developmental	B-X
and	B-X
cellular	B-X
processes	B-X
in	B-X
eukaryotes	B-X
.	B-X
CAND1	B-X
is	B-X
a	B-X
biochemical	B-X
inhibitor	B-X
of	B-X
CRLs	B-X
,	B-X
yet	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
promote	B-X
CRL	B-X
activity	B-X
in	B-X
plant	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
analyze	B-X
CAND1	B-X
function	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
developing	B-X
metazoan	B-X
organism	B-X
.	B-X
Caenorhabditis	B-X
elegans	B-X
CAND-1	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
all	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
it	B-X
physically	B-X
interacts	B-X
with	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
is	B-X
required	B-X
for	B-X
cullin	B-X
activity	B-X
in	B-X
animals	B-X
and	B-X
plants	B-X
.	B-X
In	B-X
cand-1	B-X
mutants	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
neddylated	B-X
isoforms	B-X
of	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
are	B-X
increased	B-X
,	B-X
indicating	B-X
that	B-X
CAND-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
cullin	B-X
neddylation	B-X
.	B-X
cand-1	B-X
mutants	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
partial	B-X
loss	B-X
of	B-X
cullin	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
CAND-1	B-X
facilitates	B-X
CRL	B-X
functions	B-X
.	B-X
cand-1	B-X
mutants	B-X
exhibit	B-X
impenetrant	B-X
phenotypes	B-X
,	B-X
including	B-X
developmental	B-X
arrest	B-X
,	B-X
morphological	B-X
defects	B-X
of	B-X
the	B-X
vulva	B-X
and	B-X
tail	B-X
,	B-X
and	B-X
reduced	B-X
fecundity	B-X
.	B-X
cand-1	B-X
mutants	B-X
share	B-X
with	B-X
cul-1	B-X
and	B-X
lin-23	B-X
mutants	B-X
the	B-X
phenotypes	B-X
of	B-X
supernumerary	B-X
seam	B-X
cell	B-X
divisions	B-X
,	B-X
defective	B-X
alae	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
target	B-X
the	B-X
glutamate	B-X
receptor	B-X
GLR-1	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
cand-1	B-X
mutants	B-X
have	B-X
phenotypes	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
complex	B-X
,	B-X
but	B-X
lack	B-X
phenotypes	B-X
associated	B-X
with	B-X
other	B-X
specific	B-X
CRL	B-X
complexes	B-X
,	B-X
suggests	B-X
that	B-X
CAND-1	B-X
is	B-X
differentially	B-X
required	B-X
for	B-X
the	B-X
activity	B-X
of	B-X
distinct	B-X
CRL	B-X
complexes	B-X
.	B-X

Cullin	O
-	O
RING	O
ubiquitin	B-Protein
ligases	O
(	O
CRLs	O
)	O
are	O
critical	O
regulators	O
of	O
multiple	O
developmental	O
and	O
cellular	O
processes	O
in	O
eukaryotes	O
.	O
<EOS>	B-X
Cullin-RING	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
are	B-X
large	B-X
and	B-X
diverse	B-X
multisubunit	B-X
protein	B-X
complexes	B-X
that	B-X
contribute	B-X
to	B-X
about	B-X
one-fifth	B-X
of	B-X
ubiquitin-dependent	B-X
protein	B-X
turnover	B-X
in	B-X
cells	B-X
.	B-X
CRLs	B-X
are	B-X
activated	B-X
by	B-X
the	B-X
attachment	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
neural	B-X
precursor	B-X
cell	B-X
expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
8	B-X
(	B-X
NEDD8	B-X
)	B-X
to	B-X
the	B-X
cullin	B-X
subunits	B-X
.	B-X
This	B-X
cullin	B-X
neddylation	B-X
is	B-X
essential	B-X
for	B-X
a	B-X
plethora	B-X
of	B-X
CRL-regulated	B-X
cellular	B-X
processes	B-X
and	B-X
is	B-X
vital	B-X
for	B-X
life	B-X
.	B-X
In	B-X
mammals	B-X
,	B-X
neddylation	B-X
is	B-X
promoted	B-X
by	B-X
the	B-X
five	B-X
co-E3	B-X
ligases	B-X
,	B-X
defective	B-X
in	B-X
cullin	B-X
neddylation	B-X
1	B-X
domain-containing	B-X
1-5	B-X
(	B-X
DCNL1-5	B-X
)	B-X
;	B-X
however	B-X
,	B-X
their	B-X
functional	B-X
regulation	B-X
within	B-X
the	B-X
CRL	B-X
complex	B-X
remains	B-X
elusive	B-X
.	B-X
We	B-X
found	B-X
here	B-X
that	B-X
the	B-X
ubiquitin-associated	B-X
(	B-X
UBA	B-X
)	B-X
domain-containing	B-X
DCNL1	B-X
is	B-X
monoubiquitylated	B-X
when	B-X
bound	B-X
to	B-X
CRLs	B-X
and	B-X
that	B-X
this	B-X
monoubiquitylation	B-X
depends	B-X
on	B-X
the	B-X
CRL-associated	B-X
Ariadne	B-X
RBR	B-X
ligases	B-X
TRIAD1	B-X
(	B-X
ARIH2	B-X
)	B-X
and	B-X
HHARI	B-X
(	B-X
ARIH1	B-X
)	B-X
and	B-X
strictly	B-X
requires	B-X
the	B-X
DCNL1	B-X
's	B-X
UBA	B-X
domain	B-X
.	B-X

CAND1	B-Protein
is	O
a	O
biochemical	O
inhibitor	O
of	O
CRLs	O
,	O
yet	O
has	O
been	O
shown	O
to	O
promote	O
CRL	O
activity	O
in	O
plant	O
and	O
mammalian	O
cells	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
are	B-X
critical	B-X
regulators	B-X
of	B-X
multiple	B-X
developmental	B-X
and	B-X
cellular	B-X
processes	B-X
in	B-X
eukaryotes	B-X
.	B-X
CAND1	B-X
is	B-X
a	B-X
biochemical	B-X
inhibitor	B-X
of	B-X
CRLs	B-X
,	B-X
yet	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
promote	B-X
CRL	B-X
activity	B-X
in	B-X
plant	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
analyze	B-X
CAND1	B-X
function	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
developing	B-X
metazoan	B-X
organism	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
is	B-X
required	B-X
for	B-X
cullin	B-X
activity	B-X
in	B-X
animals	B-X
and	B-X
plants	B-X
.	B-X
cand-1	B-X
mutants	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
partial	B-X
loss	B-X
of	B-X
cullin	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
CAND-1	B-X
facilitates	B-X
CRL	B-X
functions	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
cand-1	B-X
mutants	B-X
have	B-X
phenotypes	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
complex	B-X
,	B-X
but	B-X
lack	B-X
phenotypes	B-X
associated	B-X
with	B-X
other	B-X
specific	B-X
CRL	B-X
complexes	B-X
,	B-X
suggests	B-X
that	B-X
CAND-1	B-X
is	B-X
differentially	B-X
required	B-X
for	B-X
the	B-X
activity	B-X
of	B-X
distinct	B-X
CRL	B-X
complexes	B-X
.	B-X

Here	O
we	O
analyze	O
CAND1	B-Protein
function	O
in	O
the	O
context	O
of	O
a	O
developing	O
metazoan	O
organism	O
.	O
<EOS>	B-X
CAND1	B-X
is	B-X
a	B-X
biochemical	B-X
inhibitor	B-X
of	B-X
CRLs	B-X
,	B-X
yet	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
promote	B-X
CRL	B-X
activity	B-X
in	B-X
plant	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
analyze	B-X
CAND1	B-X
function	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
developing	B-X
metazoan	B-X
organism	B-X
.	B-X
cand-1	B-X
mutants	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
partial	B-X
loss	B-X
of	B-X
cullin	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
CAND-1	B-X
facilitates	B-X
CRL	B-X
functions	B-X
.	B-X

Caenorhabditis	O
elegans	O
CAND	B-Protein
-	I-Protein
1	I-Protein
is	O
capable	O
of	O
binding	O
to	O
all	O
of	O
the	O
cullins	O
,	O
and	O
we	O
show	O
that	O
it	O
physically	O
interacts	O
with	O
CUL	B-Protein
-	I-Protein
2	I-Protein
and	O
CUL	B-Protein
-	I-Protein
4	I-Protein
in	O
vivo	O
.	O
<EOS>	B-X
CAND1	B-X
is	B-X
a	B-X
biochemical	B-X
inhibitor	B-X
of	B-X
CRLs	B-X
,	B-X
yet	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
promote	B-X
CRL	B-X
activity	B-X
in	B-X
plant	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
analyze	B-X
CAND1	B-X
function	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
developing	B-X
metazoan	B-X
organism	B-X
.	B-X
Caenorhabditis	B-X
elegans	B-X
CAND-1	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
all	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
it	B-X
physically	B-X
interacts	B-X
with	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
cand-1	B-X
mutants	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
neddylated	B-X
isoforms	B-X
of	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
are	B-X
increased	B-X
,	B-X
indicating	B-X
that	B-X
CAND-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
cullin	B-X
neddylation	B-X
.	B-X
cand-1	B-X
mutants	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
partial	B-X
loss	B-X
of	B-X
cullin	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
CAND-1	B-X
facilitates	B-X
CRL	B-X
functions	B-X
.	B-X
cand-1	B-X
mutants	B-X
exhibit	B-X
impenetrant	B-X
phenotypes	B-X
,	B-X
including	B-X
developmental	B-X
arrest	B-X
,	B-X
morphological	B-X
defects	B-X
of	B-X
the	B-X
vulva	B-X
and	B-X
tail	B-X
,	B-X
and	B-X
reduced	B-X
fecundity	B-X
.	B-X
cand-1	B-X
mutants	B-X
share	B-X
with	B-X
cul-1	B-X
and	B-X
lin-23	B-X
mutants	B-X
the	B-X
phenotypes	B-X
of	B-X
supernumerary	B-X
seam	B-X
cell	B-X
divisions	B-X
,	B-X
defective	B-X
alae	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
target	B-X
the	B-X
glutamate	B-X
receptor	B-X
GLR-1	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
cand-1	B-X
mutants	B-X
have	B-X
phenotypes	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
complex	B-X
,	B-X
but	B-X
lack	B-X
phenotypes	B-X
associated	B-X
with	B-X
other	B-X
specific	B-X
CRL	B-X
complexes	B-X
,	B-X
suggests	B-X
that	B-X
CAND-1	B-X
is	B-X
differentially	B-X
required	B-X
for	B-X
the	B-X
activity	B-X
of	B-X
distinct	B-X
CRL	B-X
complexes	B-X
.	B-X

The	O
covalent	O
attachment	O
of	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
is	O
required	O
for	O
cullin	O
activity	O
in	O
animals	O
and	O
plants	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
are	B-X
critical	B-X
regulators	B-X
of	B-X
multiple	B-X
developmental	B-X
and	B-X
cellular	B-X
processes	B-X
in	B-X
eukaryotes	B-X
.	B-X
CAND1	B-X
is	B-X
a	B-X
biochemical	B-X
inhibitor	B-X
of	B-X
CRLs	B-X
,	B-X
yet	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
promote	B-X
CRL	B-X
activity	B-X
in	B-X
plant	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Caenorhabditis	B-X
elegans	B-X
CAND-1	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
all	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
it	B-X
physically	B-X
interacts	B-X
with	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
is	B-X
required	B-X
for	B-X
cullin	B-X
activity	B-X
in	B-X
animals	B-X
and	B-X
plants	B-X
.	B-X
In	B-X
cand-1	B-X
mutants	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
neddylated	B-X
isoforms	B-X
of	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
are	B-X
increased	B-X
,	B-X
indicating	B-X
that	B-X
CAND-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
cullin	B-X
neddylation	B-X
.	B-X
cand-1	B-X
mutants	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
partial	B-X
loss	B-X
of	B-X
cullin	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
CAND-1	B-X
facilitates	B-X
CRL	B-X
functions	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
cand-1	B-X
mutants	B-X
have	B-X
phenotypes	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
complex	B-X
,	B-X
but	B-X
lack	B-X
phenotypes	B-X
associated	B-X
with	B-X
other	B-X
specific	B-X
CRL	B-X
complexes	B-X
,	B-X
suggests	B-X
that	B-X
CAND-1	B-X
is	B-X
differentially	B-X
required	B-X
for	B-X
the	B-X
activity	B-X
of	B-X
distinct	B-X
CRL	B-X
complexes	B-X
.	B-X

In	O
cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
,	O
the	O
levels	O
of	O
the	O
neddylated	O
isoforms	O
of	O
CUL	B-Protein
-	I-Protein
2	I-Protein
and	O
CUL	B-Protein
-	I-Protein
4	I-Protein
are	O
increased	O
,	O
indicating	O
that	O
CAND	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
negative	O
regulator	O
of	O
cullin	O
neddylation	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
are	B-X
critical	B-X
regulators	B-X
of	B-X
multiple	B-X
developmental	B-X
and	B-X
cellular	B-X
processes	B-X
in	B-X
eukaryotes	B-X
.	B-X
CAND1	B-X
is	B-X
a	B-X
biochemical	B-X
inhibitor	B-X
of	B-X
CRLs	B-X
,	B-X
yet	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
promote	B-X
CRL	B-X
activity	B-X
in	B-X
plant	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
analyze	B-X
CAND1	B-X
function	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
developing	B-X
metazoan	B-X
organism	B-X
.	B-X
Caenorhabditis	B-X
elegans	B-X
CAND-1	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
all	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
it	B-X
physically	B-X
interacts	B-X
with	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
is	B-X
required	B-X
for	B-X
cullin	B-X
activity	B-X
in	B-X
animals	B-X
and	B-X
plants	B-X
.	B-X
In	B-X
cand-1	B-X
mutants	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
neddylated	B-X
isoforms	B-X
of	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
are	B-X
increased	B-X
,	B-X
indicating	B-X
that	B-X
CAND-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
cullin	B-X
neddylation	B-X
.	B-X
cand-1	B-X
mutants	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
partial	B-X
loss	B-X
of	B-X
cullin	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
CAND-1	B-X
facilitates	B-X
CRL	B-X
functions	B-X
.	B-X
cand-1	B-X
mutants	B-X
exhibit	B-X
impenetrant	B-X
phenotypes	B-X
,	B-X
including	B-X
developmental	B-X
arrest	B-X
,	B-X
morphological	B-X
defects	B-X
of	B-X
the	B-X
vulva	B-X
and	B-X
tail	B-X
,	B-X
and	B-X
reduced	B-X
fecundity	B-X
.	B-X
cand-1	B-X
mutants	B-X
share	B-X
with	B-X
cul-1	B-X
and	B-X
lin-23	B-X
mutants	B-X
the	B-X
phenotypes	B-X
of	B-X
supernumerary	B-X
seam	B-X
cell	B-X
divisions	B-X
,	B-X
defective	B-X
alae	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
target	B-X
the	B-X
glutamate	B-X
receptor	B-X
GLR-1	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
cand-1	B-X
mutants	B-X
have	B-X
phenotypes	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
complex	B-X
,	B-X
but	B-X
lack	B-X
phenotypes	B-X
associated	B-X
with	B-X
other	B-X
specific	B-X
CRL	B-X
complexes	B-X
,	B-X
suggests	B-X
that	B-X
CAND-1	B-X
is	B-X
differentially	B-X
required	B-X
for	B-X
the	B-X
activity	B-X
of	B-X
distinct	B-X
CRL	B-X
complexes	B-X
.	B-X

cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
are	O
hypersensitive	O
to	O
the	O
partial	O
loss	O
of	O
cullin	O
activity	O
,	O
suggesting	O
that	O
CAND	B-Protein
-	I-Protein
1	I-Protein
facilitates	O
CRL	O
functions	O
.	O

cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
exhibit	O
impenetrant	O
phenotypes	O
,	O
including	O
developmental	O
arrest	O
,	O
morphological	O
defects	O
of	O
the	O
vulva	O
and	O
tail	O
,	O
and	O
reduced	O
fecundity	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
are	B-X
critical	B-X
regulators	B-X
of	B-X
multiple	B-X
developmental	B-X
and	B-X
cellular	B-X
processes	B-X
in	B-X
eukaryotes	B-X
.	B-X
CAND1	B-X
is	B-X
a	B-X
biochemical	B-X
inhibitor	B-X
of	B-X
CRLs	B-X
,	B-X
yet	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
promote	B-X
CRL	B-X
activity	B-X
in	B-X
plant	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
analyze	B-X
CAND1	B-X
function	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
developing	B-X
metazoan	B-X
organism	B-X
.	B-X
Caenorhabditis	B-X
elegans	B-X
CAND-1	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
all	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
it	B-X
physically	B-X
interacts	B-X
with	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
cand-1	B-X
mutants	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
neddylated	B-X
isoforms	B-X
of	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
are	B-X
increased	B-X
,	B-X
indicating	B-X
that	B-X
CAND-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
cullin	B-X
neddylation	B-X
.	B-X
cand-1	B-X
mutants	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
partial	B-X
loss	B-X
of	B-X
cullin	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
CAND-1	B-X
facilitates	B-X
CRL	B-X
functions	B-X
.	B-X
cand-1	B-X
mutants	B-X
exhibit	B-X
impenetrant	B-X
phenotypes	B-X
,	B-X
including	B-X
developmental	B-X
arrest	B-X
,	B-X
morphological	B-X
defects	B-X
of	B-X
the	B-X
vulva	B-X
and	B-X
tail	B-X
,	B-X
and	B-X
reduced	B-X
fecundity	B-X
.	B-X
cand-1	B-X
mutants	B-X
share	B-X
with	B-X
cul-1	B-X
and	B-X
lin-23	B-X
mutants	B-X
the	B-X
phenotypes	B-X
of	B-X
supernumerary	B-X
seam	B-X
cell	B-X
divisions	B-X
,	B-X
defective	B-X
alae	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
target	B-X
the	B-X
glutamate	B-X
receptor	B-X
GLR-1	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
cand-1	B-X
mutants	B-X
have	B-X
phenotypes	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
complex	B-X
,	B-X
but	B-X
lack	B-X
phenotypes	B-X
associated	B-X
with	B-X
other	B-X
specific	B-X
CRL	B-X
complexes	B-X
,	B-X
suggests	B-X
that	B-X
CAND-1	B-X
is	B-X
differentially	B-X
required	B-X
for	B-X
the	B-X
activity	B-X
of	B-X
distinct	B-X
CRL	B-X
complexes	B-X
.	B-X

cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
share	O
with	O
cul	B-Protein
-	I-Protein
1	I-Protein
and	O
lin	B-Protein
-	I-Protein
23	I-Protein
mutants	O
the	O
phenotypes	O
of	O
supernumerary	O
seam	O
cell	O
divisions	O
,	O
defective	O
alae	O
formation	O
,	O
and	O
the	O
accumulation	O
of	O
the	O
SCF	O
(	O
LIN	B-Protein
-	I-Protein
23	I-Protein
)	O
target	O
the	O
glutamate	O
receptor	O
GLR	B-Protein
-	I-Protein
1	I-Protein
.	O

The	O
observation	O
that	O
cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
have	O
phenotypes	O
associated	O
with	O
the	O
loss	O
of	O
the	O
SCF	O
(	O
LIN	B-Protein
-	I-Protein
23	I-Protein
)	O
complex	O
,	O
but	O
lack	O
phenotypes	O
associated	O
with	O
other	O
specific	O
CRL	O
complexes	O
,	O
suggests	O
that	O
CAND	B-Protein
-	I-Protein
1	I-Protein
is	O
differentially	O
required	O
for	O
the	O
activity	O
of	O
distinct	O
CRL	O
complexes	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
are	B-X
critical	B-X
regulators	B-X
of	B-X
multiple	B-X
developmental	B-X
and	B-X
cellular	B-X
processes	B-X
in	B-X
eukaryotes	B-X
.	B-X
CAND1	B-X
is	B-X
a	B-X
biochemical	B-X
inhibitor	B-X
of	B-X
CRLs	B-X
,	B-X
yet	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
promote	B-X
CRL	B-X
activity	B-X
in	B-X
plant	B-X
and	B-X
mammalian	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
analyze	B-X
CAND1	B-X
function	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
developing	B-X
metazoan	B-X
organism	B-X
.	B-X
Caenorhabditis	B-X
elegans	B-X
CAND-1	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
to	B-X
all	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
it	B-X
physically	B-X
interacts	B-X
with	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
is	B-X
required	B-X
for	B-X
cullin	B-X
activity	B-X
in	B-X
animals	B-X
and	B-X
plants	B-X
.	B-X
In	B-X
cand-1	B-X
mutants	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
neddylated	B-X
isoforms	B-X
of	B-X
CUL-2	B-X
and	B-X
CUL-4	B-X
are	B-X
increased	B-X
,	B-X
indicating	B-X
that	B-X
CAND-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
cullin	B-X
neddylation	B-X
.	B-X
cand-1	B-X
mutants	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
partial	B-X
loss	B-X
of	B-X
cullin	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
CAND-1	B-X
facilitates	B-X
CRL	B-X
functions	B-X
.	B-X
cand-1	B-X
mutants	B-X
exhibit	B-X
impenetrant	B-X
phenotypes	B-X
,	B-X
including	B-X
developmental	B-X
arrest	B-X
,	B-X
morphological	B-X
defects	B-X
of	B-X
the	B-X
vulva	B-X
and	B-X
tail	B-X
,	B-X
and	B-X
reduced	B-X
fecundity	B-X
.	B-X
cand-1	B-X
mutants	B-X
share	B-X
with	B-X
cul-1	B-X
and	B-X
lin-23	B-X
mutants	B-X
the	B-X
phenotypes	B-X
of	B-X
supernumerary	B-X
seam	B-X
cell	B-X
divisions	B-X
,	B-X
defective	B-X
alae	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
target	B-X
the	B-X
glutamate	B-X
receptor	B-X
GLR-1	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
cand-1	B-X
mutants	B-X
have	B-X
phenotypes	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
SCF	B-X
(	B-X
LIN-23	B-X
)	B-X
complex	B-X
,	B-X
but	B-X
lack	B-X
phenotypes	B-X
associated	B-X
with	B-X
other	B-X
specific	B-X
CRL	B-X
complexes	B-X
,	B-X
suggests	B-X
that	B-X
CAND-1	B-X
is	B-X
differentially	B-X
required	B-X
for	B-X
the	B-X
activity	B-X
of	B-X
distinct	B-X
CRL	B-X
complexes	B-X
.	B-X

Engineering	O
a	O
protein	O
-	O
protein	O
interface	O
using	O
a	O
computationally	O
designed	O
library	O
.	O
<EOS>	B-X
Computational	B-X
algorithms	B-X
for	B-X
protein	B-X
design	B-X
can	B-X
sample	B-X
large	B-X
regions	B-X
of	B-X
sequence	B-X
space	B-X
,	B-X
but	B-X
suffer	B-X
from	B-X
undersampling	B-X
of	B-X
conformational	B-X
space	B-X
and	B-X
energy	B-X
function	B-X
inaccuracies	B-X
.	B-X
Experimental	B-X
screening	B-X
of	B-X
combinatorial	B-X
protein	B-X
libraries	B-X
avoids	B-X
the	B-X
need	B-X
for	B-X
accurate	B-X
energy	B-X
functions	B-X
,	B-X
but	B-X
has	B-X
limited	B-X
access	B-X
to	B-X
vast	B-X
amounts	B-X
of	B-X
sequence	B-X
space	B-X
.	B-X
Three	B-X
E6AP	B-X
libraries	B-X
were	B-X
constructed	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
naive	B-X
library	B-X
in	B-X
which	B-X
all	B-X
20	B-X
amino	B-X
acids	B-X
were	B-X
allowed	B-X
at	B-X
every	B-X
position	B-X
on	B-X
the	B-X
target-binding	B-X
surface	B-X
of	B-X
E6AP	B-X
(	B-X
13	B-X
positions	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
semidirected	B-X
library	B-X
that	B-X
varied	B-X
the	B-X
same	B-X
residue	B-X
positions	B-X
as	B-X
in	B-X
the	B-X
naive	B-X
library	B-X
but	B-X
disallowed	B-X
mutations	B-X
computationally	B-X
predicted	B-X
to	B-X
destabilize	B-X
E6AP	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
a	B-X
directed	B-X
library	B-X
that	B-X
used	B-X
docking	B-X
and	B-X
sequence	B-X
optimization	B-X
simulations	B-X
to	B-X
identify	B-X
mutations	B-X
predicted	B-X
to	B-X
be	B-X
favorable	B-X
for	B-X
binding	B-X
Ubc12	B-X
.	B-X
Both	B-X
of	B-X
the	B-X
directed	B-X
libraries	B-X
showed	B-X
>	B-X
30-fold	B-X
enrichment	B-X
over	B-X
the	B-X
naive	B-X
library	B-X
after	B-X
the	B-X
first	B-X
round	B-X
of	B-X
screening	B-X
with	B-X
a	B-X
split-dihydrofolate	B-X
reductase	B-X
complementation	B-X
assay	B-X
and	B-X
produced	B-X
multiple	B-X
tight	B-X
binders	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
<	B-X
100	B-X
nM	B-X
)	B-X
after	B-X
four	B-X
rounds	B-X
of	B-X
selection	B-X
.	B-X
Four	B-X
rounds	B-X
of	B-X
selection	B-X
with	B-X
the	B-X
naive	B-X
library	B-X
failed	B-X
to	B-X
produce	B-X
any	B-X
binders	B-X
with	B-X
K	B-X
(	B-X
d	B-X
)	B-X
's	B-X
lower	B-X
than	B-X
50	B-X
μM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
protein	B-X
design	B-X
simulations	B-X
can	B-X
be	B-X
used	B-X
to	B-X
create	B-X
directed	B-X
libraries	B-X
that	B-X
are	B-X
enriched	B-X
in	B-X
tight	B-X
binders	B-X
and	B-X
that	B-X
in	B-X
some	B-X
cases	B-X
it	B-X
is	B-X
sufficient	B-X
to	B-X
computationally	B-X
screen	B-X
for	B-X
well-folded	B-X
sequences	B-X
without	B-X
explicit	B-X
binding	B-X
calculations	B-X
.	B-X

Computational	O
algorithms	O
for	O
protein	O
design	O
can	O
sample	O
large	O
regions	O
of	O
sequence	O
space	O
,	O
but	O
suffer	O
from	O
undersampling	O
of	O
conformational	O
space	O
and	O
energy	O
function	O
inaccuracies	O
.	O
<EOS>	B-X
Computational	B-X
algorithms	B-X
for	B-X
protein	B-X
design	B-X
can	B-X
sample	B-X
large	B-X
regions	B-X
of	B-X
sequence	B-X
space	B-X
,	B-X
but	B-X
suffer	B-X
from	B-X
undersampling	B-X
of	B-X
conformational	B-X
space	B-X
and	B-X
energy	B-X
function	B-X
inaccuracies	B-X
.	B-X
Experimental	B-X
screening	B-X
of	B-X
combinatorial	B-X
protein	B-X
libraries	B-X
avoids	B-X
the	B-X
need	B-X
for	B-X
accurate	B-X
energy	B-X
functions	B-X
,	B-X
but	B-X
has	B-X
limited	B-X
access	B-X
to	B-X
vast	B-X
amounts	B-X
of	B-X
sequence	B-X
space	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
test	B-X
if	B-X
these	B-X
two	B-X
traditionally	B-X
alternative	B-X
,	B-X
but	B-X
potentially	B-X
complementary	B-X
approaches	B-X
can	B-X
be	B-X
combined	B-X
to	B-X
design	B-X
a	B-X
variant	B-X
of	B-X
the	B-X
ubiquitin-ligase	B-X
E6AP	B-X
that	B-X
will	B-X
bind	B-X
to	B-X
a	B-X
nonnatural	B-X
partner	B-X
,	B-X
the	B-X
NEDD8-conjugating	B-X
enzyme	B-X
Ubc12	B-X
.	B-X
Three	B-X
E6AP	B-X
libraries	B-X
were	B-X
constructed	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
naive	B-X
library	B-X
in	B-X
which	B-X
all	B-X
20	B-X
amino	B-X
acids	B-X
were	B-X
allowed	B-X
at	B-X
every	B-X
position	B-X
on	B-X
the	B-X
target-binding	B-X
surface	B-X
of	B-X
E6AP	B-X
(	B-X
13	B-X
positions	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
semidirected	B-X
library	B-X
that	B-X
varied	B-X
the	B-X
same	B-X
residue	B-X
positions	B-X
as	B-X
in	B-X
the	B-X
naive	B-X
library	B-X
but	B-X
disallowed	B-X
mutations	B-X
computationally	B-X
predicted	B-X
to	B-X
destabilize	B-X
E6AP	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
a	B-X
directed	B-X
library	B-X
that	B-X
used	B-X
docking	B-X
and	B-X
sequence	B-X
optimization	B-X
simulations	B-X
to	B-X
identify	B-X
mutations	B-X
predicted	B-X
to	B-X
be	B-X
favorable	B-X
for	B-X
binding	B-X
Ubc12	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
protein	B-X
design	B-X
simulations	B-X
can	B-X
be	B-X
used	B-X
to	B-X
create	B-X
directed	B-X
libraries	B-X
that	B-X
are	B-X
enriched	B-X
in	B-X
tight	B-X
binders	B-X
and	B-X
that	B-X
in	B-X
some	B-X
cases	B-X
it	B-X
is	B-X
sufficient	B-X
to	B-X
computationally	B-X
screen	B-X
for	B-X
well-folded	B-X
sequences	B-X
without	B-X
explicit	B-X
binding	B-X
calculations	B-X
.	B-X

Experimental	O
screening	O
of	O
combinatorial	O
protein	O
libraries	O
avoids	O
the	O
need	O
for	O
accurate	O
energy	O
functions	O
,	O
but	O
has	O
limited	O
access	O
to	O
vast	O
amounts	O
of	O
sequence	O
space	O
.	O
<EOS>	B-X
Computational	B-X
algorithms	B-X
for	B-X
protein	B-X
design	B-X
can	B-X
sample	B-X
large	B-X
regions	B-X
of	B-X
sequence	B-X
space	B-X
,	B-X
but	B-X
suffer	B-X
from	B-X
undersampling	B-X
of	B-X
conformational	B-X
space	B-X
and	B-X
energy	B-X
function	B-X
inaccuracies	B-X
.	B-X
Experimental	B-X
screening	B-X
of	B-X
combinatorial	B-X
protein	B-X
libraries	B-X
avoids	B-X
the	B-X
need	B-X
for	B-X
accurate	B-X
energy	B-X
functions	B-X
,	B-X
but	B-X
has	B-X
limited	B-X
access	B-X
to	B-X
vast	B-X
amounts	B-X
of	B-X
sequence	B-X
space	B-X
.	B-X
Three	B-X
E6AP	B-X
libraries	B-X
were	B-X
constructed	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
naive	B-X
library	B-X
in	B-X
which	B-X
all	B-X
20	B-X
amino	B-X
acids	B-X
were	B-X
allowed	B-X
at	B-X
every	B-X
position	B-X
on	B-X
the	B-X
target-binding	B-X
surface	B-X
of	B-X
E6AP	B-X
(	B-X
13	B-X
positions	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
semidirected	B-X
library	B-X
that	B-X
varied	B-X
the	B-X
same	B-X
residue	B-X
positions	B-X
as	B-X
in	B-X
the	B-X
naive	B-X
library	B-X
but	B-X
disallowed	B-X
mutations	B-X
computationally	B-X
predicted	B-X
to	B-X
destabilize	B-X
E6AP	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
a	B-X
directed	B-X
library	B-X
that	B-X
used	B-X
docking	B-X
and	B-X
sequence	B-X
optimization	B-X
simulations	B-X
to	B-X
identify	B-X
mutations	B-X
predicted	B-X
to	B-X
be	B-X
favorable	B-X
for	B-X
binding	B-X
Ubc12	B-X
.	B-X
Both	B-X
of	B-X
the	B-X
directed	B-X
libraries	B-X
showed	B-X
>	B-X
30-fold	B-X
enrichment	B-X
over	B-X
the	B-X
naive	B-X
library	B-X
after	B-X
the	B-X
first	B-X
round	B-X
of	B-X
screening	B-X
with	B-X
a	B-X
split-dihydrofolate	B-X
reductase	B-X
complementation	B-X
assay	B-X
and	B-X
produced	B-X
multiple	B-X
tight	B-X
binders	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
<	B-X
100	B-X
nM	B-X
)	B-X
after	B-X
four	B-X
rounds	B-X
of	B-X
selection	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
protein	B-X
design	B-X
simulations	B-X
can	B-X
be	B-X
used	B-X
to	B-X
create	B-X
directed	B-X
libraries	B-X
that	B-X
are	B-X
enriched	B-X
in	B-X
tight	B-X
binders	B-X
and	B-X
that	B-X
in	B-X
some	B-X
cases	B-X
it	B-X
is	B-X
sufficient	B-X
to	B-X
computationally	B-X
screen	B-X
for	B-X
well-folded	B-X
sequences	B-X
without	B-X
explicit	B-X
binding	B-X
calculations	B-X
.	B-X

Here	O
,	O
we	O
test	O
if	O
these	O
two	O
traditionally	O
alternative	O
,	O
but	O
potentially	O
complementary	O
approaches	O
can	O
be	O
combined	O
to	O
design	O
a	O
variant	O
of	O
the	O
ubiquitin	B-Protein
-	O
ligase	O
E6AP	B-Protein
that	O
will	O
bind	O
to	O
a	O
nonnatural	O
partner	O
,	O
the	O
NEDD8	B-Protein
-	O
conjugating	O
enzyme	O
Ubc12	B-Protein
.	O
<EOS>	B-X
Computational	B-X
algorithms	B-X
for	B-X
protein	B-X
design	B-X
can	B-X
sample	B-X
large	B-X
regions	B-X
of	B-X
sequence	B-X
space	B-X
,	B-X
but	B-X
suffer	B-X
from	B-X
undersampling	B-X
of	B-X
conformational	B-X
space	B-X
and	B-X
energy	B-X
function	B-X
inaccuracies	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
test	B-X
if	B-X
these	B-X
two	B-X
traditionally	B-X
alternative	B-X
,	B-X
but	B-X
potentially	B-X
complementary	B-X
approaches	B-X
can	B-X
be	B-X
combined	B-X
to	B-X
design	B-X
a	B-X
variant	B-X
of	B-X
the	B-X
ubiquitin-ligase	B-X
E6AP	B-X
that	B-X
will	B-X
bind	B-X
to	B-X
a	B-X
nonnatural	B-X
partner	B-X
,	B-X
the	B-X
NEDD8-conjugating	B-X
enzyme	B-X
Ubc12	B-X
.	B-X
Three	B-X
E6AP	B-X
libraries	B-X
were	B-X
constructed	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
naive	B-X
library	B-X
in	B-X
which	B-X
all	B-X
20	B-X
amino	B-X
acids	B-X
were	B-X
allowed	B-X
at	B-X
every	B-X
position	B-X
on	B-X
the	B-X
target-binding	B-X
surface	B-X
of	B-X
E6AP	B-X
(	B-X
13	B-X
positions	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
semidirected	B-X
library	B-X
that	B-X
varied	B-X
the	B-X
same	B-X
residue	B-X
positions	B-X
as	B-X
in	B-X
the	B-X
naive	B-X
library	B-X
but	B-X
disallowed	B-X
mutations	B-X
computationally	B-X
predicted	B-X
to	B-X
destabilize	B-X
E6AP	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
a	B-X
directed	B-X
library	B-X
that	B-X
used	B-X
docking	B-X
and	B-X
sequence	B-X
optimization	B-X
simulations	B-X
to	B-X
identify	B-X
mutations	B-X
predicted	B-X
to	B-X
be	B-X
favorable	B-X
for	B-X
binding	B-X
Ubc12	B-X
.	B-X
Both	B-X
of	B-X
the	B-X
directed	B-X
libraries	B-X
showed	B-X
>	B-X
30-fold	B-X
enrichment	B-X
over	B-X
the	B-X
naive	B-X
library	B-X
after	B-X
the	B-X
first	B-X
round	B-X
of	B-X
screening	B-X
with	B-X
a	B-X
split-dihydrofolate	B-X
reductase	B-X
complementation	B-X
assay	B-X
and	B-X
produced	B-X
multiple	B-X
tight	B-X
binders	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
<	B-X
100	B-X
nM	B-X
)	B-X
after	B-X
four	B-X
rounds	B-X
of	B-X
selection	B-X
.	B-X
Four	B-X
rounds	B-X
of	B-X
selection	B-X
with	B-X
the	B-X
naive	B-X
library	B-X
failed	B-X
to	B-X
produce	B-X
any	B-X
binders	B-X
with	B-X
K	B-X
(	B-X
d	B-X
)	B-X
's	B-X
lower	B-X
than	B-X
50	B-X
μM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
protein	B-X
design	B-X
simulations	B-X
can	B-X
be	B-X
used	B-X
to	B-X
create	B-X
directed	B-X
libraries	B-X
that	B-X
are	B-X
enriched	B-X
in	B-X
tight	B-X
binders	B-X
and	B-X
that	B-X
in	B-X
some	B-X
cases	B-X
it	B-X
is	B-X
sufficient	B-X
to	B-X
computationally	B-X
screen	B-X
for	B-X
well-folded	B-X
sequences	B-X
without	B-X
explicit	B-X
binding	B-X
calculations	B-X
.	B-X

Three	O
E6AP	B-Protein
libraries	O
were	O
constructed	O
:	O
(	O
i	O
)	O
a	O
naive	O
library	O
in	O
which	O
all	O
20	O
amino	O
acids	O
were	O
allowed	O
at	O
every	O
position	O
on	O
the	O
target	O
-	O
binding	O
surface	O
of	O
E6AP	B-Protein
(	O
13	O
positions	O
)	O
,	O
(	O
ii	O
)	O
a	O
semidirected	O
library	O
that	O
varied	O
the	O
same	O
residue	O
positions	O
as	O
in	O
the	O
naive	O
library	O
but	O
disallowed	O
mutations	O
computationally	O
predicted	O
to	O
destabilize	O
E6AP	B-Protein
,	O
and	O
(	O
iii	O
)	O
a	O
directed	O
library	O
that	O
used	O
docking	O
and	O
sequence	O
optimization	O
simulations	O
to	O
identify	O
mutations	O
predicted	O
to	O
be	O
favorable	O
for	O
binding	O
Ubc12	B-Protein
.	O

Both	O
of	O
the	O
directed	O
libraries	O
showed	O
>	O
30	O
-	O
fold	O
enrichment	O
over	O
the	O
naive	O
library	O
after	O
the	O
first	O
round	O
of	O
screening	O
with	O
a	O
split	O
-	O
dihydrofolate	B-Protein
reductase	I-Protein
complementation	O
assay	O
and	O
produced	O
multiple	O
tight	O
binders	O
(	O
K	O
(	O
d	O
)	O
<	O
100	O
nM	O
)	O
after	O
four	O
rounds	O
of	O
selection	O
.	O
<EOS>	B-X
Experimental	B-X
screening	B-X
of	B-X
combinatorial	B-X
protein	B-X
libraries	B-X
avoids	B-X
the	B-X
need	B-X
for	B-X
accurate	B-X
energy	B-X
functions	B-X
,	B-X
but	B-X
has	B-X
limited	B-X
access	B-X
to	B-X
vast	B-X
amounts	B-X
of	B-X
sequence	B-X
space	B-X
.	B-X
Three	B-X
E6AP	B-X
libraries	B-X
were	B-X
constructed	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
naive	B-X
library	B-X
in	B-X
which	B-X
all	B-X
20	B-X
amino	B-X
acids	B-X
were	B-X
allowed	B-X
at	B-X
every	B-X
position	B-X
on	B-X
the	B-X
target-binding	B-X
surface	B-X
of	B-X
E6AP	B-X
(	B-X
13	B-X
positions	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
semidirected	B-X
library	B-X
that	B-X
varied	B-X
the	B-X
same	B-X
residue	B-X
positions	B-X
as	B-X
in	B-X
the	B-X
naive	B-X
library	B-X
but	B-X
disallowed	B-X
mutations	B-X
computationally	B-X
predicted	B-X
to	B-X
destabilize	B-X
E6AP	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
a	B-X
directed	B-X
library	B-X
that	B-X
used	B-X
docking	B-X
and	B-X
sequence	B-X
optimization	B-X
simulations	B-X
to	B-X
identify	B-X
mutations	B-X
predicted	B-X
to	B-X
be	B-X
favorable	B-X
for	B-X
binding	B-X
Ubc12	B-X
.	B-X
Both	B-X
of	B-X
the	B-X
directed	B-X
libraries	B-X
showed	B-X
>	B-X
30-fold	B-X
enrichment	B-X
over	B-X
the	B-X
naive	B-X
library	B-X
after	B-X
the	B-X
first	B-X
round	B-X
of	B-X
screening	B-X
with	B-X
a	B-X
split-dihydrofolate	B-X
reductase	B-X
complementation	B-X
assay	B-X
and	B-X
produced	B-X
multiple	B-X
tight	B-X
binders	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
<	B-X
100	B-X
nM	B-X
)	B-X
after	B-X
four	B-X
rounds	B-X
of	B-X
selection	B-X
.	B-X
Four	B-X
rounds	B-X
of	B-X
selection	B-X
with	B-X
the	B-X
naive	B-X
library	B-X
failed	B-X
to	B-X
produce	B-X
any	B-X
binders	B-X
with	B-X
K	B-X
(	B-X
d	B-X
)	B-X
's	B-X
lower	B-X
than	B-X
50	B-X
μM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
protein	B-X
design	B-X
simulations	B-X
can	B-X
be	B-X
used	B-X
to	B-X
create	B-X
directed	B-X
libraries	B-X
that	B-X
are	B-X
enriched	B-X
in	B-X
tight	B-X
binders	B-X
and	B-X
that	B-X
in	B-X
some	B-X
cases	B-X
it	B-X
is	B-X
sufficient	B-X
to	B-X
computationally	B-X
screen	B-X
for	B-X
well-folded	B-X
sequences	B-X
without	B-X
explicit	B-X
binding	B-X
calculations	B-X
.	B-X

Four	O
rounds	O
of	O
selection	O
with	O
the	O
naive	O
library	O
failed	O
to	O
produce	O
any	O
binders	O
with	O
K	O
(	O
d	O
)	O
'	O
s	O
lower	O
than	O
50	O
mu	O
M	O
.	O

These	O
results	O
indicate	O
that	O
protein	O
design	O
simulations	O
can	O
be	O
used	O
to	O
create	O
directed	O
libraries	O
that	O
are	O
enriched	O
in	O
tight	O
binders	O
and	O
that	O
in	O
some	O
cases	O
it	O
is	O
sufficient	O
to	O
computationally	O
screen	O
for	O
well	O
-	O
folded	O
sequences	O
without	O
explicit	O
binding	O
calculations	O
.	O
<EOS>	B-X
Computational	B-X
algorithms	B-X
for	B-X
protein	B-X
design	B-X
can	B-X
sample	B-X
large	B-X
regions	B-X
of	B-X
sequence	B-X
space	B-X
,	B-X
but	B-X
suffer	B-X
from	B-X
undersampling	B-X
of	B-X
conformational	B-X
space	B-X
and	B-X
energy	B-X
function	B-X
inaccuracies	B-X
.	B-X
Experimental	B-X
screening	B-X
of	B-X
combinatorial	B-X
protein	B-X
libraries	B-X
avoids	B-X
the	B-X
need	B-X
for	B-X
accurate	B-X
energy	B-X
functions	B-X
,	B-X
but	B-X
has	B-X
limited	B-X
access	B-X
to	B-X
vast	B-X
amounts	B-X
of	B-X
sequence	B-X
space	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
test	B-X
if	B-X
these	B-X
two	B-X
traditionally	B-X
alternative	B-X
,	B-X
but	B-X
potentially	B-X
complementary	B-X
approaches	B-X
can	B-X
be	B-X
combined	B-X
to	B-X
design	B-X
a	B-X
variant	B-X
of	B-X
the	B-X
ubiquitin-ligase	B-X
E6AP	B-X
that	B-X
will	B-X
bind	B-X
to	B-X
a	B-X
nonnatural	B-X
partner	B-X
,	B-X
the	B-X
NEDD8-conjugating	B-X
enzyme	B-X
Ubc12	B-X
.	B-X
Three	B-X
E6AP	B-X
libraries	B-X
were	B-X
constructed	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
naive	B-X
library	B-X
in	B-X
which	B-X
all	B-X
20	B-X
amino	B-X
acids	B-X
were	B-X
allowed	B-X
at	B-X
every	B-X
position	B-X
on	B-X
the	B-X
target-binding	B-X
surface	B-X
of	B-X
E6AP	B-X
(	B-X
13	B-X
positions	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
semidirected	B-X
library	B-X
that	B-X
varied	B-X
the	B-X
same	B-X
residue	B-X
positions	B-X
as	B-X
in	B-X
the	B-X
naive	B-X
library	B-X
but	B-X
disallowed	B-X
mutations	B-X
computationally	B-X
predicted	B-X
to	B-X
destabilize	B-X
E6AP	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
a	B-X
directed	B-X
library	B-X
that	B-X
used	B-X
docking	B-X
and	B-X
sequence	B-X
optimization	B-X
simulations	B-X
to	B-X
identify	B-X
mutations	B-X
predicted	B-X
to	B-X
be	B-X
favorable	B-X
for	B-X
binding	B-X
Ubc12	B-X
.	B-X
Both	B-X
of	B-X
the	B-X
directed	B-X
libraries	B-X
showed	B-X
>	B-X
30-fold	B-X
enrichment	B-X
over	B-X
the	B-X
naive	B-X
library	B-X
after	B-X
the	B-X
first	B-X
round	B-X
of	B-X
screening	B-X
with	B-X
a	B-X
split-dihydrofolate	B-X
reductase	B-X
complementation	B-X
assay	B-X
and	B-X
produced	B-X
multiple	B-X
tight	B-X
binders	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
<	B-X
100	B-X
nM	B-X
)	B-X
after	B-X
four	B-X
rounds	B-X
of	B-X
selection	B-X
.	B-X
Four	B-X
rounds	B-X
of	B-X
selection	B-X
with	B-X
the	B-X
naive	B-X
library	B-X
failed	B-X
to	B-X
produce	B-X
any	B-X
binders	B-X
with	B-X
K	B-X
(	B-X
d	B-X
)	B-X
's	B-X
lower	B-X
than	B-X
50	B-X
μM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
protein	B-X
design	B-X
simulations	B-X
can	B-X
be	B-X
used	B-X
to	B-X
create	B-X
directed	B-X
libraries	B-X
that	B-X
are	B-X
enriched	B-X
in	B-X
tight	B-X
binders	B-X
and	B-X
that	B-X
in	B-X
some	B-X
cases	B-X
it	B-X
is	B-X
sufficient	B-X
to	B-X
computationally	B-X
screen	B-X
for	B-X
well-folded	B-X
sequences	B-X
without	B-X
explicit	B-X
binding	B-X
calculations	B-X
.	B-X

Involvement	O
of	O
a	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
protein	O
in	O
the	O
regulation	O
of	O
angiotensinogen	O
production	O
by	O
an	O
angiotensin	B-Protein
II	I-Protein
analog	O
in	O
HepG2	O
cells	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
angiotensin	B-X
II	B-X
(	B-X
AII	B-X
)	B-X
agonist	B-X
,	B-X
Sar1-AII	B-X
,	B-X
inhibits	B-X
production	B-X
and	B-X
release	B-X
of	B-X
angiotensinogen	B-X
in	B-X
human	B-X
hepatoma	B-X
HepG2	B-X
cells	B-X
was	B-X
examined	B-X
.	B-X
Pretreatment	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
attenuated	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
block	B-X
angiotensinogen	B-X
production	B-X
.	B-X
This	B-X
effect	B-X
could	B-X
be	B-X
correlated	B-X
with	B-X
the	B-X
in	B-X
situ	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
apparent	B-X
molecular	B-X
weight	B-X
39,000-41,000	B-X
on	B-X
SDS-PAGE	B-X
,	B-X
and	B-X
attenuation	B-X
of	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
inhibit	B-X
cAMP	B-X
accumulation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
cAMP	B-X
in	B-X
angiotensinogen	B-X
production	B-X
was	B-X
examined	B-X
.	B-X
Although	B-X
neither	B-X
forskolin	B-X
nor	B-X
glucagon	B-X
had	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
angiotensinogen	B-X
production	B-X
agents	B-X
producing	B-X
a	B-X
sustained	B-X
increase	B-X
in	B-X
intracellular	B-X
cAMP	B-X
(	B-X
8-bromo-cAMP	B-X
,	B-X
dibutyryl-cAMP	B-X
,	B-X
cholera	B-X
toxin	B-X
)	B-X
were	B-X
able	B-X
to	B-X
increase	B-X
angiotensinogen	B-X
production	B-X
.	B-X
Although	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
intracellular	B-X
cAMP	B-X
is	B-X
a	B-X
regulatory	B-X
factor	B-X
in	B-X
angiotensinogen	B-X
production	B-X
other	B-X
evidence	B-X
suggests	B-X
that	B-X
modulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
is	B-X
not	B-X
entirely	B-X
responsible	B-X
for	B-X
the	B-X
effects	B-X
of	B-X
Sar1-AII	B-X
.	B-X

The	O
cellular	O
mechanism	O
by	O
which	O
the	O
angiotensin	B-Protein
II	I-Protein
(	O
AII	B-Protein
)	O
agonist	O
,	O
Sar1	O
-	O
AII	O
,	O
inhibits	O
production	O
and	O
release	O
of	O
angiotensinogen	B-Protein
in	O
human	O
hepatoma	O
HepG2	O
cells	O
was	O
examined	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
angiotensin	B-X
II	B-X
(	B-X
AII	B-X
)	B-X
agonist	B-X
,	B-X
Sar1-AII	B-X
,	B-X
inhibits	B-X
production	B-X
and	B-X
release	B-X
of	B-X
angiotensinogen	B-X
in	B-X
human	B-X
hepatoma	B-X
HepG2	B-X
cells	B-X
was	B-X
examined	B-X
.	B-X
Pretreatment	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
attenuated	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
block	B-X
angiotensinogen	B-X
production	B-X
.	B-X
This	B-X
effect	B-X
could	B-X
be	B-X
correlated	B-X
with	B-X
the	B-X
in	B-X
situ	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
apparent	B-X
molecular	B-X
weight	B-X
39,000-41,000	B-X
on	B-X
SDS-PAGE	B-X
,	B-X
and	B-X
attenuation	B-X
of	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
inhibit	B-X
cAMP	B-X
accumulation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
cAMP	B-X
in	B-X
angiotensinogen	B-X
production	B-X
was	B-X
examined	B-X
.	B-X
Although	B-X
neither	B-X
forskolin	B-X
nor	B-X
glucagon	B-X
had	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
angiotensinogen	B-X
production	B-X
agents	B-X
producing	B-X
a	B-X
sustained	B-X
increase	B-X
in	B-X
intracellular	B-X
cAMP	B-X
(	B-X
8-bromo-cAMP	B-X
,	B-X
dibutyryl-cAMP	B-X
,	B-X
cholera	B-X
toxin	B-X
)	B-X
were	B-X
able	B-X
to	B-X
increase	B-X
angiotensinogen	B-X
production	B-X
.	B-X
Although	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
intracellular	B-X
cAMP	B-X
is	B-X
a	B-X
regulatory	B-X
factor	B-X
in	B-X
angiotensinogen	B-X
production	B-X
other	B-X
evidence	B-X
suggests	B-X
that	B-X
modulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
is	B-X
not	B-X
entirely	B-X
responsible	B-X
for	B-X
the	B-X
effects	B-X
of	B-X
Sar1-AII	B-X
.	B-X

Pretreatment	O
of	O
HepG2	O
cells	O
with	O
pertussis	O
toxin	O
attenuated	O
the	O
ability	O
of	O
Sar1	O
-	O
AII	O
to	O
block	O
angiotensinogen	B-Protein
production	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
angiotensin	B-X
II	B-X
(	B-X
AII	B-X
)	B-X
agonist	B-X
,	B-X
Sar1-AII	B-X
,	B-X
inhibits	B-X
production	B-X
and	B-X
release	B-X
of	B-X
angiotensinogen	B-X
in	B-X
human	B-X
hepatoma	B-X
HepG2	B-X
cells	B-X
was	B-X
examined	B-X
.	B-X
Pretreatment	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
attenuated	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
block	B-X
angiotensinogen	B-X
production	B-X
.	B-X
This	B-X
effect	B-X
could	B-X
be	B-X
correlated	B-X
with	B-X
the	B-X
in	B-X
situ	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
apparent	B-X
molecular	B-X
weight	B-X
39,000-41,000	B-X
on	B-X
SDS-PAGE	B-X
,	B-X
and	B-X
attenuation	B-X
of	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
inhibit	B-X
cAMP	B-X
accumulation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
cAMP	B-X
in	B-X
angiotensinogen	B-X
production	B-X
was	B-X
examined	B-X
.	B-X
Although	B-X
neither	B-X
forskolin	B-X
nor	B-X
glucagon	B-X
had	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
angiotensinogen	B-X
production	B-X
agents	B-X
producing	B-X
a	B-X
sustained	B-X
increase	B-X
in	B-X
intracellular	B-X
cAMP	B-X
(	B-X
8-bromo-cAMP	B-X
,	B-X
dibutyryl-cAMP	B-X
,	B-X
cholera	B-X
toxin	B-X
)	B-X
were	B-X
able	B-X
to	B-X
increase	B-X
angiotensinogen	B-X
production	B-X
.	B-X
Although	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
intracellular	B-X
cAMP	B-X
is	B-X
a	B-X
regulatory	B-X
factor	B-X
in	B-X
angiotensinogen	B-X
production	B-X
other	B-X
evidence	B-X
suggests	B-X
that	B-X
modulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
is	B-X
not	B-X
entirely	B-X
responsible	B-X
for	B-X
the	B-X
effects	B-X
of	B-X
Sar1-AII	B-X
.	B-X

This	O
effect	O
could	O
be	O
correlated	O
with	O
the	O
in	O
situ	O
ADP	O
-	O
ribosylation	O
of	O
a	O
protein	O
(	O
s	O
)	O
of	O
apparent	O
molecular	O
weight	O
39	O
,	O
000	O
-	O
41	O
,	O
000	O
on	O
SDS	O
-	O
PAGE	O
,	O
and	O
attenuation	O
of	O
the	O
ability	O
of	O
Sar1	O
-	O
AII	O
to	O
inhibit	O
cAMP	O
accumulation	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
angiotensin	B-X
II	B-X
(	B-X
AII	B-X
)	B-X
agonist	B-X
,	B-X
Sar1-AII	B-X
,	B-X
inhibits	B-X
production	B-X
and	B-X
release	B-X
of	B-X
angiotensinogen	B-X
in	B-X
human	B-X
hepatoma	B-X
HepG2	B-X
cells	B-X
was	B-X
examined	B-X
.	B-X
Pretreatment	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
attenuated	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
block	B-X
angiotensinogen	B-X
production	B-X
.	B-X
This	B-X
effect	B-X
could	B-X
be	B-X
correlated	B-X
with	B-X
the	B-X
in	B-X
situ	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
apparent	B-X
molecular	B-X
weight	B-X
39,000-41,000	B-X
on	B-X
SDS-PAGE	B-X
,	B-X
and	B-X
attenuation	B-X
of	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
inhibit	B-X
cAMP	B-X
accumulation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
cAMP	B-X
in	B-X
angiotensinogen	B-X
production	B-X
was	B-X
examined	B-X
.	B-X
A	B-X
transient	B-X
increase	B-X
in	B-X
cAMP	B-X
accumulation	B-X
above	B-X
basal	B-X
could	B-X
be	B-X
evoked	B-X
by	B-X
forskolin	B-X
(	B-X
8-fold	B-X
)	B-X
or	B-X
by	B-X
glucagon	B-X
(	B-X
5-fold	B-X
)	B-X
using	B-X
insulin-deficient	B-X
media	B-X
.	B-X
Although	B-X
neither	B-X
forskolin	B-X
nor	B-X
glucagon	B-X
had	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
angiotensinogen	B-X
production	B-X
agents	B-X
producing	B-X
a	B-X
sustained	B-X
increase	B-X
in	B-X
intracellular	B-X
cAMP	B-X
(	B-X
8-bromo-cAMP	B-X
,	B-X
dibutyryl-cAMP	B-X
,	B-X
cholera	B-X
toxin	B-X
)	B-X
were	B-X
able	B-X
to	B-X
increase	B-X
angiotensinogen	B-X
production	B-X
.	B-X
Although	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
intracellular	B-X
cAMP	B-X
is	B-X
a	B-X
regulatory	B-X
factor	B-X
in	B-X
angiotensinogen	B-X
production	B-X
other	B-X
evidence	B-X
suggests	B-X
that	B-X
modulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
is	B-X
not	B-X
entirely	B-X
responsible	B-X
for	B-X
the	B-X
effects	B-X
of	B-X
Sar1-AII	B-X
.	B-X

The	O
role	O
of	O
cAMP	O
in	O
angiotensinogen	B-Protein
production	O
was	O
examined	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
angiotensin	B-X
II	B-X
(	B-X
AII	B-X
)	B-X
agonist	B-X
,	B-X
Sar1-AII	B-X
,	B-X
inhibits	B-X
production	B-X
and	B-X
release	B-X
of	B-X
angiotensinogen	B-X
in	B-X
human	B-X
hepatoma	B-X
HepG2	B-X
cells	B-X
was	B-X
examined	B-X
.	B-X
Pretreatment	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
attenuated	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
block	B-X
angiotensinogen	B-X
production	B-X
.	B-X
This	B-X
effect	B-X
could	B-X
be	B-X
correlated	B-X
with	B-X
the	B-X
in	B-X
situ	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
apparent	B-X
molecular	B-X
weight	B-X
39,000-41,000	B-X
on	B-X
SDS-PAGE	B-X
,	B-X
and	B-X
attenuation	B-X
of	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
inhibit	B-X
cAMP	B-X
accumulation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
cAMP	B-X
in	B-X
angiotensinogen	B-X
production	B-X
was	B-X
examined	B-X
.	B-X
A	B-X
transient	B-X
increase	B-X
in	B-X
cAMP	B-X
accumulation	B-X
above	B-X
basal	B-X
could	B-X
be	B-X
evoked	B-X
by	B-X
forskolin	B-X
(	B-X
8-fold	B-X
)	B-X
or	B-X
by	B-X
glucagon	B-X
(	B-X
5-fold	B-X
)	B-X
using	B-X
insulin-deficient	B-X
media	B-X
.	B-X
Although	B-X
neither	B-X
forskolin	B-X
nor	B-X
glucagon	B-X
had	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
angiotensinogen	B-X
production	B-X
agents	B-X
producing	B-X
a	B-X
sustained	B-X
increase	B-X
in	B-X
intracellular	B-X
cAMP	B-X
(	B-X
8-bromo-cAMP	B-X
,	B-X
dibutyryl-cAMP	B-X
,	B-X
cholera	B-X
toxin	B-X
)	B-X
were	B-X
able	B-X
to	B-X
increase	B-X
angiotensinogen	B-X
production	B-X
.	B-X
Although	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
intracellular	B-X
cAMP	B-X
is	B-X
a	B-X
regulatory	B-X
factor	B-X
in	B-X
angiotensinogen	B-X
production	B-X
other	B-X
evidence	B-X
suggests	B-X
that	B-X
modulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
is	B-X
not	B-X
entirely	B-X
responsible	B-X
for	B-X
the	B-X
effects	B-X
of	B-X
Sar1-AII	B-X
.	B-X

A	O
transient	O
increase	O
in	O
cAMP	O
accumulation	O
above	O
basal	O
could	O
be	O
evoked	O
by	O
forskolin	O
(	O
8	O
-	O
fold	O
)	O
or	O
by	O
glucagon	B-Protein
(	O
5	O
-	O
fold	O
)	O
using	O
insulin	B-Protein
-	O
deficient	O
media	O
.	O
<EOS>	B-X
This	B-X
effect	B-X
could	B-X
be	B-X
correlated	B-X
with	B-X
the	B-X
in	B-X
situ	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
apparent	B-X
molecular	B-X
weight	B-X
39,000-41,000	B-X
on	B-X
SDS-PAGE	B-X
,	B-X
and	B-X
attenuation	B-X
of	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
inhibit	B-X
cAMP	B-X
accumulation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
cAMP	B-X
in	B-X
angiotensinogen	B-X
production	B-X
was	B-X
examined	B-X
.	B-X
A	B-X
transient	B-X
increase	B-X
in	B-X
cAMP	B-X
accumulation	B-X
above	B-X
basal	B-X
could	B-X
be	B-X
evoked	B-X
by	B-X
forskolin	B-X
(	B-X
8-fold	B-X
)	B-X
or	B-X
by	B-X
glucagon	B-X
(	B-X
5-fold	B-X
)	B-X
using	B-X
insulin-deficient	B-X
media	B-X
.	B-X
Although	B-X
neither	B-X
forskolin	B-X
nor	B-X
glucagon	B-X
had	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
angiotensinogen	B-X
production	B-X
agents	B-X
producing	B-X
a	B-X
sustained	B-X
increase	B-X
in	B-X
intracellular	B-X
cAMP	B-X
(	B-X
8-bromo-cAMP	B-X
,	B-X
dibutyryl-cAMP	B-X
,	B-X
cholera	B-X
toxin	B-X
)	B-X
were	B-X
able	B-X
to	B-X
increase	B-X
angiotensinogen	B-X
production	B-X
.	B-X
Although	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
intracellular	B-X
cAMP	B-X
is	B-X
a	B-X
regulatory	B-X
factor	B-X
in	B-X
angiotensinogen	B-X
production	B-X
other	B-X
evidence	B-X
suggests	B-X
that	B-X
modulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
is	B-X
not	B-X
entirely	B-X
responsible	B-X
for	B-X
the	B-X
effects	B-X
of	B-X
Sar1-AII	B-X
.	B-X

Although	O
neither	O
forskolin	O
nor	O
glucagon	B-Protein
had	O
a	O
significant	O
effect	O
on	O
angiotensinogen	B-Protein
production	O
agents	O
producing	O
a	O
sustained	O
increase	O
in	O
intracellular	O
cAMP	O
(	O
8	O
-	O
bromo	O
-	O
cAMP	O
,	O
dibutyryl	O
-	O
cAMP	O
,	O
cholera	O
toxin	O
)	O
were	O
able	O
to	O
increase	O
angiotensinogen	B-Protein
production	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
angiotensin	B-X
II	B-X
(	B-X
AII	B-X
)	B-X
agonist	B-X
,	B-X
Sar1-AII	B-X
,	B-X
inhibits	B-X
production	B-X
and	B-X
release	B-X
of	B-X
angiotensinogen	B-X
in	B-X
human	B-X
hepatoma	B-X
HepG2	B-X
cells	B-X
was	B-X
examined	B-X
.	B-X
Pretreatment	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
pertussis	B-X
toxin	B-X
attenuated	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
block	B-X
angiotensinogen	B-X
production	B-X
.	B-X
This	B-X
effect	B-X
could	B-X
be	B-X
correlated	B-X
with	B-X
the	B-X
in	B-X
situ	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
apparent	B-X
molecular	B-X
weight	B-X
39,000-41,000	B-X
on	B-X
SDS-PAGE	B-X
,	B-X
and	B-X
attenuation	B-X
of	B-X
the	B-X
ability	B-X
of	B-X
Sar1-AII	B-X
to	B-X
inhibit	B-X
cAMP	B-X
accumulation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
cAMP	B-X
in	B-X
angiotensinogen	B-X
production	B-X
was	B-X
examined	B-X
.	B-X
A	B-X
transient	B-X
increase	B-X
in	B-X
cAMP	B-X
accumulation	B-X
above	B-X
basal	B-X
could	B-X
be	B-X
evoked	B-X
by	B-X
forskolin	B-X
(	B-X
8-fold	B-X
)	B-X
or	B-X
by	B-X
glucagon	B-X
(	B-X
5-fold	B-X
)	B-X
using	B-X
insulin-deficient	B-X
media	B-X
.	B-X
Although	B-X
neither	B-X
forskolin	B-X
nor	B-X
glucagon	B-X
had	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
angiotensinogen	B-X
production	B-X
agents	B-X
producing	B-X
a	B-X
sustained	B-X
increase	B-X
in	B-X
intracellular	B-X
cAMP	B-X
(	B-X
8-bromo-cAMP	B-X
,	B-X
dibutyryl-cAMP	B-X
,	B-X
cholera	B-X
toxin	B-X
)	B-X
were	B-X
able	B-X
to	B-X
increase	B-X
angiotensinogen	B-X
production	B-X
.	B-X
Although	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
intracellular	B-X
cAMP	B-X
is	B-X
a	B-X
regulatory	B-X
factor	B-X
in	B-X
angiotensinogen	B-X
production	B-X
other	B-X
evidence	B-X
suggests	B-X
that	B-X
modulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
is	B-X
not	B-X
entirely	B-X
responsible	B-X
for	B-X
the	B-X
effects	B-X
of	B-X
Sar1-AII	B-X
.	B-X

Although	O
these	O
data	O
indicate	O
that	O
intracellular	O
cAMP	O
is	O
a	O
regulatory	O
factor	O
in	O
angiotensinogen	B-Protein
production	O
other	O
evidence	O
suggests	O
that	O
modulation	O
of	O
intracellular	O
cAMP	O
is	O
not	O
entirely	O
responsible	O
for	O
the	O
effects	O
of	O
Sar1	O
-	O
AII	O
.	O

Evidence	O
for	O
a	O
non	O
-	O
myristoylated	O
pool	O
of	O
the	O
80	O
kDa	O
protein	O
kinase	O
C	O
substrate	O
of	O
rat	O
brain	O
.	O
<EOS>	B-X
A	B-X
protein	B-X
of	B-X
80	B-X
kDa	B-X
apparent	B-X
molecular	B-X
mass	B-X
was	B-X
found	B-X
to	B-X
be	B-X
specifically	B-X
myristolylated	B-X
in	B-X
rat	B-X
brain	B-X
cytosols	B-X
derived	B-X
from	B-X
either	B-X
whole	B-X
brain	B-X
or	B-X
synaptosomes	B-X
.	B-X
The	B-X
attachment	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
took	B-X
place	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
protein	B-X
synthesis	B-X
,	B-X
since	B-X
the	B-X
cytosols	B-X
did	B-X
not	B-X
incorporate	B-X
[	B-X
14C	B-X
]	B-X
lysine	B-X
into	B-X
protein	B-X
,	B-X
nor	B-X
did	B-X
cycloheximide	B-X
affect	B-X
the	B-X
incorporation	B-X
of	B-X
the	B-X
myristic	B-X
acid	B-X
into	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
fatty	B-X
acid	B-X
was	B-X
incorporated	B-X
into	B-X
the	B-X
protein	B-X
via	B-X
an	B-X
acid-labile/alkali-resistant	B-X
band	B-X
,	B-X
and	B-X
Pronase	B-X
digestion	B-X
of	B-X
the	B-X
labelled	B-X
protein	B-X
showed	B-X
that	B-X
the	B-X
lipid	B-X
was	B-X
covalently	B-X
linked	B-X
to	B-X
a	B-X
glycine	B-X
residue	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggested	B-X
that	B-X
the	B-X
myristic	B-X
acid	B-X
was	B-X
amide-linked	B-X
to	B-X
the	B-X
N-terminal	B-X
residue	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
identified	B-X
as	B-X
one	B-X
of	B-X
the	B-X
major	B-X
protein	B-X
kinase	B-X
C	B-X
substrates	B-X
,	B-X
the	B-X
MARCKS	B-X
(	B-X
myristoylated	B-X
alanine-rich	B-X
C	B-X
kinase	B-X
substrate	B-X
)	B-X
protein	B-X
,	B-X
by	B-X
showing	B-X
that	B-X
Ca2+	B-X
stimulated	B-X
its	B-X
phosphorylation	B-X
,	B-X
by	B-X
its	B-X
heat	B-X
stability	B-X
and	B-X
by	B-X
immune	B-X
precipitation	B-X
(	B-X
using	B-X
an	B-X
antiserum	B-X
to	B-X
the	B-X
MARCKS	B-X
protein	B-X
)	B-X
.	B-X
Incorporation	B-X
of	B-X
myristic	B-X
acid	B-X
into	B-X
intact	B-X
protein	B-X
continued	B-X
for	B-X
up	B-X
to	B-X
12	B-X
h	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
over	B-X
this	B-X
period	B-X
some	B-X
degradation	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
.	B-X
In	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
the	B-X
pattern	B-X
of	B-X
loss	B-X
of	B-X
the	B-X
incorporated	B-X
fatty	B-X
acid	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
protein	B-X
itself	B-X
,	B-X
and	B-X
therefore	B-X
the	B-X
loss	B-X
of	B-X
radioactivity	B-X
probably	B-X
reflects	B-X
protein	B-X
degradation	B-X
rather	B-X
than	B-X
specific	B-X
de-acylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
pool	B-X
of	B-X
unacylated	B-X
MARCKS	B-X
protein	B-X
in	B-X
the	B-X
rat	B-X
brain	B-X
.	B-X

A	O
protein	O
of	O
80	O
kDa	O
apparent	O
molecular	O
mass	O
was	O
found	O
to	O
be	O
specifically	O
myristolylated	O
in	O
rat	O
brain	O
cytosols	O
derived	O
from	O
either	O
whole	O
brain	O
or	O
synaptosomes	O
.	O
<EOS>	B-X
This	B-X
has	B-X
been	B-X
greatly	B-X
accelerated	B-X
by	B-X
the	B-X
application	B-X
of	B-X
various	B-X
evolving	B-X
proteomic	B-X
techniques	B-X
,	B-X
enabling	B-X
more	B-X
efficient	B-X
protein	B-X
resolution	B-X
,	B-X
more	B-X
accurate	B-X
protein	B-X
identification	B-X
,	B-X
and	B-X
more	B-X
comprehensive	B-X
characterization	B-X
of	B-X
proteins	B-X
undergoing	B-X
quantitative	B-X
and	B-X
qualitative	B-X
changes	B-X
.	B-X
More	B-X
recently	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
the	B-X
classical	B-X
subcellular	B-X
fractionation	B-X
techniques	B-X
for	B-X
the	B-X
isolation	B-X
of	B-X
synaptosomes	B-X
from	B-X
the	B-X
brain	B-X
with	B-X
the	B-X
various	B-X
proteomic	B-X
analyses	B-X
has	B-X
facilitated	B-X
this	B-X
effort	B-X
.	B-X
This	B-X
has	B-X
resulted	B-X
from	B-X
the	B-X
enrichment	B-X
of	B-X
many	B-X
low	B-X
abundant	B-X
proteins	B-X
comprising	B-X
the	B-X
fundamental	B-X
structure	B-X
and	B-X
molecular	B-X
machinery	B-X
of	B-X
brain	B-X
neurotransmission	B-X
and	B-X
neuroplasticity	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
various	B-X
subproteomes	B-X
obtained	B-X
from	B-X
the	B-X
synapse	B-X
,	B-X
such	B-X
as	B-X
synaptic	B-X
vesicles	B-X
,	B-X
synaptic	B-X
membranes	B-X
,	B-X
presynaptic	B-X
particles	B-X
,	B-X
synaptodendrosomes	B-X
,	B-X
and	B-X
postsynaptic	B-X
densities	B-X
(	B-X
PSD	B-X
)	B-X
holds	B-X
great	B-X
promise	B-X
for	B-X
improving	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
temporal	B-X
and	B-X
spatial	B-X
processes	B-X
that	B-X
coordinate	B-X
synaptic	B-X
proteins	B-X
in	B-X
closely	B-X
related	B-X
complexes	B-X
under	B-X
both	B-X
normal	B-X
and	B-X
diseased	B-X
states	B-X
.	B-X

The	O
attachment	O
of	O
the	O
fatty	O
acid	O
took	O
place	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
,	O
since	O
the	O
cytosols	O
did	O
not	O
incorporate	O
[	O
14C	O
]	O
lysine	O
into	O
protein	O
,	O
nor	O
did	O
cycloheximide	O
affect	O
the	O
incorporation	O
of	O
the	O
myristic	O
acid	O
into	O
the	O
protein	O
.	O

The	O
fatty	O
acid	O
was	O
incorporated	O
into	O
the	O
protein	O
via	O
an	O
acid	O
-	O
labile	O
/	O
alkali	O
-	O
resistant	O
band	O
,	O
and	O
Pronase	O
digestion	O
of	O
the	O
labelled	O
protein	O
showed	O
that	O
the	O
lipid	O
was	O
covalently	O
linked	O
to	O
a	O
glycine	O
residue	O
.	O
<EOS>	B-X
A	B-X
protein	B-X
of	B-X
80	B-X
kDa	B-X
apparent	B-X
molecular	B-X
mass	B-X
was	B-X
found	B-X
to	B-X
be	B-X
specifically	B-X
myristolylated	B-X
in	B-X
rat	B-X
brain	B-X
cytosols	B-X
derived	B-X
from	B-X
either	B-X
whole	B-X
brain	B-X
or	B-X
synaptosomes	B-X
.	B-X
The	B-X
attachment	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
took	B-X
place	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
protein	B-X
synthesis	B-X
,	B-X
since	B-X
the	B-X
cytosols	B-X
did	B-X
not	B-X
incorporate	B-X
[	B-X
14C	B-X
]	B-X
lysine	B-X
into	B-X
protein	B-X
,	B-X
nor	B-X
did	B-X
cycloheximide	B-X
affect	B-X
the	B-X
incorporation	B-X
of	B-X
the	B-X
myristic	B-X
acid	B-X
into	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
fatty	B-X
acid	B-X
was	B-X
incorporated	B-X
into	B-X
the	B-X
protein	B-X
via	B-X
an	B-X
acid-labile/alkali-resistant	B-X
band	B-X
,	B-X
and	B-X
Pronase	B-X
digestion	B-X
of	B-X
the	B-X
labelled	B-X
protein	B-X
showed	B-X
that	B-X
the	B-X
lipid	B-X
was	B-X
covalently	B-X
linked	B-X
to	B-X
a	B-X
glycine	B-X
residue	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggested	B-X
that	B-X
the	B-X
myristic	B-X
acid	B-X
was	B-X
amide-linked	B-X
to	B-X
the	B-X
N-terminal	B-X
residue	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
identified	B-X
as	B-X
one	B-X
of	B-X
the	B-X
major	B-X
protein	B-X
kinase	B-X
C	B-X
substrates	B-X
,	B-X
the	B-X
MARCKS	B-X
(	B-X
myristoylated	B-X
alanine-rich	B-X
C	B-X
kinase	B-X
substrate	B-X
)	B-X
protein	B-X
,	B-X
by	B-X
showing	B-X
that	B-X
Ca2+	B-X
stimulated	B-X
its	B-X
phosphorylation	B-X
,	B-X
by	B-X
its	B-X
heat	B-X
stability	B-X
and	B-X
by	B-X
immune	B-X
precipitation	B-X
(	B-X
using	B-X
an	B-X
antiserum	B-X
to	B-X
the	B-X
MARCKS	B-X
protein	B-X
)	B-X
.	B-X
Incorporation	B-X
of	B-X
myristic	B-X
acid	B-X
into	B-X
intact	B-X
protein	B-X
continued	B-X
for	B-X
up	B-X
to	B-X
12	B-X
h	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
over	B-X
this	B-X
period	B-X
some	B-X
degradation	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
.	B-X
In	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
the	B-X
pattern	B-X
of	B-X
loss	B-X
of	B-X
the	B-X
incorporated	B-X
fatty	B-X
acid	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
protein	B-X
itself	B-X
,	B-X
and	B-X
therefore	B-X
the	B-X
loss	B-X
of	B-X
radioactivity	B-X
probably	B-X
reflects	B-X
protein	B-X
degradation	B-X
rather	B-X
than	B-X
specific	B-X
de-acylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
pool	B-X
of	B-X
unacylated	B-X
MARCKS	B-X
protein	B-X
in	B-X
the	B-X
rat	B-X
brain	B-X
.	B-X

Together	O
,	O
these	O
data	O
suggested	O
that	O
the	O
myristic	O
acid	O
was	O
amide	O
-	O
linked	O
to	O
the	O
N	O
-	O
terminal	O
residue	O
of	O
the	O
protein	O
.	O

The	O
protein	O
was	O
identified	O
as	O
one	O
of	O
the	O
major	O
protein	O
kinase	O
C	O
substrates	O
,	O
the	O
MARCKS	B-Protein
(	O
myristoylated	B-Protein
alanine	I-Protein
-	I-Protein
rich	I-Protein
C	I-Protein
kinase	I-Protein
substrate	I-Protein
)	O
protein	O
,	O
by	O
showing	O
that	O
Ca2	O
+	O
stimulated	O
its	O
phosphorylation	O
,	O
by	O
its	O
heat	O
stability	O
and	O
by	O
immune	O
precipitation	O
(	O
using	O
an	O
antiserum	O
to	O
the	O
MARCKS	B-Protein
protein	O
)	O
.	O

Incorporation	O
of	O
myristic	O
acid	O
into	O
intact	O
protein	O
continued	O
for	O
up	O
to	O
12	O
h	O
,	O
despite	O
the	O
fact	O
that	O
over	O
this	O
period	O
some	O
degradation	O
of	O
the	O
protein	O
could	O
be	O
demonstrated	O
.	O
<EOS>	B-X
A	B-X
protein	B-X
of	B-X
80	B-X
kDa	B-X
apparent	B-X
molecular	B-X
mass	B-X
was	B-X
found	B-X
to	B-X
be	B-X
specifically	B-X
myristolylated	B-X
in	B-X
rat	B-X
brain	B-X
cytosols	B-X
derived	B-X
from	B-X
either	B-X
whole	B-X
brain	B-X
or	B-X
synaptosomes	B-X
.	B-X
The	B-X
attachment	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
took	B-X
place	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
protein	B-X
synthesis	B-X
,	B-X
since	B-X
the	B-X
cytosols	B-X
did	B-X
not	B-X
incorporate	B-X
[	B-X
14C	B-X
]	B-X
lysine	B-X
into	B-X
protein	B-X
,	B-X
nor	B-X
did	B-X
cycloheximide	B-X
affect	B-X
the	B-X
incorporation	B-X
of	B-X
the	B-X
myristic	B-X
acid	B-X
into	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
fatty	B-X
acid	B-X
was	B-X
incorporated	B-X
into	B-X
the	B-X
protein	B-X
via	B-X
an	B-X
acid-labile/alkali-resistant	B-X
band	B-X
,	B-X
and	B-X
Pronase	B-X
digestion	B-X
of	B-X
the	B-X
labelled	B-X
protein	B-X
showed	B-X
that	B-X
the	B-X
lipid	B-X
was	B-X
covalently	B-X
linked	B-X
to	B-X
a	B-X
glycine	B-X
residue	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggested	B-X
that	B-X
the	B-X
myristic	B-X
acid	B-X
was	B-X
amide-linked	B-X
to	B-X
the	B-X
N-terminal	B-X
residue	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
identified	B-X
as	B-X
one	B-X
of	B-X
the	B-X
major	B-X
protein	B-X
kinase	B-X
C	B-X
substrates	B-X
,	B-X
the	B-X
MARCKS	B-X
(	B-X
myristoylated	B-X
alanine-rich	B-X
C	B-X
kinase	B-X
substrate	B-X
)	B-X
protein	B-X
,	B-X
by	B-X
showing	B-X
that	B-X
Ca2+	B-X
stimulated	B-X
its	B-X
phosphorylation	B-X
,	B-X
by	B-X
its	B-X
heat	B-X
stability	B-X
and	B-X
by	B-X
immune	B-X
precipitation	B-X
(	B-X
using	B-X
an	B-X
antiserum	B-X
to	B-X
the	B-X
MARCKS	B-X
protein	B-X
)	B-X
.	B-X
Incorporation	B-X
of	B-X
myristic	B-X
acid	B-X
into	B-X
intact	B-X
protein	B-X
continued	B-X
for	B-X
up	B-X
to	B-X
12	B-X
h	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
over	B-X
this	B-X
period	B-X
some	B-X
degradation	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
.	B-X
In	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
the	B-X
pattern	B-X
of	B-X
loss	B-X
of	B-X
the	B-X
incorporated	B-X
fatty	B-X
acid	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
protein	B-X
itself	B-X
,	B-X
and	B-X
therefore	B-X
the	B-X
loss	B-X
of	B-X
radioactivity	B-X
probably	B-X
reflects	B-X
protein	B-X
degradation	B-X
rather	B-X
than	B-X
specific	B-X
de-acylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
pool	B-X
of	B-X
unacylated	B-X
MARCKS	B-X
protein	B-X
in	B-X
the	B-X
rat	B-X
brain	B-X
.	B-X

In	O
pulse	O
-	O
chase	O
experiments	O
,	O
the	O
pattern	O
of	O
loss	O
of	O
the	O
incorporated	O
fatty	O
acid	O
was	O
similar	O
to	O
that	O
of	O
the	O
protein	O
itself	O
,	O
and	O
therefore	O
the	O
loss	O
of	O
radioactivity	O
probably	O
reflects	O
protein	O
degradation	O
rather	O
than	O
specific	O
de	O
-	O
acylation	O
of	O
the	O
protein	O
.	O
<EOS>	B-X
A	B-X
protein	B-X
of	B-X
80	B-X
kDa	B-X
apparent	B-X
molecular	B-X
mass	B-X
was	B-X
found	B-X
to	B-X
be	B-X
specifically	B-X
myristolylated	B-X
in	B-X
rat	B-X
brain	B-X
cytosols	B-X
derived	B-X
from	B-X
either	B-X
whole	B-X
brain	B-X
or	B-X
synaptosomes	B-X
.	B-X
The	B-X
attachment	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
took	B-X
place	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
protein	B-X
synthesis	B-X
,	B-X
since	B-X
the	B-X
cytosols	B-X
did	B-X
not	B-X
incorporate	B-X
[	B-X
14C	B-X
]	B-X
lysine	B-X
into	B-X
protein	B-X
,	B-X
nor	B-X
did	B-X
cycloheximide	B-X
affect	B-X
the	B-X
incorporation	B-X
of	B-X
the	B-X
myristic	B-X
acid	B-X
into	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
fatty	B-X
acid	B-X
was	B-X
incorporated	B-X
into	B-X
the	B-X
protein	B-X
via	B-X
an	B-X
acid-labile/alkali-resistant	B-X
band	B-X
,	B-X
and	B-X
Pronase	B-X
digestion	B-X
of	B-X
the	B-X
labelled	B-X
protein	B-X
showed	B-X
that	B-X
the	B-X
lipid	B-X
was	B-X
covalently	B-X
linked	B-X
to	B-X
a	B-X
glycine	B-X
residue	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggested	B-X
that	B-X
the	B-X
myristic	B-X
acid	B-X
was	B-X
amide-linked	B-X
to	B-X
the	B-X
N-terminal	B-X
residue	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
identified	B-X
as	B-X
one	B-X
of	B-X
the	B-X
major	B-X
protein	B-X
kinase	B-X
C	B-X
substrates	B-X
,	B-X
the	B-X
MARCKS	B-X
(	B-X
myristoylated	B-X
alanine-rich	B-X
C	B-X
kinase	B-X
substrate	B-X
)	B-X
protein	B-X
,	B-X
by	B-X
showing	B-X
that	B-X
Ca2+	B-X
stimulated	B-X
its	B-X
phosphorylation	B-X
,	B-X
by	B-X
its	B-X
heat	B-X
stability	B-X
and	B-X
by	B-X
immune	B-X
precipitation	B-X
(	B-X
using	B-X
an	B-X
antiserum	B-X
to	B-X
the	B-X
MARCKS	B-X
protein	B-X
)	B-X
.	B-X
Incorporation	B-X
of	B-X
myristic	B-X
acid	B-X
into	B-X
intact	B-X
protein	B-X
continued	B-X
for	B-X
up	B-X
to	B-X
12	B-X
h	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
over	B-X
this	B-X
period	B-X
some	B-X
degradation	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
.	B-X
In	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
the	B-X
pattern	B-X
of	B-X
loss	B-X
of	B-X
the	B-X
incorporated	B-X
fatty	B-X
acid	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
protein	B-X
itself	B-X
,	B-X
and	B-X
therefore	B-X
the	B-X
loss	B-X
of	B-X
radioactivity	B-X
probably	B-X
reflects	B-X
protein	B-X
degradation	B-X
rather	B-X
than	B-X
specific	B-X
de-acylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
pool	B-X
of	B-X
unacylated	B-X
MARCKS	B-X
protein	B-X
in	B-X
the	B-X
rat	B-X
brain	B-X
.	B-X

Together	O
,	O
these	O
results	O
suggest	O
that	O
there	O
is	O
a	O
pool	O
of	O
unacylated	O
MARCKS	B-Protein
protein	O
in	O
the	O
rat	O
brain	O
.	O
<EOS>	B-X
A	B-X
protein	B-X
of	B-X
80	B-X
kDa	B-X
apparent	B-X
molecular	B-X
mass	B-X
was	B-X
found	B-X
to	B-X
be	B-X
specifically	B-X
myristolylated	B-X
in	B-X
rat	B-X
brain	B-X
cytosols	B-X
derived	B-X
from	B-X
either	B-X
whole	B-X
brain	B-X
or	B-X
synaptosomes	B-X
.	B-X
The	B-X
attachment	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
took	B-X
place	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
protein	B-X
synthesis	B-X
,	B-X
since	B-X
the	B-X
cytosols	B-X
did	B-X
not	B-X
incorporate	B-X
[	B-X
14C	B-X
]	B-X
lysine	B-X
into	B-X
protein	B-X
,	B-X
nor	B-X
did	B-X
cycloheximide	B-X
affect	B-X
the	B-X
incorporation	B-X
of	B-X
the	B-X
myristic	B-X
acid	B-X
into	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
fatty	B-X
acid	B-X
was	B-X
incorporated	B-X
into	B-X
the	B-X
protein	B-X
via	B-X
an	B-X
acid-labile/alkali-resistant	B-X
band	B-X
,	B-X
and	B-X
Pronase	B-X
digestion	B-X
of	B-X
the	B-X
labelled	B-X
protein	B-X
showed	B-X
that	B-X
the	B-X
lipid	B-X
was	B-X
covalently	B-X
linked	B-X
to	B-X
a	B-X
glycine	B-X
residue	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggested	B-X
that	B-X
the	B-X
myristic	B-X
acid	B-X
was	B-X
amide-linked	B-X
to	B-X
the	B-X
N-terminal	B-X
residue	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
identified	B-X
as	B-X
one	B-X
of	B-X
the	B-X
major	B-X
protein	B-X
kinase	B-X
C	B-X
substrates	B-X
,	B-X
the	B-X
MARCKS	B-X
(	B-X
myristoylated	B-X
alanine-rich	B-X
C	B-X
kinase	B-X
substrate	B-X
)	B-X
protein	B-X
,	B-X
by	B-X
showing	B-X
that	B-X
Ca2+	B-X
stimulated	B-X
its	B-X
phosphorylation	B-X
,	B-X
by	B-X
its	B-X
heat	B-X
stability	B-X
and	B-X
by	B-X
immune	B-X
precipitation	B-X
(	B-X
using	B-X
an	B-X
antiserum	B-X
to	B-X
the	B-X
MARCKS	B-X
protein	B-X
)	B-X
.	B-X
Incorporation	B-X
of	B-X
myristic	B-X
acid	B-X
into	B-X
intact	B-X
protein	B-X
continued	B-X
for	B-X
up	B-X
to	B-X
12	B-X
h	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
over	B-X
this	B-X
period	B-X
some	B-X
degradation	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
.	B-X
In	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
the	B-X
pattern	B-X
of	B-X
loss	B-X
of	B-X
the	B-X
incorporated	B-X
fatty	B-X
acid	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
protein	B-X
itself	B-X
,	B-X
and	B-X
therefore	B-X
the	B-X
loss	B-X
of	B-X
radioactivity	B-X
probably	B-X
reflects	B-X
protein	B-X
degradation	B-X
rather	B-X
than	B-X
specific	B-X
de-acylation	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
pool	B-X
of	B-X
unacylated	B-X
MARCKS	B-X
protein	B-X
in	B-X
the	B-X
rat	B-X
brain	B-X
.	B-X

Identification	O
of	O
amino	O
acids	O
in	O
the	O
gamma	O
-	O
carboxylation	O
recognition	O
site	O
on	O
the	O
propeptide	O
of	O
prothrombin	B-Protein
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
prothrombin	B-X
cDNA	B-X
modified	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
using	B-X
a	B-X
system	B-X
that	B-X
yields	B-X
functional	B-X
fully	B-X
carboxylated	B-X
prothrombin	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Conformation-specific	B-X
anti-prothrombin	B-X
:	B-X
Ca	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
antibodies	B-X
measure	B-X
native	B-X
completely	B-X
carboxylated	B-X
prothrombin	B-X
;	B-X
anti-prothrombin	B-X
:	B-X
total	B-X
antibodies	B-X
measure	B-X
all	B-X
forms	B-X
of	B-X
prothrombin	B-X
,	B-X
regardless	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
content	B-X
.	B-X
Mutation	B-X
of	B-X
His-18	B-X
to	B-X
Gly	B-X
,	B-X
Val-17	B-X
to	B-X
Ser	B-X
,	B-X
Leu-15	B-X
to	B-X
Gly	B-X
or	B-X
Asp	B-X
,	B-X
or	B-X
Ala-10	B-X
to	B-X
Asp	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
partial	B-X
(	B-X
30-65	B-X
%	B-X
)	B-X
inhibition	B-X
of	B-X
gamma-carboxylation	B-X
.	B-X
Mutation	B-X
of	B-X
Ala-14	B-X
to	B-X
Ser	B-X
or	B-X
Ser-8	B-X
to	B-X
Val	B-X
did	B-X
not	B-X
inhibit	B-X
gamma-carboxylation	B-X
.	B-X
From	B-X
this	B-X
and	B-X
earlier	B-X
work	B-X
,	B-X
residues	B-X
whose	B-X
mutation	B-X
leads	B-X
to	B-X
a	B-X
significant	B-X
impairment	B-X
of	B-X
carboxylation	B-X
include	B-X
His-18	B-X
,	B-X
Val-17	B-X
,	B-X
Phe-16	B-X
,	B-X
Leu-15	B-X
,	B-X
and	B-X
Ala-10	B-X
.	B-X
Residues	B-X
whose	B-X
mutation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
include	B-X
Ala-14	B-X
,	B-X
Ser-8	B-X
,	B-X
Arg-4	B-X
,	B-X
and	B-X
Arg-1	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
size	B-X
of	B-X
the	B-X
recognition	B-X
site	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
carboxylation	B-X
of	B-X
propeptide-containing	B-X
synthetic	B-X
peptides	B-X
was	B-X
compared	B-X
.	B-X
A	B-X
28-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
prothrombin	B-X
,	B-X
and	B-X
a	B-X
54-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+36	B-X
of	B-X
prothrombin	B-X
,	B-X
were	B-X
carboxylated	B-X
by	B-X
partially	B-X
purified	B-X
bovine	B-X
carboxylase	B-X
with	B-X
similar	B-X
Km	B-X
values	B-X
of	B-X
2-5	B-X
microM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
gamma-carboxyglutamic	B-X
acid-rich	B-X
region	B-X
of	B-X
prothrombin	B-X
makes	B-X
a	B-X
minimal	B-X
contribution	B-X
to	B-X
carboxylase	B-X
binding	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

A	O
gamma	O
-	O
carboxylation	O
recognition	O
site	O
on	O
the	O
propeptide	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
blood	O
coagulation	O
proteins	O
directs	O
the	O
carboxylation	O
of	O
glutamic	O
acid	O
residues	O
by	O
binding	O
to	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
.	O

To	O
determine	O
residues	O
that	O
define	O
this	O
site	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
mutation	O
of	O
certain	O
residues	O
in	O
the	O
prothrombin	B-Protein
propeptide	O
on	O
the	O
extent	O
of	O
carboxylation	O
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
prothrombin	B-X
cDNA	B-X
modified	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
using	B-X
a	B-X
system	B-X
that	B-X
yields	B-X
functional	B-X
fully	B-X
carboxylated	B-X
prothrombin	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Conformation-specific	B-X
anti-prothrombin	B-X
:	B-X
Ca	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
antibodies	B-X
measure	B-X
native	B-X
completely	B-X
carboxylated	B-X
prothrombin	B-X
;	B-X
anti-prothrombin	B-X
:	B-X
total	B-X
antibodies	B-X
measure	B-X
all	B-X
forms	B-X
of	B-X
prothrombin	B-X
,	B-X
regardless	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
content	B-X
.	B-X
Mutation	B-X
of	B-X
His-18	B-X
to	B-X
Gly	B-X
,	B-X
Val-17	B-X
to	B-X
Ser	B-X
,	B-X
Leu-15	B-X
to	B-X
Gly	B-X
or	B-X
Asp	B-X
,	B-X
or	B-X
Ala-10	B-X
to	B-X
Asp	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
partial	B-X
(	B-X
30-65	B-X
%	B-X
)	B-X
inhibition	B-X
of	B-X
gamma-carboxylation	B-X
.	B-X
Mutation	B-X
of	B-X
Ala-14	B-X
to	B-X
Ser	B-X
or	B-X
Ser-8	B-X
to	B-X
Val	B-X
did	B-X
not	B-X
inhibit	B-X
gamma-carboxylation	B-X
.	B-X
From	B-X
this	B-X
and	B-X
earlier	B-X
work	B-X
,	B-X
residues	B-X
whose	B-X
mutation	B-X
leads	B-X
to	B-X
a	B-X
significant	B-X
impairment	B-X
of	B-X
carboxylation	B-X
include	B-X
His-18	B-X
,	B-X
Val-17	B-X
,	B-X
Phe-16	B-X
,	B-X
Leu-15	B-X
,	B-X
and	B-X
Ala-10	B-X
.	B-X
Residues	B-X
whose	B-X
mutation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
include	B-X
Ala-14	B-X
,	B-X
Ser-8	B-X
,	B-X
Arg-4	B-X
,	B-X
and	B-X
Arg-1	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
size	B-X
of	B-X
the	B-X
recognition	B-X
site	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
carboxylation	B-X
of	B-X
propeptide-containing	B-X
synthetic	B-X
peptides	B-X
was	B-X
compared	B-X
.	B-X
A	B-X
28-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
prothrombin	B-X
,	B-X
and	B-X
a	B-X
54-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+36	B-X
of	B-X
prothrombin	B-X
,	B-X
were	B-X
carboxylated	B-X
by	B-X
partially	B-X
purified	B-X
bovine	B-X
carboxylase	B-X
with	B-X
similar	B-X
Km	B-X
values	B-X
of	B-X
2-5	B-X
microM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
gamma-carboxyglutamic	B-X
acid-rich	B-X
region	B-X
of	B-X
prothrombin	B-X
makes	B-X
a	B-X
minimal	B-X
contribution	B-X
to	B-X
carboxylase	B-X
binding	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

The	O
prothrombin	B-Protein
cDNA	O
modified	O
by	O
site	O
-	O
specific	O
mutagenesis	O
was	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
using	O
a	O
system	O
that	O
yields	O
functional	O
fully	O
carboxylated	O
prothrombin	B-Protein
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
prothrombin	B-X
cDNA	B-X
modified	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
using	B-X
a	B-X
system	B-X
that	B-X
yields	B-X
functional	B-X
fully	B-X
carboxylated	B-X
prothrombin	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Conformation-specific	B-X
anti-prothrombin	B-X
:	B-X
Ca	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
antibodies	B-X
measure	B-X
native	B-X
completely	B-X
carboxylated	B-X
prothrombin	B-X
;	B-X
anti-prothrombin	B-X
:	B-X
total	B-X
antibodies	B-X
measure	B-X
all	B-X
forms	B-X
of	B-X
prothrombin	B-X
,	B-X
regardless	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
content	B-X
.	B-X
Residues	B-X
whose	B-X
mutation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
include	B-X
Ala-14	B-X
,	B-X
Ser-8	B-X
,	B-X
Arg-4	B-X
,	B-X
and	B-X
Arg-1	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
size	B-X
of	B-X
the	B-X
recognition	B-X
site	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
carboxylation	B-X
of	B-X
propeptide-containing	B-X
synthetic	B-X
peptides	B-X
was	B-X
compared	B-X
.	B-X
A	B-X
28-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
prothrombin	B-X
,	B-X
and	B-X
a	B-X
54-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+36	B-X
of	B-X
prothrombin	B-X
,	B-X
were	B-X
carboxylated	B-X
by	B-X
partially	B-X
purified	B-X
bovine	B-X
carboxylase	B-X
with	B-X
similar	B-X
Km	B-X
values	B-X
of	B-X
2-5	B-X
microM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
gamma-carboxyglutamic	B-X
acid-rich	B-X
region	B-X
of	B-X
prothrombin	B-X
makes	B-X
a	B-X
minimal	B-X
contribution	B-X
to	B-X
carboxylase	B-X
binding	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

The	O
cell	O
supernatants	O
containing	O
recombinant	O
prothrombin	B-Protein
were	O
evaluated	O
for	O
the	O
extent	O
of	O
gamma	O
-	O
carboxylation	O
by	O
immunoassay	O
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
prothrombin	B-X
cDNA	B-X
modified	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
using	B-X
a	B-X
system	B-X
that	B-X
yields	B-X
functional	B-X
fully	B-X
carboxylated	B-X
prothrombin	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Conformation-specific	B-X
anti-prothrombin	B-X
:	B-X
Ca	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
antibodies	B-X
measure	B-X
native	B-X
completely	B-X
carboxylated	B-X
prothrombin	B-X
;	B-X
anti-prothrombin	B-X
:	B-X
total	B-X
antibodies	B-X
measure	B-X
all	B-X
forms	B-X
of	B-X
prothrombin	B-X
,	B-X
regardless	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
content	B-X
.	B-X
Mutation	B-X
of	B-X
His-18	B-X
to	B-X
Gly	B-X
,	B-X
Val-17	B-X
to	B-X
Ser	B-X
,	B-X
Leu-15	B-X
to	B-X
Gly	B-X
or	B-X
Asp	B-X
,	B-X
or	B-X
Ala-10	B-X
to	B-X
Asp	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
partial	B-X
(	B-X
30-65	B-X
%	B-X
)	B-X
inhibition	B-X
of	B-X
gamma-carboxylation	B-X
.	B-X
Mutation	B-X
of	B-X
Ala-14	B-X
to	B-X
Ser	B-X
or	B-X
Ser-8	B-X
to	B-X
Val	B-X
did	B-X
not	B-X
inhibit	B-X
gamma-carboxylation	B-X
.	B-X
From	B-X
this	B-X
and	B-X
earlier	B-X
work	B-X
,	B-X
residues	B-X
whose	B-X
mutation	B-X
leads	B-X
to	B-X
a	B-X
significant	B-X
impairment	B-X
of	B-X
carboxylation	B-X
include	B-X
His-18	B-X
,	B-X
Val-17	B-X
,	B-X
Phe-16	B-X
,	B-X
Leu-15	B-X
,	B-X
and	B-X
Ala-10	B-X
.	B-X
Residues	B-X
whose	B-X
mutation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
include	B-X
Ala-14	B-X
,	B-X
Ser-8	B-X
,	B-X
Arg-4	B-X
,	B-X
and	B-X
Arg-1	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
size	B-X
of	B-X
the	B-X
recognition	B-X
site	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
carboxylation	B-X
of	B-X
propeptide-containing	B-X
synthetic	B-X
peptides	B-X
was	B-X
compared	B-X
.	B-X
A	B-X
28-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
prothrombin	B-X
,	B-X
and	B-X
a	B-X
54-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+36	B-X
of	B-X
prothrombin	B-X
,	B-X
were	B-X
carboxylated	B-X
by	B-X
partially	B-X
purified	B-X
bovine	B-X
carboxylase	B-X
with	B-X
similar	B-X
Km	B-X
values	B-X
of	B-X
2-5	B-X
microM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
gamma-carboxyglutamic	B-X
acid-rich	B-X
region	B-X
of	B-X
prothrombin	B-X
makes	B-X
a	B-X
minimal	B-X
contribution	B-X
to	B-X
carboxylase	B-X
binding	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

Conformation	O
-	O
specific	O
anti	O
-	O
prothrombin	B-Protein
:	O
Ca	O
(	O
II	O
)	O
-	O
specific	O
antibodies	O
measure	O
native	O
completely	O
carboxylated	O
prothrombin	B-Protein
;	O
anti	O
-	O
prothrombin	B-Protein
:	O
total	O
antibodies	O
measure	O
all	O
forms	O
of	O
prothrombin	B-Protein
,	O
regardless	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
content	O
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
prothrombin	B-X
cDNA	B-X
modified	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
using	B-X
a	B-X
system	B-X
that	B-X
yields	B-X
functional	B-X
fully	B-X
carboxylated	B-X
prothrombin	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Conformation-specific	B-X
anti-prothrombin	B-X
:	B-X
Ca	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
antibodies	B-X
measure	B-X
native	B-X
completely	B-X
carboxylated	B-X
prothrombin	B-X
;	B-X
anti-prothrombin	B-X
:	B-X
total	B-X
antibodies	B-X
measure	B-X
all	B-X
forms	B-X
of	B-X
prothrombin	B-X
,	B-X
regardless	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
content	B-X
.	B-X
Mutation	B-X
of	B-X
His-18	B-X
to	B-X
Gly	B-X
,	B-X
Val-17	B-X
to	B-X
Ser	B-X
,	B-X
Leu-15	B-X
to	B-X
Gly	B-X
or	B-X
Asp	B-X
,	B-X
or	B-X
Ala-10	B-X
to	B-X
Asp	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
partial	B-X
(	B-X
30-65	B-X
%	B-X
)	B-X
inhibition	B-X
of	B-X
gamma-carboxylation	B-X
.	B-X
Mutation	B-X
of	B-X
Ala-14	B-X
to	B-X
Ser	B-X
or	B-X
Ser-8	B-X
to	B-X
Val	B-X
did	B-X
not	B-X
inhibit	B-X
gamma-carboxylation	B-X
.	B-X
A	B-X
28-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
prothrombin	B-X
,	B-X
and	B-X
a	B-X
54-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+36	B-X
of	B-X
prothrombin	B-X
,	B-X
were	B-X
carboxylated	B-X
by	B-X
partially	B-X
purified	B-X
bovine	B-X
carboxylase	B-X
with	B-X
similar	B-X
Km	B-X
values	B-X
of	B-X
2-5	B-X
microM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
gamma-carboxyglutamic	B-X
acid-rich	B-X
region	B-X
of	B-X
prothrombin	B-X
makes	B-X
a	B-X
minimal	B-X
contribution	B-X
to	B-X
carboxylase	B-X
binding	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

Mutation	O
of	O
His	O
-	O
18	O
to	O
Gly	O
,	O
Val	O
-	O
17	O
to	O
Ser	O
,	O
Leu	O
-	O
15	O
to	O
Gly	O
or	O
Asp	O
,	O
or	O
Ala	O
-	O
10	O
to	O
Asp	O
was	O
associated	O
with	O
a	O
partial	O
(	O
30	O
-	O
65	O
%	O
)	O
inhibition	O
of	O
gamma	O
-	O
carboxylation	O
.	O
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
coupled	B-X
with	B-X
quantitative	B-X
PCR	B-X
(	B-X
qPCR	B-X
)	B-X
has	B-X
in	B-X
the	B-X
last	B-X
15	B-X
years	B-X
become	B-X
a	B-X
basic	B-X
mainstream	B-X
tool	B-X
in	B-X
genomic	B-X
research	B-X
.	B-X
Since	B-X
the	B-X
discovery	B-X
of	B-X
the	B-X
JAK2	B-X
V617F	B-X
mutation	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
myeloproliferative	B-X
neoplasms	B-X
(	B-X
MPN	B-X
)	B-X
of	B-X
polycythemia	B-X
vera	B-X
,	B-X
essential	B-X
thrombocythemia	B-X
and	B-X
primary	B-X
myelofibrosis	B-X
ten	B-X
years	B-X
ago	B-X
,	B-X
further	B-X
MPN-specific	B-X
mutational	B-X
events	B-X
,	B-X
notably	B-X
in	B-X
JAK2	B-X
exon	B-X
12	B-X
,	B-X
MPL	B-X
exon	B-X
10	B-X
and	B-X
CALR	B-X
exon	B-X
9	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
The	B-X
advantages	B-X
and	B-X
limitations	B-X
of	B-X
these	B-X
approaches	B-X
in	B-X
identifying	B-X
and	B-X
quantitating	B-X
the	B-X
common	B-X
MPN-associated	B-X
mutations	B-X
are	B-X
considered	B-X
herein	B-X
with	B-X
particular	B-X
regard	B-X
to	B-X
their	B-X
clinical	B-X
utility	B-X
.	B-X
The	B-X
evolution	B-X
of	B-X
molecular	B-X
diagnostic	B-X
applications	B-X
and	B-X
platforms	B-X
has	B-X
occurred	B-X
in	B-X
parallel	B-X
with	B-X
the	B-X
discovery	B-X
of	B-X
MPN-associated	B-X
mutations	B-X
,	B-X
and	B-X
it	B-X
therefore	B-X
appears	B-X
likely	B-X
that	B-X
emerging	B-X
technologies	B-X
such	B-X
as	B-X
next-generation	B-X
sequencing	B-X
and	B-X
digital	B-X
PCR	B-X
will	B-X
in	B-X
the	B-X
future	B-X
play	B-X
an	B-X
increasing	B-X
role	B-X
in	B-X
the	B-X
molecular	B-X
diagnosis	B-X
of	B-X
MPN	B-X
.	B-X

Mutation	O
of	O
Ala	O
-	O
14	O
to	O
Ser	O
or	O
Ser	O
-	O
8	O
to	O
Val	O
did	O
not	O
inhibit	O
gamma	O
-	O
carboxylation	O
.	O
<EOS>	B-X
Mutation	B-X
and	B-X
drug-resistance	B-X
rates	B-X
were	B-X
estimated	B-X
in	B-X
Stata	B-X
16.0	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
the	B-X
drug-resistance	B-X
rate	B-X
was	B-X
10.18	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
7.85-12.51	B-X
)	B-X
.	B-X
Subgroup	B-X
analysis	B-X
showed	B-X
the	B-X
highest	B-X
resistance	B-X
rate	B-X
was	B-X
in	B-X
the	B-X
Western	B-X
Pacific	B-X
region	B-X
(	B-X
17.05	B-X
%	B-X
,	B-X
95	B-X
%	B-X
CI:1.80	B-X
to	B-X
13.78	B-X
)	B-X
,	B-X
and	B-X
it	B-X
was	B-X
higher	B-X
after	B-X
2009	B-X
than	B-X
before	B-X
[	B-X
(	B-X
11.39	B-X
%	B-X
,	B-X
7.46-15.33	B-X
)	B-X
vs.	B-X
6.59	B-X
%	B-X
(	B-X
3.66-9.53	B-X
)	B-X
]	B-X
.	B-X
We	B-X
can	B-X
conclude	B-X
that	B-X
the	B-X
rate	B-X
among	B-X
new	B-X
cases	B-X
(	B-X
7.25	B-X
%	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
4.65-9.84	B-X
)	B-X
was	B-X
lower	B-X
than	B-X
the	B-X
relapsed	B-X
(	B-X
14.26	B-X
%	B-X
,	B-X
95	B-X
CI	B-X
%	B-X
:	B-X
9.82-18.71	B-X
)	B-X
.	B-X
Mutation	B-X
rates	B-X
of	B-X
Folp1	B-X
,	B-X
RpoB	B-X
and	B-X
GyrA	B-X
were	B-X
4.40	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
3.02-5.77	B-X
)	B-X
,	B-X
3.66	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
2.41-4.90	B-X
)	B-X
and	B-X
1.28	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.87-1.71	B-X
)	B-X
respectively	B-X
,	B-X
while	B-X
the	B-X
rate	B-X
for	B-X
polygenes	B-X
mutation	B-X
was	B-X
1.73	B-X
%	B-X
(	B-X
0.83-2.63	B-X
)	B-X
.	B-X
For	B-X
further	B-X
analysis	B-X
,	B-X
we	B-X
used	B-X
368	B-X
drug-resistant	B-X
strains	B-X
as	B-X
research	B-X
subjects	B-X
and	B-X
found	B-X
that	B-X
codons	B-X
(	B-X
Ser	B-X
,	B-X
Pro	B-X
,	B-X
Ala	B-X
)	B-X
on	B-X
RpoB	B-X
,	B-X
Folp1	B-X
and	B-X
GyrA	B-X
are	B-X
the	B-X
most	B-X
common	B-X
mutation	B-X
sites	B-X
in	B-X
the	B-X
determining	B-X
region	B-X
(	B-X
DRDR	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
most	B-X
common	B-X
substitution	B-X
patterns	B-X
of	B-X
Folp1	B-X
,	B-X
RpoB	B-X
,	B-X
and	B-X
GyrA	B-X
are	B-X
Pro→Leu	B-X
,	B-X
Ser→Leu	B-X
,	B-X
and	B-X
Ala→Val	B-X
.	B-X

From	O
this	O
and	O
earlier	O
work	O
,	O
residues	O
whose	O
mutation	O
leads	O
to	O
a	O
significant	O
impairment	O
of	O
carboxylation	O
include	O
His	O
-	O
18	O
,	O
Val	O
-	O
17	O
,	O
Phe	O
-	O
16	O
,	O
Leu	O
-	O
15	O
,	O
and	O
Ala	O
-	O
10	O
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Mutation	B-X
of	B-X
His-18	B-X
to	B-X
Gly	B-X
,	B-X
Val-17	B-X
to	B-X
Ser	B-X
,	B-X
Leu-15	B-X
to	B-X
Gly	B-X
or	B-X
Asp	B-X
,	B-X
or	B-X
Ala-10	B-X
to	B-X
Asp	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
partial	B-X
(	B-X
30-65	B-X
%	B-X
)	B-X
inhibition	B-X
of	B-X
gamma-carboxylation	B-X
.	B-X
Mutation	B-X
of	B-X
Ala-14	B-X
to	B-X
Ser	B-X
or	B-X
Ser-8	B-X
to	B-X
Val	B-X
did	B-X
not	B-X
inhibit	B-X
gamma-carboxylation	B-X
.	B-X
From	B-X
this	B-X
and	B-X
earlier	B-X
work	B-X
,	B-X
residues	B-X
whose	B-X
mutation	B-X
leads	B-X
to	B-X
a	B-X
significant	B-X
impairment	B-X
of	B-X
carboxylation	B-X
include	B-X
His-18	B-X
,	B-X
Val-17	B-X
,	B-X
Phe-16	B-X
,	B-X
Leu-15	B-X
,	B-X
and	B-X
Ala-10	B-X
.	B-X
Residues	B-X
whose	B-X
mutation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
include	B-X
Ala-14	B-X
,	B-X
Ser-8	B-X
,	B-X
Arg-4	B-X
,	B-X
and	B-X
Arg-1	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
size	B-X
of	B-X
the	B-X
recognition	B-X
site	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
carboxylation	B-X
of	B-X
propeptide-containing	B-X
synthetic	B-X
peptides	B-X
was	B-X
compared	B-X
.	B-X
A	B-X
28-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
prothrombin	B-X
,	B-X
and	B-X
a	B-X
54-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+36	B-X
of	B-X
prothrombin	B-X
,	B-X
were	B-X
carboxylated	B-X
by	B-X
partially	B-X
purified	B-X
bovine	B-X
carboxylase	B-X
with	B-X
similar	B-X
Km	B-X
values	B-X
of	B-X
2-5	B-X
microM	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

Residues	O
whose	O
mutation	O
does	O
not	O
alter	O
the	O
carboxylation	O
recognition	O
site	O
include	O
Ala	O
-	O
14	O
,	O
Ser	O
-	O
8	O
,	O
Arg	O
-	O
4	O
,	O
and	O
Arg	O
-	O
1	O
.	O
<EOS>	B-X
Antithrombin	B-X
is	B-X
a	B-X
key	B-X
endogenous	B-X
anticoagulant	B-X
whose	B-X
deficiency	B-X
constitutes	B-X
a	B-X
strong	B-X
risk	B-X
factor	B-X
for	B-X
thrombosis	B-X
.	B-X
Molecular	B-X
analysis	B-X
of	B-X
SERPINC1	B-X
,	B-X
the	B-X
gene	B-X
encoding	B-X
antithrombin	B-X
,	B-X
has	B-X
been	B-X
restricted	B-X
so	B-X
far	B-X
to	B-X
cases	B-X
with	B-X
confirmed	B-X
or	B-X
familial	B-X
antithrombin	B-X
deficiency	B-X
.	B-X
However	B-X
,	B-X
some	B-X
pathogenic	B-X
mutations	B-X
are	B-X
not	B-X
detected	B-X
by	B-X
current	B-X
functional	B-X
methods	B-X
and	B-X
other	B-X
gene	B-X
defects	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
only	B-X
observed	B-X
under	B-X
specific	B-X
conditions	B-X
.	B-X
Up	B-X
to	B-X
80	B-X
%	B-X
of	B-X
patients	B-X
with	B-X
antithrombin	B-X
deficiency	B-X
have	B-X
SERPINC1	B-X
gene	B-X
defects	B-X
,	B-X
mostly	B-X
(	B-X
90	B-X
%	B-X
of	B-X
the	B-X
315	B-X
gene	B-X
defects	B-X
described	B-X
so	B-X
far	B-X
)	B-X
point	B-X
mutations	B-X
or	B-X
small	B-X
deletions	B-X
or	B-X
insertions	B-X
affecting	B-X
the	B-X
7	B-X
exons	B-X
or	B-X
flanking	B-X
regions	B-X
.	B-X
The	B-X
description	B-X
of	B-X
new	B-X
SERPINC1	B-X
gene	B-X
defects	B-X
may	B-X
reveal	B-X
new	B-X
residues	B-X
with	B-X
functional	B-X
or	B-X
structural	B-X
relevance	B-X
and	B-X
new	B-X
mechanisms	B-X
causing	B-X
deficiency	B-X
of	B-X
this	B-X
endogenous	B-X
anticoagulant	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
still	B-X
up	B-X
to	B-X
10-15	B-X
%	B-X
of	B-X
cases	B-X
with	B-X
antithrombin	B-X
deficiency	B-X
of	B-X
unknown	B-X
cause	B-X
,	B-X
whose	B-X
study	B-X
may	B-X
reveal	B-X
new	B-X
genes	B-X
and	B-X
mechanisms	B-X
involved	B-X
in	B-X
thrombosis	B-X
.	B-X

To	O
determine	O
the	O
size	O
of	O
the	O
recognition	O
site	O
,	O
the	O
in	O
vitro	O
carboxylation	O
of	O
propeptide	O
-	O
containing	O
synthetic	O
peptides	O
was	O
compared	O
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
prothrombin	B-X
cDNA	B-X
modified	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
using	B-X
a	B-X
system	B-X
that	B-X
yields	B-X
functional	B-X
fully	B-X
carboxylated	B-X
prothrombin	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Mutation	B-X
of	B-X
His-18	B-X
to	B-X
Gly	B-X
,	B-X
Val-17	B-X
to	B-X
Ser	B-X
,	B-X
Leu-15	B-X
to	B-X
Gly	B-X
or	B-X
Asp	B-X
,	B-X
or	B-X
Ala-10	B-X
to	B-X
Asp	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
partial	B-X
(	B-X
30-65	B-X
%	B-X
)	B-X
inhibition	B-X
of	B-X
gamma-carboxylation	B-X
.	B-X
Mutation	B-X
of	B-X
Ala-14	B-X
to	B-X
Ser	B-X
or	B-X
Ser-8	B-X
to	B-X
Val	B-X
did	B-X
not	B-X
inhibit	B-X
gamma-carboxylation	B-X
.	B-X
From	B-X
this	B-X
and	B-X
earlier	B-X
work	B-X
,	B-X
residues	B-X
whose	B-X
mutation	B-X
leads	B-X
to	B-X
a	B-X
significant	B-X
impairment	B-X
of	B-X
carboxylation	B-X
include	B-X
His-18	B-X
,	B-X
Val-17	B-X
,	B-X
Phe-16	B-X
,	B-X
Leu-15	B-X
,	B-X
and	B-X
Ala-10	B-X
.	B-X
Residues	B-X
whose	B-X
mutation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
include	B-X
Ala-14	B-X
,	B-X
Ser-8	B-X
,	B-X
Arg-4	B-X
,	B-X
and	B-X
Arg-1	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
size	B-X
of	B-X
the	B-X
recognition	B-X
site	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
carboxylation	B-X
of	B-X
propeptide-containing	B-X
synthetic	B-X
peptides	B-X
was	B-X
compared	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

A	O
28	O
-	O
residue	O
peptide	O
,	O
based	O
upon	O
residues	O
-	O
18	O
to	O
+	O
10	O
of	O
prothrombin	B-Protein
,	O
and	O
a	O
54	O
-	O
residue	O
peptide	O
,	O
based	O
upon	O
residues	O
-	O
18	O
to	O
+	O
36	O
of	O
prothrombin	B-Protein
,	O
were	O
carboxylated	O
by	O
partially	O
purified	O
bovine	O
carboxylase	O
with	O
similar	O
Km	O
values	O
of	O
2	O
-	O
5	O
microM	O
.	O

These	O
results	O
indicate	O
that	O
the	O
gamma	O
-	O
carboxyglutamic	O
acid	O
-	O
rich	O
region	O
of	O
prothrombin	B-Protein
makes	O
a	O
minimal	O
contribution	O
to	O
carboxylase	O
binding	O
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
prothrombin	B-X
cDNA	B-X
modified	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
using	B-X
a	B-X
system	B-X
that	B-X
yields	B-X
functional	B-X
fully	B-X
carboxylated	B-X
prothrombin	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Conformation-specific	B-X
anti-prothrombin	B-X
:	B-X
Ca	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
antibodies	B-X
measure	B-X
native	B-X
completely	B-X
carboxylated	B-X
prothrombin	B-X
;	B-X
anti-prothrombin	B-X
:	B-X
total	B-X
antibodies	B-X
measure	B-X
all	B-X
forms	B-X
of	B-X
prothrombin	B-X
,	B-X
regardless	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
content	B-X
.	B-X
Mutation	B-X
of	B-X
His-18	B-X
to	B-X
Gly	B-X
,	B-X
Val-17	B-X
to	B-X
Ser	B-X
,	B-X
Leu-15	B-X
to	B-X
Gly	B-X
or	B-X
Asp	B-X
,	B-X
or	B-X
Ala-10	B-X
to	B-X
Asp	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
partial	B-X
(	B-X
30-65	B-X
%	B-X
)	B-X
inhibition	B-X
of	B-X
gamma-carboxylation	B-X
.	B-X
Mutation	B-X
of	B-X
Ala-14	B-X
to	B-X
Ser	B-X
or	B-X
Ser-8	B-X
to	B-X
Val	B-X
did	B-X
not	B-X
inhibit	B-X
gamma-carboxylation	B-X
.	B-X
A	B-X
28-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
prothrombin	B-X
,	B-X
and	B-X
a	B-X
54-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+36	B-X
of	B-X
prothrombin	B-X
,	B-X
were	B-X
carboxylated	B-X
by	B-X
partially	B-X
purified	B-X
bovine	B-X
carboxylase	B-X
with	B-X
similar	B-X
Km	B-X
values	B-X
of	B-X
2-5	B-X
microM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
gamma-carboxyglutamic	B-X
acid-rich	B-X
region	B-X
of	B-X
prothrombin	B-X
makes	B-X
a	B-X
minimal	B-X
contribution	B-X
to	B-X
carboxylase	B-X
binding	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

A	O
molecular	O
surface	O
of	O
about	O
five	O
amino	O
acids	O
located	O
within	O
the	O
propeptide	O
appears	O
to	O
define	O
the	O
carboxylation	O
recognition	O
site	O
on	O
the	O
precursor	O
forms	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
proteins	O
.	O
<EOS>	B-X
A	B-X
gamma-carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
propeptide	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
blood	B-X
coagulation	B-X
proteins	B-X
directs	B-X
the	B-X
carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
residues	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
.	B-X
To	B-X
determine	B-X
residues	B-X
that	B-X
define	B-X
this	B-X
site	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
mutation	B-X
of	B-X
certain	B-X
residues	B-X
in	B-X
the	B-X
prothrombin	B-X
propeptide	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
carboxylation	B-X
.	B-X
The	B-X
prothrombin	B-X
cDNA	B-X
modified	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
using	B-X
a	B-X
system	B-X
that	B-X
yields	B-X
functional	B-X
fully	B-X
carboxylated	B-X
prothrombin	B-X
.	B-X
The	B-X
cell	B-X
supernatants	B-X
containing	B-X
recombinant	B-X
prothrombin	B-X
were	B-X
evaluated	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
by	B-X
immunoassay	B-X
.	B-X
Conformation-specific	B-X
anti-prothrombin	B-X
:	B-X
Ca	B-X
(	B-X
II	B-X
)	B-X
-specific	B-X
antibodies	B-X
measure	B-X
native	B-X
completely	B-X
carboxylated	B-X
prothrombin	B-X
;	B-X
anti-prothrombin	B-X
:	B-X
total	B-X
antibodies	B-X
measure	B-X
all	B-X
forms	B-X
of	B-X
prothrombin	B-X
,	B-X
regardless	B-X
of	B-X
gamma-carboxyglutamic	B-X
acid	B-X
content	B-X
.	B-X
Mutation	B-X
of	B-X
His-18	B-X
to	B-X
Gly	B-X
,	B-X
Val-17	B-X
to	B-X
Ser	B-X
,	B-X
Leu-15	B-X
to	B-X
Gly	B-X
or	B-X
Asp	B-X
,	B-X
or	B-X
Ala-10	B-X
to	B-X
Asp	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
partial	B-X
(	B-X
30-65	B-X
%	B-X
)	B-X
inhibition	B-X
of	B-X
gamma-carboxylation	B-X
.	B-X
Mutation	B-X
of	B-X
Ala-14	B-X
to	B-X
Ser	B-X
or	B-X
Ser-8	B-X
to	B-X
Val	B-X
did	B-X
not	B-X
inhibit	B-X
gamma-carboxylation	B-X
.	B-X
From	B-X
this	B-X
and	B-X
earlier	B-X
work	B-X
,	B-X
residues	B-X
whose	B-X
mutation	B-X
leads	B-X
to	B-X
a	B-X
significant	B-X
impairment	B-X
of	B-X
carboxylation	B-X
include	B-X
His-18	B-X
,	B-X
Val-17	B-X
,	B-X
Phe-16	B-X
,	B-X
Leu-15	B-X
,	B-X
and	B-X
Ala-10	B-X
.	B-X
Residues	B-X
whose	B-X
mutation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
include	B-X
Ala-14	B-X
,	B-X
Ser-8	B-X
,	B-X
Arg-4	B-X
,	B-X
and	B-X
Arg-1	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
size	B-X
of	B-X
the	B-X
recognition	B-X
site	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
carboxylation	B-X
of	B-X
propeptide-containing	B-X
synthetic	B-X
peptides	B-X
was	B-X
compared	B-X
.	B-X
A	B-X
28-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+10	B-X
of	B-X
prothrombin	B-X
,	B-X
and	B-X
a	B-X
54-residue	B-X
peptide	B-X
,	B-X
based	B-X
upon	B-X
residues	B-X
-18	B-X
to	B-X
+36	B-X
of	B-X
prothrombin	B-X
,	B-X
were	B-X
carboxylated	B-X
by	B-X
partially	B-X
purified	B-X
bovine	B-X
carboxylase	B-X
with	B-X
similar	B-X
Km	B-X
values	B-X
of	B-X
2-5	B-X
microM	B-X
.	B-X
A	B-X
molecular	B-X
surface	B-X
of	B-X
about	B-X
five	B-X
amino	B-X
acids	B-X
located	B-X
within	B-X
the	B-X
propeptide	B-X
appears	B-X
to	B-X
define	B-X
the	B-X
carboxylation	B-X
recognition	B-X
site	B-X
on	B-X
the	B-X
precursor	B-X
forms	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
.	B-X

[	O
Experimental	O
animal	O
research	O
on	O
the	O
thrombolytic	O
effect	O
of	O
acyl	O
-	O
plasmin	B-Protein
]	O
.	O
<EOS>	B-X
Plasmin	B-X
was	B-X
acylated	B-X
by	B-X
reaction	B-X
with	B-X
benzoic	B-X
acid	B-X
or	B-X
p-chlorobenzoic	B-X
acid	B-X
p'-amidinophenyl	B-X
ester	B-X
.	B-X
Enzymatically	B-X
inactive	B-X
acyl-plasmin	B-X
is	B-X
reactivated	B-X
in	B-X
buffer	B-X
(	B-X
pH	B-X
7.5	B-X
)	B-X
with	B-X
a	B-X
half-life	B-X
of	B-X
22	B-X
min	B-X
(	B-X
benzoyl-plasmin	B-X
)	B-X
and	B-X
9	B-X
min	B-X
(	B-X
p-chlorobenzoyl-plasmin	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Plasmin	B-X
is	B-X
rapidly	B-X
inactivated	B-X
in	B-X
plasma	B-X
by	B-X
naturally	B-X
occurring	B-X
plasma	B-X
inhibitors	B-X
so	B-X
that	B-X
also	B-X
upon	B-X
incubation	B-X
of	B-X
acyl-plasmin	B-X
in	B-X
plasma	B-X
only	B-X
low	B-X
enzymatic	B-X
activity	B-X
is	B-X
detectable	B-X
.	B-X
Following	B-X
high	B-X
doses	B-X
of	B-X
plasmin	B-X
fibrinogenolysis	B-X
typical	B-X
of	B-X
nonspecific	B-X
proteolysis	B-X
occurs	B-X
in	B-X
vivo	B-X
but	B-X
no	B-X
fibrinolytic	B-X
effects	B-X
is	B-X
demonstrable	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
acyl-plasmins	B-X
are	B-X
able	B-X
either	B-X
to	B-X
prevent	B-X
microthrombosis	B-X
in	B-X
the	B-X
lungs	B-X
induced	B-X
by	B-X
infusion	B-X
of	B-X
thrombin	B-X
or	B-X
to	B-X
achieve	B-X
repatency	B-X
of	B-X
the	B-X
microvasculature	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
microthrombosis	B-X
.	B-X

Plasmin	B-Protein
was	O
acylated	O
by	O
reaction	O
with	O
benzoic	O
acid	O
or	O
p	O
-	O
chlorobenzoic	O
acid	O
p	O
'	O
-	O
amidinophenyl	O
ester	O
.	O
<EOS>	B-X
Plasmin	B-X
was	B-X
acylated	B-X
by	B-X
reaction	B-X
with	B-X
benzoic	B-X
acid	B-X
or	B-X
p-chlorobenzoic	B-X
acid	B-X
p'-amidinophenyl	B-X
ester	B-X
.	B-X
Enzymatically	B-X
inactive	B-X
acyl-plasmin	B-X
is	B-X
reactivated	B-X
in	B-X
buffer	B-X
(	B-X
pH	B-X
7.5	B-X
)	B-X
with	B-X
a	B-X
half-life	B-X
of	B-X
22	B-X
min	B-X
(	B-X
benzoyl-plasmin	B-X
)	B-X
and	B-X
9	B-X
min	B-X
(	B-X
p-chlorobenzoyl-plasmin	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Plasmin	B-X
is	B-X
rapidly	B-X
inactivated	B-X
in	B-X
plasma	B-X
by	B-X
naturally	B-X
occurring	B-X
plasma	B-X
inhibitors	B-X
so	B-X
that	B-X
also	B-X
upon	B-X
incubation	B-X
of	B-X
acyl-plasmin	B-X
in	B-X
plasma	B-X
only	B-X
low	B-X
enzymatic	B-X
activity	B-X
is	B-X
detectable	B-X
.	B-X
Following	B-X
high	B-X
doses	B-X
of	B-X
plasmin	B-X
fibrinogenolysis	B-X
typical	B-X
of	B-X
nonspecific	B-X
proteolysis	B-X
occurs	B-X
in	B-X
vivo	B-X
but	B-X
no	B-X
fibrinolytic	B-X
effects	B-X
is	B-X
demonstrable	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
acyl-plasmins	B-X
are	B-X
able	B-X
either	B-X
to	B-X
prevent	B-X
microthrombosis	B-X
in	B-X
the	B-X
lungs	B-X
induced	B-X
by	B-X
infusion	B-X
of	B-X
thrombin	B-X
or	B-X
to	B-X
achieve	B-X
repatency	B-X
of	B-X
the	B-X
microvasculature	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
microthrombosis	B-X
.	B-X

Enzymatically	O
inactive	O
acyl	O
-	O
plasmin	B-Protein
is	O
reactivated	O
in	O
buffer	O
(	O
pH	O
7	O
.	O
5	O
)	O
with	O
a	O
half	O
-	O
life	O
of	O
22	O
min	O
(	O
benzoyl	O
-	O
plasmin	B-Protein
)	O
and	O
9	O
min	O
(	O
p	O
-	O
chlorobenzoyl	O
-	O
plasmin	B-Protein
)	O
,	O
respectively	O
.	O
<EOS>	B-X
Plasmin	B-X
was	B-X
acylated	B-X
by	B-X
reaction	B-X
with	B-X
benzoic	B-X
acid	B-X
or	B-X
p-chlorobenzoic	B-X
acid	B-X
p'-amidinophenyl	B-X
ester	B-X
.	B-X
Enzymatically	B-X
inactive	B-X
acyl-plasmin	B-X
is	B-X
reactivated	B-X
in	B-X
buffer	B-X
(	B-X
pH	B-X
7.5	B-X
)	B-X
with	B-X
a	B-X
half-life	B-X
of	B-X
22	B-X
min	B-X
(	B-X
benzoyl-plasmin	B-X
)	B-X
and	B-X
9	B-X
min	B-X
(	B-X
p-chlorobenzoyl-plasmin	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Plasmin	B-X
is	B-X
rapidly	B-X
inactivated	B-X
in	B-X
plasma	B-X
by	B-X
naturally	B-X
occurring	B-X
plasma	B-X
inhibitors	B-X
so	B-X
that	B-X
also	B-X
upon	B-X
incubation	B-X
of	B-X
acyl-plasmin	B-X
in	B-X
plasma	B-X
only	B-X
low	B-X
enzymatic	B-X
activity	B-X
is	B-X
detectable	B-X
.	B-X
Following	B-X
high	B-X
doses	B-X
of	B-X
plasmin	B-X
fibrinogenolysis	B-X
typical	B-X
of	B-X
nonspecific	B-X
proteolysis	B-X
occurs	B-X
in	B-X
vivo	B-X
but	B-X
no	B-X
fibrinolytic	B-X
effects	B-X
is	B-X
demonstrable	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
acyl-plasmins	B-X
are	B-X
able	B-X
either	B-X
to	B-X
prevent	B-X
microthrombosis	B-X
in	B-X
the	B-X
lungs	B-X
induced	B-X
by	B-X
infusion	B-X
of	B-X
thrombin	B-X
or	B-X
to	B-X
achieve	B-X
repatency	B-X
of	B-X
the	B-X
microvasculature	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
microthrombosis	B-X
.	B-X

Plasmin	B-Protein
is	O
rapidly	O
inactivated	O
in	O
plasma	O
by	O
naturally	O
occurring	O
plasma	O
inhibitors	O
so	O
that	O
also	O
upon	O
incubation	O
of	O
acyl	O
-	O
plasmin	B-Protein
in	O
plasma	O
only	O
low	O
enzymatic	O
activity	O
is	O
detectable	O
.	O
<EOS>	B-X
Plasmin	B-X
was	B-X
acylated	B-X
by	B-X
reaction	B-X
with	B-X
benzoic	B-X
acid	B-X
or	B-X
p-chlorobenzoic	B-X
acid	B-X
p'-amidinophenyl	B-X
ester	B-X
.	B-X
Enzymatically	B-X
inactive	B-X
acyl-plasmin	B-X
is	B-X
reactivated	B-X
in	B-X
buffer	B-X
(	B-X
pH	B-X
7.5	B-X
)	B-X
with	B-X
a	B-X
half-life	B-X
of	B-X
22	B-X
min	B-X
(	B-X
benzoyl-plasmin	B-X
)	B-X
and	B-X
9	B-X
min	B-X
(	B-X
p-chlorobenzoyl-plasmin	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Plasmin	B-X
is	B-X
rapidly	B-X
inactivated	B-X
in	B-X
plasma	B-X
by	B-X
naturally	B-X
occurring	B-X
plasma	B-X
inhibitors	B-X
so	B-X
that	B-X
also	B-X
upon	B-X
incubation	B-X
of	B-X
acyl-plasmin	B-X
in	B-X
plasma	B-X
only	B-X
low	B-X
enzymatic	B-X
activity	B-X
is	B-X
detectable	B-X
.	B-X
Following	B-X
high	B-X
doses	B-X
of	B-X
plasmin	B-X
fibrinogenolysis	B-X
typical	B-X
of	B-X
nonspecific	B-X
proteolysis	B-X
occurs	B-X
in	B-X
vivo	B-X
but	B-X
no	B-X
fibrinolytic	B-X
effects	B-X
is	B-X
demonstrable	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
acyl-plasmins	B-X
are	B-X
able	B-X
either	B-X
to	B-X
prevent	B-X
microthrombosis	B-X
in	B-X
the	B-X
lungs	B-X
induced	B-X
by	B-X
infusion	B-X
of	B-X
thrombin	B-X
or	B-X
to	B-X
achieve	B-X
repatency	B-X
of	B-X
the	B-X
microvasculature	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
microthrombosis	B-X
.	B-X

Following	O
high	O
doses	O
of	O
plasmin	O
fibrinogenolysis	O
typical	O
of	O
nonspecific	O
proteolysis	O
occurs	O
in	O
vivo	O
but	O
no	O
fibrinolytic	O
effects	O
is	O
demonstrable	O
.	O
<EOS>	B-X
Enzymatically	B-X
inactive	B-X
acyl-plasmin	B-X
is	B-X
reactivated	B-X
in	B-X
buffer	B-X
(	B-X
pH	B-X
7.5	B-X
)	B-X
with	B-X
a	B-X
half-life	B-X
of	B-X
22	B-X
min	B-X
(	B-X
benzoyl-plasmin	B-X
)	B-X
and	B-X
9	B-X
min	B-X
(	B-X
p-chlorobenzoyl-plasmin	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Plasmin	B-X
is	B-X
rapidly	B-X
inactivated	B-X
in	B-X
plasma	B-X
by	B-X
naturally	B-X
occurring	B-X
plasma	B-X
inhibitors	B-X
so	B-X
that	B-X
also	B-X
upon	B-X
incubation	B-X
of	B-X
acyl-plasmin	B-X
in	B-X
plasma	B-X
only	B-X
low	B-X
enzymatic	B-X
activity	B-X
is	B-X
detectable	B-X
.	B-X
Following	B-X
high	B-X
doses	B-X
of	B-X
plasmin	B-X
fibrinogenolysis	B-X
typical	B-X
of	B-X
nonspecific	B-X
proteolysis	B-X
occurs	B-X
in	B-X
vivo	B-X
but	B-X
no	B-X
fibrinolytic	B-X
effects	B-X
is	B-X
demonstrable	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
acyl-plasmins	B-X
are	B-X
able	B-X
either	B-X
to	B-X
prevent	B-X
microthrombosis	B-X
in	B-X
the	B-X
lungs	B-X
induced	B-X
by	B-X
infusion	B-X
of	B-X
thrombin	B-X
or	B-X
to	B-X
achieve	B-X
repatency	B-X
of	B-X
the	B-X
microvasculature	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
microthrombosis	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
acyl	O
-	O
plasmins	B-Protein
are	O
able	O
either	O
to	O
prevent	O
microthrombosis	O
in	O
the	O
lungs	O
induced	O
by	O
infusion	O
of	O
thrombin	B-Protein
or	O
to	O
achieve	O
repatency	O
of	O
the	O
microvasculature	O
after	O
the	O
onset	O
of	O
microthrombosis	O
.	O
<EOS>	B-X
Plasmin	B-X
was	B-X
acylated	B-X
by	B-X
reaction	B-X
with	B-X
benzoic	B-X
acid	B-X
or	B-X
p-chlorobenzoic	B-X
acid	B-X
p'-amidinophenyl	B-X
ester	B-X
.	B-X
Enzymatically	B-X
inactive	B-X
acyl-plasmin	B-X
is	B-X
reactivated	B-X
in	B-X
buffer	B-X
(	B-X
pH	B-X
7.5	B-X
)	B-X
with	B-X
a	B-X
half-life	B-X
of	B-X
22	B-X
min	B-X
(	B-X
benzoyl-plasmin	B-X
)	B-X
and	B-X
9	B-X
min	B-X
(	B-X
p-chlorobenzoyl-plasmin	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Plasmin	B-X
is	B-X
rapidly	B-X
inactivated	B-X
in	B-X
plasma	B-X
by	B-X
naturally	B-X
occurring	B-X
plasma	B-X
inhibitors	B-X
so	B-X
that	B-X
also	B-X
upon	B-X
incubation	B-X
of	B-X
acyl-plasmin	B-X
in	B-X
plasma	B-X
only	B-X
low	B-X
enzymatic	B-X
activity	B-X
is	B-X
detectable	B-X
.	B-X
Following	B-X
high	B-X
doses	B-X
of	B-X
plasmin	B-X
fibrinogenolysis	B-X
typical	B-X
of	B-X
nonspecific	B-X
proteolysis	B-X
occurs	B-X
in	B-X
vivo	B-X
but	B-X
no	B-X
fibrinolytic	B-X
effects	B-X
is	B-X
demonstrable	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
acyl-plasmins	B-X
are	B-X
able	B-X
either	B-X
to	B-X
prevent	B-X
microthrombosis	B-X
in	B-X
the	B-X
lungs	B-X
induced	B-X
by	B-X
infusion	B-X
of	B-X
thrombin	B-X
or	B-X
to	B-X
achieve	B-X
repatency	B-X
of	B-X
the	B-X
microvasculature	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
microthrombosis	B-X
.	B-X

Spectroscopic	O
analysis	O
of	O
acylated	O
and	O
deacylated	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
covalently	B-X
bound	B-X
fatty	B-X
acid	B-X
on	B-X
the	B-X
conformation	B-X
of	B-X
the	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
ultraviolet	B-X
and	B-X
intrinsic	B-X
fluorescence	B-X
spectroscopy	B-X
.	B-X
With	B-X
dimethyl	B-X
sulfoxide	B-X
used	B-X
as	B-X
a	B-X
perturbant	B-X
,	B-X
the	B-X
exposure	B-X
of	B-X
Trp	B-X
and	B-X
Tyr	B-X
residues	B-X
in	B-X
various	B-X
mixtures	B-X
of	B-X
chloroform-methanol	B-X
was	B-X
evaluated	B-X
by	B-X
difference	B-X
spectroscopy	B-X
of	B-X
the	B-X
proteolipid	B-X
protein	B-X
(	B-X
APL	B-X
)	B-X
and	B-X
its	B-X
chemically	B-X
deacylated	B-X
form	B-X
(	B-X
d-APL	B-X
)	B-X
.	B-X
Values	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
were	B-X
indistinguishable	B-X
from	B-X
those	B-X
of	B-X
the	B-X
acylated	B-X
protein	B-X
,	B-X
suggesting	B-X
that	B-X
fatty	B-X
acids	B-X
do	B-X
not	B-X
affect	B-X
protein	B-X
conformation	B-X
in	B-X
organic	B-X
solvents	B-X
.	B-X
However	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
the	B-X
two	B-X
forms	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
by	B-X
intrinsic	B-X
fluorescence	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
excited	B-X
at	B-X
295	B-X
nm	B-X
,	B-X
the	B-X
maximum	B-X
emission	B-X
wavelength	B-X
for	B-X
the	B-X
acylated	B-X
protein	B-X
was	B-X
330	B-X
nm	B-X
,	B-X
whereas	B-X
it	B-X
was	B-X
335	B-X
nm	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
.	B-X

The	O
effect	O
of	O
covalently	O
bound	O
fatty	O
acid	O
on	O
the	O
conformation	O
of	O
the	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
has	O
been	O
studied	O
by	O
ultraviolet	O
and	O
intrinsic	O
fluorescence	O
spectroscopy	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
covalently	B-X
bound	B-X
fatty	B-X
acid	B-X
on	B-X
the	B-X
conformation	B-X
of	B-X
the	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
ultraviolet	B-X
and	B-X
intrinsic	B-X
fluorescence	B-X
spectroscopy	B-X
.	B-X
With	B-X
dimethyl	B-X
sulfoxide	B-X
used	B-X
as	B-X
a	B-X
perturbant	B-X
,	B-X
the	B-X
exposure	B-X
of	B-X
Trp	B-X
and	B-X
Tyr	B-X
residues	B-X
in	B-X
various	B-X
mixtures	B-X
of	B-X
chloroform-methanol	B-X
was	B-X
evaluated	B-X
by	B-X
difference	B-X
spectroscopy	B-X
of	B-X
the	B-X
proteolipid	B-X
protein	B-X
(	B-X
APL	B-X
)	B-X
and	B-X
its	B-X
chemically	B-X
deacylated	B-X
form	B-X
(	B-X
d-APL	B-X
)	B-X
.	B-X
These	B-X
conformational	B-X
changes	B-X
correlate	B-X
well	B-X
with	B-X
changes	B-X
in	B-X
intrinsic	B-X
viscosity	B-X
.	B-X
Values	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
were	B-X
indistinguishable	B-X
from	B-X
those	B-X
of	B-X
the	B-X
acylated	B-X
protein	B-X
,	B-X
suggesting	B-X
that	B-X
fatty	B-X
acids	B-X
do	B-X
not	B-X
affect	B-X
protein	B-X
conformation	B-X
in	B-X
organic	B-X
solvents	B-X
.	B-X
In	B-X
water	B-X
,	B-X
UV	B-X
difference	B-X
spectroscopy	B-X
indicated	B-X
that	B-X
the	B-X
number	B-X
of	B-X
Tyr	B-X
and	B-X
Trp	B-X
groups	B-X
exposed	B-X
in	B-X
both	B-X
APL	B-X
and	B-X
d-APL	B-X
was	B-X
relatively	B-X
small	B-X
and	B-X
was	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
size	B-X
of	B-X
the	B-X
perturbant	B-X
.	B-X
However	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
the	B-X
two	B-X
forms	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
by	B-X
intrinsic	B-X
fluorescence	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
excited	B-X
at	B-X
295	B-X
nm	B-X
,	B-X
the	B-X
maximum	B-X
emission	B-X
wavelength	B-X
for	B-X
the	B-X
acylated	B-X
protein	B-X
was	B-X
330	B-X
nm	B-X
,	B-X
whereas	B-X
it	B-X
was	B-X
335	B-X
nm	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
.	B-X
Protein	B-X
aggregation	B-X
appears	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
fatty	B-X
acids	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
fluorescence	B-X
differences	B-X
between	B-X
APL	B-X
and	B-X
d-APL	B-X
are	B-X
related	B-X
to	B-X
factors	B-X
other	B-X
than	B-X
aggregation	B-X
.	B-X

With	O
dimethyl	O
sulfoxide	O
used	O
as	O
a	O
perturbant	O
,	O
the	O
exposure	O
of	O
Trp	O
and	O
Tyr	O
residues	O
in	O
various	O
mixtures	O
of	O
chloroform	O
-	O
methanol	O
was	O
evaluated	O
by	O
difference	O
spectroscopy	O
of	O
the	O
proteolipid	B-Protein
protein	I-Protein
(	O
APL	B-Protein
)	O
and	O
its	O
chemically	O
deacylated	O
form	O
(	O
d	O
-	O
APL	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
covalently	B-X
bound	B-X
fatty	B-X
acid	B-X
on	B-X
the	B-X
conformation	B-X
of	B-X
the	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
ultraviolet	B-X
and	B-X
intrinsic	B-X
fluorescence	B-X
spectroscopy	B-X
.	B-X
With	B-X
dimethyl	B-X
sulfoxide	B-X
used	B-X
as	B-X
a	B-X
perturbant	B-X
,	B-X
the	B-X
exposure	B-X
of	B-X
Trp	B-X
and	B-X
Tyr	B-X
residues	B-X
in	B-X
various	B-X
mixtures	B-X
of	B-X
chloroform-methanol	B-X
was	B-X
evaluated	B-X
by	B-X
difference	B-X
spectroscopy	B-X
of	B-X
the	B-X
proteolipid	B-X
protein	B-X
(	B-X
APL	B-X
)	B-X
and	B-X
its	B-X
chemically	B-X
deacylated	B-X
form	B-X
(	B-X
d-APL	B-X
)	B-X
.	B-X
The	B-X
fraction	B-X
of	B-X
chromophoric	B-X
groups	B-X
exposed	B-X
increased	B-X
with	B-X
the	B-X
proportion	B-X
of	B-X
chloroform	B-X
with	B-X
25	B-X
%	B-X
of	B-X
the	B-X
groups	B-X
exposed	B-X
in	B-X
1:2	B-X
chloroform-methanol	B-X
and	B-X
98	B-X
%	B-X
in	B-X
3:1	B-X
chloroform-methanol	B-X
.	B-X
These	B-X
conformational	B-X
changes	B-X
correlate	B-X
well	B-X
with	B-X
changes	B-X
in	B-X
intrinsic	B-X
viscosity	B-X
.	B-X
Values	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
were	B-X
indistinguishable	B-X
from	B-X
those	B-X
of	B-X
the	B-X
acylated	B-X
protein	B-X
,	B-X
suggesting	B-X
that	B-X
fatty	B-X
acids	B-X
do	B-X
not	B-X
affect	B-X
protein	B-X
conformation	B-X
in	B-X
organic	B-X
solvents	B-X
.	B-X
In	B-X
water	B-X
,	B-X
UV	B-X
difference	B-X
spectroscopy	B-X
indicated	B-X
that	B-X
the	B-X
number	B-X
of	B-X
Tyr	B-X
and	B-X
Trp	B-X
groups	B-X
exposed	B-X
in	B-X
both	B-X
APL	B-X
and	B-X
d-APL	B-X
was	B-X
relatively	B-X
small	B-X
and	B-X
was	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
size	B-X
of	B-X
the	B-X
perturbant	B-X
.	B-X
However	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
the	B-X
two	B-X
forms	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
by	B-X
intrinsic	B-X
fluorescence	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
excited	B-X
at	B-X
295	B-X
nm	B-X
,	B-X
the	B-X
maximum	B-X
emission	B-X
wavelength	B-X
for	B-X
the	B-X
acylated	B-X
protein	B-X
was	B-X
330	B-X
nm	B-X
,	B-X
whereas	B-X
it	B-X
was	B-X
335	B-X
nm	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
d-APL	B-X
were	B-X
more	B-X
easily	B-X
quenched	B-X
by	B-X
acrylamide	B-X
than	B-X
in	B-X
APL	B-X
,	B-X
indicating	B-X
that	B-X
they	B-X
were	B-X
more	B-X
exposed	B-X
,	B-X
or	B-X
in	B-X
a	B-X
more	B-X
hydrophilic	B-X
environment	B-X
,	B-X
following	B-X
deacylation	B-X
.	B-X
Protein	B-X
aggregation	B-X
appears	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
fatty	B-X
acids	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
fluorescence	B-X
differences	B-X
between	B-X
APL	B-X
and	B-X
d-APL	B-X
are	B-X
related	B-X
to	B-X
factors	B-X
other	B-X
than	B-X
aggregation	B-X
.	B-X

The	O
fraction	O
of	O
chromophoric	O
groups	O
exposed	O
increased	O
with	O
the	O
proportion	O
of	O
chloroform	O
with	O
25	O
%	O
of	O
the	O
groups	O
exposed	O
in	O
1	O
:	O
2	O
chloroform	O
-	O
methanol	O
and	O
98	O
%	O
in	O
3	O
:	O
1	O
chloroform	O
-	O
methanol	O
.	O
<EOS>	B-X
With	B-X
dimethyl	B-X
sulfoxide	B-X
used	B-X
as	B-X
a	B-X
perturbant	B-X
,	B-X
the	B-X
exposure	B-X
of	B-X
Trp	B-X
and	B-X
Tyr	B-X
residues	B-X
in	B-X
various	B-X
mixtures	B-X
of	B-X
chloroform-methanol	B-X
was	B-X
evaluated	B-X
by	B-X
difference	B-X
spectroscopy	B-X
of	B-X
the	B-X
proteolipid	B-X
protein	B-X
(	B-X
APL	B-X
)	B-X
and	B-X
its	B-X
chemically	B-X
deacylated	B-X
form	B-X
(	B-X
d-APL	B-X
)	B-X
.	B-X
The	B-X
fraction	B-X
of	B-X
chromophoric	B-X
groups	B-X
exposed	B-X
increased	B-X
with	B-X
the	B-X
proportion	B-X
of	B-X
chloroform	B-X
with	B-X
25	B-X
%	B-X
of	B-X
the	B-X
groups	B-X
exposed	B-X
in	B-X
1:2	B-X
chloroform-methanol	B-X
and	B-X
98	B-X
%	B-X
in	B-X
3:1	B-X
chloroform-methanol	B-X
.	B-X
In	B-X
water	B-X
,	B-X
UV	B-X
difference	B-X
spectroscopy	B-X
indicated	B-X
that	B-X
the	B-X
number	B-X
of	B-X
Tyr	B-X
and	B-X
Trp	B-X
groups	B-X
exposed	B-X
in	B-X
both	B-X
APL	B-X
and	B-X
d-APL	B-X
was	B-X
relatively	B-X
small	B-X
and	B-X
was	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
size	B-X
of	B-X
the	B-X
perturbant	B-X
.	B-X
However	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
the	B-X
two	B-X
forms	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
by	B-X
intrinsic	B-X
fluorescence	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
excited	B-X
at	B-X
295	B-X
nm	B-X
,	B-X
the	B-X
maximum	B-X
emission	B-X
wavelength	B-X
for	B-X
the	B-X
acylated	B-X
protein	B-X
was	B-X
330	B-X
nm	B-X
,	B-X
whereas	B-X
it	B-X
was	B-X
335	B-X
nm	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
d-APL	B-X
were	B-X
more	B-X
easily	B-X
quenched	B-X
by	B-X
acrylamide	B-X
than	B-X
in	B-X
APL	B-X
,	B-X
indicating	B-X
that	B-X
they	B-X
were	B-X
more	B-X
exposed	B-X
,	B-X
or	B-X
in	B-X
a	B-X
more	B-X
hydrophilic	B-X
environment	B-X
,	B-X
following	B-X
deacylation	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

These	O
conformational	O
changes	O
correlate	O
well	O
with	O
changes	O
in	O
intrinsic	O
viscosity	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
covalently	B-X
bound	B-X
fatty	B-X
acid	B-X
on	B-X
the	B-X
conformation	B-X
of	B-X
the	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
ultraviolet	B-X
and	B-X
intrinsic	B-X
fluorescence	B-X
spectroscopy	B-X
.	B-X
These	B-X
conformational	B-X
changes	B-X
correlate	B-X
well	B-X
with	B-X
changes	B-X
in	B-X
intrinsic	B-X
viscosity	B-X
.	B-X
However	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
the	B-X
two	B-X
forms	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
by	B-X
intrinsic	B-X
fluorescence	B-X
.	B-X
Even	B-X
while	B-X
the	B-X
chemical	B-X
shifts	B-X
fall	B-X
very	B-X
close	B-X
to	B-X
random	B-X
coil	B-X
values	B-X
,	B-X
as	B-X
expected	B-X
for	B-X
an	B-X
intrinsically	B-X
disordered	B-X
protein	B-X
,	B-X
substantial	B-X
deviations	B-X
in	B-X
the	B-X
pressure	B-X
dependence	B-X
of	B-X
the	B-X
chemical	B-X
shifts	B-X
are	B-X
seen	B-X
relative	B-X
to	B-X
those	B-X
in	B-X
short	B-X
model	B-X
peptides	B-X
.	B-X
The	B-X
linear	B-X
pressure	B-X
response	B-X
of	B-X
(	B-X
1	B-X
)	B-X
H	B-X
(	B-X
N	B-X
)	B-X
chemical	B-X
shift	B-X
,	B-X
commonly	B-X
linked	B-X
to	B-X
H-bond	B-X
length	B-X
change	B-X
,	B-X
correlates	B-X
well	B-X
with	B-X
those	B-X
in	B-X
short	B-X
model	B-X
peptides	B-X
,	B-X
and	B-X
is	B-X
found	B-X
to	B-X
be	B-X
anticorrelated	B-X
with	B-X
its	B-X
temperature	B-X
dependence	B-X
.	B-X
The	B-X
backbone	B-X
dynamics	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
not	B-X
visibly	B-X
affected	B-X
beyond	B-X
the	B-X
effect	B-X
of	B-X
slight	B-X
increase	B-X
in	B-X
water	B-X
viscosity	B-X
at	B-X
2500	B-X
bar	B-X
.	B-X

Values	O
for	O
the	O
deacylated	O
form	O
were	O
indistinguishable	O
from	O
those	O
of	O
the	O
acylated	O
protein	O
,	O
suggesting	O
that	O
fatty	O
acids	O
do	O
not	O
affect	O
protein	O
conformation	O
in	O
organic	O
solvents	O
.	O

In	O
water	O
,	O
UV	O
difference	O
spectroscopy	O
indicated	O
that	O
the	O
number	O
of	O
Tyr	O
and	O
Trp	O
groups	O
exposed	O
in	O
both	O
APL	B-Protein
and	O
d	O
-	O
APL	B-Protein
was	O
relatively	O
small	O
and	O
was	O
independent	O
of	O
the	O
molecular	O
size	O
of	O
the	O
perturbant	O
.	O

However	O
,	O
differences	O
in	O
the	O
environment	O
of	O
the	O
Trp	O
groups	O
in	O
the	O
two	O
forms	O
of	O
the	O
protein	O
could	O
be	O
demonstrated	O
by	O
intrinsic	O
fluorescence	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
covalently	B-X
bound	B-X
fatty	B-X
acid	B-X
on	B-X
the	B-X
conformation	B-X
of	B-X
the	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
ultraviolet	B-X
and	B-X
intrinsic	B-X
fluorescence	B-X
spectroscopy	B-X
.	B-X
With	B-X
dimethyl	B-X
sulfoxide	B-X
used	B-X
as	B-X
a	B-X
perturbant	B-X
,	B-X
the	B-X
exposure	B-X
of	B-X
Trp	B-X
and	B-X
Tyr	B-X
residues	B-X
in	B-X
various	B-X
mixtures	B-X
of	B-X
chloroform-methanol	B-X
was	B-X
evaluated	B-X
by	B-X
difference	B-X
spectroscopy	B-X
of	B-X
the	B-X
proteolipid	B-X
protein	B-X
(	B-X
APL	B-X
)	B-X
and	B-X
its	B-X
chemically	B-X
deacylated	B-X
form	B-X
(	B-X
d-APL	B-X
)	B-X
.	B-X
The	B-X
fraction	B-X
of	B-X
chromophoric	B-X
groups	B-X
exposed	B-X
increased	B-X
with	B-X
the	B-X
proportion	B-X
of	B-X
chloroform	B-X
with	B-X
25	B-X
%	B-X
of	B-X
the	B-X
groups	B-X
exposed	B-X
in	B-X
1:2	B-X
chloroform-methanol	B-X
and	B-X
98	B-X
%	B-X
in	B-X
3:1	B-X
chloroform-methanol	B-X
.	B-X
These	B-X
conformational	B-X
changes	B-X
correlate	B-X
well	B-X
with	B-X
changes	B-X
in	B-X
intrinsic	B-X
viscosity	B-X
.	B-X
Values	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
were	B-X
indistinguishable	B-X
from	B-X
those	B-X
of	B-X
the	B-X
acylated	B-X
protein	B-X
,	B-X
suggesting	B-X
that	B-X
fatty	B-X
acids	B-X
do	B-X
not	B-X
affect	B-X
protein	B-X
conformation	B-X
in	B-X
organic	B-X
solvents	B-X
.	B-X
In	B-X
water	B-X
,	B-X
UV	B-X
difference	B-X
spectroscopy	B-X
indicated	B-X
that	B-X
the	B-X
number	B-X
of	B-X
Tyr	B-X
and	B-X
Trp	B-X
groups	B-X
exposed	B-X
in	B-X
both	B-X
APL	B-X
and	B-X
d-APL	B-X
was	B-X
relatively	B-X
small	B-X
and	B-X
was	B-X
independent	B-X
of	B-X
the	B-X
molecular	B-X
size	B-X
of	B-X
the	B-X
perturbant	B-X
.	B-X
However	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
the	B-X
two	B-X
forms	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
by	B-X
intrinsic	B-X
fluorescence	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
excited	B-X
at	B-X
295	B-X
nm	B-X
,	B-X
the	B-X
maximum	B-X
emission	B-X
wavelength	B-X
for	B-X
the	B-X
acylated	B-X
protein	B-X
was	B-X
330	B-X
nm	B-X
,	B-X
whereas	B-X
it	B-X
was	B-X
335	B-X
nm	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
d-APL	B-X
were	B-X
more	B-X
easily	B-X
quenched	B-X
by	B-X
acrylamide	B-X
than	B-X
in	B-X
APL	B-X
,	B-X
indicating	B-X
that	B-X
they	B-X
were	B-X
more	B-X
exposed	B-X
,	B-X
or	B-X
in	B-X
a	B-X
more	B-X
hydrophilic	B-X
environment	B-X
,	B-X
following	B-X
deacylation	B-X
.	B-X
Protein	B-X
aggregation	B-X
appears	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
fatty	B-X
acids	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
fluorescence	B-X
differences	B-X
between	B-X
APL	B-X
and	B-X
d-APL	B-X
are	B-X
related	B-X
to	B-X
factors	B-X
other	B-X
than	B-X
aggregation	B-X
.	B-X

When	O
the	O
protein	O
was	O
excited	O
at	O
295	O
nm	O
,	O
the	O
maximum	O
emission	O
wavelength	O
for	O
the	O
acylated	O
protein	O
was	O
330	O
nm	O
,	O
whereas	O
it	O
was	O
335	O
nm	O
for	O
the	O
deacylated	O
form	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
covalently	B-X
bound	B-X
fatty	B-X
acid	B-X
on	B-X
the	B-X
conformation	B-X
of	B-X
the	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
ultraviolet	B-X
and	B-X
intrinsic	B-X
fluorescence	B-X
spectroscopy	B-X
.	B-X
With	B-X
dimethyl	B-X
sulfoxide	B-X
used	B-X
as	B-X
a	B-X
perturbant	B-X
,	B-X
the	B-X
exposure	B-X
of	B-X
Trp	B-X
and	B-X
Tyr	B-X
residues	B-X
in	B-X
various	B-X
mixtures	B-X
of	B-X
chloroform-methanol	B-X
was	B-X
evaluated	B-X
by	B-X
difference	B-X
spectroscopy	B-X
of	B-X
the	B-X
proteolipid	B-X
protein	B-X
(	B-X
APL	B-X
)	B-X
and	B-X
its	B-X
chemically	B-X
deacylated	B-X
form	B-X
(	B-X
d-APL	B-X
)	B-X
.	B-X
The	B-X
fraction	B-X
of	B-X
chromophoric	B-X
groups	B-X
exposed	B-X
increased	B-X
with	B-X
the	B-X
proportion	B-X
of	B-X
chloroform	B-X
with	B-X
25	B-X
%	B-X
of	B-X
the	B-X
groups	B-X
exposed	B-X
in	B-X
1:2	B-X
chloroform-methanol	B-X
and	B-X
98	B-X
%	B-X
in	B-X
3:1	B-X
chloroform-methanol	B-X
.	B-X
These	B-X
conformational	B-X
changes	B-X
correlate	B-X
well	B-X
with	B-X
changes	B-X
in	B-X
intrinsic	B-X
viscosity	B-X
.	B-X
Values	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
were	B-X
indistinguishable	B-X
from	B-X
those	B-X
of	B-X
the	B-X
acylated	B-X
protein	B-X
,	B-X
suggesting	B-X
that	B-X
fatty	B-X
acids	B-X
do	B-X
not	B-X
affect	B-X
protein	B-X
conformation	B-X
in	B-X
organic	B-X
solvents	B-X
.	B-X
However	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
environment	B-X
of	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
the	B-X
two	B-X
forms	B-X
of	B-X
the	B-X
protein	B-X
could	B-X
be	B-X
demonstrated	B-X
by	B-X
intrinsic	B-X
fluorescence	B-X
.	B-X
When	B-X
the	B-X
protein	B-X
was	B-X
excited	B-X
at	B-X
295	B-X
nm	B-X
,	B-X
the	B-X
maximum	B-X
emission	B-X
wavelength	B-X
for	B-X
the	B-X
acylated	B-X
protein	B-X
was	B-X
330	B-X
nm	B-X
,	B-X
whereas	B-X
it	B-X
was	B-X
335	B-X
nm	B-X
for	B-X
the	B-X
deacylated	B-X
form	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Trp	B-X
groups	B-X
in	B-X
d-APL	B-X
were	B-X
more	B-X
easily	B-X
quenched	B-X
by	B-X
acrylamide	B-X
than	B-X
in	B-X
APL	B-X
,	B-X
indicating	B-X
that	B-X
they	B-X
were	B-X
more	B-X
exposed	B-X
,	B-X
or	B-X
in	B-X
a	B-X
more	B-X
hydrophilic	B-X
environment	B-X
,	B-X
following	B-X
deacylation	B-X
.	B-X

Furthermore	O
,	O
the	O
Trp	O
groups	O
in	O
d	O
-	O
APL	B-Protein
were	O
more	O
easily	O
quenched	O
by	O
acrylamide	O
than	O
in	O
APL	B-Protein
,	O
indicating	O
that	O
they	O
were	O
more	O
exposed	O
,	O
or	O
in	O
a	O
more	O
hydrophilic	O
environment	O
,	O
following	O
deacylation	O
.	O

Protein	O
aggregation	O
appears	O
to	O
be	O
independent	O
of	O
the	O
presence	O
of	O
fatty	O
acids	O
,	O
suggesting	O
that	O
the	O
fluorescence	O
differences	O
between	O
APL	B-Protein
and	O
d	O
-	O
APL	B-Protein
are	O
related	O
to	O
factors	O
other	O
than	O
aggregation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cell	O
-	O
type	O
-	O
specific	O
and	O
site	O
-	O
specific	O
N	O
-	O
glycosylation	O
of	O
type	O
I	O
and	O
type	O
II	O
human	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
.	O
<EOS>	B-X
Tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
t-PA	B-X
)	B-X
is	B-X
an	B-X
important	B-X
initiator	B-X
of	B-X
fibrinolysis	B-X
.	B-X
The	B-X
t-PA	B-X
polypeptide	B-X
has	B-X
four	B-X
potential	B-X
N-glycosylation	B-X
sites	B-X
of	B-X
which	B-X
three	B-X
are	B-X
occupied	B-X
in	B-X
type	B-X
I	B-X
(	B-X
Asn-117	B-X
,	B-X
-184	B-X
,	B-X
and	B-X
-448	B-X
)	B-X
and	B-X
two	B-X
in	B-X
type	B-X
II	B-X
(	B-X
Asn-117	B-X
and	B-X
-448	B-X
)	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
elucidate	B-X
the	B-X
factors	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
on	B-X
this	B-X
polypeptide	B-X
,	B-X
we	B-X
have	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
sequential	B-X
exoglycosidase	B-X
digestion	B-X
,	B-X
methylation	B-X
analysis	B-X
,	B-X
and	B-X
controlled	B-X
acetolysis	B-X
to	B-X
determine	B-X
the	B-X
oligosaccharide	B-X
structures	B-X
at	B-X
each	B-X
of	B-X
the	B-X
N-glycosylation	B-X
sites	B-X
of	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
t-PA	B-X
when	B-X
isolated	B-X
from	B-X
a	B-X
human	B-X
colon	B-X
fibroblast	B-X
cell	B-X
strain	B-X
and	B-X
from	B-X
a	B-X
Bowes	B-X
melanoma	B-X
cell	B-X
line	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
the	B-X
following	B-X
:	B-X
(	B-X
i	B-X
)	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
t-PA	B-X
are	B-X
N-glycosylated	B-X
in	B-X
an	B-X
identical	B-X
way	B-X
at	B-X
Asn-117	B-X
and	B-X
Asn-448	B-X
,	B-X
when	B-X
isolated	B-X
from	B-X
the	B-X
same	B-X
cell	B-X
line	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
Asn-117	B-X
is	B-X
predominantly	B-X
associated	B-X
with	B-X
oligomannose-type	B-X
structures	B-X
in	B-X
all	B-X
cases	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
Asn-184	B-X
and	B-X
Asn-448	B-X
are	B-X
predominantly	B-X
associated	B-X
with	B-X
complex-type	B-X
structures	B-X
when	B-X
t-PA	B-X
is	B-X
isolated	B-X
from	B-X
fibroblast	B-X
cells	B-X
,	B-X
but	B-X
with	B-X
both	B-X
complex-	B-X
and	B-X
oligomannose-type	B-X
structures	B-X
when	B-X
isolated	B-X
from	B-X
melanoma	B-X
cells	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
fibroblast	B-X
cell	B-X
derived	B-X
t-PA	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
neutral	B-X
and	B-X
sialylated	B-X
oligosaccharides	B-X
,	B-X
while	B-X
melanoma	B-X
cell	B-X
derived	B-X
t-PA	B-X
is	B-X
also	B-X
associated	B-X
with	B-X
sulfated	B-X
oligosaccharides	B-X
,	B-X
which	B-X
are	B-X
located	B-X
exclusively	B-X
at	B-X
Asn-448	B-X
of	B-X
type	B-X
II	B-X
t-PA	B-X
;	B-X
(	B-X
v	B-X
)	B-X
no	B-X
complex-type	B-X
structures	B-X
occur	B-X
in	B-X
common	B-X
between	B-X
t-PA	B-X
from	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
.	B-X

Tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
t	B-Protein
-	I-Protein
PA	I-Protein
)	O
is	O
an	O
important	O
initiator	O
of	O
fibrinolysis	O
.	O
<EOS>	B-X
This	B-X
is	B-X
achieved	B-X
by	B-X
the	B-X
fibrinolytic	B-X
system	B-X
,	B-X
an	B-X
enzymatic	B-X
process	B-X
that	B-X
regulates	B-X
the	B-X
activation	B-X
of	B-X
plasminogen	B-X
into	B-X
its	B-X
proteolytic	B-X
form	B-X
,	B-X
plasmin	B-X
.	B-X
This	B-X
is	B-X
a	B-X
self-regulated	B-X
event	B-X
as	B-X
the	B-X
very	B-X
presence	B-X
of	B-X
fibrin	B-X
initiates	B-X
plasminogen	B-X
activation	B-X
on	B-X
the	B-X
fibrin	B-X
surface	B-X
due	B-X
to	B-X
the	B-X
presentation	B-X
of	B-X
exposed	B-X
C-terminal	B-X
lysine	B-X
residues	B-X
in	B-X
fibrin	B-X
that	B-X
allow	B-X
plasminogen	B-X
to	B-X
position	B-X
itself	B-X
via	B-X
its	B-X
lysine	B-X
binding	B-X
sites	B-X
and	B-X
to	B-X
be	B-X
more	B-X
efficiently	B-X
cleaved	B-X
by	B-X
tissue-type	B-X
plasminogen	B-X
activator	B-X
(	B-X
t-PA	B-X
)	B-X
.	B-X
Hence	B-X
fibrin	B-X
,	B-X
the	B-X
ultimate	B-X
substrate	B-X
of	B-X
plasmin	B-X
during	B-X
fibrinolysis	B-X
,	B-X
is	B-X
indeed	B-X
an	B-X
essential	B-X
cofactor	B-X
in	B-X
the	B-X
cascade	B-X
.	B-X
So	B-X
what	B-X
drives	B-X
t-PA-mediated	B-X
plasminogen	B-X
activation	B-X
when	B-X
fibrin	B-X
is	B-X
not	B-X
available	B-X
?	B-X
This	B-X
review	B-X
will	B-X
describe	B-X
the	B-X
broadening	B-X
role	B-X
of	B-X
the	B-X
fibrinolytic	B-X
system	B-X
highlighting	B-X
the	B-X
importance	B-X
of	B-X
fibrin	B-X
and	B-X
other	B-X
key	B-X
proteins	B-X
as	B-X
facilitators	B-X
during	B-X
t-PA-mediated	B-X
plasminogen	B-X
activation	B-X
.	B-X

The	O
t	B-Protein
-	I-Protein
PA	I-Protein
polypeptide	O
has	O
four	O
potential	O
N	O
-	O
glycosylation	O
sites	O
of	O
which	O
three	O
are	O
occupied	O
in	O
type	O
I	O
(	O
Asn	O
-	O
117	O
,	O
-	O
184	O
,	O
and	O
-	O
448	O
)	O
and	O
two	O
in	O
type	O
II	O
(	O
Asn	O
-	O
117	O
and	O
-	O
448	O
)	O
.	O

In	O
an	O
effort	O
to	O
elucidate	O
the	O
factors	O
controlling	O
the	O
expression	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
on	O
this	O
polypeptide	O
,	O
we	O
have	O
used	O
a	O
combination	O
of	O
sequential	O
exoglycosidase	O
digestion	O
,	O
methylation	O
analysis	O
,	O
and	O
controlled	O
acetolysis	O
to	O
determine	O
the	O
oligosaccharide	O
structures	O
at	O
each	O
of	O
the	O
N	O
-	O
glycosylation	O
sites	O
of	O
type	O
I	O
and	O
type	O
II	O
t	B-Protein
-	I-Protein
PA	I-Protein
when	O
isolated	O
from	O
a	O
human	O
colon	O
fibroblast	O
cell	O
strain	O
and	O
from	O
a	O
Bowes	O
melanoma	O
cell	O
line	O
.	O

Our	O
results	O
suggest	O
the	O
following	O
:	O
(	O
i	O
)	O
type	O
I	O
and	O
type	O
II	O
t	B-Protein
-	I-Protein
PA	I-Protein
are	O
N	O
-	O
glycosylated	O
in	O
an	O
identical	O
way	O
at	O
Asn	O
-	O
117	O
and	O
Asn	O
-	O
448	O
,	O
when	O
isolated	O
from	O
the	O
same	O
cell	O
line	O
;	O
(	O
ii	O
)	O
Asn	O
-	O
117	O
is	O
predominantly	O
associated	O
with	O
oligomannose	O
-	O
type	O
structures	O
in	O
all	O
cases	O
;	O
(	O
iii	O
)	O
Asn	O
-	O
184	O
and	O
Asn	O
-	O
448	O
are	O
predominantly	O
associated	O
with	O
complex	O
-	O
type	O
structures	O
when	O
t	B-Protein
-	I-Protein
PA	I-Protein
is	O
isolated	O
from	O
fibroblast	O
cells	O
,	O
but	O
with	O
both	O
complex	O
-	O
and	O
oligomannose	O
-	O
type	O
structures	O
when	O
isolated	O
from	O
melanoma	O
cells	O
;	O
(	O
iv	O
)	O
fibroblast	O
cell	O
derived	O
t	B-Protein
-	I-Protein
PA	I-Protein
is	O
associated	O
with	O
both	O
neutral	O
and	O
sialylated	O
oligosaccharides	O
,	O
while	O
melanoma	O
cell	O
derived	O
t	B-Protein
-	I-Protein
PA	I-Protein
is	O
also	O
associated	O
with	O
sulfated	O
oligosaccharides	O
,	O
which	O
are	O
located	O
exclusively	O
at	O
Asn	O
-	O
448	O
of	O
type	O
II	O
t	B-Protein
-	I-Protein
PA	I-Protein
;	O
(	O
v	O
)	O
no	O
complex	O
-	O
type	O
structures	O
occur	O
in	O
common	O
between	O
t	B-Protein
-	I-Protein
PA	I-Protein
from	O
the	O
two	O
cell	O
lines	O
.	O

These	O
results	O
indicate	O
that	O
the	O
t	B-Protein
-	I-Protein
PA	I-Protein
glycoprotein	O
is	O
secreted	O
by	O
each	O
cell	O
line	O
as	O
a	O
set	O
of	O
glycoforms	O
,	O
each	O
glycoform	O
being	O
unique	O
with	O
respect	O
to	O
the	O
nature	O
and	O
disposition	O
of	O
oligosaccharides	O
on	O
a	O
common	O
polypeptide	O
.	O

Further	O
,	O
the	O
two	O
cell	O
lines	O
express	O
no	O
glycoform	O
in	O
common	O
,	O
despite	O
expressing	O
the	O
same	O
t	B-Protein
-	I-Protein
PA	I-Protein
polypeptide	O
.	O
<EOS>	B-X
Tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
t-PA	B-X
)	B-X
is	B-X
an	B-X
important	B-X
initiator	B-X
of	B-X
fibrinolysis	B-X
.	B-X
The	B-X
t-PA	B-X
polypeptide	B-X
has	B-X
four	B-X
potential	B-X
N-glycosylation	B-X
sites	B-X
of	B-X
which	B-X
three	B-X
are	B-X
occupied	B-X
in	B-X
type	B-X
I	B-X
(	B-X
Asn-117	B-X
,	B-X
-184	B-X
,	B-X
and	B-X
-448	B-X
)	B-X
and	B-X
two	B-X
in	B-X
type	B-X
II	B-X
(	B-X
Asn-117	B-X
and	B-X
-448	B-X
)	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
elucidate	B-X
the	B-X
factors	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
on	B-X
this	B-X
polypeptide	B-X
,	B-X
we	B-X
have	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
sequential	B-X
exoglycosidase	B-X
digestion	B-X
,	B-X
methylation	B-X
analysis	B-X
,	B-X
and	B-X
controlled	B-X
acetolysis	B-X
to	B-X
determine	B-X
the	B-X
oligosaccharide	B-X
structures	B-X
at	B-X
each	B-X
of	B-X
the	B-X
N-glycosylation	B-X
sites	B-X
of	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
t-PA	B-X
when	B-X
isolated	B-X
from	B-X
a	B-X
human	B-X
colon	B-X
fibroblast	B-X
cell	B-X
strain	B-X
and	B-X
from	B-X
a	B-X
Bowes	B-X
melanoma	B-X
cell	B-X
line	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
the	B-X
following	B-X
:	B-X
(	B-X
i	B-X
)	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
t-PA	B-X
are	B-X
N-glycosylated	B-X
in	B-X
an	B-X
identical	B-X
way	B-X
at	B-X
Asn-117	B-X
and	B-X
Asn-448	B-X
,	B-X
when	B-X
isolated	B-X
from	B-X
the	B-X
same	B-X
cell	B-X
line	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
Asn-117	B-X
is	B-X
predominantly	B-X
associated	B-X
with	B-X
oligomannose-type	B-X
structures	B-X
in	B-X
all	B-X
cases	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
Asn-184	B-X
and	B-X
Asn-448	B-X
are	B-X
predominantly	B-X
associated	B-X
with	B-X
complex-type	B-X
structures	B-X
when	B-X
t-PA	B-X
is	B-X
isolated	B-X
from	B-X
fibroblast	B-X
cells	B-X
,	B-X
but	B-X
with	B-X
both	B-X
complex-	B-X
and	B-X
oligomannose-type	B-X
structures	B-X
when	B-X
isolated	B-X
from	B-X
melanoma	B-X
cells	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
fibroblast	B-X
cell	B-X
derived	B-X
t-PA	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
neutral	B-X
and	B-X
sialylated	B-X
oligosaccharides	B-X
,	B-X
while	B-X
melanoma	B-X
cell	B-X
derived	B-X
t-PA	B-X
is	B-X
also	B-X
associated	B-X
with	B-X
sulfated	B-X
oligosaccharides	B-X
,	B-X
which	B-X
are	B-X
located	B-X
exclusively	B-X
at	B-X
Asn-448	B-X
of	B-X
type	B-X
II	B-X
t-PA	B-X
;	B-X
(	B-X
v	B-X
)	B-X
no	B-X
complex-type	B-X
structures	B-X
occur	B-X
in	B-X
common	B-X
between	B-X
t-PA	B-X
from	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
t-PA	B-X
glycoprotein	B-X
is	B-X
secreted	B-X
by	B-X
each	B-X
cell	B-X
line	B-X
as	B-X
a	B-X
set	B-X
of	B-X
glycoforms	B-X
,	B-X
each	B-X
glycoform	B-X
being	B-X
unique	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
nature	B-X
and	B-X
disposition	B-X
of	B-X
oligosaccharides	B-X
on	B-X
a	B-X
common	B-X
polypeptide	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
express	B-X
no	B-X
glycoform	B-X
in	B-X
common	B-X
,	B-X
despite	B-X
expressing	B-X
the	B-X
same	B-X
t-PA	B-X
polypeptide	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
these	B-X
results	B-X
for	B-X
both	B-X
the	B-X
control	B-X
of	B-X
oligosaccharide	B-X
processing	B-X
in	B-X
different	B-X
cell	B-X
lines	B-X
and	B-X
the	B-X
genetic	B-X
engineering	B-X
of	B-X
mammalian	B-X
glycoproteins	B-X
are	B-X
discussed	B-X
.	B-X

The	O
implications	O
of	O
these	O
results	O
for	O
both	O
the	O
control	O
of	O
oligosaccharide	O
processing	O
in	O
different	O
cell	O
lines	O
and	O
the	O
genetic	O
engineering	O
of	O
mammalian	O
glycoproteins	O
are	O
discussed	O
.	O
<EOS>	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
elucidate	B-X
the	B-X
factors	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
N-linked	B-X
oligosaccharides	B-X
on	B-X
this	B-X
polypeptide	B-X
,	B-X
we	B-X
have	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
sequential	B-X
exoglycosidase	B-X
digestion	B-X
,	B-X
methylation	B-X
analysis	B-X
,	B-X
and	B-X
controlled	B-X
acetolysis	B-X
to	B-X
determine	B-X
the	B-X
oligosaccharide	B-X
structures	B-X
at	B-X
each	B-X
of	B-X
the	B-X
N-glycosylation	B-X
sites	B-X
of	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
t-PA	B-X
when	B-X
isolated	B-X
from	B-X
a	B-X
human	B-X
colon	B-X
fibroblast	B-X
cell	B-X
strain	B-X
and	B-X
from	B-X
a	B-X
Bowes	B-X
melanoma	B-X
cell	B-X
line	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
the	B-X
following	B-X
:	B-X
(	B-X
i	B-X
)	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
t-PA	B-X
are	B-X
N-glycosylated	B-X
in	B-X
an	B-X
identical	B-X
way	B-X
at	B-X
Asn-117	B-X
and	B-X
Asn-448	B-X
,	B-X
when	B-X
isolated	B-X
from	B-X
the	B-X
same	B-X
cell	B-X
line	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
Asn-117	B-X
is	B-X
predominantly	B-X
associated	B-X
with	B-X
oligomannose-type	B-X
structures	B-X
in	B-X
all	B-X
cases	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
Asn-184	B-X
and	B-X
Asn-448	B-X
are	B-X
predominantly	B-X
associated	B-X
with	B-X
complex-type	B-X
structures	B-X
when	B-X
t-PA	B-X
is	B-X
isolated	B-X
from	B-X
fibroblast	B-X
cells	B-X
,	B-X
but	B-X
with	B-X
both	B-X
complex-	B-X
and	B-X
oligomannose-type	B-X
structures	B-X
when	B-X
isolated	B-X
from	B-X
melanoma	B-X
cells	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
fibroblast	B-X
cell	B-X
derived	B-X
t-PA	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
neutral	B-X
and	B-X
sialylated	B-X
oligosaccharides	B-X
,	B-X
while	B-X
melanoma	B-X
cell	B-X
derived	B-X
t-PA	B-X
is	B-X
also	B-X
associated	B-X
with	B-X
sulfated	B-X
oligosaccharides	B-X
,	B-X
which	B-X
are	B-X
located	B-X
exclusively	B-X
at	B-X
Asn-448	B-X
of	B-X
type	B-X
II	B-X
t-PA	B-X
;	B-X
(	B-X
v	B-X
)	B-X
no	B-X
complex-type	B-X
structures	B-X
occur	B-X
in	B-X
common	B-X
between	B-X
t-PA	B-X
from	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
t-PA	B-X
glycoprotein	B-X
is	B-X
secreted	B-X
by	B-X
each	B-X
cell	B-X
line	B-X
as	B-X
a	B-X
set	B-X
of	B-X
glycoforms	B-X
,	B-X
each	B-X
glycoform	B-X
being	B-X
unique	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
nature	B-X
and	B-X
disposition	B-X
of	B-X
oligosaccharides	B-X
on	B-X
a	B-X
common	B-X
polypeptide	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
express	B-X
no	B-X
glycoform	B-X
in	B-X
common	B-X
,	B-X
despite	B-X
expressing	B-X
the	B-X
same	B-X
t-PA	B-X
polypeptide	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
these	B-X
results	B-X
for	B-X
both	B-X
the	B-X
control	B-X
of	B-X
oligosaccharide	B-X
processing	B-X
in	B-X
different	B-X
cell	B-X
lines	B-X
and	B-X
the	B-X
genetic	B-X
engineering	B-X
of	B-X
mammalian	B-X
glycoproteins	B-X
are	B-X
discussed	B-X
.	B-X

Role	O
of	O
variant	O
prealbumin	B-Protein
in	O
the	O
pathogenesis	O
of	O
familial	O
amyloidotic	O
polyneuropathy	O
:	O
fate	O
of	O
normal	O
and	O
variant	O
prealbumin	B-Protein
in	O
the	O
circulation	O
.	O
<EOS>	B-X
Role	B-X
of	B-X
variant	B-X
prealbumin	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
familial	B-X
amyloidotic	B-X
polyneuropathy	B-X
:	B-X
fate	B-X
of	B-X
normal	B-X
and	B-X
variant	B-X
prealbumin	B-X
in	B-X
the	B-X
circulation	B-X
of	B-X
rats	B-X
.	B-X
According	B-X
to	B-X
recent	B-X
studies	B-X
on	B-X
protein	B-X
chemistry	B-X
and	B-X
genetic	B-X
engineering	B-X
,	B-X
replacement	B-X
of	B-X
the	B-X
Val30	B-X
residue	B-X
of	B-X
prealbumin	B-X
by	B-X
methionine	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
amyloid	B-X
deposit	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
familial	B-X
amyloidotic	B-X
polyneuropathy	B-X
(	B-X
FAP	B-X
)	B-X
.	B-X
However	B-X
,	B-X
only	B-X
limited	B-X
information	B-X
is	B-X
available	B-X
concerning	B-X
the	B-X
behavior	B-X
of	B-X
prealbumin	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
To	B-X
obtain	B-X
the	B-X
molecular	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
amyloid	B-X
deposition	B-X
,	B-X
it	B-X
is	B-X
indispensable	B-X
to	B-X
know	B-X
the	B-X
fates	B-X
of	B-X
normal	B-X
and	B-X
variant	B-X
prealbumin	B-X
in	B-X
vivo	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
fates	B-X
of	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
were	B-X
studied	B-X
in	B-X
normal	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
animals	B-X
that	B-X
were	B-X
challenged	B-X
with	B-X
acute	B-X
inflammation	B-X
induced	B-X
by	B-X
turpentine	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
in	B-X
vitro	B-X
photooxidation	B-X
of	B-X
prealbumin	B-X
samples	B-X
on	B-X
their	B-X
behavior	B-X
was	B-X
also	B-X
examined	B-X
in	B-X
vivo	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
no	B-X
appreciable	B-X
difference	B-X
between	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
factors	B-X
other	B-X
than	B-X
the	B-X
rate	B-X
of	B-X
transfer	B-X
of	B-X
the	B-X
variant	B-X
form	B-X
prealbumin	B-X
from	B-X
plasma	B-X
to	B-X
an	B-X
extravascular	B-X
compartment	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
amyloid	B-X
deposition	B-X
in	B-X
FAP	B-X
patients	B-X
.	B-X

According	O
to	O
recent	O
studies	O
on	O
protein	O
chemistry	O
and	O
genetic	O
engineering	O
,	O
replacement	O
of	O
the	O
Val30	O
residue	O
of	O
prealbumin	B-Protein
by	O
methionine	O
is	O
believed	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
formation	O
of	O
amyloid	B-Protein
deposit	O
and	O
the	O
pathogenesis	O
of	O
familial	O
amyloidotic	O
polyneuropathy	O
(	O
FAP	O
)	O
.	O
<EOS>	B-X
According	B-X
to	B-X
recent	B-X
studies	B-X
on	B-X
protein	B-X
chemistry	B-X
and	B-X
genetic	B-X
engineering	B-X
,	B-X
replacement	B-X
of	B-X
the	B-X
Val30	B-X
residue	B-X
of	B-X
prealbumin	B-X
by	B-X
methionine	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
amyloid	B-X
deposit	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
familial	B-X
amyloidotic	B-X
polyneuropathy	B-X
(	B-X
FAP	B-X
)	B-X
.	B-X
However	B-X
,	B-X
only	B-X
limited	B-X
information	B-X
is	B-X
available	B-X
concerning	B-X
the	B-X
behavior	B-X
of	B-X
prealbumin	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
To	B-X
obtain	B-X
the	B-X
molecular	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
amyloid	B-X
deposition	B-X
,	B-X
it	B-X
is	B-X
indispensable	B-X
to	B-X
know	B-X
the	B-X
fates	B-X
of	B-X
normal	B-X
and	B-X
variant	B-X
prealbumin	B-X
in	B-X
vivo	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
fates	B-X
of	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
were	B-X
studied	B-X
in	B-X
normal	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
animals	B-X
that	B-X
were	B-X
challenged	B-X
with	B-X
acute	B-X
inflammation	B-X
induced	B-X
by	B-X
turpentine	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
in	B-X
vitro	B-X
photooxidation	B-X
of	B-X
prealbumin	B-X
samples	B-X
on	B-X
their	B-X
behavior	B-X
was	B-X
also	B-X
examined	B-X
in	B-X
vivo	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
no	B-X
appreciable	B-X
difference	B-X
between	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
factors	B-X
other	B-X
than	B-X
the	B-X
rate	B-X
of	B-X
transfer	B-X
of	B-X
the	B-X
variant	B-X
form	B-X
prealbumin	B-X
from	B-X
plasma	B-X
to	B-X
an	B-X
extravascular	B-X
compartment	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
amyloid	B-X
deposition	B-X
in	B-X
FAP	B-X
patients	B-X
.	B-X

However	O
,	O
only	O
limited	O
information	O
is	O
available	O
concerning	O
the	O
behavior	O
of	O
prealbumin	B-Protein
in	O
the	O
circulation	O
.	O
<EOS>	B-X
According	B-X
to	B-X
recent	B-X
studies	B-X
on	B-X
protein	B-X
chemistry	B-X
and	B-X
genetic	B-X
engineering	B-X
,	B-X
replacement	B-X
of	B-X
the	B-X
Val30	B-X
residue	B-X
of	B-X
prealbumin	B-X
by	B-X
methionine	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
amyloid	B-X
deposit	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
familial	B-X
amyloidotic	B-X
polyneuropathy	B-X
(	B-X
FAP	B-X
)	B-X
.	B-X
However	B-X
,	B-X
only	B-X
limited	B-X
information	B-X
is	B-X
available	B-X
concerning	B-X
the	B-X
behavior	B-X
of	B-X
prealbumin	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
To	B-X
obtain	B-X
the	B-X
molecular	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
amyloid	B-X
deposition	B-X
,	B-X
it	B-X
is	B-X
indispensable	B-X
to	B-X
know	B-X
the	B-X
fates	B-X
of	B-X
normal	B-X
and	B-X
variant	B-X
prealbumin	B-X
in	B-X
vivo	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
fates	B-X
of	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
were	B-X
studied	B-X
in	B-X
normal	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
animals	B-X
that	B-X
were	B-X
challenged	B-X
with	B-X
acute	B-X
inflammation	B-X
induced	B-X
by	B-X
turpentine	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
in	B-X
vitro	B-X
photooxidation	B-X
of	B-X
prealbumin	B-X
samples	B-X
on	B-X
their	B-X
behavior	B-X
was	B-X
also	B-X
examined	B-X
in	B-X
vivo	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
no	B-X
appreciable	B-X
difference	B-X
between	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
factors	B-X
other	B-X
than	B-X
the	B-X
rate	B-X
of	B-X
transfer	B-X
of	B-X
the	B-X
variant	B-X
form	B-X
prealbumin	B-X
from	B-X
plasma	B-X
to	B-X
an	B-X
extravascular	B-X
compartment	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
amyloid	B-X
deposition	B-X
in	B-X
FAP	B-X
patients	B-X
.	B-X

To	O
obtain	O
the	O
molecular	O
insight	O
into	O
the	O
mechanism	O
of	O
amyloid	B-Protein
deposition	O
,	O
it	O
is	O
indispensable	O
to	O
know	O
the	O
fates	O
of	O
normal	O
and	O
variant	O
prealbumin	B-Protein
in	O
vivo	O
.	O
<EOS>	B-X
According	B-X
to	B-X
recent	B-X
studies	B-X
on	B-X
protein	B-X
chemistry	B-X
and	B-X
genetic	B-X
engineering	B-X
,	B-X
replacement	B-X
of	B-X
the	B-X
Val30	B-X
residue	B-X
of	B-X
prealbumin	B-X
by	B-X
methionine	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
amyloid	B-X
deposit	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
familial	B-X
amyloidotic	B-X
polyneuropathy	B-X
(	B-X
FAP	B-X
)	B-X
.	B-X
However	B-X
,	B-X
only	B-X
limited	B-X
information	B-X
is	B-X
available	B-X
concerning	B-X
the	B-X
behavior	B-X
of	B-X
prealbumin	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
To	B-X
obtain	B-X
the	B-X
molecular	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
amyloid	B-X
deposition	B-X
,	B-X
it	B-X
is	B-X
indispensable	B-X
to	B-X
know	B-X
the	B-X
fates	B-X
of	B-X
normal	B-X
and	B-X
variant	B-X
prealbumin	B-X
in	B-X
vivo	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
fates	B-X
of	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
were	B-X
studied	B-X
in	B-X
normal	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
animals	B-X
that	B-X
were	B-X
challenged	B-X
with	B-X
acute	B-X
inflammation	B-X
induced	B-X
by	B-X
turpentine	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
in	B-X
vitro	B-X
photooxidation	B-X
of	B-X
prealbumin	B-X
samples	B-X
on	B-X
their	B-X
behavior	B-X
was	B-X
also	B-X
examined	B-X
in	B-X
vivo	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
no	B-X
appreciable	B-X
difference	B-X
between	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
factors	B-X
other	B-X
than	B-X
the	B-X
rate	B-X
of	B-X
transfer	B-X
of	B-X
the	B-X
variant	B-X
form	B-X
prealbumin	B-X
from	B-X
plasma	B-X
to	B-X
an	B-X
extravascular	B-X
compartment	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
amyloid	B-X
deposition	B-X
in	B-X
FAP	B-X
patients	B-X
.	B-X

Thus	O
,	O
the	O
fates	O
of	O
prealbumin	B-Protein
samples	O
from	O
normal	O
and	O
FAP	O
patients	O
were	O
studied	O
in	O
normal	O
rats	O
as	O
well	O
as	O
in	O
animals	O
that	O
were	O
challenged	O
with	O
acute	O
inflammation	O
induced	O
by	O
turpentine	O
.	O
<EOS>	B-X
According	B-X
to	B-X
recent	B-X
studies	B-X
on	B-X
protein	B-X
chemistry	B-X
and	B-X
genetic	B-X
engineering	B-X
,	B-X
replacement	B-X
of	B-X
the	B-X
Val30	B-X
residue	B-X
of	B-X
prealbumin	B-X
by	B-X
methionine	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
amyloid	B-X
deposit	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
familial	B-X
amyloidotic	B-X
polyneuropathy	B-X
(	B-X
FAP	B-X
)	B-X
.	B-X
However	B-X
,	B-X
only	B-X
limited	B-X
information	B-X
is	B-X
available	B-X
concerning	B-X
the	B-X
behavior	B-X
of	B-X
prealbumin	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
To	B-X
obtain	B-X
the	B-X
molecular	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
amyloid	B-X
deposition	B-X
,	B-X
it	B-X
is	B-X
indispensable	B-X
to	B-X
know	B-X
the	B-X
fates	B-X
of	B-X
normal	B-X
and	B-X
variant	B-X
prealbumin	B-X
in	B-X
vivo	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
fates	B-X
of	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
were	B-X
studied	B-X
in	B-X
normal	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
animals	B-X
that	B-X
were	B-X
challenged	B-X
with	B-X
acute	B-X
inflammation	B-X
induced	B-X
by	B-X
turpentine	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
in	B-X
vitro	B-X
photooxidation	B-X
of	B-X
prealbumin	B-X
samples	B-X
on	B-X
their	B-X
behavior	B-X
was	B-X
also	B-X
examined	B-X
in	B-X
vivo	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
no	B-X
appreciable	B-X
difference	B-X
between	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
factors	B-X
other	B-X
than	B-X
the	B-X
rate	B-X
of	B-X
transfer	B-X
of	B-X
the	B-X
variant	B-X
form	B-X
prealbumin	B-X
from	B-X
plasma	B-X
to	B-X
an	B-X
extravascular	B-X
compartment	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
amyloid	B-X
deposition	B-X
in	B-X
FAP	B-X
patients	B-X
.	B-X

The	O
effect	O
of	O
in	O
vitro	O
photooxidation	O
of	O
prealbumin	B-Protein
samples	O
on	O
their	O
behavior	O
was	O
also	O
examined	O
in	O
vivo	O
.	O
<EOS>	B-X
According	B-X
to	B-X
recent	B-X
studies	B-X
on	B-X
protein	B-X
chemistry	B-X
and	B-X
genetic	B-X
engineering	B-X
,	B-X
replacement	B-X
of	B-X
the	B-X
Val30	B-X
residue	B-X
of	B-X
prealbumin	B-X
by	B-X
methionine	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
amyloid	B-X
deposit	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
familial	B-X
amyloidotic	B-X
polyneuropathy	B-X
(	B-X
FAP	B-X
)	B-X
.	B-X
However	B-X
,	B-X
only	B-X
limited	B-X
information	B-X
is	B-X
available	B-X
concerning	B-X
the	B-X
behavior	B-X
of	B-X
prealbumin	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
To	B-X
obtain	B-X
the	B-X
molecular	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
amyloid	B-X
deposition	B-X
,	B-X
it	B-X
is	B-X
indispensable	B-X
to	B-X
know	B-X
the	B-X
fates	B-X
of	B-X
normal	B-X
and	B-X
variant	B-X
prealbumin	B-X
in	B-X
vivo	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
fates	B-X
of	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
were	B-X
studied	B-X
in	B-X
normal	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
animals	B-X
that	B-X
were	B-X
challenged	B-X
with	B-X
acute	B-X
inflammation	B-X
induced	B-X
by	B-X
turpentine	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
in	B-X
vitro	B-X
photooxidation	B-X
of	B-X
prealbumin	B-X
samples	B-X
on	B-X
their	B-X
behavior	B-X
was	B-X
also	B-X
examined	B-X
in	B-X
vivo	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
no	B-X
appreciable	B-X
difference	B-X
between	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
factors	B-X
other	B-X
than	B-X
the	B-X
rate	B-X
of	B-X
transfer	B-X
of	B-X
the	B-X
variant	B-X
form	B-X
prealbumin	B-X
from	B-X
plasma	B-X
to	B-X
an	B-X
extravascular	B-X
compartment	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
amyloid	B-X
deposition	B-X
in	B-X
FAP	B-X
patients	B-X
.	B-X

Kinetic	O
analysis	O
revealed	O
no	O
appreciable	O
difference	O
between	O
prealbumin	B-Protein
samples	O
from	O
normal	O
and	O
FAP	O
patients	O
.	O
<EOS>	B-X
According	B-X
to	B-X
recent	B-X
studies	B-X
on	B-X
protein	B-X
chemistry	B-X
and	B-X
genetic	B-X
engineering	B-X
,	B-X
replacement	B-X
of	B-X
the	B-X
Val30	B-X
residue	B-X
of	B-X
prealbumin	B-X
by	B-X
methionine	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
amyloid	B-X
deposit	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
familial	B-X
amyloidotic	B-X
polyneuropathy	B-X
(	B-X
FAP	B-X
)	B-X
.	B-X
However	B-X
,	B-X
only	B-X
limited	B-X
information	B-X
is	B-X
available	B-X
concerning	B-X
the	B-X
behavior	B-X
of	B-X
prealbumin	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
To	B-X
obtain	B-X
the	B-X
molecular	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
amyloid	B-X
deposition	B-X
,	B-X
it	B-X
is	B-X
indispensable	B-X
to	B-X
know	B-X
the	B-X
fates	B-X
of	B-X
normal	B-X
and	B-X
variant	B-X
prealbumin	B-X
in	B-X
vivo	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
fates	B-X
of	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
were	B-X
studied	B-X
in	B-X
normal	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
animals	B-X
that	B-X
were	B-X
challenged	B-X
with	B-X
acute	B-X
inflammation	B-X
induced	B-X
by	B-X
turpentine	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
in	B-X
vitro	B-X
photooxidation	B-X
of	B-X
prealbumin	B-X
samples	B-X
on	B-X
their	B-X
behavior	B-X
was	B-X
also	B-X
examined	B-X
in	B-X
vivo	B-X
.	B-X
Kinetic	B-X
analysis	B-X
revealed	B-X
no	B-X
appreciable	B-X
difference	B-X
between	B-X
prealbumin	B-X
samples	B-X
from	B-X
normal	B-X
and	B-X
FAP	B-X
patients	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
factors	B-X
other	B-X
than	B-X
the	B-X
rate	B-X
of	B-X
transfer	B-X
of	B-X
the	B-X
variant	B-X
form	B-X
prealbumin	B-X
from	B-X
plasma	B-X
to	B-X
an	B-X
extravascular	B-X
compartment	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
amyloid	B-X
deposition	B-X
in	B-X
FAP	B-X
patients	B-X
.	B-X

These	O
results	O
suggest	O
that	O
factors	O
other	O
than	O
the	O
rate	O
of	O
transfer	O
of	O
the	O
variant	O
form	O
prealbumin	B-Protein
from	O
plasma	O
to	O
an	O
extravascular	O
compartment	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
amyloid	B-Protein
deposition	O
in	O
FAP	O
patients	O
.	O

Characterization	O
of	O
tyrosylprotein	O
sulfotransferase	O
from	O
rat	O
liver	O
and	O
other	O
tissues	O
.	O
<EOS>	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
describe	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
that	B-X
is	B-X
capable	B-X
of	B-X
catalyzing	B-X
the	B-X
transfer	B-X
of	B-X
a	B-X
sulfate	B-X
moiety	B-X
from	B-X
3'-phosphoadenosine	B-X
5'-phosphosulfate	B-X
(	B-X
PAPS	B-X
)	B-X
to	B-X
the	B-X
synthetic	B-X
polymer	B-X
,	B-X
poly-	B-X
(	B-X
Glu6	B-X
,	B-X
Ala3	B-X
,	B-X
Tyr1	B-X
)	B-X
(	B-X
EAY	B-X
;	B-X
Mr	B-X
47,000	B-X
)	B-X
using	B-X
a	B-X
simple	B-X
filter	B-X
paper	B-X
assay	B-X
.	B-X
Following	B-X
sucrose	B-X
density	B-X
gradient	B-X
centrifugation	B-X
and	B-X
comparison	B-X
with	B-X
known	B-X
subcellular	B-X
marker	B-X
enzyme	B-X
activities	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
distribution	B-X
similar	B-X
to	B-X
the	B-X
Golgi	B-X
enzyme	B-X
,	B-X
galactosyltransferase	B-X
.	B-X
Using	B-X
the	B-X
enriched	B-X
Golgi	B-X
preparation	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
displayed	B-X
a	B-X
pH	B-X
optimum	B-X
of	B-X
6.7	B-X
and	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
20	B-X
mM	B-X
Mn2+	B-X
for	B-X
maximal	B-X
activity	B-X
.	B-X
Co2+	B-X
(	B-X
20	B-X
mM	B-X
)	B-X
was	B-X
able	B-X
to	B-X
produce	B-X
26	B-X
%	B-X
of	B-X
the	B-X
maximal	B-X
stimulation	B-X
observed	B-X
with	B-X
Mn2+	B-X
,	B-X
whereas	B-X
other	B-X
metal	B-X
ions	B-X
,	B-X
such	B-X
as	B-X
Mg2+	B-X
,	B-X
Ca2+	B-X
,	B-X
and	B-X
Co2+	B-X
,	B-X
were	B-X
not	B-X
effective	B-X
in	B-X
stimulating	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
.	B-X
Whereas	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
native	B-X
membrane-bound	B-X
state	B-X
,	B-X
EAY	B-X
sulfation	B-X
was	B-X
maximally	B-X
enhanced	B-X
3-fold	B-X
when	B-X
assayed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Lubrol	B-X
Px	B-X
.	B-X
Under	B-X
the	B-X
optimal	B-X
conditions	B-X
for	B-X
assaying	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
a	B-X
rat	B-X
liver	B-X
enriched	B-X
Golgi	B-X
fraction	B-X
,	B-X
significant	B-X
degradation	B-X
of	B-X
the	B-X
sulfate	B-X
donor	B-X
,	B-X
PAPS	B-X
,	B-X
was	B-X
observed	B-X
.	B-X
Using	B-X
the	B-X
optimized	B-X
conditions	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
membrane-bound	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
the	B-X
crude	B-X
microsomal	B-X
pellets	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
rat	B-X
tissues	B-X
,	B-X
including	B-X
lung	B-X
,	B-X
pituitary	B-X
,	B-X
and	B-X
cerebellum	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
livers	B-X
from	B-X
different	B-X
species	B-X
.	B-X

The	O
sulfoconjugation	O
of	O
tyrosyl	O
residues	O
is	O
a	O
widespread	O
post	O
-	O
translational	O
modification	O
of	O
biologically	O
active	O
peptides	O
and	O
proteins	O
.	O
<EOS>	B-X
The	B-X
sulfoconjugation	B-X
of	B-X
tyrosyl	B-X
residues	B-X
is	B-X
a	B-X
widespread	B-X
post-translational	B-X
modification	B-X
of	B-X
biologically	B-X
active	B-X
peptides	B-X
and	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
describe	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
that	B-X
is	B-X
capable	B-X
of	B-X
catalyzing	B-X
the	B-X
transfer	B-X
of	B-X
a	B-X
sulfate	B-X
moiety	B-X
from	B-X
3'-phosphoadenosine	B-X
5'-phosphosulfate	B-X
(	B-X
PAPS	B-X
)	B-X
to	B-X
the	B-X
synthetic	B-X
polymer	B-X
,	B-X
poly-	B-X
(	B-X
Glu6	B-X
,	B-X
Ala3	B-X
,	B-X
Tyr1	B-X
)	B-X
(	B-X
EAY	B-X
;	B-X
Mr	B-X
47,000	B-X
)	B-X
using	B-X
a	B-X
simple	B-X
filter	B-X
paper	B-X
assay	B-X
.	B-X
Following	B-X
sucrose	B-X
density	B-X
gradient	B-X
centrifugation	B-X
and	B-X
comparison	B-X
with	B-X
known	B-X
subcellular	B-X
marker	B-X
enzyme	B-X
activities	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
distribution	B-X
similar	B-X
to	B-X
the	B-X
Golgi	B-X
enzyme	B-X
,	B-X
galactosyltransferase	B-X
.	B-X
Using	B-X
the	B-X
enriched	B-X
Golgi	B-X
preparation	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
displayed	B-X
a	B-X
pH	B-X
optimum	B-X
of	B-X
6.7	B-X
and	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
20	B-X
mM	B-X
Mn2+	B-X
for	B-X
maximal	B-X
activity	B-X
.	B-X
Co2+	B-X
(	B-X
20	B-X
mM	B-X
)	B-X
was	B-X
able	B-X
to	B-X
produce	B-X
26	B-X
%	B-X
of	B-X
the	B-X
maximal	B-X
stimulation	B-X
observed	B-X
with	B-X
Mn2+	B-X
,	B-X
whereas	B-X
other	B-X
metal	B-X
ions	B-X
,	B-X
such	B-X
as	B-X
Mg2+	B-X
,	B-X
Ca2+	B-X
,	B-X
and	B-X
Co2+	B-X
,	B-X
were	B-X
not	B-X
effective	B-X
in	B-X
stimulating	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
.	B-X
Whereas	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
native	B-X
membrane-bound	B-X
state	B-X
,	B-X
EAY	B-X
sulfation	B-X
was	B-X
maximally	B-X
enhanced	B-X
3-fold	B-X
when	B-X
assayed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Lubrol	B-X
Px	B-X
.	B-X
Using	B-X
the	B-X
optimized	B-X
conditions	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
membrane-bound	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
the	B-X
crude	B-X
microsomal	B-X
pellets	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
rat	B-X
tissues	B-X
,	B-X
including	B-X
lung	B-X
,	B-X
pituitary	B-X
,	B-X
and	B-X
cerebellum	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
livers	B-X
from	B-X
different	B-X
species	B-X
.	B-X

In	O
this	O
paper	O
we	O
describe	O
the	O
characterization	O
of	O
a	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
that	O
is	O
capable	O
of	O
catalyzing	O
the	O
transfer	O
of	O
a	O
sulfate	O
moiety	O
from	O
3	O
'	O
-	O
phosphoadenosine	O
5	O
'	O
-	O
phosphosulfate	O
(	O
PAPS	O
)	O
to	O
the	O
synthetic	O
polymer	O
,	O
poly	O
-	O
(	O
Glu6	O
,	O
Ala3	O
,	O
Tyr1	O
)	O
(	O
EAY	O
;	O
Mr	O
47	O
,	O
000	O
)	O
using	O
a	O
simple	O
filter	O
paper	O
assay	O
.	O

Following	O
sucrose	O
density	O
gradient	O
centrifugation	O
and	O
comparison	O
with	O
known	O
subcellular	O
marker	O
enzyme	O
activities	O
,	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
shown	O
to	O
have	O
a	O
distribution	O
similar	O
to	O
the	O
Golgi	O
enzyme	O
,	O
galactosyltransferase	O
.	O

Using	O
the	O
enriched	O
Golgi	O
preparation	O
,	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
displayed	O
a	O
pH	O
optimum	O
of	O
6	O
.	O
7	O
and	O
required	O
the	O
presence	O
of	O
20	O
mM	O
Mn2	O
+	O
for	O
maximal	O
activity	O
.	O

Co2	O
+	O
(	O
20	O
mM	O
)	O
was	O
able	O
to	O
produce	O
26	O
%	O
of	O
the	O
maximal	O
stimulation	O
observed	O
with	O
Mn2	O
+	O
,	O
whereas	O
other	O
metal	O
ions	O
,	O
such	O
as	O
Mg2	O
+	O
,	O
Ca2	O
+	O
,	O
and	O
Co2	O
+	O
,	O
were	O
not	O
effective	O
in	O
stimulating	O
tyrosylprotein	O
sulfotransferase	O
activity	O
.	O

Whereas	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
observed	O
in	O
the	O
native	O
membrane	O
-	O
bound	O
state	O
,	O
EAY	O
sulfation	O
was	O
maximally	O
enhanced	O
3	O
-	O
fold	O
when	O
assayed	O
in	O
the	O
presence	O
of	O
Lubrol	O
Px	O
.	O
<EOS>	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
describe	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
that	B-X
is	B-X
capable	B-X
of	B-X
catalyzing	B-X
the	B-X
transfer	B-X
of	B-X
a	B-X
sulfate	B-X
moiety	B-X
from	B-X
3'-phosphoadenosine	B-X
5'-phosphosulfate	B-X
(	B-X
PAPS	B-X
)	B-X
to	B-X
the	B-X
synthetic	B-X
polymer	B-X
,	B-X
poly-	B-X
(	B-X
Glu6	B-X
,	B-X
Ala3	B-X
,	B-X
Tyr1	B-X
)	B-X
(	B-X
EAY	B-X
;	B-X
Mr	B-X
47,000	B-X
)	B-X
using	B-X
a	B-X
simple	B-X
filter	B-X
paper	B-X
assay	B-X
.	B-X
Following	B-X
sucrose	B-X
density	B-X
gradient	B-X
centrifugation	B-X
and	B-X
comparison	B-X
with	B-X
known	B-X
subcellular	B-X
marker	B-X
enzyme	B-X
activities	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
distribution	B-X
similar	B-X
to	B-X
the	B-X
Golgi	B-X
enzyme	B-X
,	B-X
galactosyltransferase	B-X
.	B-X
Using	B-X
the	B-X
enriched	B-X
Golgi	B-X
preparation	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
displayed	B-X
a	B-X
pH	B-X
optimum	B-X
of	B-X
6.7	B-X
and	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
20	B-X
mM	B-X
Mn2+	B-X
for	B-X
maximal	B-X
activity	B-X
.	B-X
Co2+	B-X
(	B-X
20	B-X
mM	B-X
)	B-X
was	B-X
able	B-X
to	B-X
produce	B-X
26	B-X
%	B-X
of	B-X
the	B-X
maximal	B-X
stimulation	B-X
observed	B-X
with	B-X
Mn2+	B-X
,	B-X
whereas	B-X
other	B-X
metal	B-X
ions	B-X
,	B-X
such	B-X
as	B-X
Mg2+	B-X
,	B-X
Ca2+	B-X
,	B-X
and	B-X
Co2+	B-X
,	B-X
were	B-X
not	B-X
effective	B-X
in	B-X
stimulating	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
.	B-X
Whereas	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
native	B-X
membrane-bound	B-X
state	B-X
,	B-X
EAY	B-X
sulfation	B-X
was	B-X
maximally	B-X
enhanced	B-X
3-fold	B-X
when	B-X
assayed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Lubrol	B-X
Px	B-X
.	B-X
Under	B-X
the	B-X
optimal	B-X
conditions	B-X
for	B-X
assaying	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
a	B-X
rat	B-X
liver	B-X
enriched	B-X
Golgi	B-X
fraction	B-X
,	B-X
significant	B-X
degradation	B-X
of	B-X
the	B-X
sulfate	B-X
donor	B-X
,	B-X
PAPS	B-X
,	B-X
was	B-X
observed	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
both	B-X
NaF	B-X
and	B-X
5'-AMP	B-X
to	B-X
the	B-X
incubation	B-X
mixture	B-X
was	B-X
found	B-X
to	B-X
effectively	B-X
prevent	B-X
PAPS	B-X
degradation	B-X
and	B-X
increase	B-X
the	B-X
amount	B-X
of	B-X
product	B-X
formed	B-X
in	B-X
the	B-X
assay	B-X
by	B-X
10-fold	B-X
.	B-X
Using	B-X
the	B-X
optimized	B-X
conditions	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
membrane-bound	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
the	B-X
crude	B-X
microsomal	B-X
pellets	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
rat	B-X
tissues	B-X
,	B-X
including	B-X
lung	B-X
,	B-X
pituitary	B-X
,	B-X
and	B-X
cerebellum	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
livers	B-X
from	B-X
different	B-X
species	B-X
.	B-X

Under	O
the	O
optimal	O
conditions	O
for	O
assaying	O
the	O
sulfation	O
of	O
EAY	O
by	O
a	O
rat	O
liver	O
enriched	O
Golgi	O
fraction	O
,	O
significant	O
degradation	O
of	O
the	O
sulfate	O
donor	O
,	O
PAPS	O
,	O
was	O
observed	O
.	O
<EOS>	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
describe	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
that	B-X
is	B-X
capable	B-X
of	B-X
catalyzing	B-X
the	B-X
transfer	B-X
of	B-X
a	B-X
sulfate	B-X
moiety	B-X
from	B-X
3'-phosphoadenosine	B-X
5'-phosphosulfate	B-X
(	B-X
PAPS	B-X
)	B-X
to	B-X
the	B-X
synthetic	B-X
polymer	B-X
,	B-X
poly-	B-X
(	B-X
Glu6	B-X
,	B-X
Ala3	B-X
,	B-X
Tyr1	B-X
)	B-X
(	B-X
EAY	B-X
;	B-X
Mr	B-X
47,000	B-X
)	B-X
using	B-X
a	B-X
simple	B-X
filter	B-X
paper	B-X
assay	B-X
.	B-X
Following	B-X
sucrose	B-X
density	B-X
gradient	B-X
centrifugation	B-X
and	B-X
comparison	B-X
with	B-X
known	B-X
subcellular	B-X
marker	B-X
enzyme	B-X
activities	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
distribution	B-X
similar	B-X
to	B-X
the	B-X
Golgi	B-X
enzyme	B-X
,	B-X
galactosyltransferase	B-X
.	B-X
Using	B-X
the	B-X
enriched	B-X
Golgi	B-X
preparation	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
displayed	B-X
a	B-X
pH	B-X
optimum	B-X
of	B-X
6.7	B-X
and	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
20	B-X
mM	B-X
Mn2+	B-X
for	B-X
maximal	B-X
activity	B-X
.	B-X
Co2+	B-X
(	B-X
20	B-X
mM	B-X
)	B-X
was	B-X
able	B-X
to	B-X
produce	B-X
26	B-X
%	B-X
of	B-X
the	B-X
maximal	B-X
stimulation	B-X
observed	B-X
with	B-X
Mn2+	B-X
,	B-X
whereas	B-X
other	B-X
metal	B-X
ions	B-X
,	B-X
such	B-X
as	B-X
Mg2+	B-X
,	B-X
Ca2+	B-X
,	B-X
and	B-X
Co2+	B-X
,	B-X
were	B-X
not	B-X
effective	B-X
in	B-X
stimulating	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
.	B-X
Whereas	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
native	B-X
membrane-bound	B-X
state	B-X
,	B-X
EAY	B-X
sulfation	B-X
was	B-X
maximally	B-X
enhanced	B-X
3-fold	B-X
when	B-X
assayed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Lubrol	B-X
Px	B-X
.	B-X
Under	B-X
the	B-X
optimal	B-X
conditions	B-X
for	B-X
assaying	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
a	B-X
rat	B-X
liver	B-X
enriched	B-X
Golgi	B-X
fraction	B-X
,	B-X
significant	B-X
degradation	B-X
of	B-X
the	B-X
sulfate	B-X
donor	B-X
,	B-X
PAPS	B-X
,	B-X
was	B-X
observed	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
both	B-X
NaF	B-X
and	B-X
5'-AMP	B-X
to	B-X
the	B-X
incubation	B-X
mixture	B-X
was	B-X
found	B-X
to	B-X
effectively	B-X
prevent	B-X
PAPS	B-X
degradation	B-X
and	B-X
increase	B-X
the	B-X
amount	B-X
of	B-X
product	B-X
formed	B-X
in	B-X
the	B-X
assay	B-X
by	B-X
10-fold	B-X
.	B-X
Using	B-X
the	B-X
optimized	B-X
conditions	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
membrane-bound	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
the	B-X
crude	B-X
microsomal	B-X
pellets	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
rat	B-X
tissues	B-X
,	B-X
including	B-X
lung	B-X
,	B-X
pituitary	B-X
,	B-X
and	B-X
cerebellum	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
livers	B-X
from	B-X
different	B-X
species	B-X
.	B-X

The	O
addition	O
of	O
both	O
NaF	O
and	O
5	O
'	O
-	O
AMP	O
to	O
the	O
incubation	O
mixture	O
was	O
found	O
to	O
effectively	O
prevent	O
PAPS	O
degradation	O
and	O
increase	O
the	O
amount	O
of	O
product	O
formed	O
in	O
the	O
assay	O
by	O
10	O
-	O
fold	O
.	O

Using	O
the	O
optimized	O
conditions	O
for	O
the	O
sulfation	O
of	O
EAY	O
by	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
,	O
membrane	O
-	O
bound	O
sulfotransferase	O
activity	O
was	O
also	O
observed	O
in	O
the	O
crude	O
microsomal	O
pellets	O
of	O
a	O
variety	O
of	O
rat	O
tissues	O
,	O
including	O
lung	O
,	O
pituitary	O
,	O
and	O
cerebellum	O
,	O
as	O
well	O
as	O
in	O
livers	O
from	O
different	O
species	O
.	O
<EOS>	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
describe	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
that	B-X
is	B-X
capable	B-X
of	B-X
catalyzing	B-X
the	B-X
transfer	B-X
of	B-X
a	B-X
sulfate	B-X
moiety	B-X
from	B-X
3'-phosphoadenosine	B-X
5'-phosphosulfate	B-X
(	B-X
PAPS	B-X
)	B-X
to	B-X
the	B-X
synthetic	B-X
polymer	B-X
,	B-X
poly-	B-X
(	B-X
Glu6	B-X
,	B-X
Ala3	B-X
,	B-X
Tyr1	B-X
)	B-X
(	B-X
EAY	B-X
;	B-X
Mr	B-X
47,000	B-X
)	B-X
using	B-X
a	B-X
simple	B-X
filter	B-X
paper	B-X
assay	B-X
.	B-X
Following	B-X
sucrose	B-X
density	B-X
gradient	B-X
centrifugation	B-X
and	B-X
comparison	B-X
with	B-X
known	B-X
subcellular	B-X
marker	B-X
enzyme	B-X
activities	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
distribution	B-X
similar	B-X
to	B-X
the	B-X
Golgi	B-X
enzyme	B-X
,	B-X
galactosyltransferase	B-X
.	B-X
Using	B-X
the	B-X
enriched	B-X
Golgi	B-X
preparation	B-X
,	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
displayed	B-X
a	B-X
pH	B-X
optimum	B-X
of	B-X
6.7	B-X
and	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
20	B-X
mM	B-X
Mn2+	B-X
for	B-X
maximal	B-X
activity	B-X
.	B-X
Co2+	B-X
(	B-X
20	B-X
mM	B-X
)	B-X
was	B-X
able	B-X
to	B-X
produce	B-X
26	B-X
%	B-X
of	B-X
the	B-X
maximal	B-X
stimulation	B-X
observed	B-X
with	B-X
Mn2+	B-X
,	B-X
whereas	B-X
other	B-X
metal	B-X
ions	B-X
,	B-X
such	B-X
as	B-X
Mg2+	B-X
,	B-X
Ca2+	B-X
,	B-X
and	B-X
Co2+	B-X
,	B-X
were	B-X
not	B-X
effective	B-X
in	B-X
stimulating	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
.	B-X
Whereas	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
native	B-X
membrane-bound	B-X
state	B-X
,	B-X
EAY	B-X
sulfation	B-X
was	B-X
maximally	B-X
enhanced	B-X
3-fold	B-X
when	B-X
assayed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Lubrol	B-X
Px	B-X
.	B-X
Under	B-X
the	B-X
optimal	B-X
conditions	B-X
for	B-X
assaying	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
a	B-X
rat	B-X
liver	B-X
enriched	B-X
Golgi	B-X
fraction	B-X
,	B-X
significant	B-X
degradation	B-X
of	B-X
the	B-X
sulfate	B-X
donor	B-X
,	B-X
PAPS	B-X
,	B-X
was	B-X
observed	B-X
.	B-X
Using	B-X
the	B-X
optimized	B-X
conditions	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
EAY	B-X
by	B-X
rat	B-X
liver	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
membrane-bound	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
the	B-X
crude	B-X
microsomal	B-X
pellets	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
rat	B-X
tissues	B-X
,	B-X
including	B-X
lung	B-X
,	B-X
pituitary	B-X
,	B-X
and	B-X
cerebellum	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
livers	B-X
from	B-X
different	B-X
species	B-X
.	B-X

Role	O
of	O
counter	O
ions	O
in	O
trypsin	O
acylation	O
.	O
<EOS>	B-X
The	B-X
Asp102-carboxylate	B-X
negative	B-X
charge	B-X
of	B-X
the	B-X
trypsin	B-X
catalytic-triad	B-X
has	B-X
been	B-X
substituted	B-X
in	B-X
part	B-X
by	B-X
Cl-	B-X
counter-ions	B-X
.	B-X
A	B-X
His57-imidazolium	B-X
cation	B-X
and	B-X
Ser195-tetrahedral	B-X
oxyanion	B-X
ionpair	B-X
generated	B-X
in	B-X
the	B-X
acylation	B-X
step	B-X
of	B-X
catalysis	B-X
is	B-X
stabilized	B-X
by	B-X
the	B-X
negative	B-X
charge	B-X
of	B-X
Asp102	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
correct	B-X
location	B-X
of	B-X
this	B-X
negative	B-X
charge	B-X
has	B-X
been	B-X
investigated	B-X
by	B-X
experimental	B-X
analysis	B-X
of	B-X
the	B-X
NaCl	B-X
influence	B-X
on	B-X
the	B-X
acylation-rate	B-X
of	B-X
trypsin	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
electrostatic	B-X
,	B-X
potential	B-X
calculations	B-X
.	B-X
The	B-X
acylation-rate	B-X
was	B-X
determined	B-X
with	B-X
stopped-flow	B-X
technique	B-X
under	B-X
pseudo-first	B-X
order	B-X
conditions	B-X
,	B-X
by	B-X
using	B-X
4-nitrophenyl-4'-guanidinium	B-X
benzoate	B-X
active	B-X
site	B-X
titrant	B-X
at	B-X
pH	B-X
4.25	B-X
+/-	B-X
0.04	B-X
,	B-X
in	B-X
an	B-X
unbuffered	B-X
solution	B-X
of	B-X
I	B-X
=	B-X
O	B-X
or	B-X
0.5	B-X
M	B-X
NaCl	B-X
.	B-X
The	B-X
acylation-rate	B-X
constants	B-X
,	B-X
kappa	B-X
2	B-X
,	B-X
are	B-X
:	B-X
kappa	B-X
H2O	B-X
=	B-X
0.32	B-X
+/-	B-X
0.02	B-X
s-1	B-X
and	B-X
kappa	B-X
NaCl	B-X
=	B-X
3.5	B-X
+/-	B-X
0.5	B-X
s-1	B-X
,	B-X
and	B-X
they	B-X
correlate	B-X
to	B-X
beta-trypsin	B-X
(	B-X
the	B-X
most	B-X
rapid	B-X
single-chained	B-X
form	B-X
of	B-X
the	B-X
enzyme	B-X
)	B-X
.	B-X
The	B-X
rate	B-X
increasing	B-X
effect	B-X
of	B-X
NaCl	B-X
,	B-X
together	B-X
with	B-X
the	B-X
calculated	B-X
electrostatic	B-X
energies	B-X
,	B-X
indicate	B-X
that	B-X
the	B-X
negative	B-X
charge	B-X
contribution	B-X
of	B-X
the	B-X
Asp102-carboxylate	B-X
to	B-X
the	B-X
stabilization	B-X
of	B-X
the	B-X
imidazolium	B-X
cation	B-X
and	B-X
tetrahedral	B-X
oxyanion	B-X
intermediate	B-X
is	B-X
larger	B-X
of	B-X
more	B-X
orders	B-X
,	B-X
than	B-X
that	B-X
of	B-X
the	B-X
Cl-	B-X
counter-ion	B-X
,	B-X
located	B-X
in	B-X
a	B-X
less	B-X
favourable	B-X
position	B-X
.	B-X

NaCl	O
effect	O
.	O
<EOS>	B-X
Remarkably	B-X
,	B-X
the	B-X
production	B-X
of	B-X
welan	B-X
gum	B-X
could	B-X
be	B-X
further	B-X
increased	B-X
by	B-X
adding	B-X
4	B-X
mM	B-X
NaCl	B-X
at	B-X
32	B-X
h	B-X
fermentation	B-X
,	B-X
reaching	B-X
30.12	B-X
±	B-X
0.25	B-X
g/L	B-X
(	B-X
28.66	B-X
%	B-X
higher	B-X
than	B-X
no	B-X
adding	B-X
)	B-X
,	B-X
and	B-X
the	B-X
NaCl-WG	B-X
solution	B-X
had	B-X
stronger	B-X
structural	B-X
,	B-X
impact	B-X
resistance	B-X
,	B-X
and	B-X
temperature	B-X
resistance	B-X
than	B-X
H	B-X
There	B-X
are	B-X
,	B-X
however	B-X
,	B-X
concerns	B-X
about	B-X
the	B-X
insecticidal	B-X
effects	B-X
of	B-X
Bt	B-X
cotton	B-X
on	B-X
target	B-X
insect	B-X
pests	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
a	B-X
Bt	B-X
cotton	B-X
variety	B-X
,	B-X
GK19	B-X
,	B-X
and	B-X
its	B-X
nontransgenic	B-X
parent	B-X
variety	B-X
,	B-X
Simian-3	B-X
,	B-X
were	B-X
used	B-X
as	B-X
experimental	B-X
models	B-X
for	B-X
investigating	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
exogenous	B-X
insecticidal	B-X
proteins	B-X
in	B-X
Bt	B-X
cotton	B-X
under	B-X
NaCl	B-X
stress	B-X
on	B-X
the	B-X
feeding	B-X
behavior	B-X
and	B-X
nutritional	B-X
parameters	B-X
of	B-X
Helicoverpa	B-X
armigera	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
exogenous	B-X
insecticidal	B-X
proteins	B-X
in	B-X
GK19	B-X
was	B-X
significantly	B-X
inhibited	B-X
under	B-X
NaCl	B-X
stress	B-X
.	B-X
However	B-X
,	B-X
the	B-X
feeding	B-X
,	B-X
crawling	B-X
,	B-X
resting	B-X
and	B-X
spinning	B-X
down	B-X
behavior	B-X
of	B-X
the	B-X
5th	B-X
instar	B-X
H.	B-X
armigera	B-X
larvae	B-X
on	B-X
GK19	B-X
Bt	B-X
cotton	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
amount	B-X
of	B-X
food	B-X
consumed	B-X
and	B-X
feces	B-X
produced	B-X
by	B-X
these	B-X
larvae	B-X
,	B-X
did	B-X
not	B-X
markedly	B-X
differ	B-X
under	B-X
different	B-X
NaCl	B-X
concentrations	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
mean	B-X
relative	B-X
growth	B-X
rate	B-X
(	B-X
MRGR	B-X
)	B-X
,	B-X
relative	B-X
growth	B-X
rate	B-X
(	B-X
RGR	B-X
)	B-X
,	B-X
approximate	B-X
digestibility	B-X
(	B-X
AD	B-X
)	B-X
,	B-X
efficiency	B-X
of	B-X
conversion	B-X
of	B-X
ingested	B-X
food	B-X
(	B-X
ECI	B-X
)	B-X
and	B-X
efficiency	B-X
of	B-X
conversion	B-X
of	B-X
digested	B-X
food	B-X
(	B-X
ECD	B-X
)	B-X
of	B-X
the	B-X
larvae	B-X
markedly	B-X
decreased	B-X
in	B-X
response	B-X
to	B-X
NaCl	B-X
stress	B-X
.	B-X
Under	B-X
the	B-X
same	B-X
concentration	B-X
of	B-X
NaCl	B-X
,	B-X
the	B-X
nutritional	B-X
parameters	B-X
of	B-X
the	B-X
bollworm	B-X
larvae	B-X
on	B-X
GK19	B-X
Bt	B-X
cotton	B-X
or	B-X
Simian-3	B-X
nontransgenic	B-X
cotton	B-X
were	B-X
different	B-X
.	B-X
However	B-X
,	B-X
the	B-X
interaction	B-X
between	B-X
salt	B-X
stress	B-X
and	B-X
cotton	B-X
variety	B-X
had	B-X
no	B-X
significant	B-X
effect	B-X
on	B-X
the	B-X
feeding	B-X
behavior	B-X
or	B-X
nutritional	B-X
parameters	B-X
of	B-X
H.	B-X
armigera	B-X
larvae	B-X
.	B-X
These	B-X
results	B-X
may	B-X
provide	B-X
a	B-X
scientific	B-X
basis	B-X
for	B-X
determining	B-X
the	B-X
effect	B-X
of	B-X
exogenous	B-X
insecticidal	B-X
protein	B-X
expression	B-X
in	B-X
Bt	B-X
cotton	B-X
under	B-X
NaCl	B-X
stress	B-X
on	B-X
H.	B-X
armigera	B-X
and	B-X
can	B-X
therefore	B-X
be	B-X
useful	B-X
for	B-X
the	B-X
effective	B-X
application	B-X
of	B-X
Bt	B-X
cotton	B-X
in	B-X
saline-alkali	B-X
soils	B-X
to	B-X
prevent	B-X
and	B-X
control	B-X
H.	B-X
armigera	B-X
.	B-X

The	O
Asp102	O
-	O
carboxylate	O
negative	O
charge	O
of	O
the	O
trypsin	O
catalytic	O
-	O
triad	O
has	O
been	O
substituted	O
in	O
part	O
by	O
Cl	O
-	O
counter	O
-	O
ions	O
.	O
<EOS>	B-X
The	B-X
Asp102-carboxylate	B-X
negative	B-X
charge	B-X
of	B-X
the	B-X
trypsin	B-X
catalytic-triad	B-X
has	B-X
been	B-X
substituted	B-X
in	B-X
part	B-X
by	B-X
Cl-	B-X
counter-ions	B-X
.	B-X
A	B-X
His57-imidazolium	B-X
cation	B-X
and	B-X
Ser195-tetrahedral	B-X
oxyanion	B-X
ionpair	B-X
generated	B-X
in	B-X
the	B-X
acylation	B-X
step	B-X
of	B-X
catalysis	B-X
is	B-X
stabilized	B-X
by	B-X
the	B-X
negative	B-X
charge	B-X
of	B-X
Asp102	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
correct	B-X
location	B-X
of	B-X
this	B-X
negative	B-X
charge	B-X
has	B-X
been	B-X
investigated	B-X
by	B-X
experimental	B-X
analysis	B-X
of	B-X
the	B-X
NaCl	B-X
influence	B-X
on	B-X
the	B-X
acylation-rate	B-X
of	B-X
trypsin	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
electrostatic	B-X
,	B-X
potential	B-X
calculations	B-X
.	B-X
The	B-X
acylation-rate	B-X
was	B-X
determined	B-X
with	B-X
stopped-flow	B-X
technique	B-X
under	B-X
pseudo-first	B-X
order	B-X
conditions	B-X
,	B-X
by	B-X
using	B-X
4-nitrophenyl-4'-guanidinium	B-X
benzoate	B-X
active	B-X
site	B-X
titrant	B-X
at	B-X
pH	B-X
4.25	B-X
+/-	B-X
0.04	B-X
,	B-X
in	B-X
an	B-X
unbuffered	B-X
solution	B-X
of	B-X
I	B-X
=	B-X
O	B-X
or	B-X
0.5	B-X
M	B-X
NaCl	B-X
.	B-X
The	B-X
acylation-rate	B-X
constants	B-X
,	B-X
kappa	B-X
2	B-X
,	B-X
are	B-X
:	B-X
kappa	B-X
H2O	B-X
=	B-X
0.32	B-X
+/-	B-X
0.02	B-X
s-1	B-X
and	B-X
kappa	B-X
NaCl	B-X
=	B-X
3.5	B-X
+/-	B-X
0.5	B-X
s-1	B-X
,	B-X
and	B-X
they	B-X
correlate	B-X
to	B-X
beta-trypsin	B-X
(	B-X
the	B-X
most	B-X
rapid	B-X
single-chained	B-X
form	B-X
of	B-X
the	B-X
enzyme	B-X
)	B-X
.	B-X
The	B-X
rate	B-X
increasing	B-X
effect	B-X
of	B-X
NaCl	B-X
,	B-X
together	B-X
with	B-X
the	B-X
calculated	B-X
electrostatic	B-X
energies	B-X
,	B-X
indicate	B-X
that	B-X
the	B-X
negative	B-X
charge	B-X
contribution	B-X
of	B-X
the	B-X
Asp102-carboxylate	B-X
to	B-X
the	B-X
stabilization	B-X
of	B-X
the	B-X
imidazolium	B-X
cation	B-X
and	B-X
tetrahedral	B-X
oxyanion	B-X
intermediate	B-X
is	B-X
larger	B-X
of	B-X
more	B-X
orders	B-X
,	B-X
than	B-X
that	B-X
of	B-X
the	B-X
Cl-	B-X
counter-ion	B-X
,	B-X
located	B-X
in	B-X
a	B-X
less	B-X
favourable	B-X
position	B-X
.	B-X

A	O
His57	O
-	O
imidazolium	O
cation	O
and	O
Ser195	O
-	O
tetrahedral	O
oxyanion	O
ionpair	O
generated	O
in	O
the	O
acylation	O
step	O
of	O
catalysis	O
is	O
stabilized	O
by	O
the	O
negative	O
charge	O
of	O
Asp102	O
.	O
<EOS>	B-X
The	B-X
Asp102-carboxylate	B-X
negative	B-X
charge	B-X
of	B-X
the	B-X
trypsin	B-X
catalytic-triad	B-X
has	B-X
been	B-X
substituted	B-X
in	B-X
part	B-X
by	B-X
Cl-	B-X
counter-ions	B-X
.	B-X
A	B-X
His57-imidazolium	B-X
cation	B-X
and	B-X
Ser195-tetrahedral	B-X
oxyanion	B-X
ionpair	B-X
generated	B-X
in	B-X
the	B-X
acylation	B-X
step	B-X
of	B-X
catalysis	B-X
is	B-X
stabilized	B-X
by	B-X
the	B-X
negative	B-X
charge	B-X
of	B-X
Asp102	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
correct	B-X
location	B-X
of	B-X
this	B-X
negative	B-X
charge	B-X
has	B-X
been	B-X
investigated	B-X
by	B-X
experimental	B-X
analysis	B-X
of	B-X
the	B-X
NaCl	B-X
influence	B-X
on	B-X
the	B-X
acylation-rate	B-X
of	B-X
trypsin	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
electrostatic	B-X
,	B-X
potential	B-X
calculations	B-X
.	B-X
The	B-X
acylation-rate	B-X
was	B-X
determined	B-X
with	B-X
stopped-flow	B-X
technique	B-X
under	B-X
pseudo-first	B-X
order	B-X
conditions	B-X
,	B-X
by	B-X
using	B-X
4-nitrophenyl-4'-guanidinium	B-X
benzoate	B-X
active	B-X
site	B-X
titrant	B-X
at	B-X
pH	B-X
4.25	B-X
+/-	B-X
0.04	B-X
,	B-X
in	B-X
an	B-X
unbuffered	B-X
solution	B-X
of	B-X
I	B-X
=	B-X
O	B-X
or	B-X
0.5	B-X
M	B-X
NaCl	B-X
.	B-X
The	B-X
acylation-rate	B-X
constants	B-X
,	B-X
kappa	B-X
2	B-X
,	B-X
are	B-X
:	B-X
kappa	B-X
H2O	B-X
=	B-X
0.32	B-X
+/-	B-X
0.02	B-X
s-1	B-X
and	B-X
kappa	B-X
NaCl	B-X
=	B-X
3.5	B-X
+/-	B-X
0.5	B-X
s-1	B-X
,	B-X
and	B-X
they	B-X
correlate	B-X
to	B-X
beta-trypsin	B-X
(	B-X
the	B-X
most	B-X
rapid	B-X
single-chained	B-X
form	B-X
of	B-X
the	B-X
enzyme	B-X
)	B-X
.	B-X
The	B-X
rate	B-X
increasing	B-X
effect	B-X
of	B-X
NaCl	B-X
,	B-X
together	B-X
with	B-X
the	B-X
calculated	B-X
electrostatic	B-X
energies	B-X
,	B-X
indicate	B-X
that	B-X
the	B-X
negative	B-X
charge	B-X
contribution	B-X
of	B-X
the	B-X
Asp102-carboxylate	B-X
to	B-X
the	B-X
stabilization	B-X
of	B-X
the	B-X
imidazolium	B-X
cation	B-X
and	B-X
tetrahedral	B-X
oxyanion	B-X
intermediate	B-X
is	B-X
larger	B-X
of	B-X
more	B-X
orders	B-X
,	B-X
than	B-X
that	B-X
of	B-X
the	B-X
Cl-	B-X
counter-ion	B-X
,	B-X
located	B-X
in	B-X
a	B-X
less	B-X
favourable	B-X
position	B-X
.	B-X

The	O
importance	O
of	O
correct	O
location	O
of	O
this	O
negative	O
charge	O
has	O
been	O
investigated	O
by	O
experimental	O
analysis	O
of	O
the	O
NaCl	O
influence	O
on	O
the	O
acylation	O
-	O
rate	O
of	O
trypsin	O
,	O
as	O
well	O
as	O
by	O
electrostatic	O
,	O
potential	O
calculations	O
.	O
<EOS>	B-X
The	B-X
Asp102-carboxylate	B-X
negative	B-X
charge	B-X
of	B-X
the	B-X
trypsin	B-X
catalytic-triad	B-X
has	B-X
been	B-X
substituted	B-X
in	B-X
part	B-X
by	B-X
Cl-	B-X
counter-ions	B-X
.	B-X
A	B-X
His57-imidazolium	B-X
cation	B-X
and	B-X
Ser195-tetrahedral	B-X
oxyanion	B-X
ionpair	B-X
generated	B-X
in	B-X
the	B-X
acylation	B-X
step	B-X
of	B-X
catalysis	B-X
is	B-X
stabilized	B-X
by	B-X
the	B-X
negative	B-X
charge	B-X
of	B-X
Asp102	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
correct	B-X
location	B-X
of	B-X
this	B-X
negative	B-X
charge	B-X
has	B-X
been	B-X
investigated	B-X
by	B-X
experimental	B-X
analysis	B-X
of	B-X
the	B-X
NaCl	B-X
influence	B-X
on	B-X
the	B-X
acylation-rate	B-X
of	B-X
trypsin	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
electrostatic	B-X
,	B-X
potential	B-X
calculations	B-X
.	B-X
The	B-X
acylation-rate	B-X
was	B-X
determined	B-X
with	B-X
stopped-flow	B-X
technique	B-X
under	B-X
pseudo-first	B-X
order	B-X
conditions	B-X
,	B-X
by	B-X
using	B-X
4-nitrophenyl-4'-guanidinium	B-X
benzoate	B-X
active	B-X
site	B-X
titrant	B-X
at	B-X
pH	B-X
4.25	B-X
+/-	B-X
0.04	B-X
,	B-X
in	B-X
an	B-X
unbuffered	B-X
solution	B-X
of	B-X
I	B-X
=	B-X
O	B-X
or	B-X
0.5	B-X
M	B-X
NaCl	B-X
.	B-X
The	B-X
acylation-rate	B-X
constants	B-X
,	B-X
kappa	B-X
2	B-X
,	B-X
are	B-X
:	B-X
kappa	B-X
H2O	B-X
=	B-X
0.32	B-X
+/-	B-X
0.02	B-X
s-1	B-X
and	B-X
kappa	B-X
NaCl	B-X
=	B-X
3.5	B-X
+/-	B-X
0.5	B-X
s-1	B-X
,	B-X
and	B-X
they	B-X
correlate	B-X
to	B-X
beta-trypsin	B-X
(	B-X
the	B-X
most	B-X
rapid	B-X
single-chained	B-X
form	B-X
of	B-X
the	B-X
enzyme	B-X
)	B-X
.	B-X
The	B-X
rate	B-X
increasing	B-X
effect	B-X
of	B-X
NaCl	B-X
,	B-X
together	B-X
with	B-X
the	B-X
calculated	B-X
electrostatic	B-X
energies	B-X
,	B-X
indicate	B-X
that	B-X
the	B-X
negative	B-X
charge	B-X
contribution	B-X
of	B-X
the	B-X
Asp102-carboxylate	B-X
to	B-X
the	B-X
stabilization	B-X
of	B-X
the	B-X
imidazolium	B-X
cation	B-X
and	B-X
tetrahedral	B-X
oxyanion	B-X
intermediate	B-X
is	B-X
larger	B-X
of	B-X
more	B-X
orders	B-X
,	B-X
than	B-X
that	B-X
of	B-X
the	B-X
Cl-	B-X
counter-ion	B-X
,	B-X
located	B-X
in	B-X
a	B-X
less	B-X
favourable	B-X
position	B-X
.	B-X

The	O
acylation	O
-	O
rate	O
was	O
determined	O
with	O
stopped	O
-	O
flow	O
technique	O
under	O
pseudo	O
-	O
first	O
order	O
conditions	O
,	O
by	O
using	O
4	O
-	O
nitrophenyl	O
-	O
4	O
'	O
-	O
guanidinium	O
benzoate	O
active	O
site	O
titrant	O
at	O
pH	O
4	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
in	O
an	O
unbuffered	O
solution	O
of	O
I	O
=	O
O	O
or	O
0	O
.	O
5	O
M	O
NaCl	O
.	O

The	O
acylation	O
-	O
rate	O
constants	O
,	O
kappa	O
2	O
,	O
are	O
:	O
kappa	O
H2O	O
=	O
0	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
02	O
s	O
-	O
1	O
and	O
kappa	O
NaCl	O
=	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
s	O
-	O
1	O
,	O
and	O
they	O
correlate	O
to	O
beta	B-Protein
-	I-Protein
trypsin	I-Protein
(	O
the	O
most	O
rapid	O
single	O
-	O
chained	O
form	O
of	O
the	O
enzyme	O
)	O
.	O

The	O
rate	O
increasing	O
effect	O
of	O
NaCl	O
,	O
together	O
with	O
the	O
calculated	O
electrostatic	O
energies	O
,	O
indicate	O
that	O
the	O
negative	O
charge	O
contribution	O
of	O
the	O
Asp102	O
-	O
carboxylate	O
to	O
the	O
stabilization	O
of	O
the	O
imidazolium	O
cation	O
and	O
tetrahedral	O
oxyanion	O
intermediate	O
is	O
larger	O
of	O
more	O
orders	O
,	O
than	O
that	O
of	O
the	O
Cl	O
-	O
counter	O
-	O
ion	O
,	O
located	O
in	O
a	O
less	O
favourable	O
position	O
.	O

Effect	O
of	O
oxidation	O
on	O
the	O
stability	O
of	O
tuberculin	O
purified	O
protein	O
derivative	O
(	O
PPD	O
)	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
work	B-X
was	B-X
two-fold	B-X
:	B-X
firstly	B-X
,	B-X
to	B-X
collect	B-X
data	B-X
on	B-X
the	B-X
effect	B-X
that	B-X
air	B-X
may	B-X
have	B-X
on	B-X
the	B-X
biological	B-X
potency	B-X
of	B-X
a	B-X
dilute	B-X
solution	B-X
of	B-X
tuberculin	B-X
PPD	B-X
(	B-X
5	B-X
TU/dose	B-X
)	B-X
,	B-X
and	B-X
secondly	B-X
,	B-X
to	B-X
find	B-X
out	B-X
whether	B-X
or	B-X
not	B-X
the	B-X
solubility	B-X
of	B-X
a	B-X
tuberculin	B-X
PPD	B-X
preparation	B-X
stored	B-X
in	B-X
powder	B-X
form	B-X
would	B-X
be	B-X
affected	B-X
by	B-X
air	B-X
over	B-X
a	B-X
long	B-X
period	B-X
of	B-X
time	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
air	B-X
in	B-X
the	B-X
headspace	B-X
of	B-X
multidose	B-X
vials	B-X
containing	B-X
a	B-X
dilute	B-X
tuberculin	B-X
PPD	B-X
solution	B-X
contributed	B-X
to	B-X
the	B-X
lowering	B-X
of	B-X
its	B-X
potency	B-X
by	B-X
approximately	B-X
50	B-X
%	B-X
over	B-X
a	B-X
period	B-X
of	B-X
4	B-X
months	B-X
at	B-X
5	B-X
degrees	B-X
C	B-X
,	B-X
and	B-X
that	B-X
thereafter	B-X
the	B-X
potency	B-X
remained	B-X
constant	B-X
for	B-X
up	B-X
to	B-X
12	B-X
months	B-X
.	B-X
It	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
approximately	B-X
55	B-X
%	B-X
of	B-X
a	B-X
PPD	B-X
preparation	B-X
,	B-X
stored	B-X
in	B-X
powder	B-X
form	B-X
over	B-X
a	B-X
period	B-X
of	B-X
7	B-X
years	B-X
at	B-X
24	B-X
degrees	B-X
C	B-X
in	B-X
containers	B-X
closed	B-X
with	B-X
non-absorbent	B-X
cotton	B-X
plugs	B-X
,	B-X
allowing	B-X
free	B-X
access	B-X
of	B-X
air	B-X
,	B-X
became	B-X
insoluble	B-X
,	B-X
whereas	B-X
when	B-X
an	B-X
identical	B-X
preparation	B-X
was	B-X
stored	B-X
for	B-X
the	B-X
same	B-X
length	B-X
of	B-X
time	B-X
,	B-X
at	B-X
24	B-X
degrees	B-X
C	B-X
or	B-X
for	B-X
at	B-X
least	B-X
14	B-X
years	B-X
at	B-X
5	B-X
degrees	B-X
C	B-X
,	B-X
in	B-X
tightly	B-X
closed	B-X
containers	B-X
,	B-X
it	B-X
retained	B-X
its	B-X
solubility	B-X
.	B-X
The	B-X
partial	B-X
loss	B-X
of	B-X
potency	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
some	B-X
solubility	B-X
were	B-X
attributed	B-X
to	B-X
the	B-X
denaturation	B-X
of	B-X
PPD	B-X
through	B-X
the	B-X
process	B-X
of	B-X
air	B-X
oxidation	B-X
.	B-X
To	B-X
reduce	B-X
the	B-X
loss	B-X
of	B-X
potency	B-X
of	B-X
tuberculin	B-X
PPD	B-X
products	B-X
through	B-X
the	B-X
process	B-X
of	B-X
oxidation	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
:	B-X
firstly	B-X
,	B-X
the	B-X
vials	B-X
be	B-X
filled	B-X
as	B-X
fully	B-X
as	B-X
possible	B-X
to	B-X
minimize	B-X
the	B-X
amount	B-X
of	B-X
air	B-X
trapped	B-X
in	B-X
the	B-X
headspace	B-X
,	B-X
or	B-X
the	B-X
filling	B-X
of	B-X
vials	B-X
be	B-X
carried	B-X
out	B-X
under	B-X
nitrogen	B-X
so	B-X
as	B-X
to	B-X
expel	B-X
any	B-X
air	B-X
in	B-X
the	B-X
headspace	B-X
.	B-X

The	O
purpose	O
of	O
the	O
present	O
work	O
was	O
two	O
-	O
fold	O
:	O
firstly	O
,	O
to	O
collect	O
data	O
on	O
the	O
effect	O
that	O
air	O
may	O
have	O
on	O
the	O
biological	O
potency	O
of	O
a	O
dilute	O
solution	O
of	O
tuberculin	O
PPD	O
(	O
5	O
TU	O
/	O
dose	O
)	O
,	O
and	O
secondly	O
,	O
to	O
find	O
out	O
whether	O
or	O
not	O
the	O
solubility	O
of	O
a	O
tuberculin	O
PPD	O
preparation	O
stored	O
in	O
powder	O
form	O
would	O
be	O
affected	O
by	O
air	O
over	O
a	O
long	O
period	O
of	O
time	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
work	B-X
was	B-X
two-fold	B-X
:	B-X
firstly	B-X
,	B-X
to	B-X
collect	B-X
data	B-X
on	B-X
the	B-X
effect	B-X
that	B-X
air	B-X
may	B-X
have	B-X
on	B-X
the	B-X
biological	B-X
potency	B-X
of	B-X
a	B-X
dilute	B-X
solution	B-X
of	B-X
tuberculin	B-X
PPD	B-X
(	B-X
5	B-X
TU/dose	B-X
)	B-X
,	B-X
and	B-X
secondly	B-X
,	B-X
to	B-X
find	B-X
out	B-X
whether	B-X
or	B-X
not	B-X
the	B-X
solubility	B-X
of	B-X
a	B-X
tuberculin	B-X
PPD	B-X
preparation	B-X
stored	B-X
in	B-X
powder	B-X
form	B-X
would	B-X
be	B-X
affected	B-X
by	B-X
air	B-X
over	B-X
a	B-X
long	B-X
period	B-X
of	B-X
time	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
air	B-X
in	B-X
the	B-X
headspace	B-X
of	B-X
multidose	B-X
vials	B-X
containing	B-X
a	B-X
dilute	B-X
tuberculin	B-X
PPD	B-X
solution	B-X
contributed	B-X
to	B-X
the	B-X
lowering	B-X
of	B-X
its	B-X
potency	B-X
by	B-X
approximately	B-X
50	B-X
%	B-X
over	B-X
a	B-X
period	B-X
of	B-X
4	B-X
months	B-X
at	B-X
5	B-X
degrees	B-X
C	B-X
,	B-X
and	B-X
that	B-X
thereafter	B-X
the	B-X
potency	B-X
remained	B-X
constant	B-X
for	B-X
up	B-X
to	B-X
12	B-X
months	B-X
.	B-X
It	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
approximately	B-X
55	B-X
%	B-X
of	B-X
a	B-X
PPD	B-X
preparation	B-X
,	B-X
stored	B-X
in	B-X
powder	B-X
form	B-X
over	B-X
a	B-X
period	B-X
of	B-X
7	B-X
years	B-X
at	B-X
24	B-X
degrees	B-X
C	B-X
in	B-X
containers	B-X
closed	B-X
with	B-X
non-absorbent	B-X
cotton	B-X
plugs	B-X
,	B-X
allowing	B-X
free	B-X
access	B-X
of	B-X
air	B-X
,	B-X
became	B-X
insoluble	B-X
,	B-X
whereas	B-X
when	B-X
an	B-X
identical	B-X
preparation	B-X
was	B-X
stored	B-X
for	B-X
the	B-X
same	B-X
length	B-X
of	B-X
time	B-X
,	B-X
at	B-X
24	B-X
degrees	B-X
C	B-X
or	B-X
for	B-X
at	B-X
least	B-X
14	B-X
years	B-X
at	B-X
5	B-X
degrees	B-X
C	B-X
,	B-X
in	B-X
tightly	B-X
closed	B-X
containers	B-X
,	B-X
it	B-X
retained	B-X
its	B-X
solubility	B-X
.	B-X
The	B-X
partial	B-X
loss	B-X
of	B-X
potency	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
some	B-X
solubility	B-X
were	B-X
attributed	B-X
to	B-X
the	B-X
denaturation	B-X
of	B-X
PPD	B-X
through	B-X
the	B-X
process	B-X
of	B-X
air	B-X
oxidation	B-X
.	B-X
To	B-X
reduce	B-X
the	B-X
loss	B-X
of	B-X
potency	B-X
of	B-X
tuberculin	B-X
PPD	B-X
products	B-X
through	B-X
the	B-X
process	B-X
of	B-X
oxidation	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
:	B-X
firstly	B-X
,	B-X
the	B-X
vials	B-X
be	B-X
filled	B-X
as	B-X
fully	B-X
as	B-X
possible	B-X
to	B-X
minimize	B-X
the	B-X
amount	B-X
of	B-X
air	B-X
trapped	B-X
in	B-X
the	B-X
headspace	B-X
,	B-X
or	B-X
the	B-X
filling	B-X
of	B-X
vials	B-X
be	B-X
carried	B-X
out	B-X
under	B-X
nitrogen	B-X
so	B-X
as	B-X
to	B-X
expel	B-X
any	B-X
air	B-X
in	B-X
the	B-X
headspace	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

It	O
was	O
shown	O
that	O
the	O
presence	O
of	O
air	O
in	O
the	O
headspace	O
of	O
multidose	O
vials	O
containing	O
a	O
dilute	O
tuberculin	O
PPD	O
solution	O
contributed	O
to	O
the	O
lowering	O
of	O
its	O
potency	O
by	O
approximately	O
50	O
%	O
over	O
a	O
period	O
of	O
4	O
months	O
at	O
5	O
degrees	O
C	O
,	O
and	O
that	O
thereafter	O
the	O
potency	O
remained	O
constant	O
for	O
up	O
to	O
12	O
months	O
.	O

It	O
was	O
also	O
shown	O
that	O
approximately	O
55	O
%	O
of	O
a	O
PPD	O
preparation	O
,	O
stored	O
in	O
powder	O
form	O
over	O
a	O
period	O
of	O
7	O
years	O
at	O
24	O
degrees	O
C	O
in	O
containers	O
closed	O
with	O
non	O
-	O
absorbent	O
cotton	O
plugs	O
,	O
allowing	O
free	O
access	O
of	O
air	O
,	O
became	O
insoluble	O
,	O
whereas	O
when	O
an	O
identical	O
preparation	O
was	O
stored	O
for	O
the	O
same	O
length	O
of	O
time	O
,	O
at	O
24	O
degrees	O
C	O
or	O
for	O
at	O
least	O
14	O
years	O
at	O
5	O
degrees	O
C	O
,	O
in	O
tightly	O
closed	O
containers	O
,	O
it	O
retained	O
its	O
solubility	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
work	B-X
was	B-X
two-fold	B-X
:	B-X
firstly	B-X
,	B-X
to	B-X
collect	B-X
data	B-X
on	B-X
the	B-X
effect	B-X
that	B-X
air	B-X
may	B-X
have	B-X
on	B-X
the	B-X
biological	B-X
potency	B-X
of	B-X
a	B-X
dilute	B-X
solution	B-X
of	B-X
tuberculin	B-X
PPD	B-X
(	B-X
5	B-X
TU/dose	B-X
)	B-X
,	B-X
and	B-X
secondly	B-X
,	B-X
to	B-X
find	B-X
out	B-X
whether	B-X
or	B-X
not	B-X
the	B-X
solubility	B-X
of	B-X
a	B-X
tuberculin	B-X
PPD	B-X
preparation	B-X
stored	B-X
in	B-X
powder	B-X
form	B-X
would	B-X
be	B-X
affected	B-X
by	B-X
air	B-X
over	B-X
a	B-X
long	B-X
period	B-X
of	B-X
time	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
air	B-X
in	B-X
the	B-X
headspace	B-X
of	B-X
multidose	B-X
vials	B-X
containing	B-X
a	B-X
dilute	B-X
tuberculin	B-X
PPD	B-X
solution	B-X
contributed	B-X
to	B-X
the	B-X
lowering	B-X
of	B-X
its	B-X
potency	B-X
by	B-X
approximately	B-X
50	B-X
%	B-X
over	B-X
a	B-X
period	B-X
of	B-X
4	B-X
months	B-X
at	B-X
5	B-X
degrees	B-X
C	B-X
,	B-X
and	B-X
that	B-X
thereafter	B-X
the	B-X
potency	B-X
remained	B-X
constant	B-X
for	B-X
up	B-X
to	B-X
12	B-X
months	B-X
.	B-X
It	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
approximately	B-X
55	B-X
%	B-X
of	B-X
a	B-X
PPD	B-X
preparation	B-X
,	B-X
stored	B-X
in	B-X
powder	B-X
form	B-X
over	B-X
a	B-X
period	B-X
of	B-X
7	B-X
years	B-X
at	B-X
24	B-X
degrees	B-X
C	B-X
in	B-X
containers	B-X
closed	B-X
with	B-X
non-absorbent	B-X
cotton	B-X
plugs	B-X
,	B-X
allowing	B-X
free	B-X
access	B-X
of	B-X
air	B-X
,	B-X
became	B-X
insoluble	B-X
,	B-X
whereas	B-X
when	B-X
an	B-X
identical	B-X
preparation	B-X
was	B-X
stored	B-X
for	B-X
the	B-X
same	B-X
length	B-X
of	B-X
time	B-X
,	B-X
at	B-X
24	B-X
degrees	B-X
C	B-X
or	B-X
for	B-X
at	B-X
least	B-X
14	B-X
years	B-X
at	B-X
5	B-X
degrees	B-X
C	B-X
,	B-X
in	B-X
tightly	B-X
closed	B-X
containers	B-X
,	B-X
it	B-X
retained	B-X
its	B-X
solubility	B-X
.	B-X
The	B-X
partial	B-X
loss	B-X
of	B-X
potency	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
some	B-X
solubility	B-X
were	B-X
attributed	B-X
to	B-X
the	B-X
denaturation	B-X
of	B-X
PPD	B-X
through	B-X
the	B-X
process	B-X
of	B-X
air	B-X
oxidation	B-X
.	B-X
To	B-X
reduce	B-X
the	B-X
loss	B-X
of	B-X
potency	B-X
of	B-X
tuberculin	B-X
PPD	B-X
products	B-X
through	B-X
the	B-X
process	B-X
of	B-X
oxidation	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
:	B-X
firstly	B-X
,	B-X
the	B-X
vials	B-X
be	B-X
filled	B-X
as	B-X
fully	B-X
as	B-X
possible	B-X
to	B-X
minimize	B-X
the	B-X
amount	B-X
of	B-X
air	B-X
trapped	B-X
in	B-X
the	B-X
headspace	B-X
,	B-X
or	B-X
the	B-X
filling	B-X
of	B-X
vials	B-X
be	B-X
carried	B-X
out	B-X
under	B-X
nitrogen	B-X
so	B-X
as	B-X
to	B-X
expel	B-X
any	B-X
air	B-X
in	B-X
the	B-X
headspace	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

The	O
partial	O
loss	O
of	O
potency	O
and	O
the	O
loss	O
of	O
some	O
solubility	O
were	O
attributed	O
to	O
the	O
denaturation	O
of	O
PPD	O
through	O
the	O
process	O
of	O
air	O
oxidation	O
.	O

To	O
reduce	O
the	O
loss	O
of	O
potency	O
of	O
tuberculin	O
PPD	O
products	O
through	O
the	O
process	O
of	O
oxidation	O
,	O
it	O
was	O
suggested	O
that	O
:	O
firstly	O
,	O
the	O
vials	O
be	O
filled	O
as	O
fully	O
as	O
possible	O
to	O
minimize	O
the	O
amount	O
of	O
air	O
trapped	O
in	O
the	O
headspace	O
,	O
or	O
the	O
filling	O
of	O
vials	O
be	O
carried	O
out	O
under	O
nitrogen	O
so	O
as	O
to	O
expel	O
any	O
air	O
in	O
the	O
headspace	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
work	B-X
was	B-X
two-fold	B-X
:	B-X
firstly	B-X
,	B-X
to	B-X
collect	B-X
data	B-X
on	B-X
the	B-X
effect	B-X
that	B-X
air	B-X
may	B-X
have	B-X
on	B-X
the	B-X
biological	B-X
potency	B-X
of	B-X
a	B-X
dilute	B-X
solution	B-X
of	B-X
tuberculin	B-X
PPD	B-X
(	B-X
5	B-X
TU/dose	B-X
)	B-X
,	B-X
and	B-X
secondly	B-X
,	B-X
to	B-X
find	B-X
out	B-X
whether	B-X
or	B-X
not	B-X
the	B-X
solubility	B-X
of	B-X
a	B-X
tuberculin	B-X
PPD	B-X
preparation	B-X
stored	B-X
in	B-X
powder	B-X
form	B-X
would	B-X
be	B-X
affected	B-X
by	B-X
air	B-X
over	B-X
a	B-X
long	B-X
period	B-X
of	B-X
time	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
air	B-X
in	B-X
the	B-X
headspace	B-X
of	B-X
multidose	B-X
vials	B-X
containing	B-X
a	B-X
dilute	B-X
tuberculin	B-X
PPD	B-X
solution	B-X
contributed	B-X
to	B-X
the	B-X
lowering	B-X
of	B-X
its	B-X
potency	B-X
by	B-X
approximately	B-X
50	B-X
%	B-X
over	B-X
a	B-X
period	B-X
of	B-X
4	B-X
months	B-X
at	B-X
5	B-X
degrees	B-X
C	B-X
,	B-X
and	B-X
that	B-X
thereafter	B-X
the	B-X
potency	B-X
remained	B-X
constant	B-X
for	B-X
up	B-X
to	B-X
12	B-X
months	B-X
.	B-X
It	B-X
was	B-X
also	B-X
shown	B-X
that	B-X
approximately	B-X
55	B-X
%	B-X
of	B-X
a	B-X
PPD	B-X
preparation	B-X
,	B-X
stored	B-X
in	B-X
powder	B-X
form	B-X
over	B-X
a	B-X
period	B-X
of	B-X
7	B-X
years	B-X
at	B-X
24	B-X
degrees	B-X
C	B-X
in	B-X
containers	B-X
closed	B-X
with	B-X
non-absorbent	B-X
cotton	B-X
plugs	B-X
,	B-X
allowing	B-X
free	B-X
access	B-X
of	B-X
air	B-X
,	B-X
became	B-X
insoluble	B-X
,	B-X
whereas	B-X
when	B-X
an	B-X
identical	B-X
preparation	B-X
was	B-X
stored	B-X
for	B-X
the	B-X
same	B-X
length	B-X
of	B-X
time	B-X
,	B-X
at	B-X
24	B-X
degrees	B-X
C	B-X
or	B-X
for	B-X
at	B-X
least	B-X
14	B-X
years	B-X
at	B-X
5	B-X
degrees	B-X
C	B-X
,	B-X
in	B-X
tightly	B-X
closed	B-X
containers	B-X
,	B-X
it	B-X
retained	B-X
its	B-X
solubility	B-X
.	B-X
The	B-X
partial	B-X
loss	B-X
of	B-X
potency	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
some	B-X
solubility	B-X
were	B-X
attributed	B-X
to	B-X
the	B-X
denaturation	B-X
of	B-X
PPD	B-X
through	B-X
the	B-X
process	B-X
of	B-X
air	B-X
oxidation	B-X
.	B-X
To	B-X
reduce	B-X
the	B-X
loss	B-X
of	B-X
potency	B-X
of	B-X
tuberculin	B-X
PPD	B-X
products	B-X
through	B-X
the	B-X
process	B-X
of	B-X
oxidation	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
:	B-X
firstly	B-X
,	B-X
the	B-X
vials	B-X
be	B-X
filled	B-X
as	B-X
fully	B-X
as	B-X
possible	B-X
to	B-X
minimize	B-X
the	B-X
amount	B-X
of	B-X
air	B-X
trapped	B-X
in	B-X
the	B-X
headspace	B-X
,	B-X
or	B-X
the	B-X
filling	B-X
of	B-X
vials	B-X
be	B-X
carried	B-X
out	B-X
under	B-X
nitrogen	B-X
so	B-X
as	B-X
to	B-X
expel	B-X
any	B-X
air	B-X
in	B-X
the	B-X
headspace	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

Interference	O
of	O
active	O
site	O
specific	O
reagents	O
in	O
plasminogen	B-Protein
-	O
streptokinase	B-Protein
active	O
site	O
formation	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
observed	B-X
slow	B-X
,	B-X
non-Michaelis-Menten	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
native	B-X
cat	B-X
plasminogen	B-X
by	B-X
catalytic	B-X
concentrations	B-X
of	B-X
streptokinase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
reasons	B-X
for	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
undertook	B-X
to	B-X
study	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
plasminogen-streptokinase	B-X
activator	B-X
complex	B-X
under	B-X
the	B-X
same	B-X
plasminogen	B-X
activation	B-X
conditions	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
this	B-X
study	B-X
show	B-X
that	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
in	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
strongly	B-X
the	B-X
specific	B-X
substrates	B-X
(	B-X
S	B-X
)	B-X
p-nitrophenyl	B-X
p-guanidinobenzoate	B-X
(	B-X
NPGB	B-X
)	B-X
and	B-X
H-D-valyl-L-leucyl-L-lysyl-p-nitroanilide	B-X
,	B-X
through	B-X
the	B-X
active	B-X
site	B-X
is	B-X
incapable	B-X
of	B-X
hydrolyzing	B-X
these	B-X
substrates	B-X
.	B-X
Streptokinase	B-X
binds	B-X
to	B-X
this	B-X
zymogen-substrate	B-X
complex	B-X
to	B-X
create	B-X
the	B-X
ternary	B-X
plasminogen-S-streptokinase	B-X
complex	B-X
,	B-X
which	B-X
then	B-X
slowly	B-X
converts	B-X
to	B-X
an	B-X
acylated	B-X
plasminogen-streptokinase	B-X
form	B-X
.	B-X
This	B-X
acylation	B-X
reaction	B-X
is	B-X
550	B-X
times	B-X
slower	B-X
than	B-X
acylation	B-X
of	B-X
the	B-X
preformed	B-X
plasminogen-streptokinase	B-X
complex	B-X
by	B-X
NPGB	B-X
.	B-X
The	B-X
same	B-X
reaction	B-X
also	B-X
occurs	B-X
with	B-X
human	B-X
plasminogen	B-X
,	B-X
though	B-X
the	B-X
acylation	B-X
reaction	B-X
is	B-X
10	B-X
times	B-X
faster	B-X
than	B-X
when	B-X
the	B-X
cat	B-X
zymogen	B-X
is	B-X
used	B-X
.	B-X
NPGB	B-X
binds	B-X
specifically	B-X
to	B-X
plasminogen	B-X
but	B-X
not	B-X
to	B-X
streptokinase	B-X
.	B-X
These	B-X
studies	B-X
proved	B-X
that	B-X
inhibition	B-X
of	B-X
cat	B-X
plasminogen	B-X
activation	B-X
by	B-X
streptokinase	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
activator	B-X
complex	B-X
formation	B-X
.	B-X
We	B-X
conclude	B-X
from	B-X
our	B-X
studies	B-X
that	B-X
streptokinase	B-X
binding	B-X
to	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
occurs	B-X
at	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
of	B-X
the	B-X
zymogen	B-X
.	B-X
Consequently	B-X
,	B-X
it	B-X
is	B-X
probable	B-X
that	B-X
plasminogen	B-X
activation	B-X
in	B-X
vivo	B-X
is	B-X
inhibited	B-X
by	B-X
binding	B-X
of	B-X
active	B-X
site	B-X
specific	B-X
inhibitors	B-X
to	B-X
plasminogen	B-X
.	B-X

We	O
have	O
recently	O
observed	O
slow	O
,	O
non	O
-	O
Michaelis	O
-	O
Menten	O
kinetics	O
of	O
activation	O
of	O
native	O
cat	O
plasminogen	B-Protein
by	O
catalytic	O
concentrations	O
of	O
streptokinase	B-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
observed	B-X
slow	B-X
,	B-X
non-Michaelis-Menten	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
native	B-X
cat	B-X
plasminogen	B-X
by	B-X
catalytic	B-X
concentrations	B-X
of	B-X
streptokinase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
reasons	B-X
for	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
undertook	B-X
to	B-X
study	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
plasminogen-streptokinase	B-X
activator	B-X
complex	B-X
under	B-X
the	B-X
same	B-X
plasminogen	B-X
activation	B-X
conditions	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
this	B-X
study	B-X
show	B-X
that	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
in	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
strongly	B-X
the	B-X
specific	B-X
substrates	B-X
(	B-X
S	B-X
)	B-X
p-nitrophenyl	B-X
p-guanidinobenzoate	B-X
(	B-X
NPGB	B-X
)	B-X
and	B-X
H-D-valyl-L-leucyl-L-lysyl-p-nitroanilide	B-X
,	B-X
through	B-X
the	B-X
active	B-X
site	B-X
is	B-X
incapable	B-X
of	B-X
hydrolyzing	B-X
these	B-X
substrates	B-X
.	B-X
Streptokinase	B-X
binds	B-X
to	B-X
this	B-X
zymogen-substrate	B-X
complex	B-X
to	B-X
create	B-X
the	B-X
ternary	B-X
plasminogen-S-streptokinase	B-X
complex	B-X
,	B-X
which	B-X
then	B-X
slowly	B-X
converts	B-X
to	B-X
an	B-X
acylated	B-X
plasminogen-streptokinase	B-X
form	B-X
.	B-X
This	B-X
acylation	B-X
reaction	B-X
is	B-X
550	B-X
times	B-X
slower	B-X
than	B-X
acylation	B-X
of	B-X
the	B-X
preformed	B-X
plasminogen-streptokinase	B-X
complex	B-X
by	B-X
NPGB	B-X
.	B-X
The	B-X
same	B-X
reaction	B-X
also	B-X
occurs	B-X
with	B-X
human	B-X
plasminogen	B-X
,	B-X
though	B-X
the	B-X
acylation	B-X
reaction	B-X
is	B-X
10	B-X
times	B-X
faster	B-X
than	B-X
when	B-X
the	B-X
cat	B-X
zymogen	B-X
is	B-X
used	B-X
.	B-X
NPGB	B-X
binds	B-X
specifically	B-X
to	B-X
plasminogen	B-X
but	B-X
not	B-X
to	B-X
streptokinase	B-X
.	B-X
These	B-X
studies	B-X
proved	B-X
that	B-X
inhibition	B-X
of	B-X
cat	B-X
plasminogen	B-X
activation	B-X
by	B-X
streptokinase	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
activator	B-X
complex	B-X
formation	B-X
.	B-X
We	B-X
conclude	B-X
from	B-X
our	B-X
studies	B-X
that	B-X
streptokinase	B-X
binding	B-X
to	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
occurs	B-X
at	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
of	B-X
the	B-X
zymogen	B-X
.	B-X
Consequently	B-X
,	B-X
it	B-X
is	B-X
probable	B-X
that	B-X
plasminogen	B-X
activation	B-X
in	B-X
vivo	B-X
is	B-X
inhibited	B-X
by	B-X
binding	B-X
of	B-X
active	B-X
site	B-X
specific	B-X
inhibitors	B-X
to	B-X
plasminogen	B-X
.	B-X

In	O
order	O
to	O
understand	O
the	O
reasons	O
for	O
this	O
phenomenon	O
,	O
we	O
undertook	O
to	O
study	O
the	O
formation	O
of	O
the	O
plasminogen	B-Protein
-	O
streptokinase	B-Protein
activator	O
complex	O
under	O
the	O
same	O
plasminogen	B-Protein
activation	O
conditions	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
show	O
that	O
the	O
potential	O
active	O
site	O
in	O
both	O
cat	O
and	O
human	O
plasminogen	B-Protein
is	O
capable	O
of	O
binding	O
strongly	O
the	O
specific	O
substrates	O
(	O
S	O
)	O
p	O
-	O
nitrophenyl	O
p	O
-	O
guanidinobenzoate	O
(	O
NPGB	O
)	O
and	O
H	O
-	O
D	O
-	O
valyl	O
-	O
L	O
-	O
leucyl	O
-	O
L	O
-	O
lysyl	O
-	O
p	O
-	O
nitroanilide	O
,	O
through	O
the	O
active	O
site	O
is	O
incapable	O
of	O
hydrolyzing	O
these	O
substrates	O
.	O

Binding	O
studies	O
support	O
these	O
and	O
the	O
following	O
conclusions	O
.	O
<EOS>	B-X
Twin	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
both	B-X
genetic	B-X
and	B-X
environmental	B-X
factors	B-X
influence	B-X
risk	B-X
for	B-X
posttraumatic	B-X
stress	B-X
disorder	B-X
(	B-X
PTSD	B-X
)	B-X
,	B-X
and	B-X
there	B-X
is	B-X
some	B-X
evidence	B-X
supporting	B-X
the	B-X
interplay	B-X
of	B-X
genes	B-X
and	B-X
environment	B-X
(	B-X
GxE	B-X
)	B-X
.	B-X
Many	B-X
GxE	B-X
studies	B-X
within	B-X
the	B-X
PTSD	B-X
literature	B-X
have	B-X
focused	B-X
on	B-X
genes	B-X
implicated	B-X
in	B-X
the	B-X
stress	B-X
response	B-X
system	B-X
,	B-X
such	B-X
as	B-X
FK506	B-X
binding	B-X
protein	B-X
51	B-X
(	B-X
FKBP5	B-X
)	B-X
.	B-X
In	B-X
this	B-X
article	B-X
we	B-X
reviewed	B-X
and	B-X
complemented	B-X
with	B-X
additional	B-X
bioinformatic	B-X
analysis	B-X
existing	B-X
data	B-X
on	B-X
genome-wide	B-X
NF-Y	B-X
binding	B-X
characterization	B-X
in	B-X
human	B-X
,	B-X
reaching	B-X
the	B-X
following	B-X
main	B-X
conclusions	B-X
:	B-X
(	B-X
1	B-X
)	B-X
about	B-X
half	B-X
of	B-X
NF-Y	B-X
binding	B-X
sites	B-X
are	B-X
located	B-X
at	B-X
promoters	B-X
,	B-X
about	B-X
60-80	B-X
base	B-X
pairs	B-X
from	B-X
transcription	B-X
start	B-X
sites	B-X
;	B-X
NF-Y	B-X
binding	B-X
to	B-X
distal	B-X
genomic	B-X
regions	B-X
takes	B-X
place	B-X
at	B-X
inactive	B-X
chromatin	B-X
loci	B-X
and/or	B-X
DNA	B-X
repetitive	B-X
elements	B-X
more	B-X
often	B-X
than	B-X
active	B-X
enhancers	B-X
;	B-X
(	B-X
2	B-X
)	B-X
on	B-X
almost	B-X
half	B-X
of	B-X
its	B-X
binding	B-X
sites	B-X
,	B-X
regardless	B-X
of	B-X
their	B-X
genomic	B-X
localization	B-X
(	B-X
promoters	B-X
or	B-X
distal	B-X
regions	B-X
)	B-X
,	B-X
NF-Y	B-X
finds	B-X
on	B-X
DNA	B-X
more	B-X
than	B-X
one	B-X
CCAAT-box	B-X
,	B-X
and	B-X
most	B-X
of	B-X
those	B-X
multiple	B-X
CCAAT	B-X
binding	B-X
loci	B-X
present	B-X
precise	B-X
spacing	B-X
and	B-X
organization	B-X
of	B-X
the	B-X
elements	B-X
composing	B-X
them	B-X
;	B-X
(	B-X
3	B-X
)	B-X
there	B-X
exists	B-X
a	B-X
well	B-X
defined	B-X
class	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
show	B-X
genome-wide	B-X
co-localization	B-X
with	B-X
NF-Y	B-X
.	B-X
The	B-X
main	B-X
conclusion	B-X
of	B-X
these	B-X
studies	B-X
was	B-X
that	B-X
several	B-X
levels	B-X
of	B-X
glycan	B-X
ligand	B-X
recognition	B-X
exist	B-X
for	B-X
galectins	B-X
:	B-X
(	B-X
i	B-X
)	B-X
disaccharide	B-X
Galβ1-4GlcNAc	B-X
(	B-X
LN	B-X
,	B-X
N-acetyllactosamine	B-X
)	B-X
binds	B-X
stronger	B-X
than	B-X
β-galactopyranose	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
substitution	B-X
at	B-X
O-2	B-X
and	B-X
O-3	B-X
of	B-X
galactose	B-X
residue	B-X
as	B-X
well	B-X
as	B-X
core	B-X
fragments	B-X
(	B-X
``	B-X
right	B-X
''	B-X
from	B-X
GlcNAc	B-X
)	B-X
provides	B-X
significant	B-X
increase	B-X
in	B-X
affinity	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
similarly	B-X
glycosylated	B-X
proteins	B-X
can	B-X
differ	B-X
significantly	B-X
in	B-X
affinity	B-X
to	B-X
galectins	B-X
.	B-X
The	B-X
following	B-X
conclusions	B-X
from	B-X
these	B-X
studies	B-X
were	B-X
made	B-X
:	B-X
(	B-X
i	B-X
)	B-X
cellular	B-X
galectins	B-X
have	B-X
practically	B-X
no	B-X
ability	B-X
to	B-X
bind	B-X
disaccharide	B-X
LNn	B-X
,	B-X
but	B-X
display	B-X
affinity	B-X
to	B-X
3'-substituted	B-X
oligolactosamines	B-X
and	B-X
oligomers	B-X
LNn	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
tandem-repeat	B-X
type	B-X
galectins	B-X
recognize	B-X
another	B-X
disaccharide	B-X
,	B-X
namely	B-X
Galβ1-3GlcNAc	B-X
(	B-X
Le	B-X
(	B-X
c	B-X
)	B-X
)	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
tandem-repeat	B-X
type	B-X
galectins	B-X
conserve	B-X
the	B-X
ability	B-X
to	B-X
display	B-X
high	B-X
affinity	B-X
to	B-X
blood	B-X
group	B-X
antigens	B-X
of	B-X
ABH	B-X
system	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
in	B-X
general	B-X
,	B-X
when	B-X
galectins	B-X
are	B-X
immersed	B-X
into	B-X
glycocalyx	B-X
,	B-X
they	B-X
are	B-X
more	B-X
selective	B-X
regarding	B-X
glycan	B-X
interactions	B-X
.	B-X

Streptokinase	B-Protein
binds	O
to	O
this	O
zymogen	O
-	O
substrate	O
complex	O
to	O
create	O
the	O
ternary	O
plasminogen	B-Protein
-	O
S	O
-	O
streptokinase	B-Protein
complex	O
,	O
which	O
then	O
slowly	O
converts	O
to	O
an	O
acylated	O
plasminogen	B-Protein
-	O
streptokinase	B-Protein
form	O
.	O

This	O
acylation	O
reaction	O
is	O
550	O
times	O
slower	O
than	O
acylation	O
of	O
the	O
preformed	O
plasminogen	B-Protein
-	O
streptokinase	B-Protein
complex	O
by	O
NPGB	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
observed	B-X
slow	B-X
,	B-X
non-Michaelis-Menten	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
native	B-X
cat	B-X
plasminogen	B-X
by	B-X
catalytic	B-X
concentrations	B-X
of	B-X
streptokinase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
reasons	B-X
for	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
undertook	B-X
to	B-X
study	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
plasminogen-streptokinase	B-X
activator	B-X
complex	B-X
under	B-X
the	B-X
same	B-X
plasminogen	B-X
activation	B-X
conditions	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
this	B-X
study	B-X
show	B-X
that	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
in	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
strongly	B-X
the	B-X
specific	B-X
substrates	B-X
(	B-X
S	B-X
)	B-X
p-nitrophenyl	B-X
p-guanidinobenzoate	B-X
(	B-X
NPGB	B-X
)	B-X
and	B-X
H-D-valyl-L-leucyl-L-lysyl-p-nitroanilide	B-X
,	B-X
through	B-X
the	B-X
active	B-X
site	B-X
is	B-X
incapable	B-X
of	B-X
hydrolyzing	B-X
these	B-X
substrates	B-X
.	B-X
Streptokinase	B-X
binds	B-X
to	B-X
this	B-X
zymogen-substrate	B-X
complex	B-X
to	B-X
create	B-X
the	B-X
ternary	B-X
plasminogen-S-streptokinase	B-X
complex	B-X
,	B-X
which	B-X
then	B-X
slowly	B-X
converts	B-X
to	B-X
an	B-X
acylated	B-X
plasminogen-streptokinase	B-X
form	B-X
.	B-X
This	B-X
acylation	B-X
reaction	B-X
is	B-X
550	B-X
times	B-X
slower	B-X
than	B-X
acylation	B-X
of	B-X
the	B-X
preformed	B-X
plasminogen-streptokinase	B-X
complex	B-X
by	B-X
NPGB	B-X
.	B-X
The	B-X
same	B-X
reaction	B-X
also	B-X
occurs	B-X
with	B-X
human	B-X
plasminogen	B-X
,	B-X
though	B-X
the	B-X
acylation	B-X
reaction	B-X
is	B-X
10	B-X
times	B-X
faster	B-X
than	B-X
when	B-X
the	B-X
cat	B-X
zymogen	B-X
is	B-X
used	B-X
.	B-X
NPGB	B-X
binds	B-X
specifically	B-X
to	B-X
plasminogen	B-X
but	B-X
not	B-X
to	B-X
streptokinase	B-X
.	B-X
These	B-X
studies	B-X
proved	B-X
that	B-X
inhibition	B-X
of	B-X
cat	B-X
plasminogen	B-X
activation	B-X
by	B-X
streptokinase	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
activator	B-X
complex	B-X
formation	B-X
.	B-X
We	B-X
conclude	B-X
from	B-X
our	B-X
studies	B-X
that	B-X
streptokinase	B-X
binding	B-X
to	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
occurs	B-X
at	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
of	B-X
the	B-X
zymogen	B-X
.	B-X
Consequently	B-X
,	B-X
it	B-X
is	B-X
probable	B-X
that	B-X
plasminogen	B-X
activation	B-X
in	B-X
vivo	B-X
is	B-X
inhibited	B-X
by	B-X
binding	B-X
of	B-X
active	B-X
site	B-X
specific	B-X
inhibitors	B-X
to	B-X
plasminogen	B-X
.	B-X

The	O
same	O
reaction	O
also	O
occurs	O
with	O
human	O
plasminogen	B-Protein
,	O
though	O
the	O
acylation	O
reaction	O
is	O
10	O
times	O
faster	O
than	O
when	O
the	O
cat	O
zymogen	O
is	O
used	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
observed	B-X
slow	B-X
,	B-X
non-Michaelis-Menten	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
native	B-X
cat	B-X
plasminogen	B-X
by	B-X
catalytic	B-X
concentrations	B-X
of	B-X
streptokinase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
reasons	B-X
for	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
undertook	B-X
to	B-X
study	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
plasminogen-streptokinase	B-X
activator	B-X
complex	B-X
under	B-X
the	B-X
same	B-X
plasminogen	B-X
activation	B-X
conditions	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
this	B-X
study	B-X
show	B-X
that	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
in	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
strongly	B-X
the	B-X
specific	B-X
substrates	B-X
(	B-X
S	B-X
)	B-X
p-nitrophenyl	B-X
p-guanidinobenzoate	B-X
(	B-X
NPGB	B-X
)	B-X
and	B-X
H-D-valyl-L-leucyl-L-lysyl-p-nitroanilide	B-X
,	B-X
through	B-X
the	B-X
active	B-X
site	B-X
is	B-X
incapable	B-X
of	B-X
hydrolyzing	B-X
these	B-X
substrates	B-X
.	B-X
Streptokinase	B-X
binds	B-X
to	B-X
this	B-X
zymogen-substrate	B-X
complex	B-X
to	B-X
create	B-X
the	B-X
ternary	B-X
plasminogen-S-streptokinase	B-X
complex	B-X
,	B-X
which	B-X
then	B-X
slowly	B-X
converts	B-X
to	B-X
an	B-X
acylated	B-X
plasminogen-streptokinase	B-X
form	B-X
.	B-X
This	B-X
acylation	B-X
reaction	B-X
is	B-X
550	B-X
times	B-X
slower	B-X
than	B-X
acylation	B-X
of	B-X
the	B-X
preformed	B-X
plasminogen-streptokinase	B-X
complex	B-X
by	B-X
NPGB	B-X
.	B-X
The	B-X
same	B-X
reaction	B-X
also	B-X
occurs	B-X
with	B-X
human	B-X
plasminogen	B-X
,	B-X
though	B-X
the	B-X
acylation	B-X
reaction	B-X
is	B-X
10	B-X
times	B-X
faster	B-X
than	B-X
when	B-X
the	B-X
cat	B-X
zymogen	B-X
is	B-X
used	B-X
.	B-X
NPGB	B-X
binds	B-X
specifically	B-X
to	B-X
plasminogen	B-X
but	B-X
not	B-X
to	B-X
streptokinase	B-X
.	B-X
These	B-X
studies	B-X
proved	B-X
that	B-X
inhibition	B-X
of	B-X
cat	B-X
plasminogen	B-X
activation	B-X
by	B-X
streptokinase	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
activator	B-X
complex	B-X
formation	B-X
.	B-X
We	B-X
conclude	B-X
from	B-X
our	B-X
studies	B-X
that	B-X
streptokinase	B-X
binding	B-X
to	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
occurs	B-X
at	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
of	B-X
the	B-X
zymogen	B-X
.	B-X
Consequently	B-X
,	B-X
it	B-X
is	B-X
probable	B-X
that	B-X
plasminogen	B-X
activation	B-X
in	B-X
vivo	B-X
is	B-X
inhibited	B-X
by	B-X
binding	B-X
of	B-X
active	B-X
site	B-X
specific	B-X
inhibitors	B-X
to	B-X
plasminogen	B-X
.	B-X

NPGB	O
binds	O
specifically	O
to	O
plasminogen	B-Protein
but	O
not	O
to	O
streptokinase	B-Protein
.	O

These	O
studies	O
proved	O
that	O
inhibition	O
of	O
cat	O
plasminogen	B-Protein
activation	O
by	O
streptokinase	B-Protein
occurs	O
at	O
the	O
level	O
of	O
activator	O
complex	O
formation	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
observed	B-X
slow	B-X
,	B-X
non-Michaelis-Menten	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
native	B-X
cat	B-X
plasminogen	B-X
by	B-X
catalytic	B-X
concentrations	B-X
of	B-X
streptokinase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
reasons	B-X
for	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
undertook	B-X
to	B-X
study	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
plasminogen-streptokinase	B-X
activator	B-X
complex	B-X
under	B-X
the	B-X
same	B-X
plasminogen	B-X
activation	B-X
conditions	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
this	B-X
study	B-X
show	B-X
that	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
in	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
strongly	B-X
the	B-X
specific	B-X
substrates	B-X
(	B-X
S	B-X
)	B-X
p-nitrophenyl	B-X
p-guanidinobenzoate	B-X
(	B-X
NPGB	B-X
)	B-X
and	B-X
H-D-valyl-L-leucyl-L-lysyl-p-nitroanilide	B-X
,	B-X
through	B-X
the	B-X
active	B-X
site	B-X
is	B-X
incapable	B-X
of	B-X
hydrolyzing	B-X
these	B-X
substrates	B-X
.	B-X
Binding	B-X
studies	B-X
support	B-X
these	B-X
and	B-X
the	B-X
following	B-X
conclusions	B-X
.	B-X
Streptokinase	B-X
binds	B-X
to	B-X
this	B-X
zymogen-substrate	B-X
complex	B-X
to	B-X
create	B-X
the	B-X
ternary	B-X
plasminogen-S-streptokinase	B-X
complex	B-X
,	B-X
which	B-X
then	B-X
slowly	B-X
converts	B-X
to	B-X
an	B-X
acylated	B-X
plasminogen-streptokinase	B-X
form	B-X
.	B-X
This	B-X
acylation	B-X
reaction	B-X
is	B-X
550	B-X
times	B-X
slower	B-X
than	B-X
acylation	B-X
of	B-X
the	B-X
preformed	B-X
plasminogen-streptokinase	B-X
complex	B-X
by	B-X
NPGB	B-X
.	B-X
The	B-X
same	B-X
reaction	B-X
also	B-X
occurs	B-X
with	B-X
human	B-X
plasminogen	B-X
,	B-X
though	B-X
the	B-X
acylation	B-X
reaction	B-X
is	B-X
10	B-X
times	B-X
faster	B-X
than	B-X
when	B-X
the	B-X
cat	B-X
zymogen	B-X
is	B-X
used	B-X
.	B-X
NPGB	B-X
binds	B-X
specifically	B-X
to	B-X
plasminogen	B-X
but	B-X
not	B-X
to	B-X
streptokinase	B-X
.	B-X
These	B-X
studies	B-X
proved	B-X
that	B-X
inhibition	B-X
of	B-X
cat	B-X
plasminogen	B-X
activation	B-X
by	B-X
streptokinase	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
activator	B-X
complex	B-X
formation	B-X
.	B-X
We	B-X
conclude	B-X
from	B-X
our	B-X
studies	B-X
that	B-X
streptokinase	B-X
binding	B-X
to	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
occurs	B-X
at	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
of	B-X
the	B-X
zymogen	B-X
.	B-X
Consequently	B-X
,	B-X
it	B-X
is	B-X
probable	B-X
that	B-X
plasminogen	B-X
activation	B-X
in	B-X
vivo	B-X
is	B-X
inhibited	B-X
by	B-X
binding	B-X
of	B-X
active	B-X
site	B-X
specific	B-X
inhibitors	B-X
to	B-X
plasminogen	B-X
.	B-X

We	O
conclude	O
from	O
our	O
studies	O
that	O
streptokinase	B-Protein
binding	O
to	O
both	O
cat	O
and	O
human	O
plasminogen	B-Protein
occurs	O
at	O
the	O
potential	O
active	O
site	O
of	O
the	O
zymogen	O
.	O

Consequently	O
,	O
it	O
is	O
probable	O
that	O
plasminogen	B-Protein
activation	O
in	O
vivo	O
is	O
inhibited	O
by	O
binding	O
of	O
active	O
site	O
specific	O
inhibitors	O
to	O
plasminogen	B-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
observed	B-X
slow	B-X
,	B-X
non-Michaelis-Menten	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
native	B-X
cat	B-X
plasminogen	B-X
by	B-X
catalytic	B-X
concentrations	B-X
of	B-X
streptokinase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
reasons	B-X
for	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
undertook	B-X
to	B-X
study	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
plasminogen-streptokinase	B-X
activator	B-X
complex	B-X
under	B-X
the	B-X
same	B-X
plasminogen	B-X
activation	B-X
conditions	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
this	B-X
study	B-X
show	B-X
that	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
in	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
is	B-X
capable	B-X
of	B-X
binding	B-X
strongly	B-X
the	B-X
specific	B-X
substrates	B-X
(	B-X
S	B-X
)	B-X
p-nitrophenyl	B-X
p-guanidinobenzoate	B-X
(	B-X
NPGB	B-X
)	B-X
and	B-X
H-D-valyl-L-leucyl-L-lysyl-p-nitroanilide	B-X
,	B-X
through	B-X
the	B-X
active	B-X
site	B-X
is	B-X
incapable	B-X
of	B-X
hydrolyzing	B-X
these	B-X
substrates	B-X
.	B-X
Streptokinase	B-X
binds	B-X
to	B-X
this	B-X
zymogen-substrate	B-X
complex	B-X
to	B-X
create	B-X
the	B-X
ternary	B-X
plasminogen-S-streptokinase	B-X
complex	B-X
,	B-X
which	B-X
then	B-X
slowly	B-X
converts	B-X
to	B-X
an	B-X
acylated	B-X
plasminogen-streptokinase	B-X
form	B-X
.	B-X
This	B-X
acylation	B-X
reaction	B-X
is	B-X
550	B-X
times	B-X
slower	B-X
than	B-X
acylation	B-X
of	B-X
the	B-X
preformed	B-X
plasminogen-streptokinase	B-X
complex	B-X
by	B-X
NPGB	B-X
.	B-X
The	B-X
same	B-X
reaction	B-X
also	B-X
occurs	B-X
with	B-X
human	B-X
plasminogen	B-X
,	B-X
though	B-X
the	B-X
acylation	B-X
reaction	B-X
is	B-X
10	B-X
times	B-X
faster	B-X
than	B-X
when	B-X
the	B-X
cat	B-X
zymogen	B-X
is	B-X
used	B-X
.	B-X
NPGB	B-X
binds	B-X
specifically	B-X
to	B-X
plasminogen	B-X
but	B-X
not	B-X
to	B-X
streptokinase	B-X
.	B-X
These	B-X
studies	B-X
proved	B-X
that	B-X
inhibition	B-X
of	B-X
cat	B-X
plasminogen	B-X
activation	B-X
by	B-X
streptokinase	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
activator	B-X
complex	B-X
formation	B-X
.	B-X
We	B-X
conclude	B-X
from	B-X
our	B-X
studies	B-X
that	B-X
streptokinase	B-X
binding	B-X
to	B-X
both	B-X
cat	B-X
and	B-X
human	B-X
plasminogen	B-X
occurs	B-X
at	B-X
the	B-X
potential	B-X
active	B-X
site	B-X
of	B-X
the	B-X
zymogen	B-X
.	B-X
Consequently	B-X
,	B-X
it	B-X
is	B-X
probable	B-X
that	B-X
plasminogen	B-X
activation	B-X
in	B-X
vivo	B-X
is	B-X
inhibited	B-X
by	B-X
binding	B-X
of	B-X
active	B-X
site	B-X
specific	B-X
inhibitors	B-X
to	B-X
plasminogen	B-X
.	B-X

Biosynthesis	O
of	O
GlyCAM	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
mucin	O
-	O
like	O
ligand	O
for	O
L	B-Protein
-	I-Protein
selectin	I-Protein
.	O
<EOS>	B-X
L-selectin	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
selectin	B-X
family	B-X
of	B-X
leukocyte-endothelial	B-X
adhesion	B-X
proteins	B-X
,	B-X
mediates	B-X
the	B-X
initial	B-X
attachment	B-X
of	B-X
lymphocytes	B-X
to	B-X
lymph	B-X
node	B-X
high	B-X
endothelial	B-X
venules	B-X
during	B-X
lymphocyte	B-X
recirculation	B-X
.	B-X
One	B-X
of	B-X
the	B-X
endothelial-associated	B-X
ligands	B-X
for	B-X
L-selectin	B-X
is	B-X
GlyCAM-1	B-X
,	B-X
a	B-X
mucin-like	B-X
glycoprotein	B-X
,	B-X
which	B-X
presents	B-X
novel	B-X
sulfated	B-X
,	B-X
sialylated	B-X
and	B-X
fucosylated	B-X
O-glycans	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
generation	B-X
of	B-X
these	B-X
glycans	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
biosynthesis	B-X
of	B-X
GlyCAM-1	B-X
in	B-X
lymph	B-X
node	B-X
organ	B-X
culture	B-X
.	B-X
Using	B-X
peptide-specific	B-X
antibodies	B-X
,	B-X
lectins	B-X
,	B-X
and	B-X
recombinant	B-X
L-selectin	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
following	B-X
species	B-X
of	B-X
GlyCAM-1	B-X
:	B-X
unglycosylated	B-X
(	B-X
<	B-X
28	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
GalNAc	B-X
only	B-X
(	B-X
28-33	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
sialic	B-X
acid	B-X
,	B-X
fucose	B-X
,	B-X
and	B-X
sulfate	B-X
but	B-X
lacking	B-X
L-selectin	B-X
reactivity	B-X
(	B-X
40-50	B-X
kDa	B-X
)	B-X
;	B-X
and	B-X
mature	B-X
(	B-X
L-selectin-reactive	B-X
)	B-X
ligand	B-X
(	B-X
50-60	B-X
kDa	B-X
)	B-X
.	B-X
Pulse-chase	B-X
labeling	B-X
at	B-X
15	B-X
degrees	B-X
C	B-X
suggested	B-X
that	B-X
GalNAc	B-X
is	B-X
added	B-X
in	B-X
a	B-X
pre-Golgi	B-X
compartment	B-X
.	B-X

L	B-Protein
-	I-Protein
selectin	I-Protein
,	O
a	O
member	O
of	O
the	O
selectin	O
family	O
of	O
leukocyte	O
-	O
endothelial	O
adhesion	O
proteins	O
,	O
mediates	O
the	O
initial	O
attachment	O
of	O
lymphocytes	O
to	O
lymph	O
node	O
high	O
endothelial	O
venules	O
during	O
lymphocyte	O
recirculation	O
.	O
<EOS>	B-X
L-selectin	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
selectin	B-X
family	B-X
of	B-X
leukocyte-endothelial	B-X
adhesion	B-X
proteins	B-X
,	B-X
mediates	B-X
the	B-X
initial	B-X
attachment	B-X
of	B-X
lymphocytes	B-X
to	B-X
lymph	B-X
node	B-X
high	B-X
endothelial	B-X
venules	B-X
during	B-X
lymphocyte	B-X
recirculation	B-X
.	B-X
One	B-X
of	B-X
the	B-X
endothelial-associated	B-X
ligands	B-X
for	B-X
L-selectin	B-X
is	B-X
GlyCAM-1	B-X
,	B-X
a	B-X
mucin-like	B-X
glycoprotein	B-X
,	B-X
which	B-X
presents	B-X
novel	B-X
sulfated	B-X
,	B-X
sialylated	B-X
and	B-X
fucosylated	B-X
O-glycans	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
generation	B-X
of	B-X
these	B-X
glycans	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
biosynthesis	B-X
of	B-X
GlyCAM-1	B-X
in	B-X
lymph	B-X
node	B-X
organ	B-X
culture	B-X
.	B-X
Using	B-X
peptide-specific	B-X
antibodies	B-X
,	B-X
lectins	B-X
,	B-X
and	B-X
recombinant	B-X
L-selectin	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
following	B-X
species	B-X
of	B-X
GlyCAM-1	B-X
:	B-X
unglycosylated	B-X
(	B-X
<	B-X
28	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
GalNAc	B-X
only	B-X
(	B-X
28-33	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
sialic	B-X
acid	B-X
,	B-X
fucose	B-X
,	B-X
and	B-X
sulfate	B-X
but	B-X
lacking	B-X
L-selectin	B-X
reactivity	B-X
(	B-X
40-50	B-X
kDa	B-X
)	B-X
;	B-X
and	B-X
mature	B-X
(	B-X
L-selectin-reactive	B-X
)	B-X
ligand	B-X
(	B-X
50-60	B-X
kDa	B-X
)	B-X
.	B-X
This	B-X
ordering	B-X
will	B-X
help	B-X
to	B-X
identify	B-X
the	B-X
critical	B-X
acceptor	B-X
structures	B-X
recognized	B-X
by	B-X
lymph	B-X
node	B-X
glycosyltransferases	B-X
and	B-X
sulfotransferases	B-X
.	B-X

One	O
of	O
the	O
endothelial	O
-	O
associated	O
ligands	O
for	O
L	B-Protein
-	I-Protein
selectin	I-Protein
is	O
GlyCAM	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
mucin	O
-	O
like	O
glycoprotein	O
,	O
which	O
presents	O
novel	O
sulfated	O
,	O
sialylated	O
and	O
fucosylated	O
O	O
-	O
glycans	O
.	O
<EOS>	B-X
L-selectin	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
selectin	B-X
family	B-X
of	B-X
leukocyte-endothelial	B-X
adhesion	B-X
proteins	B-X
,	B-X
mediates	B-X
the	B-X
initial	B-X
attachment	B-X
of	B-X
lymphocytes	B-X
to	B-X
lymph	B-X
node	B-X
high	B-X
endothelial	B-X
venules	B-X
during	B-X
lymphocyte	B-X
recirculation	B-X
.	B-X
One	B-X
of	B-X
the	B-X
endothelial-associated	B-X
ligands	B-X
for	B-X
L-selectin	B-X
is	B-X
GlyCAM-1	B-X
,	B-X
a	B-X
mucin-like	B-X
glycoprotein	B-X
,	B-X
which	B-X
presents	B-X
novel	B-X
sulfated	B-X
,	B-X
sialylated	B-X
and	B-X
fucosylated	B-X
O-glycans	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
generation	B-X
of	B-X
these	B-X
glycans	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
biosynthesis	B-X
of	B-X
GlyCAM-1	B-X
in	B-X
lymph	B-X
node	B-X
organ	B-X
culture	B-X
.	B-X
Using	B-X
peptide-specific	B-X
antibodies	B-X
,	B-X
lectins	B-X
,	B-X
and	B-X
recombinant	B-X
L-selectin	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
following	B-X
species	B-X
of	B-X
GlyCAM-1	B-X
:	B-X
unglycosylated	B-X
(	B-X
<	B-X
28	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
GalNAc	B-X
only	B-X
(	B-X
28-33	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
sialic	B-X
acid	B-X
,	B-X
fucose	B-X
,	B-X
and	B-X
sulfate	B-X
but	B-X
lacking	B-X
L-selectin	B-X
reactivity	B-X
(	B-X
40-50	B-X
kDa	B-X
)	B-X
;	B-X
and	B-X
mature	B-X
(	B-X
L-selectin-reactive	B-X
)	B-X
ligand	B-X
(	B-X
50-60	B-X
kDa	B-X
)	B-X
.	B-X
Pulse-chase	B-X
labeling	B-X
at	B-X
15	B-X
degrees	B-X
C	B-X
suggested	B-X
that	B-X
GalNAc	B-X
is	B-X
added	B-X
in	B-X
a	B-X
pre-Golgi	B-X
compartment	B-X
.	B-X

In	O
order	O
to	O
understand	O
the	O
generation	O
of	O
these	O
glycans	O
,	O
we	O
have	O
examined	O
the	O
biosynthesis	O
of	O
GlyCAM	B-Protein
-	I-Protein
1	I-Protein
in	O
lymph	O
node	O
organ	O
culture	O
.	O
<EOS>	B-X
L-selectin	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
selectin	B-X
family	B-X
of	B-X
leukocyte-endothelial	B-X
adhesion	B-X
proteins	B-X
,	B-X
mediates	B-X
the	B-X
initial	B-X
attachment	B-X
of	B-X
lymphocytes	B-X
to	B-X
lymph	B-X
node	B-X
high	B-X
endothelial	B-X
venules	B-X
during	B-X
lymphocyte	B-X
recirculation	B-X
.	B-X
One	B-X
of	B-X
the	B-X
endothelial-associated	B-X
ligands	B-X
for	B-X
L-selectin	B-X
is	B-X
GlyCAM-1	B-X
,	B-X
a	B-X
mucin-like	B-X
glycoprotein	B-X
,	B-X
which	B-X
presents	B-X
novel	B-X
sulfated	B-X
,	B-X
sialylated	B-X
and	B-X
fucosylated	B-X
O-glycans	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
generation	B-X
of	B-X
these	B-X
glycans	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
biosynthesis	B-X
of	B-X
GlyCAM-1	B-X
in	B-X
lymph	B-X
node	B-X
organ	B-X
culture	B-X
.	B-X
Using	B-X
peptide-specific	B-X
antibodies	B-X
,	B-X
lectins	B-X
,	B-X
and	B-X
recombinant	B-X
L-selectin	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
following	B-X
species	B-X
of	B-X
GlyCAM-1	B-X
:	B-X
unglycosylated	B-X
(	B-X
<	B-X
28	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
GalNAc	B-X
only	B-X
(	B-X
28-33	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
sialic	B-X
acid	B-X
,	B-X
fucose	B-X
,	B-X
and	B-X
sulfate	B-X
but	B-X
lacking	B-X
L-selectin	B-X
reactivity	B-X
(	B-X
40-50	B-X
kDa	B-X
)	B-X
;	B-X
and	B-X
mature	B-X
(	B-X
L-selectin-reactive	B-X
)	B-X
ligand	B-X
(	B-X
50-60	B-X
kDa	B-X
)	B-X
.	B-X
Pulse-chase	B-X
labeling	B-X
at	B-X
15	B-X
degrees	B-X
C	B-X
suggested	B-X
that	B-X
GalNAc	B-X
is	B-X
added	B-X
in	B-X
a	B-X
pre-Golgi	B-X
compartment	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
sialylation	B-X
precedes	B-X
both	B-X
fucosylation	B-X
and	B-X
sulfation	B-X
during	B-X
biosynthesis	B-X
.	B-X
This	B-X
ordering	B-X
will	B-X
help	B-X
to	B-X
identify	B-X
the	B-X
critical	B-X
acceptor	B-X
structures	B-X
recognized	B-X
by	B-X
lymph	B-X
node	B-X
glycosyltransferases	B-X
and	B-X
sulfotransferases	B-X
.	B-X

Using	O
peptide	O
-	O
specific	O
antibodies	O
,	O
lectins	O
,	O
and	O
recombinant	O
L	B-Protein
-	I-Protein
selectin	I-Protein
,	O
we	O
detected	O
the	O
following	O
species	O
of	O
GlyCAM	B-Protein
-	I-Protein
1	I-Protein
:	O
unglycosylated	O
(	O
<	O
28	O
kDa	O
)	O
;	O
modified	O
with	O
GalNAc	O
only	O
(	O
28	O
-	O
33	O
kDa	O
)	O
;	O
modified	O
with	O
sialic	O
acid	O
,	O
fucose	O
,	O
and	O
sulfate	O
but	O
lacking	O
L	B-Protein
-	I-Protein
selectin	I-Protein
reactivity	O
(	O
40	O
-	O
50	O
kDa	O
)	O
;	O
and	O
mature	O
(	O
L	B-Protein
-	I-Protein
selectin	I-Protein
-	O
reactive	O
)	O
ligand	O
(	O
50	O
-	O
60	O
kDa	O
)	O
.	O
<EOS>	B-X
L-selectin	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
selectin	B-X
family	B-X
of	B-X
leukocyte-endothelial	B-X
adhesion	B-X
proteins	B-X
,	B-X
mediates	B-X
the	B-X
initial	B-X
attachment	B-X
of	B-X
lymphocytes	B-X
to	B-X
lymph	B-X
node	B-X
high	B-X
endothelial	B-X
venules	B-X
during	B-X
lymphocyte	B-X
recirculation	B-X
.	B-X
One	B-X
of	B-X
the	B-X
endothelial-associated	B-X
ligands	B-X
for	B-X
L-selectin	B-X
is	B-X
GlyCAM-1	B-X
,	B-X
a	B-X
mucin-like	B-X
glycoprotein	B-X
,	B-X
which	B-X
presents	B-X
novel	B-X
sulfated	B-X
,	B-X
sialylated	B-X
and	B-X
fucosylated	B-X
O-glycans	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
generation	B-X
of	B-X
these	B-X
glycans	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
biosynthesis	B-X
of	B-X
GlyCAM-1	B-X
in	B-X
lymph	B-X
node	B-X
organ	B-X
culture	B-X
.	B-X
Using	B-X
peptide-specific	B-X
antibodies	B-X
,	B-X
lectins	B-X
,	B-X
and	B-X
recombinant	B-X
L-selectin	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
following	B-X
species	B-X
of	B-X
GlyCAM-1	B-X
:	B-X
unglycosylated	B-X
(	B-X
<	B-X
28	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
GalNAc	B-X
only	B-X
(	B-X
28-33	B-X
kDa	B-X
)	B-X
;	B-X
modified	B-X
with	B-X
sialic	B-X
acid	B-X
,	B-X
fucose	B-X
,	B-X
and	B-X
sulfate	B-X
but	B-X
lacking	B-X
L-selectin	B-X
reactivity	B-X
(	B-X
40-50	B-X
kDa	B-X
)	B-X
;	B-X
and	B-X
mature	B-X
(	B-X
L-selectin-reactive	B-X
)	B-X
ligand	B-X
(	B-X
50-60	B-X
kDa	B-X
)	B-X
.	B-X
Pulse-chase	B-X
labeling	B-X
at	B-X
15	B-X
degrees	B-X
C	B-X
suggested	B-X
that	B-X
GalNAc	B-X
is	B-X
added	B-X
in	B-X
a	B-X
pre-Golgi	B-X
compartment	B-X
.	B-X

Pulse	O
-	O
chase	O
labeling	O
at	O
15	O
degrees	O
C	O
suggested	O
that	O
GalNAc	O
is	O
added	O
in	O
a	O
pre	O
-	O
Golgi	O
compartment	O
.	O

Treatment	O
with	O
brefeldin	O
A	O
almost	O
completely	O
blocked	O
sulfation	O
,	O
indicating	O
that	O
this	O
modification	O
occurs	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
.	O
<EOS>	B-X
Pulse-chase	B-X
labeling	B-X
at	B-X
15	B-X
degrees	B-X
C	B-X
suggested	B-X
that	B-X
GalNAc	B-X
is	B-X
added	B-X
in	B-X
a	B-X
pre-Golgi	B-X
compartment	B-X
.	B-X
Treatment	B-X
with	B-X
brefeldin	B-X
A	B-X
almost	B-X
completely	B-X
blocked	B-X
sulfation	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
modification	B-X
occurs	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
.	B-X
Two	B-X
distinct	B-X
sialylation	B-X
events	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
brefeldin	B-X
A	B-X
,	B-X
while	B-X
fucosylation	B-X
was	B-X
partially	B-X
blocked	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
sialylation	B-X
precedes	B-X
both	B-X
fucosylation	B-X
and	B-X
sulfation	B-X
during	B-X
biosynthesis	B-X
.	B-X
This	B-X
ordering	B-X
will	B-X
help	B-X
to	B-X
identify	B-X
the	B-X
critical	B-X
acceptor	B-X
structures	B-X
recognized	B-X
by	B-X
lymph	B-X
node	B-X
glycosyltransferases	B-X
and	B-X
sulfotransferases	B-X
.	B-X

Two	O
distinct	O
sialylation	O
events	O
occurred	O
in	O
the	O
presence	O
of	O
brefeldin	O
A	O
,	O
while	O
fucosylation	O
was	O
partially	O
blocked	O
.	O
<EOS>	B-X
Treatment	B-X
with	B-X
brefeldin	B-X
A	B-X
almost	B-X
completely	B-X
blocked	B-X
sulfation	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
modification	B-X
occurs	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
.	B-X
Two	B-X
distinct	B-X
sialylation	B-X
events	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
brefeldin	B-X
A	B-X
,	B-X
while	B-X
fucosylation	B-X
was	B-X
partially	B-X
blocked	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
sialylation	B-X
precedes	B-X
both	B-X
fucosylation	B-X
and	B-X
sulfation	B-X
during	B-X
biosynthesis	B-X
.	B-X

We	O
conclude	O
that	O
sialylation	O
precedes	O
both	O
fucosylation	O
and	O
sulfation	O
during	O
biosynthesis	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
generation	B-X
of	B-X
these	B-X
glycans	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
biosynthesis	B-X
of	B-X
GlyCAM-1	B-X
in	B-X
lymph	B-X
node	B-X
organ	B-X
culture	B-X
.	B-X
Treatment	B-X
with	B-X
brefeldin	B-X
A	B-X
almost	B-X
completely	B-X
blocked	B-X
sulfation	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
modification	B-X
occurs	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
.	B-X
Two	B-X
distinct	B-X
sialylation	B-X
events	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
brefeldin	B-X
A	B-X
,	B-X
while	B-X
fucosylation	B-X
was	B-X
partially	B-X
blocked	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
sialylation	B-X
precedes	B-X
both	B-X
fucosylation	B-X
and	B-X
sulfation	B-X
during	B-X
biosynthesis	B-X
.	B-X

This	O
ordering	O
will	O
help	O
to	O
identify	O
the	O
critical	O
acceptor	O
structures	O
recognized	O
by	O
lymph	O
node	O
glycosyltransferases	O
and	O
sulfotransferases	O
.	O
<EOS>	B-X
L-selectin	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
selectin	B-X
family	B-X
of	B-X
leukocyte-endothelial	B-X
adhesion	B-X
proteins	B-X
,	B-X
mediates	B-X
the	B-X
initial	B-X
attachment	B-X
of	B-X
lymphocytes	B-X
to	B-X
lymph	B-X
node	B-X
high	B-X
endothelial	B-X
venules	B-X
during	B-X
lymphocyte	B-X
recirculation	B-X
.	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
generation	B-X
of	B-X
these	B-X
glycans	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
biosynthesis	B-X
of	B-X
GlyCAM-1	B-X
in	B-X
lymph	B-X
node	B-X
organ	B-X
culture	B-X
.	B-X
This	B-X
ordering	B-X
will	B-X
help	B-X
to	B-X
identify	B-X
the	B-X
critical	B-X
acceptor	B-X
structures	B-X
recognized	B-X
by	B-X
lymph	B-X
node	B-X
glycosyltransferases	B-X
and	B-X
sulfotransferases	B-X
.	B-X

Properties	O
of	O
type	B-Protein
II	I-Protein
inositol	I-Protein
polyphosphate	I-Protein
5	I-Protein
-	I-Protein
phosphatase	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
isolated	B-X
additional	B-X
cDNA	B-X
clones	B-X
encoding	B-X
type	B-X
II	B-X
inositol	B-X
polyphosphate	B-X
5-phosphatase	B-X
(	B-X
5-phosphatase	B-X
II	B-X
)	B-X
resulting	B-X
in	B-X
a	B-X
combined	B-X
cDNA	B-X
of	B-X
3076	B-X
nucleotides	B-X
encoding	B-X
a	B-X
protein	B-X
of	B-X
942	B-X
amino	B-X
acids	B-X
.	B-X
The	B-X
5-phosphatase	B-X
II	B-X
hydrolyzed	B-X
both	B-X
Ins	B-X
(	B-X
1,4,5	B-X
)	B-X
P3	B-X
to	B-X
Ins	B-X
(	B-X
1,4	B-X
)	B-X
P2	B-X
and	B-X
the	B-X
phospholipid	B-X
PtdIns	B-X
(	B-X
4,5	B-X
)	B-X
P2	B-X
to	B-X
PtdIns	B-X
(	B-X
4	B-X
)	B-X
P	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
There	B-X
are	B-X
two	B-X
motifs	B-X
highly	B-X
conserved	B-X
between	B-X
types	B-X
I	B-X
and	B-X
II	B-X
5-phosphatase	B-X
and	B-X
several	B-X
other	B-X
proteins	B-X
presumed	B-X
to	B-X
be	B-X
inositol	B-X
phosphatases	B-X
suggesting	B-X
a	B-X
possible	B-X
role	B-X
in	B-X
catalysis	B-X
.	B-X
The	B-X
type	B-X
II	B-X
5-phosphatase	B-X
also	B-X
contains	B-X
homology	B-X
to	B-X
several	B-X
GTPase	B-X
activating	B-X
proteins	B-X
although	B-X
no	B-X
such	B-X
activity	B-X
for	B-X
5-phosphatase	B-X
II	B-X
was	B-X
found	B-X
.	B-X
We	B-X
found	B-X
evidence	B-X
for	B-X
isoprenylation	B-X
by	B-X
demonstrating	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
mevalonate	B-X
into	B-X
native	B-X
but	B-X
not	B-X
C939S	B-X
mutant	B-X
5-phosphatase	B-X
II	B-X
expressed	B-X
in	B-X
Sf9	B-X
insect	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
membrane	B-X
localization	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
5-phosphatase	B-X
II	B-X
toward	B-X
its	B-X
lipid	B-X
substrate	B-X
PtdIns	B-X
(	B-X
4,5	B-X
)	B-X
P2	B-X
is	B-X
reduced	B-X
by	B-X
eliminating	B-X
5-phosphatase	B-X
II	B-X
isoprenylation	B-X
in	B-X
the	B-X
mutant	B-X
C939S	B-X
relative	B-X
to	B-X
the	B-X
native	B-X
enzyme	B-X
.	B-X

We	O
have	O
isolated	O
additional	O
cDNA	O
clones	O
encoding	O
type	B-Protein
II	I-Protein
inositol	I-Protein
polyphosphate	I-Protein
5	I-Protein
-	I-Protein
phosphatase	I-Protein
(	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
)	O
resulting	O
in	O
a	O
combined	O
cDNA	O
of	O
3076	O
nucleotides	O
encoding	O
a	O
protein	O
of	O
942	O
amino	O
acids	O
.	O

The	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
hydrolyzed	O
both	O
Ins	O
(	O
1	O
,	O
4	O
,	O
5	O
)	O
P3	O
to	O
Ins	O
(	O
1	O
,	O
4	O
)	O
P2	O
and	O
the	O
phospholipid	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
to	O
PtdIns	O
(	O
4	O
)	O
P	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

There	O
are	O
two	O
motifs	O
highly	O
conserved	O
between	O
types	B-Protein
I	I-Protein
and	O
II	B-Protein
5	I-Protein
-	I-Protein
phosphatase	I-Protein
and	O
several	O
other	O
proteins	O
presumed	O
to	O
be	O
inositol	O
phosphatases	O
suggesting	O
a	O
possible	O
role	O
in	O
catalysis	O
.	O
<EOS>	B-X
We	B-X
have	B-X
isolated	B-X
additional	B-X
cDNA	B-X
clones	B-X
encoding	B-X
type	B-X
II	B-X
inositol	B-X
polyphosphate	B-X
5-phosphatase	B-X
(	B-X
5-phosphatase	B-X
II	B-X
)	B-X
resulting	B-X
in	B-X
a	B-X
combined	B-X
cDNA	B-X
of	B-X
3076	B-X
nucleotides	B-X
encoding	B-X
a	B-X
protein	B-X
of	B-X
942	B-X
amino	B-X
acids	B-X
.	B-X
The	B-X
5-phosphatase	B-X
II	B-X
hydrolyzed	B-X
both	B-X
Ins	B-X
(	B-X
1,4,5	B-X
)	B-X
P3	B-X
to	B-X
Ins	B-X
(	B-X
1,4	B-X
)	B-X
P2	B-X
and	B-X
the	B-X
phospholipid	B-X
PtdIns	B-X
(	B-X
4,5	B-X
)	B-X
P2	B-X
to	B-X
PtdIns	B-X
(	B-X
4	B-X
)	B-X
P	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
There	B-X
are	B-X
two	B-X
motifs	B-X
highly	B-X
conserved	B-X
between	B-X
types	B-X
I	B-X
and	B-X
II	B-X
5-phosphatase	B-X
and	B-X
several	B-X
other	B-X
proteins	B-X
presumed	B-X
to	B-X
be	B-X
inositol	B-X
phosphatases	B-X
suggesting	B-X
a	B-X
possible	B-X
role	B-X
in	B-X
catalysis	B-X
.	B-X
The	B-X
type	B-X
II	B-X
5-phosphatase	B-X
also	B-X
contains	B-X
homology	B-X
to	B-X
several	B-X
GTPase	B-X
activating	B-X
proteins	B-X
although	B-X
no	B-X
such	B-X
activity	B-X
for	B-X
5-phosphatase	B-X
II	B-X
was	B-X
found	B-X
.	B-X
The	B-X
predicted	B-X
protein	B-X
ends	B-X
with	B-X
the	B-X
sequence	B-X
CNPL	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
isoprenylated	B-X
as	B-X
a	B-X
mechanism	B-X
for	B-X
membrane	B-X
attachment	B-X
.	B-X
We	B-X
found	B-X
evidence	B-X
for	B-X
isoprenylation	B-X
by	B-X
demonstrating	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
mevalonate	B-X
into	B-X
native	B-X
but	B-X
not	B-X
C939S	B-X
mutant	B-X
5-phosphatase	B-X
II	B-X
expressed	B-X
in	B-X
Sf9	B-X
insect	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
membrane	B-X
localization	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
5-phosphatase	B-X
II	B-X
toward	B-X
its	B-X
lipid	B-X
substrate	B-X
PtdIns	B-X
(	B-X
4,5	B-X
)	B-X
P2	B-X
is	B-X
reduced	B-X
by	B-X
eliminating	B-X
5-phosphatase	B-X
II	B-X
isoprenylation	B-X
in	B-X
the	B-X
mutant	B-X
C939S	B-X
relative	B-X
to	B-X
the	B-X
native	B-X
enzyme	B-X
.	B-X

The	O
type	B-Protein
II	I-Protein
5	I-Protein
-	I-Protein
phosphatase	I-Protein
also	O
contains	O
homology	O
to	O
several	O
GTPase	O
activating	O
proteins	O
although	O
no	O
such	O
activity	O
for	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
was	O
found	O
.	O
<EOS>	B-X
We	B-X
have	B-X
isolated	B-X
additional	B-X
cDNA	B-X
clones	B-X
encoding	B-X
type	B-X
II	B-X
inositol	B-X
polyphosphate	B-X
5-phosphatase	B-X
(	B-X
5-phosphatase	B-X
II	B-X
)	B-X
resulting	B-X
in	B-X
a	B-X
combined	B-X
cDNA	B-X
of	B-X
3076	B-X
nucleotides	B-X
encoding	B-X
a	B-X
protein	B-X
of	B-X
942	B-X
amino	B-X
acids	B-X
.	B-X
The	B-X
5-phosphatase	B-X
II	B-X
hydrolyzed	B-X
both	B-X
Ins	B-X
(	B-X
1,4,5	B-X
)	B-X
P3	B-X
to	B-X
Ins	B-X
(	B-X
1,4	B-X
)	B-X
P2	B-X
and	B-X
the	B-X
phospholipid	B-X
PtdIns	B-X
(	B-X
4,5	B-X
)	B-X
P2	B-X
to	B-X
PtdIns	B-X
(	B-X
4	B-X
)	B-X
P	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
There	B-X
are	B-X
two	B-X
motifs	B-X
highly	B-X
conserved	B-X
between	B-X
types	B-X
I	B-X
and	B-X
II	B-X
5-phosphatase	B-X
and	B-X
several	B-X
other	B-X
proteins	B-X
presumed	B-X
to	B-X
be	B-X
inositol	B-X
phosphatases	B-X
suggesting	B-X
a	B-X
possible	B-X
role	B-X
in	B-X
catalysis	B-X
.	B-X
The	B-X
type	B-X
II	B-X
5-phosphatase	B-X
also	B-X
contains	B-X
homology	B-X
to	B-X
several	B-X
GTPase	B-X
activating	B-X
proteins	B-X
although	B-X
no	B-X
such	B-X
activity	B-X
for	B-X
5-phosphatase	B-X
II	B-X
was	B-X
found	B-X
.	B-X
We	B-X
found	B-X
evidence	B-X
for	B-X
isoprenylation	B-X
by	B-X
demonstrating	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
mevalonate	B-X
into	B-X
native	B-X
but	B-X
not	B-X
C939S	B-X
mutant	B-X
5-phosphatase	B-X
II	B-X
expressed	B-X
in	B-X
Sf9	B-X
insect	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
membrane	B-X
localization	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
5-phosphatase	B-X
II	B-X
toward	B-X
its	B-X
lipid	B-X
substrate	B-X
PtdIns	B-X
(	B-X
4,5	B-X
)	B-X
P2	B-X
is	B-X
reduced	B-X
by	B-X
eliminating	B-X
5-phosphatase	B-X
II	B-X
isoprenylation	B-X
in	B-X
the	B-X
mutant	B-X
C939S	B-X
relative	B-X
to	B-X
the	B-X
native	B-X
enzyme	B-X
.	B-X

The	O
predicted	O
protein	O
ends	O
with	O
the	O
sequence	O
CNPL	O
,	O
suggesting	O
that	O
it	O
is	O
isoprenylated	O
as	O
a	O
mechanism	O
for	O
membrane	O
attachment	O
.	O
<EOS>	B-X
We	B-X
have	B-X
isolated	B-X
additional	B-X
cDNA	B-X
clones	B-X
encoding	B-X
type	B-X
II	B-X
inositol	B-X
polyphosphate	B-X
5-phosphatase	B-X
(	B-X
5-phosphatase	B-X
II	B-X
)	B-X
resulting	B-X
in	B-X
a	B-X
combined	B-X
cDNA	B-X
of	B-X
3076	B-X
nucleotides	B-X
encoding	B-X
a	B-X
protein	B-X
of	B-X
942	B-X
amino	B-X
acids	B-X
.	B-X
There	B-X
are	B-X
two	B-X
motifs	B-X
highly	B-X
conserved	B-X
between	B-X
types	B-X
I	B-X
and	B-X
II	B-X
5-phosphatase	B-X
and	B-X
several	B-X
other	B-X
proteins	B-X
presumed	B-X
to	B-X
be	B-X
inositol	B-X
phosphatases	B-X
suggesting	B-X
a	B-X
possible	B-X
role	B-X
in	B-X
catalysis	B-X
.	B-X
The	B-X
type	B-X
II	B-X
5-phosphatase	B-X
also	B-X
contains	B-X
homology	B-X
to	B-X
several	B-X
GTPase	B-X
activating	B-X
proteins	B-X
although	B-X
no	B-X
such	B-X
activity	B-X
for	B-X
5-phosphatase	B-X
II	B-X
was	B-X
found	B-X
.	B-X
The	B-X
predicted	B-X
protein	B-X
ends	B-X
with	B-X
the	B-X
sequence	B-X
CNPL	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
is	B-X
isoprenylated	B-X
as	B-X
a	B-X
mechanism	B-X
for	B-X
membrane	B-X
attachment	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
membrane	B-X
localization	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
5-phosphatase	B-X
II	B-X
toward	B-X
its	B-X
lipid	B-X
substrate	B-X
PtdIns	B-X
(	B-X
4,5	B-X
)	B-X
P2	B-X
is	B-X
reduced	B-X
by	B-X
eliminating	B-X
5-phosphatase	B-X
II	B-X
isoprenylation	B-X
in	B-X
the	B-X
mutant	B-X
C939S	B-X
relative	B-X
to	B-X
the	B-X
native	B-X
enzyme	B-X
.	B-X

We	O
found	O
evidence	O
for	O
isoprenylation	O
by	O
demonstrating	O
incorporation	O
of	O
[	O
3H	O
]	O
mevalonate	O
into	O
native	O
but	O
not	O
C939S	O
mutant	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
expressed	O
in	O
Sf9	O
insect	O
cells	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
membrane	O
localization	O
and	O
the	O
activity	O
of	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
toward	O
its	O
lipid	O
substrate	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
is	O
reduced	O
by	O
eliminating	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
isoprenylation	O
in	O
the	O
mutant	O
C939S	O
relative	O
to	O
the	O
native	O
enzyme	O
.	O

Farnesol	O
is	O
utilized	O
for	O
protein	O
isoprenylation	O
and	O
the	O
biosynthesis	O
of	O
cholesterol	O
in	O
mammalian	O
cells	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
obtained	B-X
indicating	B-X
that	B-X
free	B-X
farnesol	B-X
(	B-X
F-OH	B-X
)	B-X
can	B-X
be	B-X
utilized	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
When	B-X
rat	B-X
C6	B-X
glial	B-X
cells	B-X
and	B-X
an	B-X
African	B-X
green	B-X
monkey	B-X
kidney	B-X
cell	B-X
line	B-X
(	B-X
CV-1	B-X
)	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
,	B-X
radioactivity	B-X
was	B-X
incorporated	B-X
into	B-X
cholesterol	B-X
,	B-X
ubiquinone	B-X
(	B-X
CoQ	B-X
)	B-X
and	B-X
isoprenylated	B-X
proteins	B-X
.	B-X
The	B-X
incorporation	B-X
of	B-X
label	B-X
from	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
into	B-X
cholesterol	B-X
in	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
squalestatin	B-X
1	B-X
(	B-X
SQ	B-X
)	B-X
which	B-X
specifically	B-X
inhibits	B-X
the	B-X
conversion	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
F-P-P	B-X
)	B-X
to	B-X
squalene	B-X
.	B-X
This	B-X
result	B-X
strongly	B-X
suggests	B-X
that	B-X
cholesterol	B-X
,	B-X
and	B-X
probably	B-X
CoQ	B-X
and	B-X
protein	B-X
,	B-X
is	B-X
metabolically	B-X
labeled	B-X
via	B-X
F-P-P.	B-X
SDS-PAGE	B-X
analysis	B-X
of	B-X
the	B-X
delipidated	B-X
protein	B-X
fractions	B-X
from	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
revealed	B-X
several	B-X
labeled	B-X
polypeptides	B-X
.	B-X
Consistent	B-X
with	B-X
these	B-X
proteins	B-X
being	B-X
modified	B-X
by	B-X
isoprenylation	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
A	B-X
different	B-X
set	B-X
of	B-X
polypeptides	B-X
was	B-X
labeled	B-X
when	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
geranylgeraniol	B-X
(	B-X
GG-OH	B-X
)	B-X
.	B-X
Both	B-X
sets	B-X
of	B-X
proteins	B-X
appear	B-X
to	B-X
be	B-X
metabolically	B-X
labeled	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
,	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
-labeled	B-X
F-Cys	B-X
and	B-X
geranylgeranyl-cysteine	B-X
(	B-X
GG-Cys	B-X
)	B-X
were	B-X
liberated	B-X
from	B-X
these	B-X
proteins	B-X
by	B-X
Pronase	B-X
E	B-X
treatment	B-X
.	B-X
These	B-X
cellular	B-X
and	B-X
biochemical	B-X
studies	B-X
indicate	B-X
that	B-X
F-OH	B-X
can	B-X
be	B-X
used	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
and	B-X
protein	B-X
isoprenylation	B-X
in	B-X
mammalian	B-X
cells	B-X
after	B-X
being	B-X
converted	B-X
to	B-X
F-P-P	B-X
by	B-X
phosphorylation	B-X
reactions	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X

Evidence	O
has	O
been	O
obtained	O
indicating	O
that	O
free	O
farnesol	O
(	O
F	O
-	O
OH	O
)	O
can	O
be	O
utilized	O
for	O
isoprenoid	O
biosynthesis	O
in	O
mammalian	O
cells	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
obtained	B-X
indicating	B-X
that	B-X
free	B-X
farnesol	B-X
(	B-X
F-OH	B-X
)	B-X
can	B-X
be	B-X
utilized	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
When	B-X
rat	B-X
C6	B-X
glial	B-X
cells	B-X
and	B-X
an	B-X
African	B-X
green	B-X
monkey	B-X
kidney	B-X
cell	B-X
line	B-X
(	B-X
CV-1	B-X
)	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
,	B-X
radioactivity	B-X
was	B-X
incorporated	B-X
into	B-X
cholesterol	B-X
,	B-X
ubiquinone	B-X
(	B-X
CoQ	B-X
)	B-X
and	B-X
isoprenylated	B-X
proteins	B-X
.	B-X
The	B-X
incorporation	B-X
of	B-X
label	B-X
from	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
into	B-X
cholesterol	B-X
in	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
squalestatin	B-X
1	B-X
(	B-X
SQ	B-X
)	B-X
which	B-X
specifically	B-X
inhibits	B-X
the	B-X
conversion	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
F-P-P	B-X
)	B-X
to	B-X
squalene	B-X
.	B-X
This	B-X
result	B-X
strongly	B-X
suggests	B-X
that	B-X
cholesterol	B-X
,	B-X
and	B-X
probably	B-X
CoQ	B-X
and	B-X
protein	B-X
,	B-X
is	B-X
metabolically	B-X
labeled	B-X
via	B-X
F-P-P.	B-X
SDS-PAGE	B-X
analysis	B-X
of	B-X
the	B-X
delipidated	B-X
protein	B-X
fractions	B-X
from	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
revealed	B-X
several	B-X
labeled	B-X
polypeptides	B-X
.	B-X
Pronase	B-X
E	B-X
digestion	B-X
released	B-X
a	B-X
major	B-X
labeled	B-X
product	B-X
with	B-X
the	B-X
chromatographic	B-X
mobility	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
farnesyl-cysteine	B-X
(	B-X
F-Cys	B-X
)	B-X
.	B-X
A	B-X
different	B-X
set	B-X
of	B-X
polypeptides	B-X
was	B-X
labeled	B-X
when	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
geranylgeraniol	B-X
(	B-X
GG-OH	B-X
)	B-X
.	B-X
Both	B-X
sets	B-X
of	B-X
proteins	B-X
appear	B-X
to	B-X
be	B-X
metabolically	B-X
labeled	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
,	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
-labeled	B-X
F-Cys	B-X
and	B-X
geranylgeranyl-cysteine	B-X
(	B-X
GG-Cys	B-X
)	B-X
were	B-X
liberated	B-X
from	B-X
these	B-X
proteins	B-X
by	B-X
Pronase	B-X
E	B-X
treatment	B-X
.	B-X
These	B-X
cellular	B-X
and	B-X
biochemical	B-X
studies	B-X
indicate	B-X
that	B-X
F-OH	B-X
can	B-X
be	B-X
used	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
and	B-X
protein	B-X
isoprenylation	B-X
in	B-X
mammalian	B-X
cells	B-X
after	B-X
being	B-X
converted	B-X
to	B-X
F-P-P	B-X
by	B-X
phosphorylation	B-X
reactions	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X

When	O
rat	O
C6	O
glial	O
cells	O
and	O
an	O
African	O
green	O
monkey	O
kidney	O
cell	O
line	O
(	O
CV	O
-	O
1	O
)	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
F	O
-	O
OH	O
,	O
radioactivity	O
was	O
incorporated	O
into	O
cholesterol	O
,	O
ubiquinone	O
(	O
CoQ	O
)	O
and	O
isoprenylated	O
proteins	O
.	O

The	O
incorporation	O
of	O
label	O
from	O
[	O
3H	O
]	O
F	O
-	O
OH	O
into	O
cholesterol	O
in	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
was	O
blocked	O
by	O
squalestatin	O
1	O
(	O
SQ	O
)	O
which	O
specifically	O
inhibits	O
the	O
conversion	O
of	O
farnesyl	O
pyrophosphate	O
(	O
F	O
-	O
P	O
-	O
P	O
)	O
to	O
squalene	O
.	O

This	O
result	O
strongly	O
suggests	O
that	O
cholesterol	O
,	O
and	O
probably	O
CoQ	O
and	O
protein	O
,	O
is	O
metabolically	O
labeled	O
via	O
F	O
-	O
P	O
-	O
P	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
of	O
the	O
delipidated	O
protein	O
fractions	O
from	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
revealed	O
several	O
labeled	O
polypeptides	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
obtained	B-X
indicating	B-X
that	B-X
free	B-X
farnesol	B-X
(	B-X
F-OH	B-X
)	B-X
can	B-X
be	B-X
utilized	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
When	B-X
rat	B-X
C6	B-X
glial	B-X
cells	B-X
and	B-X
an	B-X
African	B-X
green	B-X
monkey	B-X
kidney	B-X
cell	B-X
line	B-X
(	B-X
CV-1	B-X
)	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
,	B-X
radioactivity	B-X
was	B-X
incorporated	B-X
into	B-X
cholesterol	B-X
,	B-X
ubiquinone	B-X
(	B-X
CoQ	B-X
)	B-X
and	B-X
isoprenylated	B-X
proteins	B-X
.	B-X
The	B-X
incorporation	B-X
of	B-X
label	B-X
from	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
into	B-X
cholesterol	B-X
in	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
squalestatin	B-X
1	B-X
(	B-X
SQ	B-X
)	B-X
which	B-X
specifically	B-X
inhibits	B-X
the	B-X
conversion	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
F-P-P	B-X
)	B-X
to	B-X
squalene	B-X
.	B-X
This	B-X
result	B-X
strongly	B-X
suggests	B-X
that	B-X
cholesterol	B-X
,	B-X
and	B-X
probably	B-X
CoQ	B-X
and	B-X
protein	B-X
,	B-X
is	B-X
metabolically	B-X
labeled	B-X
via	B-X
F-P-P.	B-X
SDS-PAGE	B-X
analysis	B-X
of	B-X
the	B-X
delipidated	B-X
protein	B-X
fractions	B-X
from	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
revealed	B-X
several	B-X
labeled	B-X
polypeptides	B-X
.	B-X
Consistent	B-X
with	B-X
these	B-X
proteins	B-X
being	B-X
modified	B-X
by	B-X
isoprenylation	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
Pronase	B-X
E	B-X
digestion	B-X
released	B-X
a	B-X
major	B-X
labeled	B-X
product	B-X
with	B-X
the	B-X
chromatographic	B-X
mobility	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
farnesyl-cysteine	B-X
(	B-X
F-Cys	B-X
)	B-X
.	B-X
A	B-X
different	B-X
set	B-X
of	B-X
polypeptides	B-X
was	B-X
labeled	B-X
when	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
geranylgeraniol	B-X
(	B-X
GG-OH	B-X
)	B-X
.	B-X
Both	B-X
sets	B-X
of	B-X
proteins	B-X
appear	B-X
to	B-X
be	B-X
metabolically	B-X
labeled	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
,	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
-labeled	B-X
F-Cys	B-X
and	B-X
geranylgeranyl-cysteine	B-X
(	B-X
GG-Cys	B-X
)	B-X
were	B-X
liberated	B-X
from	B-X
these	B-X
proteins	B-X
by	B-X
Pronase	B-X
E	B-X
treatment	B-X
.	B-X
These	B-X
cellular	B-X
and	B-X
biochemical	B-X
studies	B-X
indicate	B-X
that	B-X
F-OH	B-X
can	B-X
be	B-X
used	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
and	B-X
protein	B-X
isoprenylation	B-X
in	B-X
mammalian	B-X
cells	B-X
after	B-X
being	B-X
converted	B-X
to	B-X
F-P-P	B-X
by	B-X
phosphorylation	B-X
reactions	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X

Consistent	O
with	O
these	O
proteins	O
being	O
modified	O
by	O
isoprenylation	O
of	O
cysteine	O
residues	O
.	O
<EOS>	B-X
A	B-X
family	B-X
of	B-X
GTP-binding	B-X
regulatory	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
transduces	B-X
signals	B-X
across	B-X
the	B-X
plasma	B-X
membrane	B-X
from	B-X
a	B-X
large	B-X
number	B-X
of	B-X
receptors	B-X
to	B-X
a	B-X
smaller	B-X
number	B-X
of	B-X
effectors	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
G	B-X
protein	B-X
gamma	B-X
subunits	B-X
,	B-X
the	B-X
post-translational	B-X
modifications	B-X
include	B-X
the	B-X
prenylation	B-X
of	B-X
a	B-X
cysteine	B-X
residue	B-X
within	B-X
a	B-X
carboxyl-terminal	B-X
CAAX	B-X
motif	B-X
.	B-X
Although	B-X
prenylation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
involve	B-X
the	B-X
addition	B-X
of	B-X
either	B-X
a	B-X
C15	B-X
farnesyl	B-X
or	B-X
a	B-X
C20	B-X
geranylgeranyl	B-X
group	B-X
to	B-X
proteins	B-X
,	B-X
the	B-X
structural	B-X
requirements	B-X
and	B-X
functional	B-X
consequences	B-X
of	B-X
adding	B-X
different	B-X
types	B-X
of	B-X
prenyl	B-X
groups	B-X
to	B-X
various	B-X
members	B-X
of	B-X
the	B-X
gamma	B-X
subunit	B-X
family	B-X
have	B-X
not	B-X
been	B-X
examined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
gamma	B-X
2	B-X
subunit	B-X
is	B-X
modified	B-X
by	B-X
a	B-X
C20	B-X
geranylgeranyl	B-X
group	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
geranylgeranylation	B-X
target	B-X
sequence	B-X
in	B-X
this	B-X
protein	B-X
.	B-X
However	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
gamma	B-X
1	B-X
and	B-X
mutant	B-X
gamma	B-X
2	B-X
(	B-X
Ser-71	B-X
)	B-X
subunits	B-X
are	B-X
modified	B-X
by	B-X
both	B-X
C15	B-X
farnesyl	B-X
and	B-X
C20	B-X
geranylgeranyl	B-X
groups	B-X
,	B-X
despite	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
accepted	B-X
farnesylation	B-X
target	B-X
sequence	B-X
in	B-X
both	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X

Pronase	O
E	O
digestion	O
released	O
a	O
major	O
labeled	O
product	O
with	O
the	O
chromatographic	O
mobility	O
of	O
[	O
3H	O
]	O
farnesyl	O
-	O
cysteine	O
(	O
F	O
-	O
Cys	O
)	O
.	O

A	O
different	O
set	O
of	O
polypeptides	O
was	O
labeled	O
when	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
geranylgeraniol	O
(	O
GG	O
-	O
OH	O
)	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
obtained	B-X
indicating	B-X
that	B-X
free	B-X
farnesol	B-X
(	B-X
F-OH	B-X
)	B-X
can	B-X
be	B-X
utilized	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
When	B-X
rat	B-X
C6	B-X
glial	B-X
cells	B-X
and	B-X
an	B-X
African	B-X
green	B-X
monkey	B-X
kidney	B-X
cell	B-X
line	B-X
(	B-X
CV-1	B-X
)	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
,	B-X
radioactivity	B-X
was	B-X
incorporated	B-X
into	B-X
cholesterol	B-X
,	B-X
ubiquinone	B-X
(	B-X
CoQ	B-X
)	B-X
and	B-X
isoprenylated	B-X
proteins	B-X
.	B-X
The	B-X
incorporation	B-X
of	B-X
label	B-X
from	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
into	B-X
cholesterol	B-X
in	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
squalestatin	B-X
1	B-X
(	B-X
SQ	B-X
)	B-X
which	B-X
specifically	B-X
inhibits	B-X
the	B-X
conversion	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
F-P-P	B-X
)	B-X
to	B-X
squalene	B-X
.	B-X
This	B-X
result	B-X
strongly	B-X
suggests	B-X
that	B-X
cholesterol	B-X
,	B-X
and	B-X
probably	B-X
CoQ	B-X
and	B-X
protein	B-X
,	B-X
is	B-X
metabolically	B-X
labeled	B-X
via	B-X
F-P-P.	B-X
SDS-PAGE	B-X
analysis	B-X
of	B-X
the	B-X
delipidated	B-X
protein	B-X
fractions	B-X
from	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
revealed	B-X
several	B-X
labeled	B-X
polypeptides	B-X
.	B-X
Pronase	B-X
E	B-X
digestion	B-X
released	B-X
a	B-X
major	B-X
labeled	B-X
product	B-X
with	B-X
the	B-X
chromatographic	B-X
mobility	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
farnesyl-cysteine	B-X
(	B-X
F-Cys	B-X
)	B-X
.	B-X
A	B-X
different	B-X
set	B-X
of	B-X
polypeptides	B-X
was	B-X
labeled	B-X
when	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
geranylgeraniol	B-X
(	B-X
GG-OH	B-X
)	B-X
.	B-X
Both	B-X
sets	B-X
of	B-X
proteins	B-X
appear	B-X
to	B-X
be	B-X
metabolically	B-X
labeled	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
,	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
-labeled	B-X
F-Cys	B-X
and	B-X
geranylgeranyl-cysteine	B-X
(	B-X
GG-Cys	B-X
)	B-X
were	B-X
liberated	B-X
from	B-X
these	B-X
proteins	B-X
by	B-X
Pronase	B-X
E	B-X
treatment	B-X
.	B-X
These	B-X
cellular	B-X
and	B-X
biochemical	B-X
studies	B-X
indicate	B-X
that	B-X
F-OH	B-X
can	B-X
be	B-X
used	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
and	B-X
protein	B-X
isoprenylation	B-X
in	B-X
mammalian	B-X
cells	B-X
after	B-X
being	B-X
converted	B-X
to	B-X
F-P-P	B-X
by	B-X
phosphorylation	B-X
reactions	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X

Both	O
sets	O
of	O
proteins	O
appear	O
to	O
be	O
metabolically	O
labeled	O
by	O
[	O
3H	O
]	O
mevalonolactone	O
,	O
and	O
[	O
3H	O
]	O
-	O
labeled	O
F	O
-	O
Cys	O
and	O
geranylgeranyl	O
-	O
cysteine	O
(	O
GG	O
-	O
Cys	O
)	O
were	O
liberated	O
from	O
these	O
proteins	O
by	O
Pronase	O
E	O
treatment	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
obtained	B-X
indicating	B-X
that	B-X
free	B-X
farnesol	B-X
(	B-X
F-OH	B-X
)	B-X
can	B-X
be	B-X
utilized	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
When	B-X
rat	B-X
C6	B-X
glial	B-X
cells	B-X
and	B-X
an	B-X
African	B-X
green	B-X
monkey	B-X
kidney	B-X
cell	B-X
line	B-X
(	B-X
CV-1	B-X
)	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
,	B-X
radioactivity	B-X
was	B-X
incorporated	B-X
into	B-X
cholesterol	B-X
,	B-X
ubiquinone	B-X
(	B-X
CoQ	B-X
)	B-X
and	B-X
isoprenylated	B-X
proteins	B-X
.	B-X
The	B-X
incorporation	B-X
of	B-X
label	B-X
from	B-X
[	B-X
3H	B-X
]	B-X
F-OH	B-X
into	B-X
cholesterol	B-X
in	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
squalestatin	B-X
1	B-X
(	B-X
SQ	B-X
)	B-X
which	B-X
specifically	B-X
inhibits	B-X
the	B-X
conversion	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
F-P-P	B-X
)	B-X
to	B-X
squalene	B-X
.	B-X
This	B-X
result	B-X
strongly	B-X
suggests	B-X
that	B-X
cholesterol	B-X
,	B-X
and	B-X
probably	B-X
CoQ	B-X
and	B-X
protein	B-X
,	B-X
is	B-X
metabolically	B-X
labeled	B-X
via	B-X
F-P-P.	B-X
SDS-PAGE	B-X
analysis	B-X
of	B-X
the	B-X
delipidated	B-X
protein	B-X
fractions	B-X
from	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
revealed	B-X
several	B-X
labeled	B-X
polypeptides	B-X
.	B-X
Consistent	B-X
with	B-X
these	B-X
proteins	B-X
being	B-X
modified	B-X
by	B-X
isoprenylation	B-X
of	B-X
cysteine	B-X
residues	B-X
.	B-X
Pronase	B-X
E	B-X
digestion	B-X
released	B-X
a	B-X
major	B-X
labeled	B-X
product	B-X
with	B-X
the	B-X
chromatographic	B-X
mobility	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
farnesyl-cysteine	B-X
(	B-X
F-Cys	B-X
)	B-X
.	B-X
A	B-X
different	B-X
set	B-X
of	B-X
polypeptides	B-X
was	B-X
labeled	B-X
when	B-X
C6	B-X
and	B-X
CV-1	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
geranylgeraniol	B-X
(	B-X
GG-OH	B-X
)	B-X
.	B-X
Both	B-X
sets	B-X
of	B-X
proteins	B-X
appear	B-X
to	B-X
be	B-X
metabolically	B-X
labeled	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
,	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
-labeled	B-X
F-Cys	B-X
and	B-X
geranylgeranyl-cysteine	B-X
(	B-X
GG-Cys	B-X
)	B-X
were	B-X
liberated	B-X
from	B-X
these	B-X
proteins	B-X
by	B-X
Pronase	B-X
E	B-X
treatment	B-X
.	B-X
These	B-X
cellular	B-X
and	B-X
biochemical	B-X
studies	B-X
indicate	B-X
that	B-X
F-OH	B-X
can	B-X
be	B-X
used	B-X
for	B-X
isoprenoid	B-X
biosynthesis	B-X
and	B-X
protein	B-X
isoprenylation	B-X
in	B-X
mammalian	B-X
cells	B-X
after	B-X
being	B-X
converted	B-X
to	B-X
F-P-P	B-X
by	B-X
phosphorylation	B-X
reactions	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X

These	O
cellular	O
and	O
biochemical	O
studies	O
indicate	O
that	O
F	O
-	O
OH	O
can	O
be	O
used	O
for	O
isoprenoid	O
biosynthesis	O
and	O
protein	O
isoprenylation	O
in	O
mammalian	O
cells	O
after	O
being	O
converted	O
to	O
F	O
-	O
P	O
-	O
P	O
by	O
phosphorylation	O
reactions	O
that	O
remain	O
to	O
be	O
elucidated	O
.	O

ADP	O
-	O
ribosylation	O
of	O
Rhizobium	O
meliloti	O
glutamine	B-Protein
synthetase	I-Protein
III	I-Protein
in	O
vivo	O
.	O
<EOS>	B-X
The	B-X
control	B-X
of	B-X
glutamine	B-X
synthetase	B-X
(	B-X
GS	B-X
)	B-X
,	B-X
the	B-X
first	B-X
enzyme	B-X
in	B-X
the	B-X
main	B-X
pathway	B-X
used	B-X
by	B-X
Rhizobium	B-X
meliloti	B-X
to	B-X
assimilate	B-X
ammonia	B-X
,	B-X
is	B-X
central	B-X
to	B-X
cellular	B-X
nitrogen	B-X
metabolism	B-X
.	B-X
R.	B-X
meliloti	B-X
is	B-X
unusual	B-X
in	B-X
having	B-X
three	B-X
distinct	B-X
types	B-X
of	B-X
GS	B-X
,	B-X
including	B-X
a	B-X
unique	B-X
GS	B-X
,	B-X
GSIII	B-X
,	B-X
that	B-X
differs	B-X
considerably	B-X
from	B-X
both	B-X
GSI	B-X
,	B-X
which	B-X
resembles	B-X
other	B-X
bacterial	B-X
GS	B-X
proteins	B-X
and	B-X
GSII	B-X
,	B-X
which	B-X
resembles	B-X
the	B-X
GS	B-X
found	B-X
in	B-X
eukaryotes	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
GSIII	B-X
can	B-X
be	B-X
post-translationally	B-X
modified	B-X
in	B-X
vivo	B-X
by	B-X
ADP-ribosylation	B-X
at	B-X
an	B-X
arginine	B-X
residue	B-X
.	B-X
32PO4	B-X
attached	B-X
to	B-X
GSIII	B-X
during	B-X
bacterial	B-X
growth	B-X
as	B-X
part	B-X
of	B-X
the	B-X
modifying	B-X
group	B-X
could	B-X
be	B-X
removed	B-X
by	B-X
treatment	B-X
with	B-X
snake	B-X
venom	B-X
phosphodiesterase	B-X
or	B-X
by	B-X
turkey	B-X
erythrocyte	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
.	B-X
Treatment	B-X
of	B-X
modified	B-X
GSIII	B-X
with	B-X
hydroxylamine	B-X
at	B-X
neutral	B-X
pH	B-X
releases	B-X
a	B-X
chromophore	B-X
that	B-X
has	B-X
the	B-X
retention	B-X
time	B-X
of	B-X
ADP-ribose	B-X
when	B-X
analyzed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
ADP-ribosylation	B-X
inhibits	B-X
GSIII	B-X
activity	B-X
.	B-X

The	O
control	O
of	O
glutamine	O
synthetase	O
(	O
GS	O
)	O
,	O
the	O
first	O
enzyme	O
in	O
the	O
main	O
pathway	O
used	O
by	O
Rhizobium	O
meliloti	O
to	O
assimilate	O
ammonia	O
,	O
is	O
central	O
to	O
cellular	O
nitrogen	O
metabolism	O
.	O
<EOS>	B-X
The	B-X
control	B-X
of	B-X
glutamine	B-X
synthetase	B-X
(	B-X
GS	B-X
)	B-X
,	B-X
the	B-X
first	B-X
enzyme	B-X
in	B-X
the	B-X
main	B-X
pathway	B-X
used	B-X
by	B-X
Rhizobium	B-X
meliloti	B-X
to	B-X
assimilate	B-X
ammonia	B-X
,	B-X
is	B-X
central	B-X
to	B-X
cellular	B-X
nitrogen	B-X
metabolism	B-X
.	B-X
R.	B-X
meliloti	B-X
is	B-X
unusual	B-X
in	B-X
having	B-X
three	B-X
distinct	B-X
types	B-X
of	B-X
GS	B-X
,	B-X
including	B-X
a	B-X
unique	B-X
GS	B-X
,	B-X
GSIII	B-X
,	B-X
that	B-X
differs	B-X
considerably	B-X
from	B-X
both	B-X
GSI	B-X
,	B-X
which	B-X
resembles	B-X
other	B-X
bacterial	B-X
GS	B-X
proteins	B-X
and	B-X
GSII	B-X
,	B-X
which	B-X
resembles	B-X
the	B-X
GS	B-X
found	B-X
in	B-X
eukaryotes	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
GSIII	B-X
can	B-X
be	B-X
post-translationally	B-X
modified	B-X
in	B-X
vivo	B-X
by	B-X
ADP-ribosylation	B-X
at	B-X
an	B-X
arginine	B-X
residue	B-X
.	B-X
32PO4	B-X
attached	B-X
to	B-X
GSIII	B-X
during	B-X
bacterial	B-X
growth	B-X
as	B-X
part	B-X
of	B-X
the	B-X
modifying	B-X
group	B-X
could	B-X
be	B-X
removed	B-X
by	B-X
treatment	B-X
with	B-X
snake	B-X
venom	B-X
phosphodiesterase	B-X
or	B-X
by	B-X
turkey	B-X
erythrocyte	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
.	B-X
Treatment	B-X
of	B-X
modified	B-X
GSIII	B-X
with	B-X
hydroxylamine	B-X
at	B-X
neutral	B-X
pH	B-X
releases	B-X
a	B-X
chromophore	B-X
that	B-X
has	B-X
the	B-X
retention	B-X
time	B-X
of	B-X
ADP-ribose	B-X
when	B-X
analyzed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
ADP-ribosylation	B-X
inhibits	B-X
GSIII	B-X
activity	B-X
.	B-X

R	O
.	O
meliloti	O
is	O
unusual	O
in	O
having	O
three	O
distinct	O
types	O
of	O
GS	O
,	O
including	O
a	O
unique	O
GS	O
,	O
GSIII	B-Protein
,	O
that	O
differs	O
considerably	O
from	O
both	O
GSI	B-Protein
,	O
which	O
resembles	O
other	O
bacterial	O
GS	O
proteins	O
and	O
GSII	B-Protein
,	O
which	O
resembles	O
the	O
GS	O
found	O
in	O
eukaryotes	O
.	O

We	O
show	O
here	O
that	O
GSIII	B-Protein
can	O
be	O
post	O
-	O
translationally	O
modified	O
in	O
vivo	O
by	O
ADP	O
-	O
ribosylation	O
at	O
an	O
arginine	O
residue	O
.	O
<EOS>	B-X
R.	B-X
meliloti	B-X
is	B-X
unusual	B-X
in	B-X
having	B-X
three	B-X
distinct	B-X
types	B-X
of	B-X
GS	B-X
,	B-X
including	B-X
a	B-X
unique	B-X
GS	B-X
,	B-X
GSIII	B-X
,	B-X
that	B-X
differs	B-X
considerably	B-X
from	B-X
both	B-X
GSI	B-X
,	B-X
which	B-X
resembles	B-X
other	B-X
bacterial	B-X
GS	B-X
proteins	B-X
and	B-X
GSII	B-X
,	B-X
which	B-X
resembles	B-X
the	B-X
GS	B-X
found	B-X
in	B-X
eukaryotes	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
GSIII	B-X
can	B-X
be	B-X
post-translationally	B-X
modified	B-X
in	B-X
vivo	B-X
by	B-X
ADP-ribosylation	B-X
at	B-X
an	B-X
arginine	B-X
residue	B-X
.	B-X
32PO4	B-X
attached	B-X
to	B-X
GSIII	B-X
during	B-X
bacterial	B-X
growth	B-X
as	B-X
part	B-X
of	B-X
the	B-X
modifying	B-X
group	B-X
could	B-X
be	B-X
removed	B-X
by	B-X
treatment	B-X
with	B-X
snake	B-X
venom	B-X
phosphodiesterase	B-X
or	B-X
by	B-X
turkey	B-X
erythrocyte	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
.	B-X
Treatment	B-X
of	B-X
modified	B-X
GSIII	B-X
with	B-X
hydroxylamine	B-X
at	B-X
neutral	B-X
pH	B-X
releases	B-X
a	B-X
chromophore	B-X
that	B-X
has	B-X
the	B-X
retention	B-X
time	B-X
of	B-X
ADP-ribose	B-X
when	B-X
analyzed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
ADP-ribosylation	B-X
inhibits	B-X
GSIII	B-X
activity	B-X
.	B-X

32PO4	O
attached	O
to	O
GSIII	B-Protein
during	O
bacterial	O
growth	O
as	O
part	O
of	O
the	O
modifying	O
group	O
could	O
be	O
removed	O
by	O
treatment	O
with	O
snake	O
venom	O
phosphodiesterase	O
or	O
by	O
turkey	O
erythrocyte	O
ADP	B-Protein
-	I-Protein
ribosylarginine	I-Protein
hydrolase	I-Protein
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
reversible	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
involving	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
ADP-ribose	B-X
moiety	B-X
of	B-X
NAD	B-X
to	B-X
an	B-X
acceptor	B-X
protein	B-X
or	B-X
amino	B-X
acid	B-X
.	B-X
NAD	B-X
:	B-X
arginine	B-X
ADP-ribosyltransferase	B-X
,	B-X
purified	B-X
from	B-X
numerous	B-X
animal	B-X
tissues	B-X
,	B-X
catalyzes	B-X
the	B-X
transfer	B-X
of	B-X
ADP-ribose	B-X
to	B-X
an	B-X
arginine	B-X
residue	B-X
in	B-X
proteins	B-X
.	B-X
The	B-X
reverse	B-X
reaction	B-X
,	B-X
catalyzed	B-X
by	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
,	B-X
removes	B-X
ADP-ribose	B-X
,	B-X
regenerating	B-X
free	B-X
arginine	B-X
.	B-X
An	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
,	B-X
purified	B-X
extensively	B-X
from	B-X
turkey	B-X
erythrocytes	B-X
,	B-X
was	B-X
a	B-X
39-kDa	B-X
monomeric	B-X
protein	B-X
under	B-X
denaturing	B-X
and	B-X
non-denaturing	B-X
conditions	B-X
,	B-X
and	B-X
was	B-X
activated	B-X
by	B-X
Mg2+	B-X
and	B-X
dithiothreitol	B-X
.	B-X
The	B-X
ADP-ribose	B-X
moiety	B-X
was	B-X
critical	B-X
for	B-X
substrate	B-X
recognition	B-X
;	B-X
the	B-X
enzyme	B-X
hydrolyzed	B-X
ADP-ribosylarginine	B-X
and	B-X
(	B-X
2-phospho-ADP-ribosyl	B-X
)	B-X
arginine	B-X
but	B-X
not	B-X
phosphoribosylarginine	B-X
or	B-X
ribosylarginine	B-X
.	B-X
The	B-X
hydrolase	B-X
cDNA	B-X
was	B-X
cloned	B-X
from	B-X
rat	B-X
and	B-X
subsequently	B-X
from	B-X
mouse	B-X
and	B-X
human	B-X
brain	B-X
.	B-X
The	B-X
rat	B-X
hydrolase	B-X
gene	B-X
contained	B-X
a	B-X
1086-base	B-X
pair	B-X
open	B-X
reading	B-X
frame	B-X
,	B-X
with	B-X
deduced	B-X
amino	B-X
acid	B-X
sequences	B-X
identical	B-X
to	B-X
those	B-X
obtained	B-X
by	B-X
amino	B-X
terminal	B-X
sequencing	B-X
of	B-X
the	B-X
protein	B-X
or	B-X
of	B-X
HPLC-purified	B-X
tryptic	B-X
peptides	B-X
.	B-X
Deduced	B-X
amino	B-X
acid	B-X
sequences	B-X
from	B-X
the	B-X
mouse	B-X
and	B-X
human	B-X
hydrolase	B-X
cDNAs	B-X
were	B-X
94	B-X
%	B-X
and	B-X
83	B-X
%	B-X
identical	B-X
,	B-X
respectively	B-X
to	B-X
the	B-X
rat	B-X
.	B-X
Anti-rat	B-X
brain	B-X
hydrolase	B-X
polyclonal	B-X
antibodies	B-X
reacted	B-X
with	B-X
turkey	B-X
erythrocyte	B-X
,	B-X
mouse	B-X
and	B-X
bovine	B-X
brain	B-X
hydrolase	B-X
.	B-X
The	B-X
rat	B-X
hydrolase	B-X
,	B-X
expressed	B-X
in	B-X
E.	B-X
coli	B-X
,	B-X
demonstrated	B-X
enhanced	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Mg2+	B-X
and	B-X
thiol	B-X
,	B-X
whereas	B-X
the	B-X
recombinant	B-X
human	B-X
hydrolase	B-X
was	B-X
stimulated	B-X
by	B-X
Mg2+	B-X
but	B-X
was	B-X
thiol-independent	B-X
.	B-X
In	B-X
the	B-X
rat	B-X
and	B-X
mouse	B-X
enzymes	B-X
,	B-X
there	B-X
are	B-X
five	B-X
cysteines	B-X
in	B-X
identical	B-X
positions	B-X
;	B-X
four	B-X
of	B-X
the	B-X
cysteines	B-X
are	B-X
conserved	B-X
in	B-X
the	B-X
human	B-X
hydrolase	B-X
.	B-X

Treatment	O
of	O
modified	O
GSIII	B-Protein
with	O
hydroxylamine	O
at	O
neutral	O
pH	O
releases	O
a	O
chromophore	O
that	O
has	O
the	O
retention	O
time	O
of	O
ADP	O
-	O
ribose	O
when	O
analyzed	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O
<EOS>	B-X
R.	B-X
meliloti	B-X
is	B-X
unusual	B-X
in	B-X
having	B-X
three	B-X
distinct	B-X
types	B-X
of	B-X
GS	B-X
,	B-X
including	B-X
a	B-X
unique	B-X
GS	B-X
,	B-X
GSIII	B-X
,	B-X
that	B-X
differs	B-X
considerably	B-X
from	B-X
both	B-X
GSI	B-X
,	B-X
which	B-X
resembles	B-X
other	B-X
bacterial	B-X
GS	B-X
proteins	B-X
and	B-X
GSII	B-X
,	B-X
which	B-X
resembles	B-X
the	B-X
GS	B-X
found	B-X
in	B-X
eukaryotes	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
GSIII	B-X
can	B-X
be	B-X
post-translationally	B-X
modified	B-X
in	B-X
vivo	B-X
by	B-X
ADP-ribosylation	B-X
at	B-X
an	B-X
arginine	B-X
residue	B-X
.	B-X
32PO4	B-X
attached	B-X
to	B-X
GSIII	B-X
during	B-X
bacterial	B-X
growth	B-X
as	B-X
part	B-X
of	B-X
the	B-X
modifying	B-X
group	B-X
could	B-X
be	B-X
removed	B-X
by	B-X
treatment	B-X
with	B-X
snake	B-X
venom	B-X
phosphodiesterase	B-X
or	B-X
by	B-X
turkey	B-X
erythrocyte	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
.	B-X
Treatment	B-X
of	B-X
modified	B-X
GSIII	B-X
with	B-X
hydroxylamine	B-X
at	B-X
neutral	B-X
pH	B-X
releases	B-X
a	B-X
chromophore	B-X
that	B-X
has	B-X
the	B-X
retention	B-X
time	B-X
of	B-X
ADP-ribose	B-X
when	B-X
analyzed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
ADP-ribosylation	B-X
inhibits	B-X
GSIII	B-X
activity	B-X
.	B-X

ADP	O
-	O
ribosylation	O
inhibits	O
GSIII	B-Protein
activity	O
.	O
<EOS>	B-X
R.	B-X
meliloti	B-X
is	B-X
unusual	B-X
in	B-X
having	B-X
three	B-X
distinct	B-X
types	B-X
of	B-X
GS	B-X
,	B-X
including	B-X
a	B-X
unique	B-X
GS	B-X
,	B-X
GSIII	B-X
,	B-X
that	B-X
differs	B-X
considerably	B-X
from	B-X
both	B-X
GSI	B-X
,	B-X
which	B-X
resembles	B-X
other	B-X
bacterial	B-X
GS	B-X
proteins	B-X
and	B-X
GSII	B-X
,	B-X
which	B-X
resembles	B-X
the	B-X
GS	B-X
found	B-X
in	B-X
eukaryotes	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
GSIII	B-X
can	B-X
be	B-X
post-translationally	B-X
modified	B-X
in	B-X
vivo	B-X
by	B-X
ADP-ribosylation	B-X
at	B-X
an	B-X
arginine	B-X
residue	B-X
.	B-X
32PO4	B-X
attached	B-X
to	B-X
GSIII	B-X
during	B-X
bacterial	B-X
growth	B-X
as	B-X
part	B-X
of	B-X
the	B-X
modifying	B-X
group	B-X
could	B-X
be	B-X
removed	B-X
by	B-X
treatment	B-X
with	B-X
snake	B-X
venom	B-X
phosphodiesterase	B-X
or	B-X
by	B-X
turkey	B-X
erythrocyte	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
.	B-X
Treatment	B-X
of	B-X
modified	B-X
GSIII	B-X
with	B-X
hydroxylamine	B-X
at	B-X
neutral	B-X
pH	B-X
releases	B-X
a	B-X
chromophore	B-X
that	B-X
has	B-X
the	B-X
retention	B-X
time	B-X
of	B-X
ADP-ribose	B-X
when	B-X
analyzed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
ADP-ribosylation	B-X
inhibits	B-X
GSIII	B-X
activity	B-X
.	B-X

Recombinant	O
expression	O
and	O
evaluation	O
of	O
the	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	B-Protein
acetyltransferase	I-Protein
component	I-Protein
of	I-Protein
the	I-Protein
human	I-Protein
pyruvate	I-Protein
dehydrogenase	I-Protein
complex	I-Protein
.	O
<EOS>	B-X
The	B-X
subunits	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
component	B-X
of	B-X
mammalian	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC	B-X
)	B-X
associate	B-X
to	B-X
form	B-X
a	B-X
large	B-X
inner	B-X
core	B-X
with	B-X
a	B-X
protruding	B-X
structure	B-X
composed	B-X
of	B-X
three	B-X
globular	B-X
domains	B-X
connected	B-X
by	B-X
mobile	B-X
linker	B-X
regions	B-X
.	B-X
This	B-X
exterior	B-X
region	B-X
of	B-X
E2	B-X
includes	B-X
two	B-X
lipoyl	B-X
domains	B-X
which	B-X
engage	B-X
not	B-X
only	B-X
in	B-X
the	B-X
intermediate	B-X
reactions	B-X
of	B-X
the	B-X
complex	B-X
but	B-X
also	B-X
have	B-X
integral	B-X
roles	B-X
in	B-X
the	B-X
kinase-phosphatase	B-X
regulatory	B-X
interconversion	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
(	B-X
E1	B-X
)	B-X
component	B-X
.	B-X
To	B-X
facilitate	B-X
understanding	B-X
of	B-X
these	B-X
roles	B-X
,	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
human	B-X
PDC	B-X
were	B-X
expressed	B-X
as	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-linked	B-X
fusion	B-X
proteins	B-X
from	B-X
plasmid	B-X
inserts	B-X
prepared	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
procedures	B-X
.	B-X
The	B-X
NH2-terminal	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L1	B-X
,	B-X
and	B-X
the	B-X
interior	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L2	B-X
,	B-X
are	B-X
connected	B-X
by	B-X
a	B-X
30-amino-acid	B-X
hinge	B-X
region	B-X
,	B-X
H1	B-X
.	B-X
Constructs	B-X
designed	B-X
and	B-X
expressed	B-X
were	B-X
E2L1	B-X
(	B-X
1-98	B-X
)	B-X
,	B-X
E2L1.H1	B-X
(	B-X
1-128	B-X
)	B-X
,	B-X
E2L2	B-X
(	B-X
120-233	B-X
)	B-X
,	B-X
E2H1.L2	B-X
(	B-X
98-233	B-X
)	B-X
,	B-X
and	B-X
E2L1.H1.L2	B-X
(	B-X
1-233	B-X
)	B-X
,	B-X
where	B-X
numbers	B-X
in	B-X
parentheses	B-X
give	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
for	B-X
the	B-X
portions	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
incorporated	B-X
into	B-X
a	B-X
construct	B-X
.	B-X
The	B-X
domains	B-X
were	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
with	B-X
and	B-X
without	B-X
lipoate	B-X
supplementation	B-X
.	B-X
Sequencing	B-X
of	B-X
insert	B-X
DNAs	B-X
and	B-X
NH2-terminal	B-X
sequencing	B-X
confirmed	B-X
that	B-X
domains	B-X
were	B-X
produced	B-X
as	B-X
designed	B-X
.	B-X
Measurement	B-X
of	B-X
masses	B-X
by	B-X
electrospray	B-X
mass	B-X
spectrometry	B-X
indicated	B-X
that	B-X
constructs	B-X
with	B-X
lipoylated	B-X
,	B-X
nonlipoylated	B-X
,	B-X
and	B-X
octanoylated	B-X
forms	B-X
were	B-X
produced	B-X
when	B-X
expression	B-X
was	B-X
with	B-X
E.	B-X
coli	B-X
grown	B-X
without	B-X
lipoate	B-X
supplementation	B-X
and	B-X
that	B-X
fully	B-X
lipoylated	B-X
forms	B-X
were	B-X
produced	B-X
upon	B-X
lipoate	B-X
supplementation	B-X
.	B-X
The	B-X
lipoylation	B-X
status	B-X
was	B-X
confirmed	B-X
,	B-X
following	B-X
delipoylation	B-X
with	B-X
Enterococcus	B-X
faecalis	B-X
lipoamidase	B-X
,	B-X
by	B-X
the	B-X
expected	B-X
decrease	B-X
in	B-X
mass	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
in	B-X
native	B-X
gel	B-X
electrophoresis	B-X
of	B-X
a	B-X
shift	B-X
to	B-X
a	B-X
slower	B-X
mobility	B-X
(	B-X
possibly	B-X
less	B-X
compact	B-X
)	B-X
form	B-X
.	B-X
Constructs	B-X
were	B-X
used	B-X
in	B-X
E1-catalyzed	B-X
reductive-acetylation	B-X
reaction	B-X
in	B-X
proportion	B-X
to	B-X
their	B-X
degree	B-X
of	B-X
lipoylation	B-X
and	B-X
were	B-X
effective	B-X
substrates	B-X
in	B-X
a	B-X
NADH-dependent	B-X
dihydrolipoyl	B-X
dehydrogenase	B-X
reduction	B-X
reaction	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
have	B-X
produced	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
in	B-X
sorting	B-X
the	B-X
specific	B-X
roles	B-X
of	B-X
E2L1	B-X
and	B-X
E2L2	B-X
in	B-X
facilitating	B-X
catalytic	B-X
and	B-X
regulatory	B-X
processes	B-X
.	B-X

The	O
subunits	O
of	O
the	O
dihydrolipoyl	B-Protein
acetyltransferase	I-Protein
(	I-Protein
E2	I-Protein
)	I-Protein
component	I-Protein
of	I-Protein
mammalian	I-Protein
pyruvate	I-Protein
dehydrogenase	I-Protein
complex	I-Protein
(	O
PDC	O
)	O
associate	O
to	O
form	O
a	O
large	O
inner	O
core	O
with	O
a	O
protruding	O
structure	O
composed	O
of	O
three	O
globular	O
domains	O
connected	O
by	O
mobile	O
linker	O
regions	O
.	O

This	O
exterior	O
region	O
of	O
E2	B-Protein
includes	O
two	O
lipoyl	O
domains	O
which	O
engage	O
not	O
only	O
in	O
the	O
intermediate	O
reactions	O
of	O
the	O
complex	O
but	O
also	O
have	O
integral	O
roles	O
in	O
the	O
kinase	O
-	O
phosphatase	O
regulatory	O
interconversion	O
of	O
the	O
pyruvate	O
dehydrogenase	O
(	O
E1	O
)	O
component	O
.	O

To	O
facilitate	O
understanding	O
of	O
these	O
roles	O
,	O
lipoyl	O
domain	O
constructs	O
of	O
the	O
E2	B-Protein
component	I-Protein
of	O
human	O
PDC	O
were	O
expressed	O
as	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
(	O
GST	B-Protein
)	O
-	O
linked	O
fusion	O
proteins	O
from	O
plasmid	O
inserts	O
prepared	O
by	O
polymerase	O
chain	O
reaction	O
procedures	O
.	O
<EOS>	B-X
The	B-X
subunits	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
component	B-X
of	B-X
mammalian	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC	B-X
)	B-X
associate	B-X
to	B-X
form	B-X
a	B-X
large	B-X
inner	B-X
core	B-X
with	B-X
a	B-X
protruding	B-X
structure	B-X
composed	B-X
of	B-X
three	B-X
globular	B-X
domains	B-X
connected	B-X
by	B-X
mobile	B-X
linker	B-X
regions	B-X
.	B-X
This	B-X
exterior	B-X
region	B-X
of	B-X
E2	B-X
includes	B-X
two	B-X
lipoyl	B-X
domains	B-X
which	B-X
engage	B-X
not	B-X
only	B-X
in	B-X
the	B-X
intermediate	B-X
reactions	B-X
of	B-X
the	B-X
complex	B-X
but	B-X
also	B-X
have	B-X
integral	B-X
roles	B-X
in	B-X
the	B-X
kinase-phosphatase	B-X
regulatory	B-X
interconversion	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
(	B-X
E1	B-X
)	B-X
component	B-X
.	B-X
To	B-X
facilitate	B-X
understanding	B-X
of	B-X
these	B-X
roles	B-X
,	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
human	B-X
PDC	B-X
were	B-X
expressed	B-X
as	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-linked	B-X
fusion	B-X
proteins	B-X
from	B-X
plasmid	B-X
inserts	B-X
prepared	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
procedures	B-X
.	B-X
The	B-X
NH2-terminal	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L1	B-X
,	B-X
and	B-X
the	B-X
interior	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L2	B-X
,	B-X
are	B-X
connected	B-X
by	B-X
a	B-X
30-amino-acid	B-X
hinge	B-X
region	B-X
,	B-X
H1	B-X
.	B-X
Constructs	B-X
designed	B-X
and	B-X
expressed	B-X
were	B-X
E2L1	B-X
(	B-X
1-98	B-X
)	B-X
,	B-X
E2L1.H1	B-X
(	B-X
1-128	B-X
)	B-X
,	B-X
E2L2	B-X
(	B-X
120-233	B-X
)	B-X
,	B-X
E2H1.L2	B-X
(	B-X
98-233	B-X
)	B-X
,	B-X
and	B-X
E2L1.H1.L2	B-X
(	B-X
1-233	B-X
)	B-X
,	B-X
where	B-X
numbers	B-X
in	B-X
parentheses	B-X
give	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
for	B-X
the	B-X
portions	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
incorporated	B-X
into	B-X
a	B-X
construct	B-X
.	B-X
The	B-X
domains	B-X
were	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
with	B-X
and	B-X
without	B-X
lipoate	B-X
supplementation	B-X
.	B-X
GST	B-X
constructs	B-X
were	B-X
purified	B-X
to	B-X
homogeneity	B-X
by	B-X
affinity	B-X
chromatography	B-X
and	B-X
selectively	B-X
released	B-X
by	B-X
thrombin	B-X
treatment	B-X
.	B-X
Sequencing	B-X
of	B-X
insert	B-X
DNAs	B-X
and	B-X
NH2-terminal	B-X
sequencing	B-X
confirmed	B-X
that	B-X
domains	B-X
were	B-X
produced	B-X
as	B-X
designed	B-X
.	B-X
Measurement	B-X
of	B-X
masses	B-X
by	B-X
electrospray	B-X
mass	B-X
spectrometry	B-X
indicated	B-X
that	B-X
constructs	B-X
with	B-X
lipoylated	B-X
,	B-X
nonlipoylated	B-X
,	B-X
and	B-X
octanoylated	B-X
forms	B-X
were	B-X
produced	B-X
when	B-X
expression	B-X
was	B-X
with	B-X
E.	B-X
coli	B-X
grown	B-X
without	B-X
lipoate	B-X
supplementation	B-X
and	B-X
that	B-X
fully	B-X
lipoylated	B-X
forms	B-X
were	B-X
produced	B-X
upon	B-X
lipoate	B-X
supplementation	B-X
.	B-X
The	B-X
lipoylation	B-X
status	B-X
was	B-X
confirmed	B-X
,	B-X
following	B-X
delipoylation	B-X
with	B-X
Enterococcus	B-X
faecalis	B-X
lipoamidase	B-X
,	B-X
by	B-X
the	B-X
expected	B-X
decrease	B-X
in	B-X
mass	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
in	B-X
native	B-X
gel	B-X
electrophoresis	B-X
of	B-X
a	B-X
shift	B-X
to	B-X
a	B-X
slower	B-X
mobility	B-X
(	B-X
possibly	B-X
less	B-X
compact	B-X
)	B-X
form	B-X
.	B-X
Constructs	B-X
were	B-X
used	B-X
in	B-X
E1-catalyzed	B-X
reductive-acetylation	B-X
reaction	B-X
in	B-X
proportion	B-X
to	B-X
their	B-X
degree	B-X
of	B-X
lipoylation	B-X
and	B-X
were	B-X
effective	B-X
substrates	B-X
in	B-X
a	B-X
NADH-dependent	B-X
dihydrolipoyl	B-X
dehydrogenase	B-X
reduction	B-X
reaction	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
have	B-X
produced	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
in	B-X
sorting	B-X
the	B-X
specific	B-X
roles	B-X
of	B-X
E2L1	B-X
and	B-X
E2L2	B-X
in	B-X
facilitating	B-X
catalytic	B-X
and	B-X
regulatory	B-X
processes	B-X
.	B-X

The	O
NH2	O
-	O
terminal	O
lipoyl	O
domain	O
,	O
E2L1	O
,	O
and	O
the	O
interior	O
lipoyl	O
domain	O
,	O
E2L2	O
,	O
are	O
connected	O
by	O
a	O
30	O
-	O
amino	O
-	O
acid	O
hinge	O
region	O
,	O
H1	O
.	O
<EOS>	B-X
The	B-X
subunits	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
component	B-X
of	B-X
mammalian	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC	B-X
)	B-X
associate	B-X
to	B-X
form	B-X
a	B-X
large	B-X
inner	B-X
core	B-X
with	B-X
a	B-X
protruding	B-X
structure	B-X
composed	B-X
of	B-X
three	B-X
globular	B-X
domains	B-X
connected	B-X
by	B-X
mobile	B-X
linker	B-X
regions	B-X
.	B-X
This	B-X
exterior	B-X
region	B-X
of	B-X
E2	B-X
includes	B-X
two	B-X
lipoyl	B-X
domains	B-X
which	B-X
engage	B-X
not	B-X
only	B-X
in	B-X
the	B-X
intermediate	B-X
reactions	B-X
of	B-X
the	B-X
complex	B-X
but	B-X
also	B-X
have	B-X
integral	B-X
roles	B-X
in	B-X
the	B-X
kinase-phosphatase	B-X
regulatory	B-X
interconversion	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
(	B-X
E1	B-X
)	B-X
component	B-X
.	B-X
To	B-X
facilitate	B-X
understanding	B-X
of	B-X
these	B-X
roles	B-X
,	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
human	B-X
PDC	B-X
were	B-X
expressed	B-X
as	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-linked	B-X
fusion	B-X
proteins	B-X
from	B-X
plasmid	B-X
inserts	B-X
prepared	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
procedures	B-X
.	B-X
The	B-X
NH2-terminal	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L1	B-X
,	B-X
and	B-X
the	B-X
interior	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L2	B-X
,	B-X
are	B-X
connected	B-X
by	B-X
a	B-X
30-amino-acid	B-X
hinge	B-X
region	B-X
,	B-X
H1	B-X
.	B-X
Constructs	B-X
designed	B-X
and	B-X
expressed	B-X
were	B-X
E2L1	B-X
(	B-X
1-98	B-X
)	B-X
,	B-X
E2L1.H1	B-X
(	B-X
1-128	B-X
)	B-X
,	B-X
E2L2	B-X
(	B-X
120-233	B-X
)	B-X
,	B-X
E2H1.L2	B-X
(	B-X
98-233	B-X
)	B-X
,	B-X
and	B-X
E2L1.H1.L2	B-X
(	B-X
1-233	B-X
)	B-X
,	B-X
where	B-X
numbers	B-X
in	B-X
parentheses	B-X
give	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
for	B-X
the	B-X
portions	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
incorporated	B-X
into	B-X
a	B-X
construct	B-X
.	B-X
The	B-X
domains	B-X
were	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
with	B-X
and	B-X
without	B-X
lipoate	B-X
supplementation	B-X
.	B-X
Sequencing	B-X
of	B-X
insert	B-X
DNAs	B-X
and	B-X
NH2-terminal	B-X
sequencing	B-X
confirmed	B-X
that	B-X
domains	B-X
were	B-X
produced	B-X
as	B-X
designed	B-X
.	B-X
Measurement	B-X
of	B-X
masses	B-X
by	B-X
electrospray	B-X
mass	B-X
spectrometry	B-X
indicated	B-X
that	B-X
constructs	B-X
with	B-X
lipoylated	B-X
,	B-X
nonlipoylated	B-X
,	B-X
and	B-X
octanoylated	B-X
forms	B-X
were	B-X
produced	B-X
when	B-X
expression	B-X
was	B-X
with	B-X
E.	B-X
coli	B-X
grown	B-X
without	B-X
lipoate	B-X
supplementation	B-X
and	B-X
that	B-X
fully	B-X
lipoylated	B-X
forms	B-X
were	B-X
produced	B-X
upon	B-X
lipoate	B-X
supplementation	B-X
.	B-X
The	B-X
lipoylation	B-X
status	B-X
was	B-X
confirmed	B-X
,	B-X
following	B-X
delipoylation	B-X
with	B-X
Enterococcus	B-X
faecalis	B-X
lipoamidase	B-X
,	B-X
by	B-X
the	B-X
expected	B-X
decrease	B-X
in	B-X
mass	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
in	B-X
native	B-X
gel	B-X
electrophoresis	B-X
of	B-X
a	B-X
shift	B-X
to	B-X
a	B-X
slower	B-X
mobility	B-X
(	B-X
possibly	B-X
less	B-X
compact	B-X
)	B-X
form	B-X
.	B-X
Constructs	B-X
were	B-X
used	B-X
in	B-X
E1-catalyzed	B-X
reductive-acetylation	B-X
reaction	B-X
in	B-X
proportion	B-X
to	B-X
their	B-X
degree	B-X
of	B-X
lipoylation	B-X
and	B-X
were	B-X
effective	B-X
substrates	B-X
in	B-X
a	B-X
NADH-dependent	B-X
dihydrolipoyl	B-X
dehydrogenase	B-X
reduction	B-X
reaction	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
have	B-X
produced	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
in	B-X
sorting	B-X
the	B-X
specific	B-X
roles	B-X
of	B-X
E2L1	B-X
and	B-X
E2L2	B-X
in	B-X
facilitating	B-X
catalytic	B-X
and	B-X
regulatory	B-X
processes	B-X
.	B-X

Constructs	O
designed	O
and	O
expressed	O
were	O
E2L1	O
(	O
1	O
-	O
98	O
)	O
,	O
E2L1	O
.	O
H1	O
(	O
1	O
-	O
128	O
)	O
,	O
E2L2	O
(	O
120	O
-	O
233	O
)	O
,	O
E2H1	O
.	O
L2	O
(	O
98	O
-	O
233	O
)	O
,	O
and	O
E2L1	O
.	O
H1	O
.	O
L2	O
(	O
1	O
-	O
233	O
)	O
,	O
where	O
numbers	O
in	O
parentheses	O
give	O
the	O
amino	O
acid	O
sequence	O
for	O
the	O
portions	O
of	O
the	O
E2	B-Protein
component	I-Protein
incorporated	O
into	O
a	O
construct	O
.	O

The	O
domains	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
with	O
and	O
without	O
lipoate	O
supplementation	O
.	O
<EOS>	B-X
The	B-X
subunits	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
component	B-X
of	B-X
mammalian	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC	B-X
)	B-X
associate	B-X
to	B-X
form	B-X
a	B-X
large	B-X
inner	B-X
core	B-X
with	B-X
a	B-X
protruding	B-X
structure	B-X
composed	B-X
of	B-X
three	B-X
globular	B-X
domains	B-X
connected	B-X
by	B-X
mobile	B-X
linker	B-X
regions	B-X
.	B-X
This	B-X
exterior	B-X
region	B-X
of	B-X
E2	B-X
includes	B-X
two	B-X
lipoyl	B-X
domains	B-X
which	B-X
engage	B-X
not	B-X
only	B-X
in	B-X
the	B-X
intermediate	B-X
reactions	B-X
of	B-X
the	B-X
complex	B-X
but	B-X
also	B-X
have	B-X
integral	B-X
roles	B-X
in	B-X
the	B-X
kinase-phosphatase	B-X
regulatory	B-X
interconversion	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
(	B-X
E1	B-X
)	B-X
component	B-X
.	B-X
To	B-X
facilitate	B-X
understanding	B-X
of	B-X
these	B-X
roles	B-X
,	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
human	B-X
PDC	B-X
were	B-X
expressed	B-X
as	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-linked	B-X
fusion	B-X
proteins	B-X
from	B-X
plasmid	B-X
inserts	B-X
prepared	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
procedures	B-X
.	B-X
Constructs	B-X
designed	B-X
and	B-X
expressed	B-X
were	B-X
E2L1	B-X
(	B-X
1-98	B-X
)	B-X
,	B-X
E2L1.H1	B-X
(	B-X
1-128	B-X
)	B-X
,	B-X
E2L2	B-X
(	B-X
120-233	B-X
)	B-X
,	B-X
E2H1.L2	B-X
(	B-X
98-233	B-X
)	B-X
,	B-X
and	B-X
E2L1.H1.L2	B-X
(	B-X
1-233	B-X
)	B-X
,	B-X
where	B-X
numbers	B-X
in	B-X
parentheses	B-X
give	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
for	B-X
the	B-X
portions	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
incorporated	B-X
into	B-X
a	B-X
construct	B-X
.	B-X
The	B-X
domains	B-X
were	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
with	B-X
and	B-X
without	B-X
lipoate	B-X
supplementation	B-X
.	B-X
Sequencing	B-X
of	B-X
insert	B-X
DNAs	B-X
and	B-X
NH2-terminal	B-X
sequencing	B-X
confirmed	B-X
that	B-X
domains	B-X
were	B-X
produced	B-X
as	B-X
designed	B-X
.	B-X
Measurement	B-X
of	B-X
masses	B-X
by	B-X
electrospray	B-X
mass	B-X
spectrometry	B-X
indicated	B-X
that	B-X
constructs	B-X
with	B-X
lipoylated	B-X
,	B-X
nonlipoylated	B-X
,	B-X
and	B-X
octanoylated	B-X
forms	B-X
were	B-X
produced	B-X
when	B-X
expression	B-X
was	B-X
with	B-X
E.	B-X
coli	B-X
grown	B-X
without	B-X
lipoate	B-X
supplementation	B-X
and	B-X
that	B-X
fully	B-X
lipoylated	B-X
forms	B-X
were	B-X
produced	B-X
upon	B-X
lipoate	B-X
supplementation	B-X
.	B-X

GST	B-Protein
constructs	O
were	O
purified	O
to	O
homogeneity	O
by	O
affinity	O
chromatography	O
and	O
selectively	O
released	O
by	O
thrombin	B-Protein
treatment	O
.	O
<EOS>	B-X
To	B-X
facilitate	B-X
understanding	B-X
of	B-X
these	B-X
roles	B-X
,	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
human	B-X
PDC	B-X
were	B-X
expressed	B-X
as	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-linked	B-X
fusion	B-X
proteins	B-X
from	B-X
plasmid	B-X
inserts	B-X
prepared	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
procedures	B-X
.	B-X
GST	B-X
constructs	B-X
were	B-X
purified	B-X
to	B-X
homogeneity	B-X
by	B-X
affinity	B-X
chromatography	B-X
and	B-X
selectively	B-X
released	B-X
by	B-X
thrombin	B-X
treatment	B-X
.	B-X
Measurement	B-X
of	B-X
masses	B-X
by	B-X
electrospray	B-X
mass	B-X
spectrometry	B-X
indicated	B-X
that	B-X
constructs	B-X
with	B-X
lipoylated	B-X
,	B-X
nonlipoylated	B-X
,	B-X
and	B-X
octanoylated	B-X
forms	B-X
were	B-X
produced	B-X
when	B-X
expression	B-X
was	B-X
with	B-X
E.	B-X
coli	B-X
grown	B-X
without	B-X
lipoate	B-X
supplementation	B-X
and	B-X
that	B-X
fully	B-X
lipoylated	B-X
forms	B-X
were	B-X
produced	B-X
upon	B-X
lipoate	B-X
supplementation	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
have	B-X
produced	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
in	B-X
sorting	B-X
the	B-X
specific	B-X
roles	B-X
of	B-X
E2L1	B-X
and	B-X
E2L2	B-X
in	B-X
facilitating	B-X
catalytic	B-X
and	B-X
regulatory	B-X
processes	B-X
.	B-X

Sequencing	O
of	O
insert	O
DNAs	O
and	O
NH2	O
-	O
terminal	O
sequencing	O
confirmed	O
that	O
domains	O
were	O
produced	O
as	O
designed	O
.	O
<EOS>	B-X
The	B-X
subunits	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
component	B-X
of	B-X
mammalian	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC	B-X
)	B-X
associate	B-X
to	B-X
form	B-X
a	B-X
large	B-X
inner	B-X
core	B-X
with	B-X
a	B-X
protruding	B-X
structure	B-X
composed	B-X
of	B-X
three	B-X
globular	B-X
domains	B-X
connected	B-X
by	B-X
mobile	B-X
linker	B-X
regions	B-X
.	B-X
This	B-X
exterior	B-X
region	B-X
of	B-X
E2	B-X
includes	B-X
two	B-X
lipoyl	B-X
domains	B-X
which	B-X
engage	B-X
not	B-X
only	B-X
in	B-X
the	B-X
intermediate	B-X
reactions	B-X
of	B-X
the	B-X
complex	B-X
but	B-X
also	B-X
have	B-X
integral	B-X
roles	B-X
in	B-X
the	B-X
kinase-phosphatase	B-X
regulatory	B-X
interconversion	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
(	B-X
E1	B-X
)	B-X
component	B-X
.	B-X
To	B-X
facilitate	B-X
understanding	B-X
of	B-X
these	B-X
roles	B-X
,	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
human	B-X
PDC	B-X
were	B-X
expressed	B-X
as	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-linked	B-X
fusion	B-X
proteins	B-X
from	B-X
plasmid	B-X
inserts	B-X
prepared	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
procedures	B-X
.	B-X
The	B-X
NH2-terminal	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L1	B-X
,	B-X
and	B-X
the	B-X
interior	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L2	B-X
,	B-X
are	B-X
connected	B-X
by	B-X
a	B-X
30-amino-acid	B-X
hinge	B-X
region	B-X
,	B-X
H1	B-X
.	B-X
Constructs	B-X
designed	B-X
and	B-X
expressed	B-X
were	B-X
E2L1	B-X
(	B-X
1-98	B-X
)	B-X
,	B-X
E2L1.H1	B-X
(	B-X
1-128	B-X
)	B-X
,	B-X
E2L2	B-X
(	B-X
120-233	B-X
)	B-X
,	B-X
E2H1.L2	B-X
(	B-X
98-233	B-X
)	B-X
,	B-X
and	B-X
E2L1.H1.L2	B-X
(	B-X
1-233	B-X
)	B-X
,	B-X
where	B-X
numbers	B-X
in	B-X
parentheses	B-X
give	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
for	B-X
the	B-X
portions	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
incorporated	B-X
into	B-X
a	B-X
construct	B-X
.	B-X
The	B-X
domains	B-X
were	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
with	B-X
and	B-X
without	B-X
lipoate	B-X
supplementation	B-X
.	B-X
Sequencing	B-X
of	B-X
insert	B-X
DNAs	B-X
and	B-X
NH2-terminal	B-X
sequencing	B-X
confirmed	B-X
that	B-X
domains	B-X
were	B-X
produced	B-X
as	B-X
designed	B-X
.	B-X
Measurement	B-X
of	B-X
masses	B-X
by	B-X
electrospray	B-X
mass	B-X
spectrometry	B-X
indicated	B-X
that	B-X
constructs	B-X
with	B-X
lipoylated	B-X
,	B-X
nonlipoylated	B-X
,	B-X
and	B-X
octanoylated	B-X
forms	B-X
were	B-X
produced	B-X
when	B-X
expression	B-X
was	B-X
with	B-X
E.	B-X
coli	B-X
grown	B-X
without	B-X
lipoate	B-X
supplementation	B-X
and	B-X
that	B-X
fully	B-X
lipoylated	B-X
forms	B-X
were	B-X
produced	B-X
upon	B-X
lipoate	B-X
supplementation	B-X
.	B-X
The	B-X
lipoylation	B-X
status	B-X
was	B-X
confirmed	B-X
,	B-X
following	B-X
delipoylation	B-X
with	B-X
Enterococcus	B-X
faecalis	B-X
lipoamidase	B-X
,	B-X
by	B-X
the	B-X
expected	B-X
decrease	B-X
in	B-X
mass	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
in	B-X
native	B-X
gel	B-X
electrophoresis	B-X
of	B-X
a	B-X
shift	B-X
to	B-X
a	B-X
slower	B-X
mobility	B-X
(	B-X
possibly	B-X
less	B-X
compact	B-X
)	B-X
form	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
have	B-X
produced	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
in	B-X
sorting	B-X
the	B-X
specific	B-X
roles	B-X
of	B-X
E2L1	B-X
and	B-X
E2L2	B-X
in	B-X
facilitating	B-X
catalytic	B-X
and	B-X
regulatory	B-X
processes	B-X
.	B-X

Measurement	O
of	O
masses	O
by	O
electrospray	O
mass	O
spectrometry	O
indicated	O
that	O
constructs	O
with	O
lipoylated	O
,	O
nonlipoylated	O
,	O
and	O
octanoylated	O
forms	O
were	O
produced	O
when	O
expression	O
was	O
with	O
E	O
.	O
coli	O
grown	O
without	O
lipoate	O
supplementation	O
and	O
that	O
fully	O
lipoylated	O
forms	O
were	O
produced	O
upon	O
lipoate	O
supplementation	O
.	O

The	O
lipoylation	O
status	O
was	O
confirmed	O
,	O
following	O
delipoylation	O
with	O
Enterococcus	O
faecalis	O
lipoamidase	O
,	O
by	O
the	O
expected	O
decrease	O
in	O
mass	O
and	O
by	O
the	O
observation	O
in	O
native	O
gel	O
electrophoresis	O
of	O
a	O
shift	O
to	O
a	O
slower	O
mobility	O
(	O
possibly	O
less	O
compact	O
)	O
form	O
.	O
<EOS>	B-X
The	B-X
subunits	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
component	B-X
of	B-X
mammalian	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC	B-X
)	B-X
associate	B-X
to	B-X
form	B-X
a	B-X
large	B-X
inner	B-X
core	B-X
with	B-X
a	B-X
protruding	B-X
structure	B-X
composed	B-X
of	B-X
three	B-X
globular	B-X
domains	B-X
connected	B-X
by	B-X
mobile	B-X
linker	B-X
regions	B-X
.	B-X
Sequencing	B-X
of	B-X
insert	B-X
DNAs	B-X
and	B-X
NH2-terminal	B-X
sequencing	B-X
confirmed	B-X
that	B-X
domains	B-X
were	B-X
produced	B-X
as	B-X
designed	B-X
.	B-X
Measurement	B-X
of	B-X
masses	B-X
by	B-X
electrospray	B-X
mass	B-X
spectrometry	B-X
indicated	B-X
that	B-X
constructs	B-X
with	B-X
lipoylated	B-X
,	B-X
nonlipoylated	B-X
,	B-X
and	B-X
octanoylated	B-X
forms	B-X
were	B-X
produced	B-X
when	B-X
expression	B-X
was	B-X
with	B-X
E.	B-X
coli	B-X
grown	B-X
without	B-X
lipoate	B-X
supplementation	B-X
and	B-X
that	B-X
fully	B-X
lipoylated	B-X
forms	B-X
were	B-X
produced	B-X
upon	B-X
lipoate	B-X
supplementation	B-X
.	B-X
The	B-X
lipoylation	B-X
status	B-X
was	B-X
confirmed	B-X
,	B-X
following	B-X
delipoylation	B-X
with	B-X
Enterococcus	B-X
faecalis	B-X
lipoamidase	B-X
,	B-X
by	B-X
the	B-X
expected	B-X
decrease	B-X
in	B-X
mass	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
in	B-X
native	B-X
gel	B-X
electrophoresis	B-X
of	B-X
a	B-X
shift	B-X
to	B-X
a	B-X
slower	B-X
mobility	B-X
(	B-X
possibly	B-X
less	B-X
compact	B-X
)	B-X
form	B-X
.	B-X
Constructs	B-X
were	B-X
used	B-X
in	B-X
E1-catalyzed	B-X
reductive-acetylation	B-X
reaction	B-X
in	B-X
proportion	B-X
to	B-X
their	B-X
degree	B-X
of	B-X
lipoylation	B-X
and	B-X
were	B-X
effective	B-X
substrates	B-X
in	B-X
a	B-X
NADH-dependent	B-X
dihydrolipoyl	B-X
dehydrogenase	B-X
reduction	B-X
reaction	B-X
.	B-X

Constructs	O
were	O
used	O
in	O
E1	O
-	O
catalyzed	O
reductive	O
-	O
acetylation	O
reaction	O
in	O
proportion	O
to	O
their	O
degree	O
of	O
lipoylation	O
and	O
were	O
effective	O
substrates	O
in	O
a	O
NADH	O
-	O
dependent	O
dihydrolipoyl	B-Protein
dehydrogenase	I-Protein
reduction	O
reaction	O
.	O

Thus	O
,	O
we	O
have	O
produced	O
lipoyl	O
domain	O
constructs	O
that	O
can	O
be	O
employed	O
in	O
sorting	O
the	O
specific	O
roles	O
of	O
E2L1	O
and	O
E2L2	O
in	O
facilitating	O
catalytic	O
and	O
regulatory	O
processes	O
.	O
<EOS>	B-X
The	B-X
subunits	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
component	B-X
of	B-X
mammalian	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC	B-X
)	B-X
associate	B-X
to	B-X
form	B-X
a	B-X
large	B-X
inner	B-X
core	B-X
with	B-X
a	B-X
protruding	B-X
structure	B-X
composed	B-X
of	B-X
three	B-X
globular	B-X
domains	B-X
connected	B-X
by	B-X
mobile	B-X
linker	B-X
regions	B-X
.	B-X
This	B-X
exterior	B-X
region	B-X
of	B-X
E2	B-X
includes	B-X
two	B-X
lipoyl	B-X
domains	B-X
which	B-X
engage	B-X
not	B-X
only	B-X
in	B-X
the	B-X
intermediate	B-X
reactions	B-X
of	B-X
the	B-X
complex	B-X
but	B-X
also	B-X
have	B-X
integral	B-X
roles	B-X
in	B-X
the	B-X
kinase-phosphatase	B-X
regulatory	B-X
interconversion	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
(	B-X
E1	B-X
)	B-X
component	B-X
.	B-X
To	B-X
facilitate	B-X
understanding	B-X
of	B-X
these	B-X
roles	B-X
,	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
human	B-X
PDC	B-X
were	B-X
expressed	B-X
as	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-linked	B-X
fusion	B-X
proteins	B-X
from	B-X
plasmid	B-X
inserts	B-X
prepared	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
procedures	B-X
.	B-X
The	B-X
NH2-terminal	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L1	B-X
,	B-X
and	B-X
the	B-X
interior	B-X
lipoyl	B-X
domain	B-X
,	B-X
E2L2	B-X
,	B-X
are	B-X
connected	B-X
by	B-X
a	B-X
30-amino-acid	B-X
hinge	B-X
region	B-X
,	B-X
H1	B-X
.	B-X
Constructs	B-X
designed	B-X
and	B-X
expressed	B-X
were	B-X
E2L1	B-X
(	B-X
1-98	B-X
)	B-X
,	B-X
E2L1.H1	B-X
(	B-X
1-128	B-X
)	B-X
,	B-X
E2L2	B-X
(	B-X
120-233	B-X
)	B-X
,	B-X
E2H1.L2	B-X
(	B-X
98-233	B-X
)	B-X
,	B-X
and	B-X
E2L1.H1.L2	B-X
(	B-X
1-233	B-X
)	B-X
,	B-X
where	B-X
numbers	B-X
in	B-X
parentheses	B-X
give	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
for	B-X
the	B-X
portions	B-X
of	B-X
the	B-X
E2	B-X
component	B-X
incorporated	B-X
into	B-X
a	B-X
construct	B-X
.	B-X
The	B-X
domains	B-X
were	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
with	B-X
and	B-X
without	B-X
lipoate	B-X
supplementation	B-X
.	B-X
GST	B-X
constructs	B-X
were	B-X
purified	B-X
to	B-X
homogeneity	B-X
by	B-X
affinity	B-X
chromatography	B-X
and	B-X
selectively	B-X
released	B-X
by	B-X
thrombin	B-X
treatment	B-X
.	B-X
Sequencing	B-X
of	B-X
insert	B-X
DNAs	B-X
and	B-X
NH2-terminal	B-X
sequencing	B-X
confirmed	B-X
that	B-X
domains	B-X
were	B-X
produced	B-X
as	B-X
designed	B-X
.	B-X
Measurement	B-X
of	B-X
masses	B-X
by	B-X
electrospray	B-X
mass	B-X
spectrometry	B-X
indicated	B-X
that	B-X
constructs	B-X
with	B-X
lipoylated	B-X
,	B-X
nonlipoylated	B-X
,	B-X
and	B-X
octanoylated	B-X
forms	B-X
were	B-X
produced	B-X
when	B-X
expression	B-X
was	B-X
with	B-X
E.	B-X
coli	B-X
grown	B-X
without	B-X
lipoate	B-X
supplementation	B-X
and	B-X
that	B-X
fully	B-X
lipoylated	B-X
forms	B-X
were	B-X
produced	B-X
upon	B-X
lipoate	B-X
supplementation	B-X
.	B-X
The	B-X
lipoylation	B-X
status	B-X
was	B-X
confirmed	B-X
,	B-X
following	B-X
delipoylation	B-X
with	B-X
Enterococcus	B-X
faecalis	B-X
lipoamidase	B-X
,	B-X
by	B-X
the	B-X
expected	B-X
decrease	B-X
in	B-X
mass	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
in	B-X
native	B-X
gel	B-X
electrophoresis	B-X
of	B-X
a	B-X
shift	B-X
to	B-X
a	B-X
slower	B-X
mobility	B-X
(	B-X
possibly	B-X
less	B-X
compact	B-X
)	B-X
form	B-X
.	B-X
Constructs	B-X
were	B-X
used	B-X
in	B-X
E1-catalyzed	B-X
reductive-acetylation	B-X
reaction	B-X
in	B-X
proportion	B-X
to	B-X
their	B-X
degree	B-X
of	B-X
lipoylation	B-X
and	B-X
were	B-X
effective	B-X
substrates	B-X
in	B-X
a	B-X
NADH-dependent	B-X
dihydrolipoyl	B-X
dehydrogenase	B-X
reduction	B-X
reaction	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
have	B-X
produced	B-X
lipoyl	B-X
domain	B-X
constructs	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
in	B-X
sorting	B-X
the	B-X
specific	B-X
roles	B-X
of	B-X
E2L1	B-X
and	B-X
E2L2	B-X
in	B-X
facilitating	B-X
catalytic	B-X
and	B-X
regulatory	B-X
processes	B-X
.	B-X

Lipoic	O
acid	O
metabolism	O
in	O
Escherichia	O
coli	O
:	O
the	O
lplA	B-Protein
and	O
lipB	B-Protein
genes	O
define	O
redundant	O
pathways	O
for	O
ligation	O
of	O
lipoyl	O
groups	O
to	O
apoprotein	O
.	O
<EOS>	B-X
Lipoic	B-X
acid	B-X
is	B-X
a	B-X
covalently	B-X
bound	B-X
disulfide-containing	B-X
cofactor	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
,	B-X
alpha-ketoglutarate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
glycine	B-X
cleavage	B-X
enzyme	B-X
complexes	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
First	B-X
,	B-X
analysis	B-X
of	B-X
lplA	B-X
null	B-X
mutants	B-X
revealed	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
second	B-X
lipoyl	B-X
ligase	B-X
enzyme	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
The	B-X
lipB-dependent	B-X
ligase	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
aberrantly	B-X
modified	B-X
octanoyl-proteins	B-X
in	B-X
lipoate-deficient	B-X
cells	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
Although	B-X
mutations	B-X
in	B-X
two	B-X
genes	B-X
(	B-X
fadD	B-X
and	B-X
fadL	B-X
)	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
failed	B-X
to	B-X
affect	B-X
lipoate	B-X
utilization	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
smp	B-X
gene	B-X
severely	B-X
decreased	B-X
lipoate	B-X
utilization	B-X
.	B-X
USA	B-X
91:3720-3724	B-X
,	B-X
1994	B-X
)	B-X
showed	B-X
this	B-X
mutation	B-X
(	B-X
now	B-X
called	B-X
lplA1	B-X
)	B-X
to	B-X
be	B-X
a	B-X
G76S	B-X
substitution	B-X
in	B-X
the	B-X
LplA	B-X
ligase	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
allele	B-X
,	B-X
the	B-X
cloned	B-X
lplA1	B-X
allele	B-X
conferred	B-X
a	B-X
threefold	B-X
increase	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
discriminate	B-X
against	B-X
the	B-X
selenium-containing	B-X
analog	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

Lipoic	O
acid	O
is	O
a	O
covalently	O
bound	O
disulfide	O
-	O
containing	O
cofactor	O
required	O
for	O
function	O
of	O
the	O
pyruvate	O
dehydrogenase	O
,	O
alpha	O
-	O
ketoglutarate	O
dehydrogenase	O
,	O
and	O
glycine	O
cleavage	O
enzyme	O
complexes	O
of	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
Lipoic	B-X
acid	B-X
is	B-X
a	B-X
covalently	B-X
bound	B-X
disulfide-containing	B-X
cofactor	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
,	B-X
alpha-ketoglutarate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
glycine	B-X
cleavage	B-X
enzyme	B-X
complexes	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
First	B-X
,	B-X
analysis	B-X
of	B-X
lplA	B-X
null	B-X
mutants	B-X
revealed	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
second	B-X
lipoyl	B-X
ligase	B-X
enzyme	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
Although	B-X
mutations	B-X
in	B-X
two	B-X
genes	B-X
(	B-X
fadD	B-X
and	B-X
fadL	B-X
)	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
failed	B-X
to	B-X
affect	B-X
lipoate	B-X
utilization	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
smp	B-X
gene	B-X
severely	B-X
decreased	B-X
lipoate	B-X
utilization	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
allele	B-X
,	B-X
the	B-X
cloned	B-X
lplA1	B-X
allele	B-X
conferred	B-X
a	B-X
threefold	B-X
increase	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
discriminate	B-X
against	B-X
the	B-X
selenium-containing	B-X
analog	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

Recently	O
we	O
described	O
the	O
isolation	O
of	O
the	O
lplA	B-Protein
locus	O
,	O
the	O
first	O
gene	O
known	O
to	O
encode	O
a	O
lipoyl	O
-	O
protein	O
ligase	O
for	O
the	O
attachment	O
of	O
lipoyl	O
groups	O
to	O
lipoate	O
-	O
dependent	O
apoenzymes	O
(	O
T	O
.	O
W	O
.	O
Morris	O
,	O
K	O
.	O
E	O
.	O
Reed	O
,	O
and	O
J	O
.	O
E	O
.	O
Cronan	O
,	O
Jr	O
.	O
,	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
269	O
:	O
16091	O
-	O
16100	O
,	O
1994	O
)	O
.	O

Here	O
,	O
we	O
report	O
an	O
unexpected	O
redundancy	O
between	O
the	O
functions	O
of	O
lplA	B-Protein
and	O
lipB	B-Protein
,	O
a	O
gene	O
previously	O
identified	O
as	O
a	O
putative	O
lipoate	O
biosynthetic	O
locus	O
.	O
<EOS>	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
First	B-X
,	B-X
analysis	B-X
of	B-X
lplA	B-X
null	B-X
mutants	B-X
revealed	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
second	B-X
lipoyl	B-X
ligase	B-X
enzyme	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
The	B-X
lipB-dependent	B-X
ligase	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
aberrantly	B-X
modified	B-X
octanoyl-proteins	B-X
in	B-X
lipoate-deficient	B-X
cells	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
Although	B-X
mutations	B-X
in	B-X
two	B-X
genes	B-X
(	B-X
fadD	B-X
and	B-X
fadL	B-X
)	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
failed	B-X
to	B-X
affect	B-X
lipoate	B-X
utilization	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
smp	B-X
gene	B-X
severely	B-X
decreased	B-X
lipoate	B-X
utilization	B-X
.	B-X
DNA	B-X
sequencing	B-X
of	B-X
the	B-X
previously	B-X
identified	B-X
slr1	B-X
selenolipoate	B-X
resistance	B-X
mutation	B-X
(	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
Proc	B-X
.	B-X
USA	B-X
91:3720-3724	B-X
,	B-X
1994	B-X
)	B-X
showed	B-X
this	B-X
mutation	B-X
(	B-X
now	B-X
called	B-X
lplA1	B-X
)	B-X
to	B-X
be	B-X
a	B-X
G76S	B-X
substitution	B-X
in	B-X
the	B-X
LplA	B-X
ligase	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
allele	B-X
,	B-X
the	B-X
cloned	B-X
lplA1	B-X
allele	B-X
conferred	B-X
a	B-X
threefold	B-X
increase	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
discriminate	B-X
against	B-X
the	B-X
selenium-containing	B-X
analog	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

First	O
,	O
analysis	O
of	O
lplA	B-Protein
null	O
mutants	O
revealed	O
the	O
existence	O
of	O
a	O
second	O
lipoyl	O
ligase	O
enzyme	O
.	O
<EOS>	B-X
Lipoic	B-X
acid	B-X
is	B-X
a	B-X
covalently	B-X
bound	B-X
disulfide-containing	B-X
cofactor	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
,	B-X
alpha-ketoglutarate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
glycine	B-X
cleavage	B-X
enzyme	B-X
complexes	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
First	B-X
,	B-X
analysis	B-X
of	B-X
lplA	B-X
null	B-X
mutants	B-X
revealed	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
second	B-X
lipoyl	B-X
ligase	B-X
enzyme	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
The	B-X
lipB-dependent	B-X
ligase	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
aberrantly	B-X
modified	B-X
octanoyl-proteins	B-X
in	B-X
lipoate-deficient	B-X
cells	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
USA	B-X
91:3720-3724	B-X
,	B-X
1994	B-X
)	B-X
showed	B-X
this	B-X
mutation	B-X
(	B-X
now	B-X
called	B-X
lplA1	B-X
)	B-X
to	B-X
be	B-X
a	B-X
G76S	B-X
substitution	B-X
in	B-X
the	B-X
LplA	B-X
ligase	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
allele	B-X
,	B-X
the	B-X
cloned	B-X
lplA1	B-X
allele	B-X
conferred	B-X
a	B-X
threefold	B-X
increase	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
discriminate	B-X
against	B-X
the	B-X
selenium-containing	B-X
analog	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

We	O
found	O
that	O
lplA	B-Protein
null	O
mutants	O
displayed	O
no	O
growth	O
defects	O
unless	O
combined	O
with	O
lipA	B-Protein
(	O
lipoate	O
synthesis	O
)	O
or	O
lipB	B-Protein
mutations	O
and	O
that	O
overexpression	O
of	O
wild	O
-	O
type	O
LplA	B-Protein
suppressed	O
lipB	B-Protein
null	O
mutations	O
.	O
<EOS>	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
First	B-X
,	B-X
analysis	B-X
of	B-X
lplA	B-X
null	B-X
mutants	B-X
revealed	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
second	B-X
lipoyl	B-X
ligase	B-X
enzyme	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
The	B-X
lipB-dependent	B-X
ligase	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
aberrantly	B-X
modified	B-X
octanoyl-proteins	B-X
in	B-X
lipoate-deficient	B-X
cells	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
Although	B-X
mutations	B-X
in	B-X
two	B-X
genes	B-X
(	B-X
fadD	B-X
and	B-X
fadL	B-X
)	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
failed	B-X
to	B-X
affect	B-X
lipoate	B-X
utilization	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
smp	B-X
gene	B-X
severely	B-X
decreased	B-X
lipoate	B-X
utilization	B-X
.	B-X
DNA	B-X
sequencing	B-X
of	B-X
the	B-X
previously	B-X
identified	B-X
slr1	B-X
selenolipoate	B-X
resistance	B-X
mutation	B-X
(	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
Proc	B-X
.	B-X
USA	B-X
91:3720-3724	B-X
,	B-X
1994	B-X
)	B-X
showed	B-X
this	B-X
mutation	B-X
(	B-X
now	B-X
called	B-X
lplA1	B-X
)	B-X
to	B-X
be	B-X
a	B-X
G76S	B-X
substitution	B-X
in	B-X
the	B-X
LplA	B-X
ligase	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
allele	B-X
,	B-X
the	B-X
cloned	B-X
lplA1	B-X
allele	B-X
conferred	B-X
a	B-X
threefold	B-X
increase	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
discriminate	B-X
against	B-X
the	B-X
selenium-containing	B-X
analog	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

Assays	O
of	O
growth	O
,	O
transport	O
,	O
lipoyl	O
-	O
protein	O
content	O
,	O
and	O
apoprotein	O
modification	O
demonstrated	O
that	O
lplA	B-Protein
encoded	O
a	O
ligase	O
for	O
the	O
incorporation	O
of	O
exogenously	O
supplied	O
lipoate	O
,	O
whereas	O
lipB	B-Protein
was	O
required	O
for	O
function	O
of	O
the	O
second	O
lipoyl	O
ligase	O
,	O
which	O
utilizes	O
lipoyl	O
groups	O
generated	O
via	O
endogenous	O
(	O
lipA	B-Protein
-	O
mediated	O
)	O
biosynthesis	O
.	O
<EOS>	B-X
Lipoic	B-X
acid	B-X
is	B-X
a	B-X
covalently	B-X
bound	B-X
disulfide-containing	B-X
cofactor	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
,	B-X
alpha-ketoglutarate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
glycine	B-X
cleavage	B-X
enzyme	B-X
complexes	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
First	B-X
,	B-X
analysis	B-X
of	B-X
lplA	B-X
null	B-X
mutants	B-X
revealed	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
second	B-X
lipoyl	B-X
ligase	B-X
enzyme	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
The	B-X
lipB-dependent	B-X
ligase	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
aberrantly	B-X
modified	B-X
octanoyl-proteins	B-X
in	B-X
lipoate-deficient	B-X
cells	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
Although	B-X
mutations	B-X
in	B-X
two	B-X
genes	B-X
(	B-X
fadD	B-X
and	B-X
fadL	B-X
)	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
failed	B-X
to	B-X
affect	B-X
lipoate	B-X
utilization	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
smp	B-X
gene	B-X
severely	B-X
decreased	B-X
lipoate	B-X
utilization	B-X
.	B-X
DNA	B-X
sequencing	B-X
of	B-X
the	B-X
previously	B-X
identified	B-X
slr1	B-X
selenolipoate	B-X
resistance	B-X
mutation	B-X
(	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
Proc	B-X
.	B-X
USA	B-X
91:3720-3724	B-X
,	B-X
1994	B-X
)	B-X
showed	B-X
this	B-X
mutation	B-X
(	B-X
now	B-X
called	B-X
lplA1	B-X
)	B-X
to	B-X
be	B-X
a	B-X
G76S	B-X
substitution	B-X
in	B-X
the	B-X
LplA	B-X
ligase	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
allele	B-X
,	B-X
the	B-X
cloned	B-X
lplA1	B-X
allele	B-X
conferred	B-X
a	B-X
threefold	B-X
increase	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
discriminate	B-X
against	B-X
the	B-X
selenium-containing	B-X
analog	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

The	O
lipB	B-Protein
-	O
dependent	O
ligase	O
was	O
further	O
shown	O
to	O
cause	O
the	O
accumulation	O
of	O
aberrantly	O
modified	O
octanoyl	O
-	O
proteins	O
in	O
lipoate	O
-	O
deficient	O
cells	O
.	O
<EOS>	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
First	B-X
,	B-X
analysis	B-X
of	B-X
lplA	B-X
null	B-X
mutants	B-X
revealed	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
second	B-X
lipoyl	B-X
ligase	B-X
enzyme	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
The	B-X
lipB-dependent	B-X
ligase	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
aberrantly	B-X
modified	B-X
octanoyl-proteins	B-X
in	B-X
lipoate-deficient	B-X
cells	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
Although	B-X
mutations	B-X
in	B-X
two	B-X
genes	B-X
(	B-X
fadD	B-X
and	B-X
fadL	B-X
)	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
failed	B-X
to	B-X
affect	B-X
lipoate	B-X
utilization	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
smp	B-X
gene	B-X
severely	B-X
decreased	B-X
lipoate	B-X
utilization	B-X
.	B-X
DNA	B-X
sequencing	B-X
of	B-X
the	B-X
previously	B-X
identified	B-X
slr1	B-X
selenolipoate	B-X
resistance	B-X
mutation	B-X
(	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
Proc	B-X
.	B-X
USA	B-X
91:3720-3724	B-X
,	B-X
1994	B-X
)	B-X
showed	B-X
this	B-X
mutation	B-X
(	B-X
now	B-X
called	B-X
lplA1	B-X
)	B-X
to	B-X
be	B-X
a	B-X
G76S	B-X
substitution	B-X
in	B-X
the	B-X
LplA	B-X
ligase	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

Lipoate	O
uptake	O
assays	O
of	O
strains	O
that	O
overproduced	O
lipoate	O
-	O
accepting	O
apoproteins	O
also	O
demonstrated	O
coupling	O
between	O
transport	O
and	O
the	O
subsequent	O
ligation	O
of	O
lipoate	O
to	O
apoprotein	O
by	O
the	O
LplA	B-Protein
enzyme	O
.	O
<EOS>	B-X
Lipoic	B-X
acid	B-X
is	B-X
a	B-X
covalently	B-X
bound	B-X
disulfide-containing	B-X
cofactor	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
,	B-X
alpha-ketoglutarate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
glycine	B-X
cleavage	B-X
enzyme	B-X
complexes	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
First	B-X
,	B-X
analysis	B-X
of	B-X
lplA	B-X
null	B-X
mutants	B-X
revealed	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
second	B-X
lipoyl	B-X
ligase	B-X
enzyme	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
The	B-X
lipB-dependent	B-X
ligase	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
aberrantly	B-X
modified	B-X
octanoyl-proteins	B-X
in	B-X
lipoate-deficient	B-X
cells	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
Although	B-X
mutations	B-X
in	B-X
two	B-X
genes	B-X
(	B-X
fadD	B-X
and	B-X
fadL	B-X
)	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
failed	B-X
to	B-X
affect	B-X
lipoate	B-X
utilization	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
smp	B-X
gene	B-X
severely	B-X
decreased	B-X
lipoate	B-X
utilization	B-X
.	B-X
DNA	B-X
sequencing	B-X
of	B-X
the	B-X
previously	B-X
identified	B-X
slr1	B-X
selenolipoate	B-X
resistance	B-X
mutation	B-X
(	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
Proc	B-X
.	B-X
USA	B-X
91:3720-3724	B-X
,	B-X
1994	B-X
)	B-X
showed	B-X
this	B-X
mutation	B-X
(	B-X
now	B-X
called	B-X
lplA1	B-X
)	B-X
to	B-X
be	B-X
a	B-X
G76S	B-X
substitution	B-X
in	B-X
the	B-X
LplA	B-X
ligase	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

Although	O
mutations	O
in	O
two	O
genes	O
(	O
fadD	B-Protein
and	O
fadL	B-Protein
)	O
involved	O
in	O
fatty	O
acid	O
failed	O
to	O
affect	O
lipoate	O
utilization	O
,	O
disruption	O
of	O
the	O
smp	B-Protein
gene	O
severely	O
decreased	O
lipoate	O
utilization	O
.	O
<EOS>	B-X
Lipoic	B-X
acid	B-X
is	B-X
a	B-X
covalently	B-X
bound	B-X
disulfide-containing	B-X
cofactor	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
,	B-X
alpha-ketoglutarate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
glycine	B-X
cleavage	B-X
enzyme	B-X
complexes	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
Recently	B-X
we	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
lplA	B-X
locus	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
known	B-X
to	B-X
encode	B-X
a	B-X
lipoyl-protein	B-X
ligase	B-X
for	B-X
the	B-X
attachment	B-X
of	B-X
lipoyl	B-X
groups	B-X
to	B-X
lipoate-dependent	B-X
apoenzymes	B-X
(	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unexpected	B-X
redundancy	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
lplA	B-X
and	B-X
lipB	B-X
,	B-X
a	B-X
gene	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
lipoate	B-X
biosynthetic	B-X
locus	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
,	B-X
transport	B-X
,	B-X
lipoyl-protein	B-X
content	B-X
,	B-X
and	B-X
apoprotein	B-X
modification	B-X
demonstrated	B-X
that	B-X
lplA	B-X
encoded	B-X
a	B-X
ligase	B-X
for	B-X
the	B-X
incorporation	B-X
of	B-X
exogenously	B-X
supplied	B-X
lipoate	B-X
,	B-X
whereas	B-X
lipB	B-X
was	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
second	B-X
lipoyl	B-X
ligase	B-X
,	B-X
which	B-X
utilizes	B-X
lipoyl	B-X
groups	B-X
generated	B-X
via	B-X
endogenous	B-X
(	B-X
lipA-mediated	B-X
)	B-X
biosynthesis	B-X
.	B-X
The	B-X
lipB-dependent	B-X
ligase	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
aberrantly	B-X
modified	B-X
octanoyl-proteins	B-X
in	B-X
lipoate-deficient	B-X
cells	B-X
.	B-X
Lipoate	B-X
uptake	B-X
assays	B-X
of	B-X
strains	B-X
that	B-X
overproduced	B-X
lipoate-accepting	B-X
apoproteins	B-X
also	B-X
demonstrated	B-X
coupling	B-X
between	B-X
transport	B-X
and	B-X
the	B-X
subsequent	B-X
ligation	B-X
of	B-X
lipoate	B-X
to	B-X
apoprotein	B-X
by	B-X
the	B-X
LplA	B-X
enzyme	B-X
.	B-X
Although	B-X
mutations	B-X
in	B-X
two	B-X
genes	B-X
(	B-X
fadD	B-X
and	B-X
fadL	B-X
)	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
failed	B-X
to	B-X
affect	B-X
lipoate	B-X
utilization	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
smp	B-X
gene	B-X
severely	B-X
decreased	B-X
lipoate	B-X
utilization	B-X
.	B-X
DNA	B-X
sequencing	B-X
of	B-X
the	B-X
previously	B-X
identified	B-X
slr1	B-X
selenolipoate	B-X
resistance	B-X
mutation	B-X
(	B-X
K.	B-X
E.	B-X
Reed	B-X
,	B-X
T.	B-X
W.	B-X
Morris	B-X
,	B-X
and	B-X
J.	B-X
E.	B-X
Cronan	B-X
,	B-X
Jr.	B-X
,	B-X
Proc	B-X
.	B-X
These	B-X
results	B-X
support	B-X
a	B-X
two-pathway/two-ligase	B-X
model	B-X
of	B-X
lipoate	B-X
metabolism	B-X
in	B-X
E.	B-X
coli	B-X
.	B-X

DNA	O
sequencing	O
of	O
the	O
previously	O
identified	O
slr1	B-Protein
selenolipoate	O
resistance	O
mutation	O
(	O
K	O
.	O
E	O
.	O
Reed	O
,	O
T	O
.	O
W	O
.	O
Morris	O
,	O
and	O
J	O
.	O
E	O
.	O
Cronan	O
,	O
Jr	O
.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
91	O
:	O
3720	O
-	O
3724	O
,	O
1994	O
)	O
showed	O
this	O
mutation	O
(	O
now	O
called	O
lplA1	B-Protein
)	O
to	O
be	O
a	O
G76S	O
substitution	O
in	O
the	O
LplA	B-Protein
ligase	O
.	O

When	O
compared	O
with	O
the	O
wild	O
-	O
type	O
allele	O
,	O
the	O
cloned	O
lplA1	B-Protein
allele	O
conferred	O
a	O
threefold	O
increase	O
in	O
the	O
ability	O
to	O
discriminate	O
against	O
the	O
selenium	O
-	O
containing	O
analog	O
.	O
<EOS>	B-X
Lipoic	B-X
acid	B-X
is	B-X
a	B-X
covalently	B-X
bound	B-X
disulfide-containing	B-X
cofactor	B-X
required	B-X
for	B-X
function	B-X
of	B-X
the	B-X
pyruvate	B-X
dehydrogenase	B-X
,	B-X
alpha-ketoglutarate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
glycine	B-X
cleavage	B-X
enzyme	B-X
complexes	B-X
of	B-X
Escherichia	B-X
coli	B-X
.	B-X
We	B-X
found	B-X
that	B-X
lplA	B-X
null	B-X
mutants	B-X
displayed	B-X
no	B-X
growth	B-X
defects	B-X
unless	B-X
combined	B-X
with	B-X
lipA	B-X
(	B-X
lipoate	B-X
synthesis	B-X
)	B-X
or	B-X
lipB	B-X
mutations	B-X
and	B-X
that	B-X
overexpression	B-X
of	B-X
wild-type	B-X
LplA	B-X
suppressed	B-X
lipB	B-X
null	B-X
mutations	B-X
.	B-X
USA	B-X
91:3720-3724	B-X
,	B-X
1994	B-X
)	B-X
showed	B-X
this	B-X
mutation	B-X
(	B-X
now	B-X
called	B-X
lplA1	B-X
)	B-X
to	B-X
be	B-X
a	B-X
G76S	B-X
substitution	B-X
in	B-X
the	B-X
LplA	B-X
ligase	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
allele	B-X
,	B-X
the	B-X
cloned	B-X
lplA1	B-X
allele	B-X
conferred	B-X
a	B-X
threefold	B-X
increase	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
discriminate	B-X
against	B-X
the	B-X
selenium-containing	B-X
analog	B-X
.	B-X

These	O
results	O
support	O
a	O
two	O
-	O
pathway	O
/	O
two	O
-	O
ligase	O
model	O
of	O
lipoate	O
metabolism	O
in	O
E	O
.	O
coli	O
.	O

Regulation	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
by	O
glucose	O
in	O
culture	O
medium	O
:	O
involvement	O
of	O
Gi	O
protein	O
.	O
<EOS>	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
glucose	B-X
concentrations	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
results	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
Na+/glucose	B-X
cotransport	B-X
activity	B-X
in	B-X
the	B-X
epithelial	B-X
cells	B-X
.	B-X
To	B-X
study	B-X
this	B-X
regulation	B-X
of	B-X
Na+/glucose	B-X
cotransport	B-X
in	B-X
LLC-PK1	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
attempted	B-X
to	B-X
examine	B-X
the	B-X
involvement	B-X
of	B-X
Gi	B-X
protein	B-X
.	B-X
The	B-X
immunoblotting	B-X
with	B-X
an	B-X
antibody	B-X
for	B-X
the	B-X
carboxy-terminal	B-X
of	B-X
alpha	B-X
subunit	B-X
of	B-X
Gi	B-X
protein	B-X
(	B-X
Gi	B-X
alpha	B-X
)	B-X
revealed	B-X
no	B-X
significant	B-X
change	B-X
in	B-X
the	B-X
level	B-X
of	B-X
Gi	B-X
alpha	B-X
in	B-X
cells	B-X
cultured	B-X
with	B-X
low	B-X
(	B-X
5	B-X
mM	B-X
)	B-X
or	B-X
high	B-X
(	B-X
25	B-X
mM	B-X
)	B-X
glucose	B-X
concentrations	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
cultured	B-X
with	B-X
low	B-X
glucose	B-X
concentrations	B-X
induced	B-X
the	B-X
increases	B-X
of	B-X
both	B-X
islet	B-X
activating	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
Gi	B-X
alpha	B-X
and	B-X
Na+/glucose	B-X
cotransport	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
close	B-X
relationship	B-X
between	B-X
the	B-X
concentration	B-X
of	B-X
the	B-X
heterotrimeric	B-X
form	B-X
of	B-X
Gi	B-X
protein	B-X
(	B-X
Gi	B-X
alpha	B-X
beta	B-X
gamma	B-X
)	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
Na+/glucose	B-X
cotransport	B-X
in	B-X
LLC-PK1	B-X
cells	B-X
.	B-X

The	O
reduction	O
of	O
the	O
glucose	O
concentrations	O
in	O
the	O
culture	O
medium	O
results	O
in	O
an	O
increase	O
in	O
Na	O
+	O
/	O
glucose	O
cotransport	O
activity	O
in	O
the	O
epithelial	O
cells	O
.	O

To	O
study	O
this	O
regulation	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
,	O
we	O
have	O
attempted	O
to	O
examine	O
the	O
involvement	O
of	O
Gi	O
protein	O
.	O
<EOS>	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
glucose	B-X
concentrations	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
results	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
Na+/glucose	B-X
cotransport	B-X
activity	B-X
in	B-X
the	B-X
epithelial	B-X
cells	B-X
.	B-X
To	B-X
study	B-X
this	B-X
regulation	B-X
of	B-X
Na+/glucose	B-X
cotransport	B-X
in	B-X
LLC-PK1	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
attempted	B-X
to	B-X
examine	B-X
the	B-X
involvement	B-X
of	B-X
Gi	B-X
protein	B-X
.	B-X
The	B-X
immunoblotting	B-X
with	B-X
an	B-X
antibody	B-X
for	B-X
the	B-X
carboxy-terminal	B-X
of	B-X
alpha	B-X
subunit	B-X
of	B-X
Gi	B-X
protein	B-X
(	B-X
Gi	B-X
alpha	B-X
)	B-X
revealed	B-X
no	B-X
significant	B-X
change	B-X
in	B-X
the	B-X
level	B-X
of	B-X
Gi	B-X
alpha	B-X
in	B-X
cells	B-X
cultured	B-X
with	B-X
low	B-X
(	B-X
5	B-X
mM	B-X
)	B-X
or	B-X
high	B-X
(	B-X
25	B-X
mM	B-X
)	B-X
glucose	B-X
concentrations	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
cultured	B-X
with	B-X
low	B-X
glucose	B-X
concentrations	B-X
induced	B-X
the	B-X
increases	B-X
of	B-X
both	B-X
islet	B-X
activating	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
Gi	B-X
alpha	B-X
and	B-X
Na+/glucose	B-X
cotransport	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
close	B-X
relationship	B-X
between	B-X
the	B-X
concentration	B-X
of	B-X
the	B-X
heterotrimeric	B-X
form	B-X
of	B-X
Gi	B-X
protein	B-X
(	B-X
Gi	B-X
alpha	B-X
beta	B-X
gamma	B-X
)	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
Na+/glucose	B-X
cotransport	B-X
in	B-X
LLC-PK1	B-X
cells	B-X
.	B-X

The	O
immunoblotting	O
with	O
an	O
antibody	O
for	O
the	O
carboxy	O
-	O
terminal	O
of	O
alpha	O
subunit	O
of	O
Gi	O
protein	O
(	O
Gi	O
alpha	O
)	O
revealed	O
no	O
significant	O
change	O
in	O
the	O
level	O
of	O
Gi	O
alpha	O
in	O
cells	O
cultured	O
with	O
low	O
(	O
5	O
mM	O
)	O
or	O
high	O
(	O
25	O
mM	O
)	O
glucose	O
concentrations	O
.	O
<EOS>	B-X
Girdin	B-X
,	B-X
as	B-X
an	B-X
actin-binding	B-X
protein	B-X
,	B-X
plays	B-X
a	B-X
major	B-X
role	B-X
in	B-X
maintaining	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
actin	B-X
skeleton	B-X
structure	B-X
and	B-X
affects	B-X
the	B-X
growth	B-X
,	B-X
development	B-X
,	B-X
and	B-X
migration	B-X
of	B-X
neurons	B-X
.	B-X
This	B-X
study	B-X
discusses	B-X
the	B-X
mechanism	B-X
of	B-X
Girdin	B-X
in	B-X
brain	B-X
degeneration	B-X
caused	B-X
by	B-X
high	B-X
glucose	B-X
stimulation	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
Girdin	B-X
in	B-X
diabetic	B-X
patients	B-X
.	B-X
The	B-X
positive	B-X
expression	B-X
rate	B-X
of	B-X
Girdin	B-X
in	B-X
the	B-X
diabetic	B-X
group	B-X
was	B-X
17.2	B-X
%	B-X
(	B-X
5/29	B-X
)	B-X
,	B-X
which	B-X
was	B-X
obviously	B-X
lower	B-X
than	B-X
the	B-X
positive	B-X
expression	B-X
rate	B-X
of	B-X
83.3	B-X
%	B-X
(	B-X
20/24	B-X
)	B-X
in	B-X
the	B-X
non-diabetic	B-X
group	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
Girdin	B-X
and	B-X
its	B-X
signaling	B-X
pathway-related	B-X
proteins	B-X
Akt	B-X
and	B-X
STAT3	B-X
in	B-X
hippocampal	B-X
neurons	B-X
induced	B-X
by	B-X
high	B-X
glucose	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
control	B-X
group	B-X
(	B-X
glucose	B-X
concentration	B-X
=	B-X
25	B-X
mmol/L	B-X
)	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
Girdin	B-X
in	B-X
the	B-X
high-glucose	B-X
group	B-X
(	B-X
glucose	B-X
concentration	B-X
=	B-X
225	B-X
mmol/L	B-X
)	B-X
was	B-X
reduced	B-X
(	B-X

In	O
contrast	O
,	O
the	O
cultured	O
with	O
low	O
glucose	O
concentrations	O
induced	O
the	O
increases	O
of	O
both	O
islet	O
activating	O
protein	O
(	O
IAP	O
)	O
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
Gi	O
alpha	O
and	O
Na	O
+	O
/	O
glucose	O
cotransport	O
activity	O
.	O
<EOS>	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
glucose	B-X
concentrations	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
results	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
Na+/glucose	B-X
cotransport	B-X
activity	B-X
in	B-X
the	B-X
epithelial	B-X
cells	B-X
.	B-X
To	B-X
study	B-X
this	B-X
regulation	B-X
of	B-X
Na+/glucose	B-X
cotransport	B-X
in	B-X
LLC-PK1	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
attempted	B-X
to	B-X
examine	B-X
the	B-X
involvement	B-X
of	B-X
Gi	B-X
protein	B-X
.	B-X
The	B-X
immunoblotting	B-X
with	B-X
an	B-X
antibody	B-X
for	B-X
the	B-X
carboxy-terminal	B-X
of	B-X
alpha	B-X
subunit	B-X
of	B-X
Gi	B-X
protein	B-X
(	B-X
Gi	B-X
alpha	B-X
)	B-X
revealed	B-X
no	B-X
significant	B-X
change	B-X
in	B-X
the	B-X
level	B-X
of	B-X
Gi	B-X
alpha	B-X
in	B-X
cells	B-X
cultured	B-X
with	B-X
low	B-X
(	B-X
5	B-X
mM	B-X
)	B-X
or	B-X
high	B-X
(	B-X
25	B-X
mM	B-X
)	B-X
glucose	B-X
concentrations	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
cultured	B-X
with	B-X
low	B-X
glucose	B-X
concentrations	B-X
induced	B-X
the	B-X
increases	B-X
of	B-X
both	B-X
islet	B-X
activating	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
Gi	B-X
alpha	B-X
and	B-X
Na+/glucose	B-X
cotransport	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
this	B-X
increase	B-X
in	B-X
the	B-X
transport	B-X
activity	B-X
was	B-X
blocked	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
IAP	B-X
in	B-X
a	B-X
dose	B-X
dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
close	B-X
relationship	B-X
between	B-X
the	B-X
concentration	B-X
of	B-X
the	B-X
heterotrimeric	B-X
form	B-X
of	B-X
Gi	B-X
protein	B-X
(	B-X
Gi	B-X
alpha	B-X
beta	B-X
gamma	B-X
)	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
Na+/glucose	B-X
cotransport	B-X
in	B-X
LLC-PK1	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
this	O
increase	O
in	O
the	O
transport	O
activity	O
was	O
blocked	O
by	O
the	O
presence	O
of	O
IAP	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

These	O
results	O
suggest	O
that	O
there	O
is	O
a	O
close	O
relationship	O
between	O
the	O
concentration	O
of	O
the	O
heterotrimeric	O
form	O
of	O
Gi	O
protein	O
(	O
Gi	O
alpha	O
beta	O
gamma	O
)	O
and	O
the	O
activity	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
.	O
<EOS>	B-X
The	B-X
reduction	B-X
of	B-X
the	B-X
glucose	B-X
concentrations	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
results	B-X
in	B-X
an	B-X
increase	B-X
in	B-X
Na+/glucose	B-X
cotransport	B-X
activity	B-X
in	B-X
the	B-X
epithelial	B-X
cells	B-X
.	B-X
To	B-X
study	B-X
this	B-X
regulation	B-X
of	B-X
Na+/glucose	B-X
cotransport	B-X
in	B-X
LLC-PK1	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
attempted	B-X
to	B-X
examine	B-X
the	B-X
involvement	B-X
of	B-X
Gi	B-X
protein	B-X
.	B-X
The	B-X
immunoblotting	B-X
with	B-X
an	B-X
antibody	B-X
for	B-X
the	B-X
carboxy-terminal	B-X
of	B-X
alpha	B-X
subunit	B-X
of	B-X
Gi	B-X
protein	B-X
(	B-X
Gi	B-X
alpha	B-X
)	B-X
revealed	B-X
no	B-X
significant	B-X
change	B-X
in	B-X
the	B-X
level	B-X
of	B-X
Gi	B-X
alpha	B-X
in	B-X
cells	B-X
cultured	B-X
with	B-X
low	B-X
(	B-X
5	B-X
mM	B-X
)	B-X
or	B-X
high	B-X
(	B-X
25	B-X
mM	B-X
)	B-X
glucose	B-X
concentrations	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
cultured	B-X
with	B-X
low	B-X
glucose	B-X
concentrations	B-X
induced	B-X
the	B-X
increases	B-X
of	B-X
both	B-X
islet	B-X
activating	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
Gi	B-X
alpha	B-X
and	B-X
Na+/glucose	B-X
cotransport	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
this	B-X
increase	B-X
in	B-X
the	B-X
transport	B-X
activity	B-X
was	B-X
blocked	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
IAP	B-X
in	B-X
a	B-X
dose	B-X
dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
a	B-X
close	B-X
relationship	B-X
between	B-X
the	B-X
concentration	B-X
of	B-X
the	B-X
heterotrimeric	B-X
form	B-X
of	B-X
Gi	B-X
protein	B-X
(	B-X
Gi	B-X
alpha	B-X
beta	B-X
gamma	B-X
)	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
Na+/glucose	B-X
cotransport	B-X
in	B-X
LLC-PK1	B-X
cells	B-X
.	B-X

Posttranslational	O
modification	O
of	O
nitrogenase	O
.	O
<EOS>	B-X
In	B-X
microbes	B-X
that	B-X
fix	B-X
nitrogen	B-X
,	B-X
nitrogenase	B-X
catalyzes	B-X
the	B-X
conversion	B-X
of	B-X
N2	B-X
to	B-X
ammonia	B-X
in	B-X
an	B-X
ATP-demanding	B-X
reaction	B-X
.	B-X
To	B-X
help	B-X
conserve	B-X
energy	B-X
some	B-X
bacteria	B-X
inhibit	B-X
nitrogenase	B-X
activity	B-X
upon	B-X
exposure	B-X
to	B-X
ammonium	B-X
.	B-X
The	B-X
purple	B-X
nonsulfur	B-X
phototrophic	B-X
bacterium	B-X
Rhodopseudomonas	B-X
palustris	B-X
strain	B-X
CGA009	B-X
can	B-X
synthesize	B-X
three	B-X
functional	B-X
nitrogenase	B-X
isoenzymes	B-X
:	B-X
a	B-X
molybdenum	B-X
nitrogenase	B-X
,	B-X
a	B-X
vanadium	B-X
nitrogenase	B-X
,	B-X
and	B-X
an	B-X
iron	B-X
nitrogenase	B-X
.	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
in	B-X
some	B-X
alphaproteobacteria	B-X
,	B-X
including	B-X
R.	B-X
palustris	B-X
,	B-X
molybdenum	B-X
nitrogenase	B-X
activity	B-X
is	B-X
inhibited	B-X
by	B-X
ADP-ribosylation	B-X
when	B-X
cells	B-X
are	B-X
exposed	B-X
to	B-X
ammonium	B-X
.	B-X
Some	B-X
iron	B-X
nitrogenases	B-X
are	B-X
also	B-X
posttranslationally	B-X
modified	B-X
.	B-X
However	B-X
,	B-X
the	B-X
posttranslational	B-X
modification	B-X
of	B-X
vanadium	B-X
nitrogenase	B-X
has	B-X
not	B-X
been	B-X
reported	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
alternative	B-X
nitrogenases	B-X
of	B-X
R.	B-X
palustris	B-X
and	B-X
determined	B-X
that	B-X
both	B-X
its	B-X
vanadium	B-X
nitrogenase	B-X
and	B-X
its	B-X
iron	B-X
nitrogenase	B-X
activities	B-X
were	B-X
inhibited	B-X
and	B-X
posttranslationally	B-X
modified	B-X
when	B-X
cells	B-X
are	B-X
exposed	B-X
to	B-X
ammonium	B-X
.	B-X
Vanadium	B-X
nitrogenase	B-X
is	B-X
not	B-X
found	B-X
in	B-X
all	B-X
strains	B-X
of	B-X
R.	B-X
palustris	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
may	B-X
have	B-X
been	B-X
acquired	B-X
by	B-X
horizontal	B-X
gene	B-X
transfer	B-X
.	B-X
Also	B-X
,	B-X
phylogenetic	B-X
analyses	B-X
of	B-X
the	B-X
three	B-X
nitrogenases	B-X
suggest	B-X
that	B-X
VnfH	B-X
,	B-X
the	B-X
target	B-X
of	B-X
ADP-ribosylation	B-X
,	B-X
may	B-X
be	B-X
the	B-X
product	B-X
of	B-X
a	B-X
gene	B-X
duplication	B-X
of	B-X
nifH	B-X
,	B-X
the	B-X
molybdenum	B-X
nitrogenase	B-X
homolog	B-X
.	B-X

Differences	O
between	O
the	O
purple	O
bacterium	O
Rhodospirillum	O
rubrum	O
and	O
the	O
cyanobacterium	O
Anabaena	O
variabilis	O
.	O
<EOS>	B-X
In	B-X
the	B-X
photosynthetic	B-X
bacteria	B-X
Rhodospirillum	B-X
rubrum	B-X
and	B-X
Rhodopseudomonas	B-X
capsulatus	B-X
post-translational	B-X
regulation	B-X
of	B-X
nitrogenase	B-X
is	B-X
due	B-X
to	B-X
ADP-ribosylation	B-X
of	B-X
the	B-X
Fe-protein	B-X
,	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
[	B-X
Burris	B-X
,	B-X
R.	B-X
H.	B-X
(	B-X
1991	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
ADP-ribosylation	B-X
holds	B-X
true	B-X
for	B-X
the	B-X
filamentous	B-X
cyanobacterium	B-X
Anabaena	B-X
variabilis	B-X
.	B-X
Genes	B-X
coding	B-X
for	B-X
the	B-X
nitrogenase-modifying	B-X
enzymes	B-X
dinitrogenase	B-X
reductase-activating	B-X
glycohydrolase	B-X
(	B-X
DRAG	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyl	B-X
transferase	B-X
(	B-X
DRAT	B-X
)	B-X
from	B-X
R.	B-X
rubrum	B-X
have	B-X
been	B-X
subcloned	B-X
and	B-X
overexpressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
After	B-X
isolation	B-X
under	B-X
anaerobic	B-X
conditions	B-X
,	B-X
both	B-X
proteins	B-X
were	B-X
functional	B-X
as	B-X
determined	B-X
by	B-X
in-vitro	B-X
assays	B-X
using	B-X
nitrogenase	B-X
from	B-X
R.	B-X
rubrum	B-X
as	B-X
substrate	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
R.	B-X
rubrum	B-X
enzyme	B-X
,	B-X
nitrogenase	B-X
from	B-X
A.	B-X
variabilis	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
DRAG	B-X
or	B-X
DRAT	B-X
.	B-X
155	B-X
,	B-X
157-165	B-X
]	B-X
,	B-X
immunoblotting	B-X
of	B-X
the	B-X
inactive	B-X
,	B-X
modified	B-X
form	B-X
of	B-X
the	B-X
Fe-protein	B-X
from	B-X
R.	B-X
rubrum	B-X
but	B-X
not	B-X
that	B-X
from	B-X
A.	B-X
variabilis	B-X
showed	B-X
a	B-X
strong	B-X
cross	B-X
reaction	B-X
.	B-X
Furthermore	B-X
,	B-X
differently	B-X
to	B-X
R.	B-X
rubrum	B-X
no	B-X
ADP-ribosylated	B-X
proteins	B-X
could	B-X
be	B-X
detected	B-X
at	B-X
all	B-X
,	B-X
indicating	B-X
the	B-X
absence	B-X
of	B-X
this	B-X
posttranslational	B-X
modification	B-X
in	B-X
A.	B-X
variabilis	B-X
.	B-X

In	O
the	O
photosynthetic	O
bacteria	O
Rhodospirillum	O
rubrum	O
and	O
Rhodopseudomonas	O
capsulatus	O
post	O
-	O
translational	O
regulation	O
of	O
nitrogenase	O
is	O
due	O
to	O
ADP	O
-	O
ribosylation	O
of	O
the	O
Fe	O
-	O
protein	O
,	O
the	O
dinitrogenase	B-Protein
reductase	I-Protein
[	O
Burris	O
,	O
R	O
.	O
H	O
.	O
(	O
1991	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
266	O
,	O
9339	O
-	O
9342	O
]	O
.	O

This	O
mechanism	O
has	O
been	O
assumed	O
to	O
be	O
responsible	O
for	O
nitrogenase	O
modification	O
in	O
a	O
variety	O
of	O
organisms	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
ADP	O
-	O
ribosylation	O
holds	O
true	O
for	O
the	O
filamentous	O
cyanobacterium	O
Anabaena	O
variabilis	O
.	O
<EOS>	B-X
In	B-X
the	B-X
photosynthetic	B-X
bacteria	B-X
Rhodospirillum	B-X
rubrum	B-X
and	B-X
Rhodopseudomonas	B-X
capsulatus	B-X
post-translational	B-X
regulation	B-X
of	B-X
nitrogenase	B-X
is	B-X
due	B-X
to	B-X
ADP-ribosylation	B-X
of	B-X
the	B-X
Fe-protein	B-X
,	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
[	B-X
Burris	B-X
,	B-X
R.	B-X
H.	B-X
(	B-X
1991	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
ADP-ribosylation	B-X
holds	B-X
true	B-X
for	B-X
the	B-X
filamentous	B-X
cyanobacterium	B-X
Anabaena	B-X
variabilis	B-X
.	B-X
Genes	B-X
coding	B-X
for	B-X
the	B-X
nitrogenase-modifying	B-X
enzymes	B-X
dinitrogenase	B-X
reductase-activating	B-X
glycohydrolase	B-X
(	B-X
DRAG	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyl	B-X
transferase	B-X
(	B-X
DRAT	B-X
)	B-X
from	B-X
R.	B-X
rubrum	B-X
have	B-X
been	B-X
subcloned	B-X
and	B-X
overexpressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
R.	B-X
rubrum	B-X
enzyme	B-X
,	B-X
nitrogenase	B-X
from	B-X
A.	B-X
variabilis	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
DRAG	B-X
or	B-X
DRAT	B-X
.	B-X
Using	B-X
specific	B-X
antibodies	B-X
against	B-X
arginine-bound	B-X
ADP-ribose	B-X
[	B-X
Meyer	B-X
,	B-X
T.	B-X
&	B-X
Hilz	B-X
,	B-X
H.	B-X
(	B-X
1986	B-X
)	B-X
Eur	B-X
.	B-X
155	B-X
,	B-X
157-165	B-X
]	B-X
,	B-X
immunoblotting	B-X
of	B-X
the	B-X
inactive	B-X
,	B-X
modified	B-X
form	B-X
of	B-X
the	B-X
Fe-protein	B-X
from	B-X
R.	B-X
rubrum	B-X
but	B-X
not	B-X
that	B-X
from	B-X
A.	B-X
variabilis	B-X
showed	B-X
a	B-X
strong	B-X
cross	B-X
reaction	B-X
.	B-X
Furthermore	B-X
,	B-X
differently	B-X
to	B-X
R.	B-X
rubrum	B-X
no	B-X
ADP-ribosylated	B-X
proteins	B-X
could	B-X
be	B-X
detected	B-X
at	B-X
all	B-X
,	B-X
indicating	B-X
the	B-X
absence	B-X
of	B-X
this	B-X
posttranslational	B-X
modification	B-X
in	B-X
A.	B-X
variabilis	B-X
.	B-X

Genes	O
coding	O
for	O
the	O
nitrogenase	O
-	O
modifying	O
enzymes	O
dinitrogenase	B-Protein
reductase	I-Protein
-	I-Protein
activating	I-Protein
glycohydrolase	I-Protein
(	O
DRAG	B-Protein
)	O
and	O
dinitrogenase	B-Protein
reductase	I-Protein
ADP	I-Protein
-	I-Protein
ribosyl	I-Protein
transferase	I-Protein
(	O
DRAT	B-Protein
)	O
from	O
R	O
.	O
rubrum	O
have	O
been	O
subcloned	O
and	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O

After	O
isolation	O
under	O
anaerobic	O
conditions	O
,	O
both	O
proteins	O
were	O
functional	O
as	O
determined	O
by	O
in	O
-	O
vitro	O
assays	O
using	O
nitrogenase	O
from	O
R	O
.	O
rubrum	O
as	O
substrate	O
.	O

In	O
contrast	O
to	O
the	O
R	O
.	O
rubrum	O
enzyme	O
,	O
nitrogenase	O
from	O
A	O
.	O
variabilis	O
was	O
not	O
affected	O
by	O
DRAG	B-Protein
or	O
DRAT	B-Protein
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
system	B-X
where	B-X
mono-ADP-ribosylation	B-X
regulates	B-X
the	B-X
activity	B-X
of	B-X
an	B-X
enzyme	B-X
:	B-X
the	B-X
regulation	B-X
of	B-X
nitrogenase	B-X
in	B-X
bacteria	B-X
.	B-X
When	B-X
the	B-X
nitrogenase	B-X
product	B-X
,	B-X
ammonium	B-X
,	B-X
becomes	B-X
available	B-X
,	B-X
the	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
covalently	B-X
links	B-X
an	B-X
ADP-ribose	B-X
moiety	B-X
to	B-X
a	B-X
specific	B-X
arginine	B-X
residue	B-X
on	B-X
nitrogenase	B-X
switching-off	B-X
nitrogenase	B-X
activity	B-X
.	B-X
After	B-X
ammonium	B-X
exhaustion	B-X
,	B-X
the	B-X
ADP-ribosylhydrolase	B-X
(	B-X
DraG	B-X
)	B-X
removes	B-X
the	B-X
modifying	B-X
group	B-X
,	B-X
restoring	B-X
nitrogenase	B-X
activity	B-X
.	B-X
Structural	B-X
comparisons	B-X
indicated	B-X
that	B-X
bacterial	B-X
DraG	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
Archaea	B-X
and	B-X
mammalian	B-X
ADP-ribosylhydrolases	B-X
(	B-X
ARH	B-X
)	B-X
.	B-X
In	B-X
all	B-X
available	B-X
structures	B-X
,	B-X
the	B-X
ARH	B-X
active	B-X
site	B-X
consists	B-X
of	B-X
a	B-X
hydrophilic	B-X
cleft	B-X
carrying	B-X
a	B-X
binuclear	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
or	B-X
Mn	B-X
(	B-X
2+	B-X
)	B-X
cluster	B-X
,	B-X
which	B-X
is	B-X
critical	B-X
for	B-X
catalysis	B-X
.	B-X

Neither	O
could	O
inactive	O
nitrogenase	O
be	O
restored	O
by	O
DRAG	B-Protein
,	O
nor	O
nitrogenase	O
activity	O
suppressed	O
by	O
DRAT	B-Protein
.	O
<EOS>	B-X
In	B-X
the	B-X
photosynthetic	B-X
bacteria	B-X
Rhodospirillum	B-X
rubrum	B-X
and	B-X
Rhodopseudomonas	B-X
capsulatus	B-X
post-translational	B-X
regulation	B-X
of	B-X
nitrogenase	B-X
is	B-X
due	B-X
to	B-X
ADP-ribosylation	B-X
of	B-X
the	B-X
Fe-protein	B-X
,	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
[	B-X
Burris	B-X
,	B-X
R.	B-X
H.	B-X
(	B-X
1991	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
This	B-X
mechanism	B-X
has	B-X
been	B-X
assumed	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
nitrogenase	B-X
modification	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
organisms	B-X
.	B-X
Genes	B-X
coding	B-X
for	B-X
the	B-X
nitrogenase-modifying	B-X
enzymes	B-X
dinitrogenase	B-X
reductase-activating	B-X
glycohydrolase	B-X
(	B-X
DRAG	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyl	B-X
transferase	B-X
(	B-X
DRAT	B-X
)	B-X
from	B-X
R.	B-X
rubrum	B-X
have	B-X
been	B-X
subcloned	B-X
and	B-X
overexpressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
After	B-X
isolation	B-X
under	B-X
anaerobic	B-X
conditions	B-X
,	B-X
both	B-X
proteins	B-X
were	B-X
functional	B-X
as	B-X
determined	B-X
by	B-X
in-vitro	B-X
assays	B-X
using	B-X
nitrogenase	B-X
from	B-X
R.	B-X
rubrum	B-X
as	B-X
substrate	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
R.	B-X
rubrum	B-X
enzyme	B-X
,	B-X
nitrogenase	B-X
from	B-X
A.	B-X
variabilis	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
DRAG	B-X
or	B-X
DRAT	B-X
.	B-X
Neither	B-X
could	B-X
inactive	B-X
nitrogenase	B-X
be	B-X
restored	B-X
by	B-X
DRAG	B-X
,	B-X
nor	B-X
nitrogenase	B-X
activity	B-X
suppressed	B-X
by	B-X
DRAT	B-X
.	B-X
155	B-X
,	B-X
157-165	B-X
]	B-X
,	B-X
immunoblotting	B-X
of	B-X
the	B-X
inactive	B-X
,	B-X
modified	B-X
form	B-X
of	B-X
the	B-X
Fe-protein	B-X
from	B-X
R.	B-X
rubrum	B-X
but	B-X
not	B-X
that	B-X
from	B-X
A.	B-X
variabilis	B-X
showed	B-X
a	B-X
strong	B-X
cross	B-X
reaction	B-X
.	B-X
Furthermore	B-X
,	B-X
differently	B-X
to	B-X
R.	B-X
rubrum	B-X
no	B-X
ADP-ribosylated	B-X
proteins	B-X
could	B-X
be	B-X
detected	B-X
at	B-X
all	B-X
,	B-X
indicating	B-X
the	B-X
absence	B-X
of	B-X
this	B-X
posttranslational	B-X
modification	B-X
in	B-X
A.	B-X
variabilis	B-X
.	B-X

Using	O
specific	O
antibodies	O
against	O
arginine	O
-	O
bound	O
ADP	O
-	O
ribose	O
[	O
Meyer	O
,	O
T	O
.	O
&	O
Hilz	O
,	O
H	O
.	O
(	O
1986	O
)	O
Eur	O
.	O
J	O
.	O
Biochem	O
.	O
155	O
,	O
157	O
-	O
165	O
]	O
,	O
immunoblotting	O
of	O
the	O
inactive	O
,	O
modified	O
form	O
of	O
the	O
Fe	O
-	O
protein	O
from	O
R	O
.	O
rubrum	O
but	O
not	O
that	O
from	O
A	O
.	O
variabilis	O
showed	O
a	O
strong	O
cross	O
reaction	O
.	O
<EOS>	B-X
Arginine-specific	B-X
mono-ADP-ribosylation	B-X
of	B-X
proteins	B-X
and	B-X
arginine-specific	B-X
mono-ADP-ribosyltransferase	B-X
occur	B-X
in	B-X
heart	B-X
.	B-X
We	B-X
developed	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
,	B-X
R-28	B-X
,	B-X
against	B-X
ADP-ribosylpolyarginine	B-X
that	B-X
recognized	B-X
mono-ADP-ribosylated	B-X
proteins	B-X
and	B-X
identified	B-X
the	B-X
major	B-X
mono-ADP-ribosylation	B-X
products	B-X
of	B-X
quail	B-X
heart	B-X
.	B-X
Treatment	B-X
of	B-X
Immobilon-bound	B-X
ADP-ribosylated	B-X
Gs	B-X
protein	B-X
with	B-X
hydroxylamine	B-X
under	B-X
conditions	B-X
that	B-X
remove	B-X
ADP-ribose	B-X
from	B-X
its	B-X
arginines	B-X
eliminated	B-X
R-28	B-X
immunoreactivity	B-X
to	B-X
Gs	B-X
.	B-X
Also	B-X
,	B-X
R-28	B-X
immunoreactivity	B-X
to	B-X
quail	B-X
heart	B-X
proteins	B-X
was	B-X
removed	B-X
by	B-X
NaOH	B-X
and	B-X
phosphodiesterase	B-X
I	B-X
treatments	B-X
.	B-X
Similar	B-X
treatment	B-X
with	B-X
mercuric	B-X
chloride	B-X
did	B-X
not	B-X
remove	B-X
the	B-X
immunoreactivity	B-X
but	B-X
did	B-X
remove	B-X
exogenously	B-X
(	B-X
via	B-X
in	B-X
vitro	B-X
pertussis	B-X
toxin	B-X
treatment	B-X
)	B-X
added	B-X
ADP-ribose	B-X
from	B-X
cysteine	B-X
of	B-X
cardiac	B-X
Gi/Go	B-X
proteins	B-X
.	B-X
The	B-X
antiserum	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
react	B-X
with	B-X
ADP-ribosylasparagine	B-X
of	B-X
Rho	B-X
(	B-X
formed	B-X
by	B-X
C3	B-X
toxin	B-X
)	B-X
,	B-X
ADP-ribosyldiphthamide	B-X
of	B-X
elongation	B-X
factor	B-X
2	B-X
(	B-X
formed	B-X
by	B-X
diphtheria	B-X
toxin	B-X
)	B-X
in	B-X
quail	B-X
heart	B-X
preparations	B-X
,	B-X
or	B-X
polyADP-ribosylated	B-X
proteins	B-X
of	B-X
a	B-X
neonate	B-X
rat	B-X
cardiac	B-X
nuclear	B-X
preparation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
R-28	B-X
antiserum	B-X
appears	B-X
to	B-X
contain	B-X
predominantly	B-X
antibodies	B-X
directed	B-X
against	B-X
ADP-ribosylarginine	B-X
.	B-X
To	B-X
test	B-X
the	B-X
usefulness	B-X
of	B-X
R-28	B-X
,	B-X
immunoblotting	B-X
of	B-X
subcellular	B-X
fractions	B-X
of	B-X
quail	B-X
heart	B-X
was	B-X
performed	B-X
.	B-X
R-28	B-X
showed	B-X
the	B-X
greatest	B-X
immunoreactivity	B-X
in	B-X
the	B-X
sarcolemma	B-X
with	B-X
significant	B-X
immunoreactivity	B-X
in	B-X
denser	B-X
membrane	B-X
fractions	B-X
.	B-X
Hydroxylamine	B-X
treatment	B-X
eliminated	B-X
immunoreactivity	B-X
in	B-X
the	B-X
sarcolemma	B-X
and	B-X
denser	B-X
membrane	B-X
fractions	B-X
but	B-X
not	B-X
the	B-X
cytosol	B-X
,	B-X
suggesting	B-X
the	B-X
membranous	B-X
immunoreactive	B-X
bands	B-X
contain	B-X
ADP-ribosylarginine	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
that	B-X
recognizes	B-X
ADP-ribosylarginine	B-X
proteins	B-X
has	B-X
been	B-X
raised	B-X
.	B-X
The	B-X
usefulness	B-X
of	B-X
the	B-X
antiserum	B-X
is	B-X
demonstrated	B-X
by	B-X
the	B-X
characterization	B-X
of	B-X
endogenous	B-X
arginine	B-X
mono-ADP-ribosylation	B-X
products	B-X
in	B-X
quail	B-X
heart	B-X
.	B-X
The	B-X
quail	B-X
heart	B-X
has	B-X
several	B-X
sarcolemmal	B-X
and	B-X
denser	B-X
membrane	B-X
fraction	B-X
proteins	B-X
that	B-X
appear	B-X
to	B-X
be	B-X
mono-ADP-ribosylated	B-X
on	B-X
arginines	B-X
.	B-X

Furthermore	O
,	O
differently	O
to	O
R	O
.	O
rubrum	O
no	O
ADP	O
-	O
ribosylated	O
proteins	O
could	O
be	O
detected	O
at	O
all	O
,	O
indicating	O
the	O
absence	O
of	O
this	O
posttranslational	O
modification	O
in	O
A	O
.	O
variabilis	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
an	O
isoprenylated	O
67	O
kDa	O
protein	O
.	O
<EOS>	B-X
The	B-X
cDNA	B-X
coding	B-X
for	B-X
a	B-X
67	B-X
kDa	B-X
protein	B-X
(	B-X
p67	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
rat	B-X
Schwann	B-X
cell	B-X
library	B-X
.	B-X
A	B-X
recombinant	B-X
form	B-X
of	B-X
p67	B-X
expressed	B-X
in	B-X
bacteria	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
polyclonal	B-X
anti-p67	B-X
antibodies	B-X
.	B-X
By	B-X
immunoblot	B-X
analysis	B-X
p67	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
most	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
examined	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
p67	B-X
was	B-X
a	B-X
substrate	B-X
for	B-X
isoprenylation	B-X
in	B-X
vitro	B-X
by	B-X
geranylgeranylpyrophosphate	B-X
.	B-X
p67	B-X
was	B-X
associated	B-X
predominantly	B-X
with	B-X
the	B-X
particulate	B-X
fraction	B-X
of	B-X
rat	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
rat	B-X
p67	B-X
sequence	B-X
was	B-X
highly	B-X
homologous	B-X
to	B-X
a	B-X
family	B-X
of	B-X
recently	B-X
described	B-X
human	B-X
and	B-X
mouse	B-X
gamma-interferon	B-X
inducible	B-X
,	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
proteins	B-X
.	B-X

The	O
cDNA	O
coding	O
for	O
a	O
67	O
kDa	O
protein	O
(	O
p67	B-Protein
)	O
was	O
isolated	O
from	O
a	O
rat	O
Schwann	O
cell	O
library	O
.	O
<EOS>	B-X
The	B-X
cDNA	B-X
coding	B-X
for	B-X
a	B-X
67	B-X
kDa	B-X
protein	B-X
(	B-X
p67	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
rat	B-X
Schwann	B-X
cell	B-X
library	B-X
.	B-X
A	B-X
recombinant	B-X
form	B-X
of	B-X
p67	B-X
expressed	B-X
in	B-X
bacteria	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
polyclonal	B-X
anti-p67	B-X
antibodies	B-X
.	B-X
By	B-X
immunoblot	B-X
analysis	B-X
p67	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
most	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
examined	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
p67	B-X
was	B-X
a	B-X
substrate	B-X
for	B-X
isoprenylation	B-X
in	B-X
vitro	B-X
by	B-X
geranylgeranylpyrophosphate	B-X
.	B-X
p67	B-X
was	B-X
associated	B-X
predominantly	B-X
with	B-X
the	B-X
particulate	B-X
fraction	B-X
of	B-X
rat	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
rat	B-X
p67	B-X
sequence	B-X
was	B-X
highly	B-X
homologous	B-X
to	B-X
a	B-X
family	B-X
of	B-X
recently	B-X
described	B-X
human	B-X
and	B-X
mouse	B-X
gamma-interferon	B-X
inducible	B-X
,	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
proteins	B-X
.	B-X

A	O
recombinant	O
form	O
of	O
p67	B-Protein
expressed	O
in	O
bacteria	O
was	O
used	O
to	O
produce	O
polyclonal	O
anti	O
-	O
p67	B-Protein
antibodies	O
.	O
<EOS>	B-X
The	B-X
cDNA	B-X
coding	B-X
for	B-X
a	B-X
67	B-X
kDa	B-X
protein	B-X
(	B-X
p67	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
rat	B-X
Schwann	B-X
cell	B-X
library	B-X
.	B-X
A	B-X
recombinant	B-X
form	B-X
of	B-X
p67	B-X
expressed	B-X
in	B-X
bacteria	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
polyclonal	B-X
anti-p67	B-X
antibodies	B-X
.	B-X
By	B-X
immunoblot	B-X
analysis	B-X
p67	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
most	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
examined	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
p67	B-X
was	B-X
a	B-X
substrate	B-X
for	B-X
isoprenylation	B-X
in	B-X
vitro	B-X
by	B-X
geranylgeranylpyrophosphate	B-X
.	B-X
p67	B-X
was	B-X
associated	B-X
predominantly	B-X
with	B-X
the	B-X
particulate	B-X
fraction	B-X
of	B-X
rat	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
rat	B-X
p67	B-X
sequence	B-X
was	B-X
highly	B-X
homologous	B-X
to	B-X
a	B-X
family	B-X
of	B-X
recently	B-X
described	B-X
human	B-X
and	B-X
mouse	B-X
gamma-interferon	B-X
inducible	B-X
,	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
proteins	B-X
.	B-X

By	O
immunoblot	O
analysis	O
p67	B-Protein
was	O
found	O
to	O
be	O
expressed	O
in	O
most	O
tissues	O
and	O
cell	O
lines	O
examined	O
.	O
<EOS>	B-X
The	B-X
cDNA	B-X
coding	B-X
for	B-X
a	B-X
67	B-X
kDa	B-X
protein	B-X
(	B-X
p67	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
rat	B-X
Schwann	B-X
cell	B-X
library	B-X
.	B-X
A	B-X
recombinant	B-X
form	B-X
of	B-X
p67	B-X
expressed	B-X
in	B-X
bacteria	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
polyclonal	B-X
anti-p67	B-X
antibodies	B-X
.	B-X
By	B-X
immunoblot	B-X
analysis	B-X
p67	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
most	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
examined	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
p67	B-X
was	B-X
a	B-X
substrate	B-X
for	B-X
isoprenylation	B-X
in	B-X
vitro	B-X
by	B-X
geranylgeranylpyrophosphate	B-X
.	B-X
p67	B-X
was	B-X
associated	B-X
predominantly	B-X
with	B-X
the	B-X
particulate	B-X
fraction	B-X
of	B-X
rat	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
rat	B-X
p67	B-X
sequence	B-X
was	B-X
highly	B-X
homologous	B-X
to	B-X
a	B-X
family	B-X
of	B-X
recently	B-X
described	B-X
human	B-X
and	B-X
mouse	B-X
gamma-interferon	B-X
inducible	B-X
,	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
proteins	B-X
.	B-X

Inspection	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
revealed	O
a	O
COOH	O
-	O
terminal	O
consensus	O
sequence	O
for	O
isoprenylation	O
.	O
<EOS>	B-X
Inspection	B-X
of	B-X
the	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
revealed	B-X
a	B-X
COOH-terminal	B-X
consensus	B-X
sequence	B-X
for	B-X
isoprenylation	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
p67	B-X
was	B-X
a	B-X
substrate	B-X
for	B-X
isoprenylation	B-X
in	B-X
vitro	B-X
by	B-X
geranylgeranylpyrophosphate	B-X
.	B-X
The	B-X
rat	B-X
p67	B-X
sequence	B-X
was	B-X
highly	B-X
homologous	B-X
to	B-X
a	B-X
family	B-X
of	B-X
recently	B-X
described	B-X
human	B-X
and	B-X
mouse	B-X
gamma-interferon	B-X
inducible	B-X
,	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
proteins	B-X
.	B-X

Consistent	O
with	O
this	O
finding	O
,	O
p67	B-Protein
was	O
a	O
substrate	O
for	O
isoprenylation	O
in	O
vitro	O
by	O
geranylgeranylpyrophosphate	O
.	O
<EOS>	B-X
The	B-X
cDNA	B-X
coding	B-X
for	B-X
a	B-X
67	B-X
kDa	B-X
protein	B-X
(	B-X
p67	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
rat	B-X
Schwann	B-X
cell	B-X
library	B-X
.	B-X
A	B-X
recombinant	B-X
form	B-X
of	B-X
p67	B-X
expressed	B-X
in	B-X
bacteria	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
polyclonal	B-X
anti-p67	B-X
antibodies	B-X
.	B-X
By	B-X
immunoblot	B-X
analysis	B-X
p67	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
most	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
examined	B-X
.	B-X
Inspection	B-X
of	B-X
the	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
revealed	B-X
a	B-X
COOH-terminal	B-X
consensus	B-X
sequence	B-X
for	B-X
isoprenylation	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
p67	B-X
was	B-X
a	B-X
substrate	B-X
for	B-X
isoprenylation	B-X
in	B-X
vitro	B-X
by	B-X
geranylgeranylpyrophosphate	B-X
.	B-X
p67	B-X
was	B-X
associated	B-X
predominantly	B-X
with	B-X
the	B-X
particulate	B-X
fraction	B-X
of	B-X
rat	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
rat	B-X
p67	B-X
sequence	B-X
was	B-X
highly	B-X
homologous	B-X
to	B-X
a	B-X
family	B-X
of	B-X
recently	B-X
described	B-X
human	B-X
and	B-X
mouse	B-X
gamma-interferon	B-X
inducible	B-X
,	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
proteins	B-X
.	B-X

p67	B-Protein
was	O
associated	O
predominantly	O
with	O
the	O
particulate	O
fraction	O
of	O
rat	O
smooth	O
muscle	O
cells	O
.	O
<EOS>	B-X
The	B-X
cDNA	B-X
coding	B-X
for	B-X
a	B-X
67	B-X
kDa	B-X
protein	B-X
(	B-X
p67	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
rat	B-X
Schwann	B-X
cell	B-X
library	B-X
.	B-X
A	B-X
recombinant	B-X
form	B-X
of	B-X
p67	B-X
expressed	B-X
in	B-X
bacteria	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
polyclonal	B-X
anti-p67	B-X
antibodies	B-X
.	B-X
By	B-X
immunoblot	B-X
analysis	B-X
p67	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
most	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
examined	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
p67	B-X
was	B-X
a	B-X
substrate	B-X
for	B-X
isoprenylation	B-X
in	B-X
vitro	B-X
by	B-X
geranylgeranylpyrophosphate	B-X
.	B-X
p67	B-X
was	B-X
associated	B-X
predominantly	B-X
with	B-X
the	B-X
particulate	B-X
fraction	B-X
of	B-X
rat	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
rat	B-X
p67	B-X
sequence	B-X
was	B-X
highly	B-X
homologous	B-X
to	B-X
a	B-X
family	B-X
of	B-X
recently	B-X
described	B-X
human	B-X
and	B-X
mouse	B-X
gamma-interferon	B-X
inducible	B-X
,	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
proteins	B-X
.	B-X

The	O
rat	O
p67	B-Protein
sequence	O
was	O
highly	O
homologous	O
to	O
a	O
family	O
of	O
recently	O
described	O
human	O
and	O
mouse	O
gamma	B-Protein
-	I-Protein
interferon	I-Protein
inducible	O
,	O
guanine	O
nucleotide	O
binding	O
proteins	O
.	O
<EOS>	B-X
The	B-X
cDNA	B-X
coding	B-X
for	B-X
a	B-X
67	B-X
kDa	B-X
protein	B-X
(	B-X
p67	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
rat	B-X
Schwann	B-X
cell	B-X
library	B-X
.	B-X
A	B-X
recombinant	B-X
form	B-X
of	B-X
p67	B-X
expressed	B-X
in	B-X
bacteria	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
polyclonal	B-X
anti-p67	B-X
antibodies	B-X
.	B-X
By	B-X
immunoblot	B-X
analysis	B-X
p67	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
most	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
examined	B-X
.	B-X
Inspection	B-X
of	B-X
the	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
revealed	B-X
a	B-X
COOH-terminal	B-X
consensus	B-X
sequence	B-X
for	B-X
isoprenylation	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
p67	B-X
was	B-X
a	B-X
substrate	B-X
for	B-X
isoprenylation	B-X
in	B-X
vitro	B-X
by	B-X
geranylgeranylpyrophosphate	B-X
.	B-X
p67	B-X
was	B-X
associated	B-X
predominantly	B-X
with	B-X
the	B-X
particulate	B-X
fraction	B-X
of	B-X
rat	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
rat	B-X
p67	B-X
sequence	B-X
was	B-X
highly	B-X
homologous	B-X
to	B-X
a	B-X
family	B-X
of	B-X
recently	B-X
described	B-X
human	B-X
and	B-X
mouse	B-X
gamma-interferon	B-X
inducible	B-X
,	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
proteins	B-X
.	B-X

The	O
use	O
of	O
active	O
centre	O
acylation	O
to	O
control	O
the	O
pharmacokinetic	O
profile	O
of	O
a	O
recombinant	O
chimaeric	O
plasminogen	B-Protein
activator	O
.	O
<EOS>	B-X
Recombinant	B-X
hybrid	B-X
plasminogen	B-X
activators	B-X
consisting	B-X
of	B-X
the	B-X
``	B-X
A	B-X
''	B-X
chain	B-X
of	B-X
plasminogen	B-X
linked	B-X
to	B-X
the	B-X
``	B-X
B	B-X
''	B-X
chain	B-X
of	B-X
t-PA	B-X
that	B-X
are	B-X
inhibited	B-X
rapidly	B-X
by	B-X
plasma	B-X
protease	B-X
inhibitors	B-X
have	B-X
recently	B-X
been	B-X
described	B-X
(	B-X
Robinson	B-X
et	B-X
al	B-X
.	B-X
Active	B-X
centre	B-X
acylation	B-X
appeared	B-X
to	B-X
protect	B-X
the	B-X
hybrid	B-X
from	B-X
inhibition	B-X
and	B-X
allowed	B-X
material	B-X
to	B-X
circulate	B-X
as	B-X
potentially	B-X
active	B-X
species	B-X
for	B-X
prolonged	B-X
periods	B-X
.	B-X
Clearance	B-X
rates	B-X
of	B-X
a	B-X
range	B-X
of	B-X
acyl	B-X
derivatives	B-X
of	B-X
the	B-X
hybrid	B-X
were	B-X
7-35-fold	B-X
slower	B-X
than	B-X
for	B-X
native	B-X
hybrid	B-X
and	B-X
20-100-fold	B-X
slower	B-X
than	B-X
for	B-X
t-PA.	B-X
Clearance	B-X
rates	B-X
were	B-X
influenced	B-X
markedly	B-X
by	B-X
deacylation	B-X
rate	B-X
,	B-X
such	B-X
that	B-X
clearance	B-X
half-life	B-X
correlated	B-X
well	B-X
with	B-X
deacylation	B-X
half-life	B-X
.	B-X
We	B-X
have	B-X
thus	B-X
shown	B-X
that	B-X
it	B-X
is	B-X
feasible	B-X
to	B-X
control	B-X
the	B-X
pharmacokinetic	B-X
profile	B-X
of	B-X
a	B-X
recombinant	B-X
hybrid	B-X
plasminogen	B-X
activator	B-X
over	B-X
a	B-X
wide	B-X
range	B-X
by	B-X
selection	B-X
of	B-X
an	B-X
appropriate	B-X
acyl	B-X
group	B-X
for	B-X
attachment	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Such	B-X
control	B-X
is	B-X
not	B-X
possible	B-X
with	B-X
plasminogen	B-X
activators	B-X
that	B-X
are	B-X
cleared	B-X
predominantly	B-X
by	B-X
mechanisms	B-X
other	B-X
than	B-X
inhibition	B-X
.	B-X

Recombinant	O
hybrid	O
plasminogen	B-Protein
activators	O
consisting	O
of	O
the	O
"	O
A	O
"	O
chain	O
of	O
plasminogen	B-Protein
linked	O
to	O
the	O
"	O
B	O
"	O
chain	O
of	O
t	B-Protein
-	I-Protein
PA	I-Protein
that	O
are	O
inhibited	O
rapidly	O
by	O
plasma	O
protease	O
inhibitors	O
have	O
recently	O
been	O
described	O
(	O
Robinson	O
et	O
al	O
.	O
Circulation	O
1992	O
;	O
86	O
:	O
548	O
-	O
552	O
)	O
.	O

We	O
have	O
now	O
shown	O
that	O
following	O
bolus	O
administration	O
of	O
native	O
hybrid	O
to	O
guinea	O
pigs	O
,	O
fibrinolytic	O
activity	O
was	O
cleared	O
rapidly	O
from	O
the	O
circulation	O
.	O
<EOS>	B-X
Recombinant	B-X
hybrid	B-X
plasminogen	B-X
activators	B-X
consisting	B-X
of	B-X
the	B-X
``	B-X
A	B-X
''	B-X
chain	B-X
of	B-X
plasminogen	B-X
linked	B-X
to	B-X
the	B-X
``	B-X
B	B-X
''	B-X
chain	B-X
of	B-X
t-PA	B-X
that	B-X
are	B-X
inhibited	B-X
rapidly	B-X
by	B-X
plasma	B-X
protease	B-X
inhibitors	B-X
have	B-X
recently	B-X
been	B-X
described	B-X
(	B-X
Robinson	B-X
et	B-X
al	B-X
.	B-X
We	B-X
have	B-X
now	B-X
shown	B-X
that	B-X
following	B-X
bolus	B-X
administration	B-X
of	B-X
native	B-X
hybrid	B-X
to	B-X
guinea	B-X
pigs	B-X
,	B-X
fibrinolytic	B-X
activity	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
the	B-X
circulation	B-X
.	B-X
Active	B-X
centre	B-X
acylation	B-X
appeared	B-X
to	B-X
protect	B-X
the	B-X
hybrid	B-X
from	B-X
inhibition	B-X
and	B-X
allowed	B-X
material	B-X
to	B-X
circulate	B-X
as	B-X
potentially	B-X
active	B-X
species	B-X
for	B-X
prolonged	B-X
periods	B-X
.	B-X
Clearance	B-X
rates	B-X
of	B-X
a	B-X
range	B-X
of	B-X
acyl	B-X
derivatives	B-X
of	B-X
the	B-X
hybrid	B-X
were	B-X
7-35-fold	B-X
slower	B-X
than	B-X
for	B-X
native	B-X
hybrid	B-X
and	B-X
20-100-fold	B-X
slower	B-X
than	B-X
for	B-X
t-PA.	B-X
Clearance	B-X
rates	B-X
were	B-X
influenced	B-X
markedly	B-X
by	B-X
deacylation	B-X
rate	B-X
,	B-X
such	B-X
that	B-X
clearance	B-X
half-life	B-X
correlated	B-X
well	B-X
with	B-X
deacylation	B-X
half-life	B-X
.	B-X
We	B-X
have	B-X
thus	B-X
shown	B-X
that	B-X
it	B-X
is	B-X
feasible	B-X
to	B-X
control	B-X
the	B-X
pharmacokinetic	B-X
profile	B-X
of	B-X
a	B-X
recombinant	B-X
hybrid	B-X
plasminogen	B-X
activator	B-X
over	B-X
a	B-X
wide	B-X
range	B-X
by	B-X
selection	B-X
of	B-X
an	B-X
appropriate	B-X
acyl	B-X
group	B-X
for	B-X
attachment	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Such	B-X
control	B-X
is	B-X
not	B-X
possible	B-X
with	B-X
plasminogen	B-X
activators	B-X
that	B-X
are	B-X
cleared	B-X
predominantly	B-X
by	B-X
mechanisms	B-X
other	B-X
than	B-X
inhibition	B-X
.	B-X

Active	O
centre	O
acylation	O
appeared	O
to	O
protect	O
the	O
hybrid	O
from	O
inhibition	O
and	O
allowed	O
material	O
to	O
circulate	O
as	O
potentially	O
active	O
species	O
for	O
prolonged	O
periods	O
.	O
<EOS>	B-X
Recombinant	B-X
hybrid	B-X
plasminogen	B-X
activators	B-X
consisting	B-X
of	B-X
the	B-X
``	B-X
A	B-X
''	B-X
chain	B-X
of	B-X
plasminogen	B-X
linked	B-X
to	B-X
the	B-X
``	B-X
B	B-X
''	B-X
chain	B-X
of	B-X
t-PA	B-X
that	B-X
are	B-X
inhibited	B-X
rapidly	B-X
by	B-X
plasma	B-X
protease	B-X
inhibitors	B-X
have	B-X
recently	B-X
been	B-X
described	B-X
(	B-X
Robinson	B-X
et	B-X
al	B-X
.	B-X
We	B-X
have	B-X
now	B-X
shown	B-X
that	B-X
following	B-X
bolus	B-X
administration	B-X
of	B-X
native	B-X
hybrid	B-X
to	B-X
guinea	B-X
pigs	B-X
,	B-X
fibrinolytic	B-X
activity	B-X
was	B-X
cleared	B-X
rapidly	B-X
from	B-X
the	B-X
circulation	B-X
.	B-X
Active	B-X
centre	B-X
acylation	B-X
appeared	B-X
to	B-X
protect	B-X
the	B-X
hybrid	B-X
from	B-X
inhibition	B-X
and	B-X
allowed	B-X
material	B-X
to	B-X
circulate	B-X
as	B-X
potentially	B-X
active	B-X
species	B-X
for	B-X
prolonged	B-X
periods	B-X
.	B-X
Clearance	B-X
rates	B-X
of	B-X
a	B-X
range	B-X
of	B-X
acyl	B-X
derivatives	B-X
of	B-X
the	B-X
hybrid	B-X
were	B-X
7-35-fold	B-X
slower	B-X
than	B-X
for	B-X
native	B-X
hybrid	B-X
and	B-X
20-100-fold	B-X
slower	B-X
than	B-X
for	B-X
t-PA.	B-X
Clearance	B-X
rates	B-X
were	B-X
influenced	B-X
markedly	B-X
by	B-X
deacylation	B-X
rate	B-X
,	B-X
such	B-X
that	B-X
clearance	B-X
half-life	B-X
correlated	B-X
well	B-X
with	B-X
deacylation	B-X
half-life	B-X
.	B-X
We	B-X
have	B-X
thus	B-X
shown	B-X
that	B-X
it	B-X
is	B-X
feasible	B-X
to	B-X
control	B-X
the	B-X
pharmacokinetic	B-X
profile	B-X
of	B-X
a	B-X
recombinant	B-X
hybrid	B-X
plasminogen	B-X
activator	B-X
over	B-X
a	B-X
wide	B-X
range	B-X
by	B-X
selection	B-X
of	B-X
an	B-X
appropriate	B-X
acyl	B-X
group	B-X
for	B-X
attachment	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Such	B-X
control	B-X
is	B-X
not	B-X
possible	B-X
with	B-X
plasminogen	B-X
activators	B-X
that	B-X
are	B-X
cleared	B-X
predominantly	B-X
by	B-X
mechanisms	B-X
other	B-X
than	B-X
inhibition	B-X
.	B-X

Clearance	O
rates	O
of	O
a	O
range	O
of	O
acyl	O
derivatives	O
of	O
the	O
hybrid	O
were	O
7	O
-	O
35	O
-	O
fold	O
slower	O
than	O
for	O
native	O
hybrid	O
and	O
20	O
-	O
100	O
-	O
fold	O
slower	O
than	O
for	O
t	B-Protein
-	I-Protein
PA	I-Protein
.	O

Clearance	O
rates	O
were	O
influenced	O
markedly	O
by	O
deacylation	O
rate	O
,	O
such	O
that	O
clearance	O
half	O
-	O
life	O
correlated	O
well	O
with	O
deacylation	O
half	O
-	O
life	O
.	O
<EOS>	B-X
Clearance	B-X
rates	B-X
of	B-X
a	B-X
range	B-X
of	B-X
acyl	B-X
derivatives	B-X
of	B-X
the	B-X
hybrid	B-X
were	B-X
7-35-fold	B-X
slower	B-X
than	B-X
for	B-X
native	B-X
hybrid	B-X
and	B-X
20-100-fold	B-X
slower	B-X
than	B-X
for	B-X
t-PA.	B-X
Clearance	B-X
rates	B-X
were	B-X
influenced	B-X
markedly	B-X
by	B-X
deacylation	B-X
rate	B-X
,	B-X
such	B-X
that	B-X
clearance	B-X
half-life	B-X
correlated	B-X
well	B-X
with	B-X
deacylation	B-X
half-life	B-X
.	B-X

We	O
have	O
thus	O
shown	O
that	O
it	O
is	O
feasible	O
to	O
control	O
the	O
pharmacokinetic	O
profile	O
of	O
a	O
recombinant	O
hybrid	O
plasminogen	B-Protein
activator	O
over	O
a	O
wide	O
range	O
by	O
selection	O
of	O
an	O
appropriate	O
acyl	O
group	O
for	O
attachment	O
to	O
the	O
active	O
site	O
.	O

Such	O
control	O
is	O
not	O
possible	O
with	O
plasminogen	B-Protein
activators	O
that	O
are	O
cleared	O
predominantly	O
by	O
mechanisms	O
other	O
than	O
inhibition	O
.	O
<EOS>	B-X
There	B-X
are	B-X
two	B-X
common	B-X
misconceptions	B-X
about	B-X
case-control	B-X
studies	B-X
:	B-X
that	B-X
matching	B-X
in	B-X
itself	B-X
eliminates	B-X
(	B-X
controls	B-X
)	B-X
confounding	B-X
by	B-X
the	B-X
matching	B-X
factors	B-X
,	B-X
and	B-X
that	B-X
if	B-X
matching	B-X
has	B-X
been	B-X
performed	B-X
,	B-X
then	B-X
a	B-X
“	B-X
matched	B-X
analysis	B-X
”	B-X
is	B-X
required	B-X
.	B-X
However	B-X
,	B-X
matching	B-X
in	B-X
a	B-X
case-control	B-X
study	B-X
does	B-X
not	B-X
control	B-X
for	B-X
confounding	B-X
by	B-X
the	B-X
matching	B-X
factors	B-X
;	B-X
in	B-X
fact	B-X
it	B-X
can	B-X
introduce	B-X
confounding	B-X
by	B-X
the	B-X
matching	B-X
factors	B-X
even	B-X
when	B-X
it	B-X
did	B-X
not	B-X
exist	B-X
in	B-X
the	B-X
source	B-X
population	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
matched	B-X
design	B-X
may	B-X
require	B-X
controlling	B-X
for	B-X
the	B-X
matching	B-X
factors	B-X
in	B-X
the	B-X
analysis	B-X
.	B-X
Provided	B-X
that	B-X
there	B-X
are	B-X
no	B-X
problems	B-X
of	B-X
sparse	B-X
data	B-X
,	B-X
control	B-X
for	B-X
the	B-X
matching	B-X
factors	B-X
can	B-X
be	B-X
obtained	B-X
,	B-X
with	B-X
no	B-X
loss	B-X
of	B-X
validity	B-X
and	B-X
a	B-X
possible	B-X
increase	B-X
in	B-X
precision	B-X
,	B-X
using	B-X
a	B-X
“	B-X
standard	B-X
”	B-X
(	B-X
unconditional	B-X
)	B-X
analysis	B-X
,	B-X
and	B-X
a	B-X
“	B-X
matched	B-X
”	B-X
(	B-X
conditional	B-X
)	B-X
analysis	B-X
may	B-X
not	B-X
be	B-X
required	B-X
or	B-X
appropriate	B-X
.	B-X

The	O
31	O
-	O
kDa	O
precursor	O
of	O
interleukin	B-Protein
1	I-Protein
alpha	I-Protein
is	O
myristoylated	O
on	O
specific	O
lysines	O
within	O
the	O
16	O
-	O
kDa	O
N	O
-	O
terminal	O
propiece	O
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
interleukin	B-X
1	B-X
alpha	B-X
(	B-X
IL-1	B-X
alpha	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
mediator	B-X
of	B-X
the	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
A	B-X
unique	B-X
determinant	B-X
of	B-X
its	B-X
activity	B-X
as	B-X
compared	B-X
with	B-X
IL-1	B-X
beta	B-X
may	B-X
be	B-X
its	B-X
association	B-X
with	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
While	B-X
the	B-X
biologic	B-X
activity	B-X
of	B-X
``	B-X
membrane	B-X
IL-1	B-X
''	B-X
has	B-X
been	B-X
extensively	B-X
reported	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
membrane	B-X
binding	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
report	B-X
that	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
is	B-X
myristoylated	B-X
on	B-X
specific	B-X
internal	B-X
lysine	B-X
residues	B-X
.	B-X
Immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid-radiolabeled	B-X
human	B-X
monocyte	B-X
lysates	B-X
with	B-X
IgG	B-X
antibodies	B-X
to	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
recovered	B-X
a	B-X
protein	B-X
with	B-X
the	B-X
physicochemical	B-X
properties	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
(	B-X
16	B-X
kDa	B-X
,	B-X
pI	B-X
4.45	B-X
)	B-X
.	B-X
Glycyl	B-X
N-myristoylation	B-X
of	B-X
this	B-X
protein	B-X
is	B-X
precluded	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
glycine	B-X
residue	B-X
at	B-X
position	B-X
2	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
propiece	B-X
is	B-X
myristoylated	B-X
on	B-X
epsilon-amino	B-X
groups	B-X
of	B-X
lysine	B-X
.	B-X
To	B-X
determine	B-X
which	B-X
lysine	B-X
(	B-X
s	B-X
)	B-X
are	B-X
acylated	B-X
,	B-X
a	B-X
series	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
all	B-X
lysines	B-X
found	B-X
in	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
were	B-X
used	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
myristoylation	B-X
assay	B-X
containing	B-X
peptide	B-X
,	B-X
myristoyl-CoA	B-X
,	B-X
and	B-X
monocyte	B-X
lysate	B-X
as	B-X
enzyme	B-X
source	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
reaction	B-X
products	B-X
by	B-X
reverse-phase	B-X
HPLC	B-X
and	B-X
gas-phase	B-X
sequencing	B-X
demonstrated	B-X
the	B-X
specific	B-X
myristoylation	B-X
of	B-X
Lys-82	B-X
and	B-X
Lys-83	B-X
,	B-X
yielding	B-X
predominantly	B-X
monoacylated	B-X
product	B-X
.	B-X
A	B-X
conserved	B-X
sequence	B-X
in	B-X
the	B-X
IL-1	B-X
beta	B-X
propiece	B-X
was	B-X
myristoylated	B-X
with	B-X
at	B-X
least	B-X
8-fold	B-X
less	B-X
efficiency	B-X
.	B-X
Acylation	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
by	B-X
a	B-X
previously	B-X
unrecognized	B-X
lysyl	B-X
epsilon-amino	B-X
N-myristoyl-transferase	B-X
activity	B-X
may	B-X
facilitate	B-X
its	B-X
specific	B-X
membrane	B-X
targeting	B-X
.	B-X

The	O
cytokine	O
interleukin	B-Protein
1	I-Protein
alpha	I-Protein
(	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
)	O
is	O
a	O
critical	O
mediator	O
of	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O
<EOS>	B-X
STING	B-X
(	B-X
stimulator	B-X
of	B-X
interferon	B-X
genes	B-X
)	B-X
is	B-X
known	B-X
to	B-X
control	B-X
the	B-X
induction	B-X
of	B-X
innate	B-X
immune	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
the	B-X
recognition	B-X
of	B-X
cytosolic	B-X
DNA	B-X
species	B-X
,	B-X
including	B-X
the	B-X
genomes	B-X
of	B-X
viruses	B-X
such	B-X
as	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
(	B-X
HSV-1	B-X
)	B-X
.	B-X
However	B-X
,	B-X
while	B-X
STING	B-X
is	B-X
essential	B-X
for	B-X
protection	B-X
of	B-X
the	B-X
host	B-X
against	B-X
numerous	B-X
DNA	B-X
pathogens	B-X
,	B-X
sustained	B-X
STING	B-X
activity	B-X
can	B-X
lead	B-X
to	B-X
lethal	B-X
inflammatory	B-X
disease	B-X
.	B-X
Furthermore	B-X
,	B-X
TANK-binding	B-X
kinase	B-X
1	B-X
(	B-X
TBK1	B-X
)	B-X
associated	B-X
with	B-X
STING	B-X
was	B-X
found	B-X
to	B-X
facilitate	B-X
dsDNA-mediated	B-X
canonical	B-X
activation	B-X
of	B-X
NF-κB	B-X
as	B-X
well	B-X
as	B-X
IRF3	B-X
to	B-X
promote	B-X
proinflammatory	B-X
gene	B-X
transcription	B-X
.	B-X
Our	B-X
findings	B-X
detail	B-X
a	B-X
novel	B-X
dsDNA-mediated	B-X
NF-κB	B-X
activation	B-X
pathway	B-X
facilitated	B-X
through	B-X
a	B-X
STING-TRAF6-TBK1	B-X
axis	B-X
and	B-X
suggest	B-X
a	B-X
target	B-X
for	B-X
therapeutic	B-X
intervention	B-X
to	B-X
plausibly	B-X
stimulate	B-X
antiviral	B-X
activity	B-X
or	B-X
,	B-X
alternatively	B-X
,	B-X
avert	B-X
dsDNA-mediated	B-X
inflammatory	B-X
disease	B-X
.	B-X

A	O
unique	O
determinant	O
of	O
its	O
activity	O
as	O
compared	O
with	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
may	O
be	O
its	O
association	O
with	O
the	O
plasma	O
membrane	O
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
interleukin	B-X
1	B-X
alpha	B-X
(	B-X
IL-1	B-X
alpha	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
mediator	B-X
of	B-X
the	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
A	B-X
unique	B-X
determinant	B-X
of	B-X
its	B-X
activity	B-X
as	B-X
compared	B-X
with	B-X
IL-1	B-X
beta	B-X
may	B-X
be	B-X
its	B-X
association	B-X
with	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
While	B-X
the	B-X
biologic	B-X
activity	B-X
of	B-X
``	B-X
membrane	B-X
IL-1	B-X
''	B-X
has	B-X
been	B-X
extensively	B-X
reported	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
membrane	B-X
binding	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
report	B-X
that	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
is	B-X
myristoylated	B-X
on	B-X
specific	B-X
internal	B-X
lysine	B-X
residues	B-X
.	B-X
Immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid-radiolabeled	B-X
human	B-X
monocyte	B-X
lysates	B-X
with	B-X
IgG	B-X
antibodies	B-X
to	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
recovered	B-X
a	B-X
protein	B-X
with	B-X
the	B-X
physicochemical	B-X
properties	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
(	B-X
16	B-X
kDa	B-X
,	B-X
pI	B-X
4.45	B-X
)	B-X
.	B-X
To	B-X
determine	B-X
which	B-X
lysine	B-X
(	B-X
s	B-X
)	B-X
are	B-X
acylated	B-X
,	B-X
a	B-X
series	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
all	B-X
lysines	B-X
found	B-X
in	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
were	B-X
used	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
myristoylation	B-X
assay	B-X
containing	B-X
peptide	B-X
,	B-X
myristoyl-CoA	B-X
,	B-X
and	B-X
monocyte	B-X
lysate	B-X
as	B-X
enzyme	B-X
source	B-X
.	B-X
A	B-X
conserved	B-X
sequence	B-X
in	B-X
the	B-X
IL-1	B-X
beta	B-X
propiece	B-X
was	B-X
myristoylated	B-X
with	B-X
at	B-X
least	B-X
8-fold	B-X
less	B-X
efficiency	B-X
.	B-X
Acylation	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
by	B-X
a	B-X
previously	B-X
unrecognized	B-X
lysyl	B-X
epsilon-amino	B-X
N-myristoyl-transferase	B-X
activity	B-X
may	B-X
facilitate	B-X
its	B-X
specific	B-X
membrane	B-X
targeting	B-X
.	B-X

While	O
the	O
biologic	O
activity	O
of	O
"	O
membrane	O
IL	O
-	O
1	O
"	O
has	O
been	O
extensively	O
reported	O
,	O
the	O
mechanism	O
of	O
membrane	O
binding	O
remains	O
unclear	O
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
interleukin	B-X
1	B-X
alpha	B-X
(	B-X
IL-1	B-X
alpha	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
mediator	B-X
of	B-X
the	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
A	B-X
unique	B-X
determinant	B-X
of	B-X
its	B-X
activity	B-X
as	B-X
compared	B-X
with	B-X
IL-1	B-X
beta	B-X
may	B-X
be	B-X
its	B-X
association	B-X
with	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
While	B-X
the	B-X
biologic	B-X
activity	B-X
of	B-X
``	B-X
membrane	B-X
IL-1	B-X
''	B-X
has	B-X
been	B-X
extensively	B-X
reported	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
membrane	B-X
binding	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
report	B-X
that	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
is	B-X
myristoylated	B-X
on	B-X
specific	B-X
internal	B-X
lysine	B-X
residues	B-X
.	B-X
Immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid-radiolabeled	B-X
human	B-X
monocyte	B-X
lysates	B-X
with	B-X
IgG	B-X
antibodies	B-X
to	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
recovered	B-X
a	B-X
protein	B-X
with	B-X
the	B-X
physicochemical	B-X
properties	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
(	B-X
16	B-X
kDa	B-X
,	B-X
pI	B-X
4.45	B-X
)	B-X
.	B-X
To	B-X
determine	B-X
which	B-X
lysine	B-X
(	B-X
s	B-X
)	B-X
are	B-X
acylated	B-X
,	B-X
a	B-X
series	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
all	B-X
lysines	B-X
found	B-X
in	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
were	B-X
used	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
myristoylation	B-X
assay	B-X
containing	B-X
peptide	B-X
,	B-X
myristoyl-CoA	B-X
,	B-X
and	B-X
monocyte	B-X
lysate	B-X
as	B-X
enzyme	B-X
source	B-X
.	B-X
A	B-X
conserved	B-X
sequence	B-X
in	B-X
the	B-X
IL-1	B-X
beta	B-X
propiece	B-X
was	B-X
myristoylated	B-X
with	B-X
at	B-X
least	B-X
8-fold	B-X
less	B-X
efficiency	B-X
.	B-X
Acylation	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
by	B-X
a	B-X
previously	B-X
unrecognized	B-X
lysyl	B-X
epsilon-amino	B-X
N-myristoyl-transferase	B-X
activity	B-X
may	B-X
facilitate	B-X
its	B-X
specific	B-X
membrane	B-X
targeting	B-X
.	B-X

We	O
report	O
that	O
the	O
N	O
terminus	O
of	O
the	O
31	O
-	O
kDa	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
precursor	O
is	O
myristoylated	O
on	O
specific	O
internal	O
lysine	O
residues	O
.	O

Immunoprecipitation	O
of	O
[	O
3H	O
]	O
myristic	O
acid	O
-	O
radiolabeled	O
human	O
monocyte	O
lysates	O
with	O
IgG	O
antibodies	O
to	O
the	O
31	O
-	O
kDa	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
precursor	O
recovered	O
a	O
protein	O
with	O
the	O
physicochemical	O
properties	O
of	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
N	O
-	O
terminal	O
propiece	O
(	O
16	O
kDa	O
,	O
pI	O
4	O
.	O
45	O
)	O
.	O

Glycyl	O
N	O
-	O
myristoylation	O
of	O
this	O
protein	O
is	O
precluded	O
by	O
the	O
absence	O
of	O
a	O
glycine	O
residue	O
at	O
position	O
2	O
,	O
suggesting	O
that	O
the	O
propiece	O
is	O
myristoylated	O
on	O
epsilon	O
-	O
amino	O
groups	O
of	O
lysine	O
.	O
<EOS>	B-X
We	B-X
report	B-X
that	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
is	B-X
myristoylated	B-X
on	B-X
specific	B-X
internal	B-X
lysine	B-X
residues	B-X
.	B-X
Immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid-radiolabeled	B-X
human	B-X
monocyte	B-X
lysates	B-X
with	B-X
IgG	B-X
antibodies	B-X
to	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
recovered	B-X
a	B-X
protein	B-X
with	B-X
the	B-X
physicochemical	B-X
properties	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
(	B-X
16	B-X
kDa	B-X
,	B-X
pI	B-X
4.45	B-X
)	B-X
.	B-X
Glycyl	B-X
N-myristoylation	B-X
of	B-X
this	B-X
protein	B-X
is	B-X
precluded	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
glycine	B-X
residue	B-X
at	B-X
position	B-X
2	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
propiece	B-X
is	B-X
myristoylated	B-X
on	B-X
epsilon-amino	B-X
groups	B-X
of	B-X
lysine	B-X
.	B-X
To	B-X
determine	B-X
which	B-X
lysine	B-X
(	B-X
s	B-X
)	B-X
are	B-X
acylated	B-X
,	B-X
a	B-X
series	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
all	B-X
lysines	B-X
found	B-X
in	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
were	B-X
used	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
myristoylation	B-X
assay	B-X
containing	B-X
peptide	B-X
,	B-X
myristoyl-CoA	B-X
,	B-X
and	B-X
monocyte	B-X
lysate	B-X
as	B-X
enzyme	B-X
source	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
reaction	B-X
products	B-X
by	B-X
reverse-phase	B-X
HPLC	B-X
and	B-X
gas-phase	B-X
sequencing	B-X
demonstrated	B-X
the	B-X
specific	B-X
myristoylation	B-X
of	B-X
Lys-82	B-X
and	B-X
Lys-83	B-X
,	B-X
yielding	B-X
predominantly	B-X
monoacylated	B-X
product	B-X
.	B-X
A	B-X
conserved	B-X
sequence	B-X
in	B-X
the	B-X
IL-1	B-X
beta	B-X
propiece	B-X
was	B-X
myristoylated	B-X
with	B-X
at	B-X
least	B-X
8-fold	B-X
less	B-X
efficiency	B-X
.	B-X
Acylation	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
by	B-X
a	B-X
previously	B-X
unrecognized	B-X
lysyl	B-X
epsilon-amino	B-X
N-myristoyl-transferase	B-X
activity	B-X
may	B-X
facilitate	B-X
its	B-X
specific	B-X
membrane	B-X
targeting	B-X
.	B-X

To	O
determine	O
which	O
lysine	O
(	O
s	O
)	O
are	O
acylated	O
,	O
a	O
series	O
of	O
synthetic	O
peptides	O
containing	O
all	O
lysines	O
found	O
in	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
N	O
-	O
terminal	O
propiece	O
were	O
used	O
in	O
an	O
in	O
vitro	O
myristoylation	O
assay	O
containing	O
peptide	O
,	O
myristoyl	O
-	O
CoA	O
,	O
and	O
monocyte	O
lysate	O
as	O
enzyme	O
source	O
.	O

Analysis	O
of	O
the	O
reaction	O
products	O
by	O
reverse	O
-	O
phase	O
HPLC	O
and	O
gas	O
-	O
phase	O
sequencing	O
demonstrated	O
the	O
specific	O
myristoylation	O
of	O
Lys	O
-	O
82	O
and	O
Lys	O
-	O
83	O
,	O
yielding	O
predominantly	O
monoacylated	O
product	O
.	O
<EOS>	B-X
We	B-X
report	B-X
that	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
is	B-X
myristoylated	B-X
on	B-X
specific	B-X
internal	B-X
lysine	B-X
residues	B-X
.	B-X
Glycyl	B-X
N-myristoylation	B-X
of	B-X
this	B-X
protein	B-X
is	B-X
precluded	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
glycine	B-X
residue	B-X
at	B-X
position	B-X
2	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
propiece	B-X
is	B-X
myristoylated	B-X
on	B-X
epsilon-amino	B-X
groups	B-X
of	B-X
lysine	B-X
.	B-X
To	B-X
determine	B-X
which	B-X
lysine	B-X
(	B-X
s	B-X
)	B-X
are	B-X
acylated	B-X
,	B-X
a	B-X
series	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
all	B-X
lysines	B-X
found	B-X
in	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
were	B-X
used	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
myristoylation	B-X
assay	B-X
containing	B-X
peptide	B-X
,	B-X
myristoyl-CoA	B-X
,	B-X
and	B-X
monocyte	B-X
lysate	B-X
as	B-X
enzyme	B-X
source	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
reaction	B-X
products	B-X
by	B-X
reverse-phase	B-X
HPLC	B-X
and	B-X
gas-phase	B-X
sequencing	B-X
demonstrated	B-X
the	B-X
specific	B-X
myristoylation	B-X
of	B-X
Lys-82	B-X
and	B-X
Lys-83	B-X
,	B-X
yielding	B-X
predominantly	B-X
monoacylated	B-X
product	B-X
.	B-X
Acylation	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
by	B-X
a	B-X
previously	B-X
unrecognized	B-X
lysyl	B-X
epsilon-amino	B-X
N-myristoyl-transferase	B-X
activity	B-X
may	B-X
facilitate	B-X
its	B-X
specific	B-X
membrane	B-X
targeting	B-X
.	B-X

A	O
conserved	O
sequence	O
in	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
propiece	O
was	O
myristoylated	O
with	O
at	O
least	O
8	O
-	O
fold	O
less	O
efficiency	O
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
interleukin	B-X
1	B-X
alpha	B-X
(	B-X
IL-1	B-X
alpha	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
mediator	B-X
of	B-X
the	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
A	B-X
unique	B-X
determinant	B-X
of	B-X
its	B-X
activity	B-X
as	B-X
compared	B-X
with	B-X
IL-1	B-X
beta	B-X
may	B-X
be	B-X
its	B-X
association	B-X
with	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
While	B-X
the	B-X
biologic	B-X
activity	B-X
of	B-X
``	B-X
membrane	B-X
IL-1	B-X
''	B-X
has	B-X
been	B-X
extensively	B-X
reported	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
membrane	B-X
binding	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
report	B-X
that	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
is	B-X
myristoylated	B-X
on	B-X
specific	B-X
internal	B-X
lysine	B-X
residues	B-X
.	B-X
Immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid-radiolabeled	B-X
human	B-X
monocyte	B-X
lysates	B-X
with	B-X
IgG	B-X
antibodies	B-X
to	B-X
the	B-X
31-kDa	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
recovered	B-X
a	B-X
protein	B-X
with	B-X
the	B-X
physicochemical	B-X
properties	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
(	B-X
16	B-X
kDa	B-X
,	B-X
pI	B-X
4.45	B-X
)	B-X
.	B-X
Glycyl	B-X
N-myristoylation	B-X
of	B-X
this	B-X
protein	B-X
is	B-X
precluded	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
glycine	B-X
residue	B-X
at	B-X
position	B-X
2	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
propiece	B-X
is	B-X
myristoylated	B-X
on	B-X
epsilon-amino	B-X
groups	B-X
of	B-X
lysine	B-X
.	B-X
To	B-X
determine	B-X
which	B-X
lysine	B-X
(	B-X
s	B-X
)	B-X
are	B-X
acylated	B-X
,	B-X
a	B-X
series	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
all	B-X
lysines	B-X
found	B-X
in	B-X
the	B-X
IL-1	B-X
alpha	B-X
N-terminal	B-X
propiece	B-X
were	B-X
used	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
myristoylation	B-X
assay	B-X
containing	B-X
peptide	B-X
,	B-X
myristoyl-CoA	B-X
,	B-X
and	B-X
monocyte	B-X
lysate	B-X
as	B-X
enzyme	B-X
source	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
reaction	B-X
products	B-X
by	B-X
reverse-phase	B-X
HPLC	B-X
and	B-X
gas-phase	B-X
sequencing	B-X
demonstrated	B-X
the	B-X
specific	B-X
myristoylation	B-X
of	B-X
Lys-82	B-X
and	B-X
Lys-83	B-X
,	B-X
yielding	B-X
predominantly	B-X
monoacylated	B-X
product	B-X
.	B-X
A	B-X
conserved	B-X
sequence	B-X
in	B-X
the	B-X
IL-1	B-X
beta	B-X
propiece	B-X
was	B-X
myristoylated	B-X
with	B-X
at	B-X
least	B-X
8-fold	B-X
less	B-X
efficiency	B-X
.	B-X
Acylation	B-X
of	B-X
the	B-X
IL-1	B-X
alpha	B-X
precursor	B-X
by	B-X
a	B-X
previously	B-X
unrecognized	B-X
lysyl	B-X
epsilon-amino	B-X
N-myristoyl-transferase	B-X
activity	B-X
may	B-X
facilitate	B-X
its	B-X
specific	B-X
membrane	B-X
targeting	B-X
.	B-X

Acylation	O
of	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
precursor	O
by	O
a	O
previously	O
unrecognized	O
lysyl	O
epsilon	O
-	O
amino	O
N	O
-	O
myristoyl	O
-	O
transferase	O
activity	O
may	O
facilitate	O
its	O
specific	O
membrane	O
targeting	O
.	O

Nerve	B-Protein
growth	I-Protein
factor	I-Protein
induces	O
a	O
succession	O
of	O
increases	O
in	O
isoprenylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
PC	O
-	O
12	O
pheochromocytoma	O
cells	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

Pheochromocytoma	O
(	O
PC	O
-	O
12	O
)	O
cells	O
exposed	O
to	O
nerve	B-Protein
growth	I-Protein
factor	I-Protein
(	O
NGF	B-Protein
)	O
acquire	O
a	O
sympathetic	O
neuron	O
-	O
like	O
phenotype	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X

This	O
NGF	B-Protein
-	O
response	O
is	O
blocked	O
by	O
methylation	O
inhibitors	O
and	O
can	O
be	O
mimicked	O
by	O
the	O
farnesylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
protein	O
p21ras	B-Protein
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

The	O
implicated	O
involvement	O
of	O
prenylation	O
,	O
methylation	O
and	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
in	O
the	O
NGF	B-Protein
-	O
response	O
has	O
been	O
studied	O
by	O
directly	O
measuring	O
3H	O
-	O
mevalonic	O
acid	O
(	O
MVA	O
)	O
-	O
metabolites	O
incorporated	O
into	O
proteins	O
,	O
protein	O
carboxy	O
[	O
methyl	O
-	O
3H	O
]	O
ester	O
formation	O
and	O
levels	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
proteins	O
in	O
NGF	B-Protein
-	O
induced	O
PC	O
-	O
12	O
cells	O
.	O

We	O
demonstrate	O
that	O
NGF	B-Protein
induces	O
a	O
2	O
-	O
3	O
-	O
fold	O
increase	O
in	O
21	O
-	O
24	O
kDa	O
methylated	O
membrane	O
proteins	O
that	O
incorporate	O
3H	O
-	O
MVA	O
-	O
metabolites	O
,	O
and	O
bind	O
GTP	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

Levels	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
in	O
these	O
proteins	O
were	O
increased	O
by	O
2	O
-	O
3	O
-	O
fold	O
.	O
<EOS>	B-X
Overexpression	B-X
of	B-X
human	B-X
(	B-X
h	B-X
)	B-X
or	B-X
bovine	B-X
(	B-X
b	B-X
)	B-X
growth	B-X
hormone	B-X
(	B-X
GH	B-X
)	B-X
in	B-X
transgenic	B-X
mice	B-X
is	B-X
associated	B-X
with	B-X
marked	B-X
(	B-X
2-	B-X
to	B-X
12-fold	B-X
)	B-X
and	B-X
significant	B-X
increase	B-X
in	B-X
hepatic	B-X
binding	B-X
of	B-X
GH	B-X
and	B-X
prolactin	B-X
(	B-X
PRL	B-X
)	B-X
.	B-X
This	B-X
is	B-X
due	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
GH	B-X
and	B-X
PRL	B-X
receptors	B-X
(	B-X
GHR	B-X
,	B-X
PRLR	B-X
)	B-X
per	B-X
mg	B-X
of	B-X
microsomal	B-X
protein	B-X
without	B-X
changes	B-X
in	B-X
binding	B-X
affinity	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
hepatic	B-X
GHR	B-X
was	B-X
accompanied	B-X
by	B-X
significant	B-X
increases	B-X
in	B-X
plasma	B-X
GH-binding	B-X
protein	B-X
(	B-X
GHBP	B-X
)	B-X
and	B-X
in	B-X
mean	B-X
residence	B-X
time	B-X
of	B-X
injected	B-X
GH	B-X
.	B-X
Site-directed	B-X
in	B-X
vitro	B-X
mutagenesis	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
hGH	B-X
and	B-X
bGH	B-X
analogs	B-X
mutated	B-X
within	B-X
one	B-X
of	B-X
the	B-X
sites	B-X
involved	B-X
in	B-X
binding	B-X
to	B-X
GHR	B-X
and	B-X
PRLR	B-X
.	B-X
Mutating	B-X
hGH	B-X
to	B-X
produce	B-X
amino	B-X
acid	B-X
identity	B-X
with	B-X
bGH	B-X
at	B-X
Position	B-X
11	B-X
,	B-X
18	B-X
(	B-X
within	B-X
Helix	B-X
1	B-X
)	B-X
,	B-X
57	B-X
,	B-X
or	B-X
60	B-X
(	B-X
within	B-X
the	B-X
loop	B-X
between	B-X
Helix	B-X
1	B-X
and	B-X
2	B-X
)	B-X
did	B-X
not	B-X
affect	B-X
binding	B-X
to	B-X
GHR	B-X
in	B-X
vitro	B-X
,	B-X
or	B-X
somatotropic	B-X
activity	B-X
in	B-X
transgenic	B-X
mice	B-X
in	B-X
vivo	B-X
but	B-X
reduced	B-X
lactogenic	B-X
activity	B-X
in	B-X
Nb2	B-X
cells	B-X
by	B-X
22	B-X
%	B-X
-45	B-X
%	B-X
.	B-X
Mutations	B-X
of	B-X
bGH	B-X
designed	B-X
to	B-X
produce	B-X
amino	B-X
acid	B-X
identity	B-X
with	B-X
hGH	B-X
at	B-X
one	B-X
to	B-X
four	B-X
of	B-X
the	B-X
corresponding	B-X
positions	B-X
in	B-X
the	B-X
bGH	B-X
molecule	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
binding	B-X
to	B-X
GHR	B-X
or	B-X
somatotropic	B-X
activity	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
failed	B-X
to	B-X
produce	B-X
significant	B-X
binding	B-X
to	B-X
PRLR	B-X
but	B-X
resulted	B-X
in	B-X
alterations	B-X
in	B-X
the	B-X
effects	B-X
on	B-X
the	B-X
hypothalamic	B-X
and	B-X
anterior	B-X
pituitary	B-X
function	B-X
in	B-X
transgenic	B-X
mice	B-X
.	B-X

Methylation	O
and	O
membrane	O
association	O
of	O
the	O
small	O
GTP	O
-	O
binding	O
proteins	O
were	O
blocked	O
by	O
lovastatin	O
,	O
an	O
inhibitor	O
of	O
3	B-Protein
-	I-Protein
hydroxy	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
methylglutaryl	I-Protein
-	I-Protein
CoA	I-Protein
(	I-Protein
HMG	I-Protein
-	I-Protein
CoA	I-Protein
)	I-Protein
reductase	I-Protein
,	O
which	O
also	O
enhanced	O
their	O
labeling	O
by	O
3H	O
-	O
MVA	O
-	O
metabolites	O
.	O
<EOS>	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

Cycloheximide	O
reduced	O
the	O
levels	O
of	O
[	O
methyl	O
-	O
3H	O
]	O
labeled	O
21	O
-	O
24	O
kDa	O
proteins	O
and	O
of	O
the	O
overlapping	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
binding	O
-	O
proteins	O
.	O
<EOS>	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

About	O
70	O
%	O
of	O
the	O
[	O
methyl	O
-	O
3H	O
]	O
-	O
groups	O
found	O
in	O
these	O
proteins	O
were	O
recovered	O
from	O
two	O
dimensional	O
gel	O
blots	O
in	O
nine	O
distinct	O
spots	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
proteins	O
.	O
<EOS>	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

Taken	O
together	O
these	O
results	O
strongly	O
suggest	O
that	O
in	O
PC	O
-	O
12	O
cells	O
,	O
NGF	B-Protein
induces	O
an	O
increase	O
in	O
the	O
synthesis	O
of	O
prenylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

The	O
efficacy	O
of	O
lovastatin	O
blockage	O
of	O
protein	O
methylation	O
and	O
enhancement	O
of	O
3H	O
-	O
MVA	O
-	O
metabolites	O
incorporation	O
into	O
GTP	O
-	O
binding	O
proteins	O
was	O
lower	O
in	O
NGF	B-Protein
-	O
induced	O
cells	O
than	O
in	O
controls	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

This	O
suggests	O
that	O
NGF	B-Protein
also	O
induces	O
an	O
increase	O
in	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
activity	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X

At	O
the	O
early	O
phase	O
of	O
the	O
NGF	B-Protein
response	O
in	O
PC	O
-	O
12	O
cells	O
(	O
15	O
min	O
-	O
1	O
h	O
)	O
,	O
the	O
levels	O
of	O
two	O
small	O
GTP	O
-	O
binding	O
proteins	O
(	O
molecular	O
mass	O
of	O
21	O
-	O
22	O
kDa	O
and	O
23	O
-	O
24	O
kDa	O
)	O
were	O
increased	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

Thus	O
,	O
at	O
least	O
two	O
proteins	O
,	O
of	O
which	O
one	O
but	O
not	O
the	O
other	O
may	O
be	O
p21ras	B-Protein
,	O
appear	O
to	O
be	O
involved	O
in	O
the	O
early	O
response	O
.	O
<EOS>	B-X
These	B-X
domains	B-X
comprise	B-X
a	B-X
cluster	B-X
of	B-X
four	B-X
closely	B-X
packed	B-X
EF	B-X
hands	B-X
,	B-X
a	B-X
ZZ	B-X
domain	B-X
,	B-X
and	B-X
two	B-X
coiled-coil	B-X
regions	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
dystrophin	B-X
and	B-X
dystrobrevin	B-X
branches	B-X
share	B-X
one	B-X
or	B-X
two	B-X
binding	B-X
sites	B-X
for	B-X
members	B-X
of	B-X
the	B-X
syntrophin	B-X
family	B-X
of	B-X
adaptor	B-X
proteins	B-X
,	B-X
and	B-X
the	B-X
dystrophins	B-X
and	B-X
some	B-X
dystrotelins	B-X
share	B-X
a	B-X
WW	B-X
domain	B-X
.	B-X
Almost	B-X
all	B-X
animals	B-X
have	B-X
at	B-X
least	B-X
one	B-X
member	B-X
of	B-X
each	B-X
branch	B-X
,	B-X
with	B-X
multiple	B-X
paralogous	B-X
members	B-X
of	B-X
the	B-X
dystrophin	B-X
and	B-X
dystrobrevin	B-X
branches	B-X
in	B-X
the	B-X
vertebrates	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
humans	B-X
,	B-X
6	B-X
genes	B-X
,	B-X
19	B-X
promoters	B-X
,	B-X
and	B-X
10	B-X
alternatively	B-X
spliced	B-X
exons	B-X
conspire	B-X
to	B-X
generate	B-X
a	B-X
staggering	B-X
array	B-X
of	B-X
proteins	B-X
,	B-X
with	B-X
at	B-X
least	B-X
one	B-X
in	B-X
almost	B-X
every	B-X
tissue	B-X
of	B-X
the	B-X
body	B-X
.	B-X

After	O
a	O
lag	O
period	O
of	O
24	O
h	O
with	O
NGF	B-Protein
,	O
a	O
second	O
more	O
robust	O
phase	O
of	O
increase	O
in	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
was	O
apparent	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

This	O
relatively	O
late	O
response	O
,	O
which	O
was	O
almost	O
completed	O
within	O
24	O
h	O
,	O
may	O
reflect	O
involvement	O
of	O
small	O
GTP	O
-	O
binding	O
proteins	O
in	O
neurite	O
-	O
outgrowth	O
and	O
in	O
the	O
functional	O
activity	O
of	O
the	O
differentiated	O
cells	O
.	O
<EOS>	B-X
Pheochromocytoma	B-X
(	B-X
PC-12	B-X
)	B-X
cells	B-X
exposed	B-X
to	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
acquire	B-X
a	B-X
sympathetic	B-X
neuron-like	B-X
phenotype	B-X
.	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
NGF	B-X
also	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

Many	O
small	O
GTP	O
-	O
binding	O
proteins	O
were	O
increased	O
during	O
the	O
second	O
phase	O
,	O
precluding	O
electrophoretic	O
separation	O
of	O
all	O
of	O
them	O
.	O
<EOS>	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X

3	O
proteins	O
,	O
however	O
,	O
were	O
well	O
separated	O
(	O
one	O
23	O
-	O
24	O
kDa	O
protein	O
and	O
two	O
21	O
-	O
22	O
kDa	O
proteins	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
<EOS>	B-X
This	B-X
NGF-response	B-X
is	B-X
blocked	B-X
by	B-X
methylation	B-X
inhibitors	B-X
and	B-X
can	B-X
be	B-X
mimicked	B-X
by	B-X
the	B-X
farnesylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
protein	B-X
p21ras	B-X
.	B-X
The	B-X
implicated	B-X
involvement	B-X
of	B-X
prenylation	B-X
,	B-X
methylation	B-X
and	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
in	B-X
the	B-X
NGF-response	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
directly	B-X
measuring	B-X
3H-mevalonic	B-X
acid	B-X
(	B-X
MVA	B-X
)	B-X
-metabolites	B-X
incorporated	B-X
into	B-X
proteins	B-X
,	B-X
protein	B-X
carboxy	B-X
[	B-X
methyl-3H	B-X
]	B-X
ester	B-X
formation	B-X
and	B-X
levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
NGF-induced	B-X
PC-12	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
NGF	B-X
induces	B-X
a	B-X
2-3-fold	B-X
increase	B-X
in	B-X
21-24	B-X
kDa	B-X
methylated	B-X
membrane	B-X
proteins	B-X
that	B-X
incorporate	B-X
3H-MVA-metabolites	B-X
,	B-X
and	B-X
bind	B-X
GTP	B-X
.	B-X
Levels	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
increased	B-X
by	B-X
2-3-fold	B-X
.	B-X
Methylation	B-X
and	B-X
membrane	B-X
association	B-X
of	B-X
the	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
blocked	B-X
by	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
3-hydroxy-3-methylglutaryl-CoA	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
which	B-X
also	B-X
enhanced	B-X
their	B-X
labeling	B-X
by	B-X
3H-MVA-metabolites	B-X
.	B-X
Cycloheximide	B-X
reduced	B-X
the	B-X
levels	B-X
of	B-X
[	B-X
methyl-3H	B-X
]	B-X
labeled	B-X
21-24	B-X
kDa	B-X
proteins	B-X
and	B-X
of	B-X
the	B-X
overlapping	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP	B-X
binding-proteins	B-X
.	B-X
About	B-X
70	B-X
%	B-X
of	B-X
the	B-X
[	B-X
methyl-3H	B-X
]	B-X
-groups	B-X
found	B-X
in	B-X
these	B-X
proteins	B-X
were	B-X
recovered	B-X
from	B-X
two	B-X
dimensional	B-X
gel	B-X
blots	B-X
in	B-X
nine	B-X
distinct	B-X
spots	B-X
of	B-X
[	B-X
alpha-32P	B-X
]	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
in	B-X
PC-12	B-X
cells	B-X
,	B-X
NGF	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prenylated	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
lovastatin	B-X
blockage	B-X
of	B-X
protein	B-X
methylation	B-X
and	B-X
enhancement	B-X
of	B-X
3H-MVA-metabolites	B-X
incorporation	B-X
into	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
NGF-induced	B-X
cells	B-X
than	B-X
in	B-X
controls	B-X
.	B-X
At	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
the	B-X
NGF	B-X
response	B-X
in	B-X
PC-12	B-X
cells	B-X
(	B-X
15	B-X
min-1	B-X
h	B-X
)	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
two	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
molecular	B-X
mass	B-X
of	B-X
21-22	B-X
kDa	B-X
and	B-X
23-24	B-X
kDa	B-X
)	B-X
were	B-X
increased	B-X
.	B-X
Thus	B-X
,	B-X
at	B-X
least	B-X
two	B-X
proteins	B-X
,	B-X
of	B-X
which	B-X
one	B-X
but	B-X
not	B-X
the	B-X
other	B-X
may	B-X
be	B-X
p21ras	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
response	B-X
.	B-X
After	B-X
a	B-X
lag	B-X
period	B-X
of	B-X
24	B-X
h	B-X
with	B-X
NGF	B-X
,	B-X
a	B-X
second	B-X
more	B-X
robust	B-X
phase	B-X
of	B-X
increase	B-X
in	B-X
methylated	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
was	B-X
apparent	B-X
.	B-X
This	B-X
relatively	B-X
late	B-X
response	B-X
,	B-X
which	B-X
was	B-X
almost	B-X
completed	B-X
within	B-X
24	B-X
h	B-X
,	B-X
may	B-X
reflect	B-X
involvement	B-X
of	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
in	B-X
neurite-outgrowth	B-X
and	B-X
in	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
the	B-X
differentiated	B-X
cells	B-X
.	B-X
Many	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
were	B-X
increased	B-X
during	B-X
the	B-X
second	B-X
phase	B-X
,	B-X
precluding	B-X
electrophoretic	B-X
separation	B-X
of	B-X
all	B-X
of	B-X
them	B-X
.	B-X
3	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
were	B-X
well	B-X
separated	B-X
(	B-X
one	B-X
23-24	B-X
kDa	B-X
protein	B-X
and	B-X
two	B-X
21-22	B-X
kDa	B-X
proteins	B-X
)	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

Posttranslational	O
regulation	O
of	O
nitrogenase	O
in	O
Rhodobacter	O
capsulatus	O
:	O
existence	O
of	O
two	O
independent	O
regulatory	O
effects	O
of	O
ammonium	O
.	O
<EOS>	B-X
In	B-X
the	B-X
photosynthetic	B-X
bacterium	B-X
Rhodobacter	B-X
capsulatus	B-X
,	B-X
nitrogenase	B-X
activity	B-X
is	B-X
regulated	B-X
by	B-X
ADP-ribosylation	B-X
of	B-X
component	B-X
II	B-X
in	B-X
response	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
ammonium	B-X
to	B-X
cultures	B-X
or	B-X
to	B-X
the	B-X
removal	B-X
of	B-X
light	B-X
.	B-X
The	B-X
ammonium	B-X
stimulus	B-X
results	B-X
in	B-X
a	B-X
fast	B-X
and	B-X
almost	B-X
complete	B-X
inhibition	B-X
of	B-X
the	B-X
in	B-X
vivo	B-X
acetylene	B-X
reduction	B-X
activity	B-X
,	B-X
termed	B-X
switch-off	B-X
,	B-X
which	B-X
is	B-X
reversed	B-X
after	B-X
the	B-X
ammonium	B-X
is	B-X
exhausted	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
of	B-X
the	B-X
response	B-X
of	B-X
cells	B-X
to	B-X
ammonium	B-X
,	B-X
ADP-ribosylation	B-X
of	B-X
component	B-X
II	B-X
occurred	B-X
but	B-X
could	B-X
not	B-X
account	B-X
for	B-X
the	B-X
extent	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
inhibition	B-X
of	B-X
activity	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
response	B-X
was	B-X
confirmed	B-X
with	B-X
strains	B-X
expressing	B-X
mutant	B-X
component	B-X
II	B-X
proteins	B-X
;	B-X
although	B-X
these	B-X
proteins	B-X
are	B-X
not	B-X
a	B-X
substrate	B-X
for	B-X
ADP-ribosylation	B-X
,	B-X
the	B-X
strains	B-X
continued	B-X
to	B-X
exhibit	B-X
a	B-X
switch-off	B-X
response	B-X
to	B-X
ammonium	B-X
.	B-X
This	B-X
second	B-X
regulatory	B-X
response	B-X
of	B-X
nitrogenase	B-X
to	B-X
ammonium	B-X
was	B-X
found	B-X
to	B-X
be	B-X
synchronous	B-X
with	B-X
ADP-ribosylation	B-X
and	B-X
was	B-X
responsible	B-X
for	B-X
the	B-X
bulk	B-X
of	B-X
the	B-X
observed	B-X
effects	B-X
on	B-X
nitrogenase	B-X
activity	B-X
.	B-X
In	B-X
comparison	B-X
,	B-X
ADP-ribosylation	B-X
in	B-X
R.	B-X
capsulatus	B-X
was	B-X
found	B-X
to	B-X
be	B-X
relatively	B-X
slow	B-X
and	B-X
incomplete	B-X
but	B-X
responded	B-X
independently	B-X
to	B-X
both	B-X
known	B-X
stimuli	B-X
,	B-X
darkness	B-X
and	B-X
ammonium	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
in	B-X
vitro	B-X
nitrogenase	B-X
activity	B-X
of	B-X
both	B-X
the	B-X
wild	B-X
type	B-X
and	B-X
strains	B-X
whose	B-X
component	B-X
II	B-X
proteins	B-X
can	B-X
not	B-X
be	B-X
ADP-ribosylated	B-X
,	B-X
it	B-X
seems	B-X
likely	B-X
that	B-X
the	B-X
second	B-X
response	B-X
blocks	B-X
either	B-X
the	B-X
ATP	B-X
or	B-X
the	B-X
electron	B-X
supply	B-X
to	B-X
nitrogenase	B-X
.	B-X

In	O
the	O
photosynthetic	O
bacterium	O
Rhodobacter	O
capsulatus	O
,	O
nitrogenase	O
activity	O
is	O
regulated	O
by	O
ADP	O
-	O
ribosylation	O
of	O
component	B-Protein
II	I-Protein
in	O
response	O
to	O
the	O
addition	O
of	O
ammonium	O
to	O
cultures	O
or	O
to	O
the	O
removal	O
of	O
light	O
.	O

The	O
ammonium	O
stimulus	O
results	O
in	O
a	O
fast	O
and	O
almost	O
complete	O
inhibition	O
of	O
the	O
in	O
vivo	O
acetylene	O
reduction	O
activity	O
,	O
termed	O
switch	O
-	O
off	O
,	O
which	O
is	O
reversed	O
after	O
the	O
ammonium	O
is	O
exhausted	O
.	O

In	O
the	O
present	O
study	O
of	O
the	O
response	O
of	O
cells	O
to	O
ammonium	O
,	O
ADP	O
-	O
ribosylation	O
of	O
component	B-Protein
II	I-Protein
occurred	O
but	O
could	O
not	O
account	O
for	O
the	O
extent	O
and	O
timing	O
of	O
the	O
inhibition	O
of	O
activity	O
.	O

The	O
presence	O
of	O
an	O
additional	O
response	O
was	O
confirmed	O
with	O
strains	O
expressing	O
mutant	O
component	B-Protein
II	I-Protein
proteins	O
;	O
although	O
these	O
proteins	O
are	O
not	O
a	O
substrate	O
for	O
ADP	O
-	O
ribosylation	O
,	O
the	O
strains	O
continued	O
to	O
exhibit	O
a	O
switch	O
-	O
off	O
response	O
to	O
ammonium	O
.	O
<EOS>	B-X
Using	B-X
oligonucleotide-probed	B-X
Northern	B-X
blotting	B-X
experiments	B-X
,	B-X
a	B-X
500-nucleotide	B-X
czcN	B-X
message	B-X
and	B-X
a	B-X
400-nucleotide	B-X
czcI	B-X
message	B-X
were	B-X
found	B-X
,	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
6	B-X
,	B-X
200-nucleotide	B-X
czcCBA	B-X
message	B-X
(	B-X
D.	B-X
Van	B-X
der	B-X
Lelie	B-X
et	B-X
al.	B-X
,	B-X
Mol	B-X
.	B-X
23:493-503	B-X
,	B-X
1997	B-X
)	B-X
was	B-X
confirmed	B-X
.	B-X
Reverse	B-X
transcription-PCR	B-X
gave	B-X
evidence	B-X
for	B-X
additional	B-X
continuous	B-X
transcription	B-X
from	B-X
czcN	B-X
to	B-X
czcC	B-X
and	B-X
from	B-X
czcD	B-X
to	B-X
czcS	B-X
,	B-X
but	B-X
not	B-X
between	B-X
czcA	B-X
and	B-X
czcD	B-X
nor	B-X
between	B-X
czcS	B-X
and	B-X
a	B-X
131-amino-acid	B-X
open	B-X
reading	B-X
frame	B-X
following	B-X
czcS	B-X
.	B-X
The	B-X
CzcR	B-X
putative	B-X
response	B-X
regulator	B-X
was	B-X
purified	B-X
and	B-X
shown	B-X
to	B-X
bind	B-X
in	B-X
the	B-X
5	B-X
'	B-X
region	B-X
of	B-X
czcN	B-X
.	B-X
A	B-X
reporter	B-X
strain	B-X
carrying	B-X
a	B-X
czcNIC-lacZ-czcBADRS	B-X
determinant	B-X
on	B-X
plasmid	B-X
pMOL30	B-X
was	B-X
constructed	B-X
,	B-X
as	B-X
were	B-X
DeltaczcR	B-X
and	B-X
DeltaczcS	B-X
mutants	B-X
of	B-X
this	B-X
strain	B-X
and	B-X
of	B-X
AE128	B-X
(	B-X
pMOL30	B-X
)	B-X
wild	B-X
type	B-X
.	B-X
Experiments	B-X
on	B-X
(	B-X
i	B-X
)	B-X
growth	B-X
of	B-X
these	B-X
strains	B-X
in	B-X
liquid	B-X
culture	B-X
containing	B-X
5	B-X
mM	B-X
Zn2+	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
induction	B-X
of	B-X
the	B-X
beta-galactosidase	B-X
in	B-X
the	B-X
reporter	B-X
strains	B-X
by	B-X
zinc	B-X
,	B-X
cobalt	B-X
,	B-X
and	B-X
cadmium	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
cDNA	B-X
analysis	B-X
of	B-X
czcCBA	B-X
mRNA	B-X
synthesis	B-X
under	B-X
inducing	B-X
and	B-X
noninducing	B-X
conditions	B-X
showed	B-X
that	B-X
the	B-X
CzcRS	B-X
two-component	B-X
regulatory	B-X
system	B-X
is	B-X
involved	B-X
in	B-X
Czc	B-X
regulation	B-X
.	B-X

This	O
second	O
regulatory	O
response	O
of	O
nitrogenase	O
to	O
ammonium	O
was	O
found	O
to	O
be	O
synchronous	O
with	O
ADP	O
-	O
ribosylation	O
and	O
was	O
responsible	O
for	O
the	O
bulk	O
of	O
the	O
observed	O
effects	O
on	O
nitrogenase	O
activity	O
.	O
<EOS>	B-X
In	B-X
the	B-X
photosynthetic	B-X
bacterium	B-X
Rhodobacter	B-X
capsulatus	B-X
,	B-X
nitrogenase	B-X
activity	B-X
is	B-X
regulated	B-X
by	B-X
ADP-ribosylation	B-X
of	B-X
component	B-X
II	B-X
in	B-X
response	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
ammonium	B-X
to	B-X
cultures	B-X
or	B-X
to	B-X
the	B-X
removal	B-X
of	B-X
light	B-X
.	B-X
The	B-X
ammonium	B-X
stimulus	B-X
results	B-X
in	B-X
a	B-X
fast	B-X
and	B-X
almost	B-X
complete	B-X
inhibition	B-X
of	B-X
the	B-X
in	B-X
vivo	B-X
acetylene	B-X
reduction	B-X
activity	B-X
,	B-X
termed	B-X
switch-off	B-X
,	B-X
which	B-X
is	B-X
reversed	B-X
after	B-X
the	B-X
ammonium	B-X
is	B-X
exhausted	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
of	B-X
the	B-X
response	B-X
of	B-X
cells	B-X
to	B-X
ammonium	B-X
,	B-X
ADP-ribosylation	B-X
of	B-X
component	B-X
II	B-X
occurred	B-X
but	B-X
could	B-X
not	B-X
account	B-X
for	B-X
the	B-X
extent	B-X
and	B-X
timing	B-X
of	B-X
the	B-X
inhibition	B-X
of	B-X
activity	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
response	B-X
was	B-X
confirmed	B-X
with	B-X
strains	B-X
expressing	B-X
mutant	B-X
component	B-X
II	B-X
proteins	B-X
;	B-X
although	B-X
these	B-X
proteins	B-X
are	B-X
not	B-X
a	B-X
substrate	B-X
for	B-X
ADP-ribosylation	B-X
,	B-X
the	B-X
strains	B-X
continued	B-X
to	B-X
exhibit	B-X
a	B-X
switch-off	B-X
response	B-X
to	B-X
ammonium	B-X
.	B-X
This	B-X
second	B-X
regulatory	B-X
response	B-X
of	B-X
nitrogenase	B-X
to	B-X
ammonium	B-X
was	B-X
found	B-X
to	B-X
be	B-X
synchronous	B-X
with	B-X
ADP-ribosylation	B-X
and	B-X
was	B-X
responsible	B-X
for	B-X
the	B-X
bulk	B-X
of	B-X
the	B-X
observed	B-X
effects	B-X
on	B-X
nitrogenase	B-X
activity	B-X
.	B-X
In	B-X
comparison	B-X
,	B-X
ADP-ribosylation	B-X
in	B-X
R.	B-X
capsulatus	B-X
was	B-X
found	B-X
to	B-X
be	B-X
relatively	B-X
slow	B-X
and	B-X
incomplete	B-X
but	B-X
responded	B-X
independently	B-X
to	B-X
both	B-X
known	B-X
stimuli	B-X
,	B-X
darkness	B-X
and	B-X
ammonium	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
in	B-X
vitro	B-X
nitrogenase	B-X
activity	B-X
of	B-X
both	B-X
the	B-X
wild	B-X
type	B-X
and	B-X
strains	B-X
whose	B-X
component	B-X
II	B-X
proteins	B-X
can	B-X
not	B-X
be	B-X
ADP-ribosylated	B-X
,	B-X
it	B-X
seems	B-X
likely	B-X
that	B-X
the	B-X
second	B-X
response	B-X
blocks	B-X
either	B-X
the	B-X
ATP	B-X
or	B-X
the	B-X
electron	B-X
supply	B-X
to	B-X
nitrogenase	B-X
.	B-X

In	O
comparison	O
,	O
ADP	O
-	O
ribosylation	O
in	O
R	O
.	O
capsulatus	O
was	O
found	O
to	O
be	O
relatively	O
slow	O
and	O
incomplete	O
but	O
responded	O
independently	O
to	O
both	O
known	O
stimuli	O
,	O
darkness	O
and	O
ammonium	O
.	O

Based	O
on	O
the	O
in	O
vitro	O
nitrogenase	O
activity	O
of	O
both	O
the	O
wild	O
type	O
and	O
strains	O
whose	O
component	B-Protein
II	I-Protein
proteins	O
cannot	O
be	O
ADP	O
-	O
ribosylated	O
,	O
it	O
seems	O
likely	O
that	O
the	O
second	O
response	O
blocks	O
either	O
the	O
ATP	O
or	O
the	O
electron	O
supply	O
to	O
nitrogenase	O
.	O
<EOS>	B-X
Photosynthetic	B-X
microorganisms	B-X
could	B-X
readily	B-X
serve	B-X
as	B-X
powerhouses	B-X
to	B-X
successively	B-X
produce	B-X
this	B-X
type	B-X
of	B-X
energy	B-X
.	B-X
Here	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
central	B-X
features	B-X
of	B-X
the	B-X
energy	B-X
metabolism	B-X
that	B-X
sustains	B-X
N2	B-X
fixation	B-X
,	B-X
with	B-X
emphasis	B-X
on	B-X
the	B-X
bacterial	B-X
respiratory	B-X
chain	B-X
supplying	B-X
the	B-X
electrons	B-X
and	B-X
ATP	B-X
required	B-X
for	B-X
the	B-X
nitrogenase	B-X
reaction	B-X
.	B-X
We	B-X
discuss	B-X
common	B-X
trends	B-X
and	B-X
specific	B-X
variations	B-X
in	B-X
the	B-X
integrated	B-X
process	B-X
of	B-X
respiratory	B-X
electron	B-X
transport	B-X
and	B-X
N2	B-X
fixation	B-X
.	B-X
As	B-X
one	B-X
of	B-X
the	B-X
essential	B-X
macronutrient	B-X
components	B-X
in	B-X
the	B-X
medium	B-X
,	B-X
the	B-X
uptake	B-X
of	B-X
nitrogen	B-X
sources	B-X
severely	B-X
regulates	B-X
the	B-X
cell	B-X
's	B-X
metabolism	B-X
.	B-X

In	O
vitro	O
and	O
in	O
vivo	O
functional	O
characterization	O
of	O
bovine	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O
<EOS>	B-X
Coagulation	B-X
factor	B-X
IX	B-X
is	B-X
a	B-X
serine	B-X
protease	B-X
for	B-X
which	B-X
high-level	B-X
expression	B-X
of	B-X
biologically	B-X
active	B-X
protein	B-X
in	B-X
heterologous	B-X
cells	B-X
is	B-X
limited	B-X
due	B-X
to	B-X
inefficient	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
propeptide	B-X
as	B-X
well	B-X
as	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
multiple	B-X
amino-terminal	B-X
glutamic	B-X
acid	B-X
residues	B-X
.	B-X
We	B-X
have	B-X
overexpressed	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
cDNA	B-X
and	B-X
monitored	B-X
its	B-X
ability	B-X
to	B-X
improve	B-X
factor	B-X
IX	B-X
processing	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
From	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
bovine	B-X
liver	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
,	B-X
degenerate	B-X
oligonucleotides	B-X
were	B-X
used	B-X
to	B-X
isolate	B-X
a	B-X
3.5-kbp	B-X
bovine	B-X
cDNA	B-X
that	B-X
encoded	B-X
a	B-X
758-residue	B-X
open	B-X
reading	B-X
frame	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
cDNA	B-X
in	B-X
COS-1	B-X
and	B-X
CHO	B-X
cells	B-X
yielded	B-X
17-	B-X
and	B-X
16-fold	B-X
increases	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
gamma-carboxylase	B-X
activity	B-X
of	B-X
microsomal	B-X
preparations	B-X
,	B-X
respectively	B-X
.	B-X
Anti-serum	B-X
raised	B-X
against	B-X
a	B-X
predicted	B-X
peptide	B-X
sequence	B-X
reacted	B-X
with	B-X
a	B-X
94-kDa	B-X
polypeptide	B-X
in	B-X
the	B-X
partially	B-X
purified	B-X
bovine	B-X
liver	B-X
preparation	B-X
as	B-X
well	B-X
as	B-X
in	B-X
stably	B-X
transfected	B-X
CHO	B-X
cells	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
antibody	B-X
reactivity	B-X
correlated	B-X
with	B-X
the	B-X
increased	B-X
ability	B-X
to	B-X
carboxylate	B-X
a	B-X
peptide	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
strongly	B-X
support	B-X
the	B-X
conclusion	B-X
that	B-X
the	B-X
cDNA	B-X
encodes	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
the	B-X
gamma-carboxylase	B-X
expression	B-X
vector	B-X
into	B-X
factor	B-X
IX-expressing	B-X
CHO	B-X
cells	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
specific	B-X
procoagulant	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CHO	B-X
cells	B-X
to	B-X
modify	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
gamma-carboxyglutamic	B-X
acid	B-X
in	B-X
secreted	B-X
factor	B-X
IX	B-X
is	B-X
not	B-X
limited	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
alone	B-X
.	B-X

Coagulation	B-Protein
factor	I-Protein
IX	I-Protein
is	O
a	O
serine	O
protease	O
for	O
which	O
high	O
-	O
level	O
expression	O
of	O
biologically	O
active	O
protein	O
in	O
heterologous	O
cells	O
is	O
limited	O
due	O
to	O
inefficient	O
proteolytic	O
removal	O
of	O
the	O
propeptide	O
as	O
well	O
as	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
multiple	O
amino	O
-	O
terminal	O
glutamic	O
acid	O
residues	O
.	O
<EOS>	B-X
Coagulation	B-X
factor	B-X
IX	B-X
is	B-X
a	B-X
serine	B-X
protease	B-X
for	B-X
which	B-X
high-level	B-X
expression	B-X
of	B-X
biologically	B-X
active	B-X
protein	B-X
in	B-X
heterologous	B-X
cells	B-X
is	B-X
limited	B-X
due	B-X
to	B-X
inefficient	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
propeptide	B-X
as	B-X
well	B-X
as	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
multiple	B-X
amino-terminal	B-X
glutamic	B-X
acid	B-X
residues	B-X
.	B-X
We	B-X
have	B-X
overexpressed	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
cDNA	B-X
and	B-X
monitored	B-X
its	B-X
ability	B-X
to	B-X
improve	B-X
factor	B-X
IX	B-X
processing	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
From	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
bovine	B-X
liver	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
,	B-X
degenerate	B-X
oligonucleotides	B-X
were	B-X
used	B-X
to	B-X
isolate	B-X
a	B-X
3.5-kbp	B-X
bovine	B-X
cDNA	B-X
that	B-X
encoded	B-X
a	B-X
758-residue	B-X
open	B-X
reading	B-X
frame	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
cDNA	B-X
in	B-X
COS-1	B-X
and	B-X
CHO	B-X
cells	B-X
yielded	B-X
17-	B-X
and	B-X
16-fold	B-X
increases	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
gamma-carboxylase	B-X
activity	B-X
of	B-X
microsomal	B-X
preparations	B-X
,	B-X
respectively	B-X
.	B-X
Anti-serum	B-X
raised	B-X
against	B-X
a	B-X
predicted	B-X
peptide	B-X
sequence	B-X
reacted	B-X
with	B-X
a	B-X
94-kDa	B-X
polypeptide	B-X
in	B-X
the	B-X
partially	B-X
purified	B-X
bovine	B-X
liver	B-X
preparation	B-X
as	B-X
well	B-X
as	B-X
in	B-X
stably	B-X
transfected	B-X
CHO	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
strongly	B-X
support	B-X
the	B-X
conclusion	B-X
that	B-X
the	B-X
cDNA	B-X
encodes	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
the	B-X
gamma-carboxylase	B-X
expression	B-X
vector	B-X
into	B-X
factor	B-X
IX-expressing	B-X
CHO	B-X
cells	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
specific	B-X
procoagulant	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
transfection	B-X
of	B-X
an	B-X
expression	B-X
vector	B-X
encoding	B-X
the	B-X
propeptide	B-X
processing	B-X
enzyme	B-X
PACE	B-X
(	B-X
paired	B-X
basic	B-X
amino	B-X
acid	B-X
cleaving	B-X
enzyme	B-X
)	B-X
did	B-X
improve	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
by	B-X
3-fold	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CHO	B-X
cells	B-X
to	B-X
modify	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
gamma-carboxyglutamic	B-X
acid	B-X
in	B-X
secreted	B-X
factor	B-X
IX	B-X
is	B-X
not	B-X
limited	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
alone	B-X
.	B-X

We	O
have	O
overexpressed	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
cDNA	O
and	O
monitored	O
its	O
ability	O
to	O
improve	O
factor	B-Protein
IX	I-Protein
processing	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
.	O
<EOS>	B-X
Coagulation	B-X
factor	B-X
IX	B-X
is	B-X
a	B-X
serine	B-X
protease	B-X
for	B-X
which	B-X
high-level	B-X
expression	B-X
of	B-X
biologically	B-X
active	B-X
protein	B-X
in	B-X
heterologous	B-X
cells	B-X
is	B-X
limited	B-X
due	B-X
to	B-X
inefficient	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
propeptide	B-X
as	B-X
well	B-X
as	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
multiple	B-X
amino-terminal	B-X
glutamic	B-X
acid	B-X
residues	B-X
.	B-X
We	B-X
have	B-X
overexpressed	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
cDNA	B-X
and	B-X
monitored	B-X
its	B-X
ability	B-X
to	B-X
improve	B-X
factor	B-X
IX	B-X
processing	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
From	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
bovine	B-X
liver	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
,	B-X
degenerate	B-X
oligonucleotides	B-X
were	B-X
used	B-X
to	B-X
isolate	B-X
a	B-X
3.5-kbp	B-X
bovine	B-X
cDNA	B-X
that	B-X
encoded	B-X
a	B-X
758-residue	B-X
open	B-X
reading	B-X
frame	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
cDNA	B-X
in	B-X
COS-1	B-X
and	B-X
CHO	B-X
cells	B-X
yielded	B-X
17-	B-X
and	B-X
16-fold	B-X
increases	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
gamma-carboxylase	B-X
activity	B-X
of	B-X
microsomal	B-X
preparations	B-X
,	B-X
respectively	B-X
.	B-X
Anti-serum	B-X
raised	B-X
against	B-X
a	B-X
predicted	B-X
peptide	B-X
sequence	B-X
reacted	B-X
with	B-X
a	B-X
94-kDa	B-X
polypeptide	B-X
in	B-X
the	B-X
partially	B-X
purified	B-X
bovine	B-X
liver	B-X
preparation	B-X
as	B-X
well	B-X
as	B-X
in	B-X
stably	B-X
transfected	B-X
CHO	B-X
cells	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
antibody	B-X
reactivity	B-X
correlated	B-X
with	B-X
the	B-X
increased	B-X
ability	B-X
to	B-X
carboxylate	B-X
a	B-X
peptide	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
strongly	B-X
support	B-X
the	B-X
conclusion	B-X
that	B-X
the	B-X
cDNA	B-X
encodes	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
the	B-X
gamma-carboxylase	B-X
expression	B-X
vector	B-X
into	B-X
factor	B-X
IX-expressing	B-X
CHO	B-X
cells	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
specific	B-X
procoagulant	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
transfection	B-X
of	B-X
an	B-X
expression	B-X
vector	B-X
encoding	B-X
the	B-X
propeptide	B-X
processing	B-X
enzyme	B-X
PACE	B-X
(	B-X
paired	B-X
basic	B-X
amino	B-X
acid	B-X
cleaving	B-X
enzyme	B-X
)	B-X
did	B-X
improve	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
by	B-X
3-fold	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CHO	B-X
cells	B-X
to	B-X
modify	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
gamma-carboxyglutamic	B-X
acid	B-X
in	B-X
secreted	B-X
factor	B-X
IX	B-X
is	B-X
not	B-X
limited	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
alone	B-X
.	B-X

From	O
amino	O
acid	O
sequence	O
analysis	O
of	O
bovine	O
liver	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
,	O
degenerate	O
oligonucleotides	O
were	O
used	O
to	O
isolate	O
a	O
3	O
.	O
5	O
-	O
kbp	O
bovine	O
cDNA	O
that	O
encoded	O
a	O
758	O
-	O
residue	O
open	O
reading	O
frame	O
.	O
<EOS>	B-X
Coagulation	B-X
factor	B-X
IX	B-X
is	B-X
a	B-X
serine	B-X
protease	B-X
for	B-X
which	B-X
high-level	B-X
expression	B-X
of	B-X
biologically	B-X
active	B-X
protein	B-X
in	B-X
heterologous	B-X
cells	B-X
is	B-X
limited	B-X
due	B-X
to	B-X
inefficient	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
propeptide	B-X
as	B-X
well	B-X
as	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
multiple	B-X
amino-terminal	B-X
glutamic	B-X
acid	B-X
residues	B-X
.	B-X
We	B-X
have	B-X
overexpressed	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
cDNA	B-X
and	B-X
monitored	B-X
its	B-X
ability	B-X
to	B-X
improve	B-X
factor	B-X
IX	B-X
processing	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
From	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
bovine	B-X
liver	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
,	B-X
degenerate	B-X
oligonucleotides	B-X
were	B-X
used	B-X
to	B-X
isolate	B-X
a	B-X
3.5-kbp	B-X
bovine	B-X
cDNA	B-X
that	B-X
encoded	B-X
a	B-X
758-residue	B-X
open	B-X
reading	B-X
frame	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
cDNA	B-X
in	B-X
COS-1	B-X
and	B-X
CHO	B-X
cells	B-X
yielded	B-X
17-	B-X
and	B-X
16-fold	B-X
increases	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
gamma-carboxylase	B-X
activity	B-X
of	B-X
microsomal	B-X
preparations	B-X
,	B-X
respectively	B-X
.	B-X
Anti-serum	B-X
raised	B-X
against	B-X
a	B-X
predicted	B-X
peptide	B-X
sequence	B-X
reacted	B-X
with	B-X
a	B-X
94-kDa	B-X
polypeptide	B-X
in	B-X
the	B-X
partially	B-X
purified	B-X
bovine	B-X
liver	B-X
preparation	B-X
as	B-X
well	B-X
as	B-X
in	B-X
stably	B-X
transfected	B-X
CHO	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
strongly	B-X
support	B-X
the	B-X
conclusion	B-X
that	B-X
the	B-X
cDNA	B-X
encodes	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
the	B-X
gamma-carboxylase	B-X
expression	B-X
vector	B-X
into	B-X
factor	B-X
IX-expressing	B-X
CHO	B-X
cells	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
specific	B-X
procoagulant	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
transfection	B-X
of	B-X
an	B-X
expression	B-X
vector	B-X
encoding	B-X
the	B-X
propeptide	B-X
processing	B-X
enzyme	B-X
PACE	B-X
(	B-X
paired	B-X
basic	B-X
amino	B-X
acid	B-X
cleaving	B-X
enzyme	B-X
)	B-X
did	B-X
improve	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
by	B-X
3-fold	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CHO	B-X
cells	B-X
to	B-X
modify	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
gamma-carboxyglutamic	B-X
acid	B-X
in	B-X
secreted	B-X
factor	B-X
IX	B-X
is	B-X
not	B-X
limited	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
alone	B-X
.	B-X

Expression	O
of	O
the	O
cDNA	O
in	O
COS	O
-	O
1	O
and	O
CHO	O
cells	O
yielded	O
17	O
-	O
and	O
16	O
-	O
fold	O
increases	O
in	O
the	O
in	O
vitro	O
gamma	O
-	O
carboxylase	O
activity	O
of	O
microsomal	O
preparations	O
,	O
respectively	O
.	O

Anti	O
-	O
serum	O
raised	O
against	O
a	O
predicted	O
peptide	O
sequence	O
reacted	O
with	O
a	O
94	O
-	O
kDa	O
polypeptide	O
in	O
the	O
partially	O
purified	O
bovine	O
liver	O
preparation	O
as	O
well	O
as	O
in	O
stably	O
transfected	O
CHO	O
cells	O
.	O
<EOS>	B-X
Coagulation	B-X
factor	B-X
IX	B-X
is	B-X
a	B-X
serine	B-X
protease	B-X
for	B-X
which	B-X
high-level	B-X
expression	B-X
of	B-X
biologically	B-X
active	B-X
protein	B-X
in	B-X
heterologous	B-X
cells	B-X
is	B-X
limited	B-X
due	B-X
to	B-X
inefficient	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
propeptide	B-X
as	B-X
well	B-X
as	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
multiple	B-X
amino-terminal	B-X
glutamic	B-X
acid	B-X
residues	B-X
.	B-X
We	B-X
have	B-X
overexpressed	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
cDNA	B-X
and	B-X
monitored	B-X
its	B-X
ability	B-X
to	B-X
improve	B-X
factor	B-X
IX	B-X
processing	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
From	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
bovine	B-X
liver	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
,	B-X
degenerate	B-X
oligonucleotides	B-X
were	B-X
used	B-X
to	B-X
isolate	B-X
a	B-X
3.5-kbp	B-X
bovine	B-X
cDNA	B-X
that	B-X
encoded	B-X
a	B-X
758-residue	B-X
open	B-X
reading	B-X
frame	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
cDNA	B-X
in	B-X
COS-1	B-X
and	B-X
CHO	B-X
cells	B-X
yielded	B-X
17-	B-X
and	B-X
16-fold	B-X
increases	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
gamma-carboxylase	B-X
activity	B-X
of	B-X
microsomal	B-X
preparations	B-X
,	B-X
respectively	B-X
.	B-X
Anti-serum	B-X
raised	B-X
against	B-X
a	B-X
predicted	B-X
peptide	B-X
sequence	B-X
reacted	B-X
with	B-X
a	B-X
94-kDa	B-X
polypeptide	B-X
in	B-X
the	B-X
partially	B-X
purified	B-X
bovine	B-X
liver	B-X
preparation	B-X
as	B-X
well	B-X
as	B-X
in	B-X
stably	B-X
transfected	B-X
CHO	B-X
cells	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
antibody	B-X
reactivity	B-X
correlated	B-X
with	B-X
the	B-X
increased	B-X
ability	B-X
to	B-X
carboxylate	B-X
a	B-X
peptide	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
the	B-X
gamma-carboxylase	B-X
expression	B-X
vector	B-X
into	B-X
factor	B-X
IX-expressing	B-X
CHO	B-X
cells	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
specific	B-X
procoagulant	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
transfection	B-X
of	B-X
an	B-X
expression	B-X
vector	B-X
encoding	B-X
the	B-X
propeptide	B-X
processing	B-X
enzyme	B-X
PACE	B-X
(	B-X
paired	B-X
basic	B-X
amino	B-X
acid	B-X
cleaving	B-X
enzyme	B-X
)	B-X
did	B-X
improve	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
by	B-X
3-fold	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CHO	B-X
cells	B-X
to	B-X
modify	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
gamma-carboxyglutamic	B-X
acid	B-X
in	B-X
secreted	B-X
factor	B-X
IX	B-X
is	B-X
not	B-X
limited	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
alone	B-X
.	B-X

The	O
amount	O
of	O
antibody	O
reactivity	O
correlated	O
with	O
the	O
increased	O
ability	O
to	O
carboxylate	O
a	O
peptide	O
substrate	O
in	O
vitro	O
.	O
<EOS>	B-X
Coagulation	B-X
factor	B-X
IX	B-X
is	B-X
a	B-X
serine	B-X
protease	B-X
for	B-X
which	B-X
high-level	B-X
expression	B-X
of	B-X
biologically	B-X
active	B-X
protein	B-X
in	B-X
heterologous	B-X
cells	B-X
is	B-X
limited	B-X
due	B-X
to	B-X
inefficient	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
propeptide	B-X
as	B-X
well	B-X
as	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
multiple	B-X
amino-terminal	B-X
glutamic	B-X
acid	B-X
residues	B-X
.	B-X
We	B-X
have	B-X
overexpressed	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
cDNA	B-X
and	B-X
monitored	B-X
its	B-X
ability	B-X
to	B-X
improve	B-X
factor	B-X
IX	B-X
processing	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
cDNA	B-X
in	B-X
COS-1	B-X
and	B-X
CHO	B-X
cells	B-X
yielded	B-X
17-	B-X
and	B-X
16-fold	B-X
increases	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
gamma-carboxylase	B-X
activity	B-X
of	B-X
microsomal	B-X
preparations	B-X
,	B-X
respectively	B-X
.	B-X
Anti-serum	B-X
raised	B-X
against	B-X
a	B-X
predicted	B-X
peptide	B-X
sequence	B-X
reacted	B-X
with	B-X
a	B-X
94-kDa	B-X
polypeptide	B-X
in	B-X
the	B-X
partially	B-X
purified	B-X
bovine	B-X
liver	B-X
preparation	B-X
as	B-X
well	B-X
as	B-X
in	B-X
stably	B-X
transfected	B-X
CHO	B-X
cells	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
antibody	B-X
reactivity	B-X
correlated	B-X
with	B-X
the	B-X
increased	B-X
ability	B-X
to	B-X
carboxylate	B-X
a	B-X
peptide	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
transfection	B-X
of	B-X
an	B-X
expression	B-X
vector	B-X
encoding	B-X
the	B-X
propeptide	B-X
processing	B-X
enzyme	B-X
PACE	B-X
(	B-X
paired	B-X
basic	B-X
amino	B-X
acid	B-X
cleaving	B-X
enzyme	B-X
)	B-X
did	B-X
improve	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
by	B-X
3-fold	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CHO	B-X
cells	B-X
to	B-X
modify	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
gamma-carboxyglutamic	B-X
acid	B-X
in	B-X
secreted	B-X
factor	B-X
IX	B-X
is	B-X
not	B-X
limited	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
alone	B-X
.	B-X

These	O
results	O
strongly	O
support	O
the	O
conclusion	O
that	O
the	O
cDNA	O
encodes	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
.	O
<EOS>	B-X
Coagulation	B-X
factor	B-X
IX	B-X
is	B-X
a	B-X
serine	B-X
protease	B-X
for	B-X
which	B-X
high-level	B-X
expression	B-X
of	B-X
biologically	B-X
active	B-X
protein	B-X
in	B-X
heterologous	B-X
cells	B-X
is	B-X
limited	B-X
due	B-X
to	B-X
inefficient	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
propeptide	B-X
as	B-X
well	B-X
as	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
multiple	B-X
amino-terminal	B-X
glutamic	B-X
acid	B-X
residues	B-X
.	B-X
We	B-X
have	B-X
overexpressed	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
cDNA	B-X
and	B-X
monitored	B-X
its	B-X
ability	B-X
to	B-X
improve	B-X
factor	B-X
IX	B-X
processing	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
From	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
bovine	B-X
liver	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
,	B-X
degenerate	B-X
oligonucleotides	B-X
were	B-X
used	B-X
to	B-X
isolate	B-X
a	B-X
3.5-kbp	B-X
bovine	B-X
cDNA	B-X
that	B-X
encoded	B-X
a	B-X
758-residue	B-X
open	B-X
reading	B-X
frame	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
cDNA	B-X
in	B-X
COS-1	B-X
and	B-X
CHO	B-X
cells	B-X
yielded	B-X
17-	B-X
and	B-X
16-fold	B-X
increases	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
gamma-carboxylase	B-X
activity	B-X
of	B-X
microsomal	B-X
preparations	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
results	B-X
strongly	B-X
support	B-X
the	B-X
conclusion	B-X
that	B-X
the	B-X
cDNA	B-X
encodes	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
the	B-X
gamma-carboxylase	B-X
expression	B-X
vector	B-X
into	B-X
factor	B-X
IX-expressing	B-X
CHO	B-X
cells	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
specific	B-X
procoagulant	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CHO	B-X
cells	B-X
to	B-X
modify	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
gamma-carboxyglutamic	B-X
acid	B-X
in	B-X
secreted	B-X
factor	B-X
IX	B-X
is	B-X
not	B-X
limited	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
alone	B-X
.	B-X

Transient	O
transfection	O
of	O
the	O
gamma	B-Protein
-	I-Protein
carboxylase	I-Protein
expression	O
vector	O
into	O
factor	B-Protein
IX	I-Protein
-	O
expressing	O
CHO	O
cells	O
did	O
not	O
improve	O
the	O
specific	O
procoagulant	O
activity	O
of	O
secreted	O
factor	B-Protein
IX	I-Protein
.	O

In	O
contrast	O
,	O
transfection	O
of	O
an	O
expression	O
vector	O
encoding	O
the	O
propeptide	O
processing	O
enzyme	O
PACE	B-Protein
(	O
paired	B-Protein
basic	I-Protein
amino	I-Protein
acid	I-Protein
cleaving	I-Protein
enzyme	I-Protein
)	O
did	O
improve	O
the	O
specific	O
activity	O
of	O
secreted	O
factor	B-Protein
IX	I-Protein
by	O
3	O
-	O
fold	O
.	O
<EOS>	B-X
Coagulation	B-X
factor	B-X
IX	B-X
is	B-X
a	B-X
serine	B-X
protease	B-X
for	B-X
which	B-X
high-level	B-X
expression	B-X
of	B-X
biologically	B-X
active	B-X
protein	B-X
in	B-X
heterologous	B-X
cells	B-X
is	B-X
limited	B-X
due	B-X
to	B-X
inefficient	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
propeptide	B-X
as	B-X
well	B-X
as	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
multiple	B-X
amino-terminal	B-X
glutamic	B-X
acid	B-X
residues	B-X
.	B-X
We	B-X
have	B-X
overexpressed	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
cDNA	B-X
and	B-X
monitored	B-X
its	B-X
ability	B-X
to	B-X
improve	B-X
factor	B-X
IX	B-X
processing	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
From	B-X
amino	B-X
acid	B-X
sequence	B-X
analysis	B-X
of	B-X
bovine	B-X
liver	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
,	B-X
degenerate	B-X
oligonucleotides	B-X
were	B-X
used	B-X
to	B-X
isolate	B-X
a	B-X
3.5-kbp	B-X
bovine	B-X
cDNA	B-X
that	B-X
encoded	B-X
a	B-X
758-residue	B-X
open	B-X
reading	B-X
frame	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
cDNA	B-X
in	B-X
COS-1	B-X
and	B-X
CHO	B-X
cells	B-X
yielded	B-X
17-	B-X
and	B-X
16-fold	B-X
increases	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
gamma-carboxylase	B-X
activity	B-X
of	B-X
microsomal	B-X
preparations	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
antibody	B-X
reactivity	B-X
correlated	B-X
with	B-X
the	B-X
increased	B-X
ability	B-X
to	B-X
carboxylate	B-X
a	B-X
peptide	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
the	B-X
gamma-carboxylase	B-X
expression	B-X
vector	B-X
into	B-X
factor	B-X
IX-expressing	B-X
CHO	B-X
cells	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
specific	B-X
procoagulant	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
transfection	B-X
of	B-X
an	B-X
expression	B-X
vector	B-X
encoding	B-X
the	B-X
propeptide	B-X
processing	B-X
enzyme	B-X
PACE	B-X
(	B-X
paired	B-X
basic	B-X
amino	B-X
acid	B-X
cleaving	B-X
enzyme	B-X
)	B-X
did	B-X
improve	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
secreted	B-X
factor	B-X
IX	B-X
by	B-X
3-fold	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CHO	B-X
cells	B-X
to	B-X
modify	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
gamma-carboxyglutamic	B-X
acid	B-X
in	B-X
secreted	B-X
factor	B-X
IX	B-X
is	B-X
not	B-X
limited	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
gamma-carboxylase	B-X
alone	B-X
.	B-X

These	O
results	O
demonstrate	O
that	O
the	O
ability	O
of	O
CHO	O
cells	O
to	O
modify	O
glutamic	O
acid	O
residues	O
to	O
gamma	O
-	O
carboxyglutamic	O
acid	O
in	O
secreted	O
factor	B-Protein
IX	I-Protein
is	O
not	O
limited	O
by	O
the	O
expression	O
of	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
alone	O
.	O

Processive	O
post	O
-	O
translational	O
modification	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
Tau	B-X
isoforms	B-X
and	B-X
post-translational	B-X
modification	B-X
(	B-X
PTM	B-X
)	B-X
stoichiometry	B-X
in	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
,	B-X
we	B-X
generated	B-X
a	B-X
high-resolution	B-X
quantitative	B-X
proteomics	B-X
map	B-X
of	B-X
95	B-X
PTMs	B-X
on	B-X
multiple	B-X
isoforms	B-X
of	B-X
Tau	B-X
isolated	B-X
from	B-X
postmortem	B-X
human	B-X
tissue	B-X
from	B-X
49	B-X
AD	B-X
and	B-X
42	B-X
control	B-X
subjects	B-X
.	B-X
Since	B-X
all	B-X
newly	B-X
synthesized	B-X
proteins	B-X
enter	B-X
the	B-X
ER	B-X
in	B-X
an	B-X
unfolded	B-X
manner	B-X
,	B-X
folding	B-X
must	B-X
occur	B-X
within	B-X
the	B-X
ER	B-X
lumen	B-X
or	B-X
co-translationally	B-X
,	B-X
rendering	B-X
misfolding	B-X
events	B-X
a	B-X
serious	B-X
threat	B-X
.	B-X
Mass	B-X
spectrometry	B-X
has	B-X
been	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
is	B-X
a	B-X
processive	B-X
post-translational	B-X
modification	B-X
(	B-X
i.e	B-X
.	B-X
Kinetic	B-X
experiments	B-X
and	B-X
arguments	B-X
were	B-X
used	B-X
to	B-X
show	B-X
that	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
is	B-X
not	B-X
distributive	B-X
but	B-X
rather	B-X
is	B-X
one	B-X
of	B-X
the	B-X
first	B-X
well	B-X
documented	B-X
examples	B-X
of	B-X
an	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
a	B-X
processive	B-X
post-translation	B-X
modification	B-X
.	B-X

Vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
a	O
peptide	O
substrate	O
.	O
<EOS>	B-X
The	B-X
unique	B-X
and	B-X
characteristic	B-X
feature	B-X
of	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
is	B-X
the	B-X
presence	B-X
of	B-X
gamma-carboxyglutamyl	B-X
(	B-X
Gla	B-X
)	B-X
residues	B-X
formed	B-X
during	B-X
the	B-X
posttranslational	B-X
processing	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
The	B-X
energy	B-X
needed	B-X
to	B-X
drive	B-X
this	B-X
microsomal	B-X
carboxylation	B-X
event	B-X
comes	B-X
from	B-X
the	B-X
reoxidation	B-X
of	B-X
the	B-X
reduced	B-X
,	B-X
hydronaphthoquinone	B-X
form	B-X
of	B-X
vitamin	B-X
K	B-X
to	B-X
its	B-X
2,3-epoxide	B-X
.	B-X
The	B-X
primary	B-X
gene	B-X
product	B-X
of	B-X
the	B-X
vitamin	B-X
K-dependent	B-X
proteins	B-X
contains	B-X
a	B-X
homologous	B-X
propeptide	B-X
extension	B-X
between	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
the	B-X
mature	B-X
protein	B-X
and	B-X
signal	B-X
peptide	B-X
.	B-X
This	B-X
region	B-X
,	B-X
which	B-X
is	B-X
cleaved	B-X
before	B-X
secretion	B-X
of	B-X
these	B-X
proteins	B-X
,	B-X
serves	B-X
to	B-X
dock	B-X
the	B-X
protein	B-X
substrate	B-X
to	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
carboxylation	B-X
event	B-X
,	B-X
and	B-X
to	B-X
also	B-X
alter	B-X
the	B-X
apparent	B-X
Km	B-X
of	B-X
the	B-X
Glu	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
The	B-X
order	B-X
in	B-X
which	B-X
the	B-X
multiple	B-X
Glu	B-X
sites	B-X
on	B-X
the	B-X
substrate	B-X
proteins	B-X
are	B-X
carboxylated	B-X
is	B-X
unknown	B-X
,	B-X
but	B-X
elucidation	B-X
of	B-X
this	B-X
property	B-X
of	B-X
the	B-X
enzyme	B-X
and	B-X
further	B-X
details	B-X
of	B-X
the	B-X
bioorganic	B-X
mechanism	B-X
should	B-X
be	B-X
aided	B-X
by	B-X
recent	B-X
reports	B-X
of	B-X
purification	B-X
of	B-X
this	B-X
unique	B-X
carboxylase	B-X
.	B-X

Mass	O
spectrometry	O
has	O
been	O
used	O
to	O
demonstrate	O
that	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
is	O
a	O
processive	O
post	O
-	O
translational	O
modification	O
(	O
i	O
.	O
e	O
.	O
multiple	O
carboxylations	O
occur	O
during	O
a	O
single	O
association	O
between	O
enzyme	O
and	O
substrate	O
)	O
.	O

Purified	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
can	O
carboxylate	O
as	O
many	O
as	O
12	O
glutamate	O
residues	O
in	O
FIXQ	O
/	O
S	O
,	O
a	O
peptide	O
substrate	O
based	O
on	O
amino	O
acids	O
-	O
18	O
to	O
41	O
of	O
the	O
human	O
blood	O
clotting	O
enzyme	O
factor	B-Protein
IX	I-Protein
.	O

Mass	O
spectrometry	O
was	O
used	O
to	O
determine	O
the	O
number	O
of	O
gamma	O
-	O
carboxyl	O
groups	O
added	O
to	O
FIXQ	O
/	O
S	O
by	O
the	O
carboxylase	O
during	O
an	O
in	O
vitro	O
reaction	O
.	O

Despite	O
the	O
fact	O
that	O
most	O
substrate	O
molecules	O
in	O
a	O
reaction	O
were	O
uncarboxylated	O
,	O
almost	O
all	O
carboxylated	O
FIXQ	O
/	O
S	O
molecules	O
were	O
carboxylated	O
many	O
times	O
.	O

This	O
observation	O
can	O
only	O
be	O
explained	O
by	O
two	O
types	O
of	O
mechanisms	O
.	O
<EOS>	B-X
Inadvertent	B-X
perioperative	B-X
hypothermia	B-X
is	B-X
a	B-X
phenomenon	B-X
that	B-X
can	B-X
occur	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
suppression	B-X
of	B-X
the	B-X
central	B-X
mechanisms	B-X
of	B-X
temperature	B-X
regulation	B-X
due	B-X
to	B-X
anaesthesia	B-X
,	B-X
and	B-X
of	B-X
prolonged	B-X
exposure	B-X
of	B-X
large	B-X
surfaces	B-X
of	B-X
skin	B-X
to	B-X
cold	B-X
temperatures	B-X
in	B-X
operating	B-X
rooms	B-X
.	B-X
The	B-X
comorbidity	B-X
migraine-epilepsy	B-X
might	B-X
be	B-X
explained	B-X
in	B-X
these	B-X
cases	B-X
by	B-X
a	B-X
neuronal	B-X
hyperexcitability	B-X
,	B-X
which	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
both	B-X
diseases	B-X
:	B-X
a	B-X
higher	B-X
concentration	B-X
of	B-X
extracellular	B-X
glutamate	B-X
,	B-X
the	B-X
main	B-X
excitatory	B-X
neurotransmitter	B-X
,	B-X
leads	B-X
in	B-X
fact	B-X
as	B-X
a	B-X
result	B-X
a	B-X
Cortical	B-X
Spreading	B-X
Depression	B-X
(	B-X
the	B-X
pathophysiological	B-X
mechanism	B-X
at	B-X
the	B-X
base	B-X
of	B-X
aura	B-X
)	B-X
and	B-X
convulsions	B-X
;	B-X
antiepileptic	B-X
drugs	B-X
such	B-X
as	B-X
topiramate	B-X
are	B-X
,	B-X
therefore	B-X
,	B-X
used	B-X
also	B-X
in	B-X
migraine	B-X
prophylaxis	B-X
.	B-X
A	B-X
genetic	B-X
link	B-X
between	B-X
these	B-X
two	B-X
diseases	B-X
is	B-X
particularly	B-X
evident	B-X
in	B-X
familial	B-X
hemiplegic	B-X
migraine	B-X
:	B-X
mutations	B-X
of	B-X
ATP1A2	B-X
,	B-X
SCN1A	B-X
and	B-X
CACNA1A	B-X
genes	B-X
,	B-X
identified	B-X
in	B-X
this	B-X
disease	B-X
,	B-X
have	B-X
also	B-X
been	B-X
involved	B-X
in	B-X
different	B-X
types	B-X
of	B-X
epilepsy	B-X
and	B-X
febrile	B-X
seizures	B-X
.	B-X
There	B-X
are	B-X
at	B-X
least	B-X
two	B-X
approaches	B-X
to	B-X
the	B-X
definition	B-X
of	B-X
consciousness	B-X
.	B-X
With	B-X
this	B-X
approach	B-X
,	B-X
some	B-X
aspects	B-X
of	B-X
consciousness	B-X
,	B-X
by	B-X
definition	B-X
,	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
external	B-X
observations	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
outside	B-X
the	B-X
scope	B-X
of	B-X
scientific	B-X
research	B-X
.	B-X
Current	B-X
scientific	B-X
communities	B-X
proceed	B-X
from	B-X
the	B-X
assumption	B-X
that	B-X
the	B-X
physical	B-X
substrate	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
consciousness	B-X
is	B-X
a	B-X
neural	B-X
network	B-X
that	B-X
unites	B-X
various	B-X
types	B-X
of	B-X
neurons	B-X
located	B-X
in	B-X
various	B-X
brain	B-X
structures	B-X
.	B-X
Many	B-X
neuroscientists	B-X
attach	B-X
a	B-X
key	B-X
role	B-X
in	B-X
this	B-X
process	B-X
to	B-X
the	B-X
cortical	B-X
and	B-X
thalamocortical	B-X
neural	B-X
networks	B-X
.	B-X

In	O
a	O
processive	O
mechanism	O
,	O
multiple	O
carboxylations	O
could	O
occur	O
during	O
a	O
single	O
substrate	O
binding	O
event	O
.	O

Alternatively	O
,	O
a	O
distributive	O
mechanism	O
could	O
result	O
in	O
the	O
observed	O
behavior	O
if	O
the	O
initial	O
carboxylation	O
event	O
results	O
in	O
a	O
substrate	O
that	O
is	O
additionally	O
carboxylated	O
far	O
more	O
efficiently	O
than	O
the	O
uncarboxylated	O
FIXQ	O
/	O
S	O
.	O

Kinetic	O
experiments	O
and	O
arguments	O
were	O
used	O
to	O
show	O
that	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
is	O
not	O
distributive	O
but	O
rather	O
is	O
one	O
of	O
the	O
first	O
well	O
documented	O
examples	O
of	O
an	O
enzyme	O
that	O
catalyzes	O
a	O
processive	O
post	O
-	O
translation	O
modification	O
.	O

Size	O
variations	O
in	O
the	O
mucin	O
-	O
type	O
domain	O
of	O
hamster	O
oviductin	B-Protein
:	O
identification	O
of	O
the	O
polypeptide	O
precursors	O
and	O
characterization	O
of	O
their	O
biosynthetic	O
maturation	O
.	O
<EOS>	B-X
The	B-X
recent	B-X
sequencing	B-X
of	B-X
a	B-X
cDNA	B-X
clone	B-X
for	B-X
hamster	B-X
oviductin	B-X
revealed	B-X
that	B-X
this	B-X
zona	B-X
pellucida-associated	B-X
glycoprotein	B-X
is	B-X
a	B-X
particularly	B-X
intriguing	B-X
chimeric	B-X
molecule	B-X
because	B-X
it	B-X
encloses	B-X
regions	B-X
of	B-X
significant	B-X
similarity	B-X
with	B-X
chitinase-related	B-X
proteins	B-X
as	B-X
well	B-X
as	B-X
a	B-X
carboxyterminal	B-X
mucin-type	B-X
domain	B-X
.	B-X
This	B-X
domain	B-X
contains	B-X
contiguous	B-X
Ser/Thr-rich	B-X
repeated	B-X
stretches	B-X
of	B-X
15	B-X
amino	B-X
acids	B-X
;	B-X
similar	B-X
units	B-X
are	B-X
also	B-X
found	B-X
in	B-X
the	B-X
deduced	B-X
sequence	B-X
of	B-X
human	B-X
oviductin	B-X
.	B-X
Such	B-X
structural	B-X
domains	B-X
constitute	B-X
a	B-X
central	B-X
feature	B-X
of	B-X
mucins	B-X
.	B-X
We	B-X
amplified	B-X
this	B-X
region	B-X
from	B-X
16	B-X
hamster	B-X
oviductin	B-X
cDNA	B-X
clones	B-X
and	B-X
identified	B-X
three	B-X
length	B-X
variants	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
biosynthetic	B-X
maturation	B-X
of	B-X
the	B-X
glycoprotein	B-X
,	B-X
a	B-X
high-titer	B-X
antiserum	B-X
against	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
internal	B-X
sequences	B-X
of	B-X
hamster	B-X
oviductin	B-X
was	B-X
produced	B-X
and	B-X
used	B-X
in	B-X
pulse-chase	B-X
experiments	B-X
.	B-X
Two	B-X
major	B-X
and	B-X
one	B-X
minor	B-X
polypeptide	B-X
precursors	B-X
were	B-X
identified	B-X
from	B-X
tunicamycin-treated	B-X
cell	B-X
lysates	B-X
and	B-X
in	B-X
vitro	B-X
translated	B-X
products	B-X
from	B-X
oviductal	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
+	B-X
RNA	B-X
.	B-X
Using	B-X
glycosylation	B-X
and	B-X
transport	B-X
inhibitors	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
dissect	B-X
the	B-X
posttranslational	B-X
sequential	B-X
steps	B-X
leading	B-X
to	B-X
the	B-X
final	B-X
maturation	B-X
of	B-X
hamster	B-X
oviductin	B-X
and	B-X
proposed	B-X
a	B-X
compartmental	B-X
model	B-X
for	B-X
its	B-X
biosynthesis	B-X
.	B-X
The	B-X
polypeptide	B-X
precursors	B-X
are	B-X
rapidly	B-X
converted	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
into	B-X
an	B-X
N-	B-X
and	B-X
O-glycosylated	B-X
premature	B-X
form	B-X
of	B-X
80-90	B-X
kDa	B-X
(	B-X
time	B-X
<	B-X
20	B-X
min	B-X
)	B-X
,	B-X
which	B-X
is	B-X
further	B-X
O-glycosylated	B-X
and	B-X
sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
,	B-X
giving	B-X
rise	B-X
to	B-X
the	B-X
secreted	B-X
species	B-X
of	B-X
160-350	B-X
kDa	B-X
.	B-X
The	B-X
polymorphism	B-X
in	B-X
the	B-X
heavily	B-X
O-glycosylated	B-X
region	B-X
of	B-X
hamster	B-X
oviductin	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
glycoprotein	B-X
.	B-X
Such	B-X
changes	B-X
may	B-X
alter	B-X
the	B-X
putative	B-X
biological	B-X
function	B-X
of	B-X
the	B-X
different	B-X
variants	B-X
mediated	B-X
by	B-X
their	B-X
mucin-type	B-X
domain	B-X
,	B-X
such	B-X
as	B-X
protection	B-X
of	B-X
the	B-X
embryo	B-X
and/or	B-X
adhesion-related	B-X
phenomena	B-X
.	B-X

The	O
recent	O
sequencing	O
of	O
a	O
cDNA	O
clone	O
for	O
hamster	O
oviductin	B-Protein
revealed	O
that	O
this	O
zona	O
pellucida	O
-	O
associated	O
glycoprotein	O
is	O
a	O
particularly	O
intriguing	O
chimeric	O
molecule	O
because	O
it	O
encloses	O
regions	O
of	O
significant	O
similarity	O
with	O
chitinase	O
-	O
related	O
proteins	O
as	O
well	O
as	O
a	O
carboxyterminal	O
mucin	O
-	O
type	O
domain	O
.	O
<EOS>	B-X
The	B-X
recent	B-X
sequencing	B-X
of	B-X
a	B-X
cDNA	B-X
clone	B-X
for	B-X
hamster	B-X
oviductin	B-X
revealed	B-X
that	B-X
this	B-X
zona	B-X
pellucida-associated	B-X
glycoprotein	B-X
is	B-X
a	B-X
particularly	B-X
intriguing	B-X
chimeric	B-X
molecule	B-X
because	B-X
it	B-X
encloses	B-X
regions	B-X
of	B-X
significant	B-X
similarity	B-X
with	B-X
chitinase-related	B-X
proteins	B-X
as	B-X
well	B-X
as	B-X
a	B-X
carboxyterminal	B-X
mucin-type	B-X
domain	B-X
.	B-X
This	B-X
domain	B-X
contains	B-X
contiguous	B-X
Ser/Thr-rich	B-X
repeated	B-X
stretches	B-X
of	B-X
15	B-X
amino	B-X
acids	B-X
;	B-X
similar	B-X
units	B-X
are	B-X
also	B-X
found	B-X
in	B-X
the	B-X
deduced	B-X
sequence	B-X
of	B-X
human	B-X
oviductin	B-X
.	B-X
Such	B-X
structural	B-X
domains	B-X
constitute	B-X
a	B-X
central	B-X
feature	B-X
of	B-X
mucins	B-X
.	B-X
We	B-X
amplified	B-X
this	B-X
region	B-X
from	B-X
16	B-X
hamster	B-X
oviductin	B-X
cDNA	B-X
clones	B-X
and	B-X
identified	B-X
three	B-X
length	B-X
variants	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
biosynthetic	B-X
maturation	B-X
of	B-X
the	B-X
glycoprotein	B-X
,	B-X
a	B-X
high-titer	B-X
antiserum	B-X
against	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
internal	B-X
sequences	B-X
of	B-X
hamster	B-X
oviductin	B-X
was	B-X
produced	B-X
and	B-X
used	B-X
in	B-X
pulse-chase	B-X
experiments	B-X
.	B-X
Using	B-X
glycosylation	B-X
and	B-X
transport	B-X
inhibitors	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
dissect	B-X
the	B-X
posttranslational	B-X
sequential	B-X
steps	B-X
leading	B-X
to	B-X
the	B-X
final	B-X
maturation	B-X
of	B-X
hamster	B-X
oviductin	B-X
and	B-X
proposed	B-X
a	B-X
compartmental	B-X
model	B-X
for	B-X
its	B-X
biosynthesis	B-X
.	B-X
The	B-X
polymorphism	B-X
in	B-X
the	B-X
heavily	B-X
O-glycosylated	B-X
region	B-X
of	B-X
hamster	B-X
oviductin	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
glycoprotein	B-X
.	B-X
Such	B-X
changes	B-X
may	B-X
alter	B-X
the	B-X
putative	B-X
biological	B-X
function	B-X
of	B-X
the	B-X
different	B-X
variants	B-X
mediated	B-X
by	B-X
their	B-X
mucin-type	B-X
domain	B-X
,	B-X
such	B-X
as	B-X
protection	B-X
of	B-X
the	B-X
embryo	B-X
and/or	B-X
adhesion-related	B-X
phenomena	B-X
.	B-X

This	O
domain	O
contains	O
contiguous	O
Ser	O
/	O
Thr	O
-	O
rich	O
repeated	O
stretches	O
of	O
15	O
amino	O
acids	O
;	O
similar	O
units	O
are	O
also	O
found	O
in	O
the	O
deduced	O
sequence	O
of	O
human	O
oviductin	O
.	O
<EOS>	B-X
The	B-X
recent	B-X
sequencing	B-X
of	B-X
a	B-X
cDNA	B-X
clone	B-X
for	B-X
hamster	B-X
oviductin	B-X
revealed	B-X
that	B-X
this	B-X
zona	B-X
pellucida-associated	B-X
glycoprotein	B-X
is	B-X
a	B-X
particularly	B-X
intriguing	B-X
chimeric	B-X
molecule	B-X
because	B-X
it	B-X
encloses	B-X
regions	B-X
of	B-X
significant	B-X
similarity	B-X
with	B-X
chitinase-related	B-X
proteins	B-X
as	B-X
well	B-X
as	B-X
a	B-X
carboxyterminal	B-X
mucin-type	B-X
domain	B-X
.	B-X
This	B-X
domain	B-X
contains	B-X
contiguous	B-X
Ser/Thr-rich	B-X
repeated	B-X
stretches	B-X
of	B-X
15	B-X
amino	B-X
acids	B-X
;	B-X
similar	B-X
units	B-X
are	B-X
also	B-X
found	B-X
in	B-X
the	B-X
deduced	B-X
sequence	B-X
of	B-X
human	B-X
oviductin	B-X
.	B-X
Such	B-X
structural	B-X
domains	B-X
constitute	B-X
a	B-X
central	B-X
feature	B-X
of	B-X
mucins	B-X
.	B-X
We	B-X
amplified	B-X
this	B-X
region	B-X
from	B-X
16	B-X
hamster	B-X
oviductin	B-X
cDNA	B-X
clones	B-X
and	B-X
identified	B-X
three	B-X
length	B-X
variants	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
biosynthetic	B-X
maturation	B-X
of	B-X
the	B-X
glycoprotein	B-X
,	B-X
a	B-X
high-titer	B-X
antiserum	B-X
against	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
internal	B-X
sequences	B-X
of	B-X
hamster	B-X
oviductin	B-X
was	B-X
produced	B-X
and	B-X
used	B-X
in	B-X
pulse-chase	B-X
experiments	B-X
.	B-X
Using	B-X
glycosylation	B-X
and	B-X
transport	B-X
inhibitors	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
dissect	B-X
the	B-X
posttranslational	B-X
sequential	B-X
steps	B-X
leading	B-X
to	B-X
the	B-X
final	B-X
maturation	B-X
of	B-X
hamster	B-X
oviductin	B-X
and	B-X
proposed	B-X
a	B-X
compartmental	B-X
model	B-X
for	B-X
its	B-X
biosynthesis	B-X
.	B-X
The	B-X
polymorphism	B-X
in	B-X
the	B-X
heavily	B-X
O-glycosylated	B-X
region	B-X
of	B-X
hamster	B-X
oviductin	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
glycoprotein	B-X
.	B-X
Such	B-X
changes	B-X
may	B-X
alter	B-X
the	B-X
putative	B-X
biological	B-X
function	B-X
of	B-X
the	B-X
different	B-X
variants	B-X
mediated	B-X
by	B-X
their	B-X
mucin-type	B-X
domain	B-X
,	B-X
such	B-X
as	B-X
protection	B-X
of	B-X
the	B-X
embryo	B-X
and/or	B-X
adhesion-related	B-X
phenomena	B-X
.	B-X

Such	O
structural	O
domains	O
constitute	O
a	O
central	O
feature	O
of	O
mucins	O
.	O
<EOS>	B-X
The	B-X
N‑terminus	B-X
constitutes	B-X
of	B-X
two	B-X
somatomedin	B-X
B	B-X
(	B-X
SMB	B-X
)	B-X
homology	B-X
domains	B-X
that	B-X
contain	B-X
14	B-X
cysteines	B-X
.	B-X
The	B-X
central	B-X
region	B-X
is	B-X
a	B-X
putative	B-X
heparin‑binding	B-X
domain	B-X
(	B-X
pHBD	B-X
)	B-X
and	B-X
the	B-X
C‑terminus	B-X
contains	B-X
mucin‑like	B-X
repeats	B-X
.	B-X
C‑terminal	B-X
repeats-truncated	B-X
rhHAPO	B-X
(	B-X
rhHAPOΔmucin	B-X
)	B-X
was	B-X
also	B-X
found	B-X
to	B-X
be	B-X
assembled	B-X
into	B-X
a	B-X
multimer	B-X
,	B-X
while	B-X
deletion	B-X
of	B-X
pHBD	B-X
(	B-X
rhHAPOΔmucin‑pHBD	B-X
)	B-X
caused	B-X
the	B-X
protein	B-X
to	B-X
remain	B-X
in	B-X
a	B-X
dimeric	B-X
form	B-X
,	B-X
demonstrating	B-X
that	B-X
SMB	B-X
domains	B-X
participate	B-X
in	B-X
self‑aggregation	B-X
of	B-X
the	B-X
molecule	B-X
and	B-X
that	B-X
the	B-X
pHBD	B-X
region	B-X
promotes	B-X
the	B-X
tetramerization	B-X
.	B-X
Such	B-X
structural	B-X
domains	B-X
constitute	B-X
a	B-X
central	B-X
feature	B-X
of	B-X
mucins	B-X
.	B-X

We	O
amplified	O
this	O
region	O
from	O
16	O
hamster	O
oviductin	B-Protein
cDNA	O
clones	O
and	O
identified	O
three	O
length	O
variants	O
.	O
<EOS>	B-X
The	B-X
recent	B-X
sequencing	B-X
of	B-X
a	B-X
cDNA	B-X
clone	B-X
for	B-X
hamster	B-X
oviductin	B-X
revealed	B-X
that	B-X
this	B-X
zona	B-X
pellucida-associated	B-X
glycoprotein	B-X
is	B-X
a	B-X
particularly	B-X
intriguing	B-X
chimeric	B-X
molecule	B-X
because	B-X
it	B-X
encloses	B-X
regions	B-X
of	B-X
significant	B-X
similarity	B-X
with	B-X
chitinase-related	B-X
proteins	B-X
as	B-X
well	B-X
as	B-X
a	B-X
carboxyterminal	B-X
mucin-type	B-X
domain	B-X
.	B-X
This	B-X
domain	B-X
contains	B-X
contiguous	B-X
Ser/Thr-rich	B-X
repeated	B-X
stretches	B-X
of	B-X
15	B-X
amino	B-X
acids	B-X
;	B-X
similar	B-X
units	B-X
are	B-X
also	B-X
found	B-X
in	B-X
the	B-X
deduced	B-X
sequence	B-X
of	B-X
human	B-X
oviductin	B-X
.	B-X
We	B-X
amplified	B-X
this	B-X
region	B-X
from	B-X
16	B-X
hamster	B-X
oviductin	B-X
cDNA	B-X
clones	B-X
and	B-X
identified	B-X
three	B-X
length	B-X
variants	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
biosynthetic	B-X
maturation	B-X
of	B-X
the	B-X
glycoprotein	B-X
,	B-X
a	B-X
high-titer	B-X
antiserum	B-X
against	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
internal	B-X
sequences	B-X
of	B-X
hamster	B-X
oviductin	B-X
was	B-X
produced	B-X
and	B-X
used	B-X
in	B-X
pulse-chase	B-X
experiments	B-X
.	B-X
Two	B-X
major	B-X
and	B-X
one	B-X
minor	B-X
polypeptide	B-X
precursors	B-X
were	B-X
identified	B-X
from	B-X
tunicamycin-treated	B-X
cell	B-X
lysates	B-X
and	B-X
in	B-X
vitro	B-X
translated	B-X
products	B-X
from	B-X
oviductal	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
+	B-X
RNA	B-X
.	B-X
Their	B-X
apparent	B-X
molecular	B-X
masses	B-X
correlate	B-X
with	B-X
the	B-X
predicted	B-X
lengths	B-X
of	B-X
the	B-X
three	B-X
size	B-X
variants	B-X
identified	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
amplification	B-X
.	B-X
Using	B-X
glycosylation	B-X
and	B-X
transport	B-X
inhibitors	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
dissect	B-X
the	B-X
posttranslational	B-X
sequential	B-X
steps	B-X
leading	B-X
to	B-X
the	B-X
final	B-X
maturation	B-X
of	B-X
hamster	B-X
oviductin	B-X
and	B-X
proposed	B-X
a	B-X
compartmental	B-X
model	B-X
for	B-X
its	B-X
biosynthesis	B-X
.	B-X
The	B-X
polypeptide	B-X
precursors	B-X
are	B-X
rapidly	B-X
converted	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
into	B-X
an	B-X
N-	B-X
and	B-X
O-glycosylated	B-X
premature	B-X
form	B-X
of	B-X
80-90	B-X
kDa	B-X
(	B-X
time	B-X
<	B-X
20	B-X
min	B-X
)	B-X
,	B-X
which	B-X
is	B-X
further	B-X
O-glycosylated	B-X
and	B-X
sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
,	B-X
giving	B-X
rise	B-X
to	B-X
the	B-X
secreted	B-X
species	B-X
of	B-X
160-350	B-X
kDa	B-X
.	B-X
The	B-X
polymorphism	B-X
in	B-X
the	B-X
heavily	B-X
O-glycosylated	B-X
region	B-X
of	B-X
hamster	B-X
oviductin	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
glycoprotein	B-X
.	B-X
Such	B-X
changes	B-X
may	B-X
alter	B-X
the	B-X
putative	B-X
biological	B-X
function	B-X
of	B-X
the	B-X
different	B-X
variants	B-X
mediated	B-X
by	B-X
their	B-X
mucin-type	B-X
domain	B-X
,	B-X
such	B-X
as	B-X
protection	B-X
of	B-X
the	B-X
embryo	B-X
and/or	B-X
adhesion-related	B-X
phenomena	B-X
.	B-X

In	O
order	O
to	O
elucidate	O
the	O
biosynthetic	O
maturation	O
of	O
the	O
glycoprotein	O
,	O
a	O
high	O
-	O
titer	O
antiserum	O
against	O
synthetic	O
peptides	O
derived	O
from	O
internal	O
sequences	O
of	O
hamster	O
oviductin	B-Protein
was	O
produced	O
and	O
used	O
in	O
pulse	O
-	O
chase	O
experiments	O
.	O
<EOS>	B-X
The	B-X
recent	B-X
sequencing	B-X
of	B-X
a	B-X
cDNA	B-X
clone	B-X
for	B-X
hamster	B-X
oviductin	B-X
revealed	B-X
that	B-X
this	B-X
zona	B-X
pellucida-associated	B-X
glycoprotein	B-X
is	B-X
a	B-X
particularly	B-X
intriguing	B-X
chimeric	B-X
molecule	B-X
because	B-X
it	B-X
encloses	B-X
regions	B-X
of	B-X
significant	B-X
similarity	B-X
with	B-X
chitinase-related	B-X
proteins	B-X
as	B-X
well	B-X
as	B-X
a	B-X
carboxyterminal	B-X
mucin-type	B-X
domain	B-X
.	B-X
This	B-X
domain	B-X
contains	B-X
contiguous	B-X
Ser/Thr-rich	B-X
repeated	B-X
stretches	B-X
of	B-X
15	B-X
amino	B-X
acids	B-X
;	B-X
similar	B-X
units	B-X
are	B-X
also	B-X
found	B-X
in	B-X
the	B-X
deduced	B-X
sequence	B-X
of	B-X
human	B-X
oviductin	B-X
.	B-X
We	B-X
amplified	B-X
this	B-X
region	B-X
from	B-X
16	B-X
hamster	B-X
oviductin	B-X
cDNA	B-X
clones	B-X
and	B-X
identified	B-X
three	B-X
length	B-X
variants	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
biosynthetic	B-X
maturation	B-X
of	B-X
the	B-X
glycoprotein	B-X
,	B-X
a	B-X
high-titer	B-X
antiserum	B-X
against	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
internal	B-X
sequences	B-X
of	B-X
hamster	B-X
oviductin	B-X
was	B-X
produced	B-X
and	B-X
used	B-X
in	B-X
pulse-chase	B-X
experiments	B-X
.	B-X
Using	B-X
glycosylation	B-X
and	B-X
transport	B-X
inhibitors	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
dissect	B-X
the	B-X
posttranslational	B-X
sequential	B-X
steps	B-X
leading	B-X
to	B-X
the	B-X
final	B-X
maturation	B-X
of	B-X
hamster	B-X
oviductin	B-X
and	B-X
proposed	B-X
a	B-X
compartmental	B-X
model	B-X
for	B-X
its	B-X
biosynthesis	B-X
.	B-X
The	B-X
polymorphism	B-X
in	B-X
the	B-X
heavily	B-X
O-glycosylated	B-X
region	B-X
of	B-X
hamster	B-X
oviductin	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
glycoprotein	B-X
.	B-X

Two	O
major	O
and	O
one	O
minor	O
polypeptide	O
precursors	O
were	O
identified	O
from	O
tunicamycin	O
-	O
treated	O
cell	O
lysates	O
and	O
in	O
vitro	O
translated	O
products	O
from	O
oviductal	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
.	O
<EOS>	B-X
The	B-X
recent	B-X
sequencing	B-X
of	B-X
a	B-X
cDNA	B-X
clone	B-X
for	B-X
hamster	B-X
oviductin	B-X
revealed	B-X
that	B-X
this	B-X
zona	B-X
pellucida-associated	B-X
glycoprotein	B-X
is	B-X
a	B-X
particularly	B-X
intriguing	B-X
chimeric	B-X
molecule	B-X
because	B-X
it	B-X
encloses	B-X
regions	B-X
of	B-X
significant	B-X
similarity	B-X
with	B-X
chitinase-related	B-X
proteins	B-X
as	B-X
well	B-X
as	B-X
a	B-X
carboxyterminal	B-X
mucin-type	B-X
domain	B-X
.	B-X
We	B-X
amplified	B-X
this	B-X
region	B-X
from	B-X
16	B-X
hamster	B-X
oviductin	B-X
cDNA	B-X
clones	B-X
and	B-X
identified	B-X
three	B-X
length	B-X
variants	B-X
.	B-X
Two	B-X
major	B-X
and	B-X
one	B-X
minor	B-X
polypeptide	B-X
precursors	B-X
were	B-X
identified	B-X
from	B-X
tunicamycin-treated	B-X
cell	B-X
lysates	B-X
and	B-X
in	B-X
vitro	B-X
translated	B-X
products	B-X
from	B-X
oviductal	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
+	B-X
RNA	B-X
.	B-X
Their	B-X
apparent	B-X
molecular	B-X
masses	B-X
correlate	B-X
with	B-X
the	B-X
predicted	B-X
lengths	B-X
of	B-X
the	B-X
three	B-X
size	B-X
variants	B-X
identified	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
amplification	B-X
.	B-X
The	B-X
polypeptide	B-X
precursors	B-X
are	B-X
rapidly	B-X
converted	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
into	B-X
an	B-X
N-	B-X
and	B-X
O-glycosylated	B-X
premature	B-X
form	B-X
of	B-X
80-90	B-X
kDa	B-X
(	B-X
time	B-X
<	B-X
20	B-X
min	B-X
)	B-X
,	B-X
which	B-X
is	B-X
further	B-X
O-glycosylated	B-X
and	B-X
sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
,	B-X
giving	B-X
rise	B-X
to	B-X
the	B-X
secreted	B-X
species	B-X
of	B-X
160-350	B-X
kDa	B-X
.	B-X
The	B-X
polymorphism	B-X
in	B-X
the	B-X
heavily	B-X
O-glycosylated	B-X
region	B-X
of	B-X
hamster	B-X
oviductin	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
glycoprotein	B-X
.	B-X

Their	O
apparent	O
molecular	O
masses	O
correlate	O
with	O
the	O
predicted	O
lengths	O
of	O
the	O
three	O
size	O
variants	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
.	O
<EOS>	B-X
We	B-X
amplified	B-X
this	B-X
region	B-X
from	B-X
16	B-X
hamster	B-X
oviductin	B-X
cDNA	B-X
clones	B-X
and	B-X
identified	B-X
three	B-X
length	B-X
variants	B-X
.	B-X
Two	B-X
major	B-X
and	B-X
one	B-X
minor	B-X
polypeptide	B-X
precursors	B-X
were	B-X
identified	B-X
from	B-X
tunicamycin-treated	B-X
cell	B-X
lysates	B-X
and	B-X
in	B-X
vitro	B-X
translated	B-X
products	B-X
from	B-X
oviductal	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
+	B-X
RNA	B-X
.	B-X
Their	B-X
apparent	B-X
molecular	B-X
masses	B-X
correlate	B-X
with	B-X
the	B-X
predicted	B-X
lengths	B-X
of	B-X
the	B-X
three	B-X
size	B-X
variants	B-X
identified	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
amplification	B-X
.	B-X
The	B-X
polymorphism	B-X
in	B-X
the	B-X
heavily	B-X
O-glycosylated	B-X
region	B-X
of	B-X
hamster	B-X
oviductin	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
glycoprotein	B-X
.	B-X
Such	B-X
changes	B-X
may	B-X
alter	B-X
the	B-X
putative	B-X
biological	B-X
function	B-X
of	B-X
the	B-X
different	B-X
variants	B-X
mediated	B-X
by	B-X
their	B-X
mucin-type	B-X
domain	B-X
,	B-X
such	B-X
as	B-X
protection	B-X
of	B-X
the	B-X
embryo	B-X
and/or	B-X
adhesion-related	B-X
phenomena	B-X
.	B-X

Using	O
glycosylation	O
and	O
transport	O
inhibitors	O
,	O
we	O
sought	O
to	O
dissect	O
the	O
posttranslational	O
sequential	O
steps	O
leading	O
to	O
the	O
final	O
maturation	O
of	O
hamster	O
oviductin	B-Protein
and	O
proposed	O
a	O
compartmental	O
model	O
for	O
its	O
biosynthesis	O
.	O

The	O
polypeptide	O
precursors	O
are	O
rapidly	O
converted	O
in	O
the	O
endoplasmic	O
reticulum	O
into	O
an	O
N	O
-	O
and	O
O	O
-	O
glycosylated	O
premature	O
form	O
of	O
80	O
-	O
90	O
kDa	O
(	O
time	O
<	O
20	O
min	O
)	O
,	O
which	O
is	O
further	O
O	O
-	O
glycosylated	O
and	O
sulfated	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
,	O
giving	O
rise	O
to	O
the	O
secreted	O
species	O
of	O
160	O
-	O
350	O
kDa	O
.	O

The	O
polymorphism	O
in	O
the	O
heavily	O
O	O
-	O
glycosylated	O
region	O
of	O
hamster	O
oviductin	B-Protein
is	O
predicted	O
to	O
increase	O
the	O
heterogeneity	O
of	O
the	O
glycoprotein	O
.	O
<EOS>	B-X
The	B-X
recent	B-X
sequencing	B-X
of	B-X
a	B-X
cDNA	B-X
clone	B-X
for	B-X
hamster	B-X
oviductin	B-X
revealed	B-X
that	B-X
this	B-X
zona	B-X
pellucida-associated	B-X
glycoprotein	B-X
is	B-X
a	B-X
particularly	B-X
intriguing	B-X
chimeric	B-X
molecule	B-X
because	B-X
it	B-X
encloses	B-X
regions	B-X
of	B-X
significant	B-X
similarity	B-X
with	B-X
chitinase-related	B-X
proteins	B-X
as	B-X
well	B-X
as	B-X
a	B-X
carboxyterminal	B-X
mucin-type	B-X
domain	B-X
.	B-X
This	B-X
domain	B-X
contains	B-X
contiguous	B-X
Ser/Thr-rich	B-X
repeated	B-X
stretches	B-X
of	B-X
15	B-X
amino	B-X
acids	B-X
;	B-X
similar	B-X
units	B-X
are	B-X
also	B-X
found	B-X
in	B-X
the	B-X
deduced	B-X
sequence	B-X
of	B-X
human	B-X
oviductin	B-X
.	B-X
We	B-X
amplified	B-X
this	B-X
region	B-X
from	B-X
16	B-X
hamster	B-X
oviductin	B-X
cDNA	B-X
clones	B-X
and	B-X
identified	B-X
three	B-X
length	B-X
variants	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
biosynthetic	B-X
maturation	B-X
of	B-X
the	B-X
glycoprotein	B-X
,	B-X
a	B-X
high-titer	B-X
antiserum	B-X
against	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
internal	B-X
sequences	B-X
of	B-X
hamster	B-X
oviductin	B-X
was	B-X
produced	B-X
and	B-X
used	B-X
in	B-X
pulse-chase	B-X
experiments	B-X
.	B-X
Their	B-X
apparent	B-X
molecular	B-X
masses	B-X
correlate	B-X
with	B-X
the	B-X
predicted	B-X
lengths	B-X
of	B-X
the	B-X
three	B-X
size	B-X
variants	B-X
identified	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
amplification	B-X
.	B-X
Using	B-X
glycosylation	B-X
and	B-X
transport	B-X
inhibitors	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
dissect	B-X
the	B-X
posttranslational	B-X
sequential	B-X
steps	B-X
leading	B-X
to	B-X
the	B-X
final	B-X
maturation	B-X
of	B-X
hamster	B-X
oviductin	B-X
and	B-X
proposed	B-X
a	B-X
compartmental	B-X
model	B-X
for	B-X
its	B-X
biosynthesis	B-X
.	B-X
The	B-X
polypeptide	B-X
precursors	B-X
are	B-X
rapidly	B-X
converted	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
into	B-X
an	B-X
N-	B-X
and	B-X
O-glycosylated	B-X
premature	B-X
form	B-X
of	B-X
80-90	B-X
kDa	B-X
(	B-X
time	B-X
<	B-X
20	B-X
min	B-X
)	B-X
,	B-X
which	B-X
is	B-X
further	B-X
O-glycosylated	B-X
and	B-X
sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
,	B-X
giving	B-X
rise	B-X
to	B-X
the	B-X
secreted	B-X
species	B-X
of	B-X
160-350	B-X
kDa	B-X
.	B-X
The	B-X
polymorphism	B-X
in	B-X
the	B-X
heavily	B-X
O-glycosylated	B-X
region	B-X
of	B-X
hamster	B-X
oviductin	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
glycoprotein	B-X
.	B-X

Such	O
changes	O
may	O
alter	O
the	O
putative	O
biological	O
function	O
of	O
the	O
different	O
variants	O
mediated	O
by	O
their	O
mucin	O
-	O
type	O
domain	O
,	O
such	O
as	O
protection	O
of	O
the	O
embryo	O
and	O
/	O
or	O
adhesion	O
-	O
related	O
phenomena	O
.	O
<EOS>	B-X
The	B-X
skin	B-X
's	B-X
main	B-X
function	B-X
is	B-X
to	B-X
act	B-X
as	B-X
a	B-X
physical	B-X
barrier	B-X
against	B-X
harmful	B-X
substances	B-X
.	B-X
Medical	B-X
adhesive-related	B-X
skin	B-X
injury	B-X
(	B-X
MARSI	B-X
)	B-X
is	B-X
a	B-X
prevalent	B-X
and	B-X
under-reported	B-X
condition	B-X
that	B-X
compromises	B-X
the	B-X
skin	B-X
's	B-X
integrity	B-X
.	B-X
Morphology	B-X
of	B-X
senescent	B-X
cells	B-X
is	B-X
constantly	B-X
changing	B-X
at	B-X
the	B-X
molecular	B-X
level	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
leads	B-X
to	B-X
disruption	B-X
of	B-X
their	B-X
function	B-X
.	B-X
It	B-X
is	B-X
connected	B-X
with	B-X
reduced	B-X
ability	B-X
to	B-X
synthesize	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
and	B-X
leads	B-X
to	B-X
the	B-X
dysfunction	B-X
of	B-X
integrin	B-X
adhesion	B-X
molecules	B-X
and	B-X
adhesion	B-X
clusters	B-X
.	B-X
Signaling	B-X
through	B-X
paxillin	B-X
affects	B-X
the	B-X
long-term	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
,	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
organization	B-X
of	B-X
the	B-X
ECM	B-X
.	B-X
Correct	B-X
functioning	B-X
of	B-X
the	B-X
ECM	B-X
is	B-X
important	B-X
for	B-X
the	B-X
wound	B-X
healing	B-X
processes	B-X
and	B-X
regeneration	B-X
of	B-X
tissues	B-X
or	B-X
tissue	B-X
repair	B-X
.	B-X
Decrease	B-X
or	B-X
lack	B-X
of	B-X
paxillin	B-X
expression	B-X
results	B-X
in	B-X
changes	B-X
in	B-X
the	B-X
structure	B-X
and	B-X
integrity	B-X
of	B-X
the	B-X
ECM	B-X
,	B-X
which	B-X
are	B-X
manifested	B-X
by	B-X
aging	B-X
of	B-X
cells	B-X
and	B-X
organs	B-X
.	B-X
Restoration	B-X
of	B-X
the	B-X
cellular	B-X
matrix	B-X
connections	B-X
would	B-X
be	B-X
a	B-X
significant	B-X
element	B-X
in	B-X
the	B-X
processes	B-X
related	B-X
to	B-X
the	B-X
anti-aging	B-X
activities	B-X
.	B-X

Design	O
and	O
synthesis	O
of	O
non	O
-	O
peptide	O
Ras	O
CAAX	O
mimetics	O
as	O
potent	O
farnesyltransferase	O
inhibitors	O
.	O
<EOS>	B-X
Cysteine	B-X
farnesylation	B-X
of	B-X
the	B-X
ras	B-X
oncogene	B-X
product	B-X
Ras	B-X
is	B-X
required	B-X
for	B-X
its	B-X
transforming	B-X
activity	B-X
and	B-X
is	B-X
catalyzed	B-X
by	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
.	B-X
The	B-X
Ras	B-X
carboxyl	B-X
terminal	B-X
tetrapeptide	B-X
CAAX	B-X
(	B-X
C	B-X
is	B-X
cysteine	B-X
,	B-X
A	B-X
is	B-X
any	B-X
aliphatic	B-X
amino	B-X
acid	B-X
,	B-X
X	B-X
is	B-X
methionine	B-X
or	B-X
serine	B-X
)	B-X
is	B-X
the	B-X
minimum	B-X
sequence	B-X
for	B-X
FTase	B-X
recognition	B-X
.	B-X
We	B-X
report	B-X
here	B-X
the	B-X
design	B-X
,	B-X
synthesis	B-X
,	B-X
and	B-X
biological	B-X
characterization	B-X
of	B-X
Ras	B-X
CAAX	B-X
non-peptide	B-X
mimetics	B-X
in	B-X
which	B-X
the	B-X
cysteine	B-X
is	B-X
linked	B-X
through	B-X
a	B-X
reduced	B-X
pseudopeptide	B-X
bond	B-X
to	B-X
4-amino-3'-carboxybiphenyl	B-X
.	B-X
These	B-X
non-peptide	B-X
mimetics	B-X
are	B-X
potent	B-X
inhibitors	B-X
of	B-X
FTase	B-X
(	B-X
IC50	B-X
=	B-X
40	B-X
nM	B-X
for	B-X
the	B-X
most	B-X
potent	B-X
inhibitor	B-X
)	B-X
and	B-X
are	B-X
highly	B-X
selective	B-X
for	B-X
FTase	B-X
over	B-X
GGTase	B-X
I	B-X
(	B-X
geranylgeranyltransferase	B-X
I	B-X
)	B-X
.	B-X

Cysteine	O
farnesylation	O
of	O
the	O
ras	O
oncogene	O
product	O
Ras	O
is	O
required	O
for	O
its	O
transforming	O
activity	O
and	O
is	O
catalyzed	O
by	O
farnesyltransferase	O
(	O
FTase	O
)	O
.	O
<EOS>	B-X
Mutated	B-X
forms	B-X
of	B-X
ras	B-X
are	B-X
found	B-X
in	B-X
many	B-X
human	B-X
tumors	B-X
and	B-X
the	B-X
rate	B-X
of	B-X
incidence	B-X
is	B-X
significantly	B-X
higher	B-X
in	B-X
colon	B-X
and	B-X
pancreatic	B-X
cancers	B-X
.	B-X
The	B-X
protein	B-X
product	B-X
from	B-X
the	B-X
ras	B-X
oncogene	B-X
is	B-X
a	B-X
small	B-X
G-protein	B-X
,	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
(	B-X
Ras	B-X
)	B-X
that	B-X
is	B-X
known	B-X
to	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
signal	B-X
transduction	B-X
cascade	B-X
and	B-X
cell	B-X
differentiation	B-X
and	B-X
proliferation	B-X
.	B-X
Mutated	B-X
Ras	B-X
is	B-X
unable	B-X
to	B-X
regulate	B-X
itself	B-X
and	B-X
remains	B-X
constantly	B-X
activated	B-X
,	B-X
leading	B-X
to	B-X
uncontrolled	B-X
cell	B-X
growth	B-X
.	B-X
The	B-X
function	B-X
of	B-X
Ras	B-X
in	B-X
signal	B-X
transduction	B-X
requires	B-X
its	B-X
location	B-X
near	B-X
the	B-X
growth	B-X
factor	B-X
receptor	B-X
at	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X
However	B-X
,	B-X
Ras	B-X
does	B-X
not	B-X
have	B-X
a	B-X
transmembrane	B-X
domain	B-X
.	B-X
Ras	B-X
requires	B-X
farnesylation	B-X
to	B-X
increase	B-X
its	B-X
hydrophobicity	B-X
and	B-X
subsequent	B-X
plasma	B-X
membrane	B-X
association	B-X
for	B-X
its	B-X
transforming	B-X
activity	B-X
.	B-X
This	B-X
key	B-X
post-translational	B-X
modification	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
enzyme	B-X
Ras	B-X
famesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
,	B-X
which	B-X
transfers	B-X
a	B-X
famesyl	B-X
group	B-X
from	B-X
farnesylpyrophosphate	B-X
to	B-X
the	B-X
C-terminal	B-X
cysteine	B-X
of	B-X
the	B-X
Ras	B-X
protein	B-X
.	B-X
The	B-X
requirement	B-X
has	B-X
focused	B-X
attention	B-X
on	B-X
FTase	B-X
as	B-X
a	B-X
target	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X
Selective	B-X
inhibition	B-X
of	B-X
FTase	B-X
will	B-X
prevent	B-X
Ras	B-X
protein	B-X
from	B-X
association	B-X
with	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
leading	B-X
to	B-X
a	B-X
disruption	B-X
of	B-X
oncogenic	B-X
Ras	B-X
function	B-X
.	B-X

The	O
Ras	O
carboxyl	O
terminal	O
tetrapeptide	O
CAAX	O
(	O
C	O
is	O
cysteine	O
,	O
A	O
is	O
any	O
aliphatic	O
amino	O
acid	O
,	O
X	O
is	O
methionine	O
or	O
serine	O
)	O
is	O
the	O
minimum	O
sequence	O
for	O
FTase	O
recognition	O
.	O
<EOS>	B-X
Cysteine	B-X
farnesylation	B-X
of	B-X
the	B-X
ras	B-X
oncogene	B-X
product	B-X
Ras	B-X
is	B-X
required	B-X
for	B-X
its	B-X
transforming	B-X
activity	B-X
and	B-X
is	B-X
catalyzed	B-X
by	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
.	B-X
The	B-X
Ras	B-X
carboxyl	B-X
terminal	B-X
tetrapeptide	B-X
CAAX	B-X
(	B-X
C	B-X
is	B-X
cysteine	B-X
,	B-X
A	B-X
is	B-X
any	B-X
aliphatic	B-X
amino	B-X
acid	B-X
,	B-X
X	B-X
is	B-X
methionine	B-X
or	B-X
serine	B-X
)	B-X
is	B-X
the	B-X
minimum	B-X
sequence	B-X
for	B-X
FTase	B-X
recognition	B-X
.	B-X
We	B-X
report	B-X
here	B-X
the	B-X
design	B-X
,	B-X
synthesis	B-X
,	B-X
and	B-X
biological	B-X
characterization	B-X
of	B-X
Ras	B-X
CAAX	B-X
non-peptide	B-X
mimetics	B-X
in	B-X
which	B-X
the	B-X
cysteine	B-X
is	B-X
linked	B-X
through	B-X
a	B-X
reduced	B-X
pseudopeptide	B-X
bond	B-X
to	B-X
4-amino-3'-carboxybiphenyl	B-X
.	B-X
These	B-X
non-peptide	B-X
mimetics	B-X
are	B-X
potent	B-X
inhibitors	B-X
of	B-X
FTase	B-X
(	B-X
IC50	B-X
=	B-X
40	B-X
nM	B-X
for	B-X
the	B-X
most	B-X
potent	B-X
inhibitor	B-X
)	B-X
and	B-X
are	B-X
highly	B-X
selective	B-X
for	B-X
FTase	B-X
over	B-X
GGTase	B-X
I	B-X
(	B-X
geranylgeranyltransferase	B-X
I	B-X
)	B-X
.	B-X
Structure-activity	B-X
studies	B-X
reveal	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
position	B-X
of	B-X
the	B-X
carboxylic	B-X
acid	B-X
on	B-X
the	B-X
aryl	B-X
ring	B-X
as	B-X
well	B-X
as	B-X
the	B-X
reduction	B-X
of	B-X
the	B-X
cysteine	B-X
amide	B-X
bond	B-X
.	B-X
Substitution	B-X
at	B-X
the	B-X
2-position	B-X
of	B-X
4-amino-3'-carboxybiphenyl	B-X
increases	B-X
inhibitory	B-X
potency	B-X
,	B-X
while	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
carboxylic	B-X
acid	B-X
results	B-X
in	B-X
a	B-X
10-fold	B-X
loss	B-X
of	B-X
inhibitory	B-X
activity	B-X
.	B-X

We	O
report	O
here	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
characterization	O
of	O
Ras	O
CAAX	O
non	O
-	O
peptide	O
mimetics	O
in	O
which	O
the	O
cysteine	O
is	O
linked	O
through	O
a	O
reduced	O
pseudopeptide	O
bond	O
to	O
4	O
-	O
amino	O
-	O
3	O
'	O
-	O
carboxybiphenyl	O
.	O
<EOS>	B-X
Cysteine	B-X
farnesylation	B-X
of	B-X
the	B-X
ras	B-X
oncogene	B-X
product	B-X
Ras	B-X
is	B-X
required	B-X
for	B-X
its	B-X
transforming	B-X
activity	B-X
and	B-X
is	B-X
catalyzed	B-X
by	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
.	B-X
The	B-X
Ras	B-X
carboxyl	B-X
terminal	B-X
tetrapeptide	B-X
CAAX	B-X
(	B-X
C	B-X
is	B-X
cysteine	B-X
,	B-X
A	B-X
is	B-X
any	B-X
aliphatic	B-X
amino	B-X
acid	B-X
,	B-X
X	B-X
is	B-X
methionine	B-X
or	B-X
serine	B-X
)	B-X
is	B-X
the	B-X
minimum	B-X
sequence	B-X
for	B-X
FTase	B-X
recognition	B-X
.	B-X
We	B-X
report	B-X
here	B-X
the	B-X
design	B-X
,	B-X
synthesis	B-X
,	B-X
and	B-X
biological	B-X
characterization	B-X
of	B-X
Ras	B-X
CAAX	B-X
non-peptide	B-X
mimetics	B-X
in	B-X
which	B-X
the	B-X
cysteine	B-X
is	B-X
linked	B-X
through	B-X
a	B-X
reduced	B-X
pseudopeptide	B-X
bond	B-X
to	B-X
4-amino-3'-carboxybiphenyl	B-X
.	B-X
These	B-X
non-peptide	B-X
mimetics	B-X
are	B-X
potent	B-X
inhibitors	B-X
of	B-X
FTase	B-X
(	B-X
IC50	B-X
=	B-X
40	B-X
nM	B-X
for	B-X
the	B-X
most	B-X
potent	B-X
inhibitor	B-X
)	B-X
and	B-X
are	B-X
highly	B-X
selective	B-X
for	B-X
FTase	B-X
over	B-X
GGTase	B-X
I	B-X
(	B-X
geranylgeranyltransferase	B-X
I	B-X
)	B-X
.	B-X
They	B-X
are	B-X
not	B-X
substrates	B-X
for	B-X
farnesylation	B-X
,	B-X
do	B-X
not	B-X
have	B-X
peptidic	B-X
features	B-X
,	B-X
and	B-X
have	B-X
no	B-X
hydrolyzable	B-X
bonds	B-X
.	B-X
Structure-activity	B-X
studies	B-X
reveal	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
position	B-X
of	B-X
the	B-X
carboxylic	B-X
acid	B-X
on	B-X
the	B-X
aryl	B-X
ring	B-X
as	B-X
well	B-X
as	B-X
the	B-X
reduction	B-X
of	B-X
the	B-X
cysteine	B-X
amide	B-X
bond	B-X
.	B-X
Substitution	B-X
at	B-X
the	B-X
2-position	B-X
of	B-X
4-amino-3'-carboxybiphenyl	B-X
increases	B-X
inhibitory	B-X
potency	B-X
,	B-X
while	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
carboxylic	B-X
acid	B-X
results	B-X
in	B-X
a	B-X
10-fold	B-X
loss	B-X
of	B-X
inhibitory	B-X
activity	B-X
.	B-X

These	O
non	O
-	O
peptide	O
mimetics	O
are	O
potent	O
inhibitors	O
of	O
FTase	O
(	O
IC50	O
=	O
40	O
nM	O
for	O
the	O
most	O
potent	O
inhibitor	O
)	O
and	O
are	O
highly	O
selective	O
for	O
FTase	O
over	O
GGTase	O
I	O
(	O
geranylgeranyltransferase	O
I	O
)	O
.	O
<EOS>	B-X
Cysteine	B-X
farnesylation	B-X
of	B-X
the	B-X
ras	B-X
oncogene	B-X
product	B-X
Ras	B-X
is	B-X
required	B-X
for	B-X
its	B-X
transforming	B-X
activity	B-X
and	B-X
is	B-X
catalyzed	B-X
by	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
.	B-X
The	B-X
Ras	B-X
carboxyl	B-X
terminal	B-X
tetrapeptide	B-X
CAAX	B-X
(	B-X
C	B-X
is	B-X
cysteine	B-X
,	B-X
A	B-X
is	B-X
any	B-X
aliphatic	B-X
amino	B-X
acid	B-X
,	B-X
X	B-X
is	B-X
methionine	B-X
or	B-X
serine	B-X
)	B-X
is	B-X
the	B-X
minimum	B-X
sequence	B-X
for	B-X
FTase	B-X
recognition	B-X
.	B-X
We	B-X
report	B-X
here	B-X
the	B-X
design	B-X
,	B-X
synthesis	B-X
,	B-X
and	B-X
biological	B-X
characterization	B-X
of	B-X
Ras	B-X
CAAX	B-X
non-peptide	B-X
mimetics	B-X
in	B-X
which	B-X
the	B-X
cysteine	B-X
is	B-X
linked	B-X
through	B-X
a	B-X
reduced	B-X
pseudopeptide	B-X
bond	B-X
to	B-X
4-amino-3'-carboxybiphenyl	B-X
.	B-X
These	B-X
non-peptide	B-X
mimetics	B-X
are	B-X
potent	B-X
inhibitors	B-X
of	B-X
FTase	B-X
(	B-X
IC50	B-X
=	B-X
40	B-X
nM	B-X
for	B-X
the	B-X
most	B-X
potent	B-X
inhibitor	B-X
)	B-X
and	B-X
are	B-X
highly	B-X
selective	B-X
for	B-X
FTase	B-X
over	B-X
GGTase	B-X
I	B-X
(	B-X
geranylgeranyltransferase	B-X
I	B-X
)	B-X
.	B-X
Substitution	B-X
at	B-X
the	B-X
2-position	B-X
of	B-X
4-amino-3'-carboxybiphenyl	B-X
increases	B-X
inhibitory	B-X
potency	B-X
,	B-X
while	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
carboxylic	B-X
acid	B-X
results	B-X
in	B-X
a	B-X
10-fold	B-X
loss	B-X
of	B-X
inhibitory	B-X
activity	B-X
.	B-X

They	O
are	O
not	O
substrates	O
for	O
farnesylation	O
,	O
do	O
not	O
have	O
peptidic	O
features	O
,	O
and	O
have	O
no	O
hydrolyzable	O
bonds	O
.	O

Structure	O
-	O
activity	O
studies	O
reveal	O
the	O
importance	O
of	O
the	O
position	O
of	O
the	O
carboxylic	O
acid	O
on	O
the	O
aryl	O
ring	O
as	O
well	O
as	O
the	O
reduction	O
of	O
the	O
cysteine	O
amide	O
bond	O
.	O
<EOS>	B-X
Cysteine	B-X
farnesylation	B-X
of	B-X
the	B-X
ras	B-X
oncogene	B-X
product	B-X
Ras	B-X
is	B-X
required	B-X
for	B-X
its	B-X
transforming	B-X
activity	B-X
and	B-X
is	B-X
catalyzed	B-X
by	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
.	B-X
The	B-X
Ras	B-X
carboxyl	B-X
terminal	B-X
tetrapeptide	B-X
CAAX	B-X
(	B-X
C	B-X
is	B-X
cysteine	B-X
,	B-X
A	B-X
is	B-X
any	B-X
aliphatic	B-X
amino	B-X
acid	B-X
,	B-X
X	B-X
is	B-X
methionine	B-X
or	B-X
serine	B-X
)	B-X
is	B-X
the	B-X
minimum	B-X
sequence	B-X
for	B-X
FTase	B-X
recognition	B-X
.	B-X
We	B-X
report	B-X
here	B-X
the	B-X
design	B-X
,	B-X
synthesis	B-X
,	B-X
and	B-X
biological	B-X
characterization	B-X
of	B-X
Ras	B-X
CAAX	B-X
non-peptide	B-X
mimetics	B-X
in	B-X
which	B-X
the	B-X
cysteine	B-X
is	B-X
linked	B-X
through	B-X
a	B-X
reduced	B-X
pseudopeptide	B-X
bond	B-X
to	B-X
4-amino-3'-carboxybiphenyl	B-X
.	B-X
They	B-X
are	B-X
not	B-X
substrates	B-X
for	B-X
farnesylation	B-X
,	B-X
do	B-X
not	B-X
have	B-X
peptidic	B-X
features	B-X
,	B-X
and	B-X
have	B-X
no	B-X
hydrolyzable	B-X
bonds	B-X
.	B-X
Structure-activity	B-X
studies	B-X
reveal	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
position	B-X
of	B-X
the	B-X
carboxylic	B-X
acid	B-X
on	B-X
the	B-X
aryl	B-X
ring	B-X
as	B-X
well	B-X
as	B-X
the	B-X
reduction	B-X
of	B-X
the	B-X
cysteine	B-X
amide	B-X
bond	B-X
.	B-X
Substitution	B-X
at	B-X
the	B-X
2-position	B-X
of	B-X
4-amino-3'-carboxybiphenyl	B-X
increases	B-X
inhibitory	B-X
potency	B-X
,	B-X
while	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
carboxylic	B-X
acid	B-X
results	B-X
in	B-X
a	B-X
10-fold	B-X
loss	B-X
of	B-X
inhibitory	B-X
activity	B-X
.	B-X

Substitution	O
at	O
the	O
2	O
-	O
position	O
of	O
4	O
-	O
amino	O
-	O
3	O
'	O
-	O
carboxybiphenyl	O
increases	O
inhibitory	O
potency	O
,	O
while	O
the	O
removal	O
of	O
the	O
carboxylic	O
acid	O
results	O
in	O
a	O
10	O
-	O
fold	O
loss	O
of	O
inhibitory	O
activity	O
.	O

Multiple	O
palmitoylation	O
of	O
synaptotagmin	O
and	O
the	O
t	O
-	O
SNARE	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
.	O

Synaptotagmin	O
,	O
a	O
likely	O
calcium	O
sensor	O
for	O
synaptic	O
transmission	O
,	O
and	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
,	O
a	O
t	O
-	O
SNARE	O
of	O
the	O
presynaptic	O
plasma	O
membrane	O
,	O
are	O
key	O
proteins	O
for	O
the	O
docking	O
and	O
fusion	O
of	O
synaptic	O
and	O
other	O
vesicles	O
.	O

We	O
report	O
that	O
both	O
synaptotagmin	O
and	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
are	O
palmitoylated	O
with	O
their	O
fatty	O
acids	O
attached	O
in	O
a	O
labile	O
thioester	O
-	O
type	O
bond	O
.	O

A	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
mutant	O
with	O
deleted	O
palmitoylation	O
sites	O
is	O
found	O
exclusively	O
in	O
the	O
cytosol	O
after	O
cell	O
fractionation	O
,	O
whereas	O
the	O
palmitoylated	O
form	O
of	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
is	O
membrane	O
-	O
bound	O
,	O
establishing	O
that	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
is	O
membrane	O
-	O
anchored	O
via	O
covalently	O
linked	O
palmitate	O
.	O
<EOS>	B-X
Synaptotagmin	B-X
,	B-X
a	B-X
likely	B-X
calcium	B-X
sensor	B-X
for	B-X
synaptic	B-X
transmission	B-X
,	B-X
and	B-X
SNAP-25	B-X
,	B-X
a	B-X
t-SNARE	B-X
of	B-X
the	B-X
presynaptic	B-X
plasma	B-X
membrane	B-X
,	B-X
are	B-X
key	B-X
proteins	B-X
for	B-X
the	B-X
docking	B-X
and	B-X
fusion	B-X
of	B-X
synaptic	B-X
and	B-X
other	B-X
vesicles	B-X
.	B-X
We	B-X
report	B-X
that	B-X
both	B-X
synaptotagmin	B-X
and	B-X
SNAP-25	B-X
are	B-X
palmitoylated	B-X
with	B-X
their	B-X
fatty	B-X
acids	B-X
attached	B-X
in	B-X
a	B-X
labile	B-X
thioester-type	B-X
bond	B-X
.	B-X
A	B-X
SNAP-25	B-X
mutant	B-X
with	B-X
deleted	B-X
palmitoylation	B-X
sites	B-X
is	B-X
found	B-X
exclusively	B-X
in	B-X
the	B-X
cytosol	B-X
after	B-X
cell	B-X
fractionation	B-X
,	B-X
whereas	B-X
the	B-X
palmitoylated	B-X
form	B-X
of	B-X
SNAP-25	B-X
is	B-X
membrane-bound	B-X
,	B-X
establishing	B-X
that	B-X
SNAP-25	B-X
is	B-X
membrane-anchored	B-X
via	B-X
covalently	B-X
linked	B-X
palmitate	B-X
.	B-X

Rate	O
limitations	O
in	O
posttranslational	O
processing	O
by	O
the	O
mammary	O
gland	O
of	O
transgenic	O
animals	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
Gamma	B-X
carboxylation	B-X
is	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
posttranslational	B-X
modification	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

Our	O
studies	O
in	O
transgenic	O
animal	O
bioreactors	O
sought	O
to	O
determine	O
the	O
rate	O
limitations	O
in	O
posttranslational	O
processing	O
of	O
recombinant	O
human	O
protein	B-Protein
C	I-Protein
(	O
rhPC	B-Protein
)	O
made	O
in	O
mammary	O
gland	O
of	O
mice	O
and	O
pigs	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
Human	B-X
protein	B-X
C	B-X
(	B-X
hPC	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
plasma	B-X
protein	B-X
containing	B-X
nine	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
(	B-X
gla	B-X
)	B-X
residues	B-X
that	B-X
bind	B-X
calcium	B-X
at	B-X
about	B-X
1	B-X
to	B-X
3	B-X
mM	B-X
.	B-X
Gamma	B-X
carboxylation	B-X
is	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
posttranslational	B-X
modification	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rhPC	B-X
synthesis	B-X
rate	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
was	B-X
studied	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
Promoter	B-X
elements	B-X
of	B-X
the	B-X
murine	B-X
whey	B-X
acid	B-X
protein	B-X
(	B-X
mWAP	B-X
)	B-X
gene	B-X
were	B-X
used	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
transgenes	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
11	B-X
+/-	B-X
4	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
895	B-X
+/-	B-X
21	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
Transgenic	B-X
pigs	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
100	B-X
to	B-X
500	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
800	B-X
to	B-X
2000	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
monoclonal	B-X
antibody	B-X
(	B-X
7D7B10-mAb	B-X
)	B-X
that	B-X
binds	B-X
an	B-X
epitope	B-X
in	B-X
the	B-X
gla	B-X
domain	B-X
of	B-X
hPC	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
calcium	B-X
was	B-X
used	B-X
to	B-X
study	B-X
the	B-X
conformational	B-X
behavior	B-X
of	B-X
immunopurified	B-X
rhPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
lower	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
calcium-dependent	B-X
binding	B-X
inhibition	B-X
by	B-X
7D7B10-mAb	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
higher	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
less	B-X
calcium-dependent	B-X
response	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

Human	O
protein	B-Protein
C	I-Protein
(	O
hPC	B-Protein
)	O
is	O
a	O
complex	O
plasma	O
protein	O
containing	O
nine	O
gamma	O
-	O
carboxylated	O
glutamic	O
acid	O
(	O
gla	O
)	O
residues	O
that	O
bind	O
calcium	O
at	O
about	O
1	O
to	O
3	O
mM	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
Human	B-X
protein	B-X
C	B-X
(	B-X
hPC	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
plasma	B-X
protein	B-X
containing	B-X
nine	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
(	B-X
gla	B-X
)	B-X
residues	B-X
that	B-X
bind	B-X
calcium	B-X
at	B-X
about	B-X
1	B-X
to	B-X
3	B-X
mM	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rhPC	B-X
synthesis	B-X
rate	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
was	B-X
studied	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
Promoter	B-X
elements	B-X
of	B-X
the	B-X
murine	B-X
whey	B-X
acid	B-X
protein	B-X
(	B-X
mWAP	B-X
)	B-X
gene	B-X
were	B-X
used	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
transgenes	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
11	B-X
+/-	B-X
4	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
895	B-X
+/-	B-X
21	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
Transgenic	B-X
pigs	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
100	B-X
to	B-X
500	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
800	B-X
to	B-X
2000	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
monoclonal	B-X
antibody	B-X
(	B-X
7D7B10-mAb	B-X
)	B-X
that	B-X
binds	B-X
an	B-X
epitope	B-X
in	B-X
the	B-X
gla	B-X
domain	B-X
of	B-X
hPC	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
calcium	B-X
was	B-X
used	B-X
to	B-X
study	B-X
the	B-X
conformational	B-X
behavior	B-X
of	B-X
immunopurified	B-X
rhPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
lower	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
calcium-dependent	B-X
binding	B-X
inhibition	B-X
by	B-X
7D7B10-mAb	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
higher	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
less	B-X
calcium-dependent	B-X
response	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

Gamma	O
carboxylation	O
is	O
a	O
vitamin	O
K	O
-	O
dependent	O
posttranslational	O
modification	O
.	O
<EOS>	B-X
Vitamin	B-X
K-dependent	B-X
(	B-X
VKD	B-X
)	B-X
proteins	B-X
undergo	B-X
an	B-X
unusual	B-X
post-translational	B-X
modification	B-X
,	B-X
which	B-X
is	B-X
the	B-X
conversion	B-X
of	B-X
specific	B-X
Glu	B-X
residues	B-X
to	B-X
carboxylated	B-X
Glu	B-X
(	B-X
Gla	B-X
)	B-X
.	B-X
Gla	B-X
generation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
VKD	B-X
proteins	B-X
,	B-X
and	B-X
occurs	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
during	B-X
their	B-X
secretion	B-X
to	B-X
either	B-X
the	B-X
cell	B-X
surface	B-X
or	B-X
from	B-X
the	B-X
cell	B-X
.	B-X
The	B-X
gamma-glutamyl	B-X
carboxylase	B-X
produces	B-X
Gla	B-X
using	B-X
reduced	B-X
vitamin	B-X
K	B-X
,	B-X
which	B-X
becomes	B-X
oxygenated	B-X
to	B-X
vitamin	B-X
K	B-X
epoxide	B-X
.	B-X
Reduced	B-X
vitamin	B-X
K	B-X
is	B-X
then	B-X
regenerated	B-X
by	B-X
a	B-X
vitamin	B-X
K	B-X
oxidoreductase	B-X
(	B-X
VKORC1	B-X
)	B-X
,	B-X
and	B-X
this	B-X
interconversion	B-X
of	B-X
oxygenated	B-X
and	B-X
reduced	B-X
vitamin	B-X
K	B-X
is	B-X
referred	B-X
to	B-X
as	B-X
the	B-X
vitamin	B-X
K	B-X
cycle	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
VKD	B-X
proteins	B-X
support	B-X
hemostasis	B-X
,	B-X
which	B-X
is	B-X
suppressed	B-X
during	B-X
therapy	B-X
with	B-X
warfarin	B-X
that	B-X
inhibits	B-X
VKORC1	B-X
activity	B-X
.	B-X
VKD	B-X
proteins	B-X
also	B-X
impact	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
physiologies	B-X
beyond	B-X
hemostasis	B-X
,	B-X
which	B-X
includes	B-X
regulation	B-X
of	B-X
calcification	B-X
,	B-X
apoptosis	B-X
,	B-X
complement	B-X
,	B-X
growth	B-X
control	B-X
,	B-X
signal	B-X
transduction	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
review	B-X
covers	B-X
the	B-X
roles	B-X
of	B-X
VKD	B-X
proteins	B-X
,	B-X
how	B-X
they	B-X
become	B-X
activated	B-X
,	B-X
and	B-X
how	B-X
disruption	B-X
of	B-X
carboxylation	B-X
can	B-X
lead	B-X
to	B-X
disease	B-X
.	B-X
VKD	B-X
proteins	B-X
contain	B-X
clusters	B-X
of	B-X
Gla	B-X
residues	B-X
that	B-X
form	B-X
a	B-X
calcium-binding	B-X
module	B-X
important	B-X
for	B-X
activity	B-X
,	B-X
and	B-X
carboxylase	B-X
processivity	B-X
allows	B-X
the	B-X
generation	B-X
of	B-X
multiple	B-X
Glas	B-X
.	B-X

The	O
effect	O
of	O
rhPC	B-Protein
synthesis	O
rate	O
on	O
the	O
extent	O
of	O
gamma	O
-	O
carboxylation	O
of	O
glutamic	O
acid	O
was	O
studied	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
Human	B-X
protein	B-X
C	B-X
(	B-X
hPC	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
plasma	B-X
protein	B-X
containing	B-X
nine	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
(	B-X
gla	B-X
)	B-X
residues	B-X
that	B-X
bind	B-X
calcium	B-X
at	B-X
about	B-X
1	B-X
to	B-X
3	B-X
mM	B-X
.	B-X
Gamma	B-X
carboxylation	B-X
is	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
posttranslational	B-X
modification	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rhPC	B-X
synthesis	B-X
rate	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
was	B-X
studied	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
Promoter	B-X
elements	B-X
of	B-X
the	B-X
murine	B-X
whey	B-X
acid	B-X
protein	B-X
(	B-X
mWAP	B-X
)	B-X
gene	B-X
were	B-X
used	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
transgenes	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
11	B-X
+/-	B-X
4	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
895	B-X
+/-	B-X
21	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
Transgenic	B-X
pigs	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
100	B-X
to	B-X
500	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
800	B-X
to	B-X
2000	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
monoclonal	B-X
antibody	B-X
(	B-X
7D7B10-mAb	B-X
)	B-X
that	B-X
binds	B-X
an	B-X
epitope	B-X
in	B-X
the	B-X
gla	B-X
domain	B-X
of	B-X
hPC	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
calcium	B-X
was	B-X
used	B-X
to	B-X
study	B-X
the	B-X
conformational	B-X
behavior	B-X
of	B-X
immunopurified	B-X
rhPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
lower	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
calcium-dependent	B-X
binding	B-X
inhibition	B-X
by	B-X
7D7B10-mAb	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
higher	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
less	B-X
calcium-dependent	B-X
response	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

We	O
have	O
perturbed	O
the	O
biosynthesis	O
of	O
rhPC	B-Protein
by	O
using	O
two	O
different	O
transgenes	O
to	O
direct	O
mammary	O
gland	O
-	O
specific	O
expression	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rhPC	B-X
synthesis	B-X
rate	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
was	B-X
studied	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
Promoter	B-X
elements	B-X
of	B-X
the	B-X
murine	B-X
whey	B-X
acid	B-X
protein	B-X
(	B-X
mWAP	B-X
)	B-X
gene	B-X
were	B-X
used	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
transgenes	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
11	B-X
+/-	B-X
4	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
895	B-X
+/-	B-X
21	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
Transgenic	B-X
pigs	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
100	B-X
to	B-X
500	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
800	B-X
to	B-X
2000	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
monoclonal	B-X
antibody	B-X
(	B-X
7D7B10-mAb	B-X
)	B-X
that	B-X
binds	B-X
an	B-X
epitope	B-X
in	B-X
the	B-X
gla	B-X
domain	B-X
of	B-X
hPC	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
calcium	B-X
was	B-X
used	B-X
to	B-X
study	B-X
the	B-X
conformational	B-X
behavior	B-X
of	B-X
immunopurified	B-X
rhPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
lower	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
calcium-dependent	B-X
binding	B-X
inhibition	B-X
by	B-X
7D7B10-mAb	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
higher	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
less	B-X
calcium-dependent	B-X
response	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

Promoter	O
elements	O
of	O
the	O
murine	O
whey	B-Protein
acid	I-Protein
protein	I-Protein
(	O
mWAP	B-Protein
)	O
gene	O
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
hPC	B-Protein
-	O
cDNA	O
and	O
hPC	B-Protein
-	O
genomic	O
transgenes	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
Human	B-X
protein	B-X
C	B-X
(	B-X
hPC	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
plasma	B-X
protein	B-X
containing	B-X
nine	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
(	B-X
gla	B-X
)	B-X
residues	B-X
that	B-X
bind	B-X
calcium	B-X
at	B-X
about	B-X
1	B-X
to	B-X
3	B-X
mM	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rhPC	B-X
synthesis	B-X
rate	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
was	B-X
studied	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
Promoter	B-X
elements	B-X
of	B-X
the	B-X
murine	B-X
whey	B-X
acid	B-X
protein	B-X
(	B-X
mWAP	B-X
)	B-X
gene	B-X
were	B-X
used	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
transgenes	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
11	B-X
+/-	B-X
4	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
895	B-X
+/-	B-X
21	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
Transgenic	B-X
pigs	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
100	B-X
to	B-X
500	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
800	B-X
to	B-X
2000	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
monoclonal	B-X
antibody	B-X
(	B-X
7D7B10-mAb	B-X
)	B-X
that	B-X
binds	B-X
an	B-X
epitope	B-X
in	B-X
the	B-X
gla	B-X
domain	B-X
of	B-X
hPC	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
calcium	B-X
was	B-X
used	B-X
to	B-X
study	B-X
the	B-X
conformational	B-X
behavior	B-X
of	B-X
immunopurified	B-X
rhPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
lower	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
calcium-dependent	B-X
binding	B-X
inhibition	B-X
by	B-X
7D7B10-mAb	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
higher	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
less	B-X
calcium-dependent	B-X
response	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

Transgenic	O
mice	O
with	O
hPC	B-Protein
-	O
cDNA	O
and	O
hPC	B-Protein
-	O
genomic	O
sequences	O
gave	O
expression	O
levels	O
of	O
11	O
+	O
/	O
-	O
4	O
micrograms	O
rhPC	B-Protein
/	O
ml	O
of	O
milk	O
and	O
895	O
+	O
/	O
-	O
21	O
micrograms	O
rhPC	B-Protein
/	O
ml	O
of	O
milk	O
,	O
respectively	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
Human	B-X
protein	B-X
C	B-X
(	B-X
hPC	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
plasma	B-X
protein	B-X
containing	B-X
nine	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
(	B-X
gla	B-X
)	B-X
residues	B-X
that	B-X
bind	B-X
calcium	B-X
at	B-X
about	B-X
1	B-X
to	B-X
3	B-X
mM	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rhPC	B-X
synthesis	B-X
rate	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
was	B-X
studied	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
Promoter	B-X
elements	B-X
of	B-X
the	B-X
murine	B-X
whey	B-X
acid	B-X
protein	B-X
(	B-X
mWAP	B-X
)	B-X
gene	B-X
were	B-X
used	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
transgenes	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
11	B-X
+/-	B-X
4	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
895	B-X
+/-	B-X
21	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
Transgenic	B-X
pigs	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
100	B-X
to	B-X
500	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
800	B-X
to	B-X
2000	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
monoclonal	B-X
antibody	B-X
(	B-X
7D7B10-mAb	B-X
)	B-X
that	B-X
binds	B-X
an	B-X
epitope	B-X
in	B-X
the	B-X
gla	B-X
domain	B-X
of	B-X
hPC	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
calcium	B-X
was	B-X
used	B-X
to	B-X
study	B-X
the	B-X
conformational	B-X
behavior	B-X
of	B-X
immunopurified	B-X
rhPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
lower	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
calcium-dependent	B-X
binding	B-X
inhibition	B-X
by	B-X
7D7B10-mAb	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
higher	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
less	B-X
calcium-dependent	B-X
response	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

Transgenic	O
pigs	O
with	O
hPC	B-Protein
-	O
cDNA	O
and	O
hPC	B-Protein
-	O
genomic	O
sequences	O
gave	O
expression	O
levels	O
of	O
100	O
to	O
500	O
micrograms	O
rhPC	B-Protein
/	O
ml	O
of	O
milk	O
and	O
800	O
to	O
2000	O
micrograms	O
rhPC	B-Protein
/	O
ml	O
of	O
milk	O
,	O
respectively	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
Human	B-X
protein	B-X
C	B-X
(	B-X
hPC	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
plasma	B-X
protein	B-X
containing	B-X
nine	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
(	B-X
gla	B-X
)	B-X
residues	B-X
that	B-X
bind	B-X
calcium	B-X
at	B-X
about	B-X
1	B-X
to	B-X
3	B-X
mM	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rhPC	B-X
synthesis	B-X
rate	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
was	B-X
studied	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
Promoter	B-X
elements	B-X
of	B-X
the	B-X
murine	B-X
whey	B-X
acid	B-X
protein	B-X
(	B-X
mWAP	B-X
)	B-X
gene	B-X
were	B-X
used	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
transgenes	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
11	B-X
+/-	B-X
4	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
895	B-X
+/-	B-X
21	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
Transgenic	B-X
pigs	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
100	B-X
to	B-X
500	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
800	B-X
to	B-X
2000	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
monoclonal	B-X
antibody	B-X
(	B-X
7D7B10-mAb	B-X
)	B-X
that	B-X
binds	B-X
an	B-X
epitope	B-X
in	B-X
the	B-X
gla	B-X
domain	B-X
of	B-X
hPC	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
calcium	B-X
was	B-X
used	B-X
to	B-X
study	B-X
the	B-X
conformational	B-X
behavior	B-X
of	B-X
immunopurified	B-X
rhPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
lower	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
calcium-dependent	B-X
binding	B-X
inhibition	B-X
by	B-X
7D7B10-mAb	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
higher	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
less	B-X
calcium-dependent	B-X
response	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

A	O
monoclonal	O
antibody	O
(	O
7D7B10	O
-	O
mAb	O
)	O
that	O
binds	O
an	O
epitope	O
in	O
the	O
gla	O
domain	O
of	O
hPC	B-Protein
in	O
the	O
absence	O
of	O
calcium	O
was	O
used	O
to	O
study	O
the	O
conformational	O
behavior	O
of	O
immunopurified	O
rhPC	B-Protein
.	O

Immunopurified	O
rhPC	B-Protein
from	O
lower	O
expressing	O
mice	O
and	O
pigs	O
gave	O
a	O
calcium	O
-	O
dependent	O
binding	O
inhibition	O
by	O
7D7B10	O
-	O
mAb	O
similar	O
to	O
that	O
of	O
hPC	B-Protein
.	O

Immunopurified	O
rhPC	B-Protein
from	O
higher	O
expressing	O
mice	O
and	O
pigs	O
gave	O
a	O
less	O
calcium	O
-	O
dependent	O
response	O
.	O

This	O
study	O
suggests	O
that	O
a	O
rate	O
limitation	O
in	O
gamma	O
-	O
carboxylation	O
by	O
the	O
mammary	O
gland	O
occurs	O
at	O
expression	O
levels	O
about	O
>	O
20	O
micrograms	O
/	O
ml	O
in	O
mice	O
and	O
>	O
500	O
micrograms	O
/	O
ml	O
in	O
pigs	O
.	O
<EOS>	B-X
Our	B-X
studies	B-X
in	B-X
transgenic	B-X
animal	B-X
bioreactors	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
rate	B-X
limitations	B-X
in	B-X
posttranslational	B-X
processing	B-X
of	B-X
recombinant	B-X
human	B-X
protein	B-X
C	B-X
(	B-X
rhPC	B-X
)	B-X
made	B-X
in	B-X
mammary	B-X
gland	B-X
of	B-X
mice	B-X
and	B-X
pigs	B-X
.	B-X
Human	B-X
protein	B-X
C	B-X
(	B-X
hPC	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
plasma	B-X
protein	B-X
containing	B-X
nine	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
(	B-X
gla	B-X
)	B-X
residues	B-X
that	B-X
bind	B-X
calcium	B-X
at	B-X
about	B-X
1	B-X
to	B-X
3	B-X
mM	B-X
.	B-X
Gamma	B-X
carboxylation	B-X
is	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
posttranslational	B-X
modification	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rhPC	B-X
synthesis	B-X
rate	B-X
on	B-X
the	B-X
extent	B-X
of	B-X
gamma-carboxylation	B-X
of	B-X
glutamic	B-X
acid	B-X
was	B-X
studied	B-X
.	B-X
We	B-X
have	B-X
perturbed	B-X
the	B-X
biosynthesis	B-X
of	B-X
rhPC	B-X
by	B-X
using	B-X
two	B-X
different	B-X
transgenes	B-X
to	B-X
direct	B-X
mammary	B-X
gland-specific	B-X
expression	B-X
.	B-X
Promoter	B-X
elements	B-X
of	B-X
the	B-X
murine	B-X
whey	B-X
acid	B-X
protein	B-X
(	B-X
mWAP	B-X
)	B-X
gene	B-X
were	B-X
used	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
transgenes	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
11	B-X
+/-	B-X
4	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
895	B-X
+/-	B-X
21	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
Transgenic	B-X
pigs	B-X
with	B-X
hPC-cDNA	B-X
and	B-X
hPC-genomic	B-X
sequences	B-X
gave	B-X
expression	B-X
levels	B-X
of	B-X
100	B-X
to	B-X
500	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
and	B-X
800	B-X
to	B-X
2000	B-X
micrograms	B-X
rhPC/ml	B-X
of	B-X
milk	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
monoclonal	B-X
antibody	B-X
(	B-X
7D7B10-mAb	B-X
)	B-X
that	B-X
binds	B-X
an	B-X
epitope	B-X
in	B-X
the	B-X
gla	B-X
domain	B-X
of	B-X
hPC	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
calcium	B-X
was	B-X
used	B-X
to	B-X
study	B-X
the	B-X
conformational	B-X
behavior	B-X
of	B-X
immunopurified	B-X
rhPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
lower	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
calcium-dependent	B-X
binding	B-X
inhibition	B-X
by	B-X
7D7B10-mAb	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hPC	B-X
.	B-X
Immunopurified	B-X
rhPC	B-X
from	B-X
higher	B-X
expressing	B-X
mice	B-X
and	B-X
pigs	B-X
gave	B-X
a	B-X
less	B-X
calcium-dependent	B-X
response	B-X
.	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
a	B-X
rate	B-X
limitation	B-X
in	B-X
gamma-carboxylation	B-X
by	B-X
the	B-X
mammary	B-X
gland	B-X
occurs	B-X
at	B-X
expression	B-X
levels	B-X
about	B-X
>	B-X
20	B-X
micrograms/ml	B-X
in	B-X
mice	B-X
and	B-X
>	B-X
500	B-X
micrograms/ml	B-X
in	B-X
pigs	B-X
.	B-X

Identification	O
and	O
isoprenylation	O
of	O
plant	O
GTP	O
-	O
binding	O
proteins	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
isoprenylated	B-X
plant	B-X
GTP-binding	B-X
proteins	B-X
,	B-X
Arabidopsis	B-X
thaliana	B-X
and	B-X
Nicotiana	B-X
tabacum	B-X
cDNA	B-X
expression	B-X
libraries	B-X
were	B-X
screened	B-X
for	B-X
cDNA-encoded	B-X
proteins	B-X
capable	B-X
of	B-X
binding	B-X
[	B-X
32P	B-X
]	B-X
GTP	B-X
in	B-X
vitro	B-X
.	B-X
ATGB2	B-X
,	B-X
an	B-X
Arabidopsis	B-X
homologue	B-X
of	B-X
the	B-X
GTP-binding	B-X
protein	B-X
Rab2	B-X
,	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
for	B-X
a	B-X
geranylgeranyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
GGTase	B-X
)	B-X
present	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
In	B-X
vitro	B-X
geranylgeranylation	B-X
of	B-X
an	B-X
Arabidopsis	B-X
Rab1	B-X
protein	B-X
containing	B-X
a	B-X
carboxyl-terminal-CCGQ	B-X
sequence	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
type	B-X
II	B-X
GGTase-like	B-X
activity	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
Several	B-X
other	B-X
proteins	B-X
were	B-X
also	B-X
identified	B-X
by	B-X
in	B-X
vitro	B-X
GTP	B-X
binding	B-X
,	B-X
including	B-X
Arabidopsis	B-X
and	B-X
tobacco	B-X
homologues	B-X
of	B-X
Rab11	B-X
,	B-X
ARF	B-X
(	B-X
ADP-ribosylation	B-X
factor	B-X
)	B-X
and	B-X
Sar	B-X
proteins	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
novel	B-X
22	B-X
kDa	B-X
Arabidopsis	B-X
protein	B-X
(	B-X
ATG81	B-X
)	B-X
.	B-X
This	B-X
22	B-X
kDa	B-X
protein	B-X
had	B-X
consensus	B-X
GTP-binding	B-X
motifs	B-X
and	B-X
bound	B-X
GTP	B-X
with	B-X
high	B-X
specificity	B-X
,	B-X
but	B-X
its	B-X
structure	B-X
was	B-X
not	B-X
closely	B-X
related	B-X
to	B-X
that	B-X
of	B-X
any	B-X
known	B-X
GTP-binding	B-X
protein	B-X
(	B-X
it	B-X
most	B-X
resembled	B-X
proteins	B-X
within	B-X
the	B-X
ARF/Sar	B-X
and	B-X
G	B-X
protein	B-X
alpha-subunit	B-X
superfamilies	B-X
)	B-X
.	B-X

To	O
identify	O
isoprenylated	O
plant	O
GTP	O
-	O
binding	O
proteins	O
,	O
Arabidopsis	O
thaliana	O
and	O
Nicotiana	O
tabacum	O
cDNA	O
expression	O
libraries	O
were	O
screened	O
for	O
cDNA	O
-	O
encoded	O
proteins	O
capable	O
of	O
binding	O
[	O
32P	O
]	O
GTP	O
in	O
vitro	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
isoprenylated	B-X
plant	B-X
GTP-binding	B-X
proteins	B-X
,	B-X
Arabidopsis	B-X
thaliana	B-X
and	B-X
Nicotiana	B-X
tabacum	B-X
cDNA	B-X
expression	B-X
libraries	B-X
were	B-X
screened	B-X
for	B-X
cDNA-encoded	B-X
proteins	B-X
capable	B-X
of	B-X
binding	B-X
[	B-X
32P	B-X
]	B-X
GTP	B-X
in	B-X
vitro	B-X
.	B-X
ATGB2	B-X
,	B-X
an	B-X
Arabidopsis	B-X
homologue	B-X
of	B-X
the	B-X
GTP-binding	B-X
protein	B-X
Rab2	B-X
,	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
for	B-X
a	B-X
geranylgeranyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
GGTase	B-X
)	B-X
present	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
this	B-X
protein	B-X
contains	B-X
a	B-X
-GCCG	B-X
sequence	B-X
,	B-X
which	B-X
has	B-X
not	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
recognized	B-X
by	B-X
any	B-X
prenyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
PTase	B-X
)	B-X
,	B-X
but	B-X
which	B-X
most	B-X
closely	B-X
resembles	B-X
that	B-X
isoprenylated	B-X
by	B-X
the	B-X
type	B-X
II	B-X
GGTase	B-X
(	B-X
-XXCC	B-X
,	B-X
-XCXC	B-X
,	B-X
or	B-X
-CCXX	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
geranylgeranylation	B-X
of	B-X
an	B-X
Arabidopsis	B-X
Rab1	B-X
protein	B-X
containing	B-X
a	B-X
carboxyl-terminal-CCGQ	B-X
sequence	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
type	B-X
II	B-X
GGTase-like	B-X
activity	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
Several	B-X
other	B-X
proteins	B-X
were	B-X
also	B-X
identified	B-X
by	B-X
in	B-X
vitro	B-X
GTP	B-X
binding	B-X
,	B-X
including	B-X
Arabidopsis	B-X
and	B-X
tobacco	B-X
homologues	B-X
of	B-X
Rab11	B-X
,	B-X
ARF	B-X
(	B-X
ADP-ribosylation	B-X
factor	B-X
)	B-X
and	B-X
Sar	B-X
proteins	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
novel	B-X
22	B-X
kDa	B-X
Arabidopsis	B-X
protein	B-X
(	B-X
ATG81	B-X
)	B-X
.	B-X
This	B-X
22	B-X
kDa	B-X
protein	B-X
had	B-X
consensus	B-X
GTP-binding	B-X
motifs	B-X
and	B-X
bound	B-X
GTP	B-X
with	B-X
high	B-X
specificity	B-X
,	B-X
but	B-X
its	B-X
structure	B-X
was	B-X
not	B-X
closely	B-X
related	B-X
to	B-X
that	B-X
of	B-X
any	B-X
known	B-X
GTP-binding	B-X
protein	B-X
(	B-X
it	B-X
most	B-X
resembled	B-X
proteins	B-X
within	B-X
the	B-X
ARF/Sar	B-X
and	B-X
G	B-X
protein	B-X
alpha-subunit	B-X
superfamilies	B-X
)	B-X
.	B-X

ATGB2	B-Protein
,	O
an	O
Arabidopsis	O
homologue	O
of	O
the	O
GTP	O
-	O
binding	O
protein	O
Rab2	B-Protein
,	O
was	O
found	O
to	O
bind	O
GTP	O
in	O
vitro	O
and	O
to	O
be	O
a	O
substrate	O
for	O
a	O
geranylgeranyl	O
:	O
protein	O
transferase	O
(	O
GGTase	O
)	O
present	O
in	O
plant	O
extracts	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
isoprenylated	B-X
plant	B-X
GTP-binding	B-X
proteins	B-X
,	B-X
Arabidopsis	B-X
thaliana	B-X
and	B-X
Nicotiana	B-X
tabacum	B-X
cDNA	B-X
expression	B-X
libraries	B-X
were	B-X
screened	B-X
for	B-X
cDNA-encoded	B-X
proteins	B-X
capable	B-X
of	B-X
binding	B-X
[	B-X
32P	B-X
]	B-X
GTP	B-X
in	B-X
vitro	B-X
.	B-X
ATGB2	B-X
,	B-X
an	B-X
Arabidopsis	B-X
homologue	B-X
of	B-X
the	B-X
GTP-binding	B-X
protein	B-X
Rab2	B-X
,	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
for	B-X
a	B-X
geranylgeranyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
GGTase	B-X
)	B-X
present	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
this	B-X
protein	B-X
contains	B-X
a	B-X
-GCCG	B-X
sequence	B-X
,	B-X
which	B-X
has	B-X
not	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
recognized	B-X
by	B-X
any	B-X
prenyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
PTase	B-X
)	B-X
,	B-X
but	B-X
which	B-X
most	B-X
closely	B-X
resembles	B-X
that	B-X
isoprenylated	B-X
by	B-X
the	B-X
type	B-X
II	B-X
GGTase	B-X
(	B-X
-XXCC	B-X
,	B-X
-XCXC	B-X
,	B-X
or	B-X
-CCXX	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
geranylgeranylation	B-X
of	B-X
an	B-X
Arabidopsis	B-X
Rab1	B-X
protein	B-X
containing	B-X
a	B-X
carboxyl-terminal-CCGQ	B-X
sequence	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
type	B-X
II	B-X
GGTase-like	B-X
activity	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
Several	B-X
other	B-X
proteins	B-X
were	B-X
also	B-X
identified	B-X
by	B-X
in	B-X
vitro	B-X
GTP	B-X
binding	B-X
,	B-X
including	B-X
Arabidopsis	B-X
and	B-X
tobacco	B-X
homologues	B-X
of	B-X
Rab11	B-X
,	B-X
ARF	B-X
(	B-X
ADP-ribosylation	B-X
factor	B-X
)	B-X
and	B-X
Sar	B-X
proteins	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
novel	B-X
22	B-X
kDa	B-X
Arabidopsis	B-X
protein	B-X
(	B-X
ATG81	B-X
)	B-X
.	B-X
This	B-X
22	B-X
kDa	B-X
protein	B-X
had	B-X
consensus	B-X
GTP-binding	B-X
motifs	B-X
and	B-X
bound	B-X
GTP	B-X
with	B-X
high	B-X
specificity	B-X
,	B-X
but	B-X
its	B-X
structure	B-X
was	B-X
not	B-X
closely	B-X
related	B-X
to	B-X
that	B-X
of	B-X
any	B-X
known	B-X
GTP-binding	B-X
protein	B-X
(	B-X
it	B-X
most	B-X
resembled	B-X
proteins	B-X
within	B-X
the	B-X
ARF/Sar	B-X
and	B-X
G	B-X
protein	B-X
alpha-subunit	B-X
superfamilies	B-X
)	B-X
.	B-X

The	O
carboxyl	O
terminus	O
of	O
this	O
protein	O
contains	O
a	O
-	O
GCCG	O
sequence	O
,	O
which	O
has	O
not	O
previously	O
been	O
shown	O
to	O
be	O
recognized	O
by	O
any	O
prenyl	O
:	O
protein	O
transferase	O
(	O
PTase	O
)	O
,	O
but	O
which	O
most	O
closely	O
resembles	O
that	O
isoprenylated	O
by	O
the	O
type	O
II	O
GGTase	O
(	O
-	O
XXCC	O
,	O
-	O
XCXC	O
,	O
or	O
-	O
CCXX	O
)	O
.	O

In	O
vitro	O
geranylgeranylation	O
of	O
an	O
Arabidopsis	O
Rab1	B-Protein
protein	O
containing	O
a	O
carboxyl	O
-	O
terminal	O
-	O
CCGQ	O
sequence	O
confirmed	O
the	O
presence	O
of	O
a	O
type	O
II	O
GGTase	O
-	O
like	O
activity	O
in	O
plant	O
extracts	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
isoprenylated	B-X
plant	B-X
GTP-binding	B-X
proteins	B-X
,	B-X
Arabidopsis	B-X
thaliana	B-X
and	B-X
Nicotiana	B-X
tabacum	B-X
cDNA	B-X
expression	B-X
libraries	B-X
were	B-X
screened	B-X
for	B-X
cDNA-encoded	B-X
proteins	B-X
capable	B-X
of	B-X
binding	B-X
[	B-X
32P	B-X
]	B-X
GTP	B-X
in	B-X
vitro	B-X
.	B-X
ATGB2	B-X
,	B-X
an	B-X
Arabidopsis	B-X
homologue	B-X
of	B-X
the	B-X
GTP-binding	B-X
protein	B-X
Rab2	B-X
,	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
for	B-X
a	B-X
geranylgeranyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
GGTase	B-X
)	B-X
present	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
this	B-X
protein	B-X
contains	B-X
a	B-X
-GCCG	B-X
sequence	B-X
,	B-X
which	B-X
has	B-X
not	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
recognized	B-X
by	B-X
any	B-X
prenyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
PTase	B-X
)	B-X
,	B-X
but	B-X
which	B-X
most	B-X
closely	B-X
resembles	B-X
that	B-X
isoprenylated	B-X
by	B-X
the	B-X
type	B-X
II	B-X
GGTase	B-X
(	B-X
-XXCC	B-X
,	B-X
-XCXC	B-X
,	B-X
or	B-X
-CCXX	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
geranylgeranylation	B-X
of	B-X
an	B-X
Arabidopsis	B-X
Rab1	B-X
protein	B-X
containing	B-X
a	B-X
carboxyl-terminal-CCGQ	B-X
sequence	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
type	B-X
II	B-X
GGTase-like	B-X
activity	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
Several	B-X
other	B-X
proteins	B-X
were	B-X
also	B-X
identified	B-X
by	B-X
in	B-X
vitro	B-X
GTP	B-X
binding	B-X
,	B-X
including	B-X
Arabidopsis	B-X
and	B-X
tobacco	B-X
homologues	B-X
of	B-X
Rab11	B-X
,	B-X
ARF	B-X
(	B-X
ADP-ribosylation	B-X
factor	B-X
)	B-X
and	B-X
Sar	B-X
proteins	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
novel	B-X
22	B-X
kDa	B-X
Arabidopsis	B-X
protein	B-X
(	B-X
ATG81	B-X
)	B-X
.	B-X
This	B-X
22	B-X
kDa	B-X
protein	B-X
had	B-X
consensus	B-X
GTP-binding	B-X
motifs	B-X
and	B-X
bound	B-X
GTP	B-X
with	B-X
high	B-X
specificity	B-X
,	B-X
but	B-X
its	B-X
structure	B-X
was	B-X
not	B-X
closely	B-X
related	B-X
to	B-X
that	B-X
of	B-X
any	B-X
known	B-X
GTP-binding	B-X
protein	B-X
(	B-X
it	B-X
most	B-X
resembled	B-X
proteins	B-X
within	B-X
the	B-X
ARF/Sar	B-X
and	B-X
G	B-X
protein	B-X
alpha-subunit	B-X
superfamilies	B-X
)	B-X
.	B-X

Several	O
other	O
proteins	O
were	O
also	O
identified	O
by	O
in	O
vitro	O
GTP	O
binding	O
,	O
including	O
Arabidopsis	O
and	O
tobacco	O
homologues	O
of	O
Rab11	B-Protein
,	O
ARF	O
(	O
ADP	O
-	O
ribosylation	O
factor	O
)	O
and	O
Sar	O
proteins	O
,	O
as	O
well	O
as	O
a	O
novel	O
22	O
kDa	O
Arabidopsis	O
protein	O
(	O
ATG81	B-Protein
)	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
isoprenylated	B-X
plant	B-X
GTP-binding	B-X
proteins	B-X
,	B-X
Arabidopsis	B-X
thaliana	B-X
and	B-X
Nicotiana	B-X
tabacum	B-X
cDNA	B-X
expression	B-X
libraries	B-X
were	B-X
screened	B-X
for	B-X
cDNA-encoded	B-X
proteins	B-X
capable	B-X
of	B-X
binding	B-X
[	B-X
32P	B-X
]	B-X
GTP	B-X
in	B-X
vitro	B-X
.	B-X
ATGB2	B-X
,	B-X
an	B-X
Arabidopsis	B-X
homologue	B-X
of	B-X
the	B-X
GTP-binding	B-X
protein	B-X
Rab2	B-X
,	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
for	B-X
a	B-X
geranylgeranyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
GGTase	B-X
)	B-X
present	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
this	B-X
protein	B-X
contains	B-X
a	B-X
-GCCG	B-X
sequence	B-X
,	B-X
which	B-X
has	B-X
not	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
recognized	B-X
by	B-X
any	B-X
prenyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
PTase	B-X
)	B-X
,	B-X
but	B-X
which	B-X
most	B-X
closely	B-X
resembles	B-X
that	B-X
isoprenylated	B-X
by	B-X
the	B-X
type	B-X
II	B-X
GGTase	B-X
(	B-X
-XXCC	B-X
,	B-X
-XCXC	B-X
,	B-X
or	B-X
-CCXX	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
geranylgeranylation	B-X
of	B-X
an	B-X
Arabidopsis	B-X
Rab1	B-X
protein	B-X
containing	B-X
a	B-X
carboxyl-terminal-CCGQ	B-X
sequence	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
type	B-X
II	B-X
GGTase-like	B-X
activity	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
Several	B-X
other	B-X
proteins	B-X
were	B-X
also	B-X
identified	B-X
by	B-X
in	B-X
vitro	B-X
GTP	B-X
binding	B-X
,	B-X
including	B-X
Arabidopsis	B-X
and	B-X
tobacco	B-X
homologues	B-X
of	B-X
Rab11	B-X
,	B-X
ARF	B-X
(	B-X
ADP-ribosylation	B-X
factor	B-X
)	B-X
and	B-X
Sar	B-X
proteins	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
novel	B-X
22	B-X
kDa	B-X
Arabidopsis	B-X
protein	B-X
(	B-X
ATG81	B-X
)	B-X
.	B-X
This	B-X
22	B-X
kDa	B-X
protein	B-X
had	B-X
consensus	B-X
GTP-binding	B-X
motifs	B-X
and	B-X
bound	B-X
GTP	B-X
with	B-X
high	B-X
specificity	B-X
,	B-X
but	B-X
its	B-X
structure	B-X
was	B-X
not	B-X
closely	B-X
related	B-X
to	B-X
that	B-X
of	B-X
any	B-X
known	B-X
GTP-binding	B-X
protein	B-X
(	B-X
it	B-X
most	B-X
resembled	B-X
proteins	B-X
within	B-X
the	B-X
ARF/Sar	B-X
and	B-X
G	B-X
protein	B-X
alpha-subunit	B-X
superfamilies	B-X
)	B-X
.	B-X

This	O
22	O
kDa	O
protein	O
had	O
consensus	O
GTP	O
-	O
binding	O
motifs	O
and	O
bound	O
GTP	O
with	O
high	O
specificity	O
,	O
but	O
its	O
structure	O
was	O
not	O
closely	O
related	O
to	O
that	O
of	O
any	O
known	O
GTP	O
-	O
binding	O
protein	O
(	O
it	O
most	O
resembled	O
proteins	O
within	O
the	O
ARF	O
/	O
Sar	O
and	O
G	O
protein	O
alpha	O
-	O
subunit	O
superfamilies	O
)	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
isoprenylated	B-X
plant	B-X
GTP-binding	B-X
proteins	B-X
,	B-X
Arabidopsis	B-X
thaliana	B-X
and	B-X
Nicotiana	B-X
tabacum	B-X
cDNA	B-X
expression	B-X
libraries	B-X
were	B-X
screened	B-X
for	B-X
cDNA-encoded	B-X
proteins	B-X
capable	B-X
of	B-X
binding	B-X
[	B-X
32P	B-X
]	B-X
GTP	B-X
in	B-X
vitro	B-X
.	B-X
ATGB2	B-X
,	B-X
an	B-X
Arabidopsis	B-X
homologue	B-X
of	B-X
the	B-X
GTP-binding	B-X
protein	B-X
Rab2	B-X
,	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
for	B-X
a	B-X
geranylgeranyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
GGTase	B-X
)	B-X
present	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
The	B-X
carboxyl	B-X
terminus	B-X
of	B-X
this	B-X
protein	B-X
contains	B-X
a	B-X
-GCCG	B-X
sequence	B-X
,	B-X
which	B-X
has	B-X
not	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
recognized	B-X
by	B-X
any	B-X
prenyl	B-X
:	B-X
protein	B-X
transferase	B-X
(	B-X
PTase	B-X
)	B-X
,	B-X
but	B-X
which	B-X
most	B-X
closely	B-X
resembles	B-X
that	B-X
isoprenylated	B-X
by	B-X
the	B-X
type	B-X
II	B-X
GGTase	B-X
(	B-X
-XXCC	B-X
,	B-X
-XCXC	B-X
,	B-X
or	B-X
-CCXX	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
geranylgeranylation	B-X
of	B-X
an	B-X
Arabidopsis	B-X
Rab1	B-X
protein	B-X
containing	B-X
a	B-X
carboxyl-terminal-CCGQ	B-X
sequence	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
type	B-X
II	B-X
GGTase-like	B-X
activity	B-X
in	B-X
plant	B-X
extracts	B-X
.	B-X
Several	B-X
other	B-X
proteins	B-X
were	B-X
also	B-X
identified	B-X
by	B-X
in	B-X
vitro	B-X
GTP	B-X
binding	B-X
,	B-X
including	B-X
Arabidopsis	B-X
and	B-X
tobacco	B-X
homologues	B-X
of	B-X
Rab11	B-X
,	B-X
ARF	B-X
(	B-X
ADP-ribosylation	B-X
factor	B-X
)	B-X
and	B-X
Sar	B-X
proteins	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
novel	B-X
22	B-X
kDa	B-X
Arabidopsis	B-X
protein	B-X
(	B-X
ATG81	B-X
)	B-X
.	B-X
This	B-X
22	B-X
kDa	B-X
protein	B-X
had	B-X
consensus	B-X
GTP-binding	B-X
motifs	B-X
and	B-X
bound	B-X
GTP	B-X
with	B-X
high	B-X
specificity	B-X
,	B-X
but	B-X
its	B-X
structure	B-X
was	B-X
not	B-X
closely	B-X
related	B-X
to	B-X
that	B-X
of	B-X
any	B-X
known	B-X
GTP-binding	B-X
protein	B-X
(	B-X
it	B-X
most	B-X
resembled	B-X
proteins	B-X
within	B-X
the	B-X
ARF/Sar	B-X
and	B-X
G	B-X
protein	B-X
alpha-subunit	B-X
superfamilies	B-X
)	B-X
.	B-X

Molecular	O
cloning	O
and	O
characterization	O
of	O
nlpH	B-Protein
,	O
encoding	O
a	O
novel	O
,	O
surface	O
-	O
exposed	O
,	O
polymorphic	O
,	O
plasmid	O
-	O
encoded	O
33	O
-	O
kilodalton	O
lipoprotein	O
of	O
Borrelia	O
afzelii	O
.	O
<EOS>	B-X
Borrelia	B-X
burgdorferi	B-X
sensu	B-X
lato	B-X
organisms	B-X
,	B-X
comprising	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
,	B-X
Borrelia	B-X
afzelii	B-X
,	B-X
and	B-X
Borrelia	B-X
garinii	B-X
,	B-X
are	B-X
tick-borne	B-X
pathogens	B-X
causing	B-X
Lyme	B-X
borreliosis	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
identify	B-X
putative	B-X
virulence	B-X
determinants	B-X
,	B-X
a	B-X
B.	B-X
afzelii	B-X
DNA	B-X
library	B-X
was	B-X
screened	B-X
for	B-X
Congo	B-X
red	B-X
dye	B-X
binding	B-X
,	B-X
a	B-X
property	B-X
associated	B-X
with	B-X
virulence	B-X
in	B-X
pathogenic	B-X
bacteria	B-X
.	B-X
One	B-X
clone	B-X
was	B-X
found	B-X
to	B-X
carry	B-X
a	B-X
663-nucleotide-long	B-X
open	B-X
reading	B-X
frame	B-X
encoding	B-X
a	B-X
Congo	B-X
red	B-X
dye-binding	B-X
protein	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
25,660	B-X
Da	B-X
.	B-X
The	B-X
lipoprotein	B-X
nature	B-X
was	B-X
demonstrated	B-X
by	B-X
incorporation	B-X
of	B-X
radioactive	B-X
palmitate	B-X
;	B-X
hence	B-X
,	B-X
this	B-X
protein	B-X
has	B-X
been	B-X
termed	B-X
NlpH	B-X
,	B-X
for	B-X
new	B-X
lipoprotein	B-X
H.	B-X
NlpH	B-X
is	B-X
located	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
B.	B-X
afzelii	B-X
,	B-X
and	B-X
the	B-X
nlpH	B-X
gene	B-X
is	B-X
found	B-X
on	B-X
a	B-X
circular	B-X
plasmid	B-X
.	B-X
The	B-X
nlpH	B-X
gene	B-X
is	B-X
also	B-X
found	B-X
in	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
and	B-X
B.	B-X
garinii	B-X
.	B-X
Immediately	B-X
upstream	B-X
of	B-X
nlpH	B-X
is	B-X
located	B-X
a	B-X
smaller	B-X
reading	B-X
frame	B-X
encoding	B-X
a	B-X
polypeptide	B-X
containing	B-X
the	B-X
casein	B-X
kinase	B-X
II	B-X
phosphorylation	B-X
recognition	B-X
sequence	B-X
,	B-X
(	B-X
Ser/Thr	B-X
)	B-X
-X-Y-	B-X
(	B-X
Glu/Asp	B-X
)	B-X
,	B-X
repeated	B-X
10	B-X
times	B-X
.	B-X

Borrelia	O
burgdorferi	O
sensu	O
lato	O
organisms	O
,	O
comprising	O
B	O
.	O
burgdorferi	O
sensu	O
stricto	O
,	O
Borrelia	O
afzelii	O
,	O
and	O
Borrelia	O
garinii	O
,	O
are	O
tick	O
-	O
borne	O
pathogens	O
causing	O
Lyme	O
borreliosis	O
in	O
humans	O
.	O
<EOS>	B-X
Borrelia	B-X
burgdorferi	B-X
sensu	B-X
lato	B-X
organisms	B-X
,	B-X
comprising	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
,	B-X
Borrelia	B-X
afzelii	B-X
,	B-X
and	B-X
Borrelia	B-X
garinii	B-X
,	B-X
are	B-X
tick-borne	B-X
pathogens	B-X
causing	B-X
Lyme	B-X
borreliosis	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
identify	B-X
putative	B-X
virulence	B-X
determinants	B-X
,	B-X
a	B-X
B.	B-X
afzelii	B-X
DNA	B-X
library	B-X
was	B-X
screened	B-X
for	B-X
Congo	B-X
red	B-X
dye	B-X
binding	B-X
,	B-X
a	B-X
property	B-X
associated	B-X
with	B-X
virulence	B-X
in	B-X
pathogenic	B-X
bacteria	B-X
.	B-X
The	B-X
amino	B-X
acid	B-X
sequence	B-X
deduced	B-X
from	B-X
its	B-X
nucleotide	B-X
sequence	B-X
was	B-X
found	B-X
to	B-X
include	B-X
a	B-X
consensus	B-X
bacterial	B-X
lipidation	B-X
site	B-X
present	B-X
at	B-X
residues	B-X
15	B-X
to	B-X
18	B-X
(	B-X
Leu-Ser-Gly-Cys	B-X
)	B-X
.	B-X
The	B-X
lipoprotein	B-X
nature	B-X
was	B-X
demonstrated	B-X
by	B-X
incorporation	B-X
of	B-X
radioactive	B-X
palmitate	B-X
;	B-X
hence	B-X
,	B-X
this	B-X
protein	B-X
has	B-X
been	B-X
termed	B-X
NlpH	B-X
,	B-X
for	B-X
new	B-X
lipoprotein	B-X
H.	B-X
NlpH	B-X
is	B-X
located	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
B.	B-X
afzelii	B-X
,	B-X
and	B-X
the	B-X
nlpH	B-X
gene	B-X
is	B-X
found	B-X
on	B-X
a	B-X
circular	B-X
plasmid	B-X
.	B-X
The	B-X
nlpH	B-X
gene	B-X
is	B-X
also	B-X
found	B-X
in	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
and	B-X
B.	B-X
garinii	B-X
.	B-X

To	O
identify	O
putative	O
virulence	O
determinants	O
,	O
a	O
B	O
.	O
afzelii	O
DNA	O
library	O
was	O
screened	O
for	O
Congo	O
red	O
dye	O
binding	O
,	O
a	O
property	O
associated	O
with	O
virulence	O
in	O
pathogenic	O
bacteria	O
.	O

One	O
clone	O
was	O
found	O
to	O
carry	O
a	O
663	O
-	O
nucleotide	O
-	O
long	O
open	O
reading	O
frame	O
encoding	O
a	O
Congo	O
red	O
dye	O
-	O
binding	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
25	O
,	O
660	O
Da	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
putative	B-X
virulence	B-X
determinants	B-X
,	B-X
a	B-X
B.	B-X
afzelii	B-X
DNA	B-X
library	B-X
was	B-X
screened	B-X
for	B-X
Congo	B-X
red	B-X
dye	B-X
binding	B-X
,	B-X
a	B-X
property	B-X
associated	B-X
with	B-X
virulence	B-X
in	B-X
pathogenic	B-X
bacteria	B-X
.	B-X
One	B-X
clone	B-X
was	B-X
found	B-X
to	B-X
carry	B-X
a	B-X
663-nucleotide-long	B-X
open	B-X
reading	B-X
frame	B-X
encoding	B-X
a	B-X
Congo	B-X
red	B-X
dye-binding	B-X
protein	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
25,660	B-X
Da	B-X
.	B-X
The	B-X
amino	B-X
acid	B-X
sequence	B-X
deduced	B-X
from	B-X
its	B-X
nucleotide	B-X
sequence	B-X
was	B-X
found	B-X
to	B-X
include	B-X
a	B-X
consensus	B-X
bacterial	B-X
lipidation	B-X
site	B-X
present	B-X
at	B-X
residues	B-X
15	B-X
to	B-X
18	B-X
(	B-X
Leu-Ser-Gly-Cys	B-X
)	B-X
.	B-X
The	B-X
lipoprotein	B-X
nature	B-X
was	B-X
demonstrated	B-X
by	B-X
incorporation	B-X
of	B-X
radioactive	B-X
palmitate	B-X
;	B-X
hence	B-X
,	B-X
this	B-X
protein	B-X
has	B-X
been	B-X
termed	B-X
NlpH	B-X
,	B-X
for	B-X
new	B-X
lipoprotein	B-X
H.	B-X
NlpH	B-X
is	B-X
located	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
B.	B-X
afzelii	B-X
,	B-X
and	B-X
the	B-X
nlpH	B-X
gene	B-X
is	B-X
found	B-X
on	B-X
a	B-X
circular	B-X
plasmid	B-X
.	B-X
The	B-X
nlpH	B-X
gene	B-X
is	B-X
also	B-X
found	B-X
in	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
and	B-X
B.	B-X
garinii	B-X
.	B-X
Immediately	B-X
upstream	B-X
of	B-X
nlpH	B-X
is	B-X
located	B-X
a	B-X
smaller	B-X
reading	B-X
frame	B-X
encoding	B-X
a	B-X
polypeptide	B-X
containing	B-X
the	B-X
casein	B-X
kinase	B-X
II	B-X
phosphorylation	B-X
recognition	B-X
sequence	B-X
,	B-X
(	B-X
Ser/Thr	B-X
)	B-X
-X-Y-	B-X
(	B-X
Glu/Asp	B-X
)	B-X
,	B-X
repeated	B-X
10	B-X
times	B-X
.	B-X

The	O
amino	O
acid	O
sequence	O
deduced	O
from	O
its	O
nucleotide	O
sequence	O
was	O
found	O
to	O
include	O
a	O
consensus	O
bacterial	O
lipidation	O
site	O
present	O
at	O
residues	O
15	O
to	O
18	O
(	O
Leu	O
-	O
Ser	O
-	O
Gly	O
-	O
Cys	O
)	O
.	O
<EOS>	B-X
One	B-X
clone	B-X
was	B-X
found	B-X
to	B-X
carry	B-X
a	B-X
663-nucleotide-long	B-X
open	B-X
reading	B-X
frame	B-X
encoding	B-X
a	B-X
Congo	B-X
red	B-X
dye-binding	B-X
protein	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
25,660	B-X
Da	B-X
.	B-X
The	B-X
amino	B-X
acid	B-X
sequence	B-X
deduced	B-X
from	B-X
its	B-X
nucleotide	B-X
sequence	B-X
was	B-X
found	B-X
to	B-X
include	B-X
a	B-X
consensus	B-X
bacterial	B-X
lipidation	B-X
site	B-X
present	B-X
at	B-X
residues	B-X
15	B-X
to	B-X
18	B-X
(	B-X
Leu-Ser-Gly-Cys	B-X
)	B-X
.	B-X
The	B-X
lipoprotein	B-X
nature	B-X
was	B-X
demonstrated	B-X
by	B-X
incorporation	B-X
of	B-X
radioactive	B-X
palmitate	B-X
;	B-X
hence	B-X
,	B-X
this	B-X
protein	B-X
has	B-X
been	B-X
termed	B-X
NlpH	B-X
,	B-X
for	B-X
new	B-X
lipoprotein	B-X
H.	B-X
NlpH	B-X
is	B-X
located	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
B.	B-X
afzelii	B-X
,	B-X
and	B-X
the	B-X
nlpH	B-X
gene	B-X
is	B-X
found	B-X
on	B-X
a	B-X
circular	B-X
plasmid	B-X
.	B-X
The	B-X
nlpH	B-X
gene	B-X
is	B-X
also	B-X
found	B-X
in	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
and	B-X
B.	B-X
garinii	B-X
.	B-X
Immediately	B-X
upstream	B-X
of	B-X
nlpH	B-X
is	B-X
located	B-X
a	B-X
smaller	B-X
reading	B-X
frame	B-X
encoding	B-X
a	B-X
polypeptide	B-X
containing	B-X
the	B-X
casein	B-X
kinase	B-X
II	B-X
phosphorylation	B-X
recognition	B-X
sequence	B-X
,	B-X
(	B-X
Ser/Thr	B-X
)	B-X
-X-Y-	B-X
(	B-X
Glu/Asp	B-X
)	B-X
,	B-X
repeated	B-X
10	B-X
times	B-X
.	B-X

The	O
lipoprotein	O
nature	O
was	O
demonstrated	O
by	O
incorporation	O
of	O
radioactive	O
palmitate	O
;	O
hence	O
,	O
this	O
protein	O
has	O
been	O
termed	O
NlpH	B-Protein
,	O
for	O
new	O
lipoprotein	O
H	O
.	O
<EOS>	B-X
To	B-X
circumvent	B-X
the	B-X
present	B-X
chemical	B-X
route	B-X
of	B-X
synthesis	B-X
for	B-X
lipopeptide-antigen	B-X
conjugates	B-X
,	B-X
the	B-X
lipoprotein	B-X
property	B-X
of	B-X
the	B-X
pColE2-P9-encoded	B-X
lysis	B-X
protein	B-X
,	B-X
CelB	B-X
,	B-X
was	B-X
used	B-X
to	B-X
create	B-X
the	B-X
bacterial	B-X
fusion	B-X
plasmid	B-X
,	B-X
pKLY3	B-X
,	B-X
to	B-X
produce	B-X
lipopeptide-antigen	B-X
chimeras	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
Under	B-X
control	B-X
of	B-X
the	B-X
promoter	B-X
,	B-X
ptrc	B-X
,	B-X
is	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
celB	B-X
gene	B-X
coding	B-X
for	B-X
a	B-X
lipoprotein	B-X
signal	B-X
peptide	B-X
and	B-X
the	B-X
first	B-X
five	B-X
amino	B-X
acids	B-X
(	B-X
aa	B-X
)	B-X
(	B-X
CQANY	B-X
)	B-X
of	B-X
the	B-X
mature	B-X
lysis	B-X
protein	B-X
.	B-X
As	B-X
model	B-X
systems	B-X
for	B-X
the	B-X
synthesis	B-X
of	B-X
small	B-X
and	B-X
large	B-X
lipopeptide-antigens	B-X
,	B-X
DNA	B-X
sequences	B-X
coding	B-X
for	B-X
the	B-X
P2	B-X
peptide	B-X
and	B-X
E.	B-X
coli	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PhoA	B-X
)	B-X
were	B-X
fused	B-X
in	B-X
frame	B-X
to	B-X
the	B-X
region	B-X
of	B-X
celB	B-X
coding	B-X
for	B-X
a	B-X
lipoprotein	B-X
signal	B-X
peptide	B-X
and	B-X
CQANY	B-X
.	B-X
Inducible	B-X
expression	B-X
of	B-X
stable	B-X
lipohexapeptide	B-X
CQANYV	B-X
,	B-X
lipo-CQANY-P2	B-X
,	B-X
and	B-X
lipo-CQANYA-PhoA	B-X
,	B-X
was	B-X
demonstrated	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
lipid	B-X
moiety	B-X
on	B-X
the	B-X
products	B-X
was	B-X
confirmed	B-X
by	B-X
demonstrating	B-X
the	B-X
incorporation	B-X
of	B-X
radioactive	B-X
palmitic	B-X
acid	B-X
and	B-X
inhibition	B-X
of	B-X
processing	B-X
by	B-X
globomycin	B-X
.	B-X
The	B-X
lipid-modified	B-X
peptides	B-X
were	B-X
also	B-X
identified	B-X
by	B-X
incorporation	B-X
of	B-X
radioactive	B-X
tyrosine	B-X
,	B-X
and	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
P2	B-X
peptide	B-X
was	B-X
verified	B-X
immunologically	B-X
.	B-X

NlpH	B-Protein
is	O
located	O
on	O
the	O
surface	O
of	O
B	O
.	O
afzelii	O
,	O
and	O
the	O
nlpH	B-Protein
gene	O
is	O
found	O
on	O
a	O
circular	O
plasmid	O
.	O
<EOS>	B-X
Borrelia	B-X
burgdorferi	B-X
sensu	B-X
lato	B-X
organisms	B-X
,	B-X
comprising	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
,	B-X
Borrelia	B-X
afzelii	B-X
,	B-X
and	B-X
Borrelia	B-X
garinii	B-X
,	B-X
are	B-X
tick-borne	B-X
pathogens	B-X
causing	B-X
Lyme	B-X
borreliosis	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
identify	B-X
putative	B-X
virulence	B-X
determinants	B-X
,	B-X
a	B-X
B.	B-X
afzelii	B-X
DNA	B-X
library	B-X
was	B-X
screened	B-X
for	B-X
Congo	B-X
red	B-X
dye	B-X
binding	B-X
,	B-X
a	B-X
property	B-X
associated	B-X
with	B-X
virulence	B-X
in	B-X
pathogenic	B-X
bacteria	B-X
.	B-X
One	B-X
clone	B-X
was	B-X
found	B-X
to	B-X
carry	B-X
a	B-X
663-nucleotide-long	B-X
open	B-X
reading	B-X
frame	B-X
encoding	B-X
a	B-X
Congo	B-X
red	B-X
dye-binding	B-X
protein	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
25,660	B-X
Da	B-X
.	B-X
The	B-X
amino	B-X
acid	B-X
sequence	B-X
deduced	B-X
from	B-X
its	B-X
nucleotide	B-X
sequence	B-X
was	B-X
found	B-X
to	B-X
include	B-X
a	B-X
consensus	B-X
bacterial	B-X
lipidation	B-X
site	B-X
present	B-X
at	B-X
residues	B-X
15	B-X
to	B-X
18	B-X
(	B-X
Leu-Ser-Gly-Cys	B-X
)	B-X
.	B-X
The	B-X
lipoprotein	B-X
nature	B-X
was	B-X
demonstrated	B-X
by	B-X
incorporation	B-X
of	B-X
radioactive	B-X
palmitate	B-X
;	B-X
hence	B-X
,	B-X
this	B-X
protein	B-X
has	B-X
been	B-X
termed	B-X
NlpH	B-X
,	B-X
for	B-X
new	B-X
lipoprotein	B-X
H.	B-X
NlpH	B-X
is	B-X
located	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
B.	B-X
afzelii	B-X
,	B-X
and	B-X
the	B-X
nlpH	B-X
gene	B-X
is	B-X
found	B-X
on	B-X
a	B-X
circular	B-X
plasmid	B-X
.	B-X
The	B-X
nlpH	B-X
gene	B-X
is	B-X
also	B-X
found	B-X
in	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
and	B-X
B.	B-X
garinii	B-X
.	B-X
Immediately	B-X
upstream	B-X
of	B-X
nlpH	B-X
is	B-X
located	B-X
a	B-X
smaller	B-X
reading	B-X
frame	B-X
encoding	B-X
a	B-X
polypeptide	B-X
containing	B-X
the	B-X
casein	B-X
kinase	B-X
II	B-X
phosphorylation	B-X
recognition	B-X
sequence	B-X
,	B-X
(	B-X
Ser/Thr	B-X
)	B-X
-X-Y-	B-X
(	B-X
Glu/Asp	B-X
)	B-X
,	B-X
repeated	B-X
10	B-X
times	B-X
.	B-X

The	O
nlpH	B-Protein
gene	O
is	O
also	O
found	O
in	O
B	O
.	O
burgdorferi	O
sensu	O
stricto	O
and	O
B	O
.	O
garinii	O
.	O

Immediately	O
upstream	O
of	O
nlpH	B-Protein
is	O
located	O
a	O
smaller	O
reading	O
frame	O
encoding	O
a	O
polypeptide	O
containing	O
the	O
casein	O
kinase	O
II	O
phosphorylation	O
recognition	O
sequence	O
,	O
(	O
Ser	O
/	O
Thr	O
)	O
-	O
X	O
-	O
Y	O
-	O
(	O
Glu	O
/	O
Asp	O
)	O
,	O
repeated	O
10	O
times	O
.	O

Fatty	O
acylation	O
of	O
the	O
rat	O
and	O
human	O
asialoglycoprotein	O
receptors	O
.	O
<EOS>	B-X
Functional	B-X
rat	B-X
or	B-X
human	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomeric	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
.	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
The	B-X
degree	B-X
of	B-X
acylation	B-X
is	B-X
>	B-X
/=90	B-X
%	B-X
per	B-X
subunit	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X

A	O
conserved	O
cytoplasmic	O
cysteine	O
residue	O
is	O
acylated	O
in	O
all	O
receptor	O
subunits	O
.	O
<EOS>	B-X
Functional	B-X
rat	B-X
or	B-X
human	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomeric	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
.	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
single	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
each	B-X
RHL	B-X
or	B-X
HHL	B-X
subunit	B-X
is	B-X
fatty	B-X
acylated	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X

Functional	O
rat	O
or	O
human	O
asialoglycoprotein	O
receptors	O
(	O
ASGP	O
-	O
Rs	O
)	O
are	O
hetero	O
-	O
oligomeric	O
integral	O
membrane	O
glycoproteins	O
.	O
<EOS>	B-X
Functional	B-X
rat	B-X
or	B-X
human	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomeric	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
.	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X
This	B-X
result	B-X
also	B-X
shows	B-X
that	B-X
Cys57	B-X
within	B-X
the	B-X
transmembrane	B-X
domain	B-X
of	B-X
HHL1	B-X
is	B-X
not	B-X
normally	B-X
palmitoylated	B-X
.	B-X

Rat	O
ASGP	O
-	O
R	O
contains	O
three	O
subunits	O
,	O
designated	O
rat	O
hepatic	B-Protein
lectins	I-Protein
(	I-Protein
RHL	I-Protein
)	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
and	O
3	B-Protein
;	O
human	O
ASGP	O
-	O
R	O
contains	O
two	O
subunits	O
,	O
HHL1	B-Protein
and	O
HHL2	B-Protein
.	O
<EOS>	B-X
The	B-X
rat	B-X
asialoglycoprotein	B-X
receptor	B-X
(	B-X
ASGPR	B-X
)	B-X
is	B-X
an	B-X
integral	B-X
transmembrane	B-X
glycoprotein	B-X
composed	B-X
of	B-X
three	B-X
polypeptide	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
Each	B-X
subunit	B-X
contains	B-X
one	B-X
or	B-X
more	B-X
Ser	B-X
and	B-X
Thr	B-X
residues	B-X
in	B-X
its	B-X
cytoplasmic	B-X
domain	B-X
that	B-X
are	B-X
potential	B-X
sites	B-X
of	B-X
phosphorylation	B-X
;	B-X
in	B-X
addition	B-X
,	B-X
RHL1	B-X
also	B-X
contains	B-X
one	B-X
cytoplasmic	B-X
Tyr	B-X
.	B-X
Based	B-X
on	B-X
[	B-X
32P	B-X
]	B-X
PO4	B-X
metabolic	B-X
radiolabeling	B-X
experiments	B-X
,	B-X
Takahashi	B-X
et	B-X
al	B-X
.	B-X
(	B-X
1985	B-X
)	B-X
Biochem	B-X
.	B-X
Res	B-X
.	B-X
126	B-X
,	B-X
1054-1060	B-X
)	B-X
concluded	B-X
that	B-X
RHL2	B-X
and	B-X
RHL3	B-X
are	B-X
phosphoproteins	B-X
but	B-X
that	B-X
RHL1	B-X
is	B-X
not	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
RHL1	B-X
in	B-X
active	B-X
ASGPR	B-X
is	B-X
,	B-X
in	B-X
fact	B-X
,	B-X
a	B-X
phosphoprotein	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
using	B-X
anti-Tyr	B-X
(	B-X
P	B-X
)	B-X
antibody	B-X
identified	B-X
Tyr	B-X
(	B-X
P	B-X
)	B-X
in	B-X
RHL1	B-X
of	B-X
affinity-purified	B-X
ASGPRs	B-X
.	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
which	B-X
do	B-X
not	B-X
contain	B-X
Tyr	B-X
in	B-X
their	B-X
cytoplasmic	B-X
domains	B-X
,	B-X
did	B-X
not	B-X
react	B-X
with	B-X
this	B-X
antibody	B-X
.	B-X
When	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
radiolabeled	B-X
metabolically	B-X
with	B-X
[	B-X
32P	B-X
]	B-X
PO4	B-X
,	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
became	B-X
radiolabeled	B-X
.	B-X
Each	B-X
ASGPR	B-X
subunit	B-X
was	B-X
radiolabeled	B-X
to	B-X
a	B-X
similar	B-X
extent	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
the	B-X
ligand	B-X
asialo-orosomucoid	B-X
,	B-X
indicating	B-X
that	B-X
functioning	B-X
of	B-X
the	B-X
ASGPR	B-X
does	B-X
not	B-X
change	B-X
its	B-X
steady-state	B-X
23P-radiolabeling	B-X
.	B-X
Phosphoamino	B-X
acid	B-X
analysis	B-X
of	B-X
radiolabeled	B-X
ASGPR	B-X
subunits	B-X
identified	B-X
Ser	B-X
(	B-X
P	B-X
)	B-X
as	B-X
the	B-X
predominant	B-X
(	B-X
approximately	B-X
95	B-X
%	B-X
)	B-X
and	B-X
Thr	B-X
(	B-X
P	B-X
)	B-X
as	B-X
a	B-X
minor	B-X
(	B-X
approximately	B-X
5	B-X
%	B-X
)	B-X
phosphoamino	B-X
acid	B-X
in	B-X
each	B-X
polypeptide	B-X
and	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
Tyr	B-X
(	B-X
P	B-X
)	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
in	B-X
RHL1	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
of	B-X
hepatocytes	B-X
with	B-X
3	B-X
mM	B-X
vandate	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
for	B-X
30	B-X
min	B-X
doubled	B-X
the	B-X
steady-state	B-X
level	B-X
of	B-X
Tyr	B-X
(	B-X
P	B-X
)	B-X
in	B-X
RHL1	B-X
.	B-X

Both	O
receptors	O
are	O
covalently	O
modified	O
by	O
fatty	O
acylation	O
(	O
Zeng	O
,	O
F	O
.	O
-	O
Y	O
.	O
,	O
Kaphalia	O
,	O
B	O
.	O
S	O
.	O
,	O
Ansari	O
,	O
G	O
.	O
A	O
.	O
S	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1995	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
21382	O
-	O
21387	O
;	O
Zeng	O
,	O
F	O
.	O
-	O
Y	O
.	O
,	O
Oka	O
,	O
J	O
.	O
A	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1996	O
)	O
Biochem	O
.	O
Biophys	O
.	O
Res	O
.	O
Commun	O
.	O
218	O
,	O
325	O
-	O
330	O
)	O
.	O

We	O
report	O
here	O
that	O
the	O
single	O
Cys	O
residue	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
each	O
RHL	O
or	O
HHL	O
subunit	O
is	O
fatty	O
acylated	O
.	O
<EOS>	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
single	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
each	B-X
RHL	B-X
or	B-X
HHL	B-X
subunit	B-X
is	B-X
fatty	B-X
acylated	B-X
.	B-X
The	B-X
degree	B-X
of	B-X
acylation	B-X
is	B-X
>	B-X
/=90	B-X
%	B-X
per	B-X
subunit	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X
This	B-X
result	B-X
also	B-X
shows	B-X
that	B-X
Cys57	B-X
within	B-X
the	B-X
transmembrane	B-X
domain	B-X
of	B-X
HHL1	B-X
is	B-X
not	B-X
normally	B-X
palmitoylated	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X
Cys57	B-X
in	B-X
HHL1	B-X
and	B-X
probably	B-X
Cys56	B-X
in	B-X
RHL1	B-X
are	B-X
not	B-X
palmitoylated	B-X
.	B-X

The	O
degree	O
of	O
acylation	O
is	O
>	O
/	O
=	O
90	O
%	O
per	O
subunit	O
.	O
<EOS>	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
single	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
each	B-X
RHL	B-X
or	B-X
HHL	B-X
subunit	B-X
is	B-X
fatty	B-X
acylated	B-X
.	B-X
The	B-X
degree	B-X
of	B-X
acylation	B-X
is	B-X
>	B-X
/=90	B-X
%	B-X
per	B-X
subunit	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X

Deacylation	O
of	O
affinity	O
-	O
purified	O
ASGP	O
-	O
Rs	O
with	O
hydroxylamine	O
results	O
in	O
the	O
spontaneous	O
formation	O
of	O
dimers	O
through	O
reversible	O
disulfide	O
bonds	O
,	O
indicating	O
that	O
deacylation	O
concomitantly	O
generates	O
free	O
thiol	O
groups	O
.	O
<EOS>	B-X
Functional	B-X
rat	B-X
or	B-X
human	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomeric	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
.	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X

Reaction	O
of	O
hydroxylamine	O
-	O
treated	O
ASGP	O
-	O
R	O
with	O
[	O
14C	O
]	O
iodoacetamide	O
resulted	O
in	O
the	O
specific	O
incorporation	O
of	O
radioactivity	O
into	O
all	O
RHL	O
and	O
HHL	O
subunits	O
,	O
verifying	O
that	O
fatty	O
acids	O
are	O
attached	O
via	O
thioester	O
linkages	O
.	O
<EOS>	B-X
Functional	B-X
rat	B-X
or	B-X
human	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomeric	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
.	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
Res	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
single	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
each	B-X
RHL	B-X
or	B-X
HHL	B-X
subunit	B-X
is	B-X
fatty	B-X
acylated	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X
This	B-X
result	B-X
also	B-X
shows	B-X
that	B-X
Cys57	B-X
within	B-X
the	B-X
transmembrane	B-X
domain	B-X
of	B-X
HHL1	B-X
is	B-X
not	B-X
normally	B-X
palmitoylated	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X
Cys57	B-X
in	B-X
HHL1	B-X
and	B-X
probably	B-X
Cys56	B-X
in	B-X
RHL1	B-X
are	B-X
not	B-X
palmitoylated	B-X
.	B-X

To	O
identify	O
the	O
Cys	O
residue	O
involved	O
in	O
the	O
thioester	O
linkages	O
,	O
14C	O
-	O
carboxyamidomethylated	O
RHL	O
subunits	O
were	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
digested	O
in	O
-	O
gel	O
with	O
trypsin	O
,	O
and	O
the	O
resulting	O
peptides	O
were	O
separated	O
by	O
reverse	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O
<EOS>	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
A.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1996	B-X
)	B-X
Biochem	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
single	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
each	B-X
RHL	B-X
or	B-X
HHL	B-X
subunit	B-X
is	B-X
fatty	B-X
acylated	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X
This	B-X
result	B-X
also	B-X
shows	B-X
that	B-X
Cys57	B-X
within	B-X
the	B-X
transmembrane	B-X
domain	B-X
of	B-X
HHL1	B-X
is	B-X
not	B-X
normally	B-X
palmitoylated	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X
Cys57	B-X
in	B-X
HHL1	B-X
and	B-X
probably	B-X
Cys56	B-X
in	B-X
RHL1	B-X
are	B-X
not	B-X
palmitoylated	B-X
.	B-X

Amino	O
acid	O
sequence	O
of	O
radioactive	O
peptides	O
revealed	O
that	O
Cys35	O
in	O
RHL1	B-Protein
and	O
Cys54	O
in	O
RHL2	B-Protein
and	O
RHL3	B-Protein
were	O
radiolabeled	O
and	O
,	O
therefore	O
,	O
are	O
fatty	O
acylation	O
sites	O
.	O
<EOS>	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
single	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
each	B-X
RHL	B-X
or	B-X
HHL	B-X
subunit	B-X
is	B-X
fatty	B-X
acylated	B-X
.	B-X
The	B-X
degree	B-X
of	B-X
acylation	B-X
is	B-X
>	B-X
/=90	B-X
%	B-X
per	B-X
subunit	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X
Cys57	B-X
in	B-X
HHL1	B-X
and	B-X
probably	B-X
Cys56	B-X
in	B-X
RHL1	B-X
are	B-X
not	B-X
palmitoylated	B-X
.	B-X

Fatty	O
acylation	O
of	O
HHL	O
subunits	O
was	O
analyzed	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O
<EOS>	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
single	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
each	B-X
RHL	B-X
or	B-X
HHL	B-X
subunit	B-X
is	B-X
fatty	B-X
acylated	B-X
.	B-X
The	B-X
degree	B-X
of	B-X
acylation	B-X
is	B-X
>	B-X
/=90	B-X
%	B-X
per	B-X
subunit	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X
This	B-X
result	B-X
also	B-X
shows	B-X
that	B-X
Cys57	B-X
within	B-X
the	B-X
transmembrane	B-X
domain	B-X
of	B-X
HHL1	B-X
is	B-X
not	B-X
normally	B-X
palmitoylated	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X
Cys57	B-X
in	B-X
HHL1	B-X
and	B-X
probably	B-X
Cys56	B-X
in	B-X
RHL1	B-X
are	B-X
not	B-X
palmitoylated	B-X
.	B-X

Metabolic	O
labeling	O
of	O
Cos7	O
cells	O
transfected	O
with	O
wild	O
type	O
HHL1	B-Protein
cDNA	O
resulted	O
in	O
substantial	O
incorporation	O
of	O
[	O
3H	O
]	O
palmitate	O
into	O
purified	O
HHL1	B-Protein
.	O
<EOS>	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X
This	B-X
result	B-X
also	B-X
shows	B-X
that	B-X
Cys57	B-X
within	B-X
the	B-X
transmembrane	B-X
domain	B-X
of	B-X
HHL1	B-X
is	B-X
not	B-X
normally	B-X
palmitoylated	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X
Cys57	B-X
in	B-X
HHL1	B-X
and	B-X
probably	B-X
Cys56	B-X
in	B-X
RHL1	B-X
are	B-X
not	B-X
palmitoylated	B-X
.	B-X

Incorporation	O
of	O
[	O
3H	O
]	O
palmitate	O
into	O
a	O
C36S	O
mutant	O
of	O
HHL1	B-Protein
was	O
negligible	O
(	O
approximately	O
1	O
%	O
)	O
compared	O
with	O
wild	O
type	O
.	O
<EOS>	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
270	B-X
,	B-X
21382-21387	B-X
;	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
A.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1996	B-X
)	B-X
Biochem	B-X
.	B-X
218	B-X
,	B-X
325-330	B-X
)	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X
This	B-X
result	B-X
also	B-X
shows	B-X
that	B-X
Cys57	B-X
within	B-X
the	B-X
transmembrane	B-X
domain	B-X
of	B-X
HHL1	B-X
is	B-X
not	B-X
normally	B-X
palmitoylated	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X
Cys57	B-X
in	B-X
HHL1	B-X
and	B-X
probably	B-X
Cys56	B-X
in	B-X
RHL1	B-X
are	B-X
not	B-X
palmitoylated	B-X
.	B-X

This	O
result	O
also	O
shows	O
that	O
Cys57	O
within	O
the	O
transmembrane	O
domain	O
of	O
HHL1	B-Protein
is	O
not	O
normally	O
palmitoylated	O
.	O

We	O
conclude	O
that	O
Cys35	O
in	O
RHL1	B-Protein
,	O
Cys54	O
in	O
RHL2	B-Protein
and	O
RHL3	B-Protein
,	O
and	O
Cys36	O
in	O
HHL1	B-Protein
are	O
fatty	O
acylated	O
.	O
<EOS>	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
single	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
each	B-X
RHL	B-X
or	B-X
HHL	B-X
subunit	B-X
is	B-X
fatty	B-X
acylated	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X
This	B-X
result	B-X
also	B-X
shows	B-X
that	B-X
Cys57	B-X
within	B-X
the	B-X
transmembrane	B-X
domain	B-X
of	B-X
HHL1	B-X
is	B-X
not	B-X
normally	B-X
palmitoylated	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
,	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
,	B-X
and	B-X
Cys36	B-X
in	B-X
HHL1	B-X
are	B-X
fatty	B-X
acylated	B-X
.	B-X
Cys57	B-X
in	B-X
HHL1	B-X
and	B-X
probably	B-X
Cys56	B-X
in	B-X
RHL1	B-X
are	B-X
not	B-X
palmitoylated	B-X
.	B-X

Cys57	O
in	O
HHL1	B-Protein
and	O
probably	O
Cys56	O
in	O
RHL1	B-Protein
are	O
not	O
palmitoylated	O
.	O

HSDJ	B-Protein
,	O
a	O
human	O
homolog	O
of	O
DnaJ	B-Protein
,	O
is	O
farnesylated	O
and	O
is	O
involved	O
in	O
protein	O
import	O
into	O
mitochondria	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
HSDJ	B-X
,	B-X
a	B-X
human	B-X
homolog	B-X
of	B-X
bacterial	B-X
DnaJ	B-X
and	B-X
yeast	B-X
YDJ1p/MAS5	B-X
,	B-X
in	B-X
mitochondrial	B-X
protein	B-X
import	B-X
was	B-X
examined	B-X
.	B-X
Recombinant	B-X
HSDJ	B-X
was	B-X
purified	B-X
and	B-X
an	B-X
antibody	B-X
was	B-X
prepared	B-X
.	B-X
HSDJ	B-X
mRNA	B-X
was	B-X
heat-induced	B-X
in	B-X
cultured	B-X
cells	B-X
.	B-X
In	B-X
pulse-labeling	B-X
and	B-X
chase	B-X
experiments	B-X
using	B-X
COS-7	B-X
cells	B-X
,	B-X
the	B-X
endogenous	B-X
HSDJ	B-X
homolog	B-X
was	B-X
prenylated	B-X
.	B-X
Transiently	B-X
expressed	B-X
HSDJ	B-X
was	B-X
also	B-X
prenylated	B-X
,	B-X
whereas	B-X
its	B-X
mutant	B-X
C394S	B-X
in	B-X
which	B-X
cysteine	B-X
of	B-X
the	B-X
``	B-X
CaaX	B-X
box	B-X
''	B-X
was	B-X
mutated	B-X
to	B-X
serine	B-X
,	B-X
was	B-X
not	B-X
.	B-X
HSDJ	B-X
,	B-X
but	B-X
not	B-X
C394S	B-X
,	B-X
synthesized	B-X
in	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
was	B-X
farnesylated	B-X
.	B-X
The	B-X
HSDJ	B-X
antibody	B-X
inhibited	B-X
import	B-X
of	B-X
ornithine	B-X
transcarbamylase	B-X
precursor	B-X
(	B-X
pOTC	B-X
)	B-X
into	B-X
isolated	B-X
mitochondria	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
pOTC	B-X
synthesis	B-X
,	B-X
but	B-X
not	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
import	B-X
assay	B-X
.	B-X
Coexpression	B-X
of	B-X
HSDJ	B-X
or	B-X
C394S	B-X
resulted	B-X
in	B-X
slight	B-X
retardation	B-X
of	B-X
the	B-X
pOTC	B-X
processing	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HSDJ	B-X
is	B-X
involved	B-X
in	B-X
an	B-X
early	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
protein	B-X
import	B-X
into	B-X
mitochondria	B-X
.	B-X

The	O
role	O
of	O
HSDJ	B-Protein
,	O
a	O
human	O
homolog	O
of	O
bacterial	O
DnaJ	B-Protein
and	O
yeast	O
YDJ1p	B-Protein
/	O
MAS5	B-Protein
,	O
in	O
mitochondrial	O
protein	O
import	O
was	O
examined	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
HSDJ	B-X
,	B-X
a	B-X
human	B-X
homolog	B-X
of	B-X
bacterial	B-X
DnaJ	B-X
and	B-X
yeast	B-X
YDJ1p/MAS5	B-X
,	B-X
in	B-X
mitochondrial	B-X
protein	B-X
import	B-X
was	B-X
examined	B-X
.	B-X
Recombinant	B-X
HSDJ	B-X
was	B-X
purified	B-X
and	B-X
an	B-X
antibody	B-X
was	B-X
prepared	B-X
.	B-X
HSDJ	B-X
mRNA	B-X
was	B-X
heat-induced	B-X
in	B-X
cultured	B-X
cells	B-X
.	B-X
In	B-X
pulse-labeling	B-X
and	B-X
chase	B-X
experiments	B-X
using	B-X
COS-7	B-X
cells	B-X
,	B-X
the	B-X
endogenous	B-X
HSDJ	B-X
homolog	B-X
was	B-X
prenylated	B-X
.	B-X
Transiently	B-X
expressed	B-X
HSDJ	B-X
was	B-X
also	B-X
prenylated	B-X
,	B-X
whereas	B-X
its	B-X
mutant	B-X
C394S	B-X
in	B-X
which	B-X
cysteine	B-X
of	B-X
the	B-X
``	B-X
CaaX	B-X
box	B-X
''	B-X
was	B-X
mutated	B-X
to	B-X
serine	B-X
,	B-X
was	B-X
not	B-X
.	B-X
HSDJ	B-X
,	B-X
but	B-X
not	B-X
C394S	B-X
,	B-X
synthesized	B-X
in	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
was	B-X
farnesylated	B-X
.	B-X
The	B-X
HSDJ	B-X
antibody	B-X
inhibited	B-X
import	B-X
of	B-X
ornithine	B-X
transcarbamylase	B-X
precursor	B-X
(	B-X
pOTC	B-X
)	B-X
into	B-X
isolated	B-X
mitochondria	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
pOTC	B-X
synthesis	B-X
,	B-X
but	B-X
not	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
import	B-X
assay	B-X
.	B-X
Coexpression	B-X
of	B-X
HSDJ	B-X
or	B-X
C394S	B-X
resulted	B-X
in	B-X
slight	B-X
retardation	B-X
of	B-X
the	B-X
pOTC	B-X
processing	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HSDJ	B-X
is	B-X
involved	B-X
in	B-X
an	B-X
early	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
protein	B-X
import	B-X
into	B-X
mitochondria	B-X
.	B-X

Recombinant	O
HSDJ	B-Protein
was	O
purified	O
and	O
an	O
antibody	O
was	O
prepared	O
.	O

HSDJ	B-Protein
mRNA	O
was	O
heat	O
-	O
induced	O
in	O
cultured	O
cells	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
HSDJ	B-X
,	B-X
a	B-X
human	B-X
homolog	B-X
of	B-X
bacterial	B-X
DnaJ	B-X
and	B-X
yeast	B-X
YDJ1p/MAS5	B-X
,	B-X
in	B-X
mitochondrial	B-X
protein	B-X
import	B-X
was	B-X
examined	B-X
.	B-X
Recombinant	B-X
HSDJ	B-X
was	B-X
purified	B-X
and	B-X
an	B-X
antibody	B-X
was	B-X
prepared	B-X
.	B-X
HSDJ	B-X
mRNA	B-X
was	B-X
heat-induced	B-X
in	B-X
cultured	B-X
cells	B-X
.	B-X
In	B-X
pulse-labeling	B-X
and	B-X
chase	B-X
experiments	B-X
using	B-X
COS-7	B-X
cells	B-X
,	B-X
the	B-X
endogenous	B-X
HSDJ	B-X
homolog	B-X
was	B-X
prenylated	B-X
.	B-X
Transiently	B-X
expressed	B-X
HSDJ	B-X
was	B-X
also	B-X
prenylated	B-X
,	B-X
whereas	B-X
its	B-X
mutant	B-X
C394S	B-X
in	B-X
which	B-X
cysteine	B-X
of	B-X
the	B-X
``	B-X
CaaX	B-X
box	B-X
''	B-X
was	B-X
mutated	B-X
to	B-X
serine	B-X
,	B-X
was	B-X
not	B-X
.	B-X
HSDJ	B-X
,	B-X
but	B-X
not	B-X
C394S	B-X
,	B-X
synthesized	B-X
in	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
was	B-X
farnesylated	B-X
.	B-X
The	B-X
HSDJ	B-X
antibody	B-X
inhibited	B-X
import	B-X
of	B-X
ornithine	B-X
transcarbamylase	B-X
precursor	B-X
(	B-X
pOTC	B-X
)	B-X
into	B-X
isolated	B-X
mitochondria	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
pOTC	B-X
synthesis	B-X
,	B-X
but	B-X
not	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
import	B-X
assay	B-X
.	B-X
In	B-X
transient	B-X
expression	B-X
of	B-X
pOTC	B-X
in	B-X
COS-7	B-X
cells	B-X
,	B-X
pOTC	B-X
was	B-X
synthesized	B-X
and	B-X
processed	B-X
to	B-X
the	B-X
mature	B-X
form	B-X
with	B-X
an	B-X
apparent	B-X
half-life	B-X
of	B-X
2-3	B-X
min	B-X
.	B-X
Coexpression	B-X
of	B-X
HSDJ	B-X
or	B-X
C394S	B-X
resulted	B-X
in	B-X
slight	B-X
retardation	B-X
of	B-X
the	B-X
pOTC	B-X
processing	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HSDJ	B-X
is	B-X
involved	B-X
in	B-X
an	B-X
early	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
protein	B-X
import	B-X
into	B-X
mitochondria	B-X
.	B-X

In	O
pulse	O
-	O
labeling	O
and	O
chase	O
experiments	O
using	O
COS	O
-	O
7	O
cells	O
,	O
the	O
endogenous	O
HSDJ	B-Protein
homolog	O
was	O
prenylated	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
HSDJ	B-X
,	B-X
a	B-X
human	B-X
homolog	B-X
of	B-X
bacterial	B-X
DnaJ	B-X
and	B-X
yeast	B-X
YDJ1p/MAS5	B-X
,	B-X
in	B-X
mitochondrial	B-X
protein	B-X
import	B-X
was	B-X
examined	B-X
.	B-X
Recombinant	B-X
HSDJ	B-X
was	B-X
purified	B-X
and	B-X
an	B-X
antibody	B-X
was	B-X
prepared	B-X
.	B-X
HSDJ	B-X
mRNA	B-X
was	B-X
heat-induced	B-X
in	B-X
cultured	B-X
cells	B-X
.	B-X
In	B-X
pulse-labeling	B-X
and	B-X
chase	B-X
experiments	B-X
using	B-X
COS-7	B-X
cells	B-X
,	B-X
the	B-X
endogenous	B-X
HSDJ	B-X
homolog	B-X
was	B-X
prenylated	B-X
.	B-X
Transiently	B-X
expressed	B-X
HSDJ	B-X
was	B-X
also	B-X
prenylated	B-X
,	B-X
whereas	B-X
its	B-X
mutant	B-X
C394S	B-X
in	B-X
which	B-X
cysteine	B-X
of	B-X
the	B-X
``	B-X
CaaX	B-X
box	B-X
''	B-X
was	B-X
mutated	B-X
to	B-X
serine	B-X
,	B-X
was	B-X
not	B-X
.	B-X
HSDJ	B-X
,	B-X
but	B-X
not	B-X
C394S	B-X
,	B-X
synthesized	B-X
in	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
was	B-X
farnesylated	B-X
.	B-X
The	B-X
HSDJ	B-X
antibody	B-X
inhibited	B-X
import	B-X
of	B-X
ornithine	B-X
transcarbamylase	B-X
precursor	B-X
(	B-X
pOTC	B-X
)	B-X
into	B-X
isolated	B-X
mitochondria	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
pOTC	B-X
synthesis	B-X
,	B-X
but	B-X
not	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
import	B-X
assay	B-X
.	B-X
In	B-X
transient	B-X
expression	B-X
of	B-X
pOTC	B-X
in	B-X
COS-7	B-X
cells	B-X
,	B-X
pOTC	B-X
was	B-X
synthesized	B-X
and	B-X
processed	B-X
to	B-X
the	B-X
mature	B-X
form	B-X
with	B-X
an	B-X
apparent	B-X
half-life	B-X
of	B-X
2-3	B-X
min	B-X
.	B-X
Coexpression	B-X
of	B-X
HSDJ	B-X
or	B-X
C394S	B-X
resulted	B-X
in	B-X
slight	B-X
retardation	B-X
of	B-X
the	B-X
pOTC	B-X
processing	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HSDJ	B-X
is	B-X
involved	B-X
in	B-X
an	B-X
early	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
protein	B-X
import	B-X
into	B-X
mitochondria	B-X
.	B-X

Transiently	O
expressed	O
HSDJ	B-Protein
was	O
also	O
prenylated	O
,	O
whereas	O
its	O
mutant	O
C394S	O
in	O
which	O
cysteine	O
of	O
the	O
"	O
CaaX	O
box	O
"	O
was	O
mutated	O
to	O
serine	O
,	O
was	O
not	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
HSDJ	B-X
,	B-X
a	B-X
human	B-X
homolog	B-X
of	B-X
bacterial	B-X
DnaJ	B-X
and	B-X
yeast	B-X
YDJ1p/MAS5	B-X
,	B-X
in	B-X
mitochondrial	B-X
protein	B-X
import	B-X
was	B-X
examined	B-X
.	B-X
Recombinant	B-X
HSDJ	B-X
was	B-X
purified	B-X
and	B-X
an	B-X
antibody	B-X
was	B-X
prepared	B-X
.	B-X
HSDJ	B-X
mRNA	B-X
was	B-X
heat-induced	B-X
in	B-X
cultured	B-X
cells	B-X
.	B-X
In	B-X
pulse-labeling	B-X
and	B-X
chase	B-X
experiments	B-X
using	B-X
COS-7	B-X
cells	B-X
,	B-X
the	B-X
endogenous	B-X
HSDJ	B-X
homolog	B-X
was	B-X
prenylated	B-X
.	B-X
Transiently	B-X
expressed	B-X
HSDJ	B-X
was	B-X
also	B-X
prenylated	B-X
,	B-X
whereas	B-X
its	B-X
mutant	B-X
C394S	B-X
in	B-X
which	B-X
cysteine	B-X
of	B-X
the	B-X
``	B-X
CaaX	B-X
box	B-X
''	B-X
was	B-X
mutated	B-X
to	B-X
serine	B-X
,	B-X
was	B-X
not	B-X
.	B-X
HSDJ	B-X
,	B-X
but	B-X
not	B-X
C394S	B-X
,	B-X
synthesized	B-X
in	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
was	B-X
farnesylated	B-X
.	B-X
The	B-X
HSDJ	B-X
antibody	B-X
inhibited	B-X
import	B-X
of	B-X
ornithine	B-X
transcarbamylase	B-X
precursor	B-X
(	B-X
pOTC	B-X
)	B-X
into	B-X
isolated	B-X
mitochondria	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
pOTC	B-X
synthesis	B-X
,	B-X
but	B-X
not	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
import	B-X
assay	B-X
.	B-X
Coexpression	B-X
of	B-X
HSDJ	B-X
or	B-X
C394S	B-X
resulted	B-X
in	B-X
slight	B-X
retardation	B-X
of	B-X
the	B-X
pOTC	B-X
processing	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HSDJ	B-X
is	B-X
involved	B-X
in	B-X
an	B-X
early	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
protein	B-X
import	B-X
into	B-X
mitochondria	B-X
.	B-X

HSDJ	B-Protein
,	O
but	O
not	O
C394S	O
,	O
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysate	O
was	O
farnesylated	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
an	B-X
anatomical	B-X
variation	B-X
of	B-X
the	B-X
nasolacrimal	B-X
duct	B-X
,	B-X
termed	B-X
high	B-X
sac-duct	B-X
junction	B-X
(	B-X
HSDJ	B-X
)	B-X
morphology	B-X
,	B-X
that	B-X
is	B-X
seen	B-X
on	B-X
DCG	B-X
,	B-X
which	B-X
could	B-X
lead	B-X
to	B-X
more	B-X
difficult	B-X
,	B-X
and	B-X
possibly	B-X
unsuccessful	B-X
,	B-X
intubation	B-X
of	B-X
the	B-X
nasolacrimal	B-X
duct	B-X
(	B-X
NLD	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
overexpression	B-X
of	B-X
the	B-X
chaperone	B-X
HDJ-2/HSDJ	B-X
in	B-X
HeLa	B-X
cells	B-X
decreased	B-X
ataxin-1	B-X
aggregation	B-X
,	B-X
suggesting	B-X
that	B-X
protein	B-X
misfolding	B-X
might	B-X
underlie	B-X
NI	B-X
formation	B-X
.	B-X
Two	B-X
type	B-X
I	B-X
DnaJ	B-X
homologs	B-X
DjA1	B-X
(	B-X
DNAJA1	B-X
;	B-X
dj2	B-X
,	B-X
HSDJ/hdj-2	B-X
,	B-X
rdj1	B-X
)	B-X
and	B-X
DjA2	B-X
(	B-X
DNAJA2	B-X
;	B-X
dj3	B-X
,	B-X
rdj2	B-X
)	B-X
work	B-X
similarly	B-X
as	B-X
a	B-X
cochaperone	B-X
of	B-X
Hsp70s	B-X
in	B-X
protein	B-X
folding	B-X
and	B-X
mitochondrial	B-X
protein	B-X
import	B-X
in	B-X
vitro	B-X
.	B-X
However	B-X
,	B-X
subsequent	B-X
refolding	B-X
of	B-X
the	B-X
luciferase	B-X
required	B-X
addition	B-X
of	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
.	B-X

The	O
HSDJ	B-Protein
antibody	O
inhibited	O
import	O
of	O
ornithine	B-Protein
transcarbamylase	I-Protein
precursor	O
(	O
pOTC	B-Protein
)	O
into	O
isolated	O
mitochondria	O
when	O
added	O
prior	O
to	O
pOTC	B-Protein
synthesis	O
,	O
but	O
not	O
when	O
added	O
prior	O
to	O
import	O
assay	O
.	O

In	O
transient	O
expression	O
of	O
pOTC	B-Protein
in	O
COS	O
-	O
7	O
cells	O
,	O
pOTC	B-Protein
was	O
synthesized	O
and	O
processed	O
to	O
the	O
mature	O
form	O
with	O
an	O
apparent	O
half	O
-	O
life	O
of	O
2	O
-	O
3	O
min	O
.	O

Coexpression	O
of	O
HSDJ	B-Protein
or	O
C394S	O
resulted	O
in	O
slight	O
retardation	O
of	O
the	O
pOTC	B-Protein
processing	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
HSDJ	B-X
,	B-X
a	B-X
human	B-X
homolog	B-X
of	B-X
bacterial	B-X
DnaJ	B-X
and	B-X
yeast	B-X
YDJ1p/MAS5	B-X
,	B-X
in	B-X
mitochondrial	B-X
protein	B-X
import	B-X
was	B-X
examined	B-X
.	B-X
Recombinant	B-X
HSDJ	B-X
was	B-X
purified	B-X
and	B-X
an	B-X
antibody	B-X
was	B-X
prepared	B-X
.	B-X
HSDJ	B-X
mRNA	B-X
was	B-X
heat-induced	B-X
in	B-X
cultured	B-X
cells	B-X
.	B-X
In	B-X
pulse-labeling	B-X
and	B-X
chase	B-X
experiments	B-X
using	B-X
COS-7	B-X
cells	B-X
,	B-X
the	B-X
endogenous	B-X
HSDJ	B-X
homolog	B-X
was	B-X
prenylated	B-X
.	B-X
Transiently	B-X
expressed	B-X
HSDJ	B-X
was	B-X
also	B-X
prenylated	B-X
,	B-X
whereas	B-X
its	B-X
mutant	B-X
C394S	B-X
in	B-X
which	B-X
cysteine	B-X
of	B-X
the	B-X
``	B-X
CaaX	B-X
box	B-X
''	B-X
was	B-X
mutated	B-X
to	B-X
serine	B-X
,	B-X
was	B-X
not	B-X
.	B-X
HSDJ	B-X
,	B-X
but	B-X
not	B-X
C394S	B-X
,	B-X
synthesized	B-X
in	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
was	B-X
farnesylated	B-X
.	B-X
The	B-X
HSDJ	B-X
antibody	B-X
inhibited	B-X
import	B-X
of	B-X
ornithine	B-X
transcarbamylase	B-X
precursor	B-X
(	B-X
pOTC	B-X
)	B-X
into	B-X
isolated	B-X
mitochondria	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
pOTC	B-X
synthesis	B-X
,	B-X
but	B-X
not	B-X
when	B-X
added	B-X
prior	B-X
to	B-X
import	B-X
assay	B-X
.	B-X
In	B-X
transient	B-X
expression	B-X
of	B-X
pOTC	B-X
in	B-X
COS-7	B-X
cells	B-X
,	B-X
pOTC	B-X
was	B-X
synthesized	B-X
and	B-X
processed	B-X
to	B-X
the	B-X
mature	B-X
form	B-X
with	B-X
an	B-X
apparent	B-X
half-life	B-X
of	B-X
2-3	B-X
min	B-X
.	B-X
Coexpression	B-X
of	B-X
HSDJ	B-X
or	B-X
C394S	B-X
resulted	B-X
in	B-X
slight	B-X
retardation	B-X
of	B-X
the	B-X
pOTC	B-X
processing	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HSDJ	B-X
is	B-X
involved	B-X
in	B-X
an	B-X
early	B-X
step	B-X
(	B-X
s	B-X
)	B-X
of	B-X
protein	B-X
import	B-X
into	B-X
mitochondria	B-X
.	B-X

These	O
results	O
indicate	O
that	O
HSDJ	B-Protein
is	O
involved	O
in	O
an	O
early	O
step	O
(	O
s	O
)	O
of	O
protein	O
import	O
into	O
mitochondria	O
.	O

Farnesyl	O
:	O
proteintransferase	O
inhibitors	O
as	O
agents	O
to	O
inhibit	O
tumor	O
growth	O
.	O
<EOS>	B-X
Ras	B-X
,	B-X
a	B-X
signal-transducing	B-X
protein	B-X
involved	B-X
in	B-X
mediating	B-X
growth	B-X
factor-stimulated	B-X
proliferation	B-X
,	B-X
is	B-X
mutationally	B-X
activated	B-X
in	B-X
over	B-X
30	B-X
%	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
The	B-X
essential	B-X
,	B-X
first	B-X
modification	B-X
of	B-X
Ras	B-X
is	B-X
farnesylation	B-X
catalyzed	B-X
by	B-X
the	B-X
enzyme	B-X
farnesyl	B-X
:	B-X
proteintransferase	B-X
(	B-X
FPTase	B-X
)	B-X
.	B-X
Inhibitors	B-X
of	B-X
FPTase	B-X
(	B-X
FTIs	B-X
)	B-X
are	B-X
currently	B-X
being	B-X
tested	B-X
to	B-X
determine	B-X
if	B-X
they	B-X
are	B-X
capable	B-X
of	B-X
tumor	B-X
growth	B-X
inhibition	B-X
.	B-X

Ras	O
,	O
a	O
signal	O
-	O
transducing	O
protein	O
involved	O
in	O
mediating	O
growth	O
factor	O
-	O
stimulated	O
proliferation	O
,	O
is	O
mutationally	O
activated	O
in	O
over	O
30	O
%	O
of	O
human	O
tumors	O
.	O

To	O
be	O
functional	O
Ras	O
must	O
bind	O
to	O
the	O
inner	O
surface	O
of	O
the	O
plasma	O
membrane	O
,	O
with	O
post	O
-	O
translational	O
lipid	O
modifications	O
being	O
necessary	O
for	O
this	O
localization	O
.	O

The	O
essential	O
,	O
first	O
modification	O
of	O
Ras	O
is	O
farnesylation	O
catalyzed	O
by	O
the	O
enzyme	O
farnesyl	O
:	O
proteintransferase	O
(	O
FPTase	O
)	O
.	O
<EOS>	B-X
Ras	B-X
,	B-X
a	B-X
signal-transducing	B-X
protein	B-X
involved	B-X
in	B-X
mediating	B-X
growth	B-X
factor-stimulated	B-X
proliferation	B-X
,	B-X
is	B-X
mutationally	B-X
activated	B-X
in	B-X
over	B-X
30	B-X
%	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
To	B-X
be	B-X
functional	B-X
Ras	B-X
must	B-X
bind	B-X
to	B-X
the	B-X
inner	B-X
surface	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
with	B-X
post-translational	B-X
lipid	B-X
modifications	B-X
being	B-X
necessary	B-X
for	B-X
this	B-X
localization	B-X
.	B-X
The	B-X
essential	B-X
,	B-X
first	B-X
modification	B-X
of	B-X
Ras	B-X
is	B-X
farnesylation	B-X
catalyzed	B-X
by	B-X
the	B-X
enzyme	B-X
farnesyl	B-X
:	B-X
proteintransferase	B-X
(	B-X
FPTase	B-X
)	B-X
.	B-X
Inhibitors	B-X
of	B-X
FPTase	B-X
(	B-X
FTIs	B-X
)	B-X
are	B-X
currently	B-X
being	B-X
tested	B-X
to	B-X
determine	B-X
if	B-X
they	B-X
are	B-X
capable	B-X
of	B-X
tumor	B-X
growth	B-X
inhibition	B-X
.	B-X

Inhibitors	O
of	O
FPTase	O
(	O
FTIs	O
)	O
are	O
currently	O
being	O
tested	O
to	O
determine	O
if	O
they	O
are	O
capable	O
of	O
tumor	O
growth	O
inhibition	O
.	O
<EOS>	B-X
Ras	B-X
,	B-X
a	B-X
signal-transducing	B-X
protein	B-X
involved	B-X
in	B-X
mediating	B-X
growth	B-X
factor-stimulated	B-X
proliferation	B-X
,	B-X
is	B-X
mutationally	B-X
activated	B-X
in	B-X
over	B-X
30	B-X
%	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
The	B-X
essential	B-X
,	B-X
first	B-X
modification	B-X
of	B-X
Ras	B-X
is	B-X
farnesylation	B-X
catalyzed	B-X
by	B-X
the	B-X
enzyme	B-X
farnesyl	B-X
:	B-X
proteintransferase	B-X
(	B-X
FPTase	B-X
)	B-X
.	B-X
Inhibitors	B-X
of	B-X
FPTase	B-X
(	B-X
FTIs	B-X
)	B-X
are	B-X
currently	B-X
being	B-X
tested	B-X
to	B-X
determine	B-X
if	B-X
they	B-X
are	B-X
capable	B-X
of	B-X
tumor	B-X
growth	B-X
inhibition	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
our	B-X
efforts	B-X
,	B-X
along	B-X
with	B-X
those	B-X
of	B-X
other	B-X
groups	B-X
,	B-X
in	B-X
testing	B-X
the	B-X
biological	B-X
and	B-X
biochemical	B-X
effects	B-X
of	B-X
FTIs	B-X
.	B-X

Here	O
we	O
describe	O
our	O
efforts	O
,	O
along	O
with	O
those	O
of	O
other	O
groups	O
,	O
in	O
testing	O
the	O
biological	O
and	O
biochemical	O
effects	O
of	O
FTIs	O
.	O
<EOS>	B-X
Inhibitors	B-X
of	B-X
FPTase	B-X
(	B-X
FTIs	B-X
)	B-X
are	B-X
currently	B-X
being	B-X
tested	B-X
to	B-X
determine	B-X
if	B-X
they	B-X
are	B-X
capable	B-X
of	B-X
tumor	B-X
growth	B-X
inhibition	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
our	B-X
efforts	B-X
,	B-X
along	B-X
with	B-X
those	B-X
of	B-X
other	B-X
groups	B-X
,	B-X
in	B-X
testing	B-X
the	B-X
biological	B-X
and	B-X
biochemical	B-X
effects	B-X
of	B-X
FTIs	B-X
.	B-X

Long	O
-	O
term	O
alcohol	O
effects	O
on	O
hepatic	O
phosphoglucomutase	B-Protein
activities	O
in	O
relation	O
to	O
posttranslational	O
modification	O
of	O
the	O
protein	O
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
protein	B-X
modification	B-X
catalyzed	B-X
by	B-X
two	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
mono-ADP-ribosyltransferase	B-X
and	B-X
poly-ADP-ribose	B-X
polymerases	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
long-term	B-X
alcohol	B-X
intake	B-X
remarkably	B-X
enhanced	B-X
an	B-X
endogenous	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
58	B-X
kDa	B-X
protein	B-X
in	B-X
rat	B-X
liver	B-X
and	B-X
also	B-X
identified	B-X
the	B-X
58	B-X
kDa	B-X
protein	B-X
as	B-X
phosphoglucomutase	B-X
(	B-X
PGM	B-X
)	B-X
.	B-X
To	B-X
assess	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
long-term	B-X
alcohol	B-X
intake	B-X
on	B-X
PGM	B-X
activities	B-X
in	B-X
connection	B-X
with	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
It	B-X
was	B-X
of	B-X
note	B-X
that	B-X
ADP-ribosylation	B-X
of	B-X
exogenous	B-X
PGM	B-X
was	B-X
remarkably	B-X
increased	B-X
by	B-X
adding	B-X
rat	B-X
liver	B-X
plasma	B-X
membranes	B-X
,	B-X
and	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
increase	B-X
was	B-X
greater	B-X
in	B-X
alcohol-fed	B-X
rats	B-X
than	B-X
in	B-X
pair-fed	B-X
controls	B-X
.	B-X
Furthermore	B-X
,	B-X
PGM	B-X
activities	B-X
were	B-X
significantly	B-X
increased	B-X
after	B-X
long-term	B-X
alcohol	B-X
intake	B-X
concomitant	B-X
with	B-X
increased	B-X
ADP-ribosyltransferase	B-X
activities	B-X
toward	B-X
PGM	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
variety	B-X
of	B-X
roles	B-X
of	B-X
PGM	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
such	B-X
as	B-X
carbohydrate	B-X
metabolism	B-X
and	B-X
Ca2+	B-X
homeostasis	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
increased	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
long-term	B-X
alcohol	B-X
effects	B-X
on	B-X
hepatocytes	B-X
.	B-X

ADP	O
-	O
ribosylation	O
is	O
a	O
posttranslational	O
protein	O
modification	O
catalyzed	O
by	O
two	O
classes	O
of	O
enzymes	O
:	O
mono	O
-	O
ADP	O
-	O
ribosyltransferase	O
and	O
poly	O
-	O
ADP	O
-	O
ribose	O
polymerases	O
.	O
<EOS>	B-X
Mono-ADP-ribosylation	B-X
is	B-X
a	B-X
reversible	B-X
post-translational	B-X
protein	B-X
modification	B-X
that	B-X
modulates	B-X
the	B-X
function	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
different	B-X
cellular	B-X
processes	B-X
,	B-X
including	B-X
signal	B-X
transduction	B-X
,	B-X
protein	B-X
transport	B-X
,	B-X
transcription	B-X
,	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
DNA	B-X
repair	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
mammals	B-X
,	B-X
mono-ADP-ribosylation	B-X
is	B-X
mainly	B-X
catalyzed	B-X
by	B-X
members	B-X
of	B-X
two	B-X
different	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
ARTCs	B-X
and	B-X
ARTDs	B-X
.	B-X
The	B-X
human	B-X
ARTC	B-X
family	B-X
is	B-X
composed	B-X
of	B-X
four	B-X
structurally	B-X
related	B-X
ecto-mono-ARTs	B-X
,	B-X
expressed	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
or	B-X
secreted	B-X
into	B-X
the	B-X
extracellular	B-X
compartment	B-X
that	B-X
are	B-X
either	B-X
active	B-X
mono-ARTs	B-X
(	B-X
hARTC1	B-X
,	B-X
hARTC5	B-X
)	B-X
or	B-X
inactive	B-X
proteins	B-X
(	B-X
hARTC3	B-X
,	B-X
hARTC4	B-X
)	B-X
.	B-X
The	B-X
human	B-X
ARTD	B-X
enzyme	B-X
family	B-X
consists	B-X
of	B-X
17	B-X
multidomain	B-X
proteins	B-X
that	B-X
can	B-X
be	B-X
divided	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
their	B-X
catalytic	B-X
activity	B-X
into	B-X
polymerases	B-X
(	B-X
ARTD1-6	B-X
)	B-X
,	B-X
mono-ART	B-X
(	B-X
ARTD7-17	B-X
)	B-X
,	B-X
and	B-X
the	B-X
inactive	B-X
ARTD13	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
ADP-ribosylation	B-X
was	B-X
intensively	B-X
studied	B-X
,	B-X
and	B-X
research	B-X
was	B-X
dominated	B-X
by	B-X
studies	B-X
focusing	B-X
on	B-X
the	B-X
role	B-X
of	B-X
this	B-X
modification	B-X
and	B-X
its	B-X
implication	B-X
on	B-X
various	B-X
cellular	B-X
processes	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
provide	B-X
a	B-X
general	B-X
overview	B-X
of	B-X
the	B-X
ARTC	B-X
enzymes	B-X
.	B-X
In	B-X
the	B-X
following	B-X
sections	B-X
,	B-X
we	B-X
will	B-X
report	B-X
the	B-X
mono-ADP-ribosylation	B-X
reactions	B-X
that	B-X
are	B-X
catalysed	B-X
by	B-X
the	B-X
active	B-X
ARTC	B-X
enzymes	B-X
,	B-X
with	B-X
a	B-X
particular	B-X
focus	B-X
on	B-X
hARTC1	B-X
that	B-X
recently	B-X
has	B-X
been	B-X
intensively	B-X
studied	B-X
with	B-X
the	B-X
discovery	B-X
of	B-X
new	B-X
targets	B-X
and	B-X
functions	B-X
.	B-X

We	O
previously	O
demonstrated	O
that	O
long	O
-	O
term	O
alcohol	O
intake	O
remarkably	O
enhanced	O
an	O
endogenous	O
ADP	O
-	O
ribosylation	O
of	O
a	O
58	O
kDa	O
protein	O
in	O
rat	O
liver	O
and	O
also	O
identified	O
the	O
58	O
kDa	O
protein	O
as	O
phosphoglucomutase	B-Protein
(	O
PGM	B-Protein
)	O
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
protein	B-X
modification	B-X
catalyzed	B-X
by	B-X
two	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
mono-ADP-ribosyltransferase	B-X
and	B-X
poly-ADP-ribose	B-X
polymerases	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
long-term	B-X
alcohol	B-X
intake	B-X
remarkably	B-X
enhanced	B-X
an	B-X
endogenous	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
58	B-X
kDa	B-X
protein	B-X
in	B-X
rat	B-X
liver	B-X
and	B-X
also	B-X
identified	B-X
the	B-X
58	B-X
kDa	B-X
protein	B-X
as	B-X
phosphoglucomutase	B-X
(	B-X
PGM	B-X
)	B-X
.	B-X
To	B-X
assess	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
long-term	B-X
alcohol	B-X
intake	B-X
on	B-X
PGM	B-X
activities	B-X
in	B-X
connection	B-X
with	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
was	B-X
mono-	B-X
rather	B-X
than	B-X
poly-ADP-ribosylation	B-X
.	B-X
Also	B-X
,	B-X
nonenzymatic	B-X
binding	B-X
of	B-X
ADP-ribose	B-X
was	B-X
excluded	B-X
.	B-X
It	B-X
was	B-X
of	B-X
note	B-X
that	B-X
ADP-ribosylation	B-X
of	B-X
exogenous	B-X
PGM	B-X
was	B-X
remarkably	B-X
increased	B-X
by	B-X
adding	B-X
rat	B-X
liver	B-X
plasma	B-X
membranes	B-X
,	B-X
and	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
increase	B-X
was	B-X
greater	B-X
in	B-X
alcohol-fed	B-X
rats	B-X
than	B-X
in	B-X
pair-fed	B-X
controls	B-X
.	B-X
Furthermore	B-X
,	B-X
PGM	B-X
activities	B-X
were	B-X
significantly	B-X
increased	B-X
after	B-X
long-term	B-X
alcohol	B-X
intake	B-X
concomitant	B-X
with	B-X
increased	B-X
ADP-ribosyltransferase	B-X
activities	B-X
toward	B-X
PGM	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
variety	B-X
of	B-X
roles	B-X
of	B-X
PGM	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
such	B-X
as	B-X
carbohydrate	B-X
metabolism	B-X
and	B-X
Ca2+	B-X
homeostasis	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
increased	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
long-term	B-X
alcohol	B-X
effects	B-X
on	B-X
hepatocytes	B-X
.	B-X

To	O
assess	O
biological	O
significance	O
of	O
this	O
phenomenon	O
,	O
we	O
tested	O
the	O
effects	O
of	O
long	O
-	O
term	O
alcohol	O
intake	O
on	O
PGM	B-Protein
activities	O
in	O
connection	O
with	O
posttranslational	O
modification	O
of	O
the	O
protein	O
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
protein	B-X
modification	B-X
catalyzed	B-X
by	B-X
two	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
mono-ADP-ribosyltransferase	B-X
and	B-X
poly-ADP-ribose	B-X
polymerases	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
long-term	B-X
alcohol	B-X
intake	B-X
remarkably	B-X
enhanced	B-X
an	B-X
endogenous	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
58	B-X
kDa	B-X
protein	B-X
in	B-X
rat	B-X
liver	B-X
and	B-X
also	B-X
identified	B-X
the	B-X
58	B-X
kDa	B-X
protein	B-X
as	B-X
phosphoglucomutase	B-X
(	B-X
PGM	B-X
)	B-X
.	B-X
To	B-X
assess	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
long-term	B-X
alcohol	B-X
intake	B-X
on	B-X
PGM	B-X
activities	B-X
in	B-X
connection	B-X
with	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
was	B-X
mono-	B-X
rather	B-X
than	B-X
poly-ADP-ribosylation	B-X
.	B-X
It	B-X
was	B-X
of	B-X
note	B-X
that	B-X
ADP-ribosylation	B-X
of	B-X
exogenous	B-X
PGM	B-X
was	B-X
remarkably	B-X
increased	B-X
by	B-X
adding	B-X
rat	B-X
liver	B-X
plasma	B-X
membranes	B-X
,	B-X
and	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
increase	B-X
was	B-X
greater	B-X
in	B-X
alcohol-fed	B-X
rats	B-X
than	B-X
in	B-X
pair-fed	B-X
controls	B-X
.	B-X
Furthermore	B-X
,	B-X
PGM	B-X
activities	B-X
were	B-X
significantly	B-X
increased	B-X
after	B-X
long-term	B-X
alcohol	B-X
intake	B-X
concomitant	B-X
with	B-X
increased	B-X
ADP-ribosyltransferase	B-X
activities	B-X
toward	B-X
PGM	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
variety	B-X
of	B-X
roles	B-X
of	B-X
PGM	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
such	B-X
as	B-X
carbohydrate	B-X
metabolism	B-X
and	B-X
Ca2+	B-X
homeostasis	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
increased	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
long-term	B-X
alcohol	B-X
effects	B-X
on	B-X
hepatocytes	B-X
.	B-X

ADP	O
-	O
ribosylation	O
of	O
PGM	B-Protein
was	O
mono	O
-	O
rather	O
than	O
poly	O
-	O
ADP	O
-	O
ribosylation	O
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
protein	B-X
modification	B-X
catalyzed	B-X
by	B-X
two	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
mono-ADP-ribosyltransferase	B-X
and	B-X
poly-ADP-ribose	B-X
polymerases	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
long-term	B-X
alcohol	B-X
intake	B-X
remarkably	B-X
enhanced	B-X
an	B-X
endogenous	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
58	B-X
kDa	B-X
protein	B-X
in	B-X
rat	B-X
liver	B-X
and	B-X
also	B-X
identified	B-X
the	B-X
58	B-X
kDa	B-X
protein	B-X
as	B-X
phosphoglucomutase	B-X
(	B-X
PGM	B-X
)	B-X
.	B-X
To	B-X
assess	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
long-term	B-X
alcohol	B-X
intake	B-X
on	B-X
PGM	B-X
activities	B-X
in	B-X
connection	B-X
with	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
was	B-X
mono-	B-X
rather	B-X
than	B-X
poly-ADP-ribosylation	B-X
.	B-X
Also	B-X
,	B-X
nonenzymatic	B-X
binding	B-X
of	B-X
ADP-ribose	B-X
was	B-X
excluded	B-X
.	B-X
It	B-X
was	B-X
of	B-X
note	B-X
that	B-X
ADP-ribosylation	B-X
of	B-X
exogenous	B-X
PGM	B-X
was	B-X
remarkably	B-X
increased	B-X
by	B-X
adding	B-X
rat	B-X
liver	B-X
plasma	B-X
membranes	B-X
,	B-X
and	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
increase	B-X
was	B-X
greater	B-X
in	B-X
alcohol-fed	B-X
rats	B-X
than	B-X
in	B-X
pair-fed	B-X
controls	B-X
.	B-X
Furthermore	B-X
,	B-X
PGM	B-X
activities	B-X
were	B-X
significantly	B-X
increased	B-X
after	B-X
long-term	B-X
alcohol	B-X
intake	B-X
concomitant	B-X
with	B-X
increased	B-X
ADP-ribosyltransferase	B-X
activities	B-X
toward	B-X
PGM	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
variety	B-X
of	B-X
roles	B-X
of	B-X
PGM	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
such	B-X
as	B-X
carbohydrate	B-X
metabolism	B-X
and	B-X
Ca2+	B-X
homeostasis	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
increased	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
long-term	B-X
alcohol	B-X
effects	B-X
on	B-X
hepatocytes	B-X
.	B-X

Also	O
,	O
nonenzymatic	O
binding	O
of	O
ADP	O
-	O
ribose	O
was	O
excluded	O
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
protein	B-X
modification	B-X
catalyzed	B-X
by	B-X
two	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
mono-ADP-ribosyltransferase	B-X
and	B-X
poly-ADP-ribose	B-X
polymerases	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
long-term	B-X
alcohol	B-X
intake	B-X
remarkably	B-X
enhanced	B-X
an	B-X
endogenous	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
58	B-X
kDa	B-X
protein	B-X
in	B-X
rat	B-X
liver	B-X
and	B-X
also	B-X
identified	B-X
the	B-X
58	B-X
kDa	B-X
protein	B-X
as	B-X
phosphoglucomutase	B-X
(	B-X
PGM	B-X
)	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
was	B-X
mono-	B-X
rather	B-X
than	B-X
poly-ADP-ribosylation	B-X
.	B-X
Also	B-X
,	B-X
nonenzymatic	B-X
binding	B-X
of	B-X
ADP-ribose	B-X
was	B-X
excluded	B-X
.	B-X
It	B-X
was	B-X
of	B-X
note	B-X
that	B-X
ADP-ribosylation	B-X
of	B-X
exogenous	B-X
PGM	B-X
was	B-X
remarkably	B-X
increased	B-X
by	B-X
adding	B-X
rat	B-X
liver	B-X
plasma	B-X
membranes	B-X
,	B-X
and	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
increase	B-X
was	B-X
greater	B-X
in	B-X
alcohol-fed	B-X
rats	B-X
than	B-X
in	B-X
pair-fed	B-X
controls	B-X
.	B-X
Furthermore	B-X
,	B-X
PGM	B-X
activities	B-X
were	B-X
significantly	B-X
increased	B-X
after	B-X
long-term	B-X
alcohol	B-X
intake	B-X
concomitant	B-X
with	B-X
increased	B-X
ADP-ribosyltransferase	B-X
activities	B-X
toward	B-X
PGM	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
variety	B-X
of	B-X
roles	B-X
of	B-X
PGM	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
such	B-X
as	B-X
carbohydrate	B-X
metabolism	B-X
and	B-X
Ca2+	B-X
homeostasis	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
increased	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
long-term	B-X
alcohol	B-X
effects	B-X
on	B-X
hepatocytes	B-X
.	B-X

It	O
was	O
of	O
note	O
that	O
ADP	O
-	O
ribosylation	O
of	O
exogenous	O
PGM	B-Protein
was	O
remarkably	O
increased	O
by	O
adding	O
rat	O
liver	O
plasma	O
membranes	O
,	O
and	O
that	O
the	O
extent	O
of	O
the	O
increase	O
was	O
greater	O
in	O
alcohol	O
-	O
fed	O
rats	O
than	O
in	O
pair	O
-	O
fed	O
controls	O
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
protein	B-X
modification	B-X
catalyzed	B-X
by	B-X
two	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
mono-ADP-ribosyltransferase	B-X
and	B-X
poly-ADP-ribose	B-X
polymerases	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
long-term	B-X
alcohol	B-X
intake	B-X
remarkably	B-X
enhanced	B-X
an	B-X
endogenous	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
58	B-X
kDa	B-X
protein	B-X
in	B-X
rat	B-X
liver	B-X
and	B-X
also	B-X
identified	B-X
the	B-X
58	B-X
kDa	B-X
protein	B-X
as	B-X
phosphoglucomutase	B-X
(	B-X
PGM	B-X
)	B-X
.	B-X
To	B-X
assess	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
long-term	B-X
alcohol	B-X
intake	B-X
on	B-X
PGM	B-X
activities	B-X
in	B-X
connection	B-X
with	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
was	B-X
mono-	B-X
rather	B-X
than	B-X
poly-ADP-ribosylation	B-X
.	B-X
Also	B-X
,	B-X
nonenzymatic	B-X
binding	B-X
of	B-X
ADP-ribose	B-X
was	B-X
excluded	B-X
.	B-X
It	B-X
was	B-X
of	B-X
note	B-X
that	B-X
ADP-ribosylation	B-X
of	B-X
exogenous	B-X
PGM	B-X
was	B-X
remarkably	B-X
increased	B-X
by	B-X
adding	B-X
rat	B-X
liver	B-X
plasma	B-X
membranes	B-X
,	B-X
and	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
increase	B-X
was	B-X
greater	B-X
in	B-X
alcohol-fed	B-X
rats	B-X
than	B-X
in	B-X
pair-fed	B-X
controls	B-X
.	B-X
Furthermore	B-X
,	B-X
PGM	B-X
activities	B-X
were	B-X
significantly	B-X
increased	B-X
after	B-X
long-term	B-X
alcohol	B-X
intake	B-X
concomitant	B-X
with	B-X
increased	B-X
ADP-ribosyltransferase	B-X
activities	B-X
toward	B-X
PGM	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
variety	B-X
of	B-X
roles	B-X
of	B-X
PGM	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
such	B-X
as	B-X
carbohydrate	B-X
metabolism	B-X
and	B-X
Ca2+	B-X
homeostasis	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
increased	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
long-term	B-X
alcohol	B-X
effects	B-X
on	B-X
hepatocytes	B-X
.	B-X

Furthermore	O
,	O
PGM	B-Protein
activities	O
were	O
significantly	O
increased	O
after	O
long	O
-	O
term	O
alcohol	O
intake	O
concomitant	O
with	O
increased	O
ADP	O
-	O
ribosyltransferase	O
activities	O
toward	O
PGM	B-Protein
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
protein	B-X
modification	B-X
catalyzed	B-X
by	B-X
two	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
mono-ADP-ribosyltransferase	B-X
and	B-X
poly-ADP-ribose	B-X
polymerases	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
long-term	B-X
alcohol	B-X
intake	B-X
remarkably	B-X
enhanced	B-X
an	B-X
endogenous	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
58	B-X
kDa	B-X
protein	B-X
in	B-X
rat	B-X
liver	B-X
and	B-X
also	B-X
identified	B-X
the	B-X
58	B-X
kDa	B-X
protein	B-X
as	B-X
phosphoglucomutase	B-X
(	B-X
PGM	B-X
)	B-X
.	B-X
To	B-X
assess	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
long-term	B-X
alcohol	B-X
intake	B-X
on	B-X
PGM	B-X
activities	B-X
in	B-X
connection	B-X
with	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
was	B-X
mono-	B-X
rather	B-X
than	B-X
poly-ADP-ribosylation	B-X
.	B-X
Also	B-X
,	B-X
nonenzymatic	B-X
binding	B-X
of	B-X
ADP-ribose	B-X
was	B-X
excluded	B-X
.	B-X
It	B-X
was	B-X
of	B-X
note	B-X
that	B-X
ADP-ribosylation	B-X
of	B-X
exogenous	B-X
PGM	B-X
was	B-X
remarkably	B-X
increased	B-X
by	B-X
adding	B-X
rat	B-X
liver	B-X
plasma	B-X
membranes	B-X
,	B-X
and	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
increase	B-X
was	B-X
greater	B-X
in	B-X
alcohol-fed	B-X
rats	B-X
than	B-X
in	B-X
pair-fed	B-X
controls	B-X
.	B-X
Furthermore	B-X
,	B-X
PGM	B-X
activities	B-X
were	B-X
significantly	B-X
increased	B-X
after	B-X
long-term	B-X
alcohol	B-X
intake	B-X
concomitant	B-X
with	B-X
increased	B-X
ADP-ribosyltransferase	B-X
activities	B-X
toward	B-X
PGM	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
variety	B-X
of	B-X
roles	B-X
of	B-X
PGM	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
such	B-X
as	B-X
carbohydrate	B-X
metabolism	B-X
and	B-X
Ca2+	B-X
homeostasis	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
increased	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
long-term	B-X
alcohol	B-X
effects	B-X
on	B-X
hepatocytes	B-X
.	B-X

In	O
view	O
of	O
the	O
variety	O
of	O
roles	O
of	O
PGM	B-Protein
in	O
the	O
liver	O
,	O
such	O
as	O
carbohydrate	O
metabolism	O
and	O
Ca2	O
+	O
homeostasis	O
,	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
increased	O
ADP	O
-	O
ribosylation	O
of	O
PGM	B-Protein
may	O
play	O
a	O
role	O
in	O
long	O
-	O
term	O
alcohol	O
effects	O
on	O
hepatocytes	O
.	O
<EOS>	B-X
ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
protein	B-X
modification	B-X
catalyzed	B-X
by	B-X
two	B-X
classes	B-X
of	B-X
enzymes	B-X
:	B-X
mono-ADP-ribosyltransferase	B-X
and	B-X
poly-ADP-ribose	B-X
polymerases	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
long-term	B-X
alcohol	B-X
intake	B-X
remarkably	B-X
enhanced	B-X
an	B-X
endogenous	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
58	B-X
kDa	B-X
protein	B-X
in	B-X
rat	B-X
liver	B-X
and	B-X
also	B-X
identified	B-X
the	B-X
58	B-X
kDa	B-X
protein	B-X
as	B-X
phosphoglucomutase	B-X
(	B-X
PGM	B-X
)	B-X
.	B-X
To	B-X
assess	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
phenomenon	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
long-term	B-X
alcohol	B-X
intake	B-X
on	B-X
PGM	B-X
activities	B-X
in	B-X
connection	B-X
with	B-X
posttranslational	B-X
modification	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
was	B-X
mono-	B-X
rather	B-X
than	B-X
poly-ADP-ribosylation	B-X
.	B-X
Also	B-X
,	B-X
nonenzymatic	B-X
binding	B-X
of	B-X
ADP-ribose	B-X
was	B-X
excluded	B-X
.	B-X
It	B-X
was	B-X
of	B-X
note	B-X
that	B-X
ADP-ribosylation	B-X
of	B-X
exogenous	B-X
PGM	B-X
was	B-X
remarkably	B-X
increased	B-X
by	B-X
adding	B-X
rat	B-X
liver	B-X
plasma	B-X
membranes	B-X
,	B-X
and	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
increase	B-X
was	B-X
greater	B-X
in	B-X
alcohol-fed	B-X
rats	B-X
than	B-X
in	B-X
pair-fed	B-X
controls	B-X
.	B-X
Furthermore	B-X
,	B-X
PGM	B-X
activities	B-X
were	B-X
significantly	B-X
increased	B-X
after	B-X
long-term	B-X
alcohol	B-X
intake	B-X
concomitant	B-X
with	B-X
increased	B-X
ADP-ribosyltransferase	B-X
activities	B-X
toward	B-X
PGM	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
variety	B-X
of	B-X
roles	B-X
of	B-X
PGM	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
such	B-X
as	B-X
carbohydrate	B-X
metabolism	B-X
and	B-X
Ca2+	B-X
homeostasis	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
increased	B-X
ADP-ribosylation	B-X
of	B-X
PGM	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
long-term	B-X
alcohol	B-X
effects	B-X
on	B-X
hepatocytes	B-X
.	B-X

Specific	O
isoprenyl	O
group	O
linked	O
to	O
transducin	B-Protein
gamma	I-Protein
-	O
subunit	O
is	O
a	O
determinant	O
of	O
its	O
unique	O
signaling	O
properties	O
among	O
G	O
-	O
proteins	O
.	O

Among	O
11	O
subtypes	O
of	O
heterotrimeric	O
G	O
-	O
protein	O
gamma	O
-	O
subunit	O
,	O
gamma1	B-Protein
(	O
rod	O
)	O
,	O
gamma8	B-Protein
(	O
cone	O
)	O
and	O
gamma11	B-Protein
are	O
modified	O
with	O
farnesyl	O
while	O
the	O
others	O
are	O
modified	O
with	O
geranylgeranyl	O
at	O
the	O
C	O
-	O
terminus	O
.	O

To	O
understand	O
the	O
role	O
of	O
specific	O
isoprenylation	O
(	O
farnesylation	O
)	O
of	O
retinal	O
transducin	O
,	O
we	O
examined	O
how	O
and	O
to	O
what	O
extent	O
the	O
type	O
of	O
isoprenyl	O
group	O
affects	O
transducin	O
-	O
beta	O
gamma	B-Protein
(	O
beta1	B-Protein
gamma1	B-Protein
)	O
functions	O
such	O
as	O
interactions	O
with	O
membranes	O
,	O
Galpha	O
/	O
receptor	O
,	O
and	O
effectors	O
.	O
<EOS>	B-X
Among	B-X
11	B-X
subtypes	B-X
of	B-X
heterotrimeric	B-X
G-protein	B-X
gamma-subunit	B-X
,	B-X
gamma1	B-X
(	B-X
rod	B-X
)	B-X
,	B-X
gamma8	B-X
(	B-X
cone	B-X
)	B-X
and	B-X
gamma11	B-X
are	B-X
modified	B-X
with	B-X
farnesyl	B-X
while	B-X
the	B-X
others	B-X
are	B-X
modified	B-X
with	B-X
geranylgeranyl	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
properties	B-X
of	B-X
Gbeta	B-X
gamma	B-X
are	B-X
strongly	B-X
affected	B-X
by	B-X
the	B-X
type	B-X
of	B-X
functionally	B-X
indispensable	B-X
isoprenylation	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
Ggamma	B-X
.	B-X
The	B-X
relative	B-X
contribution	B-X
of	B-X
the	B-X
two	B-X
factors	B-X
depends	B-X
on	B-X
proteins	B-X
with	B-X
which	B-X
Gbeta	B-X
gamma	B-X
interacts	B-X
.	B-X

To	O
this	O
end	O
,	O
the	O
C	O
-	O
terminal	O
farnesylation	O
signal	O
sequence	O
(	O
CVIS	O
)	O
of	O
gamma1	B-Protein
was	O
replaced	O
by	O
a	O
geranylgeranylation	O
signal	O
(	O
CVIL	O
)	O
,	O
and	O
the	O
resultant	O
mutant	O
(	O
S74L	O
)	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
gamma1	B-Protein
was	O
coexpressed	O
with	O
beta1	B-Protein
in	O
the	O
baculovirus	O
-	O
Tn5	O
insect	O
cell	O
system	O
.	O
<EOS>	B-X
Among	B-X
11	B-X
subtypes	B-X
of	B-X
heterotrimeric	B-X
G-protein	B-X
gamma-subunit	B-X
,	B-X
gamma1	B-X
(	B-X
rod	B-X
)	B-X
,	B-X
gamma8	B-X
(	B-X
cone	B-X
)	B-X
and	B-X
gamma11	B-X
are	B-X
modified	B-X
with	B-X
farnesyl	B-X
while	B-X
the	B-X
others	B-X
are	B-X
modified	B-X
with	B-X
geranylgeranyl	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
properties	B-X
of	B-X
Gbeta	B-X
gamma	B-X
are	B-X
strongly	B-X
affected	B-X
by	B-X
the	B-X
type	B-X
of	B-X
functionally	B-X
indispensable	B-X
isoprenylation	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
Ggamma	B-X
.	B-X
The	B-X
relative	B-X
contribution	B-X
of	B-X
the	B-X
two	B-X
factors	B-X
depends	B-X
on	B-X
proteins	B-X
with	B-X
which	B-X
Gbeta	B-X
gamma	B-X
interacts	B-X
.	B-X

Both	O
gamma1WT	B-Protein
and	O
gamma1S74L	B-Protein
expressed	O
as	O
a	O
beta	O
gamma	O
complex	O
were	O
mixtures	O
modified	O
with	O
farnesyl	O
and	O
geranylgeranyl	O
groups	O
.	O
<EOS>	B-X
Among	B-X
11	B-X
subtypes	B-X
of	B-X
heterotrimeric	B-X
G-protein	B-X
gamma-subunit	B-X
,	B-X
gamma1	B-X
(	B-X
rod	B-X
)	B-X
,	B-X
gamma8	B-X
(	B-X
cone	B-X
)	B-X
and	B-X
gamma11	B-X
are	B-X
modified	B-X
with	B-X
farnesyl	B-X
while	B-X
the	B-X
others	B-X
are	B-X
modified	B-X
with	B-X
geranylgeranyl	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
properties	B-X
of	B-X
Gbeta	B-X
gamma	B-X
are	B-X
strongly	B-X
affected	B-X
by	B-X
the	B-X
type	B-X
of	B-X
functionally	B-X
indispensable	B-X
isoprenylation	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
Ggamma	B-X
.	B-X
The	B-X
relative	B-X
contribution	B-X
of	B-X
the	B-X
two	B-X
factors	B-X
depends	B-X
on	B-X
proteins	B-X
with	B-X
which	B-X
Gbeta	B-X
gamma	B-X
interacts	B-X
.	B-X

The	O
ratio	O
of	O
farnesyl	O
to	O
geranylgeranyl	O
in	O
preparations	O
of	O
beta1	B-Protein
gamma1WT	B-Protein
and	O
beta1	B-Protein
gamma1S74L	B-Protein
purified	O
from	O
the	O
Tn5	O
cell	O
membrane	O
fraction	O
was	O
about	O
1	O
:	O
2	O
and	O
1	O
:	O
6	O
,	O
respectively	O
.	O
<EOS>	B-X
Among	B-X
11	B-X
subtypes	B-X
of	B-X
heterotrimeric	B-X
G-protein	B-X
gamma-subunit	B-X
,	B-X
gamma1	B-X
(	B-X
rod	B-X
)	B-X
,	B-X
gamma8	B-X
(	B-X
cone	B-X
)	B-X
and	B-X
gamma11	B-X
are	B-X
modified	B-X
with	B-X
farnesyl	B-X
while	B-X
the	B-X
others	B-X
are	B-X
modified	B-X
with	B-X
geranylgeranyl	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X

These	O
two	O
forms	O
of	O
recombinant	O
beta1	B-Protein
gamma1	B-Protein
and	O
retinal	O
beta1	B-Protein
gamma1	B-Protein
were	O
different	O
in	O
their	O
abilities	O
to	O
associate	O
with	O
rod	O
outer	O
segment	O
membranes	O
with	O
the	O
following	O
rank	O
order	O
:	O
beta1	B-Protein
gamma1S74L	B-Protein
>	O
beta1	B-Protein
gamma1WT	B-Protein
>	O
retinal	O
beta1	B-Protein
gamma1	B-Protein
.	O
<EOS>	B-X
Among	B-X
11	B-X
subtypes	B-X
of	B-X
heterotrimeric	B-X
G-protein	B-X
gamma-subunit	B-X
,	B-X
gamma1	B-X
(	B-X
rod	B-X
)	B-X
,	B-X
gamma8	B-X
(	B-X
cone	B-X
)	B-X
and	B-X
gamma11	B-X
are	B-X
modified	B-X
with	B-X
farnesyl	B-X
while	B-X
the	B-X
others	B-X
are	B-X
modified	B-X
with	B-X
geranylgeranyl	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X
The	B-X
relative	B-X
contribution	B-X
of	B-X
the	B-X
two	B-X
factors	B-X
depends	B-X
on	B-X
proteins	B-X
with	B-X
which	B-X
Gbeta	B-X
gamma	B-X
interacts	B-X
.	B-X

Functionally	O
,	O
beta1	B-Protein
gamma1S74L	B-Protein
was	O
the	O
most	O
potent	O
to	O
promote	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
ribosylation	O
of	O
transducin	O
-	O
alpha	O
(	O
Talpha	O
)	O
,	O
to	O
stimulate	O
metarhodopsin	B-Protein
II	I-Protein
-	O
catalyzed	O
GTPgammaS	O
-	O
binding	O
reaction	O
to	O
Talpha	O
and	O
to	O
modulate	O
adenylyl	O
cyclase	O
and	O
phospholipase	O
C	O
activities	O
.	O
<EOS>	B-X
Among	B-X
11	B-X
subtypes	B-X
of	B-X
heterotrimeric	B-X
G-protein	B-X
gamma-subunit	B-X
,	B-X
gamma1	B-X
(	B-X
rod	B-X
)	B-X
,	B-X
gamma8	B-X
(	B-X
cone	B-X
)	B-X
and	B-X
gamma11	B-X
are	B-X
modified	B-X
with	B-X
farnesyl	B-X
while	B-X
the	B-X
others	B-X
are	B-X
modified	B-X
with	B-X
geranylgeranyl	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X

All	O
of	O
the	O
beta1	B-Protein
gamma1	B-Protein
functions	O
absolutely	O
required	O
the	O
isoprenylation	O
of	O
the	O
gamma	O
-	O
subunit	O
.	O
<EOS>	B-X
Among	B-X
11	B-X
subtypes	B-X
of	B-X
heterotrimeric	B-X
G-protein	B-X
gamma-subunit	B-X
,	B-X
gamma1	B-X
(	B-X
rod	B-X
)	B-X
,	B-X
gamma8	B-X
(	B-X
cone	B-X
)	B-X
and	B-X
gamma11	B-X
are	B-X
modified	B-X
with	B-X
farnesyl	B-X
while	B-X
the	B-X
others	B-X
are	B-X
modified	B-X
with	B-X
geranylgeranyl	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
properties	B-X
of	B-X
Gbeta	B-X
gamma	B-X
are	B-X
strongly	B-X
affected	B-X
by	B-X
the	B-X
type	B-X
of	B-X
functionally	B-X
indispensable	B-X
isoprenylation	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
Ggamma	B-X
.	B-X
The	B-X
relative	B-X
contribution	B-X
of	B-X
the	B-X
two	B-X
factors	B-X
depends	B-X
on	B-X
proteins	B-X
with	B-X
which	B-X
Gbeta	B-X
gamma	B-X
interacts	B-X
.	B-X

As	O
for	O
the	O
interaction	O
with	O
Goalpha	B-Protein
and	O
adenylyl	O
cyclase	O
,	O
predominantly	O
geranylgeranylated	O
beta1	B-Protein
gamma1S74L	B-Protein
was	O
less	O
effective	O
than	O
geranylgeranylated	O
beta1	B-Protein
gamma2	B-Protein
purified	O
from	O
bovine	O
brain	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X

These	O
results	O
demonstrate	O
that	O
the	O
properties	O
of	O
Gbeta	O
gamma	O
are	O
strongly	O
affected	O
by	O
the	O
type	O
of	O
functionally	O
indispensable	O
isoprenylation	O
in	O
addition	O
to	O
the	O
amino	O
acid	O
sequence	O
of	O
Ggamma	O
.	O

The	O
relative	O
contribution	O
of	O
the	O
two	O
factors	O
depends	O
on	O
proteins	O
with	O
which	O
Gbeta	O
gamma	O
interacts	O
.	O
<EOS>	B-X
Among	B-X
11	B-X
subtypes	B-X
of	B-X
heterotrimeric	B-X
G-protein	B-X
gamma-subunit	B-X
,	B-X
gamma1	B-X
(	B-X
rod	B-X
)	B-X
,	B-X
gamma8	B-X
(	B-X
cone	B-X
)	B-X
and	B-X
gamma11	B-X
are	B-X
modified	B-X
with	B-X
farnesyl	B-X
while	B-X
the	B-X
others	B-X
are	B-X
modified	B-X
with	B-X
geranylgeranyl	B-X
at	B-X
the	B-X
C-terminus	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
isoprenylation	B-X
(	B-X
farnesylation	B-X
)	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
and	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
type	B-X
of	B-X
isoprenyl	B-X
group	B-X
affects	B-X
transducin-beta	B-X
gamma	B-X
(	B-X
beta1	B-X
gamma1	B-X
)	B-X
functions	B-X
such	B-X
as	B-X
interactions	B-X
with	B-X
membranes	B-X
,	B-X
Galpha/receptor	B-X
,	B-X
and	B-X
effectors	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
the	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
sequence	B-X
(	B-X
CVIS	B-X
)	B-X
of	B-X
gamma1	B-X
was	B-X
replaced	B-X
by	B-X
a	B-X
geranylgeranylation	B-X
signal	B-X
(	B-X
CVIL	B-X
)	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
mutant	B-X
(	B-X
S74L	B-X
)	B-X
or	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
gamma1	B-X
was	B-X
coexpressed	B-X
with	B-X
beta1	B-X
in	B-X
the	B-X
baculovirus-Tn5	B-X
insect	B-X
cell	B-X
system	B-X
.	B-X
Both	B-X
gamma1WT	B-X
and	B-X
gamma1S74L	B-X
expressed	B-X
as	B-X
a	B-X
beta	B-X
gamma	B-X
complex	B-X
were	B-X
mixtures	B-X
modified	B-X
with	B-X
farnesyl	B-X
and	B-X
geranylgeranyl	B-X
groups	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
farnesyl	B-X
to	B-X
geranylgeranyl	B-X
in	B-X
preparations	B-X
of	B-X
beta1	B-X
gamma1WT	B-X
and	B-X
beta1	B-X
gamma1S74L	B-X
purified	B-X
from	B-X
the	B-X
Tn5	B-X
cell	B-X
membrane	B-X
fraction	B-X
was	B-X
about	B-X
1:2	B-X
and	B-X
1:6	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
two	B-X
forms	B-X
of	B-X
recombinant	B-X
beta1	B-X
gamma1	B-X
and	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
were	B-X
different	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
associate	B-X
with	B-X
rod	B-X
outer	B-X
segment	B-X
membranes	B-X
with	B-X
the	B-X
following	B-X
rank	B-X
order	B-X
:	B-X
beta1	B-X
gamma1S74L	B-X
>	B-X
beta1	B-X
gamma1WT	B-X
>	B-X
retinal	B-X
beta1	B-X
gamma1	B-X
.	B-X
Functionally	B-X
,	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
to	B-X
promote	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
transducin-alpha	B-X
(	B-X
Talpha	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
metarhodopsin	B-X
II-catalyzed	B-X
GTPgammaS-binding	B-X
reaction	B-X
to	B-X
Talpha	B-X
and	B-X
to	B-X
modulate	B-X
adenylyl	B-X
cyclase	B-X
and	B-X
phospholipase	B-X
C	B-X
activities	B-X
.	B-X
All	B-X
of	B-X
the	B-X
beta1	B-X
gamma1	B-X
functions	B-X
absolutely	B-X
required	B-X
the	B-X
isoprenylation	B-X
of	B-X
the	B-X
gamma-subunit	B-X
.	B-X
As	B-X
for	B-X
the	B-X
interaction	B-X
with	B-X
Goalpha	B-X
and	B-X
adenylyl	B-X
cyclase	B-X
,	B-X
predominantly	B-X
geranylgeranylated	B-X
beta1	B-X
gamma1S74L	B-X
was	B-X
less	B-X
effective	B-X
than	B-X
geranylgeranylated	B-X
beta1	B-X
gamma2	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
properties	B-X
of	B-X
Gbeta	B-X
gamma	B-X
are	B-X
strongly	B-X
affected	B-X
by	B-X
the	B-X
type	B-X
of	B-X
functionally	B-X
indispensable	B-X
isoprenylation	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
Ggamma	B-X
.	B-X
The	B-X
relative	B-X
contribution	B-X
of	B-X
the	B-X
two	B-X
factors	B-X
depends	B-X
on	B-X
proteins	B-X
with	B-X
which	B-X
Gbeta	B-X
gamma	B-X
interacts	B-X
.	B-X

What	O
does	O
insulin	B-Protein
do	O
to	O
Ras	O
?	O
<EOS>	B-X
The	B-X
molecular	B-X
mechanisms	B-X
of	B-X
cellular	B-X
insulin	B-X
action	B-X
have	B-X
been	B-X
the	B-X
focus	B-X
of	B-X
much	B-X
investigation	B-X
since	B-X
the	B-X
discovery	B-X
of	B-X
the	B-X
hormone	B-X
100	B-X
years	B-X
ago	B-X
.	B-X
Insulin	B-X
action	B-X
is	B-X
impaired	B-X
in	B-X
metabolic	B-X
syndrome	B-X
,	B-X
a	B-X
condition	B-X
known	B-X
as	B-X
insulin	B-X
resistance	B-X
.	B-X
The	B-X
receptor	B-X
is	B-X
an	B-X
α2β2	B-X
heterodimer	B-X
that	B-X
binds	B-X
to	B-X
insulin	B-X
with	B-X
high	B-X
affinity	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
its	B-X
tyrosine	B-X
kinase	B-X
activity	B-X
.	B-X
Phosphorylation	B-X
of	B-X
Shc	B-X
leads	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
Ras/MAP	B-X
kinase	B-X
pathway	B-X
.	B-X
Among	B-X
the	B-X
cellular	B-X
processes	B-X
controlled	B-X
by	B-X
insulin	B-X
are	B-X
vesicle	B-X
trafficking	B-X
,	B-X
activities	B-X
of	B-X
metabolic	B-X
enzymes	B-X
,	B-X
transcriptional	B-X
factors	B-X
,	B-X
and	B-X
degradation	B-X
of	B-X
insulin	B-X
itself	B-X
.	B-X

The	O
Ras	O
pathway	O
lies	O
in	O
the	O
center	O
of	O
signalling	O
cascades	O
of	O
numerous	O
growth	O
-	O
promoting	O
factors	O
.	O

The	O
Ras	O
pathway	O
appears	O
to	O
connect	O
signalling	O
events	O
that	O
begin	O
at	O
the	O
plasma	O
membrane	O
with	O
nuclear	O
events	O
.	O
<EOS>	B-X
The	B-X
Ras	B-X
pathway	B-X
lies	B-X
in	B-X
the	B-X
center	B-X
of	B-X
signalling	B-X
cascades	B-X
of	B-X
numerous	B-X
growth-promoting	B-X
factors	B-X
.	B-X
The	B-X
Ras	B-X
pathway	B-X
appears	B-X
to	B-X
connect	B-X
signalling	B-X
events	B-X
that	B-X
begin	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
with	B-X
nuclear	B-X
events	B-X
.	B-X
Insulin	B-X
is	B-X
one	B-X
of	B-X
the	B-X
major	B-X
stimulants	B-X
of	B-X
the	B-X
Ras	B-X
signalling	B-X
pathway	B-X
.	B-X
The	B-X
influence	B-X
of	B-X
insulin	B-X
on	B-X
this	B-X
pathway	B-X
consists	B-X
of	B-X
five	B-X
important	B-X
events	B-X
:	B-X
(	B-X
1	B-X
)	B-X
p21Ras	B-X
activation	B-X
is	B-X
promoted	B-X
by	B-X
insulin	B-X
stimulation	B-X
of	B-X
the	B-X
guanine	B-X
nucleotide	B-X
exchange	B-X
factor	B-X
,	B-X
Sos	B-X
,	B-X
resulting	B-X
in	B-X
increased	B-X
GTP-loading	B-X
of	B-X
p21Ras	B-X
;	B-X
(	B-X
2	B-X
)	B-X
p21Ras	B-X
deactivation	B-X
involves	B-X
the	B-X
hyperphosphorylation	B-X
of	B-X
Sos	B-X
;	B-X
(	B-X
3	B-X
)	B-X
insulin	B-X
increases	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
activity	B-X
that	B-X
farnesylates	B-X
p21Ras	B-X
;	B-X
(	B-X
4	B-X
)	B-X
increased	B-X
amounts	B-X
of	B-X
farnesylated	B-X
p21Ras	B-X
translocate	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
where	B-X
they	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
other	B-X
growth-promoting	B-X
agents	B-X
;	B-X
and	B-X
(	B-X
5	B-X
)	B-X
cellular	B-X
responses	B-X
to	B-X
other	B-X
growth	B-X
factors	B-X
are	B-X
potentiated	B-X
by	B-X
insulin-stimulated	B-X
pre-loading	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
with	B-X
farnesylated	B-X
p21Ras	B-X
.	B-X

Insulin	B-Protein
is	O
one	O
of	O
the	O
major	O
stimulants	O
of	O
the	O
Ras	O
signalling	O
pathway	O
.	O
<EOS>	B-X
The	B-X
Ras	B-X
pathway	B-X
lies	B-X
in	B-X
the	B-X
center	B-X
of	B-X
signalling	B-X
cascades	B-X
of	B-X
numerous	B-X
growth-promoting	B-X
factors	B-X
.	B-X
The	B-X
Ras	B-X
pathway	B-X
appears	B-X
to	B-X
connect	B-X
signalling	B-X
events	B-X
that	B-X
begin	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
with	B-X
nuclear	B-X
events	B-X
.	B-X
Insulin	B-X
is	B-X
one	B-X
of	B-X
the	B-X
major	B-X
stimulants	B-X
of	B-X
the	B-X
Ras	B-X
signalling	B-X
pathway	B-X
.	B-X
The	B-X
influence	B-X
of	B-X
insulin	B-X
on	B-X
this	B-X
pathway	B-X
consists	B-X
of	B-X
five	B-X
important	B-X
events	B-X
:	B-X
(	B-X
1	B-X
)	B-X
p21Ras	B-X
activation	B-X
is	B-X
promoted	B-X
by	B-X
insulin	B-X
stimulation	B-X
of	B-X
the	B-X
guanine	B-X
nucleotide	B-X
exchange	B-X
factor	B-X
,	B-X
Sos	B-X
,	B-X
resulting	B-X
in	B-X
increased	B-X
GTP-loading	B-X
of	B-X
p21Ras	B-X
;	B-X
(	B-X
2	B-X
)	B-X
p21Ras	B-X
deactivation	B-X
involves	B-X
the	B-X
hyperphosphorylation	B-X
of	B-X
Sos	B-X
;	B-X
(	B-X
3	B-X
)	B-X
insulin	B-X
increases	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
activity	B-X
that	B-X
farnesylates	B-X
p21Ras	B-X
;	B-X
(	B-X
4	B-X
)	B-X
increased	B-X
amounts	B-X
of	B-X
farnesylated	B-X
p21Ras	B-X
translocate	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
where	B-X
they	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
other	B-X
growth-promoting	B-X
agents	B-X
;	B-X
and	B-X
(	B-X
5	B-X
)	B-X
cellular	B-X
responses	B-X
to	B-X
other	B-X
growth	B-X
factors	B-X
are	B-X
potentiated	B-X
by	B-X
insulin-stimulated	B-X
pre-loading	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
with	B-X
farnesylated	B-X
p21Ras	B-X
.	B-X

The	O
influence	O
of	O
insulin	B-Protein
on	O
this	O
pathway	O
consists	O
of	O
five	O
important	O
events	O
:	O
(	O
1	O
)	O
p21Ras	B-Protein
activation	O
is	O
promoted	O
by	O
insulin	B-Protein
stimulation	O
of	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
,	O
Sos	O
,	O
resulting	O
in	O
increased	O
GTP	O
-	O
loading	O
of	O
p21Ras	B-Protein
;	O
(	O
2	O
)	O
p21Ras	B-Protein
deactivation	O
involves	O
the	O
hyperphosphorylation	O
of	O
Sos	O
;	O
(	O
3	O
)	O
insulin	B-Protein
increases	O
farnesyltransferase	O
(	O
FTase	O
)	O
activity	O
that	O
farnesylates	O
p21Ras	B-Protein
;	O
(	O
4	O
)	O
increased	O
amounts	O
of	O
farnesylated	O
p21Ras	B-Protein
translocate	O
to	O
the	O
plasma	O
membrane	O
where	O
they	O
can	O
be	O
activated	O
by	O
other	O
growth	O
-	O
promoting	O
agents	O
;	O
and	O
(	O
5	O
)	O
cellular	O
responses	O
to	O
other	O
growth	O
factors	O
are	O
potentiated	O
by	O
insulin	B-Protein
-	O
stimulated	O
pre	O
-	O
loading	O
of	O
the	O
plasma	O
membrane	O
with	O
farnesylated	O
p21Ras	B-Protein
.	O
<EOS>	B-X
The	B-X
Ras	B-X
pathway	B-X
lies	B-X
in	B-X
the	B-X
center	B-X
of	B-X
signalling	B-X
cascades	B-X
of	B-X
numerous	B-X
growth-promoting	B-X
factors	B-X
.	B-X
The	B-X
Ras	B-X
pathway	B-X
appears	B-X
to	B-X
connect	B-X
signalling	B-X
events	B-X
that	B-X
begin	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
with	B-X
nuclear	B-X
events	B-X
.	B-X
Insulin	B-X
is	B-X
one	B-X
of	B-X
the	B-X
major	B-X
stimulants	B-X
of	B-X
the	B-X
Ras	B-X
signalling	B-X
pathway	B-X
.	B-X
The	B-X
influence	B-X
of	B-X
insulin	B-X
on	B-X
this	B-X
pathway	B-X
consists	B-X
of	B-X
five	B-X
important	B-X
events	B-X
:	B-X
(	B-X
1	B-X
)	B-X
p21Ras	B-X
activation	B-X
is	B-X
promoted	B-X
by	B-X
insulin	B-X
stimulation	B-X
of	B-X
the	B-X
guanine	B-X
nucleotide	B-X
exchange	B-X
factor	B-X
,	B-X
Sos	B-X
,	B-X
resulting	B-X
in	B-X
increased	B-X
GTP-loading	B-X
of	B-X
p21Ras	B-X
;	B-X
(	B-X
2	B-X
)	B-X
p21Ras	B-X
deactivation	B-X
involves	B-X
the	B-X
hyperphosphorylation	B-X
of	B-X
Sos	B-X
;	B-X
(	B-X
3	B-X
)	B-X
insulin	B-X
increases	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
activity	B-X
that	B-X
farnesylates	B-X
p21Ras	B-X
;	B-X
(	B-X
4	B-X
)	B-X
increased	B-X
amounts	B-X
of	B-X
farnesylated	B-X
p21Ras	B-X
translocate	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
where	B-X
they	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
other	B-X
growth-promoting	B-X
agents	B-X
;	B-X
and	B-X
(	B-X
5	B-X
)	B-X
cellular	B-X
responses	B-X
to	B-X
other	B-X
growth	B-X
factors	B-X
are	B-X
potentiated	B-X
by	B-X
insulin-stimulated	B-X
pre-loading	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
with	B-X
farnesylated	B-X
p21Ras	B-X
.	B-X

3	O
-	O
Hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitors	O
increase	O
fibrinolytic	O
activity	O
in	O
rat	O
aortic	O
endothelial	O
cells	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X
Aortas	B-X
isolated	B-X
from	B-X
rats	B-X
treated	B-X
for	B-X
2	B-X
days	B-X
with	B-X
lovastatin	B-X
(	B-X
4	B-X
mg/kg	B-X
body	B-X
wt	B-X
per	B-X
day	B-X
)	B-X
showed	B-X
a	B-X
3-fold	B-X
increase	B-X
in	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
activity	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
SVARECs	B-X
,	B-X
the	B-X
maximal	B-X
response	B-X
was	B-X
observed	B-X
when	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
48	B-X
hours	B-X
with	B-X
50	B-X
micromol/L	B-X
HRI	B-X
.	B-X
An	B-X
increase	B-X
of	B-X
tPA	B-X
mRNA	B-X
was	B-X
also	B-X
in	B-X
evidence	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HRI	B-X
inhibited	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
mRNA	B-X
.	B-X
C3	B-X
exoenzyme	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
geranylgeranylated-activated	B-X
Rho	B-X
protein	B-X
,	B-X
reproduced	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
on	B-X
tPA	B-X
and	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
blocked	B-X
its	B-X
reversal	B-X
by	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HRI	B-X
can	B-X
modify	B-X
the	B-X
fibrinolytic	B-X
potential	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
likely	B-X
via	B-X
inhibition	B-X
of	B-X
geranylgeranylated	B-X
Rho	B-X
protein	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

Role	O
of	O
geranylgeranylation	O
and	O
Rho	O
proteins	O
.	O
<EOS>	B-X
Anchoring	B-X
of	B-X
small	B-X
G-proteins	B-X
to	B-X
cellular	B-X
membranes	B-X
via	B-X
a	B-X
covalently	B-X
bound	B-X
lipophylic	B-X
prenyl	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
functioning	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
Rho	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
good	B-X
candidate	B-X
as	B-X
a	B-X
target	B-X
for	B-X
inhibitors	B-X
of	B-X
PGGT-1	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
the	B-X
Rho-associated	B-X
coiled-coil	B-X
containing	B-X
protein	B-X
kinase	B-X
(	B-X
ROCK	B-X
)	B-X
-mediated	B-X
di-phosphorylation	B-X
of	B-X
myosin	B-X
light	B-X
chain	B-X
(	B-X
MLC	B-X
)	B-X
and	B-X
actin	B-X
bundle	B-X
formation	B-X
at	B-X
the	B-X
cell	B-X
periphery	B-X
as	B-X
early	B-X
events	B-X
of	B-X
the	B-X
endothelial	B-X
barrier	B-X
disruption	B-X
.	B-X
We	B-X
herein	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
RhoA	B-X
during	B-X
early	B-X
events	B-X
of	B-X
barrier	B-X
disruption	B-X
.	B-X
Thrombin	B-X
increased	B-X
a	B-X
GTP-bound	B-X
form	B-X
of	B-X
RhoA	B-X
and	B-X
phosphorylation	B-X
of	B-X
myosin	B-X
phosphatase	B-X
target	B-X
subunit	B-X
1	B-X
(	B-X
MYPT1	B-X
)	B-X
at	B-X
the	B-X
ROCK	B-X
site	B-X
.	B-X
The	B-X
intracellular	B-X
introduction	B-X
of	B-X
the	B-X
inhibitory	B-X
protein	B-X
of	B-X
RhoA	B-X
inhibited	B-X
the	B-X
thrombin-induced	B-X
di-phosphorylation	B-X
of	B-X
MLC	B-X
.	B-X
However	B-X
,	B-X
knockdown	B-X
of	B-X
either	B-X
one	B-X
of	B-X
RhoA	B-X
,	B-X
RhoB	B-X
or	B-X
RhoC	B-X
failed	B-X
to	B-X
inhibit	B-X
thrombin-induced	B-X
MLC	B-X
di-phosphorylation	B-X
.	B-X
The	B-X
findings	B-X
suggest	B-X
that	B-X
Rho	B-X
proteins	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
during	B-X
early	B-X
events	B-X
of	B-X
thrombin-induced	B-X
barrier	B-X
disruption	B-X
.	B-X

3	O
-	O
Hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
(	O
HMG	O
CoA	O
)	O
reductase	O
inhibitors	O
(	O
HRIs	O
)	O
have	O
been	O
recently	O
shown	O
to	O
prevent	O
atherosclerosis	O
progression	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
Aortas	B-X
isolated	B-X
from	B-X
rats	B-X
treated	B-X
for	B-X
2	B-X
days	B-X
with	B-X
lovastatin	B-X
(	B-X
4	B-X
mg/kg	B-X
body	B-X
wt	B-X
per	B-X
day	B-X
)	B-X
showed	B-X
a	B-X
3-fold	B-X
increase	B-X
in	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
activity	B-X
.	B-X
C3	B-X
exoenzyme	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
geranylgeranylated-activated	B-X
Rho	B-X
protein	B-X
,	B-X
reproduced	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
on	B-X
tPA	B-X
and	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
blocked	B-X
its	B-X
reversal	B-X
by	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

Clinical	O
benefit	O
results	O
from	O
combined	O
actions	O
on	O
various	O
components	O
of	O
the	O
atherosclerotic	O
lesion	O
.	O
<EOS>	B-X
Clinical	B-X
benefit	B-X
results	B-X
from	B-X
combined	B-X
actions	B-X
on	B-X
various	B-X
components	B-X
of	B-X
the	B-X
atherosclerotic	B-X
lesion	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X

This	O
study	O
was	O
designed	O
to	O
identify	O
the	O
effects	O
of	O
HRI	O
on	O
one	O
of	O
these	O
components	O
,	O
the	O
endothelial	O
fibrinolytic	O
system	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
Clinical	B-X
benefit	B-X
results	B-X
from	B-X
combined	B-X
actions	B-X
on	B-X
various	B-X
components	B-X
of	B-X
the	B-X
atherosclerotic	B-X
lesion	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
SVARECs	B-X
,	B-X
the	B-X
maximal	B-X
response	B-X
was	B-X
observed	B-X
when	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
48	B-X
hours	B-X
with	B-X
50	B-X
micromol/L	B-X
HRI	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HRI	B-X
inhibited	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
mRNA	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
HRI	B-X
were	B-X
reversed	B-X
by	B-X
mevalonate	B-X
and	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
LDL	B-X
cholesterol	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
and	B-X
were	B-X
not	B-X
induced	B-X
by	B-X
alpha-hydroxyfarnesyl	B-X
phosphonic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
protein	B-X
farnesyl	B-X
transferase	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
HRI	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
disruption	B-X
of	B-X
cellular	B-X
actin	B-X
filaments	B-X
without	B-X
modification	B-X
of	B-X
microtubules	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HRI	B-X
can	B-X
modify	B-X
the	B-X
fibrinolytic	B-X
potential	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
likely	B-X
via	B-X
inhibition	B-X
of	B-X
geranylgeranylated	B-X
Rho	B-X
protein	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

Aortas	O
isolated	O
from	O
rats	O
treated	O
for	O
2	O
days	O
with	O
lovastatin	O
(	O
4	O
mg	O
/	O
kg	O
body	O
wt	O
per	O
day	O
)	O
showed	O
a	O
3	O
-	O
fold	O
increase	O
in	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
tPA	B-Protein
)	O
activity	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
Aortas	B-X
isolated	B-X
from	B-X
rats	B-X
treated	B-X
for	B-X
2	B-X
days	B-X
with	B-X
lovastatin	B-X
(	B-X
4	B-X
mg/kg	B-X
body	B-X
wt	B-X
per	B-X
day	B-X
)	B-X
showed	B-X
a	B-X
3-fold	B-X
increase	B-X
in	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
activity	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
SVARECs	B-X
,	B-X
the	B-X
maximal	B-X
response	B-X
was	B-X
observed	B-X
when	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
48	B-X
hours	B-X
with	B-X
50	B-X
micromol/L	B-X
HRI	B-X
.	B-X
An	B-X
increase	B-X
of	B-X
tPA	B-X
mRNA	B-X
was	B-X
also	B-X
in	B-X
evidence	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HRI	B-X
inhibited	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
mRNA	B-X
.	B-X
C3	B-X
exoenzyme	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
geranylgeranylated-activated	B-X
Rho	B-X
protein	B-X
,	B-X
reproduced	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
on	B-X
tPA	B-X
and	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
blocked	B-X
its	B-X
reversal	B-X
by	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
.	B-X
A	B-X
disrupter	B-X
of	B-X
actin	B-X
filaments	B-X
,	B-X
cytochalasin	B-X
D	B-X
,	B-X
induced	B-X
the	B-X
same	B-X
effect	B-X
as	B-X
lovastatin	B-X
on	B-X
tPA	B-X
,	B-X
whereas	B-X
a	B-X
disrupter	B-X
of	B-X
microtubules	B-X
,	B-X
nocodazole	B-X
,	B-X
did	B-X
not	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

In	O
a	O
rat	O
aortic	O
endothelial	O
cell	O
line	O
(	O
SVARECs	O
)	O
and	O
in	O
human	O
nontransformed	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
HRI	O
induced	O
an	O
increase	O
in	O
tPA	B-Protein
activity	O
and	O
antigen	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

In	O
SVARECs	O
,	O
the	O
maximal	O
response	O
was	O
observed	O
when	O
cells	O
were	O
incubated	O
for	O
48	O
hours	O
with	O
50	O
micromol	O
/	O
L	O
HRI	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
SVARECs	B-X
,	B-X
the	B-X
maximal	B-X
response	B-X
was	B-X
observed	B-X
when	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
48	B-X
hours	B-X
with	B-X
50	B-X
micromol/L	B-X
HRI	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HRI	B-X
inhibited	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
mRNA	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
HRI	B-X
were	B-X
reversed	B-X
by	B-X
mevalonate	B-X
and	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
LDL	B-X
cholesterol	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
and	B-X
were	B-X
not	B-X
induced	B-X
by	B-X
alpha-hydroxyfarnesyl	B-X
phosphonic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
protein	B-X
farnesyl	B-X
transferase	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
HRI	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
disruption	B-X
of	B-X
cellular	B-X
actin	B-X
filaments	B-X
without	B-X
modification	B-X
of	B-X
microtubules	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HRI	B-X
can	B-X
modify	B-X
the	B-X
fibrinolytic	B-X
potential	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
likely	B-X
via	B-X
inhibition	B-X
of	B-X
geranylgeranylated	B-X
Rho	B-X
protein	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

An	O
increase	O
of	O
tPA	B-Protein
mRNA	O
was	O
also	O
in	O
evidence	O
.	O
<EOS>	B-X
When	B-X
one	B-X
of	B-X
three	B-X
tumor	B-X
promoters	B-X
,	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
,	B-X
aplysiatoxin	B-X
and	B-X
dihydroteleocidin	B-X
B	B-X
,	B-X
was	B-X
added	B-X
during	B-X
selection	B-X
with	B-X
cadmium	B-X
chloride	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
appearance	B-X
of	B-X
resistant	B-X
cells	B-X
increased	B-X
more	B-X
than	B-X
50-fold	B-X
.	B-X
Both	B-X
clones	B-X
produced	B-X
much	B-X
higher	B-X
levels	B-X
of	B-X
metallothionein	B-X
I	B-X
mRNA	B-X
than	B-X
the	B-X
parental	B-X
CHL	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
c-Ha-ras	B-X
and	B-X
c-myc	B-X
genes	B-X
were	B-X
amplified	B-X
in	B-X
a	B-X
bladder	B-X
cancer	B-X
removed	B-X
surgically	B-X
and	B-X
in	B-X
a	B-X
transplanted	B-X
rat	B-X
hepatocellular	B-X
carcinoma	B-X
,	B-X
Morris	B-X
hepatoma	B-X
7794A	B-X
,	B-X
respectively	B-X
.	B-X
Since	B-X
we	B-X
previously	B-X
had	B-X
shown	B-X
that	B-X
EGF	B-X
stimulates	B-X
EGF	B-X
receptor	B-X
synthesis	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
we	B-X
tested	B-X
whether	B-X
hormones	B-X
that	B-X
stimulate	B-X
PtdIns	B-X
(	B-X
4,5	B-X
)	B-X
P2	B-X
hydrolysis	B-X
would	B-X
increase	B-X
EGF	B-X
receptor	B-X
protein	B-X
synthesis	B-X
and	B-X
mRNA	B-X
levels	B-X
.	B-X
Epinephrine	B-X
,	B-X
angiotensin	B-X
II	B-X
,	B-X
and	B-X
[	B-X
Arg8	B-X
]	B-X
vasopressin	B-X
activate	B-X
phospholipase	B-X
C	B-X
in	B-X
WB	B-X
cells	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
accumulation	B-X
of	B-X
the	B-X
inositol	B-X
phosphates	B-X
,	B-X
inositol	B-X
monophosphate	B-X
,	B-X
inositol	B-X
bisphosphate	B-X
,	B-X
and	B-X
inositol	B-X
trisphosphate	B-X
.	B-X
A	B-X
3-4-h	B-X
treatment	B-X
with	B-X
each	B-X
hormone	B-X
also	B-X
increased	B-X
the	B-X
rate	B-X
of	B-X
EGF	B-X
receptor	B-X
protein	B-X
synthesis	B-X
by	B-X
3-6-fold	B-X
as	B-X
assessed	B-X
by	B-X
immunoprecipitation	B-X
of	B-X
EGF	B-X
receptor	B-X
from	B-X
[	B-X
35S	B-X
]	B-X
methionine-labeled	B-X
cells	B-X
.	B-X
Northern	B-X
blot	B-X
analyses	B-X
of	B-X
WB	B-X
cell	B-X
EGF	B-X
receptor	B-X
mRNA	B-X
levels	B-X
revealed	B-X
that	B-X
agents	B-X
linked	B-X
to	B-X
the	B-X
phosphoinositide	B-X
signaling	B-X
system	B-X
increased	B-X
receptor	B-X
mRNA	B-X
content	B-X
within	B-X
1-2	B-X
h.	B-X
A	B-X
maximal	B-X
increase	B-X
of	B-X
3-7-fold	B-X
was	B-X
observed	B-X
after	B-X
a	B-X
3-h	B-X
exposure	B-X
to	B-X
EGF	B-X
and	B-X
hormones	B-X
.	B-X
The	B-X
phorbol	B-X
ester	B-X
,	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
protein	B-X
kinase	B-X
C	B-X
also	B-X
stimulated	B-X
EGF	B-X
receptor	B-X
synthesis	B-X
.	B-X
Pretreatment	B-X
of	B-X
WB	B-X
cells	B-X
for	B-X
18	B-X
h	B-X
with	B-X
high	B-X
concentrations	B-X
of	B-X
TPA	B-X
``	B-X
down-regulated	B-X
''	B-X
protein	B-X
kinase	B-X
C	B-X
and	B-X
blocked	B-X
TPA-directed	B-X
EGF	B-X
receptor	B-X
mRNA	B-X
synthesis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
EGF	B-X
on	B-X
EGF	B-X
receptor	B-X
mRNA	B-X
levels	B-X
was	B-X
not	B-X
significantly	B-X
decreased	B-X
by	B-X
TPA	B-X
pretreatment	B-X
.	B-X
Epinephrine-induced	B-X
increases	B-X
in	B-X
EGF	B-X
receptor	B-X
mRNA	B-X
were	B-X
reduced	B-X
from	B-X
4-	B-X
to	B-X
2-fold	B-X
.	B-X

In	O
contrast	O
,	O
HRI	O
inhibited	O
plasminogen	B-Protein
activator	I-Protein
inhibitor	I-Protein
-	I-Protein
1	I-Protein
activity	O
and	O
mRNA	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X
Aortas	B-X
isolated	B-X
from	B-X
rats	B-X
treated	B-X
for	B-X
2	B-X
days	B-X
with	B-X
lovastatin	B-X
(	B-X
4	B-X
mg/kg	B-X
body	B-X
wt	B-X
per	B-X
day	B-X
)	B-X
showed	B-X
a	B-X
3-fold	B-X
increase	B-X
in	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
activity	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
SVARECs	B-X
,	B-X
the	B-X
maximal	B-X
response	B-X
was	B-X
observed	B-X
when	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
48	B-X
hours	B-X
with	B-X
50	B-X
micromol/L	B-X
HRI	B-X
.	B-X
An	B-X
increase	B-X
of	B-X
tPA	B-X
mRNA	B-X
was	B-X
also	B-X
in	B-X
evidence	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HRI	B-X
inhibited	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
mRNA	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
HRI	B-X
were	B-X
reversed	B-X
by	B-X
mevalonate	B-X
and	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
LDL	B-X
cholesterol	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
and	B-X
were	B-X
not	B-X
induced	B-X
by	B-X
alpha-hydroxyfarnesyl	B-X
phosphonic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
protein	B-X
farnesyl	B-X
transferase	B-X
.	B-X
C3	B-X
exoenzyme	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
geranylgeranylated-activated	B-X
Rho	B-X
protein	B-X
,	B-X
reproduced	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
on	B-X
tPA	B-X
and	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
blocked	B-X
its	B-X
reversal	B-X
by	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
HRI	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
disruption	B-X
of	B-X
cellular	B-X
actin	B-X
filaments	B-X
without	B-X
modification	B-X
of	B-X
microtubules	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HRI	B-X
can	B-X
modify	B-X
the	B-X
fibrinolytic	B-X
potential	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
likely	B-X
via	B-X
inhibition	B-X
of	B-X
geranylgeranylated	B-X
Rho	B-X
protein	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

The	O
effects	O
of	O
HRI	O
were	O
reversed	O
by	O
mevalonate	O
and	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
by	O
LDL	O
cholesterol	O
and	O
farnesyl	O
pyrophosphate	O
,	O
and	O
were	O
not	O
induced	O
by	O
alpha	O
-	O
hydroxyfarnesyl	O
phosphonic	O
acid	O
,	O
an	O
inhibitor	O
of	O
protein	O
farnesyl	O
transferase	O
.	O

C3	B-Protein
exoenzyme	I-Protein
,	O
an	O
inhibitor	O
of	O
the	O
geranylgeranylated	O
-	O
activated	O
Rho	O
protein	O
,	O
reproduced	O
the	O
effect	O
of	O
lovastatin	O
on	O
tPA	B-Protein
and	O
plasminogen	B-Protein
activator	I-Protein
inhibitor	I-Protein
-	I-Protein
1	I-Protein
activity	O
and	O
blocked	O
its	O
reversal	O
by	O
geranylgeranyl	O
pyrophosphate	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X
Aortas	B-X
isolated	B-X
from	B-X
rats	B-X
treated	B-X
for	B-X
2	B-X
days	B-X
with	B-X
lovastatin	B-X
(	B-X
4	B-X
mg/kg	B-X
body	B-X
wt	B-X
per	B-X
day	B-X
)	B-X
showed	B-X
a	B-X
3-fold	B-X
increase	B-X
in	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
activity	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
An	B-X
increase	B-X
of	B-X
tPA	B-X
mRNA	B-X
was	B-X
also	B-X
in	B-X
evidence	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HRI	B-X
inhibited	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
mRNA	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
HRI	B-X
were	B-X
reversed	B-X
by	B-X
mevalonate	B-X
and	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
LDL	B-X
cholesterol	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
and	B-X
were	B-X
not	B-X
induced	B-X
by	B-X
alpha-hydroxyfarnesyl	B-X
phosphonic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
protein	B-X
farnesyl	B-X
transferase	B-X
.	B-X
C3	B-X
exoenzyme	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
geranylgeranylated-activated	B-X
Rho	B-X
protein	B-X
,	B-X
reproduced	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
on	B-X
tPA	B-X
and	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
blocked	B-X
its	B-X
reversal	B-X
by	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
HRI	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
disruption	B-X
of	B-X
cellular	B-X
actin	B-X
filaments	B-X
without	B-X
modification	B-X
of	B-X
microtubules	B-X
.	B-X
A	B-X
disrupter	B-X
of	B-X
actin	B-X
filaments	B-X
,	B-X
cytochalasin	B-X
D	B-X
,	B-X
induced	B-X
the	B-X
same	B-X
effect	B-X
as	B-X
lovastatin	B-X
on	B-X
tPA	B-X
,	B-X
whereas	B-X
a	B-X
disrupter	B-X
of	B-X
microtubules	B-X
,	B-X
nocodazole	B-X
,	B-X
did	B-X
not	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HRI	B-X
can	B-X
modify	B-X
the	B-X
fibrinolytic	B-X
potential	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
likely	B-X
via	B-X
inhibition	B-X
of	B-X
geranylgeranylated	B-X
Rho	B-X
protein	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

The	O
effect	O
of	O
HRI	O
was	O
associated	O
with	O
a	O
disruption	O
of	O
cellular	O
actin	O
filaments	O
without	O
modification	O
of	O
microtubules	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
SVARECs	B-X
,	B-X
the	B-X
maximal	B-X
response	B-X
was	B-X
observed	B-X
when	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
48	B-X
hours	B-X
with	B-X
50	B-X
micromol/L	B-X
HRI	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HRI	B-X
inhibited	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
mRNA	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
HRI	B-X
were	B-X
reversed	B-X
by	B-X
mevalonate	B-X
and	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
LDL	B-X
cholesterol	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
and	B-X
were	B-X
not	B-X
induced	B-X
by	B-X
alpha-hydroxyfarnesyl	B-X
phosphonic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
protein	B-X
farnesyl	B-X
transferase	B-X
.	B-X
C3	B-X
exoenzyme	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
geranylgeranylated-activated	B-X
Rho	B-X
protein	B-X
,	B-X
reproduced	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
on	B-X
tPA	B-X
and	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
blocked	B-X
its	B-X
reversal	B-X
by	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
HRI	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
disruption	B-X
of	B-X
cellular	B-X
actin	B-X
filaments	B-X
without	B-X
modification	B-X
of	B-X
microtubules	B-X
.	B-X
A	B-X
disrupter	B-X
of	B-X
actin	B-X
filaments	B-X
,	B-X
cytochalasin	B-X
D	B-X
,	B-X
induced	B-X
the	B-X
same	B-X
effect	B-X
as	B-X
lovastatin	B-X
on	B-X
tPA	B-X
,	B-X
whereas	B-X
a	B-X
disrupter	B-X
of	B-X
microtubules	B-X
,	B-X
nocodazole	B-X
,	B-X
did	B-X
not	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HRI	B-X
can	B-X
modify	B-X
the	B-X
fibrinolytic	B-X
potential	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
likely	B-X
via	B-X
inhibition	B-X
of	B-X
geranylgeranylated	B-X
Rho	B-X
protein	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

A	O
disrupter	O
of	O
actin	O
filaments	O
,	O
cytochalasin	O
D	O
,	O
induced	O
the	O
same	O
effect	O
as	O
lovastatin	O
on	O
tPA	B-Protein
,	O
whereas	O
a	O
disrupter	O
of	O
microtubules	O
,	O
nocodazole	O
,	O
did	O
not	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X
Aortas	B-X
isolated	B-X
from	B-X
rats	B-X
treated	B-X
for	B-X
2	B-X
days	B-X
with	B-X
lovastatin	B-X
(	B-X
4	B-X
mg/kg	B-X
body	B-X
wt	B-X
per	B-X
day	B-X
)	B-X
showed	B-X
a	B-X
3-fold	B-X
increase	B-X
in	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
activity	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
An	B-X
increase	B-X
of	B-X
tPA	B-X
mRNA	B-X
was	B-X
also	B-X
in	B-X
evidence	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
HRI	B-X
were	B-X
reversed	B-X
by	B-X
mevalonate	B-X
and	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
LDL	B-X
cholesterol	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
and	B-X
were	B-X
not	B-X
induced	B-X
by	B-X
alpha-hydroxyfarnesyl	B-X
phosphonic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
protein	B-X
farnesyl	B-X
transferase	B-X
.	B-X
C3	B-X
exoenzyme	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
geranylgeranylated-activated	B-X
Rho	B-X
protein	B-X
,	B-X
reproduced	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
on	B-X
tPA	B-X
and	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
blocked	B-X
its	B-X
reversal	B-X
by	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
HRI	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
disruption	B-X
of	B-X
cellular	B-X
actin	B-X
filaments	B-X
without	B-X
modification	B-X
of	B-X
microtubules	B-X
.	B-X
A	B-X
disrupter	B-X
of	B-X
actin	B-X
filaments	B-X
,	B-X
cytochalasin	B-X
D	B-X
,	B-X
induced	B-X
the	B-X
same	B-X
effect	B-X
as	B-X
lovastatin	B-X
on	B-X
tPA	B-X
,	B-X
whereas	B-X
a	B-X
disrupter	B-X
of	B-X
microtubules	B-X
,	B-X
nocodazole	B-X
,	B-X
did	B-X
not	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HRI	B-X
can	B-X
modify	B-X
the	B-X
fibrinolytic	B-X
potential	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
likely	B-X
via	B-X
inhibition	B-X
of	B-X
geranylgeranylated	B-X
Rho	B-X
protein	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

In	O
conclusion	O
,	O
HRI	O
can	O
modify	O
the	O
fibrinolytic	O
potential	O
of	O
endothelial	O
cells	O
,	O
likely	O
via	O
inhibition	O
of	O
geranylgeranylated	O
Rho	O
protein	O
and	O
disruption	O
of	O
the	O
actin	O
filaments	O
.	O
<EOS>	B-X
3-Hydroxy-3-methylglutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG	B-X
CoA	B-X
)	B-X
reductase	B-X
inhibitors	B-X
(	B-X
HRIs	B-X
)	B-X
have	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
prevent	B-X
atherosclerosis	B-X
progression	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
identify	B-X
the	B-X
effects	B-X
of	B-X
HRI	B-X
on	B-X
one	B-X
of	B-X
these	B-X
components	B-X
,	B-X
the	B-X
endothelial	B-X
fibrinolytic	B-X
system	B-X
.	B-X
In	B-X
a	B-X
rat	B-X
aortic	B-X
endothelial	B-X
cell	B-X
line	B-X
(	B-X
SVARECs	B-X
)	B-X
and	B-X
in	B-X
human	B-X
nontransformed	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
HRI	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
tPA	B-X
activity	B-X
and	B-X
antigen	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
SVARECs	B-X
,	B-X
the	B-X
maximal	B-X
response	B-X
was	B-X
observed	B-X
when	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
48	B-X
hours	B-X
with	B-X
50	B-X
micromol/L	B-X
HRI	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
HRI	B-X
inhibited	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
mRNA	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
HRI	B-X
were	B-X
reversed	B-X
by	B-X
mevalonate	B-X
and	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
by	B-X
LDL	B-X
cholesterol	B-X
and	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
and	B-X
were	B-X
not	B-X
induced	B-X
by	B-X
alpha-hydroxyfarnesyl	B-X
phosphonic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
protein	B-X
farnesyl	B-X
transferase	B-X
.	B-X
C3	B-X
exoenzyme	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
geranylgeranylated-activated	B-X
Rho	B-X
protein	B-X
,	B-X
reproduced	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
on	B-X
tPA	B-X
and	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
activity	B-X
and	B-X
blocked	B-X
its	B-X
reversal	B-X
by	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
HRI	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
disruption	B-X
of	B-X
cellular	B-X
actin	B-X
filaments	B-X
without	B-X
modification	B-X
of	B-X
microtubules	B-X
.	B-X
A	B-X
disrupter	B-X
of	B-X
actin	B-X
filaments	B-X
,	B-X
cytochalasin	B-X
D	B-X
,	B-X
induced	B-X
the	B-X
same	B-X
effect	B-X
as	B-X
lovastatin	B-X
on	B-X
tPA	B-X
,	B-X
whereas	B-X
a	B-X
disrupter	B-X
of	B-X
microtubules	B-X
,	B-X
nocodazole	B-X
,	B-X
did	B-X
not	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HRI	B-X
can	B-X
modify	B-X
the	B-X
fibrinolytic	B-X
potential	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
likely	B-X
via	B-X
inhibition	B-X
of	B-X
geranylgeranylated	B-X
Rho	B-X
protein	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
actin	B-X
filaments	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
of	B-X
fibrinolytic	B-X
activity	B-X
of	B-X
endothelial	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
HRI	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
.	B-X

The	O
resulting	O
increase	O
of	O
fibrinolytic	O
activity	O
of	O
endothelial	O
cells	O
may	O
contribute	O
to	O
the	O
beneficial	O
effects	O
of	O
HRI	O
in	O
the	O
progression	O
of	O
atherosclerosis	O
.	O

Cleavage	O
of	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-Protein
by	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
.	O

NEDD8	B-Protein
is	O
a	O
novel	O
ubiquitin	B-Protein
-	O
like	O
protein	O
that	O
has	O
been	O
shown	O
to	O
conjugate	O
to	O
nuclear	O
proteins	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitination	O
and	O
sentrinization	O
.	O

To	O
identify	O
proteins	O
that	O
are	O
involved	O
in	O
the	O
NEDD8	B-Protein
-	O
conjugation	O
and	O
de	O
-	O
conjugation	O
pathway	O
,	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
was	O
used	O
to	O
screen	O
a	O
human	O
heart	O
cDNA	O
library	O
using	O
NEDD8	B-Protein
as	O
a	O
bait	O
.	O
<EOS>	B-X
NEDD8	B-X
is	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
nuclear	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
To	B-X
identify	B-X
proteins	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
NEDD8-conjugation	B-X
and	B-X
de-conjugation	B-X
pathway	B-X
,	B-X
the	B-X
yeast	B-X
two-hybrid	B-X
system	B-X
was	B-X
used	B-X
to	B-X
screen	B-X
a	B-X
human	B-X
heart	B-X
cDNA	B-X
library	B-X
using	B-X
NEDD8	B-X
as	B-X
a	B-X
bait	B-X
.	B-X
Seven	B-X
strongly	B-X
positive	B-X
clones	B-X
were	B-X
found	B-X
to	B-X
contain	B-X
a	B-X
cDNA	B-X
insert	B-X
encoding	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
,	B-X
UCH-L3	B-X
.	B-X
In	B-X
vitro	B-X
GST	B-X
pull-down	B-X
assay	B-X
demonstrated	B-X
that	B-X
UCH-L3	B-X
bound	B-X
to	B-X
both	B-X
NEDD8	B-X
and	B-X
ubiquitin	B-X
.	B-X
Recombinant	B-X
UCH-L3	B-X
,	B-X
but	B-X
not	B-X
UCH-L1	B-X
,	B-X
was	B-X
able	B-X
to	B-X
cleave	B-X
the	B-X
C-terminus	B-X
of	B-X
NEDD8	B-X
.	B-X
Thus	B-X
,	B-X
UCH-L3	B-X
can	B-X
function	B-X
as	B-X
a	B-X
C-terminal	B-X
hydrolase	B-X
for	B-X
both	B-X
NEDD8	B-X
and	B-X
ubiquitin	B-X
.	B-X
UCH-L3	B-X
may	B-X
play	B-X
a	B-X
physiologically	B-X
significant	B-X
role	B-X
in	B-X
the	B-X
cleavage	B-X
of	B-X
the	B-X
C-terminus	B-X
of	B-X
NEDD8	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
NEDD8	B-X
to	B-X
conjugate	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X

Seven	O
strongly	O
positive	O
clones	O
were	O
found	O
to	O
contain	O
a	O
cDNA	O
insert	O
encoding	O
the	O
ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
,	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
.	O
<EOS>	B-X
NEDD8	B-X
is	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
nuclear	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
To	B-X
identify	B-X
proteins	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
NEDD8-conjugation	B-X
and	B-X
de-conjugation	B-X
pathway	B-X
,	B-X
the	B-X
yeast	B-X
two-hybrid	B-X
system	B-X
was	B-X
used	B-X
to	B-X
screen	B-X
a	B-X
human	B-X
heart	B-X
cDNA	B-X
library	B-X
using	B-X
NEDD8	B-X
as	B-X
a	B-X
bait	B-X
.	B-X
Seven	B-X
strongly	B-X
positive	B-X
clones	B-X
were	B-X
found	B-X
to	B-X
contain	B-X
a	B-X
cDNA	B-X
insert	B-X
encoding	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
,	B-X
UCH-L3	B-X
.	B-X
In	B-X
vitro	B-X
GST	B-X
pull-down	B-X
assay	B-X
demonstrated	B-X
that	B-X
UCH-L3	B-X
bound	B-X
to	B-X
both	B-X
NEDD8	B-X
and	B-X
ubiquitin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
UCH-L3	B-X
did	B-X
not	B-X
bind	B-X
to	B-X
sentrin-1	B-X
,	B-X
sentrin-2	B-X
,	B-X
or	B-X
sentrin-3	B-X
.	B-X
Recombinant	B-X
UCH-L3	B-X
,	B-X
but	B-X
not	B-X
UCH-L1	B-X
,	B-X
was	B-X
able	B-X
to	B-X
cleave	B-X
the	B-X
C-terminus	B-X
of	B-X
NEDD8	B-X
.	B-X
Thus	B-X
,	B-X
UCH-L3	B-X
can	B-X
function	B-X
as	B-X
a	B-X
C-terminal	B-X
hydrolase	B-X
for	B-X
both	B-X
NEDD8	B-X
and	B-X
ubiquitin	B-X
.	B-X
UCH-L3	B-X
may	B-X
play	B-X
a	B-X
physiologically	B-X
significant	B-X
role	B-X
in	B-X
the	B-X
cleavage	B-X
of	B-X
the	B-X
C-terminus	B-X
of	B-X
NEDD8	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
NEDD8	B-X
to	B-X
conjugate	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X

In	O
vitro	O
GST	O
pull	O
-	O
down	O
assay	O
demonstrated	O
that	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
bound	O
to	O
both	O
NEDD8	B-Protein
and	O
ubiquitin	B-Protein
.	O
<EOS>	B-X
NEDD8	B-X
is	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
nuclear	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
To	B-X
identify	B-X
proteins	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
NEDD8-conjugation	B-X
and	B-X
de-conjugation	B-X
pathway	B-X
,	B-X
the	B-X
yeast	B-X
two-hybrid	B-X
system	B-X
was	B-X
used	B-X
to	B-X
screen	B-X
a	B-X
human	B-X
heart	B-X
cDNA	B-X
library	B-X
using	B-X
NEDD8	B-X
as	B-X
a	B-X
bait	B-X
.	B-X
Seven	B-X
strongly	B-X
positive	B-X
clones	B-X
were	B-X
found	B-X
to	B-X
contain	B-X
a	B-X
cDNA	B-X
insert	B-X
encoding	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
,	B-X
UCH-L3	B-X
.	B-X
In	B-X
vitro	B-X
GST	B-X
pull-down	B-X
assay	B-X
demonstrated	B-X
that	B-X
UCH-L3	B-X
bound	B-X
to	B-X
both	B-X
NEDD8	B-X
and	B-X
ubiquitin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
UCH-L3	B-X
did	B-X
not	B-X
bind	B-X
to	B-X
sentrin-1	B-X
,	B-X
sentrin-2	B-X
,	B-X
or	B-X
sentrin-3	B-X
.	B-X
Recombinant	B-X
UCH-L3	B-X
,	B-X
but	B-X
not	B-X
UCH-L1	B-X
,	B-X
was	B-X
able	B-X
to	B-X
cleave	B-X
the	B-X
C-terminus	B-X
of	B-X
NEDD8	B-X
.	B-X
Thus	B-X
,	B-X
UCH-L3	B-X
can	B-X
function	B-X
as	B-X
a	B-X
C-terminal	B-X
hydrolase	B-X
for	B-X
both	B-X
NEDD8	B-X
and	B-X
ubiquitin	B-X
.	B-X
UCH-L3	B-X
may	B-X
play	B-X
a	B-X
physiologically	B-X
significant	B-X
role	B-X
in	B-X
the	B-X
cleavage	B-X
of	B-X
the	B-X
C-terminus	B-X
of	B-X
NEDD8	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
NEDD8	B-X
to	B-X
conjugate	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X

In	O
contrast	O
,	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
did	O
not	O
bind	O
to	O
sentrin	B-Protein
-	I-Protein
1	I-Protein
,	O
sentrin	B-Protein
-	I-Protein
2	I-Protein
,	O
or	O
sentrin	B-Protein
-	I-Protein
3	I-Protein
.	O
<EOS>	B-X
SUMO	B-X
is	B-X
conjugated	B-X
to	B-X
lysine	B-X
residues	B-X
in	B-X
target	B-X
proteins	B-X
through	B-X
an	B-X
isopeptide	B-X
linkage	B-X
catalyzed	B-X
by	B-X
SUMO-specific	B-X
activating	B-X
(	B-X
E1	B-X
)	B-X
,	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
,	B-X
and	B-X
ligating	B-X
(	B-X
E3	B-X
)	B-X
enzymes	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
ubiquitination/deubiquitination	B-X
machinery	B-X
,	B-X
the	B-X
biochemistry	B-X
of	B-X
SUMOylation	B-X
and	B-X
de-SUMOylation	B-X
is	B-X
relatively	B-X
modest	B-X
.	B-X
SUMO-1	B-X
usually	B-X
modifies	B-X
a	B-X
substrate	B-X
as	B-X
a	B-X
monomer	B-X
;	B-X
however	B-X
,	B-X
SUMO-2/3	B-X
can	B-X
form	B-X
poly-SUMO	B-X
chains	B-X
.	B-X
The	B-X
monomeric	B-X
SUMO-1	B-X
or	B-X
poly-SUMO	B-X
chains	B-X
can	B-X
interact	B-X
with	B-X
other	B-X
proteins	B-X
through	B-X
SUMO-interactive	B-X
motif	B-X
(	B-X
SIM	B-X
)	B-X
.	B-X
After	B-X
20	B-X
yr	B-X
of	B-X
research	B-X
,	B-X
SUMO	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
biological	B-X
pathways	B-X
.	B-X

Recombinant	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
,	O
but	O
not	O
UCH	B-Protein
-	I-Protein
L1	I-Protein
,	O
was	O
able	O
to	O
cleave	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-Protein
.	O
<EOS>	B-X
NEDD8	B-X
is	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
that	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
nuclear	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
To	B-X
identify	B-X
proteins	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
NEDD8-conjugation	B-X
and	B-X
de-conjugation	B-X
pathway	B-X
,	B-X
the	B-X
yeast	B-X
two-hybrid	B-X
system	B-X
was	B-X
used	B-X
to	B-X
screen	B-X
a	B-X
human	B-X
heart	B-X
cDNA	B-X
library	B-X
using	B-X
NEDD8	B-X
as	B-X
a	B-X
bait	B-X
.	B-X
Seven	B-X
strongly	B-X
positive	B-X
clones	B-X
were	B-X
found	B-X
to	B-X
contain	B-X
a	B-X
cDNA	B-X
insert	B-X
encoding	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
,	B-X
UCH-L3	B-X
.	B-X
In	B-X
vitro	B-X
GST	B-X
pull-down	B-X
assay	B-X
demonstrated	B-X
that	B-X
UCH-L3	B-X
bound	B-X
to	B-X
both	B-X
NEDD8	B-X
and	B-X
ubiquitin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
UCH-L3	B-X
did	B-X
not	B-X
bind	B-X
to	B-X
sentrin-1	B-X
,	B-X
sentrin-2	B-X
,	B-X
or	B-X
sentrin-3	B-X
.	B-X
Recombinant	B-X
UCH-L3	B-X
,	B-X
but	B-X
not	B-X
UCH-L1	B-X
,	B-X
was	B-X
able	B-X
to	B-X
cleave	B-X
the	B-X
C-terminus	B-X
of	B-X
NEDD8	B-X
.	B-X
Thus	B-X
,	B-X
UCH-L3	B-X
can	B-X
function	B-X
as	B-X
a	B-X
C-terminal	B-X
hydrolase	B-X
for	B-X
both	B-X
NEDD8	B-X
and	B-X
ubiquitin	B-X
.	B-X
UCH-L3	B-X
may	B-X
play	B-X
a	B-X
physiologically	B-X
significant	B-X
role	B-X
in	B-X
the	B-X
cleavage	B-X
of	B-X
the	B-X
C-terminus	B-X
of	B-X
NEDD8	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
NEDD8	B-X
to	B-X
conjugate	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X

Thus	O
,	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
can	O
function	O
as	O
a	O
C	O
-	O
terminal	O
hydrolase	O
for	O
both	O
NEDD8	B-Protein
and	O
ubiquitin	B-Protein
.	O

UCH	B-Protein
-	I-Protein
L3	I-Protein
may	O
play	O
a	O
physiologically	O
significant	O
role	O
in	O
the	O
cleavage	O
of	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-Protein
,	O
which	O
is	O
required	O
for	O
NEDD8	B-Protein
to	O
conjugate	O
to	O
target	O
proteins	O
.	O

Crm1p	B-Protein
mediates	O
regulated	O
nuclear	O
export	O
of	O
a	O
yeast	O
AP	O
-	O
1	O
-	O
like	O
transcription	O
factor	O
.	O
<EOS>	B-X
The	B-X
yeast	B-X
AP-1-like	B-X
transcription	B-X
factor	B-X
,	B-X
Yap1p	B-X
,	B-X
activates	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X
Yap1p	B-X
is	B-X
normally	B-X
cytoplasmic	B-X
and	B-X
inactive	B-X
,	B-X
but	B-X
will	B-X
activate	B-X
by	B-X
nuclear	B-X
translocation	B-X
if	B-X
cells	B-X
are	B-X
placed	B-X
in	B-X
an	B-X
oxidative	B-X
environment	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Yap1p	B-X
is	B-X
a	B-X
target	B-X
of	B-X
the	B-X
beta-karyopherin-like	B-X
nuclear	B-X
exporter	B-X
,	B-X
Crm1p	B-X
.	B-X
Yap1p	B-X
is	B-X
constitutively	B-X
nuclear	B-X
in	B-X
a	B-X
crm1	B-X
mutant	B-X
,	B-X
and	B-X
Crm1p	B-X
binds	B-X
to	B-X
a	B-X
nuclear	B-X
export	B-X
sequence	B-X
(	B-X
NES	B-X
)	B-X
-like	B-X
sequence	B-X
in	B-X
Yap1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
RanGTP	B-X
.	B-X
Recognition	B-X
of	B-X
Yap1p	B-X
by	B-X
Crm1p	B-X
is	B-X
inhibited	B-X
by	B-X
oxidation	B-X
,	B-X
and	B-X
this	B-X
inhibition	B-X
requires	B-X
at	B-X
least	B-X
one	B-X
of	B-X
the	B-X
three	B-X
cysteine	B-X
residues	B-X
flanking	B-X
the	B-X
NES	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Yap1p	B-X
localization	B-X
is	B-X
largely	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
that	B-X
the	B-X
oxidation	B-X
state	B-X
affects	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
Yap1p	B-X
NES	B-X
to	B-X
Crm1p	B-X
directly	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
a	B-X
mutation	B-X
in	B-X
RanGAP	B-X
(	B-X
rna1-1	B-X
)	B-X
is	B-X
synthetically	B-X
lethal	B-X
with	B-X
crm1	B-X
mutants	B-X
.	B-X
Yap1p	B-X
export	B-X
is	B-X
inhibited	B-X
in	B-X
both	B-X
rna1-1	B-X
and	B-X
prp20	B-X
(	B-X
RanGNRF	B-X
)	B-X
mutant	B-X
strains	B-X
,	B-X
but	B-X
Yap1p	B-X
rapidly	B-X
accumulates	B-X
at	B-X
the	B-X
nuclear	B-X
periphery	B-X
after	B-X
shifting	B-X
rna1-1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
mutant	B-X
cells	B-X
to	B-X
the	B-X
non-permissive	B-X
temperature	B-X
.	B-X
Thus	B-X
,	B-X
disassembly	B-X
of	B-X
export	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
RanGTP	B-X
hydrolysis	B-X
may	B-X
be	B-X
required	B-X
for	B-X
release	B-X
of	B-X
substrate	B-X
from	B-X
a	B-X
terminal	B-X
binding	B-X
site	B-X
at	B-X
the	B-X
nuclear	B-X
pore	B-X
complex	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X

The	O
yeast	O
AP	O
-	O
1	O
-	O
like	O
transcription	O
factor	O
,	O
Yap1p	B-Protein
,	O
activates	O
genes	O
required	O
for	O
the	O
response	O
to	O
oxidative	O
stress	O
.	O
<EOS>	B-X
The	B-X
yeast	B-X
AP-1-like	B-X
transcription	B-X
factor	B-X
,	B-X
Yap1p	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
oxidative	B-X
stress	B-X
response	B-X
in	B-X
budding	B-X
yeast	B-X
.	B-X
Yap1p	B-X
is	B-X
located	B-X
predominantly	B-X
in	B-X
the	B-X
cytoplasm	B-X
;	B-X
however	B-X
,	B-X
upon	B-X
imposition	B-X
of	B-X
oxidative	B-X
stress	B-X
,	B-X
Yap1p	B-X
concentrates	B-X
in	B-X
the	B-X
nucleus	B-X
and	B-X
activates	B-X
target	B-X
genes	B-X
.	B-X
Yap1p	B-X
is	B-X
constitutively	B-X
transported	B-X
in	B-X
and	B-X
out	B-X
of	B-X
the	B-X
nucleus	B-X
.	B-X
Oxidative	B-X
stress	B-X
inhibits	B-X
the	B-X
Crm1p/Xpo1p-dependent	B-X
nuclear	B-X
export	B-X
step	B-X
,	B-X
resulting	B-X
in	B-X
nuclear	B-X
accumulation	B-X
of	B-X
Yap1p	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
mechanism	B-X
for	B-X
Yap1p	B-X
nuclear	B-X
import	B-X
,	B-X
and	B-X
determined	B-X
whether	B-X
the	B-X
import	B-X
step	B-X
is	B-X
affected	B-X
by	B-X
oxidative	B-X
stress	B-X
.	B-X
The	B-X
nuclear	B-X
accumulation	B-X
of	B-X
Yap1p	B-X
required	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
,	B-X
Ran/Gsp1p	B-X
.	B-X
Under	B-X
conditions	B-X
in	B-X
pse1-1	B-X
cells	B-X
carrying	B-X
a	B-X
temperature-sensitive	B-X
mutation	B-X
of	B-X
the	B-X
importin	B-X
beta	B-X
family	B-X
member	B-X
PSE1/KAP121	B-X
,	B-X
nuclear	B-X
translocation	B-X
of	B-X
Yap1p	B-X
was	B-X
inhibited	B-X
dramatically	B-X
.	B-X
In	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
Yap1p	B-X
could	B-X
directly	B-X
bind	B-X
to	B-X
Pse1p	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
was	B-X
dissociated	B-X
by	B-X
Ran-GTP	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pse1p	B-X
is	B-X
the	B-X
nuclear	B-X
import	B-X
receptor	B-X
for	B-X
Yap1p	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
Pse1p	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
Kap123p	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
to	B-X
Pse1p	B-X
,	B-X
has	B-X
a	B-X
minor	B-X
effect	B-X
on	B-X
the	B-X
nuclear	B-X
import	B-X
of	B-X
Yap1p	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
identified	B-X
the	B-X
nuclear	B-X
localization	B-X
signal	B-X
of	B-X
Yap1p	B-X
and	B-X
demonstrated	B-X
that	B-X
the	B-X
nuclear	B-X
import	B-X
of	B-X
Yap1p	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
oxidative	B-X
stress	B-X
.	B-X

Yap1p	B-Protein
is	O
normally	O
cytoplasmic	O
and	O
inactive	O
,	O
but	O
will	O
activate	O
by	O
nuclear	O
translocation	O
if	O
cells	O
are	O
placed	O
in	O
an	O
oxidative	O
environment	O
.	O

Here	O
we	O
show	O
that	O
Yap1p	B-Protein
is	O
a	O
target	O
of	O
the	O
beta	O
-	O
karyopherin	O
-	O
like	O
nuclear	O
exporter	O
,	O
Crm1p	B-Protein
.	O
<EOS>	B-X
The	B-X
yeast	B-X
AP-1-like	B-X
transcription	B-X
factor	B-X
,	B-X
Yap1p	B-X
,	B-X
activates	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X
Yap1p	B-X
is	B-X
normally	B-X
cytoplasmic	B-X
and	B-X
inactive	B-X
,	B-X
but	B-X
will	B-X
activate	B-X
by	B-X
nuclear	B-X
translocation	B-X
if	B-X
cells	B-X
are	B-X
placed	B-X
in	B-X
an	B-X
oxidative	B-X
environment	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Yap1p	B-X
is	B-X
a	B-X
target	B-X
of	B-X
the	B-X
beta-karyopherin-like	B-X
nuclear	B-X
exporter	B-X
,	B-X
Crm1p	B-X
.	B-X
Yap1p	B-X
is	B-X
constitutively	B-X
nuclear	B-X
in	B-X
a	B-X
crm1	B-X
mutant	B-X
,	B-X
and	B-X
Crm1p	B-X
binds	B-X
to	B-X
a	B-X
nuclear	B-X
export	B-X
sequence	B-X
(	B-X
NES	B-X
)	B-X
-like	B-X
sequence	B-X
in	B-X
Yap1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
RanGTP	B-X
.	B-X
Recognition	B-X
of	B-X
Yap1p	B-X
by	B-X
Crm1p	B-X
is	B-X
inhibited	B-X
by	B-X
oxidation	B-X
,	B-X
and	B-X
this	B-X
inhibition	B-X
requires	B-X
at	B-X
least	B-X
one	B-X
of	B-X
the	B-X
three	B-X
cysteine	B-X
residues	B-X
flanking	B-X
the	B-X
NES	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Yap1p	B-X
localization	B-X
is	B-X
largely	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
that	B-X
the	B-X
oxidation	B-X
state	B-X
affects	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
Yap1p	B-X
NES	B-X
to	B-X
Crm1p	B-X
directly	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
a	B-X
mutation	B-X
in	B-X
RanGAP	B-X
(	B-X
rna1-1	B-X
)	B-X
is	B-X
synthetically	B-X
lethal	B-X
with	B-X
crm1	B-X
mutants	B-X
.	B-X
Yap1p	B-X
export	B-X
is	B-X
inhibited	B-X
in	B-X
both	B-X
rna1-1	B-X
and	B-X
prp20	B-X
(	B-X
RanGNRF	B-X
)	B-X
mutant	B-X
strains	B-X
,	B-X
but	B-X
Yap1p	B-X
rapidly	B-X
accumulates	B-X
at	B-X
the	B-X
nuclear	B-X
periphery	B-X
after	B-X
shifting	B-X
rna1-1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
mutant	B-X
cells	B-X
to	B-X
the	B-X
non-permissive	B-X
temperature	B-X
.	B-X
Thus	B-X
,	B-X
disassembly	B-X
of	B-X
export	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
RanGTP	B-X
hydrolysis	B-X
may	B-X
be	B-X
required	B-X
for	B-X
release	B-X
of	B-X
substrate	B-X
from	B-X
a	B-X
terminal	B-X
binding	B-X
site	B-X
at	B-X
the	B-X
nuclear	B-X
pore	B-X
complex	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X

Yap1p	B-Protein
is	O
constitutively	O
nuclear	O
in	O
a	O
crm1	B-Protein
mutant	O
,	O
and	O
Crm1p	B-Protein
binds	O
to	O
a	O
nuclear	O
export	O
sequence	O
(	O
NES	O
)	O
-	O
like	O
sequence	O
in	O
Yap1p	B-Protein
in	O
the	O
presence	O
of	O
RanGTP	B-Protein
.	O

Recognition	O
of	O
Yap1p	B-Protein
by	O
Crm1p	B-Protein
is	O
inhibited	O
by	O
oxidation	O
,	O
and	O
this	O
inhibition	O
requires	O
at	O
least	O
one	O
of	O
the	O
three	O
cysteine	O
residues	O
flanking	O
the	O
NES	O
.	O
<EOS>	B-X
The	B-X
yeast	B-X
AP-1-like	B-X
transcription	B-X
factor	B-X
,	B-X
Yap1p	B-X
,	B-X
activates	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X
Yap1p	B-X
is	B-X
normally	B-X
cytoplasmic	B-X
and	B-X
inactive	B-X
,	B-X
but	B-X
will	B-X
activate	B-X
by	B-X
nuclear	B-X
translocation	B-X
if	B-X
cells	B-X
are	B-X
placed	B-X
in	B-X
an	B-X
oxidative	B-X
environment	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Yap1p	B-X
is	B-X
a	B-X
target	B-X
of	B-X
the	B-X
beta-karyopherin-like	B-X
nuclear	B-X
exporter	B-X
,	B-X
Crm1p	B-X
.	B-X
Yap1p	B-X
is	B-X
constitutively	B-X
nuclear	B-X
in	B-X
a	B-X
crm1	B-X
mutant	B-X
,	B-X
and	B-X
Crm1p	B-X
binds	B-X
to	B-X
a	B-X
nuclear	B-X
export	B-X
sequence	B-X
(	B-X
NES	B-X
)	B-X
-like	B-X
sequence	B-X
in	B-X
Yap1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
RanGTP	B-X
.	B-X
Recognition	B-X
of	B-X
Yap1p	B-X
by	B-X
Crm1p	B-X
is	B-X
inhibited	B-X
by	B-X
oxidation	B-X
,	B-X
and	B-X
this	B-X
inhibition	B-X
requires	B-X
at	B-X
least	B-X
one	B-X
of	B-X
the	B-X
three	B-X
cysteine	B-X
residues	B-X
flanking	B-X
the	B-X
NES	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Yap1p	B-X
localization	B-X
is	B-X
largely	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
that	B-X
the	B-X
oxidation	B-X
state	B-X
affects	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
Yap1p	B-X
NES	B-X
to	B-X
Crm1p	B-X
directly	B-X
.	B-X
Yap1p	B-X
export	B-X
is	B-X
inhibited	B-X
in	B-X
both	B-X
rna1-1	B-X
and	B-X
prp20	B-X
(	B-X
RanGNRF	B-X
)	B-X
mutant	B-X
strains	B-X
,	B-X
but	B-X
Yap1p	B-X
rapidly	B-X
accumulates	B-X
at	B-X
the	B-X
nuclear	B-X
periphery	B-X
after	B-X
shifting	B-X
rna1-1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
mutant	B-X
cells	B-X
to	B-X
the	B-X
non-permissive	B-X
temperature	B-X
.	B-X

These	O
results	O
suggest	O
that	O
Yap1p	B-Protein
localization	O
is	O
largely	O
regulated	O
at	O
the	O
level	O
of	O
nuclear	O
export	O
,	O
and	O
that	O
the	O
oxidation	O
state	O
affects	O
the	O
accessibility	O
of	O
the	O
Yap1p	B-Protein
NES	O
to	O
Crm1p	B-Protein
directly	O
.	O
<EOS>	B-X
The	B-X
yeast	B-X
AP-1-like	B-X
transcription	B-X
factor	B-X
,	B-X
Yap1p	B-X
,	B-X
activates	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X
Yap1p	B-X
is	B-X
normally	B-X
cytoplasmic	B-X
and	B-X
inactive	B-X
,	B-X
but	B-X
will	B-X
activate	B-X
by	B-X
nuclear	B-X
translocation	B-X
if	B-X
cells	B-X
are	B-X
placed	B-X
in	B-X
an	B-X
oxidative	B-X
environment	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Yap1p	B-X
is	B-X
a	B-X
target	B-X
of	B-X
the	B-X
beta-karyopherin-like	B-X
nuclear	B-X
exporter	B-X
,	B-X
Crm1p	B-X
.	B-X
Yap1p	B-X
is	B-X
constitutively	B-X
nuclear	B-X
in	B-X
a	B-X
crm1	B-X
mutant	B-X
,	B-X
and	B-X
Crm1p	B-X
binds	B-X
to	B-X
a	B-X
nuclear	B-X
export	B-X
sequence	B-X
(	B-X
NES	B-X
)	B-X
-like	B-X
sequence	B-X
in	B-X
Yap1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
RanGTP	B-X
.	B-X
Recognition	B-X
of	B-X
Yap1p	B-X
by	B-X
Crm1p	B-X
is	B-X
inhibited	B-X
by	B-X
oxidation	B-X
,	B-X
and	B-X
this	B-X
inhibition	B-X
requires	B-X
at	B-X
least	B-X
one	B-X
of	B-X
the	B-X
three	B-X
cysteine	B-X
residues	B-X
flanking	B-X
the	B-X
NES	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Yap1p	B-X
localization	B-X
is	B-X
largely	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
that	B-X
the	B-X
oxidation	B-X
state	B-X
affects	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
Yap1p	B-X
NES	B-X
to	B-X
Crm1p	B-X
directly	B-X
.	B-X
Yap1p	B-X
export	B-X
is	B-X
inhibited	B-X
in	B-X
both	B-X
rna1-1	B-X
and	B-X
prp20	B-X
(	B-X
RanGNRF	B-X
)	B-X
mutant	B-X
strains	B-X
,	B-X
but	B-X
Yap1p	B-X
rapidly	B-X
accumulates	B-X
at	B-X
the	B-X
nuclear	B-X
periphery	B-X
after	B-X
shifting	B-X
rna1-1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
mutant	B-X
cells	B-X
to	B-X
the	B-X
non-permissive	B-X
temperature	B-X
.	B-X
Thus	B-X
,	B-X
disassembly	B-X
of	B-X
export	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
RanGTP	B-X
hydrolysis	B-X
may	B-X
be	B-X
required	B-X
for	B-X
release	B-X
of	B-X
substrate	B-X
from	B-X
a	B-X
terminal	B-X
binding	B-X
site	B-X
at	B-X
the	B-X
nuclear	B-X
pore	B-X
complex	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X

We	O
also	O
show	O
that	O
a	O
mutation	O
in	O
RanGAP	B-Protein
(	O
rna1	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
synthetically	O
lethal	O
with	O
crm1	B-Protein
mutants	O
.	O
<EOS>	B-X
The	B-X
yeast	B-X
AP-1-like	B-X
transcription	B-X
factor	B-X
,	B-X
Yap1p	B-X
,	B-X
activates	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X
Yap1p	B-X
is	B-X
normally	B-X
cytoplasmic	B-X
and	B-X
inactive	B-X
,	B-X
but	B-X
will	B-X
activate	B-X
by	B-X
nuclear	B-X
translocation	B-X
if	B-X
cells	B-X
are	B-X
placed	B-X
in	B-X
an	B-X
oxidative	B-X
environment	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Yap1p	B-X
is	B-X
a	B-X
target	B-X
of	B-X
the	B-X
beta-karyopherin-like	B-X
nuclear	B-X
exporter	B-X
,	B-X
Crm1p	B-X
.	B-X
Yap1p	B-X
is	B-X
constitutively	B-X
nuclear	B-X
in	B-X
a	B-X
crm1	B-X
mutant	B-X
,	B-X
and	B-X
Crm1p	B-X
binds	B-X
to	B-X
a	B-X
nuclear	B-X
export	B-X
sequence	B-X
(	B-X
NES	B-X
)	B-X
-like	B-X
sequence	B-X
in	B-X
Yap1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
RanGTP	B-X
.	B-X
Recognition	B-X
of	B-X
Yap1p	B-X
by	B-X
Crm1p	B-X
is	B-X
inhibited	B-X
by	B-X
oxidation	B-X
,	B-X
and	B-X
this	B-X
inhibition	B-X
requires	B-X
at	B-X
least	B-X
one	B-X
of	B-X
the	B-X
three	B-X
cysteine	B-X
residues	B-X
flanking	B-X
the	B-X
NES	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Yap1p	B-X
localization	B-X
is	B-X
largely	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
that	B-X
the	B-X
oxidation	B-X
state	B-X
affects	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
Yap1p	B-X
NES	B-X
to	B-X
Crm1p	B-X
directly	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
a	B-X
mutation	B-X
in	B-X
RanGAP	B-X
(	B-X
rna1-1	B-X
)	B-X
is	B-X
synthetically	B-X
lethal	B-X
with	B-X
crm1	B-X
mutants	B-X
.	B-X
Yap1p	B-X
export	B-X
is	B-X
inhibited	B-X
in	B-X
both	B-X
rna1-1	B-X
and	B-X
prp20	B-X
(	B-X
RanGNRF	B-X
)	B-X
mutant	B-X
strains	B-X
,	B-X
but	B-X
Yap1p	B-X
rapidly	B-X
accumulates	B-X
at	B-X
the	B-X
nuclear	B-X
periphery	B-X
after	B-X
shifting	B-X
rna1-1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
mutant	B-X
cells	B-X
to	B-X
the	B-X
non-permissive	B-X
temperature	B-X
.	B-X

Yap1p	B-Protein
export	O
is	O
inhibited	O
in	O
both	O
rna1	B-Protein
-	I-Protein
1	I-Protein
and	O
prp20	B-Protein
(	O
RanGNRF	B-Protein
)	O
mutant	O
strains	O
,	O
but	O
Yap1p	B-Protein
rapidly	O
accumulates	O
at	O
the	O
nuclear	O
periphery	O
after	O
shifting	O
rna1	B-Protein
-	I-Protein
1	I-Protein
,	O
but	O
not	O
other	O
mutant	O
cells	O
to	O
the	O
non	O
-	O
permissive	O
temperature	O
.	O
<EOS>	B-X
The	B-X
yeast	B-X
AP-1-like	B-X
transcription	B-X
factor	B-X
,	B-X
Yap1p	B-X
,	B-X
activates	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X
Yap1p	B-X
is	B-X
normally	B-X
cytoplasmic	B-X
and	B-X
inactive	B-X
,	B-X
but	B-X
will	B-X
activate	B-X
by	B-X
nuclear	B-X
translocation	B-X
if	B-X
cells	B-X
are	B-X
placed	B-X
in	B-X
an	B-X
oxidative	B-X
environment	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Yap1p	B-X
is	B-X
a	B-X
target	B-X
of	B-X
the	B-X
beta-karyopherin-like	B-X
nuclear	B-X
exporter	B-X
,	B-X
Crm1p	B-X
.	B-X
Yap1p	B-X
is	B-X
constitutively	B-X
nuclear	B-X
in	B-X
a	B-X
crm1	B-X
mutant	B-X
,	B-X
and	B-X
Crm1p	B-X
binds	B-X
to	B-X
a	B-X
nuclear	B-X
export	B-X
sequence	B-X
(	B-X
NES	B-X
)	B-X
-like	B-X
sequence	B-X
in	B-X
Yap1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
RanGTP	B-X
.	B-X
Recognition	B-X
of	B-X
Yap1p	B-X
by	B-X
Crm1p	B-X
is	B-X
inhibited	B-X
by	B-X
oxidation	B-X
,	B-X
and	B-X
this	B-X
inhibition	B-X
requires	B-X
at	B-X
least	B-X
one	B-X
of	B-X
the	B-X
three	B-X
cysteine	B-X
residues	B-X
flanking	B-X
the	B-X
NES	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Yap1p	B-X
localization	B-X
is	B-X
largely	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
that	B-X
the	B-X
oxidation	B-X
state	B-X
affects	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
Yap1p	B-X
NES	B-X
to	B-X
Crm1p	B-X
directly	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
a	B-X
mutation	B-X
in	B-X
RanGAP	B-X
(	B-X
rna1-1	B-X
)	B-X
is	B-X
synthetically	B-X
lethal	B-X
with	B-X
crm1	B-X
mutants	B-X
.	B-X
Yap1p	B-X
export	B-X
is	B-X
inhibited	B-X
in	B-X
both	B-X
rna1-1	B-X
and	B-X
prp20	B-X
(	B-X
RanGNRF	B-X
)	B-X
mutant	B-X
strains	B-X
,	B-X
but	B-X
Yap1p	B-X
rapidly	B-X
accumulates	B-X
at	B-X
the	B-X
nuclear	B-X
periphery	B-X
after	B-X
shifting	B-X
rna1-1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
mutant	B-X
cells	B-X
to	B-X
the	B-X
non-permissive	B-X
temperature	B-X
.	B-X
Thus	B-X
,	B-X
disassembly	B-X
of	B-X
export	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
RanGTP	B-X
hydrolysis	B-X
may	B-X
be	B-X
required	B-X
for	B-X
release	B-X
of	B-X
substrate	B-X
from	B-X
a	B-X
terminal	B-X
binding	B-X
site	B-X
at	B-X
the	B-X
nuclear	B-X
pore	B-X
complex	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X

Thus	O
,	O
disassembly	O
of	O
export	O
complexes	O
in	O
response	O
to	O
RanGTP	B-Protein
hydrolysis	O
may	O
be	O
required	O
for	O
release	O
of	O
substrate	O
from	O
a	O
terminal	O
binding	O
site	O
at	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
.	O
<EOS>	B-X
The	B-X
yeast	B-X
AP-1-like	B-X
transcription	B-X
factor	B-X
,	B-X
Yap1p	B-X
,	B-X
activates	B-X
genes	B-X
required	B-X
for	B-X
the	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X
Yap1p	B-X
is	B-X
normally	B-X
cytoplasmic	B-X
and	B-X
inactive	B-X
,	B-X
but	B-X
will	B-X
activate	B-X
by	B-X
nuclear	B-X
translocation	B-X
if	B-X
cells	B-X
are	B-X
placed	B-X
in	B-X
an	B-X
oxidative	B-X
environment	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Yap1p	B-X
is	B-X
a	B-X
target	B-X
of	B-X
the	B-X
beta-karyopherin-like	B-X
nuclear	B-X
exporter	B-X
,	B-X
Crm1p	B-X
.	B-X
Yap1p	B-X
is	B-X
constitutively	B-X
nuclear	B-X
in	B-X
a	B-X
crm1	B-X
mutant	B-X
,	B-X
and	B-X
Crm1p	B-X
binds	B-X
to	B-X
a	B-X
nuclear	B-X
export	B-X
sequence	B-X
(	B-X
NES	B-X
)	B-X
-like	B-X
sequence	B-X
in	B-X
Yap1p	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
RanGTP	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Yap1p	B-X
localization	B-X
is	B-X
largely	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
that	B-X
the	B-X
oxidation	B-X
state	B-X
affects	B-X
the	B-X
accessibility	B-X
of	B-X
the	B-X
Yap1p	B-X
NES	B-X
to	B-X
Crm1p	B-X
directly	B-X
.	B-X
Yap1p	B-X
export	B-X
is	B-X
inhibited	B-X
in	B-X
both	B-X
rna1-1	B-X
and	B-X
prp20	B-X
(	B-X
RanGNRF	B-X
)	B-X
mutant	B-X
strains	B-X
,	B-X
but	B-X
Yap1p	B-X
rapidly	B-X
accumulates	B-X
at	B-X
the	B-X
nuclear	B-X
periphery	B-X
after	B-X
shifting	B-X
rna1-1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
mutant	B-X
cells	B-X
to	B-X
the	B-X
non-permissive	B-X
temperature	B-X
.	B-X
Thus	B-X
,	B-X
disassembly	B-X
of	B-X
export	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
RanGTP	B-X
hydrolysis	B-X
may	B-X
be	B-X
required	B-X
for	B-X
release	B-X
of	B-X
substrate	B-X
from	B-X
a	B-X
terminal	B-X
binding	B-X
site	B-X
at	B-X
the	B-X
nuclear	B-X
pore	B-X
complex	B-X
(	B-X
NPC	B-X
)	B-X
.	B-X

The	O
dynamic	O
role	O
of	O
GRP78	B-Protein
/	O
BiP	B-Protein
in	O
the	O
coordination	O
of	O
mRNA	O
translation	O
with	O
protein	O
processing	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

The	O
role	O
of	O
GRP78	B-Protein
/	O
BiP	B-Protein
in	O
coordinating	O
endoplasmic	O
reticular	O
(	O
ER	O
)	O
protein	O
processing	O
with	O
mRNA	O
translation	O
was	O
examined	O
in	O
GH3	O
pituitary	O
cells	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
ADP-ribosylation	B-X
was	B-X
reversed	B-X
in	B-X
90	B-X
min	B-X
by	B-X
cycloheximide	B-X
removal	B-X
in	B-X
a	B-X
manner	B-X
accelerated	B-X
by	B-X
ER	B-X
stressors	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

ADP	O
-	O
ribosylation	O
of	O
GRP78	B-Protein
and	O
eukaryotic	B-Protein
initiation	I-Protein
factor	I-Protein
(	I-Protein
eIF	I-Protein
)	I-Protein
-	I-Protein
2alpha	I-Protein
phosphorylation	O
were	O
assessed	O
,	O
respectively	O
,	O
as	O
indices	O
of	O
chaperone	O
inactivation	O
and	O
the	O
inhibition	O
of	O
translational	O
initiation	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
ADP-ribosylation	B-X
was	B-X
reversed	B-X
in	B-X
90	B-X
min	B-X
by	B-X
cycloheximide	B-X
removal	B-X
in	B-X
a	B-X
manner	B-X
accelerated	B-X
by	B-X
ER	B-X
stressors	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

Inhibition	O
of	O
protein	O
processing	O
by	O
ER	O
stress	O
(	O
ionomycin	O
and	O
dithiothreitol	O
)	O
resulted	O
in	O
GRP78	B-Protein
deribosylation	O
and	O
eIF	O
-	O
2	O
phosphorylation	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
ADP-ribosylation	B-X
was	B-X
reversed	B-X
in	B-X
90	B-X
min	B-X
by	B-X
cycloheximide	B-X
removal	B-X
in	B-X
a	B-X
manner	B-X
accelerated	B-X
by	B-X
ER	B-X
stressors	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

Suppression	O
of	O
translation	O
relative	O
to	O
ER	O
protein	O
processing	O
(	O
cycloheximide	O
)	O
produced	O
approximately	O
50	O
%	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-Protein
within	O
90	O
min	O
without	O
eIF	O
-	O
2	O
phosphorylation	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
ADP-ribosylation	B-X
was	B-X
reversed	B-X
in	B-X
90	B-X
min	B-X
by	B-X
cycloheximide	B-X
removal	B-X
in	B-X
a	B-X
manner	B-X
accelerated	B-X
by	B-X
ER	B-X
stressors	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

ADP	O
-	O
ribosylation	O
was	O
reversed	O
in	O
90	O
min	O
by	O
cycloheximide	O
removal	O
in	O
a	O
manner	O
accelerated	O
by	O
ER	O
stressors	O
.	O

Cycloheximide	O
sharply	O
reduced	O
eIF	O
-	O
2	O
phosphorylation	O
in	O
response	O
to	O
ER	O
stressors	O
for	O
about	O
30	O
min	O
;	O
sensitivity	O
returned	O
as	O
GRP78	B-Protein
became	O
increasingly	O
ADP	O
-	O
ribosylated	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
ADP-ribosylation	B-X
was	B-X
reversed	B-X
in	B-X
90	B-X
min	B-X
by	B-X
cycloheximide	B-X
removal	B-X
in	B-X
a	B-X
manner	B-X
accelerated	B-X
by	B-X
ER	B-X
stressors	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

Reduced	O
sensitivity	O
of	O
eIF	O
-	O
2	O
to	O
phosphorylation	O
appeared	O
to	O
derive	O
from	O
the	O
accumulation	O
of	O
free	O
,	O
unmodified	O
chaperone	O
as	O
proteins	O
completed	O
processing	O
without	O
replacements	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

Prolonged	O
(	O
24	O
h	O
)	O
incubations	O
with	O
cycloheximide	O
resulted	O
in	O
the	O
selective	O
loss	O
of	O
the	O
ADP	O
-	O
ribosylated	O
form	O
of	O
GRP78	B-Protein
and	O
increased	O
sensitivity	O
of	O
eIF	O
-	O
2	O
phosphorylation	O
in	O
response	O
to	O
ER	O
stressors	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
ADP-ribosylation	B-X
was	B-X
reversed	B-X
in	B-X
90	B-X
min	B-X
by	B-X
cycloheximide	B-X
removal	B-X
in	B-X
a	B-X
manner	B-X
accelerated	B-X
by	B-X
ER	B-X
stressors	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

Brefeldin	O
A	O
decreased	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-Protein
in	O
parallel	O
with	O
increased	O
eIF	O
-	O
2	O
phosphorylation	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
ADP-ribosylation	B-X
was	B-X
reversed	B-X
in	B-X
90	B-X
min	B-X
by	B-X
cycloheximide	B-X
removal	B-X
in	B-X
a	B-X
manner	B-X
accelerated	B-X
by	B-X
ER	B-X
stressors	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X

The	O
cytoplasmic	O
stressor	O
,	O
arsenite	O
,	O
which	O
inhibits	O
translational	O
initiation	O
through	O
eIF	O
-	O
2	O
phosphorylation	O
without	O
affecting	O
the	O
ER	O
,	O
also	O
produced	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
GRP78/BiP	B-X
in	B-X
coordinating	B-X
endoplasmic	B-X
reticular	B-X
(	B-X
ER	B-X
)	B-X
protein	B-X
processing	B-X
with	B-X
mRNA	B-X
translation	B-X
was	B-X
examined	B-X
in	B-X
GH3	B-X
pituitary	B-X
cells	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
and	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
(	B-X
eIF	B-X
)	B-X
-2alpha	B-X
phosphorylation	B-X
were	B-X
assessed	B-X
,	B-X
respectively	B-X
,	B-X
as	B-X
indices	B-X
of	B-X
chaperone	B-X
inactivation	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
translational	B-X
initiation	B-X
.	B-X
Inhibition	B-X
of	B-X
protein	B-X
processing	B-X
by	B-X
ER	B-X
stress	B-X
(	B-X
ionomycin	B-X
and	B-X
dithiothreitol	B-X
)	B-X
resulted	B-X
in	B-X
GRP78	B-X
deribosylation	B-X
and	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
Suppression	B-X
of	B-X
translation	B-X
relative	B-X
to	B-X
ER	B-X
protein	B-X
processing	B-X
(	B-X
cycloheximide	B-X
)	B-X
produced	B-X
approximately	B-X
50	B-X
%	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
within	B-X
90	B-X
min	B-X
without	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
ADP-ribosylation	B-X
was	B-X
reversed	B-X
in	B-X
90	B-X
min	B-X
by	B-X
cycloheximide	B-X
removal	B-X
in	B-X
a	B-X
manner	B-X
accelerated	B-X
by	B-X
ER	B-X
stressors	B-X
.	B-X
Cycloheximide	B-X
sharply	B-X
reduced	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
for	B-X
about	B-X
30	B-X
min	B-X
;	B-X
sensitivity	B-X
returned	B-X
as	B-X
GRP78	B-X
became	B-X
increasingly	B-X
ADP-ribosylated	B-X
.	B-X
Reduced	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
to	B-X
phosphorylation	B-X
appeared	B-X
to	B-X
derive	B-X
from	B-X
the	B-X
accumulation	B-X
of	B-X
free	B-X
,	B-X
unmodified	B-X
chaperone	B-X
as	B-X
proteins	B-X
completed	B-X
processing	B-X
without	B-X
replacements	B-X
.	B-X
Prolonged	B-X
(	B-X
24	B-X
h	B-X
)	B-X
incubations	B-X
with	B-X
cycloheximide	B-X
resulted	B-X
in	B-X
the	B-X
selective	B-X
loss	B-X
of	B-X
the	B-X
ADP-ribosylated	B-X
form	B-X
of	B-X
GRP78	B-X
and	B-X
increased	B-X
sensitivity	B-X
of	B-X
eIF-2	B-X
phosphorylation	B-X
in	B-X
response	B-X
to	B-X
ER	B-X
stressors	B-X
.	B-X
Brefeldin	B-X
A	B-X
decreased	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
in	B-X
parallel	B-X
with	B-X
increased	B-X
eIF-2	B-X
phosphorylation	B-X
.	B-X
The	B-X
cytoplasmic	B-X
stressor	B-X
,	B-X
arsenite	B-X
,	B-X
which	B-X
inhibits	B-X
translational	B-X
initiation	B-X
through	B-X
eIF-2	B-X
phosphorylation	B-X
without	B-X
affecting	B-X
the	B-X
ER	B-X
,	B-X
also	B-X
produced	B-X
ADP-ribosylation	B-X
of	B-X
GRP78	B-X
.	B-X